<SEC-DOCUMENT>0000950170-22-002536.txt : 20220301
<SEC-HEADER>0000950170-22-002536.hdr.sgml : 20220301
<ACCEPTANCE-DATETIME>20220301161619
ACCESSION NUMBER:		0000950170-22-002536
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		93
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220301
DATE AS OF CHANGE:		20220301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Phathom Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001783183
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				824151574
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39094
		FILM NUMBER:		22698220

	BUSINESS ADDRESS:	
		STREET 1:		100 CAMPUS DRIVE,
		STREET 2:		SUITE 102
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932
		BUSINESS PHONE:		(877) 742-8466

	MAIL ADDRESS:	
		STREET 1:		100 CAMPUS DRIVE,
		STREET 2:		SUITE 102
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>phat-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-03-01T13:48:29.3697+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:phat="http://www.phathompharma.com/20211231" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonFraction id="F_790a9cb9-9188-4ded-9206-b149f84c5071" name="us-gaap:CommitmentsAndContingencies" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_5c9dbb8a-393e-444e-8610-68189e5d86c9" name="dei:CurrentFiscalYearEndDate" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6">--12-31</ix:nonNumeric><ix:nonFraction id="F_6df742c1-1b0e-4a19-9b23-85075f7ae8ca" name="us-gaap:CommitmentsAndContingencies" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_6101410e-3515-4cea-81ab-5e3079200f62" name="phat:RepurchaseRightLapseShares" contextRef="C_c91457b5-5dc6-4bd1-a9ad-497176c5ae9b" unitRef="U_pure" decimals="6" scale="0" format="ixt:numdotdecimal">0.000208</ix:nonFraction><ix:nonNumeric id="F_b94a21cd-dcaa-4585-bab0-9b02263f175c" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_46965119-6bce-4a6d-abf3-e28dc3543e93" format="ixt-sec:durwordsen">two years</ix:nonNumeric><ix:nonFraction id="F_a6f5857d-fe54-46c6-8042-ea23f4bc4656" name="us-gaap:PreferredStockValue" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_808f8abc-4c8d-4093-8dc3-817145973bca" name="dei:AmendmentFlag" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6">false</ix:nonNumeric><ix:nonNumeric id="F_c5534db8-5d86-4eaa-80e7-cd1983ac8153" name="dei:DocumentFiscalPeriodFocus" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6">FY</ix:nonNumeric><ix:nonNumeric id="F_363c3080-c309-4c9a-8ecc-58fdc9844485" name="dei:EntityCentralIndexKey" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6">0001783183</ix:nonNumeric><ix:nonFraction id="F_d8219ef5-f760-4856-ae0b-f47cd083e034" name="us-gaap:PreferredStockValue" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="phat-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_83965ad4-28b1-4afc-8889-5d7cdbc079ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9960611-efe5-44c4-a8c6-f1f963d5a52b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_20586d23-36ef-4d60-8bc6-81acfe59236b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:SiliconValleyBankTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_17839630-7f10-4b51-bf7c-a8f7ffc8fab6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_caf206af-24fe-4015-adc8-87b45d8a8636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_861c796b-ff5c-4f2f-83b8-902fd93be0af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4dfdb6b-5b03-4e72-951e-81ecb345c403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b03a9ab9-4538-4d34-b658-218482e16bbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91313c0e-8879-4034-8725-8b3f8639f719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-29</xbrli:startDate><xbrli:endDate>2019-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d2e408c-4d50-4188-92b1-018f98519206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:PCIPharmaServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:ClinicalManufacturingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3cd1a70e-7077-4da4-a87c-da5e90015997"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:DrugProductOrSubstanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a529bff-3f22-42e8-80c8-4ec27c2967c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">phat:StockOptionsAndPerformanceBasedUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2511355-1d5e-4278-9953-83e4963ae813"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db21078b-51b9-43f8-8e98-683590c04e0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a36db690-2560-474a-8fbd-8050d47eb62c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_85558b4d-f67a-43d1-abe8-dbab03b741da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb1fb004-48c7-408c-a23a-a166c26e4c3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b04891d2-7dba-42b2-a181-d9f6bb277f08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4181602-e907-4a44-b1b6-077897333d0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:SiliconValleyBankTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-14</xbrli:startDate><xbrli:endDate>2019-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c7240c2-23a4-4f2e-bdf7-8d45f209d98b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_206f3b3c-5da1-4c5f-91a2-624aa167dbf3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d09d3095-f7e4-4678-97ca-b059f5088ae2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87fd58b8-211c-4048-8771-2e2c36ba57bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c645a10-1007-43f6-af0d-91ee63fc5c04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33fee96d-a213-48c4-a5ad-68ccefad3cff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fad8897a-ba60-41ae-8f3d-ee922beca8a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_380ada73-fd68-4c36-b7a1-4dbbf1ceef47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca65917a-bc4e-4718-82a1-bb0697a04ae9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanAdvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-17</xbrli:startDate><xbrli:endDate>2021-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6ab3ae6-86d0-4065-ba57-907b3b0f74c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">phat:UnvestedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c52a9cb-ddf2-45f2-a3ab-4d943486cf78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-05</xbrli:startDate><xbrli:endDate>2020-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_900f5558-5afe-4b4f-8196-aa85a162d269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87f0bb77-c9b2-4912-beed-d93c6e58fd1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af4df9d7-725e-4644-8d48-2c2689576963"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">phat:PrepaidLeasePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f305fcc-4607-43ba-9d9f-9de48fa77502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">phat:PaymentInKindPikInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_478c7409-ab7e-4c39-bda4-749e3ceaf9ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7d58811-0410-450f-88fc-1f9a4230079a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanAdvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-17</xbrli:startDate><xbrli:endDate>2021-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a5762110-631a-4b1c-9b33-2acb71c21790"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81edcc29-7776-4011-b910-010591687fb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanAdvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0b3b017-48e9-4500-9fd4-aaf93a60d5dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:DrugProductOrSubstanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6951c26d-af1d-407b-bbcb-8b12126fe3f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:PCIPharmaServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:ClinicalManufacturingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe1128a5-47e8-4b19-bbed-dd56555e6e7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d695a09e-552b-4926-9fd0-d64fd565f066"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">phat:LenderWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_413a633b-7a27-41ac-8e92-4d82e9b0c253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TemporaryServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33b1043e-bfc6-4fce-ba82-e6e6e0ac95af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_efc1a669-0200-4d3b-9503-dde410805b7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_917d5eb6-6257-4bc2-9c26-1732c213fff4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fed6006f-4109-4946-b552-76ae913aeaf0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_188214ae-df7a-4194-abe9-bd6e9956a85d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-11</xbrli:startDate><xbrli:endDate>2019-10-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d962d708-ce93-405d-a90d-73e1fae4aa3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8dbe144e-0a5e-4b96-a3d3-658404346eb7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38af774f-d0ce-4768-8641-dd4bb3038da3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10d2f460-e459-411f-8dad-34d4446eecc2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:PCIPharmaServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:ClinicalManufacturingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c91457b5-5dc6-4bd1-a9ad-497176c5ae9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b72f7963-2e17-4f63-ae38-f0567547466c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d868eb98-0a9a-4d3b-9ce2-a53206123d64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">phat:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b6da75c-d2db-4900-8fad-0f82733efc5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2abff921-c9a8-4de4-b41c-9e7893e5704b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be8f5d58-327a-4e7b-acdd-e53a93782a26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b58f7ee0-6546-4bdb-8957-1ed85f98206a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60ed7ae5-368e-4841-b870-3c1b94b39311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d13ddfcd-4194-47e6-a796-f68b8150593b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bbae8c0f-df0c-4920-b864-e0c22c2199e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_955c05d2-5a1f-43ab-9d80-db08111345d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f66489f4-0ae2-4a45-862d-a14469e353c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c161eef4-fe92-48d7-944f-6e1bd1c45f50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:DrugProductOrSubstanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5335391-0999-47b9-a03b-8400c5c69127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TemporaryServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b0c76117-ced6-4a6e-a934-4d66a2de81b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-31</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5953438-3337-4945-83fd-2193a29e01a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">phat:StockOptionsAndPerformanceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff71ca2a-03d2-4397-9d0b-802dd6a7a795"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoansAggregatePrincipalAmountTranchesThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9cd5e45-1473-4fc5-b117-73d3e4b8192b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">phat:ATMOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:OpenMarketSaleAgreementWithJefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8eeb73f9-fe0f-457f-a77c-81905970cf0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-17</xbrli:startDate><xbrli:endDate>2021-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab2e6d6d-5682-41ff-9336-cabea4c3f7b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a04a8afc-8f38-4892-a76a-0ad14e22ff3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoansAggregatePrincipalAmountTranchesFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3536774-184c-4c9f-b6b0-4b72ebbf9525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_efee110a-f508-43c7-acf9-df99b6d9b882"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61898c01-23d4-4967-bc48-1597a7447fd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46965119-6bce-4a6d-abf3-e28dc3543e93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">phat:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc9746aa-75ec-4357-9a62-e52e0a26d077"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b92a549-2b7a-468d-8c11-955c21018981"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3d57991-14bf-4f93-a017-aa16c506b8db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1996f1f9-d68a-46ed-9e27-8965a2c43da4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanFirstAdvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d982be6-c196-4b4e-ae56-0b1fafa482a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_304607c5-7382-468b-88d2-4280b34bacd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c47ce7f2-8ee4-455c-93be-6ab781a08057"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ef27173-e664-4f22-9780-2b7a13c106d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a4b87ab-a1d7-48cd-a634-0d9f17511fa1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_caf5d7c1-1bad-4042-90db-0f0fb308e394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f52603aa-c039-41a2-95ea-2a152bab42c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TemporaryServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3664d4ba-d83a-42b2-94ee-819934ab325c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">phat:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e3a25e6-daa3-4b87-aabb-7aa287d515ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba31a338-f01c-4a63-899f-d02fc7b91340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_133a7a17-cc0b-4319-b5dd-153f51460267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ef2e37e-f570-4b04-bea6-8bd572cb5668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35306304-4c25-4c5b-a433-e5367fe22b87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">phat:TakedaWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6cd259d1-4f33-46a3-b5d1-c3115e02e275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:HerculesAndSvbTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc73c1d8-543b-42ca-a706-31cf63f474bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_955ca9b1-fa2d-4384-942f-920fcb5fe424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3df574b9-fe27-4d9e-a549-6a095ed65261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:SiliconValleyBankTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3ad8a65-3e01-423c-bdf8-40f8bc119501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2349ad83-214b-42ef-8534-32900ea1ab8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-17</xbrli:startDate><xbrli:endDate>2021-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e23ac301-7808-41cf-82ed-c24a17ab03b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-16</xbrli:startDate><xbrli:endDate>2020-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_17a2343c-f245-48f0-b4b2-e5e809abbd6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_241f6789-e4f7-4e5a-930f-33a8b7e5b743"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:SiliconValleyBankTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-14</xbrli:startDate><xbrli:endDate>2019-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1df5bc5b-1abb-43f6-aae5-4d3a06d655e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">phat:WarrantsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e6c878e-6e27-47fc-9b34-7dc97f3dda54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_098ad23e-df01-4a44-9fa6-756e054ae9d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd956957-4601-4ab3-a9dd-db08fb69bc8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">phat:PrepaidLeasePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_acd69431-8a06-4075-a111-6495758ee60f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:HerculesAndSvbTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12c53278-d1c8-452b-aaf8-8d9bd7427b25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_589be08d-1fdd-4132-b344-d516fb3dae6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aefa2a08-8860-4371-8c07-d0e5df47bfbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">phat:ShareBasedPaymentArrangementEmployeeAndNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9fb0785-ea03-426b-a4b8-f5ea1415baaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:PCIPharmaServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:ClinicalManufacturingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_51814a33-b695-44e9-b59a-823a169dda09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36128d75-bc37-4ecf-b73c-b936cd610fae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">phat:FoundersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1dc294ca-9c67-4d13-8135-fcee0b125f3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_32d5d9b1-7992-4d84-8226-a55e116ed6d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:SiliconValleyBankTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-14</xbrli:startDate><xbrli:endDate>2019-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cdbdb34e-8229-4188-b4a2-e7d4e7a5718c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_20fed5f8-cd13-4903-b6b5-b54dbe1e910a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_61652f9e-ae05-40dc-b6b4-3b2b4d36b133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_335b6a1d-cf50-4b89-b646-9f381f97d6d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef836273-9d6a-454c-a500-c957bc4a93a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6c9a017-a221-4c88-a8e6-7e275e06e7fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_098dcddf-024a-435f-b6ee-bf3342544e82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-10-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_58425dd1-174b-4c7a-8d6a-81deea1aee09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74f9d273-2810-4b05-a50b-39f4e9e89f17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-29</xbrli:startDate><xbrli:endDate>2019-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4d53c9a-cf55-407d-9ed4-40937c45f516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a16177c-bacc-4d09-9fc8-d0f5d55d3ee5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6e0c0e2-0899-4673-aff4-66d468643b51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">phat:WarrantsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c621285b-51be-4793-ac3f-90046055c2ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1697dfc5-540c-442e-b1a4-f9384dabddfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PartnerTypeOfPartnersCapitalAccountAxis">phat:FrazierLifeSciencesIXLimitedPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_454da93f-f097-4419-a6f9-b33d0b69cd59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43c774bf-00b3-4dcd-930e-6ffada5f2a87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-17</xbrli:startDate><xbrli:endDate>2021-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d28ef17-10f6-4591-8f1a-f0f2d4d26dae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_543d071e-badd-429f-8237-98bcd1e05d25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_966c0d74-7852-45f5-adb0-f5683894e01e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7722cfb6-10af-45ab-a5aa-9adea0d22b6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71f08e47-8ff5-4195-a019-61c121d7c840"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-17</xbrli:startDate><xbrli:endDate>2021-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_78796fa9-c62f-43b9-b92a-90c0ac2aae02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9840529e-ac70-4eb7-8d10-e6cb712b0d45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:SiliconValleyBankTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_39e4a6be-472b-4454-9622-81423cbf1cf1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoansAggregatePrincipalAmountTranchesTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd0d4a06-0d27-4385-9179-d25cf2ad0b78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoansAggregatePrincipalAmountTranchesOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8f7aeec-8c43-4d6e-857e-906c1138ff3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26050370-2bfa-4995-a133-64b6e9cefdc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce1d61e6-3a91-4de4-b8d0-dfb4084514fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TemporaryServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d15d3cd0-b504-48e2-8d5b-b29bec97767e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f13e98ac-8a46-483d-833b-1ed96212502d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:HerculesAndSvbTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea9b39a8-a8b3-4e16-ad57-51beaa82a734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b31d6f50-cf52-4cab-8313-448f4b5812e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-07</xbrli:startDate><xbrli:endDate>2019-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36815495-d09a-4025-bf79-5a42d4c3e739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_badf06b6-f9fe-4b02-beea-e7e8d5ea853c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-05-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_723f3790-161d-4bd6-86bd-87b733a399de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e42fcdbf-c245-40d9-a08b-a3024663efad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ac41c78-ea4c-491d-bef4-399d1207de36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:DrugProductOrSubstanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a86629b2-8d48-4534-a0ad-f992b4110383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d9410fc-a3f3-43cf-95a5-e68281c355c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c116e20-429c-4aa4-8fe0-8e3b8500397e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53fd8783-36da-45c7-98b2-ab70da66a761"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd423291-341d-427f-ad43-b78d594b43a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">phat:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d66f011d-89be-4560-91d7-2a57c1175688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">phat:LenderWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0e9a1bb-6f16-475b-b3dc-8ce4769c62af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0325f78e-5f19-4ce3-816b-ea35a5adfab2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">phat:ATMOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:OpenMarketSaleAgreementWithJefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_213e1528-74d7-4db2-a3ae-74c89a47e0e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_feab6596-3893-42c2-a2c0-1464c2b5d8ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">phat:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a74a6818-5881-479c-96b1-dcc3cd65fed3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-16</xbrli:startDate><xbrli:endDate>2020-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f32b69df-40b4-4e56-8da4-28475877b8ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">phat:UnvestedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c16925ab-416a-4dd6-ae22-155a64c3a8a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">phat:ATMOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed462fec-d2dc-4e80-8a94-a6e09a3934b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001783183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Option"><xbrli:measure>phat:Option</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>phat:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="border-top:2.250pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.5pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">FORM </span><span style="font-size:16.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f963568b-28ee-4bd8-baf0-9a4ec98c5ae2" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(Mark One)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7d3660fb-75af-4f93-83bc-a1b18c57e39b" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">For the fiscal year ended </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_09f33276-2fba-456f-862d-406a3aa65663" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f9f474b4-4247-49dc-8ede-0b3bfbb0a7dc" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></ix:nonNumeric></span><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.5pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">OR</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01a545f4-5c1a-4b78-b094-44129bb9d509" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">For the transition period from </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:Times New Roman;">                    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">                    </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.5pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Commission file number: </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dbd4dda9-cd3e-4f91-814a-c08096d8ce6f" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">001-39094</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.5pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_732ef9d9-b757-4123-acae-fd7b772f6e8f" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">PHATHOM PHARMACEUTICALS, INC.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Exact name of Registrant as specified in its charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.981%;"></td>
    <td style="width:2.037%;"></td>
    <td style="width:48.981%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_48f33b7c-8544-4f23-b3bb-32f3e98978a6" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_03948412-b2c1-4838-8e45-370977f67ccb" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">82-4151574</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">(State or Other Jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Incorporation or Organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_90bfb79b-6da2-4262-b9e0-5bfbfbe5eb7d" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">100 Campus Drive</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">, </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6a5d051c-9dd7-49ed-9f03-ee7dd7f219e3" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Suite 102</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c99a120-8329-4734-9606-40c3a546de48" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Florham Park</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">, </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f44d9ab2-d0f1-43cd-b4ce-27af6fa5a910" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">New Jersey</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_02e2f9ae-ffc1-42d2-abc2-ea5d9fb3f8a4" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">07932</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Registrant&#x2019;s Telephone Number, Including Area Code: (</span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cdc778eb-baf6-4fed-8cbb-9c447da5803e" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">877</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">) </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_257db812-a794-499c-bdc1-4e4f5f622fee" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">742-8466</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.5pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.007%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:20.004%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:38.989%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:21.85pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Trading Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:18.65pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e7dabba-0a07-4791-ba5c-d557ec211da6" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_86118016-fc62-4780-8719-2cfff014b390" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">PHAT</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c6c522a0-bf70-4261-8328-999af2ce1632" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(g) of the Act: None</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  &#9744;    </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a51f441-aa67-4dc2-9211-57eb9519df52" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">  &#9746;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  &#9744;    </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c3f40430-22bc-4c39-88a4-e94361a2d54a" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">  &#9746;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31681eb1-78bf-4adc-81ae-42114965d18b" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Yes </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> &#9746;    No  &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_645415da-5b45-45a1-a1e5-c89868de540b" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">  &#9746;    No  &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:22.444%;"></td>
    <td style="width:2.056%;"></td>
    <td style="width:51.019%;"></td>
    <td style="width:22.444%;"></td>
    <td style="width:2.037%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9744;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7b315cce-cc7a-4c5a-95fd-5bbcc6cb66f5" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d564545f-ce65-4c8d-a1fc-f770dd185df5" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_700a79df-8919-4081-84b4-bd6a71d62001" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:0.9668750000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1669e876-f6b4-4221-940c-94a9aa46923a" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes Oxley Act (15 U.S.C. 7262 (b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2faf01c9-2857-4350-b952-93eaa0d12ca0" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes  &#9744;    No  </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6695552c-fa8b-4a5c-b015-c19c84105475" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">As of June 30, 2021, the aggregate market value of the registrant&#x2019;s common stock held by non-affiliates of the registrant was approximately $</span><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_22f782da-1562-4185-90fc-ee674daaff0d" contextRef="C_1c116e20-429c-4aa4-8fe0-8e3b8500397e" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">684.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> million, based on the closing price of the registrant&#x2019;s common stock on the Nasdaq Global Select Market of $33.85 per share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">As of February 24, 2022, the registrant had </span><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_66424694-ad38-4e20-bc50-246d926fe0b8" contextRef="C_d13ddfcd-4194-47e6-a796-f68b8150593b" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">31,712,742</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> shares of common stock ($0.0001 par value) outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div><ix:nonNumeric id="F_ab5fdf0d-341f-42e1-9a81-e48cb32bc39f" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Certain sections of the registrant&#x2019;s definitive proxy statement for the 2022 annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K are incorporated by reference into Part III of this Form 10-K.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PHATHOM PHARMACEUTICALS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TABLE OF CONTENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FORM 10-K</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">For the Year Ended December 31, 2021</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">INDEX</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:82.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.187%;"></td>
    <td style="width:1.225%;"></td>
    <td style="width:79.836%;"></td>
    <td style="width:6.752%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART I</span></a><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Business</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1B.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 2.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Properties</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 3.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 4.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART II</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 5.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5__market_for_registrants_common_eq"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 6.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Reserved</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">122</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">123</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a__quantitative_qualitative_disclo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">136</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 8.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8__financial_statements_supplementa"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">136</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9__changes_in_disagreements_with_ac"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">136</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a__controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">137</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9B.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b__or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Other Information</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">137</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9C.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disclosure_foreign_jurisdictions"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">137</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART III</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 10.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10__directors_executive_ficers_corp"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 11.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11__executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 12.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12__security_ownership_certain_bene"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 13.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13__certain_relationships_related_t"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 14.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14__principal_accounting_fees_servi"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART IV</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 15.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15__exhibits_financial_statement_sc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibits, Financial Statement Schedules</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">139</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 16.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">139</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Signatures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">169</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> I</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This annual report on Form 10-K contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this annual report, including statements regarding our future results of operations and financial position, business strategy, research and development plans and costs, the timing and likelihood of regulatory filings and approvals, commercialization plans, pricing and reimbursement, the potential to develop future product candidates, the timing and likelihood of success of the plans and objectives of management for future operations, and future results of anticipated product development efforts, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. This annual report on Form 10-K also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In some cases, you can identify forward-looking statements by terms such as &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;should,&#x201d; &#x201c;expect,&#x201d; &#x201c;plan,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;could,&#x201d; &#x201c;intend,&#x201d; &#x201c;target,&#x201d; &#x201c;project,&#x201d; &#x201c;contemplates,&#x201d; &#x201c;believes,&#x201d; &#x201c;estimates,&#x201d; &#x201c;predicts,&#x201d; &#x201c;potential&#x201d; or &#x201c;continue&#x201d; or the negative of these terms or other similar expressions. The forward-looking statements in this annual report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, operating results, business strategy, and short term and long term business operations and objectives. These forward-looking statements speak only as of the date of this annual report and are subject to a number of risks, uncertainties and assumptions, including those described in Part I, Item 1A, &#x201c;Risk Factors.&#x201d; The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This annual report includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this annual report appear without the &#174; and &#153; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We maintain a website at www.phathompharma.com, to which we regularly post copies of our press releases as well as additional information about us. Our filings with the Securities and Exchange Commission, or SEC, are available free of charge through our website as soon as reasonably practicable after being electronically filed with or furnished to the SEC. Information contained in our website does not constitute a part of this report or our other filings with the SEC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1. Bu</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">siness</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Our initial product candidate, vonoprazan, is an oral small molecule potassium-competitive acid blocker, or P-CAB. P-CABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has shown rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits over the current standard of care as a single agent in the treatment of gastroesophageal reflux disease, or GERD, and in combination with antibiotics for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Helicobacter pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, infection. Takeda Pharmaceutical Company Limited, or Takeda, developed vonoprazan and has received marketing approval in numerous countries in Asia and Latin America as well as Russia. Vonoprazan generated approximately $850 million in net sales in its seventh full year on the market since its approval in Japan in late 2014. In May 2019, we in-licensed the U.S., European, and Canadian rights to vonoprazan from Takeda.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2021 we reported topline data from two pivotal Phase 3 clinical trials for vonoprazan: one for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection, or PHALCON-HP, and a second for the treatment of erosive GERD, also known as erosive esophagitis or EE, or PHALCON-EE. In April 2021, we reported positive topline data from PHALCON-HP, and in October 2021, we reported positive topline data from PHALCON-EE. These data are supplemented by the extensive existing clinical data generated by Takeda as part of their development program for vonoprazan in Japan and other markets. In September 2021, we submitted two new drug applications, or NDAs, for the use of vonoprazan in combination with amoxicillin and clarithromycin (vonoprazan triple therapy) and vonoprazan in combination with amoxicillin (vonoprazan dual therapy) for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in adults, and in November 2021, the U.S. Food and Drug Administration, or FDA, accepted both NDAs for filing, granted each of them Priority Review, and assigned us a Prescription Drug User Fee Act, or PDUFA, action date of May 3, 2022. Based on the results of the PHALCON-EE trial, we expect to submit an NDA for vonoprazan for the healing of all grades of erosive esophagitis and relief of heartburn, and maintenance of healing of all grades of erosive esophagitis and relief of heartburn in March 2022. In August 2019, we received Qualified Infectious Disease Product, or QIDP, and Fast Track designations from the FDA, for vonoprazan tablets in combination with amoxicillin tablets and clarithromycin tablets and with amoxicillin tablets alone for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection. In January 2021 and May 2021, respectively, we received additional Fast Track and QIDP designations to include amoxicillin capsules in addition to amoxicillin tablets. QIDP designation provides potential extension of any regulatory exclusivity awarded, if approved. We have also initiated development of vonoprazan for the treatment of symptomatic non-erosive GERD, or NERD. In February 2022, we commenced enrollment of patients in a Phase 3 trial studying </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">vonoprazan, dosed on a once-daily basis, for the treatment of NERD, with topline data expected in 2023. Also in February 2022, we reported positive topline data from a Phase 2 trial studying vonoprazan for on-demand treatment of NERD.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Vonoprazan has the potential to be the first gastric anti-secretory agent from a novel class approved in the United States, Europe, or Canada in over 30 years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If approved, we plan to independently commercialize vonoprazan in the United States. We also plan to seek commercial partnerships for vonoprazan in Europe and Canada, expand development of vonoprazan into other indications, dosing regimens and alternative formulations and packaging, and in-license or acquire additional clinical or commercial stage product candidates for the treatment of GI diseases in a capital efficient manner.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GERD and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection are two of the most common acid-related GI diseases and impact millions of people. The prevalence of GERD is estimated to be 20% of the U.S. population and 15% of the population in the five major countries in Europe (France, Germany, Italy, Spain and the United Kingdom) (collectively, the &#34;EU5&#34;). GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. Approximately 30% of GERD patients have erosive esophagitis. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">is a bacterial pathogen that infects approximately 35% of the U.S. population and 45% of the EU5 population. As a result of the chronic inflammation induced by </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection, approximately 20% of infected patients will develop a range of pathologies, including dyspepsia, peptic ulcer disease, gastric cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Over the last thirty years, the proton pump inhibitor, or PPI, class, has been the standard of care for the treatment of acid-related GI diseases. PPIs are generally used as a single agent for the treatment of GERD and in combination with antibiotics for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection. The PPI class includes drugs such as Prilosec (omeprazole), Nexium (esomeprazole), and Prevacid (lansoprazole). Prior to the introduction of generic and over-the-counter, or OTC, alternatives, annual PPI class sales reached approximately $12.5 billion in the United States, and peak sales for individual brands were approximately $3.7 billion for Prilosec, $3.5 billion for Nexium, and $3.4 billion for Prevacid in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While PPIs are the current standard of care and have experienced significant commercial success, they have significant limitations that result in a large unmet medical need. In GERD, PPI therapy is suboptimal for many patients due to the slow onset and insufficient duration of acid control which can lead to inadequate symptom relief. Approximately 15% to 45% of GERD patients remain inadequately treated with PPIs. In the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection, the standard of care consists of a combination of a PPI and at least two oral antibiotics. However, increasing antibiotic resistance has resulted in declining eradication rates with PPI-based therapy. We believe these unmet medical needs are in part driven by limitations associated with the mechanism of action and pharmacokinetics of PPIs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PPIs reduce gastric acid secretion by irreversibly binding to and inhibiting active proton pumps expressed on the parietal cells. PPIs require activation by gastric acid, but they are unstable in the presence of acid. This instability, combined with the short circulating half-life of PPIs, limits their efficacy. Additionally, because proton pumps continuously switch between active and inactive states, multiple doses of PPIs are required to inhibit enough proton pumps to achieve a clinical benefit. As a result, PPIs have a relatively slow onset of action and limited potency and duration of effect, which may result in patients experiencing only partial relief, increasing PPI dosage, and/or cycling through multiple PPIs seeking relief.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan has a differentiated mechanism of action from PPIs. Unlike PPIs, vonoprazan:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">does not require activation by gastric acid; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">is stable in the presence of acid; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">is designed to selectively concentrate in the parietal cells in both the resting and stimulated states, bind to the active pumps and remain associated with the active and inactive pumps;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">binds to the pumps in a noncovalent and reversible manner; and  </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">has a long plasma half-life that replenishes the drug at the site of action over the course of the day. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These factors have enabled vonoprazan to demonstrate more rapid and potent acid suppression versus the PPIs esomeprazole and lansoprazole in human subjects two hours after oral dosing and maintain target acid inhibition over a 24-hour period in randomized, open-label, crossover clinical trials. In contrast, PPIs require three to five days to reach steady state acid suppression and do not reliably maintain target acid inhibition over a 24-hour period. In addition, vonoprazan demonstrated approximately 10-to-100-fold better acid control compared to lansoprazole and esomeprazole.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that vonoprazan&#x2019;s anti-secretory profile may demonstrate clinically meaningful advantages over PPIs, such as:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">faster, more complete, and more durable healing of erosive esophagitis;  </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">faster, more complete, and more durable control of GERD symptoms; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">higher </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> eradication rates in combination with antibiotics compared to standard of care triple therapy and the potential for antibiotic-sparing dual therapy; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">more flexible dosing, including dosing independent of food and time of day, and, in the treatment of patients with non-erosive esophagitis, the potential for rapid symptom relief through on-demand dosing. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan has demonstrated clinical advantages over the PPI lansoprazole in the treatment of erosive esophagitis and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection in completed Phase 3 clinical trials conducted in the United States, Europe, Japan and other Asian countries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Erosive esophagitis</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  In PHALCON-EE, a Phase 3 clinical trial conducted in the United States and Europe assessing vonoprazan versus lansoprazole in the healing and maintenance of healing of erosive esophagitis, vonoprazan met its primary healing endpoint demonstrating non-inferiority to lansoprazole in the number of patients who showed complete healing of erosive esophagitis after eight weeks of treatment. Further, in a pre-specified secondary endpoint, vonoprazan demonstrated superior healing after two weeks of treatment in patients with moderate to severe erosive esophagitis compared to lansoprazole. After two weeks of treatment, 70% of patients with moderate to severe erosive esophagitis were healed after treatment with vonoprazan versus 53% with lansoprazole (p=0.0004). In the maintenance phase of the trial both doses of vonoprazan (10 mg and 20 mg) met the primary endpoint of non-inferiority compared to lansoprazole in the number of all patients who maintained healing of erosive esophagitis through week 24. Further, both vonoprazan doses also met a pre-specified secondary endpoint demonstrating superiority of maintenance of healing versus lansoprazole (79% for vonoprazan 10 mg, 81% for vonoprazan 20 mg compared to 72% for lansoprazole 15 mg) (p&lt;0.0001 for both non-inferiority comparisons; p=0.0218 for vonoprazan 10 mg superiority comparison; p=0.0068 for vonoprazan 20 mg superiority comparison). Both vonoprazan doses also met the pre-specified secondary endpoint of demonstrating superiority of the percentage of patients with moderate-to-severe disease who maintained healing of erosive esophagitis through week 24 (75% vonoprazan 10 mg, 77% vonoprazan 20 mg v. 61% lansoprazole 15 mg) (p=0.0245 for vonoprazan 10 mg superiority comparison; p=0.0098 for vonoprazan 20 mg superiority comparison).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In PHALCON-EE, vonoprazan 20 mg met the secondary endpoint of showing non-inferiority to lansoprazole 30 mg in the mean percentage of 24-hour heartburn free days over the healing period, and both vonoprazan doses met the secondary endpoint of showing non-inferiority to lansoprazole 15 mg in the mean percentage of 24-hour heartburn free days over the maintenance period. Finally, vonoprazan 20 mg was also compared to lansoprazole 30 mg in a superiority test for onset of sustained resolution of heartburn by day 3 of the healing phase but did not achieve statistical significance (p=0.2196).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A p-value is the probability that the reported result was achieved purely by chance, such that a p-value of less than or equal to 0.05 or 0.01 means that there is a 5.0% or 1.0% or less probability, respectively, that the difference between the control group and the treatment group is purely due to chance. A p-value of 0.05 or less typically represents a statistically significant result.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The results from PHALCON-EE were consistent with the results of four Phase 3 clinical trials previously conducted by Takeda, two in each of Japan and China, assessing vonoprazan versus lansoprazole in the healing and maintenance of healing of erosive esophagitis in which vonoprazan met its primary endpoint in demonstrating non-inferiority to lansoprazole.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Non-erosive esophagitis.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In PHALCON-NERD, a Phase 2 study evaluating three doses of vonoprazan (10 mg, 20 mg, and 40 mg) as an on-demand therapy for relief of episodic heartburn in subjects with NERD, all three vonoprazan doses successfully met the primary endpoint evaluating the percentage of heartburn episodes completely relieved within three hours with relief sustained for over 24 hours and were statistically significant (p&lt;0.0001) when compared to placebo. Within three hours, vonoprazan 10 mg, 20 mg, and 40 mg achieved complete and sustained relief in 56.0%, 60.6% and 70.0% of evaluable heartburn episodes, respectively, as compared to 27.3% of episodes for placebo. An evaluable heartburn episode is a heartburn episode for which the participant completes a minimum of one timed assessment after taking study medication.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2022, we initiated a Phase 3 study evaluating vonoprazan 10 mg and 20 mg as daily dosing, or QD, therapy for the treatment of NERD, and we expect topline results from this study in 2023. Further, based on the positive Phase 2 NERD on-demand data, we plan to discuss with the FDA a Phase 3 trial design to support the novel dosing regimen for vonoprazan as an on-demand treatment for episodic heartburn relief in patients with NERD, a dosing treatment regimen not approved in the U.S. for PPIs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We also conducted PHALCON-HP, a Phase 3 clinical trial in the United States and Europe studying two vonoprazan-based treatment regimens for the eradication of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection, both of which successfully met their primary endpoints and all secondary endpoints. The trial studied vonoprazan triple therapy and vonoprazan dual therapy compared to lansoprazole in combination with amoxicillin and clarithromycin, or lansoprazole triple therapy. The objective of the PHALCON-HP trial was to compare eradication rates in all treated subjects as well as in two pre-identified subgroups of patients: those patients with clarithromycin resistant strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and those patients who did not have clarithromycin or amoxicillin resistant strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> For regulatory purposes, the primary endpoint of this study was a non-inferiority comparison in the non-resistant subgroup for each of vonoprazan triple therapy and vonoprazan dual therapy compared to lansoprazole triple therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">    </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In PHALCON-HP, both vonoprazan-based regimens successfully met their primary endpoints. In the modified intent-to-treat (mITT) population, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> eradication rates were 84.7% for vonoprazan triple therapy and 78.5% for vonoprazan dual therapy compared to 78.8% with lansoprazole triple therapy (p&lt;0.0001 and p=0.0037, respectively, for non-inferiority). In the pre-specified per protocol population, a subset of the mITT population comprised of patients who were protocol compliant, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> eradication rates were 90.4% with vonoprazan triple therapy and 81.2% with vonoprazan dual therapy compared to 82.1% with lansoprazole triple therapy (p&lt;0.0001 and p=0.0077, respectively, for non-inferiority).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In PHALCON-HP vonoprazan triple therapy and vonoprazan dual therapy also met all secondary endpoints, demonstrating superior eradication rates versus lansoprazole triple therapy in all patients and in the subgroup of patients with clarithromycin resistant strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Among all patients, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> eradication rate of vonoprazan triple therapy was superior to that of lansoprazole triple therapy in both the mITT population (80.8% vs. 68.5%; p=0.0001) and the per protocol population (85.7% vs. 70.0%; p&lt;0.0001). In the subset of patients with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> strains resistant to clarithromycin, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">eradication rate with vonoprazan triple therapy was superior to that of lansoprazole triple therapy in both the mITT population (65.8% vs. 31.9%; p&lt;0.0001) and the per protocol population (67.2% vs. 29.0%; p&lt;0.0001).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Among all patients, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> eradication rate of vonoprazan dual therapy was superior to that of lansoprazole triple therapy in both the mITT population (77.2% vs. 68.5%; p=0.0063) and the per protocol population (81.1% vs. 70.0%; p=0.0013). The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> eradication rate of vonoprazan dual therapy was also superior to that of lansoprazole triple therapy in the subset of patients with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> strains resistant to clarithromycin in both the mITT population (69.6% vs. 31.9%; p&lt;0.0001) and the per protocol population (79.5% vs. 29.0%; p&lt;0.0001).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The vonoprazan triple therapy results of PHALCON-HP were consistent with the results of a Phase 3 clinical trial previously conducted by Takeda in Japan assessing vonoprazan in combination with the antibiotics amoxicillin and clarithromycin versus lansoprazole in combination with these same antibiotics in first line treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection at antibiotic doses and treatment duration (7 days) consistent with local practice in Japan. Vonoprazan dual therapy was not tested in this study.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management team has deep expertise in developing GI therapeutics, including anti-secretory agents, and direct experience developing vonoprazan at Takeda. Our Chief Executive Officer, Terrie Curran, has more than 20 years of experience in the biopharmaceutical industry. Ms. Curran served as President, Global Inflammation and Immunology (I&amp;I) Franchise and as a member of the Executive Committee at Celgene Corporation from 2017 to 2019. Ms. Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&amp;I Franchise, built the capabilities and recruited the teams that executed the successful launch of OTEZLA, which was sold to Amgen in November 2019 for $13.4 billion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Azmi Nabulsi, M.D., M.P.H., our Chief Operating Officer, is the former Deputy Chief Medical and Scientific Officer at Takeda. Our Head of Regulatory, Tom Harris, is the former Senior Vice President and Head of Global Regulatory at Takeda. Dr. Nabulsi and Mr. Harris were extensively involved with the development of vonoprazan at Takeda.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Pipeline</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following chart summarizes our current development programs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img45497886_0.jpg" alt="img45497886_0.jpg" style="width:624px;height:317px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our mission is to improve the lives of people suffering from gastrointestinal diseases. Our strategy is initially focused on developing and commercializing vonoprazan as a potential first-in-class P-CAB in the United States, Europe, and Canada for the treatment of acid-related GI diseases. Key elements of this strategy include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Obtain marketing approval of, and commercially launch, vonoprazan in erosive esophagitis and H. pylori infection</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In 2021, we reported positive topline data from Phase 3 clinical trials of vonoprazan in each of erosive esophagitis and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection. In September 2021, we submitted, and in November 2021, the FDA accepted for filing and granted Priority Review to our NDAs for vonoprazan triple therapy and vonoprazan dual therapy with a PDUFA action date of May 3, 2022. In March 2022 we plan to submit an NDA for vonoprazan in healing of all grades of erosive esophagitis and relief of heartburn, and maintenance of healing of all grades of erosive esophagitis and relief of heartburn. If the NDAs are approved by the PDUFA date, we expect to launch vonoprazan in the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection in the second half of 2022, and in erosive esophagitis in 2023. Further, if vonoprazan is approved by the FDA as a new chemical entity, we expect that vonoprazan would receive a five-year period of marketing exclusivity within the United States and QIDP designation could extend the U.S. marketing exclusivity for an additional five years.        </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Advance the clinical development of vonoprazan in non-erosive reflux disease or NERD and seek marketing approval.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Non-erosive reflux disease, or NERD, is a major subcategory of GERD and is characterized by reflux-related symptoms in the absence of esophageal mucosal erosions. We are pursuing development of vonoprazan for treatment of NERD as both an on-demand and as a continuously dosed (daily) therapy for patients with NERD. In February 2022, we initiated a Phase 3 trial of vonoprazan in patients with NERD that is evaluating a once-daily dosing regimen and expect to report topline results from that trial in 2023. Also in February 2022, we reported positive topline data from a Phase 2 trial evaluating various doses of vonoprazan as an on-demand therapy for NERD. We intend to discuss the results from this Phase 2 trial with FDA prior to finalizing the design of our Phase 3 NERD on-demand trial.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Commercialize vonoprazan in the United States</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We plan to independently commercialize vonoprazan, if approved, in the United States by building a leading specialty gastroenterology commercial infrastructure to support the adoption of vonoprazan. We believe we can successfully launch vonoprazan in the United States with a focused sales force targeting prescribers of treatments for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and GERD, particularly gastroenterologists. Prescriptions for treatments for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and GERD are both highly concentrated, with approximately 75% of prescriptions in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and 65% of prescriptions in erosive esophagitis being written by 10% of physicians We believe we have an opportunity to achieve significant share of voice and exposure to physicians given the scarcity of actively marketed anti-secretory medicines. Given the limitations of PPIs and current unmet need, we believe the commercial opportunity for vonoprazan is substantial.  </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Seek commercial partnerships to maximize the vonoprazan opportunity outside of the United States</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  To address the opportunity for vonoprazan in Europe and Canada, we plan to seek one or more partners with existing commercial infrastructure and expertise in these markets. We believe this strategy will allow us to realize the value of the market opportunity in Europe and Canada while focusing our resources on the U.S. market. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Further expand the development of vonoprazan across indications, dosing regimens, and alternative formulations and packaging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In addition to NERD, we plan to pursue vonoprazan lifecycle extension strategies in areas with clear unmet need, clinical rationale, and commercial justification. These strategies may include: (i) additional potential indications, including treatment of gastric ulcers and duodenal ulcers, Barrett&#x2019;s esophagus, and eosinophilic esophagitis; and (ii) alternative formulations and packaging, such as orally disintegrating tablets and other oral dosage forms for patients with difficulty swallowing, and an intravenous formulation for in-hospital applications. Additionally, we believe that vonoprazan has the ideal profile for an OTC product because of the potential for on-demand symptom relief and a well-tolerated safety profile.  </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">In-license or acquire additional clinical or commercial stage product candidates for the treatment of GI diseases in a capital efficient manner</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We intend to take advantage of our management team&#x2019;s GI expertise to opportunistically in-license or acquire additional innovative therapies for diseases treated by gastroenterologists. We plan to leverage our development and planned commercial infrastructure to support multiple assets targeting GI indications. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Acid-Related GI Diseases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gastric acid is a digestive fluid formed in the stomach. The highly acidic environment of the stomach causes the unfolding, or denaturing, of food proteins that are subsequently broken down by gastric enzymes. Gastric acid is secreted by the hydrogen potassium ATPase enzyme, which is known as the proton pump. Proton pumps are expressed on the channeled surfaces, or canaliculi, of parietal cells in the stomach, which secrete acid. Proton pumps are continuously synthesized and switch between active and inactive states in response to various stimuli, such as food. When activated, proton pumps increase acid secretion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GI diseases where treatment is related to acid control, such as GERD, peptic ulcer disease, Zollinger Ellison syndrome, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection, are significant medical problems because of their high prevalence, chronic nature and clinical sequelae. GERD results from the effects of acid on compromised mucosal defenses in the gastrointestinal tract. The reflux of gastric acid into the esophagus produces frequent and/or severe heartburn, indigestion, and reflux symptoms. Chronic GERD may damage esophageal tissue and progress to more severe diseases including erosive esophagitis, Barrett&#x2019;s esophagus, and esophageal cancer. GERD and related diseases are associated with impaired quality of life and substantial costs to the healthcare system given their chronic nature and sequelae. In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection, gastric acid limits the effectiveness of antibiotics used to eradicate infection. Chronic </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection can lead to dyspepsia, peptic ulcer disease, gastric cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Prevalence</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The prevalence of GI diseases is high. Approximately 20% to 40% of Western adults report chronic heartburn or regurgitation symptoms potentially related to GERD. We estimate that there are approximately 65 million individuals in the United States and 50 million individuals in the EU5 with GERD. In the United States, GERD is the most common gastroenterology-related outpatient diagnosis. Additionally, approximately 35% of the U.S. population and 45% of the EU5 population are infected with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We estimate that there are approximately 115 million individuals in the United States and 145 million individuals in the EU5 infected with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Prevalence of GERD and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Infection</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img45497886_1.jpg" alt="img45497886_1.jpg" style="width:623px;height:222px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Treatments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Treatments of acid-related GI diseases aim to provide relief of acute symptoms, healing of damaged tissue, and prevention of long-term clinical sequelae associated with chronic acid exposure. Gastric acidity is measured by the pH scale, a logarithmic scale where 7.0 describes a neutral state and lower levels indicate a higher level of acidity. The pH of the stomach typically ranges from 1.5 to 3.5. In patients with acid-related GI diseases, increasing gastric pH has been shown to improve mucosal healing rates and provide more rapid symptom relief for patients. For example, the duration of time that intra-gastric acidity is greater than pH 3.0 correlates with the healing of duodenal and gastric ulcers, and pH greater than 4.0 is correlated with the healing of erosive esophagitis. Similarly, in patients with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection, a more neutral gastric pH of 6.0 to 8.0 preserves antibiotic function and is optimal for successful eradication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Drug-induced gastric acid suppression is a key component of the management of acid-related GI diseases. Three classes of drugs with distinct mechanisms of action are principally used for treatment in the United States and Europe: antacids, histamine receptor antagonists, or H2RAs, and PPIs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Antacids</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Antacids, first commercially available in the 1930s, directly neutralize gastric acid to raise intra-gastric pH and can alleviate intermittent, mild symptoms of acid-related GI diseases, such as heartburn, but they are only effective for a short duration and require frequent administrations per day. In addition, antacids do not significantly help heal or prevent complications of acid-related diseases. Antacids include commonly-known OTC products, such as Alka-Seltzer, Pepto-Bismol, Rolaids, and TUMS.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Histamine Receptor Antagonists (H2RAs)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">H2RAs, first commercially available in the 1970s, decrease gastric acid secretion in order to raise gastric pH. H2RAs represented a dramatic improvement over antacids in the control of gastric acid and consequently in the management of acid-related GI diseases. H2RAs are also generally safe and well-tolerated. Among the H2RA class were the first commercial blockbuster drugs, Pepcid (famotidine), Tagamet (cimetidine), and Zantac (ranitidine). Zantac was the world&#x2019;s highest-selling prescription drug in the mid-1990s, with peak global sales of $3.7 billion and U.S. sales of $2.2 billion. Prior to the launch of generic H2RAs and increasing competition from PPIs, the H2RA class achieved sales of approximately $3.5 billion in the United States. H2RAs achieved commercial success despite clinical limitations, including unreliable 24-hour acid control, poor control of post-meal symptoms, and loss of efficacy over time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Proton Pump Inhibitors (PPIs)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PPIs, first commercially available in 1989, offered improved acid control over H2RAs. Pharmacodynamic data demonstrated that PPIs maintain gastric pH above target levels for a longer duration than H2RAs. A commonly used benchmark of anti-secretory activity is the percentage of time in a 24-hour period that gastric pH exceeds 4.0, which we refer to as time above pH 4.0, which ranges from 40% to 71% for PPIs versus 33% for H2RAs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Given this improved pharmacodynamic profile, PPIs demonstrated improved clinical symptom relief and healing over H2RAs. In a meta-analysis of results from 33 randomized clinical trials with over 3,000 GERD patients, a reduction in symptoms was achieved in 83% of patients taking PPIs versus 60% of those on H2RAs. In a second meta-analysis, the eight-week healing rate in patients with erosive esophagitis was 82% for PPIs versus 52% for H2RAs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The PPI class is currently the first-line treatment of acid-related GI diseases. Prior to the introduction and adoption of generic and OTC alternatives, annual PPI class sales reached approximately $12.5 billion in the United States, and peak sales for individual brands were approximately $3.7 billion for Prilosec, $3.5 billion for Nexium, and $3.4 billion for Prevacid. As recently as 2015, the last branded PPI, Dexilant (dexlansoprazole), reached approximately $530 million in sales in the United States despite limited differentiation from other PPIs. While Dexilant demonstrated a modest improvement in time above pH 4.0 compared to other PPIs, the approved dose did not demonstrate consistent superiority in Phase 3 trials against other PPIs on the healing of erosive esophagitis and has not been tested against PPIs in other indications. We believe that the commercial success of Dexilant highlights the value to physicians and patients of even incremental improvements over other PPIs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">History of Pharmaceutical Agents for Control of Gastric Acid</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img45497886_2.jpg" alt="img45497886_2.jpg" style="width:624px;height:232px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PPI Limitations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While PPIs provide clinically meaningful symptom relief and healing for millions of patients suffering from acid-related GI diseases, they are inadequate for many patients. The suboptimal anti-secretory profile of PPIs results in slow onset of symptom relief, breakthrough nighttime or postprandial heartburn, and treatment failure. A recent population-based survey with over 70,000 participants in the United States showed that 55% of patients who reported having GERD symptoms were taking PPIs, with 68% taking them daily, and 54% of daily PPI users reported persistent symptoms. This is consistent with earlier studies that have shown that approximately 15% to 45% of GERD patients are inadequately treated with PPIs, experiencing persistent, troublesome symptoms, such as heartburn and regurgitation. In approximately two-thirds of symptomatic GERD patients, reflux symptoms are not adequately controlled after the first dose of a PPI, and nearly 50% of patients still suffer from symptoms three days later. Given these limitations, more than 20% of GERD patients on PPI therapy take their PPI twice daily, which is not FDA approved, or purchase OTC heartburn treatments in addition to their prescription medicine. In a survey of approximately 1,000 GERD patients and 1,000 physicians, approximately one third of GERD patients reported persistent symptoms and were dissatisfied with PPI therapy and 35% of physicians perceived patients as somewhat satisfied to completely dissatisfied with PPI treatment. In addition, in a real world study conducted in 2020 and 2021 evaluating the perspectives and unmet needs of over 400 physicians and patients in the U.S. in the management of acid related disorders, fewer than one-third of the physician participants were satisfied with current treatment options for their patients. Moreover, fewer than 50% of patients in the study reported they were satisfied with their current treatment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In patients with more severe grades of erosive esophagitis, studies with PPIs have reported failure rates of healing of esophageal erosions exceeding 25%. Additionally, recurrence of erosions is common in healed erosive esophagitis patients receiving maintenance PPI therapy. One study reported recurrence in 15% to 23% of patients with less severe erosive esophagitis and 24% to 41% of patients with more severe erosive esophagitis. We believe that these limitations of PPIs are in part driven by their mechanism of action and pharmacokinetics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Mechanistic Differences Between PPIs and Vonoprazan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">PPIs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After oral dosing, PPIs reach the gastric parietal cells through the bloodstream. PPIs are prodrugs that are converted to their active form in the acidic environment of the secretory canaliculus of the parietal cell but degrade quickly because their active form is unstable in acid. For example, the half-life of omeprazole (Prilosec) is less than 10 minutes at pH 2.0. The active form of a PPI blocks acid production by covalently binding to active proton pumps that have moved to the surface of the secretory canaliculi after activation of the parietal cell with stimuli, such as a meal. Because PPIs bind only to actively secreting pumps, it is generally recommended that they be administered 30 to 60 minutes before a meal to achieve maximal efficacy. Once covalently bound to the proton pumps, the active PPI molecule is no longer available to bind to newly synthesized or activated proton pumps. Furthermore, given the relatively short plasma half-life of most PPIs of one to two hours, resupply of additional PPI molecules from the bloodstream is limited, and newly activated pumps are not inhibited. Due to this profile, PPI dosing over several days is required to inhibit enough proton pumps to increase gastric pH to a clinically meaningful threshold, and PPIs have a limited window of efficacy leading to incomplete acid suppression over the 24-hour dosing interval. In addition, PPIs are primarily metabolized by CYP2C19, an enzyme which has significant interpatient metabolic variability based on genotype. As a result, PPI exposure levels in some patients may not achieve target levels, potentially reducing clinical efficacy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Vonoprazan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan has a differentiated mechanism of action from PPIs. Vonoprazan is designed to selectively concentrate in the parietal cell in both the resting and stimulated states. In contrast to most PPIs, vonoprazan does not require gastric acid for activation, remains stable in the presence of gastric acid, binds to the active proton pumps in a noncovalent and reversible manner and remains associated with the active and inactive proton pumps, and remains in the secretory canaliculus where it continues to inhibit acid secretion over an extended period. Vonoprazan&#x2019;s prolonged effect is also maintained through a slow dissociation rate from the proton pumps and resupply from the bloodstream due to its seven-hour half-life. These characteristics allow vonoprazan to rapidly achieve target 24-hour acid suppression within two hours of a single dose, unlike PPIs that require three to five days to achieve stable acid suppression. In addition, vonoprazan is primarily metabolized by CYP3A4/5, an enzyme which has less genetic variability than CYP2C19, and may exhibit more consistent activity than PPIs across U.S. and European populations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The mechanistic and pharmacologic differences of PPIs and vonoprazan are summarized in the table below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img45497886_3.jpg" alt="img45497886_3.jpg" style="width:427px;height:289px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan Pharmacodynamics vs. PPIs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan&#x2019;s more rapid, potent, and durable anti-secretory effects versus the PPI lansoprazole (Prevacid) were demonstrated in a randomized, open-label, crossover clinical trial comparing 20 mg of once daily, or QD, vonoprazan to 30 mg QD of lansoprazole for 7 days in 41 healthy volunteers. As shown below, vonoprazan had a significantly higher 24-hour holding time ratio than lansoprazole for pH&gt;4 on Day 1 (62.4% vs. 22.6%) and Day 7 (87.8% vs. 42.3%) and for pH&gt;6 on Day 1 (33.1 vs. 7.4) and Day 7 (62.5% vs. 16.4%). Mean 24-hour intragastric pH for vonoprazan and lansoprazole was 4.6 and 2.8, respectively, on Day 1, and 5.9 and 3.8, respectively, on Day 7. Gastric pH levels are measured on a logarithmic scale from 0.0 to 14.0, in which each point represents a 10-fold change in acidity and higher pH values represent lower acidity. In this study, vonoprazan maintained an average pH approximately two points higher than lansoprazole at Day 7.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">      </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Improved Onset and Potency of pH Control of Vonoprazan vs. Lansoprazole at Day 1 and Day 7</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img45497886_4.jpg" alt="img45497886_4.jpg" style="width:560px;height:248px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This improved potency and duration of pH control with vonoprazan, as measured by twenty-four hour pH hold time and time above pH 4.0, was evident not only at Day 1, but also at Day 7 when lansoprazole had reached its steady state (see table below).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">24-hr Hold Time and Time Above pH 4.0 of Vonoprazan vs. Lansoprazole at Day 1 and Day 7</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img45497886_5.jpg" alt="img45497886_5.jpg" style="width:560px;height:194px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan demonstrated similarly greater time above pH 4.0 versus the PPI esomeprazole (Nexium) in a randomized, open-label, crossover clinical trial comparing 20 mg QD vonoprazan to 20 mg QD of esomeprazole in 20 healthy volunteers. In that trial, greater duration of pH control with vonoprazan, as measured by time above pH 4.0 was observed both on Day 1 and Day 7 (see table below).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Improved Time Above pH 4.0 of Vonoprazan vs. Esomeprazole at Day 1 and Day 7</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img45497886_6.jpg" alt="img45497886_6.jpg" style="width:419px;height:150px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan for the Potential Treatment of Acid-Related GI Diseases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Given the shortcomings of PPI therapy, we believe that there is a significant unmet medical need for a safe and effective anti-secretory agent with rapid, potent, and durable activity. Vonoprazan was developed in markets outside of the United States by Takeda through an extensive clinical program, including 19 Phase 3 clinical trials. As of December 2021, over </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> subjects were exposed to vonoprazan in completed and ongoing clinical trials. In head-to-head Phase 3 trials versus a PPI conducted in the U.S. and Europe, vonoprazan demonstrated faster onset of healing in patients with moderate to severe erosive esophagitis, superior maintenance of healing of erosive esophagitis patients across all levels of severity, and superior eradication rates in combination with antibiotics in patients with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection than PPI-based triple therapy. Vonoprazan received marketing approval in Japan in late 2014 and generated approximately $850 million in net sales in its seventh full year on the market in Japan. In April 2021, we reported positive top-line data from our </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> trial, and in October 2021, we reported positive top-line data from our erosive esophagitis trial. In September 2021, we submitted NDAs for vonoprazan triple therapy and vonoprazan dual therapy, each for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection in adults, which were granted priority review and received a PDUFA action date of May 3, 2022, and we expect to submit an NDA for vonoprazan for the healing of all grades of erosive esophagitis and relief of heartburn, and maintenance of healing of all grades of erosive esophagitis and relief of heartburn, in March 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan in GERD</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on the significant unmet medical need, previous Phase 3 trial results from Japan and Asia, and commercial potential, we have prioritized the development and commercialization of vonoprazan in GERD, specifically:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the healing of erosive esophagitis and relief of heartburn; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the maintenance of healing of erosive esophagitis and relief of heartburn. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also initiated our first Phase 3 trial for vonoprazan in symptomatic non-erosive GERD, or NERD, in February 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">GERD Disease Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GERD is one of the most prevalent diseases of any kind and is the most prevalent GI disease, affecting approximately 20% of the U.S. population and approximately 15% of the European population. We estimate there are approximately 65 million individuals with GERD in the United States and 50 million individuals with GERD in the EU5. GERD is a disease that develops when the reflux of acidic stomach contents into the esophagus causes troublesome symptoms and/or complications, and the term covers a spectrum of diseases, the main categories of which are erosive esophagitis and non-erosive reflux disease. These diseases are detailed below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Erosive esophagitis</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: Approximately 30% of GERD patients have erosive esophagitis, which is classified by erosions in the gastric mucosa caused by acidic reflux of stomach contents into the esophagus. Erosive esophagitis is commonly graded by the Los Angeles classification system, which characterizes the extent of erosions in the esophagus and is graded on a scale of increasing severity from A to D, with D being the most severe. Approximately 20% to 30% of erosive esophagitis patients have the moderate to severe Los Angeles Class C or D disease. Erosive esophagitis can have serious consequences. If left untreated, esophagitis may develop into peptic stricture, Barrett&#x2019;s esophagus or esophageal cancer.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Non-erosive reflux disease (NERD)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: Approximately 70% of GERD patients have NERD, which is classified by an endoscopically normal esophagus, but abnormal gastric acid exposure in the esophagus and persistent symptoms. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img45497886_7.jpg" alt="img45497886_7.jpg" style="width:496px;height:219px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GERD patients typically present with heartburn and reflux symptoms. Based on these symptoms, patients are typically treated first-line with PPIs prior to a diagnostic endoscopy for specific disease classification of erosive esophagitis or NERD. Clinical guidelines suggest that endoscopy be performed in patients who continue to have symptoms despite a four- to-eight-week course of daily PPIs or have alarm symptoms, including GI bleeding, anemia, weight loss, chest pain, or difficult or painful swallowing. Our market research suggests that most patients are treated empirically based on symptoms rather than based on endoscopic characterization of disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">GERD Treatment Paradigm</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Approximately 80% of GERD patients are pharmacologically treated with prescription or OTC medications. PPIs are currently the most effective anti-secretory agents available in the United States and Europe for relieving GERD symptoms and healing erosions in gastric mucosa. Our market research suggests that approximately 80% of patients who are pharmacologically treated receive PPIs, and more than 80% of PPI use is prescription rather than OTC. The majority of PPI use is chronic, with more than 70% of patients prescribed PPIs for daily use. According to IQVIA NDTI, there were approximately 7.2 billion PPI doses prescribed for the 12 months ended December 31, 2021.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are few treatment options for GERD patients who are inadequately managed on PPI therapy. In a real world study conducted in 2020 and 2021 evaluating the perspectives and unmet needs of over 400 physicians and patients in the U.S. in the management of acid related disorders, only half of physicians reported that their patients are getting long-lasting relief from a PPI resulting in approximately 25% of patients taking a PPI more than once a day despite patients&#x2019; concerns about long term side effects of PPI use. A limited number of patients proceed to a surgical procedure, such as Nissen fundoplication. However, this procedure results in postoperative morbidity of 5% to 20%, as well as a two- to six-week recovery period and a median hospital stay of two days.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan has the potential to be the first gastric anti-secretory agent from a novel class approved in the United States, Europe, or Canada in over 30 years. Our U.S. market research survey reported that 55% to 60% of physicians included in the survey believed that vonoprazan has demonstrated superior efficacy in the healing and maintenance of healed esophageal erosions compared to existing EE treatments, provides faster onset of action compared to existing GERD treatments, and has superior duration and magnitude of gastric pH control compared to existing GERD treatments.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Data for Vonoprazan in GERD</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Five Phase 3 clinical trials have been completed comparing vonoprazan to PPIs in erosive esophagitis: our healing and maintenance of healing trial in the United States and Europe; a healing trial in Japan; a maintenance of healing trial in Japan; a healing trial in Asia (China, Taiwan, and Korea); and a maintenance of healing trial in Asia. In addition to these Phase 3 trials, several published investigator-sponsored studies have compared vonoprazan to PPIs across dosing regimens and endpoints. Results of these clinical trials are summarized below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Healing and Maintenance of Healing of Erosive Esophagitis in the United States and Europe (PHALCON-EE)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2021, we announced that vonoprazan successfully met its primary endpoints and key secondary superiority endpoints in PHALCON-EE, our pivotal Phase 3 trial evaluating vonoprazan versus lansoprazole for the treatment of erosive esophagitis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Design for PHALCON-EE Phase 3 Erosive Esophagitis Clinical Trial</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PHALCON-EE was a randomized, double-blind, two-phase, multicenter, Phase 3 trial that enrolled 1,024 patients with EE in the U.S. and Europe. PHALCON-EE was modeled after the successful Phase 3 clinical trials conducted in Japan and Asia with limited differences, including the combination of the healing and maintenance phases into one single study whereas in Japan and Asia separate clinical trials were conducted for each of these indications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The first phase of the trial, the Healing Phase, evaluated the efficacy and safety of vonoprazan 20 mg QD compared to lansoprazole 30 mg QD for the healing of EE for up to eight weeks. In the Healing Phase, patients were assessed via endoscopy to determine complete healing following 2 weeks of treatment and, if complete healing was not achieved, a second endoscopy occurred at 8 weeks of treatment. Patients who achieved complete healing were re-randomized into the second phase of the trial, the Maintenance Phase, where vonoprazan 10 mg and 20 mg were compared to lansoprazole 15 mg to assess maintenance of healing of EE via endoscopy following 24 weeks of treatment. Heartburn symptom relief was assessed via secondary endpoints in both the Healing and Maintenance Phases of the study based on twice daily e-diary data collection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Design of US/EU Phase 3 Clinical Trial for the Healing and Maintenance of Healing of Erosive Esophagitis</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img45497886_8.jpg" alt="img45497886_8.jpg" style="width:602px;height:207px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Healing Phase</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The primary endpoint analysis of the Healing Phase was non-inferiority of vonoprazan 20 mg compared to lansoprazole 30 mg in the percentage of all patients who have complete healing of EE by Week 8. Vonoprazan met the non-inferiority criteria for the primary comparison with a healing rate of 93% compared to 85% for lansoprazole (np&lt;0.0001). Based on a prespecified exploratory comparison test, the difference in healing rates in all patients between vonoprazan and lansoprazole was also significant (nominal p&lt;0.0001). Non-inferiority analyses are conducted to evaluate whether the effect of an agent is not worse than the active control by more than a specified margin, while superiority analyses are conducted to evaluate whether an agent outperformed a comparator by a statistically significant margin.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan met the secondary superiority endpoint of healing in patients with moderate-to-severe disease, defined as patients with esophageal erosions classified as Grades C or D by the Los Angeles (LA) Classification System, at Week 2, demonstrating significantly faster healing than lansoprazole (70% for vonoprazan 20 mg and 53% for lansoprazole 30 mg) (p=0.0004). Vonoprazan also met the secondary endpoint of showing non-inferiority to lansoprazole 30 mg in the mean percentage of 24-hour heartburn free days over the healing period. In additional pre-specified secondary endpoint superiority comparisons, vonoprazan 20 mg healing rates were numerically greater than lansoprazole 30 mg in all patients at Week 2 (nominal p=0.0174) and in moderate-to-severe patients by Week 8 (nominal p&lt;0.0001), although these superiority comparisons were not tested in the pre-specified testing hierarchy.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan 20 mg was also compared to lansoprazole 30 mg in a superiority test for onset of sustained resolution of heartburn by day 3 but did not achieve statistical significance (p=0.2196).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Results of US/EU Phase 3 Clinical Trial in the Healing of Erosive Esophagitis</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img45497886_9.jpg" alt="img45497886_9.jpg" style="width:602px;height:259px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Maintenance Phase</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan met the primary and all secondary endpoints in the Maintenance Phase. The primary endpoint of the Maintenance Phase was non-inferiority of vonoprazan 10 mg and 20 mg compared to lansoprazole 15 mg in the percentage of all patients who maintained healing of EE through Week 24.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Both vonoprazan doses met the Maintenance Phase primary endpoint of non-inferiority while also meeting the pre-specified secondary comparison demonstrating superiority of maintenance of healing versus lansoprazole (79% for vonoprazan 10 mg, 81% for vonoprazan 20 mg compared to 72% for lansoprazole 15 mg) (p&lt;0.0001 for both non-inferiority comparisons; p=0.0218 for vonoprazan 10 mg superiority comparison; p=0.0068 for vonoprazan 20 mg superiority comparison).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Both vonoprazan doses also met the secondary endpoint of demonstrating superiority of the percentage of patients with moderate-to-severe disease who maintained healing of EE through Week 24 (75% vonoprazan 10 mg, 77% vonoprazan 20 mg v. 61% lansoprazole 15 mg) (p=0.0245 for vonoprazan 10 mg superiority comparison; p=0.0098 for vonoprazan 20 mg superiority comparison). Additionally, both vonoprazan doses also met the secondary endpoint of showing non-inferiority to lansoprazole 15 mg in the mean percentage of 24-hour heartburn free days over the maintenance period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Results of US/EU Phase 3 Clinical Trial in Maintenance of Healing of Erosive Esophagitis</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img45497886_10.jpg" alt="img45497886_10.jpg" style="width:602px;height:259px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Healing and Maintenance of Healing of Erosive Esophagitis Clinical Trials in Japan and Asia</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The results of PHALCON-EE were consistent with the results of earlier Phase 3 trials of vonoprazan in healing and maintenance of healing of erosive esophagitis after which it was modeled. These trials were conducted in Japan as well as other countries in Asia.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In two Phase 3 trials in healing of erosive esophagitis comparing vonoprazan 20 mg QD to lansoprazole 30 mg QD for up to eight weeks, one conducted in Japan and the other in several countries in Asia, vonoprazan achieved the primary endpoint of non-inferiority versus lansoprazole on the percent of patients with healed erosive esophagitis up to Week 8. Exploratory testing suggested higher healing rates for vonoprazan versus lansoprazole in the moderate to severe patients at Week 2 in both studies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Similarly, in two Phase 3 trials in maintenance of healing of erosive esophagitis comparing two doses of vonoprazan (10 mg and 20 mg QD) to lansoprazole 15 mg QD for 24 weeks, one conducted in Japan and the other in several countries in Asia, both vonoprazan doses achieved the primary endpoint of non-inferiority versus lansoprazole on the percent of patients with recurrence of erosive esophagitis during the 24-week maintenance period. In both studies, exploratory testing suggested higher maintenance of healing rates for both vonoprazan doses versus lansoprazole in all patients and in the moderate to severe patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Development Program in Symptomatic Non-Erosive Reflux Disease (NERD)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that there is opportunity to broadly position vonoprazan&#x2019;s use in GERD with an indication in symptomatic GERD in patients without erosions, or NERD, in addition to an indication in erosive esophagitis. We are evaluating vonoprazan as a treatment for NERD with both daily and on-demand, or as-needed, dosing regimens. NERD patients do not have esophageal erosions which require chronic treatment to prevent recurrence of erosions and its potential sequelae. We believe the rapid onset of acid control of vonoprazan may enable on-demand use for the management of heartburn in NERD patients as an alternative to chronic daily treatment with PPIs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">On Demand Dosing of Vonoprazan for the Treatment of NERD</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2022, we announced that vonoprazan (10 mg, 20 mg and 40 mg), successfully met the primary endpoint in PHALCON-NERD, a Phase 2 trial evaluating three doses of vonoprazan versus placebo as an on-demand treatment of NERD.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Design for PHALCON-NERD Phase 2 NERD On-Demand Clinical</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PHALCON-NERD was a Phase 2, randomized, double-blind, multicenter study that enrolled 458 subjects in the U.S. to evaluate the efficacy and safety of vonoprazan 10 mg, 20 mg, and 40 mg administered on demand for relief of episodic heartburn compared to placebo in subjects with symptomatic NERD (as confirmed by endoscopy).  After an initial four week vonoprazan 20 mg QD dose open-label run-in period, two hundred and seven subjects with no heartburn on the last 7 days of the run-in period who also met drug and diary compliance requirements were randomized to receive vonoprazan 10 mg, 20 mg, 40 mg or placebo on-demand for six weeks. Subjects completed an electronic diary to assess presence and severity of heartburn symptoms and use of rescue antacid (if needed).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img45497886_11.jpg" alt="img45497886_11.jpg" style="width:623px;height:296px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In this Phase 2 proof -of-concept trial, the primary endpoint was the percentage of heartburn episodes completely relieved within 3 hours and with no further heartburn reported for 24 hours after taking study drug. Within three hours, vonoprazan 10 mg, 20 mg, and 40 mg achieved complete and sustained relief in 56.0%, 60.6% and 70.0% of evaluable heartburn episodes, respectively, as compared to 27.3% of episodes for placebo.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The PHALCON-NERD open-label daily dosing run-in phase, where all participants enrolled received vonoprazan 20 mg QD for four weeks, the mean percentage of 24-hour heartburn free days observed was 65.4% (median 76.0%) over this treatment period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Results of Phase 2 NERD On Demand Dosing Trial</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img45497886_12.jpg" alt="img45497886_12.jpg" style="width:614px;height:375px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Daily Dosing of Vonoprazan for the Treatment of NERD (NERD-301)</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We initiated a single Phase 3 clinical trial of vonoprazan in symptomatic NERD in February 2022. Our trial explores both vonoprazan10 mg and 20 mg doses in the Phase 3 daily dosing study. The primary endpoint of this trial is the percentage of 24-hour heartburn-free days (without daytime or nighttime heartburn as assessed by daily diary) for each vonoprazan treatment group compared to placebo. This is the same endpoint used in other Phase 3 trials for PPIs that are approved for the treatment of NERD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">    </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Design for NERD-301 Phase 3 NERD Continuous Dosing Clinical Trial</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">NERD-301 is a Phase 3, multicenter, double-blind study of vonoprazan versus placebo assessing the relief of heartburn. Approximately 750 subjects with NERD (as confirmed by endoscopy) and heartburn symptoms will be randomized to receive vonoprazan 10 mg, vonoprazan 20 mg, or placebo QD for 4 weeks. Subjects will complete an electronic diary twice daily to record the presence and maximum severity of daytime and nighttime heartburn symptoms and use of study-supplied rescue antacid throughout the study. After the placebo-controlled treatment period, all subjects will receive blinded vonoprazan (10 mg or 20 mg QD) in a 20 week extension period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img45497886_13.jpg" alt="img45497886_13.jpg" style="width:612px;height:278px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to report topline data from this clinical trial in 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Prior Clinical Trials of Vonoprazan for the Treatment of NERD</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Takeda conducted two Phase 3 multicenter, randomized, double-blind, parallel group trials with vonoprazan in Japanese patients with endoscopically confirmed NERD. In the first clinical trial, vonoprazan demonstrated a significant reduction in symptom severity versus placebo (p=0.0139), and in the second trial, vonoprazan demonstrated a faster onset of symptom relief versus placebo (p=0.0003). However, the studies did not show a statistically significant difference in the primary endpoint of proportion of days over a 4-week period without heartburn between vonoprazan and placebo (p=0.0504 and p=0.0643). We believe that the design of these trials may have contributed to their results. For example, the first trial, which studied vonoprazan 10 mg and 20 mg, included a 1-week single blind antacid run-in period where patients were instructed to take antacids after each meal, 3 times per day. Only those patients who did not respond to the antacid treatment were randomized into the double-blind portion of the trial. We believe this design unintentionally enriched the study with patients with non-acid related, or functional disease. In contrast, none of the PPI placebo-controlled continuous dosing studies that were used for U.S. registration employed an antacid run-in period. A high number of subjects suffering from functional heartburn might explain the unusually low response rates seen in this trial both for placebo (7%) and the vonoprazan test regimens (10-12%). In addition, nearly 40% of all patients in this study did not experience a single heartburn free day during the 4 weeks of the study, which in our view is suggestive of a highly prevalent functional heartburn patient population.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the second study, the single-blind run-in period was changed to be a placebo run-in, where responders would not be eligible for double-blind period; added a specific exclusion criterion for functional heartburn; reduced the diary collection period from twice daily to once daily; and dropped the 20 mg dose choosing to study the 10 mg dose. In contrast to the first study, this study produced historically high placebo response rate (62%). Nevertheless, the data in this study show a clearer benefit of vonoprazan (73%) over placebo than the first study. While the primary endpoint of heartburn free days missed significance (p= 0.0643) due to the high placebo response, we believe this study shows that vonoprazan demonstrates improvement in NERD compared to placebo. We believe that reducing the diary to once daily may have contributed to a higher placebo response, and that not including the 20 mg dose prevented this trial from having its best chance at succeeding.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PPI NERD trials conducted in Japan have generally seen higher placebo response rates and reduced effect sizes than the U.S. PPI NERD counterpart studies. We think this is related to regional variations in identifying true heartburn over other GI related symptoms. Accordingly, we have decided to conduct our initial NERD study only at sites located in the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, in a Phase 2 clinical trial in European patients with NERD who were partial responders to high dose PPIs, vonoprazan did not demonstrate superiority versus esomeprazole in the primary endpoint of the percentage of heartburn free days over the four-week treatment period. As was the case with the NERD trials conducted by Takeda in Japanese patients, we believe this result may have been due to inclusion of patients with GI disorders unrelated to acid.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan in Combination with Antibiotics for the Treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Infection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Disease Burden and Outcomes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is a bacterial pathogen that infects approximately 35% of the U.S. population, 45% of the EU5 population, and more than 50% of the global population. We estimate that there are approximately 115 million individuals in the United States and 145 million individuals in the EU5 infected with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and we believe there are approximately 2.5 million patients treated for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection in the United States each year. As a result of the chronic inflammation induced by </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection, approximately 20% of infected patients develop a range of pathologies including dyspepsia, peptic ulcer disease, gastric cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma. Gastric cancer is the third most common cause of cancer-related death worldwide, and over 80% of gastric cancers are attributed to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection. Globally there are more than one million new cases of gastric cancer and approximately 782,000 deaths each year. Eradication of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection has been proven to reduce the incidence of gastric cancer, and the American College of Gastroenterologists, or ACG, guidelines recommend treatment for all patients diagnosed with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> eradication rates from the 1990s have fallen to current rates of &lt;80% due to increasing antibiotic resistance. In 2017, the World Health Organization (WHO) listed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> among the 16 antibiotic-resistant bacteria that pose the greatest threat to human health and designated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as a Class 1 carcinogen, meaning that it is a definite known cause of cancer. In 2014, the FDA added </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to the agency&#x2019;s list of qualifying pathogens that have the potential to pose a serious threat to public health under the GAIN Act. We believe that vonoprazan-based treatment regimens have the potential to restore eradication rates to their original rates in the United States and Europe given the clinical and post-marketing experience in the Japanese market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A recent study compiled real-world health insurance claims data in Japan from 2008 to 2016 for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> eradication. Prior to vonoprazan&#x2019;s approval in late 2014, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> eradication rate across Japan fell to below 80% as shown in the figure below. Approximately one year after vonoprazan&#x2019;s launch, the eradication rate increased to greater than 85%. From January 2015 to March 2016, the eradication rate with PPI-containing regimens in Japan was between 78% and 82% while the eradication rate with vonoprazan-containing regimens was 91% across all patients in this analysis. Results are similar in an ongoing real-world study we are conducting using a different Japanese health insurance claims database. Among patients initiating vonoprazan or a PPI between January 2015 and January 2020 to treat </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection, 80% of PPI-treated patients and 93% of vonoprazan-treated patients did not receive a second line of triple therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Eradication Rate of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Infection in Japan Before and After Launch of Vonoprazan</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img45497886_14.jpg" alt="img45497886_14.jpg" style="width:467px;height:251px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In Japan, vonoprazan-containing regimens have become the most common first line treatment. One-year post launch, approximately 80% of all treated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-infected patients received vonoprazan-based regimens. In the ongoing study of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-infected patients, vonoprazan-based regimens overtook PPI-based regimens as the most common first-line treatment between 2015 and 2019. Within this Japanese database, the number of patients using vonoprazan-based regimens increased from 6,594 to 28,956 patients, while the number of patients using a PPI-based regimen decreased from 11,238 to 2,629, shown in the figure below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Uptake of Vonoprazan-Based vs. PPI-Based Therapy for First Line Treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Infection in Japan from 2015-2019</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img45497886_15.jpg" alt="img45497886_15.jpg" style="width:539px;height:327px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Current Treatment Paradigm in the United States and Europe</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ACG treatment guidelines for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection recommend using PPIs in conjunction with antibiotics to improve antibiotic efficacy against </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection. The use of anti-secretory agents enhances the effect of antibiotics in two ways. First, anti-secretory agents increase gastric pH, which in turn increases the stability of the antibiotics. For example, amoxicillin and clarithromycin are chemically unstable at the low pH typically found in the human stomach. Second, several antibiotics, including amoxicillin and clarithromycin, are most potent against </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> at the time of maximum bacterial replication, which occurs at pH 6.0 to 8.0. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is in a dormant state at lower pH values, which reduces the effectiveness of the antibiotics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The table below shows the minimum inhibitory concentration of antibiotic required to eradicate 90% of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in vitro, or MIC90. As pH increases, the amount of antibiotic required for 90% eradication decreases substantially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> MIC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Values as a Function of pH</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img45497886_16.jpg" alt="img45497886_16.jpg" style="width:359px;height:141px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A triple therapy regimen (PPI, clarithromycin, and either amoxicillin or metronidazole) is the regimen most commonly used in clinical practice for the first-line treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection. However, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">eradication rates with PPI triple therapy in the 1990s have fallen to current levels of &lt;80%, primarily due to increased resistance of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to clarithromycin and metronidazole. A recent meta-analysis indicates that U.S. resistance rates measured from 2012 to 2016 were 20% for clarithromycin, 29% for metronidazole, and 19% for levofloxacin. Additionally, in a U.S.-based study from 2021, 65.6% of tested </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was resistant to at least one antibiotic currently used for treatment, with resistance rates of 33% clarithromycin and approximately 30% for metronidazole and levofloxacin. These figures represent a marked increase from 2009 to 2011 for both clarithromycin and metronidazole, for which resistance was 9% for clarithromycin, 21% for metronidazole, and 11% for levofloxacin. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> resistance to amoxicillin remains low despite its use in most triple therapy regimens; resistance is generally &lt;2% among isolates in the United States and Europe. There is a similar trend of increasing resistance to key antibiotics in Europe.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Given the declining eradication rates for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, quadruple therapy is recommended as first-line treatment in areas with known high rates of clarithromycin or metronidazole resistance; however, our U.S. market research study reported that physicians prescribe quadruple therapy to only 17% of first-line patients. Due predominantly to considerations of convenience and patient compliance, approximately 75% physicians surveyed in our market research expressed a preference for convenience, or combination packs compared to individual bottles for both dual and triple therapy. Further, geographic patterns of resistance in the United States are poorly understood and treatment is largely empiric, with susceptibility testing rarely conducted prior to first-line treatment. Our U.S. market research study reported that only 8% and 16% of physicians conduct resistance testing prior to prescribing treatment for first-line and second-line </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In our U.S. market research study, physicians highlighted the need for more effective and simpler first-line treatment options. For the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection, surveyed physicians highlighted the need for improved eradication rates and more convenient dosing as key unmet needs. Over 50% of surveyed physicians agreed that vonoprazan dual or triple therapy provided a superior eradication rate in patients with clarithromycin-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and, on average, 48% and 47% reported a preference to use vonoprazan first line in patients with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection, and patients with refractory </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection, respectively.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our H. pylori Phase 3 Clinical Trial in the United States and Europe &#x2013; PHALCON-HP</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2021, we announced that in PHALCON-HP, our pivotal Phase 3 clinical trial for the eradication of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection, both vonoprazan-based regimens successfully met their primary endpoints and met all secondary endpoints. The trial studied vonoprazan triple therapy and vonoprazan dual therapy compared to lansoprazole triple therapy. We believe PHALCON-HP is the largest U.S. Phase 3 registration trial ever conducted in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection, randomizing 992 patients with confirmed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PHALCON-HP was a randomized, multicenter, Phase 3 trial that enrolled 1046 patients of which 992 patients with a confirmed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection were randomized to one of three arms:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">vonoprazan dual therapy</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: vonoprazan 20 mg BID and amoxicillin 1 g TID for 14 days (n=324); </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">vonoprazan triple therapy</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: vonoprazan 20 mg BID, amoxicillin 1000 mg BID and clarithromycin 500 mg BID for 14 days (n=338); and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">PPI triple therapy</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: lansoprazole 30 mg BID, amoxicillin 1000 mg BID and clarithromycin 500 mg BID for 14 days (n=330). </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The objective of the PHALCON-HP trial was to compare eradication rates in all treated subjects as well as in two pre-identified subgroups of patients: those patients with clarithromycin resistant strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and those patients who did not have clarithromycin or amoxicillin resistant strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> For regulatory purposes, the primary endpoint of this study was a non-inferiority comparison in the non-resistant subgroup for each of vonoprazan triple therapy and vonoprazan dual therapy compared to lansoprazole triple therapy. All endpoints measured the percentage of patients with successful eradication of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection as assessed by </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">13</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">C-urea breath test four weeks after completion of treatment. The primary analysis in the non-resistant population assessed the non-inferiority of vonoprazan dual therapy compared to lansoprazole triple therapy and vonoprazan triple therapy compared to lansoprazole triple therapy. Secondary analyses for superiority were conducted in all patients and in the subgroup of patients with clarithromycin-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection. Further efficacy analyses were conducted using the pre-specified per protocol population (n=822), which is comprised of patients who were protocol compliant as defined by FDA established criteria.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Design for PHALCON-HP Phase 3 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Clinical Trial</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img45497886_17.jpg" alt="img45497886_17.jpg" style="width:581px;height:205px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Primary endpoint analysis</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Both vonoprazan-based regimens successfully met their primary endpoints in the subset of patients with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> strains that were not shown to be resistant to clarithromycin or amoxicillin. In the mITT population</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">, H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">eradication rates were 84.7% with vonoprazan triple therapy and 78.5% for vonoprazan dual therapy compared to 78.8% with lansoprazole triple therapy (p&lt;0.0001 and p=0.0037, respectively, for non-inferiority).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the per protocol population, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">eradication rates were 90.4% with vonoprazan triple therapy and 81.2% with vonoprazan dual therapy compared to 82.1% with lansoprazole triple therapy (p&lt;0.0001 and p=0.0077, respectively, for non-inferiority).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Secondary endpoint analysis</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan triple therapy and vonoprazan dual therapy also met all secondary endpoints, and demonstrated superior eradication rates versus lansoprazole triple therapy in all patients and patients with clarithromycin resistant strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Patients with clarithromycin resistant strains comprised 20.3% of the PHALCON-HP study population.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan triple therapy</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">eradication rate of vonoprazan triple therapy was superior to that of lansoprazole triple therapy among all patients in both the mITT population (80.8% vs. 68.5%; p=0.0001) and the per protocol population (85.7% vs. 70.0%; p&lt;0.0001).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">eradication rate with vonoprazan triple therapy was superior to that of lansoprazole triple therapy in the subset of patients with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">strains resistant to clarithromycin in both the mITT population (65.8% vs. 31.9%; p&lt;0.0001) and the per protocol population (67.2% vs. 29.0%; p&lt;0.0001).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan dual therapy</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">eradication rate of vonoprazan dual therapy was superior to that of lansoprazole triple therapy among all patients in both the mITT population (77.2% vs. 68.5%; p=0.0063) and the per protocol population (81.1% vs. 70.0%; p=0.0013).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">eradication rate of vonoprazan dual therapy was superior to that of lansoprazole triple therapy in the subset of patients with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">strains resistant to clarithromycin in both the mITT population (69.6% vs. 31.9%; p&lt;0.0001) and the per protocol population (79.5% vs. 29.0%; p&lt;0.0001).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Results of US/EU Phase 3 Clinical Trial in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. Pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Infection</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Primary Endpoint Analysis &#x2013;Subjects without clarithromycin or amoxicillin resistant strains</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img45497886_18.jpg" alt="img45497886_18.jpg" style="width:602px;height:202px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Secondary Endpoint Analyses &#x2013; All subject and subjects with clarithromycin resistant strains</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img45497886_19.jpg" alt="img45497886_19.jpg" style="width:602px;height:302px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Antibiotic resistance and declining eradication rates are significant clinical issues, and we believe that vonoprazan triple therapy and vonoprazan dual therapy have the potential to provide improvements over PPI-based therapies in addressing each of these issues. Vonoprazan dual therapy also has potential to spare the use of clarithromycin, representing an opportunity both for effective treatment and sound antibiotic stewardship through the avoidance of an additional antibiotic. As an alternative to multi-antibiotic drug regimens, vonoprazan dual therapy might also help to limit the spread of resistance among other pathogenic bacteria within populations. In addition, the vonoprazan triple therapy and vonoprazan dual therapy will both be available in daily dosing blister cards inclusive of the appropriate antibiotic. We believe this convenience pack has the potential to enhance compliance in a category where full adherence to treatment regimen is often a challenge.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Convenience Pack for H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2021, we submitted NDAs for vonoprazan triple therapy and vonoprazan dual therapy for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection in adults, each as a pre-packaged convenience or combination pack with either clarithromycin and amoxicillin or amoxicillin alone. In November 2021, the FDA accepted our NDAs for filing and granted Priority Review with a PDUFA action date of May 3, 2022. If approved by the PDUFA date, we expect to launch convenience packs with vonoprazan dual therapy and vonoprazan triple therapy in the second half of 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Convenience packs have the potential to improve patient adherence and treatment outcomes, and we believe there is a meaningful market opportunity for such a product. In the United States, PrevPac was formerly marketed as a pre-packaged convenience pack of lansoprazole, clarithromycin, and amoxicillin and achieved peak sales of $150 million. In Japan, vonoprazan is marketed both as a stand-alone medicine as well as in pre-packaged convenience packs with either clarithromycin and amoxicillin (Vonosap) or metronidazole and amoxicillin (Vonopion).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 3 Clinical Trial in Japan of Vonoprazan in Combination with Antibiotics to Treat H. pylori Infection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The results of PHALCON-HP were consistent with the results of a Phase 3 clinical trial in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-positive patients completed in Japan. In that trial, patients were treated with either vonoprazan triple therapy (vonoprazan 20 mg BID, amoxicillin 750 mg BID, and clarithromycin (200 mg or 400 mg) BID) or lansoprazole triple therapy (lansoprazole 30 mg BID, amoxicillin 750 mg BID, and clarithromycin (200 mg or 400 mg) BID) for seven days as is customary in Japan. The primary endpoint of the clinical trial was confirmed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> eradication determined by </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">13</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">C-urea breath test. The primary analysis was non-inferiority, and additional analyses in the second line eradication rate and eradication rate in antibiotic-resistant subgroups were also conducted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan-based triple therapy demonstrated a non-inferior eradication rate of 93% compared to 76% for lansoprazole-based triple therapy (p&lt;0.0001). Post hoc analyses suggested that vonoprazan-based triple therapy was superior to lansoprazole-based triple therapy (p&lt;0.0001). Patients who were not eradicated on vonoprazan-based triple therapy or lansoprazole-based triple therapy were treated with a triple therapy regimen of vonoprazan, amoxicillin, and metronidazole. In this second-line setting, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> eradication rate with vonoprazan triple therapy was 98%. Exploratory analysis suggested that vonoprazan-based triple therapy had significantly higher eradication rates versus the lansoprazole-based triple therapy in the subgroup of subjects with clarithromycin resistant strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Summary of Vonoprazan Safety Data</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Safety in Clinical Studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 2021, over 8,000 subjects have been exposed to vonoprazan in completed and ongoing Phase 1 to 3 clinical trials. The doses studied have ranged from 1 to 120 mg with durations up to one year.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In PHALCON-HP, both vonoprazan-based regimens were generally well tolerated with safety results comparable to patients who received lansoprazole triple therapy. The most common adverse events (&#x2265;2.0%) reported in the vonoprazan triple therapy, vonoprazan dual therapy, and lansoprazole triple therapy arms, respectively, were diarrhea (4.0%, 5.2%, and 9.6%), dysgeusia (4.3%, 0.6%, and 6.1%), abdominal pain (2.3%, 2.6% and 2.9%), headache (2.6%, 1.4%, 1.4%), vulvovaginal candidiasis (2.3%, 1.4%, 1.2%), hypertension (2.0%, 1.1%, 0.9%), and nasopharyngitis (0.3%, 2.0%, 0.9%). Overall rates of discontinuation due to adverse events were 2.3% for vonoprazan triple therapy-treated patients, 0.9% for vonoprazan dual therapy-treated patients, and 1.2% for lansoprazole triple therapy-treated patients.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, the safety results for vonoprazan observed in PHALCON-EE were consistent with the results observed in prior clinical studies. In the healing phase of the study, the most common adverse events (&#x2265;2%) were abdominal pain (2.1% for vonoprazan and 1.2% for lansoprazole), diarrhea (2.1% for vonoprazan and 2.5% for lansoprazole). Rates of discontinuation due to adverse events in the healing phase were 1% for vonoprazan 20 mg and 2.2% for lansoprazole 30 mg.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the maintenance phase of the study, the most common adverse events (&#x2265;2%) were gastritis (2.7% vonoprazan 10 mg, 6.4% vonoprazan 20 mg, 2.7% lansoprazole), diarrhea (1.0% vonoprazan 10 mg, 2.7% vonoprazan 20 mg, 4.4% lansoprazole), abdominal pain (4.1% vonoprazan 10 mg, 5.4% vonoprazan 20 mg, 2.4% lansoprazole), dyspepsia (3.7% vonoprazan 10 mg, 4.1% vonoprazan 20 mg, 2.7% lansoprazole), gastroesophageal reflux disease (2.4% vonoprazan 10 mg, 3.7% vonoprazan 20 mg, 2.0 lansoprazole), hypertension (3.0% vonoprazan 10 mg, 3.4% vonoprazan 20 mg, 2.0% lansoprazole), liver function test (1.0% vonoprazan 10 mg, 2.0% vonoprazan 20 mg, 3.0% lansoprazole), and nausea (2.0% vonoprazan 10 mg, 1.4% vonoprazan 20 mg, 1.0% lansoprazole). Rates of discontinuation due to adverse events in the maintenance phase were 0.7% for vonoprazan10 mg, 2.7% for vonoprazan 20 mg, and 0.7% for lansoprazole.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Frequency of serious adverse events, or SAEs, in the healing phase were similar between vonoprazan 20 mg and lansoprazole 30 mg at 0.6%. In the maintenance phase, SAEs were reported in 4.7% of patients for vonoprazan 20 mg, 3.4% for vonoprazan 10 mg and 2.4% for lansoprazole 15 mg. Further, this clinical trial was conducted during the 2020-2021 global pandemic, and coronavirus infection was reported in 2.1% of the vonoprazan 20 mg-treated patients and 1.8% of the lansoprazole-treated patients in the healing phase whereas in 6.1% of the vonoprazan 10 mg-treated patients, 10.1% of the vonoprazan 20 mg-treated patients and 6.7% of the lansoprazole-treated patients in the maintenance phase. There were 2 deaths in the vonoprazan 20 mg-treated patients due to coronavirus infection. None of the coronavirus infection events reported were considered related by the investigator.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In PHALCON-NERD, vonoprazan was generally well tolerated. In both phases of the trial, no adverse event was reported in more than three percent of the participants in a treatment group. There was a total of four SAEs in the daily dosing phase and no SAEs in the on-demand phase. The safety data for all vonoprazan arms were comparable to placebo and consistent with what was reported in previous studies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain earlier generation P-CABs previously under development by other companies may have been discontinued in-part due to their hepatic safety profile. These hepatic safety concerns may be compound-specific and not generalizable to the P-CAB class. It is notable that vonoprazan is based on a pyrrole chemical structure and is chemically distinct from previously discontinued P-CABs that were based on an imidazole structure. Vonoprazan has had a similar hepatic safety profile to lansoprazole across all clinical studies conducted by Takeda, in which 1.0% of subjects treated with vonoprazan 10 mg or 20 mg and 0.8% of subjects treated with lansoprazole 15 mg or 30 mg had ALT or AST elevations greater than three times the upper limit of normal or bilirubin elevations greater than two times the upper limit of normal. Similarly, in the healing phase of PHALCON-EE, transient elevations in ALT or AST greater than 3 times the upper limit of normal were observed in 0.4% of subjects treated with vonoprazan 20 mgs and 0.2% of subjects treated with lansoprazole. In the maintenance phase, transient ALT or AST elevations greater than three times the upper limit of normal were observed in 1% of subjects treated with vonoprazan 10 mg, 0.3% of subjects treated with vonoprazan 20 mg, and 2% of subjects treated with lansoprazole.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Vonoprazan Post-Marketing Safety in Japan and Asia</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The most recent post-marketing safety report from December 2021 includes an estimate of over 50 million patients who have received vonoprazan in Japan and other countries in Asia since its launch. Based on the post-marketing experience, the clinically significant adverse reactions section of the Japanese prescribing information for vonoprazan was updated to include shock, anaphylaxis, hepatic impairment, skin reactions such as toxic epidermal necrolysis, Steven-Johnson syndrome, and erythema multiforme; and events of pancytopenia, agranulocytosis, leukocytopenia, and thrombocytopenia. The incidence of these reactions was considered extremely rare (less than 1 in 100,000 patients) and a causal relationship to vonoprazan could not be ruled out. Although serious hepatic adverse events have been observed among patients exposed to vonoprazan in Japan in the post-marketing setting, these cases were typically confounded by comorbidities or other concomitant medications and believed to be idiosyncratic reactions. Post-marketing safety data, including the December 2021 post-marketing safety report, has been submitted to the PMDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan Launch in Japan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Vonoprazan Regulatory Status</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan first received approval in Japan on December 26, 2014 as TAKECAB&#174; for the following indications:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Healing and maintenance of healing of erosive esophagitis; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adjunct to antibiotics in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> treatment; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gastric ulcer; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Duodenal ulcer; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prevention of recurrence of gastric ulcer or duodenal ulcer during low-dose aspirin administration; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prevention of recurrence of gastric ulcer or duodenal ulcer during nonsteroidal anti-inflammatory drug (NSAID) administration. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan was subsequently approved in Japan in February 2016 for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in combination packs with antibiotics (Vonosap Pack 400, Vonosap Pack 800, and Vonopion Pack), and has since been approved in numerous other countries in Asia and Latin America as well as Russia.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Vonoprazan Commercialization in Japan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan was approved in Japan in December 2014. In 2021, its seventh full year on the market, vonoprazan generated approximately $850 million in net sales in Japan, a 17% increase over the prior year. In addition, in the quarter ended December 31, 2021, vonoprazan generated over $249 million in net sales, a 16% increase over the corresponding quarter from the prior year.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img45497886_20.jpg" alt="img45497886_20.jpg" style="width:570px;height:338px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that the market dynamic for anti-secretory agents in Japan is similar to that in the United States. In both countries, the anti-secretory market is largely genericized. Ahead of the vonoprazan launch in Japan, all PPIs, other than Nexium, were available as generics. As of September 2020, generic drugs in Japan represent approximately 80% of the market by volume, compared to the United States where generics are currently approximately 90% of the market by volume. Although vonoprazan and Dexilant are priced at a premium to generic PPIs in Japan and the United States, respectively, both have experienced commercial success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan Commercial Opportunity and Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The market for prevention and treatment of acid-related GI diseases in the United States and Europe is large. There were approximately 7.2 billion PPI doses prescribed for the 12 months ended December 31, 2021. We estimate that there are approximately 65 million individuals with GERD in the United States and 50 million individuals with GERD in the EU5, of whom 15% to 45% are inadequately treated with PPIs. In addition, we estimate that there are approximately 115 million individuals in the United States infected with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, of which 2.5 million are treated each year, and 145 million individuals in the EU5 infected with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Over many decades of use, multiple drug classes and individual drugs have demonstrated the substantial commercial opportunity for therapies treating acid-related GI diseases. H2RAs including Axid, Pepcid, Tagamet, and Zantac provided the first significant improvement in disease management over antacids and as a class reached $3.5 billion in annual sales. After H2RAs, PPIs emerged as the new standard of care. Prior to the introduction of generic and OTC alternatives, annual PPI class sales reached approximately $12.5 billion in the United States, and peak sales for individual brands were approximately $3.7 billion for Prilosec, approximately $3.5 billion for Nexium, and $3.4 billion for Prevacid.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As recently as 2015, the last branded PPI, Dexilant, reached approximately $530 million in sales in the United States despite limited differentiation from other PPIs. As of December 31, 2021, Dexilant was priced at a significant premium to generic PPIs on the market. Even with premium pricing, Dexilant obtained broad insurance coverage and favorable access. As of December 2021, approximately 87% of commercially covered lives and 82% of Medicare covered lives had access to Dexilant. Furthermore, of those commercially covered lives, 48% had unrestricted access to the drug without prior authorization or step edits and 28% of patients had access at the lowest branded cost tier. We believe that, if approved in our markets, vonoprazan will be the first of the next generation of anti-secretory therapies to improve the standard of care for acid-related GI diseases by providing a safe and effective treatment option for the millions of patients in need of more potent, rapid, or durable acid suppression. Additionally, we believe the results of our Phase 3 clinical trials in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and erosive esophagitis support the potential differentiation of vonoprazan compared to a standard of care PPI, and if vonoprazan is approved, could result in attractive market access and formulary positioning.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2021, we conducted a U.S. market research study with 100 gastroenterologists, 102 primary care physicians, and 40 gastroenterology advanced practice providers who treat </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection. These clinicians stated a preference to prescribe vonoprazan dual or triple therapy first line to 53% of their patients with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection, and to 52% of their patients with refractory </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection. In the same study, in terms of aspects of vonoprazan that positively impacted the intention to prescribe, 69% of clinicians said mechanism of action, and 52% said the efficacy in patients with clarithromycin-resistant strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. In December 2021, we conducted a separate U.S. market research study with 151 gastroenterologists, 100 primary care physicians, and 50 advanced practice providers who treat GERD. For the treatment of erosive esophagitis, 65% - 67% of respondents believed that vonoprazan is differentiated from standard of care PPIs, has demonstrated superior efficacy in the healing and maintenance of healing of esophageal erosions compared to lansoprazole, and delivers symptom relief.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Sales and Marketing</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are in the process of building marketing, sales, and distribution capabilities. We plan to independently commercialize vonoprazan in the United States by building a leading specialty gastroenterology-focused commercial infrastructure to support the adoption of vonoprazan. We believe we can successfully launch vonoprazan in the United States with a focused sales force targeting high prescribers of PPIs, particularly gastroenterologists and primary care physicians. PPI prescribing is highly concentrated with approximately 75% of prescriptions in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and 65% of prescriptions in erosive esophagitis being written by 10% of the PPI prescribers (approximately 51,400 prescribers), according to IQVIA data. We believe we have an opportunity to achieve significant share of voice and exposure to physicians given the scarcity of actively marketed anti-secretory medicines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To address the commercial opportunity for vonoprazan in Europe and Canada, we plan to seek one or more partners with existing commercial infrastructure and expertise in these markets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Additional Vonoprazan Development Opportunities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Indications</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we are initially focused on the development of vonoprazan for the treatment of GERD and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection, we believe there are opportunities to expand the use of vonoprazan to other indications in our licensed territories. For example, in Japan, vonoprazan is also approved for the treatment of gastric ulcers, treatment of duodenal ulcers, prevention of recurrence of gastric ulcer or duodenal ulcer during low-dose aspirin administration, and prevention of recurrence of gastric ulcer or duodenal ulcer during NSAID administration. Barrett&#x2019;s esophagus and Zollinger Ellison syndrome are severe diseases related to acid secretion where PPIs are the current standard of care. The improved acid control of vonoprazan relative to PPIs may lead to improved results over PPIs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Eosinophilic esophagitis is an autoimmune disease with significant unmet need. Although not approved for this indication, PPIs are prescribed for the treatment of eosinophilic esophagitis. Vonoprazan demonstrated similar efficacy to PPIs in an investigator-sponsored clinical trial in Japan. In this clinical trial, 112 patients with eosinophilic esophagitis were treated with vonoprazan, or the PPI rabeprazole or esomeprazole. Of patients treated with vonoprazan, 82% had complete relief of symptoms compared to 70% for esomeprazole and 76-78% for rabeprazole. Similarly, 35% of patients treated with vonoprazan demonstrated complete remission of eosinophilic esophagitis by histology, compared to 37% for esomeprazole and 31-38% for rabeprazole.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Formulations and Packaging</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Orally Disintegrating Tablet</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. An orally disintegrating tablet, or ODT, formulation for vonoprazan is currently in development by Takeda. We may conduct one or more Phase 1 trials to support potential approval of the ODT formulation. We believe that the ODT represents a meaningful commercial opportunity for patients with difficulty swallowing, as estimated peak U.S. sales of the lansoprazole ODT formulation were over $450 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intravenous Formulation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We are exploring the potential to develop an intravenous formulation of vonoprazan for use in acute bleeding, critically ill patients, or other in-hospital applications. Several PPIs have approved intravenous formulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pediatric Formulation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We are exploring the potential to develop an oral formulation, in addition to an ODT formulation, for pediatric use.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Over the Counter Use</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that vonoprazan has the ideal profile for an OTC product, including the potential for on-demand symptom relief and a well-tolerated safety profile. Sales of OTC heartburn relief products in the United States are substantial, constituting a multi-billion-dollar market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and strong emphasis on proprietary products. We face potential competition from many sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and government agencies and public and private research institutions. If vonoprazan receives marketing approval in the United States, Europe or Canada, it will compete with existing therapies and new therapies that may become available in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Some of our competitors, either alone or with their strategic partners, have substantially greater financial, technical and human resources and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of treatments and commercializing those treatments. These same competitors may invent technology that competes with vonoprazan. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and subject recruitment for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for vonoprazan, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, we expect that vonoprazan, if approved, will be priced at a premium over competitive generic products and our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that vonoprazan, if approved for the treatment of patients with erosive esophagitis and treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection in adults, will primarily compete with generic PPIs marketed by multiple pharmaceutical companies in both the prescription and OTC markets. Additionally, in March 2020, RedHill Biopharma Ltd. launched Talicia, a co-formulated capsule comprising generic omeprazole, amoxicillin, and rifabutin for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are aware of one other P-CAB in development in the United States, as well as a number of other P-CABs in territories outside of the United States that if developed and approved in our territories may compete with vonoprazan. In the United States, Neurogastrx intends to commence a Phase 3 erosive esophagitis trial for fexuprazan, under an exclusive license from Daewoong Pharmaceutical Co., Ltd., or Daewoong, sometime in 2022. Outside the United States, Daewoong recently received regulatory approval of, and plans for a first half of 2022 launch for fexuprazan in South Korea, and has out-licensed rights to develop fexuprazan in China to Shanghai Haini, a subsidiary of China&#x2019;s Yangtze River Pharmaceutical Group. Also outside the United States, revaprazan is marketed by Yuhan Corporation in South Korea, and tegoprazan is marketed by CJ Healthcare Corp. in South Korea and is currently in development in Japan by RaQualia Pharma, Inc. Additionally, Jeil Pharm has received authorization to conduct a Phase 3 trial in South Korea of its P-CAB candidate, JP-1366, in erosive esophagitis, and Cinclus Pharma AG&#x2019;s linaprazan glurate has completed a Phase 1 clinical trial in Europe and is currently in Phase 2 clinical trials. To our knowledge, none of these compounds have demonstrated superiority to PPIs on clinical endpoints.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">    </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, we are aware of several clinical-stage PPIs in territories outside of the United States that if developed and approved in our licensed territories may compete with vonoprazan. These include Dexa Medica&#x2019;s DLBS-2411, currently in Phase 3 clinical trials in Indonesia, Sihuan Pharmaceutical&#x2019;s anaprazole, currently in Phase 3 clinical trials in China, Eisai&#x2019;s azeloprazole, currently in a Phase 2 clinical trial in Japan, and Sidem Pharma&#x2019;s tenatoprazole, currently in Phase 2 clinical trials in Europe and Canada.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intellectual property, including patents, trade secrets, trademarks and copyrights, is important to our business. Our commercial success depends in part on our ability to obtain and maintain proprietary intellectual property protection for vonoprazan, as well as for future product candidates and novel discoveries, product development technologies, and know-how. Our commercial success also depends in part on our ability to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to develop and maintain protection of our proprietary position by, among other methods, licensing or filing U.S. and foreign patents and applications relating to our technology, inventions, and improvements that are important to the development and implementation of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our patent portfolio, comprising patents and patent applications exclusively licensed to us, is built with a goal of establishing broad protection that generally includes, for the product candidate compound, claims directed to composition of matter, pharmaceutical compositions or formulations, methods of synthesis, and methods of treatment using such pharmaceutical compositions or formulations. As of December 31, 2021, our patent portfolio covering vonoprazan consists solely of exclusively licensed patents and patent applications from Takeda. Subject to the terms of the license agreement we entered into with Takeda on May 7, 2019, or the Takeda License, we have licensed from Takeda exclusive rights in the United States, Europe, and Canada to patents and patent applications covering the composition of matter, formulation, use and/or manufacture of vonoprazan. Our patent portfolio comprises 11 distinct patent families protecting the technology relating to the compound vonoprazan and its synthetic intermediates, methods of synthesizing vonoprazan and related compounds, various formulations of vonoprazan products, as well as methods of treating diseases with vonoprazan and related compounds. As of December 31, 2021, our portfolio consists of approximately 22 issued U.S. patents, 5 pending U.S. applications, 13 issued European patents subsequently validated in individual European countries, 4 pending European applications, 5 issued Canadian patents, and 3 pending Canadian applications. The issued patents and pending applications have nominal expiration dates ranging from 2024 to 2038, without accounting for any available patent term adjustments or extensions. The issued U.S. patent covering the composition of matter of vonoprazan is expected to expire in August 2028, not including patent term extension. The issued U.S. patent covering the formulation of vonoprazan is expected to expire in August 2030, not including patent term extension.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term of individual patents in our portfolio depends upon the legal term of patents in the countries in which they are obtained. In most countries in which we file, including the United States, the patent term is 20 years from the earliest date of filing a non-provisional patent application. In the United States, the term of a patent may be eligible for patent term adjustment, which permits patent term restoration as compensation for delays incurred at the USPTO during the patent prosecution process. In addition, for patents that cover an FDA-approved drug, the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent. While the length of the patent term extension is related to the length of time the drug is under regulatory review, patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only one patent per approved drug may be extended under the Hatch-Waxman Act. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We plan to seek any available patent term extension to any issued patents we may be granted in any jurisdiction where such extensions are available; however, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. The relevant patent laws and their interpretation outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our technology or product candidates and could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions and improvements. We cannot guarantee that patents will be granted with respect to any of our licensed pending patent applications or with respect to any patent applications we may file in the future, nor can we be sure that any patents that may be granted to us or Takeda in the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. Moreover, issued patents do not guarantee the right to practice our technology in relation to the commercialization of our products. Issued patents only allow us to block potential competitors from practicing the claimed inventions of the issued patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, patents and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing vonoprazan and any future product candidates and practicing our proprietary technology, and any issued patents may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for vonoprazan and any future product candidates. In addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies that are outside the scope of the rights granted under any issued patents. For these reasons, we may face competition with respect to vonoprazan and any future product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any patent protection for such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us, and for employees and consultants to enter into invention assignment agreements with us. These agreements provide that all confidential information developed or made known to the individual during the course of the individual&#x2019;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Where applicable, the agreements provide that all inventions to which the individual contributed as an inventor shall be assigned to Phathom, and as such, will become our property. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, we have filed for and have received trademark registrations for our company name &#x201c;Phathom Pharmaceuticals&#x201d; in the United States, European Union, and other foreign jurisdictions, and are pursuing trademark protection in certain other foreign jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement with Takeda Pharmaceutical Company Limited</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On May 7, 2019, we and Takeda entered into the Takeda License, pursuant to which, Takeda granted us an exclusive, sublicensable (with Takeda&#x2019;s reasonable consent) license under certain patents and know how relating to vonoprazan and owned or controlled by Takeda during the term of the Takeda License to commercialize vonoprazan products using specified formulations for all human therapeutic uses in the United States, Europe and Canada, and a non-exclusive license under such patents and know how to develop and manufacture such vonoprazan products anywhere in the world (subject to Takeda&#x2019;s consent as to each country) for the purposes of commercializing the vonoprazan products in the United States, Europe and Canada. We granted Takeda a non-exclusive, royalty-free, sublicensable license under our rights in any patents and know-how that are necessary or useful to enable Takeda to develop and manufacture vonoprazan products anywhere in the world for the purposes of commercialization outside United States, Europe and Canada. We also granted Takeda an exclusive, royalty-free license under our rights in certain patents and know-how owned or controlled by us and necessary for the exploitation of vonoprazan products, in each case for Takeda to commercialize any vonoprazan product outside of the United States, Canada, and Europe and for purposes other than human therapeutic use.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the term of the Takeda License, we and our affiliates are not permitted to commercialize any pharmaceutical product, other than vonoprazan, that treats acid-related disorders, except for certain generic and OTC competing products in specified circumstances. We will be responsible, at our cost, for the development, manufacture and commercialization of the vonoprazan products. We are required to use commercially reasonable efforts to develop and commercialize the vonoprazan products in our licensed territory.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Takeda License, Takeda has the sole right and authority, with our input, to prepare, file, prosecute, and maintain all Takeda and joint patents on a worldwide basis at its own cost. We are responsible, at our cost, for preparing, filing, prosecuting, and maintaining patents on inventions made solely by us in connection with vonoprazan, subject to input from Takeda. We have the first right to enforce the licensed patent rights with respect to certain infringing products in the United States, Europe and Canada.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We paid Takeda upfront consideration consisting of a cash payment of $25.0 million, 1,084,000 shares of common stock and a warrant to purchase 7,588,000 shares of common stock, or the Takeda Warrant. We agreed to make milestone payments to Takeda upon achieving certain tiered aggregate annual net sales of licensed products in the United States, Europe and Canada up a total maximum milestone amount of $250.0 million. We also agreed to make tiered royalty payments in the low double digits to the mid-teens on net sales of licensed products, subject to specified offsets and reductions. Royalties will be payable, on a product-by-product and country-by-country basis from the first commercial sale of such product in such country, until the latest of expiration of the licensed patents covering the applicable product, expiration of regulatory exclusivity in such country, or 15 years following first commercial sale in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Takeda License will continue until the expiration of the obligation to pay royalties in all countries and on all products. We may terminate the Takeda License in its entirety without cause upon six months&#x2019; prior written notice. We and Takeda may terminate the Takeda License in the case of the other party&#x2019;s insolvency, or upon prior written notice within a specified time period for the other party&#x2019;s material uncured breach. Takeda may terminate the Takeda License in its entirety if we challenge the licensed patents, or if we assist any third party in challenging such patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not currently own or operate manufacturing facilities for the production of clinical or commercial quantities of vonoprazan. Vonoprazan is a small molecule that can be manufactured using commercially available technologies. We currently rely on Takeda to supply us with vonoprazan drug product for clinical use.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With respect to any future product candidates, we expect to continue to rely on third-party contract manufacturers to manufacture clinical supplies and commercial quantities of any approved product. Although we rely on contract manufacturers, we have personnel with manufacturing experience to oversee our relationships with Takeda, Sandoz and Catalent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Takeda Commercial Supply Agreement</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2020, we entered into a Commercial Supply Agreement with Takeda , or the Takeda Supply Agreement, pursuant to which Takeda will supply us with commercial quantities of vonoprazan bulk drug. Pursuant to the Commercial Supply Agreement, Takeda has agreed to supply us certain quantities of vonoprazan bulk drug product according to approved specifications at a fixed price per batch of bulk drug product in order to commercialize vonoprazan in accordance with the Takeda License. The Takeda Supply Agreement sets forth a minimum and maximum number of batches of vonoprazan bulk drug product that we are required to order each year, and if we do not purchase the minimum number of batches in a year, other than as a result of Takeda&#x2019;s inability to supply such batches for any reason, or as a result of force majeure, we are required to pay Takeda the amount corresponding to the shortfall. Takeda has no obligation to supply bulk drug product above the maximum number of batches specified in the Takeda Supply Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, under the Takeda Supply Agreement, Takeda will provide certain services and materials, including vonoprazan drug substance, to support the transfer of technology and Takeda manufacturing know-how to our contract manufacturing organizations, or CMOs, that we designate. Takeda has agreed to negotiate in good faith to provide reasonable additional support, including technical advice and supply of materials, to assist us with technology transfers to the CMOs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Takeda Supply Agreement will continue until the earlier of (a) two years from the date we place an order for bulk drug product for the first commercial launch of vonoprazan in any jurisdiction in the United States, Europe or Canada, and (b) December 31, 2023. The Takeda Supply Agreement may be terminated upon written notice by either party if the other party has failed to remedy a material breach within a specified cure period following written notice of such breach. The Takeda Supply Agreement will terminate immediately upon the termination of the Takeda License in accordance with its terms. We are exploring additional options for commercial supply of vonoprazan API from other third-party contract manufacturers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sandoz Supply and Packaging Agreement</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, we entered into a Supply and Packaging Services Agreement with Sandoz GmbH, or the Sandoz Supply Agreement, pursuant to which Sandoz has agreed to supply commercial quantities of amoxicillin capsules and clarithromycin tablets, to package these antibiotics with vonoprazan drug product in finished convenience packs, and to supply us with these convenience packs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Sandoz Supply Agreement, we agreed to purchase certain quantities of convenience packs from Sandoz at an agreed upon price per pack. The price per pack is fixed for the first two (2) years following launch of the convenience pack in the United State and may be adjusted thereafter based on Sandoz&#x2019;s cost increases, subject to an annual cap. The Sandoz Supply Agreement sets forth an annual minimum number of convenience packs that we must purchase each year following launch of the convenience pack product, and if we do not meet the minimum order in a given year, we are required to pay Sandoz the amount corresponding to the shortfall. Sandoz has no obligation to supply convenience packs above a maximum number of packs above a certain percentage of our forecasts. We have agreed to purchase convenience packs, amoxicillin capsules and clarithromycin tablets, in each case intended for sale in the United States, exclusively from Sandoz during the five-year period following launch.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Sandoz Supply Agreement will continue for five years from launch of the convenience pack in the U.S. and may be terminated effective at the end of the initial five-year term upon written notice by either party prior to the end of the third year following launch. In the absence of such notice, the Sandoz Supply Agreement will extend automatically for an additional three-year period, and thereafter as mutually agreed upon by the parties. The Sandoz Supply Agreement may also be terminated at any time upon written notice by either party for uncured material breach following written notice of such breach.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Catalent Commercial Supply Agreement</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2021, we entered into a Commercial Supply Agreement, or the Tablet Supply Agreement, with Catalent Pharma Solutions, LLC, or Catalent, pursuant to which Catalent has agreed to supply us with commercial quantities of vonoprazan fumarate tablets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Tablet Supply Agreement, Catalent has agreed to supply us with, and the Company has agreed to purchase from Catalent, finished vonoprazan tablets at an agreed upon price per unit. The price per unit may be adjusted annually based on increases in costs incurred by Catalent. The Tablet Supply Agreement requires us to purchase a specified percentage of its requirements of finished vonoprazan tablets from Catalent, which percentage is subject to adjustment following the third anniversary of the first day of the calendar quarter during which Catalent is scheduled to deliver the initial finished vonoprazan tablets to us intended for commercial sale, excluding validation batches, or the Commencement Date.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unless terminated earlier, the term of the Tablet Supply Agreement extends for a period of five years from the Commencement Date. The Tablet Supply Agreement will extend automatically for additional two year periods unless terminated by either party upon at least 24months prior written notice. The Tablet Supply Agreement may also be terminated at any time upon written notice by either party if the other party has failed to remedy a material breach of the terms of the Tablet Supply Agreement within a specified period following receipt of written notice of such breach.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing. A new drug must be approved by the FDA through the NDA process before it may be legally marketed in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">U.S. Drug Development Process</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">completion of preclinical laboratory tests, animal studies and formulation studies in accordance with Good Laboratory Practice, or GLP, regulations and other applicable regulations; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical trials may begin;  </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practice, or GCP, regulations to establish the safety and efficacy of the proposed drug for its intended use; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">submission to the FDA of an NDA; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of an FDA advisory committee review, if applicable; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current Good Manufacturing Practice, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#x2019;s identity, strength, quality and purity, and of selected clinical investigation sites to assess compliance with GCPs; and  </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once a pharmaceutical candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. Prior to beginning the first clinical trial with a product candidate in the United States, a sponsor must submit an IND to the FDA. The sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The sponsor will also include a protocol detailing, among other things, the objectives of the first phase of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about on-going or proposed clinical trials or non-compliance with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of one or more qualified investigators in accordance with GCP regulations, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND as well as any subsequent protocol amendments, and timely safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events. An IRB at each institution participating in the clinical trial must review and approve each protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each trial subject or his or her legal representative, monitor the study until completed and otherwise comply with IRB regulations. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: The product candidate is initially introduced into healthy human volunteers or patients with the target disease or condition. These studies test for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness.  </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: The product candidate is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks.  </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: The product candidate is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of the product&#x2019;s effectiveness for its intended use(s) and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk-benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product labeling.  </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While the IND is active, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the drug, findings from animal or in vitro testing suggesting a significant risk to humans exposed to the drug, and any clinically important increased rate of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are also requirements governing the reporting of ongoing clinical trials and completed trial results to public registries. Sponsors of certain clinical trials of FDA-regulated products are required to register and disclose specified clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is then made public as part of the disclosure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NDA Review and Approval Process</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, preclinical and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once filed, the FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#x2019;s identity, strength, quality and purity. Under current PDUFA guidelines, the FDA has a goal of ten months from the date of &#x201c;filing&#x201d; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#x201c;filing&#x201d; decision after the application is submitted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as additional clinical trials or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor to conduct Phase 4 testing, which involves clinical trials designed to further assess a drug&#x2019;s safety and effectiveness after NDA approval, and may require testing and surveillance programs to monitor the safety of approved products which have been commercialized. The FDA may also place other conditions on approval including the requirement for a risk evaluation and mitigation strategy, or REMS, to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Marketing approval may be withdrawn for non-compliance with regulatory requirements or if problems occur following initial marketing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expedited Development and Review Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA offers a number of expedited development and review programs for qualifying product candidates. The FDA has a Fast Track designation program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, product candidates are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once an NDA is submitted, the product candidate may be eligible for priority review. A Fast Track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy designation to expedite its development and review. A product candidate can receive Breakthrough Therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any marketing application for a drug submitted to the FDA for approval, including a product candidate with a Fast Track designation or Breakthrough Therapy designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product candidate is eligible for priority review if it is designed to treat a serious or life-threatening disease or condition, and if approved, would provide a significant improvement in safety or effectiveness compared to available alternatives for such disease or condition. The FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of new molecular entity NDAs under its current PDUFA review goals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, a product candidate may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA will generally require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fast Track designation, Breakthrough Therapy designation, accelerated approval, and priority do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Post-Approval Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. After approval, some types of changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to further FDA review and approval. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations. In addition, the FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any drug products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, drug sampling and distribution requirements, complying with certain electronic records and signature requirements, and complying with FDA promotion and advertising requirements. The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the market and imposes requirements and restrictions on drug manufacturers, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#x2019;s approved labeling (known as &#x201c;off-label use&#x201d;), industry-sponsored scientific and educational activities, and promotional activities involving the Internet. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#x2019;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#x2019;s communications on the subject of off-label use of their products. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#x2019;s FDA-approved labelling.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-approval clinical trials, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Marketing Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Market exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section 505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, under the GAIN Act, the FDA may designate a product as a &#x201c;qualified infectious disease product,&#x201d; or QIDP. In order to receive this designation, a drug must qualify as an antibacterial or antifungal drug for human use intended to treat serious or life-threatening infections, including those caused by either (1) an antibacterial or antifungal resistant pathogen, including novel or emerging infectious pathogens, or (2) a so-called &#x201c;qualifying pathogen&#x201d; found on a list of potentially dangerous, drug-resistant organisms established and maintained by the FDA under the law. The FDA interprets QIDP designation to apply to a specific drug product, including a specific dosage form of the product. A sponsor must request such designation before submitting a marketing application, and the FDA will respond to a request for QIDP designation within 60 days of the date the FDA receives the request. The GAIN Act permits the FDA to revoke a QIDP designation only if the request for such designation contained an untrue statement of material fact.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The benefits of QIDP designation include potential eligibility for priority review and Fast Track designation, and an extension by an additional five years of any non-patent marketing exclusivity period awarded, such as a five-year exclusivity period awarded for a new molecular entity. This extension is in addition to any pediatric exclusivity extension that may be awarded, and the extension will be awarded only to a drug first approved on or after the date of enactment. The GAIN Act provisions prohibit the grant of an exclusivity extension where the application is a supplement to an application for which an extension is in effect or has expired, is a subsequent application for a specified change to an approved product, or is an application for a product that does not meet the definition of QIDP based on the uses for which it is ultimately approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">U.S. Healthcare Fraud and Abuse Laws and Compliance Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to FDA regulation of pharmaceutical products, U.S. federal and state healthcare laws and regulations restrict business practices in the pharmaceutical industry. These laws may impact, among other things, our current and future business operations, including our clinical research activities, and constrain the business or financial arrangements and relationships with healthcare providers and other parties. These laws include anti-kickback and false claims laws, civil monetary penalties laws, and transparency laws regarding drug pricing and payments or other items of value provided to physicians and other healthcare providers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal Anti-Kickback Statute prohibits, among other things, individuals or entities from knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws prohibit, among other things, any individual or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, anesthesiology assistants and certified nurse midwives), and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Similar state and local laws and regulations may also restrict business practices in the pharmaceutical industry, such as state anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities; and state and local laws that require the registration of pharmaceutical sales representatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Violation of any of such laws or any other governmental regulations that apply may result in significant criminal, civil and administrative penalties including damages, fines, imprisonment, disgorgement, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, disgorgement, exclusion from participation in government healthcare programs and the curtailment or restructuring of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">U.S. Coverage and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidate for which we may seek regulatory approval. Sales in the United States will depend, in part, on the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health programs such as Medicare, Medicaid, TRICARE and the Veterans Administration, as well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for vonoprazan and any future product candidates can be subject to challenge, reduction or denial by third-party payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The process for determining whether a third-party payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product. In the United States, there is no uniform policy among payors for coverage or reimbursement. Decisions regarding whether to cover a product, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and approval processes. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that can require manufacturers to provide scientific and clinical support for the use of a product to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Third-party payors may not consider vonoprazan and any future product candidates to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development. Additionally, decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Medicaid is a joint federal and state program administered by the states for low&#x2011;income and disabled beneficiaries. Medicare is a federal program that is administered by the federal government covering individuals age 65 and over as well as those with certain disabilities. Under the Medicaid Drug Rebate Program, or MDRP, as a condition of having federal funds being made available to the states for covered outpatient drugs under Medicaid, pharmaceutical manufacturers must enter into an agreement with the Secretary of Health and Human Services to pay a rebate to state Medicaid programs for each unit of covered outpatient drug dispensed to a Medicaid beneficiary and paid for by the state Medicaid program. Medicaid drug rebates are based on pricing data that pharmaceutical manufacturers report on a monthly and quarterly basis to the U.S. Centers for Medicare &amp; Medicaid Services, or CMS, which is the federal agency that administers the MDRP and Medicare programs. For the MDRP, these data include the average manufacturer price, or AMP, for each drug and, in the case of innovator products, the Best Price, or BP, which represents the lowest price available from the manufacturer to any entity in the United States in any pricing structure, calculated to include all applicable sales and associated rebates, discounts and other price concessions. If a manufacturer becomes aware that its MDRP government price reporting submission for a prior quarter was incorrect or has changed as a result of recalculation of the pricing data, the manufacturer must resubmit the corrected data for up to three years after those data originally were due. If a manufacturer fails to provide information timely or is found to have knowingly submitted false information to the government, the manufacturer may be subject to civil monetary penalties and other sanctions, including termination from the MDRP.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal law requires that a manufacturer that participates in the MDRP also participate in the Public Health Service&#x2019;s 340B drug pricing program, or the 340B program, in order for federal funds to be available for the manufacturer&#x2019;s drugs under Medicaid. The 340B program is administered by the Health Resources and Services Administration, or HRSA, and requires participating manufacturers to agree to charge statutorily defined covered entities no more than the 340B &#x201c;ceiling price&#x201d; for the manufacturer&#x2019;s covered outpatient drugs used in an outpatient setting. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low&#x2011;income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the AMP and rebate amount for the covered outpatient drug as calculated under the MDRP. In general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement. Manufacturers must report 340B ceiling prices to HRSA on a quarterly basis, and HRSA publishes them to 340B covered entities. HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities for 340B&#x2011;eligible drugs. HRSA has also finalized an administrative dispute resolution process through which 340B covered entities may pursue claims against participating manufacturers for overcharges, and through which manufacturers may pursue claims against 340B covered entities for engaging in unlawful diversion or duplicate discounting of 340B drugs. In addition, legislation may be introduced that, if passed, would further expand the 340B program, such as adding further covered entities or requiring participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In order to be eligible to have drug products paid for with federal funds under Medicaid and purchased by certain federal agencies and grantees, a manufacturer must also participate in the U.S. Department of Veterans Affairs, or VA, Federal Supply Schedule, or FSS, pricing program. Under the VA/FSS program, a manufacturer must report the Non-Federal Average Manufacturer Price, or Non-FAMP, for its covered drugs to the VA and charge certain federal agencies no more than the Federal Ceiling Price, which is calculated based on Non-FAMP using a statutory formula. These four agencies are the VA, the U.S. Department of Defense, the U.S. Coast Guard, and the U.S. Public Health Service (including the Indian Health Service). The manufacturer must also pay rebates on products purchased by military personnel and dependents through the TRICARE retail pharmacy program. If a manufacturer participating in the FSS program fails to provide timely information or is found to have knowingly submitted false information, the manufacturer may be subject to civil monetary penalties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Individual states continue to consider and have enacted legislation to limit the growth of healthcare costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered by manufacturers in taking such increases, wholesale acquisition cost disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for certain drugs, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with drug price transparency requirements, including the untimely, inaccurate, or incomplete reporting of drug pricing information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">U.S. Healthcare Reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, there has been, and continues to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the profitable sale of product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Among policy makers and payors in the United States, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In March 2010, the Patient Protection and Affordable Care Act, or the Affordable Care Act, was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical industry. The Affordable Care Act, increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; required collection of rebates for drugs paid by Medicaid managed care organizations; required manufacturers to participate in a coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#x201c;branded prescription drugs&#x201d; to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded eligibility criteria for Medicaid programs; creates a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since its enactment, there have been judicial and political challenges to certain aspects of the Affordable Care Act, or ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#x2019;s decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021, through August 15, 2021, for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013, and, due to subsequent legislative amendments to the statute will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">    </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. For example, the Build Back Better Act, if enacted, would introduce substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated &#x201c;maximum fair price&#x201d; for certain selected drugs or pay an excise tax for noncompliance, and the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D. If the Build Back Better Act is not enacted, similar or other drug pricing proposals could appear in future legislation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">     </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The likelihood of implementation of these and other reform initiatives is uncertain. Moreover, in the coming years, additional legislative and regulatory changes could be made to governmental health programs that could significantly impact pharmaceutical companies and the success of our product candidates. Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, marketing cost disclosure and other transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing. It is possible that additional governmental action is taken in response to the COVID-19 pandemic. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which drugs and suppliers will be included in their healthcare programs. Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Foreign Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical trials or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union, or EU, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Regulation and Procedures Governing Marketing Authorization of Medicinal Products in the EU</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Non-clinical studies and clinical trials</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Similarly to the United States, the various phases of non-clinical and clinical research in the EU are subject to significant regulatory controls.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-clinical studies are performed to demonstrate the health or environmental safety of new biological substances. Non-clinical studies must be conducted in compliance with the principles of good laboratory practice, or GLP, as set forth in EU Directive 2004/10/EC. In particular, non-clinical studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical trials of medicinal products in the EU must be conducted in accordance with EU and national regulations and the International Conference on Harmonization, or ICH, guidelines on good clinical practices, or GCP, as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU member states, the sponsor is liable to provide &#x2018;no fault&#x2019; compensation to any study subject injured in the clinical trial.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A clinical trial application, or CTA, must be submitted to competent national health authorities and independent ethics committees, much like the FDA and IRB, respectively. Once the CTA is approved by the national health authority and the ethics committee has granted a positive opinion in relation to the conduct of the trial in the relevant member state(s), in accordance with a country&#x2019;s requirements, clinical study development may proceed. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Currently, CTAs must be submitted to the competent authority in each EU member state in which the trial will be conducted. Under the new Clinical Trials Regulation, which will become applicable on January 31, 2022, there will be a centralized application procedure where one national authority takes the lead in reviewing the application and the other national authorities have only limited involvement. The extent to which ongoing clinical trials will be governed by the Clinical Trials Regulation will depend on the duration of the individual clinical trial from January 31, 2022 onward. If an ongoing clinical trial continues for more than three years from January 31, 2022 the Clinical Trials Regulation will begin to apply to the clinical trial as of January 31, 2025.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Medicines used in clinical trials must be manufactured in accordance with good manufacturing practice, or GMP. Other national and EU-wide regulatory requirements may also apply.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Marketing Authorizations</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the EU, medicinal product candidates can only be commercialized after obtaining a marketing authorization, or MA. To obtain regulatory approval of a product candidate in the EU, we must submit a Marketing Authorization Application, or MAA. The process for doing this depends, among other things, on the nature of the medicinal product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are two types of MAs:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#34;Centralized MAs&#34; are issued by the European Commission through the centralized procedure, based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, of the EMA and are valid throughout the EU. The centralized procedure is mandatory for certain types of products, such as (i) medicinal products derived from biotechnological processes, (ii) designated orphan medicinal products, (iii) advanced medicinal therapy products, or ATMPs, such as gene therapy, somatic cell-therapy or tissue-engineered medicines and (iv) medicinal products containing a new active substance indicated for the treatment certain diseases, such as HIV/AIDS, cancer, neurodegenerative diseases, diabetes, auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for any products containing a new active substance not yet authorized in the EU, or for products that constitute a significant therapeutic, scientific or technical innovation or for which the granting of a MA would be in the interest of public health in the EU. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#34;National MAs&#34; are issued by the competent authorities of the EU member states, only cover their respective territory, and are available for product candidates not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in an EU member state, this National MA can be recognized in another member state through the mutual recognition procedure. If the product has not received a National MA in any member state at the time of application, it can be approved simultaneously in various member states through the decentralized procedure. Under the decentralized procedure an identical dossier is submitted to the competent authorities of each of the member states in which the MA is sought, one of which is selected by the applicant as the reference member state.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the EU member states make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">MAs have an initial duration of five years. After these five years, the authorization may be renewed for an unlimited period on the basis of a reevaluation of the risk-benefit balance. Under the centralized procedure and in exceptional cases, the CHMP might perform an accelerated review of a MA in no more than 150 days (not including clock stops).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Data and marketing exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The EU also provides opportunities for market exclusivity. Upon receiving MA reference medicinal product, generally receive eight years of data exclusivity and an additional two years of market exclusivity. If granted, the data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial MA of the reference product in the EU. The overall 10-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10 years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#x2019;s regulatory authorities to be a new chemical entity, and products may not qualify for data exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pediatric investigation plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the EU, MAAs for new medicinal products have to include the results of trials conducted in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA&#x2019;s Pediatric Committee, or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all EU member states and study results are included in the product information, even when negative, the product is eligible for six months&#x2019; supplementary protection certificate extension (if any is in effect at the time of approval) or, in the case of orphan pharmaceutical products, a two year extension of the orphan market exclusivity is granted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The advertising and promotion of medicinal products is also subject to laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription medicines is also prohibited in the EU. Although general requirements for advertising and promotion of medicinal products are established under EU directives, the details are governed by regulations in each member state and can differ from one country to another.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outside of the United States, the pricing of pharmaceutical products and medical devices is subject to governmental control in many countries. In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost effectiveness of a particular therapy to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. Other countries may allow companies to fix their own prices for products, but monitor and control product volumes and issue guidance to physicians to limit prescriptions. Efforts to control prices and utilization of pharmaceutical products and medical devices will likely continue as countries attempt to manage healthcare expenditures. Historically, products launched in the EU do not follow price structures of the United States and generally prices tend to be significantly lower.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Failure to comply with the aforementioned EU and member state laws may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aforementioned EU rules are generally applicable in the European Economic Area, or EEA, which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Brexit and the Regulatory Framework in the United Kingdom</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The United Kingdom, or UK, left the EU on January 31, 2020, following which existing EU medicinal product legislation continued to apply in the United Kingdom during the transition period under the terms of the EU-UK Withdrawal Agreement. The transition period, which ended on December 31, 2020, maintained access to the EU single market and to the global trade deals negotiated by the EU on behalf of its members. The transition period provided time for the UK and EU to negotiate a framework for partnership for the future, which was then crystallized in the Trade and Cooperation Agreement, or TCA, and became effective on the January 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP inspections of manufacturing facilities for medicinal products and GMP documents issued but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EU laws which have been transposed into UK law through secondary legislation continue to be applicable as &#x201c;retained EU law&#x201d;. However, new legislation such as the EU Clinical Trials Regulation or in relation to orphan medicines will not be applicable. The UK government has passed a new Medicines and Medical Devices Act 2021, which introduces delegated powers in favor of the Secretary of State or an &#x2018;appropriate authority&#x2019; to amend or supplement existing regulations in the area of medicinal products and medical devices. This allows new rules to be introduced in the future by way of secondary legislation, which aims to allow flexibility in addressing regulatory gaps and future changes in the fields of human medicines, clinical trials and medical devices.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, is the UK&#x2019;s standalone medicines and medical devices regulator. As a result of the Northern Ireland protocol, different rules will apply in Northern Ireland than in England, Wales, and Scotland, together, Great Britain, or GB; broadly, Northern Ireland will continue to follow the EU regulatory regime, but its national competent authority will remain the MHRA. The MHRA has published a guidance on how various aspects of the UK regulatory regime for medicines will operate in GB and in Northern Ireland following the expiry of the Brexit transition period on December 31, 2020. The guidance includes clinical trials, importing, exporting, and pharmacovigilance and is relevant to any business involved in the research, development, or commercialization of medicines in the UK. The new guidance was given effect via the Human Medicines Regulations (Amendment etc.) (EU Exit) Regulations 2019, or the Exit Regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, including a 150-day assessment and a rolling review procedure. All existing EU MAs for centrally authorized products were automatically converted or grandfathered into UK MAs, effective in GB (only), free of charge on January 1, 2021, unless the MA holder chooses to opt-out. After Brexit, companies established in the UK cannot use the centralized procedure and instead must follow one of the UK national authorization procedures or one of the remaining post-Brexit international cooperation procedures to obtain an MA to commercialize products in the UK. The MHRA may rely on a decision taken by the European Commission on the approval of a new (centralized procedure) MA when determining an application for a GB authorization; or use the MHRA&#x2019;s decentralized or mutual recognition procedures which enable MAs approved in EU member states (or Iceland, Liechtenstein, Norway) to be granted in GB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Data privacy and security laws</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pharmaceutical companies may be subject to federal, state and foreign data privacy, security and data breach notification laws governing the collection, use, disclosure and protection of health-related and other personal information. For example, in the U.S., HIPAA imposes privacy, security and breach reporting obligations with respect to individually identifiable health information upon &#x201c;covered entities&#x201d; (health plans, health care clearinghouses and certain health care providers), and their respective business associates, individuals or entities that create, received, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HIPAA mandates the reporting of certain breaches of health information to the Department of Health and Human Services, or HHS, to affected individuals and if the breach is large enough, to the media. Entities that are found to be in violation of HIPAA as the result of a breach of unsecured PHI, a complaint about privacy practices or an audit by the HHS may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. Even when HIPAA does not apply, according to the Federal Trade Commission or the FTC, failing to take appropriate steps to keep consumers&#x2019; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#x2019;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. In addition, certain state and non-U.S. laws, such as the California Consumer Privacy Act, or CCPA, the California Privacy Rights Act, or CPRA, and the EU General Data Protection Regulation, or GDPR, govern the privacy and security of personal information, including health-related information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Human Capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of February 24, 2022, we had 77 full-time employees, 11 of whom have a Ph.D. or M.D. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Corporate Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We were originally incorporated under the laws of the state of Delaware on January 9, 2018 under the name North Bridge IV, Inc. On March 13, 2019, we changed our name to Phathom Pharmaceuticals, Inc. and merged YamadaCo IIA, Inc., a Delaware corporation, or YamadaCo, with and into our company, with Phathom Pharmaceuticals, Inc. as the surviving entity, or the Merger. References throughout this annual report to Phathom Pharmaceuticals, Inc. include North Bridge IV, Inc. prior to the Merger. Our principal executive offices are located at 100 Campus Drive, Suite 102, Florham Park, New Jersey 07932, and our telephone number is (877) 742-8466.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Available Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our internet address is www.phathompharma.com. Our investor relations website is located at https://investors.phathompharma.com.com. We make available free of charge on our investor relations website under &#x201c;Financials and Filings&#x201d; our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, our directors&#x2019; and officers&#x2019; Section 16 reports and any amendments to those reports as soon as reasonably practicable after filing or furnishing such materials to the SEC. They are also available for free on the SEC&#x2019;s website at www.sec.gov.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We use our investor relations website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor such website, in addition to following our press releases, SEC filings and public conference calls and webcasts, information relating to our corporate governance is also included on our investor relations website. The information in or accessible through the SEC and our website are not incorporated into, and are not considered part of, this filing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1A.	Ri</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">sk Factors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">You should carefully consider the following risk factors, together with the other information contained in this annual report on Form 10-K, including our financial statements and the related notes and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201d; before making a decision to purchase or sell shares of our common stock. We cannot assure you that any of the events discussed in the risk factors below will not occur. These risks could have a material and adverse impact on our business, results of operations, financial condition and growth prospects. If that were to happen, the trading price of our common stock could decline. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations or financial condition. In this section, we first provide a summary of the more significant risks and uncertainties we face and then provide a full set of risk factors and discuss them in greater detail.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SUMMARY RISKS FACTORS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently depend entirely on the success of vonoprazan, which is our only product candidate. If we are unable to advance vonoprazan in clinical development, obtain regulatory approval and ultimately commercialize vonoprazan, or experience significant delays in doing so, our business will be materially harmed;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the results of prior clinical trials and other investigator-initiated clinical trials of vonoprazan are not necessarily predictive of our future results. Vonoprazan may not have favorable results in our clinical trials, or receive regulatory approval on a timely basis, if at all;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan and any future product candidates are subject to extensive regulation and compliance obligations, which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize vonoprazan and any future product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be successful in our efforts to expand our pipeline by identifying additional indications and formulations for which to investigate vonoprazan in the future. We may expend our limited resources to pursue a particular indication or formulation for vonoprazan and fail to capitalize on product candidates, indications or formulations that may be more profitable or for which there is a greater likelihood of success;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently have a limited marketing and no sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely on third parties to conduct our preclinical and clinical trials and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize vonoprazan and our business could be harmed;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;" id="page5"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently engage third-party manufacturers for clinical and commercial supplies. The loss of any of these suppliers, or any future single source suppliers, could harm our business;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely on the Takeda License to provide us rights to develop and commercialize vonoprazan in the United States, Europe, and Canada. If the license agreement is terminated, we would lose our rights to develop and commercialize vonoprazan;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the scope of any patent protection we obtain is not sufficiently broad, if we lose any of our patent protection, or if we are unable to maintain our existing Qualified Infectious Disease Product, or QIDP, designations for vonoprazan in combination with amoxicillin and clarithromycin for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The successful commercialization of vonoprazan or any future product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability to generate revenue;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If following commercialization of vonoprazan (or any future product candidates, if approved) we fail to comply with reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to various foreign, federal, and state healthcare and privacy laws and regulations, and our failure to comply with these laws and regulations could harm our results of operations and financial condition;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business is subject to risks arising from epidemic diseases, such as the ongoing COVID-19 pandemic;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are highly dependent on the services of our key executives and personnel, and if we are not able to retain these members of our management or recruit additional management, clinical and commercial personnel, our business will suffer; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x25cf;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The trading price of our securities is likely to be volatile, and purchasers of our securities could incur substantial losses.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Limited Operating History, Financial Position and Capital Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a late clinical-stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We commenced operations in 2018, and to date, we have focused primarily on organizing and staffing our company, business planning, raising capital, in-licensing our initial product candidate, vonoprazan, meeting with regulatory authorities, conducting our Phase 3 clinical trials of vonoprazan, preparing applications for regulatory approval for vonoprazan and preparing for a potential commercial launch. As a company, we have not yet demonstrated an ability to obtain regulatory approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully obtaining regulatory approvals for and commercializing biopharmaceutical products.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred significant operating losses since our inception. If vonoprazan is not successfully developed and approved in the United States, Europe and/or Canada, we may never generate any revenue. We have incurred cumulative net losses since our inception and, as of December 31, 2021, we had an accumulated deficit of $529.4 million. Substantially all of our losses have resulted from expenses incurred in connection with in-licensing and developing vonoprazan, commercial activities in preparation for a potential product launch, and from general and administrative costs associated with our operations. Vonoprazan will require substantial additional time and resources before we will be able to begin generating revenue from product sales, and any future product candidates will require substantial additional development time and resources before we will be able to apply for or receive regulatory approvals and begin generating revenue from product sales. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we continue our development of, seek additional regulatory approvals for, and potentially commercialize vonoprazan and seek to identify, assess, acquire, in-license, or develop additional product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing clinical trials and preclinical studies of vonoprazan and any future product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products. We are still in the early stages of a number of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. In addition, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, continue our product development efforts, diversify our product candidate pipeline or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The development and commercialization of biopharmaceutical product candidates is capital-intensive. We expect our expenses to increase in connection with our ongoing activities, particularly as we prepare to commercialize vonoprazan for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and erosive esophagitis and progress our NERD development program. In addition, if vonoprazan receives approval and is commercialized, we will be required to make milestone and royalty payments to Takeda, from whom we have in-licensed the rights to develop and commercialize vonoprazan in the United States, Europe, and Canada pursuant to the Takeda License. Furthermore, if and to the extent we seek to acquire or in-license additional product candidates in the future, we may be required to make significant upfront payments, milestone payments, and/or royalty payments. If we obtain regulatory approval for vonoprazan or any future product candidate, we also expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Because the outcome of any clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of vonoprazan or any future product candidate. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that our existing cash and cash equivalents together with the drawdown of the remaining $100 million under our loan and security agreement, or the Loan Agreement, with Hercules Capital, or Hercules, will enable us to fund our operations into mid-2023. In particular, we expect that these funds will allow us to complete our Phase 3 clinical trial studying vonoprazan for NERD (daily dosing), and launch vonoprazan for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and erosive esophagitis. We have based these estimates on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop vonoprazan or any future product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future capital requirements will depend on many factors, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs and timing of establishing or securing sales and marketing capabilities if vonoprazan or any future product candidate is approved;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the initiation, type, number, scope, results, costs and timing of, our clinical trials of vonoprazan, and preclinical studies or clinical trials of other potential product candidates we may choose to pursue in the future, including feedback received from regulatory authorities;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays and cost increases as a result of the ongoing COVID-19 pandemic;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs and timing of manufacturing for vonoprazan or any future product candidates, including commercial scale manufacturing if any product candidate is approved;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs, timing and outcome of regulatory review of vonoprazan or any future product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs associated with hiring additional personnel and consultants as our business grows particularly commercial personnel;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and amount of the milestone or other payments we must make to Takeda and any future licensors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">patients&#x2019; willingness to pay out-of-pocket for any approved products in the absence of coverage and/or adequate reimbursement from third-party payors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs associated with any products or technologies that we may in-license or acquire.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Conducting clinical trials and preclinical studies is a time consuming, expensive, and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, vonoprazan and other potential product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, would initially be derived from sales of vonoprazan, which we do not expect to be commercially available in our licensed territories until 2022, if at all.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through equity offerings, our Loan Agreement with Hercules, other debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Our Loan Agreement includes, and any future debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring additional debt, making capital expenditures or declaring dividends.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we raise funds through future collaborations, licenses and other similar arrangements, we may have to relinquish valuable rights to our future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to the Development and Regulatory Approval of Product Candidates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We currently depend entirely on the success of vonoprazan, which is our only product candidate. If we are unable to advance vonoprazan in clinical development, obtain regulatory approval and ultimately commercialize vonoprazan, or experience significant delays in doing so, our business will be materially harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently only have one product candidate, vonoprazan, which we in-licensed from Takeda. Our business presently depends entirely on our ability to successfully develop, obtain regulatory approval for, and commercialize vonoprazan in a timely manner. This may make an investment in our company riskier than similar companies that have multiple product candidates in active development that may be able to better sustain failure of a lead product candidate. In April 2021, we reported positive results from a pivotal Phase 3 clinical trial for vonoprazan triple therapy and vonoprazan dual therapy for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection, and in September 2021 we submitted NDAs for vonoprazan triple therapy and vonoprazan dual therapy for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection in adults to the FDA, which granted the NDAs Priority Review and set a PDUFA action date of May 3, 2022. In October 2021, we reported positive results from a pivotal Phase 3 trial for vonoprazan for the treatment of erosive esophagitis, and in March 2022, we plan to submit an NDA to the FDA for vonoprazan for healing of all grades of erosive esophagitis and relief of heartburn, and maintenance of healing of all grades of erosive esophagitis and relief of heartburn. In February 2022, we initiated a Phase 3 trial for vonoprazan using a daily dosing regimen for the treatment of NERD and expect to report topline results in 2023. Our assumptions about vonoprazan&#x2019;s commercial potential are based in large part on the commercial experience of vonoprazan in Japan. However, our assumptions may prove to be wrong, and we may encounter a materially and adversely different development and commercial experience. The success of vonoprazan will depend on several factors, including the following:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">acceptance by the FDA or by comparable foreign regulatory authorities of our proposed design of our clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">successful enrollment in clinical trials and completion of clinical trials with favorable results;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the willingness of the FDA, the European Medicines Agency, or EMA, and other comparable foreign regulatory authorities to accept the data from the clinical trials and preclinical studies and clinical trials conducted outside of our licensed territories by Takeda and independent investigators as part of the basis for review and approval of vonoprazan;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">demonstrating safety and efficacy to the satisfaction of applicable regulatory authorities;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the outcome, timing and cost of meeting regulatory requirements established by the FDA, EMA, and other comparable foreign regulatory authorities;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">receipt of marketing approvals from applicable regulatory authorities, including one or more NDAs from the FDA and maintaining such approvals;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">making and/or maintaining arrangements with Takeda, Catalent, Sandoz, or any future third-party manufacturers for, or establishing, commercial manufacturing capabilities and receiving/importing commercial supplies approved by FDA and other regulators from Takeda, Catalent or any future third-party manufacturer;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establishing sales, marketing and distribution capabilities and commercializing vonoprazan, if approved, whether alone or in collaboration with others;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establishment and maintenance of patent and trade secret protection or regulatory exclusivity for vonoprazan;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">maintaining an acceptable safety profile of vonoprazan following approval; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">maintaining and growing an organization of people who can develop and, if approved, commercialize, market, and sell vonoprazan to physicians, patients, healthcare payors, and others in the medical community.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The success of our business, including our ability to finance our company and generate any revenue in the future, will primarily depend on the successful completion of clinical development, regulatory approval and commercialization of vonoprazan, which may never occur. We have not yet succeeded in obtaining marketing approval for vonoprazan. If we are unable to develop or obtain regulatory approval for, or, if approved, successfully commercialize vonoprazan, we may not be able to generate sufficient revenue to continue our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">and the results of preclinical studies and early clinical trials are not necessarily predictive of future results.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical drug development is expensive and can take many years to complete, and its outcome is inherently uncertain. Even if we believe the results of our clinical trials are positive, obtaining regulatory approval may not occur on a timely basis, if at all. The results from clinical trials or preclinical studies of a product candidate may not predict the results of later clinical trials of the product candidate, and interim results of a clinical trial are not necessarily indicative of final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after the product candidate achieved promising results in earlier clinical trials. The results of our trials may not be comparable to those achieved previously, whether as a result of differences in trial design, patient population or otherwise.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For example, in our Phase 3 clinical trial for the treatment of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection, the vonoprazan dual therapy arm was not double-blinded because patients in this arm were administered amoxicillin three times daily, versus twice daily for the triple therapy regimens. Both triple therapy regimens were double-blinded. The inability to double-blind the dual therapy arm may impact how regulatory agencies or healthcare payors interpret such results. For example, the EMA has noted that it expects additional analyses of treatment compliance and drop-out rates in the dual therapy arm because it will not be double-blinded.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, in July 2019, we received scientific advice from the EMA on our Phase 3 clinical trial of vonoprazan in the healing and maintenance of healing of erosive esophagitis. For the healing phase of the study, the EMA recommended that we include an endoscopy to assess healing at Week 4 in addition to the planned endoscopies at Week 2 and Week 8 because the summary of product characteristics for lansoprazole suggests four weeks of treatment to assess healing in erosive esophagitis. We decided not to incorporate this change into the study design given the additional burden on study subjects to return for a third endoscopy in an eight-week period. This decision may impact the future summary of product characteristics for vonoprazan or may cause the EMA to require us to conduct additional clinical trials for vonoprazan to support marketing approval.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, Takeda, a third party over which we have no control, has the right to develop and commercialize vonoprazan outside of the United States, Europe, and Canada. Takeda has marketing approval for vonoprazan in certain countries in Asia and Latin America, and Takeda has ongoing clinical trials of vonoprazan in certain indications that we are also pursuing. If such ongoing trials fail to meet their primary endpoints, have serious adverse events or encounter other problems, the development potential of vonoprazan could be materially and adversely affected. In addition, if serious adverse events or other problems occur with patients using vonoprazan marketed outside of our licensed territories, or if the results of ongoing or future clinical trials of vonoprazan conducted by Takeda or others generate negative results or results that conflict with the results of our clinical trials, the FDA or other regulatory authorities may delay, limit, or deny approval of vonoprazan, require us to conduct additional clinical trials as a condition to marketing approval, or withdraw their approval of vonoprazan or otherwise restrict our ability to market and sell vonoprazan, if approved. In addition, treating physicians may be less willing to prescribe vonoprazan due to concerns over such trial results or adverse events, which would limit our ability to commercialize vonoprazan.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the foregoing reasons, our clinical trials and our efforts to obtain regulatory approval for vonoprazan may not be successful. Further, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of vonoprazan or any future product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Any difficulties or delays in the commencement or completion, or termination or suspension, of our clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before obtaining marketing approval from regulatory authorities for the sale of vonoprazan or any future product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of vonoprazan or any future product candidates in humans. We do not know whether any ongoing studies will be completed on schedule, if at all, or if any future clinical trials will begin on time. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA, EMA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials and reaching consensus among the FDA and EMA over the design of the same clinical trial;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any failure or delay in obtaining regulatory authorizations to commence a trial;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any failure or delay in reaching an agreement with contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">institutional review boards, or IRBs, or other reviewing bodies refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes to clinical trial protocols;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical sites deviating from trial protocols or dropping out of a trial;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manufacturing or obtaining sufficient quantities of vonoprazan and any future product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inability to obtain and deliver sufficient quantities of vonoprazan and any future product candidates to clinical sites;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subjects failing to enroll or remain in our trials at the rate we expect, or failing to return for post- treatment follow-up;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subjects choosing an alternative treatment for the indication for which we are developing vonoprazan and any future product candidates, or participating in competing clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">lack of adequate funding to continue the clinical trial;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subjects experiencing severe or unexpected drug-related adverse effects;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">occurrence of serious adverse events in trials of the same class of agents conducted by other companies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a facility manufacturing vonoprazan or any future product candidates or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of current good manufacturing, or cGMP, regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any changes to our manufacturing process that may be necessary or desired;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices, or GCP, or other regulatory requirements;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">third-party contractors not performing data collection or analysis in a timely or accurate manner; or</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. For example, in March 2020, due to global efforts to combat the COVID-19 pandemic, we announced a temporary pause in randomization of new patients in our Phase 3 trials and did not recommence randomizations for approximately three months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted or by the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities may impose a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing, or successful completion of a clinical trial.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, conducting clinical trials in foreign countries, as we have done for vonoprazan and may do for any future product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, principal investigators for our clinical trials currently serve and may continue to serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the clinical trial. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of vonoprazan or any future product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we experience delays in the completion of, or termination of, any clinical trial of vonoprazan or any future product candidates, the commercial prospects of vonoprazan and any future product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. We may make formulation or manufacturing changes to vonoprazan or any future product candidates, in which case we may need to conduct additional preclinical studies to bridge our modified product candidates to earlier versions. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize vonoprazan or any future product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of vonoprazan and any future product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition, and prospects significantly.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to initiate or continue clinical trials for vonoprazan or any future product candidates if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. Subject enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial, the risk that enrolled patients will not complete a clinical trial, our ability to recruit clinical trial investigators with the appropriate competencies and experience, competing clinical trials and clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating as well as any drugs under development. We will be required to identify and enroll a sufficient number of patients for each of our clinical trials. Potential patients for any planned clinical trials may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for such trials. We also may encounter difficulties in identifying and enrolling patients with a stage of disease appropriate for our clinical trials and monitoring such patients adequately during and after treatment. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible patients to participate in the clinical trials required by the FDA or comparable foreign regulatory authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. The eligibility criteria of our clinical trials further limits the pool of available trial participants. If patients are unwilling to participate in our trials for any reason, including the existence of concurrent clinical trials for similar patient or the availability of approved therapies, or we otherwise have difficulty enrolling a sufficient number of patients, the timeline for recruiting patients, conducting trials and obtaining regulatory approval of vonoprazan and any future product candidates may be delayed. Further, public health emergencies, such as the COVID-19 pandemic have and may continue to negatively affect site activation, as well as patient enrollment and retention. Our inability to enroll a sufficient number of patients for any of our future clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our assumptions used in determining expected clinical trial timelines may not be correct, and we may experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of vonoprazan or any future product candidates could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of an approved label or result in other significant negative consequences that could severely harm our business, prospects, operating results and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with vonoprazan&#x2019;s or any future product candidates&#x2019; use. Results of our ongoing or future clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by vonoprazan and any future product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition, and prospects significantly.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, if vonoprazan or any other future product candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the product candidate, if approved. We may also be required to modify our study plans based on findings in our clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 2021, more than 8,000 subjects have been exposed to vonoprazan in completed and ongoing Phase 1 to 3 clinical trials. The doses studied have ranged from 1 to 120 mg with durations up to one year. In our Phase 3 clinical trial for EE, the most common adverse reactions (&#x2265;2%) in vonoprazan-treated patients in the healing phase were abdominal pain and diarrhea and in the maintenance phase were gastritis, diarrhea, abdominal pain, dyspepsia, gastroesophageal reflux disease, hypertension, abnormal liver function test, and nausea. Of these, only two adverse events, both in the maintenance phase, exceeded 5%: gastritis (6.4%, vonoprazan 10 mg) and abdominal pain (5.4%, vonoprazan 20 mg). In our Phase 3 clinical trial evaluating vonoprazan in combination with amoxicillin and clarithromycin or amoxicillin, most common adverse reactions (&#x2265;2%) in vonoprazan triple therapy-treated patients were dysgeusia, diarrhea, headache, abdominal pain, vulvovaginal candidiasis and hypertension and with vonoprazan dual therapy-treated patients were diarrhea, abdominal pain and nasopharyngitis.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain earlier generation P-CABs previously under development by other companies may have been discontinued in part due to their hepatic safety profile. These hepatic safety concerns may be compound-specific and not generalizable to the P-CAB class. Vonoprazan has shown similar hepatic safety results to lansoprazole across all comparative clinical studies conducted by Takeda, in which 1.0% of subjects treated with vonoprazan 10 mg or 20 mg and 0.8% of subjects treated with lansoprazole 15 mg or 30 mg had ALT or AST elevations greater than three times the upper limit of normal or bilirubin elevations greater than two times the upper limit of normal. Similarly, in the healing phase of PHALCON-EE, transient elevations in ALT or AST greater than 3 times the upper limit of normal were observed in 0.4% of subjects treated with vonoprazan 20 mgs and 0.2% of subjects treated with lansoprazole. In the maintenance phase, ALT or AST greater than three times the upper limit of normal were observed in 1% of subjects treated with vonoprazan 10 mg, 0.3% of subjects treated with vonoprazan 20 mg, and 2% of subjects treated with lansoprazole. The most recent post-marketing safety report from December 2021 includes an estimate of over 50 million patients who have received vonoprazan in Japan and other countries in Asia since launch. Based on the post-marketing experience, the clinically significant adverse reactions section of the Japanese prescribing information for vonoprazan was updated to include shock, anaphylaxis, hepatic impairment, skin reactions such as toxic epidermal necrolysis, Steven- Johnson syndrome, and erythema multiforme, and events of pancytopenia, agranulocytosis, leukocytopenia, and thrombocytopenia. The incidence of these reactions was considered extremely rare (less than 1 in 100,000 patients) and a causal relationship to vonoprazan could not be ruled out. Although serious hepatic adverse events have been observed among patients exposed to vonoprazan in Japan in the post-marketing setting, these cases were typically confounded by comorbidities or other concomitant medications and are believed to be idiosyncratic reactions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The post-marketing safety data, including the December 2021 post-marketing safety report and the reported hepatic safety events, have been submitted to the PMDA. We may also observe hepatic-related events in our clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">It is possible that as we continue to test vonoprazan and any future product candidates in our clinical trials, or as the use of vonoprazan and any future product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. If any such side effects become known later in development or upon approval, such findings may harm our business, financial condition and prospects significantly. Further, if a serious safety issue is identified in connection with use of vonoprazan commercially or in third-party clinical trials in Asia or elsewhere, such issues may adversely affect the development potential of vonoprazan or result in regulatory authorities restricting our ability to develop vonoprazan.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, if vonoprazan or any future product candidate receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory authorities may withdraw, suspend or limit approvals of such product, or seek an injunction against its manufacturer;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be required to recall a product or change the way such product is administered to patients;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory authorities may require additional warnings on the label, such as a &#x201c;black box&#x201d; warning or a contraindication;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or similar risk management measures or create a medication guide outlining the risks of such side effects for distribution to patients;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be required to change the way a product is distributed or administered, conduct additional clinical trials or change the labeling of a product or be required to conduct additional post-marketing studies or surveillance;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we could be sued and held liable for harm caused to patients;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">sales of the product may decrease significantly or the product could become less competitive; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our reputation may suffer.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">As a company, we have never obtained regulatory approval for a product candidate and may be unable to do so for vonoprazan or any future product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we have completed our pivotal Phase 3 clinical trials for vonoprazan for treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection and erosive esophagitis, and have submitted NDAs for the use of vonoprazan dual therapy and vonoprazan triply therapy for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in adults, we still need to obtain regulatory approvals from the FDA. As a company, we have not previously obtained any regulatory approvals and consequently we may be unable to successfully obtain approval of vonoprazan or any future product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to timely obtain regulatory approvals could delay us in commercializing vonoprazan or any future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Vonoprazan and any future product candidates are subject to extensive regulation and compliance obligations, which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize vonoprazan and any future product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of vonoprazan and any future product candidates are subject to extensive regulation by the FDA in the United States and by comparable foreign regulatory authorities in other foreign markets. In the United States, we are not permitted to market vonoprazan and any future product candidates until we receive regulatory approval from the FDA and in the EU, we are not permitted to market vonoprazan and any future product candidates until we receive a marketing authorization from the European Commission or competent authorities of the EU member states. The process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population. The ability of the FDA and foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels and the ability to hire and retain key personnel. In addition, approval policies or regulations may change, and the FDA and EMA and comparable regulatory authorities have substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to obtaining approval to commercialize a product candidate in the United States or internationally, we must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for vonoprazan and any future product candidates are promising, such data may not be sufficient to support approval by the FDA and comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities, as the case may be, may also require us to conduct additional preclinical studies or clinical trials for vonoprazan and any future product candidates either prior to or post- approval, or may object to elements of our clinical development program.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA, EMA or other comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">such authorities may disagree with the design or implementation of our clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA, EMA, or other comparable foreign regulatory agencies for approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or in clinical trials conducted by Takeda or others outside of our licensed territories, or by patients using vonoprazan or drugs similar to vonoprazan;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be unable to demonstrate to the satisfaction of such authorities that a product candidate is safe and effective for its proposed indication and that a product candidate&#x2019;s clinical and other benefits outweigh its safety risks;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">such authorities may not agree that the data collected from clinical trials of vonoprazan, including data collected from clinical trials conducted by Takeda and independent investigators outside of our licensed territories, and any future product candidates are acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval, and such authorities may impose requirements for additional preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">such authorities may disagree regarding the formulation, labeling and/or the specifications of vonoprazan and any future product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">such authorities may find deficiencies in the manufacturing processes or facilities of Takeda, Sandoz, Catalent or any future third-party manufacturers with which we contract for clinical and commercial supplies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulations of such authorities may significantly change in a manner rendering our or any of our potential future collaborators&#x2019; clinical data insufficient for approval; or</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by the FDA, EMA, and other comparable foreign regulatory authorities in reviewing new drugs based on safety, efficacy, or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our potential future collaborators from commercializing vonoprazan and any future product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Of the large number of drugs in development, only a small percentage successfully complete the FDA, EMA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market vonoprazan and any future product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we eventually receive approval of an NDA or foreign marketing application for vonoprazan and any future product candidates, the FDA or other comparable foreign regulatory authority may grant approval contingent on the performance of costly additional clinical trials, including confirmatory Phase 3 clinical trials, Phase 4 clinical trials, and/or the implementation of a REMS or risk management measures, which may be required to ensure safe use of the drug after approval. The FDA or other comparable foreign regulatory authority also may approve a product candidate for a more limited indication or patient population than we originally requested, and the FDA or other comparable foreign regulatory authority may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Designation of vonoprazan in combination with both amoxicillin and clarithromycin, and with amoxicillin alone as a QIDP, receipt of Fast Track designation, and the potential to receive priority review, may not actually lead to faster development or regulatory review or other benefits, and do not assure FDA approval of vonoprazan or any future product candidates which may receive such designations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Generating Antibiotic Incentives Now, or GAIN, Act established certain programs intended to incentivize the development of antibacterial and antifungal drugs for human use to treat serious or life-threatening infections. Specifically, pursuant to the GAIN Act, the FDA may designate certain antimicrobial products as QIDPs, which would qualify them for certain benefits. A QIDP is an antibacterial or antifungal drug for human use intended to treat serious or life-threatening infections, including those caused by either (1) an antibacterial or antifungal resistant pathogen, including novel or emerging infectious pathogens, or (2) a so-called &#x201c;qualifying pathogen&#x201d; found on a list of potentially dangerous, drug-resistant organisms established and maintained by the FDA under the GAIN Act. The FDA interprets QIDP designation to apply to a specific drug product, including a specific dosage form of the product, and the FDA does not apply the designation to the drug substance in general or beyond the specified indications identified in the designation. The benefits of QIDP designation include eligibility for Fast Track designation, eligibility for priority review, and an extension by an additional five years of any non-patent exclusivity period awarded, such as a five-year exclusivity period awarded for a new chemical entity. This extension is in addition to any pediatric exclusivity extension that may be awarded. Receipt of QIDP designation does not assure ultimate approval by the FDA or related GAIN Act exclusivity benefits. A sponsor must request such designation before submitting a marketing application, and the FDA will respond to a request for QIDP designation within 60 days of the date the FDA receives the request.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2019, the FDA granted QIDP designation to vonoprazan tablets in combination with both amoxicillin tablets and clarithromycin tablets, and with amoxicillin tablets alone, for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection. Further, in May 2021, the FDA granted QIDP designations to vonoprazan tablets in combination with both amoxicillin capsules and clarithromycin tablets, and with amoxicillin capsules alone, respectively, for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection. Under the GAIN Act, the FDA may only revoke a QIDP designation if the request for such designation contained an untrue statement of material fact. While we believe that our request for our QIDP designations did not contain any untrue statement of material fact, if the FDA were to seek to revoke our QIDP designations covering our products containing vonoprazan in combination with both amoxicillin and clarithromycin, and with amoxicillin alone, and if FDA were successful in doing so, we would not obtain the GAIN Act exclusivity benefits for such products. If this were to occur, it could have a material, adverse effect on our business prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan in combination with both amoxicillin and clarithromycin and with amoxicillin alone has received Fast Track designation for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection and the NDAs we submitted for each of these combinations have received priority review.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Fast Track designation program is intended to expedite or facilitate the process for reviewing new drug candidates that meet certain criteria.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Specifically, new drugs are eligible for Fast Track designation if they are intended, alone or in combination with one or more drugs, to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the drug candidate and the specific indication for which it is being studied. With a Fast Track designated drug candidate, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Priority review means the FDA&#x2019;s goal is to take action on an application within 6 months (compared to 10 months under standard review) following the NDA filing date. The FDA automatically grants priority review to the first application or efficacy supplement submitted for a specific drug and indication that has received the QIDP designation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining a QIDP designation, priority review, or Fast Track designation does not change the standards for product approval but may expedite the development or approval process. Accordingly, such QIDP designations, Fast Track designations, and priority review may not actually result in faster clinical development or regulatory review or approval. Furthermore, QIDP designation, Fast Track designation, and priority review would not increase the likelihood that vonoprazan will receive marketing approval in the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be successful in our efforts to expand our pipeline by identifying and successfully developing vonoprazan for additional indications and formulations. We may expend our limited resources to pursue a particular indication or formulation for vonoprazan and fail to capitalize on product candidates, indications or formulations that may be more profitable or for which there is a greater likelihood of success.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because we have limited financial and managerial resources, we focus on specific indications and formulations for vonoprazan. As a result, we may fail to generate additional clinical development opportunities for vonoprazan for a number of reasons, including, vonoprazan may in certain indications, on further study, be shown to have harmful side effects, limited to no efficacy, or other characteristics that suggest it is unlikely to receive marketing approval and achieve market acceptance in such additional indications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For example, we believe vonoprazan may be suitable for use on a continuous (or daily) basis for the management of NERD and in February 2022 commenced a Phase 3 trial for vonoprazan daily-dosing for NERD. In addition, we believe the rapid onset of action of vonoprazan may enable on-demand, or as needed, use for the management of NERD. However, two Phase 3 clinical trials of vonoprazan in Japanese patients with endoscopically confirmed NERD conducted by Takeda did not demonstrate a statistically significant difference in symptom scores between vonoprazan and placebo. We believe that this result may be due to patient selection. In addition, Takeda conducted a Phase 2 clinical trial in Europe in 256 patients with NERD who were partial responders to high dose PPIs. Patients were randomized to receive vonoprazan 20 mg, vonoprazan 40 mg, or esomeprazole 40 mg for four weeks. Neither vonoprazan dose demonstrated a benefit versus esomeprazole on the primary endpoint of the percentage of heartburn free days over the treatment period. We believe this result may also be due to patient selection. Specifically, the above trials may not have been adequately designed to achieve appropriate patient selection. We may be incorrect in our beliefs regarding the results of such trials and any future clinical trials we conduct in NERD patients may not succeed for similar or other reasons, including as a result of our design and enrollment criteria.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, research programs to identify additional indications for vonoprazan require substantial technical, financial and human resources. We may also pursue additional formulations and packaging for vonoprazan, such as orally disintegrating tablets and other oral dosage forms for patients with difficulty swallowing, and an intravenous formulation for in-hospital applications. However, we may not successfully develop these additional formulations for chemistry-related, stability-related or other reasons. If we do not accurately evaluate the commercial potential or target market for vonoprazan or any future product candidates, we may relinquish valuable rights to that product candidate through future collaborations, licenses and other similar arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, we may pursue additional in-licenses or acquisitions of development-stage assets or programs, which entails additional risk to us. Identifying, selecting and acquiring promising product candidates requires substantial technical, financial and human resources expertise. Efforts to do so may not result in the actual acquisition or license of a particular product candidate, potentially resulting in a diversion of our management&#x2019;s time and the expenditure of our resources with no resulting benefit.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We enrolled patients in Europe in our erosive esophagitis and H. pylori trials. Additionally, we may conduct future clinical trials outside of the United States. However, the FDA and other comparable foreign regulatory authorities may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We enrolled patients in Europe in our erosive esophagitis and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">trials, and we may conduct one or more of our future clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States and not subject to an IND, acceptance of this data is subject to certain conditions imposed by the FDA. For example, where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data alone unless those data are applicable to the United States population and United States medical practice; the trials were performed by clinical investigators of recognized competence; and the data are considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Similar requirements may apply in foreign jurisdictions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For trials that are conducted only at sites outside of the United States and not subject to an IND, the FDA requires the clinical trial to have been conducted in accordance with GCP and the FDA must be able to validate the data from the clinical trial through an on-site inspection if it deems such inspection necessary. For such trials not subject to an IND, the FDA generally does not provide advance comment on the clinical protocols for the trials, and therefore there is an additional potential risk that the FDA could determine that the trial design or protocol for a non-United States clinical trial was inadequate, which could require us to conduct additional clinical trials. In addition, such foreign trials would be subject to the applicable local laws of the foreign regulatory agency and legal requirements where the trials are conducted. There can be no assurance the FDA will accept data from clinical trials conducted outside of the United States. If the FDA or comparable regulatory authority does not accept data from our clinical trials of vonoprazan and any future product candidates, it would likely result in the need for additional clinical trials, which would be costly and time consuming and delay or permanently halt our development of vonoprazan and any future product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Conducting clinical trials outside the United States also exposes us to additional risks, including risks associated with:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">additional foreign regulatory requirements;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">foreign exchange fluctuations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compliance with foreign manufacturing, customs, shipment and storage requirements;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cultural differences in medical practice and clinical research; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">diminished protection of intellectual property in some countries.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interim, top-line and preliminary data from clinical trials that we or others announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we or others, such as Takeda, may publicly disclose preliminary or top-line data from clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we or others report may differ from future results of the same clinical trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we or others may also disclose interim data from clinical trials. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary, top-line or interim data and final data could significantly harm our business prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the top-line data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, vonoprazan and any future product candidates may be harmed, which could harm our business, operating results, prospects, or financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ability of the FDA and other government agencies to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, a government agency&#x2019;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the government agency&#x2019;s ability to perform routine functions. Average review times at the FDA and other government agencies have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies, such as the EMA, may also slow the time necessary for new drugs and or modifications to approved drugs or to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the United States government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Separately, in response to the COVID-19 pandemic, in March 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, in July 2020, the FDA resumed certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA utilized this risk-based assessment system to assist in determining when and where it was safest to conduct prioritized domestic inspections. Additionally, on April 15, 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites, among other facilities. According to the guidance, the FDA may request such remote interactive evaluations where the FDA determines that remote evaluation would be appropriate based on mission needs and travel limitations. In May 2021, the FDA outlined a detailed plan to move toward a more consistent state of inspectional operations, and in July 2021, the FDA resumed standard inspectional operations of domestic facilities and was continuing to maintain this level of operation as of September 2021. More recently, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to hinder or prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Reliance on Third Parties</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We rely on the Takeda License to provide us rights to develop and commercialize vonoprazan in the United States, Europe, and Canada. If the license agreement is terminated, we would lose our rights to develop and commercialize vonoprazan.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Takeda License, we have secured an exclusive license from Takeda to commercialize vonoprazan products using specified formulations for all human therapeutic uses in the United States, Europe, and Canada, and a non-exclusive license to develop and manufacture vonoprazan products anywhere in the world (subject to Takeda&#x2019;s consent as to each country) for the purposes of commercializing the vonoprazan products in the United States, Europe, and Canada.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Takeda License will continue until the expiration of the obligation to pay royalties in all countries and on all products, unless terminated earlier. We may terminate the Takeda License in its entirety without cause upon prior written notice. We and Takeda may terminate the Takeda License in the case of the other party&#x2019;s insolvency or for the other party&#x2019;s material uncured breach. Takeda may terminate the Takeda License in its entirety if we challenge the licensed patents, or if we assist any third party in challenging such patents. In addition, if any of the commercial milestones or other cash payments become due under the terms of the Takeda License, we may not have sufficient funds available to meet our obligations, which would allow Takeda to terminate the Takeda License. If the license agreement is terminated, we would lose our rights to develop and commercialize vonoprazan, which in turn would have a material adverse effect on our business, operating results and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We rely on third parties to conduct our clinical trials. Any failure by a third party to conduct the clinical trials according to GCPs and other requirements and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize vonoprazan and any future product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are dependent on third parties to conduct our preclinical and clinical trials, including our completed and ongoing Phase 3 clinical trial of vonoprazan. Specifically, we have used and relied on, and intend to continue to use and rely on, medical institutions, clinical investigators, CROs and consultants to conduct our clinical trials in accordance with our clinical protocols and regulatory requirements. These CROs, investigators and other third parties will play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. While we have agreements governing the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for vonoprazan and any future product candidates that reach clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with product produced under cGMP or similar regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CROs, investigators or other third parties may not devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed, or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or comparable regulatory authority concludes that the financial relationship may have affected the interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any NDA or similar marketing application we submit by the FDA or by comparable regulatory authority. Any such delay or rejection could prevent us from commercializing vonoprazan and any future product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, investigators and other third parties, we may encounter challenges or delays in the future and these delays or challenges may have a material adverse impact on our business, financial condition and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We currently rely on Takeda for the manufacture of vonoprazan for clinical development and expect to continue to rely on Takeda, Catalent or other third parties for clinical supplies for the foreseeable future, and we will rely on Takeda, Catalent and other third parties to produce commercial supplies of vonoprazan drug substance and drug product, and on Sandoz for commercial supplies of amoxicillin and clarithromycin for our convenience packs. This reliance on third parties increases the risk that we will not have sufficient quantities of vonoprazan, amoxicillin, and/or clarithromycin, which could delay, prevent or impair our development or commercialization efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not own or operate manufacturing facilities and have no plans to build our own clinical or commercial scale manufacturing capabilities. Pursuant to the Takeda License, we entered into a clinical manufacturing and supply agreement with Takeda for the supply of vonoprazan for our clinical trials. In addition, we entered into a commercial supply agreement with Takeda for the commercial supply of bulk drug product and/or drug substance, a commercial supply agreement with Catalent for the commercial supply of drug product, and a commercial supply and packaging agreement with Sandoz for commercial supply of amoxicillin, clarithromycin and finished convenience packs containing vonoprazan and one or both of those antibiotics. As a result, we currently rely, and expect to continue to rely, on third parties for the manufacture of vonoprazan and related raw materials for clinical development and commercial supply. If Takeda, Catalent or Sandoz fails to fulfill its obligations under its respective supply agreement(s), or if any of the vonoprazan drug product or drug substance supplied by Takeda or Catalent cannot be utilized due to quality or cGMP or similar concerns, adverse findings during regulatory inspections or other reasons, our development plans and commercialization of vonoprazan, if approved, could be significantly delayed or otherwise adversely affected. The facilities used by Takeda or Catalent to manufacture vonoprazan and by Sandoz to manufacture amoxicillin and clarithromycin and to package the antibiotics and vonoprazan must be approved by the FDA and foreign regulatory authority pursuant to inspections that may be conducted after we submit marketing authorizations to the FDA and comparable foreign regulatory authorities. We do not control the manufacturing process of, and are completely dependent on, Takeda, Catalent and Sandoz for compliance with applicable cGMP or similar requirements. If Takeda, Catalent, Sandoz, or any other third-party manufacturer we contract with in the future, cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, including requirements related to the manufacturing of high potency compounds, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over Takeda&#x2019;s, Catalent&#x2019;s, Sandoz&#x2019;s, or any other third-party manufacturer&#x2019;s ability to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve of facilities of the third-party manufacturer for the manufacture of vonoprazan or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market vonoprazan, if approved. For example, in June 2020, the FDA issued a warning letter to Takeda following a routine inspection of aseptic (sterile) drug product manufacturing at Takeda&#x2019;s manufacturing facility located in Hikari, Yamaguchi, or the Hikari Facility. Although it is not an aseptic product, Takeda also manufactures vonoprazan drug substance and drug product at the Hikari Facility. The warning letter indicated that the FDA was not satisfied with Takeda&#x2019;s response to an FDA Form 483 issued to Takeda following the inspection and cited significant violations of cGMP for finished aseptic pharmaceuticals. Due to the issues relating to the Hikari Facility, we did not include the Hikari Facility, as a contract manufacturing site in the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">NDAs we submitted to FDA in September 2021. In October 2021, the FDA revised the inspection classification of the Hikari Facility to Voluntary Action Indicated, or VAI. Takeda has reported that this revision means the FDA determined that the conditions in the warning letter dated June 2020 have been sufficiently addressed. We have not experienced any clinical supply constraints to date as a result of the issues at the Hikari Facility, and we currently do not expect these issues will have an effect on our ongoing or future clinical trials or commercial supplies. Our failure, or Takeda&#x2019;s, Catalent&#x2019;s. Sandoz&#x2019;s or any other third-party manufacturer&#x2019;s failure, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. Furthermore, Takeda may choose to prioritize the manufacture of vonoprazan for its markets over the manufacture of vonoprazan for our licensed markets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our or Takeda&#x2019;s, Catalent&#x2019;s or Sandoz&#x2019;s failure, or the failure of any future third-party manufacturer, to execute on our manufacturing requirements, to do so on commercially reasonable terms and comply with cGMP could adversely affect our business in a number of ways, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an inability to initiate and continue clinical trials of vonoprazan or any future product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delay in submitting regulatory applications, or receiving marketing approvals, for vonoprazan and any future product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">requirements to cease development or to recall batches of vonoprazan and any future product candidates; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in the event of approval to market and commercialize vonoprazan or any future product candidates, an inability to meet commercial demands for vonoprazan or any future product candidates.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reliance on third-party manufacturers entails additional risks, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">breach of the manufacturing agreement by the third party;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure to manufacture our product according to our specifications;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure to manufacture our product according to our schedule or at all;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">misappropriation of our proprietary information, including our trade secrets and know-how; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. Moreover, there may be a limited number of manufacturers that operate under cGMP or similar regulations and that might be capable of manufacturing for us</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any performance failure on the part of Takeda, Catalent, Sandoz or any future manufacturers could delay clinical development or marketing approval, and any related remedial measures may be costly or time consuming to implement. We do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of vonoprazan and any future product candidates. If Takeda, Catalent, or Sandoz cannot perform as agreed, we may be required to replace them and we may be unable to replace them on a timely basis or at all. Further, Takeda, Catalent, Sandoz and any other third-party manufacturers we may use may experience manufacturing or shipping difficulties due to resource constraints or as a result of natural disasters, labor disputes, unstable political environments, or public health emergencies such as the COVID-19 outbreak. If Takeda, Catalent, Sandoz or other third-party manufacturers were to encounter any manufacturing or shipping difficulties or delays due to these factors, our ability to provide vonoprazan to patients in clinical trials, or to provide product for treatment of patients if approved, would be jeopardized.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current and anticipated future dependence upon others for the manufacture of vonoprazan or any future product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our reliance on third parties, including Takeda and Catalent, requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because we currently rely on Takeda and Catalent to manufacture vonoprazan and to perform quality testing, we must, at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, consulting agreements or other similar agreements with our advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets and despite our efforts to protect our trade secrets, a competitor&#x2019;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may seek to enter into collaborations, licenses and other similar arrangements and may not be successful in doing so, and even if we are, we may not realize the benefits of such relationships.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may seek to enter into collaborations, joint ventures, licenses and other similar arrangements for the development or commercialization of vonoprazan and any future product candidates, due to capital costs required to develop or commercialize vonoprazan and any future product candidates or manufacturing constraints. We may not be successful in our efforts to establish such collaborations for vonoprazan and any future product candidates because vonoprazan and any future product candidates may be deemed to be at too early of a stage of development for collaborative effort or third parties may not view vonoprazan and any future product candidates as having the requisite potential to demonstrate safety and efficacy or significant commercial opportunity. In addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process can be time consuming and complex. Further, any future collaboration agreements may restrict us from entering into additional agreements with potential collaborators. Following a strategic transaction or license, we may not achieve an economic benefit that justifies such transaction.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we are successful in our efforts to establish such collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, development or approval of a product candidate is delayed, the safety of a product candidate is questioned or sales of an approved product candidate are unsatisfactory.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, any potential future collaborations may be terminable by our strategic partners, and we may not be able to adequately protect our rights under these agreements. Furthermore, strategic partners may negotiate for certain rights to control decisions regarding the development and commercialization of vonoprazan and any future product candidates, if approved, and may not conduct those activities in the same manner as we do. Any termination of collaborations we enter into in the future, or any delay in entering into collaborations related to vonoprazan or any future product candidates, could delay the development and commercialization of vonoprazan or any future product candidates and reduce their competitiveness if they reach the market, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Commercialization of Vonoprazan and Any Future Product Candidates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if we receive regulatory approval for vonoprazan and any future product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, vonoprazan and any future product candidates, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with vonoprazan and any future product candidates, if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Following potential approval of vonoprazan or any future product candidates, the FDA, EMA or other comparable regulatory authority may impose significant restrictions on a product&#x2019;s indicated uses or marketing or impose ongoing requirements for potentially costly and time-consuming post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy of the product. The FDA and comparable regulatory authorities may also require a REMS or similar risk management measures as a condition of approval of vonoprazan or any future product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves vonoprazan or any future product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our products will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and similar requirements and GCP requirements for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our products, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal by the FDA or comparable foreign regulatory authority to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product seizure or detention, or refusal to permit the import or export of our products; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The occurrence of any event or penalty described above may inhibit our ability to commercialize vonoprazan and any future product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA&#x2019;s and other regulatory authorities&#x2019; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of vonoprazan and any future product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, may be subject to enforcement action, and we may not achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For instance, the EU has adopted the Clinical Trials Regulation, or CTR, in April 2014, which will become applicable on 31 January 2022. The CTR will be directly applicable in all EU member states, repealing the current Clinical Trials Directive. Conduct of all clinical trials performed in the EU will continue to be bound by currently applicable provisions until the new CTR becomes applicable. The extent to which ongoing clinical trials will be governed by the CTR will depend on when the CTR becomes applicable and on the duration of the individual clinical trial. If a clinical trial continues for more than three years from the day on which the CTR becomes applicable the CTR will at that time begin to apply to the clinical trial. The CTR harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which will notably contain a centralized EU portal and database.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">It is currently unclear to what extent the United Kingdom, or UK, will seek to align its regulations with the EU. The UK regulatory framework in relation to clinical trials is derived from existing EU legislation (as implemented into UK law, through secondary legislation). A decision by the UK not to closely align its regulations with the new approach that will be adopted in the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries and/or make it harder to seek a marketing authorization in the EU for our product candidates on the basis of clinical trials conducted in the UK.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, the EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. A proposal for revision of several legislative instruments related to medicinal products (potentially revising the duration of regulatory exclusivity, eligibility for expedited pathways, etc.) is expected to be adopted by the European Commission by the end of 2022. The proposed revisions, once they are agreed and adopted by the European Parliament and European Council (not expected before the end of 2024) may have a significant impact on the biopharmaceutical industry in the long term.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The commercial success of vonoprazan or any future product candidates will depend upon the degree of market acceptance of such product candidates by physicians, patients, healthcare payors and others in the medical community.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vonoprazan and any future product candidates may not be commercially successful. The commercial success of vonoprazan or any future product candidates, if approved, will depend significantly on the broad adoption and use of such product by physicians and patients for approved indications. The degree of market acceptance of vonoprazan or any future products, if approved, will depend on a number of factors, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">demonstration of clinical efficacy and safety compared to other more-established products;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the indications for which vonoprazan or any future product candidates are approved;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the limitation of our targeted patient population and other limitations or warnings contained in any FDA-approved labeling or comparable approved labeling;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">acceptance of a new drug for the relevant indication by healthcare providers and their patients;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the pricing and cost-effectiveness of our products, as well as the cost of treatment with our products in relation to alternative treatments and therapies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, including Medicare and Medicaid, private health insurers and other third-party payors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the willingness of patients to pay all, or a portion of, out-of-pocket costs associated with our products in the absence of sufficient third-party coverage or adequate reimbursement;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any restrictions on the use of our products, and the prevalence and severity of any adverse effects;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential product liability claims;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing of market introduction of our products as well as competitive drugs;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the effectiveness of our or any of our potential future collaborators&#x2019; sales and marketing strategies; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unfavorable publicity relating to the product.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If vonoprazan or any future product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors or patients, we may not generate sufficient revenue from that product and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of our products may require significant resources and may never be successful.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With respect to vonoprazan, Takeda has the right to develop and commercialize the product outside of the United States, Europe, and Canada and has received marketing approval for vonoprazan in certain countries in Asia and Latin America. We have little or no control over Takeda&#x2019;s commercialization activities with respect to vonoprazan outside of our licensed territories even though those activities could impact our ability to successfully commercialize vonoprazan. For example, Takeda can make statements or use promotional materials with respect to vonoprazan outside of our licensed territories that are inconsistent with our positioning of the product in the United States, Europe, and Canada, and could sell vonoprazan in foreign countries at prices that are dramatically lower than the prices we would charge in our licensed territories. These activities and decisions, while occurring outside of our licensed territories, could harm our commercialization strategy. In addition, product recalls or safety issues with vonoprazan outside our licensed territories could result in serious damage to the brand and impair our ability to successfully market vonoprazan in our licensed territories.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found or alleged to have improperly promoted off-label uses, we may become subject to significant liability.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, as vonoprazan and any future product candidates would be, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#x2019;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of vonoprazan or any future product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The successful commercialization of vonoprazan or any future product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability to generate revenue.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The availability of coverage and the adequacy of reimbursement by governmental healthcare programs, such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as vonoprazan or any future product candidate, if approved. Our ability to achieve coverage and acceptable levels of reimbursement for our products by third-party payors will have an effect on our ability to successfully commercialize those products. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our products as substitutable and only offer to reimburse patients for the less expensive product. Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our products, pricing of existing drugs may limit the amount we will be able to charge for our products. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products and may not be able to obtain a satisfactory financial return on products that we may develop.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining and maintaining reimbursement status is time consuming, costly and uncertain. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However, no uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of our products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with the sale of any of our products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If following commercialization of vonoprazan (or any future product candidates, if approved) we fail to comply with reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we successfully commercialize vonoprazan and any future product candidates, if approved, we will likely participate in governmental programs, such as Medicaid, that impose extensive drug price reporting and payment obligations on pharmaceutical manufacturers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Medicaid is a joint federal and state program that is administered by the states for low-income and disabled beneficiaries. Medicare is a federal program that is administered by the federal government covering individuals age 65 and over as well as those with certain disabilities. Under the Medicaid Drug Rebate Program, or MDRP, as a condition of having federal funds being made available to the states for covered outpatient drugs under Medicaid, pharmaceutical manufacturers must enter into an agreement with the Secretary of Health and Human Services to pay a rebate to state Medicaid programs for each unit of covered outpatient drug dispensed to a Medicaid beneficiary and paid for by the state Medicaid program. Medicaid drug rebates are based on pricing data that pharmaceutical manufacturers report on a monthly and quarterly basis to the U.S. Centers for Medicare &amp; Medicaid Services, or CMS, which is the federal agency that administers the MDRP and Medicare programs. For the MDRP, these data include the average manufacturer price, or AMP, for each drug and, in the case of innovator products, the Best Price, or BP, which represents the lowest price available from the manufacturer to any entity in the United States in any pricing structure, calculated to include all applicable sales and associated rebates, discounts and other price concessions. If a manufacturer becomes aware that its MDRP government price reporting submission for a prior quarter was incorrect or has changed as a result of recalculation of the pricing data, the manufacturer must resubmit the corrected data for up to three years after those data originally were due. If a manufacturer fails to provide information timely or is found to have knowingly submitted false information to the government, the manufacturer may be subject to civil monetary penalties and other sanctions, including termination from the MDRP.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal law requires that any company that participates in the MDRP also participate in the Public Health Service&#x2019;s 340B drug pricing program, or the 340B program, in order for federal funds to be available for the manufacturer&#x2019;s drugs under Medicaid. The 340B program is administered by the Health Resources and Services Administration, or HRSA, and requires participating manufacturers to agree to charge statutorily defined covered entities no more than the 340B &#x201c;ceiling price&#x201d; for the manufacturer&#x2019;s covered drugs used in an outpatient setting. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low&#x2011;income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the average manufacturer price and rebate amount for the covered outpatient drug as calculated under the MDRP. In general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement. Manufacturers must report 340B ceiling prices to HRSA on a quarterly basis, and HRSA publishes them to 340B covered entities. HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities for 340B&#x2011;eligible drugs. HRSA has also finalized an administrative dispute resolution process through which 340B covered entities may pursue claims against participating manufacturers for overcharges, and through which manufacturers may pursue claims against 340B covered entities for engaging in unlawful diversion or duplicate discounting of 340B drugs. In addition, legislation may be introduced that, if passed, would further expand the 340B program, such as adding further covered entities or requiring participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In order to be eligible to have drug products paid for with federal funds under Medicaid and purchased by certain federal agencies and grantees, a manufacturer must also participate in the U.S. Department of Veterans Affairs, or VA, Federal Supply Schedule, or FSS, pricing program. Under the VA/FSS program, a manufacturer must report the Non-Federal Average Manufacturer Price, or Non-FAMP, for its covered drugs to the VA and charge certain federal agencies no more than the Federal Ceiling Price, which is calculated based on Non-FAMP using a statutory formula. These four agencies are the VA, the U.S. Department of Defense, the U.S. Coast Guard, and the U.S. Public Health Service (including the Indian Health Service). The manufacturer must also pay rebates on products purchased by military personnel and dependents through the TRICARE retail pharmacy program. If a manufacturer participating in the FSS program fails to provide timely information or is found to have knowingly submitted false information, the manufacturer may be subject to civil monetary penalties.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Individual states continue to consider and have enacted legislation to limit the growth of healthcare costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation that may prevent or limit our ability to take price increases at certain rates or frequencies. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered by manufacturers in taking such increases, wholesale acquisition cost disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for certain drugs, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with drug price transparency requirements, including the untimely, inaccurate, or incomplete reporting of drug pricing information. If we are found to have violated state law requirements, we may become subject to penalties or other enforcement mechanisms, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by pharmaceutical manufacturers, governmental or regulatory agencies, and the courts, which can change and evolve over time. Such pricing calculations and reporting, along with any necessary restatements and recalculations, could increase costs for complying with the laws and regulations governing the MDRP and other governmental programs, and under the MDRP could result in an overage or underage in Medicaid rebate liability for past quarters. Price recalculations under the MDRP also may affect the ceiling price at which manufacturers are required to offer products under the 340B program. Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we are found to have made a misrepresentation in the reporting of ASP, if we fail to submit the required price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. CMS could also terminate our Medicaid drug rebate agreement, in which case federal payments may not be available under Medicaid for our covered outpatient drugs. We cannot assure you that our submissions will not be found to be incomplete or incorrect.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We face significant competition, and if our competitors develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize products may be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product candidates and processes competitive with vonoprazan. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of GI diseases for which we may attempt to develop vonoprazan or any future product candidates. Our competitors include larger and better funded pharmaceutical, biopharmaceutical, biotechnological and therapeutics companies. Moreover, we may also compete with universities and other research institutions who may be active in the indications we are targeting and could be in direct competition with us. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling patients for clinical trials and in identifying and in-licensing new product candidates. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that vonoprazan, if approved for the treatment of erosive esophagitis and treatment of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection, will primarily compete with generic PPIs marketed by multiple pharmaceutical companies in both the prescription and OTC markets. Additionally, in March 2020, RedHill Biopharma Ltd. launched Talicia, a co-formulated capsule comprising generic omeprazole, amoxicillin, and rifabutin for the treatment of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are aware of one other P-CAB in development in the United States, as well as a number of other P-CABs in territories outside of the United States that, if developed and approved in our territories, may compete with vonoprazan. In the United States, Neurogastrx intends to commence a Phase 3 erosive esophagitis trial for fexuprazan, under an exclusive license from Daewoong Pharmaceutical Co., Ltd., or Daewoong, sometime in 2022. Outside the United States, Daewoong recently received regulatory approval of, and plans for a first half of 2022 launch for fexuprazan in South Korea, and has out-licensed rights to develop fexuprazan in China to Shanghai Haini, a subsidiary of China&#x2019;s Yangtze River Pharmaceutical Group. Also, outside the United States, revaprazan is marketed by Yuhan Corporation in South Korea, tegoprazan is marketed by CJ Healthcare Corp. in South Korea and is currently in development in Japan by RaQualia Pharma, Inc. Additionally, Jeil Pharm has received authorization to conduct a Phase 3 trial in South Korea of its P-CAB candidate, JP-1366, in erosive esophagitis, and Cinclus Pharma AG&#x2019;s linaprazan glurate has completed a Phase 1 clinical trial in Europe and is currently in Phase 2 clinical trials. To our knowledge, none of these compounds have demonstrated superiority to PPIs on clinical endpoints.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, we are aware of several clinical-stage PPIs in territories outside of the United States that if developed and approved in our licensed territories may compete with vonoprazan. These include Dexa Medica&#x2019;s DLBS-2411, currently in Phase 3 clinical trials in Indonesia, Sihuan Pharmaceutical&#x2019;s anaprazole, currently in Phase 3 clinical trials in China, Eisai&#x2019;s azeloprazole, currently in a Phase 2 clinical trial in Japan, and Sidem Pharma&#x2019;s tenatoprazole, currently in Phase 2 clinical trials in Europe and Canada.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2012, the Food and Drug Administration Safety and Innovation Act was passed, which included the GAIN Act. The GAIN Act is intended to provide incentives for the development of new, qualified infectious disease products. In December 2016, the 21st Century Cures Act was passed, providing additional support for the development of new infectious disease products. These incentives may result in more competition in the market for new antibiotics and may cause pharmaceutical and biotechnology companies with more resources than we have to shift their efforts towards the development of product candidates that could be competitive with vonoprazan or any future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for vonoprazan or any future product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing vonoprazan or any future product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If the market opportunities for vonoprazan or any future products are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The precise incidence and prevalence for all the conditions we aim to address with vonoprazan or any future product candidates are unknown. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment of vonoprazan or any future product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics or market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of these diseases. The total addressable market across vonoprazan and any future product candidates will ultimately depend upon, among other things, the diagnosis criteria included in the final label for each of vonoprazan and any future product candidates approved for sale for these indications, the availability of alternative treatments and the safety, convenience, cost and efficacy of vonoprazan and any future product candidates relative to such alternative treatments, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We currently have a limited marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have limited internal marketing, sales or distribution capabilities, and we have never commercialized a product. If vonoprazan or any future product candidates ultimately receive regulatory approval, we must build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time consuming, or collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We plan to independently commercialize vonoprazan in the United States by building a leading specialty gastroenterology commercial infrastructure to support the adoption of vonoprazan and we plan to seek one or more partners with existing commercial infrastructure and expertise in Europe and Canada. We have no prior experience as a company in the marketing, sale and distribution of biopharmaceutical products and there are significant risks involved in building and managing a marketing and sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing vonoprazan or any future product candidates, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our future growth may depend, in part, on our ability to operate in foreign markets, particularly Europe and Canada, where we would be subject to additional regulatory burdens and other risks and uncertainties.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future growth may depend, in part, on our ability to develop and commercialize vonoprazan and any future product candidates in foreign markets, particularly Europe and Canada. We are not permitted to market or promote vonoprazan and any future product candidates before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for vonoprazan or any future product candidates. To obtain separate regulatory approval in any other countries we must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, commercial sales, pricing and distribution of vonoprazan and any future product candidates. If we obtain regulatory approval of vonoprazan and any future product candidates and ultimately commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">different regulatory requirements for approval of drugs in foreign countries;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reduced protection for intellectual property rights;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the existence of additional third-party patent rights of potential relevance to our business;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">economic weakness, including inflation, public health emergencies or political instability in particular foreign economies and markets;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compliance with tax, employment, immigration and labor laws for employees living or traveling internationally;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">foreign reimbursement, pricing and insurance regimes;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">workforce uncertainty in countries where labor unrest is common;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities internationally; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Business Operations and Industry</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to vonoprazan or any future product candidates, which may change from time to time;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">coverage and reimbursement policies with respect to vonoprazan or any future product candidates, if approved, and potential future drugs that compete with such products, if approved;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of manufacturing vonoprazan or any future product candidates, which may vary depending on the quantity of production and the terms of our agreements with Takeda, Catalent, Sandoz and any future third-party manufacturers;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters such as earthquakes, typhoons, floods and fires or public health emergencies or pandemics such as the ongoing COVID-19 pandemic;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and amount of the milestone or other payments we will be required to pay to Takeda pursuant to the Takeda License;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the level of demand for any approved products, which may vary significantly;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">future accounting pronouncements or changes in our accounting policies; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and success or failure of preclinical studies or clinical trials for vonoprazan or any future product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our business is subject to risks arising from epidemic diseases, such as the ongoing COVID-19 pandemic.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic continues to impact worldwide economic activity. A pandemic, including COVID-19 or other public health epidemic, poses the risk that we or our employees, contractors, including our CROs, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. In March 2020, due to efforts to combat the COVID-19 pandemic, we announced a temporary pause in randomization of new patients in our Phase 3 trials and did not recommence randomizations in either trial until June 2020. While it is not possible at this time to estimate the full impact that COVID-19 could have on our business, the continued spread of new variants of COVID-19 and the measures taken by the governments of countries affected could, in addition to disrupting our clinical trials, disrupt the supply chain and the manufacture or shipment of drug substance and finished drug product of vonoprazan for use in our clinical trials or in commercial distribution, which could delay our ongoing clinical trials and increase development costs, or impair our ability to successfully commercialize vonoprazan following regulatory approval, and in either case have a material adverse effect on our business, financial condition and results of operations. The COVID-19 pandemic and mitigation measures have also had an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The extent to which the COVID-19 pandemic impacts our results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our indebtedness may limit our flexibility in operating our business and adversely affect our financial health and competitive position, and all of our obligations under our indebtedness are secured by substantially all of our assets, excluding our intellectual property and certain other assets. If we default on these obligations, our lenders could foreclose on our assets.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2021, we entered into the Loan Agreement with Hercules. We borrowed $100.0 million at the inception of the Loan Agreement and may be eligible to borrow up to an additional $100.0 million. All obligations under the Loan Agreement are secured by a first priority lien on substantially all of our assets, including intellectual property and certain other assets. As a result, if we default on any of our obligations under the Loan Agreement, Hercules could foreclose on its security interest and liquidate some or all of the collateral, which would harm our business, financial condition and results of operations and could require us to reduce or cease operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In order to service this indebtedness and any additional indebtedness we may incur in the future, we need to generate cash from our operating activities or other financings. Our ability to generate cash is subject, in part, to our ability to successfully execute our business strategy, as well as general economic, financial, competitive, regulatory and other factors beyond our control. Our business may not be able to generate sufficient cash flow from operations, and future borrowings or other financings may not be available to us in an amount sufficient to enable us to service our indebtedness and fund our other liquidity needs. To the extent we are required to use cash from operations or the proceeds of any future financing to service our indebtedness instead of funding working capital or other general corporate purposes, we will be less able to plan for, or react to, changes in our business, industry and in the economy generally. This could place us at a competitive disadvantage compared to our competitors that have less indebtedness.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Loan Agreement contains customary affirmative and negative covenants that limit our ability to engage in certain transactions that may be in our long-term best interest. The affirmative covenants include, among others, covenants requiring us to maintain certain levels of cash subject to a control agreement in favor of Hercules, and commencing on May 15, 2023, certain levels of trailing three-month net product revenue from the sale of vonoprazan and products containing vonoprazan, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding our operating accounts. The negative covenants include, among others, limitations on our ability to incur additional indebtedness and liens, merge with other companies or consummate certain changes of control, acquire other companies, engage in new lines of business, make certain investments, pay dividends, transfer or dispose of assets, amend certain material agreements or enter into various specified transactions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we believe we are currently in compliance with the covenants contained in the Loan Agreement, we may breach these covenants in the future. Our ability to comply with these covenants may be affected by events and factors beyond our control. In the event that we breach one or more covenants, the lenders may choose to declare an event of default and require that we immediately repay all amounts outstanding under the Loan Agreement, terminate any commitment to extend further credit and foreclose on the collateral. The occurrence of any of these events could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are dependent on the services of our current management and other clinical and scientific personnel, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We are highly dependent upon our current senior management team and our development personnel. The loss of services of any of these individuals or personnel could delay or prevent the successful development of our product pipeline, completion of our ongoing clinical trials, initiation or completion of future clinical trials, or the commercialization of vonoprazan or any other future product candidates. Although we have executed employment agreements or offer letters with each member of our senior management team, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain their services as expected. We do not currently maintain &#x201c;key person&#x201d; life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will continue to expand and need to effectively manage our managerial, operational, financial and other resources in order to successfully pursue our clinical development and commercialization efforts. We may not be successful in maintaining our unique company culture and continuing to attract or retain qualified management and scientific and clinical personnel in the future due to the intense competition for qualified personnel among pharmaceutical, biotechnology and other businesses. Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, integrate, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have recently substantially increased the size of our organization, and we may encounter difficulties in managing our growth and expanding our operations successfully.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have substantially increased our organization from forty-seven full-time employees in December 2020 to seventy-three full-time employees as of December 31, 2021. As we continue development and pursue the potential commercialization of vonoprazan and any future product candidates, as well as function as a public company, we will continue to expand our marketing, sales, financial, regulatory, and manufacturing capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties. Our future financial performance and our ability to develop and commercialize vonoprazan and any future product candidates and to compete effectively will depend, in part, on our ability to manage our recent substantial growth and any future growth effectively.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are subject to various foreign, federal, and state healthcare laws and regulations, and our failure to comply with these laws and regulations could harm our results of operations and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers expose us to broadly applicable foreign, federal and state fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any products for which we obtain marketing approval. Such laws include, but are not limited to:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, or order, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service, for which payment may be made, in whole or in part, under any U.S. federal healthcare program, such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. civil and criminal federal false claims laws, including the civil False Claims Act, which can be enforced through civil whistleblower or qui tam actions, and civil monetary penalties laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making or causing to be made a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to certain payments and other &#x201c;transfers of value&#x201d; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) , certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, anesthesiology assistants and certified nurse midwives)and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; and </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or by the patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also be subject to additional regulation in the conduct of our business. For example, we may be subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ensuring that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly, time consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusion from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Enacted and future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize vonoprazan and any future product candidates and may affect the prices we may set.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively the Affordable Care Act, was enacted in the United States. Among the provisions of the Affordable Care Act of importance to our potential product candidates, the Affordable Care Act includes:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, which is apportioned among these entities according to their market share in certain government healthcare programs;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an extension of a manufacturers&#x2019; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since its enactment, there have been judicial and political challenges to certain aspects of the Affordable Care Act. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#x2019;s decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs. At the federal level, such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, the Build Back Better Act, if enacted, would introduce substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated &#x201c;maximum fair price&#x201d; for certain selected drugs or pay an excise tax for noncompliance, and the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D. If the Build Back Better Act is not enacted, similar or other drug pricing proposals could appear in future legislation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The likelihood of implementation of these and other reform initiatives is uncertain. In the coming years, additional legislative and regulatory changes could be made to governmental health programs that could significantly impact pharmaceutical companies and the success of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. These reforms could reduce the ultimate demand for vonoprazan and any future product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that these healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize vonoprazan and any future product candidates, if approved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We and any of our third-party manufacturers or suppliers may use potent chemical agents and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We and any of our third-party manufacturers or suppliers will use biological materials, potent chemical agents and may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety of the environment. Our operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. In the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we maintain workers&#x2019; compensation insurance for certain costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work- related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for toxic tort claims that may be asserted against us in connection with our storage or disposal of biologic, hazardous or radioactive materials.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations, which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face an inherent risk of product liability as a result of the clinical trials of vonoprazan and any future product candidates and will face an even greater risk if we obtain regulatory approval for and commercialize vonoprazan or any future product candidates. For example, we may be sued if vonoprazan or any future product candidates allegedly cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of warranties. Claims may be brought against us by clinical trial participants, patients or others using, administering or selling products that may be approved in the future. Claims could also be asserted under state consumer protection acts.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">decreased demand for our products;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injury to our reputation and significant negative media attention;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">withdrawal of clinical trial participants;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs to defend the related litigation;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a diversion of management&#x2019;s time and our resources;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">substantial monetary awards to trial participants or patients;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">significant negative financial impact;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the inability to commercialize vonoprazan and any future product candidates; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a decline in our stock price.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently maintain product liability insurance coverage in connection with our clinical trials, but do not maintain such insurance coverage for commercialization of vonoprazan and any future product candidates. Insurance coverage is increasingly expensive. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of vonoprazan and any future product candidates. Although we plan to maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies have, and future policies will also have, various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We and others, including any of our potential future collaborators, will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we or any of our potential future collaborators are successful in commercializing vonoprazan or any future product candidates, the FDA and foreign regulatory authorities would require that we and Takeda (with respect to vonoprazan) and any of our current or potential future collaborators, report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We, Takeda and any of our potential future collaborators or CROs may fail to report adverse events within the prescribed timeframe. If we, Takeda or any of our potential future collaborators or CROs fail to comply with such reporting obligations, the FDA or a foreign regulatory authority could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in approval of future products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulations, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. In addition, California enacted the CCPA on June 28, 2018, which went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. It provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the CPRA recently passed in California. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. Similar laws have passed in Virginia and Colorado and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, the FTC and many state Attorneys General continue to enforce federal and state consumer protection laws against companies for online collection, use, dissemination and security practices that appear to be unfair or deceptive. For example, according to the FTC, failing to take appropriate steps to keep consumers&#x2019; personal information secure can constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#x2019;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In Europe, GDPR, went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#x20ac;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. In addition, the GDPR increases the scrutiny of transfers of personal data from the EEA to the United States and other jurisdictions that the European Commission does not recognize as having &#x201c;adequate&#x201d; data protection laws. In 2016, the EU and United States agreed to a transfer framework for data transferred from the EU to the United States called the Privacy Shield, but in July 2020 the Court of Justice of the EU, or the CJEU, limited how organizations could lawfully transfer personal data from the EEA to the United States by invalidating the Privacy Shield for purposes of international transfers and imposing further restrictions on use of the standard contractual clauses, or SCCs. While the CJEU upheld the adequacy of the SCCs, it made clear that reliance on them alone may not necessarily be sufficient in all circumstances. Use of the SCCs must now be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular applicable surveillance laws and rights of individuals and additional measures and/or contractual provisions may need to be put in place, however, the nature of these additional measures is currently uncertain. The CJEU went on to state that if a competent supervisory authority believes that the SCCs cannot be complied with in the destination country and the required level of protection cannot be secured by other means, such supervisory authority is under an obligation to suspend or prohibit that transfer. The European Commission issued revised SCCs on June 4, 2021 to account for the decision of the CJEU and recommendations made by the European Data Protection Board. The revised SCCs must be used for relevant new data transfers from September 27, 2021; existing standard contractual clauses arrangements must be migrated to the revised clauses by December 27, 2022. There is some uncertainty around whether the revised clauses can be used for all types of data transfers, particularly whether they can be relied on for data transfers to non-EEA entities subject to the GDPR. The revised SCCs apply only to the transfer of personal data outside of the EEA and not the UK; the UK&#x2019;s Information Commissioner&#x2019;s Office launched a public consultation on its draft revised data transfers mechanisms in August 2021. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results. The European Commission issued revised SCCs on June 4, 2021 to account for the decision of the CJEU and recommendations made by the European Data Protection Board. The revised SCCs must be used for relevant new data transfers from September 27, 2021; existing standard contractual clauses arrangements must be migrated to the revised clauses by December 27, 2022. The new SCCs apply only to the transfer of personal data outside of the EEA and not the United Kingdom; the United Kingdom&#x2019;s Information Commissioner&#x2019;s Office launched a public consultation on its draft revised data transfers mechanisms in August 2021. There is some uncertainty around whether the revised clauses can be used for all types of data transfers, particularly whether they can be relied on for data transfers to non-EEA entities subject to the GDPR. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our internal computer systems, or those of any of our CROs, manufacturers, service providers, other contractors or consultants or potential future collaborators, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The United States federal and various state and foreign governments have adopted or proposed requirements regarding the collection, distribution, use, security, and storage of personally identifiable information and other data relating to individuals, and federal and state consumer protection laws are being applied to enforce regulations related to the online collection, use, and dissemination of data. Despite the implementation of security measures, our internal computer systems and those of our current and any future CROs and other service providers, contractors, consultants and collaborators are vulnerable to damage from computer viruses, cybersecurity threats, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the increased number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. If such an event were to occur and cause interruptions in our operations or result in the unauthorized disclosure of or access to personally identifiable information or individually identifiable health information (violating certain privacy laws such as GDPR), it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. Some of the federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Even though we may have contractual protections with such vendors, contractors, or other organizations, notifications and follow-up actions related to a security breach could impact our reputation, cause us to incur significant costs, including legal expenses, harm customer confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We also rely on third parties to manufacture vonoprazan and any future product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, the further development and commercialization of vonoprazan and any future product candidates could be delayed, and we could be subject to significant fines, penalties or liabilities for any noncompliance to certain privacy and security laws.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are exposed to the risk that our employees and independent contractors, including principal investigators, CROs, consultants and vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate: (i) the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies, (ii) manufacturing standards, including cGMP and similar requirements, or (iii) federal and state healthcare, security, fraud and abuse laws, data privacy and security laws, and other similar non-U.S. laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We could face criminal liability and other serious consequences for violations, which could harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#x2019;s Office of Foreign Assets Controls, and anti-corruption and anti-money laundering laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, clinical research organizations, contractors and other collaborators and partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We have engaged, and may engage in the future, third parties for clinical trials outside of the United States, and may engage third parties to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, clinical research organizations, contractors and other collaborators and partners, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and out-licensing or in-licensing of intellectual property, products or technologies, similar to our approach in in-licensing and acquiring our current product candidates. Any future transactions could increase our near and long-term expenditures, result in potentially dilutive issuances of our equity securities, including our common stock, or the incurrence of debt, contingent liabilities, amortization expenses or acquired in-process research and development expenses, any of which could affect our financial condition, liquidity and results of operations. Additional potential transactions that we may consider in the future include a variety of business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Future acquisitions may also require us to obtain additional financing, which may not be available on favorable terms or at all. These transactions may never be successful and may require significant time and attention of management. In addition, the integration of any business that we may acquire in the future may disrupt our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition. Accordingly, although we may not undertake or successfully complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for vonoprazan and any future product candidates, proprietary technologies and their uses as well as our ability to operate without infringing upon the proprietary rights of others. If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology or vonoprazan or any future product candidates, our competitive position could be harmed. We generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to vonoprazan or any future product candidates, proprietary technologies and their uses that are important to our business. We do not currently own any issued patents or pending patent applications. We also seek to protect our proprietary position by acquiring or in-licensing relevant issued patents or pending patent applications from third parties. We have in-licensed from Takeda a number of United States, European, and Canadian patents and patent applications relating to the compound vonoprazan as well as the use and manufacture of vonoprazan products.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our future patent applications or the patent applications of our current and future licensors will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents if issued will not be infringed, designed around or invalidated by third parties.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. These uncertainties and/or limitations in our ability to properly protect the intellectual property rights relating to vonoprazan and any future product candidates could have a material adverse effect on our financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot be certain that the claims in our licensor&#x2019;s U.S. pending patent applications, corresponding international patent applications and patent applications in certain foreign countries will be considered patentable by the United States Patent and Trademark Office, or USPTO, courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our licensor&#x2019;s issued patents will not be found invalid or unenforceable if challenged.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting vonoprazan and any future product candidates by obtaining and defending patents. These risks and uncertainties include the following:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">patent applications may not result in any patents being issued;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell vonoprazan and any future product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent prosecution process is also expensive and time consuming, and we and our licensor may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we and our licensor will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances such as under the Takeda License, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, directed to technology that we license from third parties. We may also require the cooperation of our licensors in order to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot be certain that patent prosecution and maintenance activities by our licensors have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in-license, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties, including our rights in vonoprazan licensed from Takeda, or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a party to the Takeda License under which we are granted rights to intellectual property that are important to our business and we may enter into additional license agreements in the future with other third parties. The Takeda License imposes, and we expect that any future license agreements where we in-license intellectual property, will impose on us, various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under these agreements, or we are subject to bankruptcy-related proceedings, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license. Additionally, if a future license agreement includes a sublicense from a third party who is not the original licensor of the intellectual property at issue, then we must rely on our direct licensor to comply with its obligations under the primary license agreements under which such licensor obtained rights in the applicable intellectual property, where we may have no relationship with the original licensor of such rights. If such a licensor fails to comply with its obligations under its upstream license agreement, the original third-party licensor may have the right to terminate the original license, which may terminate our sublicense. If this were to occur, we would no longer have rights to the applicable intellectual property unless we are able to secure our own direct license with the owner of the relevant rights, which we may not be able to do on reasonable terms, or at all, which may impact our ability to continue to develop and commercialize vonoprazan and any future product candidates incorporating the relevant intellectual property.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may need to obtain further licenses from third parties to advance our research or allow commercialization of vonoprazan and any future product candidates, and we cannot provide any assurances that third-party patents do not exist which might be enforced against vonoprazan and any future product candidates in the absence of such a license. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our right to sublicense patents and other rights to third parties;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of vonoprazan and any future product candidates, and what activities satisfy those diligence obligations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our right to transfer or assign the license; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, certain of our agreements may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. For example, if we choose to sublicense or assign to any third parties our rights under our existing license agreement with Takeda with respect to any licensed product, we may be required to wait for a certain period or until the occurrence of certain funding or development milestones.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our in-licensed pending and future patent applications may not result in patents being issued which protect vonoprazan or any future product candidates or which effectively prevent others from commercializing competitive product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we own in the future or license currently issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any future patents that we own or license, now or in the future, may be challenged or circumvented by third parties or may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know whether vonoprazan or any future product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our future patents or the patents of our current and future licensors by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our future patents or the patents of our current and future licensors may not cover vonoprazan or any future product candidates or may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review, or PGR, and inter partes review, or IPR, or other similar proceedings in the USPTO or foreign patent offices challenging our patent rights. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our predecessors and the patent examiner were unaware during prosecution. There is no assurance that all potentially relevant prior art relating to our in-licensed patents and patent applications has been found. There is also no assurance that there is not prior art of which we, our predecessors or licensors are aware, but which we do not believe affects the validity or enforceability of a claim in our in-licensed patents and patent applications, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize vonoprazan or any future product candidates and compete directly with us, without payment to us. It is possible that defects of form in the preparation or filing of our or our current and future licensors&#x2019; patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If there are material defects in the form, preparation, prosecution, or enforcement of our future patents or future patent applications or our current and future licensors&#x2019; patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any loss of patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of vonoprazan or any future product candidates, which could materially and adversely impact our business. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our future patents and future patent applications or the patents and patent applications of our current and future licensors is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize vonoprazan or any future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The patent protection and patent prosecution for vonoprazan or any future product candidates may be dependent on third parties.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property under certain current and future license agreements, such as the Takeda License. Under such arrangements, we may not have primary control over these activities for certain of licensed patents or patent applications and other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. In addition, our current and future licensors may not be fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, which could compromise such patent rights. We may in the future enter into license agreements where the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. If any of our licensors or any of our future licensors or future collaborators fail to appropriately prosecute and maintain patent protection for patents covering vonoprazan or any future product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, even where we have the right to control prosecution of patent applications or enforcement of patents we have acquired or licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to us assuming control over such activities.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Third parties may retain certain rights to the technology that they license to us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. For example, under the Takeda License, Takeda retained the rights to the inventions in all countries other than the United States, Europe, and Canada. Takeda also retained the right to develop certain drug products that contain vonoprazan where vonoprazan is not the only active pharmaceutical ingredient. It is difficult to monitor whether our predecessors or licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are limited in our ability to utilize acquired or licensed technologies, or if we lose our rights to critical in-licensed technology, we may be unable to successfully develop, out-license, market and sell our products, which could prevent or delay new product introductions. Our business strategy depends on the successful development of licensed and acquired technologies into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, out-license or market and sell our product candidate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others may be able to develop products that are similar to vonoprazan or any future product candidates but that are not covered by the claims of the patents that we own in the future or license;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we or our current and future licensors or predecessors might not have been the first to make the inventions covered by the issued patents or patent applications that we own in the future or license;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we or our current and future licensors or predecessors might not have been the first to file patent applications covering certain of the claimed inventions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">it is possible that the pending patent applications we own or license will not lead to issued patents;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">issued patents that we own in the future or license may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not develop additional proprietary technologies that are patentable; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the patents of others may have an adverse effect on our business.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Should any of these events occur, it could significantly harm our business, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import vonoprazan and any future product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations, IPR proceedings and PGR proceedings before the USPTO and/ or foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of vonoprazan and any future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As the biopharmaceutical industry expands and more patents are issued, the risk increases that vonoprazan and any future product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published we may be unaware of third-party patents that may be infringed by commercialization of vonoprazan and any future product candidates, and we cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that vonoprazan and any future product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Any claims of patent infringement asserted by third parties would be time consuming and could:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">result in costly litigation that may cause negative publicity;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">divert the time and attention of our technical personnel and management;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cause development delays;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">prevent us from commercializing vonoprazan and any future product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">require us to develop non-infringing technology, which may not be possible on a cost-effective basis;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subject us to significant liability to third parties; or</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although no third party has asserted a claim of patent infringement against us as of the date of this annual report, others may hold proprietary rights that could prevent vonoprazan and any future product candidates from being marketed.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any patent-related legal action against us claiming damages and seeking to enjoin activities relating to vonoprazan and any future product candidates or processes could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or develop vonoprazan and any future product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or our future strategic partners were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign vonoprazan and any future product candidates or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing vonoprazan and any future product candidates, which could harm our business, financial condition and operating results.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be successful in obtaining or maintaining necessary rights to vonoprazan and any future product candidates through acquisitions and in-licenses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because our development programs may in the future require the use of proprietary rights held by other third parties, the growth of our business may depend in part on our ability to acquire, in-license, or use these third-party proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for vonoprazan and any future product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business and financial condition could suffer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be involved in lawsuits to protect or enforce our future patents or the patents of our current and future licensors, which could be expensive, time consuming and unsuccessful. Further, our future issued patents or the patents of our current and future licensors could be found invalid or unenforceable if challenged in court.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Competitors may infringe our intellectual property rights or those of our current and future licensors. To prevent infringement or unauthorized use, we and/or any such licensors may be required to file infringement claims, which can be expensive and time consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own or license is not valid, is unenforceable and/or is not infringed. If we or any of our current and future licensors were to initiate legal proceedings against a third party to enforce a patent directed at vonoprazan and any future product candidates, the defendant could counterclaim that our patent or the patent of our current or future licensor is invalid and/or unenforceable in whole or in part. In patent litigation, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, non-enablement, or obviousness-type double patenting. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. In addition, if the breadth or strength of protection provided by our future patents and future patent applications or those of our current and future licensors is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would have a material adverse impact on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Derivation or interference proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Derivation or interference proceedings provoked by third parties or brought by us or declared by the USPTO or similar proceedings in foreign patent offices may be necessary to determine the priority of inventions with respect to our future patents or future patent applications or those of our current and future licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of such proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring vonoprazan and any future product candidates to market.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our future patent applications or those of our current and future licensors and the enforcement or defense of our future issued patents or those of our current and future licensors.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 16, 2011, the Leahy-Smith America Invents Act, or Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#x201c;first inventor to file&#x201d; system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the patent regardless of whether a third party was first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013 but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we may not be certain that we or our current and future licensors are the first to either (1) file any patent application related to vonoprazan and any future product candidates or (2) invent any of the inventions claimed in the patents or patent applications.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including PGR, IPR, and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our future patent applications or those of our current and future licensors and the enforcement or defense of our future issued patents or those of our current and future licensors, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect vonoprazan and any future product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our future patents or in third-party patents. In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us. Evolving judicial interpretation of patent law could also adversely affect our business. For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce the existing licensed patents and the patents we might obtain or license in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to claims challenging the inventorship or ownership of our future patents, the patents of our current and future licensors, or other intellectual property</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also be subject to claims that former employees or other third parties have an ownership interest in our future patents, the patents of our current and future licensors or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent terms may be inadequate to protect our competitive position on vonoprazan and any future product candidates for an adequate amount of time.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering vonoprazan and any future product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of product candidates, patents protecting vonoprazan and any future product candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we do not obtain patent term extension for vonoprazan and any future product candidates, our business may be materially harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depending upon the timing, duration and specifics of FDA marketing approval of vonoprazan and any future product candidates, one or more of our U.S. patents or those of our current and future licensors, may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch- Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of vonoprazan and any future product candidates. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be able to protect our intellectual property rights throughout our licensed territories.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we have issued patents and pending patent applications in the United States and certain other countries in which we intend to commercialize our products, filing, prosecuting and defending patents in all relevant countries throughout our licensed territories could be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with vonoprazan or any future product candidates, and our patents, the patents of our current and future licensors or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our intellectual property rights or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our future patents or the patents of our current and future licensors at risk of being invalidated or interpreted narrowly and our future patent applications or the patent applications of our current and future licensors at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our future patents and/or future applications and those of our current and future licensors. We have systems in place to remind us to pay these fees, and we rely on third parties to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to protect our trade secret information may be jeopardized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As is common in the biopharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of vonoprazan and any future product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biopharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We intend to use registered or unregistered trademarks or trade names to brand and market ourselves and our products. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Any collaboration arrangements that we have or may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our products.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators and partners. Under the Takeda License, for example, Takeda has certain obligations with respect to assisting with the transition of information and materials to us as well as providing clinical and commercial supply of the vonoprazan product. Collaborations and partnerships are subject to numerous risks, which may include that:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may not pursue development and commercialization of our products or may elect not to continue or renew development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disputes may arise between us and a collaborator that causes the delay or termination of the research, development or commercialization of our current or future products or that results in costly litigation or arbitration that diverts management attention and resources;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable current or future products;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a collaborator&#x2019;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intellectual property discovered through government funded programs may be subject to federal regulations such as &#x201c;march-in&#x201d; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may acquire or license in the future intellectual property rights that have been generated through the use of U.S. government funding or grant. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#x201c;march-in rights&#x201d;). The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The trading price of the shares of our common stock has been, and is likely to continue to be, highly volatile, and purchasers of our common stock could incur substantial losses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The stock market in general and the market for stock of biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the price at which they paid. Our common stock has a limited trading history and the market price has fluctuated widely, and may in the future fluctuate widely, depending upon many factors such as those discussed in this &#x201c;Risk Factors&#x201d; section and many others, some of which are beyond our control, including the following:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a relatively low-volume trading market for our shares of common stock that could cause trades of small blocks of shares to have a significant impact on the price of our shares of common stock;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">market conditions in the biopharmaceutical sector and issuance of securities analysts&#x2019; reports or recommendations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establishment of short positions by holders or non-holders of our common stock;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an inability to obtain additional funding;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">sales of our stock by insiders and stockholders, including Takeda;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to enroll patients in our ongoing and any future clinical trials;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">results of our clinical trials and preclinical studies, the results of clinical trials conducted by Takeda and others for vonoprazan, and the results of trials of our competitors or those of other companies in our market sector;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory approval of vonoprazan and any future product candidates, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any termination or loss of rights under the Takeda License;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory developments in the United States and foreign countries;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in the structure of healthcare payment systems, especially in light of reforms to the U.S. healthcare system;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the success or failure of our efforts to acquire, license or develop additional product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">innovations or new products developed by us or our competitors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manufacturing, supply or distribution delays or shortages;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any changes to our relationship with any manufacturers, suppliers, licensors, future collaborators or other strategic partners;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">achievement of expected product sales and profitability;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">variations in our financial results or those of companies that are perceived to be similar to us;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">general economic, industry and market conditions, public health emergencies or other events or factors, many of which are beyond our control;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">additions or departures of key personnel;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">intellectual property, product liability or other litigation against us;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in our capital structure, such as future issuances of securities and the incurrence of additional debt; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in accounting standards, policies, guidelines, interpretations or principles.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, in the past, stockholders have initiated class action lawsuits against biopharmaceutical companies following periods of volatility in the market prices of these companies&#x2019; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#x2019;s attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control or significantly influence all matters submitted to stockholders for approval. Furthermore, many of our current directors were appointed by our principal stockholders.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our executive officers, directors and greater than 5% stockholders, in the aggregate, own a majority of our outstanding common stock. As a result, such persons acting together have the ability to control or significantly influence all matters submitted to our board of directors or stockholders for approval, including the appointment of our management, the election and removal of directors and approval of any significant transaction, as well as our management and business affairs. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, under the terms of the Loan Agreement, we are prohibited from paying any cash dividends without the consent of the lenders. Any return to stockholders will therefore be limited to the appreciation of their stock. Shares of our common stock may not appreciate in value or even maintain the price at which stockholders have purchased their shares.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sales of a substantial number of shares of our common stock by our existing stockholders, including Takeda, in the public market could cause our stock price to fall.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could significantly reduce the market price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, up to 14,646,341 shares of common stock that are either subject to outstanding options, warrants or other rights or reserved for future issuance under our employee benefit plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, exercise limitations, and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, we filed a registration statement, which became effective on November 17, 2020, registering the resale of up to 14,499,416 shares of common stock held by Takeda and Frazier Life Sciences IX, L.P., or Frazier, including all shares of our common stock underlying the Takeda Warrant. As a result, Takeda and Frazier are each able to freely sell some or all of their shares of our common stock. Any sales by these stockholders could have a material adverse effect on the trading price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are an emerging growth company and a smaller reporting company, and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting company may make our common stock less attractive to investors.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are an emerging growth company, as defined in the JOBS Act, and may remain an emerging growth company until the last day of the fiscal year following the fifth anniversary of the completion of our IPO. However, if certain events occur prior to the end of such five-year period, including if we become a &#x201c;large accelerated filer&#x201d; as defined in Rule 12b-2 under the Exchange Act, our annual gross revenues exceed $1.07 billion or we issue more than $1.0 billion of non-convertible debt in any three- year period, we will cease to be an emerging growth company prior to the end of such five-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; disclosure;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the financial statements, unless the SEC, determines the new rules are necessary for protecting the public;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reduced disclosure obligations regarding executive compensation; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investors may find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also a smaller reporting company as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of our board of directors. The provisions in our charter documents include the following:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the exclusive right of our board of directors, unless the board of directors grants such right to the stockholders, to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the required approval of at least 66-2/3% of the shares entitled to vote to remove a director for cause, and the prohibition on removal of directors without cause;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the required approval of at least 66-2/3% of the shares entitled to vote to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and proceedings;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#x2019; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#x2019;s own slate of directors or otherwise attempting to obtain control of us.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf under Delaware statutory or common law, including any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided, that, this provision would not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. The choice of forum provisions in our amended and restated certificate of incorporation may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to these provisions, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#x2019; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our ability to use net operating loss carryforwards and other tax attributes may be limited.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire (if at all).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under recently enacted U.S. tax legislation, federal net operating loss, or NOL, carryforwards generated in periods after December 31, 2017, may be carried forward indefinitely but may only be used to offset 80% of our taxable income annually. Our NOL carryforwards are subject to review and possible adjustment by the Internal Revenue Service, or the IRS, and state tax authorities. Under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, our federal NOL carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percentage points. Our ability to utilize our NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including potential changes in connection with our IPO or future offerings. Similar rules may apply under state tax laws. We have not yet determined the amount of the cumulative change in our ownership resulting from our IPO or other transactions, or any resulting limitations on our ability to utilize our NOL carryforwards and other tax attributes. If we earn taxable income, such limitations could result in increased future tax liability to us and our future cash flows could be adversely affected. We have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recent U.S. tax legislation may materially adversely affect our financial condition, results of operations and cash flows.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Tax Act has significantly changed the U.S. federal income taxation of U.S. corporations, including by reducing the U.S. corporate income tax rate and revising the rules governing NOLs. Many of these changes became effective beginning in 2018, without any transition periods or grandfathering for existing transactions. The legislation is unclear in many respects and may continue to be subject to potential amendments and technical corrections, as well as interpretations and implementing regulations by the U.S. Treasury Department and the IRS, which have lessened or increased certain adverse impacts of the legislation and may do so in the future. We continue to work with our tax advisors to determine the full impact that the recent tax legislation as a whole will have on us. We urge our investors to consult with their legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">General Risk Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We rely on third-party manufacturers to produce vonoprazan and any future product candidates. Our ability to obtain clinical supplies of vonoprazan and any future product candidates could be disrupted if the operations of these suppliers were affected by a man-made or natural disaster or other business interruption. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our failure to meet the continued listing requirements of the Nasdaq could result in a delisting of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we fail to satisfy the continued listing requirements of the Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, any action taken by us to restore compliance with listing requirements may not allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq&#x2019;s listing requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC, annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory &#x201c;say on pay&#x201d; voting requirements that will apply to us when we cease to be an emerging growth company. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The costs we incur as a public company will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business. For example, these rules and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage in the future. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If securities or industry analysts do not publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us, our business, our market or our competitors. If securities or industry analysts do not continue coverage of our company, the trading price for our stock would be negatively impacted. In addition, if one or more of the analysts who covers us downgrades our stock, our stock price would likely decline. If one or more of these analysts ceases to cover us or fails to regularly publish reports on us, interest in our stock could decrease, which could cause our stock price or trading volume to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to Section 404 of Sarbanes-Oxley, our management is required to report upon the effectiveness of our internal control over financial reporting. When we lose our status as an &#x201c;emerging growth company&#x201d; and reach an accelerated filer threshold, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we are in the process of implementing additional financial and management controls, reporting systems and procedures; and hiring additional accounting and finance staff. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There could be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begin its Section 404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We could be subject to securities class action litigation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us, because we, like many other biotechnology and pharmaceutical companies, have recently experienced significant stock price volatility. If we face such litigation, it could result in substantial costs and a diversion of management&#x2019;s attention and resources, which could harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1B.	Unresolve</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">d Staff Comments</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 2.	Pr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">operties</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our corporate offices are located in Buffalo Grove, Illinois, and Florham Park, New Jersey. We believe that our facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For additional information, see Note 6, Lease Commitments included in Item 15 of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 3.	Legal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Proceedings</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are not currently subject to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 4.	Mine Safe</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ty Disclosures</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> II</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5__market_for_registrants_common_eq"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 5.	Market for Registrant&#x2019;s Common Equity, Related Sto</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ckholder Matters and Issuer Purchases of Equity Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Market Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock has been publicly traded on the Nasdaq Global Select Market under the symbol &#x201c;PHAT&#x201d; since our initial public offering on October 25, 2019, which was completed at a price to the public of $19.00 per share. Prior to our initial public offering, there was no public market for our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Holders of Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of February 24, 2022, there were 31,712,742 shares of our common stock outstanding held by approximately 52 holders of record of our common stock. This number was derived from our shareholder records and does not include beneficial owners of our common stock whose shares are held in the name of various dealers, clearing agencies, banks, brokers and other fiduciaries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Dividend Policy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments. In addition, under the terms of our Loan Agreement, we are prohibited from paying any cash dividends without the consent of the lenders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See Item 12 of Part III of this annual report on Form 10-K for information about our equity compensation plans which is incorporated by reference herein.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Performance Graph</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Unregistered Sales of Equity Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Proceeds</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 24, 2019, our registration statement on Form S-1 (File No. 333-234020) was declared effective by the SEC for our initial public offering. At the closing of the offering on October 29, 2019, we sold 10,997,630 shares of common stock, which included the exercise in full by the underwriters of their option to purchase 1,434,473 additional shares, at an initial public offering price of $19.00 per share and received gross proceeds of $209.0 million, which resulted in net proceeds to us of approximately $191.5 million, after deducting underwriting discounts and commissions of approximately $14.6 million and offering-related transaction costs of approximately $2.9 million. None of the expenses associated with the initial public offering were paid to directors, officers, persons owning ten percent or more of any class of equity securities, or to their associates, or to our affiliates. Goldman Sachs &amp; Co. LLC, Jefferies LLC and Evercore Group L.L.C. acted as joint book-running managers for the offering.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 the net proceeds from our initial public offering and follow on offering have been applied as follows: $151.7 million toward the clinical development of vonoprazan and $79.7 million towards working capital and general corporate purposes. As of December 31, 2021, we have used all of the net proceeds from our IPO of approximately $191.5 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Issuer Repurchases of Equity Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 6. R</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">eserved</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">122</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 7. Management&#x2019;s Discussion and Analysis of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Financial Condition and Results of Operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included elsewhere in this annual report. This discussion and analysis contains forward-looking statements based upon our current beliefs, plans and expectations that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under &#x201c;Risk Factors&#x201d; or in other parts of this annual report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Our initial product candidate, vonoprazan, is an oral small molecule P-CAB. P-CABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has shown rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits over the current standard of care as a single agent in the treatment of gastroesophageal reflux disease, or GERD, and in combination with antibiotics for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection. Takeda developed vonoprazan and has received marketing approval in numerous countries in Asia and Latin America as well as Russia. Vonoprazan generated approximately $850 million in net sales in its seventh full year on the market since its approval in Japan in late 2014. In May 2019, we in-licensed the U.S., European, and Canadian rights to vonoprazan from Takeda.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2021 we reported topline data from two pivotal Phase 3 clinical trials for vonoprazan: one for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> infection (PHALCON-HP), and a second for the treatment of erosive GERD (PHALCON-EE), also known as erosive esophagitis, or EE. In April 2021, we reported positive topline data from PHALCON-HP, and in October 2021, we reported positive topline data from PHALCON-EE. In September 2021, we submitted two new drug applications (NDAs) for treatment regimens containing vonoprazan for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pylori, and in November 2021, the U.S. Food and Drug Administration, or FDA, accepted both NDAs for filing, granted each of them Priority Review, and assigned us a Prescription Drug User Fee Act (PDUFA) action date in May 2022. Based on the results of the PHALCON-EE trial, we expect to submit an NDA for vonoprazan for the treatment of erosive esophagitis in March 2022. In August 2019, we received Qualified Infectious Disease Product, or QIDP, and Fast Track designations from the FDA, for vonoprazan tablets in combination with amoxicillin tablets and clarithromycin tablets and with amoxicillin tablets alone for the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection. In January 2021 and May 2021, respectively, we received additional Fast Track and QIDP designations to include amoxicillin capsules in addition to amoxicillin tablets. QIDP designation provides a potential extension of any regulatory exclusivity awarded, if approved. We have also initiated development of vonoprazan for the treatment of NERD. In February 2022, we commenced enrollment of patients in a Phase 3 trial studying vonoprazan, dosed on a once-daily basis, for the treatment of NERD with topline data expected in 2023. Also in February 2022, we reported positive topline data from a Phase 2 trial studying vonoprazan for on-demand treatment of NERD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If approved, we plan to independently commercialize vonoprazan in the United States. We also plan to seek commercial partnerships for vonoprazan in Europe and Canada, expand development of vonoprazan into other indications, dosing regimens and alternative formulations and packaging, and in-license or acquire additional clinical or commercial stage product candidates for the treatment of GI diseases in a capital efficient manner.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">123</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We commenced our operations in 2018 and have devoted substantially all of our resources to date to organizing and staffing our company, business planning, raising capital, in-licensing our initial product candidate, vonoprazan, meeting with regulatory authorities, conducting our Phase 3 clinical trials of vonoprazan, preparing applications for regulatory approval for vonoprazan and preparing for a potential commercial launch. Our operations to date have been funded primarily through the issuance of convertible promissory notes, commercial bank debt, the proceeds from our initial public offering and our follow-on public offering. From our inception through December 31, 2021, we have raised aggregate gross proceeds of $90.3 million from the issuance of convertible promissory notes, $100.0 million of debt, net proceeds from our initial public offering of $191.5 million from the sale of 10,997,630 shares of common stock, which included the exercise in full by the underwriters of their option to purchase 1,434,473 additional shares at a public offering price of $19.00 per share, after deducting underwriting discounts, commissions and offering costs, and net proceeds of $88.6 million from the sale of 2,250,000 shares of common stock at a public offering price of $39.48 per share after deducting underwriting discounts and commissions, and an additional $0.2 million in offering costs. As of December 31, 2021, we had cash and cash equivalents of $183.3 million. Based on our current operating plan, and subject to the potential delays and cost increases resulting from the evolving COVID-19 pandemic, we believe that our existing cash and cash equivalents together with the drawdown of the remaining $100 million under our Loan Agreement with Hercules will be sufficient to fund our operations into the middle of 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not have any products approved for sale and have incurred net losses since our inception. Our net losses for the years ended December 31, 2021 and 2020 were $143.9 million and $129.1 million, respectively. As of December 31, 2021, we had an accumulated deficit of $529.4 million. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical development activities, other research and development activities and pre-commercialization activities. We expect our expenses and operating losses will increase substantially as we advance vonoprazan through clinical trials, seek regulatory approval for vonoprazan, expand our clinical, regulatory, quality, manufacturing and commercialization capabilities, incur significant commercialization expenses for marketing, sales, manufacturing and distribution if we obtain marketing approval for vonoprazan, protect our intellectual property, expand our general and administrative support functions, including hiring additional personnel, and incur additional costs associated with operating as a public company.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never generated any revenue and do not expect to generate any revenues from product sales unless and until we successfully complete development and obtain regulatory approval for vonoprazan. Accordingly, until such time as we can generate significant revenue from sales of vonoprazan, if ever, we expect to finance our cash needs through equity offerings, our Loan Agreement, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all, and this risk could be exacerbated by the impact of COVID-19 on global economic conditions. Our failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement with Takeda</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On May 7, 2019, we and Takeda entered into the Takeda License, pursuant to which we in-licensed the U.S., European, and Canadian rights to vonoprazan fumarate. During the term of the Takeda License, we and our affiliates are not permitted to commercialize any pharmaceutical product, other than vonoprazan, that treats acid-related disorders, except for certain generic and OTC competing products in specified circumstances. We will be responsible at our cost for the development, manufacture and commercialization of vonoprazan products. We are required to use commercially reasonable efforts to develop and commercialize the vonoprazan products in our licensed territory.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Takeda License, Takeda has the sole right and authority, with our input, to prepare, file, prosecute, and maintain all Takeda and joint patents on a worldwide basis at its own cost. We are responsible, at our cost, for preparing, filing, prosecuting, and maintaining patents on inventions made solely by us in connection with vonoprazan, subject to input from Takeda.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">124</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We paid Takeda upfront consideration consisting of a cash fee of $25.0 million, 1,084,000 shares of our common stock, the Takeda Warrant to purchase 7,588,000 shares of our common stock at an exercise price of $0.00004613 per share, and issued Takeda a right to receive an additional common stock warrant, or the Takeda Warrant Right, if Takeda&#x2019;s fully-diluted ownership of the Company represented less than a certain specified percentage of the fully-diluted capitalization, including shares issuable upon conversion of then outstanding convertible promissory notes, calculated immediately prior to the closing of our IPO. The Takeda Warrant Right expired without effect since no fair value had been allocated to it upon completion of our IPO, and no additional warrant was issued. We agreed to make milestone payments to Takeda upon achieving certain tiered aggregate annual net sales of licensed products in the United States, Europe and Canada up to a total maximum milestone amount of $250.0 million. We also agreed to make tiered royalty payments at percentages in the low double digits on net sales of licensed products, subject to specified offsets and reductions. Royalties will be payable, on a product-by-product and country-by-country basis from the first commercial sale of such product in such country, until the latest of expiration of the licensed patents covering the applicable product, expiration of regulatory exclusivity in such country, or 15 years following first commercial sale in such country.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Components of Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, our research and development expenses have related to the development of vonoprazan. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses include:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in research and development efforts;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">external research and development expenses incurred under agreements with CROs, and consultants to conduct and support our ongoing clinical trials of vonoprazan; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs related to the manufacturing of vonoprazan for our clinical trials. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We plan to substantially increase our research and development expenses for the foreseeable future as we continue the development of vonoprazan. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future clinical trials and nonclinical studies of vonoprazan or any future product candidates due to the inherently unpredictable nature of clinical and preclinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future clinical development costs may vary significantly based on factors such as:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">per patient trial costs;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of trials required for approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of sites included in the trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the countries in which the trials are conducted;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the length of time required to enroll eligible patients;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of patients that participate in the trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of doses evaluated in the trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the drop-out or discontinuation rates of patients;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential additional safety monitoring requested by regulatory agencies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the duration of patient participation in the trials and follow-up;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the phase of development of the product candidate; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the efficacy and safety profile of the product candidate; and  </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays and cost increases as a result of COVID-19 </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses consist of salaries and employee-related costs, including stock-based compensation, for personnel in executive, finance, accounting, legal, human resources and other administrative functions, legal fees relating to intellectual property and corporate matters, and professional fees for accounting and consulting services. We anticipate that our general and administrative expenses will increase in the future to support our continued research and development activities, pre-commercial preparation activities for vonoprazan and, if any future product candidate receives marketing approval, commercialization activities. We also anticipate increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs associated with operating as a public company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Income</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income consists of interest on our money market funds.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">126</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Expense</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beginning on September 17, 2021, interest expense consists of (i) cash interest at a variable annual rate equal to the greater of (a) 5.50% and (b) the Prime Rate (as reported in the Wall Street Journal) plus 2.25% (the &#x201c;Interest Rate&#x201d;), (ii) payment-in-kind interest at a per annum rate of interest equal to 3.35%, and (iii) amortization of the Hercules Loan Agreement debt discount recorded in connection with the fair value of warrants issued to the lenders, the debt issuance costs incurred, and the obligation to make a final payment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to September 17, 2021, interest expense consisted of interest on our outstanding commercial bank debt with SVB at a variable annual rate equal to the greater of (a) 7.25% and (b) Prime Rate (as reported by the Wall Street Journal) plus 1.75% and amortization of the SVB Term Loan debt discount recorded in connection with the fair value of warrants issued to the lenders, the debt issuance costs incurred, and the obligation to make a final payment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Change in Fair Value of Warrant Liabilities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the entry into the Loan Agreement, we issued the lenders warrants to purchase our capital stock, or the Lender Warrants. The Lender Warrants were accounted for as liabilities as they contained a holder put right under which the lenders could have required us to pay cash in exchange for the warrants. We adjusted the carrying value of the Lender Warrants to their estimated fair value at each reporting date, with any change in fair value of the warrant liabilities recorded as an increase or decrease to change in fair value of warrant liabilities in the statements of operations. The Lender Warrants were accounted for at fair value using the Black-Scholes option-pricing model with an expected term equal to the remaining contractual term of the warrants. When we drew down an additional $25.0 million, or the Term Loan B, in March 2020, the Lender put right expired, and we recorded a final fair value adjustment and reclassified the Lender Warrants balance of $0.3 million to additional paid-in-capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Results of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comparison of the Years Ended December 31, 2021 and 2020</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our results of operations for the years ended December 31, 2021 and 2020 (in thousands):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51.071%;"></td>
    <td style="width:1.058%;"></td>
    <td style="width:1.861%;"></td>
    <td style="width:12.41%;"></td>
    <td style="width:1.245%;"></td>
    <td style="width:1.058%;"></td>
    <td style="width:1.861%;"></td>
    <td style="width:12.276%;"></td>
    <td style="width:1.245%;"></td>
    <td style="width:1.058%;"></td>
    <td style="width:1.861%;"></td>
    <td style="width:11.754%;"></td>
    <td style="width:1.245%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="8" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br />December 31,</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72,338</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98,148</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(25,810</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62,742</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,517</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,225</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135,080</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125,665</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,415</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(135,080</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(125,665</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(9,415</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,091</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1,050</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(6,788</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(4,581</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,207</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of warrant liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(95</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expense)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,056</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,048</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total other income (expense)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(8,803</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(3,403</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(5,400</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(143,883</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(129,068</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(14,815</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">127</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Research and development expenses were $72.3 million and $98.1 million for the years ended December 31, 2021 and 2020, respectively. The decrease of $25.8 million consisted of $41.1 million of clinical trial costs, $0.7 million of consulting expenses, and $0.9 million of other operating expenses partially offset by an increase of $6.5 million of chemistry manufacturing and controls, or CMC, costs related to vonoprazan, $6.3 million of personnel-related expenses and $4.1 million of expenses related to regulatory requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> General and administrative expenses were $62.7 million and $27.5 million for the years ended December 31, 2021 and 2020, respectively. The increase of $35.2 million was due to increases of $17.2 million in personnel-related expenses, $15.7 million of professional services expenses for commercial, medical affairs and other services, $1.1 million in consulting fees and $1.2 million in other expenses. Due to the planned continued buildout of administrative and commercial functions, we expect General and Administrative expenses to increase in future periods.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Income (Expense).</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Other expense of $8.8 million for the year ended December 31, 2021 consisted of $6.8 million of interest expense and $2.0 million of charges related to early extinguishment of debt. Other expense of $3.4 million for the year ended December 31, 2020 consisted of $4.6 million of interest expense on outstanding commercial bank debt, partially offset by $1.1 million of interest income and $0.1 million of other income related to the decrease in the fair value of warrant liabilities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred net losses and negative cash flows from operations since our inception and anticipate we will continue to incur net losses for the foreseeable future. As of December 31, 2021, we had cash and cash equivalents of $183.3 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Loan Agreement with Hercules</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 17, 2021, (the &#x201c;Closing Date&#x201d;), we entered into a Loan and Security Agreement (the &#x201c;Loan Agreement&#x201d;) with Hercules Capital, Inc., in its capacity as administrative agent and collateral agent and as a lender (in such capacity, the &#x201c;Agent&#x201d; or &#x201c;Hercules&#x201d;) and the other financial institutions that from time to time become parties to the Loan Agreement as lenders (collectively, the &#x201c;Lenders&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Loan Agreement provides for term loans in an aggregate principal amount of up to $200.0 million (the &#x201c;Term Loan&#x201d;) under multiple tranches. The tranches consist of (i) a first tranche consisting of term loans in an aggregate principal amount of $100.0 million, all of which was funded on the Closing Date (the &#x201c;First Advance&#x201d;), (ii) a second tranche consisting of up to an additional $50.0 million, which became available to us upon achievement of the protocol-specified primary efficacy endpoints in our Phase 3 trial studying vonoprazan for the healing and maintenance of healing of erosive esophagitis with acceptable safety data, such that the results support the submission of a New Drug Application (&#x201c;NDA&#x201d;) or supplemental NDA without the need to conduct another Phase 3 study and will be available, if specified conditions are met, through December 15, 2022, (iii) a third tranche consisting of an additional $25.0 million, which will become available to us upon the achievement of (a) FDA approval of our NDA for vonoprazan and amoxicillin, or its NDA for vonoprazan, amoxicillin and clarithromycin, in each case for an indication relating to the treatment of H. pylori with an approved indication on the claim that is generally consistent with that sought in our NDA submission&#x37e; and (b) filing of an NDA or supplemental NDA for vonoprazan for indications relating to the healing and maintenance of healing of erosive esophagitis (milestones (a) and (b), together, the &#x201c;Second Performance Milestone&#x201d;), and will be available, if specified conditions are met, through September 30, 2023, and (iv) a fourth tranche consisting of up to an additional $25.0 million, which will be available, if specified conditions are met, through March 31, 2024, upon achievement of the Second Performance Milestone. We intend to use the proceeds of the Term Loan advances for working capital and general corporate purposes. In addition, approximately $54 million of the proceeds from the First Advance was used to satisfy in full and retire our indebtedness under its previously outstanding credit facility with Silicon Valley Bank (the &#x201c;SVB Term Loan&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Term Loan will mature on October 1, 2026 (the &#x201c;Maturity Date&#x201d;). The Term Loan bears (i) cash interest at a variable annual rate equal to the greater of (a) 5.50% and (b) the Prime Rate (as reported in the Wall Street Journal) plus 2.25% (the &#x201c;Interest Rate&#x201d;) and (ii) payment-in-kind interest at a per annum rate of interest equal to 3.35%. We may make payments of interest only through October 1, 2024, which may be extended to October 1, 2025, upon the achievement of the Second Performance Milestone on or prior to September 30, 2024 and the condition that no default or event of default exists, and which is further extendable to October 1, 2026, subject to FDA approval of our NDA (or supplemental NDA) for vonoprazan for an indication relating to the healing and maintenance of healing of erosive esophagitis with an approved indication on the label that is generally consistent with that sought in our NDA submission (or supplemental NDA submission) (the &#x201c;Third Performance Milestone&#x201d;) on or prior to September 30, 2025 and no default or event of default exists (the &#x201c;interest only period&#x201d;). After the interest-only period, the principal balance and related interest will be required to be repaid in equal monthly installments and continuing until the Maturity Date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Loan Agreement contains customary closing fees, prepayment fees and provisions, events of default, and representations, warranties and covenants, including a financial covenant requiring us to maintain certain levels of cash subject to a control agreement in favor of the Agent (minus accounts payable not paid within 120 days of invoice) (&#x201c;Qualified Cash&#x201d;), and commencing on May 15, 2023, trailing three-month net product revenue from the sale of vonoprazan and products containing vonoprazan. The revenue covenant will be waived at any time in which we maintain Qualified Cash equal to at least 60.0% (prior to the Third Performance Milestone), and 35% (following the Third Performance Milestone) of the total outstanding Term Loan principal amount, or our market capitalization is at least $900.0 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As collateral for the obligations, we granted to Hercules a senior security interest in all of our right, title, and interest in, to and under substantially all of our property, inclusive of intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the entry into the Loan Agreement, we issued to Hercules a warrant (the &#x201c;Warrant&#x201d;) to purchase a number of shares of our common stock equal to 2.5% of the aggregate amount of the Term Loan advances funded, and will issue to Hercules additional warrants when future Term Loan advances are funded. On the Closing Date, we issued a Warrant for 74,782 shares of common stock. The Warrant will be exercisable for a period of seven years from the date of issuance at a per-share exercise price equal to $33.43, which was the closing price of our common stock on September 16, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Commercial Bank Debt with SVB</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On May 14, 2019, we entered into the Loan Agreement with SVB, as administrative and collateral agent, and lenders SVB and WestRiver Innovation Lending Fund VIII, L.P. We borrowed $25.0 million, Term Loan A, at the inception of the Loan Agreement and an additional $25.0 million, Term Loan B, in March 2020, which we collectively refer to as the Term Loans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The SVB Term Loan bore interest at a floating rate of the higher of the Wall Street Journal Prime rate plus 1.75% or 7.25%. Under the original SVB Loan Agreement, the monthly payments consisted of interest-only through May 31, 2021. Pursuant to the first amendment to the SVB Term Loan entered into on March 11, 2020, and the second amendment to the SVB Term Loan entered into on March 11, 2021, the interest-only payment period was initially extended through July 31, 2021, and was further extended until December 31, 2021, after we received positive data from its Phase 3 clinical trial in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection sufficient to file a new drug application, or NDA, with the FDA. The interest-only payment period could have been further extended until November 30, 2022, if we would receive positive data from its Phase 3 clinical trial in erosive esophagitis for vonoprazan sufficient to file an NDA with the FDA. Subsequent to the interest-only period, the Term Loans would have been payable in equal monthly installments of principal, plus accrued and unpaid interest through the maturity date of May 1, 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we were obligated to pay a final payment fee of 8.25% of the original principal amount of the SVB Term Loan. We could have elected to prepay all or a portion of the SVB Term Loan prior to maturity, subject to a prepayment fee of up to 2.0% of the then outstanding principal balance and payment of a pro rata portion of the final payment fee. After repayment, no SVB Term Loan amounts could have been borrowed again. The borrowings under the SVB Term Loan were collateralized by substantially all of our assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">129</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The SVB Term Loan contained certain customary affirmative and negative covenants and events of default. The affirmative covenants included, among others, covenants requiring us to maintain our legal existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding our operating accounts. The negative covenants included, among others, limitations on our ability to incur additional indebtedness and liens, merge with other companies or consummate certain changes of control, acquire other companies, engage in new lines of business, make certain investments, pay dividends, transfer or dispose of assets, amend certain material agreements or enter into various specified transactions. Upon the occurrence of an event of default, subject to any specified cure periods, all amounts owed by us would have begun to bear interest at a rate that is 4.00% above the rate effective immediately before the event of default and could have been declared immediately due and payable by SVB, as collateral agent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the SVB Term Loan, we issued Lender Warrants, which became exercisable when we borrowed Term Loan B in March 2020. The Lender Warrants are exercisable for 16,446 shares of common stock. The Lender Warrants expire ten years from the date of issuance. The Lender Warrants included a put option pursuant to which, in the event that we did not draw down Term Loan B on or before March 31, 2020, the warrant holders could have required us to repurchase the warrants for a total aggregate repurchase price of $0.5 million. Upon the Term Loan B draw in March 2020, the put option related to the Lender Warrants expired, at which time we recorded a final fair value adjustment and reclassified the Lender Warrants balance of $0.3 million to additional paid-in-capital.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">At-the-Market-Offering</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On November 10, 2020, we entered into an Open Market Sale Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">SM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, or the Sales Agreement, with Jefferies LLC, or the Sales Agent, under which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $125.0 million through the Sales Agent, or the ATM Offering. Sales of our common stock made pursuant to the Sales Agreement, if any, will be made under our shelf registration statement on Form S-3 which was filed on November 10, 2020 and declared effective by the SEC on November 16, 2020. We are not obligated to, and we cannot provide any assurances that we will, make any sales of the shares under the Sales Agreement. The Sales Agreement may be terminated by the Sales Agent or us at any time. There were no sales of our common stock under the ATM Offering for the year ended December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Underwritten Public Offering</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 16, 2020, the Company completed an underwritten public offering, in which it sold 2,250,000 shares of its common stock at a price of $42.00 per share for total gross proceeds of $94.5 million. The net purchase price after deducting underwriting discounts and commissions was $39.48 per share, which generated net proceeds of $88.8 million. We incurred an additional $0.2 million of offering expenses in connection with the public offering.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Funding Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on our current operating plan, we believe that our existing cash and cash equivalents together with the drawdown of the remaining $100 million under our Loan Agreement with Hercules will be sufficient to fund our operations into the middle of 2023. We expect such current cash and cash equivalents, when combined with our anticipated borrowing ability, will allow us to complete our ongoing Phase 3 clinical trial studying vonoprazan for NERD (daily dosing), and, if approved, launch vonoprazan for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and erosive esophagitis.. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. Additionally, the process of testing product candidates in clinical trials is costly, and the timing of progress and expenses in these trials is uncertain.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">130</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future capital requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the initiation, type, number, scope, results, costs and timing of our clinical trials of vonoprazan, and preclinical studies or clinical trials of other potential product candidates we may choose to pursue in the future, including feedback received from regulatory authorities;  </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays and cost increases as a result of COVID-19;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs and timing of manufacturing for vonoprazan or any future product candidates, including commercial scale manufacturing if any product candidate is approved; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs, timing and outcome of regulatory review of vonoprazan or any future product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs associated with hiring additional personnel and consultants as our business grows, including additional executive officers and clinical development personnel;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and amount of the milestone or other payments we must make to Takeda and any future licensors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs and timing of establishing or securing sales and marketing capabilities for vonoprazan or any future product candidate; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">patients&#x2019; willingness to pay out-of-pocket for any approved products in the absence of coverage and/or adequate reimbursement from third-party payors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs associated with any products or technologies that we may in-license or acquire.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until such time, if ever, as we can generate substantial product revenues to support our cost structure, we expect to finance our cash needs through equity offerings, the Loan Agreement, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Including our existing cash and cash equivalents, we believe that we have sufficient working capital on hand to fund operations such that there is no substantial doubt as to our ability to continue as a going concern at the date the financial statements were issued. There can be no assurance that we will be successful in acquiring additional funding, that our projections of future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years. Based on our current operating plan, we believe that our existing cash and cash equivalents together with the drawdown of the remaining $100 million under the Loan Agreement with Hercules will be sufficient to meet our anticipated cash requirements into the middle of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Flows</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth a summary of the net cash flow activity for each of the periods indicated (in thousands):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.556%;"></td>
    <td style="width:1.125%;"></td>
    <td style="width:1.901%;"></td>
    <td style="width:13.737%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:1.125%;"></td>
    <td style="width:1.901%;"></td>
    <td style="width:11.019%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:1.125%;"></td>
    <td style="width:1.901%;"></td>
    <td style="width:11.795%;"></td>
    <td style="width:1.272%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">$ Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by (used in):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(148,617</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(69,688</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(78,929</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(328</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1,040</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">712</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44,708</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114,459</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(69,751</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net increase (decrease) in cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(104,237</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43,731</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(147,968</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">132</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Activities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in operating activities was approximately $148.6 million and $69.7 million for the years ended December 31, 2021 and 2020, respectively. The net cash used in operating activities for the year ended December 31, 2021 was due to approximately $121.1 million spent on ongoing research and development and general and administrative activities and a $27.5 net change in operating assets and liabilities. The net change in operating assets and liabilities primarily related to a $28.1 million decrease in accounts payable and accrued expenses (including clinical trial expenses) in support of the growth in our operating activities, partially offset by a $0.6 million decrease in prepaid assets. The net cash used in operating activities for the year ended December 31, 2020 was due to approximately $121.4 million spent on ongoing research and development and general and administrative activities, partially offset by a $51.7 million net change in operating assets and liabilities. The net change in operating assets and liabilities primarily related to a $8.0 million decrease in prepaid clinical activities, and a $43.9 million increase in accounts payable and accrued expenses in support of the growth in our operating activities, partially offset by a $0.2 million increase in other long-term assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in investing activities for the years ended December 31, 2021 and 2020 was primarily due to the cash we paid for acquiring property, plant and equipment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by financing activities for the year ended December 31, 2021 was $44.7 million, due to $96.9 million of net proceeds from the loan agreement with Hercules and $1.9 million of proceeds related to stock option exercises partially offset by the $54.1 million repayment of the SVB Term Loan. Net cash provided by financing activities for the year ended December 31, 2020 was $114.4 million, due to $88.8 million of proceeds from our underwritten public offering, $25.0 million of proceeds from our commercial bank debt, and $0.6 million of proceeds related to stock option exercises during the year.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Contractual Obligations and Commitments</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our contractual obligations as of December 31, 2021 (in thousands):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:34.844%;"></td>
    <td style="width:1.32%;"></td>
    <td style="width:1.642%;"></td>
    <td style="width:9.755%;"></td>
    <td style="width:0.773%;"></td>
    <td style="width:1.32%;"></td>
    <td style="width:1.642%;"></td>
    <td style="width:9.41%;"></td>
    <td style="width:0.773%;"></td>
    <td style="width:1.32%;"></td>
    <td style="width:1.642%;"></td>
    <td style="width:8.875%;"></td>
    <td style="width:0.773%;"></td>
    <td style="width:1.32%;"></td>
    <td style="width:1.642%;"></td>
    <td style="width:8.851%;"></td>
    <td style="width:0.773%;"></td>
    <td style="width:1.32%;"></td>
    <td style="width:1.642%;"></td>
    <td style="width:9.588%;"></td>
    <td style="width:0.773%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Payments Due by Period</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Less than</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">1-3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">3-5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">More</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Calibri;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">than</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">1 Year</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">5 Years</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total debt, including interest<br />&#160;&#160;&#160;and final payment fee </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">146,772</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,704</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23,208</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117,860</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Minimum operating lease<br />&#160;&#160;&#160;payments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,890</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">503</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,045</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">342</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">148,662</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,207</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,253</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">118,202</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="20" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1) Our outstanding long-term debt bears interest at a variable rate. The interest amounts included herein are based on the interest rate in effect as of December 31, 2021.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the contractual obligations summarized above, on May 5, 2020, we entered into a Commercial Supply Agreement with Takeda, pursuant to which Takeda will supply commercial quantities of vonoprazan bulk drug product. We incurred $1.8 million and $0.3 million of expenses related to the Commercial Supply Agreement during the years ended December 31, 2021 and 2020, respectively. We have an estimated remaining minimum purchase obligation of approximately $0.4 million related to this agreement. As of December 31, 2021, we are unable to estimate the timing of future expenses and, therefore, any related payments are not included in the table above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, on December 30, 2020, we entered into a Supply and Packaging Services Agreement with Sandoz, pursuant to which Sandoz has agreed to supply commercial quantities of amoxicillin capsules and clarithromycin tablets, to package these antibiotics with vonoprazan, in finished convenience packs, and to supply us with these convenience packs. The supply agreement commits the Company to a minimum purchase obligation of approximately $3.8 million during the first 24-month period following the launch of the final product. As of December 31, 2021, we are unable to estimate the timing of future expenses and, therefore, any related payments are not included in the table above. We have not incurred any expenses under the agreement during the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We enter into contracts in the normal course of business for our contract research services, contract manufacturing services, professional services and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts and not included in the table above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Critical Accounting Policies and Significant Judgments and Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management&#x2019;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While our significant accounting policies are more fully described in Note 1 to our financial statements, we believe that the following accounting policies are the most critical for fully understanding and evaluating our financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued Research and Development Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of the process of preparing our financial statements, we are required to estimate our accrued expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments, if necessary. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by our vendors in connection with research and development activities for which we have not yet been invoiced.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">134</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We base our expenses related to research and development activities on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid expense accordingly. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the inception of any contractual arrangements we may enter into, we determine whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, we record the associated lease liability and corresponding right-of-use asset upon commencement of the lease using either the implicit rate or a discount rate based on our credit-adjusted secured borrowing rate commensurate with the term of the lease. Additionally, we evaluate leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease. We assess if a lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows is substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if the underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term. We account for leases that do not meet the finance lease criteria as operating leases, representing our right to use an underlying asset for the lease term. We also recognize operating lease liabilities as our obligation to make lease payments arising from the lease. We recognize operating lease liabilities with a term greater than one year and their corresponding right-of-use assets on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. As needed, we make certain adjustments to the right-of-use asset for items such as initial direct costs paid or incentives received. Because our leases do not typically provide an implicit rate, we utilize the rate of interest that we would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. We recognize lease costs on a straight-line basis over the lease term and variable lease payments as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space we lease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of the awards (generally the vesting period) on a straight-line basis with forfeitures recognized as they occur. We use the Black-Scholes valuation model to determine the fair value of our stock awards. Through December 31, 2021, our stock-based compensation expense consisted of recognized fair value related to our issuance of restricted stock awards, for which the fair value is determined based on the fair value of the underlying common stock, stock options, and ESPP awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Other Company Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">JOBS Act</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, we can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. We intend to rely on other exemptions provided by the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of Section 404(b) of Sarbanes-Oxley.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year following the fifth anniversary of the consummation of our IPO, (ii) the last day of the fiscal year in which we have total annual gross revenue of at least $1.07 billion, (iii) the last day of the fiscal year in which we are deemed to be a &#x201c;large accelerated filer&#x201d; as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year, or (iv) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recent Accounting Pronouncements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item is included in Note 1, Organization, Basis of Presentation and Summary of Significant Accounting Policies included in Item 15 of this annual report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Off-Balance Sheet Arrangements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the periods presented we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a__quantitative_qualitative_disclo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 7A.	Quantitative and Qualita</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">tive Disclosures About Market Risk</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Rate Risk</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our cash and cash equivalents consist of cash in readily available checking accounts and money market funds. As a result, the fair value of our portfolio is relatively insensitive to interest rate changes. Our long-term debt bears interest at a variable rate. A 10% increase or decrease in the interest rate on our long-term debt would not have a material effect on our financial position, results of operations or cash flows.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Effects of Inflation</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inflation generally affects us by increasing our cost of labor and research and development contract costs. We do not believe inflation has had a material effect on our results of operations during the periods presented.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8__financial_statements_supplementa"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 8.	Financial Stateme</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">nts and Supplementary Data</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The financial statements required pursuant to this item are incorporated by reference herein from the applicable information included in Item 15 of this annual report and are presented beginning on page F-1.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9__changes_in_disagreements_with_ac"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9.	Changes in and Disagreements with Acco</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">untants on Accounting and Financial Disclosure</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">136</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a__controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9A.	Control</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">s and Procedures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this annual report. Based on such evaluation, our principal executive officer and principal financial officer have concluded that as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Annual Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act). Internal control over financial reporting is a process designed under the supervision and with the participation of our management to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. Management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control&#x2014;Integrated Framework (2013 Framework). Based on this assessment, our management concluded that, as of December 31, 2021, our internal control over financial reporting was effective.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Attestation Report of the Registered Public Accounting Firm</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This annual report does not include an attestation report of our registered public accounting firm due to an exemption provided by the JOBS Act for &#x201c;emerging growth companies.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There have been no changes in our internal control over financial reporting during the fourth quarter ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b__or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9B.	Oth</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">er Information</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_disclosure_foreign_jurisdictions"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9C.	Disclosure Regarding Foreign</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Jurisdiction that Prevent Inspection</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">137</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> III</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10__directors_executive_ficers_corp"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 10.	Directors, Executive O</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">fficers and Corporate Governance</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item will be contained in our definitive proxy statement to be filed with the SEC in connection with our 2022 Annual Meeting of Stockholders, or the Definitive Proxy Statement, which is expected to be filed not later than 120 days after the end of our fiscal year ended December 31, 2021, under the headings &#x201c;Election of Directors,&#x201d; &#x201c;Executive Officers,&#x201d; and &#x201c;Section 16(a) Beneficial Ownership Reporting Compliance,&#x201d; and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Code of Conduct and Ethics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have adopted a Code of Conduct and Ethics that applies to our officers, directors and employees, which is available on our website at www.phathompharma.com. The Code of Conduct and Ethics contains general guidelines for conducting the business of our company consistent with the highest standards of business ethics and is intended to qualify as a &#x201c;code of ethics&#x201d; within the meaning of Section 406 of the Sarbanes-Oxley Act of 2002 and Item 406 of Regulation S-K. In addition, we intend to promptly disclose (1) the nature of any amendment to our Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions and (2) the nature of any waiver, including an implicit waiver, from a provision of our code of ethics that is granted to one of these specified officers, the name of such person who is granted the waiver and the date of the waiver on our website in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11__executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 11.	Execut</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ive Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item will be set forth in the section headed &#x201c;Executive Compensation and Other Information&#x201d; in our Definitive Proxy Statement and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12__security_ownership_certain_bene"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 12.	Security Ownership of Certain Beneficial O</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">wners and Management and Related Stockholder Matters</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item will be set forth in the section headed &#x201c;Security Ownership of Certain Beneficial Owners and Management&#x201d; in our Definitive Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by Item 201(d) of Regulation S-K will be set forth in the section headed &#x201c;Executive Compensation&#x201d; in our Definitive Proxy Statement and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13__certain_relationships_related_t"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 13.	Certain Relationships and Relat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ed Transactions, and Director Independence</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item will be set forth in the section headed &#x201c;Certain Relationships and Related Person Transactions,&#x201d; &#x201c;Board Independence&#x201d; and &#x201c;Committees of the Board of Directors&#x201d; in our Definitive Proxy Statement and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14__principal_accounting_fees_servi"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 14.	Principal Acco</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">unting Fees and Services</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item will be set forth in the section headed &#x201c;Independent Registered Public Accountants&#x2019; Fees&#x201d; in our Definitive Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15__exhibits_financial_statement_sc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 15. Exhibits, Finan</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">cial Statement Schedules</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">All financial statements.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The financial statements of Phathom Pharmaceuticals, Inc., together with the report thereon of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1d8d9577-c0e8-4b86-80f5-c2fb30064a7c" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ernst &amp; Young LLP</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, an independent registered public accounting firm, are included in this annual report on Form 10-K beginning on page F-1.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Financial statement schedules.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibits</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A list of exhibits is set forth on the Exhibit Index immediately preceding the signature page of this annual report on Form 10-K and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 16. Form </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">139</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Phathom Pharmaceuticals, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Index to Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.996%;"></td>
    <td style="width:6.004%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Page</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_independent_registered_public_ac"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;(PCAOB ID: </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_039e9773-0740-4892-b9dc-e3fe849a6cd1" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#balance_sheet"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statement_of_operation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statement_of_stockholders_equity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statements of Stockholders&#x2019; Equity</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#combined_statement_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_financials"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notes to Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_independent_registered_public_ac"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Report of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Independent Registered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the Stockholders and Board of Directors of Phathom Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have audited the accompanying balance sheets of Phathom Pharmaceuticals, Inc. (the Company) as of December 31, 2021 and 2020, the related statements of operations and comprehensive loss, stockholders' equity and cash flows for the years then ended, and the related notes</span><span style="background-color:rgba(244,244,244,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Ernst &amp; Young LLP</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">                                                                        </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have served as the Company&#x2019;s auditor since 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4bd69e6e-b243-4cb4-802a-0dbf01372a08" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="dei:AuditorLocation"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Iselin, New Jersey</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 1, 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PHATHOM PHARMACEUTICALS, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="balance_sheet"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Bal</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ance Sheets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands, except share and par value amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.449%;"></td>
    <td style="width:1.477%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:13.007%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.477%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:13.007%;"></td>
    <td style="width:0.921%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current assets:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0d3661b8-c27b-47cf-8ba7-ab92f49f0638" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">183,259</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c0929e84-69d8-4631-9bd2-80472688b079" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">287,496</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets (including related party amounts<br />&#160;&#160;&#160;of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_122931cb-c1c4-43c1-82c3-ec02fd2fd302" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="phat:PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3416e3a6-1891-4c37-b467-97e16e54b0ce" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="phat:PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7e78f37e-ef98-44bd-8ec8-ea122e985b1a" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,267</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b073ec6-34f9-4417-849c-ab2a28a6f907" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,872</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_643ad79c-6164-4e2b-b493-f6147af52487" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">186,526</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_542c4479-3222-426d-874e-6b7a9ff6d8c6" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">291,368</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property, plant and equipment, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae051827-b436-4ae8-bcd8-3c8184260449" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">650</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_abb408c1-0f4e-4e37-932b-0260d356d117" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">986</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_04a0c87e-bdeb-4622-8bb0-9b92e0804cdf" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,914</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd7e3c76-0d90-48ea-a2fe-2ff3707ae74e" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,373</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other long-term assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_83e43668-e7a5-41a7-9e97-b6b61e1bc354" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">341</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da29382c-0757-46b4-8e0c-def9356c721b" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">384</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4db615b2-b857-4fbb-808b-2ec004cbe441" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">189,431</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9aa27c45-fa60-4846-97b2-39a69beb1587" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">295,111</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liabilities and Stockholders&#x2019; Equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts payable (including related party amounts of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_21121b93-1ef3-4988-bd77-9b8f96d2de8d" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:AccountsPayableRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,343</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_11421a45-ed5a-4247-ac01-cfc92d87edcc" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:AccountsPayableRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">173</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">,<br />&#160;&#160;&#160;respectively)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b3590baf-fe23-4472-95b5-9195d6602e53" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,150</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1de16332-18fb-4d22-9097-122f56206e32" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,782</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued clinical trial expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a2a883a-7459-41fa-bd67-e89cd8c44ccc" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="phat:AccruedClinicalTrialExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,402</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f2a791e5-18b4-450a-803e-5b02deb320e3" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="phat:AccruedClinicalTrialExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,997</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses (including related party amounts of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5ab1f96a-424c-448c-bc10-7a2942a3a499" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="phat:AccruedExpensesRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,330</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fded6457-6714-4a55-a9d6-d82af2bf0fc5" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="phat:AccruedExpensesRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">734</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">,<br />&#160;&#160;&#160;respectively)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba03f2f9-f390-4336-93b7-c2912d9be5d8" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,405</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec78cc71-ec1d-41aa-a603-5e539cf6ea92" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,606</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued interest</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e549aa6-7ef4-40b2-9794-a6b6fd9f5e58" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">477</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1833440e-17f6-4c5e-8ed2-b0861d056382" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">312</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current portion of long-term debt</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_14f25b33-fb69-473f-a534-9eb76b9c27ef" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,353</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, current</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_edb5fb98-87ee-48d5-aeb7-146465c0e68a" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_82c08e9b-72c2-4d34-b002-b64dfafea29c" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">474</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3eb68bd6-0a0e-4f2f-bead-fc2bf7c32ff5" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,921</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f419b692-ed0d-48fb-81f1-ead72eca0e78" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,524</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term debt, net of discount</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_07b870e9-a8f6-4e57-a21c-a76e9b01f477" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">89,671</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e48d327-9af3-4f90-8563-9a1baf39f459" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39,634</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e3d881a2-0705-47d7-bf81-5948bb1315e1" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,183</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f9445a7-9160-485c-9206-b2a8462dacc0" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,557</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other long-term liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7de25211-3d16-43c2-953f-733ad4a5aa87" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3387d52-f6d8-4581-be7b-34b23ea5308d" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,125</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a3bc4cbc-158d-4dd3-86e4-864827e2b3cc" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">117,275</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9e10c840-f932-45fb-b518-1c16e5586997" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100,840</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_790a9cb9-9188-4ded-9206-b149f84c5071;"><span style="-sec-ix-hidden:F_6df742c1-1b0e-4a19-9b23-85075f7ae8ca;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commitments and contingencie</span></span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">s (Note 4)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stockholders&#x2019; equity:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preferred stock, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3212d7d-73dc-4f2e-b93a-9d14a25b59ff" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_8e362aeb-ae70-4560-8e39-bc157d527e76" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;par value; authorized shares &#x2014; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c2d85533-646e-484b-9ea8-4770e3083d58" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_53085ee7-8caa-413b-a425-7245ec48a5c0" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">40,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;at December 31, 2021 and 2020; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_932cd3f0-e5ab-4125-b7b6-8cfaab839074" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7d9d4ad3-e278-4875-98e0-8d73c60cdf8b" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_90d3134e-890e-468f-9ea4-df597f9a034b" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_1aa69dbd-4e65-4611-bf3f-e29bc46061f2" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares issued and outstanding at <br />December 31, 2021 and 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d8219ef5-f760-4856-ae0b-f47cd083e034;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a6f5857d-fe54-46c6-8042-ea23f4bc4656;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f472962-b234-454d-9720-9ef93919dddd" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_0ffed6f2-8646-4ac6-acfd-b935d8c6c1f2" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;par value; authorized shares<br />&#160;&#160;&#160;&#x2014;</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05bf5913-f9f8-46fb-a68f-28152cd8adbb" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_d30ea15f-bc4b-4074-abf2-9d9b375ee142" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">400,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;at December 31, 2021 and 2020; issued shares&#x2014;<br />&#160;&#160;&#160;</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb0f3e13-50cf-43c8-af76-5922d6da67ae" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">31,656,035</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59e0c2ba-3b49-4aba-907f-ef133b83ecc1" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">31,262,769</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;at December 31, 2021 and 2020, <br />&#160;&#160;respectively; outstanding shares&#x2014; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e755a519-2942-4f68-bc1e-4e5c207eb064" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,511,226</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7d3bed6e-bb12-4982-97fa-6d38bb196aca" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">28,516,010</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br />&#160;&#160;at December 31, 2021 and 2020, respectively</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8079d807-e1f8-40f7-b9df-c71ebd031bb8" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c732dd5-4f49-49f3-bd72-817d175e3516" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0a9f4a29-9cd6-41ed-8109-c7eec985a7ce" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">601,523</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_301a2993-b651-4cd8-8825-58714b26e862" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">579,755</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_73f38701-0726-4965-a9d4-775027dc5fbb" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">529,370</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0d2edc42-b857-433e-9447-634f2283d7a9" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">385,487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc542c41-4bac-4862-9de8-ea799aa7ebf6" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,156</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_70ca3f8f-929b-4ba6-8d5f-10b2f055fbd0" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194,271</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total liabilities and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f1b31023-1212-46e9-9e9f-892d0e12e652" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">189,431</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f7c653e-9b6a-472e-9e5d-58e9ebb20ebf" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">295,111</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">See accompanying notes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PHATHOM PHARMACEUTICALS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statement_of_operation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Statements of Opera</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">tions and Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands, except share and per share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.253%;"></td>
    <td style="width:1.467%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:13.201%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.467%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:13.03%;"></td>
    <td style="width:0.921%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development (includes related party amounts of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ed1e977-0b62-4112-9a26-a4a81e28c2c0" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:ResearchAndDevelopmentExpenseRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,933</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_37f5e0ec-f63b-4abe-8c6b-88268bacbc6b" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="phat:ResearchAndDevelopmentExpenseRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,812</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59e92989-1d0d-473a-a298-b85a4a1681ec" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,338</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52c1e6aa-e93d-4a6c-af68-23527951ebe4" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">98,148</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative (includes related party amounts of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da02b8fc-7e3e-443d-92b9-ebeee6b22487" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:GeneralAndAdministrativeExpenseRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_913afa0d-71ad-4c64-8ca1-16e163c27989" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="phat:GeneralAndAdministrativeExpenseRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">157</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6630c8d7-7f43-463b-a8cc-8d9f82fd9faa" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,742</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_740bf95e-3799-4d57-a6c3-89709cf9f375" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,517</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5ed628b0-b01c-4b6c-bdbd-eacb10786968" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">135,080</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d66c66ad-e75f-4126-bdd7-5d2065082f17" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">125,665</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e685429d-5483-4663-9f25-948bfdec0e10" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">135,080</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb15942b-8053-4c2d-8b24-186d7541ad26" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">125,665</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_11711ef8-081f-40ed-ac3a-117b323e8e0d" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac023eaa-56cf-45a6-8c79-82229c6a8b8a" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,091</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e3257590-58b0-48aa-9abe-fb3cd6672b96" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,788</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_77a7585c-0d33-4b9e-87fc-16a09d8a0c09" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,581</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of warrant liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_10442ba0-9dc4-4157-a992-5d31d15bc466" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">95</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other (expense)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f03e569-d9d3-4c4e-9311-37ad5f75c41f" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,056</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e6b49b03-da3b-4663-ab88-008eb078e3b4" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total other income (expense)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2b57158e-9411-4a58-b526-c8c3c332e16f" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,803</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_33568c88-8c14-4fc5-8db2-82ff95339462" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,403</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss and comprehensive loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b381d13-6d41-4154-9d9b-fe45c682bc8a" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">143,883</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d955e81f-e4e9-4818-97f4-c591aac79438" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">129,068</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share, basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d31bf7c8-9784-4745-be5e-73ef0611efd7" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">3.89</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1ebd0bfd-f03e-47a6-b712-792d1c9ec30a" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">3.88</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares of common stock outstanding, basic and diluted</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_88824815-d82d-4487-a3f4-4e1dc2667817" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">37,002,959</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dda75dbe-c877-4014-8398-a2b1f1ed68ec" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">33,228,158</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">See accompanying notes</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PHATHOM PHARMACEUTICALS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statement_of_stockholders_equity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Statements of Sto</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ckholders&#x2019; Equity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands, except share amounts)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:36.933%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:10.006%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.241%;"></td>
    <td style="width:6.999%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.241%;"></td>
    <td style="width:9.0%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.241%;"></td>
    <td style="width:10.017%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.241%;"></td>
    <td style="width:11.098%;"></td>
    <td style="width:0.92%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Common Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Additional<br />Paid-in</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Accumulated</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Total<br />Stockholders&#x2019;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balance at December 31, 2019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89088d4f-4ede-4b8b-aa38-8144965fbbbe" contextRef="C_589be08d-1fdd-4132-b344-d516fb3dae6d" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">24,728,258</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6c0a7348-9fbf-41d7-a7b9-10d1ad09f244" contextRef="C_589be08d-1fdd-4132-b344-d516fb3dae6d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60fc1f61-51ac-48ca-b09c-102c5afa9512" contextRef="C_9c7240c2-23a4-4f2e-bdf7-8d45f209d98b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">484,372</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8fe885bd-48e8-4dc2-b189-9e83a07e1c06" contextRef="C_36815495-d09a-4025-bf79-5a42d4c3e739" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">256,419</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5a936db6-f439-42d2-8a4f-71b3cbcca0b5" contextRef="C_33fee96d-a213-48c4-a5ad-68ccefad3cff" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">227,955</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Conversion of Lender Warrants into equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7120c2cc-63df-43df-b4ab-56258011428a" contextRef="C_a36db690-2560-474a-8fbd-8050d47eb62c" name="phat:AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">318</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_df43fd68-87ce-4ba4-8bde-33df096f543a" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="phat:AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">318</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Issuance of common stock in connection with<br />&#160;&#160;underwritten public offering, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_408d99ab-3877-4dd4-89d4-5470c815bba0" contextRef="C_fed6006f-4109-4946-b552-76ae913aeaf0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,250,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1bfb6777-4092-4884-b3a7-7e6cbb842adf" contextRef="C_20fed5f8-cd13-4903-b6b5-b54dbe1e910a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88,596</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_56a476fe-50ac-4fef-b3a7-12e582de7b66" contextRef="C_33b1043e-bfc6-4fce-ba82-e6e6e0ac95af" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88,596</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Issuance of common stock from exercise of stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c9d8d5ce-093a-4bad-b306-0801b5272439" contextRef="C_d3d57991-14bf-4f93-a017-aa16c506b8db" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">48,263</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_291e5a72-00f7-431e-b0aa-547444e47b6a" contextRef="C_a36db690-2560-474a-8fbd-8050d47eb62c" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">629</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_370601ff-3e69-4143-b653-ebdb59ca31e8" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">629</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Vesting of restricted shares</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa429977-acaa-4fc1-b5fc-80ea8d752cdb" contextRef="C_d3d57991-14bf-4f93-a017-aa16c506b8db" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,489,489</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_49753d08-e315-4126-a260-afae1856ca09" contextRef="C_d3d57991-14bf-4f93-a017-aa16c506b8db" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7196b3f7-23c5-4907-b276-65ac985ac1c1" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa06e684-b219-4311-8540-9948f4b41cc0" contextRef="C_a36db690-2560-474a-8fbd-8050d47eb62c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,840</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bc3b6ece-8089-4976-a8b4-b71be42d08de" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,840</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b7dd119-0bef-4ccb-9abe-bb5aaef6db4b" contextRef="C_2abff921-c9a8-4de4-b41c-9e7893e5704b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">129,068</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_68a89350-086c-4f69-a873-cf4f427fd445" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">129,068</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2ed4e003-5a8e-4ea3-b835-01c101fc5f23" contextRef="C_51814a33-b695-44e9-b59a-823a169dda09" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">28,516,010</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fde38ec7-1888-4f2a-8261-2ef40368edd5" contextRef="C_51814a33-b695-44e9-b59a-823a169dda09" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0be64a79-dd6c-40e1-a5de-ae87fa8a04e6" contextRef="C_d962d708-ce93-405d-a90d-73e1fae4aa3a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">579,755</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_253fbe3a-3f31-4540-84b7-afb30d74df96" contextRef="C_83965ad4-28b1-4afc-8889-5d7cdbc079ef" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">385,487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_959ceaa5-9ef0-47de-9728-5878341496a2" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194,271</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Issuance of common stock from exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f31657e5-c2ac-4927-8d26-b4306fd10c12" contextRef="C_ab2e6d6d-5682-41ff-9336-cabea4c3f7b9" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">107,583</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d8576867-0a86-498f-b530-32554a529761" contextRef="C_543d071e-badd-429f-8237-98bcd1e05d25" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,944</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c2483d05-91c1-4815-a852-4e430430f740" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,944</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Issuance of common stock from exercise of warrants</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_91f1039a-db87-4517-bac8-7f40278cdc46" contextRef="C_ab2e6d6d-5682-41ff-9336-cabea4c3f7b9" name="phat:StockIssuedDuringPeriodSharesExerciseOfWarrants" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">228,696</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">401(k) matching contribution</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6be0e9b5-35db-46ea-9b8b-662661f66830" contextRef="C_ab2e6d6d-5682-41ff-9336-cabea4c3f7b9" name="phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">26,750</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca316eaa-ba7a-41a2-ba2e-f5245362e9fe" contextRef="C_543d071e-badd-429f-8237-98bcd1e05d25" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">903</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_86e6ccf7-bc08-43ec-8b80-c0b076a135a7" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">903</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Vesting of restricted shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d526a97-a0c7-4973-b539-fa709dffb7e9" contextRef="C_ab2e6d6d-5682-41ff-9336-cabea4c3f7b9" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,601,950</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_79a1581c-d7e4-412e-a4c5-98ec34407c04" contextRef="C_543d071e-badd-429f-8237-98bcd1e05d25" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,812</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_146e675d-361a-4ed1-88d1-eb5ff5bfea31" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,812</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">ESPP shares issued</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2b9326fe-b386-4367-9569-c6ea63d6be8b" contextRef="C_ab2e6d6d-5682-41ff-9336-cabea4c3f7b9" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,237</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e1967ec6-43ad-46f4-9032-cef405fd9a33" contextRef="C_543d071e-badd-429f-8237-98bcd1e05d25" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">819</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_380e3bf1-b6a0-4aee-bbe7-a6944b8fd610" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">819</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Issuance of warrants</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8081a62-1b8f-4a0d-997a-ffa3520aaf9e" contextRef="C_543d071e-badd-429f-8237-98bcd1e05d25" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,290</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7310d791-ec86-459a-bdcb-b9a5ed8118a0" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,290</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52364b76-c2cf-4f37-bf16-53f34d2d2b05" contextRef="C_213e1528-74d7-4db2-a3ae-74c89a47e0e3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">143,883</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f001e88-675c-49d6-9669-2416b8d98535" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">143,883</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f8a0a14-6b58-4595-ba5a-0fd09779f954" contextRef="C_b03a9ab9-4538-4d34-b658-218482e16bbd" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,511,226</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9af885d4-67b1-4181-8e50-3e44ea836255" contextRef="C_b03a9ab9-4538-4d34-b658-218482e16bbd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aeab5f19-38bd-4b5c-b70e-26c77280afe8" contextRef="C_ea9b39a8-a8b3-4e16-ad57-51beaa82a734" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">601,523</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_84ec127e-15cf-45b5-ae73-6465e3a61612" contextRef="C_a86629b2-8d48-4534-a0ad-f992b4110383" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">529,370</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4fb60493-0dc9-4dd7-a1fd-e5fb0e43a5bb" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,156</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">See accompanying notes</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PHATHOM PHARMACEUTICALS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="combined_statement_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Statemen</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ts of Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.795%;"></td>
    <td style="width:1.477%;"></td>
    <td style="width:1.124%;"></td>
    <td style="width:13.263%;"></td>
    <td style="width:0.739%;"></td>
    <td style="width:1.477%;"></td>
    <td style="width:1.124%;"></td>
    <td style="width:13.263%;"></td>
    <td style="width:0.739%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Years Ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cash flows from operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_09377b70-eba7-4035-bbce-24de746d9416" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">143,883</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_33139262-4f48-4f26-89a6-ef709afde1b3" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">129,068</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Depreciation and amortization</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f24a74cc-a678-4395-9ac0-07608691fb92" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">521</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae26b02e-9eab-405d-98b9-3fa37925eeba" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">323</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_97337918-c956-4fd5-ba4f-7ba2e1161d94" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,812</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_48b91c48-c7d2-4683-ba60-3f9d255bb541" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,840</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of PIK interest debt</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f695045e-1464-4876-af71-e0d9ae6467fb" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:PaidInKindInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">990</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Amortization of debt discount</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b7ad14d3-3919-4172-9f26-74fbe4e28154" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,595</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b980f76f-b43c-4baf-a07c-58b6fd89f269" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,273</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Change in fair value of warrant liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8fdadd4c-2533-4841-a0cf-1a2fcf13f638" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">95</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Other</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6ff79c4-70a5-48ab-855f-8047a7247bb8" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">823</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab674561-18ac-4b60-94bf-1cd214d1a0fe" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">322</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets (includes related party amounts<br />&#160;&#160;&#160;of $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_498cc096-f304-4e2e-b4af-e9490a634db1" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;and $(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2317012-65c7-480b-9a2f-3b5fe26c9835" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="phat:IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">82</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">), respectively)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_357b2050-3dfe-44b8-a6b8-89af88890899" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">605</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00e9f5a1-b455-480e-91f8-cc9519eb2cb3" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7,963</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Accounts payable and accrued expenses (includes related party amounts of<br />&#160;&#160;&#160;$</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_25fb56bc-039f-4f06-924e-08d205d3cf20" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,766</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;and $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0086b722-d5a9-44ce-ad73-f028cb1b4875" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="phat:IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">399</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">, respectively)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6f4f1dff-007c-4419-9fc3-a66aed749e07" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,791</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_34939954-1b37-4075-b0b4-0f4efca13482" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,009</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Accrued clinical trial expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_13a3a803-c6c1-41d2-83ba-89050f9c9d62" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:IncreaseDecreaseInClinicalAccruedTrialExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">18,595</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c54fe228-46a9-498a-b7c6-db1b0f11e959" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="phat:IncreaseDecreaseInClinicalAccruedTrialExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,997</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Accrued interest</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_56adc2e0-b0c9-4db8-beea-6657b57747c0" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:IncreaseDecreaseInInterestPayableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">165</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d11282d7-87d4-40ee-ac3d-64d5dd5599fe" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:IncreaseDecreaseInInterestPayableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">156</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Operating right-of-use asset and lease liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9e878a00-911f-4886-8677-3a25005943c4" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">98</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e3eb366-e418-447a-8fd9-c09dd9ad270c" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="phat:IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">205</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Other long-term assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_839feedc-9da3-4125-abe8-48da1eeb8732" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00bebdb9-b895-4407-89a5-8cbdecf1d2ff" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">203</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_157fbfec-e256-4298-9d09-d62c494983f7" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">148,617</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d3348513-11ce-4702-aeea-63f7e53610f3" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">69,688</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cash flows from investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Cash paid for property, plant and equipment</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_102301a8-321b-4aeb-8693-b3cdf50c8b9d" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">328</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f2366f72-afd9-4188-b620-c092ec2ff899" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,040</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a8bd2486-f471-4913-80aa-352374be6cdd" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">328</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b94a96a2-b1ce-4b9f-82ca-0cac32bfe72c" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,040</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cash flows from financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Proceeds from underwritten public offering, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_77b4a873-3e1b-4d44-ba1a-9e49d6e110bf" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="phat:ProceedsFromUnderwrittenPublicOfferingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88,830</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Proceeds from issuance of common stock from exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_969bc409-2a65-4785-b155-118eea2f0880" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,944</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca581ebc-6f77-4955-b588-9a1f7e43bbd0" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">629</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Repayment of long-term debt</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_726be74c-edd9-4c47-ba3e-2f6338ba7f6c" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54,125</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net proceeds from issuance of long-term debt</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f890e747-da59-45ee-9e12-9901151e134f" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,889</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_738d3f30-d341-4c16-9fb8-d8e00e83a62e" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8c1a78b-6a39-4ce0-9f36-32001930a0e8" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,708</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf486c33-effd-48b4-8e6e-a29982a5e924" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">114,459</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net increase (decrease) in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cc732be3-a5bd-4a9c-a019-dd144fc56aa3" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">104,237</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6cffd943-436d-4d8e-b60b-c1cb19123776" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43,731</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Cash and cash equivalents &#x2013; beginning of period</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f6ff486f-d22b-4340-87ca-9df20a3f02a6" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">287,496</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_980449c9-a577-46b2-9625-4e7e08f546fe" contextRef="C_33fee96d-a213-48c4-a5ad-68ccefad3cff" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">243,765</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Cash and cash equivalents &#x2013; end of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d27d3727-1c38-4388-8edd-2849ef6b1201" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">183,259</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f69b754-0f4f-404e-ba46-66ecb1fd6b2b" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">287,496</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Supplemental disclosure of cash flow information</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Interest paid</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_84b121ec-4fce-4c21-b4cf-efa28004af50" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,069</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a0d33e39-cac7-46a2-be20-2dd708ed67b5" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,464</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Supplemental disclosure of noncash investing and financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of common stock warrants in connection with long-term debt</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_57ba30fe-d89c-423f-9561-60e06df5bf0b" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,290</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Property and equipment purchases included in accounts payable and accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d0afb01e-56c6-4463-b1a1-772b82224881" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59d0f476-0ed8-4511-b2af-c1ad53fa9a79" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Final interest payment fee</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b534a9a-81c3-477a-af2f-1d40d5c5b2f2" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:NonCashFinalInterestPaymentFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a238f113-cbff-4261-b8cf-42f8d59f0fc8" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="phat:NonCashFinalInterestPaymentFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,063</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Settlement of ESPP liability in common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_84ffa6aa-bd7e-4b0f-9b6b-f937e933878a" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">819</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Settlement of 401(k) liability in common stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c89be702-760e-47d1-bbe6-dcd2c39d6024" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">903</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Operating lease liabilities arising from obtaining right-of-use assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5be31f43-6746-461c-8ae3-e0723abf5a00" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="phat:OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,396</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Conversion of Lender Warrants into Equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_02178633-64f6-4d6b-81c9-fcf632db0db0" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="phat:ConversionOfWarrantLiabilitiesIntoEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">318</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Underwritten public offering costs included in accounts payable and accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e93a815-09bb-47a0-a4cc-f3b3d83e7718" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="phat:UnpaidUnderwrittenPublicOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">234</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">See accompanying notes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PHATHOM PHARMACEUTICALS, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_financials"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Financial Statements</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b79b968e-ef07-4057-91c0-30c88afdae26" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Organization, Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ba48c8c2-b14c-4b24-adfa-6179befec480" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:OrganizationAndBasisOfPresentationPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Organization and Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phathom Pharmaceuticals, Inc., or the Company or Phathom, was incorporated in the state of Delaware in January 2018. The Company is a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. The Company&#x2019;s financial statements are prepared in accordance with U.S. generally accepted accounting principles, or GAAP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7d590c67-8efd-4ba0-9ef1-b22f7019031b" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:LiquidityAndCapitalResourcesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From inception to December 31, 2021, the Company has devoted substantially all of its efforts to organizing and staffing the Company, business planning, raising capital, in-licensing its initial product candidate, vonoprazan, meeting with regulatory authorities, managing the Phase 3 clinical trials of vonoprazan, and providing other general and administrative support for these operations. The Company has a limited operating history, has never generated any revenue, and the sales and income potential of its business is unproven. The Company has incurred net losses and negative cash flows from operating activities since its inception and expects to continue to incur net losses into the foreseeable future as it continues the development and preparation for commercialization of vonoprazan. From inception to December 31, 2021, the Company has funded its operations through the issuance of convertible promissory notes, commercial bank debt, the sale of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7bd8659c-b2cb-422f-86f3-2e45beefdfd0" contextRef="C_74f9d273-2810-4b05-a50b-39f4e9e89f17" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,997,630</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock for net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_25dd0f6d-215a-4dd6-9175-53a2b99d5d75" contextRef="C_74f9d273-2810-4b05-a50b-39f4e9e89f17" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">191.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in its 2019 IPO </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> sale of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c7a42cac-af5c-49df-8196-0fcec59bd2eb" contextRef="C_feab6596-3893-42c2-a2c0-1464c2b5d8ed" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,250,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock for net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59433f1e-df2d-4f28-9553-29511fa35d51" contextRef="C_feab6596-3893-42c2-a2c0-1464c2b5d8ed" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">88.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in its December 2020 follow-on public offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities. Management is required to perform a two-step analysis over the Company&#x2019;s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (Step 2).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, if needed, that the Company&#x2019;s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_441ffb8d-7538-4b66-9acf-9579bf63c50c" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the Company&#x2019;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s financial statements relate to accruals for research and development expenses, and the valuation of warrant liabilities and various other equity instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_393bc553-14ed-4cd7-bc7b-11e09a92e4f5" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1: Observable inputs such as quoted prices in active markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying amounts of the Company&#x2019;s financial instruments, including cash and cash equivalents, are classified within the Level 1 designation discussed above, while prepaid and other current assets, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. Warrant liabilities are recorded at fair value on a recurring basis.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa0447f2-d93a-4293-85f0-e8e91b591c4f" contextRef="C_a4d53c9a-cf55-407d-9ed4-40937c45f516" name="phat:FinancialAssetsFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> financial assets measured at fair value on a recurring basis. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b8e22aad-c850-47df-a487-5ae63f6d9ce2" contextRef="C_861c796b-ff5c-4f2f-83b8-902fd93be0af" name="phat:NonfinancialAssetsFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_709d8f76-9d64-4d18-baee-2d44c673474b" contextRef="C_861c796b-ff5c-4f2f-83b8-902fd93be0af" name="us-gaap:NonfinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ne of the Company&#x2019;s non-financial assets or liabilities are recorded at fair value on a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b30a6c4-0041-4065-b5a1-d62b5cd973e1" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_55ef2dfb-b351-4616-85bc-65d48f4b4904" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2cf12213-1595-4e71-840a-31f24b3b75fd" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_98610710-2009-426d-8b3c-8b4ffb6bc2fa" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">n-recurring basis. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f60be3f-5f2c-4567-97f3-cc1e7a7652bc" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_06f1e957-6ef6-42ff-b9ef-ebb50bd2bef8" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4aa3f833-63b2-41f9-93e1-bb18084bb938" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_85f73a4d-ee1f-43b1-a6b4-107d4853979f" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> transfers between levels have occurred during the periods presented.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The warrant liabilities consist of warrants, or the Lender Warrants, issued in connection with a loan and security agreement, or the SVB Loan Agreement, for commercial bank debt (see Note 6). The Lender Warrants were accounted for as liabilities as they contained a holder put right under which the lenders could have required the Company to pay cash in exchange for the Lender Warrants. The fair value of the Lender Warrants was estimated on the date of grant using the Black-Scholes option-pricing model with an expected term equal to the remaining contractual term of the warrants. The Company estimates its expected stock volatility based on the historical volatility of a set of peer companies, which are publicly traded, and expects to continue to do so until it has adequate historical data regarding the volatility of its own publicly-traded stock price. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company uses an expected dividend yield of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_af961479-7f71-41a6-b152-3100756b0341" contextRef="C_d66f011d-89be-4560-91d7-2a57c1175688" name="phat:ExpectedCashDividendYieldRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> based on the fact that the Company has never paid cash dividends and does not expect to pay cash dividends in the foreseeable future. When the Company drew down the Term Loan B under the SVB Loan Agreement in March 2020 (see Note 6), the Lenders&#x2019; put right expired, and the Company recorded a final fair value adjustment and reclassified the Lender Warrants balance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6db117df-c6d1-4dfa-bada-5916c746b11e" contextRef="C_d695a09e-552b-4926-9fd0-d64fd565f066" name="phat:AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to additional paid-in-capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2daf474b-9d9b-4383-98c0-91219e6a472a" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:71.98%;"></td>
          <td style="width:1.317%;"></td>
          <td style="width:2.312%;"></td>
          <td style="width:22.845%;"></td>
          <td style="width:1.546%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Warrant<br />Liabilities</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2019</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b1b892a6-3416-43d9-9003-0a1ed69aa888" contextRef="C_a6e0c0e2-0899-4673-aff4-66d468643b51" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">413</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5ebd9731-4f33-4e25-b869-5df4f4ea9e78" contextRef="C_1df5bc5b-1abb-43f6-aae5-4d3a06d655e3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">95</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reclassification of Lender Warrants into equity (Note 6)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e3dc947-5ae7-417d-a9f4-1dd0b717e98f" contextRef="C_1df5bc5b-1abb-43f6-aae5-4d3a06d655e3" name="phat:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">318</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ab5df59-5292-425a-9467-c994d3212edd" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market funds.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_866aa025-4af4-4326-bfef-da05e8c5456c" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c4eef580-f331-42f4-9240-ac0014d2feec" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property, Plant, and Equipment, Net</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property, plant and equipment are recorded at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the asset. Computer equipment and related software are depreciated over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_b94a21cd-dcaa-4585-bab0-9b02263f175c;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2754ef49-e260-44f7-8d55-1c778dbcbb52" contextRef="C_dd423291-341d-427f-ad43-b78d594b43a8" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Furniture and fixtures are depreciated over</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b418953-1081-4ca2-bc0f-468f47739f3a" contextRef="C_d15d3cd0-b504-48e2-8d5b-b29bec97767e" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> three years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Leasehold improvements are amortized over the lesser of the lease term or the estimated useful lives of the related assets. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_34049330-7930-4845-bbd4-63b566e16d43" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reviews long-lived assets, including property, plant and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec773da6-aa2e-4d87-9542-3b05322244c3" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairment losses have been recorded through December 31, 2021.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb3525da-d135-4797-97d1-118420e1bc0e" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:LessorLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding right-of-use asset upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company additionally evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease. A lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows is substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if the underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term. Leases that do not meet the finance lease criteria are accounted for as an operating lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. As the Company&#x2019;s leases do not typically provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate between lease and non-lease components.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56d753e1-8bdb-4f36-ba86-7cd6f9586c93" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true" continuedAt="F_56d753e1-8bdb-4f36-ba86-7cd6f9586c93_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses and Accruals</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, employee benefits, stock-based compensation charges for those individuals involved in research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company&#x2019;s ongoing clinical trials of vonoprazan, and costs related to manufacturing vonoprazan for clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_56d753e1-8bdb-4f36-ba86-7cd6f9586c93_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has entered into various research and development contracts with clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of or after performance are reflected in the accompanying balance sheets as prepaid expenses or accrued liabilities, respectively. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ec406a2-4ec0-4925-b5af-887e09b8a208" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:InProcessResearchAndDevelopmentPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">In-Process Research and Development</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use are considered acquired in-process research and development. When the acquired in-process research and development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d29e724-98d8-41ab-8718-76048eeb79fd" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. General and administrative expenses are associated with the activities of the executive, finance, accounting, information technology, legal, medical affairs and human resource functions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e80bd69-32a4-4a6e-853e-5fb486c66734" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of the awards (generally the vesting period) on a straight-line basis with forfeitures recognized as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company also maintains an employee stock purchase program, or ESPP, under which it may issue shares. The Company estimates the fair value of stock options and shares that will be issued under the ESPP using the Black-Scholes valuation model, which requires the use of estimates. The Company recognizes stock-based compensation cost for shares that it will issue under the ESPP on a straight-line basis over the requisite service period of the award.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8dc81e5c-829d-481b-9d8c-c88eb06a0c37" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statement of operations in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a1b97e7-808c-4c7c-a481-3658dd97f6aa" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#x2019;s comprehensive loss was the same as its reported net loss for all periods presented.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1419fc2-0eb0-467e-be47-64fe437f9ff5" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segment Reporting</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cb9d0ef7-4792-44a6-800c-46ee904a9ff3" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating segment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b22a162a-abd7-4fa5-bad3-b2da4b153ec2" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company included </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_71e69eb7-a878-47f1-b3fd-dbe4d9001001" contextRef="C_35306304-4c25-4c5b-a433-e5367fe22b87" name="phat:IncrementalCommonSharesAttributableToExerciseOfWarrants" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,588,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock under its warrant, or the Takeda Warrant, issued to Takeda Pharmaceutical Company Limited, or Takeda, in connection with a May 2019 license agreement (see Note 4) in the calculation of basic weighted-average common shares outstanding from the time it became exercisable at the Company&#x2019;s IPO because the Takeda Warrant is exercisable for little consideration. During the year ended December 31, 2021, Takeda Warrants were exercised to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5d895e28-1e7c-4f5c-842b-1d4b76b3134b" contextRef="C_e42fcdbf-c245-40d9-a08b-a3024663efad" name="phat:StockIssuedDuringPeriodSharesExerciseOfWarrants" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">228,696</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. As of December 31, 2021, Takeda Warrants to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_77e93e46-2816-46ed-bc06-76488d531a35" contextRef="C_a3536774-184c-4c9f-b6b0-4b72ebbf9525" name="phat:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,359,304</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock remains exercisable. For the years ended December 31, 2021 and 2020, the Company has excluded weighted-average unvested shares of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_100a6906-71b5-49cd-9e88-1590c06e504b" contextRef="C_f32b69df-40b4-4e56-8da4-28475877b8ca" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,939,252</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d2f271a2-5f62-40bf-99e4-55be95dc781b" contextRef="C_c6ab3ae6-86d0-4065-ba57-907b3b0f74c1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,424,676</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively, from the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested common stock, options and warrants. For the periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities (warrants, stock options, and common shares subject to repurchase) would be antidilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0802efda-c992-4d7b-8377-2f7553efd092" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recently Adopted Accounting Standards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> December 2019, the Financial Accounting Standards Board, or FASB, issued </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounting Standards Update, or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ASU, No. 2019-12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ASU 2019-12, which simplifies the accounting for income taxes. ASU 2019-12 is effective for annual reporting periods, and interim periods within those annual periods, beginning after December 15, 2020 on a prospective basis, and early adoption is permitted. The Company </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a87aa88-1c1a-418a-893c-86d7c926073d" contextRef="C_caf5d7c1-1bad-4042-90db-0f0fb308e394" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adopted</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> this guidance effective </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bb69fa65-56f1-4c98-a796-2e8339e58476" contextRef="C_caf5d7c1-1bad-4042-90db-0f0fb308e394" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and the adoption did </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b44e589e-9cdd-462d-867f-71be959c15bb" contextRef="C_caf5d7c1-1bad-4042-90db-0f0fb308e394" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> have a material impact on the Company's financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board or other standard setting bodies on the Company's financial statements as well as material updates to previous assessments. There were no new material accounting standards issued or adopted in year of 2021 that impacted the Company.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c9541cf3-30f9-494e-bc88-aca833d71650" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:ComponentOfBalanceSheetDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. Balance Sheet Details</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property, Plant and Equipment, net</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7cccefaa-7edd-436a-916e-2483c1915d78" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property, plant and equipment, net, consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.824%;"></td>
        <td style="width:1.21%;"></td>
        <td style="width:2.297%;"></td>
        <td style="width:20.043%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:1.21%;"></td>
        <td style="width:2.297%;"></td>
        <td style="width:20.058%;"></td>
        <td style="width:1.531%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment and software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d1efc4ae-1760-44aa-bc90-213d8f8fc122" contextRef="C_60ed7ae5-368e-4841-b870-3c1b94b39311" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">646</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_968a3f50-269b-496c-b565-3f9b974443a2" contextRef="C_335b6a1d-cf50-4b89-b646-9f381f97d6d2" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">516</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_426c8185-1452-4baf-bb7f-58c756081af2" contextRef="C_9b6da75c-d2db-4900-8fad-0f82733efc5d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">780</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_99359439-b6bc-4243-a913-a2721c80450b" contextRef="C_2a16177c-bacc-4d09-9fc8-d0f5d55d3ee5" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">747</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f57e3cc-40bb-451b-9d4f-7f255c030593" contextRef="C_478c7409-ab7e-4c39-bda4-749e3ceaf9ef" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c7b90825-4727-4d66-a03a-2a3932d51e5a" contextRef="C_d09d3095-f7e4-4678-97ca-b059f5088ae2" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c1f92011-1347-4192-bdda-7798e498b6dc" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,502</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab6bb50d-9bff-4f20-a6a9-17404e02ab1a" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,317</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae4ce954-921b-4bf9-a2c4-c939cf886637" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">852</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a4e8721-dcae-4487-a3b6-9e864a5a3803" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">331</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property, plant and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab4b7690-9210-45df-b731-21d7f0bb7084" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">650</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_704d680a-9790-4f8d-91c5-c661c990339f" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">986</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization expense for the years ended December 31, 2021 and 2020 was approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_35c316de-f061-4d6d-a0ea-613e1d26d95d" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_db35575a-3e36-4d41-8f05-e29db501d782" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_028701d7-8fc6-44f2-9aee-d58b67294c93" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:PropertyPlantAndEquipmentDisposals" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b87385e4-5f0e-4ede-8321-4fdacf3d8c51" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:PropertyPlantAndEquipmentDisposals" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> property, plant or equipment was disposed of during the years ended December 31, 2021 and 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued Expenses</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12e471b4-004d-4278-a565-b9062316c185" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.426%;"></td>
        <td style="width:1.347%;"></td>
        <td style="width:2.296%;"></td>
        <td style="width:20.695%;"></td>
        <td style="width:0.934%;"></td>
        <td style="width:1.362%;"></td>
        <td style="width:2.296%;"></td>
        <td style="width:20.71%;"></td>
        <td style="width:0.934%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f1eb20d8-3a9c-4f30-926d-e0a388cde3c3" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="phat:AccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,165</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d19bd35-c711-49aa-b15f-644e5adb7c08" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="phat:AccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,864</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued compensation expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c4ef73b1-2f22-4112-a3a1-719f309cfcb3" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,344</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_80081fca-0e44-454c-9841-f1b82411fdb5" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,587</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued professional &amp; consulting<br />&#160;&#160;&#160;expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec3bbba9-bea5-41ac-a167-961dd748f32a" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,855</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0293b851-b016-4484-98b0-f82d8debe461" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,123</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ceb56973-aa23-4166-8e33-2d74c729a10d" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5c892cbd-d69a-4d77-a0f9-ce8856554378" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_677deddd-b3cb-41c7-bbf0-0709176d31f3" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,405</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0b401e20-1bf1-4201-9fd4-e6aad66e5451" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,606</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ff97b990-e209-4fe3-9111-197ce8ba5911" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. Related Party Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Frazier is a principal stockholder of the Company. The Company has conducted operations within office space controlled by Frazier and Frazier allocated a portion of the costs associated with this office space to the Company. In addition, Frazier paid for various goods and services, such as employee wages, insurance and expense reimbursements and various administrative services associated with the operations of the Company and charged the Company for those expenses. As of December 31, 2021 and 2020, the Company had outstanding accounts payable and accrued expenses due to Frazier in the amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_40521bba-f268-4cf9-a540-75aa2a14ff29" contextRef="C_fc9746aa-75ec-4357-9a62-e52e0a26d077" name="phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_48d0227f-7d3c-4697-842b-82881a63fbf7" contextRef="C_098ad23e-df01-4a44-9fa6-756e054ae9d3" name="phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">35,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">respectively, related to these shared operating expenses. For the years ended December 31, 2021 and 2020, the Company incurred $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_020a1438-16ac-43f6-8cf2-f4b293634121" contextRef="C_ed462fec-d2dc-4e80-8a94-a6e09a3934b5" name="phat:RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">18,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4be1d67a-58ce-42dd-9311-af312613ad61" contextRef="C_b04891d2-7dba-42b2-a181-d9f6bb277f08" name="phat:RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, of shared operating expenses.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Frazier is a principal stockholder in PCI Pharma Services, or PCI. In the third quarter of 2019, the Company engaged PCI for clinical manufacturing services. As of December 31, 2021 and 2020, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6499e33a-5a52-4185-824d-5b85e9a6390d" contextRef="C_6951c26d-af1d-407b-bbcb-8b12126fe3f0" name="phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e674f614-6fb0-40cf-a547-8c5eb4fa6a9e" contextRef="C_c9fb0785-ea03-426b-a4b8-f5ea1415baaf" name="phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, in outstanding accounts payable and accrued expenses related to these manufacturing services. For the years ended December 31, 2021 and 2020, the Company incurred $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0484477f-efd8-4c18-812d-a53d9bad7e44" contextRef="C_0d2e408c-4d50-4188-92b1-018f98519206" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f6fbd2b2-33cc-4b3c-bd5f-22fa5c02ec4b" contextRef="C_10d2f460-e459-411f-8dad-34d4446eecc2" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, of expenses related to services performed by PCI.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Takeda became a common stockholder of the Company in connection with the May 2019 license agreement (see Note 4). In conjunction with this license, Takeda provides proprietary supplies for the Company&#x2019;s ongoing clinical development of vonoprazan in addition to the exclusive license for the commercialization of vonoprazan in the United States, Canada and Europe. As of December 31, 2021 and 2020, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5ae6368-52c5-4d55-915e-d22da32c6726" contextRef="C_58425dd1-174b-4c7a-8d6a-81deea1aee09" name="phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">22,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e663b30a-8f2e-49b3-aa2e-ccd1f5656fb0" contextRef="C_38af774f-d0ce-4768-8641-dd4bb3038da3" name="phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">22,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively, in outstanding accounts payable and accrued expenses related to these supply services. The Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_faeec1f6-aaa9-42a5-994d-dde9c2cc0d79" contextRef="C_61652f9e-ae05-40dc-b6b4-3b2b4d36b133" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_943227f7-5b70-4a50-b970-19f87f2eb2ea" contextRef="C_26050370-2bfa-4995-a133-64b6e9cefdc1" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have any such supply services expenses incurred for the years ended December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On May 5, 2020, the Company entered into a Commercial Supply Agreement, or the Commercial Supply Agreement, with Takeda, pursuant to which Takeda will supply commercial quantities of vonoprazan bulk drug product or drug substance. Pursuant to the Commercial Supply Agreement, Takeda has agreed to supply the Company with, and the Company has agreed to purchase from Takeda, certain quantities of vonoprazan bulk drug product according to approved specifications at a fixed price per batch of bulk drug product in order to commercialize vonoprazan in accordance with the Takeda License. Unless terminated earlier, the term of the Commercial Supply Agreement extends for a period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad9ad401-a58e-4072-84bd-7c421d3b5b95" contextRef="C_6c52a9cb-ddf2-45f2-a3ab-4d943486cf78" name="phat:AgreementExtendsPeriodForTermination" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from the date the Company places an order for bulk drug product or drug substance for the first commercial launch of vonoprazan in any jurisdiction in the licensed territory, provided that this two-year period will expire no later than December 31, 2023. The Commercial Supply Agreement will terminate immediately upon the termination of the Takeda License in accordance with its terms. As of December 31, 2021 and 2020, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6f9c8485-c141-4a06-862d-7b031999335c" contextRef="C_a0b3b017-48e9-4500-9fd4-aaf93a60d5dd" name="phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be9ae79d-af43-42df-9c18-b2ac50892a1c" contextRef="C_3cd1a70e-7077-4da4-a87c-da5e90015997" name="phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, in outstanding accounts payable and accrued expenses related to these product costs. For the years ended December 31, 2021 and 2020, the Company incurred $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f31a50c8-986a-42dd-a894-d5211da07026" contextRef="C_1ac41c78-ea4c-491d-bef4-399d1207de36" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_33424f16-565c-4baf-82de-15c399fd9a10" contextRef="C_c161eef4-fe92-48d7-944f-6e1bd1c45f50" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, of expenses related to the Commercial Supply Agreement. The Company has a remaining minimum purchase obligation of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_82e4bd2b-61e2-43f8-a85c-f3c84b30e986" contextRef="C_caf206af-24fe-4015-adc8-87b45d8a8636" name="us-gaap:PurchaseObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to this agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Takeda License, the Company entered into a temporary services agreement, or the Temporary Services Agreement, with Takeda on November 24, 2020. Pursuant to the Temporary Services Agreement, Takeda agreed to provide or procure the provision of services related to the ongoing clinical development of vonoprazan. The Temporary Services Agreement will terminate immediately upon termination of the Takeda License in accordance with its terms. As of December 31, 2021 and 2020, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_285c08bf-8dba-4dca-9f56-130bcba76a8b" contextRef="C_413a633b-7a27-41ac-8e92-4d82e9b0c253" name="phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca08ff18-41fa-4bea-a474-7817c762479f" contextRef="C_d5335391-0999-47b9-a03b-8400c5c69127" name="phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, in outstanding accounts payable and accrued expenses related to these temporary services. For the year ended December 31, 2021 and 2020, the company incurred $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_875e2880-7edc-45e7-82f4-bf77152b35c9" contextRef="C_ce1d61e6-3a91-4de4-b8d0-dfb4084514fe" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_591ad0ba-dea4-4c23-b2b9-224252ee0eca" contextRef="C_f52603aa-c039-41a2-95ea-2a152bab42c6" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, of expenses related to the temporary services performed by Takeda.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc85d426-a15c-490c-9981-ffd42515a68d" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">O</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">n May 7, 2019, the Company entered into a license agreement with Takeda pursuant to which it was granted an exclusive license to commercialize vonoprazan fumarate in the United States, Canada and Europe, or, the Takeda License. The Company also has the right to sublicense its rights under the agreement, subject to certain conditions. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5116c245-4fbb-4c5e-a395-65872ee2bf00" contextRef="C_61652f9e-ae05-40dc-b6b4-3b2b4d36b133" name="phat:LicenseAgreementDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The agreement will remain in effect, on a country-by-country and product-by-product basis, until the later of (i) the expiration of the last to expire valid patent claim covering vonoprazan fumarate alone or in combination with at least one other therapeutically active ingredient, (ii) the expiration of the applicable regulatory exclusivity and (iii) </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a2199d0-5fc5-48ba-bb95-6f983328c002" contextRef="C_b31d6f50-cf52-4cab-8313-448f4b5812e0" name="phat:AgreementExpirationTermFromDateOfFirstCommercialSale" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from the date of first commercial sale, unless earlier terminated. The Company may terminate the Takeda License upon six months&#x2019; written notice. The Company and Takeda may terminate the Takeda License in the case of the other party&#x2019;s insolvency or material uncured breach. Takeda may terminate the Takeda License if the Company challenges, or assists in challenging, licensed patents</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">n consideration of the Takeda License, the Company (i) paid Takeda $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9eaf9c7a-e3c3-45dd-994b-989e808fa743" contextRef="C_b31d6f50-cf52-4cab-8313-448f4b5812e0" name="phat:PaymentForLicenseAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in cash, (ii) issued Takeda </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6f38477d-1dfb-417c-9b48-109af2a77ff8" contextRef="C_6e6c878e-6e27-47fc-9b34-7dc97f3dda54" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,084,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8d1d2eb2-43fd-4c18-8db0-5e2bcac3f273" contextRef="C_6e6c878e-6e27-47fc-9b34-7dc97f3dda54" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, (iii) issued the Takeda Warrant to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17115051-fa35-46e9-ae3f-55f1dc910774" contextRef="C_ba31a338-f01c-4a63-899f-d02fc7b91340" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,588,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at an exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd8710d5-4ec9-4ac6-8720-88d3d7b5fac0" contextRef="C_6e6c878e-6e27-47fc-9b34-7dc97f3dda54" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="8">0.00004613</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share at an initial fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3a706415-525b-4747-a09e-f9aa93f2c25d" contextRef="C_6e6c878e-6e27-47fc-9b34-7dc97f3dda54" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">47.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and (iv) issued a right to receive an additional common stock warrant, or, the Takeda Warrant Right, should Takeda&#x2019;s fully-diluted ownership of the Company represent less than a certain specified percentage of the fully-diluted capitalization, including shares issuable upon conversion of then outstanding convertible promissory notes, calculated immediately before the closing of the Company&#x2019;s IPO, with a nominal initial fair value due to the low probability of issuance. The Takeda Warrant Right expired without effect since no fair value had been allocated to it upon completion of the IPO, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_529fec9a-fb34-46ad-abd1-08c43c916828" contextRef="C_b31d6f50-cf52-4cab-8313-448f4b5812e0" name="phat:AdditionalWarrantIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional warrant was issued. In addition, the Company is obligated to pay Takeda up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_38b63926-b0ac-4ea1-a06d-12264ce84c10" contextRef="C_b31d6f50-cf52-4cab-8313-448f4b5812e0" name="phat:MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">250.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in sales milestones upon the achievement of specified levels of product sales, and a low double-digit royalty rate on aggregate net sales of licensed products, subject to certain adjustments. The Company incurred $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52638b20-fbbc-4220-a740-e83b1f31d7fb" contextRef="C_b31d6f50-cf52-4cab-8313-448f4b5812e0" name="phat:LicenseAgreementTransactionCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of transaction costs in connection with the Takeda License. The Takeda Warrant has an exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da314e05-927e-4f33-b090-14533f5d5da5" contextRef="C_6e6c878e-6e27-47fc-9b34-7dc97f3dda54" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="8">0.00004613</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, expires on</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a7698f7-b246-4688-9522-806a7af11cbe" contextRef="C_b31d6f50-cf52-4cab-8313-448f4b5812e0" name="phat:WarrantsExpirationDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> May 7, 2029</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and became exercisable upon the consummation of the IPO. During the year ended December 31, 2021, Takeda Warrants were exercised to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_841937b0-af20-43b0-ab7c-4b799ea648bc" contextRef="C_e42fcdbf-c245-40d9-a08b-a3024663efad" name="phat:StockIssuedDuringPeriodSharesExerciseOfWarrants" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">228,696</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. As of December 31, 2021, Takeda Warrants to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f2673d4-63c7-4e91-b34f-7762e8b9e907" contextRef="C_a3536774-184c-4c9f-b6b0-4b72ebbf9525" name="phat:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">7,359,304</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock remains exercisable. Following the October 11, 2019 increase in the Company&#x2019;s authorized shares of common stock to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8d950aa2-1b87-4c37-bc91-5c596f9aa7fd" contextRef="C_098dcddf-024a-435f-b6ee-bf3342544e82" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">50,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company recorded a non-cash charge related to the final fair value adjustment of the Takeda Warrants and reclassified the full balance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_58ff09fc-e435-4406-8cb0-55eed94fa439" contextRef="C_188214ae-df7a-4194-abe9-bd6e9956a85d" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">144.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million from warrant liabilities to additional paid-in capital</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Purchase Commitments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company entered into a supply agreement with Sandoz pursuant to which Sandoz will supply commercial quantities of amoxicillin capsules and clarithromycin tablets, package these antibiotics with vonoprazan, and provide in finished convenience packs. The supply agreement commits the Company to a minimum purchase obligation of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_12a87456-fc33-44e1-8c8a-59a4283aa27b" contextRef="C_5b92a549-2b7a-468d-8c11-955c21018981" name="phat:PurchaseObligationDueInFirstTwentyFourMonths" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">3.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the first 24-month period following the launch of the final product. The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f24c4ab4-9a64-408d-b9b9-44ef38d181f0" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:PurchaseCommitmentExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4acbb35f-12e0-4972-8150-5bf380b47549" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="phat:PurchaseCommitmentExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t incurred any expenses under the agreement during the years ended December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingencies</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event the Company becomes subject to claims or suits arising in the ordinary course of business, the Company would accrue a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65378c44-5fd0-485d-8820-33c99bb221a3" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. Lease Commitments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had operating leases for office space in both Buffalo Grove, Illinois and Florham Park, New Jersey, with weighted average remaining lease terms of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7159e930-c5be-40a5-8339-9232fae45b3a" contextRef="C_955c05d2-5a1f-43ab-9d80-db08111345d6" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.3</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_835ce569-d5e3-4c55-9a73-bea7c528fdb0" contextRef="C_d4dfdb6b-5b03-4e72-951e-81ecb345c403" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.7</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years, respectively. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a701634-b8a0-479a-8eee-a2837b68cf2e" contextRef="C_454da93f-f097-4419-a6f9-b33d0b69cd59" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><ix:nonNumeric id="F_0392c933-b198-498c-98ac-e51342c2a454" contextRef="C_be8f5d58-327a-4e7b-acdd-e53a93782a26" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Both operating leases contain an option to extend the term for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab4ddbdb-93ec-4415-bded-d4efcfef7401" contextRef="C_454da93f-f097-4419-a6f9-b33d0b69cd59" name="phat:LesseeOperatingLeaseNumberOfOptionToExtend" unitRef="U_Option" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_aa581d44-6793-4efe-b2e7-22ff1877c24e" contextRef="C_be8f5d58-327a-4e7b-acdd-e53a93782a26" name="phat:LesseeOperatingLeaseNumberOfOptionToExtend" unitRef="U_Option" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bec3d3dd-98e8-44df-9764-905d76625d5b" contextRef="C_955c05d2-5a1f-43ab-9d80-db08111345d6" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_6af6dfa2-f296-40a0-9449-6b19d701a1bc" contextRef="C_d4dfdb6b-5b03-4e72-951e-81ecb345c403" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five-year</span></ix:nonNumeric></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period</span></ix:nonNumeric></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which was not considered in the determination of the right-of-use asset or lease liability as the Company did not consider it reasonably certain that it would exercise such options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">     </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total rent expense for the years ended December 31, 2021 and 2020 was approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d00b5469-9b85-47c1-ab2b-90bb2b7b898e" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_91e44d96-2427-4632-bf78-b82140c0f636" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_67e42252-3d23-4862-b9ab-813998f1e39b" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes supplemental balance sheet information related to the operating leases as of December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.896%;"></td>
        <td style="width:1.162%;"></td>
        <td style="width:2.734%;"></td>
        <td style="width:17.62%;"></td>
        <td style="width:1.036%;"></td>
        <td style="width:1.162%;"></td>
        <td style="width:2.734%;"></td>
        <td style="width:17.62%;"></td>
        <td style="width:1.036%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ccc200a5-bc0f-4866-be73-616ed3d3a31b" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,914</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6c74635d-4c7d-42ec-9f31-a4eefccd9e1b" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,373</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3da8be59-a078-4e5c-a579-639e1412d0c3" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,914</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05800448-c8a4-4942-b4ee-8b835c2b336b" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,373</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_29dd6296-fa50-46e1-8830-0bf6aa4e204c" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">487</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ad534a3c-08c8-44e3-9a0e-99a83f774961" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">474</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, non-current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0620d10f-1d8f-4a7c-9815-12053ad00826" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,183</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_faebaa54-5c46-4bce-a03a-1f35954b56aa" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,557</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9aa5ea20-d291-405b-8379-e4ed53096690" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,670</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5d48dd44-bd61-49b6-b9b0-6ff277ea4fb0" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,031</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b595733f-412b-47e4-bb1e-4cb6e9d17db6" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the future minimum annual lease payments under the operating leases were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.098%;"></td>
        <td style="width:1.603%;"></td>
        <td style="width:2.244%;"></td>
        <td style="width:19.106%;"></td>
        <td style="width:1.211%;"></td>
        <td style="width:3.739%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3ff1c1b2-1b65-4bd7-9837-b97ee249d534" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">503</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4313f469-7ef0-4ada-8b06-f2085a989775" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">516</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f32b3a28-b014-427a-9b2a-594c5cb24f0f" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">529</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f0d07527-d018-446a-a8a6-158fd7eb79b6" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">342</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1ee5c88f-135a-4785-8977-7f1442969eea" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,890</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: amount representing interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_abe06179-e0e2-4984-94dc-97789fe11311" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">220</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e93920a0-397b-4e9f-9429-9cf63a9c1b6a" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,670</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_695dce84-18e8-4f59-b317-12f31074b0ed" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">487</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75d40bf4-4b3a-4f58-967c-106b945a9942" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,183</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4f0c651c-369b-4660-80a0-f56fae858fc9" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.56</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average incremental borrowing rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2de15486-cb8c-4800-8d77-3d723004274e" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">7.25</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating cash flows for the years ended December 31, 2021 included $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8d809468-437b-4423-88aa-e79c5152ff61" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in cash payments for operating leases, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dbbf4b12-2064-4b47-9d9d-50a97a051f40" contextRef="C_af4df9d7-725e-4644-8d48-2c2689576963" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of which were prepaid lease payments. Operating cash flows for the years ended December 31, 2020 included $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f82ee0f-d63e-46d4-80a7-6104e29f8678" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in cash payments for operating leases, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_68e80330-4586-419b-983b-031436f5fbf3" contextRef="C_dd956957-4601-4ab3-a9dd-db08fb69bc8a" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of which were prepaid lease payments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_226fd5ba-d1ad-4d0f-b027-b214e719be45" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. Debt</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ce75baca-6a60-49e5-bfb2-a5a3243b7930" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total debt consists of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.604%;"></td>
        <td style="width:1.162%;"></td>
        <td style="width:2.823%;"></td>
        <td style="width:23.535%;"></td>
        <td style="width:1.876%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term debt, current portion</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term debt, non-current portion</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d65efafb-f217-420d-a56b-5f5f493f5b7f" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="phat:LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100,990</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unamortized debt discount</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1a123fba-3af9-4db1-8267-4dba0747cbdd" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,319</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total debt, net of debt discount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae559957-8cf9-4772-8fec-ab5619d02a56" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">89,671</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 17, 2021, or the Closing Date, the Company entered into a Loan and Security Agreement, or, the Loan Agreement, with Hercules Capital, Inc., in its capacity as administrative agent and collateral agent and as a lender, or, in such capacity, the Agent or Hercules, and the other financial institutions that from time to time become parties to the Loan Agreement as lenders, or, collectively, the Lenders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Loan Agreement provides for term loans in an aggregate principal amount of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06bdcbcc-ecc3-4d65-8572-33251772babf" contextRef="C_53fd8783-36da-45c7-98b2-ab70da66a761" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">200.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, or the Term Loan, under multiple tranches. The tranches consist of (i) a first tranche consisting of term loans in an aggregate principal amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0000ab8a-702c-4538-93c3-1200670f6aa5" contextRef="C_cd0d4a06-0d27-4385-9179-d25cf2ad0b78" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">100.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, all of which was funded to the Company on the Closing Date, or First Advance, (ii) a second tranche consisting of up to an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1791dabc-cdd4-4420-abb3-45215cb41277" contextRef="C_39e4a6be-472b-4454-9622-81423cbf1cf1" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which became available to the Company upon achievement of the protocol-specified primary efficacy endpoints in the Company&#x2019;s Phase 3 trial studying vonoprazan for the healing and maintenance of healing of erosive esophagitis with acceptable safety data, such that the results support the submission of a New Drug Application, or NDA, or supplemental NDA without the need to conduct another Phase 3 study and will be available, if specified conditions are met, through December 15, 2022, (iii) a third tranche consisting of an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b94cce5-95ee-42e9-a67e-028aa770161b" contextRef="C_ff71ca2a-03d2-4397-9d0b-802dd6a7a795" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which will become available to the Company upon the achievement of (a) FDA approval of the Company&#x2019;s NDA for vonoprazan and amoxicillin, or its New Drug Application for vonoprazan, amoxicillin and clarithromycin, in each case for an indication relating to the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> with an approved indication on the claim that is generally consistent with that sought in the Company&#x2019;s NDA submission&#x37e; and (b) filing of the Company&#x2019;s NDA or supplemental NDA for vonoprazan for indications relating to the healing and maintenance of healing of erosive esophagitis, or, milestones (a) and (b), together, the Second Performance Milestone, and will be available, if specified conditions are met, through September 30, 2023, and (iv) a fourth tranche consisting of up to an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8717a2f8-e15c-43e0-8af8-e17ec052b473" contextRef="C_a04a8afc-8f38-4892-a76a-0ad14e22ff3d" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which will be available, if specified conditions are met, through March 31, 2024, upon achievement of the Second Performance Milestone.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company paid a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cd612e2e-84f3-4698-b215-c97f84b60f99" contextRef="C_2349ad83-214b-42ef-8534-32900ea1ab8b" name="phat:PaymentForFacilityCharge" unitRef="U_USD" scale="6" decimals="-4" format="ixt:numdotdecimal">1.25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million facility charge in connection with closing of the Loan Agreement and would need to pay </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1723d9bb-07c0-4220-9a22-020a14449a77" contextRef="C_2349ad83-214b-42ef-8534-32900ea1ab8b" name="phat:DebtInstrumentFacilityChargePercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of any advances made under the third and fourth tranches.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Term Loan will mature on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_21cb6de6-6e5c-4a00-8b58-0a255461b897" contextRef="C_2349ad83-214b-42ef-8534-32900ea1ab8b" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">October 1, 2026</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, or the Maturity Date. The Term Loan bears (i) cash interest at a variable annual rate equal to the greater of (a) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae63ae19-cdf0-463c-bc7c-e8298b1dbfde" contextRef="C_8eeb73f9-fe0f-457f-a77c-81905970cf0a" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">5.50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and (b) the Prime Rate (as reported in the Wall Street Journal) plus </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b559e427-ea75-4534-be52-0fb6d2e0a411" contextRef="C_43c774bf-00b3-4dcd-930e-6ffada5f2a87" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, or the &#x201c;Interest Rate&#x201d;, and (ii) payment-in-kind interest at a per annum rate of interest equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5ab3a4c1-50d4-4aed-b25a-365bd16904cb" contextRef="C_4f305fcc-4607-43ba-9d9f-9de48fa77502" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">3.35</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%. Phathom may make payments of interest only through October 1, 2024, which may be extended to October 1, 2025, upon the achievement of the Second Performance Milestone on or prior to September 30, 2024 and the condition that no default or event of default exists, and which is further extendable to October 1, 2026, subject to FDA approval of the Company&#x2019;s NDA (or supplemental NDA) for vonoprazan for an indication relating to the healing and maintenance of healing of erosive esophagitis with an approved indication on the label that is generally consistent with that sought in the Company&#x2019;s NDA submission (or supplemental NDA submission), or the Third Performance Milestone, on or prior to September 30, 2025 and no default or event of default exists (the &#x201c;interest only period&#x201d;). After the interest-only period, the principal balance and related interest will be required to be repaid in equal monthly installments and continuing until the Maturity Date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the Company is obligated to pay a final payment fee of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7cc7c6f8-ac18-4aa2-befe-fa28aaa4367f" contextRef="C_ca65917a-bc4e-4718-82a1-bb0697a04ae9" name="phat:DebtInstrumentFinalPaymentFeePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">7.50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the original principal amount of amounts actually advanced under the Term Loan, or, each a Term Loan Advance and together, the Term Loan Advances. As of December 31, 2021, the aggregate final payment fee for the first Term Loan Advance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_affd6c8a-2d41-435e-b0c8-c2ddbd10559c" contextRef="C_81edcc29-7776-4011-b910-010591687fb1" name="phat:DebtInstrumentFinalPaymentFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million has been recorded as an other long-term liability.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company may elect to prepay all or a portion of the Term Loan Advances prior to maturity, subject to a prepayment fee of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a62188f0-9f5e-46c3-905f-5f7b01176879" contextRef="C_d7d58811-0410-450f-88fc-1f9a4230079a" name="phat:DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the then outstanding principal balance of the Term Loan Advances being prepaid. After repayment, no Term Loan amounts may be borrowed again.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As collateral for the obligations, the Company has granted to Hercules a senior security interest in all of Company&#x2019;s right, title, and interest in, to and under substantially all of Company&#x2019;s property, inclusive of intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Loan Agreement contains customary closing fees, prepayment fees and provisions, events of default, and representations, warranties and covenants, including a financial covenant requiring Phathom to maintain certain levels of cash subject to a control agreement in favor of the Agent (minus accounts payable not paid within 120 days of invoice), or Qualified Cash, and commencing on May 15, 2023, trailing three-month net product revenue from the sale of vonoprazan and products containing vonoprazan. The revenue covenant will be waived at any time in which the Company maintains Qualified Cash equal to at least </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb962d4a-c8c6-477b-acd9-366719f4f405" contextRef="C_71f08e47-8ff5-4195-a019-61c121d7c840" name="phat:MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">60.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (prior to the Third Performance Milestone), and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0a2dadc4-4160-4b0b-b5ab-b42990d51bef" contextRef="C_71f08e47-8ff5-4195-a019-61c121d7c840" name="phat:MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">35</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (following the Third Performance Milestone) of the total outstanding Term Loan principal amount, or the Company&#x2019;s market capitalization is at least $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e35508a-fbb7-4a21-b974-d3cc7f51f39c" contextRef="C_71f08e47-8ff5-4195-a019-61c121d7c840" name="phat:MinimumMarketCapitalizationAmount" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">900.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. Upon the occurrence of an event of default, subject to any specified cure periods, all amounts owed by the Company may be declared immediately due and payable by Hercules, as collateral agent. As of December 31, 2021, the Company was in compliance with all applicable covenants under the Loan Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the entry into the Loan Agreement, the Company issued to Hercules a warrant, or, the Warrant, to purchase a number of shares of the Company&#x2019;s common stock equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3ef3f69a-c89c-4ddf-b834-f2c857e57b03" contextRef="C_71f08e47-8ff5-4195-a019-61c121d7c840" name="phat:PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the aggregate amount of the Term Loan advances funded, and will issue to Hercules additional warrants when future Term Loan advances are funded. On the Closing Date, the Company issued a Warrant for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_86c5083f-8e8d-4c04-bcc9-cb77b009d02f" contextRef="C_efee110a-f508-43c7-acf9-df99b6d9b882" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">74,782</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. The Warrant will be exercisable for a period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fbbe43d5-2eea-480c-8d25-11446184ac64" contextRef="C_71f08e47-8ff5-4195-a019-61c121d7c840" name="phat:ClassOfWarrantOrRightExpireTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seven years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from the date of issuance at a per-share exercise price equal to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_caa07ee5-408e-4fd3-9b28-a23c4e9078f4" contextRef="C_a5762110-631a-4b1c-9b33-2acb71c21790" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">33.43</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which was the closing price of the Company&#x2019;s common stock on September 16, 2021. The Warrant is exercisable any time until </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a1e94d0-f72e-43d8-b2ba-f91a3413d8f4" contextRef="C_71f08e47-8ff5-4195-a019-61c121d7c840" name="phat:ClassOfWarrantOrRightExpirationDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 17, 2028</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and had an initial fair value of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b7d6c944-b089-4e11-bd3e-6a49de3e69f9" contextRef="C_a5762110-631a-4b1c-9b33-2acb71c21790" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The initial $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_95192a11-eedd-4298-8c55-7f94c2dfdba9" contextRef="C_a5762110-631a-4b1c-9b33-2acb71c21790" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million fair value of the Warrant, the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c11b2809-d7ae-4df0-8125-a521fe868b65" contextRef="C_a5762110-631a-4b1c-9b33-2acb71c21790" name="phat:DebtInstrumentFinalPaymentFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million final interest payment fee and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_08e60f82-e0f0-4d66-8ffb-edd0d0a46f97" contextRef="C_a5762110-631a-4b1c-9b33-2acb71c21790" name="us-gaap:UnamortizedDebtIssuanceExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of debt issuance costs have been recorded as debt discount and are being amortized to interest expense using the effective interest method over the term of the Term Loan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_07093f2f-b1dc-478f-96bb-7d976c0fb609" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future minimum principal and interest payments under the Term Loan, including the final payment fee, as of December 31, 2021 are as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.716%;"></td>
        <td style="width:1.501%;"></td>
        <td style="width:2.823%;"></td>
        <td style="width:24.084%;"></td>
        <td style="width:1.876%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Year ending December 31:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0fc7ed1c-f487-4389-9304-dc3cb56c8704" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,704</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b72f0ff2-b07f-4067-90ca-d84a222d5a49" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,900</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6f8475ef-ed12-44f4-81c8-c63b08e6d8b0" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,308</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c045e588-b3aa-47c3-90f9-efdb8787bc7f" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,912</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f8ecb84-c079-4ff0-a7c4-f89c7f372dd8" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,948</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total principal and interest payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be0c7c00-a05c-4861-afb9-ed26de699cb6" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="phat:LongTermDebtAndInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">146,772</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less interest and final payment fee</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6f9b48fa-7dbe-4e70-9f38-ab9dfe4f4aca" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="phat:DebtInstrumentInterestAndFinalPaymentFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,772</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total term loan borrowings</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b3fc442d-da21-40d6-9d8c-012e35954d90" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to the Loan Agreement with Hercules, the Company had a loan with SVB and approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d1de7fd-75bd-4000-b15e-c9d29425edf5" contextRef="C_1996f1f9-d68a-46ed-9e27-8965a2c43da4" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">54.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the proceeds from the First Advance was used to satisfy in full and retire the Company&#x2019;s indebtedness under the SVB Term Loan with SVB, including accrued interest through the payoff date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The SVB Term Loan originated on May 14, 2019, when the Company entered into a loan and security agreement with SVB, as administrative and collateral agent, and lenders including SVB and WestRiver Innovation Lending Fund VIII, L.P. The Company borrowed $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f0b6b80-4096-4c62-b1a5-d199583a951b" contextRef="C_b72f7963-2e17-4f63-ae38-f0567547466c" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, or Term Loan A, at the inception of the Loan Agreement and an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d05e9a29-51d7-431f-98bf-8703002ec4e6" contextRef="C_a74a6818-5881-479c-96b1-dcc3cd65fed3" name="phat:DebtInstrumentAdditionalBorrowingCapacityAmounts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, or Term Loan B, on March 16, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The SVB Term Loan bore interest at a floating rate of the higher of the Wall Street Journal Prime rate plus </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa206ce2-2817-4905-b3b3-bc0dc3e61e84" contextRef="C_b4181602-e907-4a44-b1b6-077897333d0c" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% or </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_99336be4-78f2-4f32-8964-3d0c8538d147" contextRef="C_9840529e-ac70-4eb7-8d10-e6cb712b0d45" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">7.25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e38e9223-02bd-44d5-bc35-c8c33bddb038" contextRef="C_20586d23-36ef-4d60-8bc6-81acfe59236b" name="us-gaap:DebtInstrumentPaymentTerms"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the original SVB Term Loan, the monthly payments consisted of interest-only through May 31, 2021. On March 11, 2020, the Company entered into the first amendment and on March 11, 2021, the Company entered into the second amendment, or together the Amendments, to the SVB Term Loan. Pursuant to the Amendments, the interest-only payment period was initially extended through July 31, 2021, and was further extended until December 31, 2021, after the Company received positive data from its Phase 3 clinical trial in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection sufficient to file an NDA with the FDA. The interest-only payment period could have been further extended until November 30, 2022, if the Company would receive positive data from its Phase 3 clinical trial in erosive esophagitis for vonoprazan sufficient to file an NDA with the FDA.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Subsequent to the interest-only period, the SVB Term Loan would have been payable in equal monthly installments of principal, plus accrued and unpaid interest through the maturity date of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4bbb631a-89b3-4773-9b33-4c929ad968d8" contextRef="C_32d5d9b1-7992-4d84-8226-a55e116ed6d0" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 1, 2024</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the Company was obligated to pay a final payment fee of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0af8443c-1237-4cbe-b157-b50e3e7d2302" contextRef="C_32d5d9b1-7992-4d84-8226-a55e116ed6d0" name="phat:DebtInstrumentFinalPaymentFeePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">8.25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the original principal amount of the SVB Term Loan. The aggregate final payment fee for the Term Loan of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_88d3f4eb-c89b-42ec-b4e9-f0dd98b0fd97" contextRef="C_9840529e-ac70-4eb7-8d10-e6cb712b0d45" name="phat:DebtInstrumentFinalPaymentFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was recorded as an other long-term liability.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company could have elected to prepay all or a portion of the SVB Term Loan prior to maturity, subject to a prepayment fee of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aea7bf72-b961-4bf5-84d0-f4bed87d05c1" contextRef="C_241f6789-e4f7-4e5a-930f-33a8b7e5b743" name="phat:DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the then outstanding principal balance and payment of a pro rata portion of the final payment fee. After repayment, no Term Loan amounts could have been borrowed again.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The borrowings under the SVB Term Loan were collateralized by substantially all of the Company&#x2019;s assets. The SVB Term Loan included affirmative and negative covenants. The affirmative covenants included, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding its operating accounts. The negative covenants included, among others, limitations on the Company&#x2019;s ability to incur additional indebtedness and liens, merge with other companies or consummate certain changes of control, acquire other companies, engage in new lines of business, make certain investments, pay dividends, transfer or dispose of assets, amend certain material agreements or enter into various specified transactions. The SVB Term Loan also contained customary events of default, including bankruptcy, the failure to make payments when due, and a material adverse change. Upon the occurrence of an event of default, subject to any specified cure periods, all amounts owed by the Company would have begun to bear interest at a rate that is</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_062638e2-2844-4966-9b12-e2a2082f8bd4" contextRef="C_32d5d9b1-7992-4d84-8226-a55e116ed6d0" name="phat:DebtInstrumentPenaltyFeePercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">4.00</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">above the rate effective immediately before the event of default and could have been declared immediately due and payable by SVB, as collateral agent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the SVB Term Loan, the Company issued Lender Warrants to purchase stock of the Company, which expire </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1005fb18-8656-4168-9a0c-4202668ca081" contextRef="C_32d5d9b1-7992-4d84-8226-a55e116ed6d0" name="phat:LanderWarrantsExpireTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ten years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from the date of issuance. Upon completion of the IPO in 2019, the Lender Warrants became exercisable for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ad17dd51-a710-4635-99de-1f58088a4fcd" contextRef="C_3df574b9-fe27-4d9e-a549-6a095ed65261" name="phat:LenderWarrantsExercisableSharesOfCommonStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,446</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. The Lender Warrants included a put option pursuant to which, in the event that the Company did not draw down Term Loan B on or before March 31, 2020, the warrant holders could have required that the Company repurchase the warrants for a total aggregate repurchase price of</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_069d1ee1-f9d4-4222-9032-c2c4de9e5ba0" contextRef="C_32d5d9b1-7992-4d84-8226-a55e116ed6d0" name="us-gaap:PaymentsForRepurchaseOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon the Term Loan B draw in March 2020, the Lender Warrants became exercisable and the put option related to the Lender Warrants expired. Accordingly, the Company recorded a final fair value adjustment and reclassif</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ied the Lender Warrants balance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a8b311cd-bdfc-4c47-ba17-4cd16f3f5f81" contextRef="C_20586d23-36ef-4d60-8bc6-81acfe59236b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to additional paid-in-capital.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The initial $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_71687d18-1e40-4928-9d95-e10f12e6c462" contextRef="C_3df574b9-fe27-4d9e-a549-6a095ed65261" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million fair value of the Lender Warrants, the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f87b8e25-e762-4b75-acff-8ea30a851e2b" contextRef="C_9840529e-ac70-4eb7-8d10-e6cb712b0d45" name="phat:DebtInstrumentFinalPaymentFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million final payment fee and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6623301-e964-4415-8a14-ddca0181be90" contextRef="C_3df574b9-fe27-4d9e-a549-6a095ed65261" name="us-gaap:UnamortizedDebtIssuanceExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of debt issuance costs were recorded as debt discount and amortized to interest expense using the effective interest method over the term of the Term Loans prior to the retirement of the debt. Upon retirement of the debt any remaining unamortized amounts were recorded as an expense to Other income (expense).</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the years ended December 31, 2021 and 2020, the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ff92d4e4-b6a9-47c6-a498-733778518f29" contextRef="C_6cd259d1-4f33-46a3-b5d1-c3115e02e275" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5bd6c8f6-9715-41fb-8fb3-b42d5dff3ef4" contextRef="C_acd69431-8a06-4075-a111-6495758ee60f" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.6</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, of interest expense, including amortization of the debt discount, in connection with the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hercules Loan Agreement and SVB Term Loan</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As of December 31, 2021, the Company had outstanding </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">loan balance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3764b261-9193-44af-ab18-7e5a4c00fec1" contextRef="C_f13e98ac-8a46-483d-833b-1ed96212502d" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">101.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and accrued interest of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_632e53d5-7014-42d3-8cad-910d1e9771bd" contextRef="C_f13e98ac-8a46-483d-833b-1ed96212502d" name="phat:AccruedInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div><ix:nonNumeric id="F_12ee6269-6405-48d9-8578-309497042ccb" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. Stockholders&#x2019; Equity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2019, subsequent to the Merger, the Company sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b5cb6e30-dbec-4106-b363-4a3a960a61d7" contextRef="C_1697dfc5-540c-442e-b1a4-f9384dabddfa" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,491,072</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock to Frazier.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2019, the founders granted the Company a repurchase right for the </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_33e3714c-5d06-40ff-b3fc-91b57fe21e68" contextRef="C_9c645a10-1007-43f6-af0d-91ee63fc5c04" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,373,408</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock originally purchased in 2018. The Company has the right, but not the obligation, to repurchase unvested shares in the event the founder&#x2019;s relationship with the Company is terminated, subject to certain limitations, at the original purchase price of the stock. The repurchase right lapsed for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d55fe176-7495-4087-bf3c-af04430ea703" contextRef="C_9c645a10-1007-43f6-af0d-91ee63fc5c04" name="phat:StockRepurchaseProgramNumberOfSharesRightLapse" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">843,352</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares in March 2019 and the repurchase right for the remaining </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_415bc850-643b-4071-8524-bcc222937cf2" contextRef="C_9c645a10-1007-43f6-af0d-91ee63fc5c04" name="us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,530,056</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares lapses in equal monthly amounts over the following </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b45c5bea-bfc1-4d67-9b54-6807ed726ef5" contextRef="C_87fd58b8-211c-4048-8771-2e2c36ba57bf" name="us-gaap:StockRepurchaseProgramPeriodInForce1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period ending in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4625fd53-3660-44c4-9e4b-15de29e5e4a4" contextRef="C_87fd58b8-211c-4048-8771-2e2c36ba57bf" name="phat:StockRepurchaseProgramExpirationMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The fair value of the founder shares at the date the repurchase right was granted is being recognized as stock-based compensation expense on a straight-line basis over the vesting period. As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f5930f09-8d27-4be3-8c29-f732043942f2" contextRef="C_36128d75-bc37-4ecf-b73c-b936cd610fae" name="us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">395,321</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were subject to repurchase by the Company and the associated repurchase liability was not significant. The amount of recognized and unrecognized stock-based compensation related to the founder stock was immaterial for all periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2019, the Company issued Takeda </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef74ae37-3918-44d4-9952-4970d6822361" contextRef="C_fad8897a-ba60-41ae-8f3d-ee922beca8a9" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,084,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock in connection with the Takeda License.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the period from January 1, 2019 to May 6, 2019, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dbd4e93e-f5ca-4521-acd5-cae1c70c6fd3" contextRef="C_badf06b6-f9fe-4b02-beea-e7e8d5ea853c" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,524,852</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock to various employees and consultants of the Company for aggregate proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4c6ea22a-7cfd-474c-bb45-63ed59067c40" contextRef="C_badf06b6-f9fe-4b02-beea-e7e8d5ea853c" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Upon issuance, these shares were subject to a repurchase option by the Company at the original purchase price of the shares. The repurchase rights generally lapse as to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9472e555-3732-41c1-818f-278a97d58598" contextRef="C_5a4b87ab-a1d7-48cd-a634-0d9f17511fa1" name="phat:RepurchaseRightLapseRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the shares on the first anniversary of the vesting commencement date, and the repurchase right lapses as to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6101410e-3515-4cea-81ab-5e3079200f62;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1/48</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">th of the shares each one-month period thereafter, subject to the purchaser remaining continuously an employee, consultant or director of the Company. In November 2019, the Company repurchased </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_70a60e20-13f6-48fa-b3a8-1834c1a351c1" contextRef="C_12c53278-d1c8-452b-aaf8-8d9bd7427b25" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">17,560</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares at the original purchase price for an aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb3206bb-e2b0-4991-9092-dee20f18a10f" contextRef="C_206f3b3c-5da1-4c5f-91a2-624aa167dbf3" name="phat:SharesAggregateRepurchasePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.20</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55515e38-be31-4356-aa54-663cef74b575" contextRef="C_3664d4ba-d83a-42b2-94ee-819934ab325c" name="us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">749,488</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares remain available for repurchase by the Company and the associated repurchase liability was not significant.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 29, 2019, upon completion of the IPO, the Company sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f3d5a675-3eb3-4ddc-8a0b-c7036059f59e" contextRef="C_74f9d273-2810-4b05-a50b-39f4e9e89f17" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,997,630</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, which included the exercise in full by the underwriters of their option to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d2752fb7-a94e-42ca-83d7-9d9083c20750" contextRef="C_91313c0e-8879-4034-8725-8b3f8639f719" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,434,473</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4c305a8-7939-4dd1-88aa-4ddc50af9a99" contextRef="C_380ada73-fd68-4c36-b7a1-4dbbf1ceef47" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">19.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The net proceeds were approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9a552f92-86fa-400f-b0d3-97aba094acc0" contextRef="C_74f9d273-2810-4b05-a50b-39f4e9e89f17" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">191.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, after deducting underwriting discounts, commissions and offering costs.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2020, the Company entered into an Open Market Sale Agreement, or, the Sales Agreement, with Jefferies LLC, or, the Sales Agent, under which it may, from time to time, sell shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e51c1ee-ec16-40e9-a180-1800bde30e8e" contextRef="C_0325f78e-5f19-4ce3-816b-ea35a5adfab2" name="phat:AggregateOfferingPriceThroughEquityFinancing" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">125.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million through the Sales Agent, or, the ATM Offering. Pursuant to the Sales Agreement, the Company will pay the Sales Agent a commission for its services in acting as an agent in the sale of common stock in an amount equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_01e1a311-1a89-4727-9c6f-5fbd1c00a6be" contextRef="C_f9cd5e45-1473-4fc5-b117-73d3e4b8192b" name="phat:SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the gross sales price per share sold. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_44f67731-3ff7-4a7c-9afa-7115c1855e30" contextRef="C_c16925ab-416a-4dd6-ae22-155a64c3a8a2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were sold under the ATM Offering as of December 31, 2021.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 16, 2020, the Company completed an underwritten public offering, in which it sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_34b4f167-6f51-4ed7-b18d-0545f5a7595e" contextRef="C_e23ac301-7808-41cf-82ed-c24a17ab03b1" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,250,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f1ad31b0-7997-4a37-92bb-fbc7c3527581" contextRef="C_f8f7aeec-8c43-4d6e-857e-906c1138ff3a" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">42.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for total gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf88a795-a73f-46b3-99ad-2f9f78e00275" contextRef="C_e23ac301-7808-41cf-82ed-c24a17ab03b1" name="phat:ProceedsFromIssuanceInitialPublicOfferingGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">94.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The net purchase price after deducting underwriting discounts and commissions was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69ead768-b1f2-48a7-8252-a69ac3ec2672" contextRef="C_f8f7aeec-8c43-4d6e-857e-906c1138ff3a" name="phat:SharesIssuedPricePerShareAfterDeductions" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">39.48</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, which generated net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e551ab3-f106-458c-8aa6-24b15c224229" contextRef="C_e23ac301-7808-41cf-82ed-c24a17ab03b1" name="phat:NetProceedsAfterDeductingUnderwritersCommission" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">88.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company incurred an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0b310c39-1753-460c-b9b6-3392ce426afa" contextRef="C_e23ac301-7808-41cf-82ed-c24a17ab03b1" name="phat:PurchaseOfAdditionalOfferingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of offering expenses in connection with this public offering.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28a548d7-231a-439a-a82d-5d9cd77278b8" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the Company&#x2019;s unvested shares is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.994%;"></td>
        <td style="width:1.656%;"></td>
        <td style="width:1.175%;"></td>
        <td style="width:18.625%;"></td>
        <td style="width:1.549%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de27f929-e590-4e1d-aebf-b9671c0c376c" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,746,759</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share vesting</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17910fd3-faf1-4fe2-9d5c-afc1699becf4" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,601,950</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3cf547e4-15ff-41a3-bbd7-0391e7151719" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,144,809</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For accounting purposes, unvested shares of common stock are considered issued, but not outstanding until they vest.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ffe6470f-b5f4-4a7b-89ce-bce07493eead" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:CommonStockReservedForFutureIssuancesTableTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock reserved for future issuance consists of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:73.57%;"></td>
        <td style="width:1.501%;"></td>
        <td style="width:1.09%;"></td>
        <td style="width:22.748%;"></td>
        <td style="width:1.09%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1594131f-a3bb-4cda-9e61-36eb669c9c38" contextRef="C_d868eb98-0a9a-4d3b-9ce2-a53206123d64" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,450,532</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options and performance-based awards outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_50b93f31-2971-4eb2-b683-1bccbd4ece6f" contextRef="C_e5953438-3337-4945-83fd-2193a29e01a7" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,581,029</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares available for issuance under the 2019 Incentive Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bfd31cd3-58f9-490f-98b3-90a5a73af78f" contextRef="C_87f0bb77-c9b2-4912-beed-d93c6e58fd1f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,772,744</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares available for issuance under the ESPP Plan</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e821ab85-0908-4d7b-8332-be10cf88f8f4" contextRef="C_b9960611-efe5-44c4-a8c6-f1f963d5a52b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">842,036</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_40c45972-d089-462d-af82-6ca28ce99437" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">14,646,341</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is authorized to issue up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_769ca115-5487-480b-b47e-672ad2da1ae2" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" scale="6" decimals="INF" format="ixt:numdotdecimal">40</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million shares of preferred stock. As of December 31, 2021, and December 31, 2020, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e46a53dc-9363-4e28-ac73-966a887f9267" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_962638d8-015c-466e-9d35-6348cf54d6b8" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_568bce58-5b8d-4cd7-a56e-a0d6784d3f85" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a472456e-41f9-48d0-86f3-1744c93b0910" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock issued or outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Equity Incentive Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s 2019 Equity Incentive Plan, or the Existing Incentive Plan, provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards to eligible recipients, including employees, directors or consultants of the Company. The Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c04a8fb6-ce21-4bb8-a866-fb3ace61ff2e" contextRef="C_fe1128a5-47e8-4b19-bbed-dd56555e6e7b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,231,739</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock authorized for issuance under the Existing Incentive Plan, of which, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_076aef3d-d686-4f57-8419-f21be6753104" contextRef="C_17839630-7f10-4b51-bf7c-a8f7ffc8fab6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,400,528</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> stock options and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b463161d-fbfd-4a5e-986d-d58871a60fc6" contextRef="C_8dbe144e-0a5e-4b96-a3d3-658404346eb7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,260</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> restricted stock awards were granted in 2019. As a result of the adoption of the 2019 Incentive Award Plan, or the 2019 Plan, in October 2019, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4866a9a0-9313-4cca-86ae-c7949d99d44e" contextRef="C_f66489f4-0ae2-4a45-862d-a14469e353c3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> further shares are available for issuance under the Existing Incentive Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2019 Incentive Award Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2019, the board of directors adopted, and the Company&#x2019;s stockholders approved, the 2019 Plan, which became effective in connection with the IPO. Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c4977c2-16fd-486e-902f-630a4a617212" contextRef="C_cdbdb34e-8229-4188-b4a2-e7d4e7a5718c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The number of shares initially available for issuance will be increased by (i) the number of shares subject to stock options or similar awards granted under the Existing Incentive Plan that expire or otherwise terminate without having been exercised in full after the effective date of the 2019 Plan and unvested shares issued pursuant to awards granted under the Existing Incentive Plan that are forfeited to or repurchased by the Company after the effective date of the 2019 Plan, with the maximum number of shares to be added to the 2019 Plan pursuant to clause (i) above equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_61a7b6f5-920b-4fe9-b671-06a2c5b01b85" contextRef="C_e3ad8a65-3e01-423c-bdf8-40f8bc119501" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,416,788</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares, and (ii) an annual increase on January 1 of each calendar year beginning in 2020 and ending in 2029, equal to the lesser of (a) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89cc03e8-e645-4c8b-b7d1-69aee05131ee" contextRef="C_b58f7ee0-6546-4bdb-8957-1ed85f98206a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the board of directors. As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dafaa9cd-79b5-4cbf-bdf1-6b824e9700a8" contextRef="C_87f0bb77-c9b2-4912-beed-d93c6e58fd1f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,772,744</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares remain available for issuance, which reflects </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f66c3794-4f12-4d15-81cf-fa9c11acc810" contextRef="C_6a529bff-3f22-42e8-80c8-4ec27c2967c8" name="phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,915,300</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> stock options and performance-based units (&#34;PSU&#34;) granted, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9d5bcc33-dba1-4b06-89c7-f6724d5b4afa" contextRef="C_6a529bff-3f22-42e8-80c8-4ec27c2967c8" name="phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">175,430</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> cancelled or forfeited, during the year ended December 31, 2021 as well as </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">annual increases of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f8cf7e59-9a7a-416d-9017-d8347c5547f9" contextRef="C_fc73c1d8-543b-42ca-a706-31cf63f474bd" name="phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,250,511</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a106e3e8-b28d-42cd-82c6-45b66d95505d" contextRef="C_900f5558-5afe-4b4f-8196-aa85a162d269" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,158,580</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares that were authorized on January 1, 2021 and 2020. An additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6861ec42-f9cb-4e9b-a045-2b4920de835a" contextRef="C_2d28ef17-10f6-4591-8f1a-f0f2d4d26dae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,582,802</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were authorized on January 1, 2022. </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:Times New Roman;"></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Performance-based Units</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During 2020, the Company granted </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea7aeeaf-d2e7-43a5-af15-1c77da429606" contextRef="C_7e3a25e6-daa3-4b87-aabb-7aa287d515ab" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">220,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> PSUs whereby vesting depends upon the approval by the U.S. Food and Drug Administration, or FDA, of vonoprazan for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and then, or concurrent with, erosive esophagitis. In 2021, the Company granted an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_80d21cf5-1c9f-4ee9-b7fa-f6ed5ec33859" contextRef="C_723f3790-161d-4bd6-86bd-87b733a399de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">190,050</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> PSUs to employees. As of December 31, 2021, the PSU milestones had not been achieved. As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d7862ba6-e914-4cbe-89e6-595c80fb0669" contextRef="C_723f3790-161d-4bd6-86bd-87b733a399de" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> related compensation cost had been recognized. </span><span><ix:nonNumeric id="F_f2bb72b9-faf4-4582-b863-596207498df9" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" escape="true" continuedAt="F_f2bb72b9-faf4-4582-b863-596207498df9_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes PSU activity under the 2019 Incentive Award Plan during the year ended December 31, 2021.</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_f2bb72b9-faf4-4582-b863-596207498df9_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.33%;"></td>
        <td style="width:1.378%;"></td>
        <td style="width:0.949%;"></td>
        <td style="width:14.878%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:1.378%;"></td>
        <td style="width:2.296%;"></td>
        <td style="width:14.312%;"></td>
        <td style="width:0.949%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br />Stock Units</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br />Average Grant<br />Date Fair Value<br />Per Share</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f2112e7-bd1b-422f-bb7c-1022d4eb484d" contextRef="C_17a2343c-f245-48f0-b4b2-e5e809abbd6c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">220,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_845b234d-9536-4fdb-8b52-25708063138a" contextRef="C_17a2343c-f245-48f0-b4b2-e5e809abbd6c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">32.48</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5c57c809-e79b-4e2b-bc8a-f56b15be68a2" contextRef="C_723f3790-161d-4bd6-86bd-87b733a399de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">190,050</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d8e04eea-2091-4b64-88b1-f5f0ee5c0340" contextRef="C_723f3790-161d-4bd6-86bd-87b733a399de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">31.80</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b58236d5-ee75-4585-aadd-2c0341ea6042" contextRef="C_723f3790-161d-4bd6-86bd-87b733a399de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">15,750</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_935761c9-6d28-482f-b82a-a132dec5e7ff" contextRef="C_723f3790-161d-4bd6-86bd-87b733a399de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">30.63</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4a750fc8-963c-41fa-a3c6-90818f2fca63" contextRef="C_85558b4d-f67a-43d1-abe8-dbab03b741da" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">394,300</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7cf60050-f26d-4be3-be9a-27000e22306a" contextRef="C_85558b4d-f67a-43d1-abe8-dbab03b741da" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">32.23</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 there was approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_73e60f9f-02f4-49ae-80d4-343b98ac81e6" contextRef="C_85558b4d-f67a-43d1-abe8-dbab03b741da" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of related unrecognized compensation cost, which will be recognized upon vesting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2019, the board of directors adopted, and the Company&#x2019;s stockholders approved, the Employee Stock Purchase Plan, or the ESPP, which became effective in connection with the IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_97a7d19e-a9be-493c-b399-b768c4e82f83" contextRef="C_db21078b-51b9-43f8-8e98-683590c04e0e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">20</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of their eligible compensation, which includes a participant&#x2019;s gross base compensation for services to the Company, including overtime payments and excluding sales commissions, incentive compensation, bonuses, expense reimbursements, fringe benefits and other special payments. A total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_397f7dfc-5b16-43f6-bab6-7415cb6a8af6" contextRef="C_917d5eb6-6257-4bc2-9c26-1732c213fff4" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">270,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock was initially reserved for issuance under the ESPP. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2352bb94-133e-4411-b72b-b3d4f4128612" contextRef="C_9d982be6-c196-4b4e-ae56-0b1fafa482a8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the number of shares available for issuance under the ESPP will be annually increased on January 1 of each calendar year beginning in 2020 and ending in 2029, by an amount equal to the lesser of: (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e62f1206-a049-469e-be25-ad5a87d25e05" contextRef="C_0ef2e37e-f570-4b04-bea6-8bd572cb5668" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the board of directors. As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0c923fa7-6165-4aa6-a0c4-de78556023bd" contextRef="C_b9960611-efe5-44c4-a8c6-f1f963d5a52b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">842,036</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock remain available for issuance, which reflects </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_29f6f378-9fd8-43af-8984-f4b6e32939fa" contextRef="C_9d982be6-c196-4b4e-ae56-0b1fafa482a8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,237</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares sold to employees during the year ended December 31, 2021 as well as the annual increases of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cd7b468d-2ec2-449c-9e37-aa9dfd571e76" contextRef="C_304607c5-7382-468b-88d2-4280b34bacd1" name="phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">312,628</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7a6e256f-1494-473e-8377-d351f78e52a7" contextRef="C_c47ce7f2-8ee4-455c-93be-6ab781a08057" name="phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">289,645</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares that were authorized on January 1, 2021 and 2020. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81eb26c8-9ed4-458e-8113-0497ea70e873" contextRef="C_fb1fb004-48c7-408c-a23a-a166c26e4c3d" name="phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares were authorized in January 2022.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ESPP is considered a compensatory plan, and the Company recorded related stock-based compensation of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5dafc7d-936e-46bb-98e0-81f5e6f99ea1" contextRef="C_9d982be6-c196-4b4e-ae56-0b1fafa482a8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_df618466-3e8a-4972-a802-14348f30becd" contextRef="C_bbae8c0f-df0c-4920-b864-e0c22c2199e5" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2021 and 2020, respectively. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eccd5c57-c168-4f1c-8e20-7cbf55b04e72" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" escape="true" continuedAt="F_eccd5c57-c168-4f1c-8e20-7cbf55b04e72_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average assumptions used to estimate the fair value of ESPP awards using the Black-Scholes option valuation model were as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_eccd5c57-c168-4f1c-8e20-7cbf55b04e72_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.76%;"></td>
        <td style="width:1.393%;"></td>
        <td style="width:0.918%;"></td>
        <td style="width:19.529%;"></td>
        <td style="width:3.78%;"></td>
        <td style="width:1.393%;"></td>
        <td style="width:0.918%;"></td>
        <td style="width:19.529%;"></td>
        <td style="width:3.78%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assumptions:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d150614-97b6-44e7-990f-1c03f223a55a" contextRef="C_9d982be6-c196-4b4e-ae56-0b1fafa482a8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.69</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f4276651-249a-41bf-b2d9-7351cc482e32" contextRef="C_bbae8c0f-df0c-4920-b864-e0c22c2199e5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.00</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4bd6221a-8223-40b3-a063-aeab2ec09097" contextRef="C_9d982be6-c196-4b4e-ae56-0b1fafa482a8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">76.25</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f4d16b42-4a33-4dbc-a549-4719da0757a4" contextRef="C_bbae8c0f-df0c-4920-b864-e0c22c2199e5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">76.25</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aaec4018-fcc2-45ea-add8-a32af8e0dfb3" contextRef="C_9d982be6-c196-4b4e-ae56-0b1fafa482a8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.09</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4b5c7b47-5713-4c28-bd61-0b80b6bebb7e" contextRef="C_bbae8c0f-df0c-4920-b864-e0c22c2199e5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d07b5502-86cd-4292-a9bf-a69d19d0646a" contextRef="C_9d982be6-c196-4b4e-ae56-0b1fafa482a8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated weighted-average fair value of ESPP awards during 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_86d2add3-0218-4ab2-a74c-26de8c532515" contextRef="C_9d982be6-c196-4b4e-ae56-0b1fafa482a8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">14.66</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_688ca65d-321c-498b-9bbb-52408b9cbe9d" contextRef="C_bbae8c0f-df0c-4920-b864-e0c22c2199e5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">13.66</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. As of December 31, 2021, the total unrecognized compensation expense related to the ESPP was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c47f9d82-c976-4f97-93d1-d2d20e978857" contextRef="C_b9960611-efe5-44c4-a8c6-f1f963d5a52b" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">12,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which is expected to be recognized over a weighted-average period of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_84f51270-9ac2-4ab0-938e-19fcae774d80" contextRef="C_9d982be6-c196-4b4e-ae56-0b1fafa482a8" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Options</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of each employee and non-employee stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company, prior to the IPO on October 29, 2019, was a private company and lacked company-specific historical and implied volatility information. Therefore, it estimated its expected volatility based on the historical volatility of a publicly-traded set of peer companies. Due to the lack of historical exercise history, the expected term of the Company&#x2019;s stock options for employees was determined utilizing the &#x201c;simplified&#x201d; method for awards. The expected term of stock options granted to non-employees was equal to the contractual term of the option award. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c26ae09-03b3-49e1-ac9f-52231d0f4d0e" contextRef="C_6ef27173-e664-4f22-9780-2b7a13c106d7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5f2a0ed1-fb2a-4b67-947c-2aec5ecf5fee" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the Company&#x2019;s stock option activity and related information is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.8%;"></td>
        <td style="width:1.047%;"></td>
        <td style="width:1.071%;"></td>
        <td style="width:11.851%;"></td>
        <td style="width:1.071%;"></td>
        <td style="width:1.047%;"></td>
        <td style="width:1.618%;"></td>
        <td style="width:9.305%;"></td>
        <td style="width:0.94%;"></td>
        <td style="width:1.047%;"></td>
        <td style="width:1.583%;"></td>
        <td style="width:9.733%;"></td>
        <td style="width:0.785%;"></td>
        <td style="width:1.011%;"></td>
        <td style="width:1.63%;"></td>
        <td style="width:9.674%;"></td>
        <td style="width:0.785%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Options<br />Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br />Average<br />Exercise<br />Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br />Average<br />Remaining<br />Contractual<br />Term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br />Intrinsic<br />Value (in<br />thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1dcaa68f-f1cd-485f-b1c3-7a946bcd0284" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,728,742</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d976d374-2c69-42e8-8fde-07b4d9284fb0" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">21.36</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b5324adf-1b0a-466c-9a4a-3395c1f5ab17" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.10</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5bef7818-ec49-410a-b18a-b94f3eb27b7b" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34,432</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_22661180-372e-44f3-9db4-ac786cf7e67c" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,725,250</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_45b79f83-9acc-4dc4-9a9c-c9c970739838" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">37.14</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options exercised and shares vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_56d5ffc3-afd2-4b63-bb6e-ee288f15031e" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">107,583</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_20ee5c86-22e6-4cff-8574-1796ab442a6a" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">18.07</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options cancelled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f9e3e4b3-86fa-4062-8c4f-2a9be06bcabd" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">159,680</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9d2d87b0-d302-4a9b-a293-f0bfe602042e" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">32.26</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4d166bf1-c3bc-4b37-afae-69bdfdc3e7e9" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,186,729</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2c1648e8-74ba-4717-bfd7-4f08d94e9c54" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">27.53</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9cf30fc6-4f38-49f0-8d54-f223c354683b" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.43</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb1cfc34-4917-4525-9ecd-348f37a8d881" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,973</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options exercisable as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_64e44620-ac69-4b78-ae85-a155d11dc9ea" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,127,877</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d9898a3c-c913-4331-82ac-05865ad44b96" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">19.75</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3256e28f-a05f-4d96-9190-afcb63b138b9" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.91</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_18f11f15-bb63-4daf-94d2-515a8c0604de" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,880</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options vested and expected to vest as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f2830e7-25a2-483b-afaa-c2ef52b0bcff" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,186,729</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9c25405c-b888-454f-885e-38d74567be62" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">27.53</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8c230797-50e3-476f-9516-e8798f5ad946" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.43</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f8ed20f-5bbe-4414-af41-2b230dd6fbe7" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,973</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate intrinsic value of options exercisable as of December 31, 2021 and 2020 were calculated as the difference between the exercise price of the underlying options and the closing market price of the Company&#x2019;s common stock on that date, which were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_22a6909f-c0cf-461d-a67a-d5f79bf048b6" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:ClosingMarketPriceOfCommonStock" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">19.67</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55b9b8b3-d832-42f6-9fa5-82a6d9ef557f" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="phat:ClosingMarketPriceOfCommonStock" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">33.22</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share on December 31, 2021 and 2020, respectively. The aggregate intrinsic value of options exercised during the years ended December 31, 2021 and 2020 were approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4e03e350-d67a-4048-948d-c5fdbe1b727e" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2c59d2b0-cd19-4816-a699-37aa7cb7a13a" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated weighted-average fair value of employee and nonemployee director stock options granted during 2021 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d3e56b32-9341-4164-b67c-f9853a359d20" contextRef="C_aefa2a08-8860-4371-8c07-d0e5df47bfbd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">22.20</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As of December 31, 2021, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5495f8a5-8743-4046-9a11-4a507a04a9c6" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">46.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of unrecognized stock-based compensation expense, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cbc5a686-160e-48e1-a9e7-689d0517a5dc" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.6</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80d52836-c315-4342-b4cf-a339a9ccf2d1" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average assumptions used to estimate the fair value of stock options using the Black-Scholes option valuation model were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.76%;"></td>
        <td style="width:1.393%;"></td>
        <td style="width:0.918%;"></td>
        <td style="width:19.529%;"></td>
        <td style="width:3.78%;"></td>
        <td style="width:1.393%;"></td>
        <td style="width:0.918%;"></td>
        <td style="width:19.529%;"></td>
        <td style="width:3.78%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assumptions:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14e5e094-e626-4c3d-91ab-f54475b55883" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.93</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c07d0be-0c60-42ac-8e60-eb97a87946de" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.06</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52a07e27-1f27-4f24-83e6-fb2a435ebc04" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">67.46</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8af3cead-b971-4811-97fe-72e1ba5ce17e" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">65.07</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc724650-5011-48d6-8a11-008f2d02dfb9" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.68</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aec9c568-3971-4559-ac61-b6a10522b25f" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.51</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1a9468d3-75ca-43e4-8351-bf1f5708633d" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation Expense</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f914191-2994-46e5-887e-f448c9800844" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense recognized for all equity awards, including founder stock, has been reported in the statements of operations as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.173%;"></td>
        <td style="width:1.393%;"></td>
        <td style="width:2.281%;"></td>
        <td style="width:21.142%;"></td>
        <td style="width:0.919%;"></td>
        <td style="width:1.393%;"></td>
        <td style="width:2.281%;"></td>
        <td style="width:20.499%;"></td>
        <td style="width:0.919%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da7e2274-7574-4dfb-a4a5-aaba953945b3" contextRef="C_133a7a17-cc0b-4319-b5dd-153f51460267" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,838</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3d35a8d6-365a-48ad-bc75-fc2d72886533" contextRef="C_966c0d74-7852-45f5-adb0-f5683894e01e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,450</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0be4e825-1613-4975-9450-56bf2ff8ae81" contextRef="C_1dc294ca-9c67-4d13-8135-fcee0b125f3b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,974</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6d88e67-a80b-473d-a5e8-7213cbaf99d1" contextRef="C_c0e9a1bb-6f16-475b-b3dc-8ce4769c62af" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,390</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00da2b12-2c98-4b19-a30d-2e9f5257e317" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,812</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bdc4e139-99a7-4695-8ac8-e63663e0f9bb" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,840</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div><ix:nonNumeric id="F_1f4a0d66-3ad0-4585-8a79-29c6e154002a" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. Income Taxes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the years ended December 31, 2021 and 2020, the Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85e603d0-45d7-4c76-8f39-fe933e204e56" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8fae8763-e73a-4231-8bb8-cb62627bbad4" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t record a provision for income taxes due to a full valuation against its deferred taxes. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cfe167ca-1584-4739-8d4f-e939247e835a" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true" continuedAt="F_cfe167ca-1584-4739-8d4f-e939247e835a_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_cfe167ca-1584-4739-8d4f-e939247e835a_1"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.941%;"></td>
        <td style="width:1.271%;"></td>
        <td style="width:2.251%;"></td>
        <td style="width:21.069%;"></td>
        <td style="width:1.501%;"></td>
        <td style="width:1.271%;"></td>
        <td style="width:2.251%;"></td>
        <td style="width:20.946%;"></td>
        <td style="width:1.501%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income taxes computed at the statutory<br />&#160;&#160;&#160;rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6cae87c4-826d-4db3-a2da-01474d4b37b1" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">30,216</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9a6a84ed-7752-4057-b2a8-030332b64a9e" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">27,105</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent items</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ccf44253-bb59-44ef-bc06-a7c4755276c1" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:IncomeTaxReconciliationPermanentItems" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,387</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5847976-ab3a-4e6a-b225-36959b1d02da" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="phat:IncomeTaxReconciliationPermanentItems" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">291</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of warrants and<br />&#160;&#160;&#160;convertible debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3668143e-1517-4b29-85e8-e575249edd34" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="phat:IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6aeed4a6-2e88-4a4f-87cb-2c73335a6086" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="phat:IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">20</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bac2917e-b6c7-45ea-8bc9-c91c6430abe5" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,950</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9dbf47d0-25d5-4f1a-bd83-cbb975d46363" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,047</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05e5d07b-8174-44bc-9556-9ee323b17ca8" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,783</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4c6c7e98-2c9a-49e8-bde3-e68de7b41062" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,949</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2fc4a107-918d-49b0-9bc0-902ca011278d" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b438dc4-f117-4301-838f-8a7a024dcfea" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">68</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision (benefit) for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0bfbce22-c85b-4409-bc2e-68049381c69e" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_28c4b4c1-2aef-4b76-a658-223da5e80cd3" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2dcf3a2f-e02d-4fbf-a4cb-0a4ce2c1e490" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Significant components of the Company&#x2019;s net deferred tax assets are as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.235%;"></td>
        <td style="width:1.163%;"></td>
        <td style="width:2.25%;"></td>
        <td style="width:20.447%;"></td>
        <td style="width:1.515%;"></td>
        <td style="width:1.163%;"></td>
        <td style="width:2.25%;"></td>
        <td style="width:20.462%;"></td>
        <td style="width:1.515%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4c6b0aa9-f377-4577-b94d-9feb70662bf2" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60,936</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_40434b01-88ab-4060-90fc-7d3286194942" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,162</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3ce191df-2d01-479d-858b-ae55663392d1" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,694</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dda97e67-d6fd-4421-b664-ab45d903f56d" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,744</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d48593eb-cf6f-43ae-af2f-fad67ec1eee6" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,809</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2905ba86-dde7-45b0-88c0-cb1a8c1bd95c" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,929</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b3330ced-6867-4f95-b86a-b2113692bb9e" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,996</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d193fa5c-ee76-4caa-a5ce-a03678d8db0b" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,914</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f60625ce-b40f-479e-aa3a-f5e783b91520" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">85,435</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6430e121-9cea-4525-9821-bae5ed6f5601" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,749</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf5bf4d8-2b04-4734-8ba1-b61462162d04" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">85,033</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_acee7f70-f054-411c-8bdd-bf2ba96c2cdc" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,250</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca2e8458-70ae-4ac4-b486-6bcca772ff85" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">402</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2564fb1e-b6ea-4ecb-928e-a78016ef5b1c" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">499</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75618854-9a50-41b8-be04-d9a5834f3e8c" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">402</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f7218eb9-3f6b-4478-8f67-8afa8d165057" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">499</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_316d98a6-4709-4081-b0fd-a27199fe53d1" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e4a896f0-56dc-45c5-b1bb-0b1c23a86731" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based upon the Company&#x2019;s history of operating losses, the Company is unable to conclude that it is more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation allowance for its deferred tax assets as of December 31, 2021 and 2020.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, the Company had federal net operating loss carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_83f6e2c8-7412-4c86-9f67-d7b53107a75e" contextRef="C_c2511355-1d5e-4278-9953-83e4963ae813" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">290.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b3b41ac-cb7e-4b6b-9b83-9166948f5f56" contextRef="C_b6c9a017-a221-4c88-a8e6-7e275e06e7fc" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">157.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, which are carried over indefinitely.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9db05388-3061-4a77-9976-ecdccf745a18" contextRef="C_7722cfb6-10af-45ab-a5aa-9adea0d22b6a" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of state net operating loss carryforwards that begins to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_089dfb9a-943b-4ca5-964b-7225d9197070" contextRef="C_4d9410fc-a3f3-43cf-95a5-e68281c355c9" name="phat:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2036</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company has available federal research and development credits of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59aed86a-1ca2-4f73-b0f7-5de7dea7aaae" contextRef="C_c2511355-1d5e-4278-9953-83e4963ae813" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million which begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_362b0159-37e4-487b-870f-d58511d7fedb" contextRef="C_efc1a669-0200-4d3b-9503-dde410805b7b" name="phat:ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2038</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae68d396-5ad9-4dba-ab24-00d7f3e75d1f" contextRef="C_7722cfb6-10af-45ab-a5aa-9adea0d22b6a" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of state research and development credits, some of which, begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f397636e-1aba-4e04-ae86-51dc689ee19d" contextRef="C_4d9410fc-a3f3-43cf-95a5-e68281c355c9" name="phat:ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has not completed a formal analysis of the potential impact of Section 382 on its deferred tax assets as of December 31, 2021. Until this analysis has been completed, the Company has not adjusted any of its deferred tax assets, including net operating losses or research and development credits. The Company will reassess the amount of net operating losses and credits subject to limitation under Section 382 when a study is complete. Due to the existence of the valuation allowance, future changes in the deferred tax assets related to these tax attributes will not impact the Company&#x2019;s effective tax rate.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_526d0332-d5ba-4c1a-9227-9de35da8d2da" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the activity related to the Company's gross unrecognized tax benefits:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.197%;"></td>
        <td style="width:1.393%;"></td>
        <td style="width:2.311%;"></td>
        <td style="width:13.715%;"></td>
        <td style="width:0.949%;"></td>
        <td style="width:1.393%;"></td>
        <td style="width:2.311%;"></td>
        <td style="width:12.781%;"></td>
        <td style="width:0.949%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beginning balance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da26151f-377a-4d5d-8fef-8b48ee0ed44b" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">938</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b5452460-646e-49d8-b8c6-41a99aa9d45f" contextRef="C_33fee96d-a213-48c4-a5ad-68ccefad3cff" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">176</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Increases related to prior year tax positions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e8347ad6-4f5f-46a2-8221-5d8e52b8a6c9" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb85efb5-a029-440e-b3d7-0217b070ab2b" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Increases related to current year tax positions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_796dc30b-30c4-48fd-87f0-14933b4c0786" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">702</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a436cec2-52b7-47a1-974b-12a5c522885a" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">762</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ending balance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b22b4c39-b5ee-45ea-948c-7360be8fca5c" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,704</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_027a3a93-b471-4e86-9cd1-74b9fecf6599" contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">938</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company has gross unrecognized tax benefits of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f1d9b2c-f9a2-401d-91db-9b8394cff939" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a8245591-d5a9-4d14-a5ee-2c0dfc0563c8" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of which would affect the effective tax rate due to a full valuation allowance. The Company does not anticipate any significant changes in its unrecognized tax benefits over the next 12 months. The Company's policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense. The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7a0b59ad-07e7-40b1-81ed-be0e0148804e" contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accrual for interest or penalties on its balance sheet at December 31, 2021 and has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_28cf4bba-9977-4dfd-b43c-25f1703f83b7" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t recognized interest or penalties in its statement of operations for the year ended December 31, 2021.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to taxation in the United States and various states. The Company is not currently under examination by any taxing authorities. Due to the carryover of tax attributes, the statute of limitations is currently open for tax years since inception.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6716979d-59ad-4015-9b9f-acedaf74d187" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:DefinedContributionPlanTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. 401(k) Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company established a 401(k) savings plan during the year ended December 31, 2020. The Company&#x2019;s contributions to the plan are discretionary. During the years ended December 31, 2021 and 2020, the Company incurred $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c32dac71-841c-418f-bf6c-b406b700cf8a" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b03392eb-dd0c-4e82-a4f5-a437010d78e4" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, of expense related to employer contributions, which was based on a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_99bbdb05-fcfb-4c6d-ac6d-318c9a2ecf07" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_74e40b13-38f0-439d-b2f0-31b90131f77f" contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">75</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% match of employees' annual contributions. In January 2021, the Board of Directors approved the annual discretionary match for 2020, which was settled by contributing </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e29dd39-7ccf-4eb6-b657-fe523d672c6a" contextRef="C_b0c76117-ced6-4a6e-a934-4d66a2de81b3" name="phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,356</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares. In August 2021, the Board of Directors approved a semi-annual discretionary match for 2021, which was settled by contributing </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_08374ce2-91de-4cc5-adea-b1c9eb62c248" contextRef="C_955ca9b1-fa2d-4384-942f-920fcb5fe424" name="phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,394</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares. In January 2022, the Board of Directors approved a second semi-annual discretionary match for 2021, which was settled by contributing </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef53dffd-f39e-4245-a2c6-085972d76f68" contextRef="C_78796fa9-c62f-43b9-b92a-90c0ac2aae02" name="phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,756</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c8424e3c-7e7e-45a3-b085-d5fd99fc9bfd" contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. Subsequent Events</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2022, the Company entered into an operating lease for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85f4ec26-c2b0-4bdf-b25e-33a9df859b31" contextRef="C_61898c01-23d4-4967-bc48-1597a7447fd2" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">6,250</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet of office space in Florham Park, New Jersey. The lease liability and the corresponding right-of-use asset associated with this lease obligation will be recorded upon the commencement of the lease, or the date in which the underlying asset is made available for use to the Company, which is expected to occur later in 2022.</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT INDEX</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:14.143%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:34.218%;"></td>
    <td style="width:1.435%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:10.011%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:10.525%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:10.139%;"></td>
    <td style="width:2.099%;"></td>
    <td style="width:13.405%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Incorporated by Reference</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Form</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Filed</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Herewith</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519277761/d795888dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Certificate of Incorporation</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-29-19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312520254563/d10693dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Bylaws</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9-25-2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519267053/d63338dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Common Stock Certificate</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-15-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Warrant to purchase shares of common stock issued to Takeda Company Limited, dated May 7, 2019</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex43.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Warrant to purchase stock issued to Silicon Valley Bank, dated May 14, 2019</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex44.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Warrant to purchase stock issued to WestRiver Innovation Lending Fund VIII, L.P., dated May 14, 2019</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519267053/d63338dex45.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Note Purchase Agreement, dated May 7, 2019, by and among the Registrant and the other parties party thereto, as amended</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-15-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="phat-ex4_6.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Description of Registered Securities</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Phathom Pharmaceuticals, Inc. 2019 Equity Incentive Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Stock Option Grant Notice and Stock Option Agreement under the Phathom Pharmaceuticals, Inc. 2019 Equity Incentive Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Restricted Stock Grant Notice and Restricted Stock Agreement under Phathom Pharmaceuticals, Inc. 2019 Equity Incentive Plan</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519267053/d63338dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Phathom Pharmaceuticals, Inc. 2019 Incentive Award Plan and form of stock option grant notice and stock option agreement thereunder</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-15-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.5#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459020037296/phat-ex103_248.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Stock Option Grant Notice and Stock Option Agreement under the Phathom Pharmaceuticals, Inc. 2019 Incentive Award Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-6-2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.6#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459020037296/phat-ex104_77.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Performance Share Unit Grant Notice and Performance Share Unit Agreement under Phathom Pharmaceuticals, Inc. 2019 Incentive Award Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-6-2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.7#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519267053/d63338dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Phathom Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-15-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.8#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519267053/d63338dex106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Non-Employee Director Compensation Policy</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-15-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.9#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459020024514/phat-ex101_133.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Phathom Pharmaceuticals 2020 Bonus Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5-12-2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.10#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Letter Agreement, dated May 7, 2019, by and between Tadataka Yamada, M.D. and the Registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">166</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:14.143%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:35.653%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:10.011%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:10.525%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:10.139%;"></td>
    <td style="width:2.099%;"></td>
    <td style="width:13.405%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.11#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex108.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Employment Letter Agreement, dated July 21, 2019, by and between David Socks and the Registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.12#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Employment Letter Agreement, dated September 25, 2019, by and between Azmi Nabulsi, M.D., M.P.H. and the Registrant</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.9</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.13#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312520191565/d54915dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Employment Letter Agreement, dated June 25, 2020, by and between Todd Branning and the Registrant</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7-13-2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.14#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex1011.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Indemnification Agreement for Directors and Officers</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.11</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.15&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex1012.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">License Agreement, dated May 7, 2019, by and between Takeda Pharmaceuticals Company Limited and the Registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.12</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.16</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex1013.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Loan and Security Agreement, dated May 14, 2019, by and among Silicon Valley Bank, WestRiver Innovation Lending Fund VIII, L.P. and the Registrant</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.13</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.17</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459020024514/phat-ex102_134.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment to the Loan and Security Agreement, dated March 11, 2020, by and among Silicon Valley Bank, WestRiver Innovation Lending Fund VIII, L.P. and the Registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5-12-2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.18#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000119312519258922/d63338dex1014.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Employment Letter Agreement, dated August 29, 2019, by and between Terrie Curran and the Registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9-30-2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.14</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.19&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459020037296/phat-ex101_79.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Commercial Supply Agreement, by and between Takeda Pharmaceuticals Company Limited and the Registrant, dated as of April 30, 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-6-2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.20&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459021016682/phat-ex1020_1409.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 1 to Takeda License Agreement, dated September 21, 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3-30-2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.21&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459021016682/phat-ex1021_1410.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Supply and Packaging Services Agreement, by and between Sandoz GmbH and the Registrant, dated December 30, 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3-30-2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.22</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459021016682/phat-ex1022_2100.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 1 to Commercial Supply Agreement by and between Takeda Pharmaceuticals Company Limited and the Registrant, dated as of December 1, 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3-30-2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.22</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.23</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1549999999999998;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459021026309/phat-ex101_241.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Second Amendment to the Loan and Security Agreement, dated March 11, 2021, by and among Silicon Valley Bank, SVB Innovation Credit Fund VIII, L.P. and the Registran</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">t</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-Q</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5-11-2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.24</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459021042895/phat-ex102_106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Third Amendment to the Loan and Security Agreement, dated May 26, 2021, by and among Silicon Valley Bank, SVB Innovation Credit Fund VIII, L.P. and the Registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-10-2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">167</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:14.143%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:35.653%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:10.011%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:10.525%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:10.139%;"></td>
    <td style="width:2.099%;"></td>
    <td style="width:13.405%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.25#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459021042895/phat-ex103_174.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Separation and Release Agreement dated June 4, 2021, between the Registrant and Todd Branning</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-10-2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.26&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459021042895/phat-ex104_267.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Commercial Supply Agreement with Catalent Pharma Solutions, LLC entered into on July 2, 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-10-2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.27#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459021042895/phat-ex105_416.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Non-Employee Director Compensation Policy</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-10-2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.28</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459021055073/phat-ex101_211.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Loan and Security Agreement, dated September 17, 2021, by and among Hercules Capital and the Registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11-8-2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.29</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1783183/000156459021055073/phat-ex102_212.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Warrant to purchase stock issued to Hercules Capital, dated September 17, 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11-8-2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.30&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="phat-ex10_30.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">First Amendment to the Supply and Packaging Services Agreement, by and between Sandoz GmbH and the Registrant, dated December 4, 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="phat-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consent of independent registered public accounting firm</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="phat-ex24_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Power of Attorney</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="phat-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Chief Executive Officer of Phathom Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="phat-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Financial Officer of Phathom Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="phat-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.2*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="phat-ex32_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">101.INS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Inline XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL d</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">ocument.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">101.SCH</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Schema Documen</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">t</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">101.CAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">nline XBRL Taxonomy Calculation Linkbase Documen</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">t.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">101.DEF</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">nline XBRL Taxonomy Extension Definition Linkbase Documen</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">t</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">101.LAB</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">nline XBRL Taxonomy Label Linkbase Documen</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">t</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">101.PRE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">nline XBRL Presentation Linkbase Documen</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">t</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">C</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">over Page Interactive Data File (embedded within the Inline XBRL documen</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">t)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05in;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"># Indicates management contract or compensatory plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">&#134; Portions of this exhibit have been omitted for confidentiality purposes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;">* These certifications are being furnished solely to accompany this annual report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">168</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SIGNA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TURES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this annual report to be signed on its behalf by the undersigned, thereunto duly authorized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PHATHOM PHARMACEUTICALS, INC.</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Terrie Curran</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Terrie Curran</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 1, 2022</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of the Securities Exchange Act of 1934, this annual report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:29.238%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:39.515%;"></td>
    <td style="width:1.122%;"></td>
    <td style="width:29.121%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Signature</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Terrie Curran</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Terrie Curran</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">President, Chief Executive Officer and</span></p><p style="text-indent:-10.0pt;padding-left:10.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director (Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 1, 2022</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Anthony Guzzo</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Anthony Guzzo</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vice President and Chief Accounting Officer</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:-10.0pt;padding-left:10.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(acting Principal Financial Officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 1, 2022</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Michael F. Cola</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 1, 2022</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Heidi Kunz</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 1, 2022</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Asit Parikh, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 1, 2022</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">David Socks</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 1, 2022</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Mark Stenhouse</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 1, 2022</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*By: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">/s/ Terrie Curran</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Terrie Curran, Attorney-in-fact</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">169</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>2
<FILENAME>phat-ex4_6.htm
<DESCRIPTION>EX-4.6
<TEXT>
<html>
 <head>
  <title>EX-4.6</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Exhibit 4.6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:13.5pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">DESCRIPTION OF THE REGISTRANT&#x2019;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">As of December 31, 2021, Phathom Pharmaceuticals, Inc. (&#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d;) had one class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended: our common stock.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Description of Common Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">General</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The following description summarizes some of the terms of our common stock. Because it is only a summary, it does not contain all the information that may be important to you and is subject to and qualified in its entirety by reference to our amended and restated certificate of incorporation (the &#x201c;certificate of incorporation&#x201d;), and amended and restated Bylaws (&#x201c;bylaws&#x201d;), which are filed as exhibits to our most recent Annual Report on Form 10-K and are incorporated by reference herein. We encourage you to read our certificate of incorporation and our bylaws for additional information.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">As of December 31, 2021, our authorized capital stock consisted of 400,000,000 shares of common stock, $0.0001 par value per share, and 40,000,000 shares of preferred stock, $0.0001 par value per share.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Voting Rights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so choose, other than any directors that holders of any preferred stock we may issue may be entitled to elect. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt any provision inconsistent with, several of the provisions of our amended and restated certificate of incorporation.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Dividend Rights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Subject to preferences that may be applicable to any then outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared by the board of directors out of legally available funds.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Liquidation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Rights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">In the event of our liquidation, dissolution or winding up, the holders of common stock will be entitled to share ratably in the assets legally available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities, subject to the prior rights of any preferred stock then outstanding.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Rights and Preferences</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Holders of common stock have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking funds provisions applicable to the common stock.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Fully paid and nonassessable</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The outstanding shares of common stock are duly authorized, validly issued, fully paid and nonassessable.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Transfer Agent and Registrar</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">The Nasdaq Global Market Listing</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Our common stock is listed and traded on the Nasdaq Global Select Market under the ticker symbol &#x201c;PHAT.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Some provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could make the following transactions more difficult: an acquisition of us by means of a tender offer&#x37e; an acquisition of us by means of a proxy contest or otherwise&#x37e; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our shares. These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Undesignated Preferred Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The ability of our board of directors, without action by the stockholders, to issue up to 40,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Stockholder Meetings</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Our amended and restated bylaws provide that a special meeting of stockholders may be called only by our chairman of the board of directors, chief executive officer or president, or by a resolution adopted by a majority of our board of directors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Requirements for Advance Notification of Stockholder Nominations and Proposals</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Elimination of Stockholder Action by Written Consent</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation and amended and restated bylaws eliminate the right of stockholders to act by written consent without a meeting.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Staggered Board of Directors</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third party from attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Removal of Directors</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation provides that no member of our board of directors may be removed from office except for cause and, in addition to any other vote required by law, upon the approval of not less than two thirds of the total voting power of all of our outstanding voting stock then entitled to vote in the election of directors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Stockholders Not Entitled to Cumulative Voting</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Delaware Anti-Takeover Statute</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">We are subject to Section 203 of the Delaware General Corporation Law, which prohibits persons deemed to be &#x201c;interested stockholders&#x201d; from engaging in a &#x201c;business combination&#x201d; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#x201c;interested stockholder&#x201d; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#x2019;s voting stock. Generally, a &#x201c;business combination&#x201d; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Choice of Forum</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum under Delaware statutory or common law for: (i) any derivative action or proceeding brought on our behalf&#x37e; (ii) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders, creditors or other constituents&#x37e; (iii) any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our amended and restated certificate of incorporation or amended and restated bylaws&#x37e; (iv) any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws&#x37e; or (v) any action asserting a claim governed by the internal affairs doctrine. This provision would not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934 (the &#x201c;Exchange Act&#x201d;), or any other claim for which the federal courts have exclusive jurisdiction.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">In addition, our bylaws provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;).  Our certificate of incorporation and bylaws each provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. We note that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Amendment of Charter Provisions</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock, would require approval by holders of at least two thirds of the total voting power of all of our outstanding voting stock.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board of directors and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>3
<FILENAME>phat-ex10_30.htm
<DESCRIPTION>EX-10.30
<TEXT>
<html>
 <head>
  <title>EX-10.30</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THE OMISSIONS HAVE BEEN INDICATED BY &#x201c;[***].&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:13.2pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.30</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="ole_link1"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:9.38pt;font-family:Times New Roman;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;"> AMENDMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">TO THE SUPPLY AND PACKAGING SERVICES AGREEMENT DATED DECEMBER 30, 2020</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:14.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">This first addendum (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">First</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) is made on the date of the last signature of the Parties below (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">First</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Amendment Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">BETWEEN</font></p>
  <p style="text-indent:-7.021%;padding-left:6.56%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(1)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">	Sandoz GmbH</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, a limited liability company organized and existing under the laws of Austria, registered with the commercial register of the district court (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Landesgericht</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">) Innsbruck under FN 50587v, with its registered address at Biochemiestrasse 10, 6250 Kundl, Austria (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Supplier</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;); and</font></p>
  <p style="text-indent:-7.021%;padding-left:6.56%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(2)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">	Phathom Pharmaceuticals, Inc, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">a corporation validly existing under the laws of the State of Delaware, located at 2150 E. Lake Cook Road, Suite 800, Buffalo Grove, IL 60089, U.S. (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Customer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">WHEREAS</font><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(A)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Supplier and Customer have entered into a Supply and Packaging Services Agreement on December 30, 2020 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), by which Customer has entrusted Supplier to supply certain bulk products and to perform certain packaging services relating to certain proprietary pharmaceutical products. Capitalized terms used and not otherwise defined herein shall have the meaning given to them in the Agreement.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.667%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(B)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The Parties now desire to extend the scope of the agreement to the Additional Product (as defined below), as foreseen in Section 1.7 of the Agreement.</font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">NOW, THEREFORE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, in consideration of the mutual covenants and agreements set forth herein the Parties hereby agree as follows:</font></p>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">CHANGES TO THE MAIN BODY OF THE AGREEMENT</font>
   </div>
  </div>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The main body of the Agreement is hereby amended as follows (changed or new wording in italics):</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.1</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The last sentence of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Clause 1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is changed as follows:</font>
   </div>
  </div>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Supplier Bulk Supply and Packaging Services shall be subject to one single ordering and invoicing mechanism for </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">each</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Final Product.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.2</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The first paragraph of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Clause 1.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is changed as follows:</font>
   </div>
  </div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Bulk Products.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> The bulk products to be packaged under this agreement are</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">For the Original Product:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Clarithromycin 500 mg FCT, Amoxicillin 500 mg HGC and Vonoprazan 20 mg FCT</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">; and</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">For the Additional Product: Vonoprazan 20 mg FCT and Amoxicillin 500 mg HGC </font>
   </div>
  </div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(jointly referred to as &#x201c;Bulk Products&#x201d; and each of them a &#x201c;Bulk Product&#x201d;).</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.3</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The first sentence of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Clause 1.6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is hereby changed as follows:</font>
   </div>
  </div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="border-top:0.500pt solid;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Execution Version 2021/12/01		Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of  NUMPAGES  \* Arabic  \* MERGEFORMAT 14</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Phases of Cooperation.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> The cooperation of the Parties hereunder shall go through two (2) phases </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">for each the Original Product and the Additional Product:</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.4</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Clause 1.7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is changed as follows:</font>
   </div>
  </div>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Extension of Scope.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The cooperation of the Parties shall in the first instance be limited to Packaging Services and other services related to the Final Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">s</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to be marketed in the Territory. However, Customer intends potentially to launch the Final Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">s</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> in other regions. In case of such additional launches the scope of this Agreement shall be extended, and the terms modified, solely to the extent necessary to address such expanded scope.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.5</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The first sentence of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Clause 2.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is changed as follows:</font>
   </div>
  </div>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Further Implementation Services. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">In addition to the Set-up Activities covered by the LoI, Supplier shall provide the following services, as further specified in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Annex 3 (Further Im-plementation Services)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">, in relation to the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Original Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Further Implementation Services</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;):</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.6</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The following </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">new</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Clause 2.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is added to the Agreement:</font>
   </div>
  </div>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Additional Implementation Services.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> In addition to the Set-up Activities covered by the LoI and the Further Implementation Services, Supplier shall provide the following services, as further specified in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Annex 3a (Additional Implementation Services)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">, in relation to the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Additional</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> Product (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Additional Implementation Services</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">&#x201d;):</font></p>
  <div style="margin-left:10.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">a)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Procurement of Additional Equipment for Packaging Line and the Additional Product;</font>
   </div>
  </div>
  <div style="margin-left:10.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">b)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Installation &amp; Operational Qualification Dual Pack and Sample Manufacturing; and</font>
   </div>
  </div>
  <div style="margin-left:10.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">c)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Sample Manufacturing Triple Pack.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.7</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The following </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">new</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Clause 2.6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is added to the Agreement:</font>
   </div>
  </div>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Additional Implementation Fees. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">For the performance of the Additional Implementation Services, Customer shall pay to Supplier the following service fees (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Additional Implementation Fees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">&#x201d; and each of them an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Additional Implementation Fee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">&#x201d;):</font></p>
  <table style="margin-left:0.5423611111111111in;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:34.358%;"></td>
    <td style="width:19.122%;"></td>
    <td style="width:46.52%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(222,234,246,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:3.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Work Package</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(222,234,246,1);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:3.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Fee</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(222,234,246,1);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:3.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Invoice Date</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Procurement of Additional Equipment for Packaging Line and the Additional Product</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:3.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Installation &amp; Operational Qualification Dual Pack and Sample Manufacturing</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Sample Manufacturing Triple Pack</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:3.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
  </table>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Upon </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">, Supplier shall issue invoices for the Additional Implementation Fees. Clauses 6.3-6.7 shall apply mutatis mutandis.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.8</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Existing Clause 2.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is now changed to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Clause 2.7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and changed as follows:</font>
   </div>
  </div>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Timeline.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> The Parties intend that all Set-up Activities </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">relating to the Original Product and the Additional Product </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">shall be completed by end of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, except for </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">(i)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">validation of the packaging</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="border-top:0.500pt solid;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Execution Version 2021/12/01		Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of  NUMPAGES  \* Arabic  \* MERGEFORMAT 14</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">process which shall be completed no later than </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">, and</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">(ii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> stability study which shall have an overall duration of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. In the event that any Set-up Activities cannot be successfully performed and completed in such timeline, the Parties shall promptly meet to discuss</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">, in good faith, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">a path forward.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.9</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The first sentence of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Clause 3.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is changed as follows:</font>
   </div>
  </div>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Commencement. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Upon completion of the Set-up Activities (except for the stability study) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">for the Original Product and the Additional Product, respectively,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and subject to payment of the Implementation Fees </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">or the Additional Implementation Fees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Supplier shall provide the Packaging Services and Deliver </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">the relevant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Final Products to Customer and its Affiliates throughout the remaining Term.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.10</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Clause 3.7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is changed as follows:</font>
   </div>
  </div>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Purchase Obligation.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Unless this Agreement is terminated or expires earlier, Customer shall source its and its Affiliates&#x2019; entire demands for </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">each </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Final Product and for Supplier Provided Bulk Products, in each case for sale during the Exclusive Purchase Period in the Territory, exclusively from Supplier and/or Supplier-designated Affiliate for a period of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Exclusive Purchase Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) and Customer shall not, either directly or indirectly, during the Exclusive Purchase Period in the Territory, sell Final Product and/or Supplier Provided Bulk Products sourced from any party other than Supplier.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.11</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The first sentence of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Clause 5.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is changed as follows:</font>
   </div>
  </div>
  <p style="margin-left:6.56%;text-indent:0.114%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Rolling Monthly Forecasts.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Within the first </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">of each calendar month during the Term of this Agreement, Customer shall provide Supplier with a </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> rolling forecast (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Forecast</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) of its requirements of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">each Final</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Product.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.12</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Clause 5.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is changed as follows:</font>
   </div>
  </div>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Minimum Capacity.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Supplier shall at all times during the Manufacturing Phase maintain an annual minimum capacity for the provision of Packaging Services</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">, depending on the applicable </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">cumulative</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> Forecast volume for the Final Products (Original Product plus Additional Products),</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> as specified in the following chart:</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:84.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:39.504%;"></td>
    <td style="width:60.496%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(255,255,255,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Forecast Volume</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(255,255,255,1);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Minimum Capacity</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(as a % of Forecast)</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
  </table>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.13</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Sentences 1 and 2 of</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> Clause 5.6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> are changed as follows:</font>
   </div>
  </div>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Order Quantities.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Each Order shall be for full batches of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">each</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Final Product, and Supplier shall not be required to accept Orders for lesser quantities than specified in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Annex 5 (Packaging Process)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. In the event that Customer wishes to order a quantity of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">a</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Final Product of less than the Minimum Order Quantities or minimum batch sizes, Customer shall specify such quantity in an Order and Supplier shall notify Customer within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">of receipt of any such Order of the revised price for the Final Product to reflect the increased costs to Supplier of producing smaller quantities.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.14</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Clause 5.7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is changed as follows:</font>
   </div>
  </div>
  <p style="border-top:0.500pt solid;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Execution Version 2021/12/01		Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of  NUMPAGES  \* Arabic  \* MERGEFORMAT 14</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Minimum Purchase Quantity.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Customer shall, during each of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, place Orders for at least the following volumes of the Final Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">s</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Minimum Purchase Quantities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; and each of them a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Minimum Purchase Quantity&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">):</font></p>
  <table style="margin-left:0.49236111111111114in;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.676%;"></td>
    <td style="width:61.324%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(255,255,255,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Calendar Year of Delivery</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(255,255,255,1);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Minimum Purchase Quantity</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(255,255,255,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
  </table>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The Minimum Purchase Quantities for later Launch Years shall be mutually agreed by the Parties at least </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">prior to the end of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. In case the Parties fail to reach an agreement by such date, each Party may terminate this Agreement on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">prior written notice.</font></p>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">In case Customer fails to order the agreed Minimum Purchase Quantity in a given Launch Year, Customer shall pay to Supplier the difference between the respective aggregated Price (plus VAT) of (i) the quantity of Final Products actually ordered by Customer from Supplier during such Launch Year and (ii) the respective Minimum Purchase Quantity, unless such failure is directly caused by an act or omission solely attributable to Supplier. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.15</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Clause 7.2(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is changed as follows:</font>
   </div>
  </div>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The artwork, advertising and packaging information relating to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">each</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Final Product; and</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.16</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Clause 10.5 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">is changed as follows:</font>
   </div>
  </div>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Product Recalls.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The rules on recalls of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Final</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Products are set out in the Quality Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.17</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The first sentence of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Clause 13.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1 is changed as follows:</font>
   </div>
  </div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Term.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  This Agreement shall come into effect on the Effective Date </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">(for the Original Product) and the First Amendment Effective Date (for the Additional Product)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and shall continue in force for a fixed term of five (5) years following Launch </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">for the first Final Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, unless terminated earlier in accordance with its terms (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Initial Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.18</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Clause 13.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2 is changed as follows:</font>
   </div>
  </div>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Termination due to Material Breach.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Upon failure of any Party to remedy its material breach of any of its obligations under this Agreement (where remediable) on or before </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">after receipt of written notice of said breach from the other Party the Par-ty giving such notice shall have the right but not the obligation to terminate this Agreement </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">, on a product-by-product basis for the affected Final Product(s),</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> immediately (or such longer period of time as such Party shall determine) by written notice. In respect of a material breach which is not capable of remedy, the non-defaulting Party shall have the right, but not the obligation, to terminate this Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">, on a product-by-product basis for the affected Final Product(s),</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> immediately by written notice on the defaulting Party.</font></p>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">2.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">CHANGES TO ANNEXES</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">2.1</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The following definitions are hereby added or amended in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Annex 1 &#x2013; Definitions and Interpretation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (new wording in italics):</font>
   </div>
  </div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Additional Implementation Fees&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">has the meaning given to such term in Clause 2.6.</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Additional Implementation Services&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">has the meaning given to such term in Clause 2.5.</font></p>
  <p style="border-top:0.500pt solid;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Execution Version 2021/12/01		Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of  NUMPAGES  \* Arabic  \* MERGEFORMAT 14</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">&#x201c;Additional Product&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">means </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">the</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> pharmaceutical product in final packaged form (including with package leaflet and instructions for use) containing Customer Provided Bulk Products and Amoxicillin 500 mg HGC, and meeting </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">the specifications laid down in Annex 5 and/or</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> other specifications mutually agreed upon by the Parties </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">in writing.</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">&#x201c;Agreement&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">means </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">the</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Supply and Packaging Services Agreement </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">between the Parties dated December 30, 2020 as amended by the First Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">&#x201c;Final Product&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> means </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">the Original Product and/or the Additional Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;First Amendment&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">means the first amendment of the Agreement, by which the scope of the Agreement is essentially extended to the Additional Product.</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;First Amendment Effective Date&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> means the date of the last signature of the Parties of the First Amendment.</font></p>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">&#x201c;Launch&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> means</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">, on a product by product basis,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> the first </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">delivery</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> of the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">respective</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Final Product in the Territory </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">by Supplier</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Customer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">&#x201c;Launch Year&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> means</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">, on a product by product basis,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> each twelve (12) month period commencing upon Launch of the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">respective</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Final Product.  The first 12-month period following Launch shall be referred to as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">&#x201c;Launch Year 1&#x201d;,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> the second 12-month period following Launch shall be referred to as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">&#x201c;Launch Year 2&#x201d;,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> etc.</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Original Product&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> means the pharmaceutical product in final packaged form (including with package leaflet and instructions for use) containing Customer Provided Bulk Products, Clarithromycin 500 mg FCTs and Amoxicillin 500 mg HGC, and meeting the specifications laid down in Annex 5 and/or other specifications mutually agreed upon by the Parties in writing.</font></p>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">2.2</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">A new</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> Annex 3a</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">(Additional Implementation Services</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">) as attached hereto is added to the Agreement.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">2.3</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">In </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Annex 4 (Bulk Specifications)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> the term &#x201c;Finished Product&#x201d; is replaced by the term &#x201c;Final Product&#x201d;.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">2.4</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Annex 5 (Packaging Process) and Annex 6 (Prices)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> are amended as indicated in the changed versions of this Agreement as attached hereto (changed or added wording in italics).</font>
   </div>
  </div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">3.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">MISCELLANEOUS </font>
   </div>
  </div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">3.1</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The Parties agree that the Quality Agreement will be amended to reflect the extension of the Agreement to the Additional Product.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">3.2</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">	This First Amendment shall be effective as of the First Amendment Effective Date. It shall become an integral part of the Agreement, to which it shall be incorporated for all purposes. Except as otherwise expressly modified by this Amendment, the Agreement shall remain in full force and effect in accordance with its terms.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">3.3</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Both Parties hereby warrant that they have the full and necessary legal capacity to enter into and execute this Amendment. The signatories of this amendment expressly declare and confirm that they have sufficient representation rights to enter into and execute this Amendment on behalf of the Party which they represent.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">3.4</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">No modifications, amendments or supplements to the Agreement and/or this First Amendment shall be effective for any purpose unless in writing signed by both Parties, whereby electronic signatures, whether digital or encrypted, of the Parties are intended to fulfil this writing requirement and to have the same force and effect as manual signatures.</font>
   </div>
  </div>
  <p style="border-top:0.500pt solid;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Execution Version 2021/12/01		Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of  NUMPAGES  \* Arabic  \* MERGEFORMAT 14</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:6.565%;text-align:justify;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">3.5</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">For simplicity, a consolidated version of the Agreement, incorporating all changes under this First Amendment, is attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Schedule 1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(changed or added wording in italics). </font>
   </div>
  </div>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">[SIGNATURE PAGE FOLLOWS]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="border-top:0.500pt solid;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Execution Version 2021/12/01		Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of  NUMPAGES  \* Arabic  \* MERGEFORMAT 14</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, the Parties have signed this Agreement on the dates set out below:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:49.939%;"></td>
    <td style="width:50.061%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">For and on behalf of</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Sandoz GmbH</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">For and on behalf of</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Phathom Pharmaceuticals, Inc</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Signature:_____________________</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Signature: /s/ Jay Buchanan</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Name:    [***]</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Name:  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Jay Buchanan</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Title:       [***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Title:    </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Vice President, Manufacturing and Supply Chain</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Date:      [***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Date:   </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">December 4, 2021</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:49.939%;"></td>
    <td style="width:50.061%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">For and on behalf of</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Sandoz GmbH</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:24.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">For and on behalf of</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Phathom Pharmaceuticals, Inc</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Signature:_____________________</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Signature: /s/ Larry Miller</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Name:    [***]</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Name:    </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Larry Miller</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Title:       [***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Title:       </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">General Counsel</font></p></td>
   </tr>
  </table>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:49.939%;"></td>
    <td style="width:50.061%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Date:       [***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Date:  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">December 4, 2021</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;" id="novdate"><font id="novdateright"></font><font id="body"></font><font id="datefield"></font><font id="startofletter"></font><font id="addressright"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Attachments:</font></p>
  <div style="margin-left:1.315%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:2.63%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.665045346303896%;">&#x2022;</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Annex 3a &#x2013; Additional Implementation Services (new)</font>
   </div>
  </div>
  <div style="margin-left:1.315%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:2.63%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.665045346303896%;">&#x2022;</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Annex 5 &#x2013; Packaging Process (amended)</font>
   </div>
  </div>
  <div style="margin-left:1.315%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:2.63%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.665045346303896%;">&#x2022;</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Annex 6 &#x2013; Prices</font>
   </div>
  </div>
  <div style="margin-left:1.315%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:2.63%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.665045346303896%;">&#x2022;</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Schedule 1 &#x2013; Consolidated Version of the Agreement</font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="border-top:0.500pt solid;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Execution Version 2021/12/01		Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of  NUMPAGES  \* Arabic  \* MERGEFORMAT 14</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Annex 3a</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">ADDITIONAL IMPLEMENTATION SERVICES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="border-top:0.500pt solid;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Execution Version 2021/12/01		Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of  NUMPAGES  \* Arabic  \* MERGEFORMAT 14</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Annex 5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Packaging Process</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Original Product</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;"> - Specifications:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Additional Product - Specifications:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="border-top:0.500pt solid;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Execution Version 2021/12/01		Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of  NUMPAGES  \* Arabic  \* MERGEFORMAT 14</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Process Flow Chart: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Original Product</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Process Flow Chart: Additional Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="border-top:0.500pt solid;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Execution Version 2021/12/01		Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of  NUMPAGES  \* Arabic  \* MERGEFORMAT 14</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Annex 6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">PRICES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Product Price and MOQ </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">&#x2013; Original Product:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Product Price and MOQ &#x2013; Additional Product:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="border-top:0.500pt solid;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Execution Version 2021/12/01		Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of  NUMPAGES  \* Arabic  \* MERGEFORMAT 14</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">SCHEDULE 1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">CONSOLIDATED VERSION OF THE AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="border-top:0.500pt solid;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Execution Version 2021/12/01		Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of  NUMPAGES  \* Arabic  \* MERGEFORMAT 14</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>phat-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Registration Statement (Form S-8 No. 333-234357) pertaining to the 2019 Equity Incentive Plan, 2019 Incentive Award Plan, and 2019 Employee Stock Purchase Plan of Phathom Pharmaceuticals, Inc., and </font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Registration Statement (Form S-3 No. 333-250014) of Phathom Pharmaceuticals, Inc.;</font>
   </div>
  </div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of our report dated March 1, 2022, with respect to the financial statements of Phathom Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Phathom Pharmaceuticals, Inc. for the year ended December 31, 2021.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> /s/ Ernst &amp; Young</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br>Iselin, New Jersey</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 1, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2266666666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24.1
<SEQUENCE>5
<FILENAME>phat-ex24_1.htm
<DESCRIPTION>EX-24.1
<TEXT>
<html>
 <head>
  <title>EX-24.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 24.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">LIMITED POWER OF ATTORNEY</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">	KNOW ALL PERSONS BY THESE PRESENTS, that each person or entity whose signature appears below constitutes, designates and appoints each of Terrie Curran and Larry Miller, each of whom are officers of Phathom Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;), as its true and lawful attorneys-in-fact and agent, each with power of substitution, with full power to act without the other and on behalf of and as attorney for me, for the purpose of executing and filing with the Securities and Exchange Commission the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, and any and all amendments thereto, and to do all such other acts and execute all such other instruments which said attorney may deem necessary or desirable in connection therewith.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.319%;"></td>
    <td style="width:33.34%;"></td>
    <td style="width:33.34%;"></td>
   </tr>
   <tr style="height:36.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Signature</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Title</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Date</font></p></td>
   </tr>
   <tr style="height:36.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">/s/ Michael Cola</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Michael Cola</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Director</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">February 25, 2022</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:36.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">/s/ Heidi Kunz</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Heidi Kunz</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Director</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">February 24, 2022</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:36.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">/s/ Asit Parikh</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Asit Parikh</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Director</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">February 24, 2022</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:36.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">/s/ David Socks</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">David Socks</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Director</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">February 24, 2022</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:36.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">/s/ Mark Stenhouse</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Mark Stenhouse</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Director</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">February 24, 2022</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">|</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>phat-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:13.2pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 31.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:13.2pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, Terrie Curran, certify that:</font></p>
  <div style="display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">1.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I have reviewed this Annual Report on Form 10-K of Phathom Pharmaceuticals, Inc.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">2.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font>
   </div>
  </div>
  <div style="display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">3.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font>
   </div>
  </div>
  <div style="display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">4.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in exchange act rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font>
   </div>
  </div>
  <div style="margin-left:7.333%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">a)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font>
   </div>
  </div>
  <div style="margin-left:7.333%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">b)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);</font>
   </div>
  </div>
  <div style="margin-left:7.333%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">c)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font>
   </div>
  </div>
  <div style="margin-left:7.333%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">d)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font>
   </div>
  </div>
  <div style="display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">5.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font>
   </div>
  </div>
  <div style="margin-left:7.333%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">a)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font>
   </div>
  </div>
  <div style="margin-left:7.333%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">b)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font>
   </div>
  </div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:74.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.163%;"></td>
    <td style="width:50.837%;"></td>
   </tr>
   <tr style="height:1.45pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 1, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br>/s/ Terrie Curran</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Terrie Curran</font></p></td>
   </tr>
   <tr style="height:27.35pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer and President</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>phat-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:13.2pt;text-align:right;" id="doc_1_7"><font id="doc_1_6"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 31.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:13.2pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, Anthony Guzzo, certify that:</font></p>
  <div style="display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">1.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I have reviewed this Annual Report on Form 10-K of Phathom Pharmaceuticals, Inc.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">2.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font>
   </div>
  </div>
  <div style="display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">3.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font>
   </div>
  </div>
  <div style="display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">4.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in exchange act rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font>
   </div>
  </div>
  <div style="margin-left:7.333%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">a)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font>
   </div>
  </div>
  <div style="margin-left:7.333%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">b)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);</font>
   </div>
  </div>
  <div style="margin-left:7.333%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">c)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font>
   </div>
  </div>
  <div style="margin-left:7.333%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">d)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font>
   </div>
  </div>
  <div style="display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">5.</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font>
   </div>
  </div>
  <div style="margin-left:7.333%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">a)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font>
   </div>
  </div>
  <div style="margin-left:7.333%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.913280887478822%;">b)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font>
   </div>
  </div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:79.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.828%;"></td>
    <td style="width:54.172%;"></td>
   </tr>
   <tr style="height:1.45pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 1, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">s/ Anthony Guzzo</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Anthony Guzzo</font></p></td>
   </tr>
   <tr style="height:27.35pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vice President and Chief Accounting Officer (acting Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>phat-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:13.2pt;text-align:right;" id="doc_1_7"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 32.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:13.2pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:13.2pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18 U.S.C. SECTION 1350</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:13.2pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AS ADOPTED PURSUANT TO</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:13.2pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:7.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:13.2pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Annual Report on Form 10-K of Phathom Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Terrie Curran, as Chief Executive Officer of the company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:13.2pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">(1)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:13.2pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">(2)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font>
   </div>
  </div>
  <p style="text-indent:-7.914%;padding-left:7.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:13.2pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.12%;"></td>
    <td style="width:51.88%;"></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 1, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Terrie Curran</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Terrie Curran</font></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer and President</font></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>phat-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:13.2pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 32.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:13.2pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:13.2pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18 U.S.C. SECTION 1350</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:13.2pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AS ADOPTED PURSUANT TO</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:13.2pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:7.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:13.2pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Annual Report on Form 10-K of Phathom Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Anthony Guzzo, as Principal Financial Officer of the company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:13.2pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">(1)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:13.2pt;min-width:7.333%;text-align:left;">
   <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.333%;">(2)</font>
   <div style="display:inline;">
    <font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font>
   </div>
  </div>
  <p style="text-indent:-7.914%;padding-left:7.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:13.2pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:82.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:43.969%;"></td>
    <td style="width:56.031%;"></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 1, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Anthony Guzzo</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Anthony Guzzo</font></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vice President and Chief Accounting Officer (acting Principal Financial Officer)</font></p></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.12;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:7.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img45497886_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45497886_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )W!-L# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]FE;J^O?Y'RU\>OBEI_C#]G?X-:'X(TS4M*\%ZEJ%Q;7>BW6I$N9()(PMO\
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M,26"G$:@DE:]Z^+W[&O@'XP>*CXGNFU?PYXBD"K/J7A^[%O)<*!@"0,C*<
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M=:_^1*.678/:1[GHU%><_P#"]O#/_0/\8?\ A$ZU_P#(E'_"]O#/_0/\8?\
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M_C'_ ,(G6O\ Y$HY9=@YX]ST.DKSW_A>_AK_ *!_C'_PB=:_^1*/^%[^&O\
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MHY9=@YX=T>B=^*4YKSK_ (7MX9_Z!_C#_P (G6O_ )$H_P"%[>&?^@?XP_\
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M1[H]$^M+]*\Z_P"%[>&?^@?XP_\ ")UK_P"1*/\ A>WAG_H'^,/_  B=:_\
MD2CDEV8N>/='HM+7G/\ PO;PS_T#_&'_ (1.M?\ R)1_PO;PS_T#_&'_ (1.
MM?\ R)1RR[![2/='HU%><_\ "]O#/_0/\8?^$3K7_P B4?\ "]O#/_0/\8?^
M$3K7_P B4<LNP_:1[GHU%><_\+V\,_\ 0/\ &'_A$ZU_\B4?\+V\,_\ 0/\
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M8?\ A$ZU_P#(E'_"]O#/_0/\8?\ A$ZU_P#(E'++L/VD>YZ-17G/_"]O#/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:7J<"W-O))XQC5C&W()4VV0>O'M6D:4I7:Z>:,Y58QM?J?1-%11Y5%R #CD
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7='L/#_PYU'3-,LH-.T^UTR:*WM+6,1Q1*(VPJJO  ]J^?/V9OAS\0[WX+^
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MAN%,8N85DV;GEW8!SC./K6A\-='N-)U/6],\-W4)TZ&]D-PGG*^Q\LH48&5
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ML 5[AXT^#_A/Q]J46H:SIDDFH1PFW6\L[R>TG,1.3&SPNC,O^R21R?4U-?\
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MG+%O-CMV<Q(P))RJC':NK^TJ:?6WSOZ?%=+YM>1Q?V75:Z7]=/RLW\K^9@>
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MKEWK'Q2\1>%KUO$6JAM-TWQ>^GPH!=R ,(0PQGKGN3GO7L/[1#6EQX1^%_\
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M7%VDK,Z(SC-7B[H=12"EI%A1110 4444 %%%% !1110 4444 %%%% !1110
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MG'-+3 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH
M6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH
M6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 1N*0_=/TI6S36X!J7L!\E?\
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M;_T&R_'_ ##^W,%_T!0_#_Y$^3?^%W>-O^@V?_ 6#_XBC_A=WC;_ *#9_P#
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M7\J/["QO_0;+\?\ ,/[<P7_0%#\/_D3Y-_X7=XV_Z#9_\!8/_B*/^%W>-O\
MH-G_ ,!8/_B*^LO+3^ZOY4>6G]U?RH_L+&_]!LOQ_P P_MS!?] 4/P_^1/DW
M_A=WC;_H-G_P%@_^(H_X7=XV_P"@V?\ P%@_^(KZR\M/[J_E1Y:?W5_*C^PL
M;_T&R_'_ ##^W,%_T!0_#_Y$^3?^%W>-O^@V?_ 6#_XBC_A=WC;_ *#9_P#
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M7\J/["QO_0;+\?\ ,/[<P7_0%#\/_D3Y-_X7=XV_Z#9_\!8/_B*/^%W>-O\
MH-G_ ,!8/_B*^LO+3^ZOY4>6G]U?RH_L+&_]!LOQ_P P_MS!?] 4/P_^1/DW
M_A=WC;_H-G_P%@_^(H_X7=XV_P"@V?\ P%@_^(KZR\M/[J_E1Y:?W5_*C^PL
M;_T&R_'_ ##^W,%_T!0_#_Y$^3?^%W>-O^@V?_ 6#_XBC_A=WC;_ *#9_P#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHII/-074QMX)I!&TQ12PCCQN; S@9.,FIE)15V.URQ17+^!?'FG_ ! TE]0L
M%FC2.5HGCG4*ZD 'D D="#U[U'X=\?:?XF\1ZOH]E!<M)I;;9[A@HB+$XPI!
MSU#=0.E<D<;AY*FU+X_A\S9X>JN=./P[^1UM)3%Y]S2<+WZ5V71@2TE-^AI
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH 3WHI:* &_Q=:!3J* $I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH :V#FFLHP0:DHH\@/G[3]:7X1>/?&=C.-ME=
M6S:C9J3P6&3M'N2S#_@%4+#4]3^'WP;@U&S?RM8\0WP=KEL$H'R0W.1R%_\
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M"L3CY@,]?6KDWP0U6_32!?\ B][PZ7-&]JIL56-47!P5# D\*-V>!VYKKO\
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MFP[EN956W*9)9EV@A>0:]1_9/C5? 'B!@H!_X2O6UW =0+^;%92IPITVUO\
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M.<C%4M<^)?A+PS=/;ZQXHT72;B-XHGBOM0BA</("8U(9@06"L0.X!QTKY/\
M%7CSPW=?LE_!;2K?7+";4YKKPY EG'<(TV^*2'S04!R-FT@\<' ZD5Z;X9\!
M^'?%G[6GQ/O]:T6QU>ZT_2M&%H]];I,8-ZSEF3<#M.8TY'/%)T(Q3;Z7_-%+
M$2DTHK>WY'KFK?%CP5H$@CU3QAH.G2?:6LPMWJ<,1\]0I:+#,/G&Y<KU 8>M
M=;'(LT:NC!E89# Y!'UKYG^%7@'PWXAU#X_WFJ:#I^HW5QXFO+.6:ZM4D9X5
MM8&6/)!.T,[''J<UZ+^RO=37O[.?PYFGE::0Z);+YC=2 @ _0"LZE.,5=/M^
M1K3J2DTFN_X'JU%%%<YTA1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 445PWB[QG>6GCKPQX8TDQM>WLC7=Z9%W"*S0'/<8+,, ^H- '<T4@I: "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 86.XBDW5)24
M@&XXSWI,;03BI**8AAQ0,=*=2T>@R, !B>*,^G-/HI6 8!\QY_2C(Z5)246T
ML RCGUQZBI**8$?/;\:0@-UJ6DI6%892YXXI]%,?D-!^6EHI#]* .9\0_#7P
MCXKU:VU/7/"NBZSJ-J +>\U#3XIYH<'(V.ZDK@\\=ZU;_0M.U2>QFO=/M;N:
MQE\^UDN(5D:"3:5+QD@[6VLPRN#AB.]:-'-.[[DJ*[%'5M'L/$&FW.G:G8V^
MHZ?<H8Y[2[B66*53U5U8$$'T-<;8_ 'X8:?=PW-M\./"5M=02+)%-#H=JKQL
MO*LI"9!!Z$<BO0.:/PH4FNH.*>MCB=9^"'P[\2:I<:GJ_@+PSJNI7+;I[R]T
M>WFFD;&,L[(23@ <GM6_X=\+:-X/TM=,T#2+'1--C9F2STZW2WA4L<L0B  $
MGGIWK7YHH<F^H**6R.6O/ACX.U#Q!+KEWX3T2[UN5/+?4IM.A>Y9=NW:9"NX
MC'&,]/:M#3_".B:3<V5S9:-I]G<65F-/MI;>UC1X+8$'R$(&5CRJG8,+\H]*
MV>:.:.9]PY(]C,L]!TW3KC4+BTTZUMI]0D$UY+% J-<N%"AI"!\YV@+DYX K
M#T?X4^"?#]QY^F>#= TZ?[0MV9+33((F\]=P67*H#O =\-U&\^IKK^:/PHYG
MW#E6FAGZMH>GZ]';1ZE86NH1V\\=U"MW"L@BF0Y210P.'4\AAR#3==\/Z7XH
MTN;3=8TVUU;3IAB6SOH%FBD Y 9'!!YQUK2YHYI78^5'-6?PY\*Z;X9F\.6G
MAG1[?P[-GS-)AL(DM'R03F(+M.2,\CDUIP>']-M-2O=0@TZTAU"]2..YNHX$
M66=(P1&LC 98+N; .<;CCK6ES1S3YGW%RKL<SX9^&_A+P7>7-YX>\+Z-H-U=
M#%Q/INGQ6\DHSGYV106Y)/-:VDZ'IV@6[V^F6%MIT$DKSO%:0K$C2.Q9W(4#
M+,Q))[DDFM#FCFCF;!12V.=\6?#WPMX\6!?$OAK2/$*VY+0KJMC%="(G&2HD
M4X)P.GI5V_\ #>DZGIT.G7>EV=WI\+1O%:3VZ/%&T;!HV5"" 58 @CH5&.E:
MO-'-',^X^5=BO=6L-]:S6T\,<]M,ACDBE4,KJ0000>"".,'K6=-X3T2?1;31
MY-&L)-(M3%]GT]K6,P0^408MD97:NPJI7 &-HQTK9HYI7"W<YOQ7\/?"WCQ+
M=/$OAK2/$*6Y)A75K&*Y$1.,E?,4X)QVJ7Q!X#\-^*])ATG6_#^E:QI<)4Q6
M-_91SP1E1A<(RE1@<# XK?YHI\S[BY%V.8'PT\)+8WEBOA?1EM+V"*VN;?\
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M@ HHHH **:R[NM-Z"D!)13:6F M%(.*6@ HHHH **** "BBB@ HHHH ****
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MO1<#THVCTHO'L%I]U]QYU_PT9\*/^BF^#_\ P?6O_P <H_X:,^%'_13?!_\
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M!2T44B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9(%_=&WTXWDRKY@1L-L8@!B"W/ &3Q7JO_"%Z$^J7&I-I%FU]<A?/G:%6:7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@L-1BDE!)+R.,D^%/A>;P W@I],W>&9$:-K)IY?F!?S#^\W;\EB3G=FM#5_
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M =H(&17:YI3]*/;56FG)V?FQ_5Z*:DH*ZVTV$3[HIU,I?3M6!T#J*;30>@H
MDHI@Z44 /HIM%,!U%-]**0#J*2EI@%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% "&BD--;N>U+R \X\??L\_#WXE:X-9\0>'8Y]7"
M"-K^SN9K*X=. %DD@=&=>!@,2!BM[P[\,O#'A'P>WA70]$M=+T"2)H7L[52@
M=67:Q8YW%B.K$[CZUPWP>_:"TCQ?X1TB;Q3KOA_1O$VI7=Y;P:7]L2"2=8KN
M:!#'%)(78D1#.,Y.<8Z5Z3XH\8Z#X'T\:AXBUK3M!L"XC%UJ=W';1;CT7<Y
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MM^^Q.<9[9Q7->.OCQX0\%_"W4O'::SI^L:-:QL8'L;Z%UNY0#B&-]VUG)!
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MDA7/.*C\1?'RR@UWX92:-J6B7GACQ--?+?ZFMP)8H4@M'F)297"+M="&+ X
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MO?YK?(]=7A<4M(O2EKZL^;"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"'P\73;ZZ:]B;4+G2W5_-M$P["XD3[\A\MFP3D8.<9 /<:/X7\/_ !6_:?\
MB=XA\2V5OJVB^$K*"QAM]0C66!7V,9&*-D':5EP"" 7SP0*PEEM*,>=RDERM
MZK7XN5=>IO#-J\GRQC%N]KI_W>9_<?4>B^(--\3:9%J&E:A:ZI82Y\NZLIEE
MC;!P<,I(/IQ56W\9:#>6^IW$&MZ=/!I;NE])%=1LMFR EUE(.$*C.0V,8YKP
M;]BNW;1O@+JFN+!LM]1U*]U&WM8P0$C7"!%'89B/%>$:'\4M \/_ +(?BBU7
M5;6?QCXMU*X,NFQ3A[D&64*Q9.2H\M2<D '..]3'*G4K3IP=^62C]_7Y6-IY
MM[.C3J35N:+E]VWWGW0WQ$\+0V^G3-XCTH1:DCR6+&]BQ=(@R[1'=\X Y)&<
M=ZL^'O&&A>++%[S0]:T_6;2-MCW%A=).BMZ%D) -?)UE\-M,\7?M > O FJV
MRZAH_@GPC%/<V=PNZ*6<[1AQT.2T;$'KMP0037FNMS3:-\,_C?K'AH+I'AW4
MO%$&B[=.3RXH;:-GWD*H 56#HI ZAL8P<5K#*:52T8U&F[/R]Z5EU[:G-+.:
MU-N4J:<=5]RNW]^A]6_&K]HC3/!?PSUS6_"&K:+X@UJQG@MEM8[A;E4D>4*5
MD6-PP.-^.1R/P/H%YXVTSPCX?TV[\8:QI6A7,\:+(]W=);Q--M!=4WMSSGC)
M.*^//B!X8^$_B+X@?![PI\/(-*O;L:@DM]/I91M]JFUG6>0'+N0A/S$L,-TS
M@XWCO7=0USX]_$34=;N? H.BL+&UT_XA-,R);@$AK:%,ABX7<< M\XQUYZ/[
M+I3IQ4;IV<G=:[J*5O74YI9O7ISE.23VBK/W;V;;_)'W5>>+]#T_0?[<N]9T
M^UT4JKC49KI$M]K$!3YA.W!) !SSD52D^)GA"%=2:3Q3H\:Z8$-\S7\0%J&.
M%\T[ODR>!NQGM7Q+?^&;ZU_9[\&^#FU6"XA\=>+DEM!IT4\<$%FY&51)T5]H
M?#C(VG(.2.3[[\:/@_X7\!_LU^.M-\,Z);Z7$VGK+*8DR\GDD,"['+,0 >3S
MUZ5P3R^A2E&#FVY2LM.B:5]_4]&GF6(K1E.,$E&-WKU:;M^1[7=>+M"L=2T_
M3[C6;&"_U%2UG:R7*++<@<DQJ3E^/3-,C\:>'Y;K5;9-<TY[C2@&OXENHRUH
MI!(,HW?N^ 3\V. :^!-8\=:A')X/^-%_#*;*SNDT?1[/&$:*&TD$C>PDG+#/
M4!3Z"O0M5TS1_AA\,_#?AOQKH<6O>+OB!?/JVJ/J>IOIMI'/D./M$R?PIYBC
MRP"&8-CDJ#U5<E5%1O.[?1=U?F^Y+7S.6EGDJKDU!)+J^SM;[V_N/J[2_B7X
M1UZQO[W3/$^CZA9V">9=W%M?Q21P* 26D96(48!.3QQ5J?QMX>MO#8\0S:[I
MT>@,H<:H]U&+8J6V@^9G;@GC.>M?'7P)\-P_$'XU?$1;:V\,V>EV_AMM)D7P
M@C"PE:<@[E) #D;7!.T?=%9/P%6]^.VC^!OAK/!+_P (SX2>;4/$32*0L\OG
MR_9[?CJ,'./0'NHJ*F40CS2<W:/*WY)IO[^GS*IYU5GRQY%>5TO-II?=_D?>
MMG=0WUI#<VTL<]O,@DCEB8,CJ1D,"."".0?>IJ9&NR-5'0# I]?->A]:KVU"
MBBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 WO2-]TC
MVIW>HV^E'43/BC0O 7AS_AA?Q[K!T2P?5)AK=\]\]NK3>?#=7 BD#D9#($7:
M1TQ]:W/'!U[4OVC/"#W.H>&;,2>#XI-%G\8V+W=NUR9?]*$ 6:("XVF$DC)*
M>@S7U''X1T&'P[/H,>BZ<FB3K(LNF"T06T@D):0-$%VD,68MD<DG/6F>(O!'
MAWQ?I,6E:[H&EZSI<>UDL=0LX[B%2!@$(X*C X'%=WUC5MK>_P")P?5M$HO:
MWX'QY;MH7A_3=7M;B?P[XYAU?QQ90V>FZ7]HTCP[8ZJL#.Q>1FF5T.U6:-2X
M,@V[0U:&@ZE<77QP^*<=Q<>&'O%^'[_:X/"9<P)(LC[5F9OORJK==JX5E&.]
M?6<G@3PW<>&%\.2^']+?PZ$$8TE[.,V@4'(7RMNS /;':J^E_#7PCH<:QZ;X
M6T;3T2VDLU6UT^&/;!(07B 5?N,0"5Z$CD4?6(V>@OJTKK4\G^ OP]\/>&_V
M7]!NM)T*QM-0U#PI#+=74%JBSW#O;!R7<#+'<Q/)->3>)+KPM=?L7_!O^VYK
M6;P^FHZ NJC>"BQAE$@DV]@ =PZX!K[+T_3;+1]/MK"QM(;'3[:)88+6WC6.
M**-1A455X"@8  X %85I\,_".FV<MI:^%=$MK26[%^\$.G0HC7(Z3D!<&3_:
M//O41KI-MWWN:2H-JRMM8\8\41>%I/VC/A'_ ,(0VFKK(AO3J/\ 8ICQ_9(M
MCM$WE\>7YIAV;N,GY>]>3VOC+0M!_8!\6:)J&L6-IK$9U;3WT^:X1;@7+WLY
M6+R\[MQ!!QCH<]*^Q_"_P_\ #/@C[1_PCWAW2M!-TP>?^S+&*W\UO5MBC)]S
MFJ>H?";P1JFK7NJWG@[0+K5+Z)H;J\FTR!YIXV7:R2.4RRE1M()P1Q5*O%63
M3TM^%_\ ,EX>3N[[W_&W^1X==>"]"\;?M)?#Z#7M)M-9MK7P#-<Q07\"S1B3
M[1 F[8P(R%=N<=ZV/!G@GP]JW[5'Q1EOM%L+I['1M&MK7S[9'$$3QW =4!!"
M@A%! [ 5[C'X?TN'4X-2CTVS74(+8V<5XL">:D!(;RE?&0A*J=H.,@4^UT/3
M[+5;O4H-/M8-1O%C2YO(H56:=8\A [@98+N. <XR<=:S]OH[=K?B7&AJK]SY
M[^#^IZ?X5_9B\>R7EK<2:%HU_P"(HQ8:<QB=;6.YG_=0E""F%R%P1C\*\NU+
M41;ZY\ (;>S\#>'K'^WK%M+TS0+Y[W45M6A<,7G"HI3:RA\*P9F4[O7[5TO0
M=-T6SDMM.TZUT^VEEDFDAM8%B1Y'8L[E5 !9F)))Y.3FN?TWX0^!='9FT_P7
MX>L'>XCNV:VTJ!/WR-N27(09=3DANH/-:*M'FDVMR)49-1L]CY*\<KI?A+1O
MB3JUC>>"O'GA.'7KG4-<T7Q'%-INN078DR88;@')8,/W3% 2" I(Y/2?$"QM
M;CQS\2-4T36/!VH37EE:2>(O"_Q LY;::W@6V7;Y%T"&",A'.UU5P?F!)Q]/
M:A\-_">J^)(?$5YX7T:[\0P;3%JDUA#)=1E?NE92I88[8-'B7X;>$O&EY;7G
MB#PQHVN7=KC[//J5A#</#@[OD9U)7GGCO3^L*^W]:?Y$O#2MN?-OP\USPUXH
M^+7@#5_$VFV^B:-=> [63PGI>KRK+#;RF3_24B>3[\PC^S@-]XQY/0FN8\6+
M;)X/_:"F\&[W^'@UC2_M,>BG]R4 B_M?R-G',9^?;U(;WK[#\4>#=!\;Z<-/
M\1:)IVNV(82"UU.TCN8MPZ-M<$9Z\XJWI.BZ;H.E0:9IFGVNGZ= GEQ6=K"L
M4,:_W510 ![ 4+$)/F2_JX_J[:Y6_P"K'D37GP@@\6_#<Z):Z7<ZW,9$\/GP
MV$!CMS _F,WE,,6X3KNRNXKQG%>&_#_6+"/P;\*-*_L'2]7\1S:IXDN]+G\0
MZD]IIUJT=[,)'=55_.EVN JA<CYF!7FOKCPS\-O"7@F\N;OP]X8T;0KJZ&)Y
M]-L(K=Y^<_.R*"W//-)J/PQ\'ZMH$>A7OA71+O1(Y6G33KC3H7MDD9BS.(RN
MT,69B3C)+$]ZF-:,=+/^K_YE2HREJM/Z7^1\9)>-J?PY_:OQ<Z'>[8K>1SX;
M1OL F^R$2F,,3E@5P[=V4GCI7H?QZEEU/Q?\$C:7_AR+PN_VKR[GQ! UWI(U
M'R$-N)%22,&0KYWE[F^\3@;L5]):;X%\-Z.EREAH&F6*74"6LZ6UG%&)H4!"
M1N HW*H9@%/ #$=ZCC^&_A6#PJ?#$7AC1X_#9SG1TL(A9G+;C^YV[.6YZ=>:
MN6*BW>VG_ L9QPDDK7_J]SXU^(.BW,%O\5;F/Q+H.IK)8:8GBG2_!.DW-M;I
M;?; 9II'\Z5?.^S^>&56#^6,D=Z](^+#?#)_B1\"CX<?0GUW^WH19G2?*+?V
M>()@W^K_ .6>[R\9XSG'>OHWP[X1T/PCI0TS0M&T_1=,#,PLM/M4@A!/4[$
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MEA9TT]Y$)'(.&56_ 5[ZWAG1VO=2NFTNS-UJ42PWLWV=-]U&H(5)&QEU4,P
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M921SZ5TU)1[2=[\VI/L::7+RJQC:AX9T?5+W3KV[TJSNKO326LKB:W1WM2<
MF-B,H3@<C'05=U#3[;5;&>SO;>*\M+A#%-;S('CD0@@JRG@@@XP>.:N4M3S2
M[EJ$4K)'-S> /#%YI.GZ;-X=TJ73M/<26=H]E&8;9AG#1J5PA&3@J!UJSXD\
M'Z#XPMHK77M%T_6K:)_,2'4+5)T1L8W ." <$_G6W15<\][D^RIVMRH\T\>>
M#M>TBQEN_AEI?A73?$MZR0WE]JT#QA[=$*J,PKN9E^7:&.T 'BE^!OP?M/@S
MX-_LQ9EO]5NI6NM2U#8$-S.WWCCLHZ =@/>O2J2MGB*KI.C?1VOYVV^XPCA*
M4:JK6U6WE??[P6EHHKF.P**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** &FF/D!J?ZTV13AOI2ZH3V9\0_#*Y\%>*M-UN]\<?'C7_#V
MO+KNI0'3O^$^:Q$4*7,BQ 0M+E1L _"O>O$_QX\/_"&Y\/>$(M/\4^-=4N-(
M6[L/[)@_M*YOH494+M(7&YR/G+L0I&3G. ?&/A'KNA> =%UK2_%GP;\6:OJY
MU[4KC[9%X*ENTDBDN9'C82F/YAM(YKU?1;>Y\0_M%^%/$]MX?U33-$;P1<0H
M;[3WM_LLK7<#+!(",1R;5/R$@X!KT:BBY/L>;3E)15GJ;VO_ +0=AH^L1Z-8
M>%/%'B77DL8]0O\ 2]&LHI)=-CD4E%N&>58TD;#8C#ECM. 1C,US^T1X2_X0
M+3_%5DVH:O%J-Y_9EGI=C:,;^6]RP:V\E]NR1=C[@Y4 *23C!KCUU2_^!_Q=
M\?ZEJ7A3Q!KVC^*Y+;4;+5/#^F/J#I)%;K"]K,D8+QX**R$@H?,;E2#GD&^'
MNH6_PEOM5\3?#S4M4.N>,;CQ)/I6DW9BU;0XI"1%/#Y)W/.@5&9$8']XPYP5
M,>SIZ?(MU:BO\SNO&WQLT'Q)\)?B!+J4'C+P;/H$*?VG:VJI::O:JY!CD@D#
MM$=P!PRN1@'.*]%\*?$S2_%&N>*=%CAO+*]\-S10W@OE1=Z21"2.9"K',;*3
M@G!RK<<5\OZYH'CG6O@U\8-*TZ/QUX@\)3:9;IHD/B^U9M6EN_,8W"Q(46X:
M(+Y6#*N<YVY )KM?VBO!/BE/%5E<>#].O;C_ (3?2U\):S<6L+.M@AE4QWDF
MT?*$B>Z4L>.4'%7[*GM?^M"?:U%K:_R]3N(?VH/#VI:+X:NM(T+Q%KFH^((I
M;NPT73K2)[PVL<A0W4F9!'%$Q"[6=QG>H SD#M?AM\3=)^)VDW=WIT5Y87=C
M<&TO]+U.'R+NRF"@^7+'D@'#*002"#D$UX+\4/A2?!_Q:T?7VT_QE<^#'\.P
M:"/^$'NKI+FPE@D8Q^;%:LLCPLCD94-M91D#.:]!_9S\*1Z:GB?74\.^(-!3
M6+J$Q3>*=4FNM2O8HH@J2S)*6:#JRJA8MM49"]*SG"DHWBS2G4JN=I(\:^W>
M&/$7Q<^*UOXW^-&N>"FT_6EM].T^'QFVEQK ;:)BR1,X&-S'D#&<UVWP3^-C
M>&/A/XDUCQ1K6J>)] L?$,VE>&M6EMS+?ZY"6584B5 #<.9"Z!U W;23@*35
MWP#\&=*\7>-OC6GC'P?#=V6J:ZOV6;5+#_70&TB4O#(Z] P/S(>".#D5Y[K/
M@'QUK'PQT[P_J>G^)-3O?AKXK1UFL9);6\UK2 CK'+:W&Y \ZQ2X(5\YB()R
MP%='[N?NM]OR.;]Y"\EY_F>W6_[0D.I?VIIA\(>)M&\4V]@U_:Z%JEO;Q7%[
M"" TD#>>87VEAN4R!AZ=*\#^".N>([K6O@9KU_K/C3[1XHGO'U)-9UKSK*_Q
M833!X($E9$BW,,*40CRU^48S7=> _"EEXA\>Q:QIGA?X@2VVDZ9=JNL>.M2O
MU:*::,+Y%O:W19Y"PSN<!5&Q0"QXJG\._!?B"ST7]EY+G1-2@?2(;H:DLMI(
MK61.G2H//R!Y9+$+\V,DXY)HA[.,;=_\F$W4D[]O\T>N6G[0'AZ^^"-_\3UL
M]370+.*YEDMVBC%T5@E>)\+YFW)9"1\XXQG!XK2O/C1H.D^+-$T'4X[O23K6
MG/J-CJ-VL:VDNP;I(=^_(E5/G((QMY!.#7S!>-XG\+?LN^,/A'_PKWQ;J7BB
M,:E#'-9Z6SV4T,MQ+.LT=QG8_P CC$:DN6^4+FN]^.GPZU[X\:7X7^%]IILV
MDZ=:Z<FJZCXBOK%C%!,L12"VA++AG9R3(!RL893][%9*C"_O/2[^XV=:I;W5
MK9?>>[?#GX@6GQ0\*V_B'3+&_LM+NW?[&^H1K&UU"#A9T4,2(WZKNVL1@[0"
M"? _"?P[O/B]\4/BVVI>//'.E0Z3KRV5E;:+XAN+2WAC-K$^%C4E?O,>V/:O
M:O@QXDU3Q-X!L6USP]/X8UJPSI][ISV[10B6+Y2UOD8>%L!D921M(&<@UXMX
M3^(EW\(?BE\6UU/P'XXU6'5M>2\L[K1?#UQ=P31BUB3*R*-OWE/?'O64%;VB
MB:3=_9N1#>>.]2\ ^'OBUX$\<>)O$>H67ABQM-0L?$FCR11:R]C.<!?,X4S(
MZ,N\X+ DFO4?%?[0VD^%=<U72K;P]XE\3?V+#%-J]WHMFDT6GJZ;P)"TBEV\
MLARL0<@=LUXKXY\ ^,?''PW^-_CG4?#&H:=JOBC3[73]%\.8-Q?):6YRID2(
MMB21G9C&,E<8]36M\6M!%K\0-?OD\,?$/PUKEQ;V[V/B'X?2SW$.L%(P$CNX
M54Q1NC97]ZH!7^/&,=,H4Y>O_#?\$YXSJ1].GXGL7B?X]:#H;^'K;2]/U?Q;
MJNNV@U&RTO0;99+@VF%/VB3S6C2*/YE7+LI); R<U3C_ &D_"3>#I-<DBU2V
MNX=131W\/S61&IK?O@I:^3GEV!R"&*%?FW8!->)ZYX!\7:?XO\)>,_B!:>,+
M]M0\+6VE:Q)X%N[A+FSU"-V<M-%9NK21N)&R8PZJZ] "#5B'1_$_ACPM?^(O
M"OACQEH-GK6O6BZG?WLSZOXCDTV.%D^TK;7 D:-P[*@0[Y%C&=@( $>RI[)E
M^VJWNT>UZ!^T%H.HS^(;36=.UCP=J.@V']JWMGKT$:R?8_F_TA#"\B.F58?*
MQ((QBF^"_P!H+2_%WB#2])N/#7B;PU)K$+W&E7&M6*1PWZ(I=MC1R/L8)\VV
M4(V#TZUXAX)\,ZSJ7Q:\::E'X6\8>)-*U#P3+96S>/6: :I,)\M 24Q:JX<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:_\ QRCEEV#GAW1Z(HI>*\Z_X:,^%'_13?!__@]M?_CE'_#1GPH_Z*;X/_\
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M^[]"2BDI:Q.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBO05/RT^BLISE4=Y,Z(4XT_A0@I:**@T"BBB@ HJO=31VL,LTK;4C4NQP3@
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M **** "BBB@!&JGJVHII&FW=[*K-%:PO,P0#)502<9(&>/6KE8GC;CP=KO\
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MZ#+?^ LW_P 17"?\,OO_ -#(/_ $_P#QRC_AE]_^AD'_ ( G_P".4OK6?_\
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M*_Z#+?\ @+-_\17"?\,OO_T,@_\  $__ !RC_AE]_P#H9!_X G_XY1]:S_\
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M?_"]/!7_ $&6_P# 6;_XBC_A>G@K_H,M_P" LW_Q%<)_PR^__0R#_P  3_\
M'*/^&7W_ .AD'_@"?_CE'UK/_P#GQ'^O^W@^JY!_S_E]W_VIW?\ PO3P5_T&
M6_\  6;_ .(H_P"%Z>"O^@RW_@+-_P#$5PG_  R^_P#T,@_\ 3_\<H_X9??_
M *&0?^ )_P#CE'UK/_\ GQ'^O^W@^JY!_P _Y?=_]J=W_P +T\%?]!EO_ 6;
M_P"(H_X7IX*_Z#+?^ LW_P 17"?\,OO_ -#(/_ $_P#QRC_AE]_^AD'_ ( G
M_P".4?6L_P#^?$?Z_P"W@^JY!_S_ )?=_P#:G=_\+T\%?]!EO_ 6;_XBC_A>
MG@K_ *#+?^ LW_Q%<)_PR^__ $,@_P# $_\ QRC_ (9??_H9!_X G_XY1]:S
M_P#Y\1_K_MX/JN0?\_Y?=_\ :G=_\+T\%?\ 09;_ ,!9O_B*/^%Z>"O^@RW_
M ("S?_$5PG_#+[_]#(/_  !/_P <H_X9??\ Z&0?^ )_^.4?6L__ .?$?Z_[
M>#ZKD'_/^7W?_:G=_P#"]/!7_09;_P !9O\ XBC_ (7IX*_Z#+?^ LW_ ,17
M"?\ #+[_ /0R#_P!/_QRC_AE]_\ H9!_X G_ ..4?6L__P"?$?Z_[>#ZKD'_
M #_E]W_VIW?_  O3P5_T&6_\!9O_ (BC_A>G@K_H,M_X"S?_ !%<)_PR^_\
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M&[E68("V%&2<#/%?.]U^VEHUCJ]MI5Q\/_'T.IW09K>RDT9%FF5<DE$,NY@
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MW8!R]Z,TF?QI/H,&F ZDKB_BQ\5-)^#_ (1E\0ZQ%=75JLT=NEO8HKS2NYP
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M[%/AW5?$^M:Y;RZAHMC;37NAL#J,\DC1QJD3-QYDA(4L2/ODY4\CC?"ND_\
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M\LK@C/4DU/XC^!G@KQ=I.B:?JNDRW":*,:?=K?W,=Y;Y7:VVZ203?,,;LO\
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M4M% ";11M%+10 FT4;12T4 )M%&T4M% ";11M%+10 FT4;12T4 )M%&T4M%
M";11M%+10 FT4;12T4 )M%&T4M% ";11M%+10 FT4;12T4 )M%&T4M% ";11
MM%+10 FT4;12T4 )M%&T4M% ";11M%+10 FT4;12T4 )M%&T4M% ";11M%+1
M0 FT4;12T4 )7BOQD^%VN^-/%5O?:;%"\"6BPDR2;3N#N<?3##FO:Z*X<;@Z
M>.I>QJWMY';@\74P555J5K^9C^#]-FT?PKI%A<8$]M:10R!3D;E0 \_45L44
M5V4X*G%06R.24G.3D^H44459(4444 %%%% !1110 4444 ,:OFC3U7QE^W!J
MLXW26OA+0%@&/NI/*0<=.ZROT_N^U?2TBEB<=<5PO@?X1Z5X%\8^+?$UI=7U
MYJ7B69)[LW;HRQ[-VU(MJ*0H#XYSP!S7?A:\:$:C>[BTOG:_X7/,QN'GB)4D
MME)-_*_ZV/GG1I/%/[0VG^./&MW\0-6\$:%HEQ=6NE6.C7/V=$$*;C+<,.7'
M0D'!^]R!BL(_%/Q[\3?A[\%-%@\076A>)?$&J7'G:O;2&,R06S%=[(.'!4YV
MGY6*<]1CV35OV.O!>J:UJ%U'J7B'3=+U*?[1?Z#8:B8K"Z?.XEX]I/)QT88P
M,8KCO%7P1B^(7[15CHSZ1JNA>#/#?AM8M/U'31+;)#<^8"A@F VEU5O4\H>*
M^CHXK!3;2VCJO=6GNVM_>NW?Y'R]7!XZFE?>32?O/WKRO?RLE8E\)WNM?"G]
MIZ/P8WC/6_%7A_4-"DU&\&NW/VAK.12Y#*P "+\F,<#Y^YQ7DNF^)-;M?@'K
M.MZ-=SZ9XB^(GC?RK6ZLI6AG\LR9 5E8'&]77KT<^M?4G@K]FOPSX)L?$BQ7
MVL:CK.OVSVM[KVI70N+YHV4KPY7:",\?+R5&<X%-M/V9_"UGI7@#38[C4_L?
M@VZ>\LHVEC/G2L^_=-\GS$-R-NWJ:YHYAA8NUK_#?1:\MWMZV7HCH>6XN2NM
M/BMKMS-+?TN_F>875GXD^*7[2'B?PU8^-M>\/^$_#>C6]K=G2[TI)+*ZA@06
MR%DR3F3&[$9'?->;:/\ M >.?#OP)L+.SU/5-6UC7/$5QI^EZE+$;R_%C&$W
M.BL<RR;F*C/J1D$ CZQ\._!+1?#%_P".+VUN]1>\\72-)>SR2)NBRK@+%A!M
M"[VQG<>F2:P)_P!EGP;-\-="\'>9J<,6ASM<Z?JMO<B.^MYFD+F19%4+NR3_
M  XX!QD A4\PP::C4C>*Y>BZ)W?WV'4RW&M<U.=I/FZ]VK+[CR/X%ZYXTL_C
M'HUA8Q?$R[\)WEM,-5D^(%J2(9%C9HWADYVY8!=N1][OV[3]JC7O$MWXJ^&O
M@SP?KMQH&KZUJ4DTEW:RD,D42C)=01O3YV;8W#% *]#^&/P)T#X7ZC?ZK;W6
MJ:[K]\BPW&M:[=&ZNVB!R(PY  7@< #.U<YP*T=6^$ND:U\5-&\>7,]XVK:3
M:26EK;B1/LZA]P9RNW<7PY'WL8[5R2QE#ZTJMM(KMN[.UUZO\#KIX'$K!NBY
M:RDNNROK9^GYGS;\8->\3?"/4-$^'&D>)?&7B*]UQY-4U;4K-3?:K';?=\JU
M3($2Y1SE<%<9&<$&]\%_$?Q)CU?QIIND0>-IM#70Y+K2KCXAV^VXCU 8"Q^:
MQPRMG."<#;GCDGW/XI_ G0OBMJ&FZI=7NJ:'KFFAEM-8T.\-M=1HP(9 V",'
M)[9&3@C)S0TG]FGP7IO@?7/#$T%YJ<6O$2:IJ5_<F2]NI%.4=I<#YE(R,  $
MGCDUO]>PTJ"C*/O/?3K??ITV^XP_LW%1Q+E"3Y%MKTMHNO7<^>?@KXG\0+\4
M/"^G>*_%'Q$\/^++R25KFQ\0Q"72=1V<O' IV^7D X8*0.QY&?0?AO\ $K49
MM5^._C2_UJZGT32+F2TTZUFF9H(/L\;[BD9) +'9T S[YKO/ _[,GA[P;XFL
M-?N=9\0^*M2TU&CTYO$&H?:5LE(P1$H50...0>@QR!6%K'[&7@_6)_$0.M^)
MK33]<N&N[C2[?4MEHDS,&,BQ;,,<C^/=BM:F+P-:<KZ)I;)?S7=OD94\#CZ-
M./+JTWN_*RO\SP^WDUKQAX%^ 'AG7-0N=<U'7]=DUN[:^N6N)#;Q,6 )<YV^
M6YXY'!Q[]=\#?AZ/%7[2'Q(\5?\ "2Z_,OA_4!96QDO>+DG<98)3M^:%'5=J
M# X7K@9]UTWX!^'=+\8>$_$,<UZ;CPQI8TK3[=FC$"IL93(RA 2Y5B,@A?1:
MI>%_V<?#7A77/%]Y#>ZM=V?B@3_;M'NKH-99F;,C*@4$$@;=Q8G'%%3,Z+IU
M(0TNGT[RN_PL@AE-=5(3J*]GW[1LOQN?,FD^*O&>G^/-.B^('B?X@^$/$MWK
M(MK>]A19O#TH8X2-8^$8'.,C>,8)'7'NW[6WQ<USX<>&]"TKPS]H37?$%V;:
M.:SMOM-Q'"H!D:&+C?)\R@#W/(."+?AO]D;PIH.IZ3/<:SXDUW3])F6XT[1]
M5U,RV5G(IRC1QA5Z=LDCUSDUW'Q4^#^@?%[2[.VU@WEK<V$PN+#4=.G,%S:2
M CYXW&>>!U!' /! (RJXS!SQ-*HX^ZKW26GE9?FFS6E@,=#"UJ:E:3M:[=_/
M_ASYX^!NO>,[+XQ:1I]C'\3+OPI>6TW]K/X^M21#(J,T;PR9(0%@%VY&<G.>
M,<LOBKQ9JWQT\2?!_1_B)=G2M2U<7 UG[?(]W:1(C22V<$A)*L,!>" /+/JP
MKZ/\*_LXZ+X/M=;DL]=\03^(]6M_LD_B:]O%N-22+(^2.1T*J, =%SP#U (S
MX?V3?!6GZ/X3L=/?4=,N?#=\=1MM1M)4%S/,Q!<S.4(8-L0'@<( , 8K:.88
M13E*2O=67NK??F^3T\T9/+<8Z<(IVL[O7IMRKU6IYY=:/XA^)'[1?B#PEI?C
MGQ!X=\+^%]%M;2Y%CJ+O/<2. X;?)NP_S<R'+_)C)W<<AHO[0'BOX:_"?XDV
MJZM<^)[S1O$/]AZ%JFHDSRR%V8?,Q_UK*J%@#GE@#QQ70?"W]GN7XG:EX]\5
M>(IO%7@G5]0UZY2"2QN)+">6RPI5&5TPT9W>ASMZU[0/V:_ G_"J_P#A $TM
MUT%G\_<)6%QY_7SO,Z[_ *\8XQMXK6IBL'1G&E-<R7+=673XG?K<RHX7&UXN
MM3]UOFUOO?2*MTL?./@+Q+\0=.\?^#YM-3XK:E-=WT<6OKXNT[9IGDL1YDD*
MY(A"G)'/ P,]CT?A?_A*?VB[/QGXSOOB3J_@/2=-OYK+2+73KH6UM;K&%(EN
M3D>8#N&02/XL$ @5[1\/_P!G+P]X#\31^(IM4UWQ5KL$1@M;_P 27WVN2UC/
MWA%\H"@Y/;/S$# )KG-6_8U\#ZMK5_<_;O$%KI.H77VR[\.VNHE-.GF)R69-
MN[D\\,,8&W  %8/'863;6CTL^5/K=JS?W/Y&D<NQM."3=U=W7,UTT=_S1Y/\
M2O -[\1OCK\+?"NJ>.=6U.Z&DMJ%[J.DRBWB4QAS#<VZ#<L<C,O+ G/&,#BJ
MWQ ^*FO>,OBCKOAN&;XB#PEX99;!'\!6_F74URHP[W,^<CD,-N.<9X(S7T3J
M_P"SWX=U'XC:!XQM;S5=%O\ 1[:*SBMM+N%AMY8(V++%(FTDISC:" 1BLGQA
M^RSX8\4>*-3UNUUGQ%X;EU;']IVNA:B;>WO\ C]ZFTYR"0<$ Y)ZDDN.88=J
M*GKRQLM-FY7;^[8*F5XOWG3TYI7>NZ2LOQ/$;;XM?%*W^%7A?PS=S:GHGB+Q
M'XD.BV6L:U9^5?)8 1D3,C8S)^\V[CGA3R3\U6M?^'.HZ+^T=\+/!L_C?6?%
MNF12-KTD.MW"W$\$T08AM^ P1B@ 7)P=WK7N_BS]FSP9XI\!Z)X32"ZT6QT2
M19M-N-*E\J>VD!)+JY#99B222"<G=UP1#\/_ -F_P_\ #SQTWBZ'5M=UC6WL
M38R3ZS?"Z,@+*2Y9EW;\(%X(&.W>A9AAXJ4H*S?-IRK5O;7I9!++,5)QA-W7
MNZ\VR6K5NMV7OCQXN\#>"_"MOJ7C:RM=56"X633=/EMUFGFNA]T0J1][WXP#
MR<'GP36O!_C&_P#"OQ%^,_BZ)=#URXT">QTG1(L%]/M6&-TCG'[S!)[8W,<
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M^H5N>E3C&T(6>^KMT>FNNIZ>O2EIL?W13J^?/IPHHHH **** "BBB@ HHHH
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MIMP L]G?0+-#* 00&1@5;D \]P*!&CD>M&X>M>=?\,Y_"GO\,O!^?^P#:_\
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M\*/^B9>#_P#P0VO_ ,;H]WN%Y]E]YZ+N'K1FO.O^&<_A3_T3+P?_ ."*U_\
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M;H]WO^ 7GV7WGHN:,UYU_P ,Y_"K/_),O!__ ((;7_XW1_PSG\*?^B9>#_\
MP0VG_P ;I>[W'[_;\3T7</6C</6O.O\ AG/X4_\ 1,_!_P#X(;7_ .-T?\,Y
M_"C_ *)GX/\ _!#:_P#QNG[O<5Y]E]YZ+N'K1N'K7G7_  SG\*/^B9^#_P#P
M0VO_ ,;H_P"&<_A1_P!$S\'_ /@AM?\ XW1[O<+S[+[ST7</6C</6O.O^&<_
MA1_T3/P?_P""&U_^-T?\,Y_"C_HF?@__ ,$-K_\ &Z/=[A>?9?>>B[AZT;AZ
MUYU_PSG\*/\ HF?@_P#\$-K_ /&Z/^&<_A1_T3/P?_X(;7_XW1[O<+S[+[ST
M7</6C</6O.O^&<_A1_T3/P?_ ."&U_\ C='_  SG\*/^B9^#_P#P0VO_ ,;H
M]WN%Y]E]YZ+N'K1N'K7G7_#.?PH_Z)GX/_\ !#:__&Z/^&<_A1_T3/P?_P""
M&U_^-T>[W"\^R^\]%W#UHW#UKSK_ (9S^%'_ $3/P?\ ^"&U_P#C='_#.?PH
M_P"B9^#_ /P0VO\ \;H]WN%Y]E]YZ+N'K1N'K7G7_#.?PH_Z)GX/_P#!#:__
M !NC_AG/X4?]$S\'_P#@AM?_ (W1[O<+S[+[ST7</6C</6O.O^&<_A1_T3/P
M?_X(;7_XW1_PSG\*/^B9^#__  0VO_QNCW>X7GV7WGHNX>M&X>M>=?\ #.?P
MH_Z)GX/_ /!#:_\ QNC_ (9S^%'_ $3/P?\ ^"&U_P#C='N]PO/LOO/1=P]:
M-P]:\Z_X9S^%'_1,_!__ ((;7_XW1_PSG\*/^B9^#_\ P0VO_P ;H]WN%Y]E
M]YZ+N'K1N'K7G7_#.?PH_P"B9^#_ /P0VO\ \;H_X9S^%'_1,_!__@AM?_C=
M'N]PO/LOO/1=P]:-P]:\Z_X9S^%'_1,_!_\ X(;7_P"-T?\ #.?PH_Z)GX/_
M /!#:_\ QNCW>X7GV7WGHNX>M&X>M>=?\,Y_"C_HF?@__P $-K_\;H_X9S^%
M'_1,_!__ ((;7_XW1[O<+S[+[ST7</6C</6O.O\ AG/X4?\ 1,_!_P#X(;7_
M .-T?\,Y_"C_ *)GX/\ _!#:_P#QNCW>X7GV7WGHNX>M&X>M>=?\,Y_"C_HF
M?@__ ,$-K_\ &Z/^&<_A1_T3/P?_ ."&U_\ C='N]PO/LOO/1=P]:-P]:\Z_
MX9S^%'_1,_!__@AM?_C='_#.?PH_Z)GX/_\ !#:__&Z/=[A>?9?>>B[AZT;A
MZUYU_P ,Y_"C_HF?@_\ \$-K_P#&Z/\ AG/X4?\ 1,_!_P#X(;7_ .-T>[W"
M\^R^\]%W#UHW#UKSK_AG/X4?]$S\'_\ @AM?_C='_#.?PH_Z)GX/_P#!#:__
M !NCW>X7GV7WGHNX>M&X>M>=?\,Y_"C_ *)GX/\ _!#:_P#QNC_AG/X4?]$S
M\'_^"&U_^-T>[W"\^R^\]%W#UHW#UKSK_AG/X4?]$S\'_P#@AM?_ (W1_P ,
MY_"C_HF?@_\ \$-K_P#&Z/=[A>?9?>>B[AZT;AZUYU_PSG\*/^B9^#__  0V
MO_QNC_AG/X4?]$S\'_\ @AM?_C='N]PO/LOO/1=P]:-P]:\Z_P"&<_A1_P!$
MS\'_ /@AM?\ XW1_PSG\*/\ HF?@_P#\$-K_ /&Z/=[A>?9?>>B[AZT;AZUY
MU_PSG\*/^B9^#_\ P0VO_P ;H_X9S^%'_1,_!_\ X(;7_P"-T>[W"\^R^\]%
MW#UHW#UKSK_AG/X4?]$S\'_^"&U_^-T?\,Y_"C_HF?@__P $-K_\;H]WN%Y]
ME]YZ+N'K1N'K7G7_  SG\*/^B9^#_P#P0VO_ ,;H_P"&<_A1_P!$S\'_ /@A
MM?\ XW1[O<+S[+[ST7</6C</6O.O^&<_A1_T3/P?_P""&U_^-T?\,Y_"C_HF
M?@__ ,$-K_\ &Z/=[A>?9?>>B[AZT;AZUYU_PSG\*/\ HF?@_P#\$-K_ /&Z
M/^&<_A1_T3/P?_X(;7_XW1[O<+S[+[ST7</6C</6O.O^&<_A1_T3/P?_ ."&
MU_\ C='_  SG\*/^B9^#_P#P0VO_ ,;H]WN%Y]E]YZ+N'K1N'K7G7_#.?PH_
MZ)GX/_\ !#:__&Z/^&<_A1_T3/P?_P""&U_^-T>[W"\^R^\]%W#UHW#UKSK_
M (9S^%'_ $3/P?\ ^"&U_P#C='_#.?PH_P"B9^#_ /P0VO\ \;H]WN%Y]E]Y
MZ+N'K1N'K7G7_#.?PH_Z)GX/_P#!#:__ !NC_AG/X4?]$S\'_P#@AM?_ (W1
M[O<+S[+[ST7</6C</6O.O^&<_A1_T3/P?_X(;7_XW1_PSG\*/^B9^#__  0V
MO_QNCW>X7GV7WGHNX>M&X>M>=?\ #.?PH_Z)GX/_ /!#:_\ QNC_ (9S^%'_
M $3/P?\ ^"&U_P#C='N]PO/LOO/1=P]:-P]:\Z_X9S^%'_1,_!__ ((;7_XW
M1_PSG\*/^B9^#_\ P0VO_P ;H]WN%Y]E]YZ+N'K1N'K7G7_#.?PH_P"B9^#_
M /P0VO\ \;H_X9S^%'_1,_!__@AM?_C='N]PO/LOO/1=P]:-P]:\Z_X9S^%'
M_1,_!_\ X(;7_P"-T?\ #.?PH_Z)GX/_ /!#:_\ QNCW>X7GV7WGHNX>M&X>
MM>=?\,Y_"C_HF?@__P $-K_\;H_X9S^%'_1,_!__ ((;7_XW1[O<+S[+[ST7
M</6C</6O.O\ AG/X4?\ 1,_!_P#X(;7_ .-T?\,Y_"C_ *)GX/\ _!#:_P#Q
MNCW>X7GV7WGHNX>M&X>M>=?\,Y_"C_HF?@__ ,$-K_\ &Z/^&<_A1_T3/P?_
M ."&U_\ C='N]PO/LOO/1=P]:-P]:\Z_X9S^%'_1,_!__@AM?_C='_#.?PH_
MZ)GX/_\ !#:__&Z/=[A>?9?>>B[AZT;AZUYU_P ,Y_"C_HF?@_\ \$-K_P#&
MZ/\ AG/X4?\ 1,_!_P#X(;7_ .-T>[W"\^R^\]%W#UHW#UKSK_AG/X4?]$S\
M'_\ @AM?_C='_#.?PH_Z)GX/_P#!#:__ !NCW>X7GV7WGHNX>M&X>M>=?\,Y
M_"C_ *)GX/\ _!#:_P#QNC_AG/X4?]$S\'_^"&U_^-T>[W"\^R^\]%W#UHW#
MUKSK_AG/X4?]$S\'_P#@AM?_ (W1_P ,Y_"C_HF?@_\ \$-K_P#&Z/=[A>?9
M?>>B[AZT;AZUYU_PSG\*/^B9^#__  0VO_QNC_AG/X4?]$S\'_\ @AM?_C='
MN]PO/LOO/1=P]:-P]:\Z_P"&<_A1_P!$S\'_ /@AM?\ XW1_PSG\*/\ HF?@
M_P#\$-K_ /&Z/=[A>?9?>>B[AZT;AZUYU_PSG\*/^B9^#_\ P0VO_P ;H_X9
MS^%'_1,_!_\ X(;7_P"-T>[W"\^R^\]%W#UHW#UKSK_AG/X4?]$S\'_^"&U_
M^-T?\,Y_"C_HF?@__P $-K_\;H]WN%Y]E]YZ+N'K1N'K7G7_  SG\*/^B9^#
M_P#P0VO_ ,;H_P"&<_A1_P!$S\'_ /@AM?\ XW1[O<+S[+[ST7</6C</6O.O
M^&<_A1_T3/P?_P""&U_^-T?\,Y_"C_HF?@__ ,$-K_\ &Z/=[A>?9?>>B[AZ
MT;AZUYU_PSG\*/\ HF?@_P#\$-K_ /&Z/^&<_A1_T3/P?_X(;7_XW1[O<+S[
M+[ST7</6C</6O.O^&<_A1_T3/P?_ ."&U_\ C='_  SG\*/^B9^#_P#P0VO_
M ,;H]WN%Y]E]YZ+N'K1N'K7G7_#.?PH_Z)GX/_\ !#:__&Z/^&<_A1_T3/P?
M_P""&U_^-T>[W"\^R^\]%S2UYU#^SU\+K6XCFA^&WA&*6-@Z2)H5J&5@<@@B
M/(([5Z$N-O J7;H5'F>Z'T444BA**6B@!**6B@!**6B@!**6B@!**6B@!**6
MB@!**6B@!**6B@!**6B@!.E8/CCQ=9> ?".M^)-2$IT_2;.6^G6$ N4C0LP4
M$@9P.Y'4<UO5\U_\%!?%[>%?V:=>@B<I/K%Q;Z:C*V#AG#N/Q2-Q^-:4:?M:
MD8=V8UJGLJ<I]CUWX6_%/3?BS\.=.\::=:7VG:7?)))%'J:QI*$1V4LP1V4
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MC&.!M3V'C3X1_M6>$_A^WQ.\5>)=$\9:1<B^;5+O?);R^5.!);G&(2&167:
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MBR;PM:^8D%^P5E5Y6$H4A04^5HS]SKS7K5)5*K-1Y;Z$.C!RYFM3S/\ :/\
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MFTE0+"25E/G,PES*P5 N/D!R3QTKZMHI4ZTZ:M%CG1A4:<EL<#X#^%EGX/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2RUNW;9]['JU%(OW12UPGI!1110 4444 %%%% !1110 4444 %%%% !1110
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MV?X!1S2I%KZU%13CS>BTT_$^DK'Q?H>I:W=Z/9ZQ8W6KV8S<V,%TCSP#C!=
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MZU=R'XAS:==ZS+XN6[D2\LKV,R%8XW#?NUB91$(EPI"XQS70?\(O!\7OC?\
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M'&#].45?]I8CG<TTG=2VZHE95A^7D=VK.._1]#YQ^%G[//B#3?&EIKWBK3_
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M_P#X!Z)Q2[AZUYU_PHCPS_T$?&'_ (6VM?\ R71_PHCPS_T$?&'_ (6VM?\
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M_P"%A^&/^AATO_P,C_\ BJ\(_P"&;_%'_/UI?_?Z3_XBC_AF_P 4?\_6E_\
M?Z3_ .(H_M3-O^@7\0_L[*_^@K\#W?\ X6'X8_Z&'2__  ,C_P#BJ/\ A8?A
MC_H8=+_\#(__ (JO"/\ AF_Q1_S]:7_W^D_^(H_X9O\ %'_/UI?_ '^D_P#B
M*/[4S;_H%_$/[.RO_H*_ ]W_ .%A^&/^AATO_P #(_\ XJC_ (6'X8_Z&'2_
M_ R/_P"*KPC_ (9O\4?\_6E_]_I/_B*/^&;_ !1_S]:7_P!_I/\ XBC^U,V_
MZ!?Q#^SLK_Z"OP/=_P#A8?AC_H8=+_\  R/_ .*H_P"%A^&/^AATO_P,C_\
MBJ\(_P"&;_%'_/UI?_?Z3_XBC_AF_P 4?\_6E_\ ?Z3_ .(H_M3-O^@7\0_L
M[*_^@K\#W?\ X6'X8_Z&'2__  ,C_P#BJ/\ A8?AC_H8=+_\#(__ (JO"/\
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M_P"%A^&/^AATO_P,C_\ BJ\(_P"&;_%'_/UI?_?Z3_XBC_AF_P 4?\_6E_\
M?Z3_ .(H_M3-O^@7\0_L[*_^@K\#W?\ X6'X8_Z&'2__  ,C_P#BJ/\ A8?A
MC_H8=+_\#(__ (JO"/\ AF_Q1_S]:7_W^D_^(H_X9O\ %'_/UI?_ '^D_P#B
M*/[4S;_H%_$/[.RO_H*_ ]W_ .%A^&/^AATO_P #(_\ XJC_ (6'X8_Z&'2_
M_ R/_P"*KPC_ (9O\4?\_6E_]_I/_B*/^&;_ !1_S]:7_P!_I/\ XBC^U,V_
MZ!?Q#^SLK_Z"OP/=_P#A8?AC_H8=+_\  R/_ .*H_P"%A^&/^AATO_P,C_\
MBJ\(_P"&;_%'_/UI?_?Z3_XBC_AF_P 4?\_6E_\ ?Z3_ .(H_M3-O^@7\0_L
M[*_^@K\#W?\ X6'X8_Z&'2__  ,C_P#BJ/\ A8?AC_H8=+_\#(__ (JO"/\
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M_P"%A^&/^AATO_P,C_\ BJ\(_P"&;_%'_/UI?_?Z3_XBC_AF_P 4?\_6E_\
M?Z3_ .(H_M3-O^@7\0_L[*_^@K\#W?\ X6'X8_Z&'2__  ,C_P#BJ/\ A8?A
MC_H8=+_\#(__ (JO"/\ AF_Q1_S]:7_W^D_^(H_X9O\ %'_/UI?_ '^D_P#B
M*/[4S;_H%_$/[.RO_H*_ ]W_ .%A^&/^AATO_P #(_\ XJC_ (6'X8_Z&'2_
M_ R/_P"*KPC_ (9O\4?\_6E_]_I/_B*/^&;_ !1_S]:7_P!_I/\ XBC^U,V_
MZ!?Q#^SLK_Z"OP/=_P#A8?AC_H8=+_\  R/_ .*H_P"%A^&/^AATO_P,C_\
MBJ\(_P"&;_%'_/UI?_?Z3_XBC_AF_P 4?\_6E_\ ?Z3_ .(H_M3-O^@7\0_L
M[*_^@K\#W<_$/PQC_D8=+_\  R/_ .*IC?$'PQR!XATLG'_/Y'_\57A?_#.'
MB?\ Y^M+_P"_TG_Q%-/[.7B=<YN]+QU_ULA_G']*7]IYJ]\+^(_[.RO_ *"O
MP.>M[B.Z^,4<T,BRPR:^'21""K*;C(((Z\5]=+]U:^./#>GRZ3\2-+L9BK36
MNK10N4)*EEF .,^XK['7[JU/#$I2C6E-6?,7Q)&,9T8P=THZ,=1117VY\<%%
M%% !133WXI!DXI /HIO;F@=* '44@S1S3 6BFG-)UXH ?13:2D(?13>U)SS3
M&/HIF*,>U(0^BF;J/3B@!])3<_E2 >M,9)13:0T /HIOI2=:0#Z*;36XY'-,
M1)13/K2YI#'44T8(S10 ZBDI:8!1110 4444 %%%% !1110 WWI&7=]*?10!
MP?PY^#_A_P"%NI>)[W11="?Q'J+ZG??:)?,!F8DG;Q\HY/%;'Q \*KX[\#^(
M/#;W+V2:MI\]B;B-=S1>9&R;@.^,YQ72457-+FYKZD<D5'E2T/@K4_V,?C)J
MGP13X8/KO@.RT+3[@75K+96URMSJ#B1C_I,A0A,*S-E$8DJJ].:]N\8? 'Q-
MXF^,7P;\7QW.EPV7@^T>'4H&N)3*[M&%/D?N\,,CJQ0X[5]#4M=4L54EN^_X
M[G+'"4X_A^!\^V/[/^NQ_M9>(?B;/=Z<?#>IZ$-*2VCED^UA]L0)*E-@7]VW
M._OTYX\S^'/[)WQ1\$?"#XA?#*;7/"]UX:UBTNDTF1#<+.+F5D"O.3&0B;$/
M"[^3WK[.HI?6JEK7[?AL/ZK3O>W?\=SY%^)7[)/C+QI\#?A)X+T[7=*TG6/"
M<\$EYJ/F3%4V)M,EOA 78$Y ;8#@<BKVF_LY_%/XA?%CPEXD^+?BO0;_ $?P
MC-]ITNPT""1#<SA@5EFWJ K?)&2 6'RX &23]644_K56UO7\=Q?5*?Y?@?.W
MA#]FW4+7XM_&?6_$4]A=>&/'EK':16UK-)]H2/RV23S R!5)#'&TM7F,?[)W
MQOT?P/=_"O2?B)H*_#&XDDC^TW-H_P#:<5J[%GA"!-A!+'/[P$Y."HXK[7HH
MCBJL7?T_ )82DU]_XGRC\6OV1]=;3_A$_P +]3TJQU+X>[DM_P#A(/,$4X/E
MMYC&)&RQ>,D@  [SR,8/4:%\"O%Z_M,67Q,UR^T>:T_X1>/1[R&UDE\Q[K@N
MRH8POED@XRV?:OH:BI^LU&K-]U]Y7U6FG=>7X'QI9_LK_&'X9P^*/"OPO\<:
M'I?@'7KJ2Y5M0$ZZCIWF *X@9%()VA5W;@> 1M;FO2_'WP3^(C?#KPAH_A#X
MA&[U;0P/MZ^*8VN;;7LD%Q<GYW"Y#84;L!L9R U?0%%#Q-1M2=KKR%]5II-*
M^OF?,G[//[,6M_#WXIZ_\1_%+^&M.UG4;3[#'HG@NT>WTV&,F,L^& 9G)C!Y
M'4DY.1CZ87[HS3Z*QJ5)57>1O3IQIJT1N>U5=2FN+>QNI;2W6[NDC9HH&D$8
MD< E5+8.W)P,XXS5RBLS1JY\W:E^T1\5-)\<:-X3N/@U8)K&K6]Q=6L8\81E
M3'#L\PEOLW!&]>.^:]S\(ZEK.K>'+.[U_1X] UB129].AO!=I"0Q  E"J&R
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M444UFH P=2\$:+J?B[2O%%U9>;KFE036UG=>:X\N.7;Y@V@[3G8O)!(QQC)H
M\-^"]'\)7&LRZ3:&UEUB^;4;YO-=_.N&5$9\,2%RJ(,+@<=*KM\2_"*>)O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M485N$\WS+9-Y5P<G$C<G^]61\9;2.WN?VGH(($2&'PGI CCC4*J*L5UC '
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'B$;_-$V45CN*' .*U](\/>%]4-EXCL-&TUIKF&.>#4%L469HS&-A!*AA\A
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MU'1]/N3JEW%.\7,,TC#R3/AI&"J,JREL.QSM"CUR'P/X<LM0348/#^EP7T0
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M/O <MM^]Q0!Y]IOCCQ4]FEOI%[I[AK?6=4^U:K#-=F1(;XK%&FV5,(4?ALG
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M_-Y%I" 7DVEL D < 9ZD5>4Y7TH 6BBB@ HHHH **** "BBB@ HHHH ****
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M"O\ :4L+9>.0E@LCC).YSM;;M+8)KKO!^C7WA'P7XE-CX2-M+)=W%W8:!Y\
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M;LKX5R'PJR#=/L)\[!P-V/JVB@#YSO/A3XIO-22XTG1_^$=L6NFDLK/SH?\
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M-E>^TCG(S] T4 ?-?CKP[I7@F.[MM8T*PN-&DM]131=,>6VACLI'8,)(E=U
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MX7&CVZ"SFTQK_3X_+6/;'(CS@@$*P.'+ 9W9(YS7)^(?@_JGVPPVVDW$WAR
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MA71+F273I]-E@NVGLI9((4N!)<123.%==J;U"6Z(A7 +,"138_@>\EMJUO\
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MO_01_P#("T44 'V2]_Z"/_D!:/LE[_T$?_("T44 'V2]_P"@C_Y 6C[)>_\
M01_\@+110 ?9+W_H(_\ D!:/LE[_ -!'_P @+110 ?9+W_H(_P#D!:/LE[_T
M$?\ R M%% !]DO?^@C_Y 6C[)>_]!'_R M%% !]DO?\ H(_^0%H^R7O_ $$?
M_("T44 'V2]_Z"/_ ) 6C[)>_P#01_\ ("T44 'V2]_Z"/\ Y 6C[)>_]!'_
M ,@+110 ?9+W_H(_^0%H^R7O_01_\@+110 ?9+W_ *"/_D!:/LE[_P!!'_R
MM%% !]DO?^@C_P"0%H^R7O\ T$?_ " M%% !]DO?^@C_ .0%H^R7O_01_P#(
M"T44 'V2]_Z"/_D!:/LE[_T$?_("T44 'V2]_P"@C_Y 6C[)>_\ 01_\@+11
M0 ?9+W_H(_\ D!:/LE[_ -!'_P @+110 ?9+W_H(_P#D!:/LE[_T$?\ R M%
M% !]DO?^@C_Y 6C[)>_]!'_R M%% !]DO?\ H(_^0%H^R7O_ $$?_("T44 '
MV2]_Z"/_ ) 6C[)>_P#01_\ ("T44 'V2]_Z"/\ Y 6C[)>_]!'_ ,@+110
M?9+W_H(_^0%H^R7O_01_\@+110 ?9+W_ *"/_D!:/LE[_P!!'_R M%% !]DO
M?^@C_P"0%H^R7O\ T$?_ " M%% !]DO?^@C_ .0%H^R7O_01_P#("T44 'V2
M]_Z"/_D!:/LE[_T$?_("T44 'V2]_P"@C_Y 6C[)>_\ 01_\@+110 ?9+W_H
M(_\ D!:/LE[_ -!'_P @+110 ?9+W_H(_P#D!:/LE[_T$?\ R M%% !]DO?^
M@C_Y 6C[)>_]!'_R M%% !]DO?\ H(_^0%H^R7O_ $$?_("T44 'V2]_Z"/_
M ) 6C[)>_P#01_\ ("T44 'V2]_Z"/\ Y 6C[)>_]!'_ ,@+110 ?9+W_H(_
M^0%H^R7O_01_\@+110 ?9+W_ *"/_D!:/LE[_P!!'_R M%% !]DO?^@C_P"0
M%H^R7O\ T$?_ " M%% !]DO?^@C_ .0%H^R7O_01_P#("T44 'V2]_Z"/_D!
M:/LE[_T$?_("T44 'V2]_P"@C_Y 6C[)>_\ 01_\@+110 ?9+W_H(_\ D!:/
MLE[_ -!'_P @+110 ?9+W_H(_P#D!:/LE[_T$?\ R M%% !]DO?^@C_Y 6C[
M)>_]!'_R M%% !]DO?\ H(_^0%H^R7O_ $$?_("T44 'V2]_Z"/_ ) 6C[)>
M_P#01_\ ("T44 'V2]_Z"/\ Y 6C[)>_]!'_ ,@+110 ?9+W_H(_^0%H^R7O
M_01_\@+110 ?9+W_ *"/_D!:/LE[_P!!'_R M%% !]DO?^@C_P"0%H^R7O\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img45497886_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45497886_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &G!*$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]17@/F2?\]'_ .^C1YDG_/1_^^C0![]17@/F2?\ /1_^^C1YDG_/1_\ OHT
M>_45X#YDG_/1_P#OHT>9)_ST?_OHT >_45X#YDG_ #T?_OHT>9)_ST?_ +Z-
M 'OU%> ^9)_ST?\ [Z-'F2?\]'_[Z- 'OU%> ^9)_P ]'_[Z-'F2?\]'_P"^
MC0![]17@/F2?\]'_ .^C1YDG_/1_^^C0![]17@/F2?\ /1_^^C1YDG_/1_\
MOHT >_45X#YDG_/1_P#OHT>9)_ST?_OHT >^YI17 _#1F:/4]S$X:/&3G^]7
M?4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3&LI2*./+9 ^M176CZE8Q>;=6,\,><;G3 H I458M+&[OY#'9V\D[@9*QC)
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MQZ_X?U[2+>VUYGBGA !< _,>F00#UK-\4ZSI%W8V^GZ5;JR0\"8IC Q]T=Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "JU__P @ZZ_ZXO\ R-6:K7__ "#KK_KB_P#(T">Q\@)]
MQ?I3J<D$WEK^XEZ#_EF?\*=Y$W_/";_OV:]NZ/&LR.BI/(F_YX3?]^S1Y$W_
M #PF_P"_9HN@LR.BI/(F_P">$W_?LT>1-_SPF_[]FBZ"S(Z*D\B;_GA-_P!^
MS1Y$W_/";_OV:+H+,CHJ3R)O^>$W_?LT>1-_SPF_[]FBZ"S(Z*D\B;_GA-_W
M[-'D3?\ /";_ +]FBZ"S(Z*D\B;_ )X3?]^S1Y$W_/";_OV:+H+,CHJ3R)O^
M>$W_ '[-'D3?\\)O^_9HN@LR.BI/(F_YX3?]^S1Y$W_/";_OV:+H+,CHJ3R)
MO^>$W_?LT>1-_P \)O\ OV:+H+,CHJ3R)O\ GA-_W[-'D3?\\)O^_9HN@LR.
MBI/(F_YX3?\ ?LT>1-_SPE_[]FBZ"S[$=%2>1-_SPE_[]FCR)O\ GA+_ -^S
M1<+/L1T5)Y$W_/"7_OV:/(F_YX3?]^S1=!9D=%2>1-_SPF_[]FCR)O\ GA-_
MW[-%T%F1T5)Y$W_/";_OV:/(F_YX3?\ ?LT7069'14GD3?\ /";_ +]FCR)O
M^>$W_?LT7069'14GD3?\\)O^_9H\B;_GA-_W[-%T%F1T5)Y$W_/";_OV:/(F
M_P">$W_?LT7069'14GD3?\\)O^_9H\B;_GA-_P!^S1=!9D=%2>1-_P \)O\
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MT ,HI_E2?\\W_P"^31Y4G_/-_P#ODT ,HI_E2?\ /-_^^31Y4G_/-_\ ODT
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MYC_WW_[Z-'F/_??_ +Z-'U-]P^MKL?8>1ZBC(]17QYYC_P#/1_\ OLT>8_\
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M;\Z-S?WV_.@#W^BO -S?WV_.C<W]]OSH ]_HKP#<W]]OSHW-_?;\Z /?Z*\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "JU_P#\@ZZ_ZXO_ "-6:K7_
M /R#KK_KB_\ (T">Q\@)]Q?I3J:GW%^E.KW#QNH4444""BBB@ HHHH ****
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M_OK_ .@+6'0 4'I110!Z+!8^'=/\*6>I:AIBR[U"LR+EB23[CTJB=8\#\_\
M$EF_[]#_ .*K:672XO EB^KPO+:_*-B@YW9..A'O6&U_X#VMMTV?=@X^5_\
MXJ@#ETLY=3U&6/3;9W#.2D:CHN>,^E2WGA[5M/A,UU82QQ9P6X('Y$UT7@74
MM/MEO;*YG$$MQQ'*3@XQC /K70MH^IV&GW<>FWT=_#*#F*\R[ 8.<,#_ $H
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M)['R"GW%^E+34^XOTIU>V>-U#I7JNF_#+P[+X6LM:U77KBQ2X0%B[1J@8D\
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M9C(6&W&X\Y]*ZGQ7XEMM&^+MCJ\<L<]ND2I*T3!L*1AL8[XKR; (QCB@  <
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M%CMVI  .@Q0!Z9J.CZ'XEO(=4&K)&A \R,D?-CMR1BLB35-#T/Q=!/IB?Z,
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MJ.2&^O2J$5A:>*?'5Y)G=9Q8+[>-^!C^8H X?<N<9I:]&D\2Z#%JHTI=(C,
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5K_\
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M_P *\T/_ *>O^_W_ -:C_A7FA_\ 3U_W^_\ K5UE% ')_P#"O-#_ .GK_O\
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M#4MKP:A"I9I65?*.%#<'=GH?2H/A!_R2G0?^N+_^C&KSS0O^3IM3_P"N3_\
MHE: />10>E>$^,/''C33_C'-H7A^?[2LD:+!9R*/+#,G+'C/'7K6?<^+?B3\
M/_&.EV_BB_AOK6_<#RTP4VE@#M(4$$9% 'K7C/Q_I?@>338]2M[N8Z@[)%]G
M53M(VYSN8?WA6GX@\4Z/X7TQ;_5KM;>)^(P1EG/H .IKSGXV>(-1T>?PN=-N
M%B6YG<2!H4?(RF/O XZGI7(?M VNNC4=,NKB[1M(EPMK "-R2A1O)&._'<T
M?1=O.MQ;Q3ID+(H89ZX(J3->+7'BSQ3\-OAH+GQ!=V^HZO=RA-/^;<J)M!^;
M '0=OUKFKCQ/\4?#&G0>)M1UK3[ZR8JTECYR,R!NQ4 $>G!.,T ?1U4M6U.'
M1](N]2N%=H;:(RNJ ;B!Z9KSSQI\5/[(^'6F:YI4"M>ZL +9).0G]XGUP>/Q
MKA[U_BU:>"[[5]8GM[[2[NU/G6TA'F11M_$ %&,#W- 'LO@SQE8>-]&.IZ=!
M<PPB0QE;A5#9'^Z2*VK_ %"TTNPGOKZX2"U@0O)*YP%%>7?L^?\ )/I/^OIZ
MZ?XI>'[_ ,3?#_4=.TT%KL['2(''F;6!V_I^>* .7NOVA_!\%VT,=MJEP@.!
M-'"@4^XW,#^E>A>&O%.C^+=,%_H]VL\(.UQ@AD;T(/2OG_PQ\0M-\)Z/%X>\
M3^!U"1;HI;D1C>V>N0PY/N&KO/AQI?A9M&UN\^'^IWJWMW'M,%Y(O^CMR5.T
M+QUZ\\4 >@6WBW1K[Q+-H%I=B>_@0O,B#(CP<8)]?:MP&OE'P9I?C>?XEZM;
M:7JL,.L13/\ VA,7&)</\^/E.<G/85[%XE?Q[K/B\:7I=PWA_0X(]SZJT2/Y
MC8[ GIGCM0!Z;6%-XMT>+Q-#X=^U!]4E4MY"#)0  Y8]!UKS+P%XT\2MX^U;
MP7JVIQ:H88Y#!?!0IWC&.G&.:\Y&E^-W^,EW96^JPIXER2UT7 4KM&!G;_=P
M/N]J /K#-)D5XGXU\>^)TU[3_ _A^YMH=6$$?VV_D8 "3:"<$C '<G'X57\-
M^._%WA;QO8^'?%]]::I;Z@0L=S;R*Y1CP,$ <9X((H ]US1FO#/%?Q!U:^^)
M=SX8A\21>%["T^7[6T D:5^..>,'/'3IUKI/ >I>-X/$MUI6M.NM:/@M;ZS%
ML )P" 0IZ<].HQWH ]/S12#K2T %%%% !1110 4444 %%%% !1110 5B>)_%
M>E>$M-%[JDS*';9%%&I9Y7[*H'4UM&L#5?".FZUXCTS6[TSO/IH/D0AAY63_
M !,I')';F@#!T?XM:'JFK0Z;=V6JZ1/<';!_:5MY2RGT4@G]<5T7BCQ7I7A#
M3!?ZK*P5FV111KNDE;^ZJ]ZXGXNO!JL_A_P[:()]:FU".>((,M!&O+.?08I-
M:C75/CCX=TNZ'FQZ=ISW:AONER0N<=^E &WX<^*.B^(=772GM-2TN^D7=##J
M-OY1E'^SR16OKOBVTT34;73$M;K4-3NE+Q6=HJF0H.K$LRJ!]37(_&F..ST7
M2-=10M[8:C$8I0.0&/(^G'2G:WGPY\6[;Q-J"/\ V1<V!MS<K&SB"0= 0,GG
MZ=Z .U\.^(]/\4:7]NT]GV!S')'(NUXG'56'8BDT+Q%:>()=0%E%-Y-E<&W,
M[ ;)6 R=A!R0,\Y KRK2;C4M%\/:W/;P36^I>*]4:/3(77#HK9!E([ *2WX5
MWGAK5/"N@0VOA6SU6!KJ >6RDGYY.K9;&"Q/;.: .RHI!UI: "BBB@ HHHH
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M*%#A?3/?VKKO#%]X<\'VEMX;GUF!M5+;KIVR3)._+%FQ@$DG@F@#NJ*;UIU
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MG)Q&B\#&,DDD]!0![32$XYKQGP_JOQ!UG5-6\%MJ]M#=:9)^_P!;\G>Y5N5
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MUU-=T[62Z)(\ B>)E&3@ ^XKUH4 +1110 4444 %%%% !1110 4444 %%%%
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M_P --9\;V&G^&?!=W<LKK,+UKN5!"5^;<5+'IC\:]YN](TV_L!8WEA;7%H
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MV$&H37\-E;QWDZA9;A8P'<#H"W4B@#RSX5?\B+XN_P"O^[_]!K LO^36Y/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **,T4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 8\]AK+SR-#JRQQEB43R =H],TS^SM=_P"@TO\
MX#K6W10!B?V=KO\ T&E_\!UH_L[7?^@TO_@.M;=% &)_9VN_]!I?_ =:/[.U
MW_H-+_X#K6W10!B?V=KO_0:7_P !UH_L[7?^@TO_ (#K6W10!B?V=KO_ $&E
M_P# =:/[.UW_ *#2_P#@.M;=% &)_9VN_P#0:7_P'6C^SM=_Z#2_^ ZUMT4
M8G]G:[_T&E_\!UH_L[7?^@TO_@.M;=% &)_9VN_]!I?_  '6C^SM=_Z#2_\
M@.M;=% &)_9VN_\ 0:7_ ,!UH_L[7?\ H-+_ . ZUMT4 8G]G:[_ -!I?_ =
M:/[.UW_H-+_X#K6W10!B?V=KO_0:7_P'6C^SM=_Z#2_^ ZUMT4 8G]G:[_T&
ME_\  =:/[.UW_H-+_P" ZUMT4 8G]G:[_P!!I?\ P'6C^SM=_P"@TO\ X#K6
MW10!B?V=KO\ T&E_\!UH_L[7?^@TO_@.M;=% &)_9VN_]!I?_ =:/[.UW_H-
M+_X#K6W10!B?V=KO_0:7_P !UH_L[7?^@TO_ (#K6W10!B?V=KO_ $&E_P#
M=:/[.UW_ *#2_P#@.M;=% &)_9VN_P#0:7_P'6C^SM=_Z#2_^ ZUMT4 8G]G
M:[_T&E_\!UH_L[7?^@TO_@.M;=% &)_9VN_]!I?_  '6C^SM=_Z#2_\ @.M;
M=% &)_9VN_\ 0:7_ ,!UH_L[7?\ H-+_ . ZUMT4 8G]G:[_ -!I?_ =:/[.
MUW_H-+_X#K6W10!B?V=KO_0:7_P'6C^SM=_Z#2_^ ZUMT4 8G]G:[_T&E_\
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M_H-+_P" ZUMT4 8G]G:[_P!!I?\ P'6C^SM=_P"@TO\ X#K6W10!B?V=KO\
MT&E_\!UH_L[7?^@TO_@.M;=% &)_9VN_]!I?_ =:/[.UW_H-+_X#K6W10!B?
MV=KO_0:7_P !UH_L[7?^@TO_ (#K6W10!B?V=KO_ $&E_P# =:/[.UW_ *#2
M_P#@.M;=% &)_9VN_P#0:7_P'6C^SM=_Z#2_^ ZUMT4 8G]G:[_T&E_\!UH_
ML[7?^@TO_@.M;=% &)_9VN_]!I?_  '6C^SM=_Z#2_\ @.M;=% &)_9VN_\
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M_OW)_P#$T =O14<$T=S;QSPN'BD4,C#N#R#4E !1110 4444 %%%% !1110
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M#P:7PO\ \EU\6_\ 7G%_Z$* (?AE?7EUX*\52W%W/-)'>W8C>21F90%X )/
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M5<1I??#WX8:7=$_V=>7>VY&3M8!N ?S- 'H>F?&3P?J>IQ6*75S TK;(Y;B
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M'N=<U&RUW0]1&FZ]8@B&8KE)%/57'I^==K10!YOIO@+Q%JGB"TU?QQK=O?\
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M [[_ +YH W**P_[>N_\ H!WW_?-']O7?_0#OO^^: -RBL/\ MZ[_ .@'??\
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M-']O7?\ T [[_OF@#<HK#_MZ[_Z =]_WS1_;UW_T [[_ +YH W**P_[>N_\
MH!WW_?-']O7?_0#OO^^: -RBL/\ MZ[_ .@'??\ ?-']O7?_ $ [[_OF@#<H
MK#_MZ[_Z =]_WS1_;UW_ - .^_[YH W**P_[>N_^@'??]\T?V]=_] .^_P"^
M: -RBL/^WKO_ * =]_WS1_;UW_T [[_OF@#<HK#_ +>N_P#H!WW_ 'S1_;UW
M_P! .^_[YH W**P_[>N_^@'??]\T?V]=_P#0#OO^^: -RBL/^WKO_H!WW_?-
M']O7?_0#OO\ OF@#<HK#_MZ[_P"@'??]\T?V]=_] .^_[YH W**P_P"WKO\
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M [[_ +YH W**P_[>N_\ H!WW_?-']O7?_0#OO^^: -RBL/\ MZ[_ .@'??\
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M-']O7?\ T [[_OF@#<HK#_MZ[_Z =]_WS1_;UW_T [[_ +YH W**P_[>N_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img45497886_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45497886_2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #H G$# 2(  A$! Q$!_\0
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MJA2"N>15?^UIO[J?D?\ &C5O^/A?]S^IJE0!=_M:;^ZGY'_&C^UIO[J?D?\
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M*0!1110 4444 %%%% !1110 4444 5-89DT;4G0E&6UF(9>"/D.,'L<U^?\
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ML9+6W43),[EK;SW=BOD,J'>HD+K]W!%/M_&/B"P^$?Q%U+5;F&]U?3?$-S;
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M*_*W.,'!%=)9_P#"K/\ A95[8V[>&CX[U2S,ES:9C:\N+=U!9C&>SK@MP"P
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M77B_L/[CV^3X6^#Y%LU;PWIY6SM18VZ^5@1VXD$@B&#]T.H8 ]".*A\4>'O
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M_P!_5_QH_M:R_P"?RW_[^K_C5B+E%4_[6LO^?RW_ ._J_P"-']K67_/Y;_\
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MC_A M*])O^_E='10!SG_  @6E>DW_?RC_A M*])O^_E='10!SG_"!:5Z3?\
M?RC_ (0+2O2;_OY71T4 <S-X$TN.-V FR 3]_P#^M4?P]_Y!-P?6;_V5:Z:X
M_P!1)_NG^5<S\/?^01-_UV_]E6@#J:6DI: "BBB@ HHHH 3^(5QL7_)1'^A_
M]%BNR_B%<'?3W%MXVFDM(/M$XZ1DXR-G- '>4M<P-;\0?] 9?^_E']M^(/\
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M&4?\#_\ KUP/ X>2LX+2_P".YI[22ZG(ZA\ ]/OA<E-3N8)B+5;:140BW6
M(H4_>!/)SU-2ZE\$DU*RO+5]?NO+U)]^J-)#$[W9!!7DC]WM  4+P!ZUU/\
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MK6EE;ZAIF@V)MK+1I)+ ?:9#/);O#-$D^]O-6X216"J(V4<Z'PU\._$+5_\
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M<):PRS"&*:X>-&6!'E.U6D*@G//!K G_ &F?AU:ZUJ^E/X@E273%OFDN#8W
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M /6**16W"EH Y+QW_KM)_P"NQ_\ 9:ZRN3\=_P"NTG_KL?\ V6NLH 6BBDH
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M_P#!0C]O0_LJV-EX6\-6:7GC[6K0W-O<72YM=.@+L@G<?QON5MJ=/E);@!6
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M3=02-@?]%EN;<O+:Y(!.PJK<@']]SVK(T/2+C_42?[I_E7,_#W_D$3?]=O\
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M5S/P]_Y!$W_7;_V5: .II:2EH **** "BBB@!/XJ\\US4)-+\77%S"JM(N
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M@^;'7!'WL8.>OOBFQ^(K#3[W28"9KJ35/-%K+:PM-!^[3<=\B HF0,#<1N/
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MZU".T@N+?1Q<SC'VO='$#'A\K% ^?WAPQ(;J$ /J4^/]1Y_<6_XJW'UYI?\
MA/M0_P">%N/JK?XU\S6GBCXJZAKT-E<:;=:1#/%;Q3S1Z>DB6LAFM!*\;E"O
M,;W9Y9\%.0NT!O5_!-QJMUX3TN77$,>L-$1<JT8B.X,1N*CH2H5B ,?-T H
M[^3QY?NI4PV^",<*W^-;/P^_Y!,^/^>W_LJUP7/X]AWKO?A__P @FX_Z[G^0
MH ZBEI*6@ HHHH **** $_B%>9>+O^1AN_JO_H(KTW^(5YEXN_Y&*[^J_P#H
M(H Q_P#(]J4?+TX[?XTE% !].*,#T'Y444 &T;MV!NQC=CF@_-UY/_UL444
M'3^=&T=,<?Y_S^ HHH /;J.M+[]_6DHH 7)Z@D'ZTG3IP*** "@T4&@#UO2?
M^059?]<4_P#015;Q/_R +[_KD:LZ3_R"K+_KBG_H(JMXG_Y -]_US- 'EV:
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MQ5?05_99\>^%M,L=(D\ ZWHFDZE%!;1V\D,JQ7EW( B-SDM.X&0V1(RC.2O
M!F:W^UWK.G-XE&F> 8;S2]*\4Z=X2@FFUGR+BZNKL6S(S1^01$JBX&26)R,
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M^=&1ZC\Z]%_X072O[DW_ ']-'_""Z5_<F_[^F@#SK</7]:[WX?\ _()N,?\
M/?\ ]E6K/_"#:7_<F_[^FM/2])M]'A:*V#!&;<=S%N<8_I0!<I:** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
; **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img45497886_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45497886_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *A ^$# 2(  A$! Q$!_\0
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M+%_\37&T4>QI]@]K/N=E_P +5\9_]!9?_ 6+_P")H_X6KXS_ .@LO_@+%_\
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\X_%S_DHU[_UQA_\
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M?$7_ $ =4_\  1_\*.>/<.278R**U_\ A%?$7_0!U3_P$?\ PH_X17Q%_P!
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M/^$5\1?] '5/_ 1_\*.>/<.278R**U_^$5\1?] '5/\ P$?_  H_X17Q%_T
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M(!,"C I:*+(!,"C I:,T60"8%&!1GVI:+(!,"C I:*+(!,"C HS1FBR ,"C
M]*6BBR 3 HP*6BBR 3 ]*-HI:*+(!,"C I:*+(!,"C HS2T60"8'I1@4M%%D
M F!1@4M&:+(!,"C I:*+(!,"C I:*+(!,#THP*,TM%D F!1@49I:+(!,"C H
MS1FBR ,"C HS1FBR ,"C I:3-%D 8%&!2T460"8%!4&EHHL@$P*6BBF 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!Q^NZ[XCC\3?V3H5C87&VV$[FY=E(R2."#[5':>)/$=AJ
M=G;>)-)M(8;R3RHI[.0L%<] V?6J>MW.M6OQ$9]#T^"]G-@H=)I?+"KN;G/>
MK$%CXI\0:I9/KUE::?96<HG\N&42-*XZ<]AF@#MMRKU8>G6@NJ]6 ^IKS_3?
M#UEK?C+7+B_$DJ6=VCPQ!R%#\G<0.O2HM'\,6/C1+S5M<DGN)3=21Q1K,RK
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MXEG-O&D+,9@,E!CJ!W(KQG4-->+2CK5EHFJ)/&5D.JWMT5D/S#Y@@/?/3WH
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M7M6@O5+P!=S1AB _'0XYQ5CPQ9PZ)\6M0TS3P8;,PD^2"<#OP* /5:*3O2T
M%%%% !1110 4444 %%%% &4NC*OB9]9\\[FMQ!Y6WC@DYS^-:@J.:XAMQF::
M.,'H78#^=.1UD171U92.&4Y!H S=-T9=-U'4[P3F0WTHD*E<;, C'OUK#OO
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M;.EZ,NFZCJ=V)VD-]*)"A7&S / ]>M7X[B";=Y4T<FWKL8''UQ4O>@!:***
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MMX="GTF&]D6*2[%R',8)7I\O7GIUK8M]&6W\0WFKB<LUU$D9B*\+M[YK5HH
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MAQ%\(_\ "/\ VIMGE&/SMG/7.<5K65N+2Q@M@VX0QK&&(QG QFIZ* "BBB@
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MMKQ-Z@T <'X<ANK#Q-8G3/"6IZ-9R$QW2R2F2)@>C8/((]:[[Q'SX:U,=?\
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M*M6OP\M(+N(S:KJ-S80L&BL)IB8DQ]WCOBMU-#@77;K5&D=VN(! T3 ;=HH
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M';UKV>:)9H7B<91U*L/8UP5O\,Y+7[1:0>(+R+2+AB9+.- "P/;?G^E '/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 'I5;[!9_:_M7V2#[1_SV\L;_\ OK&:LT4 %%%%
M !1110 4444 %)2T4 <MJ_@;3]6U1]0%YJ%E/* )OLD^P2XX&[CTXJ;3/!>D
MZ58W]C$DLMG>G]Y#*VY1QCCN/SKHZ* .3TSP#IFGZA'=O=:A>>2=T$-U.7CB
M/JH]JUXM!M([S4KD[Y/[1"B:-R"N "..,]ZU:* .*/PTT<K-&UWJ+6[H5CMV
MN-T</N@(X/US6ZGAZVBOM.NUEF\RP@,$0)&&4C&3QU^F*V** .1OOAYI-[?2
M7"W-_;13-NFM;>X*12$]<K[^U=1;6T5I;16]O&L<4:[451P *FHH Y35/ 6F
MZGJ$EXMU?V3S',\=I/L24^K#'I6E<^&-)NM"31FM0ME& (U0D%".A!ZYK9HH
M Y32_ >FZ;J$=[+=ZAJ$T)W0_;9_,$9]0.*VK+2(+#4K^^C>1I;UE:16(P-H
M(&./>M&B@#$B\+Z<FGW]C*KSV]],TTJR$<%L=, 8Z5C#X:Z48V26^U*?#JT9
MFGW^5@YPN1P.U=I10!EKHEL-9GU,M(TDUN+=XR1MV_EG/'K61;^!-/MK)K-+
MV_: W*W*(\@(C*DG"\<#G]*ZNB@#G-=\&Z?KMVMZT]Y978789[.7RW9?0U)I
MWA+3=,TN[L8#,QO%*SW$C[I7)&,DGO6_10!D3^'K6X\-KH;RS"V6-8]X(WX7
M&.V.WI5+6O!MAK,D4QN+RSN8D$?VBTEV.RCL3W%=)10!C:%X;L?#Z2?9VFFG
MEQYMQ<2%Y'QTR:V!2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!7L?\ CRC^A_G5BJ]C_P >4?T/\ZL4 %%%% !1110
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MT?X4<M/N'-4['=_VYI/_ $$[+_P(7_&C^W-)_P"@G9?^!"_XUPG_  I30/\
MG]U#_OZ/\*/^%*:!_P _NH?]_1_A1RT^X<U3L=W_ &YI/_03LO\ P(7_ !H_
MMS2?^@G9?^!"_P"-<)_PI30/^?W4/^_H_P */^%*:!_S^ZA_W]'^%'+3[AS5
M.QW?]N:3_P!!.R_\"%_QH_MS2?\ H)V7_@0O^-<)_P *4T#_ )_=0_[^C_"C
M_A2F@?\ /[J'_?T?X4<M/N'-4['=_P!N:3_T$[+_ ,"%_P :/[<TG_H)V7_@
M0O\ C7"?\*4T#_G]U#_OZ/\ "C_A2F@?\_NH?]_1_A1RT^X<U3L=W_;FD_\
M03LO_ A?\:/[<TG_ *"=E_X$+_C7"?\ "E- _P"?W4/^_H_PH_X4IH'_ #^Z
MA_W]'^%'+3[AS5.QW?\ ;FD_]!.R_P# A?\ &C^W-)_Z"=E_X$+_ (UPG_"E
M- _Y_=0_[^C_  H_X4IH'_/[J'_?T?X4<M/N'-4['=_VYI/_ $$[+_P(7_&C
M^W-)_P"@G9?^!"_XUPG_  I30/\ G]U#_OZ/\*/^%*:!_P _NH?]_1_A1RT^
MX<U3L=W_ &YI/_03LO\ P(7_ !H_MS2?^@G9?^!"_P"-<)_PI30/^?W4/^_H
M_P */^%*:!_S^ZA_W]'^%'+3[AS5.QW?]N:3_P!!.R_\"%_QH_MS2?\ H)V7
M_@0O^-<)_P *4T#_ )_=0_[^C_"C_A2F@?\ /[J'_?T?X4<M/N'-4['=_P!N
M:3_T$[+_ ,"%_P :/[<TG_H)V7_@0O\ C7"?\*4T#_G]U#_OZ/\ "C_A2F@?
M\_NH?]_1_A1RT^X<U3L=W_;FD_\ 03LO_ A?\:/[<TG_ *"=E_X$+_C7"?\
M"E- _P"?W4/^_H_PH_X4IH'_ #^ZA_W]'^%'+3[AS5.QW?\ ;FD_]!.R_P#
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M@?\ /[J'_?T?X4<M/N'-4['=_P!N:3_T$[+_ ,"%_P :/[<TG_H)V7_@0O\
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MPA=A_P ]KC_ONCVN,_D7WAR8?^9_<;GV^T_Y^8?^^Q1]OM/^?F'_ +[%8?\
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MR* %HI,TN: "BC-)D#K0 M%4]3U2UTBS-U>2%(@P7(7/).!5S- !129%+F@
MHHHH **** "BBB@ Q28I:* $Q2T44 %%%% !1110 44UFVJS'L,UP-Q\7O#U
MM<20R6^H;HW*'$:8R#C^]0!Z!17*^'O'^A^);HVMI)-%<<E8YU"EP/3!(K1L
MO$,%[KUWI"6=]'+; EII(=L3X('RMGGK0!LT444 %%,D<1QLY!(4$X'6N9L?
M'6FZEH=[JMM:W\D5HX1XUB#2,2<?* >: .IHJGI>H)JNFP7T<,T*3+N$<Z;7
M7ZCM5R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .3NO\ DJ-E
M_P!@UO\ T)JS]+MM7UKQ/J;/K=W;V6GW_P L$;?ZP==I/]WMBN@FT>XD\9V^
ML!HOL\=F8"I)W[BQ/3&,<^M&A:1<:9?:O-,T92\NC-&$)) QT/'6@#EO#QU>
MXM+CQ!>ZS>/;V,D^RR5OEE"@_>/?MBN:3Q9'=I_:=SX[N;6^Y=;*.W<P+UPI
MP.?>O2= T"33] N=-OBD@GEE+>6Q/RO]1UK!C\->+K!186%]I#V"_+'-<6Y,
MR*?H,$B@!_\ ;]W=6?AKQ D[K:32>1>1HW[LY.W=CZ@U:N]8N5\1:O>QRRM8
M:/9D&)'PDLQ&XY]<#BM:[T%KGPI)H\MR9I6AV>?( "7_ +V!TYJ#0_#;VGAJ
M?3M3=)KB\,C7<D9X9GSG!/UH \X3Q6DD7]I2^/+B/4=ID^PBW?R-P_@/%=5J
M>L:CK5OX7?3+U[-M2WB1XSD#CDX[]#BEC\-^,+1!I]MJ&D-8J-B7,EN?/5?7
M&,9'UK<N= NGOM E2X65-.9C,\O#/D8R !C.: .5\42:GH2Z;I]SKFK1:8L3
M-/JD*;Y#)D\.>PQBK_A_5I)O#6L-;>(UU6.&!V@F8%+B,[?XP??H:V_$6FZ_
M<3QW.B7]NIV;)+6\3="W/WN.<UF:;X1U)!JE]J-Q9_VC>VIMQ':H4B7C@^N?
MPH RKUM1O_\ A#&M[G;?31OF>7YB,QG<WN<9_&M&WBUGPKXBTZ"YUJXU6PU%
MS$WVD#=$^,@CVX-27/A+59+;P\MM>06\^F1D/(,GYMI P,<@GKTXJ?3= UZ\
MUJWU+Q+>VLAL\FV@LU(3<>-[9[X[>] &+%]NB\,Z[=6$TL<UKJKS8B8@NHQE
M3CJ"*WIM3EU7Q1H]K87$B6B6_P!MG\ML;E8?(I]NE6-(TX:%8ZI_:5Q;I#<W
M4DH;?@!6 P"3CFLKX=::(+6]U$N9$GF,5LYZ^0AVK^'% "^,8[R;Q1X>BL)D
MAN7>55D<9"C8<G'KC./>F6L6L^%?$6G6UUK5QJMCJ+M$3<_?C?&01[<&M3Q+
MH&HZMJFEWFGW<=JUF7;>V2<E2 ,=P3P>1Q5;3- UV[UJWU/Q+?6DK6>[[-!9
MJ0FX\;CGOC^= &+;:I=Z3X<UAK +]LN-8>"$L,A6;'S5-J.F^(O"EH=;_P"$
MDNM1$)5KFUN/]6R_Q;?2M(>#9KC0M3T^ZN$CEN+UKJ"6+)\L\;2<XYXJK)X=
M\7:TJ6.NZII_]F*RE_LJ-YDP'9L\#/>@"34WU7Q+XDDTFPU6;2[.U@2:26W_
M -8[,.!]!3M7L]4L/A]JMOJU\EXZ*?+G (8ID8W>]6=9T#6(]8_M?PY=VT-U
M)$(9H;I28W4=#QSD4KZ#K5WX5U"RU'48[K4+SGNL,7(^5>,XH SO"^I3>)M0
MC9+V:UL],BC06:DH\S%1\[^J^@KG]:UJZ3Q#?)K/B/5-#\N4K:I#"3#)&.AX
MZGUKLI/#EY;ZQI6J:>\"3Q0+;7J.Q"S1@=L#J#GK534M&\7_ &V=;"_TRZLI
M7+*-1B+/$#_",#D"@#H= N9;O1+6::\MKR4H-\]M]QSZCT^E>::QK%Y+<WLR
M^*=1DNH';;;:3 S0(!T#,0 ?<UZ'X:T >']$&GF;S69F=W4;1N;DX'85S$/A
M/Q;96DVCV6IZ<FEON"S&(^?M;J/3VZT /DUW6-7T'P[:6MRMK>ZJK&:Y4<HJ
M]2ON:U]+T#6[!+VUN/$$]Y:30XBFE'[^)^Y!Z8JBGA#4HO#6D00WD,.KZ46,
M,H!:)\G[K#K@C%:>A6'B07<EWK^I6[_)L2VLU(B'^T<\DT <3I%O?:3\/]5U
M"+6+PL9VC1"V!&1+@L#ZGO\ 6NOM;VZL?&307=U*;.]LA-")&RJ.F-X'IP<_
MA6:OA+74T;5M&^T6+V4TIEM&)8."7W'?QZ9Z5K^*O#UWK6DVT5C/'#>V[?+(
M^<;2I5AQ[$T <Y=^)=0L/#.H:Z;F1/M][Y-H9,M'!$.-P7\&_2L:U\76NDW<
M%U;>-;G5B\BK-:7,+A2I/)4D<8]Z]!U+PO%?>&K?28Y?(>V"-!*%W;77OCN.
MOYUD6VA^+[BZC34K[28+1'#,]E!^]D ['<,#/M0!VX->;Z1I_B+Q+;7<A\27
M5G!#=RK#Y)R[$'HQ/\([ 5Z/7F?AVS\4-8WLNA:A9I%+?2K)%=QD[,'[R$=_
MK0!+=Z]K3^#75KDIJEKJ2VCRQ_*']"?P(_*KNHQ:WHUO9:/;ZU/<ZAJERV;N
M<9\E !N"CL/2K,G@V:/PS#IMO<I-=&\6[N)YLJ';/S$8S["M7Q/H,VM6]M+9
MW7V6_LY?-MY2,@'N#[&@#GWMM;\'ZC83S:[=:K8W-PMO/'=?>3<<!E/U-4]"
MLKC2O$WB;49-6NYH['YY(6/$_P C$;OICBM6V\/>)=4U.SN/$M]8M;V<@EC@
MLD;#N.A8MZ&K2>']2A\4:A.DML^C:DF+F)\B4':1\O&,<T 8UIHWB?6=,36V
M\3W5M<RJ98[2(#R0/X013+W7-9U72?#4EE=?8KZYNG@G9>4+*=I)'<<9Q[U9
MB\.^,]/M3I.GZMIYTOE$EEC;SXT/8=N/K6G_ ,(F]M#X>M[.5&BTR8RRM(2&
M?/)(XZDYH HZ7'K&@>-(-+NM9N-3M+V!Y0;C[R,N>!Z"NYK#N](N)_%NG:LC
M1B"VADC=23N);.,#&/UK<'2@ HHHH **** *]C_QY1_0_P ZL57L?^/*/Z'^
M=6* "D-+2'I0!PGBJYU2U\;Z3)I&GQWUU]EF'E22B,8RN3DUF7FJ^)?%%\?"
M]]IMGI3/M>5GEWET!Z)Z_45V=UI$\_BZQU56C\BWMY(G4D[B6*D$<8[&H_%.
M@/K5K!-9R+!J=H_F6LQ. #W4D=C0!SWCCQ#_ &9J%CHIU=](M7AWRW:1EWP.
M JX!(/'6JOA+Q+%+KJZ)!XDFUBWN8G*S3(R2Q.!GJ1R,?E6_K?A_5+Z2SU:Q
MFM(-8AA\N1)5+PR \D=,XR3SBGZ!I&OQ:A]MUN\LL(A5+:QAVH2?XB2,YH R
M[;7KVQ\$ZA'=3R2:M:S-9J7.79V.$.>_7/X5F^)-=FTN?3M O/$%QIB+:"6Y
MO=K22R.>P(!/4&NBO?"<]UXR@U198Q8 K+/"2<O*H8*<8Q_$:D\1>'M0NM2C
MU?1;BVBOUB\EX[J/=%(N<C/<$9/3UH PO!OBB.76GT:'7I-:@>%I8IYHV25&
M&<J<CD>E.\,PZ_?:7)KKZQ=3O"LZ6]D6^20C(4OZG-;N@Z1KL-V]WK5Y9EO+
M\M+:RBVQC_:)/)-3Z!HEUIGAEM,FN!'.QDQ+;G.S<201D=1F@#SS3=>G^VPM
M<>,;ZSU4N#)8ZC"5@'/*^PQG!KN)[VX/C9;47#&V;2VD,:M\A;/W@*R+OPOX
MNU2)M.U&^TB2Q?Y6N1 3<%?7TS^-;R>'IX/$$-W')&;6'3OL@W,=Y;/!Z=/Q
MH Y3PYH&N:KX;BGM_$$VGQ12S?9X;<</\[?ZP]^<_A5B75+K5M)\-SWH47<6
MJB&;;P"RM@G\<5/8^&_&6D:<EEIVJ:>L4CN91*K,8MS$_NSCT.>1US6D?"#V
MVFZ)96<ZR"RNUN9I)B093G+$ 9Y)[4 -@U>;1M6\10:A<22QPQ_;;;S&)PF.
M5'T.!^-:'AQ;W_A$XY;^:66YGC>9C(V2H;) 'L!BL+QK:0:QKFCV-K<(UT\I
MBN(D8$^2/G8-Z<J*[=XA]E:&, #9L4>G&!0!YMX<T'7=4\-PW%MX@GT^**27
M[/#;CA_G;[_XY_"K,FJW.KZ9X9GO0OVJ/51#-MX!=6P2/KC-36/AOQEI&FI8
MZ=JFGK#(SF42JS&+<Q/[LX]#GGOFM-O"#VVGZ'9V<ZN+"[6XFDE)!D.<L0!G
MDG/'ZT 4)(=:\6ZWJ<<&MW.E6%C+Y""UQO=AU)/I3;?7]5T+3=>LM0F6\N]-
M5&@N'&/,5SA=WN#5R^\/^(;#6;N_\-7MDJ7K!Y[>\5BH;^\".]2V'@^1M+U1
M-8O?M%]JF//EB7 3'W0OL#0!6TK0/$T$]GJ;>)9;EI"KW-K./W6T\D)Z'TK*
MU[Q V@>--6:$ 7%Q;P11RNI,<).!O<^@K6L=&\9":VM+W6;---MR/WELA$\J
MKT#9X&>]:$WAK[;KNKW-YY3V-_:K;[03O! Y/3'TH S/$2ZMH7@^!+.^OKN1
MI5^U7B_O)50\LR#MV^E4/!6KI/K @M?%TFJ0LA\RWU!"LP;ML/0]\C-;,&A^
M(X?#4-BFJ117MI)^YE!+),@Z+("./PS533_"NN76N6>I:]-IB?8F+Q+I\14N
M2,?,30!?\;ZA-8Z?;*FL1Z9'++MDE",\S#TC4 Y-<WX1UJ]B\6#3CJ6J7UE-
M TOF:C%L;*YY3/.*ZCQ3H6HZE<6&H:1<6\=]9,VU+I28W#8SG'TK.TSPWXC'
MBFTUK6+ZRFV0O$\,"E50$<;>.?4YH HV%CXE\3VK:]!XBEL7=V-M:(/W(4'@
M/ZT[Q?I-[>>(_#8.K7%M+*YC/V?HC!22R_7I]*L)X;\6:5YFG:)JME'I3N2C
M3HQGA#'D+C@X[9K2U_P_JES!I,VF7D3ZAITFX27F<294@DX'7F@#,NGU6XNO
M$]E:ZA=>;:PP-;E7(*L%)./KCFK%]K-QJUAX>M;"XEBGU%DDF>)MKHBX+_3N
M*UM)TB[M-=U/4+IH2MXD0"QDG#*,-U'3-4/#_A6?2/$%[?3S1R6YW+9HN<Q*
MS%F!_$F@#DM:\517WB"_M;WQ7=:'!:2F***VB9GDQP69@,=:ZOP)XB_MRSO(
M&OEOFLY BW(0H94/0D'D'@U!?^&M=LM3NKKP]<:<8KM_-E@OXBP1^Y4@=ZW?
M#VFW^GVLIU.\2YNIGW,(D"1QC^ZH]/K0!E^-;K4X;G1(=*NC!/<71CY)VMQ_
M$.XK/:#7/">KZ?-<:Y<:I97LX@G2X',;,>"OH*L^.H);F^\.PV]PUO,]Z0DP
M&=AQUQ2VGA[Q!J.KVMWXEO[-X+*3S((+-& =NS/GN/2@"KIMOJ^L^)]49];N
M[>QT^^^6&-O]8.NT_P"SVQ4-A8Z_XPBEU8>(KK3(#*RVUO:X V@_Q>M=/H>D
M7&FZAK$\[1LEY<^;&$))"^_%8*^'?%6BS3P>'=1L!ITTAD6.\1BT.>H7'6@#
M"UZ?4M8\%LE]?/%=Z=?BVF,7W9^1M8_@:W=0CUEK_3_"MEK,\;+;F>ZU!@#*
MR[B ![\5/+X*F7P;/I45Z)-0EF^TO<2# >7(//MP*6^\/^(+I=/U:&]LX=?M
MHS'(0K&"922<'N!0!'IHU?PWXFL],O=5FU2QOT?9+<?ZR.103^1Q6)86GB76
M=#OM2'B6[MQ:S2F").=^WG#GN..*Z31_#^M2ZY%K/B.]M9KBW0I;P6JD1IG@
MMSSG%6]$T*ZTWPW>:?,\)FF>9E*,2HW],\4 6_#.H3ZIX<L;VXQYTL67P.,Y
M(_I6O67X<TZ;2?#]G87#(TL*%6*$D9R3QG'K6I0 4444 %%%% !1110 4444
M %%%% !1110 R7_5/_NFO!M!\3V_A^_U5)]!&IF6Y<@D#Y/F/JIKWF7)B<#D
M[37C&BW7C'PM>ZD+'PS<7"7-PS[I(7QU.,8H ?H.H6?B/XDV=Z;2'1UAC^2W
M/#3-CZ ?I72Z+X@U6Y^(GB#39KQGL[:*1H8BJX0@KC! SW/6L:VLO%/C#Q=I
MFH:MI/\ 9L%@P8ML*$@'.!NY.>G%:>AZ3J,'Q*\1WDMC<):S0R"*9HR%<DKC
M![T 4/#&H^,O$]GJ8AUQ+=;>5@LSP*SD\X4= !QUP:U_!GC"\N?#VK3ZTXEF
MTQF#R*,;@!WQQUH^&NEW^G:;JZ7UE/;-)<,R+*A4L.>153P1X=O38^)+/4+.
M>U2\E<(94V[@<\CUH BT2\\:>)-,N->BU2W@MR7$-BT(*2 <$$]1S6+X4U"[
MTKX;>(;RSE,-S%,A5U .T[L'K]36OX>F\5>&M+G\.CP]/<R*S_9[M3B(9YR3
M]:S]'T'6(OAMX@M)=,NDNIY4:.$Q$._S G [T 7M9\4ZY:_#SP_J5O?NM[=.
M!+)L7+\G@C&/RI?$6J>,?#MK8:U-J\$L4[*'LU@"JN0._)/YBJ^LZ'JTWPX\
M-6D6F73W,$H,L2Q$M&,GJ.U;OQ%TR_U#PGI\%E93W$R21EHXD+$8 SF@"7QG
MXJU"SATJPT?:E]JA4([C)0'ICMG/K6)XEO\ QCX733(9]:6YCN+@!KA8%5\]
MT(Y&/<8Z5?\ &7A[4IK;0M9TRW,M]IRH6@/4@8.,=SFL+QSJFK:O!HT]YI,N
MFVRW:@1SG,C/ZX[#&: /8(B6A1B<DJ":?4<'_'O'_NC^524 %%%% !1110 4
M444 %%%% !1110 4444 (>M'.!ZUP=_::GK/CK4M-AUBYLK);6)I/)?YN>FS
MLON:2TDU+0Y]:T&XU&>]BCL'N;6XE;]ZO&""WUYS0!WM%<7<WET/A2+L7$WV
MG[*A\[>=^=PYSUS5>_&I:AXDTO3;;4Y[6.XTS?-(C'=@8Y7MNYZT =Y25YU8
M:5K,^K:EX9/B*]%C;!)?M._-RVX?=W=@/ZU";S4[3P1XCM)=1GFFT^<PQ7.\
MB0KGC+=<T >F4=:\\U+1==TO2F\1KXBNY;^%!-);EA]G91U4+].]0>,=3O)+
MG3[B[N=4LM#EMED,^G<,LI[,<=,4 >E4M<AX#U"*[L;A(-<?4X$<>5YZ;9XU
M]']><X-=?0 4444 4=3TJQUJS:SU&W6XMV(8QMG&1TZ59M[>&UMXX((UCBC4
M*B*,  5+BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JEAI]
MIIL+PV< BC=S(R@DY8]3S5NC% !1110 4444 %%%% !1110 4444 %%%% %>
MQ_X\H_H?YU8JO8_\>4?T/\ZL4 %!HI#0 45P^N0ZEJ/CN+3+/5)[*"2Q9IC&
MQSC</NCH&Z<^F:--CU'PWXB;19=3N=0L[JTDFA>Y;=)&Z]?F]\B@#N*#7&Z1
M=W,GPRFN7N96N!#.1,TA+9#-@YZ\5G33ZI=_\(G:VNH3027EJ1+)N+$CR\DG
ML3Z$]Z /0Z*\ZM]*UF#Q%<>&8O$5ZUE+;BY>YE8-.O.-J-VSG]*=92:CI>G^
M*=*EU.YNEL8U:WGE<F4;@>K?A0!Z'VHKS>'0->G\-V^N_P#"37JZ@EJDL<*O
M^XP%! 8'J<=2>]-\2ZSJ-]H^AW[OJ%KI-Q!YMY+IW$D;XX_X#0!Z517$> =1
MM[EKJ"T\0SZE;A0R17BD7$9[DD]1R*B\<7H&J6UE+K=[:Q-$6^RZ9$3<.V>"
M6'1: .\H&>]>7>']6U$:5XEL9+C40EI!O@:^;]^A([G]123V&MZ=X6L/$Y\1
M7\MVB0NT#./**$@8([G!ZGK0!Z#;:%IEIJMQJ=O9QI>W'^MF&=S5"FN!_%,F
MA_9R"EL+CSM_!R<8QC^M<_JB:CXE\3OHT>I7&G65K;)-(UJVV21FZ<]@*K^'
M]/O=,^(US;7E\][MT]?*FD^^4W<!O4YSS0!W_0TE<SX]N;JU\+R2V<SPS^;&
M%=&*GD^U8'B.6Z\&Z+%$VMWTDFHW0\Z\E_>&$8RPC7L.O':@#T:C->0Z-XHL
M=-UNR33O$6K:E'<3"*>'4$8@ \!E8CC!Q70RV.I:_P"*]<TY=8N[*SB$3$P2
M8?)#8"G^$=<X]J .]HKS?2],UOQ#IMW;W7B*\@BTV=X(GMVVR2E>=TC=3U Q
M[4Z76[Q_A_ITUYK1LY))3#+-%$7FF56VXC _B..M 'HQJEIEY<7L$DES8R6;
MK*R"-VW%@.C?0UYUX6U"[M/&=G8PW6MS6-W&Y)U4Y+8&04!&13KF_P!3?P7(
M\%_/'<G6?*24R$E03P/I[=* /4*#S7 FPU/PSXITACKE[?0ZC*T5Q'<,"H.
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MKUP_@2"[MM;\20WTXGN$N(P\P&-_R\''KC%=Q0 4444 %%%% !1110 4444
M%%%% !1110 AJM#?VEQ=36L-Q')-"!YB*<E,] ?0^U+?P27%E-##<-;RNA"S
M(,E#ZBO)?AOIM]+XBU29=8GC2TN/WZ!01<X)^]SQT_6@#V*CITKS2PO_ !#X
M\U34'L-8;2-,M)#%&84#.Y]\_G6GX-\0ZD^MW_AO6G$UY9Y,=P!_K%!QS^=
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M['QG'X5V=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:;?FPU"S9C%*4#J0>H([]*SM+\(ZM;^)+76]2US[=<1QO'(IBVKM(P-H'W:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M _#^ZTY+FZLK*YU.)=@==/U%,/'C@LK9Y!S7?4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 5[>TM[42"W@CB$KEW
MV*!N8]2?4\"K%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -
M<;E9?48KG/"GA8^&?M_^F"Y^USF;_5[-N>W4YKI,48H , TN*** "BBB@ Q6
M%XL\/'Q/H4NFBZ^S%V!\S9OQ@^F16[10!5TZT^PZ=;VF_?Y,83=C&<>U6<4M
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-8XU5$4855& !Z 4[% '-Z%X5ETW47U/4M4FU+46C\H3.@0*F0< #Z5TM%%
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M^?3#V%/_ )^(ZW(]:,CUKDO^$=US_H+G_OH_X4?\([KG_07/_?1_PH^MUO\
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MX;Y@4;)^8"@#O6O]1;7]*'_"0:?!;2VZ/+82*OG2DJ22O?'^!KF=5\;:G?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** *]C_QY1_0_SJQ5>Q_X\H_H?YU8H *0TM% &)K/BS1= N8;?4;U
M8I9ONC:3@>IQT'N:T!?V4R0!;B&1;D'R@K B0=\>HH?3+*66>22VC=[A DI9
M<[E&<#Z<FLS1_!VBZ%?RWMA:E)I 0"6)" ]0H["@#%\5Z9I%E:V]CI^AZ;_:
M.H2>3 WV5/D]7Z=A74:+I%MH>DP:?:)MBB7&>['N3[FL=;>:\^(;W$L,@M[*
MS"PNRD*78G.#T)Q73YH \YAU35[3Q1XCM]$TM;Z[:=';S7V1JH!ZGUYX%;,'
MCB,^$7UFXM'2>.4V[6RG):8<;14_AR"6+Q)XDDDBD1))XRC,A 88/0GK7.KH
MVHW'A>_-M;/]KM]6:ZBBD7;YH&.!GUSU]J - >+?$>FRQ7'B#08K739'5#-#
M-O:+/0N.PK?MM:EG\5W>DF)!%#;I,L@)W,3CC]:Y35==U+Q=8G0[/P_J%K+.
MRK<37<82.-<\D'/-6]4N+SPUXT.HKIEW?V5W:K!_HJ;V1EQC/Y4 7KKQ9<6U
MMXBE^SQ'^RG14Y/S@]<U4D\8ZQ8Z'-JNI:3#!%*T:6*>=S(6!Y?GY1Q63]GU
M2XT;QC)<Z=-#/<R1LD*H6)&>@Q]['?%=3K4<G_"(PQ_V0FIJ(X_.M7."5V\D
M#N1Z4 5]$U_Q%/?Q0:QHD44$X/EW-E+YR*1S\Y&<9KK!7D>@Z=_Q4=G-X;TK
M7--190;PWQVQF/\ N@$\UZV* %HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** &2)OC9,XW C/I7.^$O"8\+)>J+TW/VJ8RY,6S;[=3FNEHH Y
M>'P>(O&\_B3[;N\V/9]F\K@?+C[V?Z5E1_#9[2]NO[/\07=GIUVV9[2.,?,.
MXW$\=3VKO:* .'T[X=C3=!UC2(M49H-0QL9H>8L'_>^;MZ5+/X!$_@6W\,_V
MD5$,F_[1Y/)^8MC;N]_6NSHH JZ=9_V?IEK9^9O\B)8]^,;L#&<5C^,?"O\
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MZ'^=6* "BBB@ HHHH 3%&*6B@!,&C!^M+10 F#1CTI:* $Q1BEHH 2E HHH
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MSXD_Z!:_]\FNL_"C\*/J=3_GZP^L0_Y]HY/^V?$G_0+7_ODT?VSXD_Z!:_\
M?)KK/PH_"CZG4_Y^L/K$/^?:.3_MGQ)_T"U_[Y-']L^)/^@6O_?)KK/PH_"C
MZG4_Y^L/K$/^?:.3_MCQ)_T"Q_WR:3^V/$9_YA@_[Y-=;^%&!2^IU/\ GZP^
ML0_D1A:/?ZO=73)?60AB"Y#8(Y_&MZFTZNNC!PCRN5S"<E)W2L%%%%:D!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^M #Z*** "BBB@ HHHH **** "BBB@"O8_\ 'E']#_.K%5['_CRC^A_G5B@
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M'7\*[_3]&TW2MW]GV%M:[OO>3&%S]<4Y=(TY;R>[6QMQ<3KMEE$8W./0GN*
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MGV]J .-U&U@3X/0JL2A5MX7&!_%N7GZU:-Y!9_$+36NITA6;2S'&9&P&8LG
MSWKK6T^RDL18O:PM:@!1"4&S Z#%,NM+T^\>![FS@F:W.82Z!O+/MZ=J ..T
M2UUBZT?5(]%U"*QN1JLI:26$2 K@9&#3=?L9(M'T]/$VOF/48[DO;:A;P[$C
M/^UQ@#W-=S;6EM9JZV\$<(D<R.$7&YCU)]Z+JUM[VV>WNH4FA<8:.1<@_44
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M-298XC8*JSNN5C.1U/;/3-+97EMKWC'4M2T@>9:1Z<T,EP@^69R00!ZX /-
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M ?VA-P!@=JZR@ HHHH **** "BBB@"O8_P#'E']#_.K%5['_ (\H_H?YU8H
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M/).4(P/7!Y '4DU>\6Q*GQ'\,1'#*JA<8XXQ0!O6/Q"@F\0Q:/?:5>Z=+/\
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MYO/!FH16H8R; V%') .2/RKG-%\4Z!#\,5AEO+=98K-H9+=F =GVXX'4\]Z
M+WC;Q*9/ KWFD1SW$%VF/M,!P(1D<MZ>E9WPIL;5+-KI=$N;:Y\H;KZ5B4N<
ML?NCIQ6786=S:?!34VN%:,3,98E;.0A9<5W7P_\ ^1%TH8Q^[/\ Z$: .D'2
MEH QTHH **** "BBB@ HHHH **** "BBB@"O=6-I?QB.\M8+A <A9HPX!^AI
M\%M!:PK#;PQPQ+T2-0H'X"N<U3QK!IVKS:7'IM]>7<>T^7;1AB0PSGV SWI-
M6\;V^G:@]A;:9J&I7,0'G)9P[_*R.A/2@#HX[6V@A:**"*.)B2R*@"G/7(I8
MH8(8E@BCCCB P(T4  ?2N3\0:S::W\/=1N[1F "A71P5>-@PR".H-6;&73QX
MDL4:&7[>-+5O.W_((^.",]<]\4 ;EOI.G6<QFM=/M8)6ZO%"JL?Q IUW96E]
M&([RU@N$4Y"S1AP#]#7+S_$2S2ZD2VTK5+RTB<I)>00$Q*0<'GVJ+QYK^SP9
MYNGQW,\5^H"W%NORHI[L>V1Q^- '7&TM'M/LIMX&M0-ODE 4QZ;>E20P00VZ
MP0PQI"!@1HH"@>F!Q7,>%[73K+P9*;?3KVSMG21Y(+DGS3QSU]>U,@\2Z9HG
MA;2WM+*\D6X!%K9QKYDS8)S]?_KT = FB:3&CHFEV2K)]\+;H WUXYJTMM;I
M.TZ01+,RA6D" ,0.@)]*Q-!\5V^N7$MHUG>6%Y&H<V]W$4;:>X]15[7=9AT#
M2)M2N(WDBBQN6/&>3CO0!=BMH(9))(H8XWE.Z1E4 N?4GO5?^Q],S,?[.L\S
M?ZT^0OS]_FXY_&N?L_']C=:K;V;V&H6\5R=MO=3P%8YCV"]ZL:UXSM=)OS80
M6%]J-XJAWALXBY0'H30!T2JJ*%4 *O  '2J[Z9I\MTMW)8VSW(P1,T*EP1TY
MQFN9O/&<-YX3U"^L+>\%U!F.2W$>)8&(ZD>@]:O^"]6FU?PU:R3VUU%+'&B,
M]R,&8A1\X/<'UH WIH(KF)HIXDEC889'4,#]0:CM-/LK!&2SM(+96Y(AC" _
MD*Q-<\7VVC7JV$5G>:C?%?,:WLX][(OJ?2I=)\66.IZ;=7DBS61M/^/F&Y7:
M\7U% &S%:V\ D$,$4?F,6?8@&XGN<=33$M+:.W-LD$*PD',2H N#UXZ<US&G
M_$&ROK^"W?3M0M8+E]EO=SPE8I3VP??WK/N]=BT/QYK$CV]S=326T(BMK9"[
MOP,X'MZT ;FI:+++XBT2XMX8EL;,2+*N0H52A4 +Z<UMVEA9V*LMG:06ZN<L
M(8P@)]3BN6N_$FD:]X,OKR>VNC;QD)<6OW)4;</E/X^]7M7\56>@PVD"VUU=
MW4\8:&TMDWR%0!S^HH WHK:"!76&".-78LP1  Q/4G'4U!;Z3IMI.9[;3[2&
M5NLD<*JQ_$"LK2_%MOJEG=NME=P7=JF^2SG39*!V.#ZX-3?\)/9_\(I_PD!5
MQ;>3YNSC=_N_7/% &G/8VES-'+/:P2RQ',;R1ABA]B>E,NM*TZ]E66[L+6XD
M485Y85<CZ$BL35?&=OI2VT1L+VYOYXQ*+*WCWR*.^<<<5<T/Q+::W#,1'-:3
MV_\ K[>Z38\7N0>W% &PJJJA0 J@8 ' %5+G2]-O9A-<V%I<2 </+"K$#ZD5
MR=[\0=/FBNXX[#4'L=CQG4! ?(S@CK]:T_ ''@;3/^N9Z_[QH N>(3K4>GI'
MH$5JT['8WGMM")CJON/2I]"TB+1]$@TY0KA$_>''WV/4_C7GMW<PZ_\ $T0:
MAI&JR16I5(% (6)@P_>-@_<-=+?>/[6VO9K:RTO4M26W;;-+:0EDC/<$T =2
M+.U6T^RK;0BVQCR1&-F/ITI9+2VFMQ;RV\+P+C$;("HQTXZ5AW'C+3(?#D6N
M(7EM))!'\HPRGG@@^F*NZ'K3:W:RS_V?=V:+(507*;3(.H8#T- %#^Q9)/&5
MY?74,,FGSV2P[9,-N8,#@J:W;:WM[2%8;:&*&)>B1(%4?0"N&\4Z%I;3W6K>
M+[Z5[$.$M(8&<"(>X'<_E6I\/I;B;PR)))S-"9G^S%Y [^7V#$'K0!T<%C9V
MK2FWM((C*<R&.,+O/OCK3+;2M.LYFFM;"U@E;[SQ0JK'\0*Y#4O$]W:_$6VL
M%L-1EMA 4*1IE78D?O/]T=,^]:&J>.K6QU&:QL]-U'4YH.)_L<.\1GT)H Z8
M6\"W#7"PQB=EVM(%&XCT)ZXI(X+>!Y)(XHXWE.795 +GU)[FJ>BZW9Z]IZWE
MFS%-Q5D<89&'4$5SGQ'EM#ING65[*(K6XO%$[;MO[L D\_@* .O@AM[=2EO%
M%$&8L1&H&2>IX[U-7G_@RQ\"MJK7/AVX=[R-2I625\[>YVMU'3FO0* "BBB@
M HHHH **** *]C_QY1_0_P ZL57L?^/*/Z'^=6* "BB@T 5[NPL[^,)>6D%P
MBG(6:,. ?QIT%O!:0K#;PQ0Q#HD:A5'X#BL/7?%L.BWB64>GWNHW;)YC06<6
M]D7ID^U5W\1Z9KGA;4IIK>Y6.!"MU:N#'*G0X_+% &ZNE::JRJNGV@64[I (
M5PYZY/'-9/\ 8DLOC*ZOKF"&33YK(08?#;F# X*GMQ56X\7Z;H4&E6@L[MQ<
MVBR6T<2>8Q&.$P.2?>KF@^+;/7!=*;>XL;BU&Z:"Z7:R+ZGVH U390P:=):V
M=O%"A1@L<:A%!(]!Q6/X<\/Q6>@V%OJEC:O>6X;#,BN5RY(P2/<5E3?$VPA$
MLRZ5J<E@F0+U8?W3$>A^O%2:G?)J>J>$+Z-'1)YG=5;J,J.#0!V$EO#.\;S0
MQR-&VY"Z@E3ZCT-+/;PW,+0SQ1RQ-PR2*&4_4&N8U3QS;6&HRV-GIFHZI- <
M3_8H2XB/H36YI&KVNM6"7EFY:-L@@C#*PZJ0>A% $]I86=@C)9VD%LK')$,8
M0'\A45QI6FW5P)[C3[2:<=))(59A^)&:S-?\66N@SQ6HMKJ^O9066UM(][[1
MW/H*Y_0]9M]:^(T]W$DT.W3@LD4Z%7C8-R"#TZB@#NY;>"X@,$\,<L3#!C=0
MRD>F#Q45OIEA:1/%;6-M#'(,.D<2J&^H YKEKCXBV:7$HM-*U.]M86*27=O
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M.* .@_X1[0O^@-IV?^O5/\*TU4*H55 4#  [5@13Z:GC.]_=2I>I9*TL[/\
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M*,HFPC 0D@9.>:]"J&"VM[8%;>"*('J(T"Y_*I$E20$HZL <':<X- #J***
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MF\H9/KDXJ5$2- D:A%4855& /PH X.Q\0:;X3UW7+?7)#:/<71G@D="1,AZ
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M&UEIE[X?OKZRA0[8D<JLQ(^^,<_+W^E6M>\6:=XNT]-&T1)[J\GE3</)91
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M'M?M<.@:A-;1,RW,R ;(<'KG'/'-,MM;@UWX@6MS:1R_9?[/D$4LB%/-Y.2
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M&VAC@8G,:( ISUXJ"ST72]/E:6RTZTMY&X+10JI/X@4 /U3_ )!-YQ_RQ?\
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M#N>K45Y3_P +F;_H6+W\S_\ $T?\+F;_ *%B]_,__$T>QGV#VT.YZM17E/\
MPN9O^A8O?S/_ ,31_P +F;_H6+W\S_\ $T>QGV#VT.YZM17E/_"YF_Z%B]_,
M_P#Q-'_"YF_Z%B]_,_\ Q-'L9]@]M#N>K45Y3_PN9O\ H6+W\S_\31_PN9O^
MA8O?S/\ \31[&?8/;0[GJU%>4_\ "YF_Z%B]_,__ !-'_"YF_P"A8O?S/_Q-
M'L9]@]M#N>K45Y3_ ,+F;_H6+W\S_P#$T?\ "YF_Z%B]_,__ !-'L9]@]M#N
M>J@4M>4_\+F;_H6+W\S_ /$T?\+F;_H6+W\S_P#$T>QGV#VT.YZM17E/_"YF
M_P"A8O?S/_Q-'_"YF_Z%B]_,_P#Q-'L9]@]M#N>K45Y3_P +F;_H6+W\S_\
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MO^%'_"8O_P! Z;]?\*/[1P_?\ ^IUNQUE%<G_P )B_\ T#IOU_PH_P"$Q?\
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MQWKA&DSP,]* /1M(\0Z5KT3/IE['<;?O*,AA]0>:T\\UY-J^E6W@OXB:)/I
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M3LOER1JQ\K/9U)ZGV->AZ;</=Z9:W$F-\D2NVT8&2* +=%%% !1110 4444
M%%%% !1110 4444 %%%% ')ZYJ.K7^O+H&B3);,L0ENKMEW>6">% ]35";0/
M%6AP/?Z?XCN=5EC^9K2\48D4=0,=#4TU_;^'/'UY+J3^3:ZI%'Y,[9VAU&-I
M/;I57Q9)./M&J6OCE;"W6/Y+6)4<%@.QSGD^U '6W>M6>F:8E_J<R6D94$^8
M>0<9P!W/TJ+1?%&C>(0_]E7\=P8_O* 58>^" <>]>?:W/JETGA&=YK4RO S%
M]3!$+2XX+ #[V,XJWIT>KMXSTJ6^O?#HE <;-/+>9)'CD' (X..N* .KO/'7
MAJP9TN=5C1TE,+)L8L&'48 SCWZ5JOJ]A%IHU%[R$697<)BPVD'_ #TKE/"F
MF6,[^(YIK6*622^EC9G4'Y0!Q^IKE+I;A? ?A^.!H!"M^ZL;K/D\,=F_'.,X
MH ]'T?QAH.OW#6^F:E'/,HR4VLI/T# 9_"B]\7Z%IUV;2[OUCN!(L7E[&)W-
MT' _6N&E36Y-7TEKR]\,1LETOE?8BXD;U48!XQGK72:':6\OCGQ)<2PK)*AA
M"%AG:,'./R% &CJOC;PYHMY]DO\ 5(XIQU0(S8^NT''XU6\0:HS/H$VGWA\B
MZOD5FB;B1#V/J*Y))7OXM7NK:^T;1;+[1*) T?F3DKP6;<>_M2:.0?"?@\[L
MC^T^I_WS0!U&FZZ+/4?$<VJ7DGV2WNTCC+981YX  '3G%=%>ZK9Z?';R7,VQ
M;B18XL*6+,>0, >U<IIVG)JUUXRL).!/.$!]#M.#^!P:IZ!=R^(M<TFWG!_X
MDT#&X]/.)VJ/^^03^- 'H+N$4LS!549))Q@5ST'CWPQ<ZD+"+5X6N&;:!M8*
M3_O8Q^M6_%-U#8^&-0N)[87,20G=$20&'H2.U>7^((KF/PS:/<:QI"1EHA#8
MV,(&1D8^;.>!ZT >IZSXDTGP_$DFJWL=NKGY006)_ 9./>L+2_$"ZEXXNFM=
M0,^F?V<LJ*K90'=R<=C4"_8(_B1<MJWE M9)]D-QC;C W;<\9JKI9TMOB%K9
MTGR_*.G_ +TQ?<,F><?ITXH Z.7QQX<ADMHY-5B5[G_5@JW/)'/'R\@]<5+-
MXPT"#5UTJ34X1>L0!&,D9/8L!@'\:Y+3=,LC\)[J8VT32RI,[NPRQ8.1G/;H
M*DUO2[&W^%]F\=K&'$<$GF8^;><$MGKG)H ZG[7;P^)+UI-5E/E6@D>S*'9$
MHP=X/<U77QYX8-S!;+J\)EG *##8Y]3CC\<5DW6?^$LUW_L"_P!!5!M)L$^#
M^Y;:,/Y E+[1NW[QSF@#L'FB/BF%/[3E5S:EA9!3L89_UF>F>U5'\>>&(]2.
MGMJ\(N ^PC:VT'_>QC]:RH=K>+]-,K$*=$^9O0=ZYG[-=:9HTBZ?J&@ZMH8#
M,8KL;9BN22OKF@#K]?\ &UIHOBC3=/ENTC@<,UR?++$ J=F"!W..E:NK^+M"
MT$QKJ6HQ0-(,JN"S8]< $@5S$MY9WNM>#K^2"*WAGAD.R7&%_=G R?TK(8ZR
M/&>NFSET-)C*!C5,[_+_ (=O;;0!Z3'KFFS:0=5BNT>R5=QE3) 'T'/X56L?
M%>B:E)<I::A'(;5!),V"%13W)(Q7#6,5TGA[Q9]INM,EWJ"T>G,WEQOCGJ,#
M(QT)J[XDLQ:_"RT6RCCB5HX/.;;P5(!8OCDCUH Z73_&_AS5=0-C9:K%)<YP
M$(9<GT!(P?PJYK7B+2O#\"3:K>I;HYPH())^@&37FNI)KDNF0">^\(PP*\9A
MDMRX=6R-NW )_2ND;[$GQ'9M8,0W6""T:?&PG^/;GC- $^F:^NK>/&%CJ!N-
M-;3Q(B(WR[MQYQV-:'B2WUN^EM[+3;DZ?9LI:YOE(W(!T51GK[UAZ.=*;XI7
MQTKR]AL1YQB^X9-W./PQTKI=4UO3+34(-(U$,@O4.V1P!$W8J6SUH P?"-W?
MQZ_=Z4=7?6[".$2"]89VN3]W<.#] :KP6^O^,)+K4K77I]+M8IFBM(8!D/M[
MO^-%C#IFG?$.TM?#A18)(':_CMVW1C@E2?0YQ5GP3J=CIFC7>GWMU%;W%E<R
M>:DK!2!G(/O0!L>%=9GU+0FFO]JW5K(\-P5Z$KWQ]*SO"OC6UUW4M1LVNXVD
MCF8VZB,KF$ <DX]<U)X!_>Z/>WFTB*\OI9H]PZH< ']#6%: +I'C.*T$:WHN
M)/+50 ^W8O3OCK0!TK>/O"ZW_P!B_MB#S\XQAMN?][&W]:Z,'(R#D5PD4GA+
M_A78!:R^S?8^5)7?NQ^>[-=!X0\__A$M+^U;O-^SKG?][\: .>U:[U#7=9OK
M>+7AHFEV#")KA&"M)*1DC)(& ,5H:/?:KI.B:C)JMQ'?VUHI>VOD=3YZ8[X/
M4'O6%9Z)H%QXNUZ'7]CS&82PPW+[8RA ^9>@)XQ46GVD,D'B[2M$D:72Q"/)
M53N592/F53^ H L"Q\6MHW_"3#7Y1<F+[2-."_N=F,[?KC]:[O2K]=3TFUOD
M&%GB60#.<9%<LGB;2A\.UG-W%N%EY1BW#?YFW;MQUSFM[PM;26?A73+>4$21
MVZA@1T.* ->BBB@ HHHH KV/_'E']#_.K%5['_CRC^A_G5B@ H-%(: .+\40
MZCJ7BS3=,L]:O--CDMI9&:W/WBI7&1^-4[[3O$OA.U_M6'Q!<ZM!"P:XM[L
M9C[E3ZUIZK-#!\1=)>:6.-/L4_S.P4?>3N:=XQU^PA\/7%M#<PSW5V/(@AC<
M,68^PH U[SQ%IFG:7%J-_=I;6\JAD+]2",\ <GK3=&\3Z/XA5SI=]'<%/O*
M58#Z$ X]ZY2XMK73_%?ANUU@K]GATX1PF4C9YPX.<]\8JQ=2:<WQ%T?^R6B:
MX$4GVHV^"OE;3C=CWQ0!KW7COPS9:B;"XU:%+D-M*[6(!]V Q^M6=3N(3J6C
MG^U9+?S)&\N*(;EN>!P2.W>O/OL=S86UW_8NJ:'J.E2/(\D-^NV0?WE]3]:V
M(KZ+4AX*N8+7[+&TT@6$'(0 8X/IQ0!T-YXY\-Z>\BW6J11O'(8F38Q8,.O
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M<TC3YC+9V,<+F'R"4)'[OTZ_KUKB_ >L0ZM?ZAJEUKE[),@=Y+:0E;>*//#
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M3PE_T"8OSH_X5IX2_P"@3%^==;11[27</9Q[')?\*T\)?] F+\Z/^%:>$O\
MH$Q?G76T4>TEW#V<>QR7_"M/"7_0)B_.C_A6GA+_ *!,7YUUM%'M)=P]G'L<
ME_PK3PE_T"8OSH_X5IX2_P"@3%^==;11[27</9Q[')?\*T\)?] F+\Z/^%:>
M$O\ H$Q?G76T9H]I+N'LX]CDO^%:>$O^@3%^='_"M/"7_0)B_.NMS11[27</
M9Q[')?\ "M/"7_0)B_.C_A6GA+_H$Q?G76T9H]I+N'LX]CDO^%:>$O\ H$Q?
MG1_PK3PE_P! F+\ZZW(HS1[27</9Q[')?\*T\)?] F+\Z/\ A6GA+_H$Q?G7
M6YHH]I+N'LX]CDO^%:>$O^@3%^='_"M/"7_0)B_.NMS11[27</9Q[')?\*T\
M)?\ 0)B_.C_A6GA+_H$Q?G76YHS1[27</9Q[')?\*T\)?] F+\Z/^%:>$O\
MH$Q?G76T4>TEW#V<>QR7_"M/"7_0)B_.C_A6GA+_ *!,7YUUM%'M)=P]G'L<
ME_PK3PE_T"8OSH_X5IX2_P"@3%^==;11[27</9Q[')?\*T\)?] F+\Z/^%:>
M$O\ H$Q?G76T4>TEW#V<>QR7_"M/"7_0)B_.C_A6GA+_ *!,7YUUM%'M)=P]
MG'L<Q:?#[PQ8WL%W;Z9&D\#B2-A_"P.0:Z>BBI<F]RE%+8KV/_'E']#_ #JO
M=Z+87L_G7$"O)C&35BQ_X\H_H?YU8K.<(S5I*Y<92B[Q=C(_X1G2O^?5:/\
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MT/Y$'MZO\S,C_A&=*_Y]5H_X1G2O^?5:U\T9H^JT/Y$'MZO\S,C_ (1G2O\
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M=QI4<"QD7=VL$F\$X4^F#UKE-"\%Z/X@\/Q:QJ;376HW0:7[3Y[@Q')P% .
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M7@;<9SG-:F*,4 )VYKF-:\'1:GJ)U"QU*\TJ\=0LLMH^/- Z9']:ZC%)CG-
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MC7_A)OM4WG^7Y?D[1M^[MSGK6=:?#FSM-"U72EU"Y:/4'1W<JN4VG.!7:T4
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M1>EV86J^1C_\+;\(?\_S_P#?NC_A;?A#_G^?_OW6Q_P@OAC_ * UK_WR:/\
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M%M^$/^?Y_P#OW6Q_P@OAC_H#6O\ WR:/^$%\,?\ 0&M?^^31>EV86J^1C_\
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<% !1110 AI%ZT44#0II:** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img45497886_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45497886_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )K!70# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH HSSR),RJV /:F?:9O[_Z"DN?^/AZBJ6QDWVF;^_\
MH*/M,W]_]!4-% $WVF;^_P#H*/M,W]_]!4-% $WVF;^_^@H^TS?W_P!!4-%
M$WVF;^_^@H^TS?W_ -!4-% $WVF;^_\ H*/M,W]_]!4-% $WVF;^_P#H*/M,
MW]_]!4-% $WVF;^_^@H^TS?W_P!!4-% $WVF;^_^@H^TS?W_ -!4-% $WVF;
M^_\ H*/M,W]_]!4-% $WVF;^_P#H*/M,W]_]!4-% $WVF;^_^@H^TS?W_P!!
M4-% $WVF;^_^@H^TS?W_ -!4-% $WVF;^_\ H*/M,W]_]!4-% $WVF;^_P#H
M*/M,W]_]!4-% $WVF;^_^@H^TS?W_P!!4-% $WVF;^_^@H^TS?W_ -!4-% $
MWVF;^_\ H*/M,W]_]!4-* 3T!/X4 2_:9O[_ .@H^TS?W_T%1;6]#^5)^% $
MWVF;^_\ H*/M,W]_]!4-% $WVF;^_P#H*/M,W]_]!4-% $WVF;^_^@H^TS?W
M_P!!4-&.<=^E $WVF;^_^@H^TS?W_P!!4)!'6B@";[3-_?\ T%'VF;^_^@J&
MB@"7[3-_?_04?:9O[_Z"HJ* )?M,W]_]!1]IF_O_ *"HJ* )?M,W]_\ 04?:
M9O[_ .@J*B@"7[3-_?\ T%'VF;^_^@J*BBX$OVF;^_\ H*7[3-_?_05#11<"
M;[5-_?\ T%)]IF_O_H*BHH E^TS?W_T%'VF;^_\ H*BHH E^TS?W_P!!1]IF
M_O\ Z"HJ* )?M,W]_P#04?:9O[_Z"HJ* )?M,W]_]!1]IF_O_H*BHHN!+]IF
M_O\ Z"C[3-_?_05%11<"7[3-_?\ T%'VF;^_^@J*B@"7[3-_?_04?:9O[_Z"
MHJ*+@2_:9O[_ .@H^TS?W_T%144 2_:9O[_Z"C[3-_?_ $%144@)?M,W]_\
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MNSH-% !1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN/\ CW?Z4,#,HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM_<ZA#>27QX\N)E*\Y(Y)]ORKNN?>C\*  4444 %%%% !1110 4444 %%%%
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M:Z"?:8)7@E*="RG!(^M:]8OABQN+/3)7NH_*GN9WN&CSG9N.0/PK:H @M/\
MCW7_ 'F_]"-3U!:?\>X_WF_]"-3T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %17
M/_'M+_N'^52U'<?\>TO^X?Y4 1:?_P >$/\ NU9JMI__ !X0_P"[5FD@"BBB
MF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!!:?\>X_P!YO_0C4]06G_'N/]YO_0C4] !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !4=Q_Q[2_[A_E4E1W'_'M+_N'^5 $6G_\ 'A#_ +M6:K:?_P >$/\ NU9I
M( HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 06G_'N/\ >;_T(U/4%I_Q[C_>;_T(U/0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5'<?\>TO^X?Y5)4=Q_Q[2_[A_E0!%I__ !X0_P"[5FJVG_\ 'A#_
M +M6:2 ****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1FB
MN>UZS:..?4GUN_LH(DR8H64+Q]0>3Q0!T-&:PO"T&H1:0LNHW<UQ+.WFJ)B"
M8T/W5R .<<GW-5I?MNM:]>VD>H7%E;62JO\ H^ SNR@Y).>.>F* .FHK&\-:
MA/?Z8_VIE:XMYGMY&48#%3C./>MF@""T_P"/<?[S?^A&IZ@M/^/<?[S?^A&I
MZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *P?$=I<:B^F6:0N]L]T'N2.@103S^.*WJ* *6I7<]C9^;
M;64EX^X+Y4; '![_ (5C3-=Z)KU]=K87-Y;7H5A]G4,R.J@8(]..M=-10!C>
M&;">QTQS=(J7%Q,]Q(BG.PL<[<]\5LT44 06G_'N/]YO_0C4]06G_'N/]YO_
M $(U/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5'<?\>TO^X?Y5)4=Q_P >TO\
MN'^5 $6G_P#'A#_NU9JMI_\ QX0_[M6:2 ****8!1110 4444 %%%% !1110
M 4444 %%%% !12'I5#5-2BTNT,TF68\*HZDU,I**<GL.,7)\JW$U;4X=,MS)
M(<N>$0=6-8VC:0U^9-1U%=[39VJ>P/>FZ9ID^K70U+4N4/,<9Z8[?A75*
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MBBB@ HHHH **** "BBB@ HHHH *CN/\ CVE_W#_*I*BN/^/67_</\J (]/\
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MMC3=2@U*V66)P3CYE[@T\/\ NY.DWZ"Q'[R*JI>OJ7:6BBNPY0HHHH ****
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M8\/2-I^JW>F2''S%D_S],4IWIUU+H]&$/WE%QZK4ZNBDI:ZSF"BBB@ HHHH
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MTVQ:X=2P! "@\DFKAKEO%$C75[9Z<AY=@S8]^*PQ%1TZ;:W-J%-5*B3V&_\
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M77M'?4SIB:K9-J ZVHN$,H_X#G->86.DW=OXJ\!&ULY;<KH<D4LHA8+&WE'
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MP)."86EG51(.ORDGGJ.E>5^)KE+KQ%/MM+RVTZ72!'8SVFGR-+<GD>6S$9C
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M?AMX@_X2#P=:2.X:XME^SS<\Y7@$_48-:>S?)SF?M5S\AV%%)FEK,T"BBB@
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M@T_B>OW'7BB@45Z)PA1110 4444 %%%% !1110 4444 %%)10 $X'-<KIO\
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M04444 %%%% !1110 4444 %%%% !7/:E="PUQ9[C16N86AVI=V\!EE4YY4@
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MKG/J*FEGN+>]\YS<%EERY^;R?*VCIVSG\:G_ +.O(H)[.!K<VTS$^8['>H.
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MRPN[=GC'7-:U:3@UYF5*JJB?D>=_%_7GL?#L6D6S'[7J+[,*>=@Z^_/]*H^
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M3<*\BT/.A_';5+1N%U&-F1>G7##_ -!->NUY!\2'&@_$?P[KQ.U&^25_[H!
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MJ&FO]J96N+>9X)&48#%3C/XUL5C>&=/N+#3'-VJI<7$SW$B*<["QSMS[5LT
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MY[+^M2Q7$4X)B<-CKBN/\*^*M!\77E]!86[*+4KM:1B#(#GD#TX_6NPAMXH
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M4V1KM7KBB:&.9-LB[E],U6I)#_:%H/\ ENOY&I8IXIE+1N&4=34#V%FB%C$
M ,DY-<V=9N[CSH-*L/W9)5GY:L:M:-/<UI495-A;%EU#Q)=7LN/(@^49Z>G]
M,_C6^LNF1DE?)!/4[/\ ZU5-"TDVFF&*Y0&25MSBM#^SK3_GB/S-1AZ;4;RW
M>I>(J7G:+T6A+#<0S9$3AL=A4C,J*68X ZFHX;:&#)B3;GKR:D9%=2K#(/45
MTHYRO_:%I_SW7]:DBNH)GVQR!CUP*C_LVT_YXC\S3XK2"!]T<85NF<F@"8D
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MD_G3 N453W-_>/YT;F_O'\Z +E%4]S?WC^=&YNN3B@"Y15/<WJ?SHW-ZG\Z
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M?\\1^9H8$T4\<XW1N& [BEDE2%"\C;5'<TD4$<"[8UVCTS2RQ),A21=RGM3
M;%<13@F)PV/2I:BAMHK<$1(%!Z\U+2 ****8$%W";FTF@& 9$9!N&1R.]<W"
MGBS2[);<0V.HA!A2&,9QZ'/%=5C-+B@#G?#UY-"%TZ?2KJU<;G+L-R9))(!'
M'?BNAS1BC% "TF*6B@!",T8I:* "BBB@""T_X]Q_O-_Z$:GJ"T_X]Q_O-_Z$
M:GH **** "BBB@ HHHH 2D8X!/H*6J6K7!M=+N90<$(<?6IF^6+;'%7DDC#\
M/C[;K=]?MR 2J>V?_K5U-87A2W\K1Q)C!D8G_"MVL,*K4TWUU-L2[U6ETT"N
M<\>R>7X"UQLX/V1P#]1725R'Q.E\KX?:H?[T>W\ZZZ:O-'+4?N,Y?PEX4@\4
M?!VUTV9S$S322QRA>4/F$_\ UJ@L?A!J%Q>QQ^(-=EO-.M_]3"CMT].3\H^E
M=C\-(O*\ :6/6/=^9S75XK65649-(RC2C**;/%]2M+?X<?%'3[RW7[/I%]'Y
M;\_*O0-^7RG\:]'T;QMH>N:Q<Z7I]XLMQ ,DCH_KM/?'M4'CGP<GC'2H+3SA
M!+%,'68C)"]Q^/'Y5Q>O_"V?0X;+5/"$DGV^R&9%=^93UW#/&?:G>$TN9ZDV
MG3D^5>Z>NYYHS7CB_%W7[#[.VK>&'M[?>J2W#K(F>?FP"N,]>,UZ];7$5U;Q
MW$+AXI%#(RG((-93IRAN;0J1GL34445!H%%%% !2&EI* .7^(DOE^ =8/]Z!
ME_.JGPJB\KX?:>/[VYOS-)\59/*^'NH'IN*+^;"KOPZC\OX?Z+Q]ZV5OS%:_
M\NOF8?\ +[Y'44E%+61N,=0Z%6 ((P0>]>2?"EFT;QAXC\.L<"-S(N>^UMO\
MC7KM>0:T3X>^.FGWOW(-10(0/XB1L_\ 0B*VI:J43"JK.,NQZ_FEIM.K W"B
MBBF 48HHH 0C-(RAE*D CTIU)2 Y?6_#MK'937-JC+*IW8#'&*UM#OA?:5#(
M3EU&UL>HK0>,2(489##!KAX9M0TJ^NM.LXR[NV5X^Z/4?Y[5PU+8>HII:,[:
M=Z]-P;U1W6:3-<OI>KW%C=FPU8E6)RDC'U[9]*V=2U6#3[/SV8-G[@!^\:WC
MB(2AS/0PG0G&2BM;E+Q/J!MK$6T)_?SG: .N/\\?C5S1; :?IL41 WD;G/J3
M61HNFS:C='5M0Y).8T/Z&NH[U%%.I)U9?(NLU"*I1^88Q2XHHKK.8**** "B
MBB@ HHHH **** "BBB@ HHHH **** $-9/B2W^T:)-CJGS_E6O4<J"6)HR,A
MA@U%2//!Q*IRY9J1G>';G[3HT![H-A_#BM6N0TFZ?0=0?3KT8BD;*2=JZT,#
MR*RPT^:"3W1KB(<LVULQU%)2UT&!!:_<?_KJ_P#Z%4)ZFIK7[C_]='_G41ZF
M@!**** "L6_@:V1[E[N8W<DO[A$D8*>>%V X/&<\>_:MJL6.TU=-0FNGCL)6
M9SL9Y9,HG8 ;>/?UH 9J:/;H;AGO'N79=GE,RQ1],[L?+CKU]:;--<07GGNU
MP660,S@MY/E8&<?PYS^-7+BVU*030+);M;S')9RV] >H Q@_C5F2S+BVBW9M
MX1RIZL0,+^% $>GW"2!T>X1[HDM)%OR8_P#9Q[=*O5EVFG3P7$?F-'Y4+.4*
MD[GW9^]Q[UJ4 %%%% #D^]^!IM.3K^!IM !1110 5B:A=3RZC:+!(R6\4X21
ME/\ K&Q]WZ#^=;=8=QX;C<P>3>7L:I,)"OVE@/P% #]0@,"2W,EW-]H>3%ND
M<C >R[ <'OG_ .M4#S75O=B>87 D60&3[WD^5M&<?PYS^-3I::NFH37+)83$
MMB-I)9,HGIC;C/KZ\5H3VSW,D(<J(ERS*,\MV_#K0!%IUQ'(CHURDEQDM)&'
M!*9/W<=L=/PJ]699Z?<07$1D:+RX"^PKDL^[^]D5IT %%%% $D/^L'TITW_'
MQ;_[S?\ H)IL/^L'TITW_'Q;_P"\W_H)H GHHHH **** $KRSXA^(=8G\6Z9
MX8\/7C6]S*I,KH?7IGTP ?SKTZYN([6UEN93B*)#(Y] !DUY/\,K>3Q%XOUK
MQ=<KE2YB@)Z<^GT 7\ZVI)*\GT,*S;M!=0_X5IXTN\_;?&<I4CE%DEQ_/%=U
MX,\(VWA#1C90OYLLCEY9L8+GM^0XKH@.*6HE5E)6Z%1HQB[]0Q2T45!J&***
M* #%%%% !1110 4444 %%%% "&DQQ3J2@#RWXP:3-##I_B>Q!6YT^0+(R]=F
M<@_AS^==:WC&SC\"KXF)4Q&W\S8#UDZ;!_P+(K9U73H=5TNYL+A0T4\91@?>
MOG6RTW7+_5(_A^TC"W@O6=_91U;Z?Q?C733BJD;/I^1R592IRNEO^9[MX-\2
MQ>*O#D&H+M6?[L\8_@<=?P]*X3P+_I'QC\4W0Z;77\V3_"LZPN!\*/']Q8W4
MDBZ#?*71R"P4=CQU(Z&KWPCD6^\4>)=0C;<CN-K8Z@DD?RJG!14FMGL)5'*4
M4]T>O=J6D%+7(=@4444 )CFO#]:U,>!/BSJ5^P/V>ZMC(B#^)BH _P#'@:]Q
MKR/XO>')=6UO0'MDS+<R&T)[ 9R"?S-;4&N:TMF<^(3<;KH7O@]HTJ:5>>(+
MT%KO492=[=2H//YGFO3<56TZQATS3K:RMQMAMXUC0>P&!5JHJ2YI-FE./+%(
MP/%OA>U\5Z%)I]QA'SNAEQDQMZUYUX_\'6?AOX96D5HFZ2UN$>64#F1F^\?T
M'X5[&:YOQ[8?VAX'U> +E_L[,GU'2JIU&FET)JTTXMVU+_AJ]_M#PSIEV6#-
M-;1NQ]RHS6M7"_"6_P#MG@&T1FR\#O$P] &./TQ7=5%16FRZ;O!!1114EA11
M10 4444 %%%% !1110 5Y!X^)\1_$_0?#J?-' 5EF3V^\?\ QT&O7F8!23T
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M?I4]% $'V?\ VOTH^S_[7Z5/10!$D6QLYS39O^/BW_WC_P"@FIZ@F_X^+?\
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M<C>IP2/:M6@""T_X]Q_O-_Z$:GJ"T_X]Q_O-_P"A&IZ "BBB@ HHHH ****
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MHH **** "BBB@ HHHH **** "BBB@ HHHH #24M% "5Y/\0O#5WH.JIXU\/
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MX'YXS^->BUI6?O670SH)\MWU$I:**R-@HHHH **** $KA?%W@-?%7BW2;V?
ML;:-A<#."_.0OXUW=&*J,G%W1,H*2LSE_%_@RQ\5:&+$A()H1_HTP7_5GT^A
M]*\\U_X3G0/#*:EI%S--JUF_G2,/X@.NT>V/YU[52,H*D$9!X(/>KA6E'1/0
MSG1C+5[G,^!/%<7BSP[#=D@7<?[NY3T<=_H1@_C745X[X>/_  AOQAO](/R6
M6I_/%Z$GD ?B2/PKUZ65((7ED<+&BEF8] !WI5(I2TV84IMQ][=$E%<5X"\;
MCQ:^J(RA&M[@F)3P3$>GY?UKM:B47%V9I&2DKH****104444 %%%% !1110
M4444 %%%% !7/:UJ5M#<&RU;3Y'TV6,%9T5I S=U*J,CZUT-)C'2@#DM$O)-
M'T:YN);.[%@;K%E J;I$C..W89R?6I7O%\/^(M2FO(IS;7H22.2.(N,A0I4[
M<D'BNHQ1CWH P_"MI/;:9++<Q&*2ZN)+CRV/*ACD ^];M%% $%I_Q[C_ 'F_
M]"-3U!:?\>X_WF_]"-3T %%%% !1110 44F:,T <YXOEQ8P6X.#+)_+_ /76
MY9Q>190Q=T0 _E7GWQ*\31Z%<6K&,32J 8X<_>)/_P!85DQ?%G6[.]M9M;T
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M4_G1D^I_.@"Y4$W_ !\6_P#O-_Z":2$GS.IZ43'_ $BW_P!YO_030P)Z\O\
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M]Y)NP5XR?KU%8GAQSX?\77FBR$B"8[H<]/4?CC H [VBDS2T %%%% !1110
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M$.N6GDZ?" T4.,*<?='N.YKUW6-'LM=TN;3]0@66"08((Y![$>AJZD:1H$1
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MA90Z=86]E;KMA@C6-![ 8%;/W:=NYSKWZE^Q9I:3%+6)T!1110 A!H'6EHH
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M<\DC'?K^E &KG/>BHX(O(MHH0Q81H$W'O@8J2@ HHHH DA_U@^E.F_X^+?\
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M1Y#>HI?M)_Y]YO\ OD?XT?:3_P ^\W_?(_QH %A8'J.:3R&]12_:3_S[S?\
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MC317U721);J3=6QWH!U([BK/A76&UG1TEEC=9H_DD+# 8CN*W",TU46-<(H
M]!0 ZBDS2T %%%% !1110 4F*6CM0!Y'\3-+N?#_ (@L/&FDH1)'($N57O[X
M]QD'ZBND\%?$FP\6RO:/&;2_!)6!CG<HQR#ZY/2NW(KR/XC^$AH3VWBSP[ M
MO-9R;[A(A@$$YW?J0?K6\)1FN26YS3C*F^>.W4]4N[ZVL+=KB[N(X(5ZO(V
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M=PI>Z?-%M5UEC(7<,CD<5P&A:7!XKU_4M0O@SVZ2$(F2.IX'TKT:.-8HUC0
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M3 Z#_ODO7J.KV;ZAI-S:QR/&\B$*RG!SVKB=$L+'Q7X?E\.:TCN;.4.HW8;
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MGYUVJC:H ' &*RAX=M!X@.L*TBSE<;5.%)]3^GY4 :]%(.E+0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% $%I_Q[C_ 'F_]"-3U!:?\>X_WF_]
M"-3T )7*MH5S:^.(M3M%(M9U/GX/0X[^QXKJZ* &XI12T4 (0""",@^M(/TI
MU% &/K?ARPUZ-!<JRR(<K)'@-CT^E.L_#>D65N(8["$CNTBAF)^IK6HH 0
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M **** "BBB@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK6NWUG%J$]C;605<VX&YW90V22#QSTH Z04M8_AO4)]0TU_M3*UQ;S/!(RC
M8J<9Q[UL4 06G_'N/]YO_0C4]06G_'N/]YO_ $(U/0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !28 Z"EHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *CN/^/:7_ '#_ "J2H[C_ (]I?]P_RH BT_\ X\(?]VK-
M5M/_ ./"'_=JS20!1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *" 1@BBB@!%55&%  ]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "H[C_CVE_P!P_P JDJ.X_P"/
M:7_</\J (M/_ ./"'_=JS5;3_P#CPA_W:LTD 4444P"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (+3_CW'^\W_H1J>H+3
M_CW'^\W_ *$:GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CN/^/:7_ '#_ "J2
MH[C_ (]I?]P_RH BT_\ X\(?]VK-5M/_ ./"'_=JS20!1113 **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @M/^/<?[S?^
MA&IZ@M/^/<?[S?\ H1J>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.X_X]I?\
M</\ *I*CN/\ CVE_W#_*@"+3_P#CPA_W:LU6T_\ X\(?]VK-) %%%%, HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP0/L[8/"Y_.NS;0U;Q.FM_:#E8O*\G9Q]<Y_I5&_\)R3:C=7FGZO<:>UV/\
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M\[,PG\OE"WH,]JR]-\%:AI.U;7Q-=1Q;P[QK ,.<\YY[T =C[4444@"BBB@
MHHHH **** "BBB@ HHHH .]>>^*-,FMM8TJ\N;V6XDEN\*K<+$O'"BO0JR-;
MT-=9FL9&N#$;67S<!-V[VZ\=*8&!XNC,_BO2HK:VBO[L1N?L<QQ&5R?F)]:G
M\!JL2:K"Z>1="Y)EM5'R0CG 4^E:>M>'?[4OH+^VOI;&^A78LT:ALJ>HQ4NA
M:#'HJ3N;F2ZNKA]\UQ(,%V^G:@#7HHHI %%%% !1110 4444 %%%% !1113
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M +/YT?8Y?]G\ZT**+ 9_V.7_ &?SH^QR_P"S^=:%%%@,_P"QR_[/YT?8Y?\
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M!3^Q?]-/TH^Q?]-/TJY118"G]B_Z:?I1]B_Z:?I5RBBP%/[%_P!-/TH^Q?\
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MTMH1/)YC@ [F!;)SPOK77:AHL&HW,=R9;B">-2@EMY-C%3U4^HJ&S\,:=8"
M0+*!!<-<H"^0'88)_(F@"/Q-J%QING016$9-S<S+;Q!2 1D'H6XS@=ZRX)-6
MTIKNYFM[Z&P6V9G-]>+,1(.A7#$CM72ZCIEMJMI]GND)4,&5@<,K#H0>QJG_
M ,(U9-97-O-+=3FY&V6:67=(RCH,^E &)"+ZP'AU[C4+N:\G^6=7D.PJ(RS9
M7H3QUZU5O_M6H>$)]:EU&XBEN?EBB1R(E1V";2G0GGJ>:[*33;>74+>]8,98
M$*1C/R@'KQZUEMX0TUU5&>Z,"3":. R_NXV!S\H["@"74 FG>$94):-8K4*"
MC;2#@#KVYKGX6GT."QMDNKC9;Z<]U<!I2PWE<#KV!!P*["_L8=3L9;.X#>5(
M,-M."._%49/#=E/%<++)<2-<6ZV\CM+\Q0$D<X]Z .>2VU2WB\/J=8NS?W9"
MS,TA9-@3+?(>"<=^N:?-J5UHHUT6T]Q<I"T$4 N)3(1*YP>6/3D<'BNJDTVW
MDOK:\8-YELI6, \#(QT^E0-H-C);WT,D;.E[)YDH9L\]L>F.U &-I<.N0ZK;
M.UKJ"P,"+HW=ZDJGC@JH8[><\#UJ?Q=:KJ']EV+/.!-=J&$4A3*#[V<=:T]/
MT2#3Y_.\ZYN90NQ7N)=Y1?0>U3S:?!/?VUZ^_P VW#B, \?-UR/PH Y7SIXH
M];U)KZ[:TTX[8(?/;YFC7!+'N"1R#U[U8N(KS2TTR].I7,U]<SHDD;R$QR!O
MO )T&!SD>E=!#I5I#8SV>PO!.[M(KG.[>26S[<U4L_#EG:7*3F6ZG>($0^?+
MO$.>/EXXXH YJ>6^FT75M8;4[M<71%FD<Q55Y5<$#J,]CQ6K#'>6?B73(9+Z
MXGEG@DDNE>0^7P!C:G1><]*U!X?L?[)BTW$OV>-_,'S\DYSR>_-6CI\!U0:B
M=WGB+RASP%R3T]>: ,O4))M0\0QZ1'<RV\"V_P!HG:%RCMDX ##D?A7.637,
M6J7EO!>2-->ZA]D6Y<[G6.-6)&3WP,9_&NOO]&M[^[BNFEN(+B(%1)!)L++_
M '3ZBJ\7A;38-,6QA66-$E,\;J_SHYZD-VH HQRR:3KEQI\>I2- ;3S-U[,7
M\J0G"_,QS@YZ>U4M,>\M-6A@U2>_M[[#/EIS+;W('7:"2$^G!%;\7AS3TM+F
MWE22Y^TX\Z2=M[OCID^W:F0^&[2-B\MQ>7+A#&C7$VXQ@]=O'';\J ,#3KG4
M-3NM,A^WW"+-Y]U,5?DQ,S!![#I@]J=;7][C^S(+R8K/J4EM'/(Y>18T!+?,
M><\8![9KI;+1+33YTF@#ADMEM5RV0$7H/K67J6CK:6%M;6FGW%U"DID\R"8+
M/$YS\REL ^G7O0 :=%<6_BZ>T2^NI[.WM0WES2%R'<]R>OW3C/3FI_$K-*MA
MIJ%E6]N DA7@A!R?Z4GAK29;(WUW<1O'+>2!MDC[W"@<;R.-W)Z<59UBTN)K
MG3;BV4NUO<@NH(&4(YZ_A0!E3VO]H^+KH&>2"VLK-8CY#%&R?FX8<KP1TJC8
M76I:C:^'[0ZA/&\X>>60-\S0[2 ">YY'/KS75#2+8"_QYFZ^.9FW<_="\>G
MHM])M;2>&>%'W06_V>,9X"9!_/@4 9@B%OXPTZWB>2016,H=I'+MC<F-S'DU
MT=9.E6$R7=UJ5X +FY(4)G/E1KG"_7DDUK4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !12&J][?VFG0>?>7$<$6<;I&P,T
M 6:*K07]K=0PS6]S%)',<1LK9#'&>/P!JQ0 M%1&>,3K"9%\UAN"9Y(]:DS0
M M%)10 M%123Q0M&LDBH9&VH&/WCZ"I.W6@!:*C>5(E#.X49 R3UR<#]:2*>
M.<,8I%<*Q5MIS@CJ* ):*3)S4<D\<157D52V2 3UQR: ):*CAE2>%98G#QN
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M:]68X H FHJ*6>.$+YKJFY@BY/4GH*DSS0 M%1R2)$GF2N$0=23Q3N?_ *]
M#J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ@@9RJ]L>@K5\-R3O=2@ZA#<Q",%ECEDEVL>GS-T[\5T>U1C"CCCI0J*GW5
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C 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img45497886_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45497886_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &;!*0# 2(  A$! Q$!_\0
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MO\6/^@7;_P#? H_M?XL?] NW_P"^!7K=%'M?[J#V+_F9Y)_:_P 6/^@7;_\
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MO\6/^@7;_P#? H_M?XL?] NW_P"^!7K=%'M?[J#V+_F9Y)_:_P 6/^@7;_\
M? H_M?XL?] NW_[X%>MT4>U_NH/8O^9GDG]K_%C_ *!=O_WP*/[7^+'_ $"[
M?_O@5ZW11[7^Z@]B_P"9GDG]K_%C_H%V_P#WP*/[7^+'_0+M_P#O@5ZW11[7
M^Z@]B_YF>2?VO\6/^@7;_P#? H_M?XL?] NW_P"^!7K=%'M?[J#V+_F9Y)_:
M_P 6/^@7;_\ ? H_M?XL?] NW_[X%>MT4>U_NH/8O^9GDG]K_%C_ *!=O_WP
M*/[7^+'_ $"[?_O@5ZW11[7^Z@]B_P"9GDG]K_%C_H%V_P#WP*/[7^+'_0+M
M_P#O@5ZW11[7^Z@]B_YF>2?VO\6/^@7;_P#? H_M?XL?] NW_P"^!7K=%'M?
M[J#V+_F9Y)_:_P 6/^@7;_\ ? H_M?XL?] NW_[X%>MT4>U_NH/8O^9GDG]K
M_%C_ *!=O_WP*/[7^+'_ $"[?_O@5ZW11[7^Z@]B_P"9GDG]K_%C_H%V_P#W
MP*/[7^+'_0+M_P#O@5ZW11[7^Z@]B_YF>2?VO\6/^@7;_P#? H_M?XL?] NW
M_P"^!7K=%'M?[J#V+_F9Y)_:_P 6/^@7;_\ ? H_M?XL?] NW_[X%>MT4>U_
MNH/8O^9GDG]K_%C_ *!=O_WP*/[7^+'_ $"[?_O@5ZW11[7^Z@]B_P"9GDG]
MK_%C_H%V_P#WP*/[7^+'_0+M_P#O@5ZW11[7^Z@]B_YF>2?VO\6/^@7;_P#?
M H_M?XL?] NW_P"^!7K=%'M?[J#V+_F9Y)_:_P 6/^@7;_\ ? H_M?XL?] N
MW_[X%>MT4>U_NH/8O^9GDG]K_%C_ *!=O_WP*/[7^+'_ $"[?_O@5ZW11[7^
MZ@]B_P"9GDG]K_%C_H%V_P#WP*/[7^+'_0+M_P#O@5ZW11[7^Z@]B_YF>2?V
MO\6/^@7;_P#? H_M?XL?] NW_P"^!7K=%'M?[J#V+_F9Y)_:_P 6/^@7;_\
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M;DD*?ZI1T ]J*Y2W_P"/B^_Z^7_I172Z<;['+&K*VYZA\*?^1V\7_P#78?\
MH;UZY7D?PI_Y';Q?_P!=A_Z&]>N5S5_B.K#_  !1116)N%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4E+0>E 'RG;_ /'Q??\ 7R_]**2W_P"/B^_Z^G_I17I/<\Q;'J/PI_Y'
M;Q?_ -=A_P"AO7KE>1_"G_D=O%__ %V'_H;UZY7%7^([,/\  %%%%9&X4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45QO
MB#XI>$O"^K/IFK:A)#=HH9D6WD<8/3D BLO_ (7GX _Z"TW_ (!R_P#Q- 'H
MU%9N@Z[I_B31X-6TN9I;.?=Y;LA0G!(/! /4&M*@ HHR*,T %%%% !15*PU:
MPU7SS8W4=PL$ABD:-MP##J,^M7,B@!:*,T9H **,T9H **,T9Q0 453O-6L+
M"YMK:ZNHXY[I]D$1;YI#[#J:N4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4'
MI10>E 'RE;_\?%]_U]/_ $HHM_\ CXOO^OI_Z45Z3W/,6QZC\*?^1V\7_P#7
M8?\ H;UZY7D?PI_Y';Q?_P!=A_Z&]>N5Q5_B.S#_  !11161N%%%% !1110
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MXJU]_C3:ZM+X?D&H6V%ATXR$[P%(!!QQD<]*^F-%O;G4=%M+R\M#:7,T8:2
MG/EGTKPGQGJ-II'[2-A?ZA.MM:Q11%YGSA?W9'\S7OUI=P7UI%=6LJRP2KNC
M=>C#UH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "@]*** /E.W_X^+[_KY?\
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M_P!!RS_[^5/]BM?^?:'_ +X%'V*U_P"?:'_O@4>T#V9!_P )QX7_ .@Y9_\
M?RC_ (3CPO\ ]!RS_P"_E3_8K7_GVA_[X%'V*U_Y]H?^^!1[0/9D'_"<>%_^
M@Y9_]_*/^$X\+_\ 0<L_^_E3_8K7_GVA_P"^!1]BM?\ GVA_[X%'M ]F0?\
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MC_A./"__ $'+/_OY4_V*U_Y]H?\ O@4?8K7_ )]H?^^!1[0/9D'_  G'A?\
MZ#EG_P!_*/\ A./"_P#T'+/_ +^5/]BM?^?:'_O@4?8K7_GVA_[X%'M ]F0?
M\)QX7_Z#EG_W\H_X3GPO_P!!RR_[^5/]BM?^?:'_ +X%*ME:[A_HT/7^X*/:
M"]F?-%M+&9KQ@XVM<,5/J..:*=:@>=>C' N7Q^E%>N]SR%L>H_"G_D=O%_\
MUV'_ *&]>N5Y'\*?^1V\7_\ 78?^AO7KE<5?XCLP_P  4445D;A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %:]_U
M_P!ZJ-7KW_4#_>JC3 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "H>]35#WK2F95!****U,@HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"6#[Y^E3U!!]\_2IZX:WQ
MG;1^ ****Q-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "E
M7[P^M)2K]X?6F@/F2U_U][_U\O\ THHM?]?>_P#7R_\ 2BO;>YX2V/4/A3_R
M.WB__KL/_0WKURO(_A3_ ,CMXO\ ^NP_]#>O7*XJ_P 1V8?X HHHK(W"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *
MU[_J!_O51J]>_P"H'^]5&F 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %0]ZFJ'O6E,RJ"4445J9!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $L'WS]*GJ"#[Y^E3
MUPUOC.VC\ 4445B;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %*OWA]:2E7[P^M- ?,EK_ *^]_P"OE_Z446O^OO?^OE_Z45[;W/"6QZA\
M*?\ D=O%_P#UV'_H;UZY7D?PI_Y';Q?_ -=A_P"AO7KE<5?XCLP_P!11161N
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 5KW_ % _WJHU>O?]0/\ >JC3 **** "BBB@ K&\6W$UIX0UBXMI7BGBM
M)721#@J0I((/M6S6%XU_Y$?7/^O&;_T T >*^#=/^(_C729-0LO&T\$22^65
MGNI<Y]> :W_ _B;Q7H_Q&D\&^([\ZB""/-9BY4XR"&/./8UR7PXT+X@:EH,L
MWA;7X;"R$Q#QO,4);UP$-:OA26\\$_%DVOBVW6]U740H2_67=M!S\P! SG&.
MW2@#WF[OK33X?.OKN"UBSC?/*(U^F3Q4=EJFGZFK-87]K=A/O?9YEDV_7:37
ME/Q-;PA-XL@@UA]:U+4$0 :;8D%%'49';.<\9ZUQ6@&30_BWHXL-*N]%@N71
M3;3S;RZ,,$GIC/I0!]%WVJ:?IBJ;^_M;0-]TSS+'N^F2*DM+VTOX!/974%S#
MG'F0R!U_,'%>!_$#3=1T_P")D^JZ]H5UK6CRY^S)&S!%7L. >GIQ]:V/AIJO
M@^VU+4Y=#DU6TO1;R2?V==N#$V!GY<=2#ZXZT >OWNK:9II5;_4;.T+_ '1/
M.L>?<9(S5BWN(+N%)[::.:%ONO&P93]".#7R[H6I:+X@U/4M7\86>N:G--(?
M*2Q3<D8/8DGTP /:NP^$]Y<:=X_N],TZWU6/P_=([1+?1$%"HR">P/&/>@#9
M\ ^(-8O_ (O>(].O-3NKBR@64Q022DHF)% P.W!(KH="M-8C^)&HSW'BZTO=
M/97\O2DO"\D)^7!,?;'/YUQOPU_Y+AXI_P!R;_T:M)X)_P"3A_$'_7*7^:4
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M^%8>E?#O6X?A8GAU]3.FZI'.TR3VLI*X/&TD8.#[>U=9_P (_KO_ $.VI?\
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M22-W/H.WT%;%MX7UBTM8K:'QIJ2Q1($1396IPH& .8ZD_P"$?UW_ *'74O\
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MKG(?AMX\\(WUVO@K78%L+EMQCG*J5ZXZ@@D>HQ7H_P#PC^N_]#KJ7_@%:_\
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MH *A[U-4/>M*9E4$HHHK4R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.O$.M^,?'&M:HVHW7]@VS,EO;9_=DDX7CZ<T >L44R:6.W@DGE;;%&I=VP<
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MWUWYD^"MM"7*8=^OIG^E>C_\)A*/^9;US_P$-<=?XSLP_P !U%%<O_PF$O\
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MI9_#'P?87L5Y;:-&D\3;T?S'.#Z]:M_\)5+_ -"YK?\ X"FC_A*I?^A<UO\
M\!30!T4G,;^NT_RKQCX)6\\/B3Q.TL$L89LJ70KGY^V:]&_X2N7_ *%S6_\
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M*QT-%<]_PE,O_0NZU_X"FC_A*9?^A=UK_P !31=!8Z&BN>_X2F7_ *%W6O\
MP%-'_"4R_P#0NZU_X"FBZ"QT-%<]_P )3+_T+NM?^ IH_P"$IE_Z%W6O_ 4T
M706.AHKGO^$IE_Z%W6O_  %-'_"4R_\ 0NZU_P" IHN@L=#17/?\)3+_ -"[
MK7_@*:/^$IE_Z%W6O_ 4T7069G?%6-Y?AOJR1HSN50!57)/SK7E_@WXH7GA/
MPU;Z0?"MW=&(L?-$C)G)STV'^=>PCQ5,.1X=UL?]NII?^$MN,_\ (OZY_P"
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MJRO([*.D3HZ*YS_A+)?^A<US_P !#1_PEDO_ $+FN?\ @(:RLS:Z.CHKG/\
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MXO\ ^NP_]#>O7*\C^%/_ ".WB_\ Z[#_ -#>O7*XJ_Q'9A_@"BBBLC<****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K
M7O\ J!_O51J]>_Z@?[U4:8!1110 4444 %%%% !1110 4444 %%%% !1110
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M44 %%%% !1110 44A.T%O09KS]/B[HTXF2STG6;VYAF>*2VMK<.Z!3C<2#M
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M-PHHHH **** /-] MXI/CCXFG= 9(K*$(Q'*YQG%'BG ^-7@YA@%HIPQ'4C
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MB@ HHHH **** "BBB@ HHHH **** "H>]35#WK2F95!****U,@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"6#[Y^E3U!!]\_2IZX:
MWQG;1^ ****Q-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-, HHHH **** "BBB@ HHHH **** "BF2RQP0O+-(D<:*69W(  '4DUYI/\
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M>PIK6K^)[>W;4=;F#SVNT.D<:C"H<]3ZUU,.@Z/I\GVFSTBSBG0':T5NJM]
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M/(!R"N*ZSPYHNO>(O'B^,O$.G?V7%:VYAL;%I-\BD\,S\>F?SH Y+2D\8/\
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M&X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!6O?]0/]ZJ-7KW_ % _WJHTP"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J'O4U0]ZTIF502BBBM3(*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH E@^^?I4]0
M0??/TJ>N&M\9VT?@"BBBL3<**** "BBB@ HHHH **** "BBB@ HHHH ****
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MW"BBBF(**** "BBB@"6#[Y^E3U!!]\_2IZX:WQG;1^ ****Q-PHHHH ****
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M)(XKO;_7-(T?3#?WE_;P6,9"^<&R@). /ES7G'Q;@M9IO"?B&5!<:3;70$S
M94(Y!#'V^6DMQO89J_B_P1X@T^+0]1T;5-.TV1E6VU"2S\J)2/NE6'(S]*]5
MM(D@LH(8I&EC2-561FW%@!P<]\^M<5\3-6T*;X;:@KW5O-'<Q!+-(F5BSG[N
MT=JZ#P?!=6O@W1X+T$7*6D:N&ZCY1P?I1+8([FW1114%A1110 4444 %%%%
M!1110 4444 %%%% !5#6=8L]!T>YU2_D$=O;IN;U/L/4GTJ_7G_Q%\->*/$=
MYI?]C'3I;&T?SI;:^D94ED!XW!>2!]13CN)O0X#5=/U*[\4^$_%NL,\=UJVK
M1^1:$\6]L""BD?WB.3]:]:\3^$(O%&H:3+=WCK:6$WGM:>7E9W'3<<\8_&O+
M/'+?$+^U_"PUB+P^LXU%?L(M=^WS>,;\G[OTKT+7_&5YX0\+6;ZQ%:S>(;HB
M&*VM6(C>4\ Y/11_]:M)+:QG%F?\8/[+3P:+(V\7]I7$R+IR1*!(),_>&.<
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M_P#"%^%_^A>TO_P%3_"C_A"_"_\ T+VE_P#@*G^%/]UV8OWO='-_\+F\(?\
M/>\_\!FK*TKXA?#K1;[4+W3TO(;C49!+=/Y,C>8PS@X)P.IZ8KN?^$+\+_\
M0O:7_P" J?X4?\(7X7_Z%[2__ 5/\*7[KLP_>]T<W_PN7PA_SWO/_ 9J/^%R
M^$/^>]Y_X#-72?\ "%^%_P#H7M+_ / 5/\*/^$+\+_\ 0O:7_P" J?X4?NNS
M#][W1S1^,G@]E*F:\P1@_P"C-6;H?Q%^'GANP:QTE;RWMFE:8IY,C_.W4Y8D
MUV__  A?A?\ Z%[2_P#P%3_"C_A"_"__ $+VE_\ @*G^%'[KLP_>]T<O/\7_
M  9<P202RWC12(4=?LS#((P:HZ'\2/A]X;TJ/3-)6\M[.(DI'Y$CX).3RQ)Z
MFNV_X0OPO_T+VE_^ J?X4?\ "%^%_P#H7M+_ / 5/\*/W79A^][HX;5_B%\.
MM=N;"XU)+R>6PF$]LWDR+L<=#P1G\:U/^%R^$/\ GO>?^ K5TO\ PA?A?_H7
MM+_\!4_PH_X0OPO_ -"]I?\ X"I_A1^Z[,/WO='#Z)\0_AWX=AN(=*CO+=+B
M9IY1Y,C;G;J?F)Q]*35?B%\.M;O=/N]02\FGT^7S;9O)D78W'/!&>@ZYKN?^
M$+\+_P#0O:7_ . J?X4?\(7X7_Z%[2__  %3_"C]UV8?O>Z.;_X7+X0_Y[WG
M_@*U9.A?$#X<^&DN4TB.\MDN9/-D012,I;U )('X8KNO^$+\+_\ 0O:7_P"
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M $+VE_\ @*G^%%Z79A:KW1QW_"VO"7_/Q>?^ K4?\+:\)?\ /Q>?^ K5V/\
MPA?A?_H7M+_\!4_PH_X0OPO_ -"]I?\ X"I_A1>EV86J]T<7+\5?!T\3Q32W
M4D3@JR-:$AAZ$=Q7)QW7P>BO_MJZ3+YV[?@P2%,_[A;;^E>P?\(7X7_Z%[2_
M_ 5/\*/^$+\+_P#0O:7_ . J?X47I=F%JO='G.M>-_AYXATU-.U2.ZGM(V5D
MB6!XPI7I]TC@>E37_P 0? .J:6=-ODN+BS*A?*DM"0 .G/7/O7H'_"%^%_\
MH7M+_P# 5/\ "C_A"_"__0O:7_X"I_A1>EV86J]T>4Z'K?PJ\.7OVS2[">&Y
MQ@2-!)(5_P!W>3C\*Z7_ (6UX3_Y^+S_ ,!378_\(7X7_P"A>TO_ ,!4_P *
M/^$+\+_]"]I?_@*G^%%Z79A:KW1QW_"VO"7_ #\7G_@*U'_"VO"7_/Q>?^ K
M5V/_  A?A?\ Z%[2_P#P%3_"C_A"_"__ $+VE_\ @*G^%%Z79A:KW1QW_"VO
M"7_/Q>?^ K4?\+:\)?\ /Q>?^ K5V/\ PA?A?_H7M+_\!4_PH_X0OPO_ -"]
MI?\ X"I_A1>EV86J]T<=_P +:\)?\_%Y_P" K4?\+:\)?\_%Y_X"M78_\(7X
M7_Z%[2__  %3_"C_ (0OPO\ ]"]I?_@*G^%%Z79A:KW1QW_"VO"7_/Q>?^ K
M4?\ "VO"7_/Q>?\ @*U=C_PA?A?_ *%[2_\ P%3_  H_X0OPO_T+VE_^ J?X
M47I=F%JO=''?\+:\)?\ /Q>?^ K4?\+:\)?\_%Y_X"M78_\ "%^%_P#H7M+_
M / 5/\*/^$+\+_\ 0O:7_P" J?X47I=F%JO=''?\+:\)?\_%Y_X"FHO^%K^%
M/^>]W_X#&NV_X0OPO_T+VE_^ J?X4?\ "%^%_P#H7M+_ / 5/\*I3IKHR7&J
M^J.(_P"%K^%/^>]W_P" QI?^%K^%/^>]W_X#&NV_X0OPO_T+VE_^ J?X4?\
M"%^%_P#H7M+_ / 5/\*?M:?9D^SJ=T<3_P +7\*?\][O_P !C1_PM?PI_P ]
M[O\ \!C7;?\ "%^%_P#H7M+_ / 5/\*/^$+\+_\ 0O:7_P" J?X4>UI]F'LZ
MG='$_P#"U_"G_/>[_P# 8T?\+7\*?\][O_P&-=M_PA?A?_H7M+_\!4_PH_X0
MOPO_ -"]I?\ X"I_A1[6GV8>SJ=T<3_PM?PI_P ][O\ \!C65KGC'X>>);=(
M-7MYKI$.5+6S*R_1@01^!KTO_A"_"_\ T+VE_P#@*G^%)_PA?A?_ *%[2_\
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MZ/-]'\<> = TL:9IJ74-D,GRC [CGK]XG-8DES\(I+XWC:5+YI;<0L,@3/\
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M_ 5/\*/^$+\+_P#0O:7_ . J?X4>UI]F'LZG='$_\+7\*?\ />[_ / 8T?\
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M/^@3>?\ D?\ ^+K=N?%?PSO'TMIX+QCI8 L_W4@\K&/1N>@ZYKTO_A"_"_\
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M_P !31_PMSPC_P _%Y_X"FNN_P"$+\+_ /0O:7_X"I_A1_PA?A?_ *%[2_\
MP%3_  HY*/9_>'/7[K[CD?\ A;GA'_GXO/\ P%:@?%WPB"#]HO/_  %:NN_X
M0OPO_P!"]I?_ ("I_A0/!?A?_H7M+_\  5/\*.6BNC^\.>N^J/FRRF21KJ1<
DE7G9EX['%%?2R>$?#D8(30M.4$Y.+9!_2BMW7CV.=4)6W/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img45497886_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45497886_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $; Q8# 2(  A$! Q$!_\0
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MW_W^;_&C^U]3_P"@C=_]_F_QJE119=@YGW+O]KZG_P!!&[_[_-_C1_:^I_\
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M-']KZG_T$;O_ +_-_C5*BBR[!S2[EW^U]3_Z"-W_ -_F_P :/[7U/_H(W?\
MW^;_ !JE119=@YGW+O\ :^I_]!&[_P"_S?XT?VOJ?_01N_\ O\W^-4J/QHLN
MP<S[EW^U]3_Z"-W_ -_F_P :/[7U/_H(W?\ W^;_ !JE119=@YGW+O\ :^I_
M]!&[_P"_S?XT?VOJ?_01N_\ O\W^-4J*++L',^Y=_M?4_P#H(W?_ '^;_&C^
MU]3_ .@C=_\ ?YO\:I44K+L',^Y=_M?4_P#H(W?_ '^;_&C^U]3_ .@C=_\
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M#ADD7:P^H-6+'1]3U0,=/TZ[NPIPQ@A9\'\!7K7Q+TZTU[2/#NLHBQ7%Y/'
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M_P 5I=0C"M)9O$45NA"@<?C6^WC#3_%KR:'HVFW,-WK4R&]EF8;55>6VX)[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+XN_Z#EQ^2_X4?\ "Q?%W_0<N?R7_"N7HH]E#L'M9]SJ/^%B^+O^@Y<?DO\
MA1_PL7Q=_P!!RX_)?\*Y>BCV4.P>UGW.H_X6+XN_Z#EQ^2_X4?\ "Q?%W_0<
MN/R7_"N7HH]E#L'M9]SW'X1>)=9UZ\U--4OY+I8HT*!\?*23GI7JG:O%?@7_
M ,A#6?\ KE'_ #->UUYN(251I'HT&W!-G-^/-0NM*\$ZG>V4S0W,2*4D7JI+
MJ/Y&O!?^%B^+O^@Y<?DO^%>X_$S_ ))WJ_\ US3_ -#6OF;M71A81E%W1ABI
MRC)69U'_  L7Q=_T'+C\E_PH_P"%B^+O^@Y<?DO^%<O175[*'8Y?:S[G4?\
M"Q?%W_0<N/R7_"C_ (6+XN_Z#EQ^2_X5R]%'LH=@]K/N=1_PL7Q=_P!!RX_)
M?\*/^%B^+O\ H.7/Y+_A7+T4>SAV#VL^YU'_  L7Q=_T'+C\E_PH_P"%B^+O
M^@Y<?DO^%<O11[*'8/:S[G4?\+%\7?\ 0<N/R7_"C_A8OB[_ *#EQ^2_X5R]
M%'LH=@]K/N=1_P +%\7?]!RX_)?\*/\ A8OB[_H.7'Y+_A7+T4>RAV#VL^YU
M'_"Q?%W_ $'+C\E_PH_X6+XN_P"@Y<?DO^%<O11[*'8/:S[G4?\ "Q?%W_0<
MN/R7_"C_ (6+XN_Z#EQ^2_X5R]%'LH=@]K/N>C>"O''B74?&6EV=YJT\UO--
MM>-@,,,'VKW\"OF#X>_\C_HW_7Q_0U]05P8J*C-)'=AI.4;L*^:+WXA>+([^
MX1-;N JRLH "\ 'Z5]+U\@ZA_P A*Z_Z[/\ ^A56$BI-W0L5)Q2LSH/^%B^+
MO^@Y<?DO^%'_  L7Q=_T'+C\E_PKEZ*[?90['%[6?<ZC_A8OB[_H.7'Y+_A1
M_P +%\7?]!RX_)?\*Y>BCV4.P>UGW.H_X6+XN_Z#EQ^2_P"%'_"Q?%W_ $'+
MG\E_PKEZ*/90[![6?<ZC_A8OB[_H.7/Y+_A1_P +%\7?]!RX_)?\*Y>BCV4.
MP>UGW.H_X6+XN_Z#EQ^2_P"%'_"Q?%W_ $'+C\E_PKEZ*/90[![6?<ZC_A8O
MB[_H.7'Y+_A1_P +%\7?]!RX_)?\*Y>BCV4.P>UGW.H_X6+XN_Z#EQ^2_P"%
M'_"Q?%W_ $'+C\E_PKEZ*'2AV#VL^YU'_"Q?%W_0<N/R7_"C_A8OB[_H.7'Y
M+_A7+T4>RAV#VL^YTY^(OB[_ *#EQ^2_X45S!HI^RAV&JL^Y]C4445XQZP44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4&B@T >/?';_5Z']9O_9*\:KV7
MX[?ZO0_K-_[)7C5>KAOX2/+Q/\1G8?#WP?:>,M2O+6[NI[=;>$2*80O.3C!R
M.E=0?AWX#$Y@/C0^=NV;#/#G=G&,8ZU%\#>->U4?].J_^A5>NOAMX4NM8FEF
M\90^9),2T'FQ!LD\KUSGM6%2;YVN9FM."Y%9(XOQSX'F\'W<)6<W-E< ^5*0
M 01V.*Y+GT/X"O6/C))>I)I=H]HT>CP+A+@,#YC8 /3I@#C/7)K2TO6=>FL]
M+MO!OAB:VT^$#[0UW$B&8<<J2<>IS[UI&M)03>I$J4>=I;'BO^.*,'T/Y5Z_
M\3M%TB'QGH,TL:6\-Y(JWC+\H9=W)/X=Z[;5+/Q'IU[:-X>M]/DT6,*'L515
MD8=]K' ''3FAXC1.VX+#ZN[V/FJCOBO2+_1+#Q#\4;2Q32+K28ICNN8)U50Q
M&22NTD$'IQ7J$YU;3-2@TK2_"MO+H:J$>7SXU/OA">?QHEB4K601P][W9\[Z
M%I\>K:_I^G2NR1W,Z1,R8R 3C(S6_P"*?"5AX=\96FC_ &Z8VDIC\V>8J"@8
MC)X&.!73^(_#MKX?^+F@-8Q>5;W=Q'+L7A4;?@X_G1X^'_%X=('_ $UMO_0E
MI>T<I)KL"II1:\SB?%VD:/HVIQP:+JG]HV[1AFE#JV&],K7/_A7K?Q' 'Q2T
M0  ?ZK_T.NE\>^,;/P=K%M)#H\-UJ$\8W3/\NV,$\ ]>N:(UI)))7N-TDVVW
M:Q\_T?Y/M7LOQ3T^QU;0=$UNV@2*ZNV0;@H!97 (!/MFNK_LN^\':-9V?A;P
M]#J$A ^T2/,D6>.I).2:;Q*Y4[:B6'?,U?0^;Z*]=^+?ARW32;/Q EB+.\DD
M$=U&F.203R1P2".OO7D5;4ZBG&YC4AR.QZW\"_\ D(:S_P!<H_YFO:Z\4^!?
M_(0UG_KE'_,U[77G8G^*ST</_#1R7Q,_Y)WJ_P#US3_T-:^9NU?3/Q,_Y)WJ
M_P#US3_T-:^9NU=.#^%G-B_B04445UG(%>D^$?AUHVN>$SKFIZK<62*["0@H
M$4#')+#WKS:O8="_Y('JG_ _YK6%=M)69O02;=T10?"SPOJT<L>B>*C=7*KD
M*'C=0?<*,XKS+6='N]!U6;3;U-D\)YQT8=B/K5[P7<36OC+2)(&8-]I52!W!
M[?C7H7Q333K?Q]H=S?6DMS \698(0"\I#<#!ZYZ5*E*$^5NZ*<8RAS)69Y!^
M!_*CZ GZ5]!Z#J7B75?$,8&@?8O##1E/*N(D21/E."1G/)P,5C:'-9^'/B[J
M6B0PI'8ZB@Q%C"J^"< >A&ZA5V[Z; Z"TU/%:*]8\,>#_LWQ=OTDC_T73V:Y
M4XX^;E/P'(_"N(\<:M_;7C#4+I2/+63RH\=-J\ _CBM8U5*5D9RI\L;LYX D
MX R3VKT;PG\*[G6-,N-0UA[BQA";H$4 ._&<D$<"N!L+MK#4;:\5 [6\JRA3
MT)4@X_2O;_AUXIU/Q2/$5SJ$HVI&@BA7[D8(?I_C45Y3C&Z*H1C)V9X7,@BN
M)$!)".5!/4X.*94MU_Q^W'_75OYFHJW6QB]PHHHH$=-\/?\ D?\ 1O\ KX_H
M:^H*^7_A[_R/^C?]?']#7U!7G8SXT>CA?@"OD'4/^0E=?]=G_P#0J^OJ^0=0
M_P"0E=?]=G_]"J\%NR<7LBO1117<< 5V'P^\'VGC'4;JUN[JX@6&+>##MR>0
M.<@^M<?7J?P/_P"0_J/_ %[?^S"LJ\G&#:-:*3FDRPGPU\$2W?V.+Q@S7.XH
M(A-"6W#MC%<;XT\$WG@Z\02R>?9S$^3.!C./X2/6L36R5U[42IPPN9",=OF-
M>O\ C?%[\&=-NKG)F58"&;KV!_.LKS@XW=[FMHS3LK6/$L'IC]*/\XKV+2-8
MUDZ+IUGX'\-3PPQX:XGNX459QC^%B<'/K5KXCBV\.>(O#_B*"VCANA+BX*C&
M]<?-G'7 )JE7?-:Q/L/=O<\3HY'4$5ZU\2_#AU3Q9H=[8Q@QZJJQG:."1SD_
M53^E5/C#?0PW.F>'[7 ALH06 ['& #^ !_&JC6YFDEN3*ERW;>QYA7J<7@/P
M R(6\;!6(&1]HAZ^G2O+*[GX6>&UUSQ,+JY0&RL!YK[AP6_A'Y\_A3K74>9.
MP4K<UFKEWQY\.]+\)Z##J%IJ5S<22S+&J2[,%2"<C ]A7G-=7\0?$TGB7Q-.
MZN?L=L3%;IV '4X]2?Y"N4IT5)1]X57E<O="BBBM3(#10:*:*1]C4445X1[(
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4&BB@#Q[X[?ZO0_K-_[)7C5>
MR?'7_5:']9O_ &2O&Z]7#?PD>7B?XC/3?@K>6MGKFJ-=7$,"M;* 9'"@G=VS
M6A>?"S0[S4I[MO&5LHED,A55CR,GL=_ZUY"0#U /UI-B?W5_*E*C)R<HNUPC
M5BHJ+5['L_Q!\3Z'#;:-H-O.M[':W,<L[J=P54XP3W)R3QZ5K>*ICKK:?=Z;
MXLL[#0U0-<1"4*Y .>%')],<5X( !TXI-JYSM&?I4_5]K,KZQJSV'XJWND:A
M=^'[J2X6ZTTMB86TPWA3SGU''K5NST^XLKJSG\)>-+8:*<,\%_<[B/7 (!/T
M.*\3  .0 *"JGJH_*G]7]U),7M];M'KWB[Q[ID7CW1KVR=;I-/#+<RQCAMV
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M2&BJ12/L>BC-%>$>R%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444F: %I#P*6
MC&: /'?CKS%HGUF_]DKQNOJGQ#X1TCQ3]G_M6%Y?L^[R]LA7&[&>GT%8?_"H
M_"'_ #Y3?^!#?XUVTL3&$%%G'5P\IRNF?.5%?1O_  J3PA_SY3?^!#_XT?\
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MT;_PJ3PA_P ^4W_@0_\ C1_PJ3PA_P ^4W_@0_\ C1];AV#ZI/N?.5%?1O\
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M0_\ C1_PJ3PA_P ^4W_@0W^-'UN'8/JD^Y\Y?C1^-?1O_"I/"'_/E-_X$/\
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M6Y10!A_V+J/_ $'KG_OV/\:/[%U'_H/7/_?L?XUN44 8?]BZC_T'KG_OV/\
M&C^Q=2_Z#UQ_W['^-;E% %6PMIK6#9/=O<OG.]Q@U:HHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ/XQZ]
MXB\(^*-%U6QU6\BTJ5U$]NC?(2I!(Q[J#7ME>??&7P__ &]\.K[8FZ>R N8^
M.FWEO_'<T =C-JUO#H,FK%P;=+<W&X'@@+FO*O@YX@USQ%=:]X@UK6)VTJ*3
M9!'-(!$F22>O3 V_G7(7'C\R_L^0Z:LO^GO,-/*@Y;8/FS^(&*D\;6-UX.^#
MWAKP_ [1?VG*9;V1> Q(!P?P(_[YH ]>7XJ^!WU'["OB*V\_=LP4<+G_ ']N
MW\<UT]UJ5G9:7+J4]PBV441F>9?F78!G<,9R,>E>6S_!OP?'\/F"VH%Z+/S?
M[0:0[M^W=GTQGVZ5S_PZUB\U'X%>*+6Z=WCL8)HX6?G"F,G&?:@#TZ3XH>"X
MM*BU)_$%N+65BB'8^XD=?DQN'UQ6YHGB#2O$=B+W1[Z*[M\XWIG@^A!Y'XUX
MA\&/AQX=\2>$)]4UJR:[FDF:&/>Y"Q@=UQWY[TSX&,^E^(?&-K S&&W4E4SD
M$HS@?C0![)X@\<>&O"[K'K.KP6LK=(\,[?BJ@D?C5G0O%&B>)K8SZ-J4%W&.
MH0D,OU4X(_$5X5\*_"VF?$37]>UWQ.KWTR3D"WD<@#/<XYXZ#GM4U[I=O\._
MCQH\'AXM%::@R)+:JV0JN=I'/;N,T >RWOCKPSIVN/HMYJ\-OJ")YC12*R@+
MC.=V-O0>M0:/\1O"6OZ@;'3-<MYKKM&59"WL-P /X5XSXRT*U\2_M&6^D7S,
M+6=4\P*<%@J%L?CC%6/C-X&T+P=INE:YX>MO[/N8[D(4C<D-QN#<DG(Q^M '
MM>M^+]"\.75I:ZOJ*6LUV2(5=&.[\0"!^-1:-XX\-^(;RZM-*U:*YFM%+3A5
M8! #@G<0 1[@UXG\:I9-7M_!,TS;9;NV1I&'8L%S_,UZ9?\ @[P7X.\$ZFCJ
MVEV<]N(KN[@<B60=,9.>2>V.] %U_BQX&CO?L;^(K?SMVSA)"N?][;M_6MO6
M?%6B:!I$>JZGJ,<-A(X1)U#2*Q()&-H.>AKYXU[6M!G^&EUH_ACPC?/IT&US
MJ]VJJZ'>/F)"\YZ<$=:])\!Z;HFL_!/3$\2PQW&G6P:9A,Y"IM)P<@CL3^=
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M^@[U[C=W,=G9S7,K!8XD+L3Z 9KS?X1V,FHQ:IXUO5S>:U<.T6[JD ;"K^E
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M#/&N3%*I(SCNIQTK'\0Z;>Z!=RW\FIKJ'BW70NG631P^5' G\3*F6(QG))-
M'0Z!JE[XE\;:E?P7,R:%IV;*&,'"7,P/SN?4 Y ^E=K7E6CZEK%G#JFA>%5L
MH[/PU$(I9+N)G>]F"[FZ,NS)S\WS<]J[KPIXCB\4^&;+6(H3"+A,M&3G8W<9
M[T ;=%%% !1110 4444 %1SPQW$$D$RAXI%*.IZ$$8(J2@]* /G#3O@5K\'C
M>&2;R#H<=YYN[SP6* Y'R_D*]C\>^"+3QQX:.ERR&WEC8/;S*,[& QR.X]JZ
MO%% '@(\ ?%Q]-_X1J37H!H9_=%S(I;R_P M^/;->B6?P_CT#X8:CX:TDB:Z
MN;653+(=OFRLI&2>PR:[K%&/2@#AOA/X7U/P?X)72]62-;H7,DF(WWC:<8Y_
M"L+X8^ =;\+^*O$-_JL4 MK]B8=DH<D;V/([<$5ZMBC% 'B&J_"OQ=X;\376
ML_#_ %98$NW+/;RLHV9Y(^8%6&2<<<5J^"?AAK$?BG_A+?&NH+>ZNO,<2$%4
M., G QQV  KUK%% 'S=XWTBYUS]H6/3[.^>RNI(U:&X7K&ZQLP_#(Q^-;7_"
ML/'_ (OUVT;QQK,4FG6;Y7RF3+C/0*H !.!R:]#F^'%G-\28/&IO[@740P+<
M*NP_(5Z]>^:[3F@#RGXH_#_6/$VH^'FT."W^S:?\KAY0FT C &>O KKOB#X4
M;QIX.NM'CN/(F<K)&YY&Y3D ^QKJ,48H \./@?XE:CX!_P"$0NGTBSL+>(+&
M\;%I+C:<JA.< 9 YQ1J/P\\:7/PBTSPM;I;Q74-RS7$8N@%DCP2N3CGD]/:O
M<<48YH ^>]!\%?&7PQIHT_1KNPM;;<7VJ8&))[DE"3^-;GB?X=>,=;C\.>(?
MM-K/XETU5%Q%*5$;LK[@00 /PQ7M-)0!X7XK\ _$3Q;J6DZYJ/\ 97VFSE&V
MP@<HL:@AB=Y)R20.*Z#XF^!M=\5ZQX7N]-A@*:>^ZX$DP4K\R'CU^Z:]4Q1B
M@#A_BQX8U+Q?X)?2M)2-KDW$<F)'V# SGG\:V_!>EW6B>#=*TR]55N;:W6.0
M(VX @=CWK=Y]*,4 >6?&'PGXM\8P66G:&L']GH3)<"2<)O?^'Z@?SKE].\-_
M&_2=/BL+"_T^WMH5VQQH+< #_OCG\:][QSFC% 'FGQ!^'5_XTT'2;B.[6#Q#
MI\:GS#C;(^!N!(Z?,,CMR:YS1?AEXSU_Q98:QX^U**>&P*F*%&5M^#D#"@ #
M/7N:]NQ00<4 '3Z5YE\8/!.M>,K?2$T>.!VM9C))YLH3 XZ5Z;1CB@#S;XH>
M#-8\5^!-.TG3(X6NX)(VD$DH50 A!P>_-.\8>#=8UKX/V?ANSCA;48H;9'5I
M<+E -WS?A7H^*,&@#RW4_"-C%\%K3P_XIU"WTR2")%%RT@V1RCISW!/7ZUP5
MAX>\<2^#KFTN?&-D/"D%O(RR6UPDGF!02$#8W $X&,]Z]\U_0-.\3:-/I6J0
M>=:S ;ES@@CD$'L0:\J_X9PT#[1O_MG4/*W9\O:O3TSUH =^SBI'A'4VP=IO
M.#_P$5[/63X<\.:9X5T>/2])M_)MD);!.2S'J2>YK6H **** "BBB@ HHHH
M**** "BBB@ HHHH *Y#XE>']0\3^#I=-TQ(VN6FB<"1]HPKACS]!77GI28H
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MO!_AT>%?"UEH_G>>\"8>3& S'J0.PK=QQBC% "T444 %%%% !1110 45E_\
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M?\)%I'_/_%^M &I167_PD6D?\_\ %^M'_"1:1_S_ ,7ZT :E%9?_  D6D?\
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M)%I'_/\ Q?K0!J45E_\ "1:1_P _\7ZT?\)%I'_/_%^M &I167_PD6D?\_\
M%^M'_"1:1_S_ ,7ZT :E%9?_  D6D?\ /_%^M'_"1:1_S_Q?K0!J45E_\)%I
M'_/_ !?K1_PD6D?\_P#%^M &I167_P )%I'_ #_Q?K1_PD6D?\_\7ZT :E%9
M?_"1:1_S_P 7ZT?\)%I'_/\ Q?K0!J45E_\ "1:1_P _\7ZT?\)%I'_/_%^M
M &I167_PD6D?\_\ %^M'_"1:1_S_ ,7ZT :E%9?_  D6D?\ /_%^M'_"1:1_
MS_Q?K0!J45E_\)%I'_/_ !?K1_PD6D?\_P#%^M &I167_P )%I'_ #_Q?K1_
MPD6D?\_\7ZT :E%9?_"1:1_S_P 7ZT?\)%I'_/\ Q?K0!J45E_\ "1:1_P _
M\7ZT?\)%I'_/_%^M &I167_PD6D?\_\ %^M'_"1:1_S_ ,7ZT :E%9?_  D6
MD?\ /_%^M'_"1:1_S_Q?K0!J45E_\)%I'_/_ !?K1_PD6D?\_P#%^M &I167
M_P )%I'_ #_Q?K1_PD6D?\_\7ZT :E%9?_"1:1_S_P 7ZT?\)%I'_/\ Q?K0
M!J45E_\ "1:1_P _\7ZT?\)%I'_/_%^M &I167_PD.D'I?Q?K10!<^P6?_/I
M!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJ
MQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/
M_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^
MD'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L
M44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_
M .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I
M!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJ
MQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/
M_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^
MD'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L
M44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_
M .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I
M!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJ
MQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/
M_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^
MD'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L
M44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_
M .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I
M!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJ
MQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/
M_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^
MD'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L
M44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_
M .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I
M!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJ
MQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^D'_?L?X4?8+/
M_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L44 5_L%G_P ^
MD'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_ .?2#_OV/\*L
M44 5_L%G_P ^D'_?L?X4?8+/_GT@_P"_8_PJQ10!7^P6?_/I!_W['^%'V"S_
M .?2#_OV/\*L44 5_L%G_P ^D'_?L?X458HH *3-+7FGQ?\ '>L>!=,TZYTE
M;5GN)C&_VB,L,!<\8(H ]+I,UX<GBSXWR1JZ>%K(JP!!\H<@_P#;6O0/A]J7
MC+4K&[?QCID5C.D@$"Q* &7'/\3=Z .RHJD^KZ;%,89-0M$E!P4:=00?3&:N
MYH **JW&IV%K(([B^MH9#_#)*JG\B:L!U9 X8%2,A@>"* '454&J:>87F%];
M&*,[7?SEVJ?0G/!J1;VU>U-TES"UN!DRB0%/SZ4 3T5#;WEM>1F2UN(IT!P6
MB<,,_44VYO[2S"FZNH8 WW3+($S],T 6**9%-%/&LD4BR1MR&1@0?Q%0#4[!
MO-VWML?)_P!;B5?D_P![GC\: +5%06UY:WB%[6YAG4<%HG# ?E2/?V<<Y@>[
M@68+N,;2 ,!ZXSG% %BBH(+ZTN8FEM[F&6-?O/'(& _$5'#JNG7,WE07]K+*
M?X$F5C^0- %NBJUSJ%E9,HNKRW@+<J)957/TR:A77-)9@JZI9%B< "X3)/YT
M 7Z*9)+'#&TDKK&BC+,YP!^-0VVH65Z6%K>6\Y7J(I5;'Y&@"QFC->>_%SQK
MJO@?PY9W^DK;---="%A/&6&W:3Q@CG(%=OIMTUSI%K=S%5:2%9'(X )&30!<
MHJK;ZE8W<ACMKVWF<=5BE5B/P!JUF@ / I,UPWQ-^(<?@+2(7AMA=:A=L4@A
M)P!_M'U ].]>?I\7?'/AJ^L9/&?AZ&'3KPC8\2;"!QDYW,. <X.* /><T9KS
MWXB_$M/!^CV#Z=;K>:CJ0!M8V. %('S''U'%<QX?^*OBK3_%EEH?CK1HK(7^
M!#+&A7:3P"1D@C/7D8H ]JHH'2H+B\M;0H+FYAA+G"^8X7<?09ZT 3T56.H6
M0NA:F[M_M!Z1>:N_\LYHEU"R@G6":\MXYF^[&\@#'Z G- %FBBJL6I6,TS0Q
M7MO)*@)9$E4LH'7(S0!:HJ"VO+:\5FMKB*95."8G# 'TXJ>@ HHHH **** "
MBBB@ HHHH *3-*:\U^(GQ4M?"T8T_2&BN]7:1%<8+QVZEADO@]3T SU- 'I.
M:,U4:_@MM,%[>S101+$'DD<[57C)ZUP?AGXF?\)9\1;G2-.B']CQ6AD29XR'
MF<-C<O\ L]NG:@#T?-&:Y#QAXIO-*U/1]"TE(CJ>JS;$EF4LD"#JY48W?3(I
MGA3Q1?7OB/6/#.LB!M2TW:XGMU*I/$W1MI)VGD<9- '9YHKE?#7B.[\1Z_J\
MEOY7]A6;"VAD"'=-,/OD-G[HX'3O754 %%%% !1110 4444 %%%% !1110 4
M44&@!,T9KBO&WC*]T74=/T'0K..\UW4<F))6Q'$@XWMCMU_*L(>,O&OA/6M-
MM_&MCI<VGZC,MO'=Z:S 0N>!N#=: /4Z3-(TB(A=F"H!N+$X 'K7F_A;XDR^
M*_B3J&C6<<?]C6]L7BE*'?*P8 L#G&WD]NU 'I.>:,UQ&L>)M6N_&W_"+>'V
MM8)X+7[3=7=S$957/W4"@KR<=<\>E6/!WC-->\.WE[J:Q6EUIDTD%]M8F-&3
M.6!]"!GVH ["BN9\%:SJ7B'2)-7O8XX;:YF9[&,(5<0?PECGDD<]JZ7(H 6B
MBB@ HHHH **** "BBB@ HHHH **** "DSFLCQ-XAM/"WA^ZU>]#-%;KD(OWG
M8]%'N:\]/B/XJOI?_"0KHFCKII7SAIQ9VNO+ZXR.,XY_I0!ZU167HVN6^K>'
MK;6&1[2*6(2.EQ\ABXY#9]*XBS^*4>N_$RQ\/Z*J2Z6T<GG73(?WK*,CRSZ#
MN?>@#TK-&>O%<IXY\53>&;"RBL8$FU'4;E;:V63[JD]6/J .U5-"\3ZI#XVN
M?"6OM:SW0MA=6UU;1F-94Z,"A)VD$'N<^U ';9YI:Y33_$5WK'CF^TZQ\DZ1
MID8CNI2I+/<'G8ISP .O'45U= !1110 4444 %%%% !7AW[2?_(!T7_KZ;_T
M$U[@:\>^/NAZMKFBZ1'I.FW=\\=PS.MM"TA4;3R<#B@#+MO'OQ@CM84C\#V[
M1JBA3]EEY&./^6E=G;:OXUUCX7:O=7VEC3?$ 61+>&)"A( &" Q//+?E7&P_
M$OXHP6\<*_#N8K&H49LY^PQ76>&?$/COQ9H6M1WFD'P[J,2+]AEDMV 9CG/$
MF0>@'XT >$:1J/@R70;C3_$NFWUMKS;BNL!WE8.3P3'D=*]LL?$4GA;X*7.I
M6WB"'77M8REO>;"""3M4,"2<J2/RKE[Z?7[_ $BXTSQ;\-+C5]=.Z-=3MK90
MK9^Z2Z#C'L>U;_@;X7WMI\+M4T#6G$-SJ>YP@.[R#CY2<=><$B@#DO!/PA3Q
M]X?_ .$C\1ZU?M=7A8P^6X.T>K%@<\]ABM7X4:SJNE>(O$/@;4[I[N.TBDD@
M>1B2N." 3V(*\=JS-$O?BG\.+23P_;^&GU2V5B8)D@>54SZ,GYX/2NL^&/@#
M6-(EU?Q-XBS_ &OJ,;!80<E >3G'<\<=L4 >;?#;P)%X[OM?L[[4KRVT^WG+
MF"V<+O<DX)R".,#M1\/_  G?>)?$.L>"KG7+Z#0["21YHH' ,A#;!C(('/)'
M2O0/@AH.KZ/?^)&U/3+RR6>4&(W$+)O&6Z9'-1_"K0=8TSXH>+;V_P!+O+6U
MN#)Y,TT+*DF9LC:2.>.>* ,3X31S>%?BWK_AB&ZFEL(4D&UVX)1AAL>N./QK
MC;O6M+\:^,M5N_&E_JZ6D3E+6#3XP^SDCN"%&!Z9.?:O2_"OA_6+;X_:_J=S
MI5Y'ITWG>7<R0L(G!(QAL8.:QWT3QO\ "OQCJ=YX:T>36-+U$[O+2)I.Y(W!
M>01D^W- #?@QKD]CXXO?#MG=7MSH,T;26INXRK+M [=CSCTXKGO"G@MO&_Q+
M\3Z;+J-Q9V$=S-)<K;MM:4>80%].O/(->Q?#R?Q_JD]WJ?BUEL[*0'[-I_D(
MC+GUXW#';)S7COA6Z\5:?\1_%>H^%K9+R6VFF:XM&&?.C,I& !R2#SQS0!KO
MI5Q\'OBOHMIIFH7-QI6I.J-#*PR0Q"'<  "02"" .E,\=Z++XA^/L>CQ74EJ
MMW$B22QG#!,$D#\JUM$\.>,?B)\0K'Q'XKTQ]+L-/(9()(V0DJ<@*K<\G!)/
MI6EJ&@:P_P"T78ZLFEWC:<J -=B%O*'RL/O8QZ4 :6N?#W3?"WP[ET73O$S:
M+82W/FW=Y=_,\F0!MRNW'3L*\A\;W/@K2XM+;P-+=1ZC:OMGO4+A9<#[P).,
MYYP,5ZW\<_"FM>(]+TNYTFVDO%LI6::UC&6<'&"!WZ&N)\=V'B3Q7X5L+?1_
MA]=:38V,F7A6#;(\A&,K&!DK[XH ]'\:>"- \9Z%IVM^)=2N[-+*TW-)"Z*N
M& ))W*?2O$O W@5/%_CUSH'VF/0K"=96N;K#-M!R!P "3@\>E=M\6H/&&M:-
MH.DZ5H^JR:=]D26XBBMG)\S PKX'&/0]Z9X6\5^/O#&EVND:=\-9(+5&&]OL
MD^6)ZLQ[F@"S\1KK5?'/Q4MO MI?O9V$*@SE"?F)&YB1WX(P*R_''P]?X46=
MEXE\+ZQ? Q3*LRSN.3GC[H (]CFNE^(?@OQ.GBBQ\=>%8M]^D*&XM5&6W =E
M/WL@XQ[5AZM;_$CXLRVFDZGH)T33H9 \TDD+Q@^_S\G'H* +_P ;=4&M_"CP
MYJ@4*+N>.;:.V8V-1_&+Q/?:=X8\,Z%:W,MM%?0*]S+%]XH HVC'/\6<=\5M
M?&CPM>S?#[1=(T+3KN]^R7"J([>)I&5!&PR0/\\T_P")/@'5/$7A70=0TB,C
M6-)C0K"1AF& 2!G^(%1Q]: /'KXZ!X=^Q:CX*U+Q#_:D3J91<VX1&'<C Z9[
M'/6OJ[0M0;5O#^G:@RA7N;:.5EQC!902,?6O';+Q3\8O$%S9Z=;Z&=&,>!/>
MSVA <# )/F C/4X6O;H5DC@C260R.J@-(5 W'')P.!F@#'UWPMH&NS6]YK-C
M'.]D=\4KNR^7@YSP1W'>O&_&VK2_%WQ;8^%/#D9ETJQE\VZO,?+QP2#Z $@>
MI-=)\;[GQ5=Z;;:'X>TO4KB"Z4O=S6D+O\HX\LE1WZGU%<CX8\3^/?".CIIV
MD_#*2*-1EW^QSEY6_O,>YH N?$*!;7XT>#=/'S06]M B*PR.&8=/P%6OVALQ
MW/AF:(?OA,P4@\\8Q6M\4?"&O^(+70?%6BVY&LV,:O-;+D/R V #W!R,=>:Y
MR+1_&_Q3\8:5=>)=$?2=,T\@R*\31;L')QNY)/3T% 'T!&28T)ZD#->'_M&;
MQ;>'C&VV07#;6]#@8KW(=*\>^.^AZMK4&A#2],N[TQ7!:06\+2;1QR<=* .
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6_QH_M74/^?ZY_[^M_C0!ZI17E?]JZA_S_7/_?UO\:/[5U#_ )_KG_OZW^-
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M?^_K?XT >J45Y7_:NH?\_P!<_P#?UO\ &C^U=0_Y_KG_ +^M_C0!ZI17E?\
M:NH?\_US_P!_6_QH_M74/^?ZY_[^M_C0!ZI17E?]JZA_S_7/_?UO\:/[5U#_
M )_KG_OZW^- 'JE%>5_VKJ'_ #_7/_?UO\:/[5U#_G^N?^_K?XT >J45Y7_:
MNH?\_P!<_P#?UO\ &C^U=0_Y_KG_ +^M_C0!ZI17E?\ :NH?\_US_P!_6_QH
M_M74/^?ZY_[^M_C0!ZI17E?]JZA_S_7/_?UO\:/[5U#_ )_KG_OZW^- 'JE%
M>5_VKJ'_ #_7/_?UO\:/[5U#_G^N?^_K?XT >J45Y7_:NH?\_P!<_P#?UO\
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A=0_Y_KG_ +^M_C0!ZI17EG]JZA_S_7/_ '];_&B@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img45497886_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45497886_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'G!%$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O-OBWXEUCP[;:2VD7K6K3R2+(516W  8^\#ZFO2:\A^._\ QY:&/^FLO_H*
MUK02=1)F59VIMHX/_A9OC+_H.2?]^8__ (FC_A9OC+_H.2?]^8__ (FN3HKT
M_94^QYOM9]SK/^%F^,O^@Y)_WYC_ /B:/^%F^,O^@Y)_WYC_ /B:Y.BE[*GV
M#VL^YUG_  LWQE_T')/^_,?_ ,31_P +-\9?]!R3_OS'_P#$UR=%'LJ?8/:S
M[G6?\+-\9?\ 0<D_[\Q__$T?\+-\9?\ 0<D_[\Q__$UR=%'LJ?8/:S[G6?\
M"S?&7_0<D_[\Q_\ Q-'_  LWQE_T')/^_,?_ ,37)T4>RI]@]K/N=9_PLWQE
M_P!!R3_OS'_\31_PLWQE_P!!R3_OS'_\37)T4>RI]@]K/N=9_P +-\9?]!R3
M_OS'_P#$T?\ "S?&7_0<D_[\Q_\ Q-<G11[*GV#VL^YUG_"S?&7_ $')/^_,
M?_Q-'_"S?&7_ $')/^_,?_Q-<G11[*GV#VL^YUG_  LWQE_T')/^_,?_ ,31
M_P +-\9?]!R3_OS'_P#$UR=%'LJ?8/:S[G6?\+-\9?\ 0<D_[\Q__$T?\+-\
M9?\ 0<D_[\Q__$UR=%'LJ?8/:S[G6?\ "S?&7_0<D_[\Q_\ Q-'_  LWQE_T
M')/^_,?_ ,37)T4>RI]@]K/N=9_PLWQE_P!!R3_OS'_\31_PLWQE_P!!R3_O
MS'_\37)T4>RI]@]K/N=9_P +-\9?]!R3_OS'_P#$T?\ "S?&7_0<D_[\Q_\
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M.VZ:;"BBBL3<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML]P3G<0#]WH,>U8]QH'Q/\1V8T+7;[1[32Y $N;NS#&>9!U&"<#/? %>K44
M<+K7@RYDUOP>^E1PII^BR?.KOA@@7:,#'-4Y_ -_+\4QK221+H+,MW-!N^9[
ME590<8Z?.3UZ@5Z-10!QVC^&M0LOB3KNO3"'[%>P11P[7RV5SG(QQUKKIO\
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MJ ,#DU[!110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(-:WPWTO0F^']]JNK:/;7SV\\A+21*[E0J\ FL#Q%XA\ WNAW-OHWAR6TOW
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MP7=ZVFD0:[ ]Y(P1 %;8S'H ^-I_.O-)AGX*^+1CKJUR/_(IKI/B/H.EZ?\
M"6U2TLXHOLLMJ8610&4[U!.?H30!ZO7E.O:?K/B3XK7>CVGBG5=(M8-.BG"V
M<A"EBS Y&?85ZC;?\>D/_7-?Y5Y)KOA#3O&'QHOK749+N..'2HG4VTWEG.]Q
MR<4 ;=K\-=<MKN&=_B+XBF6-PYC>3(< ]#ST-7&U&^_X7,FG?:YOL1THR?9]
MYV;]P^;'3-0:7\'O#FDZK:ZC;W6KM-;2K*@DO"RD@Y&1CD5%?3Q6'QUL'N76
M-;S2GCA9C@,P;.,^O% &E\4=0O-,\#7%S8W4UM.)X%$D+E6 ,B@C(]1Q6/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 9]JT]?\,6/B+P__ &->23I;9C;=$P#_ ",&')!'4>E;.11F@!(T$<:H,X4
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M9&F$C J"HP-HQQU]31I'AJRT75=6U&V>=IM4F6:<2,"H8# VX P/KFMC-&:
M%HI,TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7D/QW_X\]#_ZZS?^@K7KU>0_'?\
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M%Y;7^G6]W9.LEM-&'B9,8*D<5SWQ#\1OX5\'7.IQ6\<\H98D$HRBLQP&;V%
M'-R_&>TM=EQ>^%O$5KII8 W\UH5B"GHWTK?\3_$32/"J:7+=1W$]OJ6?)EMT
MW]L@8ZG/ X]:\I\?:AJS^"YY-9^(.ES&:/:FG:5$&68G^$G.0/<BNGOXXI]4
M^&"NJ2(=QP>0<1$C]: .F\-_$RQU[71HMSI6IZ1?O&988M0A\LS+ZK46L?%3
M3=.UR?3+/2M5U8VI O)["W,D=N?]H^P]*@\7(O\ PMOP2^!OVW0SW^ZM9OPU
MUK2="M/$>FZO>6UEJ$&J3RSQW,@5G5CE6&>H(],_K0!>^$%U#?6WB6[MI/,@
MGUB:2-Q_$I.0?RKO-7_Y E__ ->\G_H)KS_X,SV]UI_B*XM%VVTNKS/$-NWY
M2<CCMQ7H&L?\@2__ .O:3_T$T >.^#/B98^&O >FVYTC5;^.V5_M=S:VY:*V
MRYX=NF>:]0OO&.BZ=X8B\07%V!83(K0D EI"W157J6]JY'P+;PK\#"!$@$EI
M<,_R_>/S<GUZ"N&UB";_ (5)\/[L7TMA96]Q_I%W''O,&6(5\>Q!H ]&TKXJ
MV-YJEO8ZGH>L:+]I<1V\^HVQCCE8] #V_&M3Q5X^T_PQ>0Z>+.^U+4ID,B6=
MA"99-@_B..@KS;6?#]O<V5O%JGQAENX)YHQ%"(5F+R9!3"HQ.<X[5TGBGQ7J
MZ^.$\-Z5J.D:0T-HL\M]J*\R@XXC[9'H30!L^&/B58>(M<?1;C3-2TC4Q'YJ
M6VH0E&D3U%5[OXJ6D6K76EV6@ZMJ-[:W)@EBLX0Y1< AR0>%.2.?[IKA/#]R
M\GQQTZ*X\5+K]Q%;2J\B1A8XB<'8I!.?6NV^'**/$WC:3:-YU, MCG'EK_C0
M!A^%?&M_??%K7;6;1]:$,WEPHLJ$I:!1RS?W58\CUS61X ^(%OX:\-W5DFCZ
MKJLZ7T\LXL;<R"!"Q(+'H*ZWPY=V\/QD\80RW$232QVXCC:0!F/EC@#O^%9?
MPD\3>'M,\*ZE;WE]:VES!>SR3B9@A92Q((S][CTS0!V%U\0M'B\)6GB2V$UW
M97,\<"K'@,K,<<@XQ@]:T?$_BBW\+Z?:WEQ;S3I<W,=LJQ8R"_0G)Z5XMMV_
M"#4-3CBDBTR3Q"MU K#A8=X^8>Q-=3\4/%&C:CH_A^RL=0M[JXFU&WE"PN'V
MJ.[8^[U[T =3XB^(]EX=UN71SIFH7M^L*3106D>]I@3@A0.> ,GVJEJ/Q8L=
M*O;:PN=#U;^T+FT6YAM(X=\C,W/E[1R& SG/'%-@16^/%VQ0%ETA-I(Y'S'.
M*9'%')\?)G=%9H]'!4D<J2P''X4 ;?@_Q[8>+I[RT2TN]/U&S(\ZRO8]DJ@]
M#BNLKSO3$5?CQK950"=(A)P.IW]:]$H XOQ+\1K/0-7.DVNE:GK.H1H))H-.
M@,C0J>A;TS5C0_'=CX@T+4-0LK.\%SIZM]IT^6/9.CA<[,'C)Q7(>*](TJ[\
M;ZA=Z)XW_P"$>\1+"BW<4AV)*,#9DM@$8QTS6C\./$VLZAKVL:%K%QIVHO9(
MD@U#3Q^[DSCY6.,%N] '7Z)XEL=;\+0^((BT5H\)E82$;HP <AO<8KG)?BKI
M-II&C:G=V-Y!:ZK-)'"S!25"\!B >0W;'-<-K$]SX>?Q!\/K7<&U>\C;353^
M&&4DR\^P'ZUTWC/2[>S\0?#C3 BF""\,87'!VQC_  H N6OQ?TB22[@OM+U;
M3[V)0T%G<VQ$UV"2!Y:=3TJ_H'Q)T_7;+5Y#I]]8WFEQ-+<6-W'LEV@9SCWK
M/UF*-OCQX<=HU+?V7/R1Z$XK$O\ CXI>/L?]"ZN??Y!0!I_\+ITIK.WO(=$U
MBXL6C5[FZA@WQVI/578<9'?%4?BMXT>#2= DTF'4;BUO+F.X^T68.R5!_P L
MB1_$>./:HO WBOPO9?!?R;J]M8F@M9([FW=@KNY!'W>ISGK61>1R:?\ !SP7
M]MS HU6*0++\OEH6<KG/L?UH ](U;XB:;H>A6&H:C:7L%W?C_1]-,1-RS?W2
MHZ'ZU6\/?$W3M:UI-&O=,U/1=1E&Z"#48#&9A_LGI6-XEU/3M-^+_AS6=1N(
METJ?3Y+>WNF.Z(3%B>HX'!'-1^/=8TO7/%7A#3='O+>[U./4X[@FV82>7"I^
M8EAP!C/% &KJ7Q7T^QU75-*AT?5+V_L)1&;>TB\QI%[N,=%'<G'457G^,FC?
MV3!?:?IFJ:D2F^YAM8"S68''[T]%/![T[P%#&?B+X]GVCS!>1(&QV*L<?I5'
MX;PQ1^"O%Q2-%)U&\!P.OR#C]?UH Z?4?B)HEAX9T_7%,]TFHX%G;6\9:6=O
M[JKZBJWASXDV>NZRFCW>D:IHU_*I:WAU&W,9F &3M/M7GFAZ?H.I?"+P?#JV
MN-HM^L\S:=>@'"2>:V>>@[=2*T]*U[Q'X;\7:+I=WXDTOQ/97]P8%:)@]U&#
M_$2,X4?6@#V>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "O(?CO_QYZ'_UUF_]!6O7J\A^
M.W_'EH?_ %UF_P#05K;#_P 5&-?^&SQ>BBBO5/*"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /3_@=_P C3J7_ %Y?^SBO=Z\(^!W_ "-.I?\ 7E_[.*]W
MKR\5_$9Z>&_AH0U0LM&T_3KR\N[2U2*>]<27#@G,C 8R<^P%:%%8'08FO>$=
M \3B,:UI5O>&,_*S@AA^((-3Z+X?TGPY9?8]'L(;.#.2L8ZGU)/)_&M2B@#&
MA\+Z);Z3>:5%I\:V-X[R7$.6Q(S?>)YSS@4FH>%-"U71H-'OM,@GT^!52*%\
M_(%&!@YR. .];5% '/V?@KPWISV\EGI,$#V\#P1-&64JC?>&<\YSUZU;TWPY
MI&D:.^DV%A%!8/NWPKDAMW7.3DYK5HH S](T?3]!T]-/TRV6WM$)*Q*Q(4GK
MC)-3WME;:E9RVEY D]O*NV2-QD,*LT4 <A:_##P59B80>';0"9#&^=S94C!Q
MDG'X5KKX9T9#IA6PC!TL8L_F;]SQCCGG@]\UL44 9]WHVG7NIV>I7-JDEY9;
MOL\I)S'NQNQSWP*S]7\$^&M>OXK_ %31K:YNH\%96!!_'!Y_&N@HH S]+T33
M=%%R-.M([87,S3S!,X9SU/\ ^JKLT23PR12*&C=2K*>X/!%/HH SK/0]-T[1
MO[(M+1(M/V,GD G&UNHZY[FDM]"TNUT5-&AL81IJ(8UMF&Y0I[<_6M*B@#E]
M(^'GA+0M06_TW0K6"Z7[L@W,5^FXG%6M>\'>'_%#1-K6E07C19",^0P'U!!K
M>HH YVQ\#>&-,N;*XL=&MK>:RW?9Y(P04W#!YSS^.:TK#1]/TN>[GLK989;N
M3SKAE)/F/@#)S[ 5H44 8=SX2T"\U^'7;C3(7U2$CR[G)##'3H<&J$_PV\'7
M,$4$V@6KQPR-*@.[(9CECG.3D]CQ75T4 4Y-.LI=.;3GM(39%/+,&P;-OIBL
M&V^'/A"RM_L]OH-JD9F6? W9WKT.<YX].E=510!GKHVG+K3ZRMJ@U!XA"T^3
MDH#D#TH&BZ<NMG61:I_:+1>09\G<4SG'I6A10!GQZ-IT6MRZREJ@U":(0R3@
MG+(#D#'2M"BB@#!UWP;X=\3M&^LZ3;W;Q_==\JP]L@@U/INB:;X8TJ2WT/3(
MH(T4NL,7!D8#@$G)YZ9-:]% 'F7A[2M>\4>/T\6>(M%_LB'3X&@LK1Y!)(7;
MJY('3&?SKO;[1M/U*]LKN\M5FN+&0R6SL2#&Q&"1@_SK0HH SY=&TZ?6K?6)
M;56U"WB:**<DY5&ZCTK,UOPY9/;:YJ5G8AM7O;![=I%8[I %^5>3CL*Z.B@#
MS?P9\.=&;POH4^O^'X/[8M( K&5?F!!_B .#^.:[;5]#TS7=-.G:I917-FV/
MW3C XZ8QTK2HH Q6\*Z%)H$>AR:9;OID:;$MW!8*,]B>1^=1Z#X-\.^&7=]&
MTFWM'?[SJ"S'\2216]10!GV.BZ=IM]?7MG:I%<WSB2YD4G,C#H3D^YZ4RPT#
M2]+L[JTLK-(;>ZD>2= 3AV<88G)[BM.B@##'A'P^/#R:!_95N=+0$+;,"P7)
MR<$G/4GO4.A^!O#'AJX>XT?1K>UG<8,BY9L>Q8G'X5T5% !VHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ KAOB-X*O/&<&G1VEW;VYM7=F,H8YW  8Q]*[FDQ3C)Q=T3**
MDK,\+_X4;K7_ $%]/_[X>C_A1NM?]!?3_P#OAZ]TQ2XK?ZU5[F7U:GV/"O\
MA1NM?]!?3_\ OAZ/^%&ZU_T%]/\ ^^'KW7%&*/K57N'U:GV/"O\ A1NM?]!?
M3_\ OAZ/^%&ZU_T%]/\ ^^'KW7%&*/K57N'U:GV/"O\ A1NM?]!?3_\ OAZ/
M^%&ZU_T%]/\ ^^'KW7%&*/K57N'U:GV/"O\ A1NM?]!?3_\ OAZ/^%&ZU_T%
M]/\ ^^'KW7%&*/K57N'U:GV/"O\ A1NM?]!?3_\ OAZ/^%&ZU_T%]/\ ^^'K
MW7%&*/K57N'U:GV/"O\ A1NM?]!?3_\ OAZ/^%&ZU_T%]/\ ^^'KW7%&*/K5
M7N'U:GV/"O\ A1NM?]!?3_\ OAZ/^%&ZU_T%]/\ ^^'KW7%&*/K57N'U:GV/
M"O\ A1NM?]!?3_\ OAZ/^%&ZU_T%]/\ ^^'KW7%&*/K57N'U:GV/"O\ A1NM
M?]!?3_\ OAZ/^%&ZU_T%]/\ ^^'KW7%&*/K57N'U:GV/"O\ A1NM?]!?3_\
MOAZ/^%&ZU_T%]/\ ^^'KW7%&*/K57N'U:GV/"O\ A1NM?]!?3_\ OAZ/^%&Z
MU_T%]/\ ^^'KW7%&*/K57N'U:GV/"O\ A1NM?]!?3_\ OAZ/^%&ZU_T%]/\
M^^'KW7%&*/K57N'U:GV/"O\ A1NM?]!?3_\ OAZ/^%&ZU_T%]/\ ^^'KW7%&
M*/K57N'U:GV/"O\ A1NM?]!?3_\ OAZ/^%&ZU_T%]/\ ^^'KW7%&*/K57N'U
M:GV/"O\ A1NM?]!?3_\ OAZ/^%&ZU_T%]/\ ^^'KW7%&*/K57N'U:GV/"O\
MA1NM?]!?3_\ OAZ/^%&ZU_T%]/\ ^^'KW7%&*/K57N'U:GV/"O\ A1NM?]!?
M3_\ OAZ/^%&ZU_T%]/\ ^^'KW7%&*/K57N'U:GV/"O\ A1NM?]!?3_\ OAZ/
M^%&ZU_T%]/\ ^^'KW7%)BCZU5[A]6I]CSGX>_#S4/!VL7=Y=WUK<)-;^4%B5
M@0=P.>>W%>C48I:QE)S=V:QBHJR"BBBI*"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHI.: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3FE'2@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *\Z^*\TL-MI7E2R1YDDSL<KG@>E>BUYO\6_^/72
M?^NDG\A0!YK]LN_^?NX_[^M_C1]LN_\ G[N/^_K?XU#10!-]LN_^?NX_[^M_
MC1]LN_\ G[N/^_K?XU#10!-]LN_^?NX_[^M_C1]LN_\ G[N/^_K?XU#10!-]
MLN_^?NX_[^M_C1]LN_\ G[N/^_K?XU#10!-]LN_^?NX_[^M_C1]LN_\ G[N/
M^_K?XU#10!-]LN_^?NX_[^M_C1]LN_\ G[N/^_K?XU#10!-]LN_^?NX_[^M_
MC1]LN_\ G[N/^_K?XU#10!-]LN_^?NX_[^M_C1]LN_\ G[N/^_K?XU#10!-]
MLN_^?NX_[^M_C1]LN_\ G[N/^_K?XU#10!-]LN_^?NX_[^M_C1]LN_\ G[N/
M^_K?XU#10!-]LN_^?NX_[^M_C1]LN_\ G[N/^_K?XU#10!-]LN_^?NX_[^M_
MC1]LN_\ G[N/^_K?XU#10!-]LN_^?NX_[^M_C1]LN_\ G[N/^_K?XU#10!-]
MLN_^?NX_[^M_C1]LN_\ G[N/^_K?XU#10!-]LN_^?NX_[^M_C1]LN_\ G[N/
M^_K?XU#10!-]LN_^?NX_[^M_C1]LN_\ G[N/^_K?XU#10!-]LN_^?NX_[^M_
MC1]LN_\ G[N/^_K?XU#10!-]LN_^?NX_[^M_C1]LN_\ G[N/^_K?XU#10!-]
MLN_^?NX_[^M_C1]LN_\ G[N/^_K?XU#10!Z#\+)YI=>O1+-+(!:\!W+?Q#UK
MU>O)/A1_R'[[_KU_]G%>MT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7F_Q;_X]=)_ZZ2?
MR%>D5YO\6_\ CUTG_KI)_(4 >7T444 %%%% !1110 4444 %%%74T;5)$5TT
MR]9&&0RV[D$?E0!2HJ\=$U8#)TN^ ]3;O_A5(@J2"""#@@T )1110 44JJ68
M*H)8G  ')-37-G=69475M- 6&5$L93/TS0!!1110 4444 %%%% !1110 444
M4 %%3P65W=([V]K/,D?WVCC+!?K@<5!B@ HHHH **** "BBB@ HHHH ****
M.]^%'_(?OO\ KU_]G%>MUY)\*/\ D/WW_7K_ .SBO6Z "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6S_PANJ_]#AJWYBN-\?Z+=Z3!8-<ZU>:B)'<*+@CY, <CZT <11110 4444
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M-_NOZ9K)R:* .RU+XE:S?V;6R106N\89XLEL=P,]/K7&]J** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8_Y'/Q9_UV@_]!- '74444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7F_Q;_X]=)_ZZ2?R%>D5YO\6_\
MCUTG_KI)_(4 >7T444 %%%% !1110 4444 %%%% %BQO)=/OH;R @20N'7/?
MVKT2[\5>#-<2"\U>RE^VQK]T(W7TR."/K7F=% '?>+_%^DZYX;BM+,2),KJ?
M*,9 4#MGI576O$VG7O@O2]-MY':\MA'O5HR%R!Z].M<710!Z'JOB3POXET^R
M.J->0SVPR88DR&..F<8P<56\7^*-*UW0K&"P,L=Q XQ"R'"CIUZ'H*X6B@#U
M235].O?#MJOB[1KV(Q !9# ^'.."&'3-7+Z[M[OX:74UK:?8[;:5BC(Q\H;
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5R/AC_D<_%G_ %V@_P#03775R/AC
M_D<_%G_7:#_T$T ==1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %>;_%O_CUTG_KI)_(5Z17F_Q;_P"/
M72?^NDG\A0!Y?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!WOPH_Y
M#]]_UZ_^SBO6Z\D^%'_(?OO^O7_V<5ZW0 4444 %%%% !1110 4444 %%%%
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M2B@#RO\ X5+>_P#06M_^_)_QH_X5+>_]!:W_ ._)_P :]4HH \K_ .%2WO\
MT%K?_OR?\:/^%2WO_06M_P#OR?\ &O5** /*_P#A4M[_ -!:W_[\G_&C_A4M
M[_T%K?\ [\G_ !KU2B@#RO\ X5+>_P#06M_^_)_QH_X5+>_]!:W_ ._)_P :
M]4HH \K_ .%2WO\ T%K?_OR?\:/^%2WO_06M_P#OR?\ &O5** /*_P#A4M[_
M -!:W_[\G_&C_A4M[_T%K?\ [\G_ !KU2B@#RO\ X5+>_P#06M_^_)_QH_X5
M+>_]!:W_ ._)_P :]4HH \K_ .%2WO\ T%K?_OR?\:/^%2WO_06M_P#OR?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH YSQCIMYJ>GV,=G"97COHI7 8#"C.3R:Z.BB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBJVHW1L=-N;I8S(T,;.$7JQ X%
M%FDKPV7Q=\8K%?[>GT".72I!YBV*QJ713TR%_>#'O70^$?BU<^-O$%IIVF^'
M[F"%=QO[F7E8L+D 8Z9(QS0!E^(_C#KA\4W>A^#?#RZG)9;A.\B.^<'!("D8
M /<UU7PU^(T?CRPNQ/:BSU&R8+<1 Y7G.",_0\=L58\8:3J]AH5S)X$TVS@U
MFZD42RHD<9*<Y)+8!-><_!VXT^QLO%-A-'=Q>)A%))>&X(PV WW1[$Y.>N:
M-#7?C)K\_B&^T[P;X>34X-/)%Q,Z.^<=2 I&!D$<YZ5U/A7XIV'B'P/J'B":
M P2Z:C-=6ZG/(&1M]C7(?LZ 2Z+KTSJ#+)=?,V.3\H./U-8GPYTDZWXE^(OA
MY7,-O=1S1*W.$)D*CB@#L_"/Q3UK5/$FEZ?KFDVEK:ZU$\NG2V[DM@ GY\D]
MAVQ75V?BF[U+XAWN@V44#Z?IUNK7EP02ZS,?E0<XZ GI7F6F^%O$GAZXT[7O
M%$%G;:7X4LI1;F.4.;D[2%X!.,G'7%;/A#Q;H'@;1(IO%.H>1K6O2M?S(8V=
MU5CA Y . !TS[T >PT5%;W$-W;Q7%O(LD,JAT=3D,",@BI: "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0#ZU,^A/^%S^$_[U_P#^ Q_QH_X7/X3_ +U__P" Q_QKY[HH^J0#ZU,^A/\
MA<_A/^]?_P#@,?\ &C_A<_A/^]?_ /@,?\:^>Z*/JD ^M3/H3_A<_A/^]?\
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MI:1/N+]*6O:6QY+W"BBBF(**** "BBB@ HHHI %%%%, HHHH&%%%% @HHHH
M****0!1110,****8@HHHH **** "BBBD,****!!1110 4444#"BBBF(U_"O_
M ".&B?\ 7_!_Z&*^KZ^4/"O_ ".&B?\ 7_!_Z&*^KZ\_&?$COPGPL****XSL
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@"IJ?_()O/\ K@__ *":^0D^XOTKZ]U/
M_D$WG_7!_P#T$U\A)]Q?I7=@_M'#C.@ZBBBNXX@HHHH **** "BBB@ HHHH
M**** "BBBD,****!!1113 ****0!1113 ****0!1113 **** "BBB@ HHHH
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MKESK.JWL!AN]3O;B(]8Y;AW7\B:4J,KNST8XUE976J/1-.G;Q;\3=3U#1_$
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M]IR,B, XKR>TU;4M/C:.RU"[MD8Y989F0$^I -$>K:E#'-%%J%VD<Q)E19F
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** *FI_\@F\_P"N#_\ H)KY"3[B_2OK
MW4_^03>?]<'_ /037R$GW%^E=V#^T<.,Z#J***[CB"BBB@ HHHH **** "BB
MB@ HHHH *['X5_\ )1=,^DO_ *+:N.J6WNKBSG6>UGE@F7[LD3E6&>O(YJ)K
MFBXE0?+),]5U/Q0WA;XQW4TA/V.?9%.N?X3T;\#^F:Z;XN^2?AX&@V^4UQ&R
ME>A!R<UX)<W-Q>3M-=3RSRMUDE<LQ^I-3S:MJ5S:BUN-0NYK=<8ADG9D&.G!
M.*P^KZQ:Z&_UC22?4]LT_2=3UOX,V-CI,OE7C897\TQ\!R3\PYKE#\,?B!_T
M$U_\&,G^%<%!KVLVL"06VK7\,2?=CBN751] #4G_  DVO_\ 0=U/_P "Y/\
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MX@N[:+;"45$;< ,@DYXYXQC'>O(_$FJ_VWXCO]2_AGE++]!P/T%5KO5=1U!
ME[J%W<J.@FF9P/S-5*TITW%N4G=LBI44DHQ5D%%%%;&(4444 %%%% !1110
M4444 %%%% !6UX._Y';0O^O^'_T(5BUM>#O^1VT+_K_A_P#0A45/A9</B1]5
M4445XYZA\=)]Q?I2TB?<7Z4M>TMCR7N%%%%,04444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 ?Y^E'^?6BBD,****8@HHHH *.]%%(8?K111
M3$%%%% !1110 4444 :_A7_D<-$_Z_X/_0Q7U?7RAX5_Y'#1/^O^#_T,5]7U
MY^,^)'?A/A84445QG8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %34_^03>?]<'_
M /037R$GW%^E?7NI_P#()O/^N#_^@FOD)/N+]*[L']HX<9T'4445W'$%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5M>#O^1VT+_K_A_P#0A6+6UX._Y';0O^O^
M'_T(5%3X67#XD?55%%%>.>H?'2?<7Z4M(GW%^E+7M+8\E[A1113$%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!K^%?^1PT3_K_@_P#0Q7U?7RAX5_Y'#1/^O^#_
M -#%?5]>?C/B1WX3X6%%%%<9V!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4U/\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img45497886_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45497886_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %X!$<# 2(  A$! Q$!_\0
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MHJN$9NBD_04!6)P <^F*0RQ]L?\ NBC[:_\ =6J-W<16-G+=W3B&WB0O)(_
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M?XBMY[G3)3-;PRF$R@85F'7'J*!FY]M?^Z*/MK_W15?:P&=IQZXH"D] 3]*
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MX1FDW_*2<=!SQ5_P+XBO!\.?$EO>:ZUH-.F:**^F3S7C4DC&,C<>"!SWKKO
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M7_B>XU8R*+Y+Z+,$B-RVT<XYQ7=:3\([B?POKMOK$MM:W^JR"1([49BMBK9
M&.HSZ=JTM(L_BIY>FZ9=7FG:?96A"RWL++++.B_PE3D#([@"@9Z+!+Y]O%-M
M*^8BOM/;(SBI*/QS[FBI **** "BBB@ HHHH **** "BBB@ HHHH OVG^H_&
MK%5[3_4?C5BK$(_W#]*R1TK6?[A^E9(Z4F,****D HHHH **** "BBB@ KQ;
MXUWPTWQ?X2O6M/MBP!W-N1_K,./EZ'K]*]IK@O&OA/5M=\;>%]5L$A-MIKEK
M@O*%8#>#P._ I@>9ZSK=U\2;W3-*TGP2NES17*S-.BC(0<')"*,<Y[]!72>/
MI;.?Q;;Z9=ZYK5U+!:B.#2]'CV,)"!R\A/?']WIBO9V=F/+$@]B:\OU+PIXO
MT?XB:AXE\+I87,>I1;)H[R3;Y1P!Z@GIF@#C/#NLZNWPR\9V-U<72G3V<0K+
M*6EA.3E2_&<&MWPMX$CUCP#%K>JZWK,MY/9LRJET5C1-ORC&.3C@DTNE_#GQ
M18Z#XOTVZ^RW$VJ#?!<B95$KD\Y7^'UKT/PKHMSI?@?3]'O@J7,5J(9=K;@#
MC!Y[TP/._@3H,":==:T+J[,PFDMO)\S]UM^4[MN/O<=:].US0M$UE(9]:M(9
MTLB98WF8JL73+<$#L.N:X_X;^&O%/A&>ZTN_MK!M(>1YDN8YLRER1@;<\#&>
MU6/BGH'B?Q/HMOI7A\1>3(Y:[+SB/<!C:O/4=<CV%(#E8-2;XD_&.PU'2(&&
MDZ%C=>$8\S!)_(G@#TYXSBO0-$\)W6D>+M9UN76)+F'4,[+-E8+!\P/!+$'I
MC@"N:\%:7X[\-0Z?I \/:#;:4LB_:I8K@M*X/WY#\WS-C_ <5TVB0^+4\6ZP
M^KW$+Z$^?[.C4IN7YAUP,],]30P.)^/2>9I6A(1D-? 8_ US(U-_#_@[Q'X+
M#L9VOH((4)^8),H8X^FW]:]&^)OA/5?%<&CIID<+_9;Q9I1)*$^4=<9ZUDZU
M\-K_ %'XK:5X@CCA.E1)$;DF0!@ZY! 7J?X:8&'\);!='^(GB>P^5%M81'GL
M,$\US&N727UKJNH:=K'B+6=3AE:26]@_T:SBC!P&"Y8L,X &1ZUZCH7@C4K3
MQUXIU&]6)-.U2/9$\<@W\]<CM7,VW@'X@6GA&_\ !T3Z6NE,TCQW6_\ >2\D
MA<9^4,<<D<9H$5M>UW5+ZP^&EY->SK-=NGGF-R@E^=?O =:O7^GWOB'X[ZKH
MHU>^L[%K0M.MM+M)0;<JN<A3G'(':K%S\/\ Q)<Z7X'M_LULLFBRC[6#<+PH
M=3D>O /%=)8>%-4@^,NH>)Y(XO[,GM&AC82 MN)7^'KV/- '#^&K*X.J^-?!
MEQJVH3:=#&)8G:7]XIQ_>^F >W%9WP]*^&OACK'B^WN+HWL8:".$R9A4DX#;
M,=<^]>@:#X-U6S^(?B36+M(5L-2BV0LLH9NF.1VK(\)^ /$5EX=U/PCK,%C_
M &+<K(8[R*7=*'_A;;G@=\8H \]3Q";;2[77-/U3Q/+XIWB:7S8MUH^?O* .
MV">?Y5W'Q6U/4+K3O!MQ:7-Q97%W+DF-BNUCLZCV/8UHZ1I'Q3TS3+/P[;W>
MFVNGVS[%U)6#RB(=!L;(_3-:?Q&\(ZQXFF\.-I_E3&PN!)</+($)&5R<=R<'
MI0,Y75-.O/ ?Q0\-_9-<U"Z749-MVMU+O#EF^8@   'L,<5!XSGM=5\:ZC:_
MVOKVJ7\<?EVNGZ0OD1P,.H>0DY[Y^4<UVGC?PGJVO>-_#FJV$<+VMA+OG+RA
M2!NSP#UXK&3P=XV\/^*=>F\.R:?)8:U(SO<7+_/;%V)+!<Y8KGOD'% '(P:_
MJMY\ ]1>XO9S-:W2112;R'5=XX+#DU-XGTG4O#7@WP_XM7Q%JDVJ230I('F_
M=8(8@!0/1<<YSDUK6OPV\3P?#+6?#;0VK7<UVDMNXN%VR*&R2?[O3H:Z+QOX
M-UG7OAQI&B6,<#7MK/"\JO,%4!48'YNAY84",SQ9J.H>*O&7A[PC'?3V5E<6
MD=[>26S;'D)'0'MC''U-2MIFO_#/1?$VHIJ\EYI2Q9L(KEC+(LA'#,>,8/&.
MX]*O>)O!6M/?Z#XB\.M;C6].MX[>:WG?$<R@=,_7/UX]*;8>$O%FOC7CXOOH
M8+?48?)CL+5_,CB.W =2<[<>G<]:!GE2:^T&DV^N6&J>)Y?%)D$TGFQ9M'W?
M>  [8)_P%?2.DWK:CI%G>O&8WFA5V4C!!(YKSC2=&^*>E:9:^'+:\TVVL;9_
M+CU,,'E$0Z#8<CIQC&:]1C#+$BO(9'50&<_Q'')P*3 \&\;:\GASXV2:A)HX
MU8"S"?9CCG/?E6Z?2C2)KSX@_$S1-3L/# T6TTMEDN'48! 8M@D*HYZ#BO0$
M\+:LGQD/B<+$---F8=XE&_=C^[UKNRQ(Y8D>YS3N!X5H?AQ_$WQ;\9V4FIWE
ME9><[3"SD"/*?,&!N(.!GG\*O_#_ %R]M/#?C#3KW73!'I4@$%]<*9&B#;@3
MC//08&>IKJO"7A35M%^(OB?6[R.%;'4'9H&24,Q&\'E>W%<[8?##69=/\965
M\T%N-6='M9$E#\JQ;# =,\?Y%%P//KW4)=.MM.UK0;[Q+/(ERHFU*\<1P-(3
MG"Q<]1ZDUT_Q U:?_A/HQXFFUFU\._9$DMGTMMGS,@R>>#\^X<GM5S5/!'Q%
MUSPI8:/>)I446F,AACCF&;GD\LV<+M ]!G=75ZSIGCU9838#2M4TV6!!+I.I
M(GEP.%&2&XW\YQS0(YK3/%*^'/A7K%_I'B9]9,;*+9+B+;-9F0XPY).2,Y],
MBN+3Q!_9EE8:QI&I>*)_$ D$ETMS%FVE4YW!1SCM7H>A?"B>71/$2ZX;:TO-
M:)*V]H/W-KAMRD8ZC(' [<59TG3?BK:V>FZ(;O3;&QM7"MJ$;"65XAGY2AR.
M>.P/O0,]'LIS=6%M<,FQIH4D*_W2R@X_6IZ100H#,68#!8]SZTM2 4444 %%
M%% !1110 4444 *OWA10.M%- :U%%%4(**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** *-[_K%^E5JUBH/4"DV+Z"E8#*HK5V+Z"C8O
MH*+#,JBM78OH*-J^@_*BP&516KM7^Z/RHVK_ '1^5%@,JBM7:O\ ='Y4FU?0
M46 RZ*U=J_W1^5&U?0?E18#*H_&M7:O]T4;5]!18#*_I16KM7T%)M7^Z/RHL
M!E_E16KM7^Z*-J_W12L%S*X]J*U=JY^Z*-J^@_*G8#*H_&M78O\ =%&Q?[HH
ML!E?C1^-:NQ?[HHV+_=%%@N97>C\:U=B_P!T4;%_NBBP7,K-%:NQ?[HHV+_=
M%*P7,K\J/RK5V+_=%&Q?[HHL%S*J.>"&ZMY;>XB26"5"DD<@W*ZG@@CN*V=B
M_P!T4;%_NBG8+GET?P;\#1W"3C2I"RN'VM<N4)!S@KG!'M7=1QQPQ+%$B1QJ
M,*B# 4>@%:^Q?[HHV+Z"BP&5^-%:NQ?04;%]!18#*XHK5V+Z"C8O]T46 ROR
MH]^]:NQ?[HHV+_=%*P7,K\?UHK5V+_=%&Q?[HHL%S*HK5V+Z"C8OH*=@,JBM
M78OH*-B^@HL!E45J[%]!1L7T%%@,JBM78OH*-B^@HL!E45J[%]!1L7T%%@,J
MBM78OH*-B^@HL!E45J[%]!1L7T%%@(;3_4?C5BD  Z"EIB$?[A^E9/I6N:;L
M'H*30&516KL7T%&Q?046&95%:NQ?04;%]!18#*HK5V+Z"C8OH*+ 95%:NQ?0
M4;%]!18#*H_&M78OH*-J_P!T?E18#*HX]JU=J_W11M7^Z*5@N973O1Q6KM7^
MZ*-J^@_*G8#*_']:..^*U=J_W11M7^Z*+ 97XT?E6KM7^Z*-J_W118+F516K
MM7^Z*-J_W1^5%@N96><YHK5V+_=%&Q?[HI6"YE?C2?C6ML7^Z*-B_P!T46"Y
ME9Y[4?CSZUJ[%_NBC8O]T46"YE9HK5V+_=%&Q?[HIV"YE49^E:NQ?[HHV+_=
M%%@N95%:NQ?[HHV+_=%*P7,K\J/RK5V+_=%&Q?[HHL%S*HK5V+_=%&Q?[HIV
M"YE?C16KL7^Z*-B^@HL!E#CO^M'Y5J[%]!1L7^Z*+ 97X_K1^-:NQ?[HHV+_
M '12L%S*'%'3I6KL7^Z*-B_W118+F5Q16KL7T%&Q?04[ 95%:NQ?04;%]!18
M#*HK5V+Z"C8OH*+ 95%:NQ?04;%]!18#*HK5V+Z"C8OH*+ 98Z\45J;!Z"BB
MP#J***8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ KC/'OA[7_$W]F:=IFH"RTQIB=2=)"DK1\8"'!]_2NSKS?XO7
M_BM=%ATOPMIM].]YD7-S:IEHT_N@]B>>: ,OX7R2V7CGQ/H6GZG=:CH%D%$<
MUP_F%9N RA\<]^GI4GQP\0:UH^DZ5;Z9!.(+F[037$4@7<0<B(\9^;KD?W:O
M_"V5]/M/[#B\$ZCH=M#'YC75VVXW$G0EC@98]?0=  *D^,6B:EK/A6S;2[*6
M]GL[^*Y,$7+LHR#@=^M $5U\3;^S33-+M_"EW=^([BW$\VF+.!Y$?(RTF.IP
M#C'>M_P5XVMO&-O=HUG+I^IV,ABO+*8[FB;M@\9!QUP.0:X-_P#A)](\6VWC
MJT\*7ES'J%B+2YTT-_I%NP/!Z=#M';O6_P##70]9&M>(/%FMV?V"?69$$=D?
MO11ID M[G^F>] $7QINM0MO#NG""ZFM-+EO4CU*XA.&CB) !SUZ^E9GPBF?_
M (2?Q#::3JMSJ?AB +Y$]R^]O-.. 3@XQGL*V?BQH6K:K;Z+>Z=8G4H-.O5N
M+K3@>;A 1QCH>G2L_P"'.CZL_CG6/$<N@OX=TRXMU@33F&W<X(._: !V/..]
M '7>+O%Y\)W>C++8>?:ZA="U>?S=ODL1\O&#NSSW'2LJT^)]G<_$'5?"IL_+
M%A$T@NS,"LA506&W'&,XZGI5[XEZ%/K_ ('NX+.(RW\#)<VBJ,GS4.1@?3(_
M&O';WP!XG3P+IVL6VGW9\0W=W.;V,1GS0DF%Y'4 ;,_\"H ]/A^*EM_PKO\
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MVB/U%>G#J: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:+GQ5K,GA[3[B");:\FU!;1C-"P#KS\X5@",\']* .V^U6_VK[+Y\?VC9O\
M*WC=MZ9QZ>]3"N/;6M0TC7;BTO[B.[CMM,-V\BP"-G.YN."<#  J%M8U^PTJ
MQU^\NK::SN)(_.LTAVF))"%&U^K$%AU S0!VSL%0LQ"J!DDG  J*"X@NH5GM
MYDEB?[KQL&4]N"*Y.ZU#6-9N-:CTZ[@M;;3\PE'AWF=MN6!/&T8XXSUJ[X")
M/@C3,@ [') [?.U '2T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2#CGVJY_PDFD_P#/XE'_  DFD_\ /XE/ZU1_F7WA["K_ "L@L=*UJ*YMVO\
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M_B#*<$4";2W-VBL'_A,_#_\ T$8J3_A,_#__ $$8J+"YEW-^BL#_ (3/P_\
M]!&*C_A,_#__ $$8J=@YEW-^BL#_ (3/P_\ ]!&*C_A,_#__ $$8J+!S+N;]
M%8'_  F?A_\ Z",5'_"9^'_^@C%18.9=S?HK _X3/P__ -!&*C_A,_#_ /T$
M8J+!S+N;]%8'_"9^'_\ H(Q4?\)GX?\ ^@C%18.9=S?HK _X3/P__P!!&*C_
M (3/P_\ ]!&*BP<R[F_16!_PF?A__H(Q4?\ "9^'_P#H(Q46#F7<WZ*P?^$S
M\/\ _02BH_X3/0/^@C%^=%@YEW-ZBJ.G:M9:M&\EC<+,J'#%>U7J12"BBB@
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M7\,?^0=>_P#70?RKO:X/X9?\@^]_ZZ#^5=Y63W.VG\(4444C0**** "BBB@
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M[/\ Z]__ &8UQ%:1V.*K\044451F%%%%( HHHH **** "BBB@ HHHH ****
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M1P.*X/O5R/5+V*ZDNDN&$\@P[X'/Z53KFQ>*5>*2Z-_B;X;#.C)OT"K^B?\
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MM%;UWX7GT_4K&WGNK9X;L@K<(QV8^M=?<>%[6WURV%E#IDB>1L-M<$DL?[Y
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M4N!M)R.<$#M75>(O&.F:+97ODWME<:E;!<V(N%\WEE7E0=P^\.U=%&7,:&0
M.5&X \ ]Z *NEV$6EZ39Z?!&(X;:%(4122%50  ">>W?FJ&I_P#(R:+_ +TO
M_H!K<K#U/_D9-%_WI?\ T T ;E(:6D- "'I7GMWX;U66]F=+=2K.2#N'2O0C
M17%B\'3Q22F]CHP^)G0;<.IYO_PBVK_\^Z_]]BC_ (1;5_\ GW7_ +[%>DY%
M&17#_8F&[O[SK_M2MV1YM_PBVK_\^Z_]]BC_ (1;5_\ GW7_ +[%>DY%&11_
M8F&[O[P_M2MV1Y[::!K5I/YJ6RG@AE+\,#VJ$^%M6W'%JJCT#CBO1\T9%5_8
M]"UN9V]2?[2JWO9'F_\ PBVK_P#/LO\ WT*7_A%M7_Y]U_[[%>CY%+D5/]BX
M:^[^\K^U:W9'F_\ PBVKX_X]E_!Q2?\ "*ZM_P ^R_\ ?8KTC-&::R7#K:3^
M\3S2MU2/-_\ A%=7[6R\=/G%+_PBVK]/LZ_]]BO1\BC(I?V+A_YG]X_[4K=D
M><)X7U974_948 YP7&#4MUX?UN[N&FDMUR<  .,*!V%>A=: :K^Q\/:W,[>H
MO[3JWO9'F_\ PBVK_P#/NO\ WV*/^$6U?_GW7_OL5Z3D49%3_8F&[O[Q_P!J
M5NR/-O\ A%M7_P"?=?\ OL4?\(MJ_P#S[K_WV*])R*3(H_L3#=V']J5NR.=\
M*Z7=Z<LXNHPF\C;\V:Z2D'6EKU</0C0IJG#9'!5JNK-SEU"BBBMC,Q/^9T;_
M *\E_P#0FK;K$_YG1O\ KR7_ -":MN@ HHHH :_^K;Z&O ;[_D(7/_75OYU[
M\_\ JV^AKP&^_P"0A<_]=6_G51.>OT*]%!Z'%>A_V-IK>'<K9P^0;,.MT%&\
MRD\#=]>,5=S",;GGE%;WB""VTJTL=*6*+[8B>9=2X&[<W(3/48'\ZR+2TGOK
MJ.VMHS)-(V%4>O\ 3\: :L[$%%=/<^"+^"WG>*[L[F6 9D@A?,BCOD5N:)HU
MA:^#Y+^:+3+J<EGW3G*K@?<SV;V]Z+HI0=]3SRBK^E:;+KNJ"T@:.%Y,L-WW
M5]N*V;GP-?P6]P\=Y9SRVXS)!$V74?3MQ1<E1;5T<O16_I?A2ZU*R2[>[M;.
M*5]D/VEL&0_[-6='\,8\8KI6I-%MB!D9=V!,.P7^>/0&BXU!LY>BN^U#08[4
MZZ]O#I<T2J''!+VXYX7 X/&?RK TWPG<W]C%=R7MG9QS,5A%R^TR8]*5P=-W
M,"BMB#PW>S>(?[$<QPW."<MRN ,]O45>N/!-[!97-PEY9SR6PS-!$^73V/X<
M\T[BY)',T5W4WA:S_P"$(MI8I[,7<CK(;AG^^3G"*WKTX]C6=+X#U&.!R+NT
M>YCC$C6JOF0?44KC=.1RU%%%40>F?#+_ )!][_UT'\J[RN#^&7_(/O?^N@_E
M7>5D]SMI?"@HHHI&AQWQ2TC4-?\ ASJ^F:7;-<7DPB\N)6 +8E1CR2!T!-;6
M@Z9'9:+I\<MG#'<Q0(K_ "+E6"X/(K7Q1B@#R7XF>&_$.I>,-*U*UT7^W](B
MMVCDTTW7DH),GYFSU!!'K]WM5CX6>$=7\.+XEM=4TV.R2[N3)!Y,@:+:1]U>
M^!TY Z5ZCBD( &2< 4 ?/,7@_P ;Q_#VY\(OX9;]S?"ZBNDN8R)OW@R "1CC
MG)KIO'G@74I_$VE^)+7P];^(8DLUL[K3)I1&1@$APQXX)([_ $KU;^T]/S_Q
M_6W_ '^7_&K$4L<L8>-U=#T93D'\: /.O!_A?4K'P?K+76A:9I5[?AQ%8V*X
M*( 0JNV2"W)Z<8QZX'/S>#/$+?L\P^&UTQSK"R!C:[TR!YQ;.<XZ<]:]G[YH
MH \C\6^'/$T&I^#-=TC1O[2FTFW,<]IYZQMDJ/XCQCZ9K&\9>%/%.JZA?B3P
M397UQ=!'MM6LK@6TMOD?=D!)W$=#CJ.YKW4D 9XXID4T4R;HI$D7.,HP(SZ<
M4 9/A+3K[2/">FZ?J=Q]IO;> )++G.3^/H,#\*\MM_A?J,WQ-U9+RV;_ (1B
M4SSQ,74J99DYP,Y&"3V[5[92=Z /*?@WX,UKPZ=2O?$5MY5XRQVEOEPQ\A!Q
MT)XX%-\*>#=:M_!?B_3+VR-O<:A/*UL'D4[P<X.03BO6<"C% '@EGX8\9W.B
M^#=,N_#,EL-#O27E^TQL'C/.[&>.XQS7<7_A[59?CAIFO1V;-I<.GO%)<!UP
MKG=@8SGN.U>B8HQ0 @ZTM&** "BBB@#!M?\ D=+[_KV3^8K>K!M?^1TOO^O9
M/YBMZ@!JQHF=JA<G)P.M.HHH X?QQ_Q^VO\ US/\ZY6NJ\<?\?MK_P!<S_.N
M5KXC-/\ >YGU&7_[O$****\\[">VO+FS9FMIFB9AABO<4Z;4+NXC*33LZ'J#
MBJU*JL[!%&68X ]ZM3G\*9#A"_,T6&U&]:#R&N9#%C&TGC'I5;.#GO6M-IGG
MZ@+"S11)#'F1W.-Q[_S%5+C3I8(!/OBEBW%"T39VMZ&M:E*MN];=3*G5I=+)
ML9]NNA<FY\]_/(P9,\XZ5&D\B1-$';RG(+H#PV/6G06XGSF>&+'_ #U;;_2E
MGMA H87-O+GC;$Y)_'BI2JVYU>Q;]FGRO<UK?68+0H\,]X5C3"0.!MS[MG./
MPK$D<R2-(W5F+'\:U=+LO-TZZN1:)<R*RK&&)QWSW'M5.:+=?K#/$EER ^ <
M+[\DUT5O:5*<6^IA2=.%22709;WUU:@K!.\8/) ]:EEU>^N(?*GG,HR""XY7
M'H>U3:Q:VML+/[)G9)#N+-P6.3S5FQTJW.F7,]R#YYB:2*,_PK_>HC2K<SIJ
M6R^02J4>55''=_,H'6-1)R;R0D#J<539F=RS,68G))[U=M[>.YTV<JN+BW_>
M9'5U/'Z<51KGJ^T23D[W-Z7L[M15K!1116)J%7]$_P"0W9_]=!5"K^B?\ANS
M_P"N@K?#?QH^IE7_ (4O0]2%+2"EK[]'R 5AK_R.LO\ UY)_Z$U;E8:_\CK+
M_P!>2?\ H34P-RBBB@ HHHH \N^)O_(;L_\ KW_]F-<17;_$W_D-V?\ U[_^
MS&N(K2.QQ5?B+NDVQO=2@M/M @CE;$C&38-HY//TSBNWLM5M[Z?4S9O%%-$8
M8;?S64#R5)SC/&>N?PKSOKP1D4$ ]:;0HSL:^LSVD?BJXGLEC:V6?*A?NGU_
M7-=A=6UEJWB2T\20ZS;)9IMD='?$BE/X0OOCG^M><=J3 )Z"E8%.QZ'I^JVE
M]<^*+E98HXYH7$6Y@"_RG!P>]<%8X^V6O_75/_0A41P>H%.CD,<J2#!9&##/
M0D'-%@E.YZIJVEQR>,K/57U&VACME4R1R28?C)X'H<UFZ;/IFJW.L7L#6GVT
MS[K8WC%4  P&QWYYKB]9U>XUV^^UW:1+)L"?NU(&/Q)K.(!Z@&CE+=74[WQM
M>PSVFD3)<V\YC;YS"PQD>W4"M]3;MXGM-6%_9^1]E\G;YPW ]>GX5Y)@>@_*
MDVCT%'*+VNIZ'X:U-%T_5["VNK2&^:[DEB-SS&P) Z_A5/Q!J3RZOI-I/J-M
M<O!(KR>1%L2,G' ;)S^E<20#VHP, 8&/2BPO:.UCT*6[@/Q6AG^TQ>2(<;]X
MVC]V>_3K2Z1);37?BJS%U;1/<N/*,D@"G@]_3FO.\#&,#'I00/046'[3J>G:
M.2VGVUI+J>G7MC%NAGBN?W;H1_=;)W#\N,5POB'[%_;UW_9Q!M=V$QTZ<XS[
MYK+*J>"!FE]Z$A2G=6"NS^&G_(P7/_7L?_0EKC*[/X:?\C!<?]>Q_P#0EH>P
MJ?Q(]5HHH-9G<5[ZY^QZ?<W6POY,32;5!).!G&!S7G^E^'%T[3_"=BEF?M#W
M9O+V=HR7SY;DDGMEBHQFO1\T4 >'VFEZE?\ VK2+R_G&JW5^TMU$FBEYH\."
M'%RSJFW:%''/)XZU<\8:CJ:WGB7RHXX[T#RXK/\ L5[AYXPBX;SLA0#D\#D>
MA->OW$\=K;2W$S;8XD+NWH ,DU7M-3BOH[2:WBG>"ZA$T<VWY0I&1GG@D&@#
MBC8ZJ8/$::<LWV^RTF.QL9&&TNQB#94GJ=W?UK!\,Z;<7=UI4>FZC)*=,CDD
M!71#:[',;($ED=\MDMGA6!*\XKV T9XYH \<CCT_4]-\/:)%I5V^HC55DU":
M:U=3$PWDLTA&&R0,8)&.N.*]CZFJD&I6]SJ%W91,6EM0AEP. 6S@9]>.GN*M
MB@!:P]3_ .1DT7_>E_\ 0#6Y6'J?_(R:+_O2_P#H!H W*#10: $/2O!M4N)Q
MJUV!/* )6'WSZU[R>E>!:K_R%[O_ *ZM_.O(S:348V9Z.7I.4KD'VFX_Y[R_
M]]FC[3<?\]Y?^^S456-/CMY=0MX[MF6W9P)"AP<>U>(I3;2ON>FU&,;M#/M-
MQ_SWE_[[-'VFX_Y[R_\ ?9KK4\'VD6N:E#=RSII]I")EE! + C/7']*KVGA_
M2;30H=4URYN42Y;$,=MC./4YZ\5U?5ZVS?XF'MZ5KI'-?:;C_GO+_P!]FC[3
M<?\ /Q+_ -]FNPC\%6P\26]H]Q*]A=0F6%T(#\8X/'O1_P (QH5Y::DNFWMU
M)=V(.XOC8>3TX]L?A1]6KVW_ !%[>C?;\#C_ +3<?\_$O_?9H^TW'_/>7_OL
MUTMMX?TBRT.VU'7;FY4W1_=16P&<>^>O'-6$\&VZ^*H-/EN)'L;F-I89(R Q
M4#H>/_U^U)8>NTM?Q&ZU+73\#DOM-Q_SWE_[[-'VFX_Y[R_]]FNN_P"$9T.]
MMM1CTR]NGO+%2SF4#8^,YQ^51G0- L_#5EJNH3WH>Y4X2(J<M[<<"F\/6ZO3
MU#V]+M^!ROVFX_Y[R_\ ?9H^TW'_ #WE_P"^S78Z)X7T34XH$:>^FN'7?(8
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M\J]#KZ; -NA%L\+%JU9V"BBBNPYS$_YG1O\ KR7_ -":MNL3_F=&_P"O)?\
MT)JVZ "BBB@!K_ZMOH:\!OO^0A<_]=6_F:]^?_5M]#7@-]_R$+G_ *ZM_.JB
M<]?H5ZW?#*PK=27U[,!:V2>9Y;/P[_P@#ZUA459SQ=CT32[^UO-*BN9Y8!'(
M+AM161ADN<;!@\GC &/2N3\*:E!I/B"VN[HD1 %'8#.W(QGZ"L8@=2!2]_<4
MK%.=W<](LX+7P]J>J:W/JEM-!,K>5'&^YVR<@$5C0W$+?#:[C\R,2->,XC+
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M[X-:\TG2I='M%$LL"R3N\I )*CU/K7):G@:G>CL)Y/\ T(UV^MNZV/A!0Q
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MICLV$Z3%RHM,@@(,_>(QD=.M:WA_QF_AWX)2ZY8:-9P2)=O%'!;JXA0E@-[
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MOW<_PI*['\A1]2?</KJ['US17R*VM:NK%6U&]# X(,S9!_.D_MO5O^@G>?\
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M4YSZTNY^ 6)V] 2>*Z"R\%ZQ>VD=PJP0B49C2:3:[?08[U2L/#VI:AJ,UC'
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M(] N[W58;ETMM+$\0Z/YP7/X5!_:6N?] 1?_  (%;E%9G<8?]I:Y_P! 1?\
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M=5XGT)%\36^G:1:!#+ K"-2<9).2<]*SM4\+:EI-K]IF\B6$-M=H)-^P]MW
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M]0 4444 >&_'7_D-:3_U[M_Z%7DU>L?';_D-Z3_U[M_Z%7D]>OAOX2/&Q/\
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M[@O08S@5FZII-UJWB/2Y)D1=-L&:Y!W?-)-@JHQZ ,Q^N/2N@HH 09[TM%%
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M-C$_YG1O^O)?_0FK;K$_YG1O^O)?_0FK;H **** &O\ ZMOH:\!OO^0A<_\
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M#%%%%(84444 %%%% !1110!Y=\3?^0W9_P#7O_[,:XBNW^)O_(;L_P#KW_\
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M*NG^'UW;6'C:RN+R>*"!8Y@TLKA57,3 <GIS6=5/E=C2DTI:FEX%L=]SX@U
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MV>BZ?I\[36ENL3LNT[>A'TJ_0 4444 -?_5M]#7@-]_R$+G_ *ZM_,U[\_\
MJV^AKP&^_P"0A<_]=6_G51.>OT*]%%%6<P4444 %%%% !1110 4444 %%%%
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M;RP/][&*JJC2.J(A9F.%4#))/0"O7H;>]U'XA:;?V-];GP[+''%&BS+L\O:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'EWQ-_Y#=G_ ->__LQKB*]QU7PWI>M7"37]N9)$7:I$C+@=>Q]ZH_\
M"!^'?^?%O^_S_P"-4I61SSI.3N>.45['_P ('X=_Y\6_[_/_ (T?\('X=_Y\
M6_[_ #_XT^8GV#/'**]C_P"$#\._\^+?]_G_ ,:/^$#\._\ /BW_ '^?_&CF
M#V#/'**]C_X0/P[_ ,^+?]_G_P :/^$#\._\^+?]_G_QHY@]@SQRBO8_^$#\
M._\ /BW_ '^?_&C_ (0/P[_SXM_W^?\ QHY@]@SQRBO8_P#A _#O_/BW_?Y_
M\:/^$#\._P#/BW_?Y_\ &CF#V#/'**]C_P"$#\._\^+?]_G_ ,:/^$#\._\
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MB2YO(W08Z#:(QP/0$5[G_P *C\&?] M__ J7_P"*H_X5'X,_Z!;_ /@5+_\
M%4OK-*][,?U:K:USQR'QCIMK?)K%OH0CUI+<1"59%$&_;M\SRPN=V/?K6#I>
MN:AI=W;217MV(8I5D:&.X9%<9R1@''/TKZ!_X5)X,_Z!;_\ @5+_ /%4?\*C
M\&?] M__  *E_P#BJ/K-+L'U:KW/&K>[D\8?$'^T9VDBM1-]KD$DNX6\2?,1
MD_3''K6'X@U0ZUXAO]1V@"XF+*!_=' _0"OH#_A4?@L]=+?_ ,"9?_BJ7_A4
M?@S_ *!;_P#@5+_\50L533T0/"5&MSYKHKZ4_P"%1^#/^@6__@5+_P#%4?\
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M+?\ ?Y_\:/\ A _#O_/BW_?Y_P#&CF'[!GCE%>Q_\('X=_Y\6_[_ #_XT?\
M"!^'?^?%O^_S_P"-','L&>.45['_ ,('X=_Y\6_[_/\ XT?\('X=_P"?%O\
MO\_^-','L&>.45['_P ('X=_Y\6_[_/_ (T?\('X=_Y\6_[_ #_XT<P>P9XY
M17L?_"!^'?\ GQ;_ +_/_C1_P@?AW_GQ;_O\_P#C1S![!GCE%>Q_\('X=_Y\
M6_[_ #_XT?\ "!^'?^?%O^_S_P"-','L&>.45['_ ,('X=_Y\6_[_/\ XT?\
M('X=_P"?%O\ O\_^-','L&>.45['_P ('X=_Y\6_[_/_ (T?\(%X=_Y\6_[_
M #_XT^87L&9'PR_Y!][_ -=!_*N\K.TK1+#18GCL(3$LARP+ELG\36C4,Z8*
MRL%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ Q1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !I
M*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C%%% !1110 4
M444 %%%% !1110 4F*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "DQ2T4 )@4M%% !1110 FX9QFEJG+9&34X+L/@1JRLN3SG]*Y".:]34T
MFQ=(IOG7[0]TS1D!>(_+S@9]<4 =W29KSV7Q-K*V\\AN!"5#F0'RV\@AL#Y0
M,C_@6:T;;5-0NM?BL(-5:6T+D+<+'&3( FXC.,=<B@#L<TN:X,^(-8-S<+YJ
MQ.IE#1L4(B50<':!N'..22*K)XHU=I!&)_E'W)2\6)FR,KG;AL9_AP>: /1"
M0!DG%&X8SGC&:X*35M7FM\RW3 3RRP-$(UPF IR#C.1DU/HVM77]J65H+W[1
M:M'&BQKLR/W8Y(QNZ]^E ';YI,UR27NJW>IM"FI/#&U_+; +"AVJJLP(R.OR
MXYJH/$.I/"LC7(CG$<1AM]B_Z42Y5NV> !TQB@#N<T9KSK4=7O9K9Y#J4JW/
MD7!DM8R%\@K(@7[N#T]<]3BEU2[U/3-5DNX;ZZF+WTD1C9@$BCV Y Q@;1W-
M 'HF:3-<')KNI26DBW.H?9;?R)FBNE\MC,X. F0,=/[N#6M>75Q%IV@2)-('
M>?YSD_/^XE.#ZC(!Y]!0!TQ8 9)P/>C->>W>IZE/91)=7SLDT*W#'RT780Y&
M.!TZ=:=)XEU@6]]+',"T<-PVPM&=FS.QMH&[G@\\'M0!Z!N (&>O2C<,D9Z5
MQQN;M?$<%M=:B[1VMVJ"1D1=V^%C@X&.3Q^/K3M3O9[#7[W9>F%91 &)53Y4
M?S9<9'8X'/'S?2@#KR0.2<#UHR,9KEVNKF_\)7[R3LVQF6.X50#(@(PW QZ]
M/2J$6KZI_8U]>07;3K!(D,8"(%5-JDOG'49/7B@#N,T@8$D @D=:\]O?$^J0
MZ9*PN]C*LKPS#RF\S:#@$XVDY'0#)HL=1U*";4[W^T6E=/LTGD&-,2AS@CID
M 9[4 >AT5Q%G ;W1=%N9KB]\VXNRDI6ZD7*YDX.&]A^53:G8+:WE_P"3<WJ^
M38+-'F[D(5][C."W/0<&@#L,TN:Y75-8F2\TY'U'^S(;BW:5R45B&QG'S UG
MP>(-6=4>6;9=EU46.Q1O0@YDZ9Z<]<<4 =UFC-< GB'4C8PSPZJMPQ1I+D>6
MG[@"15'0<9!/7TI3X@NI=8O+B.[:2W@6?R?+&5*A5(X'WN2>: .]W#CD<]/>
MC->?RZG<WD*RRZ@^VWN@J2YC/WH\@$J .IQQ4]KK-_'96JF]9)%M[=H(64,;
MLL?GY(SQ[&@#NLT5R&AZOJ<]YIYNKAI$NQ,&B,:J(RA7&"!GN1S77T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img45497886_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45497886_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )J!9H# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH S;G_CX>HJEN?^/AZBJ1A1110 4444 %%%% !1110
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M\=:OINL_"9KS2U\NR\U4C4KMVX(XQ3 V?#WC/6]<U*.230/LFBO&T@O)"P.
M.OICK6>?B+K>K7=U_P (SX<%]9VQ*O/,S#<1_=QP?7UYKKM,M_M/@JWM8L+Y
MMEL7TR5->;>#O%MIX#TV]T/7[:>WNHIF=,)Q+D #!_#Z4 ==:?$BPN/"%WKC
MVTL<MFXBFMC]X2'@#Z&J=CXV\52"RO;KPJLFEW9&V6QD,LBJ>Y49P/K7.>';
M"1/#/B37-1T6YN;34)24M ,.REL[A]/Z5S;'3K-K*Y\&:SJ+:M(X!T[RV)C]
MBW0CM0!Z-XLN[2/XA^&XYM-2:63)2=I71H_^ @X/XUJV7B^Z;Q]=>&=0M88=
MJ[[::,MF4?CQ^5<UXM:3_A8WA#[1A9RGSC_:QS5CXIVTVEW6F>*[)?WUE)Y<
MG;(.<9/YT ;MCXNN=2\>7NA6UK ;&SCW37)9MV<= .G7BLZ7QWK6JZA=0^$]
M!CU&WM&V2SS2%%9O]GUI?A?I<J>&KG5;HYNM5D>5F[X/3\^OXUYOIVE>']'O
M=0LO&7]H6=S'(3"T+,J2#T&.OUZ4: >Q^$?%D/BBSF)@-K?6S>7<V[=4/MZC
M@US'QGQ_PC-EGI]J&?RJS\+].L(K*\U&RTV\LUG<(#<RE_,4=QFJOQH8+X9L
MMQP/M0Z_2DMP,:RO_A3]CMDN(F-SY:B3]Q)]_ SV]:[3Q5XM'A9=.TW3K%;F
M\NP%MXY'V(%S@9/UKD['QW\/X;"VBGTU6E2)5<^0#E@!DY^M:'Q O-#U+3]'
MN-2TZ[:RN%#QZA#Q]G4_WL?GBF!T&@>(O$-UK+:;KWAU[)BNY+FWW20?0OTS
M65J'Q!U&YURXTKPOHHU-[8XGED8JF?0$=/\ ZQKE_!#26WCJ"T\-:O=ZGHC(
M3=221E408/&#W!Q^=3^']9B^'7B;6[77X)88KN3S8;A4RK#).,_C1H!V'AWQ
MU_;5KJ,-S8FSU:P0M-;/G:<>G?%8&F_$KQ)K>F/<Z5X8BN'ASYY\QM@'4!>Y
M.*I>&HY]=\2>(_%,=M-;Z?+;,D)D&#(=N/\ Z]5/A[X[TSPQX6EM]3BGC(D9
MX76,E9N^T'IGZT =:/%<'BSX=:O=)$8+B*%DGA)SM;'\JY3PKXMU_1O 4$FG
M>'A<V-H#Y]Q,Y //\ '6I?"MA=Q^!?%6K7$;P17ZEHD<8R!GG]:T?#Y'_"BI
MB#Q]G?G_ ($* .AE\<^9X,MM=L-+N;N:YRJ6T:D[6!P2Q'0<5EP^/]<T_6K"
MP\2:!%9)?,%B>"0O@DXYS_*N0CUC5=*^%&B-IT\MO;R3RK<W,*Y*+N/?MWK/
MUN307UW0[G1[^^OD-P@N+RZ+;"VX< L!SWH ]0\7>.)=#U2UT?2K :AJEP P
MC8D* >F<<],_E61'\1M;A\2:?H>I:!%9W,[XF+2,1M/0IZ]#5/Q7*_AGXG:?
MXENX';2WA6-IE7<$.TC^M9VN>)+/Q)\1_#LVGI*UK%)M6=T*K*3_ '<]A0!T
MM[=6J_&*U@_LV-[K[*2MT9G! ]-N=OXURMKJ?B=_BU/*--@EU%4V&U>?Y(XR
MO4'/ISBM^_8?\+XLAD9^RFLR]U2V\-?&FZO=3+QP30!48*3N)3 QZ\T ;VG7
M-J_QBO;<:;&EU]FRUUYSDM[;2=M,_P"%@:[JVH7\7AK08+V"Q.)6GF*.>O(4
M'GH:JZ6X;XYZB5.<V@(Y^E<OK<7A.XUG4GNY;_PW?QN2B%&99VYY4#IS^'-
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M76-#NXY'OYY6*6^SEP Q(]L^_K0(V;;X@^)-6@N-1T;PS#=Z9!(48B4F<_1
M<D_A7?Z=>'4-.@NVMIK9I%R89E*NA[@@UX'?)X8,5W=6EYJ.B:NDA\O32C,7
M;_9/;_ZU>S>"9M5N/"-C+K0?[:5.XR##%<_*6'KC%(9T%%%%( HHHH ****
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MO_/-ORH CI1U'UI_D2_\\V_*@02Y'[MNOI18#3HHHJA!2/\ <;Z4M(_W&^E
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M3+?E(4P6Q]]N[?C6KY$O_/-J/(E_YYM0!$RJZE74,IX(89!J#^S['_GQM?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !110>E !16?J^HR:=8O+#:R7,V#Y<:CC(!
M.6/8<=:I2:Q<_P!CV$J1Q"^O76.-6SL5B"3GN0 IH W:*YR77+O2&NHM6\B5
MX[?[1%);HR!QD@K@D\C@]>]/&HZMIUU:C53:20W)V#[/&RF)\9 .6.[)X[4
M=!17.:?KEXS6L]^;9;2\B:6/RE(:( ;L,23NX!Y %;&G3W%S:B:XC6,N240=
M0O;/O0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)F@
MP,TN*0&C- "XHQ29I1TH ,"C%%% "8%+BBB@!,"C%+10 F!2XHHH ,48HHH
M3 I<444 &*,444 )@4N*** #%&*** $Q2XHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *1_N-]*6D?[C?2@".V_P"/6+_<'\JEJ*V_X]8O]P?RJ6@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I-RCN/SI:\P\0D_P!OWO)^
M^/Y"N''8SZK!3M<Z<+AOK$^6]CT[<O\ >'YT;U_O#\Z\>R?4_G1D^I_.O*_U
M@_Z=_B>A_9#_ )_P/8=Z_P!X?G1O7^\/SKQ[)]31D^IH_P!8/^G?XC_LA_S_
M ('L.]?[P_.C>O\ >'YUX]D^IHR?4T?ZP?\ 3O\ $/[(?\_X'L.]?[P_.C>O
M]X?G7CV3ZFC)]31_K!_T[_$/[(?\_P"![#O7^\/SHWK_ 'A^=>/9/J:,GU-'
M^L'_ $[_ !#^R'_/^![#O7^\/SH!!Z$&O'LGU-=CX$Z7W_ /ZUTX3-_K%94N
M2U_,PQ.7.C3=3FO;R.QHHHKVCS HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *1_N-]*6D?[C?2@".V_X]8O]
MP?RJ6HK;_CUB_P!P?RJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ***2@!:*2B@!:#THHH Y/XAP6<WA*8WVGW5[%'(KG
M[*0)82/^6BGVK@/"4%M?>.X-8LK[5;_2]/LF\[4-0)SOZA!GC '85[51@#H/
MTH \'NO'NB>*O$@NO$-W=6^CV<H-II\4#OYY'\<A'\J]$\7Z5X>^R?\ "07.
MG?:;[$:6Z!V43.2!&K*#AOFQU!KL]J_W1^5+^% 'B?B"*\\.W M+W4KZSWV+
M74<MJS)]IO6894D=<#  Z5ZYH,EU-H-A)? BZ:W0R[A@[L<YK0(!ZC-+0 44
M4E "T4E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!'.TB0R&(*9 I*!VPI..,G' KE-9BDO]6B\G3=%O)X(D=VN
M;UXV0DG  $9!7(/^%=5/O\B3RT61]IPC-M#''3/;ZUQ.I:-;6&I>9;Z'8RO/
M$N_S]7:$AAG@#:<]>OZ4 ;6AS7!U:]2]M=,M[MXTE;['=/,S D@%MR+@<<8]
MZZ 5S/AETBEG1M.TZR+8 ,&H?:6D/H<J",?UKIN] "T45F:QJ$]G';Q6J(US
M=3"&,R?=0X)R?7@'B@#3HKG)M=NM':X@U0P3R);_ &B.2!#&'&2"NTEB"..<
M]Z>+_5M.NK0:HUK-#='9BWB9#$^,C)+'<,\=!ZT =!17-Z?KEX3:W%^UM]DO
M(6EC$2$-" -WS$D[A@'D <UL:=/<W%H)KF-8V=BR(.JKVS[T 7**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ [5YAXA_Y#][_OC^0KT_M7F'
MB'_D/WO^^/Y"O#SW^#'U/3RK^,_0S****^4/H0HHHH **** "BBB@ HHHH *
M[#P)TOO^ ?UKCZ[#P)TOO^ ?UKTLH_WN/S_(X<R_W:7R_,[*BBBOM3YD****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "D?[C?2EI'^XWTH CMO^/6+_<'\JEJ*V_X]8O\ <'\JEH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7C*C&/F]J[U<\9/-<IX6FMY-6N_L>K7&HV[V\4F9+LS"%B3E.IP>_KS76 4
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MD"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*PKY]2N];-E9W<-DL,*REY+?S3+N)! R1C&!GKU%;$T:SQ20R#*.I5ADC(/'
M45P][X1TJ75S8Z;I<8EBB$DMS<7<[",,3M 4."<[3W'04 =7IEC>V;2&ZO()
MU;&!%:B'![DX)S6E7+>&+"+2=3O+%K)(+D1))YL=Q)(DJ$D X<G:<AN.?K74
M4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]:@":BH=]Q_SQ3_OY_\ 6HWW'_/%/^_G_P!:@":BH=]Q_P \4_[^?_6I#).
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M/>@_]?L?\ZP:WO __(]Z#_U^Q_SJ*GP,NG\:/JT=**!THKQ#W@HHHH ****
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M];KR3X\?\@?1O^OE_P#T"ON\/_%1\CB/X4CP^BBBO8/%"BBB@ HHHH ****
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M9:;!!=RYW2J#GGD_3\* ->BBB@ HHI* %HI*6@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH]$HHQ17TQX8M%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_D:[&OMLJ_W6)\KCO]XD%%%%>B<@5'/!'<V\D$R[HI%*LN>H/6I** /&-5\
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MIT %-D_U;?[IIU-D_P!6W^Z: &V__'O%_N#^525';_\ 'O%_N#^524 %%%%
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M;Q:/=R".(VJ,TH!'RL<< #VS[UN>*/&/BEO!'AG5=.$EM#>KOU&ZM+<320#
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MD_\ 017B5>V_'C_D&:)_U\2?^@BO$J^FPG\(^=Q?\4****Z3E"BBB@ HHHH
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M"MO_ -<?_9C7>5P?C;_D*V__ %Q_]F->5G'^ZL[LM_WA',T445\:?3!1110
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M*#[TW_70_P A4U "8I<444 )@4M%% '/7/BC9-<FUTJ\O;6T8I/<PE J,/O
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MGB7_ )%;5_\ KRF_] -?>QW/DI;'R.GW%^E+2)]Q?I2U[J/!84444""BBB@
MHHHH **** "FO]QOI3J:_P!QOI2>PUN?8MA_R#[;_KDG\A5BJ]A_R#[;_KDG
M\A5BO"9[ZV"BBB@84444 %%%% !VKS#Q#_R'[W_?'\A7I_:O,/$/_(?O?]\?
MR%>'GO\ !CZGIY5_&?H9E%%%?*'T(4444 %%%% !1110 4444 %=AX$Z7W_
M/ZUQ]=AX$Z7W_ /ZUZ64?[W'Y_D<.9?[M+Y?F=E7DGQX_P"0/HW_ %\O_P"@
M5ZW7DGQX_P"0/HW_ %\O_P"@5]WA_P"*CY+$?PI'A]%%%>P>*%%%% !1110
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M )%ZR_ZY_P!:]W(?XTO3]3RLW_AQ]34HHHKZH\ **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ H-%!H 2O);[_D(77_79_\ T(UZU7DM]_R$+K_K
ML_\ Z$:^?S_X(>K/7RCXY>A!1117S![H4444 %%%% !1110 4444#1V/@7I?
M?[R?R-=AVKC_  +TOO\ >3^1KL.U?;95_NL3Y7'?[Q(\B^/'_(,T3_KXD_\
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M - -?>QW/DI;'R.GW%^E+2)]Q?I2U[J/!84444""BBB@ HHHH **** "FO\
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M110!#!]Z;_KH?Y"IJ@\F57<I*%#-G!3/]:-D_P#SW7_OW_\ 7H GHJ'9<?\
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M\Q_^ABJM6M-_Y"UC_P!?,?\ Z&*4MF5'XD?8-%%%>$>^%%%% !1110 4444
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MQ*O;?CQ_R#-$_P"OB3_T$5XE7TV$_A'SN+_BA11172<H4444 %%%% !1110
M5:TW_D+6/_7S'_Z&*JU:TW_D+6/_ %\Q_P#H8I2V94?B1]@T445X1[X4444
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MUY_N?U%:U9/B7_D7KS_<_J*PQ/\ !EZ&E'^)'U/,Z***_/S[ **** "BBB@
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M_(PQ_P#7-ZZ\!_O,/4Y\9_ GZ'HE9GB7_D5M7_Z\IO\ T UIUF>)?^16U?\
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MMC6Z&7<,'=@=?>@#5HHHH **** "BBB@ HHHH *#10: $KR6^_Y"%U_UV?\
M]"->M5Y+??\ (0NO^NS_ /H1KY_/_@AZL]?*/CEZ$%%%%?,'NA1110 4444
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M\T-M,E\(RE\9(V42RGA1DC#'=@Y&>,UT&A7M@5:S@N7EN>99"R,N\YY*DC#
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M^HK6K)\2_P#(O7G^Y_45AB?X,O0TH_Q(^IYG1117Y^?8!1110 4444 %%%%
M!1110 5Z=X<_Y%ZR_P"N?]:\QKT[PY_R+UE_US_K7NY#_&EZ?J>5F_\ #CZF
MI117B_CWXE>(_#WC.^TRPEM5M81&4#P;CRBL><^I-?6TZ;J.T3YRI5C35Y'M
M%)7SI_PN3Q?_ ,]K+_P&_P#KTG_"Y/%__/:Q_P# ;_Z];_4ZAA]<I'T92U\Y
M?\+D\7_\]K'_ ,!O_KT?\+D\7_\ /:Q_\!O_ *]'U.J'URD?1M)7SG_PN3Q?
M_P ]K'_P&_\ KT?\+D\7_P#/:Q_\!O\ Z]'U.J'URD?1E%?.?_"Y/%__ #VL
M?_ ;_P"O1_PN3Q?_ ,]K'_P&_P#KT?4ZH?7*1]&T5\Y?\+D\7_\ /:Q_\!O_
M *]'_"Y/%_\ SVLO_ ;_ .O1]3J!]<I'T917D7PV^(7B#Q/XI;3]3DMFMQ;/
M+B.':=P*@<Y]S7KM<\X.#LSHIU(U%="T445)84444 %!HH- "5Y+??\ (0NO
M^NS_ /H1KUJO);[_ )"%U_UV?_T(U\_G_P $/5GKY1\<O0@HHHKY@]T****
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M1$H.27(P6/I@$@?6LS3-'OHKRS^U+ D-A'(D3Q2%C+N(.2,#;C'3)KHL48H
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M'O0?^OV/^=8-;W@?_D>]!_Z_8_YU%3X&73^-'U:.E% Z45XA[P4444 %%%%
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MAXA_Y#][_OC^0KP\]_@Q]3T\J_C/T,RBBBOE#Z$**** "BBB@ HHHH ****
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M[;_CUB_W!_*I:BMO^/6+_<'\JEH **** "BBB@ HHHH **** "BBB@ HHHH
M*R?$O_(O7G^Y_45K5D^)?^1>O/\ <_J*PQ/\&7H:4?XD?4\SHHHK\_/L HHH
MH **** "BBB@ HHHH *].\.?\B]9?]<Q_.O,:].\.?\ (O67_7,?SKW<A_C2
M]/U/*S?^''U-2OFCXL_\E*U3_=A_]%+7TO7S1\6?^2E:I_NP_P#HI:^UP?\
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M'_XNC_A0US_T,,7_ ("'_P"+H^M4NX?5:O8\@HKU_P#X4-<_]##%_P" A_\
MBZ/^%#7/_0PQ?^ A_P#BZ/K5+N'U6KV/(**]?_X4-<_]##%_X"'_ .+H_P"%
M#7/_ $,,7_@(?_BZ/K5+N'U6KV/(**]?_P"%#7/_ $,,7_@(?_BZ/^%#7/\
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M'_XNC_A0US_T,,7_ ("'_P"+H^M4NX?5:O8\@HKU_P#X4-<_]##%_P" A_\
MBZ/^%#7/_0PQ?^ A_P#BZ/K5+N'U6KV/(**]?_X4-<_]##%_X"'_ .+H_P"%
M#7/_ $,,7_@(?_BZ/K5+N'U6KV/(**]?_P"%#7/_ $,,7_@(?_BZ/^%#7/\
MT,,7_@(?_BZ/K5+N'U6KV/(*WO!'_(]Z#_U^Q_SKT'_A0US_ -##%_X"'_XN
MM#0?@S<:-X@T_4VUR.46DZRF,6Q7=@],[N*F>)IN+294,-44DVCUOM2T@I:\
ML]8**** "BBB@ HHHH **** "BBB@ HHHH *1_N-]*6D?[C?2@".V_X]8O\
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MHJ;[+<_\^T__ '[;_"D^RW/_ #[3_P#?MO\ "O3NCRN5]B*BI?LMS_S[3_\
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M?WA^5%P-"BL_[7-_>'Y4?:YO[P_*BX&A16?]KF_O#\J/M<W]X?E1<#0HK/\
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M^\/RHN!H45G_ &N;^\/RH^US?WA^5%P-"BL_[7-_>'Y5?'2F M%%% !1110
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M&_S]:*Y=?%EWJ%Y?1Z%HK:A;V;%))VN!$K,.JI\IR1^%+;>.M+F\,W&M3++
MMM(89H&'SK*/X/<T#.GJ-9X7F:%9HVE3EHU<%E^HZBN4NO&=_I5I:W^L^'I+
M+3YV"F=;@2-%GIO7:,?G6):ZQ8:-\0_$^HWDH2$6L9&/O.<C  [DT >E?YXJ
M"XOK.S91=7EO 6Z"654)^F3530]1NM5TU+R[TYK$R'<D+R;FV]B>!@^U9EKX
M2M8]7U/5M8D@U![DY3SHOD@C Q@ DCZGBA ='')'+&LD;HZ,,JR,"#]"*=7"
M?#D_Z1KRV3NVC+>$6>3E1Z[?]GTKNZ0!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %,ED2&%Y9#A$4LQQG %/I& 92I&01@
MBF!3L=7T_4M-_M&SN4EL\,?- ( V]>" >*9I.N:;KMN\^F7:7,2,49E!&&';
MD5YA::B_A[PAXNT;GS+2Y,4(]1(<<?G4GA<GP-/K^F7$Q93IZ7L1;@YP01]<
ML*+ >FZ;K&GZNLYL+I9Q;RF&4J"-KCJ.15ZO,="U:;PIX(TB**"*36-9G:2-
M96VH&8\LQ],8K8G\4ZKHFM:9:ZM+IEY:7\@A66R!1HI#Z@LV1[T6 [:JFI:I
M9:/9M>:A<+!;J0"[ D GIT&:YK_A)]0U;Q!?Z?H\VFVMM8'RYKB]!??)Z*H9
M>/?-<MXD\3SZUX.UNPOXH8[_ $ZYB29H&W1N">&7\J /5XW62-)$.4<!E([@
MC(-1W=W;V%K)<W<R0PQC+NYP!_GTKD]!\2WFOWMM;Z(EN=)M(D2ZO)5)WOM&
M4C (_,TGQ/MTG\(LSSQQ^5.D@CD.!*0?N>Y/:@#:L/%>B:E=I:VM\&G==R(\
M;Q[Q_LE@,_A6S7E^OZH=<UKPM:RZ?-HRI.DXN+M=F<=(TQUS^'TKU"@ HHHI
M %%%% !1110 4444 %%%% !1110 4444 %:P[5DUK"J0A:***8!1110 4C_<
M;Z4M(_W&^E $=M_QZQ?[@_E4M16W_'K%_N#^52T %%%% !67-_KW_P!ZM2LN
M;_7R?[U)@,HHHJ1A1110 4444 %%%% !1110 4=J** (Y+B"%T26:*-G.$5W
M +'T /7\*2:YM[8*;BXAA#'"F20+D^@S7&?$^WV:%9ZN@_>:9=QS[N^W.#_.
MN;^)!N/$VHV-GI[!FM+$ZBPZ@\KC^M,1ZQ-/#;Q^9/-'$G WR.%7/;DU("",
MCGO7EWB"^'B?2?!NF)\XU"1))L<\( "3^(-=8WBBXNM8NM-T+2#J!LOEN)6G
M\J-&_N [3EJ+#.EHKF=/\;:?=:-J%_=QR63Z<Q2[@DY:-O0>N:J3^--0LM*B
MUB^\-S0:4Y&9A<!I$0]&9-O _&D!UHGA,Y@$T?G ;C'O&X#UQUQ4E>;G5]/M
M/BA=:K/.B6ATD2"0]P>1^-=EX?U>YURP-[+ISV4+MF 2/EI$[,5P-N?3FF!H
M7%Y:V8!NKJ"W!Z>=(J9^F33XIHIXQ)#+'+&>CQL&!_$<5SZ>$X9O$UYK6IRQ
M7RR*$MX)8_D@4>Q)!/O@5B>!O+7Q7XBCTIF.B)(HC4']V).<A/:@#OJ***0!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !(
M ))P!WJ.*X@N$WP31RIG!:-PP'KR*D(# AAD'@CVKS+P]J"^&+?QEITAVBQD
M:YC&<<2#@"F!Z1#=6]SN\B>*4*<-Y;AL'T.*6.>&5W2.:*1XSAU1P2I]"!TK
MR7X:>?X=U:YMK]QLO[%;]#C';)S^%:'A#5H-#\+:AXDO8I'N-5OF,42#YYFS
MA5'US18#TZBN4G\87FE7-BNNZ&]A;7K"..=+@2A7/16&T8)JU>^)I1K[:)I.
MFG4;R) ]P3-Y4<(/3+8/)],4 ;TLL<,9DED2.->K.P4#\:<K*ZAT8,K#(8'(
M(]J\[\2>)DUKPAXBTVYLWLM2LXOW]O(VX 'H0V!D'Z5I:-XH58-%T33;,W]U
M]EC:X99-J6R8ZLV#S[4 =F> 2>G7FJT.HV%S*8H+ZUEE_N1S*S?D#FL+Q_#>
MS^"[];&1DE"@ML;:64$$@'Z5PVJ7FAW]CX=M/#$"0ZQYL9$J)Y9C ^_O;OD_
M6@#U^BCG')R>YHI %%%% !1110 4444 %%%% !1110 4444 %!Z44=J -6/_
M %:_04ZFQ_ZM?]T4ZK$%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% &2_WV^II*5_]8WU-)4 %%%% PHHHH **** "BBB@ HHHH *P
M?&>G?VKX0U&V49D\HO'W^8=*WJ*8'F7PUL9=:\/:Q?Z@"9-1_P!'R1U0+M[^
MXJA\)["[GUK4KB]9C]AA%C%D<*,]!^ KUSZ<447 \C\/6^D>'Y-4TWQ-<7ME
M=)</-$RWDT*3(W3:%8 G]:DU+0X]7^'MU/H>B7MENO!<^5/,TDEPH_C&3D9]
M*]8X]/THH \MNKSPAJ&FVD$%OJFLW-TRJ=.749RRGOO#,0,>]4+[PHNO^.]=
MCMV>"\LK:.6S.<A9 00#GKZ5[#^%'2BXCG_"'B(>(M&$DJ^5?6[>3=1'C8XX
MS]#ZUR&I^)[+Q)KUWIM_J\6F:%:/Y<J;]DEXPZC/9?IUKT^CC_(H R=!O]#N
M;,6NA3VSV]L NR C"5K4?@!10,****0!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 >6^*/"FI7GQ*LYK:VG;3;IHY+ET3]V
MI0Y^;TSBI?BCX8U#5]2TFXTRVGE#?Z/<>2"=J97&[VZUZ;13N!POC/PO<3VV
MAW=C8I??V2PWV;*")DP 0 >#TZ46Z)=ZU8QZ5X(M;2W!#W-U?6 B,8]$X&6]
M^E=U_D&B@#S:'04T#Q5JTFH^'&U?3[^0SP3QV@N&B/\ =(P2*@UC2]3U/P7J
M?E>%K;3S--&+>WM+?;.\8/)<"O4/Y44 >?V6D7O@_P 0V-QI=A<3:5J$*1WM
MO"A8V\H4?/CL.>:TO'FBWVI0Z9>6,)N9-.NA.UMD#S5XR!ZGVKKJ*+@>?^)_
MMWC*/3M-LM'U"VVSI/+<WD!B6$#K@GJ?I7?HNQ%4G.U0,^M+10 4444@"BBB
M@ HHHH **** "BBB@ HHHH **** "M85DUKCH*I""BBBF 4444 %(_W&^E+2
M,,J1ZB@".W_X]HO]P?RJ6F1)Y<*(>JJ!3Z "BBB@ K+F_P!?)_O5J5ES?ZY_
M]ZDP&4445(PHHHH **** "BBB@ HHHH **** ,SQ%IXU3P[J%D5W>; P ]\9
M'ZXKS_X56MSJBZK?W^7?RUL$)!^Z-V1^HKU.BF!X]\.=+N?^$ZO8K@DP:0DD
M, (P%#.Q&,?G^-6=-M-+T'Q)KEIXEGO++[1<-<VLZ7<L$<B'ME& )_6O6**+
MB/++C1K;7O!.O2:#H]]:O<.K)+<SO(UYM.=P#$GM^.:8U]X2G\.01/#JNH7T
MH6%]*&H3ARXZ@J6P!QZ8KU8<=*._09%%P/(-3\)6VO\ CQM,*26GDZ4CP*6W
M>4X^Z"3UQTKN/!7B"75].DL[]?+U;3V\FZ0]R.-X]0:Z?_.<4?E[T >;:_XI
MAUCQ'<:#+JT>E:3;?+=3%MLER>Z*>P]376^'+WPZUJ-/T"XM7B@&?+@;./<^
MOUK<_ ?E1CZ#Z4 %%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7C_Q'L;N/QE;168/EZS&D,H /S%6/],5[!1]:8'E
M7Q9L)M/M=*OM.)1D1K$E1D^61C'ZU:\6>')[;P5X>6"&:6/2I(Y+B.'(<H!\
MQ&.<^]>E_6B@#S.XF\(ZE<:;;6%MJ6MS32J_E+J,S"WQ_&^YB!CTJ&:QL=%^
M(6J/KTMW;6.H!&M;J.YEA3*C!5F1A^M>I?AS[4=J!'DNI+H]WX<\37VDZ7?(
M@A\K^T;BY>07..RAB3@>M2:#!_PK^?2KQ6=M&UB&-+DL.89R.&^A_(9KU;\*
M/PH X[XDV=Y?>&(_L:23PQW$<MS%$"QDB'7@=1T-8?C'5=&\0^&['3-#*W>H
M>9&UM% F6@V]<X^[]*]--&!G@#/TH&0VB2QV<"3MNF6-1(WJV.?UJ:BB@ HH
MHI %%%% !1110 4444 %%%% !1110 4=J*#TI@:L?^K7_=%.IL?^K7Z"G50@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH C\B(G)0
M'-)]GB_YYK^52T4 1?9XO^>:_E1]GB_YYK^52T4 1?9XO^>:_E1]GB_YYK^5
M4-;U?^QK6*86TES)-,L$<49P69LX_E5>UUJ]-Y=6M]I9AFA@%PBV\WG&122,
M<A<-D'C]: -?[/%_SS7\J/L\7_/-?RK.MM:>YN$B.D:G"&./,EB4*OU(8URX
MGTZ^N+C4-7T_4?*FGV)<Y=(DCSM7.'&.3UQWH [G[/%_SS7\J/L\7_/-?RKG
MO%$5\FC"'3KP6T1V1IM!,CDL. Q/ P#V)K2OKQ[<I8V0WW;)\I8$K&O3<W^'
M>@"_]GB_YYK^5'V>+_GFOY5C>$DE&A+/-<2SM<2O,))?O%68E?IP16]0!%]G
MB_YYK^5'V>+_ )YK^52T4 1?9XO^>:_E1]GB_P">:_E4M% $7V>+_GFOY4?9
MXO\ GFOY5+10!%]GB_YYK^5'V>+_ )YK^52TAH C^SQ?\\U_*C[/%_SS7\JY
ME/%MY-8_VE%HQ.G+*(VE>XVN1NV[E3;R,X[CO6M=ZR]K<O"-)U.<*1^\AB4H
M>.Q+"@#0^SQ?\\U_*C[/%_SS7\JYC7KW[=/I]G)IVH20.#//!$NV3 X4$AAC
MYNO-7-%CLFT^XDT6-K><N8Y$N2[F-QP0RECT]C0!M_9XO^>:_E1]GB_YYK^5
M<A;7>H66AZG=-=O<W-S?>5!(>@4E0-H[ ?,:N3Z?!H-WILUJ\WG7%RL$S/(S
M>:&!R2"< Y';'6@#H_L\7_/-?RH^SQ?\\U_*I110!%]GB_YYK^5'V>+_ )YK
M^52T4 1?9XO^>:_E1]GB_P">:_E4M% $7V>+_GFOY4?9XO\ GFOY5+10!%]G
MB_YYK^5'V>+_ )YK^52T4 1?9XO^>:_E1]GB_P">:_E4M% $7V>+_GFOY4?9
MXO\ GFOY5+2&@"/[/%_SS7\J/L\7_/-?RK'NM=O/[8GTS3M,^U3P1K)(\DWE
M1KNS@9VGGCTIT'B!IM+M;Q=+O93.&W1VZJ_EE3@@DD=QQ0!K?9XO^>:_E1]G
MB_YYK^58.J:Y.="N98K"^MYV80Q)-& S,WI@FJ^A6VC1Z@D$5A?VE]%'O1;N
M1\NO0L!O(- '3?9XO^>:_E1]GB_YYK^5<_ FH2>,@US>AX(;1F\B,;41BR[<
M^IQGG]*K>(KVZU2VCM[&:2WMI+E(1,@^:9\Y(4]EPIR>_P#, ZG[/%_SS7\J
M/L\7_/-?RJ08 P.U+0!%]GB_YYK^5'V>+_GFOY5+10!%]GB_YYK^5'V>+_GF
MOY5+10!%]GB_YYK^5'V>+_GFOY5+10!%]GB_YYK^5'V>+_GFOY5+7+2>*KPV
MU[>6NC^;8V4CI+-)<;"VPD,47:=W0]QS0!TGV>+_ )YK^5'V>+_GFOY5GW6L
MM;3>6NE:C<#:&$D$2LIS]6%96O7YO;>PM&T_4#'<N7F@1=LOEKVX;CYBO?IF
M@#I?L\7_ #S7\J/L\7_/-?RK#T./3S#=OI-O-;7:'RY8KIW)1L9&06/8YX-9
MT%Y?Z=9>(-0GNC=S"41V^!A00BC"CL-V?6@#K?L\7_/-?RH^SQ?\\U_*N:O-
M-BT*.SOHIIWO6N88I97D8^;O<*V5S@=2> *ZF@"/[/%_SS7\J/L\7_/-?RJ6
MB@"+[/%_SS7\J/L\7_/-?RJ6B@"+[/%_SS7\J/L\7_/-?RJ6B@"+[/%_SS7\
MJ/L\7_/-?RJ6B@"+[/%_SS7\J/L\7_/-?RJ6B@"+R(A_RS7\JE%%% !1110
M4444 %%%% !1110 4444 %1F&)B247-244 1?9XO^>:_E1]GB_YYK^52T4 1
M?9XO^>:_E1]GB_YYK^52T4 1?9XO^>:_E1]GB_YYK^52T4 1?9XO^>:_E1]G
MB_YYK^52T4 1?9XO^>:_E1]GB_YYK^52T4 1?9XO^>:_E1]GB_YYK^52TAH
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M7/\ AO1(()FU812P-.FV*!IG8)'V)#$_,>I],X[5TM $7V>+_GFOY4?9XO\
MGFOY5+10!%]GB_YYK^5'V>+_ )YK^52T4 1?9XO^>:_E1]GB_P">:_E4M% $
M7V>+_GFOY4?9XO\ GFOY5DZAK=Q!K":58Z>;NY:#SV9I?+1%R1R<''3TI+;Q
M!+)IHN9-*NFF69X)(;;$NQD)!.3MR,CK0!K_ &>+_GFOY4?9XO\ GFOY53LM
M2DO1*!I]Y:LH^7[4@4,?;!-9NCQW[^)=2DO+WSUCABC5$7:B-EBV!D]MO4T
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MU/4K:ZU"U2TAM=S) )!*7<XPV1TQV^IK<Q1B@ %+110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2T7 :>9PJ-&H.!M!()Q@>PH;4BEO%,R##Q;^O>G65ZUP[QEX'8 ,IB;(^AH
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MC&?0XS^M1K>W 1C*(5)C61,$X&>Q_P#K5$NIW#JRI$GG"81?.K*.0#G!Y[T
M7&T^-H1$6?:(C%^!&*C.EQ&57WG(QNRB'=CN<C^5.^V2!_)9%\_>%P,X(/)(
M_"HY;VY$\ZQQQ^7"5#%B<G/I0!(^G*[\3RK'O#^6,8S^6:F$,AA9'F<L22'4
M $<\?E58WL^&G$<?V8-CJ=Q'KZ4V"^G=HY)EB2&0L!@G(P<9/:@"0:: V]9Y
M!-NW&0!<GC'3&/TJ%-+DBN$\NXE2-8BN\$%B21UR*+W45C,<MN5F&&(*OP2
M?3BFW5Q>-!)$3$DF8\-&6'!8#KZT 3G28-ZLAVXQGY%;=^)!(_"I'L(FAFC+
M/ME;>V.H/'3\JJKJ>V8)OA*!MFW>3)]<5$NHW)ECDDC3#AA&JNW4''S#IVH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI5S%&* *=M;M'<SW$@3?(0!M.< ?UI180B7S,OC.[R]WRY]<5:Q2XH I?V=
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDHH 6BFTM*X"T444P
H"BBB@ HHI.] A:***!A1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img45497886_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45497886_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )3!6@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ JM>_ZD?[U6:K7O^I'^]28%'%%%%(84444 %%%% !1110 4
M444 %%%% !1110 4444 %%'09-4K+6-,U*:6&QU"UN98O]8D,H8IVY Z=#0!
M=HJM?:C9:9 )[^[@M8B<!YG"C/IDTRZU;3K(0&ZO[: 3D"'S) OF$] N>M"
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M8-,_\"5_QH VJ*HW>M:78013WFHVMO#-_JI)90JO]">M4QXO\-$@#Q!IA)X
M^TK_ (T ;5%(K!E#*05(R".XK/OM?T?3)Q!?ZK9VLI&X)-,$)'K@T :-%9]C
MKND:I(T>GZG:73J,E89@Q _"M"@ HHIOF(93$'7S -Q7/('K0 ZBJEIJFGW\
MLT5G>V]Q)"=LJ12!BA]#CI5N@ HHHH **:[I$C/(P1%&69C@ 4X$$ @Y![T
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MK%GE2>A<<_TQ^-=E=W"7'P5\U<!?[.4'V(6N)U.*:T^&GA?Q!9D+<V3[=_\
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M_P"'%="X=8V(0D@'&>YKSCX:Z3ITNF:I>6%KJ-JEV##YEU+NWC!&Y> >]6M
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MUOQK<V^N'0_#^E-JNI1KNF7?L2,>Y]:-#\:W.IS7VF7NEBPURVC,@M9'.R0
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MWY4ODR?\\V_*I&1T5)Y,G_/-ORH\F3_GFWY4 1T5)Y,G_/-ORH\F3_GFWY4
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MORH\F3_GFWY4 1T5)Y,G_/-ORH\F3_GFWY4 1T5)Y,G_ #S;\J/)D_YYM^5
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M,\OFS6-K)+_?>%6;\R,U=\F3_GFWY4GDR?\ /-ORI@,HI_DR?\\V_*CR9/\
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M\V_*D!5FL;.YD62XM+>:1>C21*Q'XD4Z>UM[I EQ;PSHO198PX'X&K'DR_\
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M+W<$]O'!##<3;Y$@\R0I$6P3(^0">N0..171:9J8U.V@F1=BNC%ESDJP(!%
M&E1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT_QINA)"5>+.PS67K'B'3="$1U&<Q>;]S",V?R!K-L-;O=1\8WME"8O[.LT
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MB-KL[V>[M[9HQ-*J-(VQ 3RQ]!4^:\Q\3RZM<^*=$F@>V7S</9AP<(2 3O\
M6O2+83BUB%R4,^P>84^Z6QSCVS4SI\D4^Y5.KSMHGHH'2BLC8**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &R
M.(XV<]%&:=4-W_QZ2_[IJ:@ HQ110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% !1110!#=_\>DO^Z:FJ&[_ ./27_=-34 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!FWNI7$4_V>RL)KJ88W'(1$![EFP#]!DU36Y\31-OFL
M+":,=4MYF#GZ;L"KUSJ#V5P?M%L_V4@8GC&[:>F& Y'/<9]\5S$!U.=(IHGU
M*2_:4$R),AM2N[DCG[N.W7- '765W]KAWF&:%E.UDE0@@_R/U'%6:3Z4M !1
M110 4444 %0-_P ?R?\ 7-OYBIZ@;_C^3_KFW\Q0!/1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 &**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 %%%% !1110 4444 %%%% $-W_QZ2_[IJ:H;O\ X])?]TU-0 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR3SE[G_7)8PJ!UVC?*./;@?D*+2VNTOY[G3X$N!:7LRK"TH0$2*"Q!QQAB:
M.H^W6OD0S^>OES%1&W9B>F*>W_'\G_7-OYBN2LI[FUEMXDM!=2QNZ01>8$0R
M8)D(.. O*BNBTZ_34UM[N-2H>)LJ>JG(R#0!I4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 0W?_'I+_NFIJAN_P#CTE_W34U !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** ,7Q#'%#ITETMI:R7+,D:R31!
M@FY@NX^H&<_A63=Z1+HT,6H)/;W3"6,20R6J;7W,!^[P,KUSWZ5N>(ELWT*X
MCOH&N()-L?DJY0R,Q 5<@Y&20*Y"7PO:6203:EH[BS#J#Y>JW#-;DG"GE\'D
M@<8ZT >A4M4=-TNTTFW-O9K*(V8N?-G>4Y^KDGMTJ]0 4444 %%%% !4#?\
M'\G_ %S;^8J>H&_X_D_ZYM_,4 3T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M0W?_ !Z2_P"Z:FJ&[_X])?\ =-34 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]I/S7_&CSI/^?>3\U_QH FHID4GFQA\$9SP:?0 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)'6&WB91F3!+8+$#"#*]>HXKH[&]BU'[/=PYV21,0#U'(R#0!HT444 %%%%
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M)M<\@..HS5%_BGXFG@UNYT_PM!<6VCW+QW$S76T%%]!U+=<\8Z4 >M9%&17
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/^_?_P!>C_A,-6_Z8?\ ?O\ ^O6!11_:&)_G8?4L/_*;_P#PF&K?],/^_?\
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M[^N['?WK7HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\<'&%Z]16K87Y_X2?6[>>YQ%%Y'E([X"Y3)P/K6.^NSS_#R*]-\%O7>++QN
MW,ZJ<8]N* .U[TM)@4M !1110 4444 %0-_Q_)_US;^8J>H&_P"/Y/\ KFW\
MQ0!/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M)0!YY
MXP_Y#S?]<5_K6#6]XP_Y#S?]<5_K6#7PF8?[S/U/JL%_ CZ!1117&=04444
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MI?+^SL^1&%;$C$CL,&NPS0 M%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!C>*;K[%X?N+@W'V>-&3S9 <$1[ANP?7;G
M&.:Y^UU#P.9(5@\0EI"R[%;5IF).> 07_2M36M8:SFN[1;G5(I7"-%);:2]P
ML7K@A"&S[]*Q+?5-0:ZB5M>UQ@9 "K>'&4'GH3Y? ]^U '?4ZD[TM !1110
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M_P!"-35#:_Z@?[S?^A&IJ "BBB@ HHHH **** "BBB@ HHHH X_QUTL?J_\
M2N-KLO'72Q^K_P!*XVOBLW_WN7R_(^FR[_=H_/\ ,****\T[@HHHH **** "
MBBB@ I&^Z?I2TC?=/TIK<#UVT_X\X/\ KFO\JFJ&T_X\X/\ KFO\JFK]$A\*
M/C);L:V:\X\8_$/4_#GB*33K6TM)8EB1]TN[=DCV->D&O"?BE_R/,_\ U[Q?
MR-<^+G*%.\6=&$IQG4M)&A_PN#6_^@?I_P"3_P#Q5'_"X-;_ .@?I_\ X_\
M_%5Y[17F?6:W\QZ?U6CV/0O^%P:W_P! _3__ !__ .*H_P"%P:W_ - _3_\
MQ_\ ^*KSVBCZS6_F#ZK1_E/0O^%P:W_T#]/_ /'_ /XJC_A<&M_] _3_ /Q_
M_P"*KSVBCZS6_F#ZK1_E/0O^%P:W_P! _3__ !__ .*H_P"%P:W_ - _3_\
MQ_\ ^*KSVBCZS6_F#ZK1_E/0O^%P:W_T#]/_ /'_ /XJC_A<&M_] _3_ /Q_
M_P"*KSVBCZS6_F#ZK1_E/4-%^*.KZGKMA8RV-DD=Q.D;,F_(!..,GK7K KYO
M\)_\CCHW_7Y'_.OI&O1P=24XMR9YV,IQIR2B@HHHKL.0**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH R_$%U-9Z/)+ _EMO1&DQGRU9@&;\ 2?PKC[DR6<\Z/XEOS/#<Q-% UR
M;B)B  .,GN<C/ Q79ZY=O9:6\D<:.[ND2B094%V"Y([@9SCO6 +FYAM9+V[C
ML+B2QOOL[,;;:60[0-AR=I!;/?I0!U^:6DI: $S11BN4\2:+ILCQ0QVSF^U"
M7R@XGD 08)9\!N, ''N10!U?-'-<RFDVUWJK:5<>:]E86D7E)YS LS%@68@Y
M)^4=_6LR25%\NSU261M,M+J6%W#/_=#1ABO/&<#Z<T =S4+?\?R?]<V_F*Y6
MVU2)+2T2_NFAM[4AG9LEF/6-6 YSC!/TKIHIX[BXAFA</&\+%6'0C(H MT44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+24 >>>,/^0\W
M_7%?ZU'X:FC@OIWD9 /)888X!]JD\8?\AYO^N*_UK!KXG$U72QLIKHSZ;#T_
M:811[HT;W5OM-G':P6J6T*MN(1LY-0_VG>&S-J9B\1 PK<[<>AJI17)+$5)-
MMR.E4*<5:QLR^(9)8'Q;1K<R1B-YP>67TQ4$.JBVOA/;VL<:>7Y;Q \..YK-
MHJI8NJVFWJB5AJ2T2T-C^WY$N;=X+>.*"%2H@!R"#UYH.OR)/;-;VZ0P09Q
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M&Q)]J:Y$HPOR[?KFL"N>I-6]U'13@[MR9V_PI_Y'4?\ 7K)_-:]RKPWX4_\
M(ZC_ *]9/YK7N5>G@OX1YV-_BA116/XIUS_A&O#5[J_V?[1]F56\K?MW98+U
MP<=?2NQ*[LCC;LKLV**\9_X7R/\ H7#_ .!G_P!A1_POD?\ 0N'_ ,#/_L*V
M^KU>QA]9I=SV:J=YI5AJ$]O/>6D4TMLV^%G7)C;U%>2_\+Y'_0N'_P #/_L*
M/^%\C_H7#_X&?_84?5ZO8/K-+N>K:MHFF:[;I;ZI90W<*-O5)5R ?6J6F^#?
M#>D7JWNG:-9VURH(66./# 'KS7FW_"^1_P!"X?\ P,_^PH_X7R/^A</_ (&?
M_84?5ZO8/K-+N>NBPM!J!OQ GVLQ^49L?-LSG&?3-5(/#NC6VJOJD.FVT=\^
M=TZIACGK7EO_  OD?]"X?_ S_P"PH_X7R/\ H7#_ .!G_P!A1]7J]@^LTNY[
M-17C/_"^1_T+A_\  S_["C_A?(_Z%QO_  ,_^PI?5ZG8/K-/N>S45XS_ ,+Y
M_P"I</\ X&?_ &%=MX"\=#QO!?2#3S9_971<&;S-VX$^@QTJ949Q5VBH5X3=
MDSL****S-@HHHH **** "BBB@"&WZS?]=#_(5+45OUF_ZZ'^0J:@#&\5QR2^
M$]6CB1G=K20*JC))VG@"OGS^Q]4_Z!E]_P" S_X5]-T 5S5\,JK3;.BAB723
M21\Q-H^J;&_XEE]T_P"?=_\ "OI#204TBR5@586\8(/!!VCBKU)10PZH[,*^
M(=:UT8'C3PXGBSPG?:.2@DG3]R[YPD@^ZW'H:P/"7P\?2? VI:+K-RMQ?:J9
M3>W,3%MQ;(!!(!R :[W('7\Z@M+VUOX#-:3QS1!F0NC9&0<'GV-=)SGD[?#;
MQK>:/:^%=0U[3#X8MW49BC;[3)&IR%;C'ZUU.C^"[S2_&^N:QYUN;*]M8K>W
M0,Q==BX^;C'Y&N@MO%&BW>I?V?;ZA&]SSA & ..N&Q@_@:UNE 'EUK\*[N7X
M=77AN_OH8KIKU[R"XM\LJ-NRN<@?C4MGX(\8:UXDTK4?&6KZ;+;:2XFMX-/1
MAYDG8L6 Q^%>FTE '@'@C2?&.K:+X@@\.ZMIL%C=7TT-Q'=QL63/!9" >2">
M#7;3?#.Z@L?!ECI]Y T6@SM+.\V5:3/]T 'G.>N*]%@MH+566""*)6.XB- N
M3ZG%38H X'XC^"=2\7/I4^G7-H6L9B[6E]N\B<'^]M!/;TK"T7X>>+M#O?$.
MH6=[HUO>:G9K% 8 Z);R<9 &WH.S=?:O6Z,4 >0>"O GQ!\)%;5+_P /?8YI
M_,NYE61KB0$\_,5&3Z9K*N_@SXCELM5T^*[T.2.ZF:9+Z=9#<L,@A&."%'7D
M9^E>Z8I,4 <$O@K5&\7^%]9>:S$.E:=]DG0.Q9GQC*_+R/KBKGACPG?:)XP\
M2:O<36[V^J3"2%8R2R@?WL@#\B:[+%&* "CO11WH AM?]0/]YO\ T(U-4-K_
M *@?[S?^A&IJ "BBB@ HHHH **** "BBB@ HHHH X_QUTL?J_P#2N-KLO'72
MQ^K_ -*XVOBLW_WN7R_(^FR[_=H_/\PHHHKS3N"BBB@ HHHH **** "D;[I^
ME+2-]T_2FMP/7;3_ (\X/^N:_P JFJ&T_P"/.#_KFO\ *IJ_1(?"CXR6["O"
M/BE_R/,__7O%_(U[O7A/Q2_Y'F?_ *]XOY&N7'?POF=>!_B_(XRBBBO&/8"B
MBB@ HHHH **** "BBB@#8\)_\CCHW_7Y'_.OI&OF[PG_ ,CCHW_7Y'_.OI&O
M6P'P,\G'_&O0****[SA"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** ,[6Y[>'29C<P^?&^V,1 X
M+LQ"J,]N2.>W6N7L="G@O(IW\.S<2^;LEU<R(C' +;3PQP.^:VM:T+4=6>18
MM>FM+9PO[E+:)]I!SN#,,YR,^U,BT378Y(R_BNXD12,J;*$;AZ9VYH Z'O2T
ME+0 5ERV$TGB:WOVV^1#:R1J,\[V93G'T4UJ4A'.: ,6\@O[/5WU"PM4N_/A
M6*6)I1&05)(()S_>/Y"I=.M+JQTZ>1T62^G=IF0-@;CT7/L,#/M6KBC'_P!:
M@#GYM+O++[#=6L27MS"[O,K.(_,9P06![<GIZ59T2QDTVUM;65@TBQ,6P> 2
MPX'M6O4)_P"/Y/\ KFW\Q0!/1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !24M)0!YYXP_Y#S?]<D_K6#WQ6_XP_P"0^?\ KDO]:BM+73X]
M$6^NH))6,WE[5<BOBL51=7%S2/I</55/#09BTY$:1U1%+,QP .YKI?["ACO)
M%CL9;F)E5T_>[2@(Z'FI;*RCL]<AQ9/:MY+E0TF[<<5,<OG=<SZV&\=&WNKH
M<S<6MQ:L%N(7B8C(#C&:+>SN;O=]G@DEV_>V#.*U[QVF\+0RS,7D%TRAFZXP
M>*DMY7M_#MHUO(RNUT-Q4XR?2FL'#VO+=VM?S&\5)4[VUO8Q8+*ZN698+>21
MD^\%7.*(K.YGE:*&"221?O*HR1]:ZS66^RV=P]J[1NUVNXIP<X'%3:C);V4-
M],R.09(]XB?:2<#OVKH660OK)Z?J8/'S:NEN<='8W<LS0QV\C2I]Y O(I@M;
M@R/'Y+[T^\N.1]:Z^6);*'47N+F=(',;"53E_I]*6YU.TLKR3[3D.ZJR$1!B
MR8XR?7/Y8]ZEY?3C&\I6&L=4D[1C<XME*LRL,,IP0>QJUI7_ "%[+_KNG\Q5
M>9Q+/)(,X9B>0 >3[<58TK_D+V7_ %W3^8KSZ*2K)+N=M5MT6WV/5A2]J04O
M:OOUL?(D<_\ Q[2_[A_E7RR.@KZFG_X]I?\ </\ *OED=!7G9A]D]++_ +7R
M'H[Q.KQLR.IRK*<$'V-+)+)-(9)9'DD8Y9G8DGZGK3**\V_0]*W4***#QUHW
M **/>C/.*!!WHI,BEHLQW"BBC- FT=M\*O\ D=1_UZR?S6O<Q7AGPI_Y'4?]
M>LG\UKW.O8P7\(\?&_Q0KD/BC_R3;6?^N:?^C%KKZY#XH_\ )-M9_P"N:?\
MHQ:[Z?QKU.&I\#]#YCHHHKVSP0HHHH **** "BBB@ HHHH *]K^ W_'EKA_Z
M;1?^@M7BE>U_ ;_CRUS_ *[1?^@M7-B_X;.K"?Q4>P4445Y1ZX4444 %%%%
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M110 4444 %'>BCO0!#:_Z@?[S?\ H1J:H;7_ % _WF_]"-34 %%%% !1110
M4444 %%%% !1110!Q_CKI8_5_P"E<;79>.NEC]7_ *5QM?%9O_O<OE^1]-EW
M^[1^?YA1117FG<%%%% !1110 4444 %(WW3]*6D;[I^E-;@>NVG_ !YP?]<U
M_E4U0VG_ !YP?]<U_E4U?HD/A1\9+=A7A/Q2_P"1YG_Z]XOY&O=J\)^*7_(\
MS_\ 7O%_(URX[^%\SKP/\7Y'&4445XY[ 4444 %%%% !1110 4444 ;'A/\
MY''1O^OR/^=?2-?-WA/_ )''1O\ K\C_ )U](UZN ^!^IY.8?&O0****[SA"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** .=\3V;+8RWL=W>0N"BDQ2D+&I8!GQ[ D_A63>6]A;
M6]I+I_B.]N;D2H(HA?\ F>?EAG*CKQD_A73ZY=R66EO)$B.[ND2A^5!=@N2.
MX&<X[XKG+9IM,MI[XQ6#26M^8)2EMY9=3M4;.3M(+>^: .SI:2EH **** "B
MBB@ J!O^/Y/^N;?S%3U W_'\G_7-OYB@">BBB@ HHHH **** "BBB@ HHHH
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M0_\ +W)_C7U9HKM)H6GN[%F:VC)9CDD[1S7R%)_JV^AKZ[T/GP_IW_7K%_Z
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M5#:?\><'_7-?Y5-7Z'#X4?&RW85X3\4O^1YG_P"O>+^1KW:O"?BE_P CS/\
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M>LG\UKW.O8P7\(\;&_Q0KD/BC_R3;6?^N:?^C%KKZY#XH_\ )-M9_P"N:?\
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M]7_I7&UV7CKI8_5_Z5QM?%9O_O<OE^1]-EW^[1^?YA1117FG<%%%% !1110
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MHHH **** ,?Q0DDF@3^5!-<,K(Y@A7+2@."5QZ$#!^M8MM?Z3YD2IX+OX6W
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M ))MK/\ US3_ -&+7?3^->IPU/@?H?,=%%%>V>"%%%% !1110 4444 %%%%
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M;?)N/0G&<?[-=[6#9>'9(]5BU'4=4N-2G@1DM_.C1%BSU("  GMD\XSZUO4
M%%%% !1110 4444 %'>BCO0!#:_Z@?[S?^A&IJAM?]0/]YO_ $(U-0 4444
M%%%% !1110 4444 %%%% ''^.NEC]7_I7&UV7CKI8_5_Z5QM?%9O_O<OE^1]
M-EW^[1^?YA1117FG<%%%% !1110 4444 %(WW3]*6D;[I^E-;@>NVG_'G!_U
MS7^535#:?\><'_7-?Y5-7Z)#X4?&2W85X3\4O^1YG_Z]XOY&O=J\)^*7_(\S
M_P#7O%_(URX[^%\SKP/\7Y'&4445XY[ 4444 %%%% !1110 4444 ;'A/_D<
M=&_Z_(_YU](U\W>$_P#D<=&_Z_(_YU](UZN ^!^IY.8?&O0****[SA"BBB@
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MT_2FMP/7;3_CS@_ZYK_*IJAM/^/.#_KFO\JFK]$A\*/C);L*\)^*7_(\S_\
M7O%_(U[M7A/Q2_Y'F?\ Z]XOY&N7'?POF=>!_B_(XRBBBO'/8"BBB@ HHHH
M**** "BBB@#8\)_\CCHW_7Y'_.OI&OF[PG_R..C?]?D?\Z^D:]7 ? _4\G,/
MC7H%,E=(HGDD.$12S'T I]5=1_Y!EW_UQ?\ ]!-=Z.!Z')#XL>"R,_VQQU_X
M]I?_ (FG?\+8\%_]!C_R6E_^)KYH3_5+]!2UZ*P<>YYCQLUT/I;_ (6QX+_Z
M#'_DO+_\31_PMCP7_P!!C_R7E_\ B:^::*?U*'</KL^Q]+?\+8\%_P#08_\
M)>7_ .)H_P"%L>"_^@Q_Y+R__$U\TT4?4H=P^NS['TM_PMCP7_T&/_)>7_XF
MC_A;'@O_ *#'_DO+_P#$U\TT4?4H=P^NS['TM_PMCP7_ -!C_P EY?\ XFC_
M (6QX+_Z#'_DO+_\37S311]2AW#Z[/L?2Q^+'@O_ *"Y_P# :7_XFM+0_'/A
M[Q'?M8Z7?^?<+&9"GDNOR@@$Y8 =Q7RO7H_P3_Y'J;_KQD_]#2LZN%C"#DF:
M4L7*<U%GT'2T45PGH!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC%KOI_&O4X:GP/T/F.BBBO;/!"BBB@ HHHH **** "BBB@ KVOX#?\>6N?\
M7:+_ -!:O%*]K^ W_'EKG_7:+_T%JYL7_#9U83^*CV"BBBO*/7"BBB@ HHHH
M **** #%%%% !1110 4444 %%%% !1110!#=_P#'I+_NFIJAN_\ CTE_W34U
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG'8H* .MIU)2T %%%% !1110 5 W_'\G_7-OYBIZ@;_C^3_KFW\Q0!/1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M)0!YYXP_Y#S?\
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MK_TKC:[+QUTL?J_]*XVOBLW_ -[E\OR/ILN_W:/S_,****\T[@HHHH ****
M"BBB@ I&^Z?I2TC?=/TIK<#UVT_X\X/^N:_RJ:H;3_CS@_ZYK_*IJ_1(?"CX
MR6["O"?BE_R/,_\ U[Q?R->[5X3\4O\ D>9_^O>+^1KEQW\+YG7@?XOR.,HH
MHKQSV HHHH **** "BBB@ HHHH V/"?_ "..C?\ 7Y'_ #KZ1KYN\)_\CCHW
M_7Y'_.OI&O5P'P/U/)S#XUZ!5;4?^09=_P#7%_\ T$U9JKJ/_(,N_P#KB_\
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MM+24M !1110 4444 %0-_P ?R?\ 7-OYBIZ@;_C^3_KFW\Q0!/1110 4444
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MKVOX#?\ 'EKG_7:+_P!!:N;%_P -G5A/XJ/8****\H]<**** "BBB@ HHHH
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MXO\ ^@FN]' ]CX]3_5K]!2TB?ZM?H*6O=6QX#W"BBBF(**** "BBB@ HHHH
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M>E?\A>R_Z[I_,5MA_P"+'U,Z_P##EZ'JPI>U(*7M7Z MCX\CG_X]I?\ </\
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MLVX_X^'^M)@14445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ;13O+?^XWY4>6_]QORHL VBG>6_]QORH\M_[C?E18!M%.\M_P"XWY4>6_\
M<;\J+ -HIWEO_<;\J/+?^XWY46 =;_\ 'PGUHIT",)T)5@,^E%-"-&BBBF 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $-W_P >
MDO\ NFIJAN_^/27_ '34U !1110 4444 %%%% !1110 4444 %%%% !1110
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M!:*3-'- "T4A-&30 M%,,@$BH0<GIP<?G3N: %HI*6@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BN0
M6MI HR2IQ4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img45497886_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45497886_11.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (^!+<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2HKABD$C [2%)!J
M5NGI4%W_ ,>LIZ_(?Y5$](MCCNCP3P7K7Q+\=VEU=:;X@M8HH9?+*W$,8.<
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M:=730H4\/'EI1LC"K6J5Y<U25V%%%%=!B%%%% !1110 4444 %%%% !1110
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MI.I+GD[LTA3A3CR16AX%=_L8?#^ZUR:^1M5M;*>023:1;WFRTDYS@C;OQGD
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M_P",T?V'JO\ T-.I_P#?JU_^,UMT4>R7=_>PYWV7W(Q/[#U;_H:=3_[]6O\
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MJU_^,UMT4>R7=_>PYWV7W(Q/[#U;_H:=3_[]6O\ \9H_L/5O^AIU/_OU:_\
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M_A7?BG_HKOC#_P  ]%_^5U=Y11?R0>S7=_>S@_\ A7?BG_HKOC#_ , ]%_\
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MOQ3_ -%=\8?^ >B__*ZC_A7?BG_HKOC#_P  ]%_^5U=Y11?R0>S7=_>S@_\
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M>447\D'LUW?WLX/_ (5WXI_Z*[XP_P# /1?_ )74?\*[\4_]%=\8?^ >B_\
MRNKO**+^2#V:[O[V<'_PKOQ3_P!%=\8?^ >B_P#RNH_X5WXI_P"BN^,/_ /1
M?_E=7>447\D'LUW?WLX/_A7?BG_HKOC#_P  ]%_^5U'_  KOQ3_T5WQA_P"
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M_P!*Y:Z2N;\ _P#(!E_["%]_Z5RUTE:8?^%#T1E5_B2]0HHHK<R$KS/XN?\
M(Z?"+_L9Y_\ TS:G7IE>9_%S_D=/A%_V,\__ *9M3K2G\1C5^'[CM:***U&%
M%%%( HHHH ***!U% %/5M6LM!TRYU'4;J*RL+9#+-<3N$2-1U8D\ 5R7@#XW
M>!_BE?75GX8\00:I=VJ[Y(/+DBDVY W!9%4L,D?,,CD>HKR_]NF\N;7X,V<$
M"O)#=:Q;0W$2.5\R/:[[2>@&Y$YJCX-UB^\+_'SP_H_CCPEX:T[5[W2'71=4
M\.O,/LUO&')MY5<_-A0W( &1WSP@/I>BO'X_CQX;^+&B^(=&^&_B@R^+8=-F
MN[7_ $"5=C+@!CY\.PC<R CDX;(]:\3U?]JWQ3)X?^&VH:9>C,-F+[Q6/(A9
MI(UNDMFSE?DW,'(V[?OK1<#[,HKYCOOVA/$&CQ_%_P 8"Z34?#&@746CZ'8>
M3&(FNOE1Y&=0'90Q5OO8PY QQCC/ _[4NLVOC+P=%<_$.Q\<0:Y<Q6NI:3'H
M;V)TQI,*&BF*+Y@5C@YR3C[O.07 ^SZY_P 3>/="\&ZAHEEJ]]]CN]:N19V*
M>2[^=,<?+E5;;U7EN*^4O''[4VJ:AXV\6VUGX_LO %GH<[V>GZ=-H3WSZG)&
M65C+)L81*67&5Z C@D9,?Q0^-<?BCP#\$/B%JMJT30ZU)/>06H/+PL%?8"?X
MBF1D]^3@47 ^T>PHKQ7]F?QQXE^+&BZIXRUG7(9=/O;N2"R\/VL$833E1L8D
MDVB1I",=\8;/<!<7Q'XW^(/Q*^,WB'P/X(UZS\'V'ARVBEN]3DL4O)YYI%#!
M LGRA>>.,C:22<@  ^A**^0=:_:3\<Q?!KQ"XGM;/QOX9\0Q:/=7=M KP72E
MF&X*ZD+N*-G 7H"-N<#MM+\9?$;P)\=/"GAKQ7XEL/$FE^)K.XF,-OIR6PL7
MBC9R(V7+.,@#+')!S@$4 ?1'UZ5A>-/'&B?#OP[/KOB*]_L_2H619;CR7DVE
MV"KPBLQY(' [\\<UYZG[4W@#6]%\1W/AO6?[:O\ 1],GU.2T^R7$.4C S\TD
M:@?,RCKGG/(KYY^+E[\4/%W[-$OC#Q%XDTZ\T76W@F;0X].2(V<9F!B>*93N
M8Y"Y5]V%;J2."X'W!:W,=[:PW$+;XID$B-@C*D @X[9!'45+7RW\9_V@KOP7
MKOA+P;8^)+?P1;S:5'?7_B&XTUM0:-2I$<440!!R4.2P[@Y'?.\+_M*>(=>^
M$OQ2>#7[?5M8\+QI+IWB2WL!;BZBD8A9&@D7:K@J<C;CGOC)+@?6M%?)%[\0
MOC)H-Q\,[V7Q9I.H'QPB0KILVDHD-B[Q1D2;E.]R-^XC(7(P 0<#N/A7X_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %<5\(_\ D=/BY_V,\'_IETRN
MUKBOA'_R.GQ<_P"QG@_],NF4/X69R^*/]=#TVBBBN<Z1&^Z:Y6'_ )'W6?\
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MJ,FF7/VQ$7=(AP2FUFRON<'VKLZ "BBBF 4444 %%%% !1110 4444 %%%%
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MK484444@"BBB@ HHHH *YGXEZ-_PD'@'7[#[=>:;YMI(?M6GR^5,FT;N&P<
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M;@79LIRNY5WL2%8E2Y"E0V"PR,=*]&@^ ^B6/Q8N/']CJFM:?J=R5:ZL;6\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %<5\(_^1T^+G_8SP?\ IETRNUKBOA'_ ,CI\7/^QG@_],NF4/X6
M9R^*/]=#TVBBBN<Z1&^Z:Y6'_D?=9_[!]G_Z,N:ZIONFN5A_Y'W6?^P?9_\
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M?_QJC_AK7X4_]#3_ .4Z[_\ C5?G111_JYAOYI?>O\@_UDQ7\L?N?^9^B_\
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MKF&_FE]Z_P @_P!9,5_+'[G_ )GZ+_\ #6OPI_Z&G_RG7?\ \:H_X:U^%/\
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MGU&48^KF$)RJ):-;"T445X?D?0>84444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIY'QC17TSX>^!/@WP78?$#Q7XS%YK&A>'=4DTVST^WF,;SD,H4NRD$_ZQ.A
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MG&3ZDD]ZT/\ A1O_ %/_ (Z_\'7_ -A6F'_A0]$95?XDO4].I#TKS+_A1O\
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MHL?CB+P@+L2:]):-?&V1<[(5*C<Y[9+<#KUH Z&BBB@ HHHH **** "BBB@
MHHHH *XKX1_\CI\7/^QG@_\ 3+IE=K7%?"/_ )'3XN?]C/!_Z9=,H?PLSE\4
M?ZZ'IM%%%<YTB-]TURL/_(^ZS_V#[/\ ]&7-=4WW37*P_P#(^ZS_ -@^S_\
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M&:YNI=/2[DNII%5@N'/"\D94J1M)YR,;&H_LS?VA^SW8?"__ (23R_LLBO\
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M#_Z]?1X"_MJRC\/-^BO_ %W/G\=_"I.7Q6_5A1117L'DA1110 4444 %%%%
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M HHHH **** "BBB@ KBOA'_R.GQ<_P"QG@_],NF5VM<5\(_^1T^+G_8SP?\
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M53_X,;3_ ..T?7\)_P _8_>O\P^H8O\ Y]2^Y_Y'D5%>N_\ #)GQ6_Z%4_\
M@QM/_CM'_#)GQ6_Z%4_^#&T_^.T?7\)_S]C]Z_S#ZAB_^?4ON?\ D>145Z[_
M ,,F?%;_ *%4_P#@QM/_ ([1_P ,F?%;_H53_P"#&T_^.T?7\)_S]C]Z_P P
M^H8O_GU+[G_D>145Z[_PR9\5O^A5/_@QM/\ X[1_PR9\5O\ H53_ .#&T_\
MCM'U_"?\_8_>O\P^H8O_ )]2^Y_Y'D5%>N_\,F?%;_H53_X,;3_X[1_PR9\5
MO^A5/_@QM/\ X[1]?PG_ #]C]Z_S#ZAB_P#GU+[G_D<A\(/^2M>"?^PY8_\
MI0E?J/Z?2O@GX<?LQ_$O0/B%X7U._P##?V>QLM4M;F>;[?;-LC2969L++DX
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M%?"/_D=/BY_V,\'_ *9=,KJM+U2VUK3[>^LI?.M9TWQR $97Z'D?E7*_"/\
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MZVT+W+*TA51@;BJJ,_@/H*W***!A1112&%%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ I#W^E+2-W^E'074S/ /_ " 9?^PA
M??\ I7+725S?@'_D R_]A"^_]*Y:Z2M,/_"AZ(RJ_P 27J%%%%;F05\^?MA?
M\@GX=_\ 8T'_ --FH5]!U\^?MA?\@GX=_P#8T'_TV:A7#C_]SK?X9?DSLP7^
M]T?\4?S1XI1117\^G[\%%%% PHHHH ***OZ#)90ZU9-J,/GV'G+Y\>YAE,\D
M%2#D#D?2KA'GE&-[79$Y<D)2M>R_(H45[,OPGTV'XFW$,D)/AB*T^W8WL%"$
M8"[LY^\">O05C>%O"_ARXT36_%FK6TSZ1;W!BMM/@D8$@D 9.=Q^\HZ]C7M?
MV/B(RY6TK-ZOM'KZ'A_VUAY1YHINZ6W>6R]3S*BO5-4\&^'M=\-Z=XDT*TFT
M^V%Y':W=E),7!!8+E6)SGYE_/MBNDNO"'@.R\?0^%QH=U+-=1[Q-]K?9"=A8
M #=DYP3DYP3Q6L<EK2^W&VEG=ZWVMH9RSRC%?!*^MU9:<MKWU\SP>BO6-+^'
M6AZ%:>)-8UWS[W3M+O&M8;6-BK2\C!8@C)^<#C'0]JBU3P9X?UWPWI_B30K2
M:PM1>1VMW8RS,XP6"DALY_B7ZY[8K/\ L>NHWNN;>U];=7_6IHLZH2EI%\NU
M[:7[?UH>645[AKGA_P"'WAWQK;:!-HUS/)=F,"5;F0) 7PJC!;YLGGG.,U1\
M-?"W18_&/B?2-562XL[&!9H)M[HZ(1G/R]2!QSW'2M'DE?VBA&<6[VW>C6O8
MS6>4/9N<H26B:T6J>G<\=HKT*$>#/$/BO3H=.T74X+%5;S;>'=++.X/RXPS8
M7&<XQ_6NG\4?#?29/ .H:S;^'[KPW=VC!UCFNC*98\C)(+':<$\<$$=ZQCD]
M2I"<Z<XM1OWULK]OS-99Q2ISA"I!Q<K;VTOIW_(\6HKV7X=Z'X1\5:<\UUX8
M>"WLH0;O49KV18]X7G #8[9([ _05SFAV/A;6O&FI&WTC4KS2D7-G86N\ER!
MC+MNW*,@G)/<=,8+>4SY:<HU(VGHM_\ (%FT.:I"5.2<-7M]VC>IY[17K/Q*
M^'NG:5X+M-<M-(FT&Z\[RYK.2Y\\%3G'))YX'3'T[UJ:MX7\$>&]0\.V=UH=
MQ=7&JI&#MNI%6/) W_>SDD],XXK1Y)7C.49S2M9W=^NBZ7,EG="5.,X0;O=6
MTOIOUML>)UN^&_ NN^+TD?2=/DNHXSAI-R(F?3<Q S[#GFK7Q*\,V_A'QC>Z
M=:%OLR;'C#'+*"H."?KTSV K0\*ZIXH\4Z;:^$M'*Q0(YF,L68RB[B<NX)^7
M)^O3O7'0PL8XEX>NFVKJT>K^?^1V5\9.6%CB,.TD[.\MDOE^5SF=8\.ZGH.I
M?8;^REM[LX*Q,,EL]-I&=P[9'I6KJ?PU\3:-I;:A>:1+#:( S,'1V4'U 8L!
M^%>N7VJ6&N?%KPII*S"]DTF*037#'.^8)D G^\"N3[D]Q5;P'JUYK7Q8\66%
M[<2RV;QSH8)')50L@0  ]/E)_.O<CD^&YW#G;O+E5K::7U[]CP99SB>13Y$K
M1YI;ZZV5NW?J>#=O\_F/:DI\B[96'0 GCV!Z5[=J'A'P3HNK^&M/N-$GN9]7
MB0$K=2*L><#=][.23TX'%>'A,OGC'+EDDHM+7S=EL>_B\QC@N7FBY.2OITMJ
M]_(\.HKW*Q\ ^"[SQ=JOA..PO&O(86F_M%[ALHQ"D*%& 0 X^]GH>O6N=T7P
MQX:\-^ 8?$/B&SFU:6\N&B@MXI6C  ) .5;DX5CU[@8'-=CR6MS:SC;6[N[+
MEWOIYG$L\H..D)7TLK*[O=KKY'E]%>F?$SPOX=TOPCH&JZ#;2PK?LSEI979M
MN,A2"2.,XZ=NOKYG7E8K"SP=3V4VF[)Z;:ZGK83%1QE/VL$UJUKOH[!1117&
M=H4444 %%%% &SX+_P"1QT+_ *_X/_1BU]>U\A>"_P#D<="_Z_X/_1BU]>U^
MK<&_P:GJ?EG%W\>GZ?J%%%%?H*V/@WN%%%%,05YO\:?^9#_[&JP_]J5Z17F_
MQI_YD/\ [&JP_P#:E (](HHHH$%%%% PHHHH **** .>^(GV3_A7_B;[?O\
ML/\ 9=U]H\O[WE^4V['OC.*^,?7IC/;I7V=\1+BWM/A_XFGNX/M5K%I=T\T'
M_/1!$Q9?Q&1^-?&'KWYK2&YX^-^)!1116AY@4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1_GFBC\,^U SZR^!/V3_A56B_8MWDYGW>9][S//D\S\-^['MBK/PC
M_P"1T^+G_8SP?^F73*K? BXM[KX4Z*]M#Y$8,Z%?5UGD5V_X$P8_C5GX1_\
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M#_GV_O0?ZKU_^?B_$^Q-P]:-P]:^._\ A-/$'_0=U/\ \"Y?_BJ/^$T\0?\
M0=U/_P "Y?\ XJC_ %JH?\^W]Z#_ %6K_P#/Q?B?8FX>M&X>M?'?_":>(/\
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MLDSEF...IZU#7!F&*6,KNK%66B^Y6/2R_"O!T%2D[O5W]=0HHHKS3T@HHHH
M**** -GP7_R..A?]?\'_ *,6OKVOCKP[I]OJWB#3+&[C\VTNKJ*":/)&Y&<*
MPR"#R":]^_X9V^'O7_A'_P#R=N/_ (NOU;@W^#4]3\LXN_CT_3]3T>BO-_\
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MO=.TJ2XM6X60R)&']2-S#(XQD57T[P-KNK:S<Z5;:<S:C;#=-!(RQE><9RQ
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MP4KU!ZXHU)4X2C9I7L_^ =#8>#/ FC_"C1/%&OZ=<S2R?*ZVLSAKARS@+@L
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M_(Z?%S_L9X/_ $RZ95;X$_9/^%5:+]BW>3F?=YGWO,\^3S/PW[L>V*L_"/\
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MZ4M(>_TI=!=3,\ _\@&7_L(7W_I7+725S?@'_D R_P#80OO_ $KEKI*TP_\
M"AZ(RJ_Q)>H4445N9"&O ?VN/BEI?P7T_P"'/C'6K>\NM,TWQ.?.AL$1YF\S
M2]0B7:'95/S2 G+#@'Z5[\>E?&/_  54'_%@/#I_ZFBW_P#22[KKPD%4KQA+
M9G#C9NGAY3CNBG_P]$^%G_0O^+__  "M/_DFE_X>B?"O_H7_ !A_X!6G_P D
MU^7GK25]I_8^'ZW/B?[:Q7='ZB?\/1/A7_T+_C#_ , K3_Y)H_X>B?"O_H7_
M !A_X!6G_P DU^7=%']CX;S^\/[:Q7=?<?J)_P /1/A7_P!"_P",/_ *T_\
MDFC_ (>B?"O_ *%_QA_X!6G_ ,DU^7=%']CX;S^\/[:Q7=?<?J)_P]$^%?\
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MZ)\*_P#H7_&'_@%:?_)-?EW11_8^&\_O#^VL5W7W'ZB?\/1/A7_T+_C#_P
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MU"BBB@ KR_X^:=;:QIO@ZPO(_-M+KQ+9P31Y(W(PE5AD$'D$]Z]0KS?XT_\
M,A_]C58?^U*!H7_AG;X>_P#0O_\ D[<?_%TG_#._P]_Z%[_R=N/_ (Y7I%%
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MA0!T]JSST-%%<LI2J2<I:MG7",*<5"&B1I:#XBU#PSJ OM+N/LMT%9%DV*V
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MBN99DFO@=W;336][?D=+RUI_&K*^NNEK7/B:DK[._;&T7P/<_LZ_"3Q?X/\
M!6F>$&UZ6:XGCL[9!+ED#-&TH +J'W;<]@,!<8'QC7H8>M[:'-:VK5O0\[$4
M?83Y;WT3OZA11174<H4444 %%%% 'H/[//\ R7[X9_\ 8SZ9_P"E<5?N(.E?
MAW^SS_R7[X9_]C/IG_I7%7[B#I7Q^=?Q8^A]KD/\.?J+1117SA]0%%%% PKS
M?XT_\R'_ -C58?\ M2O2*\W^-/\ S(?_ &-5A_[4H!'I%%%% @HHHH&%%%%
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MY1;V5QHZ[;:6S5E8?=Y.6//RBNG/[2GBLQP@1::LJ;<W MF\QP""0?FQ@]\
M>U+E=A_6*?,W>VO](I_M$9_X6EJ'/_+&'_T ?_6KS6MOQEXNO/'&O2ZM?QPQ
M7,BJC+;J50;1@<$G^=8E:QV/.J24I.2"BBBJ,PHHHH ^M?@=+=S?"W1&O4\N
M;$RJN,?NQ-((S^*!3^-3?"/_ )'3XN?]C/!_Z9=,J'X'17</PMT1;U_,FQ,R
MMG/[LS2&,?@A4?A4WPC_ .1T^+G_ &,\'_IETRL);2/HX;4_ZZ'IM%%%<QVB
M-]TURL/_ "/NL_\ 8/L__1ES75-]TURL/_(^ZS_V#[/_ -&7-<M?>'K^C.BC
M]KT_5&RV"N#TK%N/!'AZ\GDFFT33I9I&+O(]JA+,3DDDCK_C6WZ45$J<9KWU
M=&D9RA\+L8'_  K_ ,-?] #3?_ 2/_XFE_X0'PU_T+^F?^ D?_Q-;W-+6/U:
MA_(ON1K[:K_._O,#_A ?#7_0OZ9_X"1__$T?\(#X:_Z%_3/_  $C_P#B:WZ*
M/JU#^1?<@]M5_F?WF!_P@/AK_H7],_\  2/_ .)H_P"$!\-?]"_IG_@)'_\
M$UOT4?5J'\B^Y![:K_,_O,#_ (0'PU_T+^F?^ D?_P 31_P@/AK_ *%_3/\
MP$C_ /B:WZ*/JU#^1?<@]M5_F?WF!_P@/AK_ *%_3/\ P$C_ /B:/^$!\-?]
M"_IG_@)'_P#$UOT4?5J'\B^Y![:K_,_O,#_A ?#7_0OZ9_X"1_\ Q-'_  @/
MAK_H7],_\!(__B:WZ*/JU#^1?<@]M5_F?WF!_P (#X:_Z%_3/_ 2/_XFC_A
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MZ=(=J7C0,(F.3@!\8SP?RKT'PU\$UU'PK!KVN^(;3PY8W) @^TH&+@YQG+*
M2!GJ>!FNU^)F@GPS\ ]*TXW,-[Y-VI6X@Y216:1E8?4$=ZASZ&D,/)Q<I=CY
MZ[&M6/PKK<FG&_31K][ )O-RMM(8L#J=X&,?C3?#>F6NL:W:6=[J":7:RL0]
MY(H98@ 3D@D=QCKWKZ/^.GVBQ\,6FGZ;KRV7F0"U31HX5+7RLR)\ISD  ]!G
M.<54I69-*ESTY3;V/E[.>>#]/\3VHKV*']GN&UCM(=:\7Z=I&KW0#1V$BJQ8
MD\*"74G)XX!&>F:Y^Q^#.HM\1$\)ZC=+8R21M,EY''YJR( 2& )&<X(ZC!!H
MYD#P]2-M-SSVE52S *-Q/8=Z](\<?"&T\#Z/<3S^*;.YU6%T7^S(HQYAW$ $
M_/D<9/W<<=:YSX<^+K;P3XFAU:YTW^TA$C"./S-FQB!A^AS@9_[ZJKW5T0Z?
MLY<LS.O_  GK>EV?VN]T>_M+7('GSVLB)ST^8C%97TZU],?"?QUKOCB7Q-?:
M^8V\*+$^U9H5"1\DE,@98!,[LY[>N3XU\._ G_">>*I(4W6VBVS>?=W#-CRH
M<DA=WJ1Q^O:H4GK<VJ4%[O(]SF)M$U&UTV'4)M/NH;"8[8KJ2%EC<\\!R,-T
M;IZ5!:6D]]=16]M#)<7$K!8XHD+,S'H !U-?0OQXO['4OA-H-QI<?E:<UV@M
MT"X'EJDBK@=N!P/2O'_A7_R4?PY_U^Q_SIJ5XW)G14*BAW.=U#3;K2;IK:]M
M)K*Y4#=!<1F-UR,C((ST]?457KZ+^(?PCLO&7Q%OI)O%-GIM_=B,V^G[/,F8
M+& 206!'W3C&>*\NT7X/:UK7C:_\.(T,4M@_^D71YC5>S =]P(('!Y[=:2FK
M!/#SC*R1PM%>MWWP!2XTV\G\-^*+'Q)=6@W2VEN%5AP<8*N_S'!QG&<=:YNW
M^&1N/AA=>,/[1V^3*8OL?D=?G5,[]W'7.-M/F1,J$X]-CB**[A/AGN^%K^,O
M[1QMF\K[%Y'7]X$SOW>_]VNMC_9Y@ATO3]2OO%MKIMC=0)()+B )AV *H,R
M-P3W&?2GS(2H3?3S/&JL:?I]SJM]!:6<+W%S,X2..,99C[5Z+HWP:@O-%NM;
MU'Q+;:5H:W+V]M=M;F0W&UR@;;N& 2#QDGBJ&J?#_4?#7B.Q@\-:U;ZU/=Q2
M/;S:;<*LNT)\PP&X)0G')R"0*7,@]C-:R.8UOPCJOAV&*>]MT2"5FC6:">.9
M-XZJ61F ;O@G/2LBO0=9MX9?A7"]I9SZ1;VVI[98;IA(;R5HSB17VKC: 05
MXW=37GU4G<FI%1=D%(:6C\<>],S/K3X%VK6?PLT2-YQ<,WGR;P<X#3R,%_X"
M& _"I_A'_P CI\7/^QG@_P#3+IE5O@1;V]K\*=%6VF\^,F=RWH[3R,Z_\!8L
M/PJS\(_^1T^+G_8SP?\ IETRL);2/H:>U/\ KH>FT445S'<(WW37*P_\C[K/
M_8/L_P#T9<UU3?=-<K#_ ,C[K/\ V#[/_P!&7-<M?>'K^C.BC]KT_5&UZ4M)
MZ4M(H****!A1110 444E "T5XCXP^.7C.S^+FK>!/!OPZMO%<VEZ=;7]Q>7/
MB%; !9BZA0C0OG!0\@UT/P?^,TWQ'U#Q!H.N>&[CP=XQ\/O"-2T:XNX[M525
M"\4L4T?$B,H/. 0001Q3$>FT4?K7!6_Q0;Q5\/=5\2>!M&E\57=K<7%I;:;)
M.EB;N:&8Q2 22 A!N5N6'.!0!WM%,C8LH++M) )7/3VI]( HJ"^O(=.LKBZN
M7\NW@C:21]I;:H&2<#D\#MS65X)\8:?\0/"6D>)-*\TZ;JMM'>6QF7:YC=<J
M2.Q([?3/I0!N4444#"BJNJ7%S:Z9=S6=K]NO(X7>&U\P1^<X4E4W'A=QP,G@
M9KE-'^)4<VM>&?#FM6$NC>+M7TE]5ETE9%N$M!'Y:RHTZ@*Q5Y H*CG!.,8I
MV$=K17#_  U^)7_"PM1\:VO]G?8/^$;UV71=WG^9]HV112>;C:-F?-QMYZ9R
M<UTOBC6O^$<\-:MJWD_:/L%I-=>3NV^9L0MMS@XSC&<'% &G17-_#7QA_P +
M"^'GAGQ1]D^P?VUIMOJ'V7S?-\KS8U?9OP-V-V,X'3IS724@"BL/QQXRTSX=
M^$-7\3:S(\6EZ7;M=7#1H7;:HS@ <DGI^-:MI=)>6D-P@81R1AUW<$ C(_'\
M>#0!/17A/Q,^-OQ-^'-GXBUB?X5Z7+X7TCSI?[5G\7QP&6!"<2&(VS%688Q&
M,G+  DUZ?\-?$VJ^,O NB:YK>@MX8U/4+9;B729+CSWMPW*JS[4RVW!/RC!)
M!'% '3T5S7Q+\9?\*[^'GB7Q1]D^W_V/IT]_]E\SR_-\N,OLW8.W.,9P?I6I
MX;U?_A(/#VEZIY/V?[=:Q7/E;MVS>@;;G SC.,X&<=J8&C1112&%%%% !17.
M_$3QI:_#GP'X@\4WT,MQ::/8S7TL4&-[K&A;:N3C)QWXJC\+O%'B;Q=X;&I>
M)O#%MX5N)BCV]K;:I]OWPM&K!V<11A3EBNT XVG!((- CL****!A1110 444
M4 %%%% !2-W^E+2'O]*.@NIF> ?^0#+_ -A"^_\ 2N6NDKF_ /\ R 9?^PA?
M?^E<M=)6F'_A0]$95?XDO4****W,A*^,?^"J?_)O_AS_ +&>#_TDNZ^SJ^,?
M^"J?_)O_ (<_[&>#_P!)+NN[ _[U3]3SLQ_W2IZ'Y8GK24K=:2OTWH?EP444
M4""BBB@ HHHH **** "BBB@ HHHH 4?A^-?5_P"P+I\&BWGQ1^(4L8>Z\)>&
M9Y[0LH)CF='8./?$3#GC#5\H XYKZF_8%U^SNO%OC?X>7\T<,7C;P]<:?;^8
M<*UP$;8OXHTI_P" UY^.O]7E;^OZ1Z&!:]O&YO?#7X;_  CT_P#9'C^*WC[P
MKJ'B/6DUJ6W*V>HS0->DN0D4F'VJG.XE0&^4<GD'K?%7[.7PRC\3?!OQ5X9^
M'VL:WX;\9:;<W%QX,M]3<S%EMTD1DF>96!7>2P\S!V# ZBO$=8^-.DZ1^RA<
M_!B\TW5;?Q=9Z^]U/))%&+90LAW(6\S?N!R""G4=:T/BQ^U/:^)/A/\ "/0?
M!USXA\/>)?!MDUK<ZC'(+7),*1'R9(I2^#M;J%X;\*\OV6(E+FBY:M]7M;0]
M3VV'C'E:3LE]]]?P/I1OV=?AMS_QBKXQ'O\ \) /_D^O//@S\6OA)X"_9S\4
M>"_$7BK7_".K:EXCGN)K'PZD@U*VC61!'&)F5DP%A 8[CD$CJ37R[_PT1\5O
M^BF^,1_W'[O_ ..5Z5\*OC;\*+CX9S>#?BUX$N]5>.\:_MO$7AU(DU*9V9BR
MSNS(7^\PW%FR" 5!56I5,'6A!^U;EJMF[_B.&,I2J+V:4='NE;\#>_:1^'MM
M\%/B!\.?&L^M:C\6_ .L0KJ&G0>([QVEGA78[0.[*?E821MG8/O$%>,GUSXL
M?%.]^,7_  3UU+Q!>:;8:.AUR&UM=.TN(1V]K!',BI&J^P_4\8& /FS]J7]H
MNS^.6H^&],\/:*_A[P3X7LS9:183$-,%PJEG() ^6-%"Y.-N=QR:OP_M">'X
M_P!C>?X2M9:E_P )$^JB^%T(H_LFSS5?!;S-^[ /\&/>M7AZCIT93C[R:^2N
MS-8BG&=6,9>ZT_F['8?LZ6J?$3]D'XZ>$[O,HT1(/$5B3_RRE5'+,OH2(,'V
M8U\FGOQBOK+X(ZFOPD_8Q^+/BJ[18[KQC-'X<TI9>LV$<2NO^RJRRG/K&17R
M=ZXS7?A?XM6WPW_1'!BOX=.^]OU8E)117H(\X****8@HHHH **** "BBB@ H
MHHH **** /0?V>?^2_?#/_L9],_]*XJ_<0=*_#O]GG_DOWPS_P"QGTS_ -*X
MJ_<1>E?'YU_&CZ'VN0_PY^HM%%%?.'U 4444#"O-_C3_ ,R'_P!C58?^U*](
MKS?XT_\ ,A_]C58?^U* 1Z11110(****!A1110 4444 <]\1/LG_  K_ ,3?
M;]_V'^R[K[1Y?WO+\IMV/?&<5\8^O3&>W2OL[XB7%O:?#_Q-/=P?:K6+2[IY
MH/\ GH@B8LOXC(_&OC#U[\UI#<\?&_$@HHHK0\P]K^ DFM1Z/JHT'6+ WH?)
MT/4(CB7IF17#@@XR.A''.."-WXM_V-I^@Z/?:SINGZ7XK^UQ2F'3W#OY8;+%
MB N1@=\\G -?.]%9.%W>YV+$<M/D2/ISXA> 9_&'C30/%EGJ>GQ:%;QP-)<R
MS=ED+Y7C!!!&.>M1>+VF7X^V)MM=M]!N#IB!)+F+S(Y_G;,1&Y1SSW!XXYKY
MHHH5/S*>)6ZB?5GB* 77A76I_B%I6BVIBC86UY:R9DD?!(V C<#GI\W//&*Y
M?P_X>F\=_L\66E:9<6WVNUN'>032$;-LKM@X!P<,"/K7SW11[/S!XF_V>ECZ
M4\/Z&;/X=Z!?>!K30Y+YH@=0U"_ ,D+E06))/&&W9';L.>+GQ(8W'Q"^&%VL
MJW,3SG_2(R"DA)C.01U!ZCV-?+]%'LRGBER\J7;\#Z/MV_XRHN3V^S_^VJUB
M?#D_\9':_P#]=[W_ -#->%T4<A'UC6]NMSZ4^'6O6=W#XW\-+_9[ZM+JMS/!
M:ZF,PW )P P[X*8/ID4WQA/J/@SX>ZS#?6_A70S?1O"+'3K=P\VY=N001EAD
M\[3@<U\VT4>S\REBGRVMJ?0NH: ?C/\ "_PS%H5]:1WVE1K%<6EPY0!A&%.<
M D=!CC!#=>U'Q0T?_A'O@+I.F?;8K][6Y2.2>%]R;P9-R@^BG*]NG0=!\]44
M*&J)^L)Q;MJU85?O#ZU]!_'/5H]"\9> ]1E3S(K3;,ZCJ0KH3CWKY[HJY1NS
M&G4=.#BNMOP/HOQ[\+9?BEXJMO$>C:U9/I$\47FR-(Q:,+UV@ CIS@D<YS6D
MOBS3O$G[0.D1Z=,EU%96,T+W$;;E9BK$@,."!GZ9SZ5\Q45'(;_65>Z74Z7X
ME.TWQ"\2%B6;^T)QSZ"1@,?@!^56_A3X#_X6%XMAT^1VBLXU\^YD4\^6,#"^
MA)(&>V<\UQ]%79VLCEYDY\TMCZI^(WPZ\3^(-+AT#P[-I6D>&H$51!YLB22^
MS;4(VY[ \GDG/ \X\#_$/PKX0\':AX8UW3;^[FGN)$NVL=JK*H( &\2(V.,?
M3.:\=HJ%#HSIEB+RYXK]3Z;^(.I>$?\ A2^F2'3+K^RY5*:9!N.^"8H^QG_>
M=!SW;KT->'?"L_\ %R/#G?\ TV/WZ'K]#7*T52AHT14K\\XSML>Z>(#_ ,91
M6ISC_2+?_P!$+73:1XBTZT^+'CS0[ZZ6PDU98E@N&(7YA#MQGU^;(]P:^9:*
M3AHM318GE=[=3Z-^'O@)_@C<:MXB\1ZK9"W^S-##%;R,6E)8-T95RWR@ #/4
M]*I^![;_ (6+\%]<T'3I[>+5'O&E,,K8"J9%<'@$@8!&<=1BOGZBER>8OK"2
MY;:6/H?Q/X=?PG^SO>Z3/=6]W<V]THG-M)O2-S,K%<GN 16/^T [?\(;X!0,
M<&U)(SU(CB _G7B%%-0L[BGB.>+BHVT2^X^@?@Y<>(H_ G_%/ZEI>L;93YFB
M7\91[?).2KANA^4X(QR>0>*Q_C]#HVF_V++9V]IIGBC/F74>FOD1\ @L5 YW
M8P2 3@^E>+44^36X/$7ARV+VJ:]J6N,C:EJ-UJ#1\(UU.TI7/4 L3]:HT459
MR-M[A1_GFBC\,^U 'UE\"?LG_"JM%^Q;O)S/N\S[WF>?)YGX;]V/;%6?A'_R
M.GQ<_P"QG@_],NF56^!%Q;W7PIT5[:'R(P9T*^KK/(KM_P "8,?QJS\(_P#D
M=/BY_P!C/!_Z9=,K&6TCZ&GM3_KH>FT445RG<(WW37*P_P#(^ZS_ -@^S_\
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MZE'+'>V<<D@>Y\P;9&DF#>8[L,9<MN..O%=C96L5A:PVL">7!!&L4:9)VJ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *0TM% SZS^!=TUY\+-$D> 6[+Y\>P#&0L
M\B!O^!!0?QJQ\(_^1T^+G_8SP?\ IETRH?@=+=S?"W1&O4\N;$RJN,?NQ-((
MS^*!3^-3?"/_ )'3XN?]C/!_Z9=,K"6TCZ&GM3_KH>FT445S'<(WW37*P_\
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M_P"2*_/FBCF86/T&_P"'@WP[_P"@+XG_ / 6V_\ DBC_ (>#?#O_ * OB?\
M\!;;_P"2*_/FBCF86/T&_P"'@WP[_P"@+XG_ / 6V_\ DBC_ (>#?#O_ * O
MB?\ \!;;_P"2*_/FBCF86/T&_P"'@WP[_P"@+XG_ / 6V_\ DBC_ (>#?#O_
M * OB?\ \!;;_P"2*_/FBCF86/T&_P"'@WP[_P"@+XG_ / 6V_\ DBC_ (>#
M?#O_ * OB?\ \!;;_P"2*_/FBCF86/T&_P"'@WP[_P"@+XG_ / 6V_\ DBC_
M (>#?#O_ * OB?\ \!;;_P"2*_/FBCF86/T&_P"'@WP[_P"@+XG_ / 6V_\
MDBC_ (>#?#O_ * OB?\ \!;;_P"2*_/FBCF86/T&_P"'@WP[_P"@+XG_ / 6
MV_\ DBC_ (>#?#O_ * OB?\ \!;;_P"2*_/FBCF86/T&_P"'@WP[_P"@+XG_
M / 6V_\ DBC_ (>#?#O_ * OB?\ \!;;_P"2*_/FBCF86/T&_P"'@WP[_P"@
M+XG_ / 6V_\ DBC_ (>#?#O_ * OB?\ \!;;_P"2*_/FBCF86/T&_P"'@WP[
M_P"@+XG_ / 6V_\ DBC_ (>#?#O_ * OB?\ \!;;_P"2*_/FBCF86/T&_P"'
M@WP[_P"@+XG_ / 6V_\ DBC_ (>#?#O_ * OB?\ \!;;_P"2*_/FBCF86/T&
M_P"'@WP[_P"@+XG_ / 6V_\ DBC_ (>#?#O_ * OB?\ \!;;_P"2*_/FBCF8
M6/T&_P"'@WP[_P"@+XG_ / 6V_\ DBC_ (>#?#O_ * OB?\ \!;;_P"2*_/F
MBCF86/T9\+_MS>!/%OB;2-#L](\11W>IWD-E"\]M;B,/(X12Q$Y.W+#. >*^
MB??K^.?U]:_)'X)?\EF\ _\ 8?L/_2F.OUN']!_*J3;W$+1115""BBB@ KS?
MXT_\R'_V-5A_[4KTBO-_C3_S(?\ V-5A_P"U* 6YZ11110(****!A1110 44
M44 87CR*[G\#^(8[!_*OGTZX6WDSC;(8FVG\#BOBO]/;K7VSXRT>X\1>$=<T
MJTE6"ZOK&>UBE8X".\;*I)] 2*^?S^S5XJ_L_P S[;H_V\M_J?M$OE;?7?Y6
M<_\  :TB['EXNG.HURH\GHKUBX_9I\5+9P-!>Z/)='_6QR3RJB_[KB(EOQ I
MUU^S3XH5X!;7^DRH0#,TTTJ%#W"@1-N'N<?057,CA^KU?Y3R6BO7)?V:/$RZ
MBB17^DM8G&^9I91*/7]V(R/_ !X4D/[,_B9M0>.74-)6Q&=LZRRF4^F4\O _
M!J.9"^KU?Y3R2BO6;7]FGQ0SS_:;_2(E /DM#-*Y<]MP,0V_FU);_LT>*FM)
MVGOM&CN5_P!5''/,Z-_O-Y0Q^"FCF0?5ZO\ *>3T5ZO_ ,,U>*_[.\S[;H_V
M_=_J!/*8@O\ UT\K/_CM+<?LT^*ELX&@O='DNC_K8Y)Y51?]UQ$2WX@4<R#Z
MO5_E/)Z*]:NOV:?%"O +:_TF5" 9FFFE0H>X4")MP]SCZ"G2_LT>)EU%$BO]
M):Q.-\S2RB4>O[L1D?\ CPHYD'U>K_*>1T5ZW#^S/XF;4'CEU#25L1G;.LLI
ME/IE/+P/P:FVO[-/BAGG^TW^D1* ?):&:5RY[;@8AM_-J.9#^KU>QY-17K%O
M^S1XJ:TG:>^T:.Y7_51QSS.C?[S>4,?@II/^&:O%?]G>9]MT?[?N_P!0)Y3$
M%_ZZ>5G_ ,=HYD'U>K_*>445ZQ<?LT^*ELX&@O='DNC_ *V.2>547_=<1$M^
M(%.NOV:?%"O +:_TF5" 9FFFE0H>X4")MP]SCZ"CF0OJ]7^4\EHKUR7]FCQ,
MNHHD5_I+6)QOF:642CU_=B,C_P >%)#^S/XF;4'CEU#25L1G;.LLIE/IE/+P
M/P:CF0?5ZO\ *>245ZS:_LT^*&>?[3?Z1$H!\EH9I7+GMN!B&W\VI+?]FCQ4
MUI.T]]HT=RO^JCCGF=&_WF\H8_!31S(/J]7^4\GHKU?_ (9J\5_V=YGVW1_M
M^[_4">4Q!?\ KIY6?_':6X_9I\5+9P-!>Z/)='_6QR3RJB_[KB(EOQ HYD'U
M>K_*>3T5ZU=?LT^*%> 6U_I,J$ S---*A0]PH$3;A[G'T%.E_9H\3+J*)%?Z
M2UB<;YFEE$H]?W8C(_\ 'A1S(/J]7^4\CHKUN']F?Q,VH/'+J&DK8C.V=993
M*?3*>7@?@U-M?V:?%#//]IO](B4 ^2T,TKESVW Q#;^;4<R']7J]CR:BO6+?
M]FCQ4UI.T]]HT=RO^JCCGF=&_P!YO*&/P4TG_#-7BO\ L[S/MNC_ &_=_J!/
M*8@O_73RL_\ CM',@^KU?Y3RBBO6+C]FGQ4MG T%[H\ET?\ 6QR3RJB_[KB(
MEOQ IUU^S3XH5X!;7^DRH0#,TTTJ%#W"@1-N'N<?04<R%]7J_P IY+17KDO[
M-'B9=11(K_26L3C?,TLHE'K^[$9'_CPI(?V9_$S:@\<NH:2MB,[9UEE,I],I
MY>!^#4<R#ZO5_E/)**]9M?V:?%#//]IO](B4 ^2T,TKESVW Q#;^;4EO^S1X
MJ:TG:>^T:.Y7_51QSS.C?[S>4,?@IHYD'U>K_*>3T5ZO_P ,U>*_[.\S[;H_
MV_=_J!/*8@O_ %T\K/\ X[2W'[-/BI;.!H+W1Y+H_P"MCDGE5%_W7$1+?B!1
MS(/J]7^4\GHKUJZ_9I\4*\ MK_294(!F:::5"A[A0(FW#W./H*6;]FCQ*NH(
ML=_I+V'5Y7ED$H]?W8C(/_?0I\R#ZO5Z(]:^!T5W#\+=$6]?S)L3,K9S^[,T
MAC'X(5'X5-\(_P#D=/BY_P!C/!_Z9=,JY\,O"=UX'\%V.BWERMY<6\EP3,F<
M%7F>1>N.BN![8JG\(_\ D=/BY_V,\'_IETRL7\,CVX*R@G_6AZ;1117,=HC?
M=-<K#_R/NL_]@^S_ /1ES75-]TURL/\ R/NL_P#8/L__ $9<URU]X>OZ,Z*/
MVO3]4;7I2TGI2TB@HHHH&%%%% !7-^)OAKX1\::A:7GB#PKHNNWEGC[/<:GI
M\-S+#@Y&QG4E>>1CI7244",+Q5X%\->.[&&R\2^']*\0V<+^9'!JME%<QHV,
M;E612%.">G/-2:;X/T'1[>]@L-"TVQ@O@%NX8+2.-;@!%C D  #X154 _P (
MP. *V/IUKB?BY\7-$^"_AJWU[7X;Z73YKZ&P']GP>?*'E.%.P$,1[(&/H">*
M>HM#7\)_#[PMX#CN8_#/AK2/#L=RRO.NE6$5J)6 (#.(U&XX)Y-5H?A;X+@T
M/4-&A\(Z#'H^H3?:+S3TTR 6]U*<$O)'LVN>!\Q!/ KF_!_QXTSQ-XR@\+:C
MX=\1>#M;N[9[RPM_$5DD(OHDQO,+1R2+N4%248AP#DKP<8OP_P#VI/#WQ&U"
M>+3?#OBF#2+5;H7OB&]TY(=,M'MRXD22<R$;L(#\H8?,O(((#LQ:'H.E_#/P
MAH,:QZ9X4T33HTM9+%5M-.AC"P2$-)"-JCY&(!*_=) STJ]I_A#0=*NK.XLM
M%T^RN+&S_L^UFM[1(WM[7(/D1D ;(\JOR#C*@XXKRW2_VK/#>H2:3=W?AWQ5
MHWA?5[A+?3_%6IZ:(=-N6<A8CN\PR1I)D;'D1%;/7'7<\9?'C3?"WBJ[\-Z=
MX=\1>,M:T^V2\U&U\.6:3?88WR8S*9'C7<P5B$0LYP?EY%%F/0[ZRT+3-/N=
M0N;33;2TN-2D\V\FAA5&N9 H3?*0 7(557+9. !T%9?ACX:>$/!-Y=7GAWPI
MHGA^\N^+BXTO3X;>27G.'9%!;GGFO./^&M?!*_#,>//LVMG0#K?]@C_0#]H,
MWF%-_D[MVTD=,;_]C/%7I?VD-,LO"NF:I?\ A'QAIVK:K?/8:9X7NM-4:M?2
M(NYF2'S2 @7+%W90 "6(XHLQ'9ZE\*_!6L:W/K.H>#M!O]8N(F@FO[G3(9+B
M2-DV,C2%-Q4H2I!.",@\5KZCX;TC6-!DT2_TRRO=&DB$#Z?<6Z26[1C "&,C
M:5&!A<=N*\VA_::\*PZ#XFOM:L]9\,ZAX?$37VAZK9;;_$S;+<Q)&SK*)&^5
M6C8C)PV"*L:#^T)H>H3:W;Z]HGB#P-=Z3IK:Q/;^([)(]]DO#3(T+R(P4\%=
MV_/&WI19A='I=[I]KJ5C+97EM#=V<\9CEMYT#QNA&"K*1@C&1C%8OAWX;^$O
M"&F7NGZ#X6T71+"]!%U:Z=I\,$4X(VG>J* V02.0>#@UQO@?]H32_&7B+2=(
MG\,>*/#3ZW ]SI%SKE@D<&H1JN\^6R.Y1MGSA90A(/3/%9/BSXR>(M%_:0\-
M^"+7PSJ=_H5YI,]U/-:BU)E?S8$$P9YPPBC$C!QM#$L"JN!1J!ZGI_A#0=)N
MK*XL=%TVSN;&S_L^UFAM$C:WM<@^0A &R+*K\@./E''%4=-^&?@_1_$D_B&P
M\*:)8^()]QFU:WTZ&.[DW?>W2JH8D]\FN(\2?M):/HNNZYI^G>&/%7BR#07\
MO6-3\/V"36MC( &>,NTB&1U5@S+$LA7(R >*] T7QMH?B+P?;^*[#4X)_#UQ
M:?;DU#<4C\C;N+G=]W '(.",'-+4-"_8Z)IVEWM]=V6GVMI=ZA*)[R:"%4>Y
MD"A0\C #>P554%N0 !T%5/%'@SP_XXTU;#Q'H>F^(;%7$BVNJ6D=S%N'1@D@
M(S[XKRW2?VK/#=])I5W=>'?%6B^&-7N$MM.\4ZIIJQ:;<L[!8CD2&2-)21L>
M5$5LYR!6EXH_:)TOP_XZUCP=9>%_%/B?Q#I=O!=SVNB6"2@PRJS*^]Y$08VX
MVL5+$_*&YP:AH>@1^#] A\,-X<31-.7PZ83;'25M8Q:&$@Y0Q;=FTY/RXK5@
MACM8DBBC6**-0JQHN%51T '8#C^E<Y\.OB!I'Q0\'V7B/1?M"V-UO4Q7<)BG
M@D1V22*1#RKHRLI'J.,BL;X@?&33? ?B#3O#T>CZQXH\2W\+W<6BZ# DLXMT
M(5YW:1TC1 Q"Y=P22  <&G9@=-'X,T"'P]<>'X]#TU-!G61)M,%K&+:42,6E
M#Q[=I#LS%N#G))ZTWQ%X&\.>,-(ATK7O#^E:WID)5H[+4K&.X@1E&%(1@5&!
MQ[>U>%?"/XZV%SK7QP\5Z_JNJ:;X7T6_M?\ 1]<2:-].5;2,2Q"%CE"9-WRH
M/F8@C=N!KN_"?[0^F>(/$FD:+JOA;Q3X*N=:5CI4OB6P2WCOF4%C&I21]DFP
M%MDH1B!P"<T68CN9O ?AJX\+CPU)X<TJ3PZJ*@T=[&)K0*#D+Y179M!]!5;2
MOAGX0T%$CTSPIHFGHEK)9*MIIT,8$$C!I(1M4#8Q )7H2!Z5Y(/VTO!W]AMK
MS^'_ !;'X7M[UM/U#Q VF)]BT^82F+]ZWF;B,[26B5U&]0<,=HZSP7^T1HWC
M+QE9>')O#_B/PU>:E:RWNE3:]8+;1:G#&PWM#AV8$ JVV0(VU@<8HLQGI>FZ
M;9Z-I]KI^GVEO96-K&L,%K;1B.**-1A410,!0    !^58-C\,/!VF6,EG:>$
M]#M;.2\74'@@TZ%4:Y&,3[0N#(/[W)R.M>=_\-7^%A'#J?\ 8OB-O!LU\-.3
MQBME'_9;2&4Q!MWF^;L,GR^9Y6TGG.,&M/Q1^T5I?A_QWK/@ZR\+>*?$_B'2
M[>"[N+71-/296AE5F#B1Y%08VXVNRL2<*&YVFH:'<>%?A_X7\#?:?^$;\-:1
MX?\ M+;KC^R;"*V\UNN6V %C[GD?C5._^$?@;5-6OM5O?!?A^[U2^B>"[OIM
M+@DFN(W4*R.Y3+*RX!#<$#!KGO\ AHCPA_PJVR\=[]0.G7UPMC;Z>+-VOY;Q
MI#$+,0#GSO,5EVY X)SC)KSZW^,E]XO_ &FOA_H2Z=XH\) :3JD]]HFM1^0E
MP,0^1+^[D>*7&),89BG((4FC49[['X=TJ#5+?4TTRRCU&WMC9PWBVZ"6* L&
M,*OMW"/*@[1QP..!3[70].LM6O-4M]/M8-3O$C2YO(X56:=8\^6KN!E@NYL
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M<6%OX>N(FU2S948J;DQ+@'*KT)!P01WI@?GG17U;X/TKPA\$_P!F70_B%?\
M@[3?&GB'Q#?&!%UJ(36]NBM*  I4@<1'G&=S<MA16#HFB?#O]HKX_P#A+3]
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MJC\/<YW/^&:_AQ_T+G_D]<__ !RM*'\*/HC&K_$EZGIU(W2O,O\ AFOX<?\
M0N?^3US_ /'*1OV;/APJD_\ ".=/^GVY/_M2MS(VOB!9^*HA9ZIX6NXY9[/<
M9]'N !%>H<?*'QE'&/E/3GFOE;]NCXA:;X^^"?A:2U$EK?VWBF*.\TZY&V>V
MD%E>Y5EZX]#T/UR![)X\^%OPL\"6MNC^%I=1U6]8Q6&F6U]<M-<OQP/WG"C(
MRW;-?-G[67P?;X<_"C1-:NDCL]4U3Q#' VGVSF2&UA-K=2>6&<EF;=&A+9[8
M&1DG6GOKYF53X?N/E&BBBI*"BBB@ HHHH **** "BBB@ HHHH */?I^.***
M/6OAG\>O^%=?"GQOX*_L+[=_PDT31_;OM?E?9LQ&/.SRVW]<]1FO)??&#_\
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M4\-:O+HJW-KJNAZQ$S:9JT+S,\<GFB%I8I%!!V[67)(YVAB]!:DGB;]H[7?
MOPCT_5]>@\*_\)%JVKC1=)U*'5U70KH,,K?/,68PP!5<M&26RFW/S C%T3]J
M)SXBNO#/B*[\(_% 7FDW.H6:_#DM>R220*K26DMH99FW,#E'W8.""!UI-/\
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M +&B+_TBO:^MJ^2?^"DG_)(/"7_8T1?^D5[5P^(RJ?#]WYGY]4444%!1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KBOA'_R.GQ<_[&>#_P!,NF5VM<5\(_\ D=/BY_V,\'_I
METRA_"S.7Q1_KH>FT445SG2(WW37*P_\C[K/_8/L_P#T9<UU3?=-<K#_ ,C[
MK/\ V#[/_P!&7-<M?>'K^C.BC]KT_5&UZ4M)Z4M(H****!A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !5&^T/3=2U"QOKO3[6ZO=/9WL[
MF>%7DMF=2CF-B"4)4[3M(R"1WJ]10(/Y]:***!A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !2'O\ 2EI#W^E'074S/ /_ " 9?^PA??\
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M_P"43_[HH_X=Q_\ 50__ "B?_=%%F!\745]H_P##N/\ ZJ'_ .43_P"Z*/\
MAW'_ -5#_P#*)_\ =%%F!\745]H_\.X_^JA_^43_ .Z*/^'<?_50_P#RB?\
MW119@?%U%?:/_#N/_JH?_E$_^Z*/^'<?_50__*)_]T468'Q=17VC_P .X_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7%?"/\ Y'3XN?\ 8SP?^F73*[6N*^$?_(Z?%S_L
M9X/_ $RZ90_A9G+XH_UT/3:***YSI&M]VN&U#7=-T/QUJ9U"_MK(2Z?:>7]I
MF6/?B2XSC<><9'YUW3=*;M&<XYK"M3=1*SV-:<U!NYR7_"P/#?'_ !/M-_\
M N/_ .*I?^%@>&O^@_IO_@7'_P#%5UNWVHV^U8NG6;^)?=_P33VD/Y?Q_P"
M<E_PL#PU_P!!_3?_  +C_P#BJ/\ A8'AK_H/Z;_X%Q__ !5=;M]J-OM2]E5_
MF7W?\$/:0_E_'_@')?\ "P/#7_0?TW_P+C_^*H_X6!X:_P"@_IO_ (%Q_P#Q
M5=;M]J-OM1[*K_,ON_X(>TA_+^/_  #DO^%@>&O^@_IO_@7'_P#%4?\ "P/#
M7_0?TW_P+C_^*KK=OM1M]J/95?YE]W_!#VD/Y?Q_X!R7_"P/#7_0?TW_ ,"X
M_P#XJC_A8'AK_H/Z;_X%Q_\ Q5=;M]J-OM1[*K_,ON_X(>TA_+^/_ .2_P"%
M@>&O^@_IO_@7'_\ %4?\+ \-?]!_3?\ P+C_ /BJZW;[4;?:CV57^9?=_P $
M/:0_E_'_ (!R7_"P/#7_ $']-_\  N/_ .*H_P"%@>&O^@_IO_@7'_\ %5UN
MWVHV^U'LJO\ ,ON_X(>TA_+^/_ .2_X6!X:_Z#^F_P#@7'_\51_PL#PU_P!!
M_3?_  +C_P#BJZW;[4;?:CV57^9?=_P0]I#^7\?^ <E_PL#PU_T']-_\"X__
M (JC_A8'AK_H/Z;_ .!<?_Q5=;M]J-OM1[*K_,ON_P""'M(?R_C_ , Y+_A8
M'AK_ *#^F_\ @7'_ /%4?\+ \-?]!_3?_ N/_P"*KK=OM1M]J/95?YE]W_!#
MVD/Y?Q_X!R7_  L#PU_T']-_\"X__BJ/^%@>&O\ H/Z;_P"!<?\ \576[?:C
M;[4>RJ_S+[O^"'M(?R_C_P  Y+_A8'AK_H/Z;_X%Q_\ Q5'_  L#PU_T']-_
M\"X__BJZW;[4;?:CV57^9?=_P0]I#^7\?^ <E_PL#PU_T']-_P# N/\ ^*H_
MX6!X:_Z#^F_^!<?_ ,576[?:C;[4>RJ_S+[O^"'M(?R_C_P#DO\ A8'AK_H/
MZ;_X%Q__ !5'_"P/#7_0?TW_ ,"X_P#XJNMV^U&WVH]E5_F7W?\ !#VD/Y?Q
M_P" <E_PL#PU_P!!_3?_  +C_P#BJ/\ A8'AK_H/Z;_X%Q__ !5=;M]J-OM1
M[*K_ #+[O^"'M(?R_C_P#DO^%@>&O^@_IO\ X%Q__%4?\+ \-?\ 0?TW_P "
MX_\ XJNMV^U&WVH]E5_F7W?\$/:0_E_'_@')?\+ \-?]!_3?_ N/_P"*H_X6
M!X:_Z#^F_P#@7'_\576[?:C;[4>RJ_S+[O\ @A[2'\OX_P# .2_X6!X:_P"@
M_IO_ (%Q_P#Q5'_"P/#7_0?TW_P+C_\ BJZW;[4;?:CV57^9?=_P0]I#^7\?
M^ <E_P + \-?]!_3?_ N/_XJC_A8'AK_ *#^F_\ @7'_ /%5UNWVHV^U'LJO
M\R^[_@A[2'\OX_\  .2_X6!X:_Z#^F_^!<?_ ,51_P + \-?]!_3?_ N/_XJ
MNMV^U&WVH]E5_F7W?\$/:0_E_'_@')?\+ \-?]!_3?\ P+C_ /BJ/^%@>&O^
M@_IO_@7'_P#%5UNWVHV^U'LJO\R^[_@A[2'\OX_\ Y+_ (6!X:_Z#^F_^!<?
M_P 51_PL#PU_T']-_P# N/\ ^*KK=OM1M]J/95?YE]W_  0]I#^7\?\ @'(_
M\)_X:/\ S']-_P# N/\ ^*H;Q]X;_P"@_IA_[?(__BJZ[;[4FT-U%/V573WE
M]W_!#VD/Y?Q_X!S/P\GCN/#HEB=989+V]=)$(*LINI2"".HP:ZFF* N .!Z4
M^NBC!TZ<8/H8SES2<NX4445J0(W2O(_CQX@TKPKK?PLU76M2L]'TRW\42>=?
M7\Z00Q[M'U)5W.Y"C+,H&3R2!7KAI*J,N5W(G'F5CRC_ (:'^%?_ $4SP?\
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M_P!%,\'_ /@^M/\ XY7K&/848]A1[2/;\0Y*G\WX?\$\G_X:'^%?_13/!_\
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M>TCV_$.2I_-^'_!/)_\ AH?X5_\ 13/!_P#X/K3_ ..4?\-#_"O_ **9X/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.G QV/ (&.] 'H%%>?:AJNI:[8":5[.SM8=4LX7M6!>3<)H6/[T.%ZG@;.0
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M/D%L*0PV A2H.&R<\<8(!U=%<EX)S;Z-J5[=M")'OKMY9HH3&2J32*-W))(
M_ 8':G>&_$&H:AJDUM=HA1K9;J"581%N4DC.WS7.#QC<$/!X.3@ ZNBN%N-8
MU#0+C5[U1!)8KJ<<36YC8RR;TB7<)-V%P6'&TYV]1G@M?%6M26<4]Q## MY$
MAM&,"Y9V(PH5;ABX*M]XF, @$\'A@=U17$:3XBUW6KR"T7['9R)Y_P!H>:W+
MG,;HH4*DV%.'(/SM@K^ S-)U76+6RN]0^UV,LEOH]K=S>=&Y,P E;'#_ "<#
M&\[LDD[>,% >E45R=[XJEALIYD6'>NHP6:I)GE7\O((S]_$AZ>@ZU5L=8\1W
MD.F@SZ;')=6+7S,+1V"#$>V,#SADY<_-D#@# SF@#MJ*YZX\3-'X-36U@Y>U
M2X$>[@;U!ZY' SWQT[5E1Z[XB^V6EE/'9VDUS/L66XB&=OER,0(DG?)S'U+C
M.X\?)\P!VU%<.WB74)&B\J"TEU!3-;F4)C<4N$C8H&D7((!;9NZKU..;%MK^
MHZH\5K:7=C!<+%))/+<6LF-R/L*B,NI&".26;'&,A@0 =A17FX\07_BW1;:_
M)M+*R_M"Q0VKHS2AO-A8G?N _B&!LY7O\W&MH_B+6M8N%DCMHX+&X:6.*26-
M/W;+NVG(G+2<J<J$7J>1MY .RHK%\07U[I^FPM9&$W4EQ#"&F1B@WR*I8J""
M< DXR.F,UBV_B36WU"5!;PO:6<XMKB5D6)"0!N?<9RR#D$+L;(P,G.0 =I17
M$V_BK4UME@N#:P:G,T"QI+;LJ0B0D!CMD82C*D#:PR< XR#6C:ZW=PZC):7E
MS83/##-*\EN&4#9Y9&Y2QVX#\C)['C.*8'2T5P7ASQAK6OQVMTEE']C9HHY_
MD11ED4L0QFR.7!"[&R !GG(UO%6O7NE@)IQ62>.%[B6-H!(?+&!NR98U49SU
M))[ X-(#IZ*XA?$VKW"O=J;.&S^V6]K' T+O(?-6/YBX<#AI>FWD+U&<BG!X
MLU6QT/3I?-BOS';V[WC?9RI7S,8)=Y@ <8' <Y/0 XH ]#HKB9_$%_-H\M_*
M^ER6<PG"64D3;\INP"Q;#GY#N&T8YY^7F./4+[6-2\.7T\UFMI)J,WE6R1L)
M5VPSJ,L7(8\'("C!('.,D [JBL;7KR_AN-.M]/>VB>YF9'DN8VD"*(V;A59<
MG*XZCK7-CQEJNG:?'<WRVEQYUE+<QQV\31[&1XU.2TAR#Y@..,8QD]: .]HK
MBH=>\0-?6VGW$-M9W-Q)^[N)X0 %",S+Y23ODG;P2X_BX^7)S=-U>ZTN&UMX
MC9/=W5W>1_:VC8HC->$< -G;\Q^7/7:,T >CT5Q>K>(]4T^*:&*>QN[ZV626
M=;:WW 1@*06#3*(R W(+,3P0.H%";Q-?V9NKZ46TR-<K]G29&'V?-HK<ON/&
M6Y( XW^O# ]#HKBYM<UVWUV'1A+82W$A21KO[-(L:QLDQP8S*3NS%UW='Z?+
MSN^'-0EU32DGG""=7EA<Q@A6:.1D+ $G .W.,GKU.,T@->BO.]:\37ES#>6S
M".;3+NWN/(F6(19V?60LWH3L4<C!Y%/L_$&HV>F:K+:O9QV^F>=/+#-&S239
MED8A2&&P84JIPV3G@8P6!Z#17#3^.+N&9H?)MQ(L;P'<&R;PLPB3&>%8(S8)
MSAEP>:@/C368[&74FL838_O44N%0(02 2_FEFP5.1L7J>?EY0'H%%<KH<=['
MXNU7[=<6UQ/]AM03;1&(8WS]5+,?7!SS^'+/$GB:\TJ\?[$$G@M_*^TQF')7
M>W&9#(H&1@#"N>>0<B@#K:*\NL=2U'0?M.HF6TF#/J3RI';%&E9+D(A9C)SM
MR.O101GO6X-:\2M=V]F\-K:33S[1-<0 X3RW8CRTG;)R@P2XSN/'RY(!VM%9
M.N6EKJ%K%;W4%M>2,Q:&WNF(BDD52>1@YP,GD'&,]LUS2;X?AKJ,*H/-MTNH
MC$K#RT99'&Q#_P \U(VKQD*!P,$  [NBN-;7M8CU[^PWFT\W;JLHN_L[JFTK
M(2@C\PEF_=D_?'!)QQS#'XXNUT37+F1;;[1IL+$'!"22+)+'G!;A6,60,G&2
M,G&: .XHKC%UO7Y+19HS9L9KJ6*...V+/'&C2+O*F93)G:A.W!7/0]1K76O"
M/PO_ &Q"T4V8%D5FW)&2<8)R,@#OGD#- &[17GVK3:E=>)M'T>^EL+J-;N*:
M0K:,$D1H+@A=K.V"&B)!SW7^[SL^(M3NM+U>VE%W';V:V5Q(\;0/(2X:(*?E
M8=V   ]1WR #J**\XOO%&J0SP?:M.:ZO;"].V&%5C+@VLQY EDP!C/4L0>$)
MP#IR:UJ,FK6=M92:<\MTD/F7_P!G9D9#'*^X*) 2OR  %N-Q/-,#M**X"/QE
MJ]UIFKW$9T^W?287,PGC<B9E:521\XV*?+X'S]2,\9/1>*)KR/2XFLKA+:9K
MFW4R,I<;6F12.&7J#Z\C/3K2 W:*X6#Q9KMU!+>1V,(LV$JQ>;Y<8#KD+\YG
M^8Y4@J43K]Y=O-B/6-3NKK3(OM<,<\=^8;J+[(\?R^0T@!!D/;!R&8'@]B*
M.RHK%UR\OX;C3;:P>VBDN9F1Y+F-I BA&?A0RY.5 ZCKFN<'C+5=.T^.YOEM
M+CSK*6YCCMXFCV,CQJ<EI#D'S <<8QC)ZT =[17%0Z]X@:^MM/N(;:SN;B3]
MW<3P@ *$9F7RDG?).W@EQ_%Q\N3FZ;J]UI<-K;Q&R>[NKN\C^UM&Q1&:\(X
M;.WYC\N>NT9H ]'HKB]6\1ZII\4T,4]C=WULLDLZVUON C 4@L&F41D!N068
MG@@=0*$WB:_LS=7THMID:Y7[.DR,/L^;16Y?<>,MR0!QO]>&!Z'17%S:YKMO
MKL.C"6PEN)"DC7?V:18UC9)C@QF4G=F+KNZ/T^7G>\-ZA+JFEQSSA!.KRPN8
MP0K-'(R%@"3@';G&3UZG&:0&M1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %(:6D/2@"CJVH'3+4S+:W-X^0JPVJ
M;G8D@=R .O4D 5A:AK.@:OHFG76JV!N[:YFVP6TUB;IUF"N2 B!^0JOR..O/
M-;&N:.-<L7M&NKFUB<CS#;.%9QG)0D@\'H<=B:QM=T*41^&K*PEN;**VO23-
M:PQYB3[/.!\NPHHY ^[W X)H NZ9I^@ZKHJVUKIUM_9J2'_0Y+,1+&X.>8G4
M;3SGD \Y[U/_ &/HYNK4C3[-I[7$,+I;JQM]J[E4$#Y  >!P.1ZUS'B739]-
MA%O:G49)IDDG>^C%Q(\T^$7#+;E &( P2508X'7%*>'6(?MLMBFH+?SR+/)N
M678P-HN<9(4'>&&!@@@#CY: /0#IMIY4Z&TA*3C;+&T8VR Y.&XYZG\S6%;>
M$XD\3?VA++9/-%*]PGD6:Q7!WJR+YL@8[U 9P/E&<#T.<;3=+N[VXLXOM^J/
M8-<9E7R[NU/$+\%I9#)@GR^X&1C&2:J16=["UX\S:O%<-$D:S*ES*/+CNI@
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MQ6&X9=IN;0[RT8 .Y_,)'SXWMWXX K-M+>]6S>6Z_M>WN[B2">YVQ7;!R;5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2/!W2-WDSD>F*I7'A*ZA\MM.OK>T\F_:^@CEM6EC3?$Z.F!(I.6=GR".N,4
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MP'2[JV6ZBM2@C8O!M+_,06(!/\(.TX YPZ\\ W.J:F^I7M[8WEWB-4BET[=
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MW74']*N5C^'='FT>&99;E)O,DWB.&,QPQ#:%VHA9BH^7. <9)/>MB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1]DO?^@B?^_"T :-%9WV2]_Z")_[\+1]DO?^@B?^_"T :-%9WV2]_P"@B?\
MOPM'V2]_Z")_[\+0!HT5G?9+W_H(G_OPM'V2]_Z")_[\+0!HT5G?9+W_ *")
M_P"_"T?9+W_H(G_OPM &C16=]DO?^@B?^_"T?9+W_H(G_OPM &C16=]DO?\
MH(G_ +\+1]DO?^@B?^_"T :-%9WV2]_Z")_[\+1]DO?^@B?^_"T :-%9WV2]
M_P"@B?\ OPM'V2]_Z")_[\+0!HT5G?9+W_H(G_OPM'V2]_Z")_[\+0!HT5G?
M9+W_ *")_P"_"T?9+W_H(G_OPM &C16=]DO?^@B?^_"T?9+W_H(G_OPM &C1
M6=]DO?\ H(G_ +\+1]DO?^@B?^_"T :-%9WV2]_Z")_[\+1]DO?^@B?^_"T
M:-%9WV2]_P"@B?\ OPM'V2]_Z")_[\+0!HT5G?9+W_H(G_OPM'V2]_Z")_[\
M+0!HT5G?9+W_ *")_P"_"T?9+W_H(G_OPM &C16=]DO?^@B?^_"T?9+W_H(G
M_OPM &C16=]DO?\ H(G_ +\+1]DO?^@B?^_"T :-%9WV2]_Z")_[\+1]DO?^
M@B?^_"T :-%9WV2]_P"@B?\ OPM'V2]_Z")_[\+0!HT5G?9+W_H(G_OPM'V2
M]_Z")_[\+0!HT5G?9+W_ *")_P"_"T?9+W_H(G_OPM &C16=]DO?^@B?^_"T
M?9+W_H(G_OPM &C16=]DO?\ H(G_ +\+1]DO?^@B?^_"T :-%9WV2]_Z")_[
M\+1]DO?^@B?^_"T :-%9WV2]_P"@B?\ OPM'V2]_Z")_[\+0!HT5G?9+W_H(
MG_OPM'V2]_Z")_[\+0!HT5G?9+W_ *")_P"_"T?9+W_H(G_OPM &C16=]DO?
M^@B?^_"T?9+W_H(G_OPM &C16=]DO?\ H(G_ +\+1]DO?^@B?^_"T :-%9WV
M2]_Z")_[\+1]DO?^@B?^_"T :-%9WV2]_P"@B?\ OPM'V2]_Z")_[\+0!HT5
MG?9+W_H(G_OPM'V2]_Z")_[\+0!HT5G?9+W_ *")_P"_"T?9+W_H(G_OPM &
MC16=]DO?^@B?^_"T?9+W_H(G_OPM &C16=]DO?\ H(G_ +\+1]DO?^@B?^_"
MT :-%9WV2]_Z")_[\+1]DO?^@B?^_"T :-%9WV2]_P"@B?\ OPM'V2]_Z")_
M[\+0!HT5G?9+W_H(G_OPM'V2]_Z")_[\+0!HT5G?9+W_ *")_P"_"T?9+W_H
M(G_OPM &C16=]COC_P Q$_\ ?A:NQ!E50S;V'!;&,GUH DHHHH **** "BBB
@@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img45497886_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45497886_12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )[!! # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "F
MTZF]Z *6L:K!HNEWNH73^7:VD+SRL.RJI8G\A7SI'^T+\0+'PMIOQ'U?0]#M
M_AM?7$:_989I3JEM;R2"-)W8_NFY(;:!T8#/7'T%XFT*'Q-H.J:1<%A;W]M)
M:R8P<*Z%3Q^)KY=OO WQ+O\ X4V7PKU_0K'2O#&FF-;[QE_::-$]C!()04@Q
MY@<JBK\W'RD\9X]C QH25JEMU>_\NM[>9X.95*\&G2;2L[6_FTM?R/<_B+\0
M=5T7Q!X4\-^&X+:[U[6[K>XNE9H[:QCP9YV"E3D JJ@GEF'7&*]$'W1S]:^4
M?#7Q,U&/Q>WBG3_#5QXK\7^,(F70=',XM5L=%MVPLDDCC$?FL3)C!W9 ],^X
M?"?XJK\2[/5(KG2[CP_K^CW)L]4TFXD61K:7&1M=>'1AR&'7%98K"2I05HZ+
M=_/\D]/4TP>-A6FTY:O9?+\^OH=][BDZ]#Q7EO[1WQ-U+X7?#O[5HD4<WB#4
MKN'2]-69<H)Y3@,?H QP>"0.U<+K/P)\=>'?"]UX@TOXL>*KWQG;VYN3%=7"
M/ID\BC<4%J5VH&P0.3C.?:LZ6%]I!3G/EYG9>=C:MC'3J.%.#ERJ[\KGH_Q[
M^*4_PA^'MUKUG8+J>H--%:6EM(^R-I9&VJ6;^Z.3U&< 9&<U?^%\GQ$DLKL_
M$%?#J76Y3:CP\)]@4CY@_FDY.?3BOE[X\ZM_PNC]GGP7\0Y-3U73Y[NYM;2?
M3;*[9++S/.=))!&006#*VUB<@8KZU\"^$1X)T%--&KZMK:AVD^U:U=FYG.[^
M'>><#L.U=F(HPPV$BFESMR3TU5K==O\ ,XL-B)XK&2:OR))K71WOT.B&=O\
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M])^(W@O]E71X?#VC%/%%C>S2S:/JMNT4ES!]I<O&OF;=C,IR&(Y'09(-?4E
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MS2T2\M7U/E3Q7X.U^X^"?P&L8M$U*6^T[5](EO;9;.0R6J)&0[2J%R@4]2V
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<']I8S_GXS[+_P"'J'Q:_P"@!X-_\ ;O_P"2:/\ AZA\6O\ H >#?_ &[_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AI:1NE 'Y5_\%3_
M /DX;0?^Q8M__2J[KXVK[)_X*H?\G#:#_P!BQ;_^E5W7QM7Z/EO^Z4S\QS/_
M 'NH%%%%>F>6%%%% !1110 4444 %%%% !1110 4M)10!Z%^SM_R<!\,O^QH
MTS_TJCK]VU^Z*_"3]G;_ ). ^&7_ &-&F?\ I5'7[MK]T5\7GO\ &AZ'W&0?
MPI^HM%%%?,GU04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4C=*6D;I0!^5?\ P50_Y.&T'_L6+?\ ]*KNOC:OLG_@JA_R<-H/_8L6_P#Z
M57=?&U?H^6?[I3/S',_][J!1117J'E!1110 4444 %%%% !1110 4444 %%%
M%(9Z%^SM_P G ?#+_L:-,_\ 2J.OW;7[HK\)/V=O^3@/AE_V-&F?^E4=?NVO
MW17Q>>_QH>A]QD'\*?J+1117S)]4%%%% !1110 4444 %%%% !1110 4444
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MZ*^+SW^-#T/N,@_A3]1:***^9/J@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *8Q_P#U=*?28'/'M0!\]_&#P+KFD:AIMS8?$WQ;IDOB'78;&)/M41M+
M/S2[D!/+#%0J,BC=U9<GU7Q=X%UCX;ZMX-U2/XG>+]4M)]<L[*?3;Z[BD^UB
M5PH";8AP/OLI!RBOR."/0/CE>:>O@O\ LR_\.P^*WUJZBTVUTB=Q''/,^2I9
M\$H$",Y8<@+D<XKQGX8Z79>#=0\.^(=5\)V]Q<KK5SX:EU)=8N[T:7*)C!"8
M5N6;Y'8%"Z[2-PXP30!]4J<K2TBYQS2T %%%% !1110 4444 %%%% !1110
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M:?I^I_"GX[>%?#5CXHU[Q-HOB?3[Z6_T_7KXWSV;VZQE+B-G^9%<LR%?N9/
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M&)U3S"R"V&_>S*=[8V\4 ?3B]*6D7[H[TM !1110 4444 %%%% !7R7\;O\
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M,)8E3#GRT$FWY5#%MJC- 'TJGW1Z4ZD7[H[4M !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %-[TZD- "'GVHS7AWQ'
M_:]\(?#'QGJ/AG5-,UNXOK'R_,DM(86B.^-9!@M*IZ..H'.:YK_AOKP#_P!
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MM_\ X_1_PWUX _Z WB/_ ,![?_X_1_96._Y]/[@_M; ?\_4>_P#_  CFF_\
M"3_V^;?=J_V3["+AG8[8=Y<JJYVKEN20,G"Y.%&,#2/@[X0T+Q8?$=AI'D:K
MOFE0M<S/##)-S,\4#.8HG?G<R*"V3DG)KQ__ (;Z\ ?] 7Q'_P" ]O\ _'Z/
M^&^O '_0%\1_^ ]O_P#'Z/[*QW_/I_<']K8'_GZCZ65N*-U?-/\ PWUX!_Z
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MCK]VU^Z*^+SW^-#T/N,@_A3]1:***^9/J@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** (Y,-D'&.AS5;2KZPUFQM[^PN;>_M9$S#=6[K(CKG^%EX
M(R.WI6-XWT_Q1J%K OAC6K#19U8F:2_T]KM77' 4"6/:<]\FO,/V5]-\60_#
M/PM<WNO:=<^'6L#Y&GQ:8T4Z$N<9F\U@P'S=$'44 >ZT4BG<,TM !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(:6D
M;I0!^:G[7G_)Q'BWZVO_ *20UX[7L7[7G_)Q'BWZVO\ Z20UX[7[/EW^YTO\
M*_(_%\P_WNK_ (G^84445Z)YX4444 %%%% !1110 4444 %%%% !1110'4]B
M_9#_ .3B/"7UNO\ TDFK]+*_-/\ 9#_Y.(\)?6Z_]))J_2ROS/B7_?(_X5^;
M/TOAK_=)?XG^2"BBBODSZT*^2_C=_P E0UOZP_\ HE*^M*^2_C=_R5#6_K#_
M .B4KXKBS_<8_P")?DS[/A7_ 'Z7^%_FCA:***_)#]8"BBB@ HHHH **** "
MBBB@ HHHH **** "MOP/_P CIH'_ &$+?_T:M8E;?@?_ )'30/\ L(6__HU:
MZ\'_ +Q3]5^9Q8W_ ':IZ/\ (^T5^ZM.IJ_=6G5_0D=D?@(4C=*6D;I3 _*O
M_@JA_P G#:#_ -BQ;_\ I5=U\;5]D_\ !5#_ ).&T'_L6+?_ -*KNOC:OT?+
M/]TIGYCF?^]U HHHKTSRT;W@OP3K7Q$\467A[P[8'4M8O"P@M5D2,OM1G;!8
M@9VHV,GD\5N^./@GXS^&^DKJ>O:3'!IS7)LFN[.]M[R.*<+GRI&AD<))@$['
MPW!XKK?V.VB3]HCPPUPTD<"QWQD>'[X3[%/N*^X X]ZM:EK7@KX>_!?Q?X5T
M/Q<GC74_$VHV<B>187%M%I\%NSOYC^<BDS/OV;4W #=\QS@\-2M45;EAY?C<
M[Z=&#H\\_/\ 0XKX>_!/Q5\2+2;4=/LX=/\ #]O*(KKQ!JUPMGIUL20#NGD(
M4D9!VKN;!&%K$\<:!H_AO6UL=$\26_BNW6%#+J%I:RPP^=SO2,2 ,ZC^^57/
M8"MKX?\ QL\4_#FQETVPNX-0\.W$@ENO#^L6Z7FG7)XY:"0%0QV@%TVMP,$8
MK%\<:]H_B;7!>Z+X:@\*P/"JRZ?:74L\1E'WW3S"656R,)D[<<&M5[7VCO\
M#Y&3]G[/1>]_6Q[1H?P'\#S>(/!_@/4]0UU/'?B;3(;Z*_MY8/[.LIKB,R6T
M,D.QI) 1L#.)% WYQ@5YC\(_AJOQ&^)%IX;O[M]+LU%Q<7]TJ R0P01/++M5
MB,MM0@>A/.<5[+H?Q,^'\_C;P'\4-0\3&SU3PUI=I#=>%ET^X-Q=75G#Y<7D
MRA6A$<FV,DLZD#=QD#/"_"GQ=X5\ ^,/#GBS4M?EU*76DU.S\0:9;Z>ZR:9'
M/&\"R+)N"S%ED+[5^Z%QU()XX5*O++>]OQU.N4*5X[;_ (:%^Q^"?ACXI:/H
MVJ?#R76M/6X\26WAR\L_$$L5R\9N 6AN%DBCC4+\D@9""00/F.X89KWPG\"^
M(-!\;/X#N/$']J>#Y8OM)UF6&2+4H&G%NTD0CC7R2)&1L,S_ "L>1C-;7AOX
MG>$_@/H&B:9H/B)/'-P?%EEK][<65E/;01VUH&"1 7"HYD<R,>!M&U1NY-5[
M_P 7>!OAOX=^(LWA;Q9_PE.H>+FAAL[2/3Y[<V%L+E;ES<F50I?]VD8$3.,E
MCG&#6*E6YM&[7T\]=;FG+1MK;S)=;^ _@B+7O%?@+2[[7I/'OAO2Y[Z6^G>!
MM/O9[>(2W$$<*)YB?+O"N9&^9.5&1CEO"OP5T75/@KXO\:7OBBUDUC3;&*[L
M]!TU_,EB5KR.W9[HE2$&'.V/(=LAB5 ^;T'6/B=X!L_'7CCXI:;XG:ZU?Q%I
M-W#;>%DL)TN;6\NX3%)YLKKY)BCW2,-KEC\ORBO)?AKXLTKP_P##_P"*&F:A
M=?9[[6M(MK:PB$;MYTB7T$K#(!"@(C'+8';.3BK@ZSCHWNOOOJB)^Q4M5T?_
M  #SCK12GL>E)7L'E=#T']G;_DX#X9?]C1IG_I5'7[MK]T5^$G[.W_)P'PR_
M[&C3/_2J.OW;7[HKXO/?XT/0^WR#^%/U%HHHKYD^J"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH Y_Q9XTT_P<VD#4/."ZKJ$6F0-$FX":0-MWD_
M=7Y>OJ1Q6\ .N*\W^/VF^$M2\ N/&VK7FD:''=0R&2QE9)9)0<1HH569SN((
M51G*@]J\T\)MX,7Q/I"VOB_XL7%P+N(0P:B^K?9G8.-JRAX@NP\!MWRX)R?0
M ^E:*1?NBEH ***YSXA7-[;>#=8;3EN6O6MVCA^QHSRJ[84,H7G(W9SVQF@#
MHZ*\T;6[?PAH^MW*VNM:?JMMILMS%;ZYJ3W0E1!]]1Y\J##%0>0>?0BK%O'<
M^%=:\*XU*^O1K#/;7JWER\JO)Y+2B1%)(C^9"-J;5PW3@4 >AT5QWB>XEU3Q
M9HF@BZN+:SN()[VX-K.\,D@C,:J@=,,!NDR=I&=O7!(KFY;[4VL;W3'GU*ZL
M-)UL6MS+9O,]ZUH8A(@W1_O"0TB L"6*J<DG)H ]5HKS30?$$UI9Z2OB#5O[
M,@L%+SSZA<"!I)'+_9X9&8C+"+YV4\YV$YYKTE#N4'.<\Y% #J*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "D-+2-TH _-3]KS_DXCQ;];7_TDAKQ
MVO8OVO/^3B/%OUM?_22&O':_9\N_W.E_A7Y'XOF'^]U?\3_,****]$\\****
M "BBB@ HHHH **** "BBB@ HHHH#J>Q?LA_\G$>$OK=?^DDU?I97YI_LA_\
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M0 4444 %%%% !3&/UI]-;K0!X5\4O^%F>*-0L8M/^'FGR1Z+K46HZ?J$WB%
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MV?I?#7^Z2_Q/\D%%%%?)GUH5\E_&[_DJ&M_6'_T2E?6E?)?QN_Y*AK?UA_\
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M2^MU_P"DDU?I97YI_LA_\G$>$OK=?^DDU?I97YGQ+_OD?\*_-GZ7PU_NDO\
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MJ_H2.R/P$*1NE+2-TI@?E7_P50_Y.&T'_L6+?_TJNZ^-J^R?^"J'_)PV@_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2^&O]TE_B?Y(****^3/K0KY+^-W_ "5#6_K#_P"B4KZTKY+^-W_)4-;^L/\
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MM+>P^*VDR7"07GB;1K&6P^R \M+-(5:VEP"3B-P3V7M0!]&+]T=J6FK]T #
MIU !1110 44PL=V._P#G_/X4;NW?KSF@!]%1ECFESTP<YH ?14>[ISUZ?Y_S
MTIZ]* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF?F.9_[W4"BBBO4/*"BBB@ HHHH **** "BBB@ HHHH ****0ST+]G;_ ).
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MC#%MK#GC&,$<5U&A:3#H.BV&F6Q<V]G EO&9#EBJJ%!/O@4 7J*** "BBB@
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MHHHK\D/U@**** "BBB@ HHHH **** "BBB@ HHHH *V_ _\ R.F@?]A"W_\
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M117R9]:%?)?QN_Y*AK?UA_\ 1*5]:5\E_&[_ )*AK?UA_P#1*5\5Q9_N,?\
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MZTM-7[H[TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEY92V"7"[37M?QJU9['0=*L;73=+U/5-7U2'3[%=9B$EK#*RLQE=>IVQI(0
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MD-+2-TH _-3]KS_DXCQ;];7_ -)(:\=KV+]KS_DXCQ;];7_TDAKQVOV?+O\
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MX/\ WBGZK\SBQO\ NU3T?Y'VBOW5IU-7[JTZOZ$CLC\!"D;I2TC=*8'Y5_\
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M'X/_ &<=+\*ZU9ZA=^)/$/B5;&[EU"UL]6N8V@CNI"2TY2.--\F6;YFS@MD
M5A>(/AC\1_#>MI-X2\4V"Z-<>(9=8GCO[1T>V$L<F]9'6=1-"&8?)@'E?[M;
M7@WQ%XS\3:L@M/B%X#U^TM95-[!I%C)),(]PW+E;IMC$9P2IY(X]0#V!?NBG
M4B_=&>M+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 ,8\]:\IUC]I/PUH>KWVFW%CJSW%G/);R-'#$5+(Q4
MD9DZ9%>L5\+?$7_DH/B?_L*77_HUJ8F?0O\ PU1X4_Z!^L_]^8O_ ([1_P -
M4>%/^@?K/_?F+_X[7RS13L(^IO\ AJCPI_T#]9_[\Q?_ !VC_AJCPI_T#M9_
M[\Q?_':^6:*+ ?4W_#4_A3_H':Q_WYB_^.T?\-3^%/\ H':Q_P!^8O\ X[7R
MS118#ZF_X:G\*?\ 0.UC_OS%_P#':/\ AJ;PG_T#M8_[\Q?_ !VOEFBBP'U-
M_P -3^%/^@=K'_?F+_X[1_PU-X3_ .@=K'_?B+_X[7RS118#ZF_X:F\)_P#0
M.UC_ +\Q?_':/^&I_"G_ $#M9_[\Q?\ QVOEFBBP'U-_PU1X4_Z!^L_]^8O_
M ([1_P -4>%/^@?K/_?F+_X[7RS118#ZF_X:H\*?] _6?^_,7_QVMCPC\?O#
M_C;Q%::-8V>I175SOV-<1QJ@VHSG)$A/13VKY!KT/]G_ /Y*YH/_ &\?^D\E
M(:/L<=*6DI:0PI#2TC=* /S4_:\_Y.(\6_6U_P#22&O':]B_:\_Y.(\6_6U_
M])(:\=K]GR[_ '.E_A7Y'XOF'^]U?\3_ #"BBBO1//"BBB@ HHHH **** "B
MBB@ HHHH **** ZGL7[(?_)Q'A+ZW7_I)-7Z65^:?[(?_)Q'A+ZW7_I)-7Z6
M5^9\2_[Y'_"OS9^E\-?[I+_$_P D%%%%?)GUH5\E_&[_ )*AK?UA_P#1*5]:
M5\E_&[_DJ&M_6'_T2E?%<6?[C'_$OR9]GPK_ +]+_"_S1PM%%%?DA^L!1110
M 4444 %%%% !1110 4444 %%%% !6WX'_P"1TT#_ +"%O_Z-6L2MOP/_ ,CI
MH'_80M__ $:M=>#_ -XI^J_,XL;_ +M4]'^1]HK]U:=35^ZM.K^A([(_ 0I&
MZ4M(W2F!^5?_  50_P"3AM!_[%BW_P#2J[KXVK[)_P""J'_)PV@_]BQ;_P#I
M5=U\;5^CY9_NE,_,<S_WNH%%%%>H>4%%%% !1110 4444 %%%% !1110 444
M4AGH7[.W_)P'PR_[&C3/_2J.OW;7[HK\)/V=O^3@/AE_V-&F?^E4=?NVOW17
MQ>>_QH>A]QD'\*?J+1117S)]4%%%% !1110 4444 %%%% !1110 4444 %%%
M% !24M% 'D_[1\"S>"=/>_M;F]\,0ZK;3:];VJL[O8J6+95?F9 _ELR@9VJU
M>=WVJ_"[Q!XN\$)\++729/%4.IV\_P!H\.V8A%MIX)%S]H9% "&,LH5_XF7
MKZ8=@A+,=JCDDFN/T'XK>!=>UY](T?Q1HE[JS,Q-I:7D3RNP!+  '+$#.<9Q
M@YH [-?NBEIL?W!Z4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH 2OA;XB?\E \3_\ 84NO_1K5]TU\+?$3
M_DH'B?\ ["EU_P"C6IH3.>HHHJB0HHHH **** "BBB@ HHHH **** "BBB@
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M2 YI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO^_2_P +_-'"T445^2'ZP%%%% !1110 4444 %%%% !1110 4444 %;?@?\
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MUA_]$I7Q7%G^XQ_Q+\F?9\*_[]+_  O\T<+1117Y(?K 4444 %%%% !1110
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M0_\ ?YO_ (BCS;O_ )X0_P#?YO\ XBK5% %7S;O_ )X0_P#?YO\ XBCS;O\
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MDV[_ .ADA_\  0__ !=?1]% 'SA_PR;=_P#0R0_^ A_^+H_X9-N_^ADA_P#
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M2BK(K>;=_P#/"'_O\W_Q%'FW?_/"'_O\W_Q%6J*Y3K*OFW?_ #PA_P"_S?\
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MS+=_]!V'_P !3_\ %T?\,RW?_0=A_P# 4_\ Q=?0.*,4?ZO9=_S[#_6#,?\
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MVKB_YS/^R<'_ "'YT?\ #I6[_P"BGP_^"(__ "11_P .E;O_ **?#_X(C_\
M)%?HOMHVT?VKB_YP_LG!_P A^='_  Z5N_\ HI\/_@B/_P D4?\ #I6[_P"B
MGP_^"(__ "17Z+[:-M']JXO^</[)P?\ (?G1_P .E;O_ **?#_X(C_\ )%'_
M  Z5N_\ HI\/_@B/_P D5^B^VC;1_:N+_G#^R<'_ "'YT?\ #I6[_P"BGP_^
M"(__ "11_P .E;O_ **?#_X(C_\ )%?HOMHVT?VKB_YP_LG!_P A^='_  Z5
MN_\ HI\/_@B/_P D4?\ #I6[_P"BGP_^"(__ "17Z+[:-M']JXO^</[)P?\
M(?G1_P .E;O_ **?#_X(C_\ )%'_  Z5O/\ HIT/_@B;_P"2*_1?;2T?VKB_
MYP_LG!_R'P/\._\ @F'=> /B%X8\3'XB0WW]BZI:ZE]E_L9H_.\F59-F_P \
M[<[<;L'&>A[_ '<LEUM&(83_ -MF_P#B*L-SVS3JXJ^)J8F2E4=VCMP^%IX5
M.--63*WFW?\ SPA_[_-_\11YMW_SPA_[_-_\15JBN8ZRKYMW_P \(?\ O\W_
M ,11YMW_ ,\(?^_S?_$5:HH J^;=_P#/"'_O\W_Q%'FW?_/"'_O\W_Q%6J*
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M#'P/\:=.T_XD:?XVF\'2:!<6'CC^S+1!&;RZ5)[2Y2(>0VU!D%%5@LG)S@@
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M9_UGQ5X__P"$DTSXBV>L)?Z/)HUI;);-:(7BEBEB57+G8=P)*D,<(N!CT/\
MX*.?#6U\<_LR^,-5O]7UBWM_#^DW5XFE65VT%I>S_(8GN549E$3+N12=NXY(
M.!@ ^@/$?Q,\(^$/['&O>*M$T,ZPXBTW^T=2AM_MK'&%AWL/,/S)PN3\P]:Z
M=?NCG-?G!\>?^$>_X3GXF_\ ";C2Q#_PHJ+_ (1[^T]I DW2[O(W_P#+7SO)
M^[\WW,5[K\8/B1XZ^%/["OASQ)I>IRZ3XWM],T"&:ZOK=+F1)I9;6*<2QR A
MB0[ALX.3P0>: /JNDK\]O''QM^-?PWO_ (MRO\3_ .V[/X<>(]"@2WGT"QB.
MJ07Y@,L$[HGR(@D(0QA7Y^9SQAJ_M,_$G4=1T?Q&/BM8Z<=0^+,?@R;P -+L
M]UM8I>")E61E,YE:,!W=CC$ORA"%) /T+I:1>5%+0 4444 %%%% &/XD\7:)
MX/@MKC7M:T_1+:YN([."74;J.W66>0XCB0N0&=CD!1R>U+<>*-'M->M="FU>
MQBUN[@>ZM]->Y1;F>%" \B1D[F52R@L!@9&3S7F?[77PQG^+W[/?C/P_8#&L
MI9_VAI<BG#QWMNPG@*GL2\8&?<U\H_"3X_:Y\2=!^-/[3FG:.M]=>&_!MKH&
MAVEQ&^P7,5N+O4"R@*2@N'3=C&Y8N".M 'Z(+TI:_/\ C_:/^)'A/2_%%I;_
M !4T_P")QN/A?>>,X=8LM,LXGT"^C13&N(1Y;0OO)59E9LQ\DC.=*W_:$^+G
MPSL]>U#5?$T?Q#>X^$R^/+.PN-'AM5LKT.%*)]G"L\&) S!V9OW?#+DT ?=U
M%?G^G[2'Q(\)Z9XHLH?BKI_Q->?X87GC*/6+'2[.-] OHT7RTQ"OEM"Y<E5F
M5GRG.1FL^/\ :H^)'AW17D3XGZ9X[N=?^%VH>+T^PZ7:(WAR_MXD=,>6"&B)
M=DVS;FWQ=0#B@#]$**^"/%_Q8^+'A/X>>"Y+[XT7ESXI\4:+=>*Q9:)X5TT3
MPVZVD3K CW&+=+:)Y"7DE)E<$!2,&N?UK]I[Q[\1+7X+:?X8^,T?@WQMXNT6
MTU77K22QTLZ5HUF%S-=R-<0M(992<1P"3!.,[5P2 ?HO17PA\<OVH?&G@[XS
MRMX8\<2ZIH6F>)]%T"ZT"VT:T73D6YV>:MQ=2D7$D["3>IMLHH4!@<.:9X=^
M.'Q<F\06GB:X^(*W6ACXP3^!6\,OHMHL,FGF9T#-,J"7S$!7:RD?=&\-DF@#
M[;\3>*M&\%Z/<:OX@U>QT+2;8 SWVI7*6\$0) !:1R%7)(')K&U/XN>!M%\(
MV/BO4?&OAZQ\+WI5;76[G58([*X+ [1'.SA&)P<8/.#Z5YI^V+XG^&W@7X;6
M'BGXD:*OB4:+JD-WH&AO,P^VZKM=+=!&#M<_.WWU95&6QE17R-\._ NC^ _B
M/\%HOB)JGA._\-ZK'XNUBZM(;B&?1=,U"Y6*0V439\O]W"QP/5I"O!!H _2^
MUN(KRWBG@D2:&10Z21L&5E(R"".HJ6OC3X#^+/$G@3_@F'!XCL[R>RUW2?"6
MI7NF75RBR&)8S.UJP60%2HC$14$$;<#!%>:ZQ\9/CKI]OXEC'Q<)>S^%MM\1
M8Y1X;L RW!WAK1,H1Y#;3DL'?@8=>X!^BM)@=:_-;X@?M=_$_5O ?Q7\:V'Q
M1TWX?WOA2UT>/3O"/]EVDPNVN[2&9IR\ZM*S.TS^6%^0"'D-DD?I+:R-):Q.
MWWF4$_7% $E+110 4444 )36)7-/IK&@!NXG/;_/I3U.5'.:_.W]HCQQ?_LQ
M_$[XY>%M%1HKOXMZ3::AX72/"YU>:1=/N50]W_>I.>^%)QUKU+5/B)XZ^$^K
M+\'/A/IOA2"S^&_@>TU74;KQ4;AOMB ,BP0"%EV$K"S-,^X;GQL[D ^P:*^)
M=6_;&^)WC2;S_A]I/A72K ?#*#X@NGB>"ZN)5=FE#VP,,L88'8H#X&,$X;.U
M=G5/VK?B5XWU.*R^'FC>$].ETWP)9>-M8/BB6XE6;[2A=;2W,+)L 5&S,^1D
M@;!U(!]@T5\81_M<_$_XF^*-+L/AUI'A+2K6]^'=KX[;_A*A<R21L\DBO;9B
M= P)" 28&T!F(;(42^!OVMOB5\:_'G@_3/ ^D^$](T;4?!MAXPU2;Q";EY+9
M'N9(+JWB:-U5FRHV.P &QBP.X!0#[*HKXJ^&O[87CWQI\0I_"]]?^ X8M2\.
M7^N:=KEA97[:;IC6\RKMFN99$COH_*<,9+=HU!![$&KGPZ_:>^+.O? OQO\
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MKY2^ <\NDWWP3EM,BVUG1M<L O\ #)IL-RLVGN,=4CB*K'V"7!QUY^KE^Z*
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M-J-T<X!Z<Y48 /?M>^$W@?Q9::-;:YX-\/ZS;Z+@:9#J&EP3I8X"@>0'0B/
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ME"O&TC&.*R)?ACX.G\_S/">AR>?I@T67=IT)\S3QTM&^7F#D_NC\O/2NFI*
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M-\)?B!9:#:Z[X0CNHM"TU-&LFBO[J"06* ;;:5XY5:>(8!V2EQDDXRQKV.C
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M86,"Z5H=[=7\4$5JD@$DEW= 37$TC3.69EX"J 6Q7T6IRM+10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5Q'BKX7Z=XH\966NW26\T7]FW.BZEI]W;B>#4;.8JWE2*Q
MV_*Z C<&&'D7'SY';TE %./1=/CU-M26QMEU)H%MFO%A43&%6++&7QG:&9B%
MS@$D]Z?JFEV6MZ=<Z?J-I!?V%U&T,]K=1+)%+&PPR.K AE(X(/!JU10!S6D?
M#/P?X?\ #47AW2_"FB:;X?BF6YCTFSTZ&*T259!*L@B50H82*KAL9#*#U&:F
M\9> /"_Q%TM=,\5^&](\3Z:L@E6SUFQBNX0XSA@DBD9&3SCO6_10!R4/@.&/
MXA+XFDG5DL]*_LG3;&.(1QV<;R+)<,"#\QD\JV&,#:(1C[QKK%Z<T4M !111
M0 4444 %%%% !1110 4444 %%%% !36Y^O\ *G4E '#^'?A;IGA_Q/KFJA+>
M\AOM3&M6EO<6ZLVGWK6_D3RPN3\OF)UP <O+DD/@=9IFCV&CQS)865M9)/.]
MS*MM$L8DE=MSR-@#+,>2QY)ZU<Q[4M &!XR\ >%_B-I::;XL\-Z1XGTY)!*M
MGK-C%=PJXR P216 (R><9YJ#Q#\,/!OBY](?7?"6AZT^CNLFFMJ&FPSFR88P
MT.]3Y9&U<%<=!Z5TU% '.ZA\/_"^J>*[+Q/=^&](N_$UC&8;769K")[RW0Y^
M5)BN]1R> 0.35?P-X-3P@-;GEO/[0U+6M3FU.]N_+V;V8+'$@7)PL<,4,0YY
M$>>I-=3@'J,T4 "\ 4M%% !1110 4444 %%%% !1110 4444 %%%% !7$3?"
M[3)_'^I^(9H[>[M=4MK-;O3+JV66-KJTE,EM=*6)"R)G&=N?DB((,8SV])0!
M4L]'L+&\O+RVL;>WO+YE>ZN(H562X95"*9& RQ"@*,YP !5?Q-X5T7QIHMQH
M_B'1[#7=(N0!/I^IVR7%O* <@-&X*MR >1VK3I: ."UOX _##Q-I^E6.L?#?
MPCJMEI,'V;3K:^T*UFCLHCR8X5:,B->!\JX'%;NB^ _#'A>'2XM'\.Z3I$.D
MPR6VGQV%C% MG%(RM)'"%4"-79$+*N 2JD]!7044 <KX?\%C1_&'B3Q)=7?V
M[4M7%O I$7EBVM($;RH -QSB26XD+=S,1T45U*]**6@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH Y'XK>!5^)7@'6/#WVDV4]U$KVMVHR;:ZC=9()AQ
MU25(W [[:IQ?"O0=4T75H-8TB$W6OW=KJVM16UW.8YKZ%(%5T8E6"J;6$  *
M"$R5RS9[FC ]* &A>%YR17G9_9]\"?\ "52>(?[&F%^T\UVL(U*Z^R17,JLL
MMS%:B7R8KA@[YG1!(2['=EB3Z-10!Y)X-_99^'7@6U6STG3]8.E"RDTXZ1J'
MB74[_3S;R(8WA:TGN7A*%21M*8';%5]:_9UT.Q\&^(]&\*Q2VU[XDMX]*U#5
M-7U6[O[I-.)*RQ02SO*Z!8WE\N-2L:N^<#FO8\#THH CM;>*SMHH((UBAB4(
MD:# 50,  >E2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% #&.&[TF
M[_ZV?\_2N3^)G@-_B!HL%C'J]UHSPW$=R)[5Y 24.Y00KKD;PAYY !V[6(<>
M=Z;X)CUCXK>++U_ _A?7X[?6+5#JVLW&;ZV5;&T/[L&VD+8!W#,BDG.<=2 >
MYBFLWS #@YKR63XM:K%_:5I*NGQ:AH<-Y+J[>5*Z)M?;9[55BP\Y6$@!SD(P
M'J,73?&VOZ]XRTC3]?MH(K_1]9;;)!;K#YBOIERXS$MS/M/?F0'!&57J0#W9
M?NBFLWS #@YKRK_A;UXN@Z'?2-8))?\ A:37)=J2.JS#R H55)8H3*PVX+'
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M6O>*O$NK?!GXB27\=KIFLZ99W<:S1>6QXMM_S0QW$ODR88@*96/W6Z': #V
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 E<UJGPQ\':WK)U?4?">AW^K%E8W]
MUIL,D^5 "GS&4MD #'/&!7344 4)-!TR9K]I-.M)&U!!%>%H%)N4 *A9./G
M!(P<\$U4TKP3X=T)XWTW0-+T]XV#(UK9QQ%2 P!&U1@XD<?1V]36P3UIU '/
M:?\ #OPKI/VPV/AG1[(WBR)<_9["*/SU?&\/A?F#8&0>N!FHF^%_@V2Q>R;P
MEH;63D%K<Z;"8S@,!E=N. S#_@1]:Z:B@#-L_#>D:=;VT%II5E:PVL#6L$<-
MNB+%"V-T:@#Y4.U<J.#M'I3/#_A31/"-F]IH>CZ?HMK(_F/!I]JD",W]XJ@
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M,<YK5HH QY/!N@3:[!K<FAZ:^LP((HM1:TC-Q&@SA5DQN Y/ /<UH6VGVMG
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MV]MI6A:;IEM;RM/##9V<<212,I5G4*  Q4D$CD@D5LT4 9Z>']+C,!33;-3
MLB1;8$'EK(<R!>. QZXZ]ZJ:3X(\.>']/^P:7H&EZ;8^<MS]FM+*.*+S5(*R
M;54#<"JD-U&!Z5MT4 95_P"%-$U566]T?3[Q6N5O"MQ:HX,Z@!9>1]\!5 ;J
M !SQ6K110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
<0 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img45497886_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45497886_13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (1!(P# 2(  A$! Q$!_\0
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M;2T4 )MHP*6B@!*,4M% "8HVBEHH 2BEHH 2BEHH 2BEHH 3:*6BB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOR_6@#[)7I2T@Z4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZTW4GNX?$9M9%BUJ*8[UF,Q&UY5R%8;B0,#L:]]7IZT +1110 4444 %%%%
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M?B6Y-A=6TEC;PI!(;>299K9HE5M@,94K(9,A@=P(Y /::*^<O"_C#Q_%X/\
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M>I5+$):7V77[R_:T&];:-]/N9F:3XIUO3]9USP_J\\=U=VEH]U!>QQA2P"\
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M$:>(;:=[:=?/43J8=)-6OKT\M"GX+U[5F\6:SH&JWB:DUFJR1W2Q"(L"!P5
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MCV\IA"==J:Z,^D**7N:2O,WU/2VT"BBBF 4444 %%%% !1110 4444 %%%%
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M]'Z4_JU.]TOQ%]9JVLW^!Q:_#@_\*_;PS_:.2S9-UY'K)OQLW?AR:ZS3[/\
ML_3K:UW^88(EBWXQG  Z=NE6/2BM(T8T]8KR^XSE6E4TD_/[SR'1]$OM6^('
MBXZ=K,VCW$4H_>1QB165LY#(2.>.#GC-=/#\*=/C\,RZ8]S-)<23?:VOB0)/
M.&<-UX'48SWKM^O':ER<YSS7-3PM.-^;6YT5,54E;ETL<GI'A#5;/5(+S4_$
MU[J0@&(X(XQ;QMZ%PI._\:L^"_"'_"'V]_"+O[4+FY:XXCV;<X&/O'/2NB_3
MZ48'I[5M&A3@^9*]O,QEB*E1<K>GH<+:?"FT70=0TR\NVN%NKLW4<T<?EM$^
M. .3GH?3K4FG_#B?^V+&_P!;UR?6GL #;1M$(E1@<AB 22??CI7;^M)^M3]5
MI)_#L5]:JM?%N<3=_#F>/6KR]T?7;C1DOCFZMXXU?<?5#GY3R><$C)QBM7P1
MX/'@O29[%;IKQ6G:97,>T@$  =3Z5T7;'4>AZ4F!QQFG"A",N>*L*=>I*/+)
MW%[GZTE%%=!SA1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7;_ O3/MGQBT.Y_L7^T#:6]T_P!N^U>5]@S&%W[/^6N[/EXY
MQOW=JXBNW^!>FB\^,6AW/]B_VB;6WNG^W?:O*^P;D"^9L_Y:[L^7CG&_=VKD
MQ?\ N\_1_P!=/Z[G5A?X\/5'UZO3I2TB]!Q2U^?GZ"+1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %(>U+2'M28'G7QB_P"9(_[&>R_]GKT6O.OC%_S)'_8SV7_L
M]>BU;V1E'XI"T445)J%%%% !1110 5%)ELKGK4M-90V00".] GJK'S1_PP/X
M"Z_VSXC_ / F#_XQ1_PP-X"_Z#/B/_P)M_\ XQ7TQQ17I_VGC/\ GZSR_P"R
M\$]731\T?\,"^ O^@SXC_P# FW_^,T?\,"^ O^@SXC_\";?_ .,U]+<T<T?V
MIC?^?K^\/[*P7_/M'S3_ ,,"^ O^@SXC_P# FW_^,T?\,"^ O^@SXC_\";?_
M .,U]+<T<T?VIC?^?K^\/[*P7_/M'S3_ ,,"^ O^@SXC_P# FW_^,T?\,"^
MO^@SXC_\";?_ .,U]+<T<T?VGC?^?K^\/[*P7_/M'S3_ ,,"^ O^@SXC_P#
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M_M3&_P#/U_>']E8+_GVCYI_X8%\!?]!GQ'_X$V__ ,9H_P"&!? 7_09\1_\
M@3;_ /QFOI;FCFC^U,;_ ,_7]X?V5@O^?:/FG_A@7P%_T&?$?_@3;_\ QFO
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MW\CS=_./N[?]JC5/V43<?VS]A\875G]H\G^SO,LHY?L>W'F[^1YN_G'W=O\
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M[,P/_/F/W([K_A=WC;_H-M_X#0__ !%'_"[O&W_0;;_P&A_^(KA:*/[3QO\
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MQ:***H HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+D*TB;EYW*-N<\KV^T_#^H'5M!TV^,]M=&YMHYO/LF+02;E!W1D]4.<@^A%
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M;.&S)6XN+R0I'&PZJ2!UX_#OU%/U[X;ZOX?N-.2;[/-;Z@ZQV]Y;R%X&9B,
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M\%>([?QI/+X7LIYK?Q9:K8:BT,+.D3*Z#S'('R@KQD\??KNPM.%9N$W;^O\
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M%L?EG46BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M -\H_P"*/YH^3Z***_ .A^]A1UZ\]O\ /^>Y]:** \@ZT444"%Z]>>W/^?\
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M]_K$_P"0;_Q\_?7[GO36Z)E\+/I*/_5CZ"GTR/\ U8^@I]?K*V/RSJ+1113
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MA"/V5KZO5GH8:@Z3G.2^)Z>B22_S$HHHKC.T**** "BBB@ KCO$'Q&O/"GQ
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M"PX)<DD<&LCP?\$O!?P_U9=2T/1C;WJ1&"&2>[GN?LT9Y*0B5V$*GIMC"C
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M%&*?^J>"_FE]Z_R'_K5COY8_<_\ ,^2_^%(^-O\ H"-_X$P__%T?\*1\;?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5C_:/G>9]JL"/L/E]//VDXW\;=N[.1G;7S910\IPWG]__ !9KB?+[CZ3TO\
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MEJ/]B;[36;+^TO.\S[38$?8?+Z>?@G&_C;MW=1G;1I?[4GA+4O[%WVNM6/\
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MD,5N%LS)N/)W;,YYZ\UY:OB_Q?'X'@\3-K$#QQS"(VIM4_>C>1EF &#GCC'
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MTIU?F_4_28[!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\)=]*^R,D3NJEWA2<M\SA0?X<<$9'. "TO[37BU;<'[)H_\ :GD>1_:YLO\
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MQ_Y-_7](X+4_V8_%J_VW_9VLZ-)L\G^R_M,4J>9G_7>?C.S'\.W=GOBDU/\
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M110 >M'K110 >M'K110 >M'K110 >M'K110 >M'K110 >M'K110 >M'K110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>]'KG@]Z]4M?@[HUJ-/S/?3_ &7S-_F7!_TC=G[^ /N]MN.G.:6T^#NBVOV
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?/7[67[1>M?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=N3UKMJ3%+0 4444 %%-+'<:5<XYY_"@!:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!C,0V/:DW
M'USTZ5\;^,O OA[XD_MR:YX>\47<RZ1=>'8&.FQWLEL-0==FV)BA4L "S[0?
MX,]C7*:??2Z;\#_VC_!^GW\VJ>#?#MPL.CSSS><L:NY\R%7[JNU> >K$]SD
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M6Z*%)WF"EV+O\SLS'+,QY/?% '5TM)2T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YI\9_C5;
M?"6'1K2WTJX\2>)M<N1::5HEFZH]P_&69SQ&@R,L0<;AVR1SW@O]HRZUJ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%_[Z!H]E(/KU/LS[&V]J-M?''_"_/'O]F_9O^$@/G;MWVT6=OYN/[N/+V?\
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M6OTP@?\ -J/92#Z]3[,^P\^]+SZU\<V?Q^\>6\EPTFN_:Q("%66T@ B/JNU
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M$:VQ&3@>H(('/H/6L.9GH>QINR2UT/"]6\-Z9HZZ[!-KFW5-/NVMH+/[(_\
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M>(-5\":/X*@\*Z?'/;ZI$DMW<+;B1KN9MI*L1W.3Z=>",8HYK-A[&$J::?\
M5SYXY'2CC:2>5ZGTZ\?UKZBBL]-\&^,/']QI]M;ND6E0WKV90&-90';&W/ ^
M56_X$:^>/%WC+4?'&JIJ&J/&]PL8B7RDVC:"2./Q/YU<9<QA4I*FM[LQ.O!Y
M]:^G_P!ENVMX? .I/#-YTDVJ2/,G_/)_)A4+_P!\JK?\"KY@KZ>_9<^R?\(#
MJ7V7?YW]J2?:LXQYGDPXQ[;/+_6IJ;&V#_B'M5%%%<A]$%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;QE2-S@_)U'."!D<\UN?%CPJOBWXT3V+ZA;:3"+..66XN6 "J .@R-S>V?\
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MNGW.H16%O%J*"2]F0LJHC)D[5Y).,!1W(YYJ7)&BP\GH_P"K'B?/?US1TX'
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MBOSVD^Q^6W]H9^P8)N=OWO+Q\V/PS7Z$K]T5A6Z'L9?]KY"T445SGL!1110
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MIM/_ -)2W%V\/[U8&&1(1R%([YQC\:_0=?NBL*W0]G+]I?(6BBBN<]<****
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M'(WEQ0DXRY*@CGC@'J.M6C\&+^UNM(EFU;2+K2+ZY^SG4;2\S"C8.5+%?O$
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M:(B7'=MT9//^SBCVD0^HU3Y=HKZDE_9=\*2:BERM]JT4*XS9K-&8F^I,9?\
M)J(OV7?"D>HO<M?:M)"W2S::/RE^A$8?\VH]I$/J-4^6Z*^HK3]EOPK;R3L^
MHZO="0$*LTT0$7NNV($D?[6:2W_99\*PV<\+ZGK-Q))]VXDFA#Q?[H6(+_WT
M#1[2(?4:I\O45]0?\,L^%O[-^S?VGK/G;L_;/.A\W'ICRMG_ ([2W'[+/A::
MS@A34M9@DC^]<1S0EY?]X-$5'X 4>TB'U&J?+U%?45W^RWX5N)+=H]0UBU$8
M =8IHB)<=VW1D\_[.*=+^R[X4DU%+E;[5HH5QFS6:,Q-]28R_P"34>TB'U&J
M?+=%?4D7[+WA./47N6OM6EA;I9M-'Y2_0B,/^;4VU_9;\*V\D[/J.L70D!"K
M--$!%[KMB!)'^UFCVD0^HU3Y=HKZAM_V6?"L-G/"^IZS<22?=N))H0\7^[MB
M"_\ ?0-)_P ,L^%O[-^S?VGK/G;L_;/.A\W'ICRMG_CM'M(C^HU=CY?HKZAN
M/V6?"TUG!"FI:S!)']ZXCFA+R_[P:(J/P I;O]EOPK<26[1ZAK%J(P ZQ31$
M2X[MNC)Y_P!G%'M(B^HU3Y=HKZDE_9=\*2:BERM]JT4*XS9K-&8F^I,9?\FH
MB_9=\*1ZB]RU]JTD+=+-IH_*7Z$1A_S:CVD0^HU3Y;HKZBM/V6_"MO).SZCJ
M]T) 0JS31 1>Z[8@21_M9I+?]EGPK#9SPOJ>LW$DGW;B2:$/%_NA8@O_ 'T#
M1[2(?4:I\O45]0?\,L^%O[-^S?VGK/G;L_;/.A\W'ICRMG_CM+<?LL^%IK."
M%-2UF"2/[UQ'-"7E_P!X-$5'X 4>TB'U&J?+U%?45W^RWX5N)+=H]0UBU$8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "F-]ZGTT_2@#X7^(%Q;W7CWQ/);0?9XAJMVC+G.769U=L_[3!F_&L"O
MN@?#_P ,+JTNIKX=TI=2F):2\6RB$SD]27VY)/UI+3X<^%+"2X>V\,Z/;O<
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M<YXX[U]RV_PW\)6EG/:0>%]&AM)_];!'I\2I)_O*%P?QI/\ A6OA'^S?[/\
M^$6T7[!G/V7^SXO*SZ[-N/TI^U78G^SY6MS'PWC."!GG(XR/7VHZXS\P'J,_
MY_6ON2X^&WA*\M(;6X\+Z-/;0?ZJ&33XF2/_ '5*X'X4MW\.?"E_);O<^&='
MN7MP!"TUA$QC Z!25X_"E[7R#^SY?S'PT>X.3CJ#_P#7H/4GOZ]/UK[GE^'O
MA:?4$OY/#>D27T8PETUC$95^C;<BB+X>^%K?4GU"+PWI,=^W#726,0E/U;;G
M]:/:^0O[/?\ ,?"XZ8'3/0=*5?O9!^:ON6U^'7A2PDN'MO#&D6[W *S-%81*
M9 >H8A>0?>DM_AOX2M+*>T@\+Z-#:3_ZV"/3XE23_>4+@_C3]JNP_P"SY?S'
MPWCY0,'TZ48R,C^+OR<_RK[D_P"%:^$?[-_L_P#X1;1?L&<_9?[/B\K/KLVX
M_2BX^&WA*\M(;6X\+Z-/;0?ZJ&33XF2/_=4K@?A1[5=@_L^7\Q\-K\N".@Y^
MGTH^Z0.FWMZ?X5]S7?PY\)W\EN]SX8T>Y>W $+36$3&,#H%)7C\*=+\/?"T^
MH)?R>&])DOHQA+IK&(RK]&VY%+VJ[!_9\OYCX7QC/MZ_XTE?=,/P]\+6^I-J
M$7AO2([]N&NDL8A*?JVW/ZTVU^'/A2PDN'MO#.CV[W *S-%81*9 >H8A>0?>
MG[5=@_L^7\Q\,>W?_/:E_/GCI7W+;_#?PE:6<]I!X7T:&TG_ -;!'I\2I)_O
M*%P?QI/^%:^$?[-_L_\ X1;1?L&<_9?[/B\K/KLVX_2CVJ[!_9\OYCX;ZCCO
MT[C^E'OVZFON2X^&WA*\M(;6X\+Z-/;0?ZJ&33XF2/\ W5*X'X4MW\.?"E_)
M;O<^&='N7MP!"TUA$QC Z!25X_"E[7R#^SY?S'PUT./3K7U!^RVMI_P@6I_9
M2WG?VK(+K>./-\F'&/;9Y?XYKT>7X>^%I]02_D\-Z1)?1C"736,1E7Z-MR*T
MK#0=-TI95LK"ULUFD\V06\*H'<@ L<#DX &3Z"HE4YE8Z*&$=*7,W<OT445D
M>D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !28I:* $VBC:/2EHH 2C%+10 F*,#TI:*
M $P*,#TI:* $VCTHI:* $Q1BEHH 3 ]*,"EHH 3 ]*-H]*6B@!*,4M% "8HP
M/2EHH 3 HP/2EHH 3:/2BEHH 3%&*6B@!,#THP*6B@!,#THVCTI:* $HQ2T4
M )BC:.N*6B@!-H]**6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6
MB@!*,4M% ";11M%+10 FT48I:* $HQ2T4 )M%&*6B@!-HHVBEHH 3:**6B@!
M-HHVBEHH 3:*-HI:* $VBC%+10 E&*6B@!-HHQ2T4 )M%&T4M% ";11M%+10
M FT4;12T4 )M%&T4M% ";11BEHH 2C%+10 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img45497886_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45497886_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &Q R4# 2(  A$! Q$!_\0
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M%//?Z5'$@>WC!_NCO0!+14?D1^A_[Z-'D1^A_,T 245'Y$?H?S-'D1^A_,T
M245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T
M245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T
M245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T
M245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T
M245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T
M245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T
M245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T
M245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T 245'Y$?H?S-'D1^A_,T
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M1_[HIY[_ $ID'^HC_P!T4 24444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4@I:2@ S0.E07ERMG:2W#*66-2Q [XKG!XYM?^?.?_OI?
M\:YZV+HT':I*QK2P]2KK!7.JHKE?^$YM?^?.?\U_QH_X3FU_Y\I_S7_&L/[3
MPG\Z-?J6(_E.JHKE?^$YM?\ GSG_ #7_ !H_X3FU_P"?.?\ -?\ &C^T\)_.
M@^I8C^4ZJBN5_P"$YM?^?*?_ +Z7_&C_ (3FU_Y\I_\ OI?\:/[3PG\Z#ZCB
M/Y#JJ*Y7_A.;7_GRG_[Z7_&C_A.;7_GRG_[Z7_&C^T\)_.@^HXC^0ZJLI_OM
M]365_P )S:_\^<_YK_C50^+;8L3]EF )]16-7,<*[6F:4\'76\3H*6N=_P"$
MMMO^?6;\Q2_\);;?\^LWYBL?K^'_ )C;ZK6_E.AI>]<[_P )=;?\^LWYBE_X
M2ZV_Y]9OS%/Z_A_YA?5*W\IT0I>]<Y_PEUM_SZS?F*/^$OMO^?2;\Q1]?PW\
MP?5*W\IT=**YS_A+[;_GTF_,4?\ "7VW_/I-^8I_VAAOYT+ZI6_E.CHKG?\
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M3ZG/KFER<YR<^N:V[[1K=([2[LY7DM+B14.[[RY-:,^@Z-;ZI%8O/<^9*/D
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M/AD%%%%>!8]@****+ & 3R!28'H*6BGJ F!Z4N!Z444.X"8'H*7 ]*** 0$
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EI*
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M)/\ GK_XZ*-DG_/7_P =%244 1[)/^>O_CHHV2?\]?\ QT5)10!'LD_YZ_\
MCHHV2?\ /7_QT5)10!'LD_YZ_P#CHHV2?\]?_'14E% $>R3_ )Z_^.BC9)_S
MU_\ '14E% $>R3_GK_XZ*-DG_/7_ ,=%244 1[)/^>O_ (Z*-DG_ #U_\=%2
M44 1[)/^>O\ XZ*-DG_/7_QT5)10!'LD_P">O_CHHV2?\]?_ !T5)10!'LD_
MYZ_^.BC9)_SU_P#'14E% $>R3_GK_P".BC9)_P ]?_'14E% $>R3_GK_ ..B
MC9)_SU_\=%244 1[)/\ GK_XZ*-DG_/7_P =%244 1[)/^>O_CHHV2?\]?\
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MSN3DVV:I):(B:W#L&?8Q'0E!Q4FR3_GJ?^^13J6B[>X#-LF?]:?^^12[)/\
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MZ-]CLFT]PA$LDB>7]H&!P/\ GIZY]_>@#LGN(HY%C>6-7;[JLP!/T%+)/'"
M99$C!. 68#/YURMC86VL:;J=[=Q+)<O/,B2L/FB",57:>J],\8JI(9M3TW2M
M0O+*34(I+%E,:1[RLQ'#8[>F>V: .W+JN-S 9Z9/6ES7)VUQ!:I:#5[I$AT]
M0C/,W#3D' SW*KG\ZZJ.1)HTDC8.C ,K Y!'M0 X]_I3(/\ 41_[HIY[_2F0
M_P"H3_=% $E%)D>M+D>M !11D>M&1ZT %%&1ZT9'K0 4AI<CUI#CU% 'G'Q6
M\-?;]+76+=,SVW$H ^]&?\#C]:L_"[Q+_:NB'3KA\W5F,*2>60]#^'^%=U/%
M'/ \,H#1R*593W!ZUX'?+>_#SQK(]MRHR8\]'C;U_'^5==+][#V?5;&$_<ES
M&Q\4];?5->AT2T)9+? 8+_%(W;\!C]:].\*Z&GA_P]:V( \Q5W2L.[GD_K7E
MOPUT=]=\3S:U>#?' YDR>C2$Y'Y?UKVSCU%+$244J2Z!25VYOJ4M3TBPUBU^
MS:A:QW$7HPZ?C2V&EV.E0"&QM8H(QV0<_GUJYD>M''J*YKNUC:RO<0@%2#@@
M]<UYOXS^&D.H"74-%58;K!9X!PLA]O0UZ3^(I.,=:JG4E!W0I14EJ>2_#/Q9
M>IJG_"/:C(73!$)D^\K#^'/IC->M]Z\+\=6<GACQY'J=L-J2N+E,="<_,*]J
MT^]CU#3[>\B8%)D# _6ML3%.U1;,SI-ZQ9@>/==_L'PQ/+&^VYG_ '47J">_
MX5YU\*]?EMO$;V%Q.[1W:';O8G#CG]>E-^(VJ2>(?%\.DVA,D=NPB51T+GJ?
MZ?A5#Q3HC^"?$EA+:D[0D<J,>[C@_J":Z*=**I\CWD93FW*ZV1[^.E**JZ?>
MQ:AIUO>0MF.:,.OT(JSD5YS5M#K6PM%)D>M&Z@"*XN(K6VDN)G"11J7=CT
MYKG/#OCO2O$E_-96OF1RH,J)!C>/45R_Q7\3_9[=="M7_>2C=<$'HO8?CUK@
M[G1-9\))I>M$F,RXD0CJA_NM]1772PZE"\GJ]C"=5J5D?1@I:PO"OB.W\2Z+
M%>1$"4?+-'G[C5N;A7+).+LS9.ZNA:*3(HW"D,6BL?Q!XET[PW8BYOI,;CA(
MUY9S["F^'O%&F^);(W%C)\R\/$WWE_"JY)6YK:"YE>QM4AHW#UJ"\O+>RM)+
MJYD6.&)2SLQZ"IW&5M8UBTT/39;Z\?;&@X'=CV KP+6O$NKZ]JTNK(TT4<#
MH(R=L2]JT]=UC4OB'XECL;%&%LKXAC[ =W:O6-'\(Z;I/AUM),22K,F+AR.9
M"?\ /%=L>7#J\M6SFDY5'IL0>!_%<7B?1U9R!?0@+.GJ?[P]C74UX%=P:A\-
MO&*RQ$O!G*$])HSV/O7MMAK=CJ&D1ZG%.@MF3<68XV^H-95Z5K2CLS2G.^CW
M1H9I:\R\0?%NWM+KR-'MUN@I^>5\[3_NX_G5G2/BWI%WMCU""2SD/4CYE_\
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M^3N!.3@D].U:UO:2:7H<=I:)YLD$(2,$XW$#CK6A10!S%UH]Y:'3KFU@-Y)
M)/.AWJI=G'+9/'&,?0UJZ%8RZ=HUO:S$&1=Q;!X&6)Q^&<5I44 (>_TJ.)0U
MN@8 C:.M2'O]*9!_J(_]T4 'D1?\\T_[YH\B+_GFG_?-244 1^1%_P \T_[Y
MH\B+_GFG_?-244 1^1%_SS3_ +YH\B+_ )YI_P!\U)10!'Y$7_/-/^^:/(B_
MYYI_WS4E% $?DQ?\\U_*N7\:>"H?%-I"(W2WNH3\DA7@@]0?TKK**<9.+NA-
M)JS,/PUX;MO#NC16"8D8'=)(1]]O6MCR8O\ GFG_ 'S4E%$FV[L$K*R(_(B_
MYYI_WS1Y$7_/-/\ OFI**0R/R(O^>:?]\T>3$/\ EFOY5)24 <)\4-#6_P##
M!NX8QYUFV_@<E3P1^N?PKG?!GBR&P\ :@L^TSV(Q"#U8-T ^AR:]8N;>.ZM9
M;>49CE0HP]01@U\SZQIL^E:W=Z800RR[ H_B]/YUVX:U6')+H<U6\7S([3X6
MZ*VJZ]<:S=KO2W.06'!D;G/X?UKK/BEHBWOAC[9%&HELVW\#^'H:WO!VB+H/
MAFUM,8E*^9*?5CS^G _"MB[MH[VSFM9ES'*A1AZ@BLYUOWO,MD7&'N6."^$^
MJ)?>'I+&4*TMH^!D<[3T_*NZNYK*QMVN+IH885^\[X %>$:#K$G@/Q;>"XB>
M1$WPR(O&X]OUQ4LUUXD^)&K"*-3]G5ONCB*(>I/K6M3#\TW*]HD1JVC;J>V6
M.H:5J:;K*YMIQ_TS8$U#KVI6>@Z/<:A<(FV-?E7 ^9NP_.O)[WX7>(]*83:;
M<)<;1G]TY5A^!P*Q-3?Q=J'V?2-2COI2K_NT="<MTZ]#4K#P;O&6@W5DE9K4
MT_!>CS^,O%TNI7XWV\4GG2G'!;.0O^>U>R:OHEGK&ES6%Q"OE2+@$#[I[$?2
MJOA/P_'X<T""R4 RXW3.!]YSUK;K*M5YI^[LBZ<+1UZG@>FWE[\._%\EO>(7
MM\[95[.G9A[_ /UZZC6_BS:1YBT6Q61O^>TRX'X#K^==AXL\&V7BN&(3.T%Q
M%]R95R<>A]:KZ%\.M"T7;(8/M=P.?-G&<'V':M95:4TI36I"A-:)Z'"Z9\6K
MN%MFIZ;#,O=HP%;\NE=-+\4?#O\ 9,EQ%$YN5'RV[1X)/UZ8KJM3\+Z+JR;;
MS3X7/9@N&'T-<A=?!_29;I9+>\N(8MV6C(W9'IFDI8>6K5AVJ+K<XC3-*UCX
MBZ^]Q.QCMU/[R7&%C'95IVMZ#K'P^UI+VSD9[8M^[GQP1_=:O<--TVTTFQCL
M[*%8H(Q@*!^I]ZDN[."^M9+:ZA66&089&&0:/K5I6M[O8/8Z7OJ<SX4\8Z7X
MELB66*WNXES+$^  .Y'M7G7C;Q/+XJU5-'T="UJ)-BA!S,_J?:E\6?#K4=&O
M3<:.DMQ9RG "<O'GL?4>]=K\/?!"Z%:C4+^,'491P#SY0]/K5_NJ?[R.O8F\
MY>ZS2\&>#K?PUIH\Q5EOI0#-(1G'^R/:NF\F/^XOY5(.M%<<I.3NSHBN5:'/
M^*_"UMXDT:2U9$2=1N@DQ]UO\#7B5GX?\2W5R^A0V]RJI)ET;(13ZD]*^C:;
MM .0!D]3BM:6(=-<NYG.DI.YP_AGX9:7I,0EU%([Z[8<^8N47V /\Z=J_P +
M=!U'<]NCV4I[Q'Y?RZ5W':@U/MJG-S7*]G&UK'@ 74OAOXN E'FPCK_=FC_Q
M_K7N.GW5EJFGPWEILDAE7<I _2LGQGX6A\3Z.\.T+=Q9>WD_VO3Z&O-OA_XH
MG\-:P^AZINCMY)"F'_Y8R9_D:WDO;PYE\2W,E^[E;HSUS5[NUTG2KF_F5 D*
M%NG4]A^=>$:-X?U'QUJNH7$4B1R &4L_3)/"_P!/PKM/B[KV(K;1('RS_O9@
MOI_"/QY_*NH^'N@_V'X7@WKBXNOWTIQSST'Y8HIMT:7/U827M)\O8\NM-7\3
M> ;T6MW YMP?]3,-R,/]D_X5+=>+O%/BNY\C387B0GA+13D?5A7MU]I]GJ4!
MAO;:.>,_PNN13K.PM-/@6&TMHX8QT5%Q2^LQ?O..H_92V3T/$%\'^/)OO"Z_
MX%=#_&I!\._&<@^<_P#?5R#_ %KW.@CBE];ET2#V$>K/ =.U#5_A_P")Q%J,
M;-&<>=$6RKJ>X/J*]0\0>--(T?0HK^$Q7$MRFZVC 'S>Y] *L>-/"</BC2BB
MA5O8LF"0^OH?8UY5X=^'FKZKJHAU&":UM(#B1WZD>B^N?6M+TZJYY:-;D^_!
M\J*$6D:_XR-_K&TR+$I=F/ ./X5^@KM/A5XD25&T&]QO3+VY;T[K_GUKTRQT
M^VTVRCL[2%8X(Q@*!7C'CW0I_"GB:'6-.!C@ED\R,K_!)W'X]?QIQJ1K)T[6
M[ X.G:1[=Y,1_P"6:?E1Y,7_ #S3_OFLOPSKL'B+0X+^$@,PVRH/X7[BM>N%
MIQ=F="=U<C,4*@DH@ [XKP#QWKO]N:])!:#-I;,40(/O'NW]/PKTOXE>)_[$
MT3[%;R8O;P%1CJB?Q'^GXUS'PY\+*VGSZG>QY-RC10AA_">I_/\ E712Y*4?
M:S^1G+FF^2)?^&.II>Z))82A6EM6^7/.4/\ ]?-=SY<8&61<#J2*\8\.3OX4
M\>FSF.V(R&!L]U)^4G^=>@^/=;&C^&Y5C;$]S^Z3U /4_EFN;$4'*NN7[1M2
MJVIOFW1YYJLK^,O'2VT _<&01)@<!!U->S6]G!:V\5O'$@2)0J\>E>>_"S1"
MD$^LS+\TG[J+/IW/\J])':EC9JZI1VB/#QT<WNQOE1_W%_*E\J//W%_*G"E[
MUQ'0,\J/^XOY4HBC_N+^5.I13$-\J/\ N+^5'E1_W%_*GTE,!/*C_N+^5'E1
M_P!Q?RIU**!#?*CQ]Q?RH$4?_/-?RI_:@=:H!HBC_P">:_E0(8O^>:_E3Z*8
MAOE1?\\U_*E\F+_GFOY4ZEIH0WR8L_ZM?RH\F/\ YYK^5.[THI@-\F/_ )YK
M^5'DQ_\ /-?RI]% AHAB_P">:_E1Y,7_ #S7\J>*!5"&^3'_ ,\U_*E\F/\
MYYK^5.I: &>3'_SS7\J7R8_^>:_E3Z*8AODQ?\\U_*CR8\?ZM?RI]':F(9Y,
M?_/-?RH\F+_GFOY5)2"@!!&B]$4?A13S13$<W>W_ (BTE9KF:"RN[53\H1C&
M_)P.Q]:DAUE[J:W@U'1;RWD,@*-PR!NQR#_2JFM7VM26<EJ^AR.K,")()-W
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M%% !1110 4444 %%%% !1110 4444 %%%% !1BBB@!,"EHHH **** "BBB@
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MY/\ OF@"2BH_-_Z9R?\ ?-'F_P#3.3_OF@"2BH_-_P"F<G_?-'F_],Y/^^:
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MP^\IDLQXW$DD_ADFK]% "'O]*9!_J(_]T4\]_I3(/]1'_NB@"2BBB@ HHHH
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M><Y'7MBL)/A!X%C=770\,I!'^E3?_%5V]% #401HJ+PJC 'L.E.HHH ****
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M?^/)_P#?%04 %%%% !1110 5DZ_X:TGQ19)9ZS:FYMT?>J"5TPWK\I&:UJ*
M.5T?X;^$M U*+4=-TGR+N/.QS<2-C/L6(J5OA_X5?7_[<;1X3J&_S/,W-MW?
MWMF=N?PKI:* *FJ:99ZSID^G:A#YUI.NV2/<5W#.<9!!'2H6T+3'T,:+):))
MIPC\H0/EAM],GFM&B@#!\/\ @SP]X5:5]&TR.V>7[[EF=L>@9B2!["MZBB@
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6BB@ HHHH **** -*Q_U'XT444"/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img45497886_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45497886_15.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *2!#P# 2(  A$! Q$!_\0
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M0 $ ]12  =!BEHH 3:#V%+@8QBBB@!, =A00#U%+10 8%)M'H*6B@ (!ZB@
M#H*** $P/04N!Z444 ( !T%! /4"EHH ,"DVCT%+10 A /44N .E%% ";1Z"
MEP#UHHH 0 #H*"H/4"EHH ,#&*3:!V%+10 A /44H '0444 )M'H*4@'J***
M $P!T%&T>@I:* # I H'04M% "8!Z@4N *** $VCT%*0#U%%% "  =!1M'H*
M6B@ P#28 ["EHH 0@'J!2XHHH 3:/04$ ]1FEHH 0 #H*-H]!2T4 & >U( !
MT%+10 A4'J!2X&,8HHH 3:!V%! /44M%   !T%)M'H*6B@ (!ZT@ '0"EHH
M0J#U I<444 )M .<"@@'J*6B@ P!VI-H]!2T4 &!2  =!2T4 )M'H*7 Q110
M F .@%! /44M% !@4FT>@I:* $(!ZC-* !T%%% ";1G.!2X!%%% "8 Z"@@'
MJ!2T4 &!C%)M ["EHH 0@'J*7 '2BB@!-H]!2X!'2BB@!  .@HV@]A2T4 &!
MC%(% Z 4M% "$ ]12X Z444 )M'H*" >HI:* $  Z"C:/04M% !@4@ '0"EH
MH 3 STI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ KD?B1_R*,G_ %VC_G775R/Q(_Y%&3_KM'_.@#HM
M+_Y!5I_UR7^57*IZ7_R"K3_KDO\ *KE !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7(_$C_D49/^NT?\ZZZN1^)'_(HR?]=H_P"=
M '1:7_R"K3_KDO\ *KE4]+_Y!5I_UR7^57* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "N1^)'_(HR?]=H_YUUU<C\2/^11D_P"N
MT?\ .@#HM+_Y!5I_UR7^57*IZ7_R"K3_ *Y+_*KE !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 444G- "T4E% "T4F:,GTH 6BDS10
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M% #J*0,K#(.13?-CSC>,T /HI&95&6.*175ONL#0 ZBF&5 <%@#3MP SD8H
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MO]U@?I2&5 <%AF@!]%(64+DGCUI%D1C@,": '44TNJG!8 TZ@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "D-+10!YWXHUF+Q%;7GA]-$NGN)0
M8TGDC 5#_>S2ZII%YX?DT#65A>\?3;;[/.D?+,/45Z"%7.=H!]<4I&1@\T >
M?Z'+,EQJGBZ^LI88Y !#"0 ^T>M2^(HY-2.C>*K"!Y?L?S&''S%3UQ78W^GV
M^I63VEPI,3C! .*DM+2&RM$MH$VQ(, =>* /.[?2[GQK>:MJD]I):6\ML;>U
M648<GN3[55C?4]5M--\+'2Y8FLW GG<?NR@[BO5  !@ 8]J,#).!GUH \SN%
MNO!=[J<%MI\]W%?@"W:)<[6Q_%76^#M(DT;P]##.H6>3]Y*!V8\FM\@'J/S%
M+0 5R/Q(Y\(29_Y[)_.NNKD?B1_R*,G_ %VC_G0!OZ5$G]EV;8Y$*_RJX\:R
M?>&:K:7_ ,@JT_ZY+_*KE #4C5!A1@4S[/'NSMYJ6B@!KHKKM8<4B1)&<J,4
M^B@"-H(W;<RY-.V+MVXXIU% $:P1JV0N#2O$DARPS3Z* &JBHNU1@4S[/'NS
MMYJ6B@!KHKC##(I$B2,?*,4^B@")H(V.2N33RBE-I'%.HH C2&-#E5P:'A20
MY9<FI** &JBJNT#BF"WC#9V\U+10 QXUD&&&:$C6,?*,4^B@"(V\9;)7FGE%
M9=I'%.HH C2%(SE5P:'A1SEER:DHH :$4+M XI@@C4Y"X-2T4 ,>))/O#-"1
MK&,*,"GT4 1>1'NSMYI[(KKM(R*=10 Q(DC.5&*1H(W.6&34E% #=B[=N.*:
ML$:G(7!J2B@!CQ)(<L,TJQJB[5&!3J* (OL\>[.WFGNBN,,.*=10 Q(DC)VC
M&:1H(V;)7FI** &E%*;<<4U((T.57!J2B@"-XDD.67-.5%1=H&!3J* (A;QA
MLA>:<\:R###-/HH 8D:1_=&,TUH(V.2N34M% #2BLNTC(]*:L*(<JN*DHH C
M>%)#EER:<$"KM XIU% $8@C4Y"\TKQ))C<,T^B@!B1J@(48S33;QEL[>:EHH
M :R*Z[6&12)"D9RJX-/HH C:&-SDKDTX(H7:!QZ4ZB@"-8(T.0N#2O$DGWAG
M%/HH 8L:H,*,"F_9X]V=O-2T4 -=%<889%(D21_=&*?10!&T$;MEER:=L7;M
MQQ3J* (UA1&W*O-*\22'+#-/HH :J*BX P*9]GC#9V\U+10 QXUD&&&:$C6/
M[HQ3Z* (C!&S;BO-/**5VD<4ZB@"-(4C.57!H>%)#EES4E% #0BA=H'%,%O&
MIR%YJ6B@!CQI(/F&:$C5!A1BGT4 1&",MN*\T]D5EVD9%.HH C2%(SE1BAH4
M<Y9<FI** &-$C1&(CY",$>M8'_"#>'?,\P:;&&+;B1W-=%10!FZAH.F:I;1V
M]Y:))'']P$?=^E5;_P .P-X>DTK3XTMT;H,<5N44 8,/A33#:64=U;K/):J-
MK-ZUJW-E;W5HUK-$#"PP5Z59HH S=+T'3=&#_8+98M_WB.]-U'P]I6K3QS7M
MG'++']UB.:U** (UB1(A$J@(%VA1T ]*%@C4[E7FI** &/$DARPS2JBHNT#B
MG44 1_9X\YV\TK1JXPPSBGT4 ,2)(\[1C-(T$;-DKS4E% #2BE=I'%-6&-&R
MJX-244 ,:)'8,PR13Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KD?B1_P BC)_UVC_G775R/Q(_Y%&3
M_KM'_.@#HM+_ .05:?\ 7)?Y5<JGI?\ R"K3_KDO\JN4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% "-]TUXU>>+->CU"ZC34&")*0!@
M<#->R-]T_2O ]0_Y"EY_UV;^==N"BI-W.3%2:2L:7_"7Z_\ ]!%OR%'_  E^
MO_\ 01;\A6+17H^RAV.+VDNYM?\ "7Z__P!!%OR%'_"7Z_\ ]!%OR%8M%'LH
M=@]I+N;7_"7^(/\ H(M^0I#XO\08/_$Q;\A6-2-T-'LH=@]I+N>T>$+VYO\
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M %<C\2/^11D_Z[1_SKKJY'XD?\BC)_UVC_G0!T6E_P#(*M/^N2_RJY5/2_\
MD%6G_7)?Y5<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP:W\1GK4O@04445F:!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?Y5<H ***3\: %HHHS0 449HH **,T9H ***3- "T449H **3-+0 44F:7-
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M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D) ZTM!&:
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MS\Y^E '<YHKB_'WB76?#>FVT^FV:3EG5978\*":ZVRF:XL8)FQNDC5CCU(H
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M-A?QSF@"CX:L/[#\7W6E:8YDT9H?-92VX12$GY0:A\5Z!96%S:ZKHY%MJ7G
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M3K"BBB@ HHHH **** "BBB@ HHHH :WW3]*\#U#_ )"EY_UV;^=>^-]T_2O
M]0_Y"EY_UV;^=>A@-Y'%C-D5Z***](X0HHHH *1ONFEI&^Z:!GL/@3_D5X/J
M:Z:N9\"?\BO!]3735X-;^(SUJ7P(****S- HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV)MW$^YI]% $'V<[L^8WTI\D?F*!N(J2B@"**+RR3O)^M->W+MN\QA]*GHH
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M+QDD!A@D5YS\-+%--UWQ+:QR2.B79(+MDUZ/+)Y<3/M+;03@=37FW@*YO?\
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MZKIFIV\,HAVO:72#;*,<;<]/PKO?!>H-J?A6RNFL_L;,N#$!P,=Q0!T%%%%
M!1110 4444 %%%% !1110 4444 %<C\2/^11D_Z[1_SKKJY'XD?\BC)_UVC_
M )T =%I?_(*M/^N2_P JN53TO_D%6G_7)?Y5<H **** "BBB@ HHHH ****
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M_(+O/^NW]*\TKTOX8_\ (+O/^NW]*Y<9_"9T8;^(=W1117CGIA1110 4444
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M?10!XIXOS_PE-[GKN_I6)6WXP_Y&J]_WOZ5B5[U+^'$\>I\;"BBBM" HHHH
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M^Z:!GL/@3_D5X/J:Z:N9\"?\BO!]3735X-;^(SUJ7P(****S- HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "N1^)'_(HR?]=H_YUUU<C\2/^11D_P"NT?\ .@#H
MM+_Y!5I_UR7^57*IZ7_R"K3_ *Y+_*KE !1110 4444 %%%% !0:*#0!S7CM
M-2/A'4'TN\^RW$<+/OQG@#-.\#W-Q>>"-,FGD+W#P?,Y[GUI?&][;67@[5&N
M95C5[=U4GN2#@52^&FH6EYX#TXVTRR>5%MDQ_"?0T 9/A:?5X?B9KNGZE?M<
MQI"DD0Q@(#GBN^NUF:V=8"!(1@$]J\XT/6]-N?C-K*0W:.SVT<:X[L,Y KN9
MO$.DP274;WL8DM%W3+GE!0!Q.H:?J?A7Q)IEY;:E-<K>2[+B"0Y&/:K/CZ-(
M(_MU[KCV,F,642G&Y_0U%8^,_#VN:Q'?SW\+O')Y=G;+RQ)XW5I>,M7\*75G
M/I>J3V\MX$)B@/,@8CC;[T 4_$6I:U:_#:TN"Y^TR*HNIH_X5[L/PJOX&:XA
MULQ:=J+ZEHTD"N9W;.U^XJ&_DU/1/A?9QSP22Q,0LZN,LD)/?\*J^ $L-.\6
M2VGA:X:?09HA)(HY6)R.>: /6:*** "BBB@ HHHH P_%W_(LWG^[7BB_=%>U
M^+O^19O/]VO%%^Z*]3 _ SS\7\2%HHHKN.0**** "G1_\?$/_71?YBFTZ/\
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M]:E\""BBBLS0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD?B1_P BC)_UVC_G
M775R/Q(_Y%&3_KM'_.@#HM+_ .05:?\ 7)?Y5<JGI?\ R"K3_KDO\JN4 %%%
M% !1110 4444 %%%% $4]M!=1[)X4E3^ZZ@BDM[.VM(S';01PH3DK&H4'\JE
M+ =3BDWK_>'YT 5X],L8I_.CLX$ESG>L8!S]:SH/#T::U=:A/(LWGC;Y;1C
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M7Y*G%>;#6=4_Y_IO^^J]%^)__((M_P#?KRVN.LWSGT.7PBZ*;1=_MC5/^?\
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M^=>A@-Y'%C-D5Z***](X0HHHH *1ONFEI&^Z:!GL'@8D>%H"!DY/%="DLC.
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MMKXCLY)85:*:%S'-"_WD;WJ%O%UA_P )<OAQ-S790NQ'1: ,3XG_ /((M_\
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MB6U,,&A65E/ %"LUQ*5*]N@'-=%BEQ0!D:#I3Z79%9F#W$IWRL!QDUKTE+0
M4444 %%%% !1110!XKXP_P"1JO?]X?RK#K<\8?\ (U7O^\/Y5AU[U+^'$\>I
M\;"BBBM" HHHH *]+^&/_(+O/^NW]*\TKTOX8_\ (+O/^NW]*Y<9_"9T8;^(
M=W1117CGIA1110 4444 %%%% !1110 4444 !KC?B3_R+:?]=5KLC7&_$G_D
M6T_ZZK6V'_BHRK?PV>5T445[AY04444""BBB@#2\/?\ (Q6'_745[I7A?A[_
M )&*P_ZZBO=*\O'?$CT,)\+"BBBN$ZPHHHH **** "BBB@ HHHH **** &M]
MT_2O ]0_Y"EY_P!=F_G7OC?=/TKP/4/^0I>?]=F_G7H8#>1Q8S9%>BBBO2.$
M**** "D;[II:1ONF@9[#X$_Y%>#ZFNFKF? G_(KP?4UTU>#6_B,]:E\""BBB
MLS0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KD?B1_R*,G_7:/^===7(_$C_D4
M9/\ KM'_ #H Z+2_^05:?]<E_E5RJ>E_\@JT_P"N2_RJY0 5%=2F"UEE R40
ML!Z\5+2'I0!XE:Z-?W6@ZOXMM]3>+4(;AY1C^ZO\!KUGPWJ,FL>&].U&5=LE
MQ LC#T)%<S<?#V4ZA<"QU>6UTJZD\VXL0N0['KSVS6C=?;[+Q#IUCIHG2R2,
M*8Q'^Z"@=V[4 8_B+1-3T"[F\1:1?R%V<>?;.?D=<U#K%_>Z;XGTOQ']@FNK
M&X@V2+$I9HFQZ5N2^%]6O-5:2]UZ2;3F;=]C\L#'XU;UK0=0U%H8;/57L[-5
MVR0JF=X^O:@#A=$UXC4?%'B>QLKEK*79"L:I\WF#J<?C67I>NV/_  M'3GAL
M;Y9I8CYIDC()8CK]*]BT[3+32[!+.UB"0IVQU/J?>LJ?PK#-XPM]?$VUX8R@
MB"\'WH Q/B?_ ,@BW_WZ\NKU+XG_ /()M_\ ?KRVN*M\9]'EW\!!11161WA1
M110 5VOPQ_Y#EU_US%<57:_#'_D.77_7,5I3^-'+C?X$CUFBBBNX^7"BBB@
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M:E4<[W//QV%A0MR]2:B@45L>>%%%% !1110!XKXP_P"1JO?]X?RK#K<\8?\
M(U7O^\/Y5AU[U+^'$\>I\;"BBBM" HHHH *]+^&/_(+O/^NW]*\TKTOX8_\
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M^N2_RJY0 44AKF/$7C&#P_>1V\D+.6&<BJA"4W:),I**NSJ**X'_ (6=:_\
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M44 !KC?B3_R+:?\ 75:[(UQOQ)_Y%M/^NJUMA_XJ,JW\-GE=%%%>X>4%%%%
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M;1TKYZ7_ %D?^^/YU]#VH!M(<C/R"NG#]3QLV^R/CF60G;GBD>X1&P<Y^E2
M = !054]0*Z3QA"X";^U,2XC=L#.?I4F.,8XH"@=% H 9).D9PV?P%.1Q(NX
M9Q[TI4'J :, <#B@#Q7Q>0?%5Z1_>_I6)6WXP_Y&J]_WOZ5B5[U+^'$\>I\;
M"BBBM" HHHH *]*^&1 TJ])_YZC^5>:UV?@OQ+IVAV%Q#>NRM))N&!VQ7)C6
ME29U8.#G5M%'IBW",VT9S]*ISZ;9'4TU&5&-PJ[5.>!^%8@^(.@CGS&S_NTI
M^(6A'K(Q_P" UXO/'N>Q]6K?RLZE)%D&5S@4S[2@;;SGZ5S(^(6A#I(X_P"
MTG_"P=!_OM_WS1SQ[A]6K?RLZMY B[CTIL<RRDA<\>M<O_PL+0CP9'Q_NT@^
M(.@@\2./HM'/'N'U:M_*SJ'G2-BK9S]*>)!LW]JS-&UVQUZ*26S)=8VVL2.]
M:N.,52:>QC*+B[-$:7".VT9S]*6298R-V>?2G!5'112D ]0#3$-259%)&<4S
M[3'NV\Y^E2@ = !1M7^Z/RH ;)(J+DYQ7&_$659/#:[<_P"N%=H0#U%<;\2
M!X<3 Q^^6ML/_%1E6_AL\LHHHKW#R0HHHH **** -'P^<>(;$G_GJ*])\9VN
MFW.F2W6K27#64"',,)()/KQ7F_A[_D8K'_KJ*]0\2>);/1&2WN=.N;L3 _ZF
M+>/QKR\=\2/0PGPLROAK=(_A<2QW;SVQ<^4K\M&OH:Z/6K^2WMA!:D&[G!$8
MSTX^]^%<QX4M6\-Z/J6J3VKI;W$IFCMD'S*OTJ[J'AVQ\7&WUB.[NK=Q&0@1
MMI&>H(KA.LR/AHMW=^&-2MI[QVN3=2*92<XY[54U+0E\*^+M)N=&FG\VY;;=
M1LY8..YQVIOP[TN7PIH6KZC=17CND\FV$C)<9X('O5C0O%PU/55N;O1]0^V3
M-MA62+"Q+]: %\:WEJVL!-=TZ[DT>/ 6Y@. A/7-=QHYL(=,MH[!F:VVCRR3
MG(^M<_XB\36[&?0FTJ[N)IT* ^5F/)'<UO>'],_LK1+:T<#<B\CT]J -&298
ML;L_A2QRK(,KG\:<0#V!H  Z 4 1&YC#%3G/TJ1I%5=QSBEVKZ#\J, ]OSH
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MB@*!T H 8\R(P4YR?:I*3 /4"EH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** (YH8YXFBE17C8<JPR#1%#'!$L<2*B*.% P!4E%
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M>\?_ 'U1]NM?^>\?_?5%T')+L38&<X&:6H/MML?^6\?_ 'T*/MMM_P _$?\
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M,XO&B[#'R@_C7I]<YX:\,0Z,TU[,D+:C<_ZZ2- H [*,>E='0 4444 %%%%
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M_P#Z["O017GWPK_Y!M__ -=A7H(KNI? CYC'?QY!1116AR!1110 &N-^)/\
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M8^($D:R+$1G#;ABFIQ>B9,\/5@N:4;&Q10**HQ"BBB@ HHHH **** "BBB@
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M7^56JJ:;_P @RU_ZYK_*K=>@MCY"?Q,****9(444&@!K?=/TKP/4/^0I>?\
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M'_GT@_[]BCZ]/L'U2/<^=/[7@_YX7'_?%']KP?\ /"X_[XKZ+_LVQ_Y](/\
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MC_LK3_\ GQM_^_8H_LK3_P#GQM_^_0K8\\YS_A9'A_\ Y[2?]\4?\+(\/_\
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M_P ^D'_?L4?7I]@^J1[GSI_:\'_/"X_[XIDFK0DC$%Q_WQ7T=_9MC_SZ0?\
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MMC_SZ0?]^Q1_9UE_SZ0?]^Q1]>GV%]4CW/G-M7@*G]Q<?]\5%_:D7_/O<?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2['2H/)L;:.",G)"#%7* "BBB@ HHHH **** "BBB@ HHHH **** "BB@]*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#7>Z/X&T#0S=M9V*;[L8F9_F+?B:IV/PWT'3KT7-NMR,$E8C.Q12?1<X% '
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
IHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img45497886_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45497886_16.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $@ MP# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "D-+2&@#RSXE^/-;\+:_;6>FO L,EL)#YD88YW,/Z"N+_P"%
MQ>+/^>MG_P!^!_C5[XW?\C=9?]>2_P#H;UYG7IT:4'!-H\ZM5FIM)G??\+B\
M6?\ /6T_[\#_ !H_X7%XL_YZVG_?@?XUP-%:>QI_RF7MJG<[[_A<7BS_ )ZV
MG_?@?XT?\+B\6?\ /6T_[\#_ !K@:*/8T_Y0]M4[G??\+B\6?\];3_OP/\:/
M^%Q>+/\ GK:?]^!_C7 T4>QI_P H>VJ=SOO^%Q>+/^>MI_WX'^-'_"XO%G_/
M6T_[\#_&N!HH]C3_ )0]M4[G??\ "XO%G_/6T_[\#_&C_A<7BS_GK:?]^!_C
M7 T4>QI_RA[:IW.^_P"%Q>+/^>MI_P!^!_C1_P +B\6?\];3_OP/\:X&BCV-
M/^4/;5.YWW_"XO%G_/6T_P"_ _QH_P"%Q>+/^>MI_P!^!_C7 T4>QI_RA[:I
MW.^_X7%XL_YZVG_?@?XT?\+B\6?\];3_ +\#_&N!HH]C3_E#VU3N=]_PN+Q9
M_P ];3_OP/\ &C_A<7BS_GK:?]^!_C7 T4>QI_RA[:IW.^_X7%XL_P">MI_W
MX'^-'_"XO%G_ #UM/^_ _P :X&BCV-/^4/;U.YWW_"XO%G_/6T_[\#_&C_A<
M7BS_ )ZVG_?@?XUP/>BCV-/^4/;5.YWW_"XO%G_/6T_[\#_&C_A<7BS_ )ZV
MG_?@?XUP-%'L:?\ *'MJG<[[_A<7BS_GK:?]^!_C1_PN+Q9_SUM/^_ _QK@:
M*/8T_P"4/;5.YWW_  N+Q9_SUM/^_ _QH_X7%XL_YZVG_?@?XUP-%'L:?\H>
MVJ=SOO\ A<7BS_GK:?\ ?@?XT?\ "XO%G_/6T_[\#_&N!HH]C3_E#VU3N=]_
MPN+Q9_SUM/\ OP/\:/\ A<7BS_GK:?\ ?@?XUP-%'L:?\H>VJ=SOO^%Q>+/^
M>MI_WX'^-'_"XO%G_/6T_P"_ _QK@:*/8T_Y0]M4[G??\+B\6?\ /6T_[\#_
M !H_X7%XL_YZVG_?@?XUP-%'L:?\H>VJ=SOO^%Q>+/\ GK:?]^!_C1_PN+Q9
M_P ];3_OP/\ &N!]:*/8T_Y0]M4[G??\+B\6?\];3_OP/\:/^%Q>+/\ GK:?
M]^!_C7 T4>QI_P H>VJ=SOO^%Q>+/^>MI_WX'^-'_"XO%G_/6T_[\#_&N!HH
M]C3_ )0]M4[G??\ "XO%G_/6T_[\#_&C_A<7BS_GK:?]^!_C7 T4>QI_RA[:
MIW.^_P"%Q>+/^>MI_P!^!_C1_P +B\6?\];3_OP/\:X&BCV-/^4/;5.YWW_"
MXO%G_/6T_P"_ _QH_P"%Q>+/^>MI_P!^!_C7 T4>QI_RA[:IW.^_X7%XL_YZ
MVG_?@?XT?\+B\6?\];3_ +\#_&N!HH]C3_E#VU3N=]_PN+Q9_P ];3_OP/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%C#I\5R)(!*6>0KC+$8X^E<M_P +SOO^@);_ /?YO\*I?&[_ )&ZR_Z\E_\
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M$*^O:Y,33C!KE.O#5)33N%%%%<ITA1110 4444 %%%% !1110 4444 %%%%
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MR"IKJZN+VY>XNIGFFD.7D<Y+&H:NG#DC8BI/GE<****T(L>Z? __ )%S4O\
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MKM&'LT1WM9@P/S-P<9%<U12=5<O8Z8.*I/F-7XA"+P]\,M-\.33K)>DJ<+Z
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M% &']K\0_P#0+M_^_P#_ /7H^U^(?^@7;_\ ?_\ ^O6Y10!A_:_$/_0+M_\
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M /UZ/M?B'_H%V_\ W_\ _KUN44 8?VOQ#_T"[?\ [_\ _P!>C[7XA_Z!=O\
M]_\ _P"O6Y10!A_:_$/_ $"[?_O_ /\ UZ/M?B'_ *!=M_W_ !6Y10!!9O<R
M6RM=Q+%-SE5;('XU/110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% "9->-_$'XU7WA7Q9/HVEZ7;7J6T2M.\C-E6/)'';!'YUZSJE_
M%I>DW=_,0([>)I#GO@9KYV^'-IHWB6T\8:KK^IV,$VJ;X(5N;E$D7/S$@$YQ
MRHS[4 ?0'AO6H_$/AO3]6BV@74"R,JG(5B/F7\#D?A6H37BO[/NN[M)U+PU/
M,K3V,Q>/:<@H3S@]_FS7+:CINJZ]\>=8T;3=5ETX7>])YD)R(P,D >^,4 ?2
M?-&3Z5\N0:/XE\'_ !,D\$:'X@F1=254:=ACY2"Q;&>& 4\^_O6C;:7J/PO^
M,^DZ;!J]Q>6^H!&F9QM\U6+ @C)[CK0!])9]J,FOGCXQ+J<WQ@T.VT>Z:VOI
MH8XX) Y78Y<@'-5/&7P^USX9V47BS2_$US<7"2J+AF!0Y8_4[@3P<T >T^/O
M$&N^'-!BO/#^BOJUVTXC:!(W<JA#$MA>>H _&M_3;BXNM+M+BZ@\BXEB5Y(B
M"-C$<CGGBO%_B_K;:]\%M"UA-T9N[F*0@'')1\U;^(OB[4/#OPP\.6>ESO!>
MZG%'&)U."JA5S@]B=PYH ]GR<5R/C_Q'X@\.:5:W'A[0GUBXEFV21)&[[%P3
MNPG/7 KREO@OXITFTT_6= \02RZP[(\REM@3=R2&)^8#OQ6I\>VU"+X?>'_[
M0D07_P!I47#6Y(0OY9W8Z<9H [3XB^/+_P $^#K'6(;&"6YGF2*2&8L N49C
MTYX(I/&OCZ]\+_#NQ\26]E;S7%PT(:*1CM&]23C'/:N1^.63\)=%SR?M,/\
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M+^.:5V=56-5SR03R,D<#/2@"G:^(_BM<)#+_ ,(?I BE"MG[: 0I[XW>E>F
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M %%%)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 444F: %K'G\.6EQ<23/-=!G8L0LN ,^@K8HH P_P#A%K+_ )[WG_?XT?\
M"+67_/>\_P"_QK<HH P_^$6LO^>]Y_W^-'_"+67_ #WO/^_QK<HH P_^$6LO
M^>]Y_P!_C1_PBUE_SWO/^_QK<HH P_\ A%K+_GO>?]_C1_PBUE_SWO/^_P :
MW** ,/\ X1:R_P">]Y_W^-'_  BUE_SWO/\ O\:W** ,/_A%K+_GO>?]_C1_
MPBUE_P ][S_O\:W** ,/_A%K+_GO>?\ ?XT?\(M9?\][S_O\:W** ,/_ (1:
MR_Y[WG_?XT?\(M9?\][S_O\ &MRB@##_ .$6LO\ GO>?]_C1_P (M9?\][S_
M +_&MRB@##_X1:R_Y[WG_?XT?\(M9?\ />\_[_&MRB@##_X1:R_Y[WG_ '^-
M'_"+67_/>\_[_&MRB@##_P"$6LO^>]Y_W^-'_"+67_/>\_[_ !K<HH P_P#A
M%K+_ )[WG_?XT?\ "+67_/>\_P"_QK<HH P_^$6LO^>]Y_W^-'_"+67_ #WO
M/^_QK<HH P_^$6LO^>]Y_P!_C1_PBUE_SWO/^_QK<HH P_\ A%K+_GO>?]_C
M1_PBUE_SWO/^_P :W** ,/\ X1:R_P">]Y_W^-'_  BUE_SWO/\ O\:W** ,
M/_A%K+_GO>?]_C1_PBUE_P ][S_O\:W** ,/_A%K+_GO>?\ ?XT?\(M9?\][
MS_O\:W** ,/_ (1:R_Y[WG_?XT?\(M9?\][S_O\ &MRB@##_ .$6LO\ GO>?
M]_C1_P (M9?\][S_ +_&MRB@##_X1:R_Y[WG_?XT?\(M9?\ />\_[_&MRB@#
M#_X1:R_Y[WG_ '^-'_"+67_/>\_[_&MRB@##_P"$6LO^>]Y_W^-'_"+67_/>
M\_[_ !K<HH P_P#A%K+_ )[WG_?XT?\ "+67_/>\_P"_QK<HH P_^$6LO^>]
MY_W^-'_"+67_ #WO/^_QK<HH P_^$6LO^>]Y_P!_C1_PBUE_SWO/^_QK<HH
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MCH@&3=R,59!W8]0<]E_6N>U@C_AJ;3N>?(7_ -$M0!UGBU?'.L>+4T[3;IM
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M>,E&&.#C/0FG>*O$GQ1T>QLO&5W?P6NG7,BB/3X6)" @E0X([@=<UN_M%_\
M(G:)_P!?8_\ 1;59^-'_ "172O\ KK:_^BVH A^(WBOQ'8:/X7\8:5J$UO8W
M$<?VNU0_NRQYYX[Y(_"MCXM^.+G2O!.G2Z!=217FK2(;>6$C<$P&_4<?C5K_
M (1Y?%/P*M-,(S(VGH\)/9U&0:\D^'1N_'7C'PSINH0EK;P_ VXGNJL2H(^N
M%H ],\=>--8\">"-$T^&<WGB&^58O.F^8YQ\S=LG) 'UKF&_X7+X5GT[4KB\
M_MB*Z<*;-&\S;D9PPVC;QGD$@5K_ ![T:]:+0_$=K T\>F3XFC0= 2&!/ME0
M/QJ#4OV@K5[+3XO#FESW.HO(JSPW"84+C!"D'DDXY_2@"[\:O$FLZ3I7AB>R
MFDT^:ZE;SXAM8@[4.TD@]"2*D^-?B?6O#>@Z#<Z3?S6DDTQ$IB(&\;<X/%8O
MQ\GGN=$\(7%U;_9IY)W>2 MN,9(0D9[XJ3]H? \,>&PQ_P"6YSZ_<H S/$M]
M\7=.T)/&%WJL%I9C8S64#<HI( W+C'.0#AN]>R>!/$,OBGP9IVKW$8CGGC_>
MJO3<#@X]JY_XM )\&M35<!1#  /^VB5-\&O^27:3]&_G0!WU%%% !1110 44
M44 %%%% !1110!Q7Q:U"33?ACK<\1(=H1#D>CD*?YUJ>'-&L[;P+8Z2($^S&
MS$;(1D,"O.?7K3/'VB/XA\#:OID2[II8&,:XZNOS*/S KC-#^+WAVS\"1&_N
M_)UBTM_*DL&4^8TJC  'H3WH O?!2=F\&WEGG,=CJ<]O$/1 00/UJW\9;^2P
M^&>H^62#<%+<D>CG!J/X8VC>&OAXU_K&+,W4TNH3^:<>4KGC/'H!5OQS:P>.
M/AE?'1Y4O%EB\ZU:/D2,AXQ^(H VK/1+*/P5#HI@3[']B$!C*Y&W9@UQ/PIL
M++Q)\+H-/U:UCN[:UO)(TCE''R-\O?G&:;:?&/PY'X$2>6Z*ZQ':B,Z?M/FF
M8+C 'IGOZ5%HL?B/P'\&[:\T_3XY]063[9=6LJ%F$;G+@ $?,!S0!'\6?%=N
M-)N?"$>EW$*3E(7U&X@(M+=<CY@PR<CIT'6O3="MX[30=.MH9UN(H;:.-95.
M0X"@9!]\5Y_K_P 5?!VI^"KE%N4OKF[M_+7350F4NPQM*XXP:Z7X::5?:)\/
M-'T_4L_:XXB74]4#,6"_@"!0!UE%%% !1110 4444 %%%% !1110 444AH \
MQMPFK?M!WIG7<-(TU%AST4N,D_K2?%%8[#Q/X*UB)0MT-42U+@<F-^"*@\27
M\7@CXOVWB&_5H])U6S%M-<A21%(O3=^&*KZWKUA\1/'WAK2M E^VV>FW'V^[
MNXQ^[3:/E&2.3DB@#UZO,-%V:K\>/$-Q.N]M+LH;>'=_"&RQQ7?3:[I=OK,&
MCRWT*:C.I>*W)^9U'<5YQJVI6W@/XPRZMJ8:'2=;M%1KK:2L<J'&&QVP10!:
M^(21Z=\1O VJPJ%N)KPV<C@<M&<<'\S7+>'O%,EOX\\7W.GZ%<ZWX@FO6B@B
M4A%B@3(^:0\*.!6W?:U9_$/XG^'K?0W-WIVBL;RYO$'R;^R@D<]*@T75+'X;
M?$3Q)::_BTL]6G^UVEZRG80<_(3VQF@#;\,>)M.UWQJ\&O>&CHOBR"$^7YC!
MS)%WVN, UZ..M>2)JEMX\^,>BWV@YGT[1(93<WJ+B-V<8"@]Z]<% "T444 %
M%%% !1110 4444 %%%% !1110!YA\7R+R7PIH<@+0:AJBB5<XW!<'!_.M[XG
M:=;7OPUUN*:)"D-JTL?'W&094CTQBLKXOV-S_86G:[9P&>;1KQ;DHHR=G\1_
M2LGQO\3=!UWP7-I7A^Y-_JFK1BVBM8U.]"_!WC'&,T =WX&O9-2\"Z'>2DM)
M-9QLQ/<XJ37/"FF>(=2TN]U 2N^FR&6&-7PC,>[#'.,<57LKC3? _@_3+?5K
MV&U@MH8[?S)#@%L=*R_B/\0(/!FC6[0/"VH7YV6@E.(U'&9&_P!D9'YT 9/Q
MFN+>^T.R\-6\0N=8U"Y3[- O+( >7]@*I_%F'51:^$=,T^PEU.>.\1Y(PIVR
M; ,;FZ*">YIGA'7/ F@RS:KJ?C"QU+Q!=C_2;V1B0O\ L1C'RJ/U_2NC\8^-
M[WPO<Z+J4<$-QX:NB!=W"(S21@C*N,'&W&.U &'=>+_'G@V[MKOQ?9Z5<:+<
M2K$\NGEMUL6. 6W#FO5(W61%=#E6 (/J*\?^(GC#1_&^CP^$?#-Q_:=]J4\8
M+VZDK BL&+,>W2O7+.$VUG! 3DQ1JA/K@ 4 3T444 %%%% !1110 4444 &*
MSK_P_HVJRB74=(L+R0# >XMDD('IE@:T:* (+2RM-/MUM[*UAMH%Z1PQA%'X
M#BH7T?3)-274GTZT:_486Z,"F4#&.'QGI[U=HH H7^AZ1JLB2:CI5C>.@PC7
M%NDA4>Q8'%*=%TIKV*];3+(W<*A8IS OF(!T"MC('TJ]10!2BT;2X=1;4(M-
MLTOG&&N5@42-]6QDTZ_TK3M5A6'4;"UO(E;<J7,*R*#Z@,#5NB@"&6TMIK0V
MLMO%);,NTPL@*%?3;TQ5.'P[HEM:36D&CZ?%;3C$T*6R*DG^\H&#^-:5% %>
MSL+/3K46MC:06MNN<101A$&>O XJ"RT32=-65;#3+*U6;_6B"!4#_P"]@<_C
M5^B@"G8:1INE+(NG:?:6:R'<XMX5C#'U.T#-3W-K;WD#074$4\+C#1RH&5OJ
M#Q4M% %#3]#TC269M-TNRLRXPQMK=(RWUV@4Z^T;2]4:-M0TVSNVB.8S<0+(
M4/MD<5=HH IW^D:;JL*1:CIUI>1(<HEQ"LBJ?4!@<47FE:=J%FMI>V%K<VRD
M%89H5=!C@84C'%7** .&\?:OXC\,Z-9Q^#]!COMY:)X8K=F$*X^4JJ8 []:Q
M?@SX(U#PW87VL:W"8=5U)]QC. R)G.".Q)YQVKU+%&* $=$D1D=0RL,%2,@B
MLZT\.:'87(N;/1M.MIP<^;#:HC?F!FM.B@"E?Z1IFJB,:CIUI>",[D%Q"LFT
M^HW XHO]'TS5(XX]0TZTNTC.8UN(%D"'V!!Q5VB@""ZL;2]M&M+NUAN+9P T
M,L89"!R,J>.U%I96NGVR6UE;0VT"?=BAC"*OT XJ>B@ HHHH **** "BBB@
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M+_0='U0QG4-)L;PQ#;']HMTDV#T&X''2M"B@#$_X0SPMG/\ PC6CY_Z\8O\
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M4 ;=%8F[Q+_SST[\VHW>)?\ GGIWYM0!MT5B;O$O_//3OS:C=XE_YYZ=^;4
M;=%8F[Q+_P \]._-J-WB7_GGIWYM0!MT5B;O$O\ SST[\VHW>)?^>>G?FU &
MW16)N\2_\\]._-J-WB7_ )YZ=^;4 ;=%8F[Q+_SST[\VHW>)?^>>G?FU &W1
M6)N\2_\ //3OS:C=XE_YYZ=^;4 ;=&:QX&U_ST\^.Q\K/S;"V<>U:_YT ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img45497886_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45497886_17.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '_!:H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_"._#[3+5U*SRI]HF!ZAWY(KLJ15"H% X P*6@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 (:X(^+?%UYJ6H0Z/X:M;NVM+AH/-:\$9)'L:[T]
M:\NTG6O$.G:KKT6E>&6U2 Z@Y:472Q[6XXP: .J\/>*+Z_U.72-:TIM.U*.,
M2A%<.CIG&585T^37%:3!KEWJUSXGUNQCL7@M&BMK19-[ =6+$<<X&*R-'\&K
MXLTB+7]3U?4#?W6Z6,PSE4B&3M4+WQ0!Z7DYI<^M>7W5QX@UOX>VZQF:[DMK
MMH+[[-)LDN(D)!(/J< FH/!4^C)K/V"TN]<L5N8GC>QU)21*Q'5'SP0,]N]
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M_,P2F1][UP* /9@<TM4='TN#1M+AL;9Y7AB'RM*^YCDYY-7J "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:* *.CVM[9:7#;ZA??;;E 0]QY>S?SQQ]*O444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)
M10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)
M10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)
M10 M%)10 M%)10 M%)10 M%)10 M%)1WH 6BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BC%&* "BC%&* "BC%&* "
MBC%&* "BC%&* "BC%&* "BC%&* "BC%&* "BC%&* "BC%&* "BC%&* "BC%&
M* "BC%&* "BC%&* "BC%&* "BC%&* "BC%&* "BC%&* "BC%&* "BC%&* "B
MC%&* "BC%&* "BC%&* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *2EI* $S2YJAK,\EMI%S/"VV1$RIQTKB_^$CU;_G[_ /'%_P *\W&Y
MG2PDU&HMSKPV"J8B+E#H>AT5YY_PD>K?\_?_ (XO^%'_  D>K?\ /W_XXO\
MA7%_K#ANS.C^R:_D>AT5YY_PD>K?\_?_ (XO^%'_  D>K?\ /W_XXO\ A1_K
M#ANS#^R:_D>AT5YY_P )'JW_ #]_^.+_ (4?\)'JW_/W_P".+_A1_K#ANS#^
MR:_D>AT5YY_PD>K?\_?_ (XO^%'_  D>K?\ /W_XXO\ A1_K#ANS#^R:_D>A
MT5YY_P )'JW_ #]_^.+_ (4?\)'JW_/W_P".+_A1_K#ANS#^R:_D>AT5YY_P
MD>K?\_?_ (XO^%'_  D>K?\ /W_XXO\ A1_K#ANS#^R:_D>AT5YY_P )'JW_
M #]_^.+_ (4?\)'JW_/W_P".+_A1_K#ANS#^R:_D>AT5YY_PD>K?\_?_ (XO
M^%'_  D>K?\ /W_XXO\ A1_K#ANS#^R:_D>AT5YY_P )'JW_ #]_^.+_ (4?
M\)'JW_/W_P".+_A1_K#ANS#^R:_D>AT5YY_PD>K?\_?_ (XO^%'_  D>K?\
M/W_XXO\ A1_K#ANS#^R:_D>AT5YY_P )'JW_ #]_^.+_ (4?\)'JW_/W_P".
M+_A1_K#ANS#^R:_D>AT5YY_PD>K?\_?_ (XO^%'_  D>K?\ /W_XXO\ A1_K
M#ANS#^R:_D>AT5YY_P )'JW_ #]_^.+_ (4?\)'JW_/W_P".+_A1_K#ANS#^
MR:_D>AT5YY_PD>K?\_?_ (XO^%'_  D>K?\ /W_XXO\ A1_K#ANS#^R:_D>A
MT5YY_P )'JW_ #]_^.+_ (4?\)'JW_/W_P".+_A1_K#ANS#^R:_D>AT5YY_P
MD>K?\_?_ (XO^%'_  D>K?\ /W_XXO\ A1_K#ANS#^R:_D>AT5YY_P )'JW_
M #]_^.+_ (4?\)'JW_/W_P".+_A1_K#ANS#^R:_D>AT5YY_PD>K?\_?_ (XO
M^%'_  D>K?\ /W_XXO\ A1_K#ANS#^R:_D>AT5YY_P )'JW_ #]_^.+_ (4?
M\)'JW_/W_P".+_A1_K#ANS#^R:_D>AT5YY_PD>K?\_?_ (XO^%'_  D>K?\
M/W_XXO\ A1_K#ANS#^R:_D>AT5YY_P )'JW_ #]_^.+_ (4?\)'JW_/W_P".
M+_A1_K#ANS#^R:_D>AT5YY_PD>K?\_?_ (XO^%'_  D>K?\ /W_XXO\ A1_K
M#ANS#^R:_D>AT5YY_P )'JW_ #]_^.+_ (4?\)'JW_/W_P".+_A1_K#ANS#^
MR:_D>AT5YY_PD>K?\_?_ (XO^%'_  D>K?\ /W_XXO\ A1_K#ANS#^R:_D>A
MT5YY_P )'JW_ #]_^.+_ (4?\)'JW_/W_P".+_A1_K#ANS#^R:_D>AT5YY_P
MD>K?\_?_ (XO^%'_  D>K?\ /W_XXO\ A1_K#ANS#^R:_D>AT5YY_P )'JW_
M #]_^.+_ (4?\)'JW_/W_P".+_A1_K#ANS#^R:_D>AT5YY_PD>K?\_?_ (XO
M^%'_  D>K?\ /W_XXO\ A1_K#ANS#^R:_D>AT5YY_P )'JW_ #]_^.+_ (4?
M\)'JW_/W_P".+_A1_K#ANS#^R:_D>AT5YY_PD>K?\_?_ (XO^%'_  D>K?\
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M56^S3_\ /[+_ -\I_A1]FG_Y_9?^^4_PHU LT56^S3_\_LO_ 'RG^%'V:?\
MY_9?^^4_PHU LTE4KE9[> RB[D;:1P57!R0/2KM "T444P"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "DI:2@#-\0?\@&\_ZY_P!:\YKT;Q!_R ;S_KG_
M %KSFOCN)/X\/3]3Z')_X4O4****^</7"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ H[T4=Z8!WKU:+_ %:_05Y3WKU:+_5K]!7U/#?VSPLX
MW@/HHHKZH\0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MCG_X]Y/]P_RJ2HY_^/>3_</\J &VG_'E!_US7^5<]XU\;6G@FRM;F[M+BY6X
ME,:B$KD$#.3DBNAM/^/*#_KFO\J\H^/G_("T;_K[;_T T /_ .%]Z+_T!M1_
M./\ ^*H_X7WHO_0&U'\X_P#XJO,@JX'RCIZ4;5_NC\J8'IO_  OO1?\ H#:C
M^<?_ ,51_P +[T7_ * VH_G'_P#%5YEM7^Z/RHVK_='Y4"/3?^%]Z+_T!M1_
M./\ ^*H_X7WHO_0&U'\X_P#XJO,MJ_W1^5&U?[H_*@#TW_A?>B_] ;4?SC_^
M*H_X7WHO_0&U'\X__BJ\RVK_ '1^5&U?[H_*@#TW_A?>B_\ 0&U'\X__ (JC
M_A?>B_\ 0&U'\X__ (JO,MJ_W1^5&U?[H_*@#TW_ (7WHO\ T!M1_./_ .*H
M_P"%]Z+_ - ;4?SC_P#BJ\RVK_='Y4;5_NC\J /3?^%]Z+_T!M1_./\ ^*H_
MX7WHO_0&U'\X_P#XJO,MJ_W1^5&U?[H_*@#TW_A?>B_] ;4?SC_^*H_X7WHO
M_0&U'\X__BJ\RVK_ '1^5&U?[H_*@#TW_A?>B_\ 0&U'\X__ (JC_A?>B_\
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M8)KPW:O]T?E78?!#CQIK@]+;_P!J"D,]MU'_ (\7^J_^A"K-5M1_X\7^J_\
MH0JS28"T444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:2@#-\0?\
M@&\_ZY_UKSFO1O$'_(!O/^N?]:\YKX[B3^/#T_4^AR?^%+U"BBBOG#UPHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3WUY+:K9JC!TQM .<YR/;MBIM6\*Z5_PCD6LZ#?W%S%YP@=)U )8G (P!^M
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MZILW_9&VXS]X?RS5:VL+J[E>*&$LZ?>7.,?G0\-532<7J-5Z;3:DK(KT5?\
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MQ!_R ;S_ *Y_UKSFOCN)/X\/3]3Z')_X4O4****^</7"BBB@ HHHH ****8
M**** #%%%% !UHHHH ****+A8****+@'6BBB@ HHHH ****+@%%%%%P"BBB@
M ZT<9Z4447%8*!110%@ZT9]J**!A1VHHH **** "BBB@ S1^%%% !SUH[444
M7%8*#[444[L84G44M%*XK!1110,**** "BBBBX :.M%%%P#H****+A8****
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MG@F>Z>WC-P-0BC$I7Y@I'(^E=');:7+XZE\/+H]DED\1RXB'FJQ0'*MU')H
MXBPT2]U&TFNX?(CMXB%>6:98QD] "3R:SR,$^QZYS7;6UTQ^'DEN+6S)-^L
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M6MN]U.(HWB1B"<S2!%_,\"NUCTS1K74=6M[&;3)KO"/:+>NKQ!2,LN[[I8'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/?\ D1M5_P"N0_\ 0A0!K:/_ ,@2P_Z]X_\ T$5=JEH__($L/^O>/_T$5=H
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MQ#^4\VHKTG^P],_Y\8/^^!1_8>F?\^,'_? H_P!7*O\ .@_MB'\IYM17I/\
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MT9J>F6FLZ9<:=?PK-:W"E)$/<5Y]!\"_"T=K+:37>L7-JRD1037?R0,?XD4
M#=]<T <7XKB#?LUZ-*8U9D\D;R!E1N[&D^+4,47P7\*&.*--SPEMB@9/DGGB
MO5A\/=&;P*GA"Y>ZNM.081YG'FJ<D@Y  X)XXK#F^"VA7'AM="GU;6YK1+@3
MH9+E&9"%*[1E,!<'H!0!Y]XS.KW?Q@\-V=C)8^8FGQ&S34@3;[RASD#N<?F!
M6CIFDZ[:_&C3+G5M4\-V^I^6%GL]-$RM+%SR1LVY^I'05Z=XE^'VA>*K*TAU
M".99K-0L%U ^R:,#'?IV':F>%?AWHOA*]FO[:2\O=0F&U[R^F\R7;Z9P!^E
M'FWAK3K._P#VBO$#7=O'/Y*EHPXR =HYQ4WAFV@LOVCM:M[:%(8'@<M&BX4Y
M )X^M>CZ;X#TS2_&=]XI@N+MKZ]&)(W=3&.,< +GMZT6G@/3+/QS<^+8Y[LW
MUPA1HV=?* (QP-N?UH \Y^&UK"/C9XR1[>+]WN*J4'R_.O3TJF/!_BGPSXCU
MC5/"3:+XBM;R7=/!*5>5>2=N"<#J1U_"O0[[X5Z'>>+CXEAN]3L;UW#RK:7
M1)B"#\P()(.!D9Q5;5/@]X>O]5GU"SO-5TB6X.9ETVY$2.?4C!H I_"7Q#HF
MIMJVG6/AY=#U*VDW7MO&VY"V2N0?7(/%>G5SOA/P5HW@VTEATN*0R3'=-<3/
MODE/JQ_PKHJ "BBB@ HHHH **** "BBB@ HHHH **** "N<\>_\ (C:K_P!<
MA_Z$*Z.N<\>_\B-JO_7(?^A"@#6T?_D"6'_7O'_Z"*NU2T?_ ) EA_U[Q_\
MH(J[0 4444 %%%% !1110 4444 %%%)0 9HK)\37<]CX;OKJVD,<T<6Y' !P
M<CUKRS_A-/$7_03D_P"^$_\ B::5S.=11>I[317BW_":>(O^@G)_WPG_ ,31
M_P )IXB_Z"<G_?"?_$T^5D^WB>TT5XM_PFGB+_H)R?\ ?"?_ !-'_":>(O\
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M/::*\6_X33Q%_P!!.3_OA/\ XFC_ (33Q%_T$Y/^^$_^)HY6'MXGM-%>+?\
M":>(O^@G)_WPG_Q-'_":>(O^@G)_WPG_ ,31RL/;Q/::*\6_X33Q%_T$Y/\
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MT4!]%%%0=(4444 %%%% !1110 4444 <AH__ "4KQ'_UPM__ $$5U]<AH_\
MR4KQ'_UPM_\ T$5U] !1110 4444 %%%% !1110 5'/_ ,>\G^X?Y5)4<_\
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M)HV4]\BK=)B@#Y=\&^'[WQ#XAN/!FHX>TT."\B16X.]RP#>W)S6M\&%OM?\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG/'O\ R(VJ_P#7(?\
MH0KHZYSQ[_R(VJ_]<A_Z$* -;1_^0)8?]>\?_H(J[5+1_P#D"6'_ %[Q_P#H
M(J[0 4444 %%%% !1110 4444 %)2TE &)XP_P"11U/_ *X_U%>)U[9XP_Y%
M'4_^N/\ 45XG5Q.6ON@HHHJC **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%>944 >F_P#"4:+_ ,_Z?]\M_A1_PE&B_P#/^G_?+?X5YE10!Z;_ ,)1HO\
MS_I_WRW^%'_"4:+_ ,_Z?]\M_A7F5% 'IO\ PE&B_P#/^G_?+?X4?\)1HO\
MS_I_WRW^%>944 >F_P#"4:+_ ,_Z?]\M_A1_PE&B_P#/^G_?+?X5YE10!Z;_
M ,)1HO\ S_I_WRW^%'_"4:+_ ,_Z?]\M_A7F5% 'IO\ PE&B_P#/\G_?+?X5
MH6EY!?6XGMI!)$20& (Z5Y%7HW@__D7(?]]__0C2&:FH_P#'B_U7_P!"%6:K
M:C_QXO\ 5?\ T(59I,"EK&K6>A:3<ZG?R&.UMD,DC 9.!Z#N:@\.^(M/\4:-
M%JNF-(]K*2%:2,H3@X/!KAOCOJ@L/AO<6X)$EY*D2_3.3^E<1X2^.7A[PQX3
MT_1QI&HO+:PA'=3'M9^Y'S=,TP/8]&\;Z)K^O7^C:?-+)=V.?/S$0@YQPW0U
MT5>*?L^VOVBU\0:ZX.^\N@JD]@,DC_QX5[70 9Q1FO/_ (N^,+[P=X3CN]+G
MCBOYIUCC+H'R.K<'VKD_$'B7XI^'O#%IXHO9-*2T41&XL5B_><D#YB1P3G^$
M\9H ]LS29%>3>-_B#J]CH_A+7-&F2WL-3F5;E9(0Y(;!X)Z<!JN_$?QWJ6FZ
MCH_AWPL\9UO4G5LL@?RXST.#QSS^5 '6>)/&NC>%+BQ@U2699;U]D"Q1%R3^
M'3K709KP_P 4)<:S\</"6C7,@N7TZ".6Y8)@.X^9FP.@K7OO'7B;Q9XSO/#?
M@C[);)IY/VK4+I=RY!QP.>,\=,T >LY%&:\Q\&^-_$"^.;KP7XKCMY;Z*,RP
MWELNU95X_A[<?RKF4^*'C+5O&6OZ-X<LDOVC?R[.,QJJP@9#.S].HX!/K0!Z
MKXC\9Z/X6N;&WU.282WS[(%BA+Y/OCIUKH,UX];>+?&*?$?P_P"%;NZMWE^R
MK-J@2!#ECEB 1TPI X],U[!WH 6BBB@ HHHH **** "BBB@ HHHH **** "N
M<\>_\B-JO_7(?^A"NCKG/'O_ "(VK?\ 7(?^A"@#6T?_ ) EA_U[Q_\ H(J[
M5+2/^0+8?]>\?_H(J[0 4444 %%%% !1110 49I#GM7/>(=-U9[B+4]&NF6Z
M@7:;9C^[F7.<'W]Z .BI*Q/#_B2VUM&B93;7\7$UK)PRG\>HK;H Q/&'_(HZ
MG_UQ_J*\3KVSQA_R*.I_]<?ZBO$ZN)RU]T%%%%48!1110 4444 %%%% !16A
M?:+J&G6D%W=0A8)Q^[99 P;C/8T+HNH-I+:H(0+-3M,A<#G..G4\T7'RLSZ*
MU--\.:MJ\1ELK1I(Q_$2%!^A/6H-1TF_TF=8;VW:)VZ9.0WT/2BX^5E*BMU?
M!NOMY6VQ+>8NY6$BXQ[G/%9^IZ1?:/,L-] 8F9<KDY!^A'%%PY6BE1^-;-CX
M4UO4;<7%M8L8F^ZSN$S[@$U1FTR]@U 6,T#)<D@!&XSGWHN+E94HKH!X)\0-
M*\0L,LO4^:H!^AS68ND7[:J--\@B\)V^6QVY_/BBX^5E*BMJZ\)ZU96LUS<6
M8CAB^^QD7_'FGVW@W7KNW2>*P_=N,C>ZJ<?0FBX<K,*BM&+0=3FU4Z8ML1>
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M8_\ 5K]!7ST:^A8_]6OT%3(Z* ^BBBH.D**** "BBB@ HHHH **** .0T?\
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M^>VH_P#@4:Q_%7@C2M)\,7]];RWIEAC#*)+@LN<@<C\:](KG/'G_ "(VJ_\
M7(?^A"@#*T_X>Z-<:;:SO+?AY(4=MMR0,D \58_X5MH?_/;4?_ HUT>C_P#(
M$L/^O>/_ -!%7: ./_X5MH?_ #VU'_P*-'_"MM#_ .>VH_\ @4:["B@#C_\
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M&64Y(4<#V'M2L:N:Y?,[3QB\MMX7TB.Q9DLF3YS'P,X&,D?C1J1>?X;64VH
M_:%D7RF;[V-QQ^F*YW3?%FI:9:?9%\BXMQ]V*X3<%^E5=7U^_P!:E1[MU"1_
M<B081?H*5A\ZW.N\>W,\.D:1''*T:,H+!3C) XJ;Q<$GL_#S7)#!Y4$C'N#U
MKCM7\0WFM0VT-RD*BW&%\M3GICG)HU7Q%>ZO9VUK<I"J6_W3&I!/&.>:+ YH
MZ/X@W%]!JMG%;O(ELL:F$)P"WM^E:'B-0S^&I;A0+UF4/ZD8'6N9M/&VJVMM
M' ZVMTL?W#<1;F7Z'(JK#JMWJOB2TNKV;>_FCKP%'H!VHL-S6YT?CJYU&'Q3
M9>0\J@*I@"YP6S^IK5UI8QX^T-@!YK(WF8[\<52\4^*[S2]>,=K]EGBV*R^:
MF_8?]D@UQ_\ PD%__;B:O(ZR72G*[Q\HXQC H2'*23-GQ>]S=^-&M!.RAF2-
M.3A>?2NANC9:7K]A97 OM2U)E79)*_R*,GH*\_U'5;G4]3;4)=B3L0<Q @#'
MIDFME_'FL/"J[;42(NT3^5F3\R?Z46)52-V:'CBTN+WQC;VUFK--)$  IQ5_
M5]0M_!>A+I5G/OU*89DE)R5SU8^GL*YMO&FI-J\>J&&T^T)$8L^6<$>O7K4\
MGCW499"\EAICN>K/;DG_ -"HLQ\\==2]X>M$M_"5UJE_=WALBYW6UNV-QR,D
M^N<UJZC<07/PUGEMK4VT!_U:,V3C/6N2L/%^I:<;D1QVSQ3OO:&2/**3Z#/%
M.N_&6IWNGW%A.ELT$_&T1X\L?[.#Q^M%@4XI6.AUFXE@^&NGB*1DW[02IP2,
M],TS5W:?X8V4DK%W!3#'D]:Y:[\17MYHD&E2I"+>'!4JIW''OFB?Q%>3Z%'H
M[I#]FCP0P4[N/4Y_I187.C7^'2PGQ*?-4%A"QCSV;(_IFKFAW6IO\1)EE>4Y
MD82H<X"]CC\JXVTNY["[CN;:0I,ARI%='_PG^K^<LRPV2OGYF6$Y<>YSFFT*
M$TDD=+I7_)2-7'K&,?\ ?(K*\%0NOC6^!1L1[PQQTYKFU\1WZ:\^LQF..Y?[
MP53L/ &,9Z<5J#Q_JZ7/G)#9(2/F58B-WUYR:5F/VD;FMHM@TNIZ_>R7ES!;
M0R-YD5L<-)P3U_"M/1[NRO/"NIM86<L%N P#3-EG..2?TKAM/\4:CIM_<W<!
MB)N26EC=24)]<9_K5P^.M6*31^59B&5=IA$1"+UR1@]:+,:J12-:X_Y)':_]
M=/\ V=JX/W'45K/XAO'\/QZ(4A^RH=RL%._J3USCO63]*:1G.2=CO?&$C?\
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MOED$8&>5/2K^GZ3%9:F\-KJ*27 C<2*8-P4<>_>D;5K8:YIP;4Y+F&$EI)9
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MBBB@ HHHH ****8!1112 **** "BBB@ HHHH **** "CK110 4444!8****
M"BBB@ H//7FBB@ P!V%! /7FBB@ Z4444 %%%% !1110 4444 %%%% !1110
M 8XHHHH **** "BBB@ HHHH ****  U]"Q_ZM?H*^>C7T+'_ *M?H*F1T4!]
M%%%0=(4444 %%%% !1110 4444 <AH__ "4KQ'_UPM__ $$5U]<AH_\ R4KQ
M'_UPM_\ T$5U] !1110 4444 %%%% !1110 5'/_ ,>\G^X?Y5)4<_\ Q[R?
M[A_E0 VT_P"/*#_KFO\ *LCQ?_R+D_\ O)_Z$*U[3_CR@_ZYK_*LCQ?_ ,BY
M/_O)_P"A"A ><=Z*#U-;5GI8_LI;UK&:]DD?:D<>X!0.I.WFF(Q:.]=(FAVP
MU>V26&5+:XA:3RG)5D(ZCU__ %U2M8[&]GE\NPE/EH2D$1=S*?\ :(^[0!D5
M)#!+<.4AC>1@"Q"\\#J:WI]!66*UV0K:S23^2\:S>8%[YSG@\=*ETU]/34KN
MWM[9T9(759?,)+X'.1T'X4 <VT,JQ)*T;"-\[6(X-,Z^];4&DPW5II83*27,
MCK(^>P[@5#=?V6RW,<4+P2Q/^Z8LS>: <'/IZT 9?7TIRQ2,CR*C%$^\V.GU
MK=L],@>&W*V+W",H:6XED:%%R>BDX!ZU8,,&G:9K5KY E\J1!N+D%@<XZ>GM
MUH YR6"6':)8V3<-RY&,CUJ/WKH?[&LS=0YWK MH+B4 G+'T'I57[/9WVFSW
M-M";:2W8%E\PL&4^YZ&@"JNK7RV!L%N"+8_P!0._KUJE73/IVF+KBZ6ML_SI
M_K3*V5)7/ Z&N:D78[K_ '210 GZ^U%;>HV^GV26L*6Q,DT*N\C2-\F3U '7
MO5VWT2WN)_(%B\4+#:EU+(R.S8ZA#U_"@#FC'((A*4.PG"L1P3Z4S\:Z;R8[
MW0]+LT@5&EF9 ^]OEYY./?TI/[%BGFN+5--NX B'R[I]^&(YY!X - &%9WUQ
M83&:VDV.5*D[0>#UZU'-%-&5>9&4R#>I(QD'N*C8$,01R/YUT4&D63ZA8Q,C
MB.6T,KX8_>YYH YVBM9K>RNM'N;JWMS!) ZJ,.6W@^N>A^E5M*MH+S48XKA@
MJ$'@M@,<<#/;)XH I=#WH[^_:M>^M(XC%')I<]G(9MI.YF1EX[GO]*G32[1O
M%,M@4;[.JDA=YR/E!ZT 8K02K D[1L(GR%?'!]:$AEE61DC9E09<CD*/>MQY
MK2'PUI_VBW-P=[A5+E0/F/.12OHUL%NY(P[1F!9K?<3E<D#!]>M '/=J*Z;^
MQ(H;F&T;3;J8,H\R[7=A2?0=,53.FV^G6ES<7D9G*3^3'&'*@XYW$CZT 9$<
M;S.$B1G8] !DTS_''2NCT4V*:[FU0O&\#, Q8&,[>5]_3-,@L;:6R6[ATUKP
MM(1+%',VZ$9Z #D_C0!S]*#M8,."#D&I+E8TN)%B21$#<+(/F ]ZNV=E#=Z3
M=2*I^TPNI!!_@/'2@"K>WUQJ$_G74GF2;<9P!Q^%-^R7!\L"%SYHS'@?>'J*
MZ"XT2RAODPC&V2W=IOG/+KD'GZBI-)M[6VO=,E2 E[BWD=F+G@@'D?AQ0!S)
M@F$'G&)Q%NV[\<9]/K4?'>NB::T7PV\LEIN3[8P2(2$ ''][K6=K-G!:7$1@
M!6.:%90A.=N>H!_"@#.HHHH *<CM&ZNAPRG(/O3:* +=]J=YJ3HUW.9"@PO
M 'Y54HHH **** #O7H_@_P#Y%R'_ 'W_ /0C7G'>O1_!_P#R+D/^^_\ Z$:
M-/4?^/%_JO\ Z$*LU6U'_CQ?ZK_Z$*LU+&>5KX3UP?M!MXE^P-_8YMMGVGS$
MQGR=N-N=W7CI3OACX4UO0/%_B>]U.P:WMKR8M;N9$;>-V>Q)'XUZE13 \L\
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M&<3>9* -_KG!.*=%J6E07D]XD=UYDR,OEE5VH2.2#GG\JP:D6WE:$2JF4+;
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MC!R3S5=-6\G6Y-02+*2,Q,;GJK<$?K3_ .T;.VMKB.PAG$EQP[2D?*N<X7%
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M>".> >OXTE27$S7%Q),0 78M@=JCH **** "BBB@ HHHH **** #O7H_@_\
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M %<YX]_Y$;5?^N0_]"%='7.>/?\ D1M5_P"N0_\ 0A0!K:/_ ,@2P_Z]X_\
MT$5=JEH__($L/^O>/_T$5=H **** "BBB@ HHHH **** "DI:* (9YXK:!II
MYDBB09:21@JJ/4D\52'B/0\?\AG3O_ I/\:R?B.!_P *\US_ *]C_,5\P[5_
MNC\JZ*-#VB;N<]:O[-I6/K3_ (2/0_\ H,Z=_P"!2?XT?\)'H?\ T&=._P#
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MO]T?E1M7^Z/RH^IKN'UM]CZT_P"$CT/_ *#.G?\ @4G^-'_"1Z'_ -!G3O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%%  :^PH?]2G^Z/Y5\>FOL.'_41_[H_E7!C.AW
M83J/HHHKB.T**** "BBB@ HHHH **** .0T?_DI7B/\ ZX6__H(KKZY#1_\
MDI7B/_KA;_\ H(KKZ "BBB@ HHHH **** "BBB@ J.?_ (]Y/]P_RJ2HY_\
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M '(/^_G_ -:O1:* /.O^$-U?^Y!_W\_^M1_PANK_ -R#_OY_]:O1:* /.O\
MA#=7_N0?]_/_ *U'_"&ZO_<@_P"_G_UJ]%HH \Z_X0W5_P"Y!_W\_P#K4?\
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M8/'% !J/_'B_U7_T(59JMJ/_ !XO]5_]"%6:3 6BBBF 4444 %%%% !1110
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *[_P *_P#( B_WW_\
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MYK?_ %[G^8KYBKZ=^(W_ "3S6_\ KW/\Q7S%7H8/X6<&+^)!11178<84444
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MYBK=&[>NY"K62T/;O$]C;W_@V_U#Q;H]CI6K(A^S&&57=R!QR.N3VK,BMO\
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MNJ_]#CJWYC_&NPHH X__ (0W5?\ H<=6_,?XT?\ "&ZK_P!#CJWYC_&NPHH
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MH **** "N_\ "O\ R (O]]__ $(UP%=_X5_Y $7^^_\ Z$: -#4?^/%_JO\
MZ$*LU6U'_CQ?ZK_Z$*LTF M%%%, HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ I*6DH Y?XC?\D\UO_KW/\Q7S%7T[\1O^2>:W_P!>Y_F*^8J]#!_"S@Q?
MQ(****[#C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M#7V'#_J(_P#='\J^/#7V'#_J(_\ ='\JX,9]D[L)U'T445Q':%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %1S_P#'O)_N'^525'/_ ,>\
MG^X?Y4 -M/\ CR@_ZYK_ "K+\5?\@";_ 'D_]"%:EI_QY0?]<U_E67XJ_P"0
M!-_O)_Z$* . K4T;3(M0:>2>1DA@7<P0?,V?_P!59=;6@1WH,]Q8RKYD8&Z
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M74USJ>I>=(S[89 H8G"]./:FR279\+64L#S-L8F0J3G:#W]J .?6RN6NC:K
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MLHI(K:,DD2-DDUE444 %%%% !7?^%?\ D 1?[[_^A&N KO\ PK_R (O]]_\
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MMS#ZI ^7/^$ \7?]"_>_DO\ C1_P@'B[_H7[W\E_QKZCXHXH^MS#ZI ^7/\
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M110 8HQ110 8HQ110 8HQ110 8HQ110 8I*6B@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "HY_P#CWD_W#_*I*CG_ ./>
M3_</\J &VG_'E!_US7^59?BK_D 3?[R?^A"M2T_X\H/^N:_RK+\5?\@";_>3
M_P!"% ' 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %=_X5_Y $7^^_\ Z$:X"N_\*_\ ( B_WW_]"- &AJ/_ !XO]5_]"%6:
MK:C_ ,>+_5?_ $(59I,!:***8!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MEZ*ZC_A"YO\ G^C_ ._9_P :/^$+F_Y_H_\ OV?\: .7HKJ/^$+F_P"?Z/\
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MV?\ &C_A"YO^?Z/_ +]G_&@#EZ*ZC_A"YO\ G^C_ ._9_P :/^$+F_Y_H_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%/_Q[R_[I
M_E4M-90RE3T(P: ([3_CR@_ZYK_*IJJ+8*JA5N+D #  DZ4OV+_IYN?^_E("
MU157[%_T\W/_ '\H^Q?]/-S_ -_*8%JBJOV+_IYN?^_E'V+_ *>;G_OY0!:H
MJK]B_P"GFY_[^4?8O^GFY_[^4 6J*J_8O^GFY_[^4?8O^GFY_P"_E %JBJOV
M+_IYN?\ OY1]B_Z>;G_OY0!:HJK]B_Z>;G_OY1]B_P"GFY_[^4 6J*J_8O\
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9_5?_ $(59JJU@C##SW#+D'!DX-6Z0'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img45497886_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45497886_18.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '2!6T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH QM0\4Z+I=XUK>W\<,Z@$HRDD
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M;_DIFE?1?ZU-X^M7T[5=-\0P<&*01R'^7Z%JZN[\.:=?:O#JD\<ANH<!")"
M,>U<MX[\36<EO=>'X[>2:]<A0 N0#UR/?_&G3J<THJ/31DU*?+&3?75$'A=?
M^$D\;7VNLI,$&$ASV.,#],'\:K:-=6VE?$G5#JCK$TC/Y3R\ 9.1R>F177^#
M-%.B>'H89%VSR_O91[GH/RQ5G6/#&E:ZRM?6P:1>!(IVMCTR*)5HJ<ETV"-"
M7)%]=]3/BU_P]=^)TM((8;B_8<7*1!L8!XW#T%<_X<_Y*MJO^X__ +)78Z/X
M9TK0BS6%MLD8;3(QW,1Z9/:BU\-Z=9:W/J\,<@O)@0[&0D'..WX"H56$5)1O
MJC1TIR<7*VC.,TU%?XOWFX X5B,CH=JU)XA4+\3](P ,A<^_-=?#X;TZ#79-
M92.3[;("&8N<<@#I^%+=>'=/O-8@U69)#=P8\M@Y _*J]O%ROY6)]A+EMYW.
M<UCPIXCOM4N+FT\026\$C92(2.-H^@.*["P@EMK""&>4RRH@#.23N/KS5G%'
M-<\JCDK,Z(TU%W1YIX_VV_B[2+N]4M8!0&],AB3_ #%7/'VM:1>>&O(M[J"X
MG=U,8C8,1SR?:NTU'3;35+4VU[ LT1YPPZ'U%8MEX#\/V-T+B.S9W!R!*Y<
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MV?\ ?/2KFG>%M+TI+M+2*1$NAB1?,)&.>GIUK:6(ARN*\C&.'J*2;.5^&_\
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M"T445!H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4AZ4M% #$1$&U551Z 8I]%% !3717&UE#*>H(R*=10 U0 ,  8
M["G444 %%%% !1110 4444 %%%% "5$]M#(VYXHV;U*@U-10)I/<:BA1M4
M= !2GI2T4#(A#&)/,$:ASU8*,U+110)*P4444#"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH 0U%]GB,F\Q(7_O%1FIJ*!-)C:=24M PHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M167YTO\ ST;\Z/.E_P">C?G1<#4HK+\Z7_GHWYT>=+_ST;\Z+@:E%9?G2_\
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MH_B+1O$$<DFD:E;WJQG#^43E?J#S0!IT5CZOXKT#0)$CU;5[6T=_NK(QR?P
M-6K36=-O],.I6E]#/9!2QF1LJ![^E %ZBN;D^('A&*UANG\0V2P3$B-]Q^;!
MP>,9K6;6=,32#JS7T/\ 9P3S#<ALH%]: +U%9L7B#2)]$;6HM0A;3%4LUR,[
M  <$],UPWQ*\9W%KX+L-8\+ZMB.XN@@N(0"'7."/F'J#0!Z7167-K5CI6B0:
MAJ]]%;1&-2TLIP"2/;^E,T?Q5H/B"1HM(U:UO)$Y*1L<C\"!0!KT5Y;J7Q:L
MX?B-::/'?6D6BQ@_:KLY.7Y&W/;!K6?5M3D^*EK;0^(;3^RI+59!IV_]X^02
M& V].G>@1WE%9.L>)M#\/B/^U]5MK,R?=$K<G\!DU8T[6M,U>Q-[IU]!<VHR
M3)&V0,>O>@9>HKFW^('A&.U%RWB&Q$)<QAMQ^\.HQC-;EC?VFIV<=W8W,=Q;
MR#*21G((I 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#7HHHJQ!1110 4444 %%%% !1110!1O?]<O^[5:K-[_ *Y?]VJU
M2QA1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH \E^.\2S:1H<3C*O?!2/8BN>^*GA;1M,D\(P6%C%:B=O*E:%<
M%QA>I[GD\UZKXQ\&6WC*"QBN;V:V%I.)E,2AMQ'8YJ+Q5X$M/%<VD27%]/;G
M37WH(U4^9TX.>GW?UIW \]\:Z'IGA[XH^"H](LXK-3+&K"$;=P$F.?4XZFI=
M/_Y.4NO^N3_^BS7H'B'P1;>(O$ND:W->S02Z9('CB1 5D(;=R3S[5%!X"LX/
M'\GBY;^<W$BE?LY0;,%<=>M '+_'S_D2['_K_3_T%J]'T;_D!:=_UZQ?^@"L
MCQKX-MO&^DPZ?=7DUHD4PF#Q(&)(!&"#]:W[2W6TLK>V5BPAB6(,1@G: ,_I
M0!Y]\<?^2:W'_7Q%_P"A5U7@O_D1]#_Z\HO_ $$4GC#PM!XQT!](N;F2VC:1
M9/,C4,1M.>AK2TC3DTC1[/38Y6E2UA6)9& !8 8R<4 3W/\ QZ3_ /7-OY&O
M$?A!X7T'6SK]SJEK%=S)=-&$EY$:G/('J?7VKVZY_P"/2?M^Z;\.#7@7PY\"
MV_BJRUFY75+[3;I+UXS-:/C>G]TC/3DT(!_A2[N- 3XC6&C22"SLX9)+<J=P
MC8$C(/<@ #\*U_AQX,\+ZM\,I;^_M8KBZN!+Y\\C?,A&<8/\.*]#\)>!](\'
MZ-+I]FK3"?)GFF )E^O8#':N5NO@CHTEQ<&RUC4K"RG8-+90D%#[<FF!YS:7
M=U-\"]9MIF=K:VOT6W9B3P3R ?08''O77WO@KPNGP4-^+:%KH6@N!>;OG,F?
M7],=*TOB9H.G>&O@_/IFF0"&WCEC..I9B1DD]R:J:3\']+UCP[I<KZSJ<5E+
M$DSV"ONB+8Y(R>,T <GXDO+J]^!7AB6[+M(MRR!FZLJMA?T %=1\:V7_ (5M
MHJEERTR;1GD_)7H&M^"-'USPM'X>DB:"SA $!BX:(CH1Z_UKC[GX'Z=>V$=M
M>>(M6N'APL$DI!$2?W57. *+B,_Q6?\ B[G@C_K@/_0:D\03Z/J?Q-N[32O"
MS:[KL$>V9[N<BWC]MIXP,CGW-=IJ7@6TU/Q1H^NO?3I-IB;(X@@VOQCD]JS]
M;^&%IJGB277K#6M2T>]G&)VLFQO]\YXZ4@.&^$ML\?CSQ3IE[9V\"/'B:TB.
M^)>3P,Y!%3_"33;!_'WBHO96[&UN&-OF)?W7[S V^GX5W/A;X;6'A'7[K5;&
M_NI/M,>R2"8!LGNQ8\Y)R?QJO%\+;*V\92>([36+^V:6X^T2VD>!&YSD@G/0
MF@9QW@6XGM-2^(EQ;DB>(2.C#DA@&(-+\)O"?AS7_!M_J6K6T5Y?3S2K/)*>
M8P #D>AY)S7H?AKP1:>&M6U>_BO)KEM3??(DB *O)X&.O6N=U'X+:1<WUS/I
M^K:AI<-U_KK:WP4?GZ]/:G<#SO1)YU^%OC;3E=WTZUN2+8EB0.<8!^@!_&M>
M_P#"NAVWP!CU*/3H1?/%',UP5^?<2,_-UQ[=*]*/PZT:+P1/X6L2]K:S\R3*
M SLW=CGJ:ENO ]K=> $\)-?3K;K&L8N @WD*?3I2N ?#>1Y/AUH3.Q8_95&3
M]*ZFLWP_HT7A[0;/289GFCM8Q&LC@ MCU XK2H ****0!1110 4444 %%%%
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M;UT]G C'?&<\?7K0!R7Q&M+^3P=X)LM6F#W;RK#+(CAMP(QG<.O!KO-0T1O
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M]FA_YYBC[-#_ ,\Q18#-HK2^S0_\\Q1]FA_YYBBP&;16E]FA_P">8H^S0_\
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MTOLT/_/,4?9H?^>8HL!FT5I?9H?^>8H^S0_\\Q18#-HK2^S0_P#/,4?9H?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** ($_X_)O]Q/ZU/4"?\?DW^XG]:GI %%%%, H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ((/];<?
M]=/_ &45/4$'^MN/^NG_ +**GH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M($_X_)O]Q/ZU/4"?\?DW^XG]:GI %%%%, HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** ((/];<?]=/\ V45/4$'^MN/^NG_LHJ>@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ***BED9'1$4,S9ZG XH EHJ'=<?\\H_P#OX?\ "C=<?\\H_P#OX?\ "@":
MBH=UQ_SRC_[^'_"C=<?\\H_^_A_PH FHJ'=<?\\H_P#OX?\ "C=<?\\H_P#O
MX?\ "@":BH=UQ_SRC_[^'_"C=<?\\H_^_A_PH FHJ'=<?\\H_P#OX?\ "C=<
M?\\H_P#OX?\ "@!$_P"/R;_=3^M3U65;A9GD\N/Y@!C>>V?;WI^ZX_YY1_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ((/];<?]=/_914]00?
MZVX_ZZ?^RBIZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ J&3_CZ@^C?RJ:H9/^/J#Z-_*@":BDHH 6BDHHU 6BDI:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5#)_Q]0?1OY5-4,G_ !]0?1OY4 2UG:MJ\6D0)--&[JS[ $QG
M.">_TK1KE_&W_(+@_P"NX_\ 037-C*LJ5&4X[HVP\%.HHOJ'_"<67_/K<?\
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MVC22WMRWGKOX#9/')R<<T >QT5Y=K?B[QE<_$.[\+^&(M+*I;1W"SW@8+&"
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MW='I-%>;?VYJG_/]+^E']N:I_P _TOZ4?ZQX?^5_@']D5NZ/2:*\V_MS5/\
MG^E_2C^W-4_Y_I?TH_UCP_\ *_P#^R*W='I-%>;?VYJG_/\ 2_I1_;FJ?\_T
MOZ4?ZQX?^5_@']D5NZ/2:*\V_MS5/^?Z7]*V?#&I7MWJK1W%S)(@B)VMZY%;
M8?/:->K&E&+NS.MEE6E!S;6AV%%%%>V>:%%%% !1110 4444 %%%% !1110
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M7K?6%N;J&>%#&R128CF4]G&.<?44 <3 FH#P=>:_-K6HR7F]HXU%PPC1/.
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M]&+PMM\O!ZXSC.,9XZ9JVM[;-?O8K*#<H@D:, _*IR <].QH M4444 %%%%
M!1110 4444 %%%% !7(-#J'B+7M2A&MW>G6MBZQ)#9[%=FQG>Q96R.<#IT-=
M'J5Y)8:?+<Q6DUVZ $0PC+MR!Q7$>(%@O=7:=O#.OBXV*K7-C*\/F+C.T[2,
MXR>M '1^%KR\GAO[.]N1=RV-R8!<A0/-&T,"<<9&[!QZ5T K \)^2FCF&WTB
MYTN.)R!%<@[WSR6)/)R2>36\.E "T444 %%%% !1110!!!_K;C_KI_[**GJ"
M#_6W'_73_P!E%3T %%%% !1110 E<]XODDCTV(H[KF89*G!Z&NBKF_&7_(+A
M_P"NP_D:X,R;6%FUV.C").O&_<X_[5<9_P"/B;_OX?\ &C[5<?\ /Q-_W\/^
M-1<T5\![:K_,_O/K/90_E1+]JN/^?B;_ +^'_&C[5<?\_$W_ '\/^-144>WJ
M_P S#V4/Y42_:KC_ )^)O^_A_P :/M5Q_P _$W_?P_XU%11[>K_,P]E#^5$O
MVJX_Y^)O^_A_QH^U7'_/Q-_W\/\ C45%'MZO\S#V4/Y42_:KC_GXF_[^'_&C
M[5<?\_$W_?P_XU%11[>K_,P]E#^5$ANKC_GXFS_UT->HQ?ZI/H*\J)X->K1?
MZI/]T5]-P[.4G4YG?8\7-X*/)9=_T'T4"BOJ#Q0HHHH **** "BBB@ HHHH
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M3-+0!!!_K;C_ *Z?^RBIZ@@_UMQ_UT_]E%3T %%%% !1110 5SGC+_D%P_\
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MT>:K1A<@G^[Z_A6CJWA(>'+BT:UU.:YD>ZD.EZ>4P(Y9,;F+9Y"CV'6@#O\
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M+FF?]>L7_H(K1K.T#_D7-,_Z]8O_ $$5HUB>@M@HHHH&%%%% !1110 4444
M%?(.L?\ (=U+_K[F_P#0S7U]7R#K'_(=U+_K[F_]#-=N"^)G!COA12HHHKT3
MS0HHHH **** "BBB@ HHH[4 >G? W_D<;[_KP;_T8E>^UX%\#?\ D<;[_KP;
M_P!&)7OM>5B_XK/7P?\ ""BBBN8Z@HHHH **** &2(DJ%)%#*>H(R#7#+<6G
MASQ/JTVJZ5<,+EE:UN[>S>8>7C'E_(#M(.3CONKO*\P\1O)/J.K7%YJ]_;+8
MW,0^S0W'EJ+9@ 7QCNQZ^U '4>#89UM=1N7LGL;6ZNS+:6SKM9$VJ"2O\.6#
M''O73#I7(^! D<&KP17\VH1Q7I5+N27S!(NQ2,'IQG''<5UXZ4 %%%% !111
M0 4444 00?ZVX_ZZ?^RBIZ@@_P!;<?\ 73_V45/0 4444 %%%% !7.>,O^07
M#_UV'\C71USGC+_D%P_]=A_(UP9G_NL_0Z<'_'CZG$T445^='UX4444P"BBB
MBP!1110 4444 !Z5ZM%_JD_W17E)Z5ZM%_JD_P!T5]1PU_R\^7ZGAYS]CY_H
M/HHHKZL\,**** "BBB@ HHHH *CN/^/:7_</\JDJ.X_X]I?]P_RH ^>E^Z/I
M2T@^Z/I2UJ><%%%% !1110 4444 %%%% !7JWPU_Y%N;_KZ?_P!!6O*:]6^&
MO_(MS?\ 7T__ *"M*6QM1^([*BBBLSK"BBB@ HHHH **** "D-+24 ?./QA_
MY*+<?]>T/\C7!UWGQA_Y*+<?]>T/\C7!U[-#^&CQ*_\ $84445J8A1110 44
M44 %%%% !7=_!_\ Y*+:?]<)O_0:X2N[^#__ "46T_ZX3?\ H-95_P"'(VH?
MQ8^I]'TM%%>,>V%%%% !1110 5#)_P ?4'T;^535#)_Q]0?1OY4 344"B@!*
M*6B@ KE]7\S5?%-OH;7ES:VPM'NV^RS-%)(0ZJ!N4@X^;G%=165K&A6VL^4T
MDMS;7$1_=W-I)Y<J ]0&]#W% '!ZA'=:+<^+C!J,[2+%8>5*9#YB*96&TMU)
MZ\GL:['Q!=30:MH444\D:S76UU5L;QCH?44EGX/TJSCU!2)[AK]%2Y>XE+M+
MMSAB?7GK["HK+P3I]I>VMW+>:E>SVC;K=[NY,GE<8P..G% '->([J62SU?5-
M.NM>NIK/S2)8;DVUO"8\\;20L@4C!ZYQ70Z%(T_BS597^\]I:L<>I4TZY\#:
M5=)=P2S7QLKIG>6R%P1 2QRQ"XXR23]:U[+2+6PNY;J'S/-EBCB8LV?E08%
M& =+B/Q/6[^T7N\6)?8+E_+^\!C;G&/:L33=)G;PSJ6J#5M0AFANKA[=+>X9
M(TQ(W#(#A^<YSG]*[>ZT2"ZUJTU7S[J&XMU*XAEVI*I_A<?Q#(I8=#LX-+GT
MU!)]GG9V?+Y.7))Y^IH Y#4=3U36-7LM/CMK^6+^S8KV1=/O5MF9V..6+*=O
ML.,U Z:^!8:7/<7UA!)J(BC9[P2W!A,3EE9U8GMP2<]^M=9?>%K"]2RVS7=K
M-9QB.*XMIMDH0#&TMW%/MO#.GV\=J 9WDMYS<>;)(6>20@@LY[\$T 8.I6D(
MO4T>"^\07<EK"K""VNY(V&[/S23Y&XG' 9NW%9>F7NJ:O:^&[6;4KRU\V6\B
MN-L^9)%C< *74\L!QN!SU]3787_AFTOM3;4%NKZUFD18YOLL_EB8+G:&&.<9
M/YFL6Z\$6L=SHEE8PSQV%H]Q(9(Y=KP.^TAE/7.=WZT 07%IJ%IK-]X>L-4O
M76>P^UV[SW+R202AB/ODY*G'3I6CI^M2>(]2T@VK3P0);?;+D*V/F(VK$_O\
MV['^S5ZST6#P[#>7MO'?:G?2+\SRS+)/(!T0,Q  ] 2!47A/1FTR"^NYX/L]
MSJ5T]S)$2"8P3\J'!(R!P<'% '1#I2T@Z4M !4/_ "^C_KF?YU-4/_+Z/^N9
M_G0!-1110 4444 %)2TE 'G?B+_D/77U7_T$5EUJ>(O^0]=?5?\ T$5"NCW[
M1B1;9BI7<#N'(]N:_.L92G/$U.57U/K</4C"A#F=M"C12JC.VU58MTP!DU:G
MTVYMK<3SA8P3@(6^8^^/2N6-*<DVEL=$JD8M)O<J45HZ;9P30W-U=;S! N=J
M'!8TW5+*.TEA:$L89HQ(@;J :U>%G[+VO0S^L0]I[/J4**WH=(L]EO;2F7[7
M<1EU8'Y5/H12PZ/9JMM;W)E-U<ABC*<*N/:MEEM9J^AE]>I>9@45O1:/:0K!
M#=^:;BX9E4J<!<' R*99:)%()S<S+E VU%;YB5SR?0<4?V;7O;^D'UZE:YB5
MO^$/^0R__7%OYBL^.TMVTF>Y$C&:-@-O0+DXK0\'_P#(9?\ ZXM_,5KE])T\
M92OU(Q=13P]2W0[JBD[TM??GRP4444 %%%% !1110 4444 <+\3_ /D$6/\
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M]2O2=*Z"WTVR6.Q@FB9YKL$[]V-GI6;;6/G:L+,L<"0JQ'<#BNF>"G'E\_\
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MO1<.3NSBNW:O5OAK_P BU-_U]/\ ^@K7F%[<_:[V:X$:1"1RP1!A5]@*]/\
MAK_R+4W_ %]/_P"@K2EL51TD=E1114'6%%%% !1110 4444 %%%% 'SA\8?^
M2BW'_7M#_(UP==Y\8?\ DHMQ_P!>T/\ (UP=>SA_X:/$Q'\1A1116IB%%%%
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M%_JD_P!T5Y2>E>K1?ZI/]T5[G#6]3Y?J>;G/V/G^@^BBBOJCPPHHHH ****
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M9_G4U0_\OH_ZYG^= $U%%% !1110 4E+24 >=^(O^0]=?5?_ $$5EUJ>(O\
MD/77U7_T$5EU^;X__>9^I]AA/X$?0****XSH"BBB@ HHHH **** "M_PA_R&
M7_ZXM_,5@5O^$/\ D,O_ -<6_F*]#*_]\I^IR8[_ '>?H=U1117Z(?)!1110
M 4444 %%%% !1110!POQ/_Y!%C_U\'_T$UYC7IWQ/_Y!%C_U\'_T$UYC6D=C
MCK?$%%%%,R"BBB@ HHHH **** "@]**#TH ]WT#_ )%S3/\ KUB_]!%:-9V@
M?\BYIG_7K%_Z"*T:R/06P4444#"BBB@ HHHH **** "OD'6/^0[J7_7W-_Z&
M:^OJ^0=8_P"0[J7_ %]S?^AFNW!?%(X,=\,2E1117HGFA1110 4444 %%%%
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M-N_$VCVMU]ADU2UBO6+(D;MD[E7)!'L"#2/XDTJRLHI;_5;-&:)9"ZMA6#9
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MN,Z HHHH **** "BBB@ K?\ "'_(9?\ ZXM_,5@5O^$/^0R__7%OYBO0RO\
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M'_'M+_N'^5 'ST/NCZ4M(/NCZ4M:GG!1110 4444 %%%% !1110 5ZM\-?\
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M/77U7_T$5EU^;X__ 'F?J?883^!'T"BBBN,Z HHHH **** "BBB@ K?\(?\
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M1110 4444 %%%% !1110 5ZM\-?^1;F_Z^G_ /05KRFO5OAK_P BW-_U]/\
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MN^@?\BYIG_7K%_Z"*T:SM _Y%S3/^O6+_P!!%:-9'H+8****!A1110 4444
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M09"/^FP_D:X,S_W2?H=.#_CQ]3B:*0&EK\[L?7A1110 4444 %%%% !1110
M'I7JT7^J3_=%>4]C7JL1S$G^Z*^IX;_Y>?+]3P\Y^Q\_T)****^J/#"BBB@
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M_&C_ (1?2O\ G@?^_C?XULT4?4</_(@^L5?YG]YC?\(OI7_/ _\ ?QO\:/\
MA%]*_P">!_[^-_C6S24?4</_ "(/K%7^9_>8W_"+Z5_S[G_OXW^-;*J%4*.@
M&!116M.A3I7]FK7(G4E/XG<6BBBMB HHHH **** "BBB@ I&4.I4]",&EHH
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M2*"BBB@ HHI,T +11FB@ I#2T4 <QK7P_P##?B'4FU#4K S73*J%Q,ZY Z<
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MFV#0W2*RJYG=L C!X)(KI\TE)U)O2XU3@G=(*6DS2U)84444 %%%% !1110
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M6DQ2U[!P!1110 4444 %%%% !1110!ROCG1;[7-/M8;"-'>.;>P9PO&TCO\
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MO,^;_P#A3_C+_GRMO_ I:/\ A3_C+_GRMO\ P*6OI#%&*/KE3R#ZE2\SYO\
M^%/^,O\ GRMO_ I:/^%/^,O^?*V_\"EKZ0Q1BCZY4\@^I4O,^;_^%/\ C+_G
MRMO_  *6E_X5!XR_Y\K;_P "EKZ/Q1BCZY4\@^I4O,\F^%W@37_"_B.ZO-5M
MX8X)+0Q*4F#G=O4]![ UZS1BEK"I-SE=G13IJFN6(4445!84444 %%%% !11
M10 4444 %%%% !1110 444E $4 /F7'O)_[**FH%% !117!?$![C1-1T;Q1#
M)-]GM)_*O(E<[3$XQN8=.#_.@#O:*\DMM6U&70/%_C>UGF/FDQ6"L252-,#>
M%Z<Y_2LR[MSX9T+1/$FG>);Z[U6[DB,D$MSYD<V_!90G;K0![=17CR:3+XA\
M0^-$N-5U*&*T<R1107!10^TD>_X#%13^(=7?X5:'G4)(WO+U;.>\_B6/GOZ\
M=: /9J*\EC@_X1'QOI>F:1K=Y?VVH02?:8;BX\[9@<.#VKG]+L1>^ -0UV?Q
M-J$>H:>\K6\0NL+&5)(!4\MGW/>@#WJBO'M7N=2\1W/@>*34+JS?4[4_:6MV
MV%@5R>.@)'?MFM'Q5:6&D6^B^%XK[7+F5BSK!!.!)< ?WY3T ]O>@#U#-%>.
M^#KA9](\5Z7K>H7EMI=FZD%KO?)"#DD"4#GH*;X TE;G69O$K:K?0:1%N^Q6
MUS>F1Y0."SC/3CIB@#V2BOGK5=1E6R7Q%I-UK;%KL%+ZYNU6-OF^Z(0#D?E7
M2Q:7+XD\5^+8;K5=1AAMT62..WN"@W[3S]/88H ]@S7(Z]\0](T'4Y--:WO[
MZZB3?-'90>9Y(ZY;D8XYIGPQOKO4/!%K)>3O/+&[Q>8_)(4\9-4_%_B*'2]1
M;2=#M+:7Q'J*;79L*(TQC?(?0#M0!L3^.=#A\+Q>(!.\EG+A8UC3,COTV!?[
MV>*=X;\9Z;XFFN+>WBNK6[MQF2VNX_+D"G^+&3Q7G>NZ%%X8T;P19"X6:WBU
M5'N9E;Y2Y.3^&:U+^5)_BUJ<MFX;RM#?SI(SG'''([]* /4A2UX ]M>P?#O2
M/$<>MZHNH-?+ G^D95$8L,;>_P".:ZBTBN_"WQ(%A:7]]>1W.E27<J7,N_?*
M,\KZ<]J /5Z*\%6V:_\ AS>^++CQ/J":Q+YF^-;G:G4KLV=N/2O8?"CO)X3T
MIY&9G:U0LS'))QW- &S1163XETM]9\/WMC'-)#+)&?+DC8J58=#D4 :U&:\;
MT?7+OQE?>&-!,L\,VG9DU3:[ DQG:%8C^]M_6I$M!XNU_P 33:SK][I_]F3&
M*VA@N/)$:@$[B/XNE 'L%&:\,35M6U[2_""7&HW<<DM]/;FYA?:TD8 PQ['C
M/.*Z/P\MSX<\<^(-'MKZ[NK..S%S''<R^8P?!Z$T >H45X3%$]WX#G\:W'BB
M^CUP%Y%C%P!&K!B GE_A6B[3>)?'=A:ZEJ]WIT-YI$<LT<$_E[VP"5&>GKZT
M >RYHKQFUU"\L_#7CK1X=1N+NTTHJ+2Y>3=(H)R1O'7IUK9T?3H/#W@>;Q-J
M.NZK)<7-BIEE:3>(\]/+3& <8% 'IM%>%:1<7>E>+_#4EF^K0P:A($D-]>"7
M[0A_BV8^7KZU-X@TBUUKQN^D:#K&HQRK*9=1NI+\B*$$\JB\9/\ *@#V^BO)
M?%7V.YUF#0[:ZUJ_ELK,$PVUT(4 _P">CR=2?P]*YRSU+5-3T#PU;RZI>1M_
M:\UL)4E^<1@+@$XPW4\D4 >^UC^(_$NG>%]/6\U%WP[>7%%$NYY7/\*CN:XS
MPQ;3:!\3]1T.#4+RXL'M5F"74OF$-W()KKO%.IZ-HNDG4]9CC>.V;?$&4%C)
MV"^] %7P_P".=*\17%U;1Q75E=6R>9);WL7EOL_O8R>*H6WQ1T"YU2.T\N^C
M@DE,,=])!BW=QV#9_I6!IVG:AJJ^(/%NI>3!?W6G/#:VD4@9HHL$Y;'?I7/W
M5Q:2? O0;<.C77VN-0@.6W[V[=: /=:*\GFTR?7/B/JNFW>IZA;V\>GPNT5M
M.4RVW\<<^E<K''J/_"L5\4MKFIM?65R(;=?.^14#[?F'\7XT ?06:,UY1J*2
M>*OB,VC:IJMY86-K8)/"EO/Y1E<XRV>_7./:KWPNEF;4O$T,FHS7\<-TB1S2
MONR "..WY>E 'I!K&\0>([3PXEF]Y'.XNKA;=/*4'#-T)R1Q6R*X#XJ?\>_A
M_P#["L7\Z ._'(!I<UXCXLNXM5O]<O-/N-:N)+$;3*EV+>"V9>< <E^E7-3O
MM1U;1O #2:E=0S7CLLTT+[6;C'TZ>HH ]BHKS'PW!<:#\0M:T.WU*ZELOL:S
MH+J7>4<CKDUR>GW=]HFIV5]KKZK)YEV0VJV>H*\$I+<+Y17IZXQ0![U17D$=
MJ/&'B#Q+/K/B"]L!IDQBM8;>X\D(H!.YA_%TK'DUO4]7T3PF;O5[BV+WTUL;
MR-]I>,8 8]CG.,D4 >[T5Y;HZOX;^([:!IVK7=_IUUI[7,JW$_FM'(,CANW3
MI[U#\-]&.H6@\1ZEK.HR-:3RK% 9SY2J"<[AU;N>M 'K&:*^>]8U&0V3^(])
MNM;=OM@V7]Q=A(S\V-HA Y'Y5TGQ$BM;R_LK>ROM0/B/4(HPD45X8H85 R7<
M?B?\B@#V"JVH7D>G:?<7LP9HH(VD8*.2 ,\5Y5K-E<:18^%_"RZ]<BTU"=UO
M;X3Y8G .U7/0<U$^[0->UGP[8:K=:AIDNDRSR+<2^:89-IQ\WO0!ZEHFL6^O
M:/;:I:I*D%PF]%E # >X!-:->*7NJZC8?"OPI9V,LD2W\B032(XC.TC[H?!V
MD^N.*V/!MKJ^E>,Q:),4L)("TMI/J8NW'3#J=HQZ?C0!W'B/Q1I_ABTBFO1/
M*\S;(8+>/?)(?0"JN@^-])\00WK1BXM);+FX@NX]DD:_WB.>*M:YJ.F6<EK;
M7=Y#:7MVS1V<LB E7QU&>!7E*+<6C>/]+>X&IW_V+S7U-!AG4K]P@<<>U '>
MZ7\3="U75(+)(K^!;EBEO<W$&R&<^BMGOVXKLQ7BVK3VUQ\/? <%LZ/=&ZMM
MBH<L& Y. >*M3Z;+KGBOQG%<:IJ,,%G$)8XK>X*#>%)'X>PQ0![!17@>-1M_
M V@^+#KFHR:D]Y'!M:;]V(]Q&TKCGIU/K72W%NWBSXC:U8ZMK%[I]OIL2?98
MK:X$.=PY8^OKS0!ZO17G?PFN)[C3=8\Z^EO"M^RK-(Y;</4>WTKT2@ HHHH
M**** "BBB@ HHHH **** "BBB@"!/^/R;_<3^M3U G_'Y-_N)_6IZ0!1113
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M20/85<TG1-.T.Q:RT^W$5NSLY0L6R6.3U)K2HH Y%_AGX0D\[=I"XE)+*)I
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MC:1WVFF".&&XR$DW X8G))P.M>R44 >>:KX2U>[\.^%;***(S:=+&UR#( %
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img45497886_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45497886_19.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *J!4\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOK3R-4ENF=U656)*#/I3EB>2W,A1P_/?E>QVE)7*:W'-:/NBU2[,\S?NX%;
M_P#U5?6'4+30</>JMR3EI9FX0'MFFL1[S3CL)T/=4K[FY_*C-<;#?R6VJ6L<
M&J2W@E8+*'.5'TJU&M]?ZY?6R7TT,*<_*<D?3TJ5BE+9>13PS6[TW.IS52YU
M"&VN8;=SF68X5:S?#MS<2_:[>XE,I@DVAVY)K.URS=O$-H!=2J9C\I!_U?\
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M;+3[J6%KH"6=X6((7H>GN#18?.CMJ6FJ,>M.I%A1110 4444 %%%% !1110
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M1/IGM75"HX88[>-8HD"(O  [5)6E"DJ4%%$5ZKJS<F+1116QD%%%% !1110
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M5Y97MU9WD;<S''4GO6W4M6=BT[JX4444AA1110 4444 %%%% !1110 4444
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M"?#G_"(3&$MYWVO<=V<[LXQ^%>S>(_!NF>*;BREU)[DBT;?'''(%4GW&.:Z
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MZD5W[10NJJ\4;*IRJL@(4^WI1Y47F^;Y:>8!C?M&['IGKBD ^BCBBD 4444
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M(^]BNA^&9S\.;(@C'[[O_MM771P00H4BABC4]0B!0?RI1%&D)BC1(U(( 10
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MC)4'M7M+00/$(GAB:(=$9 5'X4>1!Y/D^3%Y/_//8-OY=*+@>9W>G6.E^+_
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M1DCV_,'R*[_Q3H0\2^'Y]*^T_9_-96\S9OQM(/3(]*TX+6"W53'#$LFT NJ
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M[P7-)TG=V&JT;*YZANQ1FN+U?XC:5IWA*UUV%7G%YQ;PCAF;N#Z8-95KX_\
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M\M/[J_E1Y:?W5_*D\Z+_ )Z+^='G1?\ /1?SH 7RT_NK^5'EI_<7\J3SHO\
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MB_E2>=%_ST7\Z/.B_P">B_G0 >4G]U?RH$:#^!?RH\Z+_GHOYT>=%_ST7\Z
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MK<R7,DT9<W$0B<,<C:,G@=NOZ"H]+T6UT@2>09I'DP&EGD+N0!@#)[ 5I44
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M\FCMO+M(IS#!*6R9PH&6QC@9R.IZ4 :GD1?\\U_*CR(O^>:_E4E% $?D1?\
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M+I;:?_9YTVS-EG/V<P+Y>?\ =QBH(/#&@6LZ3V^B:=%-&=R21VJ*RGU! XH
MIZIXST?3-.OKP3M=+8R"*Y2V7>T3'^\.U>?:7=::OQ7L7\/W[ZM#J-O(;PS-
MYH@&,@*Q'R_3\*]8CTVQA-P8K*W0W!)GVQ*/-)ZEN.?QIECH^F:8SM8:=:6A
M?[Y@@5-WUP.: //=6\'Z?I&I6=EI<]Y)?7CR);0R2!H[.)O];(HQD<?*,D_>
MK,T?Q)JEGJUC;6^H*MLNI-IPTGRERL2J/WF<;LDY.<XYKUS[+;FZ%T8(_M 4
MH)=@WA3SC/7' XJ$:1IJZ@=0&GVHO3P;@0KYA_X%C- %RBBB@ HHHH ****
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M6%J\5N084:%2L9'3:,<?A5S% 'CFI6BZ1'K%YI33W<6D/YTMS<D.T]V3M!.
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M !1110 45GZOK%OHULDLR32O(XCB@A7=)*Q[*.!^9%5=&\2VFM&)(XKB"26
M7"),@!9<X.,$C(.,_44 ;5)G%+45QYGD2>3CS=IV9]<<4 29XHSQTKRVSOXM
M-.D7-O#>C6&E6'53.K ,Q&#O)X/S=-M7+>V^RZ'I'B.&1_[6NYT$\[,2) Y*
MX(Z8&01]* /1LT9]J\Z2"]T:5G6UEM9YXY(KB::0%9W+9$@P3PJ@\X') KL=
M!O-.N=-CBT^Y,\<"A"65E8\=2& //7- &K1110 4444 %%%% !1110 4444
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M+_VZ_P#HLUT5<[HW_(Y>)?\ MU_]%FFNI+W1T8HH%%(H**** "BBB@ HHHH
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MRF_Y[/\ I_A1Y3?\]G_3_"I** (_*;_GL_Z?X4>4W_/9_P!/\*DHH C\IO\
MGL_Z?X4>4W_/9_T_PJ2B@"/RF_Y[/^G^%'E-_P ]G_3_  J2B@"/RF_Y[/\
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M)H T_*;_ )[/^G^%'E-_SV?]/\*DHH C\IO^>S_I_A1Y3?\ /9_T_P *DHH
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MXT@>:'37&F76I0Q78>6U@ .]<'ELD< \X[D5)X?DLGOW%OX8O-,?RSF:>W5
MPR/ER&//^%)XRN!!:V*W-U)::9)<A;VX1RA1,' W#E06P"1ZU1\-R:?%XF>T
MT"_EO-,^REK@-<O.L4NY=@#,202"W&>U ':TE+3)"0C%1E@#@>] #LT9XS7G
M^C^);^;4K$2:H;JZE+_;]+$2#[& I/&!NX(QEB<U8M]7UF.PT[7YKXS6][*$
M.GB- D:MD+M8#=G..I/!- '<9HS7!6?B:]BDD:2_-Z\D3[[?RU'V:;=M1!@
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MHPVDMP07)49],UZ=IU_9:E9K<Z?=17-N>%DB?>#CWH MT444 %%%% !1110
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M&B(' SU_"BS'SHZ&BDS2FD4%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !0>E%!H XOQ%XAM;26+2Y/$OV.ZEG?<_D1MY:;20
MK!N,=@>]'A>^4ZTUC#X@?58S TA6.UCCCC.5')7G//3ZU;\79672?+>UM7DN
MMIO9X0_D_(>F2!EON\GO67X3U#49/$"VUYJD-T3;2F2"*%4,3JZ#YL'/(;C/
MO0!WM1SQF6&2,,5+*0&'45)10!PMGH>K26^C:1-IB6L6F%=]\LJ$2@#!V '<
M-W?<!P33[31]8>TTW0;FP\NTL9E=[X3(5E5,E0J@[@2<=1C -=O10!@ZWIE[
MJDDRQGRTB@/V<[L;I6ZDXZ8 Q_P(U!X5TJYT]KEWL1I]NZH$M5=6 8* S?*2
M.?SKI:* "BBB@!&W8^7&?>F?OO2/]:DHH C_ 'WI'^M)^^](_P S4M)0!YYX
MPW?VX-V,^2O3ZFL'\:Z#QE_R'1_UQ7^9KGZ^'S"<EB9V?4^IP48NA%M!^)H_
M$TY$>0X1&8XSA1FEDAEBQYD3IGIN4C/YUR<U2U]3IY87M89^-'XTZ.-Y7"1H
MSL?X5&33IX);:4Q3(4<=5-'-42YKNPK0O:RN1_C2'H>M+2'[I^E$)RYEJ$H1
MY7H>M6WG?9HL!/N#KGTJ7]]Z1_K26W_'K%_N#^52U^@4_@1\?+<C_?>D?ZT?
MOO2/]:DHJQ$?[[TC_6C]]Z1_K4E% $?[[TC_ %H_?>D?ZU)10!'^^](_UH_?
M>D?ZU)10!'^^](_UH_?>D?ZU)10!'^^](_UH_?>D?ZU)10!'^^](_P!:/WWI
M'^M244 1_OO2/]:/WWI'^M244 1_OO2/]:/WWI'^M244 1_OO2/]:3]]Z1_K
M4M!H \Q\1Y_X2"[W8SN'3_=%9=:OB3_D8;S_ 'E_]!%95? XS^//U/K<+_ C
MZ!13XHWFE6.-=SL=H'J:M3Z1?VL)FFMBD:]3D<?E6,:<I)R2T-)5(Q=F]64J
M*E@MIKEQ'#$\C'CY1FI+RQFL&1)B@=ADHK E?8T>SER\UM!N<5+EOJ5JFM/^
M/VWQ_P ]5_F*AJ:T_P"/VW_ZZI_,4Z/\2/J*K\$O0]7'F_[&/QI?WWI'^M/'
M2EK]"CLCXXC_ 'WI'^M'[[TC_6I**8$?[[TC_6C]]Z1_K4E% $?[[TC_ %H_
M?>D?ZU)10!'^^](_UH_?>D?ZU)10!'^^](_UH_?>D?ZU)10!'^^](_UH_?>D
M?ZU)10!'^^](_P!:/WWI'^M244 1_OO2/]:/WWI'^M244 -7?_'M_"G444 %
M%%% "5SNC?\ (Y>)?^W7_P!%FNBKG=&_Y'+Q+_VZ_P#HLTUU)>Z.C%% HI%#
M&1R?EDQ^&:39)_SU_P#'14E% $>R3_GK_P".BC9)_P ]?_'14E)0!'LD_P">
MO_CHKD-)\/ZHOQ&UG7;V,+;R0)!:N65B0,9.!TZ5V=% '&^.= U77FT:UM5$
MMK%>I/=$LJ@*O3@]?I6YK<NLVFG!]%M(;VZWJODRN(UV=SGVK6Q1B@#R?QEH
M_C?7?$,)&APWVC6N&CM9;M(UE? R6 .2 <\&N]\/R:S+HBMJ^G0V%VF5%I;N
MKJ%'W<'IR/RK;Q1B@#S74?!NN7VB?;I4CFUF:_CO+BU9UVLB9VQ9Z8 .>N*W
M/ VA:EI-IJ$M_$EG)>W;3K:QE6$0( QD<=NU==10!'LD_P">O_CHI=DG_/7_
M ,=%/I: (]DG_/7_ ,=%&R3_ )Z_^.BI** (]DG_ #U_\=%&R3_GK_XZ*DHH
M CV2?\]?_'11LD_YZ_\ CHJ2B@"/9)_SU_\ '11LD_YZ_P#CHJ2B@"/9)_SU
M_P#'11LD_P">O_CHJ2B@"/9)_P ]?_'11LD_YZ_^.BI** (]DG_/7_QT4;)/
M^>O_ (Z*DHH CV2?\]?_ !T4;)/^>O\ XZ*DHH CV2?\]?\ QT4;)/\ GK_X
MZ*DHH CV2?\ /7_QT4;)/^>O_CHJ2B@"+9)_SU_\=%<;\2D8>'[?<^X?:EXQ
MC^%J[:N,^)O_ "+UM_U]+_Z"U-;D5/A9Y71116APA1110 4444 %;_@D$^+[
M#!P<OSC_ &&K KH/!'_(X6'U?_T!J'L7#XD>Q[)/^>I_[Y%&R3_GK_XZ*DI3
M61W$>R3_ )Z_^.BC9)_SU_\ '14E% $>R3_GK_XZ*-DG_/7_ ,=%244 1[)/
M^>O_ (Z*-DG_ #U_\=%244 1[)/^>O\ XZ*-DG_/7_QT5)10!'LD_P">O_CH
MHV2?\]?_ !T5)10!'LD_YZ_^.BC9)_SU_P#'14E% $>R3_GK_P".BC9)_P ]
M?_'14E% $>R3_GK_ ..BC9)_SU_\=%244 1[)/\ GK_XZ*>H(')R:6B@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *0]*6@T 8'B6\,#Z9;,\,4%S=!)9ID#*@ + <\ D@ $],U7LI8(?&\
MT-I);S)=6IFD,:+NB964 %AV.XG!_NUG>(_$>FRV\^ESZYX=6=9V66&^C+H$
M!X4KN'S#CGU[4WP1<V?]H7%M9ZCX<F5H][Q:7 4D)! #,2QR!G]: .ZHHHH
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MDUZK/"(QN!4 $L2.@YZT :5%%% !1110 4444 %%%% "5SNC?\CEXE_[=?\
MT6:Z*N=T;_D<O$O_ &Z_^BS374E[HZ,44"BD4%%%% !2&EHH \M\6^)-9T_Q
M/=VUK?R10($VH%7 RH)ZCUK%_P"$Q\0_]!67_OE?\*F\=?\ (XWWTC_] 6N=
MK1)6.*<FI/4W/^$Q\0_]!67_ +Y7_"C_ (3'Q#_T%9?^^5_PK-T_3[C5+Q+2
MT56F?.T,V <#)YJWJ7AW4=+M1<W,<9BW[&,<@;:WH?2BR%>>]R?_ (3'Q#_T
M%9?^^5_PH_X3'Q#_ -!67_OE?\*BT_PW?ZG:BYMVMA&3C]Y,$/Y&J6H:?/IE
MVUM<&,R* 3Y;[AS[T[(+SM>YI?\ "8^(?^@K+_WRO^%'_"8^(?\ H*R_]\K_
M (5AT460N>7<]L\(WEQ?^&;.ZNY3+.X;<YQDX8CM]*W*YWP-_P B=I_T?_T-
MJZ*LV=L/A04444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!*XSXF_\ (O6W_7TO_H+5V=<9\3?^1>MO^OI?_06IK<SJ?"SRNBBBM3B"
MBM33?#VH:M:O<VJPF%&VNSRA<'%5[[2[O3+\6=W&$FXQ@Y4@]"#Z4A\KW*=%
M;Y\':JL1<M9[0NXXN5STS6!0#36X5T'@C_D<+#ZO_P"@-7/UT'@C_D<+#ZO_
M .@-0]AP^)'L]*:2E-9'>%%%% !1110 4444 %%</J?Q6\,Z3J5S87<E\)[=
M]DFVT8J#['N*T/\ A/M 7PS'X@>YD2QE8K'NC(=R#C 7J30!U%%8GAWQ5I/B
MB"2;3)V8Q-MDCD0HZ'W4\TOB'Q1I7A>UCN-3G9/,;9''&I=W/LHY- &U17.V
M?C?0;[P_<:Y#>8L[?B;<I#H>@!7J"?2I-)\7:3K-C=W=O-)&EI_KTGC,;H,9
M!(/J.E &]1533[^'4]/M[Z#S!#.@=/,7:V#T.*MT %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %!HI#TH Y[Q/:S-#9WMO:1W2VEP)9;9F5/-&"!@MQD$AAGTJII$T^I^*CJ4
MED-/5+5H?+>9&DG)92&PI/"XQS_>JQXMLEOCI0DMENX4NMTEF9%4S#:1QN(!
MVD[L9[5C^$O#\FD^(V\O2&M(X+>2&2Y)4K<9=2FW!)X ;.0* .]HHIKN(T9V
MSA1DX&: '45S]OXVT&ZO(+2.YN!/.^R)9+*9-S>F60"K4'B72;G4O[/ANMUQ
MDJ/W;A&(Y(#D;6..P)H UJ*R[/Q#I=_-/%;W6YH 2^Z-U&!U*D@!@/49J];W
M,5W;QW$#;XI%#(V",@]#S0!-1110 4444 %)2TE 'GWC+_D.C_KBO\S7/UT'
MC+_D.C_KBO\ ,US]?"9C_O,_4^JP/^[Q"BBBN,Z@HHHH *0_=/TI:0_=/TJH
M?$A2^%GKUM_QZQ?[@_E4M16W_'K%_N#^52U^A4_@1\;+<****L04444 %,ED
M2&-Y9&5(T!9F8X  ZDT^LCQ5'+-X3U>*!6:5[.555>I)4T <U;?%32[G4X8?
M[/U&/3YYO(AU)X2(9'] >M6M;^(5OI6JSZ=::3J.JS6J![DV4>X0@^OX<UYI
MI.J7VA^%?#FHV7B3[1(TZ6S:/A2H4DY^7.<CUQWK4U.+^V_'/BC;KC^'&@MH
MT=5=5-U\I.6R1TSCB@#UG1=9M->TFVU*Q<O;SKE21@@]"#[@Y%<SK'Q$&F^(
M+G1[/P_JNJS6RJTCV,8<+D9Y]*3X;:O:-X!TKS5M[(?-!&I<*)2K$97.,D]?
MQKD_$&C>#+RX\4:JVL7,>K6Q=BIF,120#("J<;AD4 =GJ/CU-/M-/9M%U"2]
MO(&N#9!0LD**,L7R< CTK0_X2RSDM='FMHY;AM5<+!&N P&,LQSV7@'ZBN2T
M[0;GQ5X2T77;K5Y].U*.R>.:ZV!C)$P^8L"1SCO6-9W-UI<VDMI+16RWI>ST
M^>\7<L4$8W,Y']YV/Y+0![-17.^"=<N?$'AJ*]O%C%P))(G:/[KE6*Y'UQ71
M4 %%%% !1110 4AI:0T >9^)#_Q45V?]I?\ T$5O*C'6K.X1&^S+9\L1P!CN
M:P?$G_(PWG^\/_015);ZZ6V-LMQ((#UCSQ7QKQ$:->HI*]V?1JA*K1AROH:G
MAZ-H=:3S8W7S$;RBPQNX/(K8T8?9["".X4I*UTYC#<'&#S7(M=W#M$SSR,T0
MQ&2?N_2EFO;JXD22:XDD=#E68\CZ5-+&TZ<;)/K^(ZN$G4>K_I'6:0OV:%5N
M49&>^;RPW!/O5*0S6.C7LDJE7^W;HPXZX-8$]]=73*T]Q)(5^Z6;I1<7MU=[
M?M%Q)+M^[N/2KGF$7%J*?E\R8X*2E>37F;>JWDLFF:7<RLKRY+$L 1^59LTR
M7&NK-&<H\R$'&.XJF]Q-)$D3RNT2?=0G@4ZT_P"/VW_ZZK_,5SO$.K4C\C>-
M!4Z;^?XGK:TM(.E+7W$=D?+!1113 **** "FYP,GH*=FHY(Q+$\;$[64J<'G
M!H X#P@#XH\5:MXIG&Z*WD-C8(W\ 7[S?4DBN<T$POX)^()OB&D^V7 EW<G&
M.*]2T'0;'PYIOV#3U=8?,:0^8^XEFZG-8NJ_#;PYK&KMJ5S;S+*[!I8XI2L<
MI'=E'6@"7P)Y_P#PKO2=V?-^R+LY]N*\TTTV[? ;7VN2#*;N0L6Z[_,7'XUZ
MY<>&]/N=4T[4"LL<NGJ5MTCD*H!C&"O0UCW'PS\,W6LG4Y+23>T@E>!92(68
M=RG0T <Y=>$-2N])BU2+4X+2*[TN*WO_ +2I)5%^;*>AQZU3LM<U'3]0CGT^
MPCN[R>Q,EN+MRHBLHOE7'^TQ#-_P(5ZAJFDVNK:8^GW&];9]H98VVY (('TX
MK-UWP9I'B!H'NHYHG@C,2/;2&-MA_A)';VH OZ#JR:YH5EJ:(8Q<Q+)L/\.1
MTK2JO965OIUC!96L8CMX$"1H.P JQ0 4444 %%%% !1110 E<[HW_(Y>)?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBD)H 6BDS1F@!:*3-&: %HHHH **** "DI:2@#S[QE_R'1_UQ7^9K
MGZZ#QE_R'1_UQ7^9KGZ^%S#_ 'F?J?58'^!$****XCJ"BBB@ I#]T_2EI#]T
M_2JA\2%+X6>O6W_'K%_N#^52U%;?\>L7^X/Y5+7Z%3^!'QLMPHHHJQ!1110
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MO_Z U<_70>"/^1PL/J__ * U#V*A\2/9Z4TE*:R.\**** "BBB@ KYP^,/\
MR46Z_P"O>'_T&OH^OG#XP_\ )1;K_KWA_P#0:ZL'_$.3&_PC@Z***]0\D***
M* "BBB@ KV_X#_\ ((UG_KY3_P! KQ"O;_@/_P @C6?^OE/_ $"N;%_PCJP?
M\5'KE%%%>4>N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?\]%_.GX%'%8FXSSXO\ GHOYT>?%_P ]%_.I,#TI./2@!GGQ?\]%_.@S1?\
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M  &;_"OK+BBNGZ[+L<WU&/<^3?\ A$O$?_0!U+_P&;_"C_A$O$?_ $ =2_\
M 9O\*^LLT4?79=@^HQ[GR;_PB7B/_H ZE_X#-_A1_P (EXC_ .@#J7_@,_\
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MXVED^R12)")&&&+ CYB!ZG@CI57PQH.JVNM2ZEJLLA9;=;>)9+A920#G.51
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M:\TFVO);^1FNKNX,SAI!(1Z98!03] !71CI0!SOBC4;C3[G1C!*RI)>;)4!
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MBBB@ HHHH **** "BBB@ Q1110 4444 &**** "BBB@ HQ110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !BBBB@ HHHH **** "BBB@ HHHH
M**** "C%%% !1110 4444 %%%% !BBBB@ HHHH **** (9K2"X(,L88CIDU%
M_9MG_P \!^9JW29H J_V;9_\\!^9H_LVS_YX#\S5K-+0!4_LVS_YX#\S1_9M
MG_SP'YFK>:,T 5/[-L_^> _,T?V;9_\ / ?F:M9HS0!5_LVS_P"> _,T?V;9
M_P#/ ?F:MT9H J?V;9_\\!^9H_LVS_YX#\S5K-+F@"I_9MG_ ,\!^9H_LVS_
M .> _,U;HH J?V;9_P#/ ?F:/[-L_P#G@/S-6Z* *G]FV?\ SP'YFC^S;/\
MYX#\S5O-&: *G]FV?_/ ?F:/[-L_^> _,U:S2T 5/[-L_P#G@/S-']FV?_/
M?F:MT4 5/[-L_P#G@/S-']FV?_/ ?F:MT4 5/[-L_P#G@/S-']FV?_/ ?F:M
MT4 5/[-L_P#G@/S-']FV?_/ ?F:MT4 5/[-L_P#G@/S-']FV?_/ ?F:MT4 5
M/[-L_P#G@/S-']FV?_/ ?F:MT4 5/[-L_P#G@/S-']FV?_/ ?F:MT4 5/[-L
M_P#G@/S-']FV?_/ ?F:MYHH J?V;9_\ / ?F:/[-L_\ G@/S-6Z* *G]FV?_
M #P'YFC^S;/_ )X#\S5NB@"I_9MG_P \!^9H_LVS_P"> _,U;HH J?V;9_\
M/ ?F:/[-L_\ G@/S-6Z* *G]FV?_ #P'YFC^S;/_ )X#\S5NB@"I_9MG_P \
M!^9H_LVS_P"> _,U;S1F@"I_9MG_ ,\!^9H_LVS_ .> _,U;HH J?V;9_P#/
M ?F:/[-L_P#G@/S-6Z,T 5/[-L_^> _,T?V;9_\ / ?F:MT4 5/[-L_^> _,
MT?V;9_\ / ?F:MT4 5/[-L_^> _,T?V;9_\ / ?F:MT4 5/[-L_^> _,T?V;
M9_\ / ?F:MT4 5/[-L_^> _,T?V;9_\ / ?F:MT4 5/[-L_^> _,T?V;9_\
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M\!^9JWFC- %3^S;/_G@/S-']FV?_ #P'YFK>:,T 5/[-L_\ G@/S-']FV?\
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MJ^VG0]SHK!\(:XWB/PQ9:J\8C>=270<@$$C^E;U8-6=F="=U=!1112&%%%%
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M^@J&B@";[5-_?_04?:IO[_Z"N,U/Q[;:;K-_IBZ3J-W<62+(YMU!!4C.>O&
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M*DL+RQNQ'YL:W* >8G]X?_7KHZ )OM4W]_\ 04?:IO[_ .@J&B@";[5-_?\
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M%0U/= FX; )X%0[3_=/Y5+&)12[6_NG\J-K?W3^5 "44NUO[I_*C:W]T_E0
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MK5NJM[RJ@9Z]J&!2HI=K?W3^5&T_W3^5(9QOCO0+K7IM$CBLOM5M%=;KE20
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M]AD 8[USL'PZ,&L1S?VLYTR*]:^2S,(R)3U^?/(]L4 =W1110 4444 %%%%
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M(;S G VMD;>,#H:[>*-8HDC3[J*%'T% #J*** "BBB@ HHHH **** "BBB@
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M90A_FE SEO?/'2NGE\7>'887FEUJR2))#$S&8 !QU7ZUYM\)--L7U7Q!.]I
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MWUJ2B@"/SXO[ZT>?%_?6I** (_/B_OK1Y\7]]:DHH C\^+^^M/#!N0<BEHH
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M/SH =13=Z_WA^=&]?[P_.@!U%)G/2EH 2N=T;_D<O$O_ &Z_^BS715SNC?\
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MW]: )**C\B/^[^M'D1_W?UH DHJ/R(_[OZT>1'_=_6@"2BH_(C_N_K1Y$?\
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MI)^='E'_ )Z2?G0!)14?E'_GI)^8IZC:,9)^M "T444 %%%% !1110 4444
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M_:MTV-HUG]C-K ;7&/),8V8]-O2G6UK;V4(AM8(H(AT2) JC\!0!-129YI:
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MZ$>E0WGA[2=0G6>]L8;B9<;7D7)'XUF_\)MIW_/&Y_[Y'^-'_";:=_SQN?\
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M)LD_YZ_^.BI:* .#\0>.;S1=;N-/CM(95BVX=F()RH/]:S/^%G7_ /T#[?\
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M_19KHJYW1O\ D<O$O_;K_P"BS374E[HZ,44"BD4%%,;S,_)MQ[TG[[UC_(T
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MUC$1QW^_NP?I3;?Q?97%W'&+:[CM9G9(;Z15$,K $X!W;N@/) '% '08'I2
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M\\U_[[_^M1NE_P">:_\ ??\ ]:I**11'NE_YYK_WW_\ 6HW2_P#/-?\ OO\
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MTO\ SS7_ +[_ /K5)10!'NE_YYK_ -]__6HW2_\ /-?^^_\ ZU244 1[I?\
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MO#FBZ_"JKJ]Q.@FO,9>7>2I#'J1SG'L*Z&V\(RI-91W6J/=:?8,&M;9H@"I
MPN]\Y?'T%.M/"<EM/;12:FTVEVDGFV]F80"K<XR^?F R<#'7% '/FQO-$<M]
MDBL998Y(9KCS%/VDEL^:V#GY5!&6YRP%=AH%]IUS8);Z>T@2W54*2QM&X&."
M58 \]<]Z=?:)'J,MR]Q*Q$L'DQ@#'E#.20?<A?RIFC:+)ILDT]Q>&[N951#)
MY8C 51@# )_.@#7IAE )&'_!33Z* (_.7^Z__?!H\Y?[K_\ ?!J2B@"(S*0?
ME?\ [Y->1M]YNO4]J]@/W3]*\??[[?4U\YG^T/F>SE&\_D)1117S9[84444
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MR?\ Z^(?_0J^<Z^DOBG97.K>!YK73K>2ZN&GB810C<Q ;DXKPO\ X0KQ2?\
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M:T <-XV_Y#,7_7 ?^A&N;KJO%MI<W>JQ26T$DJ"$#<@R,Y-8/]E:C_SY3?\
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M 6N6KT#QWX5\07_CK5[NST:\GMI9@4ECCRK?(HR#^!KG?^$*\4G_ )E_4?\
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M.G]PT[RI?^>4G_?!KW+H\%IC**?Y4O\ SRD_[X-'E2_\\I/^^#1="LQE%/\
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M_=SIMJNF1Z@UBTGGL9B0,APNW&.<=<UH>*$"PI<W.L7%A91A@R6S%9)9#]T
MCD]_E YHL!T&!17GD#:WJ'F6U]J5U9W%EIRS+Y;["7))!D ^]Q@$>H-/A\=:
MQ/:R7<.E6IMH!;+*TL[*[--@#:H4C@D9R10!Z#17&CQ7JS79TA-/LCK/G;0O
MGOY CQG<6V[L]L;>I%;/AO5[K6+&>6\M4MIX;AX&2.3>/EQR#@=<T ;-%%%
M!25Q%YXCOM-U[68HVCFVM L,=Q(P1,JY.U45G).!T4TVV\;:IJMMI9TK2[9I
M[RVGF;[3,\:)Y3[2.%+<]L@>^* .YHQ7$MXXN_M%DG]GPPQ2PK)+)<2.BEB2
M&5'VE#C'\3*:L'Q=>JL-^;"'^R+B?R(I1*?-R3A6*XQM)QWS@]* .NQ1BN#7
MQSJUOHUKJNH:1;);WD+M;I#<%G$BJ6"OE0 "%/()J>_\7:QIVD6]U<6&GK<3
M1&?RA/+)^[P#C"1EMW)SQMZ<T =KBC%<.GC35'N;&1=/LFL)K07UPZW#^;;0
ME006&S!8G( ![5#KGBG6(-%E^TVL=D]Y:/+9RV\Q9T(4MA\@ ' [$B@#OL48
MKB+[QW+;:I+8VEDUR+3RUN#Y4S,S,.0FR-E)'/WB*T_$L%W=V,5U;3ZF!&A<
M6MC(L4C,1D%F8C@=U]Z .DQ17G-K?:AKEO*XUBXB>QT^.16A<H'FRVXN/X@,
M;>>X-3Q>.M8N+=[J'2;7[+$]O$YDG99&:55(VJ%(P"V#DB@#T"BN-7Q5J\MV
M=(CT^R.LB8JRFX;[.(P"=V[;NSQC&WJ1]:V?#>KW.LZ;)/=VJ6T\<[PO&C[Q
ME<<YP/6@#9HHI#0 M%<KJ7B]M-FU&"6U4SVLT2QH&/[R-^2W3^%0Q(]JK3>,
M=1L[6&]N],@6UNT<VOESDON4%@'!  R >A- '98HQ7%Q>,M3MH4?4],MD>YM
MXIK-+><N69\_(^Y1M(]LBB^\7:QI]R--FTNT?4WFA1!'<-Y)21@N[<5!&">1
MCM2L!VE%<4_B[6AJD6BII5F=5-P8I,W+"!5\MG5@VW<>%Z;>II[>,[F/Q-::
M8]K;-#<SFV5XI)&97V%OF(38!\IXW;NG%.P'945PEQXQUZWU2YMCI^E-;P$1
MFY6ZD(\T\^7M\O<Q P3M!ZT^S\:ZIJEMI:Z?IMJ;N]>YC?[1*\<<9A)!/W-^
M"5XRH/J!18#N,48K'L;R[UOPT)HBME>RQE21^\$3]"1Z@'ITKD)KZ_M5O$TS
M5KNZT]WAMC=SR%\3%_F\MO3&1Z9(Q2L!Z/BEK@GUS4] U:30[4-J3R7$2027
MLY^02*V=S8)."A/3/S5-#XUU""..ZU.PM(K(3R6TK03L[B1"02H*@%<CJ2#[
M4P.WHKE-,\1:U-J]A:ZCIEK!!?Q/+%)#<,[( ,A6!4#=CT)'O75B@ HHKG?%
M=]/8#27AF>-7OXDD"L%W*3R"3QB@#HJ*X"/XA72C5%EL())+6P-[$('DVR $
M#:6=%!Y/52P]ZMS^+-9L+>[%[I5N;E$BDA%K))*FQC@E\)N&,]@: .THQ7'V
MWBO4=1$=MI]I83WP1I9O]);R50=,$+NW'G@@8QSBJ]OXRUC5)Y4TK2;5E@M1
M/*;FX9#OWLC(N%/0H>3CM0!V^*,5Q=AXTO=4%[>6UA;1Z9:Q(_FW%QL=B\8=
M>,8 &0#S],U37QYJLEIJCQV.GF:P,8*O).BS>8#L5-T08L2 .F.>M 'H&*,5
MQX\4:V;:60:3:^98QJU^GV@_*QY*Q_+\Q Y.<5GQ>-FLK2\N29+EKO4%BLDD
M5V"JT4;<A%8@#=V!ZT >@8HQ[5S^E:M=>(-%NLJ^G7*DQ><8G"^S() I/X@5
MRKW^HZ;<76D_;-3@\Z6W2(WTXDFV,X#NK@D '.!SG)'% 'I5+7 _V[JNBZO)
MH5HIU*1[J-(9KV<C8'1SAF )./+]/XJFA\;W\,,5WJ5A:Q6322P,T$[.XD0X
MX!4#:3WSGVH [BBN5TOQ#K,VLV5EJ>F6D$=Y 9XWAN&<J,9"L"H^;UQD>]=5
M0 4444 )7.Z-_P CEXE_[=?_ $6:Z*N=T;_D<O$O_;K_ .BS374E[HZ,44"B
MD4%%%1RR&.)W",Y52=J]6]A0!)17/R>+K!(K1T2:7[5$98E0#)PP7;UZDG]#
M3)?%T,!6&33;T7K3+#]D^0OE@2ISNVX.#SGM0!T76BL&/Q1'+%&L>G7C7KLZ
MM9C9YB;3@DG=MQ^/-0CQC#+*L5GIM]=R& SNL00; #@@[F'(/84 =+17/6WB
MRVOKJ2*RL[RXBBB662=%78H8$@<D$GY2.!2V/BJ/4#>1P6%PUS:JK- )822K
M9P<ARH^Z>"0>.E '045Q_P#PG]LMFUW/I5_;VZ.5:29HE& <%E^?YQ_NYK0G
M\5Q0W]Q;+IU[+%;2I%/<*$V1E\8/+ D<]@: .@I*S]3-^\48L;B&W4DM-<2K
MN\M "<@'@\XZD<9KGK36=8U,06L$\4,OERRM<^3N$JJ0%(4D8#?-^7O0!V5%
M<C#XW3[-E].NII(8!+<M!LV(-S(3\S GE3P.:NGQ9$HD1]/O$N@5$-L=F^<-
MC!7YL#KW(H Z&BLO2=9753<I]DN+66V?RY(YMN0?8J2#6H.E !12&L"]UV:Q
MURX@:-IK>.U254C #;BV,EF( 'U(H Z"BN:B\96UQ:VLEM8W5Q-<SR6ZP1-&
M2'0$L-V[;T!YSBE/C&U_T55L[HSSAB8"8U>/:0#G+?,>?X<T ='^%'X5A2^*
M+>*1F-K<M:(XCDNP%\M&(Z$$[N,\X&!4,/B^"3$DFG7L-JTSVZW+A-ID5BN,
M!MW)& <8H Z/\*/PKG(_%J2Z2FHKI5ZL,N#%YC1)O7&=V6<!?^!$'FHQXTB>
M+3YH=+O9;>^;$4J-%CODD;\X&#DXQT]10!T_X4?A7.S^*8_+)2UN(DE#BVN9
M OERLO8 '(]L@9J ^,[6SLK(7.);J2TCN)@DL<>P, <X=A^0R: .I_"BL?4K
MNYGTN&[TV\2"W8"1I_(:9MAZ;4 YSQ6-9ZUJ^K16T-K<PPS?9I)Y)#$&W$,
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MA2;3[6Z@E62Z$:";<@4NR@\)NWX]]N/>@#IJ2N=MO%T$\R[M/O8K5Y)(ENI
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MUC4M-UQ8KN[BDCD\QC MN46-0,KB0_?)XXJ-/$=]I=O;WVKR":VNK5IQ'#$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M FHI** %HI** %HI*.M "T4QW\M&;:S8&=JC)/TI0<@'!H =124"@!:*2@4
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MZ=#^-13M)9&ZCCGN"GE12G=(SD$M\QR3P/TKI!T%![47 YV]OHKQ=1:WN!+
M((\%6RN=QSCM39#';ZU=!)W6=[J$[/-/*D+DXST[5T@Z4M '+&Y0-.5O9CJ
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MSEXH%:,)(54$IR<#BB]NO)U)&>Z9F_=[8%F*.,]<+G#@_0UTO\5+1<#F;BZ
M>Y9[N>/4%E'DP!R,KQC"=&'7G'\JDNUD*:G=&XG66W<&,+*RJORJ<8S@_C71
M>M)W_"BX'.7=SY.M<W32.94"P+*RN!_N9PP]\5T@.:2EHN M%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5:&QM[>\N;N
M./$USM\ULGYMHP/TJS10 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
3 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img45497886_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img45497886_20.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *V!),# 2(  A$! Q$!_\0
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M<36\K*MNTSDDXSG&>U:3H<L>:]R(8CFERVL>G44F:Q?%FOKX9\-7>JL@=HE
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MUHSO%<RA3--&V&&XX" ]O<_2N5^'/_)6'_WIOZU7^*5D8OB3)]J=HX;D1L)
M,[5/&1],&K<5*MKV(4FJ+MW-FZ^$>N6&DOJL.L%M3C3S#$A()(Y(#>M=+\+?
M&]UK>D7EEJ#M<7EC'YBR=6D3MGU.>,]ZP;SX3Z79:4VIW'C*=;,)O\WR@01[
M?-S6I\--'\-Z5>7^J:5XCDU%$M\3HUJT?EKUR?4^U1.490=W?Y%PC*,U96^9
MP=C=R^/?$T\7B+Q$;" @E-[A4R#@* > :[/PQX3\8>'?$B2Z7?QWNB%P&8W
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M'X"\?Q>(]*N9M5N+2UNXIB-A<*-F..O7O6"IR<>9;&[J14N5[GF%U_R6\?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH!V%=313E6G)6;)A0A%W2/GSXL(LOQ)C1QE&2)3]#BNBO?@F9Y"=.UR6"TD
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M@7+//)+)XDR\C%V)L^I)S_?KV.BE&K--M/<<J4)))H\8_P"%"'_H8A_X!?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #6-)XELH[Y;?9,T
M9SFX6,F($$#[W3J:V&(')(_&N3=)M,NHGMWM[S3Q'*^P\,%+#<%(X//K0!NW
M6KV]K<FW\N>:11EQ#$7V#_:QTI;C5K:"*%UWS^<,QK A=F'K@=O>J,#7-O<W
M4MG;K<P7;+*"KJIB.P#Y@3TP >*S_"XD%W$)F!;[-)L*CY2OF\$>U &]_;%K
M]A-UE]H;88]AW[_[NWKGVI]EJ4-\9%1)HY(\%HYHRC 'H<'L<'\JPL#_ (20
M8R(S>CIG!;RI,UIL!_PE$94?\NIW_F,?UH UJ*!10 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:Q7\
M,VKW@F\^Z6#!S:B3]T<G)X^M;=% &;<Z-!<3&59;B L KB"38' XY'TXIUQI
M%O/'"B&2V, VQO;ML*CT!]*T** ,\Z/;?8?LO[S!?S#+N_>;_P"]N]:DL].C
MLF=UDEEE? :29]S$#H,^G)_.KE%  **,T4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 44AHH 7-%)2T %%%% !1110 4444 %%%% !124M !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44AJD^KV
M$=^M@]Y MVX^6(N-WY4 7J*JW.H6=DRK=7<$!;[HED"Y^F:=<7MM:1"6YN8H
M8R<!Y'"@_B: +%%5Q>6QM?M0N(C;XW>;O&W'KGI2VUY;7L1DM;B*= <%HG#
M'\* "7_CZ@^C?RJ>J\G_ !]V_P!&_D*L4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5#<SI:VLL\N?+B0NV!DX R:FJCK7_("U#_KVD_]!--*[L)N
MRN<V/B7X=_YZ7/\ WX-._P"%F>'?^>ES_P!^#7C*_='TI:]?^SZ?<\?^T*A[
M+_PLSP[_ ,]+G_OP:/\ A9GAW_GI<_\ ?@UXU13_ +/I]V+^T*G8]E_X69X=
M_P">ES_WX-'_  LSP[_STN?^_!KQJBC^SZ?=A_:%3L>R_P#"S/#O_/2Y_P"_
M!H_X69X=_P">ES_WX->-44?V?3[L/[0J=CV7_A9GAW_GI<_]^#1_PLSP[_ST
MN?\ OP:\:HH_L^GW8?VA4['LG_"RO#QY\RY_[\&NAT;6+76]/6]LRYA9BHWK
MM.0<'BOGJO9OAK_R)\7_ %VD_P#0JY<5A8487B=6%Q4ZL[2.OHHHK@/0"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $-<>\']G7:6F
MH67FVA65C<Q$$@%@<L#SD<#C-=@1D8-<])H%\UTL2ZB@L CJ5,1,H#$$C=G^
ME #'GDCU6_EM;)]25T091E'EMM'RG<1P1@\9ZTW1DC>\L8C(LRP6/'' ;< >
M#S[5H#2;FTFE.FW<4$<I!:.6 R8( 7(.X8X I$T-[587L;H17"!@TDL>\2;C
MDY ([\]: ,PHHUW['Q]G-\)"AQ@DQN<?F ?PK4VB'Q.OEC FMCO QC*G@G_O
MHT?V*WV;/VK_ $WSO/\ /V<!\8^[G[N"1C/?K5BSL)HKF2ZN[A9[AU" I'L5
M5&3@#)YYYY]* )Y/^/NW_P"!?R%6*KR_\?=O_P "_E5B@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ JCK/_ " M0_Z]I/\ T$U>JCK/_("U#_KVD_\ 033CNB9;
M,^=U^Z/I2TB_='TI:^G/F0HHHH **** "BBB@ HHHH *]F^&O_(G1?\ 7:3_
M -"KQFO9OAK_ ,B=%_UVD_\ 0JX,P_AKU._+_P")\CKZ***\8]D**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA_#7J=^7_P 3Y'7T445XQ[(4444 %%%% !1110 4444 %%%% !1110 4444
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MG/>N@8X&:Y"8QVMRFHZ9>/%"(Y7,$G*$A@",'E<GTQ0!NSZE.;I[>QM%NFB
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M'/\ TS?_ .*I?^%I:Y_S[6'_ '[?_P"*KAU^Z/I2U[ZPE&WPG@/%5K_$=O\
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M%_UVD_\ 0J\9KV;X:_\ (G1?]=I/_0JX,P_AKU._+_XGR.OHHHKQCV0HHHH
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MH6))./Q-;5 'D?BS3?#>@^)I+T>/K[0=3NFWS1K<>9NSR-R$\+Z#I76>#O\
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M *":O51UG_D!:A_U[2?^@FG'=$RV9\[K]T?2EI%^Z/I2U].?,A1110 4444
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MBBB@ HHHH **** ()?\ C[M_HW\JGJ"7_C[M_HW\JGH **** "BBB@ HHHH
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MO_Z"M>0UZ]\+O^16F_Z^W_\ 05KAQ_\ "^9VX#^*=O1117BGMA1110 4444
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M%%% !1110 5ZW\*_^1<NO^OMO_0%KR2O6_A7_P BY=?]?;?^@+7%C_X/S.S
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M?^@FG'=$RV9\[K]T?2EI%^Z/I2U].CYD*.^<444 %%%% !_G'K1110 4444
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M!N>!4AC\$:2MO9K9PF#*6ZS>:(P23C=DYZU)XJ\46OA73$NIX)KF::00V]K
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MLA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^0KJ7_7!/_0C7G]>@?"C_D*ZE_UP3_T(URXS^!(Z<)_'B>JT445X)[X4444
M%%%% !3)O]2_^Z:?3)O]2_\ NFFMQ2V/FVBBBOI8_"CYF6["BBBJ$%%%% !1
M110 4444 %>M_"O_ )%RZ_Z^V_\ 0%KR2O6_A7_R+EU_U]M_Z M<6/\ X/S.
MS ?QCNJ***\0]P**** "BBB@ J&[_P"/.?\ ZYM_*IJAN_\ CSG_ .N;?RH6
MXGL?-Z_='TI:1?NCZ4M?4+8^885ZWI.KOJWAZ7^Q9EANH8XXQ;S+M16&<G/?
M=_2O)!UKN]/\:Z5%IL@N-+*WFU!MB^59BN<$XZ=?QKDQ<'-+E5V=6%FH-\ST
M)[.W^R^$]:N[V4V%W+<E)WBBRP_V5&1C)]ZS-2N[[34T;5HKB&_@6,I;S308
M8<='&[DCZ]JICQ4;N/4;?5+8S6U[()2L+[&C8=""<CL*E'BFS%UIR-IC/IU@
MI\NV:0$N^/O,<8/TQBLE3FI7<;_\,:.I!JR=B]:W%S9>&-3N=;E9O[1 %M;R
MMEF;^\ ?NBHM"OM6U;5+.Z:1;33]/0"1TRD84>HS\S&LC4]4T_5;B6ZN(]2>
MX?HSW"$+Z#&SI]*MW_B'3;^QM[+[%>V]K"H'DP3HJLW=CE<DU3IRM\.K_ GG
MC?XM%^)E:Y=6][K=Y<VJ!())"4 XX]?QZUGU),83,Q@618OX5D8%A]2 *CKM
MBK12.63O*X5Z]\+O^16F_P"OM_\ T%:\AKU[X7?\BO+_ -?;_P#H*UQ8_P#A
M?,Z\!_%.WHHHKQ3VPHHHH **** "JFI_\@J[_P"N+_\ H)JW534_^05=_P#7
M%_\ T$TUN3+X6?.B?<'TI:1/N#Z4M?31V/FGN%%%%,04444 %%%% !1110 5
M['\,?^11_P"WF3^E>.5['\,?^11_[>9/Z5PYA_"^9W9?_%^1V5%%%>*>T%%%
M% !1110 51UG_D!:A_U[2?\ H)J]5'6?^0%J'_7M)_Z":<=T3+9GSNOW1]*6
MD7[H^E+7TY\R%%%% !1110 4444 %%%% !7LWPU_Y$Z+_KM)_P"A5XS7LWPU
M_P"1.B_Z[2?^A5P9A_#7J=^7_P 3Y'7T445XQ[(4444 %%%% !1110 4444
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M_0UW=% %73WO)+"%[^&*"[9<R112%U0^@8@9_(5:HHH **** "BBB@ HHHH
M**0YK&?Q):I>K#Y5PT)W;KI4S$I! Z_4XH VJ*SKG5XK:=H5@N;AT \SR(]P
M3/KS^-$NLVJ002Q"6X\\9C2!=S$>N* -&BL[^V+7[";K]X,/Y9BV_O _]W;Z
MU)9:C%?-(@CFAE0 M',FU@#T./3@_E0!-+_Q]V_T;^53U7D_X^[?_@7\JL4
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MHHH **** "BBB@ KU[X7?\BO-_U]O_Z"M>0UZ]\+O^16F_Z^W_\ 05KAQ_\
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M?UJ?^R+7[#]DP^TMO,F\[RW][=US[T^RTZ&Q+LCRR2/@-),Y=B!T&3V'/YT
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M?"SYT3[@^E+2)]P?2EKZ:.Q\T]PHHHIB"BBB@ HHHH **** "O8_AC_R*/\
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M (\Y_P#KFW\J%N)['S>OW1]*6D7[H^E+7U"V/F&%%%% !1110 4444 %%%%
M!7KWPN_Y%>7_ *^W_P#05KR&O7OA=_R*\W_7T_\ Z"M<./\ X7S.W ?Q3MZ*
M**\4]L**** "BBB@ JIJ?_(*N_\ KB__ *":MU4U/_D%7?\ UQ?_ -!--;DR
M^%GSHGW!]*6D3[@^E+7TT=CYI[A1113$%%%% !1110 4444 %>Q_#'_D4?\
MMYD_I7CE>Q_#'_D4?^WF3^E<.8?POF=V7_Q?D=E1117BGM!1110 4444 %4=
M9_Y 6H?]>TG_ *":O51UG_D!:A_U[2?^@FG'=$RV9\[K]T?2EI%^Z/I2U].?
M,A1110 4444 %%%% !1110 5[-\-?^1.B_Z[2?\ H5>,U[-\-?\ D3HO^NTG
M_H5<&8?PUZG?E_\ $^1U]%%%>,>R%%%% !1110 4444 %%%% !1110 4444
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MJFI_\@J[_P"N+_\ H)IK<F7PL^=$^X/I2TB?<'TI:^FCL?-/<****8@HHHH
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MK7_("U#_ *]I/_033C\2)ELSYW7[H^E+2+]T?2EKZ<^9"BBB@ HHHH ****
M"BBB@ KV;X:?\B=%_P!=I/\ T*O&:]F^&O\ R)T7_7:3_P!"K@S#^&O4[\O_
M (AU]%%%>,>R%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'M*T:2233K)('D #E23D?B:QKXV%2FXI/4VH8*=.HI-HU**!THKS3T@HHHH
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M&GV8?V=4[H\,KUOX5_\ (N77_7VW_H"UL?\ ""^&O^@3#_WTW^-:>F:38Z/
MT%A;K!$S[RJDG)Z9Y^@KGQ.,C5ARI&^&P<Z4^9LO4M)2UYQZ(4444P"BBB@
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MJ?RI?MD/J?RK/HHN(T/MD/J?RH^V0^I_*L^BBX&A]LA]3^5'VR'U/Y5GT47
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M'(^AKKZ* *6D:>-*TFULE.[R8PI;U/?]:NT44@"BBB@ HHHH **** "BBB@
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MG^IH^RP_\\_U-344 0_98?\ GG^IH^RP_P#//]34U% $/V6'_GG^IH^RP_\
M//\ 4U-10!#]EA_YY_J:/LL/_//]34U% $/V6'_GG^IH^RP_\\_U-344 0_9
M8?\ GG^IH^RP_P#//]34U% $/V6'_GG^IH^RP_\ //\ 4U-10!#]EA_YY_J:
M/LL/_//]34U% $/V6'^Y^IH^RP_W/U-344 0_98?[GZFC[+#_<_4U-10!#]E
MA_N?J:/LL/\ SS_4U-10!#]EA_YY_J:/LL/_ #S_ %-344 0_98?^>?ZFC[+
M#_SS_4U-10!#]EA_YY_J:/LL/_//]34U% $/V6'_ )Y_J:/LL/\ SS_4U-10
M!#]EA_YY_J:/LL/_ #S_ %-344 0_98?^>?ZFC[+#_SS_4U-10!#]EA_YY_J
M:/LL/]S]34U% $/V6'^Y^IH^RP_W/U-344 0_98?[GZFC[+#_<_4U-10!#]E
MA_YY_J:/LL/_ #S_ %-344 0_98?^>?ZFC[+#_SS_4U-10!#]EA_YY_J:/LL
M/_//]34U% $/V6'_ )Y_J:/LL/\ SS_4U-10!#]EA_YY_J:/LL/_ #S_ %-3
M44 0_98?^>?ZFC[+#_SS_4U-10!#]EA_YY_J:/LL/_//]34U% $/V6'_ )Y_
MJ:/LL/\ SS_4U-10!#]EA_N?J:/LL/\ <_4U-10!#]EA_N?J:/LL/]S]34U%
M $/V6'^Y^IH^RP_\\_U-344 0_98?^>?ZFC[+#_SS_4U-10!#]EA_P">?ZFC
M[+#_ ,\_U-344 0_98?^>?ZFC[+#_P \_P!34U% $/V6'_GG^IH^RP_\\_U-
M344 0_98?^>?ZFC[+#_SS_4U-10!#]EA_P">?ZFC[+#_ ,\_U-344 0_98?^
M>?ZFC[+#_<_4U-10!#]EA_N?J:/LL/\ <_4U-10!#]EA_N?J:/LL/]S]34U%
M $/V6'_GG^IH^RP_\\_U-344 0_98?\ GG^IH^RP_P#//]34U% $/V6'_GG^
MIH^RP_\ //\ 4U-10!#]EA_YY_J:/LL/]S]34U% $/V6'^Y14U%*P!1113 *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **3-&>: %HI,TM !1110 4444 %%%&: "
MBDS0#F@!:*3-&: %HI,TN: "BBB@ HHHH **** "BBC.* "BDSSBEH ****
M"BBB@ HHHH **** "BD)Q2T %%%% !129I: "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]C:J-]YJ3P26[E RBWB13OZ@DD@9SVJ]J-W?+#XKFLSYD[IIBRDOM!C88?+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5%]:-=R6JW,7GQJ&>/
M>,@'."1^!K+'_"+"ZBU(1:7]HFN/)CN5B3>TI)&-V,[L@U6'@K3QK]SK&09[
MA'1E,$94 @ $ KU'//5LX.0!CG]1\+V?A:VT>.T<M')K=J[,Z*"OKR #C.2
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M%14N-@.[&_=QDY.*T9]>UWR;SQ!'J82SM=4%B--\E"CQ^:L98OC?O.[. <9
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>31
<FILENAME>phat-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-01T13:48:38.3258+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="phat-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets" xlink:href="phat-20211231.xsd#Role_StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:href="phat-20211231.xsd#Role_StatementBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:href="phat-20211231.xsd#Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:href="phat-20211231.xsd#Role_StatementStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity" xlink:href="phat-20211231.xsd#StatementStatementsOfStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:href="phat-20211231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsParenthetical" xlink:href="phat-20211231.xsd#Role_StatementStatementsOfCashFlowsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="phat-20211231.xsd#Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetails" xlink:href="phat-20211231.xsd#Role_DisclosureBalanceSheetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="phat-20211231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="phat-20211231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitments" xlink:href="phat-20211231.xsd#Role_DisclosureLeaseCommitments" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebt" xlink:href="phat-20211231.xsd#Role_DisclosureDebt" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:href="phat-20211231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="phat-20211231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_Disclosure401KPlan" xlink:href="phat-20211231.xsd#Role_Disclosure401KPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="phat-20211231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="phat-20211231.xsd#Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="phat-20211231.xsd#Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" xlink:href="phat-20211231.xsd#Role_DisclosureBalanceSheetDetailsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsTables" xlink:href="phat-20211231.xsd#Role_DisclosureLeaseCommitmentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtTables" xlink:href="phat-20211231.xsd#Role_DisclosureDebtTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:href="phat-20211231.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="phat-20211231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="phat-20211231.xsd#Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValueDetails" xlink:href="phat-20211231.xsd#Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" xlink:href="phat-20211231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" xlink:href="phat-20211231.xsd#Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:href="phat-20211231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="phat-20211231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="phat-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" xlink:href="phat-20211231.xsd#Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails" xlink:href="phat-20211231.xsd#Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" xlink:href="phat-20211231.xsd#Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails" xlink:href="phat-20211231.xsd#Role_DisclosureDebtScheduleOfTotalDebtDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" xlink:href="phat-20211231.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" xlink:href="phat-20211231.xsd#Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="phat-20211231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfUnvestedSharesDetails" xlink:href="phat-20211231.xsd#Role_DisclosureStockholdersEquitySummaryOfUnvestedSharesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:href="phat-20211231.xsd#Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails" xlink:href="phat-20211231.xsd#Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails" xlink:href="phat-20211231.xsd#Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:href="phat-20211231.xsd#Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" xlink:href="phat-20211231.xsd#Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="phat-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" xlink:href="phat-20211231.xsd#Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:href="phat-20211231.xsd#Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails" xlink:href="phat-20211231.xsd#Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails" xlink:href="phat-20211231.xsd#Role_Disclosure401KPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="phat-20211231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AccruedClinicalTrialExpensesCurrent" xlink:label="phat_AccruedClinicalTrialExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="phat_AccruedClinicalTrialExpensesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" xlink:label="phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AccruedExpensesRelatedPartiesCurrent" xlink:label="phat_AccruedExpensesRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="phat_AccruedExpensesRelatedPartiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ResearchAndDevelopmentExpenseRelatedParty" xlink:label="phat_ResearchAndDevelopmentExpenseRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_GeneralAndAdministrativeExpenseRelatedParty" xlink:label="phat_GeneralAndAdministrativeExpenseRelatedParty"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="phat_ResearchAndDevelopmentExpenseRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="phat_GeneralAndAdministrativeExpenseRelatedParty" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" xlink:label="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="phat_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" xlink:label="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_18"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_19"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_StockIssuedDuringPeriodValueExerciseOfWarrants" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_19" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ProceedsFromUnderwrittenPublicOfferingNet" xlink:label="phat_ProceedsFromUnderwrittenPublicOfferingNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" xlink:label="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_IncreaseDecreaseInClinicalAccruedTrialExpenses" xlink:label="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_NonCashFinalInterestPaymentFee" xlink:label="phat_NonCashFinalInterestPaymentFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock" xlink:label="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" xlink:label="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock" xlink:label="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" xlink:label="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ConversionOfWarrantLiabilitiesIntoEquity" xlink:label="phat_ConversionOfWarrantLiabilitiesIntoEquity"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_UnpaidUnderwrittenPublicOfferingCosts" xlink:label="phat_UnpaidUnderwrittenPublicOfferingCosts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="phat_ProceedsFromUnderwrittenPublicOfferingNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_NonCashFinalInterestPaymentFee" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_ConversionOfWarrantLiabilitiesIntoEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_UnpaidUnderwrittenPublicOfferingCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" xlink:label="phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties" xlink:label="phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ComponentOfBalanceSheetDisclosureTextBlock" xlink:label="phat_ComponentOfBalanceSheetDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="phat_ComponentOfBalanceSheetDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitments" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebt" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_Disclosure401KPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_OrganizationAndBasisOfPresentationPolicyTextBlock" xlink:label="phat_OrganizationAndBasisOfPresentationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:label="phat_LiquidityAndCapitalResourcesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:label="us-gaap_LessorLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="phat_OrganizationAndBasisOfPresentationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="phat_LiquidityAndCapitalResourcesPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LessorLeasesPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_EmployeeStockPurchasePlanMember" xlink:label="phat_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_CommonStockReservedForFutureIssuancesTableTableTextBlock" xlink:label="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_EmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TakedaLicenseAgreementMember" xlink:label="phat_TakedaLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_UnvestedSharesMember" xlink:label="phat_UnvestedSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ComputerEquipmentAndSoftwareMember" xlink:label="phat_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LenderWarrantsMember" xlink:label="phat_LenderWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="phat_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TakedaWarrantsMember" xlink:label="phat_TakedaWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_FollowOnPublicOfferingMember" xlink:label="phat_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_FinancialAssetsFairValueDisclosure" xlink:label="phat_FinancialAssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_NonfinancialAssetsFairValueDisclosure" xlink:label="phat_NonfinancialAssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_NonfinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ExpectedCashDividendYieldRate" xlink:label="phat_ExpectedCashDividendYieldRate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" xlink:label="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_IncrementalCommonSharesAttributableToExerciseOfWarrants" xlink:label="phat_IncrementalCommonSharesAttributableToExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" xlink:label="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_TakedaLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="phat_UnvestedSharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="phat_ComputerEquipmentAndSoftwareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="phat_LenderWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="phat_TakedaPharmaceuticalCompanyLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="phat_TakedaWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="phat_FollowOnPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_FinancialAssetsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_NonfinancialAssetsFairValueDisclosure" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NonfinancialLiabilitiesFairValueDisclosure" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_ExpectedCashDividendYieldRate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_IncrementalCommonSharesAttributableToExerciseOfWarrants" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValueDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_WarrantsLiabilitiesMember" xlink:label="phat_WarrantsLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity" xlink:label="phat_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="phat_WarrantsLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="phat_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AccruedResearchAndDevelopmentExpenses" xlink:label="phat_AccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="phat_AccruedResearchAndDevelopmentExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TakedaLicenseAgreementMember" xlink:label="phat_TakedaLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrincipalOwnerMember" xlink:label="us-gaap_PrincipalOwnerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ClinicalManufacturingServicesMember" xlink:label="phat_ClinicalManufacturingServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" xlink:label="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty" xlink:label="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DrugProductOrSubstanceMember" xlink:label="phat_DrugProductOrSubstanceMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PCIPharmaServicesMember" xlink:label="phat_PCIPharmaServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_CommercialSupplyAgreementsMember" xlink:label="phat_CommercialSupplyAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TemporaryServicesAgreementMember" xlink:label="phat_TemporaryServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="phat_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AgreementExtendsPeriodForTermination" xlink:label="phat_AgreementExtendsPeriodForTermination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_TakedaLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_PrincipalOwnerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="phat_ClinicalManufacturingServicesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="phat_DrugProductOrSubstanceMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="phat_PCIPharmaServicesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_CommercialSupplyAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_TemporaryServicesAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="phat_TakedaPharmaceuticalCompanyLimitedMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="phat_AgreementExtendsPeriodForTermination" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PurchaseObligation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_CommitmentsAndContingenciesTable" xlink:label="phat_CommitmentsAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TakedaLicenseAgreementMember" xlink:label="phat_TakedaLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="phat_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_CommitmentsAndContingenciesLineItems" xlink:label="phat_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LicenseAgreementDescription" xlink:label="phat_LicenseAgreementDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AgreementExpirationTermFromDateOfFirstCommercialSale" xlink:label="phat_AgreementExpirationTermFromDateOfFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PaymentForLicenseAmount" xlink:label="phat_PaymentForLicenseAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AdditionalWarrantIssued" xlink:label="phat_AdditionalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales" xlink:label="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LicenseAgreementTransactionCosts" xlink:label="phat_LicenseAgreementTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_WarrantsExpirationDate" xlink:label="phat_WarrantsExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" xlink:label="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PurchaseObligationDueInFirstTwentyFourMonths" xlink:label="phat_PurchaseObligationDueInFirstTwentyFourMonths"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PurchaseCommitmentExpense" xlink:label="phat_PurchaseCommitmentExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_TakedaLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="phat_TakedaPharmaceuticalCompanyLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_LicenseAgreementDescription" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="phat_CommitmentsAndContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_AgreementExpirationTermFromDateOfFirstCommercialSale" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_PaymentForLicenseAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_CommonStockValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesTable" xlink:to="phat_CommitmentsAndContingenciesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_AdditionalWarrantIssued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_LicenseAgreementTransactionCosts" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_WarrantsExpirationDate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_PurchaseObligationDueInFirstTwentyFourMonths" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_PurchaseCommitmentExpense" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_IL" xlink:label="stpr_IL"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PrepaidLeasePaymentsMember" xlink:label="phat_PrepaidLeasePaymentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JE" xlink:label="country_JE"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LesseeOperatingLeaseNumberOfOptionToExtend" xlink:label="phat_LesseeOperatingLeaseNumberOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_IL" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="phat_PrepaidLeasePaymentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JE" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="phat_LesseeOperatingLeaseNumberOfOptionToExtend" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AssetsLesseeAbstract" xlink:label="phat_AssetsLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LiabilitiesLesseeAbstract" xlink:label="phat_LiabilitiesLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="phat_AssetsLesseeAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_AssetsLesseeAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_LiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="phat_LiabilitiesLesseeAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_LiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="phat_LiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount" xlink:label="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TermLoanMember" xlink:label="phat_TermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember" xlink:label="us-gaap_BaseRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LoanAgreementMember" xlink:label="phat_LoanAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PaymentForFacilityCharge" xlink:label="phat_PaymentForFacilityCharge"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_HerculesAndSvbTermLoanMember" xlink:label="phat_HerculesAndSvbTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesOneMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PaymentInKindPikInterestRateMember" xlink:label="phat_PaymentInKindPikInterestRateMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DebtInstrumentFacilityChargePercentage" xlink:label="phat_DebtInstrumentFacilityChargePercentage"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesTwoMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesThreeMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesFourMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesFourMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TermLoanAdvanceMember" xlink:label="phat_TermLoanAdvanceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TermLoanFirstAdvanceMember" xlink:label="phat_TermLoanFirstAdvanceMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DebtInstrumentFinalPaymentFeePercentage" xlink:label="phat_DebtInstrumentFinalPaymentFeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_SiliconValleyBankTermLoanMember" xlink:label="phat_SiliconValleyBankTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DebtInstrumentFinalPaymentFee" xlink:label="phat_DebtInstrumentFinalPaymentFee"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount" xlink:label="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_MinimumMarketCapitalizationAmount" xlink:label="phat_MinimumMarketCapitalizationAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock" xlink:label="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ClassOfWarrantOrRightExpireTerm" xlink:label="phat_ClassOfWarrantOrRightExpireTerm"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ClassOfWarrantOrRightExpirationDate" xlink:label="phat_ClassOfWarrantOrRightExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DebtInstrumentAdditionalBorrowingCapacityAmounts" xlink:label="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DebtInstrumentPenaltyFeePercentage" xlink:label="phat_DebtInstrumentPenaltyFeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LanderWarrantsExpireTerm" xlink:label="phat_LanderWarrantsExpireTerm"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LenderWarrantsExercisableSharesOfCommonStock" xlink:label="phat_LenderWarrantsExercisableSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AccruedInterest" xlink:label="phat_AccruedInterest"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_BaseRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="phat_LoanAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_PaymentForFacilityCharge" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="phat_HerculesAndSvbTermLoanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesOneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="phat_PaymentInKindPikInterestRateMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentFacilityChargePercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesFourMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoanAdvanceMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoanFirstAdvanceMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentFinalPaymentFeePercentage" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_SiliconValleyBankTermLoanMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentFinalPaymentFee" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_MinimumMarketCapitalizationAmount" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_ClassOfWarrantOrRightExpireTerm" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_ClassOfWarrantOrRightExpirationDate" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentPenaltyFeePercentage" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_LanderWarrantsExpireTerm" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_LenderWarrantsExercisableSharesOfCommonStock" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_AccruedInterest" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LongTermDebtAndInterest" xlink:label="phat_LongTermDebtAndInterest"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DebtInstrumentInterestAndFinalPaymentFee" xlink:label="phat_DebtInstrumentInterestAndFinalPaymentFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="phat_LongTermDebtAndInterest" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="phat_DebtInstrumentInterestAndFinalPaymentFee" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_FrazierLifeSciencesIXLimitedPartnerMember" xlink:label="phat_FrazierLifeSciencesIXLimitedPartnerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_FoundersMember" xlink:label="phat_FoundersMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TakedaLicenseAgreementMember" xlink:label="phat_TakedaLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_EmployeesMember" xlink:label="phat_EmployeesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="phat_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_OpenMarketSaleAgreementWithJefferiesLLCMember" xlink:label="phat_OpenMarketSaleAgreementWithJefferiesLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="phat_TwoThousandNineteenIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember" xlink:label="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ATMOfferingProgramMember" xlink:label="phat_ATMOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_EmployeeStockPurchasePlanMember" xlink:label="phat_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockRepurchaseProgramNumberOfSharesRightLapse" xlink:label="phat_StockRepurchaseProgramNumberOfSharesRightLapse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockOptionsAndPerformanceBasedUnitsMember" xlink:label="phat_StockOptionsAndPerformanceBasedUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:label="us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockRepurchaseProgramExpirationMonthAndYear" xlink:label="phat_StockRepurchaseProgramExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AggregateOfferingPriceThroughEquityFinancing" xlink:label="phat_AggregateOfferingPriceThroughEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare" xlink:label="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_RepurchaseRightLapseRate" xlink:label="phat_RepurchaseRightLapseRate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_RepurchaseRightLapseShares" xlink:label="phat_RepurchaseRightLapseShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_SharesAggregateRepurchasePrice" xlink:label="phat_SharesAggregateRepurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:label="phat_ProceedsFromIssuanceInitialPublicOfferingGross"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_SharesIssuedPricePerShareAfterDeductions" xlink:label="phat_SharesIssuedPricePerShareAfterDeductions"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_NetProceedsAfterDeductingUnderwritersCommission" xlink:label="phat_NetProceedsAfterDeductingUnderwritersCommission"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PurchaseOfAdditionalOfferingExpenses" xlink:label="phat_PurchaseOfAdditionalOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ClosingMarketPriceOfCommonStock" xlink:label="phat_ClosingMarketPriceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:to="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:to="phat_FrazierLifeSciencesIXLimitedPartnerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="phat_FoundersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_TakedaLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="phat_EmployeesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_TwoThousandNineteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_OpenMarketSaleAgreementWithJefferiesLLCMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_TwoThousandNineteenIncentiveAwardPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="phat_ATMOfferingProgramMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_EmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_StockRepurchaseProgramNumberOfSharesRightLapse" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="phat_StockOptionsAndPerformanceBasedUnitsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchaseProgramPeriodInForce1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_StockRepurchaseProgramExpirationMonthAndYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_AggregateOfferingPriceThroughEquityFinancing" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_RepurchaseRightLapseRate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_RepurchaseRightLapseShares" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_SharesAggregateRepurchasePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_ProceedsFromIssuanceInitialPublicOfferingGross" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_SharesIssuedPricePerShareAfterDeductions" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_NetProceedsAfterDeductingUnderwritersCommission" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_PurchaseOfAdditionalOfferingExpenses" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_ClosingMarketPriceOfCommonStock" order="41" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="42" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfUnvestedSharesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="phat_TwoThousandNineteenIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockOptionsAndPerformanceBasedAwardsMember" xlink:label="phat_StockOptionsAndPerformanceBasedAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_CommonStockWarrantMember" xlink:label="phat_CommonStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_EmployeeStockPurchasePlanMember" xlink:label="phat_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_TwoThousandNineteenIncentiveAwardPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="phat_StockOptionsAndPerformanceBasedAwardsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="phat_CommonStockWarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_EmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="phat_TwoThousandNineteenIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_TwoThousandNineteenIncentiveAwardPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_EmployeeStockPurchasePlanMember" xlink:label="phat_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_EmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice" xlink:label="phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_OperatingLossCarryforwardsExpirationYear" xlink:label="phat_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear" xlink:label="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="phat_OperatingLossCarryforwardsExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_IncomeTaxReconciliationPermanentItems" xlink:label="phat_IncomeTaxReconciliationPermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt" xlink:label="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="phat_IncomeTaxReconciliationPermanentItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" xlink:label="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JE" xlink:label="country_JE"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_AreaOfLand" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JE" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>32
<FILENAME>phat-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-01T13:48:35.0691+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.phathompharma.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:phat="http://www.phathompharma.com/20211231">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="phat-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="phat-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="phat-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="phat-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets" id="Role_StatementBalanceSheets">
        <link:definition>100010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2" id="DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2">
        <link:definition>100020 - Disclosure - Lease Commitments - Summary of Future Annual Minimum Lease Payments Under Operating Leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" id="Role_StatementBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100040 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLossParenthetical" id="Role_StatementStatementsOfOperationsAndComprehensiveLossParenthetical">
        <link:definition>100050 - Statement - Statements of Operations and Comprehensive Loss (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity" id="StatementStatementsOfStockholdersEquity">
        <link:definition>100060 - Statement - Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows" id="Role_StatementStatementsOfCashFlows">
        <link:definition>100070 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsParenthetical" id="Role_StatementStatementsOfCashFlowsParenthetical">
        <link:definition>100080 - Statement - Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>100090 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetails" id="Role_DisclosureBalanceSheetDetails">
        <link:definition>100100 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100110 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100120 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitments" id="Role_DisclosureLeaseCommitments">
        <link:definition>100130 - Disclosure - Lease Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebt" id="Role_DisclosureDebt">
        <link:definition>100140 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100150 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100160 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_Disclosure401KPlan" id="Role_Disclosure401KPlan">
        <link:definition>100170 - Disclosure - 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100180 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100190 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100200 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" id="Role_DisclosureBalanceSheetDetailsTables">
        <link:definition>100210 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsTables" id="Role_DisclosureLeaseCommitmentsTables">
        <link:definition>100220 - Disclosure - Lease Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtTables" id="Role_DisclosureDebtTables">
        <link:definition>100230 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>100240 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100250 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100260 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValueDetails" id="Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValueDetails">
        <link:definition>100270 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Reconciliation of Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" id="Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails">
        <link:definition>100280 - Disclosure - Balance Sheet Details - Schedule of Property, Plant and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" id="Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails">
        <link:definition>100290 - Disclosure - Balance Sheet Details - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" id="Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails">
        <link:definition>100300 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100310 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100320 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" id="Role_DisclosureLeaseCommitmentsAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Lease Commitments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails" id="Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails">
        <link:definition>100340 - Disclosure - Lease Commitments - Summary of Supplemental Balance Sheet Information Related to the Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" id="Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails">
        <link:definition>100350 - Disclosure - Lease Commitments - Summary of Future Annual Minimum Lease Payments Under Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails" id="Role_DisclosureDebtScheduleOfTotalDebtDetails">
        <link:definition>100360 - Disclosure - Debt - Schedule of Total Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" id="Role_DisclosureDebtAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" id="Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails">
        <link:definition>100380 - Disclosure - Debt - Schedule of Future Minimum Principal and Interest Payments Under Term Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" id="Role_DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfUnvestedSharesDetails" id="Role_DisclosureStockholdersEquitySummaryOfUnvestedSharesDetails">
        <link:definition>100400 - Disclosure - Stockholders' Equity - Summary of Unvested Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" id="Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails">
        <link:definition>100410 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails" id="Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails">
        <link:definition>100420 - Disclosure - Stockholders' Equity - Summary of PSU Activity Under the 2019 Incentive Award Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails" id="Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails">
        <link:definition>100430 - Disclosure - Stockholders' Equity - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" id="Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails">
        <link:definition>100440 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>100450 - Disclosure - Stockholders' Equity - Summary of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100460 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" id="Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails">
        <link:definition>100470 - Disclosure - Income Taxes - Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" id="Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails">
        <link:definition>100480 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails" id="Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>100490 - Disclosure - Income Taxes - Summary of Activity Related to Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails" id="Role_Disclosure401KPlanAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - 401(k) Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.phathompharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100510 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="phat_AssetsLesseeAbstract" name="AssetsLesseeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_LiabilitiesLesseeAbstract" name="LiabilitiesLesseeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" name="AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_AccruedClinicalTrialExpensesCurrent" name="AccruedClinicalTrialExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_AccruedExpensesRelatedPartiesCurrent" name="AccruedExpensesRelatedPartiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_AccruedInterest" name="AccruedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_AccruedResearchAndDevelopmentExpenses" name="AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_AdditionalWarrantIssued" name="AdditionalWarrantIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" name="AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_AggregateOfferingPriceThroughEquityFinancing" name="AggregateOfferingPriceThroughEquityFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_AgreementExpirationTermFromDateOfFirstCommercialSale" name="AgreementExpirationTermFromDateOfFirstCommercialSale" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_AgreementExtendsPeriodForTermination" name="AgreementExtendsPeriodForTermination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ClassOfWarrantOrRightExpirationDate" name="ClassOfWarrantOrRightExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ClassOfWarrantOrRightExpireTerm" name="ClassOfWarrantOrRightExpireTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" name="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="phat_ClosingMarketPriceOfCommonStock" name="ClosingMarketPriceOfCommonStock" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ConversionOfWarrantLiabilitiesIntoEquity" name="ConversionOfWarrantLiabilitiesIntoEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts" name="DebtInstrumentAdditionalBorrowingCapacityAmounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_DebtInstrumentFacilityChargePercentage" name="DebtInstrumentFacilityChargePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_DebtInstrumentFinalPaymentFee" name="DebtInstrumentFinalPaymentFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_DebtInstrumentFinalPaymentFeePercentage" name="DebtInstrumentFinalPaymentFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_DebtInstrumentInterestAndFinalPaymentFee" name="DebtInstrumentInterestAndFinalPaymentFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_DebtInstrumentPenaltyFeePercentage" name="DebtInstrumentPenaltyFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount" name="DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" name="DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ExpectedCashDividendYieldRate" name="ExpectedCashDividendYieldRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity" name="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_FinancialAssetsFairValueDisclosure" name="FinancialAssetsFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_GeneralAndAdministrativeExpenseRelatedParty" name="GeneralAndAdministrativeExpenseRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt" name="IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_IncomeTaxReconciliationPermanentItems" name="IncomeTaxReconciliationPermanentItems" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties" name="IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses" name="IncreaseDecreaseInClinicalAccruedTrialExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" name="IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" name="IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_IncrementalCommonSharesAttributableToExerciseOfWarrants" name="IncrementalCommonSharesAttributableToExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_LanderWarrantsExpireTerm" name="LanderWarrantsExpireTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_LenderWarrantsExercisableSharesOfCommonStock" name="LenderWarrantsExercisableSharesOfCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="phat_LesseeOperatingLeaseNumberOfOptionToExtend" name="LesseeOperatingLeaseNumberOfOptionToExtend" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_LicenseAgreementDescription" name="LicenseAgreementDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_LicenseAgreementTransactionCosts" name="LicenseAgreementTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_LongTermDebtAndInterest" name="LongTermDebtAndInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths" name="LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" name="LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" name="LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" name="LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" name="LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount" name="LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales" name="MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_MinimumMarketCapitalizationAmount" name="MinimumMarketCapitalizationAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone" name="MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone" name="MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_NetProceedsAfterDeductingUnderwritersCommission" name="NetProceedsAfterDeductingUnderwritersCommission" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_NonCashFinalInterestPaymentFee" name="NonCashFinalInterestPaymentFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" name="NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock" name="NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock" name="NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_NonfinancialAssetsFairValueDisclosure" name="NonfinancialAssetsFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" name="OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_PaymentForFacilityCharge" name="PaymentForFacilityCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_PaymentForLicenseAmount" name="PaymentForLicenseAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock" name="PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" name="PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_ProceedsFromIssuanceInitialPublicOfferingGross" name="ProceedsFromIssuanceInitialPublicOfferingGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_ProceedsFromUnderwrittenPublicOfferingNet" name="ProceedsFromUnderwrittenPublicOfferingNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_PurchaseCommitmentExpense" name="PurchaseCommitmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_PurchaseObligationDueInFirstTwentyFourMonths" name="PurchaseObligationDueInFirstTwentyFourMonths" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_PurchaseOfAdditionalOfferingExpenses" name="PurchaseOfAdditionalOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty" name="RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_RepurchaseRightLapseRate" name="RepurchaseRightLapseRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="phat_RepurchaseRightLapseShares" name="RepurchaseRightLapseShares" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="phat_ResearchAndDevelopmentExpenseRelatedParty" name="ResearchAndDevelopmentExpenseRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear" name="ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare" name="SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_SharesAggregateRepurchasePrice" name="SharesAggregateRepurchasePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="phat_SharesIssuedPricePerShareAfterDeductions" name="SharesIssuedPricePerShareAfterDeductions" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_StockIssuedDuringPeriodValueExerciseOfWarrants" name="StockIssuedDuringPeriodValueExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_StockRepurchaseProgramExpirationMonthAndYear" name="StockRepurchaseProgramExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_StockRepurchaseProgramNumberOfSharesRightLapse" name="StockRepurchaseProgramNumberOfSharesRightLapse" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="phat_UnpaidUnderwrittenPublicOfferingCosts" name="UnpaidUnderwrittenPublicOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="phat_WarrantsExpirationDate" name="WarrantsExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" name="OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_ATMOfferingProgramMember" name="ATMOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_ClinicalManufacturingServicesMember" name="ClinicalManufacturingServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_CommercialSupplyAgreementsMember" name="CommercialSupplyAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_CommonStockWarrantMember" name="CommonStockWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_DrugProductOrSubstanceMember" name="DrugProductOrSubstanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_EmployeesMember" name="EmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_FollowOnPublicOfferingMember" name="FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_FoundersMember" name="FoundersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_FrazierLifeSciencesIXLimitedPartnerMember" name="FrazierLifeSciencesIXLimitedPartnerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_HerculesAndSvbTermLoanMember" name="HerculesAndSvbTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_LenderWarrantsMember" name="LenderWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_LoanAgreementMember" name="LoanAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_OpenMarketSaleAgreementWithJefferiesLLCMember" name="OpenMarketSaleAgreementWithJefferiesLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_PaymentInKindPikInterestRateMember" name="PaymentInKindPikInterestRateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_PCIPharmaServicesMember" name="PCIPharmaServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_PrepaidLeasePaymentsMember" name="PrepaidLeasePaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember" name="ShareBasedPaymentArrangementEmployeeAndNonemployeeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_SiliconValleyBankTermLoanMember" name="SiliconValleyBankTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_StockOptionsAndPerformanceBasedAwardsMember" name="StockOptionsAndPerformanceBasedAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_StockOptionsAndPerformanceBasedUnitsMember" name="StockOptionsAndPerformanceBasedUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TakedaLicenseAgreementMember" name="TakedaLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TakedaPharmaceuticalCompanyLimitedMember" name="TakedaPharmaceuticalCompanyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TakedaWarrantsMember" name="TakedaWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TemporaryServicesAgreementMember" name="TemporaryServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TermLoanAdvanceMember" name="TermLoanAdvanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TermLoanFirstAdvanceMember" name="TermLoanFirstAdvanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TermLoanMember" name="TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TermLoansAggregatePrincipalAmountTranchesFourMember" name="TermLoansAggregatePrincipalAmountTranchesFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TermLoansAggregatePrincipalAmountTranchesOneMember" name="TermLoansAggregatePrincipalAmountTranchesOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember" name="TermLoansAggregatePrincipalAmountTranchesThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember" name="TermLoansAggregatePrincipalAmountTranchesTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TwoThousandNineteenEquityIncentivePlanMember" name="TwoThousandNineteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_TwoThousandNineteenIncentiveAwardPlanMember" name="TwoThousandNineteenIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_UnvestedSharesMember" name="UnvestedSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_WarrantsLiabilitiesMember" name="WarrantsLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" name="OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock" name="CommonStockReservedForFutureIssuancesTableTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_ComponentOfBalanceSheetDisclosureTextBlock" name="ComponentOfBalanceSheetDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_LiquidityAndCapitalResourcesPolicyTextBlock" name="LiquidityAndCapitalResourcesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_OrganizationAndBasisOfPresentationPolicyTextBlock" name="OrganizationAndBasisOfPresentationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" name="SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>33
<FILENAME>phat-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-01T13:48:37.8360+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_RepurchaseRightLapseRate" xlink:label="phat_RepurchaseRightLapseRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_UnpaidUnderwrittenPublicOfferingCosts" xlink:label="phat_UnpaidUnderwrittenPublicOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" xlink:label="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="phat_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount" xlink:label="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare" xlink:label="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LanderWarrantsExpireTerm" xlink:label="phat_LanderWarrantsExpireTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AccruedClinicalTrialExpensesCurrent" xlink:label="phat_AccruedClinicalTrialExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_IncrementalCommonSharesAttributableToExerciseOfWarrants" xlink:label="phat_IncrementalCommonSharesAttributableToExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PurchaseOfAdditionalOfferingExpenses" xlink:label="phat_PurchaseOfAdditionalOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_NonfinancialAssetsFairValueDisclosure" xlink:label="phat_NonfinancialAssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ExpectedCashDividendYieldRate" xlink:label="phat_ExpectedCashDividendYieldRate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_CommonStockWarrantMember" xlink:label="phat_CommonStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AgreementExpirationTermFromDateOfFirstCommercialSale" xlink:label="phat_AgreementExpirationTermFromDateOfFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AdditionalWarrantIssued" xlink:label="phat_AdditionalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockOptionsAndPerformanceBasedUnitsMember" xlink:label="phat_StockOptionsAndPerformanceBasedUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PaymentForLicenseAmount" xlink:label="phat_PaymentForLicenseAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PaymentInKindPikInterestRateMember" xlink:label="phat_PaymentInKindPikInterestRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties" xlink:label="phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" xlink:label="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_CommitmentsAndContingenciesTable" xlink:label="phat_CommitmentsAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount" xlink:label="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" xlink:label="phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LoanAgreementMember" xlink:label="phat_LoanAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember" xlink:label="us-gaap_BaseRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrincipalOwnerMember" xlink:label="us-gaap_PrincipalOwnerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PrepaidLeasePaymentsMember" xlink:label="phat_PrepaidLeasePaymentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ComponentOfBalanceSheetDisclosureTextBlock" xlink:label="phat_ComponentOfBalanceSheetDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockRepurchaseProgramExpirationMonthAndYear" xlink:label="phat_StockRepurchaseProgramExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AccruedExpensesRelatedPartiesCurrent" xlink:label="phat_AccruedExpensesRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_NonfinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LenderWarrantsExercisableSharesOfCommonStock" xlink:label="phat_LenderWarrantsExercisableSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PurchaseObligationDueInFirstTwentyFourMonths" xlink:label="phat_PurchaseObligationDueInFirstTwentyFourMonths"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" xlink:label="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_MinimumMarketCapitalizationAmount" xlink:label="phat_MinimumMarketCapitalizationAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:label="us-gaap_LessorLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TakedaWarrantsMember" xlink:label="phat_TakedaWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear" xlink:label="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" xlink:label="phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ClosingMarketPriceOfCommonStock" xlink:label="phat_ClosingMarketPriceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock" xlink:label="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_EmployeeStockPurchasePlanMember" xlink:label="phat_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt" xlink:label="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ResearchAndDevelopmentExpenseRelatedParty" xlink:label="phat_ResearchAndDevelopmentExpenseRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" xlink:label="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_GeneralAndAdministrativeExpenseRelatedParty" xlink:label="phat_GeneralAndAdministrativeExpenseRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ProceedsFromUnderwrittenPublicOfferingNet" xlink:label="phat_ProceedsFromUnderwrittenPublicOfferingNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DrugProductOrSubstanceMember" xlink:label="phat_DrugProductOrSubstanceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock" xlink:label="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty" xlink:label="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock" xlink:label="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" xlink:label="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LiabilitiesLesseeAbstract" xlink:label="phat_LiabilitiesLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:label="phat_LiquidityAndCapitalResourcesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ClassOfWarrantOrRightExpireTerm" xlink:label="phat_ClassOfWarrantOrRightExpireTerm"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TermLoanMember" xlink:label="phat_TermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AgreementExtendsPeriodForTermination" xlink:label="phat_AgreementExtendsPeriodForTermination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_CommonStockReservedForFutureIssuancesTableTableTextBlock" xlink:label="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockOptionsAndPerformanceBasedAwardsMember" xlink:label="phat_StockOptionsAndPerformanceBasedAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ClinicalManufacturingServicesMember" xlink:label="phat_ClinicalManufacturingServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember" xlink:label="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_SharesIssuedPricePerShareAfterDeductions" xlink:label="phat_SharesIssuedPricePerShareAfterDeductions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LicenseAgreementTransactionCosts" xlink:label="phat_LicenseAgreementTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesTwoMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AssetsLesseeAbstract" xlink:label="phat_AssetsLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_FollowOnPublicOfferingMember" xlink:label="phat_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ClassOfWarrantOrRightExpirationDate" xlink:label="phat_ClassOfWarrantOrRightExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:label="us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AccruedInterest" xlink:label="phat_AccruedInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ComputerEquipmentAndSoftwareMember" xlink:label="phat_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesThreeMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DebtInstrumentFinalPaymentFeePercentage" xlink:label="phat_DebtInstrumentFinalPaymentFeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_FinancialAssetsFairValueDisclosure" xlink:label="phat_FinancialAssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesFourMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesFourMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" xlink:label="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales" xlink:label="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DebtInstrumentFinalPaymentFee" xlink:label="phat_DebtInstrumentFinalPaymentFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LongTermDebtAndInterest" xlink:label="phat_LongTermDebtAndInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="phat_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LenderWarrantsMember" xlink:label="phat_LenderWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JE" xlink:label="country_JE"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_NonCashFinalInterestPaymentFee" xlink:label="phat_NonCashFinalInterestPaymentFee"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_WarrantsExpirationDate" xlink:label="phat_WarrantsExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PaymentForFacilityCharge" xlink:label="phat_PaymentForFacilityCharge"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TakedaLicenseAgreementMember" xlink:label="phat_TakedaLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_IncomeTaxReconciliationPermanentItems" xlink:label="phat_IncomeTaxReconciliationPermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice" xlink:label="phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LicenseAgreementDescription" xlink:label="phat_LicenseAgreementDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_HerculesAndSvbTermLoanMember" xlink:label="phat_HerculesAndSvbTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_IncreaseDecreaseInClinicalAccruedTrialExpenses" xlink:label="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_OpenMarketSaleAgreementWithJefferiesLLCMember" xlink:label="phat_OpenMarketSaleAgreementWithJefferiesLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AggregateOfferingPriceThroughEquityFinancing" xlink:label="phat_AggregateOfferingPriceThroughEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LesseeOperatingLeaseNumberOfOptionToExtend" xlink:label="phat_LesseeOperatingLeaseNumberOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_OperatingLossCarryforwardsExpirationYear" xlink:label="phat_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesOneMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockRepurchaseProgramNumberOfSharesRightLapse" xlink:label="phat_StockRepurchaseProgramNumberOfSharesRightLapse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" xlink:label="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_CommercialSupplyAgreementsMember" xlink:label="phat_CommercialSupplyAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DebtInstrumentInterestAndFinalPaymentFee" xlink:label="phat_DebtInstrumentInterestAndFinalPaymentFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="phat_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_NetProceedsAfterDeductingUnderwritersCommission" xlink:label="phat_NetProceedsAfterDeductingUnderwritersCommission"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_FoundersMember" xlink:label="phat_FoundersMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_FrazierLifeSciencesIXLimitedPartnerMember" xlink:label="phat_FrazierLifeSciencesIXLimitedPartnerMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PurchaseCommitmentExpense" xlink:label="phat_PurchaseCommitmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_RepurchaseRightLapseShares" xlink:label="phat_RepurchaseRightLapseShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_IL" xlink:label="stpr_IL"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:label="phat_ProceedsFromIssuanceInitialPublicOfferingGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_CommitmentsAndContingenciesLineItems" xlink:label="phat_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TemporaryServicesAgreementMember" xlink:label="phat_TemporaryServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_EmployeesMember" xlink:label="phat_EmployeesMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PCIPharmaServicesMember" xlink:label="phat_PCIPharmaServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ConversionOfWarrantLiabilitiesIntoEquity" xlink:label="phat_ConversionOfWarrantLiabilitiesIntoEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TermLoanFirstAdvanceMember" xlink:label="phat_TermLoanFirstAdvanceMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_WarrantsLiabilitiesMember" xlink:label="phat_WarrantsLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TermLoanAdvanceMember" xlink:label="phat_TermLoanAdvanceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_UnvestedSharesMember" xlink:label="phat_UnvestedSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_SiliconValleyBankTermLoanMember" xlink:label="phat_SiliconValleyBankTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="phat_TwoThousandNineteenIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity" xlink:label="phat_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_SharesAggregateRepurchasePrice" xlink:label="phat_SharesAggregateRepurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DebtInstrumentAdditionalBorrowingCapacityAmounts" xlink:label="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AccruedResearchAndDevelopmentExpenses" xlink:label="phat_AccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ATMOfferingProgramMember" xlink:label="phat_ATMOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DebtInstrumentFacilityChargePercentage" xlink:label="phat_DebtInstrumentFacilityChargePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DebtInstrumentPenaltyFeePercentage" xlink:label="phat_DebtInstrumentPenaltyFeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_OrganizationAndBasisOfPresentationPolicyTextBlock" xlink:label="phat_OrganizationAndBasisOfPresentationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liability, transfers into level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level1 To Level2 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liabilities, level 1 to level 2 transfers, amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Partner Type Of Partners Capital Account Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Partner Type of Partners' Capital Account, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RepurchaseRightLapseRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repurchase right lapse rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RepurchaseRightLapseRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Right Lapse Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RepurchaseRightLapseRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase right lapse rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Debt Instruments [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Total Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of qualified cash prior to Third performance milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Percentage of Qualified Cash on Principal Amount Prior to Third Performance Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of qualified cash on principal amount prior to third performance milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_UnpaidUnderwrittenPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unpaid underwritten public offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_UnpaidUnderwrittenPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unpaid Underwritten Public Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_UnpaidUnderwrittenPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten public offering costs included in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets (includes related party amounts of $82 and $(82), respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value Per Share, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash paid for property, plant and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">401(k) matching contribution, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution pan employer discretionary match number of shares settled.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Discretionary Match Number Of Shares Settled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer discretionary match number of shares settled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2019 equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; authorized shares-400,000,000 at December 31, 2021 and 2020; issued shares-31,656,035 and 31,262,769 at December 31, 2021 and 2020, respectively; outstanding shares- 30,511,226 and 28,516,010 at December 31, 2021 and 2020, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument prepayment fee percentage of outstanding principal amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Prepayment Fee Percentage Of Outstanding Principal Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, prepayment fee percentage of outstanding principal amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales commission payable as a percentage of sale of gross sales price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Commission Payable as a percentage of sale of Gross Sales Price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales commission payable as a percentage of sale of gross sales price per share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LanderWarrantsExpireTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lander warrants expire term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LanderWarrantsExpireTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lander Warrants Expire Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LanderWarrantsExpireTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expire term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedClinicalTrialExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical trial expenses current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedClinicalTrialExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Trial Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedClinicalTrialExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical trial expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncrementalCommonSharesAttributableToExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incremental common shares attributable to exercise of warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncrementalCommonSharesAttributableToExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable To Exercise Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncrementalCommonSharesAttributableToExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock included in calculation of basic weighted-average common shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares of common stock outstanding, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401(k) matching contribution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, equity instruments other than options, share vesting.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Share Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Share vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PurchaseOfAdditionalOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase of additional offering expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PurchaseOfAdditionalOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Of Additional Offering Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PurchaseOfAdditionalOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of additional offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Options exercisable as of December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options and Other than Options, Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, options and other than options, grants in period gross.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial fair value of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrant liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net of valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Unvested Restricted Stock Units Roll Forward Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Unvested Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonfinancialAssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nonfinancial assets fair value disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonfinancialAssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonfinancial Assets Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonfinancialAssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-financial assets fair value disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, Accounting Standards Update, adopted [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Options cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 4)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ExpectedCashDividendYieldRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected cash dividend yield rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ExpectedCashDividendYieldRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected Cash Dividend Yield Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ExpectedCashDividendYieldRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected cash dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal And Interest In Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of principal and interest in year five.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Tax Credits Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommonStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommonStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommonStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Basis Spread On Variable Rate1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, basis spread on variable rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Purchase Obligation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum purchase obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP shares issued, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AgreementExpirationTermFromDateOfFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement expiration term from date of first commercial sale.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AgreementExpirationTermFromDateOfFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Expiration Term From Date Of First Commercial Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AgreementExpirationTermFromDateOfFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement expiration term from date of first commercial sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Immaterial Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, Accounting Standards Update, Immaterial effect [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AdditionalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional warrant issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AdditionalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Warrant Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AdditionalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional warrant issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockOptionsAndPerformanceBasedUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options and Performance-based Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockOptionsAndPerformanceBasedUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock options and performance-based units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockOptionsAndPerformanceBasedUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options and performance-based units.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases included in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization basis of presentation and summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual increase to shares available for issuance percentage of outstanding common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted-Average Assumptions Used to Estimate Fair Value of ESPP Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative (includes related party amounts of $18 and $157, respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property, plant and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, issued shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentForLicenseAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for license amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentForLicenseAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment For License Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentForLicenseAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash consideration paid for license</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Stock Units, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Stock Units, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentInKindPikInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment In Kind PIK Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentInKindPikInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment in Kind PIK Interest Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentInKindPikInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment in kind PIK interest rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in accounts payable and accrued expenses related parties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Accrued Expenses Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related parties accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease liabilities arising from obtaining right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Arising From Obtaining Right Of Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities arising from obtaining right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt noncurrent excluding unamortized debt discount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Noncurrent Excluding Unamortized Debt Discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt, non-current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update 2019-12</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2019-12 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses and other assets related parties current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Assets Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets, related parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses (including related party amounts of $2,330 and $734, respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of principal and interest in year four.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal And Interest In Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Expenses From Transactions With Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expense related to services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BaseRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Floor Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BaseRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Base Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, authorized shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrincipalOwnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Principal Owner [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrincipalOwnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Frazier</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: operating lease liabilities, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PrepaidLeasePaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid lease payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PrepaidLeasePaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Lease Payments [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PrepaidLeasePaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average unvested shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ComponentOfBalanceSheetDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Component of Balance Sheet Disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ComponentOfBalanceSheetDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Component Of Balance Sheet Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ComponentOfBalanceSheetDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Details</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, maturity date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockRepurchaseProgramExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock repurchase program expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockRepurchaseProgramExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Repurchase Program Expiration Month and Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedExpensesRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses related parties current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedExpensesRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedExpensesRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses, related parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grantee Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of supplemental balance sheet information related to operating leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Supplemental Balance Sheet Information Related To Operating Leases Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Supplemental Balance Sheet Information Related to the Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonfinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Nonfinancial Liabilities Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonfinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonfinancial Liabilities Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonfinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-financial liabilities fair value disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LenderWarrantsExercisableSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lender warrants exercisable shares of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LenderWarrantsExercisableSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lender Warrants Exercisable Shares Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LenderWarrantsExercisableSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercisable shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits That Would Impact Effective Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits that would affect effective tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PurchaseObligationDueInFirstTwentyFourMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase obligation due in first twenty four months.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PurchaseObligationDueInFirstTwentyFourMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation Due In First Twenty Four Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PurchaseObligationDueInFirstTwentyFourMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase obligation in the first 24-month period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock warrants in connection with long-term debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Issuance Of Common Stock Warrants In Connection With Long Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash issuance of common stock warrants in connection with long term debt.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable (including related party amounts of $1,343 and $173, respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amount of debt instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt instrument borrowed amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Face Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increases related to current year tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of PIK interest debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Paid-in-Kind Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MinimumMarketCapitalizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum market capitalization amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MinimumMarketCapitalizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Market Capitalization Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MinimumMarketCapitalizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum market capitalization amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses and Accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value; authorized shares - 40,000,000 at December 31, 2021 and 2020; no shares issued and outstanding at December 31, 2021 and 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, $0.0001 par value authorized shares 40,000,000 at December 31, 2020 and 2019 no shares issued and outstanding at December 31, 2020 and 2019</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities, non-current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Leases Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TakedaWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Takeda warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TakedaWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Takeda Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TakedaWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Takeda Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TakedaWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Takeda Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expenses Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development tax credit carry forward expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Tax Credit Carry Forward Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision (benefit) for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of noncash investing and financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease)in prepaid expenses and other assets related parties current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related parties prepaid expenses and other assets current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic and Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area for operating lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Nonvested Performance Based Units Activity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of PSU Activity Under the 2019 Incentive Award Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at December 31, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClosingMarketPriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Closing market price of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClosingMarketPriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Closing Market Price Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClosingMarketPriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Closing market price of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, outstanding shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options cancelled or forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options Outstanding, Options cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Options cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization basis of presentation and summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Lease Payments Under Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity plan, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of principal and interest, year one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal And Interest Due Next Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss and comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NonCash settlement of defined contribution plan liability in common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of 401(k) liability in common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Settlement Of Defined Contribution Plan Liability In Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average incremental borrowing rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ESPP Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation change in fair value of warrants and convertible debt.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Fair Value Of Warrants And Convertible Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrants and convertible debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of principal and interest in year three.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal And Interest In Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of stock options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ResearchAndDevelopmentExpenseRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ResearchAndDevelopmentExpenseRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ResearchAndDevelopmentExpenseRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses, related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts payable and accrued expenses related parties current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Expenses Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Outstanding accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_GeneralAndAdministrativeExpenseRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">General and administrative expense related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_GeneralAndAdministrativeExpenseRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_GeneralAndAdministrativeExpenseRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses, related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ProceedsFromUnderwrittenPublicOfferingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from underwritten public offering, net.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ProceedsFromUnderwrittenPublicOfferingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Underwritten Public Offering Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ProceedsFromUnderwrittenPublicOfferingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from underwritten public offering, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of qualified cash following third performance milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Percentage of Qualified Cash on Principal Amount Following Third Performance Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of qualified cash on principal amount following third performance milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DrugProductOrSubstanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Drug Product or Substance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DrugProductOrSubstanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Drug Product Or Substance [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DrugProductOrSubstanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Drug product Or substance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from Initial Public Offering (IPO)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional number of shares available for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of debt funded to be issued as warrants to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Debt Funded to be Issued as Warrants to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of debt funded to be issued as warrants to purchase common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction shared operating expenses due to transactions with related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Shared Operating Expenses Due To Transactions With Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shared operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NonCash settlement of employee stock purchase plan liability in common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of ESPP liability in common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Settlement Of Employee Stock Purchase Plan Liability In Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants issued to common stock remains exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued to common stock remains exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Remains Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, number of securities called by warrants or rights, remains exercisable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents &#8211; end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents &#8211; beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance of Long-term Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Long Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of long-term debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Partner Type Of Partners Capital Account [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Partner Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Financing Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prime Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prime Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LiabilitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liabilities, lessee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LiabilitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Lessee [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LiabilitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unamortized Debt Issuance Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LiquidityAndCapitalResourcesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity and capital resources.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LiquidityAndCapitalResourcesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity And Capital Resources Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LiquidityAndCapitalResourcesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity and Capital Resources</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for grant annual increase.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Annual Increase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares remain available for issuance, annual increase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClassOfWarrantOrRightExpireTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, expire term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClassOfWarrantOrRightExpireTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expire term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClassOfWarrantOrRightExpireTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of warrant or right expire term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Term Loans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of principal and interest in year two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal And Interest In Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: amount representing interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross unrecognized tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash payments for operating lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, issued shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of long-term debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Long-term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Repayments of Long-term Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, outstanding shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AgreementExtendsPeriodForTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement extends period for termination.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AgreementExtendsPeriodForTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Extends Period For Termination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AgreementExtendsPeriodForTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement extends period for termination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock reserved for future issuances.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Reserved For Future Issuances Table Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Common Stock Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Debt, Excluding Current Maturities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt, net of discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockOptionsAndPerformanceBasedAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options and performance-based awards.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockOptionsAndPerformanceBasedAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options And Performance Based Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockOptionsAndPerformanceBasedAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options and Performance-Based Awards Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClinicalManufacturingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical manufacturing services.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClinicalManufacturingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Manufacturing Services [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClinicalManufacturingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Manufacturing Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based payment arrangement, employee and nonemployee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Payment Arrangement Employee And Nonemployee [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee and Nonemployee Director</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent Of Match</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employer matching contribution, percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of warrant liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrant liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value adjustment of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401(k) Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SharesIssuedPricePerShareAfterDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued, price per share after deductions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SharesIssuedPricePerShareAfterDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share After Deductions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SharesIssuedPricePerShareAfterDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price per share after deducting underwriting discounts and commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Other Adjustments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants exercised to purchase shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock from exercise of warrants, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares exercise of warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LicenseAgreementTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement transaction costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LicenseAgreementTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Transaction Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LicenseAgreementTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loans, Aggregate Principal Amount Tranches Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loans Aggregate Principal Amount Tranches Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loans, aggregate principal amount tranches two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AssetsLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Assets, lessee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AssetsLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Lessee [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AssetsLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Cost Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan employer contribution expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow on public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClassOfWarrantOrRightExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, expiration date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClassOfWarrantOrRightExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ClassOfWarrantOrRightExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramPeriodInForce1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program Period In Force1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramPeriodInForce1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock repurchase program, period in force</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued interest.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unamortized Discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unamortized debt discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disposals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposal of property, plant or equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets (including related party amounts of $0 and $82, respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Term loans aggregate principal amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Carrying Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total term loan borrowings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer equipment and software.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment And Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment and Related Software</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loans, Aggregate Principal Amount Tranches Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loans Aggregate Principal Amount Tranches Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loans, aggregate principal amount tranches three.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentFinalPaymentFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument final payment fee percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentFinalPaymentFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Final Payment Fee Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentFinalPaymentFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, final payment fee percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Debt, Current Maturities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of long-term debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term debt, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Options exercisable as of December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of eligible compensation contributed by participants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value Per Share, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Income Tax Contingencies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity Related to Gross Unrecognized Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Commitments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from exercise of stock options, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrual for interest or penalties related to income tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FinancialAssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial assets fair value disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FinancialAssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Assets Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FinancialAssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets fair value disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loans, Aggregate Principal Amount Tranches Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loans Aggregate Principal Amount Tranches Four [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loans, aggregate principal amount tranches four.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating right of use asset and lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Right Of Use Asset And Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating right-of-use asset and lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount payable in sales milestones upon the achievement of specified levels of product sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount Payable In Sales Milestones Upon Achievement Of Specified Levels Of Product Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum amount payable in sales milestones upon achievement of specified levels of product sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentFinalPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, final payment fee or end of term charge</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentFinalPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument final payment fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentFinalPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Final Payment Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtAndInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt and interest.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtAndInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt And Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LongTermDebtAndInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total principal and interest payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses (includes related party amounts of $2,766 and $399, respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Maturities Of Long Term Debt Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Principal and Interest Payments Under Term Loans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total other income (expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TakedaPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Takeda pharmaceutical company limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TakedaPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Takeda Pharmaceutical Company Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TakedaPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Takeda</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Options vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LenderWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lender warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LenderWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lender Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LenderWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lender Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets To Be Disposed Of</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_JE_lbl" xlink:role="http://www.xbrl.org/2003/role/label">JERSEY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_JE_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Florham Park, New Jersey</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value Per Share, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonCashFinalInterestPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash final interest payment fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonCashFinalInterestPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Final Interest Payment Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NonCashFinalInterestPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Final interest payment fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_WarrantsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants expiration date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_WarrantsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_WarrantsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, option to extend description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-Based Stock Units (PSU)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentForFacilityCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for facility charge</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentForFacilityCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for Facility Charge</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PaymentForFacilityCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for facility charge.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchases of shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TakedaLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Takeda license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TakedaLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Takeda License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TakedaLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Takeda License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TakedaLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Takeda License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Liabilities Measured at Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncomeTaxReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation permanent items.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncomeTaxReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Permanent Items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncomeTaxReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Anniversary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Interest Payable Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award options exercises and shares vested in period weighted average exercise price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises And Shares Vested In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Options exercised and shares vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LicenseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LicenseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LicenseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_HerculesAndSvbTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hercules and SVB Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_HerculesAndSvbTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hercules and SVB Term Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_HerculesAndSvbTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hercules and SVB term loan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in clinical accrued trial expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Clinical Accrued Trial Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical trial expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, authorized shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Options exercisable as of December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest or penalties related income tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Options vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OpenMarketSaleAgreementWithJefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Open Market Sale Agreement with Jefferies LLC.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OpenMarketSaleAgreementWithJefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Market Sale Agreement With Jefferies L L C [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OpenMarketSaleAgreementWithJefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open Market Sale Agreement with Jefferies LLC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Stock Units, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock awards, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants issued to purchase shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued to purchase shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AggregateOfferingPriceThroughEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate offering price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AggregateOfferingPriceThroughEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate offering price through equity financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AggregateOfferingPriceThroughEquityFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate offering price through equity financing.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumptions:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LesseeOperatingLeaseNumberOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease number of option to extend.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LesseeOperatingLeaseNumberOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Number Of Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_LesseeOperatingLeaseNumberOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease number of option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Payment Terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loans, Aggregate Principal Amount Tranches One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loans Aggregate Principal Amount Tranches One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loans, aggregate principal amount tranches one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Options vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated weighted-average fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockRepurchaseProgramNumberOfSharesRightLapse_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock repurchase program, number of shares right lapse.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockRepurchaseProgramNumberOfSharesRightLapse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program Number Of Shares Right Lapse</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockRepurchaseProgramNumberOfSharesRightLapse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock repurchase program, number of shares right lapse</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable, related parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, remaining lease terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of lender warrants into equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital conversion of warrant liability into equity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Conversion Of Warrant Liability Into Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of warrant liability into equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, rent expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommercialSupplyAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Supply Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommercialSupplyAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial supply agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes computed at the statutory rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentInterestAndFinalPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument interest and final payment fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentInterestAndFinalPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest And Final Payment Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentInterestAndFinalPaymentFee_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less interest and final payment fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock from exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value exercise of warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NetProceedsAfterDeductingUnderwritersCommission_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds after deducting underwriters commission.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NetProceedsAfterDeductingUnderwritersCommission_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds After Deducting Underwriters Commission</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_NetProceedsAfterDeductingUnderwritersCommission_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds after deducting underwriters commission</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant, and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FoundersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Founders.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FoundersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Founders [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FoundersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Founders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award stock options exercised and shares vested.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Stock Options Exercised And Shares Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Options exercised and shares vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FrazierLifeSciencesIXLimitedPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Frazier Life Sciences IX, limited partner member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FrazierLifeSciencesIXLimitedPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Frazier Life Sciences I X Limited Partner [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FrazierLifeSciencesIXLimitedPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Frazier</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PurchaseCommitmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase commitment, expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PurchaseCommitmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Commitment Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PurchaseCommitmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses incurred related to purchase commitments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RepurchaseRightLapseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repurchase right lapse shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RepurchaseRightLapseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Right Lapse Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_RepurchaseRightLapseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase right lapse each month after first anniversary, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense, weighted-average period for recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating loss carryforwards which are carried over indefinitely</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_IL_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Buffalo Grove, Illinois</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_IL_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ILLINOIS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Warrant Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to additional paid-in-capital, warrants issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adoption Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, Accounting Standards Update, Adoption date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Noncurrent Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance initial public offering gross.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance initial public offering gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization, Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TemporaryServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary services agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TemporaryServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Services Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TemporaryServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Services Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employees [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PCIPharmaServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">PCI Pharma Services.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PCIPharmaServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">P C I Pharma Services [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_PCIPharmaServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PCI Pharma Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional &amp; consulting expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ConversionOfWarrantLiabilitiesIntoEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of warrant liabilities into equity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ConversionOfWarrantLiabilitiesIntoEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Warrant Liabilities Into Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ConversionOfWarrantLiabilitiesIntoEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Lender Warrants into Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value Per Share, Unvested Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value Per Share, Unvested Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-Process Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program Number Of Shares Authorized To Be Repurchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized to repurchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted shares, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liability, transfers out of level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoanFirstAdvanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan First Advance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoanFirstAdvanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan First Advance [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoanFirstAdvanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan first advance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_WarrantsLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_WarrantsLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_WarrantsLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoanAdvanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan Advance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoanAdvanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan Advance [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TermLoanAdvanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan advance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grantee Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, renewal term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development (includes related party amounts of $4,933 and $2,812, respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_UnvestedSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_UnvestedSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_UnvestedSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SiliconValleyBankTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SVB Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SiliconValleyBankTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Silicon Valley Bank Term Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SiliconValleyBankTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">SVB term loan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Repurchase Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate repurchase price of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen incentive award plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Incentive Award Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Incentive Award Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level2 To Level1 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liabilities, level 2 to level 1 transfers, amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Stock Units, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Goodwill And Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining number of shares to be repurchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reclassification of Lender Warrants into equity (Note 6)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs reconciliations recurring basis reclass of warrant into equity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Reclass Of Warrants Into Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SharesAggregateRepurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares aggregate repurchase price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SharesAggregateRepurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Aggregate Repurchase Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_SharesAggregateRepurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares aggregate repurchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock initially reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Effective Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, interest rate percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Restricted Stock Award Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, additional borrowing capacity amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Additional Borrowing Capacity Amounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument additional borrowing capacity amounts.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other (expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Nonrecurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Nonrecurring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, cancelled or forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award, Options and Other Than Options Forfeitures and Expirations in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, options and other than options forfeitures and expirations in period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted and Issued Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ATMOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market offering program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ATMOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">A T M Offering Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_ATMOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-Market Offering Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total debt, net of debt discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Final payment of debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentFacilityChargePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, facility charge percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentFacilityChargePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Facility Charge Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentFacilityChargePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument facility charge percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentPenaltyFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument penalty fee percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentPenaltyFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Penalty Fee Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_DebtInstrumentPenaltyFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument penalty fee percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options exercisable as of December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increases related to prior year tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OrganizationAndBasisOfPresentationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OrganizationAndBasisOfPresentationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization and Basis of Presentation [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="phat_OrganizationAndBasisOfPresentationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and basis of presentation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:to="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RepurchaseRightLapseRate" xlink:to="phat_RepurchaseRightLapseRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone" xlink:to="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_UnpaidUnderwrittenPublicOfferingCosts" xlink:to="phat_UnpaidUnderwrittenPublicOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" xlink:to="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="phat_TwoThousandNineteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount" xlink:to="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare" xlink:to="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LanderWarrantsExpireTerm" xlink:to="phat_LanderWarrantsExpireTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AccruedClinicalTrialExpensesCurrent" xlink:to="phat_AccruedClinicalTrialExpensesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_IncrementalCommonSharesAttributableToExerciseOfWarrants" xlink:to="phat_IncrementalCommonSharesAttributableToExerciseOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PurchaseOfAdditionalOfferingExpenses" xlink:to="phat_PurchaseOfAdditionalOfferingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_NonfinancialAssetsFairValueDisclosure" xlink:to="phat_NonfinancialAssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ExpectedCashDividendYieldRate" xlink:to="phat_ExpectedCashDividendYieldRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_CommonStockWarrantMember" xlink:to="phat_CommonStockWarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AgreementExpirationTermFromDateOfFirstCommercialSale" xlink:to="phat_AgreementExpirationTermFromDateOfFirstCommercialSale_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AdditionalWarrantIssued" xlink:to="phat_AdditionalWarrantIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_StockOptionsAndPerformanceBasedUnitsMember" xlink:to="phat_StockOptionsAndPerformanceBasedUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PaymentForLicenseAmount" xlink:to="phat_PaymentForLicenseAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PaymentInKindPikInterestRateMember" xlink:to="phat_PaymentInKindPikInterestRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties" xlink:to="phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" xlink:to="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_CommitmentsAndContingenciesTable" xlink:to="phat_CommitmentsAndContingenciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount" xlink:to="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201912Member" xlink:to="us-gaap_AccountingStandardsUpdate201912Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" xlink:to="phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LoanAgreementMember" xlink:to="phat_LoanAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BaseRateMember" xlink:to="us-gaap_BaseRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalOwnerMember" xlink:to="us-gaap_PrincipalOwnerMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PrepaidLeasePaymentsMember" xlink:to="phat_PrepaidLeasePaymentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ComponentOfBalanceSheetDisclosureTextBlock" xlink:to="phat_ComponentOfBalanceSheetDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_StockRepurchaseProgramExpirationMonthAndYear" xlink:to="phat_StockRepurchaseProgramExpirationMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AccruedExpensesRelatedPartiesCurrent" xlink:to="phat_AccruedExpensesRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_NonfinancialLiabilitiesFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LenderWarrantsExercisableSharesOfCommonStock" xlink:to="phat_LenderWarrantsExercisableSharesOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PurchaseObligationDueInFirstTwentyFourMonths" xlink:to="phat_PurchaseObligationDueInFirstTwentyFourMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" xlink:to="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_MinimumMarketCapitalizationAmount" xlink:to="phat_MinimumMarketCapitalizationAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorLeasesPolicyTextBlock" xlink:to="us-gaap_LessorLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TakedaWarrantsMember" xlink:to="phat_TakedaWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear" xlink:to="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent" xlink:to="phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ClosingMarketPriceOfCommonStock" xlink:to="phat_ClosingMarketPriceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock" xlink:to="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_EmployeeStockPurchasePlanMember" xlink:to="phat_EmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt" xlink:to="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ResearchAndDevelopmentExpenseRelatedParty" xlink:to="phat_ResearchAndDevelopmentExpenseRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" xlink:to="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_GeneralAndAdministrativeExpenseRelatedParty" xlink:to="phat_GeneralAndAdministrativeExpenseRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ProceedsFromUnderwrittenPublicOfferingNet" xlink:to="phat_ProceedsFromUnderwrittenPublicOfferingNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone" xlink:to="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_DrugProductOrSubstanceMember" xlink:to="phat_DrugProductOrSubstanceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock" xlink:to="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty" xlink:to="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock" xlink:to="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" xlink:to="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:to="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LiabilitiesLesseeAbstract" xlink:to="phat_LiabilitiesLesseeAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:to="phat_LiquidityAndCapitalResourcesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ClassOfWarrantOrRightExpireTerm" xlink:to="phat_ClassOfWarrantOrRightExpireTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TermLoanMember" xlink:to="phat_TermLoanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AgreementExtendsPeriodForTermination" xlink:to="phat_AgreementExtendsPeriodForTermination_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock" xlink:to="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_StockOptionsAndPerformanceBasedAwardsMember" xlink:to="phat_StockOptionsAndPerformanceBasedAwardsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ClinicalManufacturingServicesMember" xlink:to="phat_ClinicalManufacturingServicesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember" xlink:to="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_SharesIssuedPricePerShareAfterDeductions" xlink:to="phat_SharesIssuedPricePerShareAfterDeductions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LicenseAgreementTransactionCosts" xlink:to="phat_LicenseAgreementTransactionCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AssetsLesseeAbstract" xlink:to="phat_AssetsLesseeAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_FollowOnPublicOfferingMember" xlink:to="phat_FollowOnPublicOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ClassOfWarrantOrRightExpirationDate" xlink:to="phat_ClassOfWarrantOrRightExpirationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:to="us-gaap_StockRepurchaseProgramPeriodInForce1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AccruedInterest" xlink:to="phat_AccruedInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ComputerEquipmentAndSoftwareMember" xlink:to="phat_ComputerEquipmentAndSoftwareMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_DebtInstrumentFinalPaymentFeePercentage" xlink:to="phat_DebtInstrumentFinalPaymentFeePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_FinancialAssetsFairValueDisclosure" xlink:to="phat_FinancialAssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TermLoansAggregatePrincipalAmountTranchesFourMember" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesFourMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" xlink:to="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales" xlink:to="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_DebtInstrumentFinalPaymentFee" xlink:to="phat_DebtInstrumentFinalPaymentFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LongTermDebtAndInterest" xlink:to="phat_LongTermDebtAndInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="phat_TakedaPharmaceuticalCompanyLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LenderWarrantsMember" xlink:to="phat_LenderWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_JE" xlink:to="country_JE_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_NonCashFinalInterestPaymentFee" xlink:to="phat_NonCashFinalInterestPaymentFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_WarrantsExpirationDate" xlink:to="phat_WarrantsExpirationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PaymentForFacilityCharge" xlink:to="phat_PaymentForFacilityCharge_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TakedaLicenseAgreementMember" xlink:to="phat_TakedaLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_IncomeTaxReconciliationPermanentItems" xlink:to="phat_IncomeTaxReconciliationPermanentItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice" xlink:to="phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LicenseAgreementDescription" xlink:to="phat_LicenseAgreementDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_HerculesAndSvbTermLoanMember" xlink:to="phat_HerculesAndSvbTermLoanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses" xlink:to="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_OpenMarketSaleAgreementWithJefferiesLLCMember" xlink:to="phat_OpenMarketSaleAgreementWithJefferiesLLCMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AggregateOfferingPriceThroughEquityFinancing" xlink:to="phat_AggregateOfferingPriceThroughEquityFinancing_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_LesseeOperatingLeaseNumberOfOptionToExtend" xlink:to="phat_LesseeOperatingLeaseNumberOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPaymentTerms" xlink:to="us-gaap_DebtInstrumentPaymentTerms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_OperatingLossCarryforwardsExpirationYear" xlink:to="phat_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TermLoansAggregatePrincipalAmountTranchesOneMember" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_StockRepurchaseProgramNumberOfSharesRightLapse" xlink:to="phat_StockRepurchaseProgramNumberOfSharesRightLapse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" xlink:to="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_CommercialSupplyAgreementsMember" xlink:to="phat_CommercialSupplyAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_DebtInstrumentInterestAndFinalPaymentFee" xlink:to="phat_DebtInstrumentInterestAndFinalPaymentFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="phat_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_NetProceedsAfterDeductingUnderwritersCommission" xlink:to="phat_NetProceedsAfterDeductingUnderwritersCommission_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_FoundersMember" xlink:to="phat_FoundersMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_FrazierLifeSciencesIXLimitedPartnerMember" xlink:to="phat_FrazierLifeSciencesIXLimitedPartnerMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PurchaseCommitmentExpense" xlink:to="phat_PurchaseCommitmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_RepurchaseRightLapseShares" xlink:to="phat_RepurchaseRightLapseShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_IL" xlink:to="stpr_IL_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:to="phat_ProceedsFromIssuanceInitialPublicOfferingGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_CommitmentsAndContingenciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TemporaryServicesAgreementMember" xlink:to="phat_TemporaryServicesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_EmployeesMember" xlink:to="phat_EmployeesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_PCIPharmaServicesMember" xlink:to="phat_PCIPharmaServicesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ConversionOfWarrantLiabilitiesIntoEquity" xlink:to="phat_ConversionOfWarrantLiabilitiesIntoEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TermLoanFirstAdvanceMember" xlink:to="phat_TermLoanFirstAdvanceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_WarrantsLiabilitiesMember" xlink:to="phat_WarrantsLiabilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TermLoanAdvanceMember" xlink:to="phat_TermLoanAdvanceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_UnvestedSharesMember" xlink:to="phat_UnvestedSharesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_SiliconValleyBankTermLoanMember" xlink:to="phat_SiliconValleyBankTermLoanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_TwoThousandNineteenIncentiveAwardPlanMember" xlink:to="phat_TwoThousandNineteenIncentiveAwardPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity" xlink:to="phat_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_SharesAggregateRepurchasePrice" xlink:to="phat_SharesAggregateRepurchasePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts" xlink:to="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_AccruedResearchAndDevelopmentExpenses" xlink:to="phat_AccruedResearchAndDevelopmentExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_ATMOfferingProgramMember" xlink:to="phat_ATMOfferingProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_DebtInstrumentFacilityChargePercentage" xlink:to="phat_DebtInstrumentFacilityChargePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_DebtInstrumentPenaltyFeePercentage" xlink:to="phat_DebtInstrumentPenaltyFeePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="phat_OrganizationAndBasisOfPresentationPolicyTextBlock" xlink:to="phat_OrganizationAndBasisOfPresentationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>34
<FILENAME>phat-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-01T13:48:38.5334+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity" xlink:href="phat-20211231.xsd#StatementStatementsOfStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:href="phat-20211231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:href="phat-20211231.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="phat-20211231.xsd#Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValueDetails" xlink:href="phat-20211231.xsd#Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" xlink:href="phat-20211231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="phat-20211231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="phat-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" xlink:href="phat-20211231.xsd#Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" xlink:href="phat-20211231.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="phat-20211231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:href="phat-20211231.xsd#Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails" xlink:href="phat-20211231.xsd#Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails" xlink:href="phat-20211231.xsd#Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" xlink:href="phat-20211231.xsd#Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="phat-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails" xlink:href="phat-20211231.xsd#Role_Disclosure401KPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="phat-20211231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" xlink:label="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="phat_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" xlink:label="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_StockIssuedDuringPeriodValueExerciseOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" xlink:label="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ProceedsFromUnderwrittenPublicOfferingNet" xlink:label="phat_ProceedsFromUnderwrittenPublicOfferingNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_NonCashFinalInterestPaymentFee" xlink:label="phat_NonCashFinalInterestPaymentFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_IncreaseDecreaseInClinicalAccruedTrialExpenses" xlink:label="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock" xlink:label="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock" xlink:label="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" xlink:label="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" xlink:label="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ConversionOfWarrantLiabilitiesIntoEquity" xlink:label="phat_ConversionOfWarrantLiabilitiesIntoEquity"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_UnpaidUnderwrittenPublicOfferingCosts" xlink:label="phat_UnpaidUnderwrittenPublicOfferingCosts"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="phat_ProceedsFromUnderwrittenPublicOfferingNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_NonCashFinalInterestPaymentFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_ConversionOfWarrantLiabilitiesIntoEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="phat_UnpaidUnderwrittenPublicOfferingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_EmployeeStockPurchasePlanMember" xlink:label="phat_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_CommonStockReservedForFutureIssuancesTableTableTextBlock" xlink:label="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="phat_CommonStockReservedForFutureIssuancesTableTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LenderWarrantsMember" xlink:label="phat_LenderWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ComputerEquipmentAndSoftwareMember" xlink:label="phat_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_UnvestedSharesMember" xlink:label="phat_UnvestedSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TakedaLicenseAgreementMember" xlink:label="phat_TakedaLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="phat_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_FollowOnPublicOfferingMember" xlink:label="phat_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TakedaWarrantsMember" xlink:label="phat_TakedaWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_FinancialAssetsFairValueDisclosure" xlink:label="phat_FinancialAssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_NonfinancialAssetsFairValueDisclosure" xlink:label="phat_NonfinancialAssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_NonfinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ExpectedCashDividendYieldRate" xlink:label="phat_ExpectedCashDividendYieldRate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" xlink:label="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_IncrementalCommonSharesAttributableToExerciseOfWarrants" xlink:label="phat_IncrementalCommonSharesAttributableToExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" xlink:label="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="phat_LenderWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="phat_ComputerEquipmentAndSoftwareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="phat_UnvestedSharesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_TakedaLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="phat_TakedaPharmaceuticalCompanyLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="phat_FollowOnPublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="phat_TakedaWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_FinancialAssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_NonfinancialAssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NonfinancialLiabilitiesFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_ExpectedCashDividendYieldRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_IncrementalCommonSharesAttributableToExerciseOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_WarrantsLiabilitiesMember" xlink:label="phat_WarrantsLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity" xlink:label="phat_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="phat_WarrantsLiabilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="phat_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrincipalOwnerMember" xlink:label="us-gaap_PrincipalOwnerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ClinicalManufacturingServicesMember" xlink:label="phat_ClinicalManufacturingServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TakedaLicenseAgreementMember" xlink:label="phat_TakedaLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" xlink:label="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_CommercialSupplyAgreementsMember" xlink:label="phat_CommercialSupplyAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DrugProductOrSubstanceMember" xlink:label="phat_DrugProductOrSubstanceMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PCIPharmaServicesMember" xlink:label="phat_PCIPharmaServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty" xlink:label="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TemporaryServicesAgreementMember" xlink:label="phat_TemporaryServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="phat_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AgreementExtendsPeriodForTermination" xlink:label="phat_AgreementExtendsPeriodForTermination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_PrincipalOwnerMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="phat_ClinicalManufacturingServicesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_TakedaLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_CommercialSupplyAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="phat_DrugProductOrSubstanceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="phat_PCIPharmaServicesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_TemporaryServicesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="phat_TakedaPharmaceuticalCompanyLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="phat_AgreementExtendsPeriodForTermination" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PurchaseObligation" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_CommitmentsAndContingenciesLineItems" xlink:label="phat_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_CommitmentsAndContingenciesTable" xlink:label="phat_CommitmentsAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TakedaLicenseAgreementMember" xlink:label="phat_TakedaLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="phat_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LicenseAgreementDescription" xlink:label="phat_LicenseAgreementDescription"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AgreementExpirationTermFromDateOfFirstCommercialSale" xlink:label="phat_AgreementExpirationTermFromDateOfFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PaymentForLicenseAmount" xlink:label="phat_PaymentForLicenseAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AdditionalWarrantIssued" xlink:label="phat_AdditionalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales" xlink:label="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LicenseAgreementTransactionCosts" xlink:label="phat_LicenseAgreementTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_WarrantsExpirationDate" xlink:label="phat_WarrantsExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" xlink:label="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PurchaseObligationDueInFirstTwentyFourMonths" xlink:label="phat_PurchaseObligationDueInFirstTwentyFourMonths"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PurchaseCommitmentExpense" xlink:label="phat_PurchaseCommitmentExpense"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_CommitmentsAndContingenciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_TakedaLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="phat_TakedaPharmaceuticalCompanyLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_LicenseAgreementDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_AgreementExpirationTermFromDateOfFirstCommercialSale" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_CommitmentsAndContingenciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_PaymentForLicenseAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="phat_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_StockIssuedDuringPeriodSharesExerciseOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_AdditionalWarrantIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_LicenseAgreementTransactionCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_WarrantsExpirationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_PurchaseObligationDueInFirstTwentyFourMonths" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="phat_CommitmentsAndContingenciesLineItems" xlink:to="phat_PurchaseCommitmentExpense" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_IL" xlink:label="stpr_IL"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PrepaidLeasePaymentsMember" xlink:label="phat_PrepaidLeasePaymentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JE" xlink:label="country_JE"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LesseeOperatingLeaseNumberOfOptionToExtend" xlink:label="phat_LesseeOperatingLeaseNumberOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_IL" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="phat_PrepaidLeasePaymentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JE" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="phat_LesseeOperatingLeaseNumberOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember" xlink:label="us-gaap_BaseRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LoanAgreementMember" xlink:label="phat_LoanAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TermLoanMember" xlink:label="phat_TermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_HerculesAndSvbTermLoanMember" xlink:label="phat_HerculesAndSvbTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PaymentForFacilityCharge" xlink:label="phat_PaymentForFacilityCharge"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesOneMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesOneMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PaymentInKindPikInterestRateMember" xlink:label="phat_PaymentInKindPikInterestRateMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DebtInstrumentFacilityChargePercentage" xlink:label="phat_DebtInstrumentFacilityChargePercentage"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesTwoMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesThreeMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TermLoansAggregatePrincipalAmountTranchesFourMember" xlink:label="phat_TermLoansAggregatePrincipalAmountTranchesFourMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TermLoanAdvanceMember" xlink:label="phat_TermLoanAdvanceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TermLoanFirstAdvanceMember" xlink:label="phat_TermLoanFirstAdvanceMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DebtInstrumentFinalPaymentFeePercentage" xlink:label="phat_DebtInstrumentFinalPaymentFeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_SiliconValleyBankTermLoanMember" xlink:label="phat_SiliconValleyBankTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DebtInstrumentFinalPaymentFee" xlink:label="phat_DebtInstrumentFinalPaymentFee"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount" xlink:label="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone" xlink:label="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_MinimumMarketCapitalizationAmount" xlink:label="phat_MinimumMarketCapitalizationAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock" xlink:label="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ClassOfWarrantOrRightExpireTerm" xlink:label="phat_ClassOfWarrantOrRightExpireTerm"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ClassOfWarrantOrRightExpirationDate" xlink:label="phat_ClassOfWarrantOrRightExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DebtInstrumentAdditionalBorrowingCapacityAmounts" xlink:label="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DebtInstrumentPenaltyFeePercentage" xlink:label="phat_DebtInstrumentPenaltyFeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LanderWarrantsExpireTerm" xlink:label="phat_LanderWarrantsExpireTerm"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LenderWarrantsExercisableSharesOfCommonStock" xlink:label="phat_LenderWarrantsExercisableSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AccruedInterest" xlink:label="phat_AccruedInterest"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_BaseRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="phat_LoanAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="phat_HerculesAndSvbTermLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_PaymentForFacilityCharge" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="phat_PaymentInKindPikInterestRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentFacilityChargePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoansAggregatePrincipalAmountTranchesFourMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoanAdvanceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_TermLoanFirstAdvanceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentFinalPaymentFeePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="phat_SiliconValleyBankTermLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentFinalPaymentFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_MinimumMarketCapitalizationAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_ClassOfWarrantOrRightExpireTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_ClassOfWarrantOrRightExpirationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentAdditionalBorrowingCapacityAmounts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_DebtInstrumentPenaltyFeePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_LanderWarrantsExpireTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_LenderWarrantsExercisableSharesOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="phat_AccruedInterest" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:label="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_FrazierLifeSciencesIXLimitedPartnerMember" xlink:label="phat_FrazierLifeSciencesIXLimitedPartnerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_FoundersMember" xlink:label="phat_FoundersMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TakedaLicenseAgreementMember" xlink:label="phat_TakedaLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_EmployeesMember" xlink:label="phat_EmployeesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="phat_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_OpenMarketSaleAgreementWithJefferiesLLCMember" xlink:label="phat_OpenMarketSaleAgreementWithJefferiesLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="phat_TwoThousandNineteenIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember" xlink:label="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ATMOfferingProgramMember" xlink:label="phat_ATMOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_EmployeeStockPurchasePlanMember" xlink:label="phat_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockRepurchaseProgramNumberOfSharesRightLapse" xlink:label="phat_StockRepurchaseProgramNumberOfSharesRightLapse"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockOptionsAndPerformanceBasedUnitsMember" xlink:label="phat_StockOptionsAndPerformanceBasedUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:label="us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockRepurchaseProgramExpirationMonthAndYear" xlink:label="phat_StockRepurchaseProgramExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AggregateOfferingPriceThroughEquityFinancing" xlink:label="phat_AggregateOfferingPriceThroughEquityFinancing"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare" xlink:label="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_RepurchaseRightLapseRate" xlink:label="phat_RepurchaseRightLapseRate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_RepurchaseRightLapseShares" xlink:label="phat_RepurchaseRightLapseShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_SharesAggregateRepurchasePrice" xlink:label="phat_SharesAggregateRepurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:label="phat_ProceedsFromIssuanceInitialPublicOfferingGross"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_SharesIssuedPricePerShareAfterDeductions" xlink:label="phat_SharesIssuedPricePerShareAfterDeductions"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_NetProceedsAfterDeductingUnderwritersCommission" xlink:label="phat_NetProceedsAfterDeductingUnderwritersCommission"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_PurchaseOfAdditionalOfferingExpenses" xlink:label="phat_PurchaseOfAdditionalOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease" xlink:label="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ClosingMarketPriceOfCommonStock" xlink:label="phat_ClosingMarketPriceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:to="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:to="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:to="phat_FrazierLifeSciencesIXLimitedPartnerMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="phat_FoundersMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_TakedaLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="phat_EmployeesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_TwoThousandNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="phat_OpenMarketSaleAgreementWithJefferiesLLCMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_TwoThousandNineteenIncentiveAwardPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="phat_ATMOfferingProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_StockRepurchaseProgramNumberOfSharesRightLapse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="phat_StockOptionsAndPerformanceBasedUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchaseProgramPeriodInForce1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_StockRepurchaseProgramExpirationMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_AggregateOfferingPriceThroughEquityFinancing" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_RepurchaseRightLapseRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_RepurchaseRightLapseShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_SharesAggregateRepurchasePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_ProceedsFromIssuanceInitialPublicOfferingGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_SharesIssuedPricePerShareAfterDeductions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_NetProceedsAfterDeductingUnderwritersCommission" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_PurchaseOfAdditionalOfferingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="41" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="phat_ClosingMarketPriceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="42" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="phat_TwoThousandNineteenIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_StockOptionsAndPerformanceBasedAwardsMember" xlink:label="phat_StockOptionsAndPerformanceBasedAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_CommonStockWarrantMember" xlink:label="phat_CommonStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_EmployeeStockPurchasePlanMember" xlink:label="phat_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_TwoThousandNineteenIncentiveAwardPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="phat_StockOptionsAndPerformanceBasedAwardsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="phat_CommonStockWarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="phat_TwoThousandNineteenIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_TwoThousandNineteenIncentiveAwardPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_EmployeeStockPurchasePlanMember" xlink:label="phat_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="phat_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_OperatingLossCarryforwardsExpirationYear" xlink:label="phat_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear" xlink:label="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="phat_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" xlink:label="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JE" xlink:label="country_JE"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_AreaOfLand" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JE" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>35
<FILENAME>phat-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-01T13:48:38.6549+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets" xlink:href="phat-20211231.xsd#Role_StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2" xlink:href="phat-20211231.xsd#DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:href="phat-20211231.xsd#Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:href="phat-20211231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" xlink:href="phat-20211231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:href="phat-20211231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" xlink:href="phat-20211231.xsd#Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails" xlink:href="phat-20211231.xsd#Role_DisclosureDebtScheduleOfTotalDebtDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" xlink:href="phat-20211231.xsd#Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" xlink:href="phat-20211231.xsd#Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:href="phat-20211231.xsd#Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="phat_AccruedClinicalTrialExpensesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AccruedClinicalTrialExpensesCurrent" xlink:label="phat_AccruedClinicalTrialExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="phat_ProceedsFromUnderwrittenPublicOfferingNet" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_PaidInKindInterest" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="5" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="11" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" order="12" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="13" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_ProceedsFromUnderwrittenPublicOfferingNet" xlink:label="phat_ProceedsFromUnderwrittenPublicOfferingNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_IncreaseDecreaseInClinicalAccruedTrialExpenses" xlink:label="phat_IncreaseDecreaseInClinicalAccruedTrialExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities" xlink:label="phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="phat_AccruedResearchAndDevelopmentExpenses" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_AccruedResearchAndDevelopmentExpenses" xlink:label="phat_AccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount" xlink:label="phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="phat_LongTermDebtAndInterest" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="phat_LongTermDebtAndInterest" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="phat_LongTermDebtAndInterest" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="phat_DebtInstrumentInterestAndFinalPaymentFee" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="phat_LongTermDebtAndInterest" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="phat_LongTermDebtAndInterest" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="phat_LongTermDebtAndInterest" xlink:to="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LongTermDebtAndInterest" xlink:label="phat_LongTermDebtAndInterest"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_DebtInstrumentInterestAndFinalPaymentFee" xlink:label="phat_DebtInstrumentInterestAndFinalPaymentFee"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive" xlink:label="phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="phat_IncomeTaxReconciliationPermanentItems" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_IncomeTaxReconciliationPermanentItems" xlink:label="phat_IncomeTaxReconciliationPermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="phat-20211231.xsd#phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt" xlink:label="phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047314156648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 24, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PHATHOM PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001783183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4151574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Campus Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Florham Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">742-8466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,712,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 684.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PHAT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Certain sections of the registrant&#8217;s definitive proxy statement for the 2022 annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K are incorporated by reference into Part III of this Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Iselin, New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047315618168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 183,259<span></span>
</td>
<td class="nump">$ 287,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets (including related party amounts of $0 and $82, respectively)</a></td>
<td class="nump">3,267<span></span>
</td>
<td class="nump">3,872<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">186,526<span></span>
</td>
<td class="nump">291,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,914<span></span>
</td>
<td class="nump">2,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">189,431<span></span>
</td>
<td class="nump">295,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable (including related party amounts of $1,343 and $173, respectively)</a></td>
<td class="nump">5,150<span></span>
</td>
<td class="nump">16,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_AccruedClinicalTrialExpensesCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">1,402<span></span>
</td>
<td class="nump">19,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses (including related party amounts of $2,330 and $734, respectively)</a></td>
<td class="nump">11,405<span></span>
</td>
<td class="nump">10,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">477<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">487<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">18,921<span></span>
</td>
<td class="nump">55,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of discount</a></td>
<td class="nump">89,671<span></span>
</td>
<td class="nump">39,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,183<span></span>
</td>
<td class="nump">1,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">4,125<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">117,275<span></span>
</td>
<td class="nump">100,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; authorized shares - 40,000,000 at December 31, 2021 and 2020; no shares issued and outstanding at December 31, 2021 and 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; authorized shares-400,000,000 at December 31, 2021 and 2020; issued shares-31,656,035 and 31,262,769 at December 31, 2021 and 2020, respectively; outstanding shares- 30,511,226 and 28,516,010 at December 31, 2021 and 2020, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">601,523<span></span>
</td>
<td class="nump">579,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(529,370)<span></span>
</td>
<td class="num">(385,487)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">72,156<span></span>
</td>
<td class="nump">194,271<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 189,431<span></span>
</td>
<td class="nump">$ 295,111<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AccruedClinicalTrialExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AccruedClinicalTrialExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047315537304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent', window );">Prepaid expenses and other current assets, related parties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable, related parties</a></td>
<td class="nump">1,343<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_AccruedExpensesRelatedPartiesCurrent', window );">Accrued expenses, related parties</a></td>
<td class="nump">$ 2,330<span></span>
</td>
<td class="nump">$ 734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized shares</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="nump">31,656,035<span></span>
</td>
<td class="nump">31,262,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="nump">30,511,226<span></span>
</td>
<td class="nump">28,516,010<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AccruedExpensesRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses related parties current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AccruedExpensesRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other assets related parties current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047315556600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (includes related party amounts of $4,933 and $2,812, respectively)</a></td>
<td class="nump">$ 72,338<span></span>
</td>
<td class="nump">$ 98,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative (includes related party amounts of $18 and $157, respectively)</a></td>
<td class="nump">62,742<span></span>
</td>
<td class="nump">27,517<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">135,080<span></span>
</td>
<td class="nump">125,665<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(135,080)<span></span>
</td>
<td class="num">(125,665)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(6,788)<span></span>
</td>
<td class="num">(4,581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense)</a></td>
<td class="num">(2,056)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(8,803)<span></span>
</td>
<td class="num">(3,403)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (143,883)<span></span>
</td>
<td class="num">$ (129,068)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (3.89)<span></span>
</td>
<td class="num">$ (3.88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares of common stock outstanding, basic and diluted</a></td>
<td class="nump">37,002,959<span></span>
</td>
<td class="nump">33,228,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047313977288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_ResearchAndDevelopmentExpenseRelatedParty', window );">Research and development expenses, related party</a></td>
<td class="nump">$ 4,933<span></span>
</td>
<td class="nump">$ 2,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_GeneralAndAdministrativeExpenseRelatedParty', window );">General and administrative expenses, related party</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 157<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_GeneralAndAdministrativeExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General and administrative expense related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_GeneralAndAdministrativeExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ResearchAndDevelopmentExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ResearchAndDevelopmentExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047311097704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Underwritten Public Offering</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Underwritten Public Offering</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Underwritten Public Offering</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 227,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 484,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (256,419)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,728,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity', window );">Conversion of warrant liability into equity</a></td>
<td class="nump">318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options</a></td>
<td class="nump">629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,489,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(129,068)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(129,068)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 194,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">579,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(385,487)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2020</a></td>
<td class="nump">28,516,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,516,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options</a></td>
<td class="nump">$ 1,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Issuance of common stock from exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">401(k) matching contribution</a></td>
<td class="nump">903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled', window );">401(k) matching contribution, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,601,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">16,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">ESPP shares issued</a></td>
<td class="nump">819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">ESPP shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants</a></td>
<td class="nump">1,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(143,883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(143,883)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 72,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 601,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (529,370)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2021</a></td>
<td class="nump">30,511,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,511,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital conversion of warrant liability into equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined contribution pan employer discretionary match number of shares settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047310991960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (143,883)<span></span>
</td>
<td class="num">$ (129,068)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">521<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">16,812<span></span>
</td>
<td class="nump">5,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Issuance of PIK interest debt</a></td>
<td class="nump">990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount</a></td>
<td class="nump">3,595<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">823<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets (includes related party amounts of $82 and $(82), respectively)</a></td>
<td class="nump">605<span></span>
</td>
<td class="nump">7,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses (includes related party amounts of $2,766 and $399, respectively)</a></td>
<td class="num">(9,791)<span></span>
</td>
<td class="nump">24,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_IncreaseDecreaseInClinicalAccruedTrialExpenses', window );">Accrued clinical trial expenses</a></td>
<td class="num">(18,595)<span></span>
</td>
<td class="nump">19,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities', window );">Operating right-of-use asset and lease liabilities</a></td>
<td class="nump">98<span></span>
</td>
<td class="num">(205)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">43<span></span>
</td>
<td class="num">(203)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(148,617)<span></span>
</td>
<td class="num">(69,688)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Cash paid for property, plant and equipment</a></td>
<td class="num">(328)<span></span>
</td>
<td class="num">(1,040)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(328)<span></span>
</td>
<td class="num">(1,040)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_ProceedsFromUnderwrittenPublicOfferingNet', window );">Proceeds from underwritten public offering, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock from exercise of stock options</a></td>
<td class="nump">1,944<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(54,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Net proceeds from issuance of long-term debt</a></td>
<td class="nump">96,889<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">44,708<span></span>
</td>
<td class="nump">114,459<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(104,237)<span></span>
</td>
<td class="nump">43,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents &#8211; beginning of period</a></td>
<td class="nump">287,496<span></span>
</td>
<td class="nump">243,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents &#8211; end of period</a></td>
<td class="nump">183,259<span></span>
</td>
<td class="nump">287,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">4,069<span></span>
</td>
<td class="nump">3,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt', window );">Issuance of common stock warrants in connection with long-term debt</a></td>
<td class="nump">1,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable and accrued expenses</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_NonCashFinalInterestPaymentFee', window );">Final interest payment fee</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">2,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock', window );">Settlement of ESPP liability in common stock</a></td>
<td class="nump">819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock', window );">Settlement of 401(k) liability in common stock</a></td>
<td class="nump">$ 903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets', window );">Operating lease liabilities arising from obtaining right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_ConversionOfWarrantLiabilitiesIntoEquity', window );">Conversion of Lender Warrants into Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_UnpaidUnderwrittenPublicOfferingCosts', window );">Underwritten public offering costs included in accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ConversionOfWarrantLiabilitiesIntoEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of warrant liabilities into equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ConversionOfWarrantLiabilitiesIntoEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_IncreaseDecreaseInClinicalAccruedTrialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in clinical accrued trial expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_IncreaseDecreaseInClinicalAccruedTrialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating right of use asset and lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_NonCashFinalInterestPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash final interest payment fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_NonCashFinalInterestPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>NonCash settlement of defined contribution plan liability in common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>NonCash settlement of employee stock purchase plan liability in common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash issuance of common stock warrants in connection with long term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease liabilities arising from obtaining right-of-use assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ProceedsFromUnderwrittenPublicOfferingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from underwritten public offering, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ProceedsFromUnderwrittenPublicOfferingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_UnpaidUnderwrittenPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unpaid underwritten public offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_UnpaidUnderwrittenPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047314053592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement Of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent', window );">Related parties prepaid expenses and other assets current</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="num">$ (82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties', window );">Related parties accounts payable and accrued expenses</a></td>
<td class="nump">$ 2,766<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accounts payable and accrued expenses related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease)in prepaid expenses and other assets related parties current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047316244232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization, Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Organization, Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Organization and Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phathom Pharmaceuticals, Inc., or the Company or Phathom, was incorporated in the state of Delaware in January 2018. The Company is a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. The Company&#8217;s financial statements are prepared in accordance with U.S. generally accepted accounting principles, or GAAP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From inception to December 31, 2021, the Company has devoted substantially all of its efforts to organizing and staffing the Company, business planning, raising capital, in-licensing its initial product candidate, vonoprazan, meeting with regulatory authorities, managing the Phase 3 clinical trials of vonoprazan, and providing other general and administrative support for these operations. The Company has a limited operating history, has never generated any revenue, and the sales and income potential of its business is unproven. The Company has incurred net losses and negative cash flows from operating activities since its inception and expects to continue to incur net losses into the foreseeable future as it continues the development and preparation for commercialization of vonoprazan. From inception to December 31, 2021, the Company has funded its operations through the issuance of convertible promissory notes, commercial bank debt, the sale of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,997,630</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock for net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">191.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in its 2019 IPO </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> sale of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock for net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in its December 2020 follow-on public offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities. Management is required to perform a two-step analysis over the Company&#8217;s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (Step 2).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, if needed, that the Company&#8217;s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the Company&#8217;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to accruals for research and development expenses, and the valuation of warrant liabilities and various other equity instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1: Observable inputs such as quoted prices in active markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying amounts of the Company&#8217;s financial instruments, including cash and cash equivalents, are classified within the Level 1 designation discussed above, while prepaid and other current assets, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. Warrant liabilities are recorded at fair value on a recurring basis.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> financial assets measured at fair value on a recurring basis. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ne of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">n-recurring basis. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> transfers between levels have occurred during the periods presented.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The warrant liabilities consist of warrants, or the Lender Warrants, issued in connection with a loan and security agreement, or the SVB Loan Agreement, for commercial bank debt (see Note 6). The Lender Warrants were accounted for as liabilities as they contained a holder put right under which the lenders could have required the Company to pay cash in exchange for the Lender Warrants. The fair value of the Lender Warrants was estimated on the date of grant using the Black-Scholes option-pricing model with an expected term equal to the remaining contractual term of the warrants. The Company estimates its expected stock volatility based on the historical volatility of a set of peer companies, which are publicly traded, and expects to continue to do so until it has adequate historical data regarding the volatility of its own publicly-traded stock price. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company uses an expected dividend yield of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> based on the fact that the Company has never paid cash dividends and does not expect to pay cash dividends in the foreseeable future. When the Company drew down the Term Loan B under the SVB Loan Agreement in March 2020 (see Note 6), the Lenders&#8217; put right expired, and the Company recorded a final fair value adjustment and reclassified the Lender Warrants balance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to additional paid-in-capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:71.98%;"/>
          <td style="width:1.317%;"/>
          <td style="width:2.312%;"/>
          <td style="width:22.845%;"/>
          <td style="width:1.546%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Warrant<br/>Liabilities</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2019</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">413</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reclassification of Lender Warrants into equity (Note 6)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">318</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table></div></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market funds.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property, Plant, and Equipment, Net</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property, plant and equipment are recorded at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the asset. Computer equipment and related software are depreciated over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_b94a21cd-dcaa-4585-bab0-9b02263f175c;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Furniture and fixtures are depreciated over</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Leasehold improvements are amortized over the lesser of the lease term or the estimated useful lives of the related assets. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reviews long-lived assets, including property, plant and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairment losses have been recorded through December 31, 2021.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding right-of-use asset upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company additionally evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease. A lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows is substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if the underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term. Leases that do not meet the finance lease criteria are accounted for as an operating lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. As the Company&#8217;s leases do not typically provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate between lease and non-lease components.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses and Accruals</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, employee benefits, stock-based compensation charges for those individuals involved in research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company&#8217;s ongoing clinical trials of vonoprazan, and costs related to manufacturing vonoprazan for clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has entered into various research and development contracts with clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of or after performance are reflected in the accompanying balance sheets as prepaid expenses or accrued liabilities, respectively. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">In-Process Research and Development</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use are considered acquired in-process research and development. When the acquired in-process research and development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. General and administrative expenses are associated with the activities of the executive, finance, accounting, information technology, legal, medical affairs and human resource functions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of the awards (generally the vesting period) on a straight-line basis with forfeitures recognized as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company also maintains an employee stock purchase program, or ESPP, under which it may issue shares. The Company estimates the fair value of stock options and shares that will be issued under the ESPP using the Black-Scholes valuation model, which requires the use of estimates. The Company recognizes stock-based compensation cost for shares that it will issue under the ESPP on a straight-line basis over the requisite service period of the award.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statement of operations in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#8217;s comprehensive loss was the same as its reported net loss for all periods presented.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segment Reporting</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating segment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company included </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,588,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock under its warrant, or the Takeda Warrant, issued to Takeda Pharmaceutical Company Limited, or Takeda, in connection with a May 2019 license agreement (see Note 4) in the calculation of basic weighted-average common shares outstanding from the time it became exercisable at the Company&#8217;s IPO because the Takeda Warrant is exercisable for little consideration. During the year ended December 31, 2021, Takeda Warrants were exercised to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">228,696</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. As of December 31, 2021, Takeda Warrants to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,359,304</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock remains exercisable. For the years ended December 31, 2021 and 2020, the Company has excluded weighted-average unvested shares of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,939,252</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,424,676</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively, from the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested common stock, options and warrants. For the periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities (warrants, stock options, and common shares subject to repurchase) would be antidilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recently Adopted Accounting Standards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> December 2019, the Financial Accounting Standards Board, or FASB, issued </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounting Standards Update, or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ASU, No. 2019-12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ASU 2019-12, which simplifies the accounting for income taxes. ASU 2019-12 is effective for annual reporting periods, and interim periods within those annual periods, beginning after December 15, 2020 on a prospective basis, and early adoption is permitted. The Company </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> this guidance effective </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and the adoption did </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> have a material impact on the Company's financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board or other standard setting bodies on the Company's financial statements as well as material updates to previous assessments. There were no new material accounting standards issued or adopted in year of 2021 that impacted the Company.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047316277464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_ComponentOfBalanceSheetDisclosureTextBlock', window );">Balance Sheet Details</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. Balance Sheet Details</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property, Plant and Equipment, net</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property, plant and equipment, net, consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.824%;"/>
        <td style="width:1.21%;"/>
        <td style="width:2.297%;"/>
        <td style="width:20.043%;"/>
        <td style="width:1.531%;"/>
        <td style="width:1.21%;"/>
        <td style="width:2.297%;"/>
        <td style="width:20.058%;"/>
        <td style="width:1.531%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment and software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">646</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">516</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">780</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">747</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,502</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,317</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">852</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">331</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property, plant and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">650</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">986</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization expense for the years ended December 31, 2021 and 2020 was approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> property, plant or equipment was disposed of during the years ended December 31, 2021 and 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued Expenses</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.426%;"/>
        <td style="width:1.347%;"/>
        <td style="width:2.296%;"/>
        <td style="width:20.695%;"/>
        <td style="width:0.934%;"/>
        <td style="width:1.362%;"/>
        <td style="width:2.296%;"/>
        <td style="width:20.71%;"/>
        <td style="width:0.934%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,165</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,864</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued compensation expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,344</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,587</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued professional &amp; consulting<br/>&#160;&#160;&#160;expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,855</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,123</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,405</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,606</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ComponentOfBalanceSheetDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Component of Balance Sheet Disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ComponentOfBalanceSheetDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047316244232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. Related Party Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Frazier is a principal stockholder of the Company. The Company has conducted operations within office space controlled by Frazier and Frazier allocated a portion of the costs associated with this office space to the Company. In addition, Frazier paid for various goods and services, such as employee wages, insurance and expense reimbursements and various administrative services associated with the operations of the Company and charged the Company for those expenses. As of December 31, 2021 and 2020, the Company had outstanding accounts payable and accrued expenses due to Frazier in the amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">respectively, related to these shared operating expenses. For the years ended December 31, 2021 and 2020, the Company incurred $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, of shared operating expenses.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Frazier is a principal stockholder in PCI Pharma Services, or PCI. In the third quarter of 2019, the Company engaged PCI for clinical manufacturing services. As of December 31, 2021 and 2020, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, in outstanding accounts payable and accrued expenses related to these manufacturing services. For the years ended December 31, 2021 and 2020, the Company incurred $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, of expenses related to services performed by PCI.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Takeda became a common stockholder of the Company in connection with the May 2019 license agreement (see Note 4). In conjunction with this license, Takeda provides proprietary supplies for the Company&#8217;s ongoing clinical development of vonoprazan in addition to the exclusive license for the commercialization of vonoprazan in the United States, Canada and Europe. As of December 31, 2021 and 2020, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively, in outstanding accounts payable and accrued expenses related to these supply services. The Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have any such supply services expenses incurred for the years ended December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On May 5, 2020, the Company entered into a Commercial Supply Agreement, or the Commercial Supply Agreement, with Takeda, pursuant to which Takeda will supply commercial quantities of vonoprazan bulk drug product or drug substance. Pursuant to the Commercial Supply Agreement, Takeda has agreed to supply the Company with, and the Company has agreed to purchase from Takeda, certain quantities of vonoprazan bulk drug product according to approved specifications at a fixed price per batch of bulk drug product in order to commercialize vonoprazan in accordance with the Takeda License. Unless terminated earlier, the term of the Commercial Supply Agreement extends for a period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from the date the Company places an order for bulk drug product or drug substance for the first commercial launch of vonoprazan in any jurisdiction in the licensed territory, provided that this two-year period will expire no later than December 31, 2023. The Commercial Supply Agreement will terminate immediately upon the termination of the Takeda License in accordance with its terms. As of December 31, 2021 and 2020, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, in outstanding accounts payable and accrued expenses related to these product costs. For the years ended December 31, 2021 and 2020, the Company incurred $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, of expenses related to the Commercial Supply Agreement. The Company has a remaining minimum purchase obligation of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to this agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Takeda License, the Company entered into a temporary services agreement, or the Temporary Services Agreement, with Takeda on November 24, 2020. Pursuant to the Temporary Services Agreement, Takeda agreed to provide or procure the provision of services related to the ongoing clinical development of vonoprazan. The Temporary Services Agreement will terminate immediately upon termination of the Takeda License in accordance with its terms. As of December 31, 2021 and 2020, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, in outstanding accounts payable and accrued expenses related to these temporary services. For the year ended December 31, 2021 and 2020, the company incurred $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, of expenses related to the temporary services performed by Takeda.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047312844184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">O</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">n May 7, 2019, the Company entered into a license agreement with Takeda pursuant to which it was granted an exclusive license to commercialize vonoprazan fumarate in the United States, Canada and Europe, or, the Takeda License. The Company also has the right to sublicense its rights under the agreement, subject to certain conditions. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The agreement will remain in effect, on a country-by-country and product-by-product basis, until the later of (i) the expiration of the last to expire valid patent claim covering vonoprazan fumarate alone or in combination with at least one other therapeutically active ingredient, (ii) the expiration of the applicable regulatory exclusivity and (iii) </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from the date of first commercial sale, unless earlier terminated. The Company may terminate the Takeda License upon six months&#8217; written notice. The Company and Takeda may terminate the Takeda License in the case of the other party&#8217;s insolvency or material uncured breach. Takeda may terminate the Takeda License if the Company challenges, or assists in challenging, licensed patents</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">n consideration of the Takeda License, the Company (i) paid Takeda $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in cash, (ii) issued Takeda </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,084,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, (iii) issued the Takeda Warrant to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,588,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at an exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.00004613</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share at an initial fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and (iv) issued a right to receive an additional common stock warrant, or, the Takeda Warrant Right, should Takeda&#8217;s fully-diluted ownership of the Company represent less than a certain specified percentage of the fully-diluted capitalization, including shares issuable upon conversion of then outstanding convertible promissory notes, calculated immediately before the closing of the Company&#8217;s IPO, with a nominal initial fair value due to the low probability of issuance. The Takeda Warrant Right expired without effect since no fair value had been allocated to it upon completion of the IPO, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional warrant was issued. In addition, the Company is obligated to pay Takeda up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">250.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in sales milestones upon the achievement of specified levels of product sales, and a low double-digit royalty rate on aggregate net sales of licensed products, subject to certain adjustments. The Company incurred $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of transaction costs in connection with the Takeda License. The Takeda Warrant has an exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.00004613</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, expires on</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> May 7, 2029</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and became exercisable upon the consummation of the IPO. During the year ended December 31, 2021, Takeda Warrants were exercised to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">228,696</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. As of December 31, 2021, Takeda Warrants to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,359,304</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock remains exercisable. Following the October 11, 2019 increase in the Company&#8217;s authorized shares of common stock to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company recorded a non-cash charge related to the final fair value adjustment of the Takeda Warrants and reclassified the full balance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">144.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million from warrant liabilities to additional paid-in capital</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Purchase Commitments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company entered into a supply agreement with Sandoz pursuant to which Sandoz will supply commercial quantities of amoxicillin capsules and clarithromycin tablets, package these antibiotics with vonoprazan, and provide in finished convenience packs. The supply agreement commits the Company to a minimum purchase obligation of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the first 24-month period following the launch of the final product. The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t incurred any expenses under the agreement during the years ended December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingencies</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event the Company becomes subject to claims or suits arising in the ordinary course of business, the Company would accrue a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047312807576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lease Commitments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. Lease Commitments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had operating leases for office space in both Buffalo Grove, Illinois and Florham Park, New Jersey, with weighted average remaining lease terms of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.7</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years, respectively. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Both operating leases contain an option to extend the term for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which was not considered in the determination of the right-of-use asset or lease liability as the Company did not consider it reasonably certain that it would exercise such options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">     </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total rent expense for the years ended December 31, 2021 and 2020 was approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes supplemental balance sheet information related to the operating leases as of December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.896%;"/>
        <td style="width:1.162%;"/>
        <td style="width:2.734%;"/>
        <td style="width:17.62%;"/>
        <td style="width:1.036%;"/>
        <td style="width:1.162%;"/>
        <td style="width:2.734%;"/>
        <td style="width:17.62%;"/>
        <td style="width:1.036%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,914</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,373</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,914</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,373</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">487</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">474</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, non-current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,183</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,557</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,670</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,031</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the future minimum annual lease payments under the operating leases were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.098%;"/>
        <td style="width:1.603%;"/>
        <td style="width:2.244%;"/>
        <td style="width:19.106%;"/>
        <td style="width:1.211%;"/>
        <td style="width:3.739%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">503</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">516</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">529</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">342</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,890</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: amount representing interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,670</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">487</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,183</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.56</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average incremental borrowing rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.25</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating cash flows for the years ended December 31, 2021 included $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in cash payments for operating leases, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of which were prepaid lease payments. Operating cash flows for the years ended December 31, 2020 included $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in cash payments for operating leases, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of which were prepaid lease payments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047312808136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. Debt</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total debt consists of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.604%;"/>
        <td style="width:1.162%;"/>
        <td style="width:2.823%;"/>
        <td style="width:23.535%;"/>
        <td style="width:1.876%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term debt, current portion</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term debt, non-current portion</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100,990</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unamortized debt discount</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,319</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total debt, net of debt discount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89,671</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 17, 2021, or the Closing Date, the Company entered into a Loan and Security Agreement, or, the Loan Agreement, with Hercules Capital, Inc., in its capacity as administrative agent and collateral agent and as a lender, or, in such capacity, the Agent or Hercules, and the other financial institutions that from time to time become parties to the Loan Agreement as lenders, or, collectively, the Lenders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Loan Agreement provides for term loans in an aggregate principal amount of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">200.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, or the Term Loan, under multiple tranches. The tranches consist of (i) a first tranche consisting of term loans in an aggregate principal amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, all of which was funded to the Company on the Closing Date, or First Advance, (ii) a second tranche consisting of up to an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which became available to the Company upon achievement of the protocol-specified primary efficacy endpoints in the Company&#8217;s Phase 3 trial studying vonoprazan for the healing and maintenance of healing of erosive esophagitis with acceptable safety data, such that the results support the submission of a New Drug Application, or NDA, or supplemental NDA without the need to conduct another Phase 3 study and will be available, if specified conditions are met, through December 15, 2022, (iii) a third tranche consisting of an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which will become available to the Company upon the achievement of (a) FDA approval of the Company&#8217;s NDA for vonoprazan and amoxicillin, or its New Drug Application for vonoprazan, amoxicillin and clarithromycin, in each case for an indication relating to the treatment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> with an approved indication on the claim that is generally consistent with that sought in the Company&#8217;s NDA submission&#894; and (b) filing of the Company&#8217;s NDA or supplemental NDA for vonoprazan for indications relating to the healing and maintenance of healing of erosive esophagitis, or, milestones (a) and (b), together, the Second Performance Milestone, and will be available, if specified conditions are met, through September 30, 2023, and (iv) a fourth tranche consisting of up to an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which will be available, if specified conditions are met, through March 31, 2024, upon achievement of the Second Performance Milestone.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company paid a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million facility charge in connection with closing of the Loan Agreement and would need to pay </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of any advances made under the third and fourth tranches.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Term Loan will mature on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">October 1, 2026</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, or the Maturity Date. The Term Loan bears (i) cash interest at a variable annual rate equal to the greater of (a) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and (b) the Prime Rate (as reported in the Wall Street Journal) plus </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, or the &#8220;Interest Rate&#8221;, and (ii) payment-in-kind interest at a per annum rate of interest equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%. Phathom may make payments of interest only through October 1, 2024, which may be extended to October 1, 2025, upon the achievement of the Second Performance Milestone on or prior to September 30, 2024 and the condition that no default or event of default exists, and which is further extendable to October 1, 2026, subject to FDA approval of the Company&#8217;s NDA (or supplemental NDA) for vonoprazan for an indication relating to the healing and maintenance of healing of erosive esophagitis with an approved indication on the label that is generally consistent with that sought in the Company&#8217;s NDA submission (or supplemental NDA submission), or the Third Performance Milestone, on or prior to September 30, 2025 and no default or event of default exists (the &#8220;interest only period&#8221;). After the interest-only period, the principal balance and related interest will be required to be repaid in equal monthly installments and continuing until the Maturity Date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the Company is obligated to pay a final payment fee of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the original principal amount of amounts actually advanced under the Term Loan, or, each a Term Loan Advance and together, the Term Loan Advances. As of December 31, 2021, the aggregate final payment fee for the first Term Loan Advance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million has been recorded as an other long-term liability.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company may elect to prepay all or a portion of the Term Loan Advances prior to maturity, subject to a prepayment fee of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the then outstanding principal balance of the Term Loan Advances being prepaid. After repayment, no Term Loan amounts may be borrowed again.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As collateral for the obligations, the Company has granted to Hercules a senior security interest in all of Company&#8217;s right, title, and interest in, to and under substantially all of Company&#8217;s property, inclusive of intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Loan Agreement contains customary closing fees, prepayment fees and provisions, events of default, and representations, warranties and covenants, including a financial covenant requiring Phathom to maintain certain levels of cash subject to a control agreement in favor of the Agent (minus accounts payable not paid within 120 days of invoice), or Qualified Cash, and commencing on May 15, 2023, trailing three-month net product revenue from the sale of vonoprazan and products containing vonoprazan. The revenue covenant will be waived at any time in which the Company maintains Qualified Cash equal to at least </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (prior to the Third Performance Milestone), and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (following the Third Performance Milestone) of the total outstanding Term Loan principal amount, or the Company&#8217;s market capitalization is at least $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">900.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. Upon the occurrence of an event of default, subject to any specified cure periods, all amounts owed by the Company may be declared immediately due and payable by Hercules, as collateral agent. As of December 31, 2021, the Company was in compliance with all applicable covenants under the Loan Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the entry into the Loan Agreement, the Company issued to Hercules a warrant, or, the Warrant, to purchase a number of shares of the Company&#8217;s common stock equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the aggregate amount of the Term Loan advances funded, and will issue to Hercules additional warrants when future Term Loan advances are funded. On the Closing Date, the Company issued a Warrant for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74,782</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. The Warrant will be exercisable for a period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seven years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from the date of issuance at a per-share exercise price equal to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33.43</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which was the closing price of the Company&#8217;s common stock on September 16, 2021. The Warrant is exercisable any time until </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 17, 2028</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and had an initial fair value of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The initial $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million fair value of the Warrant, the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million final interest payment fee and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of debt issuance costs have been recorded as debt discount and are being amortized to interest expense using the effective interest method over the term of the Term Loan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future minimum principal and interest payments under the Term Loan, including the final payment fee, as of December 31, 2021 are as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.716%;"/>
        <td style="width:1.501%;"/>
        <td style="width:2.823%;"/>
        <td style="width:24.084%;"/>
        <td style="width:1.876%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Year ending December 31:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,704</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,900</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,308</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50,912</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66,948</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total principal and interest payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">146,772</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less interest and final payment fee</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46,772</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total term loan borrowings</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to the Loan Agreement with Hercules, the Company had a loan with SVB and approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the proceeds from the First Advance was used to satisfy in full and retire the Company&#8217;s indebtedness under the SVB Term Loan with SVB, including accrued interest through the payoff date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The SVB Term Loan originated on May 14, 2019, when the Company entered into a loan and security agreement with SVB, as administrative and collateral agent, and lenders including SVB and WestRiver Innovation Lending Fund VIII, L.P. The Company borrowed $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, or Term Loan A, at the inception of the Loan Agreement and an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, or Term Loan B, on March 16, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The SVB Term Loan bore interest at a floating rate of the higher of the Wall Street Journal Prime rate plus </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% or </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the original SVB Term Loan, the monthly payments consisted of interest-only through May 31, 2021. On March 11, 2020, the Company entered into the first amendment and on March 11, 2021, the Company entered into the second amendment, or together the Amendments, to the SVB Term Loan. Pursuant to the Amendments, the interest-only payment period was initially extended through July 31, 2021, and was further extended until December 31, 2021, after the Company received positive data from its Phase 3 clinical trial in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infection sufficient to file an NDA with the FDA. The interest-only payment period could have been further extended until November 30, 2022, if the Company would receive positive data from its Phase 3 clinical trial in erosive esophagitis for vonoprazan sufficient to file an NDA with the FDA.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Subsequent to the interest-only period, the SVB Term Loan would have been payable in equal monthly installments of principal, plus accrued and unpaid interest through the maturity date of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 1, 2024</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the Company was obligated to pay a final payment fee of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the original principal amount of the SVB Term Loan. The aggregate final payment fee for the Term Loan of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was recorded as an other long-term liability.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company could have elected to prepay all or a portion of the SVB Term Loan prior to maturity, subject to a prepayment fee of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the then outstanding principal balance and payment of a pro rata portion of the final payment fee. After repayment, no Term Loan amounts could have been borrowed again.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The borrowings under the SVB Term Loan were collateralized by substantially all of the Company&#8217;s assets. The SVB Term Loan included affirmative and negative covenants. The affirmative covenants included, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding its operating accounts. The negative covenants included, among others, limitations on the Company&#8217;s ability to incur additional indebtedness and liens, merge with other companies or consummate certain changes of control, acquire other companies, engage in new lines of business, make certain investments, pay dividends, transfer or dispose of assets, amend certain material agreements or enter into various specified transactions. The SVB Term Loan also contained customary events of default, including bankruptcy, the failure to make payments when due, and a material adverse change. Upon the occurrence of an event of default, subject to any specified cure periods, all amounts owed by the Company would have begun to bear interest at a rate that is</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.00</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">above the rate effective immediately before the event of default and could have been declared immediately due and payable by SVB, as collateral agent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the SVB Term Loan, the Company issued Lender Warrants to purchase stock of the Company, which expire </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from the date of issuance. Upon completion of the IPO in 2019, the Lender Warrants became exercisable for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,446</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. The Lender Warrants included a put option pursuant to which, in the event that the Company did not draw down Term Loan B on or before March 31, 2020, the warrant holders could have required that the Company repurchase the warrants for a total aggregate repurchase price of</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon the Term Loan B draw in March 2020, the Lender Warrants became exercisable and the put option related to the Lender Warrants expired. Accordingly, the Company recorded a final fair value adjustment and reclassif</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ied the Lender Warrants balance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to additional paid-in-capital.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The initial $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million fair value of the Lender Warrants, the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million final payment fee and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of debt issuance costs were recorded as debt discount and amortized to interest expense using the effective interest method over the term of the Term Loans prior to the retirement of the debt. Upon retirement of the debt any remaining unamortized amounts were recorded as an expense to Other income (expense).</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the years ended December 31, 2021 and 2020, the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, of interest expense, including amortization of the debt discount, in connection with the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hercules Loan Agreement and SVB Term Loan</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As of December 31, 2021, the Company had outstanding </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">loan balance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and accrued interest of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047312807576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. Stockholders&#8217; Equity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2019, subsequent to the Merger, the Company sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,491,072</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock to Frazier.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2019, the founders granted the Company a repurchase right for the </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,373,408</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock originally purchased in 2018. The Company has the right, but not the obligation, to repurchase unvested shares in the event the founder&#8217;s relationship with the Company is terminated, subject to certain limitations, at the original purchase price of the stock. The repurchase right lapsed for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">843,352</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares in March 2019 and the repurchase right for the remaining </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,530,056</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares lapses in equal monthly amounts over the following </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period ending in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The fair value of the founder shares at the date the repurchase right was granted is being recognized as stock-based compensation expense on a straight-line basis over the vesting period. As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">395,321</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were subject to repurchase by the Company and the associated repurchase liability was not significant. The amount of recognized and unrecognized stock-based compensation related to the founder stock was immaterial for all periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2019, the Company issued Takeda </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,084,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock in connection with the Takeda License.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the period from January 1, 2019 to May 6, 2019, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,524,852</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock to various employees and consultants of the Company for aggregate proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Upon issuance, these shares were subject to a repurchase option by the Company at the original purchase price of the shares. The repurchase rights generally lapse as to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the shares on the first anniversary of the vesting commencement date, and the repurchase right lapses as to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6101410e-3515-4cea-81ab-5e3079200f62;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1/48</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">th of the shares each one-month period thereafter, subject to the purchaser remaining continuously an employee, consultant or director of the Company. In November 2019, the Company repurchased </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,560</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares at the original purchase price for an aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">749,488</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares remain available for repurchase by the Company and the associated repurchase liability was not significant.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 29, 2019, upon completion of the IPO, the Company sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,997,630</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, which included the exercise in full by the underwriters of their option to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,434,473</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The net proceeds were approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">191.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, after deducting underwriting discounts, commissions and offering costs.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2020, the Company entered into an Open Market Sale Agreement, or, the Sales Agreement, with Jefferies LLC, or, the Sales Agent, under which it may, from time to time, sell shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million through the Sales Agent, or, the ATM Offering. Pursuant to the Sales Agreement, the Company will pay the Sales Agent a commission for its services in acting as an agent in the sale of common stock in an amount equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the gross sales price per share sold. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were sold under the ATM Offering as of December 31, 2021.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 16, 2020, the Company completed an underwritten public offering, in which it sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for total gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The net purchase price after deducting underwriting discounts and commissions was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39.48</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, which generated net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company incurred an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of offering expenses in connection with this public offering.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the Company&#8217;s unvested shares is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.994%;"/>
        <td style="width:1.656%;"/>
        <td style="width:1.175%;"/>
        <td style="width:18.625%;"/>
        <td style="width:1.549%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,746,759</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share vesting</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,601,950</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,144,809</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For accounting purposes, unvested shares of common stock are considered issued, but not outstanding until they vest.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock reserved for future issuance consists of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:73.57%;"/>
        <td style="width:1.501%;"/>
        <td style="width:1.09%;"/>
        <td style="width:22.748%;"/>
        <td style="width:1.09%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,450,532</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options and performance-based awards outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,581,029</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares available for issuance under the 2019 Incentive Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,772,744</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares available for issuance under the ESPP Plan</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">842,036</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,646,341</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is authorized to issue up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million shares of preferred stock. As of December 31, 2021, and December 31, 2020, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock issued or outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Equity Incentive Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s 2019 Equity Incentive Plan, or the Existing Incentive Plan, provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards to eligible recipients, including employees, directors or consultants of the Company. The Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,231,739</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock authorized for issuance under the Existing Incentive Plan, of which, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,400,528</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> stock options and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,260</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> restricted stock awards were granted in 2019. As a result of the adoption of the 2019 Incentive Award Plan, or the 2019 Plan, in October 2019, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> further shares are available for issuance under the Existing Incentive Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2019 Incentive Award Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2019, the board of directors adopted, and the Company&#8217;s stockholders approved, the 2019 Plan, which became effective in connection with the IPO. Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The number of shares initially available for issuance will be increased by (i) the number of shares subject to stock options or similar awards granted under the Existing Incentive Plan that expire or otherwise terminate without having been exercised in full after the effective date of the 2019 Plan and unvested shares issued pursuant to awards granted under the Existing Incentive Plan that are forfeited to or repurchased by the Company after the effective date of the 2019 Plan, with the maximum number of shares to be added to the 2019 Plan pursuant to clause (i) above equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,416,788</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares, and (ii) an annual increase on January 1 of each calendar year beginning in 2020 and ending in 2029, equal to the lesser of (a) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the board of directors. As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,772,744</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares remain available for issuance, which reflects </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,915,300</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> stock options and performance-based units ("PSU") granted, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">175,430</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> cancelled or forfeited, during the year ended December 31, 2021 as well as </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">annual increases of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,250,511</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,158,580</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares that were authorized on January 1, 2021 and 2020. An additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,582,802</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were authorized on January 1, 2022. </span></span><span style="font-size:10.0pt;font-family:Times New Roman;"/></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Performance-based Units</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During 2020, the Company granted </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> PSUs whereby vesting depends upon the approval by the U.S. Food and Drug Administration, or FDA, of vonoprazan for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">H. pylori</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and then, or concurrent with, erosive esophagitis. In 2021, the Company granted an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">190,050</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> PSUs to employees. As of December 31, 2021, the PSU milestones had not been achieved. As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> related compensation cost had been recognized. </span><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes PSU activity under the 2019 Incentive Award Plan during the year ended December 31, 2021.</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.33%;"/>
        <td style="width:1.378%;"/>
        <td style="width:0.949%;"/>
        <td style="width:14.878%;"/>
        <td style="width:1.531%;"/>
        <td style="width:1.378%;"/>
        <td style="width:2.296%;"/>
        <td style="width:14.312%;"/>
        <td style="width:0.949%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>Stock Units</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average Grant<br/>Date Fair Value<br/>Per Share</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.48</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">190,050</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.80</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,750</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.63</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">394,300</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.23</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 there was approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of related unrecognized compensation cost, which will be recognized upon vesting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2019, the board of directors adopted, and the Company&#8217;s stockholders approved, the Employee Stock Purchase Plan, or the ESPP, which became effective in connection with the IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of their eligible compensation, which includes a participant&#8217;s gross base compensation for services to the Company, including overtime payments and excluding sales commissions, incentive compensation, bonuses, expense reimbursements, fringe benefits and other special payments. A total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">270,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock was initially reserved for issuance under the ESPP. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the number of shares available for issuance under the ESPP will be annually increased on January 1 of each calendar year beginning in 2020 and ending in 2029, by an amount equal to the lesser of: (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the board of directors. As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">842,036</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock remain available for issuance, which reflects </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,237</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares sold to employees during the year ended December 31, 2021 as well as the annual increases of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">312,628</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">289,645</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares that were authorized on January 1, 2021 and 2020. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares were authorized in January 2022.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ESPP is considered a compensatory plan, and the Company recorded related stock-based compensation of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2021 and 2020, respectively. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average assumptions used to estimate the fair value of ESPP awards using the Black-Scholes option valuation model were as follows:</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.76%;"/>
        <td style="width:1.393%;"/>
        <td style="width:0.918%;"/>
        <td style="width:19.529%;"/>
        <td style="width:3.78%;"/>
        <td style="width:1.393%;"/>
        <td style="width:0.918%;"/>
        <td style="width:19.529%;"/>
        <td style="width:3.78%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assumptions:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.69</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.00</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76.25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76.25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.09</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.15</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated weighted-average fair value of ESPP awards during 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.66</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.66</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. As of December 31, 2021, the total unrecognized compensation expense related to the ESPP was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which is expected to be recognized over a weighted-average period of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Options</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of each employee and non-employee stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company, prior to the IPO on October 29, 2019, was a private company and lacked company-specific historical and implied volatility information. Therefore, it estimated its expected volatility based on the historical volatility of a publicly-traded set of peer companies. Due to the lack of historical exercise history, the expected term of the Company&#8217;s stock options for employees was determined utilizing the &#8220;simplified&#8221; method for awards. The expected term of stock options granted to non-employees was equal to the contractual term of the option award. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the Company&#8217;s stock option activity and related information is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.8%;"/>
        <td style="width:1.047%;"/>
        <td style="width:1.071%;"/>
        <td style="width:11.851%;"/>
        <td style="width:1.071%;"/>
        <td style="width:1.047%;"/>
        <td style="width:1.618%;"/>
        <td style="width:9.305%;"/>
        <td style="width:0.94%;"/>
        <td style="width:1.047%;"/>
        <td style="width:1.583%;"/>
        <td style="width:9.733%;"/>
        <td style="width:0.785%;"/>
        <td style="width:1.011%;"/>
        <td style="width:1.63%;"/>
        <td style="width:9.674%;"/>
        <td style="width:0.785%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Options<br/>Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value (in<br/>thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,728,742</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.36</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.10</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,432</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,725,250</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37.14</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options exercised and shares vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">107,583</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.07</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options cancelled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">159,680</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.26</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,186,729</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27.53</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.43</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,973</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options exercisable as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,127,877</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.75</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.91</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,880</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options vested and expected to vest as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,186,729</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27.53</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.43</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,973</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate intrinsic value of options exercisable as of December 31, 2021 and 2020 were calculated as the difference between the exercise price of the underlying options and the closing market price of the Company&#8217;s common stock on that date, which were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.67</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33.22</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share on December 31, 2021 and 2020, respectively. The aggregate intrinsic value of options exercised during the years ended December 31, 2021 and 2020 were approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated weighted-average fair value of employee and nonemployee director stock options granted during 2021 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22.20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As of December 31, 2021, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of unrecognized stock-based compensation expense, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.6</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average assumptions used to estimate the fair value of stock options using the Black-Scholes option valuation model were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.76%;"/>
        <td style="width:1.393%;"/>
        <td style="width:0.918%;"/>
        <td style="width:19.529%;"/>
        <td style="width:3.78%;"/>
        <td style="width:1.393%;"/>
        <td style="width:0.918%;"/>
        <td style="width:19.529%;"/>
        <td style="width:3.78%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assumptions:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.93</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.06</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67.46</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65.07</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.68</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.51</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation Expense</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense recognized for all equity awards, including founder stock, has been reported in the statements of operations as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.173%;"/>
        <td style="width:1.393%;"/>
        <td style="width:2.281%;"/>
        <td style="width:21.142%;"/>
        <td style="width:0.919%;"/>
        <td style="width:1.393%;"/>
        <td style="width:2.281%;"/>
        <td style="width:20.499%;"/>
        <td style="width:0.919%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,838</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,450</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,974</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,390</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,812</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,840</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047316564776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. Income Taxes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the years ended December 31, 2021 and 2020, the Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t record a provision for income taxes due to a full valuation against its deferred taxes. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands):</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.941%;"/>
        <td style="width:1.271%;"/>
        <td style="width:2.251%;"/>
        <td style="width:21.069%;"/>
        <td style="width:1.501%;"/>
        <td style="width:1.271%;"/>
        <td style="width:2.251%;"/>
        <td style="width:20.946%;"/>
        <td style="width:1.501%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income taxes computed at the statutory<br/>&#160;&#160;&#160;rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,216</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,105</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent items</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,387</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">291</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of warrants and<br/>&#160;&#160;&#160;convertible debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,950</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,047</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,783</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,949</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision (benefit) for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.235%;"/>
        <td style="width:1.163%;"/>
        <td style="width:2.25%;"/>
        <td style="width:20.447%;"/>
        <td style="width:1.515%;"/>
        <td style="width:1.163%;"/>
        <td style="width:2.25%;"/>
        <td style="width:20.462%;"/>
        <td style="width:1.515%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60,936</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,162</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,694</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,744</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,809</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,929</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,996</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,914</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,435</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,749</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,033</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">402</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">499</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">402</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">499</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based upon the Company&#8217;s history of operating losses, the Company is unable to conclude that it is more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation allowance for its deferred tax assets as of December 31, 2021 and 2020.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, the Company had federal net operating loss carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">290.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">157.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, which are carried over indefinitely.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of state net operating loss carryforwards that begins to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2036</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company has available federal research and development credits of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million which begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2038</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of state research and development credits, some of which, begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has not completed a formal analysis of the potential impact of Section 382 on its deferred tax assets as of December 31, 2021. Until this analysis has been completed, the Company has not adjusted any of its deferred tax assets, including net operating losses or research and development credits. The Company will reassess the amount of net operating losses and credits subject to limitation under Section 382 when a study is complete. Due to the existence of the valuation allowance, future changes in the deferred tax assets related to these tax attributes will not impact the Company&#8217;s effective tax rate.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the activity related to the Company's gross unrecognized tax benefits:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.197%;"/>
        <td style="width:1.393%;"/>
        <td style="width:2.311%;"/>
        <td style="width:13.715%;"/>
        <td style="width:0.949%;"/>
        <td style="width:1.393%;"/>
        <td style="width:2.311%;"/>
        <td style="width:12.781%;"/>
        <td style="width:0.949%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beginning balance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">938</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">176</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Increases related to prior year tax positions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Increases related to current year tax positions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">702</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">762</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ending balance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,704</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">938</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company has gross unrecognized tax benefits of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">none</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of which would affect the effective tax rate due to a full valuation allowance. The Company does not anticipate any significant changes in its unrecognized tax benefits over the next 12 months. The Company's policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense. The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accrual for interest or penalties on its balance sheet at December 31, 2021 and has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t recognized interest or penalties in its statement of operations for the year ended December 31, 2021.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to taxation in the United States and various states. The Company is not currently under examination by any taxing authorities. Due to the carryover of tax attributes, the statute of limitations is currently open for tax years since inception.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047316267528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">401(k) Plan</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. 401(k) Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company established a 401(k) savings plan during the year ended December 31, 2020. The Company&#8217;s contributions to the plan are discretionary. During the years ended December 31, 2021 and 2020, the Company incurred $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, of expense related to employer contributions, which was based on a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% match of employees' annual contributions. In January 2021, the Board of Directors approved the annual discretionary match for 2020, which was settled by contributing </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,356</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares. In August 2021, the Board of Directors approved a semi-annual discretionary match for 2021, which was settled by contributing </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,394</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares. In January 2022, the Board of Directors approved a second semi-annual discretionary match for 2021, which was settled by contributing </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,756</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235116<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047314125288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. Subsequent Events</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2022, the Company entered into an operating lease for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,250</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet of office space in Florham Park, New Jersey. The lease liability and the corresponding right-of-use asset associated with this lease obligation will be recorded upon the commencement of the lease, or the date in which the underlying asset is made available for use to the Company, which is expected to occur later in 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047311262904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OrganizationAndBasisOfPresentationPolicyTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Organization and Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phathom Pharmaceuticals, Inc., or the Company or Phathom, was incorporated in the state of Delaware in January 2018. The Company is a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. The Company&#8217;s financial statements are prepared in accordance with U.S. generally accepted accounting principles, or GAAP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_LiquidityAndCapitalResourcesPolicyTextBlock', window );">Liquidity and Capital Resources</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From inception to December 31, 2021, the Company has devoted substantially all of its efforts to organizing and staffing the Company, business planning, raising capital, in-licensing its initial product candidate, vonoprazan, meeting with regulatory authorities, managing the Phase 3 clinical trials of vonoprazan, and providing other general and administrative support for these operations. The Company has a limited operating history, has never generated any revenue, and the sales and income potential of its business is unproven. The Company has incurred net losses and negative cash flows from operating activities since its inception and expects to continue to incur net losses into the foreseeable future as it continues the development and preparation for commercialization of vonoprazan. From inception to December 31, 2021, the Company has funded its operations through the issuance of convertible promissory notes, commercial bank debt, the sale of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,997,630</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock for net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">191.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in its 2019 IPO </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> sale of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock for net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in its December 2020 follow-on public offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities. Management is required to perform a two-step analysis over the Company&#8217;s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (Step 2).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, if needed, that the Company&#8217;s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the Company&#8217;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to accruals for research and development expenses, and the valuation of warrant liabilities and various other equity instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1: Observable inputs such as quoted prices in active markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying amounts of the Company&#8217;s financial instruments, including cash and cash equivalents, are classified within the Level 1 designation discussed above, while prepaid and other current assets, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. Warrant liabilities are recorded at fair value on a recurring basis.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> financial assets measured at fair value on a recurring basis. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ne of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">n-recurring basis. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> transfers between levels have occurred during the periods presented.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The warrant liabilities consist of warrants, or the Lender Warrants, issued in connection with a loan and security agreement, or the SVB Loan Agreement, for commercial bank debt (see Note 6). The Lender Warrants were accounted for as liabilities as they contained a holder put right under which the lenders could have required the Company to pay cash in exchange for the Lender Warrants. The fair value of the Lender Warrants was estimated on the date of grant using the Black-Scholes option-pricing model with an expected term equal to the remaining contractual term of the warrants. The Company estimates its expected stock volatility based on the historical volatility of a set of peer companies, which are publicly traded, and expects to continue to do so until it has adequate historical data regarding the volatility of its own publicly-traded stock price. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company uses an expected dividend yield of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> based on the fact that the Company has never paid cash dividends and does not expect to pay cash dividends in the foreseeable future. When the Company drew down the Term Loan B under the SVB Loan Agreement in March 2020 (see Note 6), the Lenders&#8217; put right expired, and the Company recorded a final fair value adjustment and reclassified the Lender Warrants balance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to additional paid-in-capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:71.98%;"/>
          <td style="width:1.317%;"/>
          <td style="width:2.312%;"/>
          <td style="width:22.845%;"/>
          <td style="width:1.546%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Warrant<br/>Liabilities</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2019</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">413</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reclassification of Lender Warrants into equity (Note 6)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">318</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market funds.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant, and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property, Plant, and Equipment, Net</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property, plant and equipment are recorded at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the asset. Computer equipment and related software are depreciated over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_b94a21cd-dcaa-4585-bab0-9b02263f175c;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Furniture and fixtures are depreciated over</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Leasehold improvements are amortized over the lesser of the lease term or the estimated useful lives of the related assets. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reviews long-lived assets, including property, plant and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairment losses have been recorded through December 31, 2021.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding right-of-use asset upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company additionally evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease. A lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows is substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if the underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term. Leases that do not meet the finance lease criteria are accounted for as an operating lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. As the Company&#8217;s leases do not typically provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate between lease and non-lease components.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses and Accruals</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses and Accruals</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, employee benefits, stock-based compensation charges for those individuals involved in research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company&#8217;s ongoing clinical trials of vonoprazan, and costs related to manufacturing vonoprazan for clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has entered into various research and development contracts with clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of or after performance are reflected in the accompanying balance sheets as prepaid expenses or accrued liabilities, respectively. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">In-Process Research and Development</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">In-Process Research and Development</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use are considered acquired in-process research and development. When the acquired in-process research and development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. General and administrative expenses are associated with the activities of the executive, finance, accounting, information technology, legal, medical affairs and human resource functions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of the awards (generally the vesting period) on a straight-line basis with forfeitures recognized as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company also maintains an employee stock purchase program, or ESPP, under which it may issue shares. The Company estimates the fair value of stock options and shares that will be issued under the ESPP using the Black-Scholes valuation model, which requires the use of estimates. The Company recognizes stock-based compensation cost for shares that it will issue under the ESPP on a straight-line basis over the requisite service period of the award.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statement of operations in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#8217;s comprehensive loss was the same as its reported net loss for all periods presented.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segment Reporting</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating segment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company included </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,588,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock under its warrant, or the Takeda Warrant, issued to Takeda Pharmaceutical Company Limited, or Takeda, in connection with a May 2019 license agreement (see Note 4) in the calculation of basic weighted-average common shares outstanding from the time it became exercisable at the Company&#8217;s IPO because the Takeda Warrant is exercisable for little consideration. During the year ended December 31, 2021, Takeda Warrants were exercised to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">228,696</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. As of December 31, 2021, Takeda Warrants to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,359,304</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock remains exercisable. For the years ended December 31, 2021 and 2020, the Company has excluded weighted-average unvested shares of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,939,252</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,424,676</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively, from the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested common stock, options and warrants. For the periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities (warrants, stock options, and common shares subject to repurchase) would be antidilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Issued Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recently Adopted Accounting Standards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> December 2019, the Financial Accounting Standards Board, or FASB, issued </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounting Standards Update, or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ASU, No. 2019-12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ASU 2019-12, which simplifies the accounting for income taxes. ASU 2019-12 is effective for annual reporting periods, and interim periods within those annual periods, beginning after December 15, 2020 on a prospective basis, and early adoption is permitted. The Company </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> this guidance effective </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and the adoption did </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> have a material impact on the Company's financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board or other standard setting bodies on the Company's financial statements as well as material updates to previous assessments. There were no new material accounting standards issued or adopted in year of 2021 that impacted the Company.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LiquidityAndCapitalResourcesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity and capital resources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LiquidityAndCapitalResourcesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_OrganizationAndBasisOfPresentationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_OrganizationAndBasisOfPresentationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements entered into by lessor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL117410129-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919352-209981<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL117410129-209981<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL119206284-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047316245064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Reconciliation of Liabilities Measured at Fair Value</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:71.98%;"/>
          <td style="width:1.317%;"/>
          <td style="width:2.312%;"/>
          <td style="width:22.845%;"/>
          <td style="width:1.546%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Warrant<br/>Liabilities</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2019</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">413</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reclassification of Lender Warrants into equity (Note 6)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">318</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047312754952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment, Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property, plant and equipment, net, consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.824%;"/>
        <td style="width:1.21%;"/>
        <td style="width:2.297%;"/>
        <td style="width:20.043%;"/>
        <td style="width:1.531%;"/>
        <td style="width:1.21%;"/>
        <td style="width:2.297%;"/>
        <td style="width:20.058%;"/>
        <td style="width:1.531%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment and software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">646</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">516</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">780</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">747</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,502</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,317</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">852</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">331</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property, plant and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">650</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">986</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.426%;"/>
        <td style="width:1.347%;"/>
        <td style="width:2.296%;"/>
        <td style="width:20.695%;"/>
        <td style="width:0.934%;"/>
        <td style="width:1.362%;"/>
        <td style="width:2.296%;"/>
        <td style="width:20.71%;"/>
        <td style="width:0.934%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,165</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,864</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued compensation expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,344</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,587</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued professional &amp; consulting<br/>&#160;&#160;&#160;expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,855</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,123</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,405</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,606</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047312779416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock', window );">Summary of Supplemental Balance Sheet Information Related to the Operating Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes supplemental balance sheet information related to the operating leases as of December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.896%;"/>
        <td style="width:1.162%;"/>
        <td style="width:2.734%;"/>
        <td style="width:17.62%;"/>
        <td style="width:1.036%;"/>
        <td style="width:1.162%;"/>
        <td style="width:2.734%;"/>
        <td style="width:17.62%;"/>
        <td style="width:1.036%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,914</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,373</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,914</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,373</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">487</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">474</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, non-current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,183</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,557</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,670</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,031</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Lease Payments Under Operating Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the future minimum annual lease payments under the operating leases were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.098%;"/>
        <td style="width:1.603%;"/>
        <td style="width:2.244%;"/>
        <td style="width:19.106%;"/>
        <td style="width:1.211%;"/>
        <td style="width:3.739%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">503</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">516</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">529</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">342</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,890</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: amount representing interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,670</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">487</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,183</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.56</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average incremental borrowing rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.25</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of supplemental balance sheet information related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047312812696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Total Debt</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total debt consists of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.604%;"/>
        <td style="width:1.162%;"/>
        <td style="width:2.823%;"/>
        <td style="width:23.535%;"/>
        <td style="width:1.876%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term debt, current portion</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term debt, non-current portion</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100,990</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unamortized debt discount</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,319</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total debt, net of debt discount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89,671</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Minimum Principal and Interest Payments Under Term Loans</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future minimum principal and interest payments under the Term Loan, including the final payment fee, as of December 31, 2021 are as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.716%;"/>
        <td style="width:1.501%;"/>
        <td style="width:2.823%;"/>
        <td style="width:24.084%;"/>
        <td style="width:1.876%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Year ending December 31:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,704</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,900</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,308</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50,912</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66,948</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total principal and interest payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">146,772</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less interest and final payment fee</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46,772</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total term loan borrowings</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047315598408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Summary of Unvested Shares</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the Company&#8217;s unvested shares is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.994%;"/>
        <td style="width:1.656%;"/>
        <td style="width:1.175%;"/>
        <td style="width:18.625%;"/>
        <td style="width:1.549%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,746,759</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share vesting</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,601,950</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,144,809</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_CommonStockReservedForFutureIssuancesTableTableTextBlock', window );">Summary of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock reserved for future issuance consists of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:73.57%;"/>
        <td style="width:1.501%;"/>
        <td style="width:1.09%;"/>
        <td style="width:22.748%;"/>
        <td style="width:1.09%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,450,532</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options and performance-based awards outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,581,029</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares available for issuance under the 2019 Incentive Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,772,744</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares available for issuance under the ESPP Plan</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">842,036</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,646,341</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Summary of PSU Activity Under the 2019 Incentive Award Plan</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes PSU activity under the 2019 Incentive Award Plan during the year ended December 31, 2021.</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.33%;"/>
        <td style="width:1.378%;"/>
        <td style="width:0.949%;"/>
        <td style="width:14.878%;"/>
        <td style="width:1.531%;"/>
        <td style="width:1.378%;"/>
        <td style="width:2.296%;"/>
        <td style="width:14.312%;"/>
        <td style="width:0.949%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>Stock Units</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average Grant<br/>Date Fair Value<br/>Per Share</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.48</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">190,050</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.80</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,750</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.63</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">394,300</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.23</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Summary of Weighted-Average Assumptions Used to Estimate Fair Value of ESPP Awards</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average assumptions used to estimate the fair value of ESPP awards using the Black-Scholes option valuation model were as follows:</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.76%;"/>
        <td style="width:1.393%;"/>
        <td style="width:0.918%;"/>
        <td style="width:19.529%;"/>
        <td style="width:3.78%;"/>
        <td style="width:1.393%;"/>
        <td style="width:0.918%;"/>
        <td style="width:19.529%;"/>
        <td style="width:3.78%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assumptions:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.69</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.00</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76.25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76.25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.09</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.15</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the Company&#8217;s stock option activity and related information is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.8%;"/>
        <td style="width:1.047%;"/>
        <td style="width:1.071%;"/>
        <td style="width:11.851%;"/>
        <td style="width:1.071%;"/>
        <td style="width:1.047%;"/>
        <td style="width:1.618%;"/>
        <td style="width:9.305%;"/>
        <td style="width:0.94%;"/>
        <td style="width:1.047%;"/>
        <td style="width:1.583%;"/>
        <td style="width:9.733%;"/>
        <td style="width:0.785%;"/>
        <td style="width:1.011%;"/>
        <td style="width:1.63%;"/>
        <td style="width:9.674%;"/>
        <td style="width:0.785%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Options<br/>Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value (in<br/>thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,728,742</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.36</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.10</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,432</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,725,250</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37.14</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options exercised and shares vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">107,583</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.07</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options cancelled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">159,680</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.26</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,186,729</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27.53</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.43</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,973</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options exercisable as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,127,877</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.75</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.91</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,880</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options vested and expected to vest as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,186,729</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27.53</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.43</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,973</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average assumptions used to estimate the fair value of stock options using the Black-Scholes option valuation model were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.76%;"/>
        <td style="width:1.393%;"/>
        <td style="width:0.918%;"/>
        <td style="width:19.529%;"/>
        <td style="width:3.78%;"/>
        <td style="width:1.393%;"/>
        <td style="width:0.918%;"/>
        <td style="width:19.529%;"/>
        <td style="width:3.78%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assumptions:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.93</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.06</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67.46</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65.07</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.68</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.51</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense recognized for all equity awards, including founder stock, has been reported in the statements of operations as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.173%;"/>
        <td style="width:1.393%;"/>
        <td style="width:2.281%;"/>
        <td style="width:21.142%;"/>
        <td style="width:0.919%;"/>
        <td style="width:1.393%;"/>
        <td style="width:2.281%;"/>
        <td style="width:20.499%;"/>
        <td style="width:0.919%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,838</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,450</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,974</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,390</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,812</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,840</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_CommonStockReservedForFutureIssuancesTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock reserved for future issuances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_CommonStockReservedForFutureIssuancesTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047320040088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands):</span><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.941%;"/>
        <td style="width:1.271%;"/>
        <td style="width:2.251%;"/>
        <td style="width:21.069%;"/>
        <td style="width:1.501%;"/>
        <td style="width:1.271%;"/>
        <td style="width:2.251%;"/>
        <td style="width:20.946%;"/>
        <td style="width:1.501%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income taxes computed at the statutory<br/>&#160;&#160;&#160;rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,216</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,105</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent items</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,387</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">291</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of warrants and<br/>&#160;&#160;&#160;convertible debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,950</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,047</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,783</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,949</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision (benefit) for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Deferred Tax Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.235%;"/>
        <td style="width:1.163%;"/>
        <td style="width:2.25%;"/>
        <td style="width:20.447%;"/>
        <td style="width:1.515%;"/>
        <td style="width:1.163%;"/>
        <td style="width:2.25%;"/>
        <td style="width:20.462%;"/>
        <td style="width:1.515%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60,936</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,162</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,694</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,744</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,809</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,929</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,996</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,914</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,435</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,749</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,033</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">402</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">499</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">402</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">499</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Activity Related to Gross Unrecognized Benefits</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the activity related to the Company's gross unrecognized tax benefits:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.197%;"/>
        <td style="width:1.393%;"/>
        <td style="width:2.311%;"/>
        <td style="width:13.715%;"/>
        <td style="width:0.949%;"/>
        <td style="width:1.393%;"/>
        <td style="width:2.311%;"/>
        <td style="width:12.781%;"/>
        <td style="width:0.949%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beginning balance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">938</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">176</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Increases related to prior year tax positions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Increases related to current year tax positions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">702</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">762</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ending balance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,704</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">938</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047309362552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 16, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 29, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 06, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 07, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount', window );">Fair value liabilities, level 1 to level 2 transfers, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Fair value liabilities, level 2 to level 1 transfers, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Fair value liability, transfers into level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Fair value liability, transfers out of level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity', window );">Conversion of lender warrants into equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 318,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member', window );">Accounting Standards Update 2019-12</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, Accounting Standards Update, adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, Accounting Standards Update, Adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, Accounting Standards Update, Immaterial effect [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=phat_UnvestedSharesMember', window );">Unvested Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted-average unvested shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,939,252<span></span>
</td>
<td class="nump">3,424,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Computer Equipment and Related Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Computer Equipment and Related Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=phat_LenderWarrantsMember', window );">Lender Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_ExpectedCashDividendYieldRate', window );">Expected cash dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=phat_TakedaWarrantsMember', window );">Takeda Warrant | Takeda License | Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_IncrementalCommonSharesAttributableToExerciseOfWarrants', window );">Shares of common stock included in calculation of basic weighted-average common shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,588,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_FinancialAssetsFairValueDisclosure', window );">Financial assets fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_NonfinancialAssetsFairValueDisclosure', window );">Non-financial assets fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosure', window );">Non-financial liabilities fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,524,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants exercised to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Takeda License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,084,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Takeda License | Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants exercised to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,588,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable', window );">Warrants issued to common stock remains exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,359,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity', window );">Conversion of lender warrants into equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 318,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital | Lender Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity', window );">Conversion of lender warrants into equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,997,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Initial Public Offering (IPO)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=phat_FollowOnPublicOfferingMember', window );">Follow-on Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued | shares</a></td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwritten Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,434,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital conversion of warrant liability into equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, number of securities called by warrants or rights, remains exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ExpectedCashDividendYieldRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected cash dividend yield rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ExpectedCashDividendYieldRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_FinancialAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial assets fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_FinancialAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_IncrementalCommonSharesAttributableToExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental common shares attributable to exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_IncrementalCommonSharesAttributableToExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_NonfinancialAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonfinancial assets fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_NonfinancialAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization basis of presentation and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 33: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of obligations not classified as financial liabilities. Includes, but is not limited to, accounts payable and accrued liabilities, commitments, obligations, and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonfinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=phat_UnvestedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=phat_UnvestedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=phat_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=phat_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=phat_LenderWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=phat_LenderWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=phat_TakedaWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=phat_TakedaWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_TakedaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_TakedaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=phat_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=phat_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047310988840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Reconciliation of Liabilities Measured at Fair Value (Details) - Warrant Liabilities - Significant Unobservable Inputs (Level 3)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">$ 413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity', window );">Reclassification of Lender Warrants into equity (Note 6)</a></td>
<td class="num">$ (318)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliations recurring basis reclass of warrant into equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=phat_WarrantsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=phat_WarrantsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047314245464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Property, Plant and Equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 1,502<span></span>
</td>
<td class="nump">$ 1,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(852)<span></span>
</td>
<td class="num">(331)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">646<span></span>
</td>
<td class="nump">516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">780<span></span>
</td>
<td class="nump">747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047312710712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Disposal of property, plant or equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047315605640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 3,165<span></span>
</td>
<td class="nump">$ 4,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation expenses</a></td>
<td class="nump">6,344<span></span>
</td>
<td class="nump">4,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional &amp; consulting expenses</a></td>
<td class="nump">1,855<span></span>
</td>
<td class="nump">1,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 11,405<span></span>
</td>
<td class="nump">$ 10,606<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047310931352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 05, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=phat_CommercialSupplyAgreementsMember', window );">Commercial Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_AgreementExtendsPeriodForTermination', window );">Agreement extends period for termination</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Minimum purchase obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember', window );">Frazier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent', window );">Outstanding accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty', window );">Shared operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_PCIPharmaServicesMember', window );">PCI Pharma Services | Clinical Manufacturing Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent', window );">Outstanding accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expense related to services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda | Takeda License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent', window );">Outstanding accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expense related to services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda | Temporary Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent', window );">Outstanding accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expense related to services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda | Drug Product or Substance | Commercial Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent', window );">Outstanding accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expense related to services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts payable and accrued expenses related parties current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AgreementExtendsPeriodForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement extends period for termination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AgreementExtendsPeriodForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction shared operating expenses due to transactions with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_CommercialSupplyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_CommercialSupplyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_PCIPharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_PCIPharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=phat_ClinicalManufacturingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=phat_ClinicalManufacturingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_TakedaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_TakedaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_TemporaryServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_TemporaryServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=phat_DrugProductOrSubstanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=phat_DrugProductOrSubstanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047315335224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 11, 2019</div></th>
<th class="th"><div>May 07, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,656,035<span></span>
</td>
<td class="nump">31,262,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (95,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_PurchaseCommitmentExpense', window );">Expenses incurred related to purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_PurchaseObligationDueInFirstTwentyFourMonths', window );">Purchase obligation in the first 24-month period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants exercised to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=phat_TakedaLicenseAgreementMember', window );">Takeda License | Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_LicenseAgreementDescription', window );">License agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The agreement will remain in effect, on a country-by-country and product-by-product basis, until the later of (i) the expiration of the last to expire valid patent claim covering vonoprazan fumarate alone or in combination with at least one other therapeutically active ingredient, (ii) the expiration of the applicable regulatory exclusivity and (iii) 15 years from the date of first commercial sale, unless earlier terminated. The Company may terminate the Takeda License upon six months&#8217; written notice. The Company and Takeda may terminate the Takeda License in the case of the other party&#8217;s insolvency or material uncured breach. Takeda may terminate the Takeda License if the Company challenges, or assists in challenging, licensed patents<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_AgreementExpirationTermFromDateOfFirstCommercialSale', window );">Agreement expiration term from date of first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_PaymentForLicenseAmount', window );">Cash consideration paid for license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,084,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00004613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Initial fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_AdditionalWarrantIssued', window );">Additional warrant issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales', window );">Maximum amount payable in sales milestones upon achievement of specified levels of product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_LicenseAgreementTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_WarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  07,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="nump">$ 144,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=phat_TakedaLicenseAgreementMember', window );">Takeda License | Takeda | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants exercised to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,588,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable', window );">Warrants issued to common stock remains exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,359,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AdditionalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional warrant issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AdditionalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AgreementExpirationTermFromDateOfFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement expiration term from date of first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AgreementExpirationTermFromDateOfFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, number of securities called by warrants or rights, remains exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LicenseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LicenseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LicenseAgreementTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LicenseAgreementTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount payable in sales milestones upon the achievement of specified levels of product sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_PaymentForLicenseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for license amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_PaymentForLicenseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_PurchaseCommitmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase commitment, expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_PurchaseCommitmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_PurchaseObligationDueInFirstTwentyFourMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase obligation due in first twenty four months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_PurchaseObligationDueInFirstTwentyFourMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_WarrantsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_WarrantsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_TakedaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_TakedaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phat_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047314326120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Commitments - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Option</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating leases, rent expense</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash payments for operating lease costs</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=phat_PrepaidLeasePaymentsMember', window );">Prepaid Lease Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash payments for operating lease costs</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_IL', window );">Buffalo Grove, Illinois</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating leases, remaining lease terms</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_LesseeOperatingLeaseNumberOfOptionToExtend', window );">Operating lease number of option to extend | Option</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease, option to extend description</a></td>
<td class="text">Both operating leases contain an option to extend the term for one additional five-year period<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JE', window );">Florham Park, New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating leases, remaining lease terms</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_LesseeOperatingLeaseNumberOfOptionToExtend', window );">Operating lease number of option to extend | Option</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease, option to extend description</a></td>
<td class="text">Both operating leases contain an option to extend the term for one additional five-year period<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LesseeOperatingLeaseNumberOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease number of option to extend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LesseeOperatingLeaseNumberOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=phat_PrepaidLeasePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=phat_PrepaidLeasePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047315188296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Commitments - Summary of Supplemental Balance Sheet Information Related to the Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_AssetsLesseeAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 1,914<span></span>
</td>
<td class="nump">$ 2,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_LiabilitiesLesseeAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">487<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">1,183<span></span>
</td>
<td class="nump">1,557<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 1,670<span></span>
</td>
<td class="nump">$ 2,031<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AssetsLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets, lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AssetsLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities, lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047314047304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Commitments - Summary of Future Annual Minimum Lease Payments Under Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">1,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest</a></td>
<td class="num">(220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">1,670<span></span>
</td>
<td class="nump">$ 2,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: operating lease liabilities, current</a></td>
<td class="num">(487)<span></span>
</td>
<td class="num">(474)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">$ 1,183<span></span>
</td>
<td class="nump">$ 1,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">3 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average incremental borrowing rate</a></td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047313591112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Total Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term debt, current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount', window );">Long-term debt, non-current portion</a></td>
<td class="nump">$ 100,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="num">(11,319)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net of debt discount</a></td>
<td class="nump">$ 89,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt noncurrent excluding unamortized debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047308279448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 17, 2021</div></th>
<th class="th"><div>May 14, 2019</div></th>
<th class="th"><div>Mar. 16, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 11, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loans aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to additional paid-in-capital, warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=phat_TermLoanMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument borrowed amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_DebtInstrumentAdditionalBorrowingCapacityAmounts', window );">Debt instrument, additional borrowing capacity amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=phat_TermLoanFirstAdvanceMember', window );">Term Loan First Advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Final payment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=phat_SiliconValleyBankTermLoanMember', window );">SVB Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_DebtInstrumentFinalPaymentFeePercentage', window );">Debt instrument, final payment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_DebtInstrumentFinalPaymentFee', window );">Debt instrument, final payment fee or end of term charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPaymentTerms', window );">Debt instrument, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Under the original SVB Term Loan, the monthly payments consisted of interest-only through May 31, 2021. On March 11, 2020, the Company entered into the first amendment and on March 11, 2021, the Company entered into the second amendment, or together the Amendments, to the SVB Term Loan. Pursuant to the Amendments, the interest-only payment period was initially extended through July 31, 2021, and was further extended until December 31, 2021, after the Company received positive data from its Phase 3 clinical trial in H. pylori infection sufficient to file an NDA with the FDA. The interest-only payment period could have been further extended until November 30, 2022, if the Company would receive positive data from its Phase 3 clinical trial in erosive esophagitis for vonoprazan sufficient to file an NDA with the FDA.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_DebtInstrumentPenaltyFeePercentage', window );">Debt instrument penalty fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_LanderWarrantsExpireTerm', window );">Warrants expire term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_LenderWarrantsExercisableSharesOfCommonStock', window );">Warrants exercisable shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Aggregate repurchase price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to additional paid-in-capital, warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=phat_SiliconValleyBankTermLoanMember', window );">SVB Term Loan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount', window );">Debt instrument, prepayment fee percentage of outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=phat_SiliconValleyBankTermLoanMember', window );">SVB Term Loan | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_DebtInstrumentFinalPaymentFee', window );">Debt instrument, final payment fee or end of term charge</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone', window );">Percentage of qualified cash prior to Third performance milestone</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone', window );">Minimum percentage of qualified cash following third performance milestone</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_MinimumMarketCapitalizationAmount', window );">Minimum market capitalization amount</a></td>
<td class="nump">$ 900,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock', window );">Percentage of debt funded to be issued as warrants to purchase common stock</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 33.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_ClassOfWarrantOrRightExpireTerm', window );">Warrants expire term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_ClassOfWarrantOrRightExpirationDate', window );">Warrants expiration date</a></td>
<td class="text">Sep. 17,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrant liabilities</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Debt issuance costs</a></td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase shares</a></td>
<td class="nump">74,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loans aggregate principal amount</a></td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_PaymentForFacilityCharge', window );">Payment for facility charge</a></td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_DebtInstrumentFacilityChargePercentage', window );">Debt instrument, facility charge percentage</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">Oct.  01,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement | Term Loan | Floor Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement | Term Loan | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement | Term Loan | Payment In Kind PIK Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate</a></td>
<td class="nump">3.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement | Term Loans, Aggregate Principal Amount Tranches One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loans aggregate principal amount</a></td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement | Term Loans, Aggregate Principal Amount Tranches Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loans aggregate principal amount</a></td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement | Term Loans, Aggregate Principal Amount Tranches Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loans aggregate principal amount</a></td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement | Term Loans, Aggregate Principal Amount Tranches Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loans aggregate principal amount</a></td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement | Term Loan Advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_DebtInstrumentFinalPaymentFeePercentage', window );">Debt instrument, final payment fee percentage</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_DebtInstrumentFinalPaymentFee', window );">Debt instrument, final payment fee or end of term charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember', window );">Loan Agreement | Term Loan Advance | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount', window );">Debt instrument, prepayment fee percentage of outstanding principal amount</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=phat_HerculesAndSvbTermLoanMember', window );">Hercules and SVB Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loans aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_AccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ClassOfWarrantOrRightExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ClassOfWarrantOrRightExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ClassOfWarrantOrRightExpireTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, expire term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ClassOfWarrantOrRightExpireTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_DebtInstrumentAdditionalBorrowingCapacityAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument additional borrowing capacity amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_DebtInstrumentAdditionalBorrowingCapacityAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_DebtInstrumentFacilityChargePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument facility charge percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_DebtInstrumentFacilityChargePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_DebtInstrumentFinalPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument final payment fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_DebtInstrumentFinalPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_DebtInstrumentFinalPaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument final payment fee percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_DebtInstrumentFinalPaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_DebtInstrumentPenaltyFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument penalty fee percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_DebtInstrumentPenaltyFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument prepayment fee percentage of outstanding principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LanderWarrantsExpireTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lander warrants expire term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LanderWarrantsExpireTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LenderWarrantsExercisableSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lender warrants exercisable shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LenderWarrantsExercisableSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_MinimumMarketCapitalizationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum market capitalization amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_MinimumMarketCapitalizationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of qualified cash on principal amount following third performance milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of qualified cash on principal amount prior to third performance milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_PaymentForFacilityCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for facility charge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_PaymentForFacilityCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of debt funded to be issued as warrants to purchase common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=phat_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=phat_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=phat_TermLoanFirstAdvanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=phat_TermLoanFirstAdvanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=phat_SiliconValleyBankTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=phat_SiliconValleyBankTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=phat_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=phat_PaymentInKindPikInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=phat_PaymentInKindPikInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=phat_TermLoansAggregatePrincipalAmountTranchesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=phat_TermLoansAggregatePrincipalAmountTranchesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=phat_TermLoansAggregatePrincipalAmountTranchesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=phat_TermLoansAggregatePrincipalAmountTranchesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=phat_TermLoansAggregatePrincipalAmountTranchesThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=phat_TermLoansAggregatePrincipalAmountTranchesThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=phat_TermLoansAggregatePrincipalAmountTranchesFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=phat_TermLoansAggregatePrincipalAmountTranchesFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=phat_TermLoanAdvanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=phat_TermLoanAdvanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=phat_HerculesAndSvbTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=phat_HerculesAndSvbTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047315570648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Future Minimum Principal and Interest Payments Under Term Loans (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 5,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo', window );">2023</a></td>
<td class="nump">5,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree', window );">2024</a></td>
<td class="nump">17,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour', window );">2025</a></td>
<td class="nump">50,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive', window );">2026</a></td>
<td class="nump">66,948<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_LongTermDebtAndInterest', window );">Total principal and interest payments</a></td>
<td class="nump">146,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_DebtInstrumentInterestAndFinalPaymentFee', window );">Less interest and final payment fee</a></td>
<td class="num">(46,772)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total term loan borrowings</a></td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_DebtInstrumentInterestAndFinalPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest and final payment fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_DebtInstrumentInterestAndFinalPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LongTermDebtAndInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt and interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LongTermDebtAndInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of principal and interest, year one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of principal and interest in year five.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of principal and interest in year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of principal and interest in year three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of principal and interest in year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047229808760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 16, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 29, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 06, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,725,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,812,000<span></span>
</td>
<td class="nump">$ 5,840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock initially reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,646,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation expense, weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_ClosingMarketPriceOfCommonStock', window );">Closing market price of common stock | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.67<span></span>
</td>
<td class="nump">$ 33.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock, shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,231,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock awards, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock, shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,158,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual increase to shares available for issuance percentage of outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Equity plan, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The number of shares initially available for issuance will be increased by (i) the number of shares subject to stock options or similar awards granted under the Existing Incentive Plan that expire or otherwise terminate without having been exercised in full after the effective date of the 2019 Plan and unvested shares issued pursuant to awards granted under the Existing Incentive Plan that are forfeited to or repurchased by the Company after the effective date of the 2019 Plan, with the maximum number of shares to be added to the 2019 Plan pursuant to clause (i) above equal to 1,416,788 shares, and (ii) an annual increase on January 1 of each calendar year beginning in 2020 and ending in 2029, equal to the lesser of (a) 5% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the board of directors. As of December 31, 2021, 1,772,744 shares remain available for issuance, which reflects 1,915,300 stock options and performance-based units ("PSU") granted, and 175,430 cancelled or forfeited, during the year ended December 31, 2021 as well as annual increases of 1,250,511 and 1,158,580 shares that were authorized on January 1, 2021 and 2020. An additional 1,582,802 shares were authorized on January 1, 2022. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease', window );">Number of shares remain available for issuance, annual increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock initially reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,772,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Incentive Award Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock, shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,582,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Incentive Award Plan | Performance-Based Stock Units (PSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock awards, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,050<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Incentive Award Plan | Stock Options and Performance-based Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,915,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod', window );">Number of shares, cancelled or forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">842,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual increase to shares available for issuance percentage of outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Equity plan, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition, the number of shares available for issuance under the ESPP will be annually increased on January 1 of each calendar year beginning in 2020 and ending in 2029, by an amount equal to the lesser of: (i) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the board of directors. As of December 31, 2021, 842,036 shares of common stock remain available for issuance, which reflects 30,237 shares sold to employees during the year ended December 31, 2021 as well as the annual increases of 312,628 and 289,645 shares that were authorized on January 1, 2021 and 2020. No additional shares were authorized in January 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease', window );">Number of shares remain available for issuance, annual increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,628<span></span>
</td>
<td class="nump">289,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock initially reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">842,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Estimated weighted-average fair value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.66<span></span>
</td>
<td class="nump">$ 13.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation expense, weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease', window );">Number of shares remain available for issuance, annual increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock, price per share | $ / shares</a></td>
<td class="nump">$ 42.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_ProceedsFromIssuanceInitialPublicOfferingGross', window );">Proceeds from issuance initial public offering gross | $</a></td>
<td class="nump">$ 94,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_SharesIssuedPricePerShareAfterDeductions', window );">Purchase price per share after deducting underwriting discounts and commissions | $ / shares</a></td>
<td class="nump">$ 39.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_NetProceedsAfterDeductingUnderwritersCommission', window );">Net proceeds after deducting underwriters commission | $</a></td>
<td class="nump">$ 88,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_PurchaseOfAdditionalOfferingExpenses', window );">Purchase of additional offering expenses | $</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=phat_ATMOfferingProgramMember', window );">At-the-Market Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember', window );">Employee and Nonemployee Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Estimated weighted-average fair value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=phat_OpenMarketSaleAgreementWithJefferiesLLCMember', window );">Open Market Sale Agreement with Jefferies LLC | At-the-Market Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare', window );">Sales commission payable as a percentage of sale of gross sales price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=phat_OpenMarketSaleAgreementWithJefferiesLLCMember', window );">Open Market Sale Agreement with Jefferies LLC | At-the-Market Offering Program | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_AggregateOfferingPriceThroughEquityFinancing', window );">Aggregate offering price through equity financing | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,524,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Number of shares authorized to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,373,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_StockRepurchaseProgramNumberOfSharesRightLapse', window );">Stock repurchase program, number of shares right lapse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">843,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased', window );">Remaining number of shares to be repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,530,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramPeriodInForce1', window );">Stock repurchase program, period in force</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_StockRepurchaseProgramExpirationMonthAndYear', window );">Stock repurchase program expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_RepurchaseRightLapseShares', window );">Repurchase right lapse each month after first anniversary, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.000208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_SharesAggregateRepurchasePrice', window );">Shares aggregate repurchase price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2019 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,416,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum percentage of eligible compensation contributed by participants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,997,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Initial Public Offering (IPO) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,434,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased', window );">Remaining number of shares to be repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">749,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_RepurchaseRightLapseRate', window );">Repurchase right lapse rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Takeda License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,084,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Founders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased', window );">Remaining number of shares to be repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Frazier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,491,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_AggregateOfferingPriceThroughEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering price through equity financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_AggregateOfferingPriceThroughEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ClosingMarketPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Closing market price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ClosingMarketPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_NetProceedsAfterDeductingUnderwritersCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds after deducting underwriters commission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_NetProceedsAfterDeductingUnderwritersCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ProceedsFromIssuanceInitialPublicOfferingGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance initial public offering gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ProceedsFromIssuanceInitialPublicOfferingGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_PurchaseOfAdditionalOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of additional offering expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_PurchaseOfAdditionalOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_RepurchaseRightLapseRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repurchase right lapse rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_RepurchaseRightLapseRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_RepurchaseRightLapseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repurchase right lapse shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_RepurchaseRightLapseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales commission payable as a percentage of sale of gross sales price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares available for grant annual increase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, options and other than options forfeitures and expirations in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, options and other than options, grants in period gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_SharesAggregateRepurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares aggregate repurchase price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_SharesAggregateRepurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_SharesIssuedPricePerShareAfterDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued, price per share after deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_SharesIssuedPricePerShareAfterDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_StockRepurchaseProgramExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Repurchase Program Expiration Month and Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_StockRepurchaseProgramExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_StockRepurchaseProgramNumberOfSharesRightLapse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock repurchase program, number of shares right lapse.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_StockRepurchaseProgramNumberOfSharesRightLapse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramPeriodInForce1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramPeriodInForce1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=phat_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=phat_StockOptionsAndPerformanceBasedUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=phat_StockOptionsAndPerformanceBasedUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=phat_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=phat_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=phat_ATMOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=phat_ATMOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_OpenMarketSaleAgreementWithJefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_OpenMarketSaleAgreementWithJefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=phat_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=phat_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=phat_TakedaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=phat_TakedaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=phat_FoundersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=phat_FoundersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis=phat_FrazierLifeSciencesIXLimitedPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnerTypeOfPartnersCapitalAccountAxis=phat_FrazierLifeSciencesIXLimitedPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047317503192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Unvested Shares (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at December 31, 2020</a></td>
<td class="nump">2,746,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting', window );">Share vesting</a></td>
<td class="num">(1,601,950)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at December 31, 2021</a></td>
<td class="nump">1,144,809<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments other than options, share vesting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047314109368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">14,646,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=phat_CommonStockWarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">7,450,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=phat_StockOptionsAndPerformanceBasedAwardsMember', window );">Stock Options and Performance-Based Awards Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">4,581,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,772,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_EmployeeStockPurchasePlanMember', window );">ESPP Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">842,036<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=phat_CommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=phat_CommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=phat_StockOptionsAndPerformanceBasedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=phat_StockOptionsAndPerformanceBasedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=phat_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=phat_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047310928040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of PSU Activity Under the 2019 Incentive Award Plan (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at December 31, 2020</a></td>
<td class="nump">2,746,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at December 31, 2021</a></td>
<td class="nump">1,144,809<span></span>
</td>
<td class="nump">2,746,759<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Incentive Award Plan | Performance-Based Stock Units (PSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at December 31, 2020</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock awards, granted</a></td>
<td class="nump">190,050<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Stock Units, Forfeited</a></td>
<td class="num">(15,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at December 31, 2021</a></td>
<td class="nump">394,300<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Unvested Beginning Balance</a></td>
<td class="nump">$ 32.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Granted</a></td>
<td class="nump">31.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Forfeited</a></td>
<td class="nump">30.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Unvested Ending Balance</a></td>
<td class="nump">$ 32.23<span></span>
</td>
<td class="nump">$ 32.48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=phat_TwoThousandNineteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047314225336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 11 months 4 days<span></span>
</td>
<td class="text">6 years 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">67.46%<span></span>
</td>
<td class="nump">65.07%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">0.51%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=phat_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">8 months 8 days<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">76.25%<span></span>
</td>
<td class="nump">76.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.09%<span></span>
</td>
<td class="nump">0.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=phat_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=phat_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047308255096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Beginning Balance</a></td>
<td class="nump">2,728,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Outstanding, Options granted</a></td>
<td class="nump">1,725,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested', window );">Options Outstanding, Options exercised and shares vested</a></td>
<td class="num">(107,583)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Outstanding, Options cancelled</a></td>
<td class="num">(159,680)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Ending Balance</a></td>
<td class="nump">4,186,729<span></span>
</td>
<td class="nump">2,728,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Outstanding, Options exercisable as of December 31, 2021</a></td>
<td class="nump">1,127,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options Outstanding, Options vested and expected to vest</a></td>
<td class="nump">4,186,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 21.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options granted</a></td>
<td class="nump">37.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options exercised and shares vested</a></td>
<td class="nump">18.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options cancelled</a></td>
<td class="nump">32.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Ending Balance</a></td>
<td class="nump">27.53<span></span>
</td>
<td class="nump">$ 21.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options exercisable as of December 31, 2021</a></td>
<td class="nump">19.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options vested and expected to vest</a></td>
<td class="nump">$ 27.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term</a></td>
<td class="text">8 years 5 months 4 days<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Options exercisable as of December 31, 2021</a></td>
<td class="text">7 years 10 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Options vested and expected to vest</a></td>
<td class="text">8 years 5 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Balance</a></td>
<td class="nump">$ 13,973<span></span>
</td>
<td class="nump">$ 34,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options exercisable as of December 31, 2021</a></td>
<td class="nump">6,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Options vested and expected to vest</a></td>
<td class="nump">$ 13,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award stock options exercised and shares vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award options exercises and shares vested in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047314050840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 16,812<span></span>
</td>
<td class="nump">$ 5,840<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">3,838<span></span>
</td>
<td class="nump">1,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 12,974<span></span>
</td>
<td class="nump">$ 4,390<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047308258488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">6,694,000<span></span>
</td>
<td class="nump">3,744,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits</a></td>
<td class="nump">1,704,000<span></span>
</td>
<td class="nump">938,000<span></span>
</td>
<td class="nump">$ 176,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would affect effective tax rate</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest or penalties related income tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrual for interest or penalties related to income tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards which are carried over indefinitely</a></td>
<td class="nump">290,100,000<span></span>
</td>
<td class="nump">$ 157,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">$ 7,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear', window );">Research and development credits expiration period</a></td>
<td class="text">2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear', window );">Research and development credits expiration period</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development tax credit carry forward expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047313555976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income taxes computed at the statutory rate</a></td>
<td class="num">$ (30,216,000)<span></span>
</td>
<td class="num">$ (27,105,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_IncomeTaxReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="nump">1,387,000<span></span>
</td>
<td class="nump">291,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt', window );">Change in fair value of warrants and convertible debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credit</a></td>
<td class="num">(2,950,000)<span></span>
</td>
<td class="num">(3,047,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">31,783,000<span></span>
</td>
<td class="nump">29,949,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="num">(68,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation change in fair value of warrants and convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_IncomeTaxReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation permanent items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_IncomeTaxReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047314293736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 60,936<span></span>
</td>
<td class="nump">$ 33,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research credits</a></td>
<td class="nump">6,694<span></span>
</td>
<td class="nump">3,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">13,809<span></span>
</td>
<td class="nump">14,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">3,996<span></span>
</td>
<td class="nump">1,914<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">85,435<span></span>
</td>
<td class="nump">53,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(85,033)<span></span>
</td>
<td class="num">(53,250)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(402)<span></span>
</td>
<td class="num">(499)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047315588008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Activity Related to Gross Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 938<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases related to prior year tax positions</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">702<span></span>
</td>
<td class="nump">762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 1,704<span></span>
</td>
<td class="nump">$ 938<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047311282296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan employer contribution expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined contribution plan, employer matching contribution, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled', window );">Employer discretionary match number of shares settled</a></td>
<td class="nump">8,356<span></span>
</td>
<td class="nump">16,756<span></span>
</td>
<td class="nump">18,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined contribution pan employer discretionary match number of shares settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>phat_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140047313704360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JE', window );">Florham Park, New Jersey | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area for operating lease</a></td>
<td class="nump">6,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>phat-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:phat="http://www.phathompharma.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="phat-20211231.xsd" xlink:type="simple"/>
    <context id="C_83965ad4-28b1-4afc-8889-5d7cdbc079ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_b9960611-efe5-44c4-a8c6-f1f963d5a52b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20586d23-36ef-4d60-8bc6-81acfe59236b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:SiliconValleyBankTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_17839630-7f10-4b51-bf7c-a8f7ffc8fab6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_caf206af-24fe-4015-adc8-87b45d8a8636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_861c796b-ff5c-4f2f-83b8-902fd93be0af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d4dfdb6b-5b03-4e72-951e-81ecb345c403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b03a9ab9-4538-4d34-b658-218482e16bbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_91313c0e-8879-4034-8725-8b3f8639f719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-29</startDate>
            <endDate>2019-10-29</endDate>
        </period>
    </context>
    <context id="C_0d2e408c-4d50-4188-92b1-018f98519206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:ClinicalManufacturingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:PCIPharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3cd1a70e-7077-4da4-a87c-da5e90015997">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:DrugProductOrSubstanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_6a529bff-3f22-42e8-80c8-4ec27c2967c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">phat:StockOptionsAndPerformanceBasedUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c2511355-1d5e-4278-9953-83e4963ae813">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_db21078b-51b9-43f8-8e98-683590c04e0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="C_a36db690-2560-474a-8fbd-8050d47eb62c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_85558b4d-f67a-43d1-abe8-dbab03b741da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fb1fb004-48c7-408c-a23a-a166c26e4c3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_b04891d2-7dba-42b2-a181-d9f6bb277f08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b4181602-e907-4a44-b1b6-077897333d0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:SiliconValleyBankTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-14</startDate>
            <endDate>2019-05-14</endDate>
        </period>
    </context>
    <context id="C_9c7240c2-23a4-4f2e-bdf7-8d45f209d98b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_206f3b3c-5da1-4c5f-91a2-624aa167dbf3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_d09d3095-f7e4-4678-97ca-b059f5088ae2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_87fd58b8-211c-4048-8771-2e2c36ba57bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_9c645a10-1007-43f6-af0d-91ee63fc5c04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="C_33fee96d-a213-48c4-a5ad-68ccefad3cff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_fad8897a-ba60-41ae-8f3d-ee922beca8a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="C_380ada73-fd68-4c36-b7a1-4dbbf1ceef47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-29</instant>
        </period>
    </context>
    <context id="C_ca65917a-bc4e-4718-82a1-bb0697a04ae9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanAdvanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-17</startDate>
            <endDate>2021-09-17</endDate>
        </period>
    </context>
    <context id="C_c6ab3ae6-86d0-4065-ba57-907b3b0f74c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">phat:UnvestedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_6c52a9cb-ddf2-45f2-a3ab-4d943486cf78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-05</startDate>
            <endDate>2020-05-05</endDate>
        </period>
    </context>
    <context id="C_900f5558-5afe-4b4f-8196-aa85a162d269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_87f0bb77-c9b2-4912-beed-d93c6e58fd1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_af4df9d7-725e-4644-8d48-2c2689576963">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">phat:PrepaidLeasePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4f305fcc-4607-43ba-9d9f-9de48fa77502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">phat:PaymentInKindPikInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-17</instant>
        </period>
    </context>
    <context id="C_478c7409-ab7e-4c39-bda4-749e3ceaf9ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d7d58811-0410-450f-88fc-1f9a4230079a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanAdvanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-17</startDate>
            <endDate>2021-09-17</endDate>
        </period>
    </context>
    <context id="C_154dd6a8-f069-4eec-86e5-92a39aa1a300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a5762110-631a-4b1c-9b33-2acb71c21790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-17</instant>
        </period>
    </context>
    <context id="C_81edcc29-7776-4011-b910-010591687fb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanAdvanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a0b3b017-48e9-4500-9fd4-aaf93a60d5dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:DrugProductOrSubstanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6951c26d-af1d-407b-bbcb-8b12126fe3f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:ClinicalManufacturingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:PCIPharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fe1128a5-47e8-4b19-bbed-dd56555e6e7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_d695a09e-552b-4926-9fd0-d64fd565f066">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">phat:LenderWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_413a633b-7a27-41ac-8e92-4d82e9b0c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TemporaryServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_33b1043e-bfc6-4fce-ba82-e6e6e0ac95af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_efc1a669-0200-4d3b-9503-dde410805b7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_917d5eb6-6257-4bc2-9c26-1732c213fff4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="C_fed6006f-4109-4946-b552-76ae913aeaf0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_188214ae-df7a-4194-abe9-bd6e9956a85d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-11</startDate>
            <endDate>2019-10-11</endDate>
        </period>
    </context>
    <context id="C_d962d708-ce93-405d-a90d-73e1fae4aa3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_8dbe144e-0a5e-4b96-a3d3-658404346eb7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_38af774f-d0ce-4768-8641-dd4bb3038da3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_10d2f460-e459-411f-8dad-34d4446eecc2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:ClinicalManufacturingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:PCIPharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c91457b5-5dc6-4bd1-a9ad-497176c5ae9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-06</instant>
        </period>
    </context>
    <context id="C_b72f7963-2e17-4f63-ae38-f0567547466c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-11</instant>
        </period>
    </context>
    <context id="C_d868eb98-0a9a-4d3b-9ce2-a53206123d64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">phat:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9b6da75c-d2db-4900-8fad-0f82733efc5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2abff921-c9a8-4de4-b41c-9e7893e5704b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_be8f5d58-327a-4e7b-acdd-e53a93782a26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b58f7ee0-6546-4bdb-8957-1ed85f98206a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_60ed7ae5-368e-4841-b870-3c1b94b39311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d13ddfcd-4194-47e6-a796-f68b8150593b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <instant>2022-02-24</instant>
        </period>
    </context>
    <context id="C_bbae8c0f-df0c-4920-b864-e0c22c2199e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_955c05d2-5a1f-43ab-9d80-db08111345d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f66489f4-0ae2-4a45-862d-a14469e353c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="C_c161eef4-fe92-48d7-944f-6e1bd1c45f50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:DrugProductOrSubstanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d5335391-0999-47b9-a03b-8400c5c69127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TemporaryServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_b0c76117-ced6-4a6e-a934-4d66a2de81b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <startDate>2021-01-31</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_e5953438-3337-4945-83fd-2193a29e01a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">phat:StockOptionsAndPerformanceBasedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ff71ca2a-03d2-4397-9d0b-802dd6a7a795">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoansAggregatePrincipalAmountTranchesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-17</instant>
        </period>
    </context>
    <context id="C_f9cd5e45-1473-4fc5-b117-73d3e4b8192b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">phat:ATMOfferingProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:OpenMarketSaleAgreementWithJefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_8eeb73f9-fe0f-457f-a77c-81905970cf0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-17</startDate>
            <endDate>2021-09-17</endDate>
        </period>
    </context>
    <context id="C_ab2e6d6d-5682-41ff-9336-cabea4c3f7b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a04a8afc-8f38-4892-a76a-0ad14e22ff3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoansAggregatePrincipalAmountTranchesFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-17</instant>
        </period>
    </context>
    <context id="C_a3536774-184c-4c9f-b6b0-4b72ebbf9525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_efee110a-f508-43c7-acf9-df99b6d9b882">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-17</instant>
        </period>
    </context>
    <context id="C_61898c01-23d4-4967-bc48-1597a7447fd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_46965119-6bce-4a6d-abf3-e28dc3543e93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">phat:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fc9746aa-75ec-4357-9a62-e52e0a26d077">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5b92a549-2b7a-468d-8c11-955c21018981">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d3d57991-14bf-4f93-a017-aa16c506b8db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_1996f1f9-d68a-46ed-9e27-8965a2c43da4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanFirstAdvanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9d982be6-c196-4b4e-ae56-0b1fafa482a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_304607c5-7382-468b-88d2-4280b34bacd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="C_c47ce7f2-8ee4-455c-93be-6ab781a08057">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="C_6ef27173-e664-4f22-9780-2b7a13c106d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5a4b87ab-a1d7-48cd-a634-0d9f17511fa1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-06</instant>
        </period>
    </context>
    <context id="C_caf5d7c1-1bad-4042-90db-0f0fb308e394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f52603aa-c039-41a2-95ea-2a152bab42c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TemporaryServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_3664d4ba-d83a-42b2-94ee-819934ab325c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">phat:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7e3a25e6-daa3-4b87-aabb-7aa287d515ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_ba31a338-f01c-4a63-899f-d02fc7b91340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-07</instant>
        </period>
    </context>
    <context id="C_133a7a17-cc0b-4319-b5dd-153f51460267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0ef2e37e-f570-4b04-bea6-8bd572cb5668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_35306304-4c25-4c5b-a433-e5367fe22b87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">phat:TakedaWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6cd259d1-4f33-46a3-b5d1-c3115e02e275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:HerculesAndSvbTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fc73c1d8-543b-42ca-a706-31cf63f474bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="C_955ca9b1-fa2d-4384-942f-920fcb5fe424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="C_3df574b9-fe27-4d9e-a549-6a095ed65261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:SiliconValleyBankTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-14</instant>
        </period>
    </context>
    <context id="C_e3ad8a65-3e01-423c-bdf8-40f8bc119501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_2349ad83-214b-42ef-8534-32900ea1ab8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-17</startDate>
            <endDate>2021-09-17</endDate>
        </period>
    </context>
    <context id="C_e23ac301-7808-41cf-82ed-c24a17ab03b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-16</startDate>
            <endDate>2020-12-16</endDate>
        </period>
    </context>
    <context id="C_17a2343c-f245-48f0-b4b2-e5e809abbd6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_241f6789-e4f7-4e5a-930f-33a8b7e5b743">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:SiliconValleyBankTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-14</startDate>
            <endDate>2019-05-14</endDate>
        </period>
    </context>
    <context id="C_1df5bc5b-1abb-43f6-aae5-4d3a06d655e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">phat:WarrantsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_6e6c878e-6e27-47fc-9b34-7dc97f3dda54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-07</instant>
        </period>
    </context>
    <context id="C_098ad23e-df01-4a44-9fa6-756e054ae9d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_dd956957-4601-4ab3-a9dd-db08fb69bc8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">phat:PrepaidLeasePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_acd69431-8a06-4075-a111-6495758ee60f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:HerculesAndSvbTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_12c53278-d1c8-452b-aaf8-8d9bd7427b25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="C_589be08d-1fdd-4132-b344-d516fb3dae6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_aefa2a08-8860-4371-8c07-d0e5df47bfbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">phat:ShareBasedPaymentArrangementEmployeeAndNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c9fb0785-ea03-426b-a4b8-f5ea1415baaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:ClinicalManufacturingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:PCIPharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_51814a33-b695-44e9-b59a-823a169dda09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_36128d75-bc37-4ecf-b73c-b936cd610fae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">phat:FoundersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1dc294ca-9c67-4d13-8135-fcee0b125f3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_32d5d9b1-7992-4d84-8226-a55e116ed6d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:SiliconValleyBankTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-14</startDate>
            <endDate>2019-05-14</endDate>
        </period>
    </context>
    <context id="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cdbdb34e-8229-4188-b4a2-e7d4e7a5718c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20fed5f8-cd13-4903-b6b5-b54dbe1e910a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_61652f9e-ae05-40dc-b6b4-3b2b4d36b133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_335b6a1d-cf50-4b89-b646-9f381f97d6d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_ef836273-9d6a-454c-a500-c957bc4a93a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b6c9a017-a221-4c88-a8e6-7e275e06e7fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_098dcddf-024a-435f-b6ee-bf3342544e82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <instant>2019-10-11</instant>
        </period>
    </context>
    <context id="C_58425dd1-174b-4c7a-8d6a-81deea1aee09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_74f9d273-2810-4b05-a50b-39f4e9e89f17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-29</startDate>
            <endDate>2019-10-29</endDate>
        </period>
    </context>
    <context id="C_a4d53c9a-cf55-407d-9ed4-40937c45f516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2a16177c-bacc-4d09-9fc8-d0f5d55d3ee5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a6e0c0e2-0899-4673-aff4-66d468643b51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">phat:WarrantsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_c621285b-51be-4793-ac3f-90046055c2ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_1697dfc5-540c-442e-b1a4-f9384dabddfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PartnerTypeOfPartnersCapitalAccountAxis">phat:FrazierLifeSciencesIXLimitedPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_454da93f-f097-4419-a6f9-b33d0b69cd59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_43c774bf-00b3-4dcd-930e-6ffada5f2a87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-17</startDate>
            <endDate>2021-09-17</endDate>
        </period>
    </context>
    <context id="C_2d28ef17-10f6-4591-8f1a-f0f2d4d26dae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_543d071e-badd-429f-8237-98bcd1e05d25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_966c0d74-7852-45f5-adb0-f5683894e01e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_7722cfb6-10af-45ab-a5aa-9adea0d22b6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_71f08e47-8ff5-4195-a019-61c121d7c840">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-17</startDate>
            <endDate>2021-09-17</endDate>
        </period>
    </context>
    <context id="C_78796fa9-c62f-43b9-b92a-90c0ac2aae02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_9840529e-ac70-4eb7-8d10-e6cb712b0d45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:SiliconValleyBankTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_39e4a6be-472b-4454-9622-81423cbf1cf1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoansAggregatePrincipalAmountTranchesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-17</instant>
        </period>
    </context>
    <context id="C_cd0d4a06-0d27-4385-9179-d25cf2ad0b78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoansAggregatePrincipalAmountTranchesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-17</instant>
        </period>
    </context>
    <context id="C_f8f7aeec-8c43-4d6e-857e-906c1138ff3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-16</instant>
        </period>
    </context>
    <context id="C_26050370-2bfa-4995-a133-64b6e9cefdc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_ce1d61e6-3a91-4de4-b8d0-dfb4084514fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TemporaryServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d15d3cd0-b504-48e2-8d5b-b29bec97767e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f13e98ac-8a46-483d-833b-1ed96212502d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:HerculesAndSvbTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ea9b39a8-a8b3-4e16-ad57-51beaa82a734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b31d6f50-cf52-4cab-8313-448f4b5812e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-07</startDate>
            <endDate>2019-05-07</endDate>
        </period>
    </context>
    <context id="C_36815495-d09a-4025-bf79-5a42d4c3e739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_badf06b6-f9fe-4b02-beea-e7e8d5ea853c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-05-06</endDate>
        </period>
    </context>
    <context id="C_723f3790-161d-4bd6-86bd-87b733a399de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">phat:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e42fcdbf-c245-40d9-a08b-a3024663efad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:TakedaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1ac41c78-ea4c-491d-bef4-399d1207de36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">phat:DrugProductOrSubstanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">phat:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:CommercialSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a86629b2-8d48-4534-a0ad-f992b4110383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4d9410fc-a3f3-43cf-95a5-e68281c355c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1c116e20-429c-4aa4-8fe0-8e3b8500397e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_53fd8783-36da-45c7-98b2-ab70da66a761">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">phat:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-17</instant>
        </period>
    </context>
    <context id="C_dd423291-341d-427f-ad43-b78d594b43a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">phat:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d66f011d-89be-4560-91d7-2a57c1175688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">phat:LenderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c0e9a1bb-6f16-475b-b3dc-8ce4769c62af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0325f78e-5f19-4ce3-816b-ea35a5adfab2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">phat:ATMOfferingProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">phat:OpenMarketSaleAgreementWithJefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_213e1528-74d7-4db2-a3ae-74c89a47e0e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_feab6596-3893-42c2-a2c0-1464c2b5d8ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">phat:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a74a6818-5881-479c-96b1-dcc3cd65fed3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">phat:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-16</startDate>
            <endDate>2020-03-16</endDate>
        </period>
    </context>
    <context id="C_f32b69df-40b4-4e56-8da4-28475877b8ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">phat:UnvestedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c16925ab-416a-4dd6-ae22-155a64c3a8a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">phat:ATMOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ed462fec-d2dc-4e80-8a94-a6e09a3934b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001783183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Option">
        <measure>phat:Option</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Segment">
        <measure>phat:Segment</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      id="F_790a9cb9-9188-4ded-9206-b149f84c5071"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_5c9dbb8a-393e-444e-8610-68189e5d86c9">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      id="F_6df742c1-1b0e-4a19-9b23-85075f7ae8ca"
      unitRef="U_USD"
      xsi:nil="true"/>
    <phat:RepurchaseRightLapseShares
      contextRef="C_c91457b5-5dc6-4bd1-a9ad-497176c5ae9b"
      decimals="6"
      id="F_6101410e-3515-4cea-81ab-5e3079200f62"
      unitRef="U_pure">0.000208</phat:RepurchaseRightLapseShares>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_46965119-6bce-4a6d-abf3-e28dc3543e93"
      id="F_b94a21cd-dcaa-4585-bab0-9b02263f175c">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PreferredStockValue
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      id="F_a6f5857d-fe54-46c6-8042-ea23f4bc4656"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:AmendmentFlag
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_808f8abc-4c8d-4093-8dc3-817145973bca">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_c5534db8-5d86-4eaa-80e7-cd1983ac8153">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_363c3080-c309-4c9a-8ecc-58fdc9844485">0001783183</dei:EntityCentralIndexKey>
    <us-gaap:PreferredStockValue
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      id="F_d8219ef5-f760-4856-ae0b-f47cd083e034"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_f963568b-28ee-4bd8-baf0-9a4ec98c5ae2">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_7d3660fb-75af-4f93-83bc-a1b18c57e39b">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_09f33276-2fba-456f-862d-406a3aa65663">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_f9f474b4-4247-49dc-8ede-0b3bfbb0a7dc">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_01a545f4-5c1a-4b78-b094-44129bb9d509">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_dbd4dda9-cd3e-4f91-814a-c08096d8ce6f">001-39094</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_732ef9d9-b757-4123-acae-fd7b772f6e8f">PHATHOM PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_48f33b7c-8544-4f23-b3bb-32f3e98978a6">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_03948412-b2c1-4838-8e45-370977f67ccb">82-4151574</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_90bfb79b-6da2-4262-b9e0-5bfbfbe5eb7d">100 Campus Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_6a5d051c-9dd7-49ed-9f03-ee7dd7f219e3">Suite 102</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_1c99a120-8329-4734-9606-40c3a546de48">Florham Park</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_f44d9ab2-d0f1-43cd-b4ce-27af6fa5a910">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_02e2f9ae-ffc1-42d2-abc2-ea5d9fb3f8a4">07932</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_cdc778eb-baf6-4fed-8cbb-9c447da5803e">877</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_257db812-a794-499c-bdc1-4e4f5f622fee">742-8466</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_6e7dabba-0a07-4791-ba5c-d557ec211da6">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_86118016-fc62-4780-8719-2cfff014b390">PHAT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_c6c522a0-bf70-4261-8328-999af2ce1632">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_4a51f441-aa67-4dc2-9211-57eb9519df52">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_c3f40430-22bc-4c39-88a4-e94361a2d54a">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_31681eb1-78bf-4adc-81ae-42114965d18b">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_645415da-5b45-45a1-a1e5-c89868de540b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_7b315cce-cc7a-4c5a-95fd-5bbcc6cb66f5">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_d564545f-ce65-4c8d-a1fc-f770dd185df5">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_700a79df-8919-4081-84b4-bd6a71d62001">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_1669e876-f6b4-4221-940c-94a9aa46923a">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_2faf01c9-2857-4350-b952-93eaa0d12ca0">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_6695552c-fa8b-4a5c-b015-c19c84105475">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_1c116e20-429c-4aa4-8fe0-8e3b8500397e"
      decimals="-5"
      id="F_22f782da-1562-4185-90fc-ee674daaff0d"
      unitRef="U_USD">684200000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_d13ddfcd-4194-47e6-a796-f68b8150593b"
      decimals="INF"
      id="F_66424694-ad38-4e20-bc50-246d926fe0b8"
      unitRef="U_shares">31712742</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_ab5fdf0d-341f-42e1-9a81-e48cb32bc39f">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"&gt;Certain sections of the registrant&#x2019;s definitive proxy statement for the 2022 annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K are incorporated by reference into Part III of this Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_1d8d9577-c0e8-4b86-80f5-c2fb30064a7c">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorFirmId
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_039e9773-0740-4892-b9dc-e3fe849a6cd1">42</dei:AuditorFirmId>
    <dei:AuditorLocation
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_4bd69e6e-b243-4cb4-802a-0dbf01372a08">Iselin, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_0d3661b8-c27b-47cf-8ba7-ab92f49f0638"
      unitRef="U_USD">183259000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_c0929e84-69d8-4631-9bd2-80472688b079"
      unitRef="U_USD">287496000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <phat:PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_122931cb-c1c4-43c1-82c3-ec02fd2fd302"
      unitRef="U_USD">0</phat:PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent>
    <phat:PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_3416e3a6-1891-4c37-b467-97e16e54b0ce"
      unitRef="U_USD">82000</phat:PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_7e78f37e-ef98-44bd-8ec8-ea122e985b1a"
      unitRef="U_USD">3267000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_1b073ec6-34f9-4417-849c-ab2a28a6f907"
      unitRef="U_USD">3872000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_643ad79c-6164-4e2b-b493-f6147af52487"
      unitRef="U_USD">186526000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_542c4479-3222-426d-874e-6b7a9ff6d8c6"
      unitRef="U_USD">291368000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_ae051827-b436-4ae8-bcd8-3c8184260449"
      unitRef="U_USD">650000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_abb408c1-0f4e-4e37-932b-0260d356d117"
      unitRef="U_USD">986000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_04a0c87e-bdeb-4622-8bb0-9b92e0804cdf"
      unitRef="U_USD">1914000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_dd7e3c76-0d90-48ea-a2fe-2ff3707ae74e"
      unitRef="U_USD">2373000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_83e43668-e7a5-41a7-9e97-b6b61e1bc354"
      unitRef="U_USD">341000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_da29382c-0757-46b4-8e0c-def9356c721b"
      unitRef="U_USD">384000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_4db615b2-b857-4fbb-808b-2ec004cbe441"
      unitRef="U_USD">189431000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_9aa27c45-fa60-4846-97b2-39a69beb1587"
      unitRef="U_USD">295111000</us-gaap:Assets>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_21121b93-1ef3-4988-bd77-9b8f96d2de8d"
      unitRef="U_USD">1343000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_11421a45-ed5a-4247-ac01-cfc92d87edcc"
      unitRef="U_USD">173000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_b3590baf-fe23-4472-95b5-9195d6602e53"
      unitRef="U_USD">5150000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_1de16332-18fb-4d22-9097-122f56206e32"
      unitRef="U_USD">16782000</us-gaap:AccountsPayableCurrent>
    <phat:AccruedClinicalTrialExpensesCurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_8a2a883a-7459-41fa-bd67-e89cd8c44ccc"
      unitRef="U_USD">1402000</phat:AccruedClinicalTrialExpensesCurrent>
    <phat:AccruedClinicalTrialExpensesCurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_f2a791e5-18b4-450a-803e-5b02deb320e3"
      unitRef="U_USD">19997000</phat:AccruedClinicalTrialExpensesCurrent>
    <phat:AccruedExpensesRelatedPartiesCurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_5ab1f96a-424c-448c-bc10-7a2942a3a499"
      unitRef="U_USD">2330000</phat:AccruedExpensesRelatedPartiesCurrent>
    <phat:AccruedExpensesRelatedPartiesCurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_fded6457-6714-4a55-a9d6-d82af2bf0fc5"
      unitRef="U_USD">734000</phat:AccruedExpensesRelatedPartiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_ba03f2f9-f390-4336-93b7-c2912d9be5d8"
      unitRef="U_USD">11405000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_ec78cc71-ec1d-41aa-a603-5e539cf6ea92"
      unitRef="U_USD">10606000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_3e549aa6-7ef4-40b2-9794-a6b6fd9f5e58"
      unitRef="U_USD">477000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_1833440e-17f6-4c5e-8ed2-b0861d056382"
      unitRef="U_USD">312000</us-gaap:InterestPayableCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_14f25b33-fb69-473f-a534-9eb76b9c27ef"
      unitRef="U_USD">7353000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_edb5fb98-87ee-48d5-aeb7-146465c0e68a"
      unitRef="U_USD">487000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_82c08e9b-72c2-4d34-b002-b64dfafea29c"
      unitRef="U_USD">474000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_3eb68bd6-0a0e-4f2f-bead-fc2bf7c32ff5"
      unitRef="U_USD">18921000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_f419b692-ed0d-48fb-81f1-ead72eca0e78"
      unitRef="U_USD">55524000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_07b870e9-a8f6-4e57-a21c-a76e9b01f477"
      unitRef="U_USD">89671000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_6e48d327-9af3-4f90-8563-9a1baf39f459"
      unitRef="U_USD">39634000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_e3d881a2-0705-47d7-bf81-5948bb1315e1"
      unitRef="U_USD">1183000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_5f9445a7-9160-485c-9206-b2a8462dacc0"
      unitRef="U_USD">1557000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_7de25211-3d16-43c2-953f-733ad4a5aa87"
      unitRef="U_USD">7500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_c3387d52-f6d8-4581-be7b-34b23ea5308d"
      unitRef="U_USD">4125000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_a3bc4cbc-158d-4dd3-86e4-864827e2b3cc"
      unitRef="U_USD">117275000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_9e10c840-f932-45fb-b518-1c16e5586997"
      unitRef="U_USD">100840000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="INF"
      id="F_c3212d7d-73dc-4f2e-b93a-9d14a25b59ff"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="INF"
      id="F_8e362aeb-ae70-4560-8e39-bc157d527e76"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="INF"
      id="F_c2d85533-646e-484b-9ea8-4770e3083d58"
      unitRef="U_shares">40000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="INF"
      id="F_53085ee7-8caa-413b-a425-7245ec48a5c0"
      unitRef="U_shares">40000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="INF"
      id="F_932cd3f0-e5ab-4125-b7b6-8cfaab839074"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="INF"
      id="F_7d9d4ad3-e278-4875-98e0-8d73c60cdf8b"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="INF"
      id="F_90d3134e-890e-468f-9ea4-df597f9a034b"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="INF"
      id="F_1aa69dbd-4e65-4611-bf3f-e29bc46061f2"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="INF"
      id="F_4f472962-b234-454d-9720-9ef93919dddd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="INF"
      id="F_0ffed6f2-8646-4ac6-acfd-b935d8c6c1f2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="INF"
      id="F_05bf5913-f9f8-46fb-a68f-28152cd8adbb"
      unitRef="U_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="INF"
      id="F_d30ea15f-bc4b-4074-abf2-9d9b375ee142"
      unitRef="U_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="INF"
      id="F_fb0f3e13-50cf-43c8-af76-5922d6da67ae"
      unitRef="U_shares">31656035</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="INF"
      id="F_59e0c2ba-3b49-4aba-907f-ef133b83ecc1"
      unitRef="U_shares">31262769</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="INF"
      id="F_e755a519-2942-4f68-bc1e-4e5c207eb064"
      unitRef="U_shares">30511226</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="INF"
      id="F_7d3bed6e-bb12-4982-97fa-6d38bb196aca"
      unitRef="U_shares">28516010</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_8079d807-e1f8-40f7-b9df-c71ebd031bb8"
      unitRef="U_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_8c732dd5-4f49-49f3-bd72-817d175e3516"
      unitRef="U_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_0a9f4a29-9cd6-41ed-8109-c7eec985a7ce"
      unitRef="U_USD">601523000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_301a2993-b651-4cd8-8825-58714b26e862"
      unitRef="U_USD">579755000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_73f38701-0726-4965-a9d4-775027dc5fbb"
      unitRef="U_USD">-529370000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_0d2edc42-b857-433e-9447-634f2283d7a9"
      unitRef="U_USD">-385487000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_fc542c41-4bac-4862-9de8-ea799aa7ebf6"
      unitRef="U_USD">72156000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_70ca3f8f-929b-4ba6-8d5f-10b2f055fbd0"
      unitRef="U_USD">194271000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_f1b31023-1212-46e9-9e9f-892d0e12e652"
      unitRef="U_USD">189431000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_3f7c653e-9b6a-472e-9e5d-58e9ebb20ebf"
      unitRef="U_USD">295111000</us-gaap:LiabilitiesAndStockholdersEquity>
    <phat:ResearchAndDevelopmentExpenseRelatedParty
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_9ed1e977-0b62-4112-9a26-a4a81e28c2c0"
      unitRef="U_USD">4933000</phat:ResearchAndDevelopmentExpenseRelatedParty>
    <phat:ResearchAndDevelopmentExpenseRelatedParty
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_37f5e0ec-f63b-4abe-8c6b-88268bacbc6b"
      unitRef="U_USD">2812000</phat:ResearchAndDevelopmentExpenseRelatedParty>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_59e92989-1d0d-473a-a298-b85a4a1681ec"
      unitRef="U_USD">72338000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_52c1e6aa-e93d-4a6c-af68-23527951ebe4"
      unitRef="U_USD">98148000</us-gaap:ResearchAndDevelopmentExpense>
    <phat:GeneralAndAdministrativeExpenseRelatedParty
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_da02b8fc-7e3e-443d-92b9-ebeee6b22487"
      unitRef="U_USD">18000</phat:GeneralAndAdministrativeExpenseRelatedParty>
    <phat:GeneralAndAdministrativeExpenseRelatedParty
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_913afa0d-71ad-4c64-8ca1-16e163c27989"
      unitRef="U_USD">157000</phat:GeneralAndAdministrativeExpenseRelatedParty>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_6630c8d7-7f43-463b-a8cc-8d9f82fd9faa"
      unitRef="U_USD">62742000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_740bf95e-3799-4d57-a6c3-89709cf9f375"
      unitRef="U_USD">27517000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_5ed628b0-b01c-4b6c-bdbd-eacb10786968"
      unitRef="U_USD">135080000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_d66c66ad-e75f-4126-bdd7-5d2065082f17"
      unitRef="U_USD">125665000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_e685429d-5483-4663-9f25-948bfdec0e10"
      unitRef="U_USD">-135080000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_bb15942b-8053-4c2d-8b24-186d7541ad26"
      unitRef="U_USD">-125665000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_11711ef8-081f-40ed-ac3a-117b323e8e0d"
      unitRef="U_USD">41000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_ac023eaa-56cf-45a6-8c79-82229c6a8b8a"
      unitRef="U_USD">1091000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_e3257590-58b0-48aa-9abe-fb3cd6672b96"
      unitRef="U_USD">6788000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_77a7585c-0d33-4b9e-87fc-16a09d8a0c09"
      unitRef="U_USD">4581000</us-gaap:InterestExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_10442ba0-9dc4-4157-a992-5d31d15bc466"
      unitRef="U_USD">-95000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_9f03e569-d9d3-4c4e-9311-37ad5f75c41f"
      unitRef="U_USD">-2056000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_e6b49b03-da3b-4663-ab88-008eb078e3b4"
      unitRef="U_USD">-8000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_2b57158e-9411-4a58-b526-c8c3c332e16f"
      unitRef="U_USD">-8803000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_33568c88-8c14-4fc5-8db2-82ff95339462"
      unitRef="U_USD">-3403000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_7b381d13-6d41-4154-9d9b-fe45c682bc8a"
      unitRef="U_USD">-143883000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_d955e81f-e4e9-4818-97f4-c591aac79438"
      unitRef="U_USD">-129068000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="2"
      id="F_d31bf7c8-9784-4745-be5e-73ef0611efd7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.89</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="2"
      id="F_1ebd0bfd-f03e-47a6-b712-792d1c9ec30a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.88</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="0"
      id="F_88824815-d82d-4487-a3f4-4e1dc2667817"
      unitRef="U_shares">37002959</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="0"
      id="F_dda75dbe-c877-4014-8398-a2b1f1ed68ec"
      unitRef="U_shares">33228158</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_589be08d-1fdd-4132-b344-d516fb3dae6d"
      decimals="INF"
      id="F_89088d4f-4ede-4b8b-aa38-8144965fbbbe"
      unitRef="U_shares">24728258</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_589be08d-1fdd-4132-b344-d516fb3dae6d"
      decimals="-3"
      id="F_6c0a7348-9fbf-41d7-a7b9-10d1ad09f244"
      unitRef="U_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9c7240c2-23a4-4f2e-bdf7-8d45f209d98b"
      decimals="-3"
      id="F_60fc1f61-51ac-48ca-b09c-102c5afa9512"
      unitRef="U_USD">484372000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_36815495-d09a-4025-bf79-5a42d4c3e739"
      decimals="-3"
      id="F_8fe885bd-48e8-4dc2-b189-9e83a07e1c06"
      unitRef="U_USD">-256419000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_33fee96d-a213-48c4-a5ad-68ccefad3cff"
      decimals="-3"
      id="F_5a936db6-f439-42d2-8a4f-71b3cbcca0b5"
      unitRef="U_USD">227955000</us-gaap:StockholdersEquity>
    <phat:AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity
      contextRef="C_a36db690-2560-474a-8fbd-8050d47eb62c"
      decimals="-3"
      id="F_7120c2cc-63df-43df-b4ab-56258011428a"
      unitRef="U_USD">318000</phat:AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity>
    <phat:AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_df43fd68-87ce-4ba4-8bde-33df096f543a"
      unitRef="U_USD">318000</phat:AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_fed6006f-4109-4946-b552-76ae913aeaf0"
      decimals="INF"
      id="F_408d99ab-3877-4dd4-89d4-5470c815bba0"
      unitRef="U_shares">2250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20fed5f8-cd13-4903-b6b5-b54dbe1e910a"
      decimals="-3"
      id="F_1bfb6777-4092-4884-b3a7-7e6cbb842adf"
      unitRef="U_USD">88596000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_33b1043e-bfc6-4fce-ba82-e6e6e0ac95af"
      decimals="-3"
      id="F_56a476fe-50ac-4fef-b3a7-12e582de7b66"
      unitRef="U_USD">88596000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_d3d57991-14bf-4f93-a017-aa16c506b8db"
      decimals="INF"
      id="F_c9d8d5ce-093a-4bad-b306-0801b5272439"
      unitRef="U_shares">48263</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a36db690-2560-474a-8fbd-8050d47eb62c"
      decimals="-3"
      id="F_291e5a72-00f7-431e-b0aa-547444e47b6a"
      unitRef="U_USD">629000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_370601ff-3e69-4143-b653-ebdb59ca31e8"
      unitRef="U_USD">629000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_d3d57991-14bf-4f93-a017-aa16c506b8db"
      decimals="INF"
      id="F_aa429977-acaa-4fc1-b5fc-80ea8d752cdb"
      unitRef="U_shares">1489489</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_d3d57991-14bf-4f93-a017-aa16c506b8db"
      decimals="-3"
      id="F_49753d08-e315-4126-a260-afae1856ca09"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_7196b3f7-23c5-4907-b276-65ac985ac1c1"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a36db690-2560-474a-8fbd-8050d47eb62c"
      decimals="-3"
      id="F_aa06e684-b219-4311-8540-9948f4b41cc0"
      unitRef="U_USD">5840000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_bc3b6ece-8089-4976-a8b4-b71be42d08de"
      unitRef="U_USD">5840000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_2abff921-c9a8-4de4-b41c-9e7893e5704b"
      decimals="-3"
      id="F_7b7dd119-0bef-4ccb-9abe-bb5aaef6db4b"
      unitRef="U_USD">-129068000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_68a89350-086c-4f69-a873-cf4f427fd445"
      unitRef="U_USD">-129068000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_51814a33-b695-44e9-b59a-823a169dda09"
      decimals="INF"
      id="F_2ed4e003-5a8e-4ea3-b835-01c101fc5f23"
      unitRef="U_shares">28516010</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_51814a33-b695-44e9-b59a-823a169dda09"
      decimals="-3"
      id="F_fde38ec7-1888-4f2a-8261-2ef40368edd5"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d962d708-ce93-405d-a90d-73e1fae4aa3a"
      decimals="-3"
      id="F_0be64a79-dd6c-40e1-a5de-ae87fa8a04e6"
      unitRef="U_USD">579755000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_83965ad4-28b1-4afc-8889-5d7cdbc079ef"
      decimals="-3"
      id="F_253fbe3a-3f31-4540-84b7-afb30d74df96"
      unitRef="U_USD">-385487000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_959ceaa5-9ef0-47de-9728-5878341496a2"
      unitRef="U_USD">194271000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_ab2e6d6d-5682-41ff-9336-cabea4c3f7b9"
      decimals="INF"
      id="F_f31657e5-c2ac-4927-8d26-b4306fd10c12"
      unitRef="U_shares">107583</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_543d071e-badd-429f-8237-98bcd1e05d25"
      decimals="-3"
      id="F_d8576867-0a86-498f-b530-32554a529761"
      unitRef="U_USD">1944000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_c2483d05-91c1-4815-a852-4e430430f740"
      unitRef="U_USD">1944000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <phat:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="C_ab2e6d6d-5682-41ff-9336-cabea4c3f7b9"
      decimals="INF"
      id="F_91f1039a-db87-4517-bac8-7f40278cdc46"
      unitRef="U_shares">228696</phat:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled
      contextRef="C_ab2e6d6d-5682-41ff-9336-cabea4c3f7b9"
      decimals="INF"
      id="F_6be0e9b5-35db-46ea-9b8b-662661f66830"
      unitRef="U_shares">26750</phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_543d071e-badd-429f-8237-98bcd1e05d25"
      decimals="-3"
      id="F_ca316eaa-ba7a-41a2-ba2e-f5245362e9fe"
      unitRef="U_USD">903000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_86e6ccf7-bc08-43ec-8b80-c0b076a135a7"
      unitRef="U_USD">903000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_ab2e6d6d-5682-41ff-9336-cabea4c3f7b9"
      decimals="INF"
      id="F_2d526a97-a0c7-4973-b539-fa709dffb7e9"
      unitRef="U_shares">1601950</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_543d071e-badd-429f-8237-98bcd1e05d25"
      decimals="-3"
      id="F_79a1581c-d7e4-412e-a4c5-98ec34407c04"
      unitRef="U_USD">16812000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_146e675d-361a-4ed1-88d1-eb5ff5bfea31"
      unitRef="U_USD">16812000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_ab2e6d6d-5682-41ff-9336-cabea4c3f7b9"
      decimals="INF"
      id="F_2b9326fe-b386-4367-9569-c6ea63d6be8b"
      unitRef="U_shares">30237</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_543d071e-badd-429f-8237-98bcd1e05d25"
      decimals="-3"
      id="F_e1967ec6-43ad-46f4-9032-cef405fd9a33"
      unitRef="U_USD">819000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_380e3bf1-b6a0-4aee-bbe7-a6944b8fd610"
      unitRef="U_USD">819000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_543d071e-badd-429f-8237-98bcd1e05d25"
      decimals="-3"
      id="F_c8081a62-1b8f-4a0d-997a-ffa3520aaf9e"
      unitRef="U_USD">1290000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_7310d791-ec86-459a-bdcb-b9a5ed8118a0"
      unitRef="U_USD">1290000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="C_213e1528-74d7-4db2-a3ae-74c89a47e0e3"
      decimals="-3"
      id="F_52364b76-c2cf-4f37-bf16-53f34d2d2b05"
      unitRef="U_USD">-143883000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_7f001e88-675c-49d6-9669-2416b8d98535"
      unitRef="U_USD">-143883000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b03a9ab9-4538-4d34-b658-218482e16bbd"
      decimals="INF"
      id="F_8f8a0a14-6b58-4595-ba5a-0fd09779f954"
      unitRef="U_shares">30511226</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b03a9ab9-4538-4d34-b658-218482e16bbd"
      decimals="-3"
      id="F_9af885d4-67b1-4181-8e50-3e44ea836255"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ea9b39a8-a8b3-4e16-ad57-51beaa82a734"
      decimals="-3"
      id="F_aeab5f19-38bd-4b5c-b70e-26c77280afe8"
      unitRef="U_USD">601523000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a86629b2-8d48-4534-a0ad-f992b4110383"
      decimals="-3"
      id="F_84ec127e-15cf-45b5-ae73-6465e3a61612"
      unitRef="U_USD">-529370000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_4fb60493-0dc9-4dd7-a1fd-e5fb0e43a5bb"
      unitRef="U_USD">72156000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_09377b70-eba7-4035-bbce-24de746d9416"
      unitRef="U_USD">-143883000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_33139262-4f48-4f26-89a6-ef709afde1b3"
      unitRef="U_USD">-129068000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_f24a74cc-a678-4395-9ac0-07608691fb92"
      unitRef="U_USD">521000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_ae26b02e-9eab-405d-98b9-3fa37925eeba"
      unitRef="U_USD">323000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_97337918-c956-4fd5-ba4f-7ba2e1161d94"
      unitRef="U_USD">16812000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_48b91c48-c7d2-4683-ba60-3f9d255bb541"
      unitRef="U_USD">5840000</us-gaap:ShareBasedCompensation>
    <us-gaap:PaidInKindInterest
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_f695045e-1464-4876-af71-e0d9ae6467fb"
      unitRef="U_USD">990000</us-gaap:PaidInKindInterest>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_b7ad14d3-3919-4172-9f26-74fbe4e28154"
      unitRef="U_USD">3595000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_b980f76f-b43c-4baf-a07c-58b6fd89f269"
      unitRef="U_USD">1273000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_8fdadd4c-2533-4841-a0cf-1a2fcf13f638"
      unitRef="U_USD">-95000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_b6ff79c4-70a5-48ab-855f-8047a7247bb8"
      unitRef="U_USD">-823000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_ab674561-18ac-4b60-94bf-1cd214d1a0fe"
      unitRef="U_USD">-322000</us-gaap:OtherNoncashIncomeExpense>
    <phat:IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_498cc096-f304-4e2e-b4af-e9490a634db1"
      unitRef="U_USD">82000</phat:IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent>
    <phat:IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_e2317012-65c7-480b-9a2f-3b5fe26c9835"
      unitRef="U_USD">-82000</phat:IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_357b2050-3dfe-44b8-a6b8-89af88890899"
      unitRef="U_USD">-605000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_00e9f5a1-b455-480e-91f8-cc9519eb2cb3"
      unitRef="U_USD">-7963000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <phat:IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_25fb56bc-039f-4f06-924e-08d205d3cf20"
      unitRef="U_USD">2766000</phat:IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties>
    <phat:IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_0086b722-d5a9-44ce-ad73-f028cb1b4875"
      unitRef="U_USD">399000</phat:IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_6f4f1dff-007c-4419-9fc3-a66aed749e07"
      unitRef="U_USD">-9791000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_34939954-1b37-4075-b0b4-0f4efca13482"
      unitRef="U_USD">24009000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <phat:IncreaseDecreaseInClinicalAccruedTrialExpenses
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_13a3a803-c6c1-41d2-83ba-89050f9c9d62"
      unitRef="U_USD">-18595000</phat:IncreaseDecreaseInClinicalAccruedTrialExpenses>
    <phat:IncreaseDecreaseInClinicalAccruedTrialExpenses
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_c54fe228-46a9-498a-b7c6-db1b0f11e959"
      unitRef="U_USD">19997000</phat:IncreaseDecreaseInClinicalAccruedTrialExpenses>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_56adc2e0-b0c9-4db8-beea-6657b57747c0"
      unitRef="U_USD">165000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_d11282d7-87d4-40ee-ac3d-64d5dd5599fe"
      unitRef="U_USD">156000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <phat:IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_9e878a00-911f-4886-8677-3a25005943c4"
      unitRef="U_USD">98000</phat:IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities>
    <phat:IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_1e3eb366-e418-447a-8fd9-c09dd9ad270c"
      unitRef="U_USD">-205000</phat:IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_839feedc-9da3-4125-abe8-48da1eeb8732"
      unitRef="U_USD">-43000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_00bebdb9-b895-4407-89a5-8cbdecf1d2ff"
      unitRef="U_USD">203000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_157fbfec-e256-4298-9d09-d62c494983f7"
      unitRef="U_USD">-148617000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_d3348513-11ce-4702-aeea-63f7e53610f3"
      unitRef="U_USD">-69688000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_102301a8-321b-4aeb-8693-b3cdf50c8b9d"
      unitRef="U_USD">328000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_f2366f72-afd9-4188-b620-c092ec2ff899"
      unitRef="U_USD">1040000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_a8bd2486-f471-4913-80aa-352374be6cdd"
      unitRef="U_USD">-328000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_b94a96a2-b1ce-4b9f-82ca-0cac32bfe72c"
      unitRef="U_USD">-1040000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <phat:ProceedsFromUnderwrittenPublicOfferingNet
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_77b4a873-3e1b-4d44-ba1a-9e49d6e110bf"
      unitRef="U_USD">88830000</phat:ProceedsFromUnderwrittenPublicOfferingNet>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_969bc409-2a65-4785-b155-118eea2f0880"
      unitRef="U_USD">1944000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_ca581ebc-6f77-4955-b588-9a1f7e43bbd0"
      unitRef="U_USD">629000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_726be74c-edd9-4c47-ba3e-2f6338ba7f6c"
      unitRef="U_USD">54125000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_f890e747-da59-45ee-9e12-9901151e134f"
      unitRef="U_USD">96889000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_738d3f30-d341-4c16-9fb8-d8e00e83a62e"
      unitRef="U_USD">25000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_c8c1a78b-6a39-4ce0-9f36-32001930a0e8"
      unitRef="U_USD">44708000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_cf486c33-effd-48b4-8e6e-a29982a5e924"
      unitRef="U_USD">114459000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_cc732be3-a5bd-4a9c-a019-dd144fc56aa3"
      unitRef="U_USD">-104237000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_6cffd943-436d-4d8e-b60b-c1cb19123776"
      unitRef="U_USD">43731000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_f6ff486f-d22b-4340-87ca-9df20a3f02a6"
      unitRef="U_USD">287496000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_33fee96d-a213-48c4-a5ad-68ccefad3cff"
      decimals="-3"
      id="F_980449c9-a577-46b2-9625-4e7e08f546fe"
      unitRef="U_USD">243765000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_d27d3727-1c38-4388-8edd-2849ef6b1201"
      unitRef="U_USD">183259000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_4f69b754-0f4f-404e-ba46-66ecb1fd6b2b"
      unitRef="U_USD">287496000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_84b121ec-4fce-4c21-b4cf-efa28004af50"
      unitRef="U_USD">4069000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_a0d33e39-cac7-46a2-be20-2dd708ed67b5"
      unitRef="U_USD">3464000</us-gaap:InterestPaidNet>
    <phat:NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_57ba30fe-d89c-423f-9561-60e06df5bf0b"
      unitRef="U_USD">1290000</phat:NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_d0afb01e-56c6-4463-b1a1-772b82224881"
      unitRef="U_USD">2000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_59d0f476-0ed8-4511-b2af-c1ad53fa9a79"
      unitRef="U_USD">145000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <phat:NonCashFinalInterestPaymentFee
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_1b534a9a-81c3-477a-af2f-1d40d5c5b2f2"
      unitRef="U_USD">7500000</phat:NonCashFinalInterestPaymentFee>
    <phat:NonCashFinalInterestPaymentFee
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_a238f113-cbff-4261-b8cf-42f8d59f0fc8"
      unitRef="U_USD">2063000</phat:NonCashFinalInterestPaymentFee>
    <phat:NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_84ffa6aa-bd7e-4b0f-9b6b-f937e933878a"
      unitRef="U_USD">819000</phat:NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock>
    <phat:NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_c89be702-760e-47d1-bbe6-dcd2c39d6024"
      unitRef="U_USD">903000</phat:NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock>
    <phat:OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_5be31f43-6746-461c-8ae3-e0723abf5a00"
      unitRef="U_USD">1396000</phat:OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets>
    <phat:ConversionOfWarrantLiabilitiesIntoEquity
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_02178633-64f6-4d6b-81c9-fcf632db0db0"
      unitRef="U_USD">318000</phat:ConversionOfWarrantLiabilitiesIntoEquity>
    <phat:UnpaidUnderwrittenPublicOfferingCosts
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_3e93a815-09bb-47a0-a4cc-f3b3d83e7718"
      unitRef="U_USD">234000</phat:UnpaidUnderwrittenPublicOfferingCosts>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_b79b968e-ef07-4057-91c0-30c88afdae26">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;1. Organization, Basis of Presentation and Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Organization and Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Phathom Pharmaceuticals, Inc., or the Company or Phathom, was incorporated in the state of Delaware in January 2018. The Company is a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. The Company&#x2019;s financial statements are prepared in accordance with U.S. generally accepted accounting principles, or GAAP.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;From inception to December 31, 2021, the Company has devoted substantially all of its efforts to organizing and staffing the Company, business planning, raising capital, in-licensing its initial product candidate, vonoprazan, meeting with regulatory authorities, managing the Phase 3 clinical trials of vonoprazan, and providing other general and administrative support for these operations. The Company has a limited operating history, has never generated any revenue, and the sales and income potential of its business is unproven. The Company has incurred net losses and negative cash flows from operating activities since its inception and expects to continue to incur net losses into the foreseeable future as it continues the development and preparation for commercialization of vonoprazan. From inception to December 31, 2021, the Company has funded its operations through the issuance of convertible promissory notes, commercial bank debt, the sale of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,997,630&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock for net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;191.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in its 2019 IPO &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and the&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; sale of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,250,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock for net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;88.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in its December 2020 follow-on public offering.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities. Management is required to perform a two-step analysis over the Company&#x2019;s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (Step 2).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, if needed, that the Company&#x2019;s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of the Company&#x2019;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s financial statements relate to accruals for research and development expenses, and the valuation of warrant liabilities and various other equity instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1: Observable inputs such as quoted prices in active markets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The carrying amounts of the Company&#x2019;s financial instruments, including cash and cash equivalents, are classified within the Level 1 designation discussed above, while prepaid and other current assets, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. Warrant liabilities are recorded at fair value on a recurring basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; financial assets measured at fair value on a recurring basis. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ne of the Company&#x2019;s non-financial assets or liabilities are recorded at fair value on a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;n-recurring basis. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; transfers between levels have occurred during the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The warrant liabilities consist of warrants, or the Lender Warrants, issued in connection with a loan and security agreement, or the SVB Loan Agreement, for commercial bank debt (see Note 6). The Lender Warrants were accounted for as liabilities as they contained a holder put right under which the lenders could have required the Company to pay cash in exchange for the Lender Warrants. The fair value of the Lender Warrants was estimated on the date of grant using the Black-Scholes option-pricing model with an expected term equal to the remaining contractual term of the warrants. The Company estimates its expected stock volatility based on the historical volatility of a set of peer companies, which are publicly traded, and expects to continue to do so until it has adequate historical data regarding the volatility of its own publicly-traded stock price. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company uses an expected dividend yield of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; based on the fact that the Company has never paid cash dividends and does not expect to pay cash dividends in the foreseeable future. When the Company drew down the Term Loan B under the SVB Loan Agreement in March 2020 (see Note 6), the Lenders&#x2019; put right expired, and the Company recorded a final fair value adjustment and reclassified the Lender Warrants balance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to additional paid-in-capital.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:71.98%;"/&gt;
          &lt;td style="width:1.317%;"/&gt;
          &lt;td style="width:2.312%;"/&gt;
          &lt;td style="width:22.845%;"/&gt;
          &lt;td style="width:1.546%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Warrant&lt;br/&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reclassification of Lender Warrants into equity (Note 6)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market funds.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property, Plant, and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property, plant and equipment are recorded at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the asset. Computer equipment and related software are depreciated over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_b94a21cd-dcaa-4585-bab0-9b02263f175c;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Furniture and fixtures are depreciated over&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Leasehold improvements are amortized over the lesser of the lease term or the estimated useful lives of the related assets. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company reviews long-lived assets, including property, plant and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; impairment losses have been recorded through December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding right-of-use asset upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company additionally evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease. A lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows is substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if the underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term. Leases that do not meet the finance lease criteria are accounted for as an operating lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. As the Company&#x2019;s leases do not typically provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate between lease and non-lease components.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Expenses and Accruals&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, employee benefits, stock-based compensation charges for those individuals involved in research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company&#x2019;s ongoing clinical trials of vonoprazan, and costs related to manufacturing vonoprazan for clinical trials.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has entered into various research and development contracts with clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of or after performance are reflected in the accompanying balance sheets as prepaid expenses or accrued liabilities, respectively. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;In-Process Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use are considered acquired in-process research and development. When the acquired in-process research and development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. General and administrative expenses are associated with the activities of the executive, finance, accounting, information technology, legal, medical affairs and human resource functions.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of the awards (generally the vesting period) on a straight-line basis with forfeitures recognized as they occur.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company also maintains an employee stock purchase program, or ESPP, under which it may issue shares. The Company estimates the fair value of stock options and shares that will be issued under the ESPP using the Black-Scholes valuation model, which requires the use of estimates. The Company recognizes stock-based compensation cost for shares that it will issue under the ESPP on a straight-line basis over the requisite service period of the award.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statement of operations in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#x2019;s comprehensive loss was the same as its reported net loss for all periods presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; operating segment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company included &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,588,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock under its warrant, or the Takeda Warrant, issued to Takeda Pharmaceutical Company Limited, or Takeda, in connection with a May 2019 license agreement (see Note 4) in the calculation of basic weighted-average common shares outstanding from the time it became exercisable at the Company&#x2019;s IPO because the Takeda Warrant is exercisable for little consideration. During the year ended December 31, 2021, Takeda Warrants were exercised to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;228,696&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock. As of December 31, 2021, Takeda Warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,359,304&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock remains exercisable. For the years ended December 31, 2021 and 2020, the Company has excluded weighted-average unvested shares of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,939,252&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,424,676&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively, from the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested common stock, options and warrants. For the periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities (warrants, stock options, and common shares subject to repurchase) would be antidilutive.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; December 2019, the Financial Accounting Standards Board, or FASB, issued &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accounting Standards Update, or &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ASU, No. 2019-12, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, or &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ASU 2019-12, which simplifies the accounting for income taxes. ASU 2019-12 is effective for annual reporting periods, and interim periods within those annual periods, beginning after December 15, 2020 on a prospective basis, and early adoption is permitted. The Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; this guidance effective &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, and the adoption did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;not&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; have a material impact on the Company's financial statements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;   &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board or other standard setting bodies on the Company's financial statements as well as material updates to previous assessments. There were no new material accounting standards issued or adopted in year of 2021 that impacted the Company.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <phat:OrganizationAndBasisOfPresentationPolicyTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_ba48c8c2-b14c-4b24-adfa-6179befec480">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Organization and Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Phathom Pharmaceuticals, Inc., or the Company or Phathom, was incorporated in the state of Delaware in January 2018. The Company is a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. The Company&#x2019;s financial statements are prepared in accordance with U.S. generally accepted accounting principles, or GAAP.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</phat:OrganizationAndBasisOfPresentationPolicyTextBlock>
    <phat:LiquidityAndCapitalResourcesPolicyTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_7d590c67-8efd-4ba0-9ef1-b22f7019031b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;From inception to December 31, 2021, the Company has devoted substantially all of its efforts to organizing and staffing the Company, business planning, raising capital, in-licensing its initial product candidate, vonoprazan, meeting with regulatory authorities, managing the Phase 3 clinical trials of vonoprazan, and providing other general and administrative support for these operations. The Company has a limited operating history, has never generated any revenue, and the sales and income potential of its business is unproven. The Company has incurred net losses and negative cash flows from operating activities since its inception and expects to continue to incur net losses into the foreseeable future as it continues the development and preparation for commercialization of vonoprazan. From inception to December 31, 2021, the Company has funded its operations through the issuance of convertible promissory notes, commercial bank debt, the sale of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,997,630&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock for net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;191.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in its 2019 IPO &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and the&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; sale of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,250,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock for net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;88.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in its December 2020 follow-on public offering.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities. Management is required to perform a two-step analysis over the Company&#x2019;s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (Step 2).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, if needed, that the Company&#x2019;s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</phat:LiquidityAndCapitalResourcesPolicyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_74f9d273-2810-4b05-a50b-39f4e9e89f17"
      decimals="INF"
      id="F_7bd8659c-b2cb-422f-86f3-2e45beefdfd0"
      unitRef="U_shares">10997630</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_74f9d273-2810-4b05-a50b-39f4e9e89f17"
      decimals="-5"
      id="F_25dd0f6d-215a-4dd6-9175-53a2b99d5d75"
      unitRef="U_USD">191500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_feab6596-3893-42c2-a2c0-1464c2b5d8ed"
      decimals="INF"
      id="F_c7a42cac-af5c-49df-8196-0fcec59bd2eb"
      unitRef="U_shares">2250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_feab6596-3893-42c2-a2c0-1464c2b5d8ed"
      decimals="-5"
      id="F_59433f1e-df2d-4f28-9553-29511fa35d51"
      unitRef="U_USD">88600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:UseOfEstimates
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_441ffb8d-7538-4b66-9acf-9579bf63c50c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of the Company&#x2019;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s financial statements relate to accruals for research and development expenses, and the valuation of warrant liabilities and various other equity instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_393bc553-14ed-4cd7-bc7b-11e09a92e4f5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1: Observable inputs such as quoted prices in active markets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The carrying amounts of the Company&#x2019;s financial instruments, including cash and cash equivalents, are classified within the Level 1 designation discussed above, while prepaid and other current assets, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. Warrant liabilities are recorded at fair value on a recurring basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; financial assets measured at fair value on a recurring basis. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ne of the Company&#x2019;s non-financial assets or liabilities are recorded at fair value on a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;n-recurring basis. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; transfers between levels have occurred during the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The warrant liabilities consist of warrants, or the Lender Warrants, issued in connection with a loan and security agreement, or the SVB Loan Agreement, for commercial bank debt (see Note 6). The Lender Warrants were accounted for as liabilities as they contained a holder put right under which the lenders could have required the Company to pay cash in exchange for the Lender Warrants. The fair value of the Lender Warrants was estimated on the date of grant using the Black-Scholes option-pricing model with an expected term equal to the remaining contractual term of the warrants. The Company estimates its expected stock volatility based on the historical volatility of a set of peer companies, which are publicly traded, and expects to continue to do so until it has adequate historical data regarding the volatility of its own publicly-traded stock price. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company uses an expected dividend yield of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; based on the fact that the Company has never paid cash dividends and does not expect to pay cash dividends in the foreseeable future. When the Company drew down the Term Loan B under the SVB Loan Agreement in March 2020 (see Note 6), the Lenders&#x2019; put right expired, and the Company recorded a final fair value adjustment and reclassified the Lender Warrants balance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to additional paid-in-capital.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:71.98%;"/&gt;
          &lt;td style="width:1.317%;"/&gt;
          &lt;td style="width:2.312%;"/&gt;
          &lt;td style="width:22.845%;"/&gt;
          &lt;td style="width:1.546%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Warrant&lt;br/&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reclassification of Lender Warrants into equity (Note 6)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <phat:FinancialAssetsFairValueDisclosure
      contextRef="C_a4d53c9a-cf55-407d-9ed4-40937c45f516"
      decimals="INF"
      id="F_aa0447f2-d93a-4293-85f0-e8e91b591c4f"
      unitRef="U_USD">0</phat:FinancialAssetsFairValueDisclosure>
    <phat:NonfinancialAssetsFairValueDisclosure
      contextRef="C_861c796b-ff5c-4f2f-83b8-902fd93be0af"
      decimals="INF"
      id="F_b8e22aad-c850-47df-a487-5ae63f6d9ce2"
      unitRef="U_USD">0</phat:NonfinancialAssetsFairValueDisclosure>
    <us-gaap:NonfinancialLiabilitiesFairValueDisclosure
      contextRef="C_861c796b-ff5c-4f2f-83b8-902fd93be0af"
      decimals="INF"
      id="F_709d8f76-9d64-4d18-baee-2d44c673474b"
      unitRef="U_USD">0</us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="INF"
      id="F_8b30a6c4-0041-4065-b5a1-d62b5cd973e1"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="INF"
      id="F_55ef2dfb-b351-4616-85bc-65d48f4b4904"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="INF"
      id="F_2cf12213-1595-4e71-840a-31f24b3b75fd"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="INF"
      id="F_98610710-2009-426d-8b3c-8b4ffb6bc2fa"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="INF"
      id="F_8f60be3f-5f2c-4567-97f3-cc1e7a7652bc"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="INF"
      id="F_06f1e957-6ef6-42ff-b9ef-ebb50bd2bef8"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="INF"
      id="F_4aa3f833-63b2-41f9-93e1-bb18084bb938"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="INF"
      id="F_85f73a4d-ee1f-43b1-a6b4-107d4853979f"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <phat:ExpectedCashDividendYieldRate
      contextRef="C_d66f011d-89be-4560-91d7-2a57c1175688"
      decimals="2"
      id="F_af961479-7f71-41a6-b152-3100756b0341"
      unitRef="U_pure">0</phat:ExpectedCashDividendYieldRate>
    <phat:AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity
      contextRef="C_d695a09e-552b-4926-9fd0-d64fd565f066"
      decimals="-5"
      id="F_6db117df-c6d1-4dfa-bada-5916c746b11e"
      unitRef="U_USD">300000</phat:AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_2daf474b-9d9b-4383-98c0-91219e6a472a">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:71.98%;"/&gt;
          &lt;td style="width:1.317%;"/&gt;
          &lt;td style="width:2.312%;"/&gt;
          &lt;td style="width:22.845%;"/&gt;
          &lt;td style="width:1.546%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Warrant&lt;br/&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reclassification of Lender Warrants into equity (Note 6)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_a6e0c0e2-0899-4673-aff4-66d468643b51"
      decimals="-3"
      id="F_b1b892a6-3416-43d9-9003-0a1ed69aa888"
      unitRef="U_USD">413000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="C_1df5bc5b-1abb-43f6-aae5-4d3a06d655e3"
      decimals="-3"
      id="F_5ebd9731-4f33-4e25-b869-5df4f4ea9e78"
      unitRef="U_USD">-95000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <phat:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity
      contextRef="C_1df5bc5b-1abb-43f6-aae5-4d3a06d655e3"
      decimals="-3"
      id="F_1e3dc947-5ae7-417d-a9f4-1dd0b717e98f"
      unitRef="U_USD">318000</phat:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_3ab5df59-5292-425a-9467-c994d3212edd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market funds.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_866aa025-4af4-4326-bfef-da05e8c5456c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_c4eef580-f331-42f4-9240-ac0014d2feec">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property, Plant, and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property, plant and equipment are recorded at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the asset. Computer equipment and related software are depreciated over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_b94a21cd-dcaa-4585-bab0-9b02263f175c;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Furniture and fixtures are depreciated over&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Leasehold improvements are amortized over the lesser of the lease term or the estimated useful lives of the related assets. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_dd423291-341d-427f-ad43-b78d594b43a8"
      id="F_2754ef49-e260-44f7-8d55-1c778dbcbb52">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_d15d3cd0-b504-48e2-8d5b-b29bec97767e"
      id="F_5b418953-1081-4ca2-bc0f-468f47739f3a">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_34049330-7930-4845-bbd4-63b566e16d43">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company reviews long-lived assets, including property, plant and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; impairment losses have been recorded through December 31, 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="INF"
      id="F_ec773da6-aa2e-4d87-9542-3b05322244c3"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:LessorLeasesPolicyTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_cb3525da-d135-4797-97d1-118420e1bc0e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding right-of-use asset upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company additionally evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease. A lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows is substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if the underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term. Leases that do not meet the finance lease criteria are accounted for as an operating lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. As the Company&#x2019;s leases do not typically provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate between lease and non-lease components.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:LessorLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_56d753e1-8bdb-4f36-ba86-7cd6f9586c93">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Expenses and Accruals&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, employee benefits, stock-based compensation charges for those individuals involved in research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company&#x2019;s ongoing clinical trials of vonoprazan, and costs related to manufacturing vonoprazan for clinical trials.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has entered into various research and development contracts with clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of or after performance are reflected in the accompanying balance sheets as prepaid expenses or accrued liabilities, respectively. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_3ec406a2-4ec0-4925-b5af-887e09b8a208">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;In-Process Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use are considered acquired in-process research and development. When the acquired in-process research and development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_6d29e724-98d8-41ab-8718-76048eeb79fd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. General and administrative expenses are associated with the activities of the executive, finance, accounting, information technology, legal, medical affairs and human resource functions.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_7e80bd69-32a4-4a6e-853e-5fb486c66734">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of the awards (generally the vesting period) on a straight-line basis with forfeitures recognized as they occur.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company also maintains an employee stock purchase program, or ESPP, under which it may issue shares. The Company estimates the fair value of stock options and shares that will be issued under the ESPP using the Black-Scholes valuation model, which requires the use of estimates. The Company recognizes stock-based compensation cost for shares that it will issue under the ESPP on a straight-line basis over the requisite service period of the award.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_8dc81e5c-829d-481b-9d8c-c88eb06a0c37">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statement of operations in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_2a1b97e7-808c-4c7c-a481-3658dd97f6aa">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#x2019;s comprehensive loss was the same as its reported net loss for all periods presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_a1419fc2-0eb0-467e-be47-64fe437f9ff5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; operating segment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="INF"
      id="F_cb9d0ef7-4792-44a6-800c-46ee904a9ff3"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_b22a162a-abd7-4fa5-bad3-b2da4b153ec2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company included &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,588,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock under its warrant, or the Takeda Warrant, issued to Takeda Pharmaceutical Company Limited, or Takeda, in connection with a May 2019 license agreement (see Note 4) in the calculation of basic weighted-average common shares outstanding from the time it became exercisable at the Company&#x2019;s IPO because the Takeda Warrant is exercisable for little consideration. During the year ended December 31, 2021, Takeda Warrants were exercised to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;228,696&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock. As of December 31, 2021, Takeda Warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,359,304&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock remains exercisable. For the years ended December 31, 2021 and 2020, the Company has excluded weighted-average unvested shares of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,939,252&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,424,676&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively, from the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested common stock, options and warrants. For the periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities (warrants, stock options, and common shares subject to repurchase) would be antidilutive.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <phat:IncrementalCommonSharesAttributableToExerciseOfWarrants
      contextRef="C_35306304-4c25-4c5b-a433-e5367fe22b87"
      decimals="INF"
      id="F_71e69eb7-a878-47f1-b3fd-dbe4d9001001"
      unitRef="U_shares">7588000</phat:IncrementalCommonSharesAttributableToExerciseOfWarrants>
    <phat:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="C_e42fcdbf-c245-40d9-a08b-a3024663efad"
      decimals="INF"
      id="F_5d895e28-1e7c-4f5c-842b-1d4b76b3134b"
      unitRef="U_shares">228696</phat:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <phat:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable
      contextRef="C_a3536774-184c-4c9f-b6b0-4b72ebbf9525"
      decimals="INF"
      id="F_77e93e46-2816-46ed-bc06-76488d531a35"
      unitRef="U_shares">7359304</phat:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f32b69df-40b4-4e56-8da4-28475877b8ca"
      decimals="0"
      id="F_100a6906-71b5-49cd-9e88-1590c06e504b"
      unitRef="U_shares">1939252</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c6ab3ae6-86d0-4065-ba57-907b3b0f74c1"
      decimals="0"
      id="F_d2f271a2-5f62-40bf-99e4-55be95dc781b"
      unitRef="U_shares">3424676</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_0802efda-c992-4d7b-8377-2f7553efd092">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; December 2019, the Financial Accounting Standards Board, or FASB, issued &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accounting Standards Update, or &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ASU, No. 2019-12, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, or &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ASU 2019-12, which simplifies the accounting for income taxes. ASU 2019-12 is effective for annual reporting periods, and interim periods within those annual periods, beginning after December 15, 2020 on a prospective basis, and early adoption is permitted. The Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; this guidance effective &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, and the adoption did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;not&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; have a material impact on the Company's financial statements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;   &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board or other standard setting bodies on the Company's financial statements as well as material updates to previous assessments. There were no new material accounting standards issued or adopted in year of 2021 that impacted the Company.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_caf5d7c1-1bad-4042-90db-0f0fb308e394"
      id="F_0a87aa88-1c1a-418a-893c-86d7c926073d">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_caf5d7c1-1bad-4042-90db-0f0fb308e394"
      id="F_bb69fa65-56f1-4c98-a796-2e8339e58476">2021-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_caf5d7c1-1bad-4042-90db-0f0fb308e394"
      id="F_b44e589e-9cdd-462d-867f-71be959c15bb">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <phat:ComponentOfBalanceSheetDisclosureTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_c9541cf3-30f9-494e-bc88-aca833d71650">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2. Balance Sheet Details&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property, Plant and Equipment, net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property, plant and equipment, net, consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.824%;"/&gt;
        &lt;td style="width:1.21%;"/&gt;
        &lt;td style="width:2.297%;"/&gt;
        &lt;td style="width:20.043%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:1.21%;"/&gt;
        &lt;td style="width:2.297%;"/&gt;
        &lt;td style="width:20.058%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation and amortization expense for the years ended December 31, 2021 and 2020 was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; property, plant or equipment was disposed of during the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Accrued Expenses&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.426%;"/&gt;
        &lt;td style="width:1.347%;"/&gt;
        &lt;td style="width:2.296%;"/&gt;
        &lt;td style="width:20.695%;"/&gt;
        &lt;td style="width:0.934%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:2.296%;"/&gt;
        &lt;td style="width:20.71%;"/&gt;
        &lt;td style="width:0.934%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued compensation expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued professional &amp;amp; consulting&lt;br/&gt;&#160;&#160;&#160;expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</phat:ComponentOfBalanceSheetDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_7cccefaa-7edd-436a-916e-2483c1915d78">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property, plant and equipment, net, consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.824%;"/&gt;
        &lt;td style="width:1.21%;"/&gt;
        &lt;td style="width:2.297%;"/&gt;
        &lt;td style="width:20.043%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:1.21%;"/&gt;
        &lt;td style="width:2.297%;"/&gt;
        &lt;td style="width:20.058%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_60ed7ae5-368e-4841-b870-3c1b94b39311"
      decimals="-3"
      id="F_d1efc4ae-1760-44aa-bc90-213d8f8fc122"
      unitRef="U_USD">646000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_335b6a1d-cf50-4b89-b646-9f381f97d6d2"
      decimals="-3"
      id="F_968a3f50-269b-496c-b565-3f9b974443a2"
      unitRef="U_USD">516000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9b6da75c-d2db-4900-8fad-0f82733efc5d"
      decimals="-3"
      id="F_426c8185-1452-4baf-bb7f-58c756081af2"
      unitRef="U_USD">780000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2a16177c-bacc-4d09-9fc8-d0f5d55d3ee5"
      decimals="-3"
      id="F_99359439-b6bc-4243-a913-a2721c80450b"
      unitRef="U_USD">747000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_478c7409-ab7e-4c39-bda4-749e3ceaf9ef"
      decimals="-3"
      id="F_1f57e3cc-40bb-451b-9d4f-7f255c030593"
      unitRef="U_USD">76000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d09d3095-f7e4-4678-97ca-b059f5088ae2"
      decimals="-3"
      id="F_c7b90825-4727-4d66-a03a-2a3932d51e5a"
      unitRef="U_USD">54000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_c1f92011-1347-4192-bdda-7798e498b6dc"
      unitRef="U_USD">1502000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_ab6bb50d-9bff-4f20-a6a9-17404e02ab1a"
      unitRef="U_USD">1317000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_ae4ce954-921b-4bf9-a2c4-c939cf886637"
      unitRef="U_USD">852000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_6a4e8721-dcae-4487-a3b6-9e864a5a3803"
      unitRef="U_USD">331000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_ab4b7690-9210-45df-b731-21d7f0bb7084"
      unitRef="U_USD">650000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_704d680a-9790-4f8d-91c5-c661c990339f"
      unitRef="U_USD">986000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-5"
      id="F_35c316de-f061-4d6d-a0ea-613e1d26d95d"
      unitRef="U_USD">500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-5"
      id="F_db35575a-3e36-4d41-8f05-e29db501d782"
      unitRef="U_USD">300000</us-gaap:Depreciation>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="INF"
      id="F_028701d7-8fc6-44f2-9aee-d58b67294c93"
      unitRef="U_USD">0</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="INF"
      id="F_b87385e4-5f0e-4ede-8321-4fdacf3d8c51"
      unitRef="U_USD">0</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_12e471b4-004d-4278-a565-b9062316c185">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.426%;"/&gt;
        &lt;td style="width:1.347%;"/&gt;
        &lt;td style="width:2.296%;"/&gt;
        &lt;td style="width:20.695%;"/&gt;
        &lt;td style="width:0.934%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:2.296%;"/&gt;
        &lt;td style="width:20.71%;"/&gt;
        &lt;td style="width:0.934%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued compensation expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued professional &amp;amp; consulting&lt;br/&gt;&#160;&#160;&#160;expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <phat:AccruedResearchAndDevelopmentExpenses
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_f1eb20d8-3a9c-4f30-926d-e0a388cde3c3"
      unitRef="U_USD">3165000</phat:AccruedResearchAndDevelopmentExpenses>
    <phat:AccruedResearchAndDevelopmentExpenses
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_2d19bd35-c711-49aa-b15f-644e5adb7c08"
      unitRef="U_USD">4864000</phat:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_c4ef73b1-2f22-4112-a3a1-719f309cfcb3"
      unitRef="U_USD">6344000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_80081fca-0e44-454c-9841-f1b82411fdb5"
      unitRef="U_USD">4587000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_ec3bbba9-bea5-41ac-a167-961dd748f32a"
      unitRef="U_USD">1855000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_0293b851-b016-4484-98b0-f82d8debe461"
      unitRef="U_USD">1123000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_ceb56973-aa23-4166-8e33-2d74c729a10d"
      unitRef="U_USD">41000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_5c892cbd-d69a-4d77-a0f9-ce8856554378"
      unitRef="U_USD">32000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_677deddd-b3cb-41c7-bbf0-0709176d31f3"
      unitRef="U_USD">11405000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_0b401e20-1bf1-4201-9fd4-e6aad66e5451"
      unitRef="U_USD">10606000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_ff97b990-e209-4fe3-9111-197ce8ba5911">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;3. Related Party Transactions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Frazier is a principal stockholder of the Company. The Company has conducted operations within office space controlled by Frazier and Frazier allocated a portion of the costs associated with this office space to the Company. In addition, Frazier paid for various goods and services, such as employee wages, insurance and expense reimbursements and various administrative services associated with the operations of the Company and charged the Company for those expenses. As of December 31, 2021 and 2020, the Company had outstanding accounts payable and accrued expenses due to Frazier in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;respectively, related to these shared operating expenses. For the years ended December 31, 2021 and 2020, the Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, of shared operating expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Frazier is a principal stockholder in PCI Pharma Services, or PCI. In the third quarter of 2019, the Company engaged PCI for clinical manufacturing services. As of December 31, 2021 and 2020, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, in outstanding accounts payable and accrued expenses related to these manufacturing services. For the years ended December 31, 2021 and 2020, the Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, of expenses related to services performed by PCI.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Takeda became a common stockholder of the Company in connection with the May 2019 license agreement (see Note 4). In conjunction with this license, Takeda provides proprietary supplies for the Company&#x2019;s ongoing clinical development of vonoprazan in addition to the exclusive license for the commercialization of vonoprazan in the United States, Canada and Europe. As of December 31, 2021 and 2020, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively, in outstanding accounts payable and accrued expenses related to these supply services. The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t have any such supply services expenses incurred for the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On May 5, 2020, the Company entered into a Commercial Supply Agreement, or the Commercial Supply Agreement, with Takeda, pursuant to which Takeda will supply commercial quantities of vonoprazan bulk drug product or drug substance. Pursuant to the Commercial Supply Agreement, Takeda has agreed to supply the Company with, and the Company has agreed to purchase from Takeda, certain quantities of vonoprazan bulk drug product according to approved specifications at a fixed price per batch of bulk drug product in order to commercialize vonoprazan in accordance with the Takeda License. Unless terminated earlier, the term of the Commercial Supply Agreement extends for a period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; from the date the Company places an order for bulk drug product or drug substance for the first commercial launch of vonoprazan in any jurisdiction in the licensed territory, provided that this two-year period will expire no later than December 31, 2023. The Commercial Supply Agreement will terminate immediately upon the termination of the Takeda License in accordance with its terms. As of December 31, 2021 and 2020, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, in outstanding accounts payable and accrued expenses related to these product costs. For the years ended December 31, 2021 and 2020, the Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, of expenses related to the Commercial Supply Agreement. The Company has a remaining minimum purchase obligation of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million related to this agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the Takeda License, the Company entered into a temporary services agreement, or the Temporary Services Agreement, with Takeda on November 24, 2020. Pursuant to the Temporary Services Agreement, Takeda agreed to provide or procure the provision of services related to the ongoing clinical development of vonoprazan. The Temporary Services Agreement will terminate immediately upon termination of the Takeda License in accordance with its terms. As of December 31, 2021 and 2020, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, in outstanding accounts payable and accrued expenses related to these temporary services. For the year ended December 31, 2021 and 2020, the company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, of expenses related to the temporary services performed by Takeda.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
      contextRef="C_fc9746aa-75ec-4357-9a62-e52e0a26d077"
      decimals="0"
      id="F_40521bba-f268-4cf9-a540-75aa2a14ff29"
      unitRef="U_USD">0</phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent>
    <phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
      contextRef="C_098ad23e-df01-4a44-9fa6-756e054ae9d3"
      decimals="0"
      id="F_48d0227f-7d3c-4697-842b-82881a63fbf7"
      unitRef="U_USD">35000</phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent>
    <phat:RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty
      contextRef="C_ed462fec-d2dc-4e80-8a94-a6e09a3934b5"
      decimals="0"
      id="F_020a1438-16ac-43f6-8cf2-f4b293634121"
      unitRef="U_USD">18000</phat:RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty>
    <phat:RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty
      contextRef="C_b04891d2-7dba-42b2-a181-d9f6bb277f08"
      decimals="-5"
      id="F_4be1d67a-58ce-42dd-9311-af312613ad61"
      unitRef="U_USD">200000</phat:RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty>
    <phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
      contextRef="C_6951c26d-af1d-407b-bbcb-8b12126fe3f0"
      decimals="-5"
      id="F_6499e33a-5a52-4185-824d-5b85e9a6390d"
      unitRef="U_USD">1700000</phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent>
    <phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
      contextRef="C_c9fb0785-ea03-426b-a4b8-f5ea1415baaf"
      decimals="-5"
      id="F_e674f614-6fb0-40cf-a547-8c5eb4fa6a9e"
      unitRef="U_USD">400000</phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_0d2e408c-4d50-4188-92b1-018f98519206"
      decimals="-5"
      id="F_0484477f-efd8-4c18-812d-a53d9bad7e44"
      unitRef="U_USD">3200000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_10d2f460-e459-411f-8dad-34d4446eecc2"
      decimals="-5"
      id="F_f6fbd2b2-33cc-4b3c-bd5f-22fa5c02ec4b"
      unitRef="U_USD">2300000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
      contextRef="C_58425dd1-174b-4c7a-8d6a-81deea1aee09"
      decimals="0"
      id="F_c5ae6368-52c5-4d55-915e-d22da32c6726"
      unitRef="U_USD">22000</phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent>
    <phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
      contextRef="C_38af774f-d0ce-4768-8641-dd4bb3038da3"
      decimals="0"
      id="F_e663b30a-8f2e-49b3-aa2e-ccd1f5656fb0"
      unitRef="U_USD">22000</phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_61652f9e-ae05-40dc-b6b4-3b2b4d36b133"
      decimals="INF"
      id="F_faeec1f6-aaa9-42a5-994d-dde9c2cc0d79"
      unitRef="U_USD">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_26050370-2bfa-4995-a133-64b6e9cefdc1"
      decimals="INF"
      id="F_943227f7-5b70-4a50-b970-19f87f2eb2ea"
      unitRef="U_USD">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <phat:AgreementExtendsPeriodForTermination
      contextRef="C_6c52a9cb-ddf2-45f2-a3ab-4d943486cf78"
      id="F_ad9ad401-a58e-4072-84bd-7c421d3b5b95">P2Y</phat:AgreementExtendsPeriodForTermination>
    <phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
      contextRef="C_a0b3b017-48e9-4500-9fd4-aaf93a60d5dd"
      decimals="-5"
      id="F_6f9c8485-c141-4a06-862d-7b031999335c"
      unitRef="U_USD">700000</phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent>
    <phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
      contextRef="C_3cd1a70e-7077-4da4-a87c-da5e90015997"
      decimals="-5"
      id="F_be9ae79d-af43-42df-9c18-b2ac50892a1c"
      unitRef="U_USD">200000</phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_1ac41c78-ea4c-491d-bef4-399d1207de36"
      decimals="-5"
      id="F_f31a50c8-986a-42dd-a894-d5211da07026"
      unitRef="U_USD">1800000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_c161eef4-fe92-48d7-944f-6e1bd1c45f50"
      decimals="-5"
      id="F_33424f16-565c-4baf-82de-15c399fd9a10"
      unitRef="U_USD">300000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:PurchaseObligation
      contextRef="C_caf206af-24fe-4015-adc8-87b45d8a8636"
      decimals="-5"
      id="F_82e4bd2b-61e2-43f8-a85c-f3c84b30e986"
      unitRef="U_USD">400000</us-gaap:PurchaseObligation>
    <phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
      contextRef="C_413a633b-7a27-41ac-8e92-4d82e9b0c253"
      decimals="-5"
      id="F_285c08bf-8dba-4dca-9f56-130bcba76a8b"
      unitRef="U_USD">200000</phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent>
    <phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
      contextRef="C_d5335391-0999-47b9-a03b-8400c5c69127"
      decimals="-5"
      id="F_ca08ff18-41fa-4bea-a474-7817c762479f"
      unitRef="U_USD">200000</phat:AccountsPayableAndAccruedExpensesRelatedPartiesCurrent>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_ce1d61e6-3a91-4de4-b8d0-dfb4084514fe"
      decimals="0"
      id="F_875e2880-7edc-45e7-82f4-bf77152b35c9"
      unitRef="U_USD">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_f52603aa-c039-41a2-95ea-2a152bab42c6"
      decimals="-5"
      id="F_591ad0ba-dea4-4c23-b2b9-224252ee0eca"
      unitRef="U_USD">200000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_bc85d426-a15c-490c-9981-ffd42515a68d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;4. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;License Agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;O&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;n May 7, 2019, the Company entered into a license agreement with Takeda pursuant to which it was granted an exclusive license to commercialize vonoprazan fumarate in the United States, Canada and Europe, or, the Takeda License. The Company also has the right to sublicense its rights under the agreement, subject to certain conditions. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The agreement will remain in effect, on a country-by-country and product-by-product basis, until the later of (i) the expiration of the last to expire valid patent claim covering vonoprazan fumarate alone or in combination with at least one other therapeutically active ingredient, (ii) the expiration of the applicable regulatory exclusivity and (iii) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; from the date of first commercial sale, unless earlier terminated. The Company may terminate the Takeda License upon six months&#x2019; written notice. The Company and Takeda may terminate the Takeda License in the case of the other party&#x2019;s insolvency or material uncured breach. Takeda may terminate the Takeda License if the Company challenges, or assists in challenging, licensed patents&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;I&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;n consideration of the Takeda License, the Company (i) paid Takeda $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in cash, (ii) issued Takeda &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,084,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock at a fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, (iii) issued the Takeda Warrant to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,588,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.00004613&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share at an initial fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;47.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, and (iv) issued a right to receive an additional common stock warrant, or, the Takeda Warrant Right, should Takeda&#x2019;s fully-diluted ownership of the Company represent less than a certain specified percentage of the fully-diluted capitalization, including shares issuable upon conversion of then outstanding convertible promissory notes, calculated immediately before the closing of the Company&#x2019;s IPO, with a nominal initial fair value due to the low probability of issuance. The Takeda Warrant Right expired without effect since no fair value had been allocated to it upon completion of the IPO, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; additional warrant was issued. In addition, the Company is obligated to pay Takeda up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;250.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in sales milestones upon the achievement of specified levels of product sales, and a low double-digit royalty rate on aggregate net sales of licensed products, subject to certain adjustments. The Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of transaction costs in connection with the Takeda License. The Takeda Warrant has an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.00004613&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, expires on&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; May 7, 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and became exercisable upon the consummation of the IPO. During the year ended December 31, 2021, Takeda Warrants were exercised to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;228,696&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock. As of December 31, 2021, Takeda Warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,359,304&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock remains exercisable. Following the October 11, 2019 increase in the Company&#x2019;s authorized shares of common stock to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company recorded a non-cash charge related to the final fair value adjustment of the Takeda Warrants and reclassified the full balance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;144.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million from warrant liabilities to additional paid-in capital&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Purchase Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2020, the Company entered into a supply agreement with Sandoz pursuant to which Sandoz will supply commercial quantities of amoxicillin capsules and clarithromycin tablets, package these antibiotics with vonoprazan, and provide in finished convenience packs. The supply agreement commits the Company to a minimum purchase obligation of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the first 24-month period following the launch of the final product. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t incurred any expenses under the agreement during the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In the event the Company becomes subject to claims or suits arising in the ordinary course of business, the Company would accrue a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <phat:LicenseAgreementDescription
      contextRef="C_61652f9e-ae05-40dc-b6b4-3b2b4d36b133"
      id="F_5116c245-4fbb-4c5e-a395-65872ee2bf00">The agreement will remain in effect, on a country-by-country and product-by-product basis, until the later of (i) the expiration of the last to expire valid patent claim covering vonoprazan fumarate alone or in combination with at least one other therapeutically active ingredient, (ii) the expiration of the applicable regulatory exclusivity and (iii) 15 years from the date of first commercial sale, unless earlier terminated. The Company may terminate the Takeda License upon six months&#x2019; written notice. The Company and Takeda may terminate the Takeda License in the case of the other party&#x2019;s insolvency or material uncured breach. Takeda may terminate the Takeda License if the Company challenges, or assists in challenging, licensed patents</phat:LicenseAgreementDescription>
    <phat:AgreementExpirationTermFromDateOfFirstCommercialSale
      contextRef="C_b31d6f50-cf52-4cab-8313-448f4b5812e0"
      id="F_9a2199d0-5fc5-48ba-bb95-6f983328c002">P15Y</phat:AgreementExpirationTermFromDateOfFirstCommercialSale>
    <phat:PaymentForLicenseAmount
      contextRef="C_b31d6f50-cf52-4cab-8313-448f4b5812e0"
      decimals="-5"
      id="F_9eaf9c7a-e3c3-45dd-994b-989e808fa743"
      unitRef="U_USD">25000000.0</phat:PaymentForLicenseAmount>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_6e6c878e-6e27-47fc-9b34-7dc97f3dda54"
      decimals="INF"
      id="F_6f38477d-1dfb-417c-9b48-109af2a77ff8"
      unitRef="U_shares">1084000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_6e6c878e-6e27-47fc-9b34-7dc97f3dda54"
      decimals="-5"
      id="F_8d1d2eb2-43fd-4c18-8db0-5e2bcac3f273"
      unitRef="U_USD">5900000</us-gaap:CommonStockValue>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_ba31a338-f01c-4a63-899f-d02fc7b91340"
      decimals="INF"
      id="F_17115051-fa35-46e9-ae3f-55f1dc910774"
      unitRef="U_shares">7588000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_6e6c878e-6e27-47fc-9b34-7dc97f3dda54"
      decimals="8"
      id="F_fd8710d5-4ec9-4ac6-8720-88d3d7b5fac0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00004613</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_6e6c878e-6e27-47fc-9b34-7dc97f3dda54"
      decimals="-5"
      id="F_3a706415-525b-4747-a09e-f9aa93f2c25d"
      unitRef="U_USD">47900000</us-gaap:WarrantsAndRightsOutstanding>
    <phat:AdditionalWarrantIssued
      contextRef="C_b31d6f50-cf52-4cab-8313-448f4b5812e0"
      decimals="INF"
      id="F_529fec9a-fb34-46ad-abd1-08c43c916828"
      unitRef="U_shares">0</phat:AdditionalWarrantIssued>
    <phat:MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales
      contextRef="C_b31d6f50-cf52-4cab-8313-448f4b5812e0"
      decimals="INF"
      id="F_38b63926-b0ac-4ea1-a06d-12264ce84c10"
      unitRef="U_USD">250000000.0</phat:MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales>
    <phat:LicenseAgreementTransactionCosts
      contextRef="C_b31d6f50-cf52-4cab-8313-448f4b5812e0"
      decimals="-5"
      id="F_52638b20-fbbc-4220-a740-e83b1f31d7fb"
      unitRef="U_USD">100000</phat:LicenseAgreementTransactionCosts>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_6e6c878e-6e27-47fc-9b34-7dc97f3dda54"
      decimals="8"
      id="F_da314e05-927e-4f33-b090-14533f5d5da5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00004613</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <phat:WarrantsExpirationDate
      contextRef="C_b31d6f50-cf52-4cab-8313-448f4b5812e0"
      id="F_5a7698f7-b246-4688-9522-806a7af11cbe">2029-05-07</phat:WarrantsExpirationDate>
    <phat:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="C_e42fcdbf-c245-40d9-a08b-a3024663efad"
      decimals="0"
      id="F_841937b0-af20-43b0-ab7c-4b799ea648bc"
      unitRef="U_shares">228696</phat:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <phat:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable
      contextRef="C_a3536774-184c-4c9f-b6b0-4b72ebbf9525"
      decimals="0"
      id="F_1f2673d4-63c7-4e91-b34f-7762e8b9e907"
      unitRef="U_shares">7359304</phat:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_098dcddf-024a-435f-b6ee-bf3342544e82"
      decimals="INF"
      id="F_8d950aa2-1b87-4c37-bc91-5c596f9aa7fd"
      unitRef="U_shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_188214ae-df7a-4194-abe9-bd6e9956a85d"
      decimals="-5"
      id="F_58ff09fc-e435-4406-8cb0-55eed94fa439"
      unitRef="U_USD">144200000</us-gaap:FairValueAdjustmentOfWarrants>
    <phat:PurchaseObligationDueInFirstTwentyFourMonths
      contextRef="C_5b92a549-2b7a-468d-8c11-955c21018981"
      decimals="INF"
      id="F_12a87456-fc33-44e1-8c8a-59a4283aa27b"
      unitRef="U_USD">3800000</phat:PurchaseObligationDueInFirstTwentyFourMonths>
    <phat:PurchaseCommitmentExpense
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="INF"
      id="F_f24c4ab4-9a64-408d-b9b9-44ef38d181f0"
      unitRef="U_USD">0</phat:PurchaseCommitmentExpense>
    <phat:PurchaseCommitmentExpense
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="INF"
      id="F_4acbb35f-12e0-4972-8150-5bf380b47549"
      unitRef="U_USD">0</phat:PurchaseCommitmentExpense>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_65378c44-5fd0-485d-8820-33c99bb221a3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;5. Lease Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company had operating leases for office space in both Buffalo Grove, Illinois and Florham Park, New Jersey, with weighted average remaining lease terms of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years, respectively. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Both operating leases contain an option to extend the term for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; period&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, which was not considered in the determination of the right-of-use asset or lease liability as the Company did not consider it reasonably certain that it would exercise such options.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;     &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The total rent expense for the years ended December 31, 2021 and 2020 was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes supplemental balance sheet information related to the operating leases as of December 31, 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.896%;"/&gt;
        &lt;td style="width:1.162%;"/&gt;
        &lt;td style="width:2.734%;"/&gt;
        &lt;td style="width:17.62%;"/&gt;
        &lt;td style="width:1.036%;"/&gt;
        &lt;td style="width:1.162%;"/&gt;
        &lt;td style="width:2.734%;"/&gt;
        &lt;td style="width:17.62%;"/&gt;
        &lt;td style="width:1.036%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the future minimum annual lease payments under the operating leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.098%;"/&gt;
        &lt;td style="width:1.603%;"/&gt;
        &lt;td style="width:2.244%;"/&gt;
        &lt;td style="width:19.106%;"/&gt;
        &lt;td style="width:1.211%;"/&gt;
        &lt;td style="width:3.739%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.56&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average incremental borrowing rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating cash flows for the years ended December 31, 2021 included $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in cash payments for operating leases, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of which were prepaid lease payments. Operating cash flows for the years ended December 31, 2020 included $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in cash payments for operating leases, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of which were prepaid lease payments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_955c05d2-5a1f-43ab-9d80-db08111345d6"
      id="F_7159e930-c5be-40a5-8339-9232fae45b3a">P3Y3M18D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_d4dfdb6b-5b03-4e72-951e-81ecb345c403"
      id="F_835ce569-d5e3-4c55-9a73-bea7c528fdb0">P3Y8M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_454da93f-f097-4419-a6f9-b33d0b69cd59"
      id="F_0a701634-b8a0-479a-8eee-a2837b68cf2e">Both operating leases contain an option to extend the term for one additional five-year period</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_be8f5d58-327a-4e7b-acdd-e53a93782a26"
      id="F_0392c933-b198-498c-98ac-e51342c2a454">Both operating leases contain an option to extend the term for one additional five-year period</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <phat:LesseeOperatingLeaseNumberOfOptionToExtend
      contextRef="C_454da93f-f097-4419-a6f9-b33d0b69cd59"
      decimals="INF"
      id="F_ab4ddbdb-93ec-4415-bded-d4efcfef7401"
      unitRef="U_Option">1</phat:LesseeOperatingLeaseNumberOfOptionToExtend>
    <phat:LesseeOperatingLeaseNumberOfOptionToExtend
      contextRef="C_be8f5d58-327a-4e7b-acdd-e53a93782a26"
      decimals="INF"
      id="F_aa581d44-6793-4efe-b2e7-22ff1877c24e"
      unitRef="U_Option">1</phat:LesseeOperatingLeaseNumberOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_955c05d2-5a1f-43ab-9d80-db08111345d6"
      id="F_bec3d3dd-98e8-44df-9764-905d76625d5b">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_d4dfdb6b-5b03-4e72-951e-81ecb345c403"
      id="F_6af6dfa2-f296-40a0-9449-6b19d701a1bc">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-5"
      id="F_d00b5469-9b85-47c1-ab2b-90bb2b7b898e"
      unitRef="U_USD">700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-5"
      id="F_91e44d96-2427-4632-bf78-b82140c0f636"
      unitRef="U_USD">500000</us-gaap:OperatingLeaseExpense>
    <phat:SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_67e42252-3d23-4862-b9ab-813998f1e39b">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes supplemental balance sheet information related to the operating leases as of December 31, 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.896%;"/&gt;
        &lt;td style="width:1.162%;"/&gt;
        &lt;td style="width:2.734%;"/&gt;
        &lt;td style="width:17.62%;"/&gt;
        &lt;td style="width:1.036%;"/&gt;
        &lt;td style="width:1.162%;"/&gt;
        &lt;td style="width:2.734%;"/&gt;
        &lt;td style="width:17.62%;"/&gt;
        &lt;td style="width:1.036%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</phat:SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_ccc200a5-bc0f-4866-be73-616ed3d3a31b"
      unitRef="U_USD">1914000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_6c74635d-4c7d-42ec-9f31-a4eefccd9e1b"
      unitRef="U_USD">2373000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_3da8be59-a078-4e5c-a579-639e1412d0c3"
      unitRef="U_USD">1914000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_05800448-c8a4-4942-b4ee-8b835c2b336b"
      unitRef="U_USD">2373000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_29dd6296-fa50-46e1-8830-0bf6aa4e204c"
      unitRef="U_USD">487000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_ad534a3c-08c8-44e3-9a0e-99a83f774961"
      unitRef="U_USD">474000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_0620d10f-1d8f-4a7c-9815-12053ad00826"
      unitRef="U_USD">1183000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_faebaa54-5c46-4bce-a03a-1f35954b56aa"
      unitRef="U_USD">1557000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_9aa5ea20-d291-405b-8379-e4ed53096690"
      unitRef="U_USD">1670000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_5d48dd44-bd61-49b6-b9b0-6ff277ea4fb0"
      unitRef="U_USD">2031000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_b595733f-412b-47e4-bb1e-4cb6e9d17db6">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the future minimum annual lease payments under the operating leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.098%;"/&gt;
        &lt;td style="width:1.603%;"/&gt;
        &lt;td style="width:2.244%;"/&gt;
        &lt;td style="width:19.106%;"/&gt;
        &lt;td style="width:1.211%;"/&gt;
        &lt;td style="width:3.739%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.56&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average incremental borrowing rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_3ff1c1b2-1b65-4bd7-9837-b97ee249d534"
      unitRef="U_USD">503000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_4313f469-7ef0-4ada-8b06-f2085a989775"
      unitRef="U_USD">516000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_f32b3a28-b014-427a-9b2a-594c5cb24f0f"
      unitRef="U_USD">529000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_f0d07527-d018-446a-a8a6-158fd7eb79b6"
      unitRef="U_USD">342000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_1ee5c88f-135a-4785-8977-7f1442969eea"
      unitRef="U_USD">1890000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_abe06179-e0e2-4984-94dc-97789fe11311"
      unitRef="U_USD">220000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_e93920a0-397b-4e9f-9429-9cf63a9c1b6a"
      unitRef="U_USD">1670000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_695dce84-18e8-4f59-b317-12f31074b0ed"
      unitRef="U_USD">487000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_75d40bf4-4b3a-4f58-967c-106b945a9942"
      unitRef="U_USD">1183000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      id="F_4f0c651c-369b-4660-80a0-f56fae858fc9">P3Y6M21D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="4"
      id="F_2de15486-cb8c-4800-8d77-3d723004274e"
      unitRef="U_pure">0.0725</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-5"
      id="F_8d809468-437b-4423-88aa-e79c5152ff61"
      unitRef="U_USD">700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_af4df9d7-725e-4644-8d48-2c2689576963"
      decimals="-5"
      id="F_dbbf4b12-2064-4b47-9d9d-50a97a051f40"
      unitRef="U_USD">100000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-5"
      id="F_7f82ee0f-d63e-46d4-80a7-6104e29f8678"
      unitRef="U_USD">900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_dd956957-4601-4ab3-a9dd-db08fb69bc8a"
      decimals="-5"
      id="F_68e80330-4586-419b-983b-031436f5fbf3"
      unitRef="U_USD">600000</us-gaap:OperatingLeasePayments>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_226fd5ba-d1ad-4d0f-b027-b214e719be45">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;6. Debt&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total debt consists of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.604%;"/&gt;
        &lt;td style="width:1.162%;"/&gt;
        &lt;td style="width:2.823%;"/&gt;
        &lt;td style="width:23.535%;"/&gt;
        &lt;td style="width:1.876%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-term debt, current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-term debt, non-current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unamortized debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total debt, net of debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On September 17, 2021, or the Closing Date, the Company entered into a Loan and Security Agreement, or, the Loan Agreement, with Hercules Capital, Inc., in its capacity as administrative agent and collateral agent and as a lender, or, in such capacity, the Agent or Hercules, and the other financial institutions that from time to time become parties to the Loan Agreement as lenders, or, collectively, the Lenders.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Loan Agreement provides for term loans in an aggregate principal amount of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;200.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, or the Term Loan, under multiple tranches. The tranches consist of (i) a first tranche consisting of term loans in an aggregate principal amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, all of which was funded to the Company on the Closing Date, or First Advance, (ii) a second tranche consisting of up to an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, which became available to the Company upon achievement of the protocol-specified primary efficacy endpoints in the Company&#x2019;s Phase 3 trial studying vonoprazan for the healing and maintenance of healing of erosive esophagitis with acceptable safety data, such that the results support the submission of a New Drug Application, or NDA, or supplemental NDA without the need to conduct another Phase 3 study and will be available, if specified conditions are met, through December 15, 2022, (iii) a third tranche consisting of an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, which will become available to the Company upon the achievement of (a) FDA approval of the Company&#x2019;s NDA for vonoprazan and amoxicillin, or its New Drug Application for vonoprazan, amoxicillin and clarithromycin, in each case for an indication relating to the treatment of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;H. pylori&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; with an approved indication on the claim that is generally consistent with that sought in the Company&#x2019;s NDA submission&#x37e; and (b) filing of the Company&#x2019;s NDA or supplemental NDA for vonoprazan for indications relating to the healing and maintenance of healing of erosive esophagitis, or, milestones (a) and (b), together, the Second Performance Milestone, and will be available, if specified conditions are met, through September 30, 2023, and (iv) a fourth tranche consisting of up to an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, which will be available, if specified conditions are met, through March 31, 2024, upon achievement of the Second Performance Milestone.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company paid a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million facility charge in connection with closing of the Loan Agreement and would need to pay &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of any advances made under the third and fourth tranches.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The Term Loan will mature on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;October 1, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, or the Maturity Date. The Term Loan bears (i) cash interest at a variable annual rate equal to the greater of (a) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% and (b) the Prime Rate (as reported in the Wall Street Journal) plus &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%, or the &#x201c;Interest Rate&#x201d;, and (ii) payment-in-kind interest at a per annum rate of interest equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.35&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%. Phathom may make payments of interest only through October 1, 2024, which may be extended to October 1, 2025, upon the achievement of the Second Performance Milestone on or prior to September 30, 2024 and the condition that no default or event of default exists, and which is further extendable to October 1, 2026, subject to FDA approval of the Company&#x2019;s NDA (or supplemental NDA) for vonoprazan for an indication relating to the healing and maintenance of healing of erosive esophagitis with an approved indication on the label that is generally consistent with that sought in the Company&#x2019;s NDA submission (or supplemental NDA submission), or the Third Performance Milestone, on or prior to September 30, 2025 and no default or event of default exists (the &#x201c;interest only period&#x201d;). After the interest-only period, the principal balance and related interest will be required to be repaid in equal monthly installments and continuing until the Maturity Date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In addition, the Company is obligated to pay a final payment fee of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the original principal amount of amounts actually advanced under the Term Loan, or, each a Term Loan Advance and together, the Term Loan Advances. As of December 31, 2021, the aggregate final payment fee for the first Term Loan Advance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million has been recorded as an other long-term liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company may elect to prepay all or a portion of the Term Loan Advances prior to maturity, subject to a prepayment fee of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the then outstanding principal balance of the Term Loan Advances being prepaid. After repayment, no Term Loan amounts may be borrowed again.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As collateral for the obligations, the Company has granted to Hercules a senior security interest in all of Company&#x2019;s right, title, and interest in, to and under substantially all of Company&#x2019;s property, inclusive of intellectual property.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Loan Agreement contains customary closing fees, prepayment fees and provisions, events of default, and representations, warranties and covenants, including a financial covenant requiring Phathom to maintain certain levels of cash subject to a control agreement in favor of the Agent (minus accounts payable not paid within 120 days of invoice), or Qualified Cash, and commencing on May 15, 2023, trailing three-month net product revenue from the sale of vonoprazan and products containing vonoprazan. The revenue covenant will be waived at any time in which the Company maintains Qualified Cash equal to at least &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% (prior to the Third Performance Milestone), and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% (following the Third Performance Milestone) of the total outstanding Term Loan principal amount, or the Company&#x2019;s market capitalization is at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;900.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. Upon the occurrence of an event of default, subject to any specified cure periods, all amounts owed by the Company may be declared immediately due and payable by Hercules, as collateral agent. As of December 31, 2021, the Company was in compliance with all applicable covenants under the Loan Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the entry into the Loan Agreement, the Company issued to Hercules a warrant, or, the Warrant, to purchase a number of shares of the Company&#x2019;s common stock equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the aggregate amount of the Term Loan advances funded, and will issue to Hercules additional warrants when future Term Loan advances are funded. On the Closing Date, the Company issued a Warrant for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;74,782&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock. The Warrant will be exercisable for a period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;seven years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; from the date of issuance at a per-share exercise price equal to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33.43&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, which was the closing price of the Company&#x2019;s common stock on September 16, 2021. The Warrant is exercisable any time until &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;September 17, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and had an initial fair value of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The initial $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million fair value of the Warrant, the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million final interest payment fee and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of debt issuance costs have been recorded as debt discount and are being amortized to interest expense using the effective interest method over the term of the Term Loan.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Future minimum principal and interest payments under the Term Loan, including the final payment fee, as of December 31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.716%;"/&gt;
        &lt;td style="width:1.501%;"/&gt;
        &lt;td style="width:2.823%;"/&gt;
        &lt;td style="width:24.084%;"/&gt;
        &lt;td style="width:1.876%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Year ending December 31:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;66,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total principal and interest payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;146,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less interest and final payment fee&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;46,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total term loan borrowings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior to the Loan Agreement with Hercules, the Company had a loan with SVB and approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;54.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of the proceeds from the First Advance was used to satisfy in full and retire the Company&#x2019;s indebtedness under the SVB Term Loan with SVB, including accrued interest through the payoff date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The SVB Term Loan originated on May 14, 2019, when the Company entered into a loan and security agreement with SVB, as administrative and collateral agent, and lenders including SVB and WestRiver Innovation Lending Fund VIII, L.P. The Company borrowed $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, or Term Loan A, at the inception of the Loan Agreement and an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, or Term Loan B, on March 16, 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The SVB Term Loan bore interest at a floating rate of the higher of the Wall Street Journal Prime rate plus &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the original SVB Term Loan, the monthly payments consisted of interest-only through May 31, 2021. On March 11, 2020, the Company entered into the first amendment and on March 11, 2021, the Company entered into the second amendment, or together the Amendments, to the SVB Term Loan. Pursuant to the Amendments, the interest-only payment period was initially extended through July 31, 2021, and was further extended until December 31, 2021, after the Company received positive data from its Phase 3 clinical trial in &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;H. pylori &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;infection sufficient to file an NDA with the FDA. The interest-only payment period could have been further extended until November 30, 2022, if the Company would receive positive data from its Phase 3 clinical trial in erosive esophagitis for vonoprazan sufficient to file an NDA with the FDA.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Subsequent to the interest-only period, the SVB Term Loan would have been payable in equal monthly installments of principal, plus accrued and unpaid interest through the maturity date of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;May 1, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In addition, the Company was obligated to pay a final payment fee of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the original principal amount of the SVB Term Loan. The aggregate final payment fee for the Term Loan of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million was recorded as an other long-term liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company could have elected to prepay all or a portion of the SVB Term Loan prior to maturity, subject to a prepayment fee of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the then outstanding principal balance and payment of a pro rata portion of the final payment fee. After repayment, no Term Loan amounts could have been borrowed again.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The borrowings under the SVB Term Loan were collateralized by substantially all of the Company&#x2019;s assets. The SVB Term Loan included affirmative and negative covenants. The affirmative covenants included, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding its operating accounts. The negative covenants included, among others, limitations on the Company&#x2019;s ability to incur additional indebtedness and liens, merge with other companies or consummate certain changes of control, acquire other companies, engage in new lines of business, make certain investments, pay dividends, transfer or dispose of assets, amend certain material agreements or enter into various specified transactions. The SVB Term Loan also contained customary events of default, including bankruptcy, the failure to make payments when due, and a material adverse change. Upon the occurrence of an event of default, subject to any specified cure periods, all amounts owed by the Company would have begun to bear interest at a rate that is&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.00&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;above the rate effective immediately before the event of default and could have been declared immediately due and payable by SVB, as collateral agent.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the SVB Term Loan, the Company issued Lender Warrants to purchase stock of the Company, which expire &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; from the date of issuance. Upon completion of the IPO in 2019, the Lender Warrants became exercisable for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,446&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock. The Lender Warrants included a put option pursuant to which, in the event that the Company did not draw down Term Loan B on or before March 31, 2020, the warrant holders could have required that the Company repurchase the warrants for a total aggregate repurchase price of&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon the Term Loan B draw in March 2020, the Lender Warrants became exercisable and the put option related to the Lender Warrants expired. Accordingly, the Company recorded a final fair value adjustment and reclassif&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ied the Lender Warrants balance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to additional paid-in-capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The initial $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million fair value of the Lender Warrants, the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million final payment fee and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of debt issuance costs were recorded as debt discount and amortized to interest expense using the effective interest method over the term of the Term Loans prior to the retirement of the debt. Upon retirement of the debt any remaining unamortized amounts were recorded as an expense to Other income (expense).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During the years ended December 31, 2021 and 2020, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.8&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.6&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, of interest expense, including amortization of the debt discount, in connection with the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Hercules Loan Agreement and SVB Term Loan&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. As of December 31, 2021, the Company had outstanding &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;loan balance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;101.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and accrued interest of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_ce75baca-6a60-49e5-bfb2-a5a3243b7930">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total debt consists of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.604%;"/&gt;
        &lt;td style="width:1.162%;"/&gt;
        &lt;td style="width:2.823%;"/&gt;
        &lt;td style="width:23.535%;"/&gt;
        &lt;td style="width:1.876%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-term debt, current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-term debt, non-current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unamortized debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total debt, net of debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <phat:LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_d65efafb-f217-420d-a56b-5f5f493f5b7f"
      unitRef="U_USD">100990000</phat:LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_1a123fba-3af9-4db1-8267-4dba0747cbdd"
      unitRef="U_USD">11319000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_ae559957-8cf9-4772-8fec-ab5619d02a56"
      unitRef="U_USD">89671000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_53fd8783-36da-45c7-98b2-ab70da66a761"
      decimals="-5"
      id="F_06bdcbcc-ecc3-4d65-8572-33251772babf"
      unitRef="U_USD">200000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_cd0d4a06-0d27-4385-9179-d25cf2ad0b78"
      decimals="-5"
      id="F_0000ab8a-702c-4538-93c3-1200670f6aa5"
      unitRef="U_USD">100000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_39e4a6be-472b-4454-9622-81423cbf1cf1"
      decimals="-5"
      id="F_1791dabc-cdd4-4420-abb3-45215cb41277"
      unitRef="U_USD">50000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_ff71ca2a-03d2-4397-9d0b-802dd6a7a795"
      decimals="-5"
      id="F_9b94cce5-95ee-42e9-a67e-028aa770161b"
      unitRef="U_USD">25000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_a04a8afc-8f38-4892-a76a-0ad14e22ff3d"
      decimals="-5"
      id="F_8717a2f8-e15c-43e0-8af8-e17ec052b473"
      unitRef="U_USD">25000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <phat:PaymentForFacilityCharge
      contextRef="C_2349ad83-214b-42ef-8534-32900ea1ab8b"
      decimals="-4"
      id="F_cd612e2e-84f3-4698-b215-c97f84b60f99"
      unitRef="U_USD">1250000</phat:PaymentForFacilityCharge>
    <phat:DebtInstrumentFacilityChargePercentage
      contextRef="C_2349ad83-214b-42ef-8534-32900ea1ab8b"
      decimals="3"
      id="F_1723d9bb-07c0-4220-9a22-020a14449a77"
      unitRef="U_pure">0.005</phat:DebtInstrumentFacilityChargePercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_2349ad83-214b-42ef-8534-32900ea1ab8b"
      id="F_21cb6de6-6e5c-4a00-8b58-0a255461b897">2026-10-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_8eeb73f9-fe0f-457f-a77c-81905970cf0a"
      decimals="4"
      id="F_ae63ae19-cdf0-463c-bc7c-e8298b1dbfde"
      unitRef="U_pure">0.0550</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_43c774bf-00b3-4dcd-930e-6ffada5f2a87"
      decimals="4"
      id="F_b559e427-ea75-4534-be52-0fb6d2e0a411"
      unitRef="U_pure">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_4f305fcc-4607-43ba-9d9f-9de48fa77502"
      decimals="4"
      id="F_5ab3a4c1-50d4-4aed-b25a-365bd16904cb"
      unitRef="U_pure">0.0335</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <phat:DebtInstrumentFinalPaymentFeePercentage
      contextRef="C_ca65917a-bc4e-4718-82a1-bb0697a04ae9"
      decimals="4"
      id="F_7cc7c6f8-ac18-4aa2-befe-fa28aaa4367f"
      unitRef="U_pure">0.0750</phat:DebtInstrumentFinalPaymentFeePercentage>
    <phat:DebtInstrumentFinalPaymentFee
      contextRef="C_81edcc29-7776-4011-b910-010591687fb1"
      decimals="-5"
      id="F_affd6c8a-2d41-435e-b0c8-c2ddbd10559c"
      unitRef="U_USD">7500000</phat:DebtInstrumentFinalPaymentFee>
    <phat:DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount
      contextRef="C_d7d58811-0410-450f-88fc-1f9a4230079a"
      decimals="4"
      id="F_a62188f0-9f5e-46c3-905f-5f7b01176879"
      unitRef="U_pure">0.0125</phat:DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount>
    <phat:MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone
      contextRef="C_71f08e47-8ff5-4195-a019-61c121d7c840"
      decimals="3"
      id="F_fb962d4a-c8c6-477b-acd9-366719f4f405"
      unitRef="U_pure">0.600</phat:MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone>
    <phat:MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone
      contextRef="C_71f08e47-8ff5-4195-a019-61c121d7c840"
      decimals="2"
      id="F_0a2dadc4-4160-4b0b-b5ab-b42990d51bef"
      unitRef="U_pure">0.35</phat:MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone>
    <phat:MinimumMarketCapitalizationAmount
      contextRef="C_71f08e47-8ff5-4195-a019-61c121d7c840"
      decimals="INF"
      id="F_1e35508a-fbb7-4a21-b974-d3cc7f51f39c"
      unitRef="U_USD">900000000.0</phat:MinimumMarketCapitalizationAmount>
    <phat:PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock
      contextRef="C_71f08e47-8ff5-4195-a019-61c121d7c840"
      decimals="3"
      id="F_3ef3f69a-c89c-4ddf-b834-f2c857e57b03"
      unitRef="U_pure">0.025</phat:PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_efee110a-f508-43c7-acf9-df99b6d9b882"
      decimals="INF"
      id="F_86c5083f-8e8d-4c04-bcc9-cb77b009d02f"
      unitRef="U_shares">74782</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <phat:ClassOfWarrantOrRightExpireTerm
      contextRef="C_71f08e47-8ff5-4195-a019-61c121d7c840"
      id="F_fbbe43d5-2eea-480c-8d25-11446184ac64">P7Y</phat:ClassOfWarrantOrRightExpireTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_a5762110-631a-4b1c-9b33-2acb71c21790"
      decimals="2"
      id="F_caa07ee5-408e-4fd3-9b28-a23c4e9078f4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">33.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <phat:ClassOfWarrantOrRightExpirationDate
      contextRef="C_71f08e47-8ff5-4195-a019-61c121d7c840"
      id="F_7a1e94d0-f72e-43d8-b2ba-f91a3413d8f4">2028-09-17</phat:ClassOfWarrantOrRightExpirationDate>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_a5762110-631a-4b1c-9b33-2acb71c21790"
      decimals="-5"
      id="F_b7d6c944-b089-4e11-bd3e-6a49de3e69f9"
      unitRef="U_USD">1300000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_a5762110-631a-4b1c-9b33-2acb71c21790"
      decimals="-5"
      id="F_95192a11-eedd-4298-8c55-7f94c2dfdba9"
      unitRef="U_USD">1300000</us-gaap:WarrantsAndRightsOutstanding>
    <phat:DebtInstrumentFinalPaymentFee
      contextRef="C_a5762110-631a-4b1c-9b33-2acb71c21790"
      decimals="-5"
      id="F_c11b2809-d7ae-4df0-8125-a521fe868b65"
      unitRef="U_USD">7500000</phat:DebtInstrumentFinalPaymentFee>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="C_a5762110-631a-4b1c-9b33-2acb71c21790"
      decimals="-5"
      id="F_08e60f82-e0f0-4d66-8ffb-edd0d0a46f97"
      unitRef="U_USD">3100000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_07093f2f-b1dc-478f-96bb-7d976c0fb609">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Future minimum principal and interest payments under the Term Loan, including the final payment fee, as of December 31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.716%;"/&gt;
        &lt;td style="width:1.501%;"/&gt;
        &lt;td style="width:2.823%;"/&gt;
        &lt;td style="width:24.084%;"/&gt;
        &lt;td style="width:1.876%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Year ending December 31:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;66,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total principal and interest payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;146,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less interest and final payment fee&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;46,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total term loan borrowings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_0fc7ed1c-f487-4389-9304-dc3cb56c8704"
      unitRef="U_USD">5704000</phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths>
    <phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_b72f0ff2-b07f-4067-90ca-d84a222d5a49"
      unitRef="U_USD">5900000</phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo>
    <phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_6f8475ef-ed12-44f4-81c8-c63b08e6d8b0"
      unitRef="U_USD">17308000</phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree>
    <phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_c045e588-b3aa-47c3-90f9-efdb8787bc7f"
      unitRef="U_USD">50912000</phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour>
    <phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_3f8ecb84-c079-4ff0-a7c4-f89c7f372dd8"
      unitRef="U_USD">66948000</phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive>
    <phat:LongTermDebtAndInterest
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_be0c7c00-a05c-4861-afb9-ed26de699cb6"
      unitRef="U_USD">146772000</phat:LongTermDebtAndInterest>
    <phat:DebtInstrumentInterestAndFinalPaymentFee
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_6f9b48fa-7dbe-4e70-9f38-ab9dfe4f4aca"
      unitRef="U_USD">46772000</phat:DebtInstrumentInterestAndFinalPaymentFee>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_b3fc442d-da21-40d6-9d8c-012e35954d90"
      unitRef="U_USD">100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_1996f1f9-d68a-46ed-9e27-8965a2c43da4"
      decimals="-5"
      id="F_2d1de7fd-75bd-4000-b15e-c9d29425edf5"
      unitRef="U_USD">54300000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_b72f7963-2e17-4f63-ae38-f0567547466c"
      decimals="-5"
      id="F_1f0b6b80-4096-4c62-b1a5-d199583a951b"
      unitRef="U_USD">25000000.0</us-gaap:DebtInstrumentFaceAmount>
    <phat:DebtInstrumentAdditionalBorrowingCapacityAmounts
      contextRef="C_a74a6818-5881-479c-96b1-dcc3cd65fed3"
      decimals="-5"
      id="F_d05e9a29-51d7-431f-98bf-8703002ec4e6"
      unitRef="U_USD">25000000.0</phat:DebtInstrumentAdditionalBorrowingCapacityAmounts>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_b4181602-e907-4a44-b1b6-077897333d0c"
      decimals="4"
      id="F_fa206ce2-2817-4905-b3b3-bc0dc3e61e84"
      unitRef="U_pure">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_9840529e-ac70-4eb7-8d10-e6cb712b0d45"
      decimals="4"
      id="F_99336be4-78f2-4f32-8964-3d0c8538d147"
      unitRef="U_pure">0.0725</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentPaymentTerms
      contextRef="C_20586d23-36ef-4d60-8bc6-81acfe59236b"
      id="F_e38e9223-02bd-44d5-bc35-c8c33bddb038">Under the original SVB Term Loan, the monthly payments consisted of interest-only through May 31, 2021. On March 11, 2020, the Company entered into the first amendment and on March 11, 2021, the Company entered into the second amendment, or together the Amendments, to the SVB Term Loan. Pursuant to the Amendments, the interest-only payment period was initially extended through July 31, 2021, and was further extended until December 31, 2021, after the Company received positive data from its Phase 3 clinical trial in H. pylori infection sufficient to file an NDA with the FDA. The interest-only payment period could have been further extended until November 30, 2022, if the Company would receive positive data from its Phase 3 clinical trial in erosive esophagitis for vonoprazan sufficient to file an NDA with the FDA.</us-gaap:DebtInstrumentPaymentTerms>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_32d5d9b1-7992-4d84-8226-a55e116ed6d0"
      id="F_4bbb631a-89b3-4773-9b33-4c929ad968d8">2024-05-01</us-gaap:DebtInstrumentMaturityDate>
    <phat:DebtInstrumentFinalPaymentFeePercentage
      contextRef="C_32d5d9b1-7992-4d84-8226-a55e116ed6d0"
      decimals="4"
      id="F_0af8443c-1237-4cbe-b157-b50e3e7d2302"
      unitRef="U_pure">0.0825</phat:DebtInstrumentFinalPaymentFeePercentage>
    <phat:DebtInstrumentFinalPaymentFee
      contextRef="C_9840529e-ac70-4eb7-8d10-e6cb712b0d45"
      decimals="-5"
      id="F_88d3f4eb-c89b-42ec-b4e9-f0dd98b0fd97"
      unitRef="U_USD">4100000</phat:DebtInstrumentFinalPaymentFee>
    <phat:DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount
      contextRef="C_241f6789-e4f7-4e5a-930f-33a8b7e5b743"
      decimals="INF"
      id="F_aea7bf72-b961-4bf5-84d0-f4bed87d05c1"
      unitRef="U_pure">0.020</phat:DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount>
    <phat:DebtInstrumentPenaltyFeePercentage
      contextRef="C_32d5d9b1-7992-4d84-8226-a55e116ed6d0"
      decimals="INF"
      id="F_062638e2-2844-4966-9b12-e2a2082f8bd4"
      unitRef="U_pure">0.0400</phat:DebtInstrumentPenaltyFeePercentage>
    <phat:LanderWarrantsExpireTerm
      contextRef="C_32d5d9b1-7992-4d84-8226-a55e116ed6d0"
      id="F_1005fb18-8656-4168-9a0c-4202668ca081">P10Y</phat:LanderWarrantsExpireTerm>
    <phat:LenderWarrantsExercisableSharesOfCommonStock
      contextRef="C_3df574b9-fe27-4d9e-a549-6a095ed65261"
      decimals="INF"
      id="F_ad17dd51-a710-4635-99de-1f58088a4fcd"
      unitRef="U_shares">16446</phat:LenderWarrantsExercisableSharesOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="C_32d5d9b1-7992-4d84-8226-a55e116ed6d0"
      decimals="-5"
      id="F_069d1ee1-f9d4-4222-9032-c2c4de9e5ba0"
      unitRef="U_USD">500000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_20586d23-36ef-4d60-8bc6-81acfe59236b"
      decimals="-5"
      id="F_a8b311cd-bdfc-4c47-ba17-4cd16f3f5f81"
      unitRef="U_USD">300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_3df574b9-fe27-4d9e-a549-6a095ed65261"
      decimals="-5"
      id="F_71687d18-1e40-4928-9d95-e10f12e6c462"
      unitRef="U_USD">400000</us-gaap:WarrantsAndRightsOutstanding>
    <phat:DebtInstrumentFinalPaymentFee
      contextRef="C_9840529e-ac70-4eb7-8d10-e6cb712b0d45"
      decimals="-5"
      id="F_f87b8e25-e762-4b75-acff-8ea30a851e2b"
      unitRef="U_USD">4100000</phat:DebtInstrumentFinalPaymentFee>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="C_3df574b9-fe27-4d9e-a549-6a095ed65261"
      decimals="-5"
      id="F_b6623301-e964-4415-8a14-ddca0181be90"
      unitRef="U_USD">200000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="C_6cd259d1-4f33-46a3-b5d1-c3115e02e275"
      decimals="-5"
      id="F_ff92d4e4-b6a9-47c6-a498-733778518f29"
      unitRef="U_USD">6800000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_acd69431-8a06-4075-a111-6495758ee60f"
      decimals="-5"
      id="F_5bd6c8f6-9715-41fb-8fb3-b42d5dff3ef4"
      unitRef="U_USD">4600000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_f13e98ac-8a46-483d-833b-1ed96212502d"
      decimals="-5"
      id="F_3764b261-9193-44af-ab18-7e5a4c00fec1"
      unitRef="U_USD">101000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <phat:AccruedInterest
      contextRef="C_f13e98ac-8a46-483d-833b-1ed96212502d"
      decimals="-5"
      id="F_632e53d5-7014-42d3-8cad-910d1e9771bd"
      unitRef="U_USD">500000</phat:AccruedInterest>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_12ee6269-6405-48d9-8578-309497042ccb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;7. Stockholders&#x2019; Equity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Common Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2019, subsequent to the Merger, the Company sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,491,072&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock to Frazier.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2019, the founders granted the Company a repurchase right for the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,373,408&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock originally purchased in 2018. The Company has the right, but not the obligation, to repurchase unvested shares in the event the founder&#x2019;s relationship with the Company is terminated, subject to certain limitations, at the original purchase price of the stock. The repurchase right lapsed for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;843,352&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares in March 2019 and the repurchase right for the remaining &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,530,056&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares lapses in equal monthly amounts over the following &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;48-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; period ending in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;March 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The fair value of the founder shares at the date the repurchase right was granted is being recognized as stock-based compensation expense on a straight-line basis over the vesting period. As of December 31, 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;395,321&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock were subject to repurchase by the Company and the associated repurchase liability was not significant. The amount of recognized and unrecognized stock-based compensation related to the founder stock was immaterial for all periods presented.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In May 2019, the Company issued Takeda &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,084,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock in connection with the Takeda License.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For the period from January 1, 2019 to May 6, 2019, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,524,852&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock to various employees and consultants of the Company for aggregate proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Upon issuance, these shares were subject to a repurchase option by the Company at the original purchase price of the shares. The repurchase rights generally lapse as to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the shares on the first anniversary of the vesting commencement date, and the repurchase right lapses as to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_6101410e-3515-4cea-81ab-5e3079200f62;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1/48&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;th of the shares each one-month period thereafter, subject to the purchaser remaining continuously an employee, consultant or director of the Company. In November 2019, the Company repurchased &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,560&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares at the original purchase price for an aggregate purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. As of December 31, 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;749,488&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares remain available for repurchase by the Company and the associated repurchase liability was not significant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On October 29, 2019, upon completion of the IPO, the Company sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,997,630&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock, which included the exercise in full by the underwriters of their option to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,434,473&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; additional shares at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. The net proceeds were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;191.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, after deducting underwriting discounts, commissions and offering costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In November 2020, the Company entered into an Open Market Sale Agreement, or, the Sales Agreement, with Jefferies LLC, or, the Sales Agent, under which it may, from time to time, sell shares of its common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;125.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million through the Sales Agent, or, the ATM Offering. Pursuant to the Sales Agreement, the Company will pay the Sales Agent a commission for its services in acting as an agent in the sale of common stock in an amount equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the gross sales price per share sold. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares were sold under the ATM Offering as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On December 16, 2020, the Company completed an underwritten public offering, in which it sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,250,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;42.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share for total gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;94.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The net purchase price after deducting underwriting discounts and commissions was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;39.48&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, which generated net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;88.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The Company incurred an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of offering expenses in connection with this public offering.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A summary of the Company&#x2019;s unvested shares is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.994%;"/&gt;
        &lt;td style="width:1.656%;"/&gt;
        &lt;td style="width:1.175%;"/&gt;
        &lt;td style="width:18.625%;"/&gt;
        &lt;td style="width:1.549%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,746,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Share vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,601,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,144,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For accounting purposes, unvested shares of common stock are considered issued, but not outstanding until they vest.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock reserved for future issuance consists of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:73.57%;"/&gt;
        &lt;td style="width:1.501%;"/&gt;
        &lt;td style="width:1.09%;"/&gt;
        &lt;td style="width:22.748%;"/&gt;
        &lt;td style="width:1.09%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,450,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options and performance-based awards outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,581,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares available for issuance under the 2019 Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,772,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares available for issuance under the ESPP Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;842,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14,646,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is authorized to issue up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million shares of preferred stock. As of December 31, 2021, and December 31, 2020, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of preferred stock issued or outstanding.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Equity Incentive Plan&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s 2019 Equity Incentive Plan, or the Existing Incentive Plan, provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards to eligible recipients, including employees, directors or consultants of the Company. The Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,231,739&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock authorized for issuance under the Existing Incentive Plan, of which, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,400,528&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; stock options and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,260&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; restricted stock awards were granted in 2019. As a result of the adoption of the 2019 Incentive Award Plan, or the 2019 Plan, in October 2019, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; further shares are available for issuance under the Existing Incentive Plan.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2019 Incentive Award Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In October 2019, the board of directors adopted, and the Company&#x2019;s stockholders approved, the 2019 Plan, which became effective in connection with the IPO. Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The number of shares initially available for issuance will be increased by (i) the number of shares subject to stock options or similar awards granted under the Existing Incentive Plan that expire or otherwise terminate without having been exercised in full after the effective date of the 2019 Plan and unvested shares issued pursuant to awards granted under the Existing Incentive Plan that are forfeited to or repurchased by the Company after the effective date of the 2019 Plan, with the maximum number of shares to be added to the 2019 Plan pursuant to clause (i) above equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,416,788&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares, and (ii) an annual increase on January 1 of each calendar year beginning in 2020 and ending in 2029, equal to the lesser of (a) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the board of directors. As of December 31, 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,772,744&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares remain available for issuance, which reflects &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,915,300&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; stock options and performance-based units ("PSU") granted, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;175,430&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; cancelled or forfeited, during the year ended December 31, 2021 as well as &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;annual increases of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,250,511&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,158,580&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares that were authorized on January 1, 2021 and 2020. An additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,582,802&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares were authorized on January 1, 2022. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"/&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Performance-based Units&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During 2020, the Company granted &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;220,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; PSUs whereby vesting depends upon the approval by the U.S. Food and Drug Administration, or FDA, of vonoprazan for &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;H. pylori&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and then, or concurrent with, erosive esophagitis. In 2021, the Company granted an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;190,050&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; PSUs to employees. As of December 31, 2021, the PSU milestones had not been achieved. As of December 31, 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; related compensation cost had been recognized. &lt;/span&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes PSU activity under the 2019 Incentive Award Plan during the year ended December 31, 2021.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.33%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:0.949%;"/&gt;
        &lt;td style="width:14.878%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:2.296%;"/&gt;
        &lt;td style="width:14.312%;"/&gt;
        &lt;td style="width:0.949%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;220,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;190,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;394,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021 there was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of related unrecognized compensation cost, which will be recognized upon vesting.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In October 2019, the board of directors adopted, and the Company&#x2019;s stockholders approved, the Employee Stock Purchase Plan, or the ESPP, which became effective in connection with the IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of their eligible compensation, which includes a participant&#x2019;s gross base compensation for services to the Company, including overtime payments and excluding sales commissions, incentive compensation, bonuses, expense reimbursements, fringe benefits and other special payments. A total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;270,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock was initially reserved for issuance under the ESPP. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In addition, the number of shares available for issuance under the ESPP will be annually increased on January 1 of each calendar year beginning in 2020 and ending in 2029, by an amount equal to the lesser of: (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the board of directors. As of December 31, 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;842,036&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock remain available for issuance, which reflects &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,237&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares sold to employees during the year ended December 31, 2021 as well as the annual increases of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;312,628&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;289,645&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares that were authorized on January 1, 2021 and 2020. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; additional shares were authorized in January 2022.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The ESPP is considered a compensatory plan, and the Company recorded related stock-based compensation of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the year ended December 31, 2021 and 2020, respectively. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The weighted-average assumptions used to estimate the fair value of ESPP awards using the Black-Scholes option valuation model were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.76%;"/&gt;
        &lt;td style="width:1.393%;"/&gt;
        &lt;td style="width:0.918%;"/&gt;
        &lt;td style="width:19.529%;"/&gt;
        &lt;td style="width:3.78%;"/&gt;
        &lt;td style="width:1.393%;"/&gt;
        &lt;td style="width:0.918%;"/&gt;
        &lt;td style="width:19.529%;"/&gt;
        &lt;td style="width:3.78%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Assumptions:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.69&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The estimated weighted-average fair value of ESPP awards during 2021 and 2020 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14.66&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.66&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively. As of December 31, 2021, the total unrecognized compensation expense related to the ESPP was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, which is expected to be recognized over a weighted-average period of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; months.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair value of each employee and non-employee stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company, prior to the IPO on October 29, 2019, was a private company and lacked company-specific historical and implied volatility information. Therefore, it estimated its expected volatility based on the historical volatility of a publicly-traded set of peer companies. Due to the lack of historical exercise history, the expected term of the Company&#x2019;s stock options for employees was determined utilizing the &#x201c;simplified&#x201d; method for awards. The expected term of stock options granted to non-employees was equal to the contractual term of the option award. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A summary of the Company&#x2019;s stock option activity and related information is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.8%;"/&gt;
        &lt;td style="width:1.047%;"/&gt;
        &lt;td style="width:1.071%;"/&gt;
        &lt;td style="width:11.851%;"/&gt;
        &lt;td style="width:1.071%;"/&gt;
        &lt;td style="width:1.047%;"/&gt;
        &lt;td style="width:1.618%;"/&gt;
        &lt;td style="width:9.305%;"/&gt;
        &lt;td style="width:0.94%;"/&gt;
        &lt;td style="width:1.047%;"/&gt;
        &lt;td style="width:1.583%;"/&gt;
        &lt;td style="width:9.733%;"/&gt;
        &lt;td style="width:0.785%;"/&gt;
        &lt;td style="width:1.011%;"/&gt;
        &lt;td style="width:1.63%;"/&gt;
        &lt;td style="width:9.674%;"/&gt;
        &lt;td style="width:0.785%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (in&lt;br/&gt;thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,728,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;34,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,725,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options exercised and shares vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;107,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;159,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,186,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.43&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options exercisable as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,127,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.91&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options vested and expected to vest as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,186,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.43&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The aggregate intrinsic value of options exercisable as of December 31, 2021 and 2020 were calculated as the difference between the exercise price of the underlying options and the closing market price of the Company&#x2019;s common stock on that date, which were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19.67&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33.22&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share on December 31, 2021 and 2020, respectively. The aggregate intrinsic value of options exercised during the years ended December 31, 2021 and 2020 were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The estimated weighted-average fair value of employee and nonemployee director stock options granted during 2021 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22.20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. As of December 31, 2021, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;46.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of unrecognized stock-based compensation expense, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The weighted-average assumptions used to estimate the fair value of stock options using the Black-Scholes option valuation model were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.76%;"/&gt;
        &lt;td style="width:1.393%;"/&gt;
        &lt;td style="width:0.918%;"/&gt;
        &lt;td style="width:19.529%;"/&gt;
        &lt;td style="width:3.78%;"/&gt;
        &lt;td style="width:1.393%;"/&gt;
        &lt;td style="width:0.918%;"/&gt;
        &lt;td style="width:19.529%;"/&gt;
        &lt;td style="width:3.78%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Assumptions:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.93&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.06&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;67.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;65.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation expense recognized for all equity awards, including founder stock, has been reported in the statements of operations as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.173%;"/&gt;
        &lt;td style="width:1.393%;"/&gt;
        &lt;td style="width:2.281%;"/&gt;
        &lt;td style="width:21.142%;"/&gt;
        &lt;td style="width:0.919%;"/&gt;
        &lt;td style="width:1.393%;"/&gt;
        &lt;td style="width:2.281%;"/&gt;
        &lt;td style="width:20.499%;"/&gt;
        &lt;td style="width:0.919%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,390&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_1697dfc5-540c-442e-b1a4-f9384dabddfa"
      decimals="INF"
      id="F_b5cb6e30-dbec-4106-b363-4a3a960a61d7"
      unitRef="U_shares">1491072</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_9c645a10-1007-43f6-af0d-91ee63fc5c04"
      decimals="INF"
      id="F_33e3714c-5d06-40ff-b3fc-91b57fe21e68"
      unitRef="U_shares">3373408</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <phat:StockRepurchaseProgramNumberOfSharesRightLapse
      contextRef="C_9c645a10-1007-43f6-af0d-91ee63fc5c04"
      decimals="INF"
      id="F_d55fe176-7495-4087-bf3c-af04430ea703"
      unitRef="U_shares">843352</phat:StockRepurchaseProgramNumberOfSharesRightLapse>
    <us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_9c645a10-1007-43f6-af0d-91ee63fc5c04"
      decimals="INF"
      id="F_415bc850-643b-4071-8524-bcc222937cf2"
      unitRef="U_shares">2530056</us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:StockRepurchaseProgramPeriodInForce1
      contextRef="C_87fd58b8-211c-4048-8771-2e2c36ba57bf"
      id="F_b45c5bea-bfc1-4d67-9b54-6807ed726ef5">P48M</us-gaap:StockRepurchaseProgramPeriodInForce1>
    <phat:StockRepurchaseProgramExpirationMonthAndYear
      contextRef="C_87fd58b8-211c-4048-8771-2e2c36ba57bf"
      id="F_4625fd53-3660-44c4-9e4b-15de29e5e4a4">2023-03</phat:StockRepurchaseProgramExpirationMonthAndYear>
    <us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_36128d75-bc37-4ecf-b73c-b936cd610fae"
      decimals="INF"
      id="F_f5930f09-8d27-4be3-8c29-f732043942f2"
      unitRef="U_shares">395321</us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_fad8897a-ba60-41ae-8f3d-ee922beca8a9"
      decimals="INF"
      id="F_ef74ae37-3918-44d4-9952-4970d6822361"
      unitRef="U_shares">1084000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_badf06b6-f9fe-4b02-beea-e7e8d5ea853c"
      decimals="INF"
      id="F_dbd4e93e-f5ca-4521-acd5-cae1c70c6fd3"
      unitRef="U_shares">2524852</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_badf06b6-f9fe-4b02-beea-e7e8d5ea853c"
      decimals="0"
      id="F_4c6ea22a-7cfd-474c-bb45-63ed59067c40"
      unitRef="U_USD">1000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <phat:RepurchaseRightLapseRate
      contextRef="C_5a4b87ab-a1d7-48cd-a634-0d9f17511fa1"
      decimals="2"
      id="F_9472e555-3732-41c1-818f-278a97d58598"
      unitRef="U_pure">0.25</phat:RepurchaseRightLapseRate>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_12c53278-d1c8-452b-aaf8-8d9bd7427b25"
      decimals="INF"
      id="F_70a60e20-13f6-48fa-b3a8-1834c1a351c1"
      unitRef="U_shares">17560</us-gaap:StockRepurchasedDuringPeriodShares>
    <phat:SharesAggregateRepurchasePrice
      contextRef="C_206f3b3c-5da1-4c5f-91a2-624aa167dbf3"
      decimals="2"
      id="F_bb3206bb-e2b0-4991-9092-dee20f18a10f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.20</phat:SharesAggregateRepurchasePrice>
    <us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_3664d4ba-d83a-42b2-94ee-819934ab325c"
      decimals="INF"
      id="F_55515e38-be31-4356-aa54-663cef74b575"
      unitRef="U_shares">749488</us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_74f9d273-2810-4b05-a50b-39f4e9e89f17"
      decimals="INF"
      id="F_f3d5a675-3eb3-4ddc-8a0b-c7036059f59e"
      unitRef="U_shares">10997630</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_91313c0e-8879-4034-8725-8b3f8639f719"
      decimals="INF"
      id="F_d2752fb7-a94e-42ca-83d7-9d9083c20750"
      unitRef="U_shares">1434473</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_380ada73-fd68-4c36-b7a1-4dbbf1ceef47"
      decimals="INF"
      id="F_d4c305a8-7939-4dd1-88aa-4ddc50af9a99"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_74f9d273-2810-4b05-a50b-39f4e9e89f17"
      decimals="-5"
      id="F_9a552f92-86fa-400f-b0d3-97aba094acc0"
      unitRef="U_USD">191500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <phat:AggregateOfferingPriceThroughEquityFinancing
      contextRef="C_0325f78e-5f19-4ce3-816b-ea35a5adfab2"
      decimals="-5"
      id="F_0e51c1ee-ec16-40e9-a180-1800bde30e8e"
      unitRef="U_USD">125000000.0</phat:AggregateOfferingPriceThroughEquityFinancing>
    <phat:SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare
      contextRef="C_f9cd5e45-1473-4fc5-b117-73d3e4b8192b"
      decimals="2"
      id="F_01e1a311-1a89-4727-9c6f-5fbd1c00a6be"
      unitRef="U_pure">0.03</phat:SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c16925ab-416a-4dd6-ae22-155a64c3a8a2"
      decimals="INF"
      id="F_44f67731-3ff7-4a7c-9afa-7115c1855e30"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e23ac301-7808-41cf-82ed-c24a17ab03b1"
      decimals="INF"
      id="F_34b4f167-6f51-4ed7-b18d-0545f5a7595e"
      unitRef="U_shares">2250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_f8f7aeec-8c43-4d6e-857e-906c1138ff3a"
      decimals="2"
      id="F_f1ad31b0-7997-4a37-92bb-fbc7c3527581"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">42.00</us-gaap:SaleOfStockPricePerShare>
    <phat:ProceedsFromIssuanceInitialPublicOfferingGross
      contextRef="C_e23ac301-7808-41cf-82ed-c24a17ab03b1"
      decimals="-5"
      id="F_bf88a795-a73f-46b3-99ad-2f9f78e00275"
      unitRef="U_USD">94500000</phat:ProceedsFromIssuanceInitialPublicOfferingGross>
    <phat:SharesIssuedPricePerShareAfterDeductions
      contextRef="C_f8f7aeec-8c43-4d6e-857e-906c1138ff3a"
      decimals="2"
      id="F_69ead768-b1f2-48a7-8252-a69ac3ec2672"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">39.48</phat:SharesIssuedPricePerShareAfterDeductions>
    <phat:NetProceedsAfterDeductingUnderwritersCommission
      contextRef="C_e23ac301-7808-41cf-82ed-c24a17ab03b1"
      decimals="-5"
      id="F_6e551ab3-f106-458c-8aa6-24b15c224229"
      unitRef="U_USD">88800000</phat:NetProceedsAfterDeductingUnderwritersCommission>
    <phat:PurchaseOfAdditionalOfferingExpenses
      contextRef="C_e23ac301-7808-41cf-82ed-c24a17ab03b1"
      decimals="-5"
      id="F_0b310c39-1753-460c-b9b6-3392ce426afa"
      unitRef="U_USD">200000</phat:PurchaseOfAdditionalOfferingExpenses>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_28a548d7-231a-439a-a82d-5d9cd77278b8">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A summary of the Company&#x2019;s unvested shares is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.994%;"/&gt;
        &lt;td style="width:1.656%;"/&gt;
        &lt;td style="width:1.175%;"/&gt;
        &lt;td style="width:18.625%;"/&gt;
        &lt;td style="width:1.549%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,746,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Share vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,601,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,144,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="INF"
      id="F_de27f929-e590-4e1d-aebf-b9671c0c376c"
      unitRef="U_shares">2746759</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="INF"
      id="F_17910fd3-faf1-4fe2-9d5c-afc1699becf4"
      unitRef="U_shares">1601950</phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="INF"
      id="F_3cf547e4-15ff-41a3-bbd7-0391e7151719"
      unitRef="U_shares">1144809</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <phat:CommonStockReservedForFutureIssuancesTableTableTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_ffe6470f-b5f4-4a7b-89ce-bce07493eead">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock reserved for future issuance consists of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:73.57%;"/&gt;
        &lt;td style="width:1.501%;"/&gt;
        &lt;td style="width:1.09%;"/&gt;
        &lt;td style="width:22.748%;"/&gt;
        &lt;td style="width:1.09%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,450,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options and performance-based awards outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,581,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares available for issuance under the 2019 Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,772,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares available for issuance under the ESPP Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;842,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14,646,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</phat:CommonStockReservedForFutureIssuancesTableTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_d868eb98-0a9a-4d3b-9ce2-a53206123d64"
      decimals="INF"
      id="F_1594131f-a3bb-4cda-9e61-36eb669c9c38"
      unitRef="U_shares">7450532</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e5953438-3337-4945-83fd-2193a29e01a7"
      decimals="INF"
      id="F_50b93f31-2971-4eb2-b683-1bccbd4ece6f"
      unitRef="U_shares">4581029</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_87f0bb77-c9b2-4912-beed-d93c6e58fd1f"
      decimals="INF"
      id="F_bfd31cd3-58f9-490f-98b3-90a5a73af78f"
      unitRef="U_shares">1772744</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b9960611-efe5-44c4-a8c6-f1f963d5a52b"
      decimals="INF"
      id="F_e821ab85-0908-4d7b-8332-be10cf88f8f4"
      unitRef="U_shares">842036</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="INF"
      id="F_40c45972-d089-462d-af82-6ca28ce99437"
      unitRef="U_shares">14646341</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="INF"
      id="F_769ca115-5487-480b-b47e-672ad2da1ae2"
      unitRef="U_shares">40000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="INF"
      id="F_e46a53dc-9363-4e28-ac73-966a887f9267"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="INF"
      id="F_962638d8-015c-466e-9d35-6348cf54d6b8"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="INF"
      id="F_568bce58-5b8d-4cd7-a56e-a0d6784d3f85"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="INF"
      id="F_a472456e-41f9-48d0-86f3-1744c93b0910"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_fe1128a5-47e8-4b19-bbed-dd56555e6e7b"
      decimals="INF"
      id="F_c04a8fb6-ce21-4bb8-a866-fb3ace61ff2e"
      unitRef="U_shares">2231739</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_17839630-7f10-4b51-bf7c-a8f7ffc8fab6"
      decimals="INF"
      id="F_076aef3d-d686-4f57-8419-f21be6753104"
      unitRef="U_shares">1400528</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_8dbe144e-0a5e-4b96-a3d3-658404346eb7"
      decimals="INF"
      id="F_b463161d-fbfd-4a5e-986d-d58871a60fc6"
      unitRef="U_shares">16260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_f66489f4-0ae2-4a45-862d-a14469e353c3"
      decimals="INF"
      id="F_4866a9a0-9313-4cca-86ae-c7949d99d44e"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_cdbdb34e-8229-4188-b4a2-e7d4e7a5718c"
      id="F_9c4977c2-16fd-486e-902f-630a4a617212">The number of shares initially available for issuance will be increased by (i) the number of shares subject to stock options or similar awards granted under the Existing Incentive Plan that expire or otherwise terminate without having been exercised in full after the effective date of the 2019 Plan and unvested shares issued pursuant to awards granted under the Existing Incentive Plan that are forfeited to or repurchased by the Company after the effective date of the 2019 Plan, with the maximum number of shares to be added to the 2019 Plan pursuant to clause (i) above equal to 1,416,788 shares, and (ii) an annual increase on January 1 of each calendar year beginning in 2020 and ending in 2029, equal to the lesser of (a) 5% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the board of directors. As of December 31, 2021, 1,772,744 shares remain available for issuance, which reflects 1,915,300 stock options and performance-based units ("PSU") granted, and 175,430 cancelled or forfeited, during the year ended December 31, 2021 as well as annual increases of 1,250,511 and 1,158,580 shares that were authorized on January 1, 2021 and 2020. An additional 1,582,802 shares were authorized on January 1, 2022. </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_e3ad8a65-3e01-423c-bdf8-40f8bc119501"
      decimals="INF"
      id="F_61a7b6f5-920b-4fe9-b671-06a2c5b01b85"
      unitRef="U_shares">1416788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_b58f7ee0-6546-4bdb-8957-1ed85f98206a"
      decimals="INF"
      id="F_89cc03e8-e645-4c8b-b7d1-69aee05131ee"
      unitRef="U_pure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_87f0bb77-c9b2-4912-beed-d93c6e58fd1f"
      decimals="INF"
      id="F_dafaa9cd-79b5-4cbf-bdf1-6b824e9700a8"
      unitRef="U_shares">1772744</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross
      contextRef="C_6a529bff-3f22-42e8-80c8-4ec27c2967c8"
      decimals="INF"
      id="F_f66c3794-4f12-4d15-81cf-fa9c11acc810"
      unitRef="U_shares">1915300</phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross>
    <phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_6a529bff-3f22-42e8-80c8-4ec27c2967c8"
      decimals="INF"
      id="F_9d5bcc33-dba1-4b06-89c7-f6724d5b4afa"
      unitRef="U_shares">175430</phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod>
    <phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease
      contextRef="C_fc73c1d8-543b-42ca-a706-31cf63f474bd"
      decimals="INF"
      id="F_f8cf7e59-9a7a-416d-9017-d8347c5547f9"
      unitRef="U_shares">1250511</phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_900f5558-5afe-4b4f-8196-aa85a162d269"
      decimals="INF"
      id="F_a106e3e8-b28d-42cd-82c6-45b66d95505d"
      unitRef="U_shares">1158580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_2d28ef17-10f6-4591-8f1a-f0f2d4d26dae"
      decimals="INF"
      id="F_6861ec42-f9cb-4e9b-a045-2b4920de835a"
      unitRef="U_shares">1582802</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_7e3a25e6-daa3-4b87-aabb-7aa287d515ab"
      decimals="INF"
      id="F_ea7aeeaf-d2e7-43a5-af15-1c77da429606"
      unitRef="U_shares">220000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_723f3790-161d-4bd6-86bd-87b733a399de"
      decimals="INF"
      id="F_80d21cf5-1c9f-4ee9-b7fa-f6ed5ec33859"
      unitRef="U_shares">190050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_723f3790-161d-4bd6-86bd-87b733a399de"
      decimals="INF"
      id="F_d7862ba6-e914-4cbe-89e6-595c80fb0669"
      unitRef="U_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_f2bb72b9-faf4-4582-b863-596207498df9">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes PSU activity under the 2019 Incentive Award Plan during the year ended December 31, 2021.&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.33%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:0.949%;"/&gt;
        &lt;td style="width:14.878%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:2.296%;"/&gt;
        &lt;td style="width:14.312%;"/&gt;
        &lt;td style="width:0.949%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;220,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;190,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;394,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_17a2343c-f245-48f0-b4b2-e5e809abbd6c"
      decimals="INF"
      id="F_0f2112e7-bd1b-422f-bb7c-1022d4eb484d"
      unitRef="U_shares">220000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_17a2343c-f245-48f0-b4b2-e5e809abbd6c"
      decimals="2"
      id="F_845b234d-9536-4fdb-8b52-25708063138a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">32.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_723f3790-161d-4bd6-86bd-87b733a399de"
      decimals="INF"
      id="F_5c57c809-e79b-4e2b-bc8a-f56b15be68a2"
      unitRef="U_shares">190050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_723f3790-161d-4bd6-86bd-87b733a399de"
      decimals="2"
      id="F_d8e04eea-2091-4b64-88b1-f5f0ee5c0340"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">31.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_723f3790-161d-4bd6-86bd-87b733a399de"
      decimals="INF"
      id="F_b58236d5-ee75-4585-aadd-2c0341ea6042"
      unitRef="U_shares">15750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_723f3790-161d-4bd6-86bd-87b733a399de"
      decimals="2"
      id="F_935761c9-6d28-482f-b82a-a132dec5e7ff"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">30.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_85558b4d-f67a-43d1-abe8-dbab03b741da"
      decimals="INF"
      id="F_4a750fc8-963c-41fa-a3c6-90818f2fca63"
      unitRef="U_shares">394300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_85558b4d-f67a-43d1-abe8-dbab03b741da"
      decimals="2"
      id="F_7cf60050-f26d-4be3-be9a-27000e22306a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">32.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_85558b4d-f67a-43d1-abe8-dbab03b741da"
      decimals="-5"
      id="F_73e60f9f-02f4-49ae-80d4-343b98ac81e6"
      unitRef="U_USD">12700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_db21078b-51b9-43f8-8e98-683590c04e0e"
      decimals="INF"
      id="F_97a7d19e-a9be-493c-b399-b768c4e82f83"
      unitRef="U_pure">0.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_917d5eb6-6257-4bc2-9c26-1732c213fff4"
      decimals="INF"
      id="F_397f7dfc-5b16-43f6-bab6-7415cb6a8af6"
      unitRef="U_shares">270000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_9d982be6-c196-4b4e-ae56-0b1fafa482a8"
      id="F_2352bb94-133e-4411-b72b-b3d4f4128612">In addition, the number of shares available for issuance under the ESPP will be annually increased on January 1 of each calendar year beginning in 2020 and ending in 2029, by an amount equal to the lesser of: (i) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the board of directors. As of December 31, 2021, 842,036 shares of common stock remain available for issuance, which reflects 30,237 shares sold to employees during the year ended December 31, 2021 as well as the annual increases of 312,628 and 289,645 shares that were authorized on January 1, 2021 and 2020. No additional shares were authorized in January 2022.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_0ef2e37e-f570-4b04-bea6-8bd572cb5668"
      decimals="INF"
      id="F_e62f1206-a049-469e-be25-ad5a87d25e05"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_b9960611-efe5-44c4-a8c6-f1f963d5a52b"
      decimals="INF"
      id="F_0c923fa7-6165-4aa6-a0c4-de78556023bd"
      unitRef="U_shares">842036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_9d982be6-c196-4b4e-ae56-0b1fafa482a8"
      decimals="INF"
      id="F_29f6f378-9fd8-43af-8984-f4b6e32939fa"
      unitRef="U_shares">30237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease
      contextRef="C_304607c5-7382-468b-88d2-4280b34bacd1"
      decimals="INF"
      id="F_cd7b468d-2ec2-449c-9e37-aa9dfd571e76"
      unitRef="U_shares">312628</phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease>
    <phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease
      contextRef="C_c47ce7f2-8ee4-455c-93be-6ab781a08057"
      decimals="INF"
      id="F_7a6e256f-1494-473e-8377-d351f78e52a7"
      unitRef="U_shares">289645</phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease>
    <phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease
      contextRef="C_fb1fb004-48c7-408c-a23a-a166c26e4c3d"
      decimals="INF"
      id="F_81eb26c8-9ed4-458e-8113-0497ea70e873"
      unitRef="U_shares">0</phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9d982be6-c196-4b4e-ae56-0b1fafa482a8"
      decimals="-5"
      id="F_c5dafc7d-936e-46bb-98e0-81f5e6f99ea1"
      unitRef="U_USD">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_bbae8c0f-df0c-4920-b864-e0c22c2199e5"
      decimals="-5"
      id="F_df618466-3e8a-4972-a802-14348f30becd"
      unitRef="U_USD">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_eccd5c57-c168-4f1c-8e20-7cbf55b04e72">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The weighted-average assumptions used to estimate the fair value of ESPP awards using the Black-Scholes option valuation model were as follows:&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.76%;"/&gt;
        &lt;td style="width:1.393%;"/&gt;
        &lt;td style="width:0.918%;"/&gt;
        &lt;td style="width:19.529%;"/&gt;
        &lt;td style="width:3.78%;"/&gt;
        &lt;td style="width:1.393%;"/&gt;
        &lt;td style="width:0.918%;"/&gt;
        &lt;td style="width:19.529%;"/&gt;
        &lt;td style="width:3.78%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Assumptions:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.69&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_9d982be6-c196-4b4e-ae56-0b1fafa482a8"
      id="F_6d150614-97b6-44e7-990f-1c03f223a55a">P0Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_bbae8c0f-df0c-4920-b864-e0c22c2199e5"
      id="F_f4276651-249a-41bf-b2d9-7351cc482e32">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_9d982be6-c196-4b4e-ae56-0b1fafa482a8"
      decimals="4"
      id="F_4bd6221a-8223-40b3-a063-aeab2ec09097"
      unitRef="U_pure">0.7625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_bbae8c0f-df0c-4920-b864-e0c22c2199e5"
      decimals="4"
      id="F_f4d16b42-4a33-4dbc-a549-4719da0757a4"
      unitRef="U_pure">0.7625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_9d982be6-c196-4b4e-ae56-0b1fafa482a8"
      decimals="4"
      id="F_aaec4018-fcc2-45ea-add8-a32af8e0dfb3"
      unitRef="U_pure">0.0009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_bbae8c0f-df0c-4920-b864-e0c22c2199e5"
      decimals="4"
      id="F_4b5c7b47-5713-4c28-bd61-0b80b6bebb7e"
      unitRef="U_pure">0.0015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_9d982be6-c196-4b4e-ae56-0b1fafa482a8"
      decimals="2"
      id="F_d07b5502-86cd-4292-a9bf-a69d19d0646a"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_9d982be6-c196-4b4e-ae56-0b1fafa482a8"
      decimals="2"
      id="F_86d2add3-0218-4ab2-a74c-26de8c532515"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_bbae8c0f-df0c-4920-b864-e0c22c2199e5"
      decimals="2"
      id="F_688ca65d-321c-498b-9bbb-52408b9cbe9d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_b9960611-efe5-44c4-a8c6-f1f963d5a52b"
      decimals="0"
      id="F_c47f9d82-c976-4f97-93d1-d2d20e978857"
      unitRef="U_USD">12000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_9d982be6-c196-4b4e-ae56-0b1fafa482a8"
      id="F_84f51270-9ac2-4ab0-938e-19fcae774d80">P0Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_6ef27173-e664-4f22-9780-2b7a13c106d7"
      decimals="2"
      id="F_7c26ae09-03b3-49e1-ac9f-52231d0f4d0e"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_5f2a0ed1-fb2a-4b67-947c-2aec5ecf5fee">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A summary of the Company&#x2019;s stock option activity and related information is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.8%;"/&gt;
        &lt;td style="width:1.047%;"/&gt;
        &lt;td style="width:1.071%;"/&gt;
        &lt;td style="width:11.851%;"/&gt;
        &lt;td style="width:1.071%;"/&gt;
        &lt;td style="width:1.047%;"/&gt;
        &lt;td style="width:1.618%;"/&gt;
        &lt;td style="width:9.305%;"/&gt;
        &lt;td style="width:0.94%;"/&gt;
        &lt;td style="width:1.047%;"/&gt;
        &lt;td style="width:1.583%;"/&gt;
        &lt;td style="width:9.733%;"/&gt;
        &lt;td style="width:0.785%;"/&gt;
        &lt;td style="width:1.011%;"/&gt;
        &lt;td style="width:1.63%;"/&gt;
        &lt;td style="width:9.674%;"/&gt;
        &lt;td style="width:0.785%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (in&lt;br/&gt;thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,728,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;34,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,725,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options exercised and shares vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;107,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;159,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,186,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.43&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options exercisable as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,127,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.91&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options vested and expected to vest as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,186,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.43&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="INF"
      id="F_1dcaa68f-f1cd-485f-b1c3-7a946bcd0284"
      unitRef="U_shares">2728742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="2"
      id="F_d976d374-2c69-42e8-8fde-07b4d9284fb0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">21.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      id="F_b5324adf-1b0a-466c-9a4a-3395c1f5ab17">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_5bef7818-ec49-410a-b18a-b94f3eb27b7b"
      unitRef="U_USD">34432000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="INF"
      id="F_22661180-372e-44f3-9db4-ac786cf7e67c"
      unitRef="U_shares">1725250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="2"
      id="F_45b79f83-9acc-4dc4-9a9c-c9c970739838"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">37.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="INF"
      id="F_56d5ffc3-afd2-4b63-bb6e-ee288f15031e"
      unitRef="U_shares">-107583</phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested>
    <phat:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="2"
      id="F_20ee5c86-22e6-4cff-8574-1796ab442a6a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.07</phat:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="INF"
      id="F_f9e3e4b3-86fa-4062-8c4f-2a9be06bcabd"
      unitRef="U_shares">159680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="2"
      id="F_9d2d87b0-d302-4a9b-a293-f0bfe602042e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">32.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="INF"
      id="F_4d166bf1-c3bc-4b37-afae-69bdfdc3e7e9"
      unitRef="U_shares">4186729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="2"
      id="F_2c1648e8-74ba-4717-bfd7-4f08d94e9c54"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">27.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_9cf30fc6-4f38-49f0-8d54-f223c354683b">P8Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_bb1cfc34-4917-4525-9ecd-348f37a8d881"
      unitRef="U_USD">13973000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="INF"
      id="F_64e44620-ac69-4b78-ae85-a155d11dc9ea"
      unitRef="U_shares">1127877</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="2"
      id="F_d9898a3c-c913-4331-82ac-05865ad44b96"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_3256e28f-a05f-4d96-9190-afcb63b138b9">P7Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_18f11f15-bb63-4daf-94d2-515a8c0604de"
      unitRef="U_USD">6880000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="INF"
      id="F_4f2830e7-25a2-483b-afaa-c2ef52b0bcff"
      unitRef="U_shares">4186729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="2"
      id="F_9c25405c-b888-454f-885e-38d74567be62"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">27.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_8c230797-50e3-476f-9516-e8798f5ad946">P8Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_5f8ed20f-5bbe-4414-af41-2b230dd6fbe7"
      unitRef="U_USD">13973000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <phat:ClosingMarketPriceOfCommonStock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="2"
      id="F_22a6909f-c0cf-461d-a67a-d5f79bf048b6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.67</phat:ClosingMarketPriceOfCommonStock>
    <phat:ClosingMarketPriceOfCommonStock
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="2"
      id="F_55b9b8b3-d832-42f6-9fa5-82a6d9ef557f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">33.22</phat:ClosingMarketPriceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-5"
      id="F_4e03e350-d67a-4048-948d-c5fdbe1b727e"
      unitRef="U_USD">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-5"
      id="F_2c59d2b0-cd19-4816-a699-37aa7cb7a13a"
      unitRef="U_USD">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_aefa2a08-8860-4371-8c07-d0e5df47bfbd"
      decimals="INF"
      id="F_d3e56b32-9341-4164-b67c-f9853a359d20"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-5"
      id="F_5495f8a5-8743-4046-9a11-4a507a04a9c6"
      unitRef="U_USD">46600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_cbc5a686-160e-48e1-a9e7-689d0517a5dc">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_80d52836-c315-4342-b4cf-a339a9ccf2d1">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The weighted-average assumptions used to estimate the fair value of stock options using the Black-Scholes option valuation model were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.76%;"/&gt;
        &lt;td style="width:1.393%;"/&gt;
        &lt;td style="width:0.918%;"/&gt;
        &lt;td style="width:19.529%;"/&gt;
        &lt;td style="width:3.78%;"/&gt;
        &lt;td style="width:1.393%;"/&gt;
        &lt;td style="width:0.918%;"/&gt;
        &lt;td style="width:19.529%;"/&gt;
        &lt;td style="width:3.78%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Assumptions:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.93&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.06&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;67.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;65.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_14e5e094-e626-4c3d-91ab-f54475b55883">P5Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      id="F_4c07d0be-0c60-42ac-8e60-eb97a87946de">P6Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="4"
      id="F_52a07e27-1f27-4f24-83e6-fb2a435ebc04"
      unitRef="U_pure">0.6746</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="4"
      id="F_8af3cead-b971-4811-97fe-72e1ba5ce17e"
      unitRef="U_pure">0.6507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="4"
      id="F_fc724650-5011-48d6-8a11-008f2d02dfb9"
      unitRef="U_pure">0.0068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="4"
      id="F_aec9c568-3971-4559-ac61-b6a10522b25f"
      unitRef="U_pure">0.0051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="2"
      id="F_1a9468d3-75ca-43e4-8351-bf1f5708633d"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_8f914191-2994-46e5-887e-f448c9800844">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation expense recognized for all equity awards, including founder stock, has been reported in the statements of operations as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.173%;"/&gt;
        &lt;td style="width:1.393%;"/&gt;
        &lt;td style="width:2.281%;"/&gt;
        &lt;td style="width:21.142%;"/&gt;
        &lt;td style="width:0.919%;"/&gt;
        &lt;td style="width:1.393%;"/&gt;
        &lt;td style="width:2.281%;"/&gt;
        &lt;td style="width:20.499%;"/&gt;
        &lt;td style="width:0.919%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,390&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_133a7a17-cc0b-4319-b5dd-153f51460267"
      decimals="-3"
      id="F_da7e2274-7574-4dfb-a4a5-aaba953945b3"
      unitRef="U_USD">3838000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_966c0d74-7852-45f5-adb0-f5683894e01e"
      decimals="-3"
      id="F_3d35a8d6-365a-48ad-bc75-fc2d72886533"
      unitRef="U_USD">1450000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1dc294ca-9c67-4d13-8135-fcee0b125f3b"
      decimals="-3"
      id="F_0be4e825-1613-4975-9450-56bf2ff8ae81"
      unitRef="U_USD">12974000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c0e9a1bb-6f16-475b-b3dc-8ce4769c62af"
      decimals="-3"
      id="F_b6d88e67-a80b-473d-a5e8-7213cbaf99d1"
      unitRef="U_USD">4390000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_00da2b12-2c98-4b19-a30d-2e9f5257e317"
      unitRef="U_USD">16812000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_bdc4e139-99a7-4695-8ac8-e63663e0f9bb"
      unitRef="U_USD">5840000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_1f4a0d66-3ad0-4585-8a79-29c6e154002a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;8. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For the years ended December 31, 2021 and 2020, the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t record a provision for income taxes due to a full valuation against its deferred taxes. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.941%;"/&gt;
        &lt;td style="width:1.271%;"/&gt;
        &lt;td style="width:2.251%;"/&gt;
        &lt;td style="width:21.069%;"/&gt;
        &lt;td style="width:1.501%;"/&gt;
        &lt;td style="width:1.271%;"/&gt;
        &lt;td style="width:2.251%;"/&gt;
        &lt;td style="width:20.946%;"/&gt;
        &lt;td style="width:1.501%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Income taxes computed at the statutory&lt;br/&gt;&#160;&#160;&#160;rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in fair value of warrants and&lt;br/&gt;&#160;&#160;&#160;convertible debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Provision (benefit) for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Significant components of the Company&#x2019;s net deferred tax assets are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.235%;"/&gt;
        &lt;td style="width:1.163%;"/&gt;
        &lt;td style="width:2.25%;"/&gt;
        &lt;td style="width:20.447%;"/&gt;
        &lt;td style="width:1.515%;"/&gt;
        &lt;td style="width:1.163%;"/&gt;
        &lt;td style="width:2.25%;"/&gt;
        &lt;td style="width:20.462%;"/&gt;
        &lt;td style="width:1.515%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;53,749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;53,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Based upon the Company&#x2019;s history of operating losses, the Company is unable to conclude that it is more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation allowance for its deferred tax assets as of December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021 and 2020, the Company had federal net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;290.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;157.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, which are carried over indefinitely.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company had approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of state net operating loss carryforwards that begins to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2036&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company has available federal research and development credits of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million which begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2038&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of state research and development credits, some of which, begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has not completed a formal analysis of the potential impact of Section 382 on its deferred tax assets as of December 31, 2021. Until this analysis has been completed, the Company has not adjusted any of its deferred tax assets, including net operating losses or research and development credits. The Company will reassess the amount of net operating losses and credits subject to limitation under Section 382 when a study is complete. Due to the existence of the valuation allowance, future changes in the deferred tax assets related to these tax attributes will not impact the Company&#x2019;s effective tax rate.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the activity related to the Company's gross unrecognized tax benefits:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.197%;"/&gt;
        &lt;td style="width:1.393%;"/&gt;
        &lt;td style="width:2.311%;"/&gt;
        &lt;td style="width:13.715%;"/&gt;
        &lt;td style="width:0.949%;"/&gt;
        &lt;td style="width:1.393%;"/&gt;
        &lt;td style="width:2.311%;"/&gt;
        &lt;td style="width:12.781%;"/&gt;
        &lt;td style="width:0.949%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Increases related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company has gross unrecognized tax benefits of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;none&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; of which would affect the effective tax rate due to a full valuation allowance. The Company does not anticipate any significant changes in its unrecognized tax benefits over the next 12 months. The Company's policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; accrual for interest or penalties on its balance sheet at December 31, 2021 and has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t recognized interest or penalties in its statement of operations for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is subject to taxation in the United States and various states. The Company is not currently under examination by any taxing authorities. Due to the carryover of tax attributes, the statute of limitations is currently open for tax years since inception.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="INF"
      id="F_85e603d0-45d7-4c76-8f39-fe933e204e56"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="INF"
      id="F_8fae8763-e73a-4231-8bb8-cb62627bbad4"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_cfe167ca-1584-4739-8d4f-e939247e835a">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands):&lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.941%;"/&gt;
        &lt;td style="width:1.271%;"/&gt;
        &lt;td style="width:2.251%;"/&gt;
        &lt;td style="width:21.069%;"/&gt;
        &lt;td style="width:1.501%;"/&gt;
        &lt;td style="width:1.271%;"/&gt;
        &lt;td style="width:2.251%;"/&gt;
        &lt;td style="width:20.946%;"/&gt;
        &lt;td style="width:1.501%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Income taxes computed at the statutory&lt;br/&gt;&#160;&#160;&#160;rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in fair value of warrants and&lt;br/&gt;&#160;&#160;&#160;convertible debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Provision (benefit) for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_6cae87c4-826d-4db3-a2da-01474d4b37b1"
      unitRef="U_USD">-30216000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_9a6a84ed-7752-4057-b2a8-030332b64a9e"
      unitRef="U_USD">-27105000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <phat:IncomeTaxReconciliationPermanentItems
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_ccf44253-bb59-44ef-bc06-a7c4755276c1"
      unitRef="U_USD">1387000</phat:IncomeTaxReconciliationPermanentItems>
    <phat:IncomeTaxReconciliationPermanentItems
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_c5847976-ab3a-4e6a-b225-36959b1d02da"
      unitRef="U_USD">291000</phat:IncomeTaxReconciliationPermanentItems>
    <phat:IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_3668143e-1517-4b29-85e8-e575249edd34"
      unitRef="U_USD">0</phat:IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt>
    <phat:IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_6aeed4a6-2e88-4a4f-87cb-2c73335a6086"
      unitRef="U_USD">-20000</phat:IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_bac2917e-b6c7-45ea-8bc9-c91c6430abe5"
      unitRef="U_USD">2950000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_9dbf47d0-25d5-4f1a-bd83-cbb975d46363"
      unitRef="U_USD">3047000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_05e5d07b-8174-44bc-9556-9ee323b17ca8"
      unitRef="U_USD">31783000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_4c6c7e98-2c9a-49e8-bde3-e68de7b41062"
      unitRef="U_USD">29949000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_2fc4a107-918d-49b0-9bc0-902ca011278d"
      unitRef="U_USD">-4000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_8b438dc4-f117-4301-838f-8a7a024dcfea"
      unitRef="U_USD">-68000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_0bfbce22-c85b-4409-bc2e-68049381c69e"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_28c4b4c1-2aef-4b76-a658-223da5e80cd3"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_2dcf3a2f-e02d-4fbf-a4cb-0a4ce2c1e490">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Significant components of the Company&#x2019;s net deferred tax assets are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.235%;"/&gt;
        &lt;td style="width:1.163%;"/&gt;
        &lt;td style="width:2.25%;"/&gt;
        &lt;td style="width:20.447%;"/&gt;
        &lt;td style="width:1.515%;"/&gt;
        &lt;td style="width:1.163%;"/&gt;
        &lt;td style="width:2.25%;"/&gt;
        &lt;td style="width:20.462%;"/&gt;
        &lt;td style="width:1.515%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;53,749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;53,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_4c6b0aa9-f377-4577-b94d-9feb70662bf2"
      unitRef="U_USD">60936000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_40434b01-88ab-4060-90fc-7d3286194942"
      unitRef="U_USD">33162000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_3ce191df-2d01-479d-858b-ae55663392d1"
      unitRef="U_USD">6694000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_dda97e67-d6fd-4421-b664-ab45d903f56d"
      unitRef="U_USD">3744000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_d48593eb-cf6f-43ae-af2f-fad67ec1eee6"
      unitRef="U_USD">13809000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_2905ba86-dde7-45b0-88c0-cb1a8c1bd95c"
      unitRef="U_USD">14929000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_b3330ced-6867-4f95-b86a-b2113692bb9e"
      unitRef="U_USD">3996000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_d193fa5c-ee76-4caa-a5ce-a03678d8db0b"
      unitRef="U_USD">1914000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_f60625ce-b40f-479e-aa3a-f5e783b91520"
      unitRef="U_USD">85435000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_6430e121-9cea-4525-9821-bae5ed6f5601"
      unitRef="U_USD">53749000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_cf5bf4d8-2b04-4734-8ba1-b61462162d04"
      unitRef="U_USD">85033000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_acee7f70-f054-411c-8bdd-bf2ba96c2cdc"
      unitRef="U_USD">53250000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_ca2e8458-70ae-4ac4-b486-6bcca772ff85"
      unitRef="U_USD">402000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_2564fb1e-b6ea-4ecb-928e-a78016ef5b1c"
      unitRef="U_USD">499000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_75618854-9a50-41b8-be04-d9a5834f3e8c"
      unitRef="U_USD">402000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_f7218eb9-3f6b-4478-8f67-8afa8d165057"
      unitRef="U_USD">499000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_316d98a6-4709-4081-b0fd-a27199fe53d1"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_e4a896f0-56dc-45c5-b1bb-0b1c23a86731"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="C_c2511355-1d5e-4278-9953-83e4963ae813"
      decimals="-5"
      id="F_83f6e2c8-7412-4c86-9f67-d7b53107a75e"
      unitRef="U_USD">290100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="C_b6c9a017-a221-4c88-a8e6-7e275e06e7fc"
      decimals="-5"
      id="F_7b3b41ac-cb7e-4b6b-9b83-9166948f5f56"
      unitRef="U_USD">157800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_7722cfb6-10af-45ab-a5aa-9adea0d22b6a"
      decimals="-5"
      id="F_9db05388-3061-4a77-9976-ecdccf745a18"
      unitRef="U_USD">400000</us-gaap:OperatingLossCarryforwards>
    <phat:OperatingLossCarryforwardsExpirationYear
      contextRef="C_4d9410fc-a3f3-43cf-95a5-e68281c355c9"
      id="F_089dfb9a-943b-4ca5-964b-7225d9197070">2036</phat:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_c2511355-1d5e-4278-9953-83e4963ae813"
      decimals="-5"
      id="F_59aed86a-1ca2-4f73-b0f7-5de7dea7aaae"
      unitRef="U_USD">7800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <phat:ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear
      contextRef="C_efc1a669-0200-4d3b-9503-dde410805b7b"
      id="F_362b0159-37e4-487b-870f-d58511d7fedb">2038</phat:ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_7722cfb6-10af-45ab-a5aa-9adea0d22b6a"
      decimals="-5"
      id="F_ae68d396-5ad9-4dba-ab24-00d7f3e75d1f"
      unitRef="U_USD">700000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <phat:ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear
      contextRef="C_4d9410fc-a3f3-43cf-95a5-e68281c355c9"
      id="F_f397636e-1aba-4e04-ae86-51dc689ee19d">2025</phat:ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_526d0332-d5ba-4c1a-9227-9de35da8d2da">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the activity related to the Company's gross unrecognized tax benefits:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.197%;"/&gt;
        &lt;td style="width:1.393%;"/&gt;
        &lt;td style="width:2.311%;"/&gt;
        &lt;td style="width:13.715%;"/&gt;
        &lt;td style="width:0.949%;"/&gt;
        &lt;td style="width:1.393%;"/&gt;
        &lt;td style="width:2.311%;"/&gt;
        &lt;td style="width:12.781%;"/&gt;
        &lt;td style="width:0.949%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Increases related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_da26151f-377a-4d5d-8fef-8b48ee0ed44b"
      unitRef="U_USD">938000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_33fee96d-a213-48c4-a5ad-68ccefad3cff"
      decimals="-3"
      id="F_b5452460-646e-49d8-b8c6-41a99aa9d45f"
      unitRef="U_USD">176000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_e8347ad6-4f5f-46a2-8221-5d8e52b8a6c9"
      unitRef="U_USD">64000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_bb85efb5-a029-440e-b3d7-0217b070ab2b"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-3"
      id="F_796dc30b-30c4-48fd-87f0-14933b4c0786"
      unitRef="U_USD">702000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-3"
      id="F_a436cec2-52b7-47a1-974b-12a5c522885a"
      unitRef="U_USD">762000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-3"
      id="F_b22b4c39-b5ee-45ea-948c-7360be8fca5c"
      unitRef="U_USD">1704000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_c621285b-51be-4793-ac3f-90046055c2ac"
      decimals="-3"
      id="F_027a3a93-b471-4e86-9cd1-74b9fecf6599"
      unitRef="U_USD">938000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="-5"
      id="F_1f1d9b2c-f9a2-401d-91db-9b8394cff939"
      unitRef="U_USD">1700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="INF"
      id="F_a8245591-d5a9-4d14-a5ee-2c0dfc0563c8"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_19130e7a-aa87-4b64-ad58-c04526b0d2d9"
      decimals="INF"
      id="F_7a0b59ad-07e7-40b1-81ed-be0e0148804e"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="INF"
      id="F_28cf4bba-9977-4dfd-b43c-25f1703f83b7"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:DefinedContributionPlanTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_6716979d-59ad-4015-9b9f-acedaf74d187">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;9. 401(k) Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company established a 401(k) savings plan during the year ended December 31, 2020. The Company&#x2019;s contributions to the plan are discretionary. During the years ended December 31, 2021 and 2020, the Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, of expense related to employer contributions, which was based on a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% match of employees' annual contributions. In January 2021, the Board of Directors approved the annual discretionary match for 2020, which was settled by contributing &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,356&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares. In August 2021, the Board of Directors approved a semi-annual discretionary match for 2021, which was settled by contributing &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,394&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares. In January 2022, the Board of Directors approved a second semi-annual discretionary match for 2021, which was settled by contributing &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,756&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="-5"
      id="F_c32dac71-841c-418f-bf6c-b406b700cf8a"
      unitRef="U_USD">800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="-5"
      id="F_b03392eb-dd0c-4e82-a4f5-a437010d78e4"
      unitRef="U_USD">300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      decimals="INF"
      id="F_99bbdb05-fcfb-4c6d-ac6d-318c9a2ecf07"
      unitRef="U_pure">0.75</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_154dd6a8-f069-4eec-86e5-92a39aa1a300"
      decimals="INF"
      id="F_74e40b13-38f0-439d-b2f0-31b90131f77f"
      unitRef="U_pure">0.75</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled
      contextRef="C_b0c76117-ced6-4a6e-a934-4d66a2de81b3"
      decimals="INF"
      id="F_8e29dd39-7ccf-4eb6-b657-fe523d672c6a"
      unitRef="U_shares">8356</phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled>
    <phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled
      contextRef="C_955ca9b1-fa2d-4384-942f-920fcb5fe424"
      decimals="INF"
      id="F_08374ce2-91de-4cc5-adea-b1c9eb62c248"
      unitRef="U_shares">18394</phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled>
    <phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled
      contextRef="C_78796fa9-c62f-43b9-b92a-90c0ac2aae02"
      decimals="INF"
      id="F_ef53dffd-f39e-4245-a2c6-085972d76f68"
      unitRef="U_shares">16756</phat:DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_ef836273-9d6a-454c-a500-c957bc4a93a6"
      id="F_c8424e3c-7e7e-45a3-b085-d5fd99fc9bfd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;10. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2022, the Company entered into an operating lease for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,250&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; rentable square feet of office space in Florham Park, New Jersey. The lease liability and the corresponding right-of-use asset associated with this lease obligation will be recorded upon the commencement of the lease, or the date in which the underlying asset is made available for use to the Company, which is expected to occur later in 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:AreaOfLand
      contextRef="C_61898c01-23d4-4967-bc48-1597a7447fd2"
      decimals="INF"
      id="F_85f4ec26-c2b0-4bdf-b25e-33a9df859b31"
      unitRef="U_sqft">6250</us-gaap:AreaOfLand>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>88
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  &"850'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  !@F%4W\SU[N\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O:95P=#E9<,G!<&!XEM(;EM8TX3DI-VWMXU;A^@'\#%W__SN
M=W"M#D+[B"_1!XQD,=V,KNN3T&'%#D1! "1]0*=2.27ZJ;GST2F:GG$/0>FC
MVB/4574/#DD910IF8!$6(I.MT4)'5.3C&6_T@@^?L<LPHP$[=-A3 EYR8'*>
M&$YCU\(5,,,(HTO?!30+,5?_Q.8.L'-R3'9)#<-0#DW.33MP>']^>LWK%K9/
MI'J-TZ]D!9T"KMAE\ENSWFP?F:RKNBZJIJCXMN:"WXG;AX_9]8??5=AY8W?V
M'QM?!&4+O^Y"?@%02P,$%     @  8)A5)E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MM@/6R0X6"<<>_)!I?*P;!:(%IXU0[0*,ENS9Y/81QED8&:E@;(S0IC"!8PN
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M%9[7JYD%841KT"]H>H=@#5:N.\%FI!,O8KU)_,]@;:*=;"'7&FJ%P<K!Q)W
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M971V0;IT,W :PZK:]^Q,69H ?EG2C$;M'.A\KI3=&"Y -_6S/U!+ P04
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MY!N.7%"<7(YAK75X894.[<7^C"#IL ?X)ITE7FS[8A"FZ73(!QSIH+=)1]>
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MOSMFM)Y160?ZOI+2;"\V0;?PXV=02P,$%     @  8)A5,8A="2&'0  P%<
M !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6S%7%F3VT:2?O>O0/1.[$H1
M(-6'[K$5T9(MCS8DNT,M>1XV]J$(%,FR !2- LBF?_WF51<)MC0SN[$/MIHD
MJBHK,RN/+[/P_<[V7]Q:ZZ&X:YO._7"V'H;-RT>/7+76K7)SN]$=_+*T?:L&
M^-BO'KE-KU5-@]KFT>7Y^=-'K3+=V:OOZ;N;_M7W=AP:T^F;OG!CVZI^_UHW
M=O?#V<69_^*C6:T'_.+1J^\W:J5O]?!Y<]/#IT=AEMJTNG/&=D6OES^<75^\
M?/T8GZ<'?C-ZYY*_"]S)PMHO^.%=_</9.1*D&UT-.(."?[;ZC6X:G C(^$/F
M/ M+XL#T;S_[6]H[[&6AG'YCF[^;>EC_</;\K*CU4HW-\-'N_J9E/T]POLHV
MCOY?[.39\[.B&MU@6QD,%+2FXW_5G?#A6P9<RH!+HIL7(BI_5(-Z]7UO=T6/
M3\-L^ =ME48#<:9#H=P./?QJ8-SPZM=^I3KSIT(6E<5KY8PK[+*XZ;73W:"8
M<UU=W++0\+=;L^K,TE2J&XKKJK)C-YAN5=S8QE1&N^\?#4 7SOZH$AI>,PV7
M)VBXN"P^V&Y8N^*GKM9U/L$CV%#8U:7?U>O+>V?\45?SXNJB+"[/+R_NF>\J
M<.F*YKOZ!BX5;VSG8*\U?[H&YF3<^G59O#6=ZBJCFN(6OM2@PX,K_NMZX88>
MM/"_[R'H<2#H,1'T^/]5;/?2@.;BI=NH2O]PML%U^ZT^>W4Q+_[W:<NFI+'3
ML]ZLU;"V+?X+![;2XP!3-JXLWG75O"QL7PQK#?)K-ZK;XT<94!8[Y0K35;;?
MV!XD5L,'>M:A_'"='W6C=JK7^,-_JFY$PB_/+Y[/BT_)E$"3*AH<4@&W</$9
MS+#2Q<+834944<F0I853#@L"^;7>@I'<X,YQC_!$JWM4(_,G?M=9^+D8P/0.
MK%%@DHN5 J6RIANT Y;!O+5Q&JR4RPC[]W][?GGQ[*\P)&BFBYJ)VP();N!?
MVK@""?0U/*?!& WKXO/\=EZL=*=[U31[_%EOD$<J2FK3 _?,IM&.V/SS]?7-
MO'AO_AA-;88];>>-VI@!%OZHG1W["J3ZM@=9P3B8#:4W6.!RI=N%[L/9+3.)
MK4%*P"2+B[L1CA/HBV&:F@:E9& W>@E\@7]A.LMJXQD*SR^7^"&9LRP6HP/%
M=J[8-*KKX.>RZ)5Q^%S%))= Y PT$5T1?(N+@'!Q9=BWK<=J@">[&BV"+HNM
M[>RF5W\J4/X6S#(.(3;V>C6";EC0'#6"VO4P!?*K59U:>;) (YTNKH+^@+QA
M'5+U=&+<#JR]!?;"0 LC>R\A^DW5X"L,VAMT>L"L#2CV0!H#S\(*X-5[.C2Y
MHA"+085-:Y#)\A0LL8;)@/*2'NA 4?UZI @PL(?ONE$S:71T%&@#?<*#U8**
M@=Q(7EY2@?-P;,8.MZ.[8VI@]-BC9G80HC36.9FUTRO>7*7<NEA"= 'JC1H5
MB2:73UPN'.J9B,XK',ZB[S80'Y"V5!9U>=3X-RV:K@@GS-*V@(7 /ZT6#?P]
M#B.<'21R",,=/29G&0^8" O/%YLIE$)ZN/G;3,+S?^YP+$=TH+3-*&!XJK?C
M:DU/&^=&.MFP'% ,<AP,;@6XW\)OJ)P=R G4,E((84_W!7:T&,H@61Q_<5Z^
M>/&L?'IU7C@P;MKQI&T+](*V5%]HI\A$F+W2NJ8'U 8^W1D(J#0<W+\4%R\N
MYD\@M&D:W">8'Z0>3.N+XMW-KYDVX>C+\O+)>7E^_B\M^?SY_.GABH&[P-ES
MF*4!A9K!SYMQ 4<?9EEJL'$KUD^T?,1UU+))F[I6H)D+K;MH616POCTP/V 9
MFB9J'AV^E27;8T%*/1SUW=I4:WI$MQOT+:Q@X 92U8')]> 2=@W&+57E?VZ,
M6IB&CX*XM@Z#6EQ[[!VQUA]'/L*U145 #6S&6M,15_7O$)#R_D ?(7S&V)HF
MV\ I,<F1 "-,Q\IV0FP%A[MG&M@=5 V03#[_8 L@/]6B7W$GGDOV,B\^H/$D
MGJ,5Z35X'.0UD ?ZCSD+,'3867##>@/SJ69/@0/:KV'"/WH*4W-P+)1LV19X
M CK0P__U5C4C>O_=6I-)QO]I\J\P$CPA'4<R.UOF(L0?Y&UTZL^ ]^,"S,8"
MDJA_@<KBP2UN^N+AO'BW9"_#%./O*%19_WAEY"0259?I, QN&F<S)L-4SM2P
M4[]C/$KH2/'91F\-<H-6X9F9I,N'&0<7NC' $"$'3"F:,C>"KX;@#W['O"YQ
MQZA4:U)T2P9ORM3!/ V$0<R^3M_!'SO=P)%L.=$@1T%VF@E$ESAYCG<DP*TR
M#5E\6'+!1E379 I0M*K#+SM+)[PGZTH[.3KG"Q0S1$_.+<>&(RUD);FJFM4#
M5L<]41ABED"ZKE$,A_,%50##]CLGN,Z[53F"AUSKR!H2'>1JT8B-/84L%!6H
M00[Y(2$PT]C43'R02:IZ"?]A3[+\7JL>SN=GMBT_073:DNU"\YDZ0_AQ:E^3
MPA#-(W<+!+3J"UB:,#/%/6AC-UX74)M@6K%1L"C$0&B(Q;P$FU-F]M&'!9V/
M-$A/C*L@%,"=L>?$ (.<>S2\$T;VV^+OKLX]"GE@]C2M!25V27H4]_N/+-%K
MRDJ :;!0/V)$B8X20QG5@WLABY^$+'[_,9QCTR82@TRH1V(.V;95O;&CDX 4
MI056RG00AXY,Q[RX;B#TE6C$9>(#UB*^4GNG<;BQ+YW=-;I>L00P)D1"MPD+
M10?!)JM]@:%0/Z"*"*-8,4M\#AB >Q\;&%J1=M<&'7R!I/2<4HB)L.X>'8,P
M39F^^ UXHXL/8'!@ =ZHCQ(D/UI!(D2&H=9+=++%$L<A3X$@F!Z,BW%K7(!-
MJL-0&4A0K<9S3,)J:7Z*.,)@KZSPCTMU%)_7"@3;JM_1H:*29CJZ![LPZ!7&
M>SPOGHLAG1FDH W)4:'_!GY3J@'1E>UF\8L%9N+"!QYHG.RR)J<$T]P9C,<@
M@2KQ$'+&[@,A/HQ\6(.A@>DUA/9DXIUN,*>1/<#Z&V7H!TAN.K<D^N*NT*B"
MBO8@>Y A/2)1T$*#"X!XK%7]%XP/%42^D+*"&@/YU^APJG69,H"2>7YZQHK9
M1@F+ZUQ[BFL-BM/2IH,2'QFCB:5ESZ,C-44F<;8:MQOV1E0J9KCD$.Q\<012
MGR[(D?J4!N;:!@Y3ZQD<X#[=^AH^HUW8^_ 3"*-\]4^)/DVW&8%X0BZ [FG5
M=!)&NY?%>[0MQ<7+XM<% D7D2V4.H;SX8Z2\GO3$L7.D](Z9!C+B.2Y?%N]H
M8"E6!CC+Y_LK$XB+0P,>:1 -K\&K5$-#F)#I_">_Y-7+XG-GCPB'%9@Y'.6!
M4$!* Z8I>$:\L"' 4)Z+XK\2;X0LP\/ P9Q88,[?=EUN:="B5&!WR4,D+NQ^
M'Y 8WU*">0X*'!M]^@/) IGQ0Q2M2M -[$3H0@RH"!'(1(?$S@!MSNA0#2!<
MW6K::2,>WM2T!(O)&VSO<44U(8)1>^1JZ=U@#Z%5ZEC*-'U+]:OF5!UFAZ_@
M)/9XP,#$2V;P]RD?U7,NTM=3YBZU<V+6#L$(D&ODK;C^T_9S8L)?(*W2I\2&
MEO5H^L0$?,L6@,()\_Q+-)<N6,(&Y2FIJJT$9:GY'%-2!Z;%UAACDL66B'?2
M^8O32F(#%_#6]QH]L9<'JB&%SWA^8%@GY1F"R,"26\7 C,,M4+*X @N%"APF
MO/WM=?$>G[N./^682D0LB@=.:]@^J,[3ATS_ 3T2XK,Z EE+\I<YS\GH[2GL
M4^S8BK5M<!:P!$6/E1^.-Z)% .[B%SZ^(";'S"E1*TQ5U9X/HD%G68%!6VF/
MU1V2RWM(I;Z<>HP0;1^WA)"J%C1[10(<G9?TZT957V:W%6P*(14R.3/OC%I;
MZT;DTPE@AGL ?X>6 S%**R8-JX"2@5*I@W[$YX3(7;8)SX$DI$7\UB_ >,[6
M0N3*OCV+#AF0)(@T>01#^H(<YQ+45_<"LY,98=$0V$V8#L<'E%[=@P36$('8
M IUHXU-3&/,'I?D)#6CF$>%5?>V9FI/E;;I?>\9KRR[):3%7>N.^S):@V(@Y
M@FHZ1 @&":MBD(&(*YQF3=DF\Y]P^D\]F:-]L3<:] X.T99""T9D"DDC@>&)
M(HATL,#!^D\_^^.?HV>9Q'-E2*?))3QR*A6?K\T6(A?@.E,)(__4O<TEO.3$
M[2"1CO@S.1@Z-GXV)\B5=H1=\6K9 8M/^J3@",X%S['66092U+W>P;0[_O83
M[I7LSVLY]--&"9?X0-D508JI(2J3(^O$_">F! A',Q&3+T](-/SDAIHLW KH
M' V#1Z,3GS(0"]5X(/@OQ?G\*@"BF"1&$ "Y/#/=3& $,3\4UY&B*T&/D:^.
M/9X%_P7F,^!Z$+^GUO2$OV1K)!%7EO*.$\'7 Y(?Y)J8^3Q\^9ULZ[O7LBN8
M^P OOW@!^WQ\<?7=&[:O"%7$U1\4+YX4#[_[J(_QQD/&42E <ML'(E 8?W7Q
M'"8XO3ZHP%\*DO7E7XLW/OZB/WZ*\5=V;'R 3V :6)O5&@Y@0U4UH&*K/1A+
MMAD,T8IT(@9!?"+1E CLA;$$%EQVJ.&;$723#ARC6H>AX#Q2>?A3@(6]U\)^
M$(-UN("456M=?>$B3!717* #_*B$QH@OX2H(5W:#AY" YC>@'6!K/X(E3&KI
M*8Y 9B$4E&!A-RY^]V!TXEE3-:J.UJEX';2X(8(!2PSDX5[P@5,,R,T;NCT,
M#-!";ZSC*E.QU+543.$74O@\+#?#&$ S\/HH%UCR>!05XR9C439QO4$GP%6X
M4*V2M"KC_2G$->69"?-:T8R,A0G#8OB=[(MVG\!ZP@^$&0ZW[",E!%@"V] [
MK\$CS(N;'F'% 3+0&SA1 ]M"/"@;#OA^ 06*SR#DS'9/^T>.(N7*.AA'^H_0
M9XO%6'1%B$A4;*[F<&CC)X^"<66ALL"'/W6=A$U87T6#/</6"+!KL)DZUA;
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MOUXQEP[F4F<N_=Z\ODIC6W*F6U;@PJ.>TZB>T%O&8_@B/:P5-:LR1Q_6M&V
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M;<]*>P/CV9-Z8<#^U %/1_TM&4$=!>F4&DYS6J[JPJZC'^<U\ )+55MWRP0
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M#3K%09[9%C*#L4\XAEPJ([=6G%1164K16NF-!5M4Y$H@07D"_R*6GRB6.KP
M>?2RM(*ZGHB"'(*M]=:=-#2Q,X%!65,%)B&9TL0(H;(PNBD&O6X-R]UR;BNZ
M]+&Z7SDPC+8,##NGJ>>AV+KBX4/@^2;"P?%&($^=$Q[H@LTO)H[==.%!V:!/
M@[S,5]QBIDK.FVH&<KB7>:QY9R[KNB#=:G2HIX6-::.+B[T'A,=GC[%A=FB^
M5S9.B)M&J!YQ=QP1F"\PRMS%ZHP/^]6!M<[D^_55JEI\'+N1O,%/U#0R2%AV
M50(;[]<*]OB!)]9OGVL/M^G_TJ+K$_ W;]%-S'3[])%MFFRVZ>.^V78UYQ8L
M=T;Z6(O!MHN;8>MJ# T^#Q> =.>!],1;LF:UN6,\CU=K*_%X0?D>W^X2Y[H2
M,VP%@Q[UF(V7?O'!FR)<M$V-]R8//S/!<?:1 -[/##X&J@<RT-R\GOT'4$L#
M!!0    (  &"853?HY;?9P@  'T4   9    >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;*U8VV[<.!+]%:(W6,P"[;ZY'=M9VX#CS& ";!!C,I>'Q3Y0%+O%
M,25J2,KMSM?OJ1*EEGIL3Q;8%UM-D74]=:JHJYWS#Z'0.HJGTE;A>E+$6+^;
MSX,J="G#S-6ZPIN-\Z6,^.FW\U![+7,^5-KY:K%X.R^EJ28W5[QV[V^N7!.M
MJ?2]%Z$I2^GW[[5UN^O)<M(M_&2V1:2%^<U5+;?ZBXZ_U/<>O^:]E-R4N@K&
M5<+KS?7D=OGN_9KV\X9?C=Z%P;,@3S+G'NC'Q_QZLB"#M-4JD@2)?X_Z3EM+
M@F#&'TGFI%=)!X?/G?0?V'?XDLF@[YS]S>2QN)Y<3$2N-[*Q\2>W^U$G?\Y(
MGG(V\%^Q:_>>K29"-2&Z,AV&!:6IVO_R*<5A<.!B\<*!53JP8KM;16SE!QGE
MS95W.^%I-Z31 [O*IV&<J2@I7Z+'6X-S\>;.E:6)B'(,0E:YN'-5--565\KH
M<#6/4$$;YRJ)>]^*6[T@;KD2GR"A".+[*M?Y6, <MO4&KCH#WZ]>E?A!JYDX
M74[%:K%:OB+OM'?XE.6=?H/#M\<.BP\F*.M"X[7X]VT6H@=J_O.*UG6O=<U:
MU_^O,+\JCBKU7:BETM<3E&+0_E%/;M8S\:H:\2^C4$U:W&Z]UK1)?!:5^"3W
MXIS"N[R<BEAH$E++:B^P07N="U-%)Z2PZ;3L3^],+,3/\D'G4M2-#XW$(O;N
M"J,*8;!!!K'U6(4460G]I&P34(2]+&Q6,%E[9:0U7[5X=)6KO?R*W9L&+"&C
MAGXVZY?*D)PO$6MA*NYD):&7O/R^\2"IJ7"^=2"9E-R=B9\'3DD;G"A@%VWT
M5+)D1&BRSB2#T/%Z$ T@['EC[_.4MOX.1F'3M8^@/;A0Y88X)K2ZAA&R%M1%
MY$ANZ,T&1V$HV BGFBKZ_4FV/TF/[$SM7=ZH2,OID5C'P&/L,9;-L0B!%VXC
MOC/_X 7]5!O$BF@.J^V6P#;R&\05X85LG(-5RDI30O^C]@#'LS&7UE4: 17L
M7IF9JI7.*9=16$WR>0^T<9"\K'43C9+6[A/9XC1"D1L.W'?F16-E72/\,K-(
MB=XV<,\A&AU<3&PC P&0L#P3>RU]$!OO2CZ=D\&0M#$>-AWP)(*TFL)F=0@"
M9ZPA2[4OR1N=CX%1H@SZ=\_ 2#0U# [F291,<'__V\5J>?Y/L?,F(JJB<O#]
M&&RP.DGY2_$)Y0H=I@M+&]I:^KA/V@*V!6<?4=![RDY)0"!7FTHU5*L9&K,J
M9M^N=3,J>54@>QJ$$:B:A P 7@P,@O0&&9UVY=L!*HB9^"BX#H)!R8QR.U8X
M9AB";RU-'Z0W8G4V6Z#-64L22*T,18*.":'1_=;E='&QGBX6"Q$*"0HD=52Z
ME'[*4W3J@8 JQ48:3_AO.*YOQ-GLLM,P39A*H@?F_B:]3VP&9H/SB-7Y].SB
MXEM4$M,1!'&F]O"[U;N8X>AB_79Y*FJDE66D[0;41ED\-G5]/K2UK8''WEQY
MX"^OE:9Z@RR9MUP$<2/#=JU'?V+)SE,>QT!OA6ML%^4>=9L&17V2&]L0!;M=
MI7TH3-WEN,NGU]R-*N*'0!0KF>@2389:*[,Q!!M$![LP]'42Q@J4K$VDAL!(
MFB(^8(*<N"I%GB+ =,%%"=R!RL(!=/C?Q! 1,#K3OHZ&]H-22QPF>D'!$LS!
M5XH8AQH=F",W> 2!91H#;ULR-!"0G+&S?6P^WG^>)EZ$3"HU^UQ"\X;;'7,S
M9@<8DLG,6"(WPA$Y5'7\\5QJ$I/GK KNI68"1L(Q*![J*B280",,J%FGV#>H
M1D-.X2IKJX<URBX0O"!F@)\$&6[C+>90YP>$C6O9H![01+>=MAK4D_QH:EH@
M+&S1#K:)KJG8%^-J)\(.M*"!V0J/;"]W"%48_=@V59P]0,EBU7(I=MV2A;3N
M2 YU[M#=-<"U102\VTN+F'.7<T.3*IW.DK #P[52P[.-7^:_8T+G<6M,_(;H
MF))%9;_L7:1P(Z)!MC<2Y3IR=565;BD,I)>&F"-<T!CS/Y#--$$HD-_]U+>Z
MY%!E6LE2=[(.M<4% %ZG.]L19&;B0\,#!/VFGHR)$3._P,2NRPQ:NZE]>F1X
M$#L,EKW=^8AE5ZN+Z=O+MP..'=+83-SRVC?H&%/WZ=GE]'2Q?D%LFM'"T/^9
M^,&A?':=AY]5=*1QN6R'94HRNNVA=1\3@VQ0J!Y3;?Z25IAXMJ".PEUE>L2E
MROF<:;YRU0DU0FK"?DLSDNVJC+F3*6=0_@=8'C7A/C:4<2BPU."YC#H.QJQI
MB8=:%"W7Z]FJ1R\/7!TG6-.R%]TKXH@UJ*&?<.MF$L=L<-^E87@] 9'T240"
M%Z_>/4*#"7%_?/7X C?<UV>N'ND%3]_IZ& L_(,VMY;#2UFZ)Z/(138Y-,0
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M[EKL:UZ_-<OFY6D#2O3]-/6[WLBN^3V[9G/U4UDT&Z?^5F0F&Q(X!0L='_/
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M(.YB1$\8'G2?:5JW\90<T"9F6-^5JQ4G- GA(3T_FM*0$+J\!?G4['DBF?S
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MO!0:8!0WP ,]/C1(H@%O,E\K'B\?1K2\A1D<-7$9>?_Q%PHD&0%Y !KQXE^
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M/#^2]P/"EZ:L^/=-R[)![\(?-T8C$&D![J_*L@E?Z '=#]Y>_Q]02P,$%
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M%H$#+HZ4#,"<*N.<G3F/L^(#H,4!LP>'.MT@T21&0!<Z7-5X?1%.O)A:JT?
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MEC]N%+!S10OP_;HLZ_8/VL#]N/'5_P!02P,$%     @  8)A5,:IXIV""
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MIZ/T>Y(XA+3/RL/,;,._Y>H>Y%@5)#P#VCK0LF1Q@95D3S*<S+#GH*<3+,)
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MX>&9U?/VP;U^M:Z87G-J#8$K@D;=X2  7;\$]<*JTD_?I;(TR_UG3H\G:N=
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MF5EGJ"5^'(%?C/"+ +_XGQH>AY@E4_B3Y9V"6\Q,2]/B2Y%.P-4(5UHV3.V
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M)ECQ9KS^6,KACM8.Y<URM9X6,;>;^>"\#@WH' CX@\WQYBPZL^C<03BQV5O
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MO1A35YAFY#<+IZLP9M?:T= .YHZ^DFB\ YUOM':'A;^@^^XN_P502P,$%
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MD4-YPRV?76BU8YJL,1HM'%7GC>"$I$-96HUO!?K9V:W,5 GLGC^!82?W?%6
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MM?Z13B-\#;[^_V,:,?4/N:WIV([CVWN/G%L6M@=SW'A#6+W$_IF*I6+;,5N
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MO!W4>1N_F+=-E6?^,O^C\G;PW7G;E'/FK^?_/6]?N"_^K[R-FVLGCGYLWKZ
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MTF,U7]J7GB7_7"^L,[@B_^WA3#O.M.8<G.!$:RP43(/*:Y3?G ^S+$DG\4-
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MFC+-(:49.+VMO_,+[?#44%]N\& 'QD_ YRNMW=/ 'QVZH^+L#U!+ P04
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MB!#2WGV/\T),20OBBB4M!-V/P>]!3@9M^4,L9IWQ59P*TO<0@U-N"K2D]T+
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M&N#SN93F:6-'KW;4'OX%4$L#!!0    (  &"850+;^ 1J ,  &$,   9
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M[VG5^,\&;/*S=M9[<7;I]5J\PV@ OGM#\)[; K3Z^^I.#XY?Q]XW]ORNV.O
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M4&@!>K_E7+T,] +U5\7\#U!+ P04    "  !@F%4A5?8UC4#  !2"P  &0
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MZ$^TJ!JX:J!X:7N@1ZYT1V4O,]WTHC +]/TEYVHW, ]HVNC)'U!+ P04
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M"\<")QV,=\#WK=;N:/CNZ_X=V6]02P,$%     @  8)A5!AA2WY% P   A4
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
M[3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]
M9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIX
MT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T
M_C6"R0_L?@!02P,$%     @  8)A5%Y )S K!   $R(   \   !X;"]W;W)K
M8F]O:RYX;6S%FE%OVS80@/\*H9>EP#I;$NVV05V@B9,M0+<8<=#7@9;.,1&*
M=$DJ:?/K1TE5<W:4PUYH/]FB:/H31=UW)/7QT=C[E3'W['NEM)LE&^^WIZ.1
M*S90"?>'V8(.9];&5L*'0WLW<EL+HG0; %^I438>3T>5D#KY]+%O:V%'^,!X
M*+PT.A0V!5\E/+KG\\TA>Y!.KJ22_L<L:;\K2%@EM:SD$Y2S9)PPMS&/?QDK
MGXSV0BT+:Y2:)6EWXBM8+XL7Q<L&\E:L7%OBQ>I&!)!9,AV'!M?2.M_6:-L7
M@?$!0N7NJ/;F4BH/=BX\_&E-O97ZKFDF7,4(74;;#_UGUXFG]O]THUFO90%S
M4]05:-_UHP75 &JWD5N7,"TJF"5]%29TR2ZT#YW$KG375*C;7&GXZZNRNVH?
M<%$?VE,93MBKL@6/!WDFE- %L+8_'6+*"*;LD$SL9"%L^,$&VI'R!C'F!&,>
MEW'9_&]3QS&S9M=;L%V=]F:?&P3)"4A^1,A_,P0Y(2 GAX1<>E/<;XPJP;K?
MV,6W&D%."<CI(2'/A=NP2V4>\0/SCJ![=QRZGX\.@GQ/0+Z/"WEM[X263^V)
MW]F9<+*E75APX8<"07X@(#\<,/2P.7@A%;[)Z9@*U>.X<#=-(90LW-2@DELK
MM!.MH'<(29E$MLFYJ2KINY'8!<*@/7T'NI"P TG9)8VLER\@'#"$BL$HI:21
MG3*'E<<LE#G2Z.K8B\,A>\%LE##2R,:XTH6I@-V*[[N#BO)#&ED0?)R>W+]A
MBQ ^,!(EA32V%>J5@V]UDX%>/.R/<TH$Z3%-L).6I)0*TL@NH#%SG"M35L@B
M6V%06>PD3(@4.)PM9Y09LLAF>!%T!PG)24=D+331=Q"*4D(6?9KQ,@P/0E*N
MR"*[ L?C03A*%EED6=!/,<>8E#^RR/Z@,2<8DW)*%MDIP\'F+5N&MLM:84S*
M,%EDP[R&^;DL9:B,,2G#9,>8;?2]N2/"G#),?K1Y1]NE&)-23'[,R0=[BS$I
MS^2'GGX\CTLM%,.8Y/I69/,,82[KJA+V1Q.8,";EGCRR>TC,W4>(LE >V4)M
M<O$K3$+3@[?&A]O=91T8D[)0'ME"/S'1<$0+UKN8E(7RR!8:Z,W+VM<6V-_-
MU@/&I"R41[;08/+VW+L8D[)0'ME"KV#V3Q%>RJ8LQ"-;B,3<>=(Y92$>V4(T
M)IXU<LI"/+*%:$R<%G/*0OP8\Y]?F#@MYN0^RQ%6RYXQIQB3LA _X,+90)C'
MF)2%>&0+[6'>0&%"#J=D9Z$SC$E9B$>VT!YFR$&V1O>;,'/ F)2%>&0+[6&B
M'.YSLW..,2D+\<@60@NH0QD(WJND+#2);:']1=57L_<)9:%)]SY"_Q)""6NI
MH?PG_(4+Y850Q<*RYJ/;+>&39B5T72MU'LJN]1<CROZ=AOY]C$__ 5!+ P04
M    "  !@F%4H9?JE,D!  "@'@  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QSS=FY;L) %(7A5T%^ (:[F"R"5&G21KR 189%++8\$P7>/@@*<JP4
M::(YE36V?/W+Q2=K/'N/^R9OVV/:;+LT.AWVQS2O-CEWSR&DY28>FC1NNWB\
M7%FU_:')EV6_#EVSW#7K&'0RF8;^YXSJ9?9SYFAQ[N)?)K:KU7897]OEYR$>
M\R^#PU?;[](FQER-%DV_CGE>A=/^?CJ%ZT'&E\G5Z.UC7O5O'U*%TD$*05H^
MR"#(R@<Y!'GYH!J"ZO)!4PB:E@]Z@*"'\D&/$/18/N@)@I[*!\D$99P0) VP
M)M!:D&LA\%H0;"$06Y!L(3!;$&TA4%N0;2%P6Q!N(9!;D&XAL%L0;R'06U%O
M)=!;46\ET%L'']L$>BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$>BOJ
MK01Z&^IM!'H;ZFT$>AOJ;01ZVV"SA$!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#
MO8U ;T.]C4!O1[V=0&]'O9U ;T>]G4!O1[V=0&\?;'83Z.VHMQ/H[:BW$^CM
MJ+<3Z.VHMQ/H[:BW$^A=H]XU@=XUZEW_I]XIG_<QW7MN:WS^?U*=+_?&^^.O
MR]O)P4NXXAS@A_3+-U!+ P04    "  !@F%4*+1H$\,!  ")'@  $P   %M#
M;VYT96YT7U1Y<&5S72YX;6S-V<ENPC 4!=!?0=E6Q'B #@(V;;<MB_Z FSP@
M(HDMVU#X^SIAD%K1J(A*O9M$B>UW7VSI;#)^VUGRO6U5UGZ2+$.P#XSY;$F5
M]JFQ5,>1N7&5#O'1+9C5V4HOB(G!8,0R4P>J0S\T-9+I^(GF>EV&WO,VOO:%
MJ2>)H](GO<?]Q"9KDFAKRR+3(8ZS39U_2^D?$M*XLIWCEX7U-W%"PLXF-",_
M!QS6O6[(N2*GWDR[\**K.(MM2^;#KB2?=I<XTZ.9SXN,<I.MJ[@D]=:1SOV2
M*%1ENB]ZTYT<X@[3_LJOSF_+= 7&F3-GK(\GYNCRN..1-*O[-A8B%XKN3SPE
MQM)7?Q\UIYU3_LOLN+T?QJW:\_"LO5V_QU_/^%3_PCX$2!\2I \%TL<0I(\1
M2!^W('W<@?1Q#](''Z T@B(J1R&5HYC*45#E**IR%%8YBJL<!5:.(JM D56@
MR"I09!4HL@H4606*K )%5H$BJT"15:#(*E%DE2BR2A19)8JL$D56B2*K1)%5
MHL@J4625*+(J%%D5BJP*15:%(JM"D56AR*I09%4HLBH4616*K$,468?_*>N[
M,:N__CG:W--*%_4QG[5_H*>?4$L! A0#%     @  8)A5 =!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M"  !@F%4W\SU[N\    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    "  !@F%4F5R<(Q &  "<)P  $P
M    @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  &"851+
M]#Z,0 <  #T=   8              " @0X(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    "  !@F%4)9&Z.P$&  #1%P  &
M    @(&$#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M 8)A5%BPF25. P  <@L  !@              ("!NQ4  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    (  &"8536% ?L(00  %H-   8
M          " @3\9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    "  !@F%4\2(P"H0"   !!@  &               @(&6'0  >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @  8)A5!@<G/)&!0  U1<
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M965T,3 N>&UL4$L! A0#%     @  8)A5-F$,)C!!@  A14  !D
M     ("!RE$  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  &"853&J>*=@@@  '<6   9              "
M@4^+  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @  8)A
M5(:"'F4F P  F@<  !D              ("!")0  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    "  !@F%4F!X#K,@"  #U!0  &0
M        @(%EEP  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   (  &"8510IDV=U!X  )AA   9              " @62:  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @  8)A5,]4EZ'\ @  108
M !D              ("!;[D  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    "  !@F%4EY6N5U$#  "3!P  &0              @(&BO
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (  &"853]@%$L
MF0,  ,<(   9              " @2K   !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @  8)A5+H&G(Q+ P  @P<  !D
M ("!^L,  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  !
M@F%4=JP,4S(&  "[$0  &0              @(%\QP  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (  &"853<8/XIJ00  $H+   9
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M970R.2YX;6Q02P$"% ,4    "  !@F%4J=J*,*H"  !#!P  &0
M    @($TY   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M  &"852^D5*)"@0  "@1   9              " @17G  !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @  8)A5*.IE+V'!@  01@  !D
M             ("!5NL  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    "  !@F%4<_.0%\D#  #.#@  &0              @($4\@  >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (  &"8525,&1&E (
M ! '   9              " @13V  !X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @  8)A5,O*L*!. P  -@H  !D              ("!
MW_@  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  !@F%4
MT'81#F "  #J!0  &0              @(%D_   >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    (  &"850]+8I0V0D  /DS   9
M      " @?O^  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @  8)A5+<8",NN @  3P<  !D              ("!"PD! 'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  !@F%43Q78K7</  #;50
M&0              @('P"P$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    (  &"853U-B<U;0(  )P%   9              " @9X; 0!X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @  8)A5.'7&C,9
M P  =@L  !D              ("!0AX! 'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    "  !@F%4"V_@$:@#  !A#   &0
M@(&2(0$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (  &"
M852%5]C6-0,  %(+   9              " @7$E 0!X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @  8)A5-WT;S.8!   N1(  !D
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M=#0X+GAM;%!+ 0(4 Q0    (  &"853%?H7"P0(  $H'   9
M  " @>8[ 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @
M 8)A5*+U/VNR @  V@<  !D              ("!WCX! 'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6Q02P$"% ,4    "  !@F%4G\1OC0T"  !'!   &0
M            @(''00$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4
M Q0    (  &"850884M^10,   (5   -              "  0M$ 0!X;"]S
M='EL97,N>&UL4$L! A0#%     @  8)A5)>*NQS     $P(   L
M     ( !>T<! %]R96QS+RYR96QS4$L! A0#%     @  8)A5%Y )S K!
M$R(   \              ( !9$@! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   (  &"852AE^J4R0$  * >   :              "  ;Q, 0!X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  &"850HM&@3PP$  (D>
M   3              "  ;U. 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   [ #L %!   +%0 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>169</ContextCount>
  <ElementCount>455</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Statements of Operations and Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLossParenthetical</Role>
      <ShortName>Statements of Operations and Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100080 - Statement - Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization, Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Lease Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitments</Role>
      <ShortName>Lease Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100170 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_Disclosure401KPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization, Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetails</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Lease Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsTables</Role>
      <ShortName>Lease Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebt</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Reconciliation of Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValueDetails</Role>
      <ShortName>Organization, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Reconciliation of Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Balance Sheet Details - Schedule of Property, Plant and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Property, Plant and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Balance Sheet Details - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Details - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Lease Commitments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails</Role>
      <ShortName>Lease Commitments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Lease Commitments - Summary of Supplemental Balance Sheet Information Related to the Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails</Role>
      <ShortName>Lease Commitments - Summary of Supplemental Balance Sheet Information Related to the Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Lease Commitments - Summary of Future Annual Minimum Lease Payments Under Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails</Role>
      <ShortName>Lease Commitments - Summary of Future Annual Minimum Lease Payments Under Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Debt - Schedule of Total Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails</Role>
      <ShortName>Debt - Schedule of Total Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails</Role>
      <ShortName>Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Debt - Schedule of Future Minimum Principal and Interest Payments Under Term Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails</Role>
      <ShortName>Debt - Schedule of Future Minimum Principal and Interest Payments Under Term Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Stockholders' Equity - Summary of Unvested Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfUnvestedSharesDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Unvested Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Stockholders' Equity - Summary of PSU Activity Under the 2019 Incentive Award Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails</Role>
      <ShortName>Stockholders' Equity - Summary of PSU Activity Under the 2019 Incentive Award Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Stockholders' Equity - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Stockholders' Equity - Summary of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Income Taxes - Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Income Taxes - Summary of Activity Related to Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Summary of Activity Related to Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100500 - Disclosure - 401(k) Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails</Role>
      <ShortName>401(k) Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="phat-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.phathompharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="phat-20211231.htm">phat-20211231.htm</File>
    <File>phat-20211231.xsd</File>
    <File>phat-20211231_cal.xml</File>
    <File>phat-20211231_def.xml</File>
    <File>phat-20211231_lab.xml</File>
    <File>phat-20211231_pre.xml</File>
    <File>phat-ex10_30.htm</File>
    <File>phat-ex23_1.htm</File>
    <File>phat-ex24_1.htm</File>
    <File>phat-ex31_1.htm</File>
    <File>phat-ex31_2.htm</File>
    <File>phat-ex32_1.htm</File>
    <File>phat-ex32_2.htm</File>
    <File>phat-ex4_6.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img45497886_0.jpg</File>
    <File>img45497886_1.jpg</File>
    <File>img45497886_10.jpg</File>
    <File>img45497886_11.jpg</File>
    <File>img45497886_12.jpg</File>
    <File>img45497886_13.jpg</File>
    <File>img45497886_14.jpg</File>
    <File>img45497886_15.jpg</File>
    <File>img45497886_16.jpg</File>
    <File>img45497886_17.jpg</File>
    <File>img45497886_18.jpg</File>
    <File>img45497886_19.jpg</File>
    <File>img45497886_2.jpg</File>
    <File>img45497886_20.jpg</File>
    <File>img45497886_3.jpg</File>
    <File>img45497886_4.jpg</File>
    <File>img45497886_5.jpg</File>
    <File>img45497886_6.jpg</File>
    <File>img45497886_7.jpg</File>
    <File>img45497886_8.jpg</File>
    <File>img45497886_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="504">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>94
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "phat-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 26,
   "contextCount": 169,
   "dts": {
    "calculationLink": {
     "local": [
      "phat-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "phat-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "phat-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "phat-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "phat-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "phat-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 555,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 5,
    "http://www.phathompharma.com/20211231": 1,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 10
   },
   "keyCustom": 91,
   "keyStandard": 364,
   "memberCustom": 37,
   "memberStandard": 28,
   "nsprefix": "phat",
   "nsuri": "http://www.phathompharma.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:ComponentOfBalanceSheetDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Balance Sheet Details",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetails",
     "shortName": "Balance Sheet Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:ComponentOfBalanceSheetDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Related Party Transactions",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Commitments and Contingencies",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Lease Commitments",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitments",
     "shortName": "Lease Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Debt",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Stockholders' Equity",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Income Taxes",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - 401(k) Plan",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_Disclosure401KPlan",
     "shortName": "401(k) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Subsequent Events",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:OrganizationAndBasisOfPresentationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:OrganizationAndBasisOfPresentationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Balance Sheets",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Organization, Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "phat:ComponentOfBalanceSheetDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Balance Sheet Details (Tables)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables",
     "shortName": "Balance Sheet Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "phat:ComponentOfBalanceSheetDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Lease Commitments (Tables)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsTables",
     "shortName": "Lease Commitments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Debt (Tables)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount",
       "span",
       "p",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_c621285b-51be-4793-ac3f-90046055c2ac",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_a6e0c0e2-0899-4673-aff4-66d468643b51",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Reconciliation of Liabilities Measured at Fair Value (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValueDetails",
     "shortName": "Organization, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Reconciliation of Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_a6e0c0e2-0899-4673-aff4-66d468643b51",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "phat:ComponentOfBalanceSheetDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Balance Sheet Details - Schedule of Property, Plant and Equipment, net (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails",
     "shortName": "Balance Sheet Details - Schedule of Property, Plant and Equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "phat:ComponentOfBalanceSheetDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "phat:ComponentOfBalanceSheetDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Balance Sheet Details - Additional Information (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails",
     "shortName": "Balance Sheet Details - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "phat:ComponentOfBalanceSheetDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "phat:PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "phat:PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "phat:ComponentOfBalanceSheetDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "phat:AccruedResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails",
     "shortName": "Balance Sheet Details - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "phat:ComponentOfBalanceSheetDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "phat:AccruedResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_6c52a9cb-ddf2-45f2-a3ab-4d943486cf78",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:AgreementExtendsPeriodForTermination",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_6c52a9cb-ddf2-45f2-a3ab-4d943486cf78",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "phat:AgreementExtendsPeriodForTermination",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_098dcddf-024a-435f-b6ee-bf3342544e82",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Lease Commitments - Additional Information (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails",
     "shortName": "Lease Commitments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Lease Commitments - Summary of Supplemental Balance Sheet Information Related to the Operating Leases (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails",
     "shortName": "Lease Commitments - Summary of Supplemental Balance Sheet Information Related to the Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Lease Commitments - Summary of Future Annual Minimum Lease Payments Under Operating Leases (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails",
     "shortName": "Lease Commitments - Summary of Future Annual Minimum Lease Payments Under Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_c621285b-51be-4793-ac3f-90046055c2ac",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Debt - Schedule of Total Debt (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails",
     "shortName": "Debt - Schedule of Total Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "-3",
      "lang": null,
      "name": "phat:LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Debt - Additional Information (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
     "shortName": "Debt - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_b72f7963-2e17-4f63-ae38-f0567547466c",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Debt - Schedule of Future Minimum Principal and Interest Payments Under Term Loans (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails",
     "shortName": "Debt - Schedule of Future Minimum Principal and Interest Payments Under Term Loans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Statements of Operations and Comprehensive Loss",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_c621285b-51be-4793-ac3f-90046055c2ac",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Stockholders' Equity - Summary of Unvested Shares (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfUnvestedSharesDetails",
     "shortName": "Stockholders' Equity - Summary of Unvested Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": "INF",
      "lang": null,
      "name": "phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "phat:CommonStockReservedForFutureIssuancesTableTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
     "shortName": "Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "phat:CommonStockReservedForFutureIssuancesTableTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_d868eb98-0a9a-4d3b-9ce2-a53206123d64",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_c621285b-51be-4793-ac3f-90046055c2ac",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Stockholders' Equity - Summary of PSU Activity Under the 2019 Incentive Award Plan (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails",
     "shortName": "Stockholders' Equity - Summary of PSU Activity Under the 2019 Incentive Award Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_723f3790-161d-4bd6-86bd-87b733a399de",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Stockholders' Equity - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails",
     "shortName": "Stockholders' Equity - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_c621285b-51be-4793-ac3f-90046055c2ac",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
     "shortName": "Stockholders' Equity - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": "INF",
      "lang": null,
      "name": "phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Stockholders' Equity - Summary of Stock-Based Compensation Expense (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails",
     "shortName": "Stockholders' Equity - Summary of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_133a7a17-cc0b-4319-b5dd-153f51460267",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Income Taxes - Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Components of Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_19130e7a-aa87-4b64-ad58-c04526b0d2d9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_c621285b-51be-4793-ac3f-90046055c2ac",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Income Taxes - Summary of Activity Related to Gross Unrecognized Tax Benefits (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Summary of Activity Related to Gross Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "phat:ResearchAndDevelopmentExpenseRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Statements of Operations and Comprehensive Loss (Parenthetical)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLossParenthetical",
     "shortName": "Statements of Operations and Comprehensive Loss (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "phat:ResearchAndDevelopmentExpenseRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - 401(k) Plan - Additional Information (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails",
     "shortName": "401(k) Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_61898c01-23d4-4967-bc48-1597a7447fd2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfLand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Subsequent Events - Additional Information (Details)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_61898c01-23d4-4967-bc48-1597a7447fd2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfLand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_sqft",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_33fee96d-a213-48c4-a5ad-68ccefad3cff",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Statements of Stockholders' Equity",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity",
     "shortName": "Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_33fee96d-a213-48c4-a5ad-68ccefad3cff",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Statements of Cash Flows",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "phat:IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - Statements of Cash Flows (Parenthetical)",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsParenthetical",
     "shortName": "Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "phat:IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Organization, Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "phat-20211231.htm",
      "contextRef": "C_ef836273-9d6a-454c-a500-c957bc4a93a6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 65,
   "tag": {
    "country_JE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JERSEY",
        "terseLabel": "Florham Park, New Jersey"
       }
      }
     },
     "localname": "JE",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "verboseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "phat_ATMOfferingProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market offering program.",
        "label": "A T M Offering Program [Member]",
        "terseLabel": "At-the-Market Offering Program"
       }
      }
     },
     "localname": "ATMOfferingProgramMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_AccountsPayableAndAccruedExpensesRelatedPartiesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts payable and accrued expenses related parties current.",
        "label": "Accounts Payable And Accrued Expenses Related Parties Current",
        "verboseLabel": "Outstanding accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedExpensesRelatedPartiesCurrent",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_AccruedClinicalTrialExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical trial expenses current.",
        "label": "Accrued Clinical Trial Expenses Current",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpensesCurrent",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_AccruedExpensesRelatedPartiesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses related parties current.",
        "label": "Accrued Expenses Related Parties Current",
        "terseLabel": "Accrued expenses, related parties"
       }
      }
     },
     "localname": "AccruedExpensesRelatedPartiesCurrent",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_AccruedInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest.",
        "label": "Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "AccruedInterest",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_AccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_AdditionalWarrantIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional warrant issued.",
        "label": "Additional Warrant Issued",
        "terseLabel": "Additional warrant issued"
       }
      }
     },
     "localname": "AdditionalWarrantIssued",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital conversion of warrant liability into equity.",
        "label": "Adjustments To Additional Paid In Capital Conversion Of Warrant Liability Into Equity",
        "terseLabel": "Conversion of warrant liability into equity",
        "verboseLabel": "Conversion of lender warrants into equity"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_AggregateOfferingPriceThroughEquityFinancing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate offering price through equity financing.",
        "label": "Aggregate offering price through equity financing",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "AggregateOfferingPriceThroughEquityFinancing",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_AgreementExpirationTermFromDateOfFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement expiration term from date of first commercial sale.",
        "label": "Agreement Expiration Term From Date Of First Commercial Sale",
        "terseLabel": "Agreement expiration term from date of first commercial sale"
       }
      }
     },
     "localname": "AgreementExpirationTermFromDateOfFirstCommercialSale",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "phat_AgreementExtendsPeriodForTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement extends period for termination.",
        "label": "Agreement Extends Period For Termination",
        "terseLabel": "Agreement extends period for termination"
       }
      }
     },
     "localname": "AgreementExtendsPeriodForTermination",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "phat_AssetsLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets, lessee.",
        "label": "Assets Lessee [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsLesseeAbstract",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "phat_ClassOfWarrantOrRightExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, expiration date.",
        "label": "Class of Warrant or Right Expiration Date",
        "terseLabel": "Warrants expiration date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExpirationDate",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "phat_ClassOfWarrantOrRightExpireTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, expire term.",
        "label": "Class of warrant or right expire term",
        "terseLabel": "Warrants expire term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExpireTerm",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "phat_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, number of securities called by warrants or rights, remains exercisable.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Remains Exercisable",
        "terseLabel": "Warrants issued to common stock remains exercisable",
        "verboseLabel": "Warrants issued to common stock remains exercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRemainsExercisable",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_ClinicalManufacturingServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical manufacturing services.",
        "label": "Clinical Manufacturing Services [Member]",
        "terseLabel": "Clinical Manufacturing Services"
       }
      }
     },
     "localname": "ClinicalManufacturingServicesMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_ClosingMarketPriceOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing market price of common stock.",
        "label": "Closing Market Price Of Common Stock",
        "terseLabel": "Closing market price of common stock"
       }
      }
     },
     "localname": "ClosingMarketPriceOfCommonStock",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "phat_CommercialSupplyAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial supply agreements.",
        "label": "Commercial Supply Agreement"
       }
      }
     },
     "localname": "CommercialSupplyAgreementsMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "phat_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "phat_CommonStockReservedForFutureIssuancesTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock reserved for future issuances.",
        "label": "Common Stock Reserved For Future Issuances Table Table [Text Block]",
        "terseLabel": "Summary of Common Stock Reserved for Future Issuance"
       }
      }
     },
     "localname": "CommonStockReservedForFutureIssuancesTableTableTextBlock",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "phat_CommonStockWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants.",
        "label": "Common Stock Warrant [Member]",
        "terseLabel": "Common stock warrants"
       }
      }
     },
     "localname": "CommonStockWarrantMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_ComponentOfBalanceSheetDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of Balance Sheet Disclosure.",
        "label": "Component Of Balance Sheet Disclosure [Text Block]",
        "terseLabel": "Balance Sheet Details"
       }
      }
     },
     "localname": "ComponentOfBalanceSheetDisclosureTextBlock",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "phat_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and software.",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer Equipment and Related Software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_ConversionOfWarrantLiabilitiesIntoEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of warrant liabilities into equity.",
        "label": "Conversion Of Warrant Liabilities Into Equity",
        "terseLabel": "Conversion of Lender Warrants into Equity"
       }
      }
     },
     "localname": "ConversionOfWarrantLiabilitiesIntoEquity",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_DebtInstrumentAdditionalBorrowingCapacityAmounts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument additional borrowing capacity amounts.",
        "label": "Debt Instrument Additional Borrowing Capacity Amounts",
        "terseLabel": "Debt instrument, additional borrowing capacity amount"
       }
      }
     },
     "localname": "DebtInstrumentAdditionalBorrowingCapacityAmounts",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_DebtInstrumentFacilityChargePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument facility charge percentage.",
        "label": "Debt Instrument Facility Charge Percentage",
        "terseLabel": "Debt instrument, facility charge percentage"
       }
      }
     },
     "localname": "DebtInstrumentFacilityChargePercentage",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_DebtInstrumentFinalPaymentFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument final payment fee.",
        "label": "Debt Instrument Final Payment Fee",
        "terseLabel": "Debt instrument, final payment fee or end of term charge"
       }
      }
     },
     "localname": "DebtInstrumentFinalPaymentFee",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_DebtInstrumentFinalPaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument final payment fee percentage.",
        "label": "Debt Instrument Final Payment Fee Percentage",
        "terseLabel": "Debt instrument, final payment fee percentage"
       }
      }
     },
     "localname": "DebtInstrumentFinalPaymentFeePercentage",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_DebtInstrumentInterestAndFinalPaymentFee": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument interest and final payment fee.",
        "label": "Debt Instrument Interest And Final Payment Fee",
        "negatedLabel": "Less interest and final payment fee"
       }
      }
     },
     "localname": "DebtInstrumentInterestAndFinalPaymentFee",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_DebtInstrumentPenaltyFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument penalty fee percentage.",
        "label": "Debt Instrument Penalty Fee Percentage",
        "terseLabel": "Debt instrument penalty fee percentage"
       }
      }
     },
     "localname": "DebtInstrumentPenaltyFeePercentage",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument prepayment fee percentage of outstanding principal amount.",
        "label": "Debt Instrument Prepayment Fee Percentage Of Outstanding Principal Amount",
        "terseLabel": "Debt instrument, prepayment fee percentage of outstanding principal amount"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution pan employer discretionary match number of shares settled.",
        "label": "Defined Contribution Plan Employer Discretionary Match Number Of Shares Settled",
        "terseLabel": "Employer discretionary match number of shares settled",
        "verboseLabel": "401(k) matching contribution, shares"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_DrugProductOrSubstanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Drug product Or substance.",
        "label": "Drug Product Or Substance [Member]",
        "terseLabel": "Drug Product or Substance"
       }
      }
     },
     "localname": "DrugProductOrSubstanceMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan",
        "verboseLabel": "ESPP Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees.",
        "label": "Employees [Member]",
        "terseLabel": "Employees"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_ExpectedCashDividendYieldRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected cash dividend yield rate.",
        "label": "Expected Cash Dividend Yield Rate",
        "terseLabel": "Expected cash dividend yield"
       }
      }
     },
     "localname": "ExpectedCashDividendYieldRate",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliations recurring basis reclass of warrant into equity.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Reclass Of Warrants Into Equity",
        "negatedLabel": "Reclassification of Lender Warrants into equity (Note 6)"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisReclassOfWarrantsIntoEquity",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_FinancialAssetsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assets fair value disclosure.",
        "label": "Financial Assets Fair Value Disclosure",
        "terseLabel": "Financial assets fair value disclosure"
       }
      }
     },
     "localname": "FinancialAssetsFairValueDisclosure",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_FollowOnPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow on public offering.",
        "label": "Follow On Public Offering [Member]",
        "terseLabel": "Follow-on Public Offering"
       }
      }
     },
     "localname": "FollowOnPublicOfferingMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_FoundersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Founders.",
        "label": "Founders [Member]",
        "terseLabel": "Founders"
       }
      }
     },
     "localname": "FoundersMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_FrazierLifeSciencesIXLimitedPartnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frazier Life Sciences IX, limited partner member.",
        "label": "Frazier Life Sciences I X Limited Partner [Member]",
        "terseLabel": "Frazier"
       }
      }
     },
     "localname": "FrazierLifeSciencesIXLimitedPartnerMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_GeneralAndAdministrativeExpenseRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General and administrative expense related party.",
        "label": "General And Administrative Expense Related Party",
        "terseLabel": "General and administrative expenses, related party"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseRelatedParty",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_HerculesAndSvbTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hercules and SVB term loan.",
        "label": "Hercules and SVB Term Loan [Member]",
        "terseLabel": "Hercules and SVB Term Loan"
       }
      }
     },
     "localname": "HerculesAndSvbTermLoanMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation change in fair value of warrants and convertible debt.",
        "label": "Income Tax Reconciliation Change In Fair Value Of Warrants And Convertible Debt",
        "terseLabel": "Change in fair value of warrants and convertible debt"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_IncomeTaxReconciliationPermanentItems": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation permanent items.",
        "label": "Income Tax Reconciliation Permanent Items",
        "terseLabel": "Permanent items"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPermanentItems",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in accounts payable and accrued expenses related parties.",
        "label": "Increase Decrease In Accounts Payable And Accrued Expenses Related Parties",
        "terseLabel": "Related parties accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_IncreaseDecreaseInClinicalAccruedTrialExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in clinical accrued trial expenses.",
        "label": "Increase Decrease In Clinical Accrued Trial Expenses",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInClinicalAccruedTrialExpenses",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating right of use asset and lease liabilities.",
        "label": "Increase Decrease In Operating Right Of Use Asset And Lease Liabilities",
        "terseLabel": "Operating right-of-use asset and lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease)in prepaid expenses and other assets related parties current.",
        "label": "Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current",
        "terseLabel": "Related parties prepaid expenses and other assets current"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_IncrementalCommonSharesAttributableToExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to exercise of warrants.",
        "label": "Incremental Common Shares Attributable To Exercise Of Warrants",
        "terseLabel": "Shares of common stock included in calculation of basic weighted-average common shares"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToExerciseOfWarrants",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_LanderWarrantsExpireTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lander warrants expire term.",
        "label": "Lander Warrants Expire Term",
        "terseLabel": "Warrants expire term"
       }
      }
     },
     "localname": "LanderWarrantsExpireTerm",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "phat_LenderWarrantsExercisableSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lender warrants exercisable shares of common stock.",
        "label": "Lender Warrants Exercisable Shares Of Common Stock",
        "terseLabel": "Warrants exercisable shares of common stock"
       }
      }
     },
     "localname": "LenderWarrantsExercisableSharesOfCommonStock",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_LenderWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lender warrants.",
        "label": "Lender Warrants [Member]",
        "terseLabel": "Lender Warrants"
       }
      }
     },
     "localname": "LenderWarrantsMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_LesseeOperatingLeaseNumberOfOptionToExtend": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease number of option to extend.",
        "label": "Lessee Operating Lease Number Of Option To Extend",
        "terseLabel": "Operating lease number of option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfOptionToExtend",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "phat_LiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities, lessee.",
        "label": "Liabilities Lessee [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesLesseeAbstract",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "phat_LicenseAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement description.",
        "label": "License Agreement Description",
        "terseLabel": "License agreement description"
       }
      }
     },
     "localname": "LicenseAgreementDescription",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "phat_LicenseAgreementTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement transaction costs.",
        "label": "License Agreement Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "LicenseAgreementTransactionCosts",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_LiquidityAndCapitalResourcesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and capital resources.",
        "label": "Liquidity And Capital Resources Policy [Text Block]",
        "terseLabel": "Liquidity and Capital Resources"
       }
      }
     },
     "localname": "LiquidityAndCapitalResourcesPolicyTextBlock",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "phat_LoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan agreement.",
        "label": "Loan Agreement [Member]",
        "terseLabel": "Loan Agreement"
       }
      }
     },
     "localname": "LoanAgreementMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_LongTermDebtAndInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt and interest.",
        "label": "Long Term Debt And Interest",
        "totalLabel": "Total principal and interest payments"
       }
      }
     },
     "localname": "LongTermDebtAndInterest",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": {
       "order": 0.0,
       "parentTag": "phat_LongTermDebtAndInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt maturities repayments of principal and interest, year one.",
        "label": "Long Term Debt Maturities Repayments Of Principal And Interest Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": {
       "order": 4.0,
       "parentTag": "phat_LongTermDebtAndInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt maturities repayments of principal and interest in year five.",
        "label": "Long Term Debt Maturities Repayments Of Principal And Interest In Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": {
       "order": 3.0,
       "parentTag": "phat_LongTermDebtAndInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt maturities repayments of principal and interest in year four.",
        "label": "Long Term Debt Maturities Repayments Of Principal And Interest In Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": {
       "order": 2.0,
       "parentTag": "phat_LongTermDebtAndInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt maturities repayments of principal and interest in year three.",
        "label": "Long Term Debt Maturities Repayments Of Principal And Interest In Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": {
       "order": 1.0,
       "parentTag": "phat_LongTermDebtAndInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt maturities repayments of principal and interest in year two.",
        "label": "Long Term Debt Maturities Repayments Of Principal And Interest In Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt noncurrent excluding unamortized debt discount.",
        "label": "Long Term Debt Noncurrent Excluding Unamortized Debt Discount",
        "terseLabel": "Long-term debt, non-current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount payable in sales milestones upon the achievement of specified levels of product sales.",
        "label": "Maximum Amount Payable In Sales Milestones Upon Achievement Of Specified Levels Of Product Sales",
        "terseLabel": "Maximum amount payable in sales milestones upon achievement of specified levels of product sales"
       }
      }
     },
     "localname": "MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_MinimumMarketCapitalizationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum market capitalization amount.",
        "label": "Minimum Market Capitalization Amount",
        "terseLabel": "Minimum market capitalization amount"
       }
      }
     },
     "localname": "MinimumMarketCapitalizationAmount",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of qualified cash on principal amount following third performance milestone.",
        "label": "Minimum Percentage of Qualified Cash on Principal Amount Following Third Performance Milestone",
        "terseLabel": "Minimum percentage of qualified cash following third performance milestone"
       }
      }
     },
     "localname": "MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of qualified cash on principal amount prior to third performance milestone.",
        "label": "Minimum Percentage of Qualified Cash on Principal Amount Prior to Third Performance Milestone",
        "terseLabel": "Percentage of qualified cash prior to Third performance milestone"
       }
      }
     },
     "localname": "MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_NetProceedsAfterDeductingUnderwritersCommission": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds after deducting underwriters commission.",
        "label": "Net Proceeds After Deducting Underwriters Commission",
        "terseLabel": "Net proceeds after deducting underwriters commission"
       }
      }
     },
     "localname": "NetProceedsAfterDeductingUnderwritersCommission",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_NonCashFinalInterestPaymentFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash final interest payment fee.",
        "label": "Non Cash Final Interest Payment Fee",
        "terseLabel": "Final interest payment fee"
       }
      }
     },
     "localname": "NonCashFinalInterestPaymentFee",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NonCash settlement of defined contribution plan liability in common stock.",
        "label": "Non Cash Settlement Of Defined Contribution Plan Liability In Common Stock",
        "terseLabel": "Settlement of 401(k) liability in common stock"
       }
      }
     },
     "localname": "NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NonCash settlement of employee stock purchase plan liability in common stock.",
        "label": "Non Cash Settlement Of Employee Stock Purchase Plan Liability In Common Stock",
        "terseLabel": "Settlement of ESPP liability in common stock"
       }
      }
     },
     "localname": "NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash issuance of common stock warrants in connection with long term debt.",
        "label": "Noncash Issuance Of Common Stock Warrants In Connection With Long Term Debt",
        "terseLabel": "Issuance of common stock warrants in connection with long-term debt"
       }
      }
     },
     "localname": "NoncashIssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_NonfinancialAssetsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonfinancial assets fair value disclosure.",
        "label": "Nonfinancial Assets Fair Value Disclosure",
        "terseLabel": "Non-financial assets fair value disclosure"
       }
      }
     },
     "localname": "NonfinancialAssetsFairValueDisclosure",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_OpenMarketSaleAgreementWithJefferiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open Market Sale Agreement with Jefferies LLC.",
        "label": "Open Market Sale Agreement With Jefferies L L C [Member]",
        "terseLabel": "Open Market Sale Agreement with Jefferies LLC"
       }
      }
     },
     "localname": "OpenMarketSaleAgreementWithJefferiesLLCMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liabilities arising from obtaining right-of-use assets",
        "label": "Operating Lease Liabilities Arising From Obtaining Right Of Use Assets",
        "terseLabel": "Operating lease liabilities arising from obtaining right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "phat_OrganizationAndBasisOfPresentationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and basis of presentation.",
        "label": "Organization and Basis of Presentation [Policy Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationAndBasisOfPresentationPolicyTextBlock",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization basis of presentation and summary of significant accounting policies.",
        "label": "Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization basis of presentation and summary of significant accounting policies.",
        "label": "Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "phat_PCIPharmaServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCI Pharma Services.",
        "label": "P C I Pharma Services [Member]",
        "terseLabel": "PCI Pharma Services"
       }
      }
     },
     "localname": "PCIPharmaServicesMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_PaymentForFacilityCharge": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for facility charge.",
        "label": "Payment for Facility Charge",
        "terseLabel": "Payment for facility charge"
       }
      }
     },
     "localname": "PaymentForFacilityCharge",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_PaymentForLicenseAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for license amount.",
        "label": "Payment For License Amount",
        "terseLabel": "Cash consideration paid for license"
       }
      }
     },
     "localname": "PaymentForLicenseAmount",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_PaymentInKindPikInterestRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment in kind PIK interest rate.",
        "label": "Payment in Kind PIK Interest Rate [Member]",
        "terseLabel": "Payment In Kind PIK Interest Rate"
       }
      }
     },
     "localname": "PaymentInKindPikInterestRateMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of debt funded to be issued as warrants to purchase common stock.",
        "label": "Percentage of Debt Funded to be Issued as Warrants to Purchase Common Stock",
        "terseLabel": "Percentage of debt funded to be issued as warrants to purchase common stock"
       }
      }
     },
     "localname": "PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other assets related parties current.",
        "label": "Prepaid Expenses And Other Assets Related Parties Current",
        "terseLabel": "Prepaid expenses and other current assets, related parties"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_PrepaidLeasePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid lease payments.",
        "label": "Prepaid Lease Payments [Member]",
        "terseLabel": "Prepaid Lease Payments"
       }
      }
     },
     "localname": "PrepaidLeasePaymentsMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_ProceedsFromIssuanceInitialPublicOfferingGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance initial public offering gross.",
        "label": "Proceeds From Issuance Initial Public Offering Gross",
        "terseLabel": "Proceeds from issuance initial public offering gross"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOfferingGross",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_ProceedsFromUnderwrittenPublicOfferingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from underwritten public offering, net.",
        "label": "Proceeds From Underwritten Public Offering Net",
        "terseLabel": "Proceeds from underwritten public offering, net"
       }
      }
     },
     "localname": "ProceedsFromUnderwrittenPublicOfferingNet",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_PurchaseCommitmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase commitment, expense.",
        "label": "Purchase Commitment Expense",
        "terseLabel": "Expenses incurred related to purchase commitments"
       }
      }
     },
     "localname": "PurchaseCommitmentExpense",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_PurchaseObligationDueInFirstTwentyFourMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase obligation due in first twenty four months.",
        "label": "Purchase Obligation Due In First Twenty Four Months",
        "terseLabel": "Purchase obligation in the first 24-month period"
       }
      }
     },
     "localname": "PurchaseObligationDueInFirstTwentyFourMonths",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_PurchaseOfAdditionalOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of additional offering expenses.",
        "label": "Purchase Of Additional Offering Expenses",
        "terseLabel": "Purchase of additional offering expenses"
       }
      }
     },
     "localname": "PurchaseOfAdditionalOfferingExpenses",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transaction shared operating expenses due to transactions with related party.",
        "label": "Related Party Transaction Shared Operating Expenses Due To Transactions With Related Party",
        "verboseLabel": "Shared operating expenses"
       }
      }
     },
     "localname": "RelatedPartyTransactionSharedOperatingExpensesDueToTransactionsWithRelatedParty",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_RepurchaseRightLapseRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchase right lapse rate.",
        "label": "Repurchase Right Lapse Rate",
        "terseLabel": "Repurchase right lapse rate"
       }
      }
     },
     "localname": "RepurchaseRightLapseRate",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_RepurchaseRightLapseShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchase right lapse shares.",
        "label": "Repurchase Right Lapse Shares",
        "terseLabel": "Repurchase right lapse each month after first anniversary, shares"
       }
      }
     },
     "localname": "RepurchaseRightLapseShares",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "phat_ResearchAndDevelopmentExpenseRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense related party.",
        "label": "Research And Development Expense Related Party",
        "terseLabel": "Research and development expenses, related party"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseRelatedParty",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax credit carry forward expiration year.",
        "label": "Research And Development Tax Credit Carry Forward Expiration Year",
        "terseLabel": "Research and development credits expiration period"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales commission payable as a percentage of sale of gross sales price per share.",
        "label": "Sales Commission Payable as a percentage of sale of Gross Sales Price per share",
        "terseLabel": "Sales commission payable as a percentage of sale of gross sales price per share"
       }
      }
     },
     "localname": "SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, share vesting.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Share Vesting",
        "negatedLabel": "Share vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfUnvestedSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant annual increase.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Annual Increase",
        "terseLabel": "Number of shares remain available for issuance, annual increase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award, options and other than options forfeitures and expirations in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Options and Other Than Options Forfeitures and Expirations in Period",
        "terseLabel": "Number of shares, cancelled or forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award, options and other than options, grants in period gross.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options and Other than Options, Grants In Period Gross",
        "terseLabel": "Number of shares, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award stock options exercised and shares vested.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Stock Options Exercised And Shares Vested",
        "terseLabel": "Options Outstanding, Options exercised and shares vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award options exercises and shares vested in period weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises And Shares Vested In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Options exercised and shares vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement, employee and nonemployee.",
        "label": "Share Based Payment Arrangement Employee And Nonemployee [Member]",
        "terseLabel": "Employee and Nonemployee Director"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeAndNonemployeeMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_SharesAggregateRepurchasePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares aggregate repurchase price.",
        "label": "Shares Aggregate Repurchase Price",
        "terseLabel": "Shares aggregate repurchase price"
       }
      }
     },
     "localname": "SharesAggregateRepurchasePrice",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "phat_SharesIssuedPricePerShareAfterDeductions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued, price per share after deductions.",
        "label": "Shares Issued Price Per Share After Deductions",
        "terseLabel": "Purchase price per share after deducting underwriting discounts and commissions"
       }
      }
     },
     "localname": "SharesIssuedPricePerShareAfterDeductions",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "phat_SiliconValleyBankTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SVB term loan.",
        "label": "Silicon Valley Bank Term Loan [Member]",
        "terseLabel": "SVB Term Loan"
       }
      }
     },
     "localname": "SiliconValleyBankTermLoanMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares exercise of warrants.",
        "label": "Issuance of common stock from exercise of warrants, shares",
        "verboseLabel": "Warrants exercised to purchase shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value exercise of warrants.",
        "label": "Issuance of common stock from exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_StockOptionsAndPerformanceBasedAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options and performance-based awards.",
        "label": "Stock Options And Performance Based Awards [Member]",
        "terseLabel": "Stock Options and Performance-Based Awards Outstanding"
       }
      }
     },
     "localname": "StockOptionsAndPerformanceBasedAwardsMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_StockOptionsAndPerformanceBasedUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options and performance-based units.",
        "label": "Stock options and performance-based units [Member]",
        "terseLabel": "Stock Options and Performance-based Units"
       }
      }
     },
     "localname": "StockOptionsAndPerformanceBasedUnitsMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_StockRepurchaseProgramExpirationMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Repurchase Program Expiration Month and Year",
        "label": "Stock repurchase program expiration period"
       }
      }
     },
     "localname": "StockRepurchaseProgramExpirationMonthAndYear",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "phat_StockRepurchaseProgramNumberOfSharesRightLapse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock repurchase program, number of shares right lapse.",
        "label": "Stock Repurchase Program Number Of Shares Right Lapse",
        "terseLabel": "Stock repurchase program, number of shares right lapse"
       }
      }
     },
     "localname": "StockRepurchaseProgramNumberOfSharesRightLapse",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of supplemental balance sheet information related to operating leases.",
        "label": "Summary Of Supplemental Balance Sheet Information Related To Operating Leases Table [Text Block]",
        "terseLabel": "Summary of Supplemental Balance Sheet Information Related to the Operating Leases"
       }
      }
     },
     "localname": "SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "phat_TakedaLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda license agreement.",
        "label": "Takeda License Agreement [Member]",
        "terseLabel": "Takeda License",
        "verboseLabel": "Takeda License Agreement"
       }
      }
     },
     "localname": "TakedaLicenseAgreementMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TakedaPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda pharmaceutical company limited.",
        "label": "Takeda Pharmaceutical Company Limited [Member]",
        "terseLabel": "Takeda"
       }
      }
     },
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TakedaWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda warrants.",
        "label": "Takeda Warrants [Member]",
        "terseLabel": "Takeda Warrants",
        "verboseLabel": "Takeda Warrant"
       }
      }
     },
     "localname": "TakedaWarrantsMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TemporaryServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary services agreement.",
        "label": "Temporary Services Agreement [Member]",
        "terseLabel": "Temporary Services Agreement"
       }
      }
     },
     "localname": "TemporaryServicesAgreementMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TermLoanAdvanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan advance.",
        "label": "Term Loan Advance [Member]",
        "terseLabel": "Term Loan Advance"
       }
      }
     },
     "localname": "TermLoanAdvanceMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TermLoanFirstAdvanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan first advance.",
        "label": "Term Loan First Advance [Member]",
        "terseLabel": "Term Loan First Advance"
       }
      }
     },
     "localname": "TermLoanFirstAdvanceMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan.",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan",
        "verboseLabel": "Term Loans"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TermLoansAggregatePrincipalAmountTranchesFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loans, aggregate principal amount tranches four.",
        "label": "Term Loans Aggregate Principal Amount Tranches Four [Member]",
        "terseLabel": "Term Loans, Aggregate Principal Amount Tranches Four"
       }
      }
     },
     "localname": "TermLoansAggregatePrincipalAmountTranchesFourMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TermLoansAggregatePrincipalAmountTranchesOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loans, aggregate principal amount tranches one.",
        "label": "Term Loans Aggregate Principal Amount Tranches One [Member]",
        "terseLabel": "Term Loans, Aggregate Principal Amount Tranches One"
       }
      }
     },
     "localname": "TermLoansAggregatePrincipalAmountTranchesOneMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TermLoansAggregatePrincipalAmountTranchesThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loans, aggregate principal amount tranches three.",
        "label": "Term Loans Aggregate Principal Amount Tranches Three [Member]",
        "terseLabel": "Term Loans, Aggregate Principal Amount Tranches Three"
       }
      }
     },
     "localname": "TermLoansAggregatePrincipalAmountTranchesThreeMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TermLoansAggregatePrincipalAmountTranchesTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loans, aggregate principal amount tranches two.",
        "label": "Term Loans Aggregate Principal Amount Tranches Two [Member]",
        "terseLabel": "Term Loans, Aggregate Principal Amount Tranches Two"
       }
      }
     },
     "localname": "TermLoansAggregatePrincipalAmountTranchesTwoMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TwoThousandNineteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 equity incentive plan.",
        "label": "Two Thousand Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenEquityIncentivePlanMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_TwoThousandNineteenIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen incentive award plan.",
        "label": "Two Thousand Nineteen Incentive Award Plan [Member]",
        "terseLabel": "2019 Incentive Award Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenIncentiveAwardPlanMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_UnpaidUnderwrittenPublicOfferingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unpaid underwritten public offering costs.",
        "label": "Unpaid Underwritten Public Offering Costs",
        "terseLabel": "Underwritten public offering costs included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "UnpaidUnderwrittenPublicOfferingCosts",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "phat_UnvestedSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested shares.",
        "label": "Unvested Shares [Member]",
        "terseLabel": "Unvested Shares"
       }
      }
     },
     "localname": "UnvestedSharesMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "phat_WarrantsExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants expiration date.",
        "label": "Warrants Expiration Date",
        "terseLabel": "Warrants expiration date"
       }
      }
     },
     "localname": "WarrantsExpirationDate",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "phat_WarrantsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants liabilities.",
        "label": "Warrants Liabilities [Member]",
        "terseLabel": "Warrant Liabilities"
       }
      }
     },
     "localname": "WarrantsLiabilitiesMember",
     "nsuri": "http://www.phathompharma.com/20211231",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r191",
      "r227",
      "r251",
      "r252",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r487",
      "r489",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r191",
      "r227",
      "r251",
      "r252",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r487",
      "r489",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r191",
      "r227",
      "r239",
      "r251",
      "r252",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r487",
      "r489",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r191",
      "r227",
      "r239",
      "r251",
      "r252",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r487",
      "r489",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r141",
      "r142",
      "r237",
      "r238",
      "r488",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r141",
      "r142",
      "r237",
      "r238",
      "r488",
      "r503",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r143",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ILLINOIS",
        "terseLabel": "Buffalo Grove, Illinois"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.",
        "label": "Accounting Standards Update 2019-12 [Member]",
        "terseLabel": "Accounting Standards Update 2019-12"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201912Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r34",
      "r435"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable (including related party amounts of $1,343 and $173, respectively)",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r34",
      "r88",
      "r428",
      "r430"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Related Parties Current",
        "terseLabel": "Accounts payable, related parties"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r37"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits Current",
        "terseLabel": "Accrued compensation expenses"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued expenses (including related party amounts of $2,330 and $734, respectively)",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r37"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Accrued professional &amp; consulting expenses"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r31",
      "r163"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less: accumulated depreciation",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r294",
      "r295",
      "r296",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r95",
      "r96",
      "r97",
      "r98",
      "r107",
      "r145",
      "r146",
      "r152",
      "r153",
      "r154",
      "r155",
      "r157",
      "r158",
      "r175",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r332",
      "r333",
      "r334",
      "r335",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r423",
      "r451",
      "r452",
      "r453",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r254",
      "r257",
      "r300",
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r187",
      "r228",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments To Additional Paid In Capital Warrant Issued",
        "terseLabel": "Adjustments to additional paid-in-capital, warrants issued",
        "verboseLabel": "Issuance of warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r257",
      "r286",
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation cost",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r57",
      "r74",
      "r211",
      "r402"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization Of Financing Costs",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "verboseLabel": "Weighted-average unvested shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area for operating lease"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r85",
      "r127",
      "r135",
      "r139",
      "r148",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r346",
      "r350",
      "r381",
      "r433",
      "r435",
      "r466",
      "r479"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r47",
      "r85",
      "r148",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r346",
      "r350",
      "r381",
      "r433",
      "r435"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r258",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Floor Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r79",
      "r80",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Property and equipment purchases included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r28",
      "r76"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r13",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r70",
      "r76",
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents \u2013 end of period",
        "periodStartLabel": "Cash and cash equivalents \u2013 beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r70",
      "r391"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r0",
      "r1",
      "r91",
      "r92",
      "r94",
      "r145",
      "r146",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r175",
      "r290",
      "r291",
      "r292",
      "r332",
      "r357",
      "r358",
      "r359",
      "r382",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r405",
      "r423",
      "r451",
      "r452",
      "r490",
      "r491",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change In Accounting Principle Accounting Standards Update Adopted",
        "terseLabel": "Change in accounting principle, Accounting Standards Update, adopted [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r0",
      "r1",
      "r91",
      "r92",
      "r101",
      "r145",
      "r146",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r175",
      "r290",
      "r291",
      "r292",
      "r332",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r382",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r405",
      "r423",
      "r451",
      "r452",
      "r490",
      "r491",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change In Accounting Principle Accounting Standards Update Adoption Date",
        "terseLabel": "Change in accounting principle, Accounting Standards Update, Adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r95",
      "r106",
      "r147",
      "r156",
      "r297",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect",
        "terseLabel": "Change in accounting principle, Accounting Standards Update, Immaterial effect [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r236",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class Of Warrant Or Right [Axis]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValueDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class Of Warrant Or Right [Domain]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValueDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "terseLabel": "Warrants exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights",
        "terseLabel": "Warrants issued to purchase shares",
        "verboseLabel": "Warrants issued to purchase shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r44",
      "r171",
      "r470",
      "r484"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 4)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r172",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Common stock reserved for future issuance (in shares)",
        "verboseLabel": "Common stock initially reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r91",
      "r92",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, authorized shares",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, issued shares",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "verboseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares",
        "terseLabel": "Common stock, outstanding shares"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical",
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20",
      "r435"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.0001 par value; authorized shares-400,000,000 at December 31, 2021 and 2020; issued shares-31,656,035 and 31,262,769 at December 31, 2021 and 2020, respectively; outstanding shares- 30,511,226 and 28,516,010 at December 31, 2021 and 2020, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "verboseLabel": "Common stock fair value"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation And Retirement Disclosure [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs Policy [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income Policy Policy [Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r115",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r83",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r205",
      "r212",
      "r213",
      "r215",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r84",
      "r89",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r201",
      "r202",
      "r203",
      "r204",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r220",
      "r221",
      "r222",
      "r223",
      "r403",
      "r467",
      "r468",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument Basis Spread On Variable Rate1",
        "terseLabel": "Debt instrument, basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r18",
      "r216",
      "r468",
      "r478"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Debt Instrument Carrying Amount",
        "terseLabel": "Long-term debt outstanding",
        "totalLabel": "Total term loan borrowings",
        "verboseLabel": "Term loans aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r188",
      "r220",
      "r221",
      "r401",
      "r403",
      "r404"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument Face Amount",
        "terseLabel": "Aggregate amount of debt instrument",
        "verboseLabel": "Debt instrument borrowed amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r39",
      "r218",
      "r401",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument Interest Rate Effective Percentage",
        "terseLabel": "Debt instrument, interest rate percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r39",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r40",
      "r191",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument Maturity Date",
        "terseLabel": "Debt instrument, maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r42",
      "r84",
      "r89",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r201",
      "r202",
      "r203",
      "r204",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r220",
      "r221",
      "r222",
      "r223",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPaymentTerms": {
     "auth_ref": [
      "r41",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.",
        "label": "Debt Instrument Payment Terms",
        "terseLabel": "Debt instrument, description"
       }
      }
     },
     "localname": "DebtInstrumentPaymentTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r42",
      "r84",
      "r89",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r201",
      "r202",
      "r203",
      "r204",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r214",
      "r220",
      "r221",
      "r222",
      "r223",
      "r229",
      "r230",
      "r231",
      "r232",
      "r400",
      "r401",
      "r403",
      "r404",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Debt Instrument [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r201",
      "r400",
      "r404"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument Unamortized Discount",
        "negatedLabel": "Unamortized debt discount",
        "totalLabel": "Debt Instrument, Unamortized Discount, Total"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets Goodwill And Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r322"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets Liabilities Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration",
        "verboseLabel": "Operating loss carryforwards which are carried over indefinitely"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r327",
      "r329",
      "r330"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research",
        "terseLabel": "Research credits",
        "verboseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Less valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan Cost Recognized",
        "terseLabel": "Defined contribution plan employer contribution expense"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Defined Contribution Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "401(k) matching contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent Of Match",
        "terseLabel": "Defined contribution plan, employer matching contribution, percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]",
        "terseLabel": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r249",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "401(k) Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_Disclosure401KPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r74",
      "r161"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization expense",
        "totalLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r74",
      "r125"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share, basic and diluted",
        "totalLabel": "Earnings Per Share, Basic and Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r110",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized",
        "terseLabel": "Unrecognized stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Unrecognized stock-based compensation expense, weighted-average period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r51",
      "r52",
      "r53",
      "r91",
      "r92",
      "r93",
      "r96",
      "r103",
      "r105",
      "r112",
      "r155",
      "r228",
      "r233",
      "r294",
      "r295",
      "r296",
      "r334",
      "r335",
      "r366",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r492",
      "r493",
      "r494",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r74",
      "r225"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment Of Warrants",
        "negatedLabel": "Change in fair value of warrant liabilities",
        "terseLabel": "Change in fair value of warrant liabilities",
        "verboseLabel": "Fair value adjustment of warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r203",
      "r220",
      "r221",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r370",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r369",
      "r370",
      "r373",
      "r374",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r203",
      "r220",
      "r221",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r370",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value Liabilities Level1 To Level2 Transfers Amount",
        "terseLabel": "Fair value liabilities, level 1 to level 2 transfers, amount"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value Liabilities Level2 To Level1 Transfers Amount",
        "terseLabel": "Fair value liabilities, level 2 to level 1 transfers, amount"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r375",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]",
        "terseLabel": "Schedule of Reconciliation of Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement Policy Policy [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3",
        "terseLabel": "Fair value liability, transfers into level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3",
        "terseLabel": "Fair value liability, transfers out of level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease",
        "terseLabel": "Change in fair value",
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r203",
      "r220",
      "r221",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r369",
      "r370",
      "r373",
      "r374",
      "r377",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value Measurements Nonrecurring [Member]",
        "terseLabel": "Fair Value, Nonrecurring"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r378",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative (includes related party amounts of $18 and $157, respectively)",
        "totalLabel": "General and Administrative Expense, Total",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r253",
      "r255",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r74",
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment Of Long Lived Assets To Be Disposed Of",
        "terseLabel": "Impairment losses"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r159",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r32",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "In-Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r165",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r86",
      "r311",
      "r320",
      "r326",
      "r337",
      "r339",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r87",
      "r104",
      "r105",
      "r126",
      "r309",
      "r338",
      "r340",
      "r486"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "totalLabel": "Provision (benefit) for income taxes",
        "verboseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r50",
      "r307",
      "r308",
      "r320",
      "r321",
      "r325",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate",
        "terseLabel": "Income taxes computed at the statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Income Tax Reconciliation Other Adjustments",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Income Tax Reconciliation Tax Credits Research",
        "negatedLabel": "Research and development credit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenProvisionForIncomeTaxesAndIncomeTaxesComputedUsingUSFederalStatutoryCorporateTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase Decrease In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses (includes related party amounts of $2,766 and $399, respectively)",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "Increase Decrease In Interest Payable Net",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase Decrease In Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets (includes related party amounts of $82 and $(82), respectively)",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r54",
      "r124",
      "r399",
      "r402",
      "r472"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r61",
      "r209",
      "r219",
      "r222",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense Debt",
        "terseLabel": "Interest expense",
        "totalLabel": "Interest Expense, Debt, Total"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r68",
      "r71",
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid Net",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r37"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r59",
      "r123"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee Lease Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee Lease Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments Under Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: amount representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee Operating Lease Option To Extend",
        "terseLabel": "Operating lease, option to extend description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Remaining Lease Term",
        "terseLabel": "Operating leases, remaining lease terms"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee Operating Leases [Text Block]",
        "terseLabel": "Lease Commitments"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorLeasesPolicyTextBlock": {
     "auth_ref": [
      "r419",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.",
        "label": "Lessor Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LessorLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36",
      "r85",
      "r136",
      "r148",
      "r176",
      "r177",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r347",
      "r350",
      "r351",
      "r381",
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r85",
      "r148",
      "r381",
      "r435",
      "r469",
      "r482"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r38",
      "r85",
      "r148",
      "r176",
      "r177",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r347",
      "r350",
      "r351",
      "r381",
      "r433",
      "r434",
      "r435"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r18",
      "r202",
      "r217",
      "r220",
      "r221",
      "r468",
      "r480"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt",
        "totalLabel": "Total debt, net of debt discount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt Current",
        "terseLabel": "Current portion of long-term debt",
        "totalLabel": "Long-term Debt, Current Maturities, Total",
        "verboseLabel": "Long-term debt, current portion"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt Noncurrent",
        "terseLabel": "Long-term debt, net of discount",
        "totalLabel": "Long-term Debt, Excluding Current Maturities, Total"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Longterm Debt Type [Axis]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r42",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Longterm Debt Type [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r70",
      "r72",
      "r75"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r48",
      "r49",
      "r53",
      "r55",
      "r75",
      "r85",
      "r95",
      "r99",
      "r100",
      "r101",
      "r102",
      "r104",
      "r105",
      "r108",
      "r127",
      "r134",
      "r137",
      "r138",
      "r140",
      "r148",
      "r176",
      "r177",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r368",
      "r381",
      "r471",
      "r485"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss",
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recently Adopted and Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonfinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of obligations not classified as financial liabilities. Includes, but is not limited to, accounts payable and accrued liabilities, commitments, obligations, and other liabilities.",
        "label": "Nonfinancial Liabilities Fair Value Disclosure",
        "terseLabel": "Non-financial liabilities fair value disclosure",
        "totalLabel": "Nonfinancial Liabilities Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "NonfinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income Expense",
        "terseLabel": "Total other income (expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income Expense [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r127",
      "r134",
      "r137",
      "r138",
      "r140"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease Expense",
        "terseLabel": "Operating leases, rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "negatedLabel": "Less: operating lease liabilities, current",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r409",
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Cash payments for operating lease costs"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r415",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted-average incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r414",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r6",
      "r90",
      "r121",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization, Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r37"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other long-term assets",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Other Liabilities, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other",
        "totalLabel": "Other Noncash Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Other (expense)",
        "totalLabel": "Other Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over Allotment Option [Member]",
        "terseLabel": "Underwritten Public Offering"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Issuance of PIK interest debt"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PartnerTypeOfPartnersCapitalAccountAxis": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of partner's capital account. Examples of classes of partners include, but not limited to, general partners, limited partners, preferred partners, and other ownership interests.",
        "label": "Partner Type Of Partners Capital Account [Axis]",
        "terseLabel": "Partner Type"
       }
      }
     },
     "localname": "PartnerTypeOfPartnersCapitalAccountAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain": {
     "auth_ref": [
      "r235",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital accounts of each type or class of partner. Examples of classes of partners include, but are not limited to, general partners, limited partners, preferred partners, and other ownership interests.",
        "label": "Partner Type Of Partners Capital Account Name [Domain]",
        "terseLabel": "Partner Type of Partners' Capital Account, Name"
       }
      }
     },
     "localname": "PartnerTypeOfPartnersCapitalAccountNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.",
        "label": "Payments For Repurchase Of Warrants",
        "terseLabel": "Aggregate repurchase price of warrants"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Cash paid for property, plant and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-Based Stock Units (PSU)"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r258",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, authorized shares",
        "verboseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r19",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, issued shares",
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "verboseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, outstanding shares",
        "verboseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r19",
      "r435"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, $0.0001 par value; authorized shares - 40,000,000 at December 31, 2021 and 2020; no shares issued and outstanding at December 31, 2021 and 2020",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "verboseLabel": "Preferred stock, $0.0001 par value authorized shares 40,000,000 at December 31, 2020 and 2019 no shares issued and outstanding at December 31, 2020 and 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r8",
      "r26",
      "r27"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets (including related party amounts of $0 and $82, respectively)"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrincipalOwnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Owner of record or known beneficial owner of more than 10 percent of the voting interests of the entity.",
        "label": "Principal Owner [Member]",
        "terseLabel": "Frazier"
       }
      }
     },
     "localname": "PrincipalOwnerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds From Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering, net of issuance costs",
        "verboseLabel": "Proceeds from Initial Public Offering (IPO)"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from issuance of shares",
        "verboseLabel": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds From Issuance Of Long Term Debt",
        "terseLabel": "Net proceeds from issuance of long-term debt",
        "totalLabel": "Proceeds from Issuance of Long-term Debt, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r64",
      "r289"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r48",
      "r49",
      "r53",
      "r69",
      "r85",
      "r95",
      "r104",
      "r105",
      "r127",
      "r134",
      "r137",
      "r138",
      "r140",
      "r148",
      "r176",
      "r177",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r345",
      "r348",
      "r349",
      "r352",
      "r353",
      "r368",
      "r381",
      "r473"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r31",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisposals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Disposals",
        "terseLabel": "Disposal of property, plant or equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisposals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r30",
      "r162"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Property, plant and equipment, gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r14",
      "r15",
      "r164",
      "r435",
      "r474",
      "r483"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Total property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r29",
      "r164",
      "r505",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property, Plant, and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r14",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r14",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Property and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Minimum purchase obligation",
        "totalLabel": "Purchase Obligation, Total"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r247",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r247",
      "r426",
      "r427",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r426"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction Expenses From Transactions With Related Party",
        "terseLabel": "Expense related to services"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r247",
      "r426",
      "r430",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r424",
      "r425",
      "r427",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "verboseLabel": "Final payment of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of long-term debt",
        "totalLabel": "Repayments of Long-term Debt, Total"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r304",
      "r449",
      "r518"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development (includes related party amounts of $4,933 and $2,812, respectively)",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses and Accruals"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r233",
      "r297",
      "r435",
      "r481",
      "r496",
      "r501"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r91",
      "r92",
      "r93",
      "r96",
      "r103",
      "r105",
      "r155",
      "r294",
      "r295",
      "r296",
      "r334",
      "r335",
      "r366",
      "r492",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stock Price Per Share",
        "terseLabel": "Common stock, price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r42",
      "r89",
      "r220",
      "r222",
      "r229",
      "r230",
      "r231",
      "r232",
      "r400",
      "r401",
      "r404",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule Of Debt Instruments [Text Block]",
        "terseLabel": "Schedule of Total Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Components of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Reconciliation Between Provision for Income Taxes and Income Taxes Computed Using U.S. Federal Statutory Corporate Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r257",
      "r285",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r257",
      "r285",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule Of Maturities Of Long Term Debt Table [Text Block]",
        "terseLabel": "Schedule of Future Minimum Principal and Interest Payments Under Term Loans"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule Of Nonvested Performance Based Units Activity Table [Text Block]",
        "terseLabel": "Summary of PSU Activity Under the 2019 Incentive Award Plan"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r31",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r428",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule Of Related Party Transactions By Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r258",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r263",
      "r274",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Weighted-Average Assumptions Used to Estimate Fair Value of ESPP Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs).",
        "label": "Schedule Of Unvested Restricted Stock Units Roll Forward Table [Text Block]",
        "terseLabel": "Summary of Unvested Shares"
       }
      }
     },
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling General And Administrative Expenses Policy [Text Block]",
        "terseLabel": "General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r256",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Description",
        "terseLabel": "Equity plan, description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
        "negatedLabel": "Number of Stock Units, Forfeited",
        "terseLabel": "Number of Stock Units, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "terseLabel": "Number of Stock Units, Granted",
        "verboseLabel": "Stock awards, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Balance at December 31, 2021",
        "periodStartLabel": "Balance at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfUnvestedSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value Per Share, Unvested Ending Balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value Per Share, Unvested Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "terseLabel": "Number of Stock Units, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]",
        "terseLabel": "Assumptions:"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate",
        "terseLabel": "Maximum percentage of eligible compensation contributed by participants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized",
        "terseLabel": "Additional number of shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Common stock, shares authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Number of shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Options Outstanding, Options exercisable as of December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Options exercisable as of December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Options Outstanding, Options cancelled",
        "terseLabel": "Options Outstanding, Options cancelled",
        "verboseLabel": "Options cancelled or forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Options Outstanding, Options granted",
        "verboseLabel": "Stock options, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Estimated weighted-average fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r265",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Options Outstanding, Ending Balance",
        "periodStartLabel": "Options Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted-Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "Options Outstanding, Options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum",
        "terseLabel": "Annual increase to shares available for issuance percentage of outstanding common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r256",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfPSUActivityUnder2019IncentiveAwardPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Options cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche One [Member]",
        "terseLabel": "First Anniversary"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r280",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndESPPAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Options exercisable as of December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Options exercisable as of December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted-Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Options vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r46",
      "r51",
      "r52",
      "r53",
      "r91",
      "r92",
      "r93",
      "r96",
      "r103",
      "r105",
      "r112",
      "r155",
      "r228",
      "r233",
      "r294",
      "r295",
      "r296",
      "r334",
      "r335",
      "r366",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r492",
      "r493",
      "r494",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows",
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r112",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows",
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r19",
      "r20",
      "r228",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "ESPP shares issued, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r228",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Common stock shares issued",
        "terseLabel": "Issuance of common stock, shares",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r228",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period Shares Restricted Stock Award Gross",
        "terseLabel": "Vesting of restricted shares, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r20",
      "r228",
      "r233",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "terseLabel": "Issuance of common stock from exercise of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r19",
      "r20",
      "r228",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "ESPP shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r228",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r19",
      "r20",
      "r228",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period Value Restricted Stock Award Gross",
        "terseLabel": "Vesting of restricted shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r46",
      "r228",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Issuance of common stock from exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Stock Repurchase Program Number Of Shares Authorized To Be Repurchased",
        "terseLabel": "Number of shares authorized to repurchase"
       }
      }
     },
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchaseProgramPeriodInForce1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Stock Repurchase Program Period In Force1",
        "terseLabel": "Stock repurchase program, period in force"
       }
      }
     },
     "localname": "StockRepurchaseProgramPeriodInForce1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased",
        "terseLabel": "Remaining number of shares to be repurchased"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r19",
      "r20",
      "r228",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period Shares",
        "terseLabel": "Repurchases of shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r23",
      "r24",
      "r85",
      "r144",
      "r148",
      "r381",
      "r435"
     ],
     "calculation": {
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets",
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r398",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r398",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r398",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r398",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r436",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r313",
      "r319",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary Of Income Tax Contingencies [Text Block]",
        "terseLabel": "Summary of Activity Related to Gross Unrecognized Benefits"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r95",
      "r96",
      "r97",
      "r98",
      "r107",
      "r145",
      "r146",
      "r152",
      "r153",
      "r154",
      "r155",
      "r157",
      "r158",
      "r175",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r332",
      "r333",
      "r334",
      "r335",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r423",
      "r451",
      "r452",
      "r453",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r306",
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "Gross unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued",
        "terseLabel": "Accrual for interest or penalties related to income tax",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Expense",
        "terseLabel": "Interest or penalties related income tax",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions",
        "terseLabel": "Increases related to current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increases related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits That Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would affect effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r113",
      "r114",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants And Rights Outstanding",
        "terseLabel": "Fair value of warrant liabilities",
        "verboseLabel": "Initial fair value of warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted-average shares of common stock outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.phathompharma.com/20211231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2611-110228"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.F)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235116"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919352-209981"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL119206284-209981"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r519": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r520": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r521": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r522": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r523": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r524": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r525": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r526": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r527": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r528": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r529": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>95
<FILENAME>0000950170-22-002536-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-002536-xbrl.zip
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M9<*>P][ J<X!MC(T;. G'UWHS#KR^O(V!Q%J [!;D1^CAY>AMD+<T\S._:2
M\!,K9.F6QX)(")X( WPC^2*=#XUOU)Z;WHQ7YI_[M/T35XN:ZIZ+W7MVB;3#
M[140=R4(*1RS2.&OY#U1Y:?"T6BJE F)LB?C1E&PU;$2!F+E?M[H8M9*P0TH
MPPPF=5OUJ^H,"^?3[0*@@XB7V%RWT^O*BYUI.UZGQD]'/TAT/S/)J31AY\FT
MM09W"5EH=5B]F6?"<IX^A5RH_P:HP074>(#JK0N?-KJ) D>>+6K=X+FQ2F0S
MW)R'33Z]AW5<S(B\F.!9*&WJE#6@_5MG'<9/_#HX*'MYG9D4[2<3?JC=S@4+
M3$8 :>%V<X2+RNVPR]@)W:;13V,009&/ME0YL<7T]!N(1BIVT66WG^5H#9N#
MVND;]L4[31K0 L'NG?TR]/NB$HCA6;'\#8TBW!V7B"1IC1^)$O6/3O9?>7HS
M87[H2A)4-#Y5GEM@ON5N;#,,LX418.&MIN> 3BJ^+3UD:5"5D+2-B^-%M43<
MG'D6!B9)9*G_;J)6),H7F*KT*<ZP:7/Q:,MQ 1C)=5->H-[)JBW]VKN; P5@
MZ)99M^NG)V2$/#>^ 9X!5 #T]TMVW\ K:%XW4X$]#(?V_8751\=0MS=\4HHS
M[-./26\:/GPM\:[O9SY@"9,R_/G.^P+W4N$S>6\<65Y0$5L2%!9S0;)AQ]L.
M:(0V5@^]LMQH@W91P$8MY(MPZ:%$J#=Y![CI&6P.WUI,*I$GW/S^VJ/V\@K\
M\<7=/JK^RG@4CFP,/CKV1Z80(4?._2C>M8 'P;$?$I^SM/#&J?1K@%]FH+6
M(?-^WU+@$5GHI:1KRXUB7*7G /H5[FCR]XAH$IDCU]O@TMQ&4.8DV$ZQ;+BR
MR'BK<N:ZX?S\]-7@:'$6 ^!]P0SFM\'@G!I\XU3S%2KI.T[;9[YL#+JZ$RFO
M A3_\YW*?Q;&CZ6.AGC@\(XX1>W.<LV;2^LV=N*S7;P$U=<3TNID@_4"XL!$
M@Y<3&%=!Z*9&<80FYJW<.6 Q;!Q^3!^#M9QG/0=\@D6"T+\U%"5:O%V-\1C*
M+Y4Z!P1O(S-.2+!M%SR4=A'!V.M_TK2<].0P=N>5^-^N+G8.N'\.8($AKY3
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M3G70LP;NG Q\R;_8#YB(8JCT&%;0U9HY;WS;[,F$6WJ26TR=1>,WCNA&BU#
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M,H6-:1X/2AE;-%L3/P%8#"0W;P"U<;U.1)A"9 E6$GW_1(GW$+]IU7 .M"7
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MZBWOR>,HR\E4#_%3.";9)A0,B&X UHLONY\(/WG+@JQ$>LMP%^*WE@#I0#>
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M(^A\KAA]$*5$L<G">)VA1+MUUFR:AAGL0>2G,VNB6.U8/@D]A5)2/XOP^$P
M_9!VECU7HL&%,?@)3DTP?BA)\A$Q+3]8GKN;2SSZV(-5F.BSBPSW8AONN%..
M$YOV(16D&#.49H5?Y0U)&"X%R(8G'+FQ>C+?E^]FH;[M;>\%W!?X!@VK23EH
MSL^V%'S#7M1UT-/O1 Y>Z0W4R=48K'W-/PY8L_KY ?N53S=8(TTT;@%G,Q1
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M!_0Y/#_F'\FDPE?H"=3S6LV@$QVQ[6YT*A7 Y-X"M#1P_=QMDCA5AR#J:$+
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MP6MMY(LK#A0+?2(^FD1EC4+EXU_;L=W'QPP=UP7!ZZ^G;@%[3\"7S]2UYRN
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MA(846UK!7'&%[)W=H1S80,Y6U (FQ>.ZQG>EL92TO=Z26:\*^L^VS0'V_.^
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MD&_S<)O@\]J$>B4J;JZ9!]T.>P#_B] 5QJD2X'WN=_O-VRP!Y+%/\(OYS4O
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M_K.GFR\-R;7R9;7&]1!A YQDEP#['7\-7,AK]![CE:K1SK?H@>2O!]+6.(A
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MMQ+0M*.[DYX;4U4,[4-+EQO ;XU(^P*)/V"T,@5>MAZ3U3Z!H:I>U(L K45
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MSW*5=^\&1_Q'+,C_&U?$D^BN%C?,1+=-1*8BQAQ;&08DR]9>G-'D]4I6:+Q
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MB[O?AB>%5W?69$TS/AN%*=NCB3#S:/K64!<>\TL (DTMPL(AFT?)P]?PX3;
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MN$]80;M\"*%.[*KA!3#$.>MP4"I%?$-KM,-SF>?'0W>IO6UPVE7_+S3=T17
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M.13C2I[7@I4 LRYCY0_>6L>Z5_-^"N+T5I;9UE6F9B7/+TFLJYQLLLX%5A_
M.$^(T_QFOG4PX(6AAC/M1%B&2>>#$Q@ ,Z./OKO54"U@ &>.$(CB^GHK)^%K
MF?7+VHQHZZ ZA? 816K\5!8M)G"9MO49TH*VUU2UO]W)X ":<OC;,.A>4^^=
M.PDFWF_51(](K0R]6U)A76ZMCFT?_ -YIO 4F$I$980E!YH[[K,CIWX3ZG@
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M1"F2;)VVW-S9?<F<=0?W/+U3\<ZT,X)3R/SSS& *NN[F]_>1W8!8/R_$]TL
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M+&\%60LRZU!NQF)J":K3==/Z@W^$^Q+P'VK=,SQJ4@#K;,ML71 =COY9-^M
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M #W_KL:OGI^*],M$F %0W+E$*.)HA*FE0<B>WY@JWQ-[?67NX]\%.)GG1ZR
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M3-SYE+?,BSU8_[PWVOB 4 %430\<M3; ]-20^T;><X-(0AT\W9ZBXCGB%TG
MO_S&\F]*5O'R J<F:;!\7_4]8";U291+Z;D?4'L[5?K\Y&]/5]@J-5I_@"_Z
MCG_ND'5:2(UDT!NX,.'F_C+F5^4S"7%%>N<-=166G-C=H63,$0%78+C7/>!9
M^QL$XZ>C)9VF]F;,MPU&/5PAB2Y^- 6_ BWO9*U%")7!G"TS9&N(N)CW ^]:
MXFA&M%NB0.)9I]+:=<?.1 >T&'V)" RYXX4JWP/"R-^B!E/YXH0$'W0K&23K
M()IU42T1P+@)/(M^&Q;O6[Z% CRM@&1TFY'.0LTW@"2[0))SDBA7C/-ON(JR
MD)HB@1J+W(<@_J%';3ZYEJ_T??1$/GK=K)0IAEFE=IU?)AA$4IW==2+WH9/F
M)!CU/S>Z**6#-ML-T,B8(M>_)N7J>;-?]29*C)68^"UMVB^5#E6IIR^?_Q4Z
M .)"WY1 A6[S)7T0?$2+\5Q]+@6[B^6[20T^I":2L#=M@T5)66G4S++7WR<E
M95YX^]:<UNYNB"W"E>[TI> Z,]QG?N[N@3Y/XCO/$\=;TBS51M^6;V9;I0 8
MARGME7YS;9LO;LA$5R&6TN%'-^R=9'<S4P%CE#/%(^8^76#8HFE_"'^!F3)!
M2BB#B-#A/8"$!5TDSETX)+#C35>3"WV ++D"3EJ3*\W[@Z5+E[^B@XN#NO\^
M%KM#IK>SPA.:8Q2N"W(,Z?$4>"@ V5.3_RF1ZEFJ)?M?]U^T)_^O7A =*Z]Y
MW+X:F\I<V94*^L=U!]:Z!]0]Q&QG\+[U=84Y:^"8G<S%ZWO X9B_8WLU& GQ
MABIA$JLV2/X]=,(&*K#Q^'\[D7MP%8^UH2UB0\"I3O/;O'N  Q\IU C34X'Q
MTZJ%.YT]:6YI@6\WQ<AQ%:C_*/[Z2S>.//OE,.7#MZ-M?P\%HAH&?'_= PQM
M2]71R+8#9J7;,P4HFZ#X1*]?8#AZ1X_W[CD:&%8,KXIS_! &TW\R _/]\84T
M06[(X<JD @=$KECP(VVKR'AGRJGKUS]N)*,^@5E6R1JW9UKK2E'&MM]:I(Q#
M("D&>9$$0]F$?BH1"5W<ME/,%]3.BM;&'4Z;# WO<0N7T$":W0-\T,!>7^?.
M3,:UZ,984_N%#Q[_:@J,(VR +TG3EU6NO&O2I,EV?&U[NV)7^=LAF7]5,6X(
M9<=B"#F?X&C)ANV' \/VR;F?A_#?TB\<Z#CBVCF*^A#'Q! 1Y5:T304]9W4I
M;VF-XHG*:(IJWQOLMR'?9"#KCU(D'+8:WP@AU5/<0K3T3WU7]I?J>D""_9_L
M5#V-OBQG-1PTUL.[W,_4)P;H%/.KS.RIKHJSKZI2*I;G!USC);$Z=_]K#V.(
MDN *]8"13%0UW_>I)C#/6S">9-:/*EYM/5AJDK9LT:$S"4XN$302G3HH'MD#
M7)30[YKB*>F<E51#0+@;=PK5!HV1_/*T+)V/?2XEO2G/.'KY(G=1 @@&+[7'
MK;FE%/P.=%E&-Z=FIFDKS*;]SA:ZG)L)@.$:<M+@>/PW%6,!X,_55^!+*1(_
M@J\@4B/=%L?" -M__M>Y+F@6)&S A:0F^D:^&,*E48\RCW1^1R;</C7@\^/E
M1SH# //;SZ_5W9<X.*7N 3UWS(D#=^23Y[\^^4&:N$1=R&BE3_">O<;9S<34
M7,1@JA :<4RDJ+]14)$-*=6_)ND7]!!)/*]A5O+ZT041JHJ\KYN?8C^_QM%)
MK!&4B<HDFHO)ZK'W*MOPH\<].O+864^U(DWZSGCM9<DM.NY?44@?H=6GD]&P
ME;9RN6 (/MUS7W_C;% >/;V=D+ZD=PP;*=F\!Y!+6HL$29)6@&OM13(/QRH-
M8S7JHHM2O#GPI35=6R2;<37Q>G;-7B'R$A\,N4QT+AGJ;S^0>&?6*Y<K1H4[
M535%Q]WJ \C"=3-$Z3<Q=G#*9U<%[[5&ZJ%#CG6-"(O6EJC5?>KB0O@9:@DZ
M2S,BX*%KVL>QK)]R0XDZRD*.&9N@2V!((H'!0/)2N/6S1?L,;)#_"_:W!:)?
MR,<-JH\OLFA'!/1(2)Y$I#DJR'BN<%0=-^>0:>BMY8L>O%_E%'0]!_(WS::;
M>NXM&;%V@'SG#OF0AQ9#_9V\**6(QMBUR$[ZGW:\MM/L;IX!+,]'6.F5/VB6
MRKP6HWE.GL:X%M<IO#_W\+U-_P9!!83;RC%U9"![WL+ NOE\V=%+XG:WMJ--
M\J8HR8\W2 0PII7Z@10L)2:>#'@U0&:OP#DO[5SS19RXX;5#&7-'(F;?>D^6
M]3TWCA/(;AA0B6&=I#MT$3FEF-]$_*M+FC/G*@_$G-U?_#7]E_?>V[B$'%^@
M8HDYL36=QX?I3.-]"EB _F'G4)K&Z\S0--6)U1@7)];5D:U+IE!4#?(RZIQ'
M9Z@3B*Z.=/"\!^#UP\A@$>F&A6UZ;WM8XNN7,#2T?[T5AB1C Z;,*21%?! \
M[@-FSZ8$)_ A65H@ G\QMJ\.Z=?CE$4K)[E8CH]IUZ%%,7"4?I0T_=U8%XX0
M'Y7A?N' I?>EA$M35#'91+EYDO$(46HC8</'7"R+SRH3$B@;)RXDK+]*8#!7
M#&V67+:/VG9ZU+/H/S7,E%FXO?;\\=$7 /U\M=^3]VETI&FJXXE'LUD2*SR.
MK>"JU5\K<_U"()('-O0]7S$:VQV]VBT N<]WV?/%TB7V/+#7DI%04]-LC9OW
MDYPBD9@Q6F_GSY1?\M*,\RN["):A_EDF\(0NDB#+2>B,2-['ZT_9"H.'65G.
M1S\G&+FB;ZL$9S'1:"Z$3-^.,T<3]27<?$*H(CR=-5[4DZ/PR2FN],RDPQKQ
M)H9@78864MSNO?& >!7B>$DW8_!BV<]PAL2T-*\XZ76 <W?RZD^DXI?7TX76
M$Q)'.8=^?-,'94:-Z ]62Q>NS1.@Q8/-&RYT!=)[@$C$#(T3ZN&"L[PC;!0^
M4%75<;Q(M8>P?%Y-HU*;4OE4?3(;Q37?B0VUC$3J!RFV7;##^7B.6!O:&VS7
MME2_<N \>AZA X]#-D%<>D@2S$DZ<>_&Q"6]C<[39IMYMEM25>N_6;?XK'R;
MP2^3$.5L<<1*\*E6ZCF%Y"$"N^F!> O=3@',-Z#I[92IA9[XP^=)+R1K@M.P
MJ*7X)4>1G K>%J_?5$RH"_[CX5(X]*Q:.E$Q^_L4"!273&-4DA@\,5[8M=Y;
MC2S= 3;9Y&\D+KX8ZM6CH@I$A9F:+.^B'.+B_YJ8R%']$V:\?AO!B?/[,Z[8
MV17Y@-$&Q+;/M[KNY:@>5<J*=&!KE,$]@!,#'F0B0/_MQMR1KF)RY_J$5X&H
MV0;*1K(=%]<Y8FN)+?OV<;Q/]$P2,+FISL3;VG:U![>\=G"^X65FW9D@06%R
M IW3=0SL!@5\&(OI^9/C*-YWPP_W6YWP/FD:KV22(*43S8AVR11? ILZ=MI^
M4;I6O'%LP.B T<*GLJCPB; %&,@%[V?"@:+U&^>MWW'-8O2M?RF7(&L7(>B(
MNHV:R#LFC'NIW9C_AC_+]:<NQ'.RM C^K#_DY"&B^C@1PT/J8/*^>T"];8S0
M/> Q)K"ODPOSS=\-\?)C>%Y?L[B'U]=N0A;[#\,?22Z#-VU##9D8T9%ADC+7
M9ICF:_T9CS6276GZR?Q)C\W6G\KZ06'EV$HKM^O=._3+^I:EH>7;.PIJ?=]V
M<JH*8KQ7UOP85$N$8T)J1)Z(4%;H=U:K>>E)/4(<#Y'0S=^81"+F^JNHW]?-
MN%29':M/"QHR+"USAJ@>>G$3DU[_W=K])?0'RH;IJ+A1QN2C@<IVW*E]G?1M
M"8.S=@6>N8;J:/9M;MV@R=P8\9B31,)]E6O9@)GTSM>HS<_+&*5><8_T0FW(
M;R5/U_WGBUD1@5LUZRP3:%ZW+AN2^,YG&%O4/6 0)LTW6PAOUQ"&>?KYE2XK
M#G\>?QM?_G58(M05YW'V1FU52%S9<&_>L9AEP<Z2O[B]2_MBA+1K&:5VZ=%T
M<<5>BJGO_N7\^3'!#63Z?(T.:I3@!V9%=862.XK@)G"D?%#BQY&(>DZS5I"
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MQ,YSXV].CC4%Z;KA05PLG'7,RM;,K8S=EQ2YM)AD!!^=F:D1Q&^ 3KC-VT%
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M%V(MLC%'1F>J<83D&=@+9;YC1!)A-#4^;@O=!K?PTSE3(-S:<,I/ I6%?^P
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ME6OCV2F<.:970(U2:8^YN-ATV1O[N3-VK61Z#U+;_0.U?59ZG*+VOI-N2M_
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MI67WPCTNY/P70EV->I3$(.0;U\"[(*$::N&$9-*^]7(^S79/%MII\!:#6+!
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M _00*U(!/B=>W@;)7>'873\]^O? _Q1W5!' :M/\G\5TM_(FLKT^_]FL>!.
MU)8GF!7TWP;> >)IXJHM_K-,[P[ !J;2PKF _!?WO[C_Q?TO[O]?N)0F'=(.
M2^[#<P26FR$E')'<.';_VZ;L_].YF_T?4$L#!!0    (  *"850@GIC/B64
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M]0>1)+H2FC^)1Z=?:$)">$8<XW16XI7U;O0S1G[R&X[=Y%F!T$M!&;<^^6
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MSOVU9J07 OH88,'"#G*(C6HAK6?C$SHJMM@'=.D JR&__/P"^TAST+2KKS"
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M1&749G>M"Z0X+6WUI52F4G<?7RR8!+$A-*$+@0*N1XXU=:^1492)'NO IN-
MD"@X5&=X#5X_ZG+U1GU:1TB6<L]7ZSV\F/Q<=]9JLK(&$6;!S<4=1I6DRXX
MA[L:C2NG=2MS/Q!(YRHY;=HI^80WXIIM&7&AD 6?V^(@#4H4:7<G0-['M6#S
MQ/W%*-KYZ^MJUA3 D[G59+5,6@NAW,[@R7)SS*M4]JPWHCI1UEV(S:53#M_O
MF::0'*NR/I_IPU?*(W>.>%YZATUR\!3A? K92#X89 C00_<@O?(<D_4NP1H^
MXO[@7.8Z>7W4MH0H8SE"\YF [YP;3G#5M8SL[FBE.5]G>:)3AP!HK/&FAX@J
MD4)=!BQBPS'Y^?(>I.P*]*8OM7^P[L;Q.&  [>J1;:Z6ED\J?(_N[:NMX2CZ
M^FR?8KOZ3.OLS&\#S0T.P@ =<Q1'S%(:!&4#W2HAW>]K0J;.@L"9Y!9;QZ_@
M 73.I-Z3N5_P0H2?93[<%;L+RO6C"VMZF(.L>T!W)C,Y2"QE]BA,Z9#ML#P#
M)8"XK %/A]*]:M*:]R*YNIY;3QF]DUY/*B&[4-R$=,M%&E<[NQPLH//]ZNK<
M=NY:J+2N[_0^K.9G]COH!/P(ZB(]'?>H^C--S%_OS=\[8"<-A[L]#PPL?L9P
MJMR6;!F]ADPJ-K7W*[F[1?D  TQ2TUU+HCA86I'H'7QLT;EHB-BM6D3D;OB0
M+5R0$Y_(%@USG$;'?$Y_OU0#^#D_UEB<8>&G5EB8JR$:OZ$[>X_T+8"7*$-D
M<L"/ Q[M*%W:,6WSJ\V_6O X1H$ KIT/[I)TBW$<4$I:\D'V^CQU+?J2?J.7
MS].,@*?ZD:WKR3/9/0?@K%WX/>UBD AB[_6HQ2B*8N$\Q<[K,3[$N34V&%<C
M,Y7J+I&[&U(?0H;<ZYR]BFB&O@JP#+0O,MW$Y_41W>=Y:_VY#7!+)V8/EH$)
MVS0)=4*N>#GNO?:1O?:J(Q9L\65TY=Q4CM/>,D9BB4C:<V.B00MGTT(LM*/.
MQ*!ZJ]0.R>=:TOD1]QDQ/O?&H&8.\SK>Z($BVY;ZWU_,K, 9G=C95SWL7_3@
M*W.M(HV#\4K0UTPOD6I'/'UX3$HI&/I@8N_!GFPR12SQXY4G&(":FREV*AEH
M&T;SV?GEE9*G^#PMVJ">9OX(L3?U5><^U"6Y<#.GBY VS 4K8(="20EMRA,=
MI<8/":T-Q;.?,B++"8M!KU!2=L\#'9SO22P2"PXI-55ER$=H.(B,RXHC?=0;
M6)S\O%-/'!AWDSCON,WE LY(C\68R$5F<\_\ZK'JQ@TZS[N;HFB=MY"J7MKR
M,F3MZ/TQ9\^.FH8Q$:E<?MJT[,(WF9L=5;=#CD1Z4/8Q4C)T*C"=>[/?'02N
MY>*]N;8OF^J9[^@+7^ML=*5VP/J+/^A$":>G2YP628CDY'K7-F:#I2S)D5 M
MA%+2\8Y,QB,/IMB>1@LN9OU75MS"_)0FX.?F<L:*8O%/GSE_VR;L-2)->\'T
M1FA KOSVB(L('UW[Y/0Q7,.U$%RN9W?88_YLO?3-4XZ/E]2#:&?!CGKPLA"R
M\I=.1T8,FS@KE7%!OI*UIM=XM9Q6@Z5N<Q.9F/S#]9\'KU.6?QC%:I5D4K+-
M8/"#E/+.QDU711T,L%EZAM"BWCKVAC")S1F;.0@:;6PV>+WEKD_WX1 ?Q(LZ
MF R6XJ= Z0[7S%C)W#;ETU)K?F=#7,,#X1DXFNKMMT0DQ91(7^4UV/V*WC>%
M/0ECO-5>SX8W%+LU62^""(RI6@P4TD*TAN8-[TGWGSD=]*UR0T[>DK*Z.&3$
M[(ILM C85:R;&#6GCW0F"\FNA(E9!7F[/HXA$L890_HOZM>%UQ1X]J D%AE%
MWPI0SQJ'+YKA^DK%2!H^D]GJKX8R@C-4$?KI(4N!DETWQTBN)M7RSNHX!7YA
MY!+9N(E]J^UKF)H@7NYU-NZ1KB='M#E-J*&?]- [A_EZ,1LW/**.*$C.[V"E
M  ^!18X< ZV<[^'(U&:YD;>[I(991?AV2=HB,BF>[AD=!['%G'3X--S]V/)Z
MAX/<Y>FK*[WI/3^683B/(8MS1 $*(YX:'AV7R^S/*N^J6DS?1X@3 0"D&UZ:
M0;'5D#O7.4AE3T<'O9GAZ,C8CH-'W!'UQBT9F(2?1&-C0BI[R9@<>X)O;D8:
MG((E15GO,GMYGH,/!VY?YF?YOBE+Q,)3/7I$7ZKI/:5\Q7[@6ODE<BD_&".\
M&'W?D@X"NYA#AQJG,X^[5FO]J/ BDUPHW<VFHDF0NP$!!]KA33KM*JZDTK%+
M<!CG&..JW.V+3:7\/AX5<<!*">XSJQMI$LA>=V1J0->X,@9F0QH9=@A20\:.
MS@R\"]V6RL,V7$LW6]BUKMC?O!]QS,W7H4%L1;C,4<[5#/A=T*ZT7D%I+?*!
M.EFH:^!C?8VZQLJQMQB9%IZ91L%)I"F-@SA3NN<HV&M@>](/6:J>P$AH.U,3
MLV^8KR%5.-,/<;;''G*X<3HLY0"*LO_8J^I#$(4+SY%N4&WZE: UJI^0+MUX
M=Z@M%6]BFVNS.4F84)9BN2-U:[>ECS^%^$TJQ]F2."@:<#?1ZNR_K#/.]K&A
M8KPZL5[*>67,N:E@13;"'6)FJ+K82OT#J2"79-02X?LH>OR2:8&M50=.L,I1
M^5WD^T5'"AK+'T@9O@\5[*?WDQ,.E<1S)OV4II?3TQH,RKM\72WFVKU- J,:
M7L0Y<'/(!2]J-P5KR9'LVN'=&US<R5W9::Y$:G4*O/]@U!%G!!1_6N+<W>CW
MDF5#:"2]^E!5%T>_N[=GEEN3]I%0586>TX4-D%&E;3=#PKHM*.MK&Q%!\7FB
MD6[L':/VNU.ED4RXYPUH6M?.]4G7#GYR<*6>O2=X/HXD[S[?<>#WV\ODS_R>
MW<+["%][71*@[OSLN%A8R.3KHT^UG\PK[RU5 2I[8U3<DY;AI2+.C@]'2]G?
MQZ1N,<&NL1B["^HQ+<?.11Q<)M-=NQ_?B>8-FWCD55RP4_V.6<5^^I;V0J#0
MW&3#'JDEV*/M.'&6,<,XI$9WJBRM\D%\*Z]Q1; JUW,[O(;LE(FT?^CCDL1&
MK46L'5I>V[!@@XF8\VC:)AR.%/.V$XIR5:8>A+X)2N"*\+P,I;)_G=]>-&T_
M+!P\+?*)<07:8(OTV#+C:I=A[[N'?+G$)Z05WNGH\DA/MP,# )QQ?G&^_T][
MWQW4Y->M^R((J$!  0$E5!NA"JA :-)$1'IO2H=0I'<"(AT"@H#2JZ T*2%T
M$$)15#JA0P#I)4%*I"2'WSW?G+DS9[[?^<ZY_]RYUS^>F7<RD_?)N_9::S]K
MORM[YX(4\)0MQ00[Q891+U9%;QR7)>5]B<V/4LD#NI/*Q73(0F-'_?4UVA%+
M72. AFS_L_A*SA7H%7!!$6SRX$/)]$P1,AD9_UK*$O4L4J!G5F+)KLBK]?R+
M'%"MBDNL]:O%-3D62517BZ@:IK(V:D\@0#/[2X?ZC92/O2&)(+.)G6D#%:P&
M8]="TX6*A6%Q 6G+M#Z1=7J_I]/DB7?=)2IY<=(]Z*MLIYA(SWCI\]T%O-6F
MZS8C?0@F)F40><-^I1KN5MQ/_)/[=>GQKS^->:Y1&'A/58N>8C?MR3\5B!G$
M^IX53#W9(F-0E?=&A'#/8RG(POD-N>I'F9G*L>W==U5Y]QC)ML1>+:;C<T#K
M;?1>63KZ.!/'@X$9AZ0SO66RZ].@_U/N26ARORRQ<1JG7+, $6*%@1GPS/GI
M;U(_E7<A5U(9LDQ*.-WDV,4KXYPK/-4M](*DM)&1:G?]HMVH51(Y>=]0S(<A
MZ)24[B>(C<MPG!5ZUF.'=AHB_*V:>K]>?&-T:V+]LE\AJH01E_; ]B=PZ#0'
MI*)@O9;\P'BH"7D(7S@).$G_2@(P;V2/1.S)A_9!S";CAFL&5NHC+E8C60SG
M:Z6^R4?(!_N"]P>6+NZV,<$:W\=B*RG@MK/2J$D7S@CG$/957>OK8?J!&@N@
MR[#@>S*TN"*TOQ\JW+9UQ%I]F7/F7&6%;&\N2"V_N;K/ &\0>F+VWG[VQJB.
MR;"7'S0C8(Y7B=?]X+Q\-U\=LMRW^W#AK ()WQ-X+!5@5XU0X!V,9"Z(:T3<
MG6EXL!PB[2%FD&3B"!;!&21XFETSP>B8#2.35I.@YVY%O[&>)]^&C(6?U4O_
MC89*=XXKM28Y]('0T3+^Q5^"QL+XXL.83TZ@0'*S($:R>5DZ&1%[,"O.JRZZ
M0L7'U<O26/@R]U2WZ@F=*LO[D[L!"2R!MJ/-SUT=^"5?*&OVK^ORQ1W-VS%M
M'A(OXY8_>+H@::G4&^M=JOL=$3UX[MIR_G(G@=39'Y,0WZO;/9?/:Q$N O@+
M>A8'I5'@ 3L\/9M&0MNNF*\4L>D^,9(]0/: .='+K90$V!J1  >R!.1OR/(B
M2_>)73&CHR3SZ](^BL;4=W9^O%3"+6B^95',3UZW@6!=LD4+CC/O"I/=:"(!
M6Y+PK<N(0"GLQ$L1A,14 %G'3P/62LL13X%;!KNRM;5]4OTUF9T'47HG-3TS
MO8NY)Q\#9B3[M&M@4AN/!)TS(B+L._..PKH 7Q Z]M@U2I:6?]\"=&$E5OGM
MC:%FI4?G11*E0C<,8\L#N=G$"Y3FCYO*C3K*ZJ(][H;,X*8:5J9:@NX4KTZ:
M)SL>3'IGP1S(,VLU'Y:4[P-Z)AH7?;T["!;&]L;.+>.\O_'&^:T:%F]I!J@2
M O5Q?9TX3&=:H_EK@:*Z5*+5Q._W.N=D0-^>JB[19$\4F! F\AUS0#>'G;9<
M<O3KD<Q;9'&O%.*N--7OF&_W5H2S*T!HZ)7EF9*=L4)T1E_X4QOI,BY]N]@[
M.)F?1E7RX/H 53:Q/V=7XTS=5A:OF<FB)T[4'>9_5P9"7@S,F3Q(DGM=FI9
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MUIZJWA*1/%?H_PP? ^QJ@,_*/_S/[6BL!MU,3TGS8;2;VXV&Z<3N2-[DH9;
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MG%R':D?)HB'C264Y/XL'%)ET(=GO0\1N5]R;6T"%;F];HL+0]W;$*GB4J$F
MZ)40F9UR3[;NIO>KS+%N'\V*FIVF##BKK%89SVG,WR9_')-7!&,+1ED*B?75
M;S_CK=A;I/"B ,L?B-4=M82/??!Z_]F]VMSXO"@Z]R0C0OFIR,# ^?6_;=$J
M%#M[6K^BE;.'UO:0^_Z/=7WM*W]=O<G\)4>7GZ&6?6:,_X$DA/3+W",!7_A&
M@ZO@JS#S2',_/(JH:OYA_TS"*S"2K9A3#0?3?Y__?D^#0;68UBCQ-%?-AZ]N
MJX>5+.2Z90ND?=*@\ZWKMDL@&__L&L\E4?D7NTPZZZSQ?L6A)Z*XU.//Z<[]
M44*>A'TC^HSP-!W[M^P]K&:+UZV0_G:AM20@,EU\'PVF;ZL**'USNO1B[MU$
M2L!\U5HZ,$^D]\ G=.<8P?>\+$X+X4LZ0_"-8Q)@[?@9YU)C-9\3/WLKTBS+
MJ:#)CUG"[H%6VFQA=@C#;!%A:Z'\"CH]^'6A?7I\:YZWRZNW2#?NN)>YUFZ9
MK[L +PXF+XO-N9?>GR*X=KA08>3U=Y)/2ON@XF6!]UY*2_:8X;R^W#CW_8/T
MMS"/HTT*&NO%50A&A@?6C^6@L/<P]0WNTPNAQKYSY9FM$I9'2#\%_31-Z]IA
M\35 6]!YCHM-94A4+B7=CYB]SHQB^?TF]#!(9(Z1;(<9=LZH/;4I^$=52:Q#
M[Q1".#A%VH-(5=M0A1.,=/9E=>&NCK;67R^VG\?(_X\VPZ"&<:!+*U4+FLW9
MD\8@A\_R31(?=Q?NMOMPNI]W&F(#\&>6-N9/I^IJ8QC_#I<^(0'/$48NML<_
M-MMS.H>R\ 7Z*-08]$;QS&>!T9J9%G3=H.!R\C,R9:DEI.,JQZ[9B<;&:0:(
M^ IB98H'1[_W_:4RC#03Y/+RN'9-_:G-$Q[/VRR[((T?(1+?KW2S\0;?J!W>
MKSP'HITU?7#,.&S2$^EZ^#+^?9D%:B(8.M[_X5Z?W3 K?V%B2,ST#JOTT2@\
M7F=J9NU()MIIXR;2HT3Q8*!2$(!F^AL4.K+IYY2:"+06/X<%4$LU-T6E*O57
M4$,'J!().N9P.H)%EW]\(BWM=AEN]5-H>)+^#>7!M:0+!TRK1-I!2]QL&%WF
MX06!XV3IX=1KA2D-EBIK!(/;HI6$-*V1<LYH3SB-/+]QH'V8U4RXU%NZM^9R
M1QBP<U[D_&E";($E5!G3)^H($$_??JG-"RYR.Y&^33Y7\UU WH%'S8$BH;/9
M\9MT[X=5X#^=Z/8/5 H2FGR'9WU=Y<R>.HL+N4P:;3_/1/==YIKI7YQM4:[7
M8/15Z 0+X-^_]8J7MVVJBLX2J^$FXE4Y1(5F>1X<Y-)H4/E:=?S:2)RS;Y4>
M0SHX34N9?"F)9FB,N[O%RB0;NS(::+"XX7I^;?+-D7<.+6K2ZU*L5?13U0[*
MK:&:X)OV; :O*L1 #*O,F@X8_#K#5 HR3OF&\OI%!.CQT*#*1*L,X;4MS_U[
M]% )Z!8Y%4>4&)GV$*T&MA)1&R^!+)W1D!\S;#]_DK$4X>06T>._GXEY=Z)M
MD($./H^*SOA!G%#IV)^4S):R;!$-ZP+<_5%H.-VJ/W(YH\14C;:KD-L.;*Y
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MX<\]W(B-A@PY<>XJ4/WX?ZJ5GQ%*T06=DL:FY>'?3[\-43MO;27?F-ZC&@C
M@'"=VOCS9^$:J ]5_"DXTJ%>_<CX 9EIN-9X:-PQIM2R&?/98E<?ZD4\X3@"
M<NEV#$<W]P2X5W1';NQN.2<VH3P0[3ZW<IE^6M#MS\!-"*4?33? 7LT&;/;U
M==4.=./Y@O=L_"E[%K_KGLU>\;4FE5%:]F#NAM2IAT-?I]79%/L/OM3SE0''
M!972;IJK.0PG(F[X_!7ME^NNU>;C2C8N<W9N[^XC1!!4+0#LY$ECK Y^.S;/
M#)9F+/V*.6EFUM1D^O<M!TXZ?R_V+D?"I4YS<((.$3,(M2O=L*0?K-69NU!
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M%>"7F3,CT*O90V/_]'$)%>/1WXQK,F.M)J5R*;9%RFADK^4AGA<6?U='O,J
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MWG[;?L+1-<7CQ6(2S+J_] BU?X.*XRES1[>279\$JITPF9STN9X%%V$? 4>
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M^/F(MM5$SZW?ES;/+ DKN&:<?;CQYHAKWU*3;0'^6\*#BRDSJ(A5YOJ7ICO
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M+)_-8Z_C7>L5AS?[KZ%;$/O'0X9R&G94AB]])A!:IZ]!KDX5%#C=EQIVS>]
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M\"W(QA1K4IKX^8TS\\@? HV31!524&K(UV4@6=NPF&2NNGF+%#65]4=%+'5
M& *-5U*S<[P7(^EFZA=W@"])V:O?ERG@UV4ROH^!EQL87F;L+S<$N_;$BRAL
M(XIF96D&*9)J1-9X6)DQK"N4A>Y[=?Q%K\!@#"^VO!^[7R,)/GOT!,F\"LZ]
M_5Q]='T'5,$N9D?2UBJ^7VZ2W(/EUTXFO^G,HN+@Y 8T-H2:8DLF<YZ+Y_$F
MP@P,2R&]4![F'[ERW7#' V7&/[53^8U/M,&?I[>T'-E,TW3V(LQU$+;BGR5[
MU#ZM&@(AQG,L1*]JJQTCFFIET9O\M/O7Z22?8+42C5UX'/2BN\^1(E'%E3#=
M_AS5Y/\TV?U3PYC4W 'J 8NEOSFBQ::\&O=#2$L;+[4/8VXQ?(W!OL!T71E7
M3J++!1GBI;KI_VL:=6[AXDOM#)K:P2*]ENI!JX:G*I,KE1>_3ESRFX<^Y#9K
MIT=^;'9/+W/^8)"-=;*:7DNNUDT<PSC.JQ98G"-Y"3=>\)N2ZC^[%L.7)R?7
M*M0,.2 F%"UX1A&9Y-!0%Y;\IO=O=L%#>C,AL\@;TV@#WRPC3*A2B[H1^0\O
MG*7(Y6^^C#)>OU'Y:_Y_ VF>)WO3\%I9!C.7JS768T>1%W>^QPQ,O!'U0_T9
MYCU]]?]<UL3?>MRGK]IR?FK_X DSBH'VI\LJQ<0K!>!%C.+KEG#J-)[,FNP7
M63DEUS_M]+XO&G\Q&T[-GC4^S[*F7OOMC1YN,=/Q:FQ7EEA=VSAB4T.H._F;
M9,[5DS+*WT'\TQ.(G%(.5"E.F,[][[]'P\<.:*IO3?,,;0R;@V@[EKRT,HYH
M^#Q_ZO2[ PH1&(LN_N!@=?CX"=[3C,_\1*&&F]Y!GM8S@L/\=X!"]13I_))!
M^<;B$U:#B M=SZ]3?Y644PDW&H(W)-A74 M5]@:"PM;LFK>$S3@M)UB3PIZR
MC>)=:H?]<5DPOZ.8<JD9&?1ZV_)!MTF9-/-*]G#TJ__(7G+8!IV76'L1>88V
MEW'!*^-"J?KO]Y?PA"Z"B$?JG#)89.J)^L;GYV+BB5.L;XZB[BGZ+R/'5,M7
M1-Y4E[8N:%FEA>Q9@<XWKB!U7K568PV9:!+B+YJ$_87"FHM_9 *(D[6M;<OW
MZ:HG+95)^(4!CZ5["^I@;YKJ0YW;$*O#$(X(K?^84IDA2;D*-04%S0-Y=LT]
M.>]\$&*0V'H+((OB$PZ(YUL;?514J;_GK]^9XY&<620>I@OU,V1$NVQ&JB>]
M_!@V;.9<<YT$C,H_^:?\CVY119+_;K^7:;PROFAETCS>4RX[&J^0G#SVV5K1
M1MV,TT+W@YD8SU\0YJ\F :7V]K#572QK>^O/?A/X^]>'Z>RL]GL# OS)1_&C
M0_CM$ES:K;_#[F<T\$I'$^)IJ<D0:IK"?6>R4_ECR4%H55W;%&_1"&U(E_XV
M_JQ<=D5:V-? -Q_-Q0GS6QN1;G?0.6GU7Q40N-V8_(?A7R,%\RCP>=%1OC*=
M_!7K:(.G%[>>SL]U"X?$T44)4F7B&CRQSV"[IV+1W8A[%&O%_M&HRE^BX'53
M0Z0[!9$FMH2^KFDH3((=U3Q4O(5&,N\'H<0?$PO+$,A!-()V^N#CUAG)*J;.
M-[F5@C]AWO*WQ97XOD,E,7*%59GY_@+\=&]DAJ2$H;ZA&3!\0M"I+)F$$.@O
M<Q_5'#_'_15ACX@! .!$48"P9YGSMMO7\]<HSOAVE<]>QJ<W_56RQ];HHZ1J
M/V39JI<;HT]-C' B;OCT]%A5),2(F[J?5.;M:TE"V:JMWTBKQ.^W8-;W!=TO
MK.O]PF)[#!&[7)!6WL06!(RR=]\!<(G7+%(_!U?\;:YL])>ZL\/XTFR9T/BB
M>=DWNARC>+W2/WOT_^PA^X<,'4BMI:5:FJ/I#!##Y_HJZC'H+<*0TUY]CR9F
M[9"*BJS[;=S\WVD!+@GQE-]3N=+5UHF' _TG ._!\ZNN[3_!;:JEJ&BSP2/K
M@/Z\&UDZ"IEF0G#X<74M*!9*)N(J[KJ1FO+J5>.PP>\C_@ZY5NWZT[U]K%8N
MGO<MLL3J2^K"$_03WQUICQAJZI-5]@?1JZ\'_CI=A^J^ -,0C,G26ICF95OV
MCQX^!QE8-1#M.F%("C\S1Y+8!R?]592R\!64S;WUJ _*1H"G(6:4P#1[4UMG
MX.I87X6*H_M: ?<.^. 2^7N9]GLBT8"'M&5"LE\X@!#AFB_4F*UW@C3^81;]
M[?$<IH->ZL^O\P <%VE>FJ>_/ME&8!;(PI]CEQZL2Y*RJQPJ_;9];&E+B_WZ
M2=&L(?2!:.\H_(8@I714 /0CJDE?25UT7=%;-HM0.CUZ>4J9O;Y$.=W%?H,C
M(2Q/P43/0A0J!6"L=;J\W*^2JR#N8TN\Z9MU.G_GP/>NTQGL;46]EE@SZ?OD
M/>$]:CPM>#/K %CDL-^GZR""S9<I+F''$M7PU(3;T/PXO[:F!;23T29DZE'?
M]H[654Z-6#BZ_[$RJOWI1J"P6@F,S->[IREFK;1'4LC,QV7FFGG*)9G#$_'T
ML!-3X(%3_*,C6B8\^P<T:_ ^:]A"A&.VZ:F3N]EI#\V:N2P_*U0]PI,DU?P'
MS^_]5V*U?;F7F2--GOYZ@RYNUY"&7^4KEEK5(3BH9/ZM+^B$&QPTE2CQ5+)<
M(D(YGCZ>-A]U?%<O@N2K>[G*@VU2F0[WPN[LWDUCU@_0N#Z9L?CIYJW1J-R,
M]B(*A1]1Z48XVL.JK=.L;E=#!HII]4IN<V9&^7L2:N--#CH]^L>4]+<]$Z8-
MR;)O%-(D E<WS'PCD\]TIEDYW,@,INH$'G+OOB_W!JS/O5=J3KE'IV8B9A,C
M>0R?P>Z <$<_M8"\K1+;J_SY6,Y'CP9V8MJ3U/M[VIDF=]G'%S%H&ZL91M*?
M[[X80<_KH(3ZHCE2Z<;TYUA%S; 4>27? 6H'P=O)L  8A[+&H,R'A??6X(4=
M=@G\\Y#G4_:/I]H[675B'@PU"'I%W)Z-)^31P\@JD:P\9_/XNHR]8GMXSM//
M9,9?U'M$(>O$.;]=$F_:TIXQFN:] QYL7;XJ=;A^V]C(5<C%4.@Z<6W;C/]4
M:^5S-U]*N5>8TNAK6;7WO1LWGVCX QZ!^+L-VB;]S'TMT=Y>"0\#K@T;UN*A
MU>V//R5?)H?QQD/#$_<LM 9-1<S;"+X=*<D\+=$??1G18KT:B[.T*&WKX&-L
MJSQIPM2G,D,X9M4DQM!SZ9A7W U"CO9'K$R@39]DKD#V%EHI73@/,4GI3?'A
MSZ H0XSB;LT.HBH1W#G.FS6",2]FE\X:*]^&.:0'_SC%$O\,:DF9Q530FR/Y
M<(F^!HTE6H#45Z1_4D,['FN"41(&?>,Z?U47'U#FE:%^ -G($8,43SC2F%*K
M/PMO$[#.@7_O_&.CEJ :3ZU9#+OO$DOF(TN+-0=F'O.<W, E:;6Q'U\+!&6Y
M/</3>OTBD#IS)SXR?:?'F&X\84YSTL$!.8.'T2N/=I!8;'!+JOOC7K=N^*SA
MWI%\^MK)/H%1O[]UP;<JVH84EPB$H3,UG*?2L@7G;[7J9F:>S:P$JC#OA]H(
M:E.FWC#[1S4YZC1$?W?3=ZPV+T.[[>6*D[PUS'IL*%!$77E6@3_4 PNQ(5W?
MF'-/'U>O=GB+0+DJ.F7;JK82SJOHX&'@^]ATSK./VRBLLJKT%+\M0C<<]GW?
MNJ6AWJ9GO)0WNAI.M/J84!STR4^%'>*ZDHEO0SGK-R^6ZNS\.E#Y#M _?OM"
ML"[<\!W/=\H7*LT&Y*MS?#Q%@P172<J5(C;@2!0%%AK3O_.0X'\E<#6",?RN
M8S*V4UA+USZ*MULEQ4#>7SZ/^!\NA!8U,0;G3A@":?A)JCCDEU-D$'B6C(A\
MQ;DABZP;/\Z:URDS0NHRLBB(VKT$<$GN.=T\3T]G!/C5I:G>4<ZFT*%(BP2A
M$)HM*4?.*/,[BX;G\UN@L.O%*%K$Y"?X:,$8$;@WGP7?;RQ#]2"DDV8DCVA>
M8IK&IN)ZG1;-SG87U;65 ^&K;P)'- ;6LO1'B\EN)1)OFQJ.".#$_D5[R,-B
MW(:&Y:$Y(+LS#(IQ:)"DH/'%B-U6=DU=@TA.72A_'W=\8(!"E4V9JR.S6-04
M;_[Z_%JB4NL=\"8&%E3O8GOJG^O(OTG!>"B>Z>VY(H:^LKBP%HD6HC TANR3
MOF-3M*MO>Z%K/,CG)/(^.;'(N'MU6/N'@:>!K1F\D(K,FHO6M5"!"4QJ!4\L
M/SXCS)QH^>Q<C*6^ET["[@ZH?.Q+#':WS07%7XOX$E,G+QY]GA]+AGW*_$ S
M79OUK"/Y2+&IX>#3=##&:]NW2FU+Q(-"WUBFBLMTTQA\<0\&9PW7H/[\/Z@H
MMAMJYH0-%''Q/LIBOA0D6 KWR(#R3IJ9-A!Q1Q"VM<2N&WEO&=Y6+ROZ.ZG&
M^+8,==!)(D^9X/&+Q.\,/V>^/90_)M]ZM=OKSN*%W[E[3%7_66+<*;,H#MP*
MEN@_+'TE5#/)T#[.7LY*UW+%NVC.;%[GH=87+U.=^^89G):LJ8C&"$%;K9;0
M1S>=VC5K!LL5-A_?QIR4K@;<OD^$!;8R!)YB3+PWPJ<2X<)OCN:$88. UKO8
M=^]C6""Y*=#% ;OD&6L4A^6AH0797MSYKH-NG])JA>[0/A\M(A-"'$S%Y:,\
M'H*H_M/,55#V=Y0*0<(M3:URJ>]2W16;Z:#3!J(L+-XKW_!TIK$X;@%5_VU_
M90[\\]"NN6<9\KKF'TD<>]*BW_EX$GX!-9.3WH1#P7HTDLM'E#SQ)Q#&45G2
M1T+HP+!. U0KN<'B"GEM[UBPS4EJTNU&OUMO_/%#%0?48#FT3DL*KN=5$^[^
MOKV<._H%*5]>U"E52_:SJAAF];6D,XNU0LQN7CN]"LN<M4E__XKD$*EE5H$>
M;&8F%=5X0NBI/5Z'UD[ZI*C7EF:1U0:3ABP(N<6'\?1'V_4>^FL')Q;RA^'0
M837Z@]L<:[,S)XM >?3WG"+2'M,OA\3><P^CA<I*&O,+,:NH:8RI,<?(,XPV
M:JAY/AV3)D0.DB90A?M?%$2!@,,MCJO"PF+'.V!UW.1,2>E_G'#^&2%I:$[J
MT;@!?^P"E80*D+]^AM)D]4'B2:+F]&;/&/]%.2M]E+NB=ZK0I>.'LAGAD%E#
M*JB!Q*P<,9BKQ78K%"%^Q"7+3X<+;G)3KC#BA(D#IOH\@IM,O:6))JLE9L%5
MDL(]:0FVO/@BG4BC+D'S4<AU[*2+MJWX.^B?;L%K8MT!5/>%L.'<120XV^G\
M5N5R8^F3*N+QOUC(_5="_"]DG+\G\&0=Y\<I-Q,:FK][_I<W2O[C!=M:T[=@
MBN%H9;*@SD+-D?5I'+:X_6:[CT<)M(U^FX7,MF<8Y"=YE +T7=\!^%&FJU>-
MF].5QEL)PT)-T [PN&O@G// 5S<D75SQ/)3%$DA1^)H(PQ1K;M2)K^]+<G\!
M? D%8.%R?,J A<L:)YDN69O!59[%D34@[A(3O>[/R)-<.KS..AGN2"W91KX#
M8M?N@ J'ZUY Y5^(O/].^;\VRL&/6I.[99.]+'0S7CY."J2FLP+:<<CA541=
M#+]?]G[_,5RL;S?@\!C, O)*4DO>JA'MPGF%+2-L.IT2[NYU_(6=)D4G<EH^
MG>XU7Z,KI1QBG-P\=@!ZK\ 9?Q<])2NT62M>LJ%A?++6,O KRFJE<3<OW*+Z
MA.]*YO_O\/\A(?:Y?L*[TU*6]CTOFI]7W5 O[;4NC1!<D*./.?%9A3:%V]R0
M \]YF)QF?$V!&Y-JU7[(ADNO!VSJ?4.S1;SD1SK,&D;'**T0!_%^XFL0Y?:J
MUC1-S$<C?A9>6[S\]PLLWV$?KK/A$EQB^P(%RBLA=6263=!4Q0<6R$!L-TJ\
M=AF//!0\N[_1J"G;W,0=/KEI RL5.A%Q/9_.!!A\/C?/N,V)=-J*P?(WJ=C'
M7;+4D5%6]>F;U*TG='2@B<KI7Q?E:2.XV<V9N_,:#E8"!3A.HB6>ZPXO#$3)
M)P0RF<E^Q>)W "G75T>>*M81_;CI!S*7 DEN6, 'YH.BZWL!,W11S"A&>7YY
ML8XH:XS0^A;%BSVW<_RO^L:?RC 4</&H@WO(74+I X5C&_0O<$<V*U.XU,@\
MS'S,P+]CM$+AHV^&GL.*XA-W5L<M1&/39]RF::B"7SF867(G*B<T#'P;)XN]
M,IA]2@8&>.$*_@-P^O]%#).\HH[QANJI(\5'6'"S6NS9G&%]-7^?--#OL^K$
M*R:\^$/N\:B% (X+8>_[MU:? O$%D 6[ N&66^(7FTT(0*?"[J]',_7'I]<(
M%B'"K&])7C0&*KLVT&IAZ(F*;#RE.7Q74TUC5U]1;K@9%'64I0#L-)\6:;B>
M%*G"FU570$D8T@,8U,&+L*^)8LVE57XGG30L\5L&FJK(TI]#G\<K%AG+OV!U
M0564B5R.<T/DI(GQ/N.SFGMNH,0%>0R6W&V$]B.]Y:)M*%*W.[G?R[GFLLS!
MZ#*'9@=MN C"<\*).Q$%4"(3NOK8> U@4@GQ/?/@\I?<2C:3?U$,_?)FY_]X
MN?#W!/5/<%)=N /Z\SOVTM/_^&+U?ZAP^4F1JVZ-&[$5E*>P#I(.\CX)=C1M
MB2TF&5G6$_!YULS+98<FUC:!9HXO15?JX/\)9>^ N\UUJ<#1*\)^Z6ECS"5R
M8[!2]07S.F94#Y)A2'R"9,53$PR8'NT#.WV1MYS;."FE\SP&"<Y%*9UK07W"
MHR@YZE,4 HK0<8?AMO2/-%;L?K.+&EEE";YN99/_[77POUND/.\ RH0[H-G.
M+G3_5HSN#G";_+-5_\$"EU&)H9$W<MH03T/,/%9BC8W* L6&M!!3#+OJ/,3D
M0_W.)V9\N;U(0_:):(!Y/7: UM)8B"J5I"+FQN$DM0+ZI>*Y)]$N635:%EL-
M!38.2O9*]6(7C )=,2/34!&I]Z.2JW/5'5!^$:@%6"-X"*NBZ"PF)R3_&8=!
M':L7$CL9 5P:_\%!'S)B]@G_H6D18K#PK5N[6];1+L-&QZKD S75B_& $6A6
M^AT03?GO/8WTV[V]TO)=UBIA#$^D4)ZD.X T\7/BK?_:]<RU#;P=,Y6PRL5I
MXI')8=XO9_/_#YW];3:F>/F-/BI$:U%2___Q8/M+<269=!O!MVO@VG(U>N+Q
MF/&P.<K!D+*P>KEN.C9D]Y@G[WE"67^S!O4NH$ .;OK&4CNYWY=A-D//0^.H
M^0R%+"U<BV1WD'SZN?BC)@.=QN:)+EJ=4%@ N\.B[E=D<K_Y*HIBA)R5?S]D
MF=MN1JLG*AP_.3P*IH_+/7'($Z2\5D6\R.-;3Y; :WUFH##)8<_;-UXG$H2I
M9B#7M\[SG@AQ-<JUU^Y\<X7CFB9CE[=%P]6?+#LM7VK]*63["?F5*HI_.L^P
MRRWUH7B!!8PN)HTPIV.R;V5&I+7Q@ZH*$.QS.4E$R=\RY:;T"&;PY 82(/%N
MC+R&.N^^D@P)A.L7<Y&D^""4&^<LM*/X;R]B< U.,FZ;J=:8?4*7RI=.1N^
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M-K43)J73>^1-$^]73MRSM'_UI7\\V>?E@G'U#L^0>LIX]9-D;2;AEH:9R+A
MKI<RCU*3M31,R>[03%YX>1O$BU%O=O3)-7Y^BQ/96;") M[<_DK4JZA#4K>I
M:Z):.!1(@=O>E2W_(6=BPFC9*TBMQ(,JG7="BSUXUE#"W7*Q/S<*EZ-TKDN]
MF[Q8MC54!XKYZ83,E4G2N;$Z+'\%3/YX7XS:>7LL] ^HSAP6*%NB:*_&ES2S
M4,A*[:=*7)Y\EMWT<#9[B\X:!33F5:Z!9O58?#TJ$J*1PO%HPPJ]Z0X,;4CF
MGX(,=W)00/X6J1=#)O>.QZ\AI\.G1"_%1B)22A&]RW.@/)G6F09G$;0-#2B
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M4,!3[5$9PS"KF.VK#Y5?L_;NH,%M?]*_Y"EB-!U8CC?A"WLI::AEK*GD/E&
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M]4HXSB(*"$(!FP^/37PTHX,2T48Z"D"H.*Z2S+D^+=RFB>XSWA/&0Y)A%Z(
ML2-1M%)" 5-)*,"S.AT%=(K*HR4@"H"E; \QP-LLY@A3NI#*G963SR'0'<(>
M-&$4@&3R@VE3CA]A[J#I0E& 5Z9PK%]:/_(1/!TT^]](65P"%I>ZY+3JZ5W
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MOI/M#5;@)O.9I:VMOG56/:F0Z7;6V68S\L$);\);0?ZN3@-W) "K$-50-ZH
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M.#. R1K?:\*$I[ZUR0$0+<@<<6F&!>_%05T=XTWZ5:WCR\![?@72#_DM_>.
M7>HE,+ZHU #KBNV;GL?;=08&-+(&M#0P_GK PI6Q-W+Q3],#%2I0@-_;RE&+
M.<9;[%T:%"()H?2]7<]YDM(BHI4EY9-C)R"*&OPB"=[1RA)5_;$Y5JYRZ#;O
M7Z1+&,[ PSA=Y<@P-;V:FW>Y#>%A;-CY)$%!2\;HFC:^*3,]FA"Z5D39J_I
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M.T*KU]=;?IBSG#_-.>)!M?IE*?+0QH</MUH>J!J5QJP<KCG7EU#=%IQ"UD8
MP8VF.Q;QO84)W2KK1H3DMOQLW*(?4H3D]LJ,_N+S>S,9)*3NXCGGSLC)?%V2
M*/[*IMFR )\$):X)*7GH=&TJD';PKDOVY.HXBO$%B;8'N/<'OS M 8]OO67*
MA&Q<<.?3?O#1PF;Q6(A,8@-MY[)BR*1!12DM5FL,[N2*J3KC+Y])Z("./4:;
M\T>?[J*7006HR5&N94X.+S3;7]P#S'*6JV=Q!GUR%;$6'5"AO(/#Z0+[)J ?
MILLB=Z13'+L'U"]Y5U^<6E$T^)3PIK6&8RG2&7?\IFC @8('+5Y7EE033T^S
MME2&76HPP$(SBL?G<M-]!SB4N\T\"0/SXQ<*HYY8JO;P24EQ 7J;3T!?1FIX
MY\>6WQ#.-(U9_L3*DS9SM!T/TYA;T H#6=I[#M&:#;E/' EH9EI;/@MGU(;,
MX1@Q9/-%#=_K6<9Q3LH:VYQ3<3!7#O_$;,S@A:VB%]['\-E1$;OE"B5C8J?0
MB:FG ";Y@WZA+B1>4&5]:_RWEXIB UU0I]@#HJ^CM6^*EU;8FI#\BVP'5@NT
M4L".UP!BK\3X@FZB?='?LX QI.T!JS_GVAXE?]=)S)<79V,\7B"XV_:)*WO)
M<>F.5M*=]3U@\]RS>U=83RDQ+S1*,;+(3-O]J&UEM<C?9B//5BDW6+;^\@OK
MN]OUM:R&O2#[[>-/ FN%?=]+WK<(G#?W1X4?-7&J\*^/R8/0I;^ZKKW:2=PV
M=_Q>2_[B:ICVHSA^=@N8V-^"-?B%Z:^NO\0M:#L>'_*K:]*O@7GI_@2"QYSC
MANK!\>7(?B$RM6!-@E:G<,US61TB5*/WU'I?Z!-?=ST3!VX57QQP;QGQED['
ME1B)63DSG21ND@[N[P4CSW#@V_KCSD_&[0[??R(NP+S9?3IG8G1Z@"=V],";
MN% HFL?PM6S4OH> >#7GN.S"1*Z[*P&% DGEGTI'?HO[S[KQQTQZLF:I*4Z
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MW7&4H/TB^40F9X[N]+?4%@2 .9(VTB\JXRU;"V/F<6I[W]V?T!396(SQ$25
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M8@0IOBM4>KCSO-QS96_MK'6D?F!K@<;CTK;])\3)N,RJ(H1+,8%71_@&FX^
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M;#.V9F'5MQ&"T5^?9YI^YO%+&LAL=GE@>DRT8G'C,MW#G&8Q ]Z9H7:H88)
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M=EMNXQ2I\KN+;5)T\Z1;75W=JAU%=U _K2]5Y:H]RN%!B)94C2.;=A;J!->
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MKGJ^JAA7L:^.ZR$$SLQ@(6/(;Y7UU^J_1?+%J\I-6/FY]HL%NW<KP!VPI1'
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MA'A$X)OK6N_"B]XGA,X%/*%8 K,I*Q\5=K+YM+'?5R[^\=DG&I$G +Y8AZU
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M_N!O#.MMVFG,JF&'Q<Z<JZU,GY/X?+7EX$V2>S;B0"?[)R;,#CP']6$_EMM
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M+1( \TQJ8Q)\5,*59<W?;I;,0/F&1)N MNE7XN?W//JXUU4NZ/]XC'EIY7-
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MBPQH7<)YGYRC(YWN(P/:=2C8BFC![+* "3129,!5R!T=U3\U.QD@MIWHML!
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M!<S53_]8)]/XN&U\UT89B%PYRG882GH_E!3W;Y[%^L]^_G2&*^8_!V**$(7
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M3_]>XR?43'-S]PZQUVNMXJ,T(%+695OS.RRSM;Y9"PNE>1KV!]L@V<@#02"
M(++3@2Y]@_W:X-!M88>J-)\KCW[P+E/E%$#Z>'+9;Z_$6QG7%=8@-<L"59IG
MET':.8NP\0O/)V8#3M^7,5B8,]K;/$<M,;%M_!/=+SFVN=F3[+^RZ"JT'1+[
M+G&WO+R^$;VVX!O M()@ (G.38NVRIXKS)C2N(BID+&S]G*LZ7YZ@3L:F^?4
MU&1C;B!( ^+0LI;\5.[G6))7_*9#E54+W2)1:+R5_55'F:G3ZZ])8.P*-!0D
MZ'I !I02P+LOQL>1V\S!%,7O^@.U1J([84'N;006MZ!:"E8#GW5@NO)6CGX#
M<T8Q/,2?\LMC17-G?![)"GS,5@3>S_53_ON[K0FGY6]2]MN_11*J=$+$OA;!
MD'3K.)""/A34G0[([CF>@21,E6U%SS?=W5N)WE^!V$ ?UE17$F#S=INSQ_I%
MQF;#?=3$746&:Y!VJT )?'AIH(.:DP\!$T&QP9CS^7])N1:2;Q:\36'DTE'/
MK-8D>$[?%O5B>F$Q8,9F9@=T"!IH"USW?U%$_/O#,%\PIT6$-YL8ETL=Z>)8
MQ#(AAL\6#)T)#.? ,<\(JK]?$] Q<,PZ2P$KD8]&/79 )2U[V)\KO?R2>_,_
M6^EE_;84[<?,BNI?:^@F73PL"KD&N^;@JEQL?U>98W<Y+G?DM4 $"P#@A)@S
ME[3^J"3\QD9Z6D-IHL=M<E&?0];Q%E*AJ'LO]Z>\ W: H FE(*CB-(4E4O&2
M ?,%X#EQ//4)M2>82)-,!D26II,!QLO@0R_2KO]:*!ZX@P_DF_@47LP>7@RE
MP.^%O+?@93D*RY@U11'U@;@4GQ!22!V"=+:'#.C0(2&UR0"$\Y82&:!?]I]K
MJD@J? %>FB=JE4G1&5-^"%LD!JTKL!_>NF1 <RV,\.4/\\T^L<\D Q0P,R$G
M!NVP@0X"XH439Z43)Q*/(=Y*YR(#,C8IQ"[(C0S Z\%:[>;ICFA7801F43*
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MKBL:TZ<2J 4NW#(RNI3<<IQ7NF*N>*SFT_,(/QY"8E\U5AY <RGP"RRWT3_
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MIHA>)]"OX1J]O&T+8R2""'Z_#X%]-60.J=FII;,NN]D!L.%WKX>FCWU&CU7
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M.I2IB2CX=<<;S29W<%++V:S-72X.J"A4/>0B=4!?VQHW][M,/^"D[(L*G,\
M;XQS=:72_;$8E6+E0';E 7:NF3O&;L[/S>0S-D7W>'1/+[([L6KRX[SIL.L5
M94QL@XEG/<<^#<-.MB47"(H>[:A)7_N:^R"?U5OD1D>-W+:,N3H/%_4.%XN7
M8 DX$)W=F>Z&A:.\4MXM]%=CMPX[*+M;XG-=>[.4XD7F&NAK82#< J$QAV P
M&8]3ZT0A(X%"CF*%6_+,[V7YO<*U*?GL:M#1BU348V.Y;<9.79--I9UW"3=P
M\QII&J%W):NY[W5(=^DO9%_.<"LUSLM[.VL_Z])1:X(A:TQ2?1RAUUBU2;F#
M+N>^,TH;C%P)]RZ_4T%ISNMJ2E$IRI?Q[[&5/#^%%502_<LD<;-?84+010!9
M&NL*H58 ;N&>Y&8H8OCNQ6R =$2N3*5I!.MQ=DM]?@/._)L6FM(' E1]8WO;
M(8$$WA(2BAN/^Z<H,9J63=<UG.4WV2U_SQ<O3;I /@+Q&G &"CC;Y__SWUU?
M-BV=F2&R9"]K]-G\Q9> ($0[G]_\CTIQ-B*$:R"C/06SB^6"@BU; W7&T[2S
MI_]]*5OW;.('#F*4U+Y;6E*]*P3I@X8E4$\,2MY7CA#\?504HPA>,JM9G?U@
M'*/L65E6@"Q/4H>"EV+T%Q[63+RLFBZP:DYEZ-].?95U==W7%E6U@C-:GJX\
M;K1F>W[%>L7S"]PM23ENE'&80^ ._*;\MR:D;?K3?AG93/7&&DNLHK!(H!H:
M6+NLZ[\^*K,I;EOCSO'67$U(]?K( V03]5T,]]NJ!7)1B1^;2.<DN:D9C]^V
MFQ_Y2';G4\>A!^>:>@>EU3[<$^@]6(^QU5QIV0F+C)DU31N<V<II.R!==%[;
M>D7\[473XST5GTX'QR;R";RZBSOP<T&/.V-#B.+57^&F@H!G\9Y9.(6"8U&3
M,6M% 7P:R+H=RF\J)NCP8ZCM6PU>?5'5M\U=3;RH0+78B//[^?!8]N-"!2"B
M! ()XQ+Q"QK.E4]>+>Y2$WVN<PML30@M$,@>*U<9I,@HK1F.F/S9*PP;D0MT
MKE)D$\D?(K#A4CM0?HVCE87B8I9A\=T)$<>\GE2Q4@DF1_LDT+KJ"L\\2Z=^
M5,S/.1FZ>UUF&0ZB]U4UP58C9UEW>@Z452L#SFBV?T,K?VAL!YMFY=]D'(=F
M4S: EQKE+"]T'\MAW5<\3S' >_<YKO,=:#I[1[25,3I;>$ LG>A4*Z,:S?,>
MO6BJU[V.@'<5;2F4.I!IST]698[PV[/80!Q_%+D$%D'*>X8ME21"C[-OS5K/
M.&'IK,".Y%DJ/W[9ADAVV/WA(E,Q*?%=6G_?(%\0M:NKFXB:Y/'_/-R"U&M]
MN@MZ<[1M^//3AP?CQG/UTQ\QG_QZC+P9%W1S,KY5J4@73#NG'V=6Y_C)G#/#
M%ZSH8WY<$20K5V@1?*,74/IY28+$;T3/06>XV-7%M9AW-OU]9I:BUHJ"Z/WU
M(6HE6FN%QTU^W8</M8%('X_E0S8_Q8-!.FA@24KU&,999"1(>LF:1!-]&Z/Y
M?M=^S' 97M$*I0HC(PW1)J4_L2S<$([HE"![ZN?J(OUD)*ASY%A+!9?S\4_7
M?3+6HW;JVOT!Z\>E)6S4]=/FJ MN0R'[C] 7P-*DB2WL<-6PMX*%B&4[@7$\
MZ,FD2)YYU<J,8-J=HN\\ 6_  T>,Y?)M$&;+JKKJ#U+2F3\,AFN['K@4^V N
M=@+,."3](A-,;NM5S2^@J7M6),=R-\>^)^UZ><B83E0MSD';46&-R81L/GE?
M[BW;:Q"X HNPOGZ@?35\21^'^-,5=9O."^BE6>T!<Z7A)"0;M"S;S=KJZR&"
M6?+BVCJ%=(H-4],5>H6UEP+-_X0_J-::RI&PNO7:?[U1T\JT.L;9)S^KZ-F_
MV^'" \S#"1(!?$BMLX%+YS6K/GVIB9P(Z)$> 5; -]9+UYJ]^YIG-^%A,,VE
MWT3 2=W",OS3I9G8X+C];]FO_S?V8&@M>(T,6Z8Q)@Y>:X#FA4B][N9UJHY9
M?< GY/K[3T;@9 CA_]#NC'\Z&MD7&Z.?;%E4URJ)B"?9C?*X#CX $!X4#<(S
M \Q: ]_5?^Y08GW&;?33.TXPL:\>$*Q&CS,K^SB]O#1P<%Q1L^QWVDC(4PZZ
M$"_#4>;X23P<:Z .,BO=,ILXD!TE?P>0_^0Y_,!0C>[!(#B@O @O->0ULT]C
MS;^7Y_[5.;Y^[6[HK! %ZVM&&C*5F(87OU8Q<MG<;=P[9!DQ%LJC0J%]MEW+
MGO7L<(MA#$V'7\GEP+TV5'4SO32-/!8RF[2:^%;K=-)I0Y.US+N!HF _+_?%
MT?S)N&L=%YFXZEBCO-A+?M=(N>%Y%'2L:8$:3SLH@-$$GV+@!&D+;AJWRCF:
MI;T"4AA_S9#K6M.+2P=-VU9=&""5E!'?L)X/?0]B5W$TCMO-07)CMFF( %I#
MG,]*:\!:./8,G^3$]CNCWYLE^0]]B';K$VJEC.@ C@-U$PY7)I.//\L-? +/
MZV=*YIO=&5\K_!YV[^RI\MO=WX7%B '_2LG3E<HV&1KT_-O66><L\&ZU^KWI
MQP^_:4EEH!5:>:(3E3P\$9#%9@;GL^JD9;=;N&1\&54/I:C<X364/Z^SG5UT
M4-.[;(M5%;5E)!4NI\.&8V0U_6F01*[ZJFQ?SG[J*@L+H)JZDR-VK:;!99GF
M*FZ8)Q),/V<^;<GS]%7)+N<=4BJ24.X"DB$OA.RTAGN!88F.=U+DM**8=55]
M0&6=KZ+(0Q.AD0+3*$.H^=U&QKWBE ]-C;&0MOBR#T!Z7*K^Q[TD;>^F:K'!
M_M#?5($B\ 7S?1N7(WRY3=JB-N\0@0779YB:-Z5[]X%*Q:T'VSN+!,8U?^0I
M?B"H"V3QU%]W>75R9 \QMGIFVG$7SX$*F(:<[?$S&-C<WE/]'V6"O)E]C0CH
M7OD*G\1SGTE!MU&GE*WP X4-R#$10$:(MCC#-ILN+BR.'8-$E_=71H\N'D;>
M+1LR1;0V7K:8S_,_9T[A^I>];6$KW:7K:-![VY]PX=.C[;":)(69VQ^JLUN6
MFT0N5.LF49!;8A;G+3"^:NW.HH'\V8Z*I#C1RL<D,%;D$H39FQ#D 4(*_'WU
MQK!K3=[,*-PHWCW#T,""RZEF.8X-"I3Y'1)L?[B;=+_)@EN,WG$0/&>0%0Q5
MUAD7][+601$&P0)[<QT)VI5R$YS4-WB/?E0^ 3H$IK.=O)? &_S0+73VY79N
M_'C77T?8M>V-PA.R![&A>2ZXP.6:2+S(BVH+^PI1N0\G+Q(5_E!F]35:DJ!J
MP>NH.K<K>. 8[/:"M853Q8R:**W_ #;?CI2)).;'[%I2594X7>;%9*%O&]?=
MVG&@H&-=:6VA?VR->YIX:>X5@P?'&U]@ +.7&.D5KL9<W(II5'L3C]E([D$D
M2U#A"EGO_1F6<(3BYH+JH8W<]FJ]Q&MW1!6_;J3KZKF3AKC0="J[17.2J5):
MPZ<MH,-G;"(1T+ PM587M1]-D!FK//GUV?I3ZYU=9=Y8>=[FP1_D^.VH;S^Z
M!XP_>H$]W=0P^15+ Q)/1BNW%RJFMRA_K8&$Y0^O&#8^M7L-5GN*'N!OZ)'1
M']:*YC37IT@8](S+@^) ;;Y9<I.[1U'DMR.W%J5%K*1NR!6JQ)-OT#@7+=^D
M@]_<-JNS[D/P81,_6>?P%3YS[[JO@+]KVOCV\*!0-:'Y>Y %QKZ$/VK>N2EP
M:K!BIN+!K6D>TNM+B@JJU,%0=J/+/XNW$99U3;[CVH;B.93L+XVO76K![<'(
M+\<\.^K<LXK*)AQR14\7'"A4-1W3$%6YH[7BH8S?^I(]6.X%NM0_Q\CQ39!^
MX[EJ_I<\<=Z#A(86X])[O5J+6<E1ZLJWZY("*QRT,2GE7S=.SO1BUA.>?[\J
M?N<@X21$[F*-=1-!:BIOD^%0[1F'*,MC_+ITP02GW?:Q>%FDD<IL^#['2?L&
MRU$/( /&</1HWLB)DRL-$]>E!,Q*,:V;+7(-=?[ J\VJ^<7><*I8A)MQ"\MU
MV]J#?9/=U%1</+\CYG<(N?);)"E:W7I2A:3($28.I_HA1OA!(5R2]53*;EY2
MBPS D?$VFMYH$WZS2L^R*Q%GS5<=:A@%.Q2-Z+,27R:GT,:_/RD\T0,%+(AL
M/(=:C*^_]]:-T2' *VUF)?WYIHH2 :PM .K0/)OA(*=BG._C,9D+I<,=;.KV
MZJSF*N_^-9T5T=Q8\DUC[T8!%[*G3:.N;/)9(PXA&N\3\Y(C$Z4'011Y8#61
MWGN^ 9\MP-'',32:8S)%[,V\X&9#\=L'PPTM&@L-O5HKL<(+X3 ^O]36B7VW
M7.<15 L":'2G^TV6]I560-)"&>. @7J"S0C4>"#NEE^[.4;C*R>VX/N KR>W
ME.)M4OC>]Q8R8'*C8%<9NS:5 =QMD.Y.G@Z"Q39N7ZZ_9FB27IVCZ*=PHOYF
MIG59)YC!?'LR8%8I7D]_3S;2J6F >3"'A64ZMCU>VJI(ZH4V_X<>OM=@G*&!
M>B+]Q[QZI4:UY8)(655&F<^-Y@4_H_.GYED^G-X0]G5!DE(75$$@L5SRE@6_
MV79"-.]'4]$R !RXQ0>^G+^A<1UO&][636;<=89H.&[!;H\=QSS;JDE-TON>
M8G:N_8+3/, %,8=X)E*0NN(0LQ;+Z!)@];!U\I54H:B2Z^U[\XN8;7."),ZW
MT$]";T3"+;\Z1=50FD^$1.HE0$CY5TYV!JRJ;W3XB%MF\<1Q2Q0FZ)>J/[E?
M51^L:U\8\%5<X."%<DL+B6O_E8/8D)^5C:;;FN-BQY2*#?7=?(>VJ8X*S_R4
MM7B/\C?3K>>KX-=B8NKGK =G>,.E$A%XJ3-CU%Z4Y]*<Q;9>PPRVR&&:QRB>
M6LEAS.'[<@RYQV>K20F]E6#G[4[R92&WFFV*WK;MW@?=3[[L4M9\.=HUEFUT
M/>E(S^O*^SZ C9H>W.1#%64 &@& UV3WE4S8[M(G)5+<S97I 5;C.!EG091>
MZHWP>Z\>]TXC]_I'6!"+89I+1O]$L/L=> U5E=TV0">?827M?^!&IG!3)9J9
M<)6%IJW@7_84Z?[[/45K_^4]1=-NOV')F/48^!^/R>:=V^Z7%=B:VO^C0N;(
MYK?@L?-81B+ KW#S[-.8@3K,'I;RWQ(U<?K);G%?+TTRC[!$)X^&11C7V+_/
MBA*.I@-1<>-N^@?K0?U5P]JL+/7X&S 9N>52ID8[FCI[K2]@A3:R8M[C_J^0
M(,ZPLU5RP\9LS>DC52C"HB0\9@5.@0OL)],90EV1<JO_G<R7C;M!AI$=<[;@
MCG3 =3I];SL$AGZ:TJF@X5.K6+-RJ$6RK(="@-;6R&!WOI-[C1T'' T54O:V
M>QT'SLM^26:QR)T/A0MB^7/-#N:S JIRZXQ[[0JAA8(*]9Y"(LJ.U>!N=$&2
M\9.0 EF8&;,W/,JG >F29!SF)?$A-?WQO&%PSI\4WKC/+R*>:1:Y@N(:#4=<
MER#O"'1U8W:'/!%/H[M'.78-1 Z"WY2QU(Q+N+Q:JPHY\-O-7].R34Z1/^'A
MX.X*'R^#@"U)_%^_^I@H]KAD-331LT:!$[RL1ZEDMKYZ+F8YT$L$O&XNY^_I
M&\ F-5O>G=E7/3$<#C+QQ$3.&-0D.@S]BN8W?_-._:?KWZ4U=++7LT$N2Z*7
M+O"3RL\<GPI)K+Y9M>0EK=[A.%8LNQ[7D=[@ [?5,SP5Q>X<,"UU^!W-9)AI
M+T$X43AX*QLVL<=#PBVRDO[A]2G,T+K/@Y61>L>U(V'CK:0UEYKQSB+>R&KP
M^X)K%= 4(?YA;>6^8V7V*%7-1SC>'Y9^J0.QR]"\<PY?:C;UTX\8)$>$PM&
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M0\S?$F()>3$;2?]CLO(!'!GA_KW+E_KA.1&@LUJ:6'GIGE)P_?O5OK(K%Z5
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MQ$LWMR^<,3?_6WQEK%FNP7WK++?+!]E'GQ#"]O&9OXF E8_P=F6\ZJ7<@42
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ME1"26<)@,[D*9)$(N.:4=<LEP+Q4,'9PFK36CFJX\LO5+6Z?62S)%?>WF)@
MEH!Y%,=$=8GET&$Y0_"[4[=@^N;O!NJ,8Q[_;=V0*_1<Y7*"@>$<B !;8-KE
M_.5NML>S"8F 5R#QJ?OA<*ST9O:9&2-LF3H9<SJ)L=T(+E7#*YY%7<*N0>XG
M_Y:"ZA\Y?T1&_HG\_ OMYF6UJ_]^M9+%1B5ECX8$%ZY+>NB6I/\;ZM7EJW7'
M)0>C4!9)!$!@R=B"N#OUV2V$V[&M^*+UT5*F^<<KK\(%4'"22%S9$7;;0LWS
M+XISB[O?*E5:_N)H'6EV@)\*RX&.N^ 73%#/+BZ5,;PU1@HO]-U*%,:AU. 3
MYUS^]J/VPX.I.:3-;]8RF7_P3:7^P3?5?3KA*EOB?&B2:B=O)EW5[J_XI+3_
MZ6X/DFR^PMW#5YG7,B4],AA<J&);)A"Q0DFIT."<3FH@^L#KY<CC(N%U%BIE
M^3GV -M8:.;HVD@IW(G2,E.443=*T+\U; GHBB!-?D:M1>$9[;T'??/SXAO>
MQ %*):V9OZ!'MVM9])VE5P'!_Y3J:)WUN!2JA_M:^A0W2J#SMXL\-Q8VNA "
MIS"4SEXSM7(WZ-WQUJ75JYSTG&JZ=:E!9\R^6Q;\XNZ/!1(7%QED1);@1"+&
MJ_'^(+KIRP3!OUK=A&>7P$-)O[E] NUKD,?8FJ$1D;+6 1.H7MV!Q^7IBK:>
M;'O!ZXXT"<A"6=U6..UQ\Y5YL%RJJ+TB$3!I.9BWG,3:RJM(ZO =P> AK;!\
MFQUD-'WL$J@S3F#>QM851+)WNE3EUM03^OR"/C!ZY+PF=5!9YPU'Z+S*4IB\
M?9&Y>YP\QND-!O4>MI7ZG.;Y'"$>1!YR,P>]PC!'RZ2,K#(%!$=G;]_Y&9-S
MJ+R8V+&R:0[&L!LFM3@M\5XKP[[H62.7D_^<N5J>.=4%SN.(;<'0ZLV4EZ U
MM29DX1RWATM+=DJ?AZT&%KTG;;T5S_(C*W</X*$@F'X"OP9- 0I$="A!_<(/
M.\4XKKG"AIWC+;\KAX]9?SE$>DA>"^JY?)-8G6%D$ZE&(W^,,X0TM8U_:>4>
M%),I='-2!XO\CL!&8_@;^^-NAL<Q&!;YIV!0OW(JN(]C#EWG<"MD$S\,7#:$
M&;_^?^R]=U13W;8W'*0*2 2EER!=$%"ZM(A($Q$0D4ZD2)4F(*&&(B!=4%!
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M:W08/2;IG<J$?@-]WX6G^@?[X1N#.[>192SL2CF%>5625Z;K.P&!"B<E08L
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M1(6D7EJ\S4Q^%?:NYQ_-A)-&^]>!B:M3B2P?C]^H=?,"8K[\.DU*_3ZDF20
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M_ ^?U:_!@PV.;"'Q'3&AR<M.03C;,\:M19J*DZS43LE304RF+U*OWKW6"+Y
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M/D[\_BPIJLWB_>?P%LAU6>8S-0UO9/FH[#T/Y*R6^):ZA:]C9-YKVF\W'>)
M]Q[X?*AS30#\+/B4G*HKW.%T90ZJHX?FCHDHE]-1&M&J6)L/R7:ZX\)BR2G=
M.&[5!;C'>(<_IA48U4B/345-C'8D)%5^<\AE=DLY,L3S,KG>I#+_UMPB'<)X
M+>C<!]126SX!N^G^[8;1B"RPP/[T<Q"<NQ(-#+", Q]*]3BH)UM9:]>DWF:W
M.':6DKIY> &@@5J!IU66'((G8G.Q2=X;AP7VZD8-.MN&/AZ]%"+BJ^',J\3
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M)^C</NSQA(*"=/ZE>&KWA1YY-<3P9#28+V)LT#J&3T<7;8;GX*??5U*LE2\
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MQ7?<3"0&?G8,GLE/V#C02%15=,D_O$[255JP3QCSR:5=>]2/$0M607/A;_U
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MX/7<GMPPT*,VI36GB);M\O6;"0(1\F?M$&\SR#(!6?9I*:P:%9G0[3NFC*C
M.J0[VV[MW%JI<L7FM[S.5_T#\)=A^J.82X>A)C%A<[^YQ\;6@9,9+P)IX9FP
M5SW&>"O>U<_K=7Y;7[JA%[4@9[<.]52CZIR>A0[MBXS&A[6@Q;4Q;JR(&,)
MP?Z\/J4+BBZF3M"#R$S-.@LY%L?72D&N%=\3G*6H]X*O=F0#]-?N6'M */>
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MY W.6","^(D8)(S/"<MX_[HZI7R/1#COY@FDW.$)&RK,.6Z=S4R"OI$L!%?
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MJ(0[27;\H(>$#\I^/]*MWRV,,F6MZMLB]-$R$85@U;[U9:51^IZMZ"]V6C%
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M"=*']C'869N YT=M(J?U*F6'5*Q0.]127LG:HL;#<O2$!+*CQ/>%+)*+O4S
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M\T-TXWT45<Q.O =L?,(#YE?.[5?.'<</KT"]6>!18> X=?99G&",Z89R,?&
MY-+W..&HFF<?2A7+./(N22;\VSGTB'GBT <.K?(ELEV42HWWB8R.TG25N>F:
M[1AMCND^-L[7-B5192,<O^^4JG"KSN2W3D%3B<0KV3;UT9(T,[0_MK[NL7B3
M)*?)\5:(_$J200WMS5UL@4[^%PJ/+.Z?2;&/])D5(U$2NK!ID Y4,GM;.!?6
M()FO:\_H+<],[=P7R;8R;3?*-T]/#,(N?"OT1I^E$-\FRGO0U=_HC5AB7+I2
M(6 1 W?=7OBNWEW]C.TQ4WQAO0:V$.=^[TK2P]\)GX;#U9LJJ\>E&)&&%T6"
MT_)P1W[*3&78^<U,LYLUQ?'IE/"/),GE.P-#(VM49I!7N6J3]GR6'VKL'4ZP
M?<[&^EYM\4@)3JB$GE53S-V\7NHRIQB\/$EWJG/./5Q5(0T\##PYODI?.3_^
MO:!/0SI]XK[4SLZ0BC#/5.;TG-,89C[OC@?Y)\1X*9[%(,?E,G>A*;0X%+E<
MV3E@#E";S].383<M=IF5=0V6/'Y )._?R"W'N/L]&N(OOV%Q%F*B<A\5H-FN
M_=5^#RQ!)&P1\P-#';UWF=OV*\G92V"O[(=5;7BVL>3Q;A^K?-AVV'9QRO;H
M,MA[;.?*E)]_FO3VZ_@)J^.X2]8]0 UXW@.P^+UH#[Z1O<:0;9.7=>A$_ND#
M,OP\;L%9UWBOI/+W/"&Q95A8"B="EBTZ3Q2G45('?#VJ'3?DFZ<='4L;TC33
M1EH;SC24FK<,8R8_>+-YQ1:W;&(3=7]N,4A>-I V2=;*@:T:8J4V\5*":<D?
MA=T#J?(H+U$G,N/ <4$B2KI'#0KKS;'^?8"HJZB%PG+>L8:<KX#ZQ:]2L)7>
MD:1#?@_]R\)1,LSYY3Q/-&3Z#M;Q(L1LO)*25K1&<"I5+YO+BN RW7L?OZ<6
M)UF\7&I>SC[]>VR_DBWX"Y^T1-M:GJV\BU)D((@<>5GSJ6./W :#T5OH&!40
M[H-UQ%-G+CY+?M=8O2[S:(DVY@N NA1C;F)R@YEV@Z9\\[P!,5%_PS$0/WQ&
M:MDCQ0HAZZ:7,+*+3*^1^!K\1?ALV3[2%L<]C? Q98=KU*LZ?B]PF2"]Q*'V
M6ZC@=O1K%\;^_I%T?3-#&;;7J*ARC):NO$E81'-QW)(D8"CY%$,X6:;B5VY)
MW8*8I7R=4:JD0C*4'._R-S+323(L\WH1S[^T]#2SD%J3#THV@UYM<+ZX>[4Z
MCM$Q7?ZXJ2UK14C@#4^9UYGT(&6X[ #:,&+8_M=GX1F(IQ'5#X;FYME5[TH*
M):Q(^J8/<LB)[3)47((36:Z2Y#LOD'9)A#DRB^6CV<47)XEC@AW6WO8Z+.H\
MIG89I/[<7_ R@2D1E$)D*9G/[[J<#*$B5&3J4)SPW>2+E4/P-]5%42L>,\P<
M+="065C?QJ^0B)M02L.Z8GY-D'W&*MT_*)CP8;A.;+4QC9/U; I(\%'W"7NG
MK:%R-\@:L16N2AOD&=K;\DJ9[:!$%V.+89AS8=HM.2M5<$=(Z#I#MTVBQ$ 9
M>VJO,5D)8^5)DF18PO%*BN#05?/U'#5N2D  5GC[C^)@=D<C]I+M[U?IDGG'
M;G3T.P.7Q\Y<)-EE"_N+_EY<BZ-E?*TR-FS3"E;9OTD37JNQHN[2,]+34P=-
MT%*73SM0R+LY8/@P$/&2S;DD ,@YXC#,/*(A3#$6='=#!F.#Y7Y3J\O!$56>
MGAPS1R"A#_N,'^;WKEE91+ZM,X,QXT8KM=^TR6+1T0'W;#((=^<< R0N  D4
M?%3GP'ZB-;;5@IB#M#8E81Q[]GMV#S=(]OY^32X>\-,M2!O%N0FXH!:0F;[P
M,"V=U]=%!;@@'\Q6XH+6W&:FG5Y0"Z@WZ4=7B<_N0[5MQT0Q#]%$'\FKJ.ZH
M?-_*". 8480FK5J&*?7S.IHSN#,A,^TC759A A/)\E_23/TH??AYOQZ'J4QM
MGM#'524G_Q2_R @,*]DS8<_)M;-&/GE$ILZUY'F\YC$(>C59$,1B;#/;DM(<
M<KQ(V>2*ER9J.D>[287O-TF3ZT =M5#<IF1=1H^/0J.CQ@UQ*A%YV\*,+'XN
M]V4&.;J5TB\/ZG4%JSA>2FH>VD')\C6_GN'U-E-HPF=;?!M3@8F^3JA?Z&,K
MS#RTAMNEU? $*=NC8._W9:Y%\Y?&G!EN4^PO%<\VLAK1#X9WEJ]_U-3U7X+I
M1U1I2R98K9<@9$LQ[OVJLH#EPJZP8TY4:H9'U6?6]$>]CVBUE^J<NPX@6Q.E
MQ.R7:5;E#C>&1:3Z,H_/-[0!KFZJN/?F(#-MZSSL T,\E6F8 QN[@V?VQG"8
M6H@4^9I'MRD\(XF=8PI5*VH6/3UP3Z%K::Z4*F#['NB(-2P($E+%AS_#<=7(
M9#-K\(Y1B7]7P^+H:EB00%";Z3),>X9$)C0AZV'U^*ZBVPW%"U^0LC 1N<*+
M'"U4ZT%>/^PRA?K;'%:);N4Y*\/7JI8(#WMS[@$59^%?704@/!O/RW('DDPK
MZGI7GW),R<_!]T ;*1G::OUN'KIY&(.YEZQ53%*E)*,B"B&>6:C:/? /_1S+
MUA.DA!S2R8TZOY=3]EH_EA5,],T)4@%@R24F!AMDJG$/F.QU6O!W+CSH>7[R
M2ESZ<%Z!T7.#C,'J8,Q&79)< A:S1RB#K5RT0);'-BGG\+W2(DY1/>:1JJAF
M>?[>,%V*/;O,QWE#4X,4K'KLC3R#^&+K24GREL"(DCUKDI&>V4EB2%C($TFR
MV.)P- .7BPK/RU.]LCBR*89AA[(\["1%"0U%B0_EN_^]MP+^JY24&@7D5RKY
M4$<'O%^J&J9%;4(IVTFN)VC:$#4W/TV<;3Y0)=D7T*,)$]72FA-8?+^-%J>8
ML8+_66&KXR 147%\'O.+;]J6PJ.Z_"'.L^>W!B4,/-_ +0I!%Z0G1WDDUE5I
M:-;#K_?1E[UFGBU7Y6N+S>J4@N: ]DBBI.8 ;W/W+0X@/-@_FT3?"Q;+R0V$
MX-AM-GQG90AZWF??K12PA:!IIOX\>,N8(<I6NVQ[[4Y*B5QO;*_"T_J51XH>
MR%IS&1- $,SGSSAL-81C^7FS%3?$"<XYCAU&($EV@9ALQZ9NF?A2LMM<[[(7
M18:J<QU5/*5K=TK94S:6GB U2$369_KI<##^8%N'Y'XJMGN/Q=22Y'/[_.?2
MM=5EVB7X,K:L\Q[(-1;S7TV_:1YSTUXEG35O2%U];II*3G/4B-7L<)EN:27'
M%MW\I2HD'7F?2\;IQ1_5,K%L55U>X!M<U1KVW, HS.-HHY/0M*(=T1BHO/)P
M1X_4CA+;=B\'%#Q7N9H.<F5T>_M]F1L$Z+5K;Q[ .^OXS2O[GT&>Q^.\H;D#
MY</0A6I1$$>6Q=G)L]@<19[Y\W0(A#Z[^,-OX(>A2,]Y=;&5GXL3-I$4QSDB
M5VP)_VFB'(6D,#D>8%8^KL+\Z+)Y@YI3;G*S_<:AJ-HA8W^1I.FM , A-V%P
M':_7?M=:RGZMTYAOFQ;;U<#+^4F1?&!Y1W#,50(687N9*KQ5U6+SF_5ST<B$
M"VMYA'L2\1J]$UFRX,C:3K4K6TFR7YF1'?^IC!5U9486KY+'-M<GLED2J"<T
M?@AXUTN^=P8-$B;WERF]FN/__G-AU,\Q9DJ_H:=<C3MIY55PXKC(C$ .YV35
MTS;/'VPK1_0^SZ)$WENI-8W+>6\&_Z*?_>+81E^^JM-=2F"!TU XQJ#-/;2T
MQ5&=QV/?D[S-_8YLLVQC^\IJ1I3:PZ50?_$E3.YTU(?5_QO:29(SGLRXA<'.
M:I! @X/OG"+L;K;Z;. R07*.\G=099ZYV\G2P>NOIXPQ$TY.?'=1QM]"I!R(
MIUIY4I8Q-Q_)(0D-2AW)-92NV-&0=WY]2L9Q7,7P'N@OU+*@]5^2&E U""2.
M]X&.R6T<D5@WVIF)[1M15AT_,ZRL@5@N$WW$I'3NR<ER19K4L9W5J^=D#]LD
MK66UMX(DFJO-HZ&$SJ&XG.@(@^*T=;Z_J)(_M%SU:RX,U]=*?H;JL2PT^(T_
MQ<29!UW4O:H*MVM/CSHL<0D1[T0E^#KE2A-73)[X6_=:]*BW/^^6@0Q5*O=2
MOW^ZR#."$N3G ZX8M.;8X4*;V("JS?J881L[1ZM+T8*L+1O%Y8MH-2^W,R=-
M^YZFWZ(;WZ=K_$W+K/?\(==O6Y9E2R?*9*FK-EY5/\5*\>3F^)9J0,4?Z/1J
M8.KVL9<5U"^6]09-LK8Y[;4?26?#QW0&,YKE+_]7>]\5U(3W=1L$*=)!FJ$'
MY"<("M)!09$2.D@/($+HA"1$2@2D(R = :6*]"Y"$KKTT$$Z":$7D=X%%*__
M>[_'^W!?[LPWW_S.S'E;#V?.WGOMM<Z<,^>0([2-M0_?XK+@1P^#G42]!$)X
M'O$8Z*?-6S#K:CD1L7(=551T[?$/@K.1JD#V5SUY[/EP6-D,D4";V#&O \%F
M6Z;JL,&^Y5&Y"'E3N3M3<;7<;BBJ_%FC&%'2ZGF]YL/3@A457P5E9XP3Q.('
M(:W0$5D&F26HV5MIY6,:T .])D5@R:*;8O>_@T<\4&G2Y23M2TML)%!K>W5B
M*0.2O'V;4CHBH9>#3K\;D,8YHJ\ F-B_PN3O-,<#2_@;+9TRUKFJ?O69B,$D
MB/&+];2Q^V2<*VQ!5RPP?JO,VK+9P/2@](W,=[--7,2L%?D-WM2(P"4]U4TL
M8D8/#D?!4=[(=3G0V2</!U'T8)@R<L0VLNXUZZ1#QO*J&DWJNB7H6=E<+3["
M<23+, N5G>ES-!Z2R%"V8C,.*PA5P-!:0.L!'=6*D>]8@TV<Q9,1DM,RF<OB
MMY7*HX1U*)L;$RL\*GV%F#RL<7M/5N]S+TIEI>$!*98L?BK&Z##]%Q/L_GYY
M]7RPG$FV=S XJ4>VEUJAG3CW$@3,N8V;W*V$+8T]I:L4N3!*V]R9ZPX[S"^3
MI,BBVU<=II;G)[,[D+[S\:^3:X()8H[2%N']Y3W;\6Q1P$B3Q476'@T_ENIH
MZ<U=4"C1Z$O:&E8NY3255!.S%$QQ,B>YE;1E]"@=A5J"Q,D3K6:&A&N)!;*'
M:=%2A>;T-?J*08R5_W%;/B?;>PHX7%-#:_S^CH-@U604;YE4D&\(7M?P^KFR
M7G%_S)2Y&2&$59W\+7JR'X[XF.7,-\WF>?0L3"^ 9 TA0BH<Y\'%U!K47.TK
MW+%9)_R^5<8#':]PQ$\-32Z/38,5+J&UN] DKBQ*4Q,*\L,2<A5;F69PWIR;
MN>$(2\>5M;]/WX,.7W329X'QU,OBG,#VFV0-,#3]2:,!3/JO%NGO8Z4R.Z/@
M=1<\,AGU+@?V%D[L.&'"^%P/]ZY5. C9/ZFX3T/!-,?-;+S9"-L[O8E-/[K3
MD*A5F <CDK.HDB+F5$'K;2)<)Q5!VSRV_I#KR=-@2^FU6#4,J7FG *'?OB9Q
MDQOPT^XK:97<M?G9)S5WND.W4^9VV3T)C<98L51Y6+&\_$/DZ$32S[?@Y"GT
M^+-:?Q>&/D=(^!VN8X<<^A>0GV8G>R=BER$P[K,:_5833^NGE@+JG6S $*;5
M+(:/J-C)0'^U!LQA89PX5-=U5)TVF74PQFONX+!ZL!XDWX-4Y:'UBQ\SJ'E8
MMV\#L6Y.RHQ:,WM*B.U:];XL\"Z;MA4:K8Y[]YS GJ[S< Q/JX:H4%X#MBV>
M+"*OQBZF- H729J6D3_ CMBZAH9ZUT%$_W9T%(6;',S82U5H$8%0A-;_-+O2
MFC(0!/KG2E.12D:\>E1$G_X!6 IN\/=K&4KVH%+:J P<*V;<DK73S+'3<';E
M=HK^M0=94'*\VCF?=JG[,N2.MTZV(N2MWSU0^D \J>BYU.//LHO-W Z^OP_=
MWD0TJZ *!BM]Z?R7PGK!:5?^H2L@(5"L!L.DDOG#2+^U1ESX^L1=#">+UK+[
MD 80ZRTB8-Y/A9OO<N:+ +C?BY:.9EF;-JE]B<7G="Q1OQ4*J=]8ZZ- ;>JE
M=-]2OM\N]@-[AWNUPEBF__J[L-";&Q0;,1MW?XF5$P@]S'8Z[YE!+#S:RP8*
MY!('1WF'CZF+U^C\VD!<Y3E<^YBI])*WY=5B"/#$]?ID7R/04V1+FU//(/2"
MT1I JQ@4_S+[B58"$?8IQN]3\CS8DUFW<( ^V+F$GSSV$ DQ*+'" Q_,/2VK
M MD/ ^B0$<HG"MS^,<O+^U48GCA2\>QQ!^Z5AY5'"M>"%P6+Q#;Z^?W.76)J
M>^^(0GE&0N0).D/'XG7/J=?S=A_G-'.6'8-[7CNTL6L,#+MO"@'NN-BZFV^&
M8'!]YEVQKSNNL<$T/*^"-7E7INHJ87E?PJ @J&KMR<C=[NAA_V1W#KU]XLP?
M@.,?0-GSFLU(_)I(:$"K)I_O65!_M0O!@^ ;N?WR7%9ZU$J3G$W$U5&U&*<;
M WAQX!DIKH<_'<Z!G7'^&O?F'6J#5FVO\*,2M$$'=/3(5S@6".&QVYH5V/F&
M%AG#-M/]1P'.CW(P;^3"X>(K8Z_[2^5F[[(/+7(<64FH<CKZX0>EJ-MYVE?R
M*KT7E7H<_9TC92)2/T5X"D?)4H"<]N7X?Q.]I#2I*(/E(-U3QC\N'"/BAK*)
M\P5?RFGSSD".9L1@7R9(,=_+"[.XJ=KB66M-&"H0#D=**-<[IAHMB)#?,% ^
ML"#(O9'PP+C[;\3+2[)U#' VIBT-*+QQG5\1/^P>T450OIK@_6?_JKS<1O^S
MLH'; %>"]^IGM"-X[H9@DH3?)9Y\?((\"#Q5*=.$%OF2ZARO (WHOR_O;5^
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MGY"_SSB)F5.#RYQD^3Y[<!=!FWKWIWV^RV)NHQ_>4---CWUXN0=8XLP<//U
MAU5C-4W3YS_!CNM"YF2[DP7<*R.0\B$R==ICN\G>V?B^C0<[]]_]\U?F._B8
MQ.[[408KOMW1']$.U_/WIL]ZNL-BK<6,VDQ9".L&N9G5X(6*UIEON@C_-0HE
MJ$B1APR,,FI=5K#)"XA,!;)YM-?2=Z[/4\,D]HUJX.M-"CX/,]["I1:?0(G#
M*9&:^K3##C%+D52">'Q3)YOI$^KS^LNONH:4OQ=BI#.5_#?Y#'$H!^##+F1_
MQ7=*39 R]VJ@7ZG# <,'F0X(OF2V9:#H.,+S9M,=F[9@!BWBR'C&QDC$B5F"
M,<X,AZO-(:Q+QUHKQXQIO38C]+T/WA"M,,_)NN&X\$:F1=,PWCW,DUF"W<[L
MU+ L1'5VK>RZ/0-B)P7OL4\V2O1+T,OP@^GGV\,+5!><XC<MXTUP_?)"#B+R
MWQ]HMPJ-074^L)K40C& X;],'LZB*CXRT/LP4"SGK\C@7?WIX\XHR[F>MCOO
MDT3KP%RA36J\VE[9+SN]HIUPB)S,$$-Y.ZR]M]+36/;.=+_#_\98D,HMA]PN
M9()!51'&:/O&%J9*>+\62D#>&+J9-V7=E9"HNID.VO]UG4<%?\MQJ&5HLOLT
MU]4IW9BH#K*]-^Q@#^1?).]!T"R&F36KO$"[RQ8_7/7YW.>+VJ# >/WXJ!$E
MU6TNLCJ,7. IEYCN)!0E*-1CXOL/+6]]Y]P5]NLH2*DK4Z,(V@,,) 1D-P>_
ME'2;>O"\)=P7>VBKD3E/<GHF6LTG:8B*UWRT7 O'$(FT1<Z?3<>G_"ICAQ0L
M:95$0Y.V.R4VC)([?]8O>BKS+74N9<OJF"4Y.4%A6UG8F?P$D8>,?>,X-LMM
M[[YFK6ES]C0.66:M3T3OXQA[7<#(VKD0%PUILIX3$%O#S_%U29"JFR8?3Q/0
M+C1F[4EF] Y_V>PKGRBY$1O?L#35*OPEW:1^O+ >%WJJ$%"_0W \$@:2>YHN
MK@"_[F6,8/;CNA.B/*H=)CVAF! )M<Y_W@H7NA!#012QY2S@8>2$L5LK:\;5
MB%&D@F#$[@DGG"[LOU@G(2' D+*[ZFO1<[ HT4TV71PH*A_C;5\!)M-G-'X,
M>!6F@ZQV3</14A#B*AXTYVAW')4UO&88?=#7>>]O+VOXH"Q981WDW&\_7EDX
M;J_U,9XK"R\K%!<%)R7<)6-J S8X; YE<W3*C6[A+K(O9BO2>;W*G@SQJWL'
M [S*<T]$'BK& +Z_)%GA31D\JL5WNYP98&OFM'BUL&ZU93TS&)_NI7I+H_7P
M>.<U3:$B&7&A4D[A4"Q@(>=-H>//()W)X]1$1<C[<*0ZVU?"O&&]"/*(1VZ%
M*D*I@4=#S_9 X\T?  UETNEM+<>X*O%5OPWK?$'=^+90!O -3?W?C:/7=8(X
MNMW%)VX19UU9B>>.F3N9RP+MHN2->:1#W$"\_%9&X[S(V(ZN*[IT\W2\0<F0
M5#P4*9:4Y<N;[;=C)!>Y ZN23G)PA3G"')2&5CM"9:[G>Y^;T#F+7TQ!;9ER
MMR^2%7 HW[60Z=WHU<0PO*X*#WH(X!G4 2YX*X#^7>Q\^N3*HO[R"=KQ:U.3
M_(CM/RE=&;H/(!T7A1DZB++]?/V0 JK=5*Y5/B,+0GQ8&69M&SNF+F0N]QJ)
MDY.")(>20/CW,99:T)&!V+!IC.GX+S'>I/P?X/*Y3CHY=C&X>(?V@F"YMJ_G
MZY7!7A$1A>,^P+:9W[R&>I)N#!F4@AUPW+LS7SO=?4M)4SG,K.9PYV!#A<#J
M@1:BQRM#0Q6.*_X Z&;F2#^=+.%9PE<%198$09]2QQM-J-Z.B(JF>Y2D<Q]7
M7SJR'2OZE,!6_[@E(0V/OYI0Q:>87'G1.3:1(=Z U562T(WPUI&DZ$Z^8[5T
M3:L?T:Z/T$>-CTX&*G438%/91=;6\U8S(X$4*$V8>$?D>9N !C)'7YY[RM[/
M]]GX+_62']AH1^]3K#?3G/;!]I,D@"^%)S@VM+X=J._7[43P"S*,NR<=)3!.
M*OBVX^%<[PR=N=;;8'ASC[OFAO;QULA_+DG,Y](?SF#S/'"#<N*UNI^,[QN0
MAE]="[I1S1%]_%5*7FCR+OM!HD*(9U(44 ?J1</9-TQ%+A/GO12G/N9_DSWW
M1<:N4D^S*Z>^[!?L#8I.[H_6N]R\679IKYD:,-^FB &"<"R!I& F+RA _2*Q
M.4L#(;DY!'BI:%8.KW+%GIUZT< V5+^W79S*'ROS76&@FU?RXQ*P7<^J>W67
M.M*-:80[MPY>HX!,LU0 W@?!!A2WONWO9/=DYLU:64=U31W<%?[DU;8#H.PS
MFJXVZ)H2KGZ#T>-%(=UY4E>_R(Q*_MV4"+"(JTDD]1_ /%DZ[[D2&O#]Q62%
MTP1OAQ(1?0^DM^=9>R?5/.%]B0)YTDA]27K7K9?3QD2U(/>'<]K=E2O9NF%P
MZQ(%SI6C,EO&_:7]X8S32L'!P=ZG;_^+P!YMZ",D+0@2"8&!,+=/0"5_)?^M
M\H(T!>!0TEOM/&U81S)4P0ZO] K51GGZ89ETSW#\]?3O/&?.>.GDI=>C;WI)
M/=RG&_'(WM*%O[F-( [^S>U.!;&;<8@0*'_PDZS#Q_S(+0N.1ZP3+]YH0KCL
MHBQFWBJP#D+GY9YJET<(4X)4[G-MCI>4\X7+9$)\9-=)$J2B6;'GPSO4@?5T
M-L!A<K@F3ST_"X#*EM =;A5JT7+2N"!'PDB5)-6/_!5B9#(,E8&!SK<PV>\X
M &+*"2C4JD:(ZHH 9_+K]VT*H&#$TG[EG.+$E_Z:.4*?%\[6X;E^YGTR?")5
M6I=4+/?9B.&#RF5:L:;O:?]LU_W6__:N ML8QF:FS.:Q'; 8*HEK1?7\0^9T
M()-:%>U<-M=WJN.>Q_ -\43J S6YCP$G::2(_F$ N%@/<:!68M'_0LCZ>H/-
M-SO)-0WTN8$U@F;'U/%;-4>GK,\=*=(\\7=V;#I#_Q=.$N?J4H*2_^K129D<
M+\<$AR8N=-B%OS'>_P..17O=0/I$U+^73'XE)6PTV!V_+*;45S'5LTS[O4K8
M)19[^(;Z"<=.THPOWZMJF9-F#V)QM'9O#7<]IU//Y$5V)WFK.NJ69L3>SDF8
M/W)-(S)(SJXI;2WX,/O1K[#)D)[[5#P-N5VV[/53,@+24NK<C\P.OUPS(("H
M>A&*3+0U"E?+#C/78 [=29L::BR=/AP(Q_B@#UQ&,Y$ Y)GDM$BN]OB4M\FW
M';-EPT\/[B)K:R.HN8+O@GDH4=:%^-![1;%7%PM#R7SSLNOG!=#W"MPOQ24T
M K?R#R2RD66N-85U/H<#;%URM#P#3'%KO=6QP0B_Q?^,48J%_437W!>7B F/
MJRZ(7</1^ !ILTE^:V]+;T*&Z,ZC2'N2?*=2.%GF*/SC;;R=W.YW52J989*?
MP;/&9MC3<YJ79QIFF)A3BT21=S5TVC% WU[@[N(&G)-DOJ>L\G(>B*G%8C&7
MNN;,)/2#$5"7I2,+$U34(CDHJMH620B688RJ*_S"46Q<RZY+9%^<XX_%Z>75
M_I6&(V[HZ;H%Q7G6(/?UN8]^H*/TEV6HT'SEL+#0A_2H6I=;@]4H[ZOX+S;6
MY^-6:KY".G5/0-:ZK'[P=ZP8\[!XY*!B4(1,G,JV#JU5S^9:=!7[CV>'%;'=
M 5@S%A::\V@SKA_(7BK#QO6LZ12KJCRW:<-25P%6B6/RTA=9P5**%Y,VH*ZI
MC/E27W<':0[$8PJIMV_13V-TZL+@W,BUC>H#<^GY:\T9P^Y<3_5CH"Z>!:TY
MJF 13UCO3 .=2:(!\/,C#X8WFC43*EAX]=YB+>YH,88M?LKIW:_()SJ2ZKWG
M/SE7J*:#:8/VDUR?N]3CKL8P1SL3S=_06ZW\DO6?AS7^KB F5V^RPCMJ$"N7
M=E932K EF"8];I/O?13.UV4N4.(G9SA1-W/<P-ZOI(-"',S=C6N%;0H&]^%H
M<Z73!.*UCS?6-K>/SU\<,.0%:*/EF!ZS_#.\:-BO[_<'X.%P\)'>ZO_SLRM)
MY1=E\]\)(&O7_6ZDCS,N&O0^L;(5^D1*@8H.X<_M7<$3A#>V)!1V9TVE38VI
MP44(]_*%GD(;M#+]&.H)-+V]G0PMY:73TE]WW.67CI0_IC,9-'FBUOJ3'0YF
M$SRFE4I_LNUBQ+:(/*I6F/90TT@7W;]V 76WHHWJ6:2H5 -WVL,A@&GK00$V
MPSO\V\_TSB--5 #LN:&%P>RR$5U"V.4?0,L['@O$JV>5OYZ5_S [O>.,*FJH
MG]"KL$K$HL5W[2^5M(7B*!HNVZI\DPYQU4#D=T+J9'?X1>I)Q:'EW/D/<=@M
M_L<Q6ON^6J358<TBT51\>%7>(5&_%5=W""=<4*]A7!WT#A05[;0*UK)S^>/K
MNP$N+A>I1)OG%F[B=.EF)<D?*E>@EJ! HGZ'1>EU;N:44>ZC$/T5O!FKRYEY
M&BO'';=II/1^'[=7CTJ<93!#<[S)&55]>>/KA(=E"]:D.>&UWV,1R5I+DK<G
M*43+UN(IUY63O? S=$J,-VQ_6(E_^F$>_?YXQ?U6X+M\#9MGR'0)W\\WJ,@T
MQ?&Z $_-Y99'6J1WI!2@J/3MGB!Y*$OQP.Q7*BKZV(#B' 8>QNBZS:+(?PHR
MU*3**770-ZJV@[E"EQAY.,,L"=-AJY,RKM4.3=%F6BMQ.YZ5L:/U1OSG$XJ[
M?P"623F42EG,5M-MM9:_(^Q;0X6QU$46%1UZ&*AX#8_U"WV$22EW%ED&@(0Y
MN)XZ>3:;GVP@^5:T%M);TZMI6&7NSDT^FK7C@2@J]4LQGGQ9[UG-?REJ2>C^
M"OU6EVSSR&!WG$&6-3@_L@^)Y[SODD-KPVAXE'\UXI)4X#)C<;WA/%K>%1?0
M!OT#H!ZF>@A.,=V_*D=7"_]NS8=^?A)BAVNJ03<7;[P,CD[TY ])IOE+JIG\
MMUX5-;CGXSW/8/P/OJ9S(]H.F^X;=UU7!2^RCM>4 +NM/+RTJJ5+2CC/X^#_
MQ)VN)L:;NV>1'Y:*A$U35MJX?O5H'%]W)JL4<I6LC;PMJ^N]LN?\57M#O!F0
MUOH*Y+HNPA+N,\Y<K'34E<PN,$T1*EL*XC[II7H,K[*RH<9*EXPUQ+&X\(K,
M<2"!EH^YZ58/+/GV,XGT-N*AS5-C6I\K:KHVW!F5T!X, $D'W)-7=&.0GV97
M4_)6/-HWZR,7AX,A*K/?=!UE[[[V-+';B.Q!XV48<A?]LQ_:(TOSYRIZG-X1
M]KV<2!&D]JX-+I'KJ+"L9^1!.E.5F @?[ ,VP^*SJ4/U1(W'-HN>O"N@^4S9
M%F=XX"E8MT]BL2FN.<=VIX%\D(A[-+M1;%6X])5A**]/P?_]+05F-O'MG4&F
MJKE#5G\ 7CFU39X;:0)O9A4^_7S/=I?488W^/D;8RY&L([_5#UG3IVDS.E%>
M(_/BXW8Y8U^&-GQP^)OU"^ZB7*91A@YT'_N2-4E4>XQ&SW[ZVRJN$FI,Q=@J
M1R/O'RC#$V[+G:=^?CRW,X-,*!UIVM?1E7X3>JSV*-U#(/R]5T5[OD#,+K>]
ME&3266.L6=';0I+KCK_X),%FQ%LE:XC[MK"U1A3@>N;EA]4S:<#D@>Q?!^TJ
M"'[JL_2AP-^5C=J,H%UC+<MX!BZ126"#N"H69J<\LIFA<;#(7NW4!$FTM8 /
MB<&,@(RB>=H,C0DJXDHHL*1(%3LU;RDN,'S^VO[+?;QAF;Y!I4RS2%E?!;;L
MHAM'.-/$L'>=0TP=;>J/Y%#K*5G[JCO= +>@#O.B<T.M6CW1?LYEH"74D4"$
MO(H0ON^G5!/*F%?J>, 3T;*$2S8WIU_[H)Q^:%I_;F731+9*Q_Y#=2O$ L=+
M4Y\S+ /YR?[]0T':9B6-(QJ(DK[+8Z7R^(CWVH80=[+?#?:)JJ+;_1824"FM
M<8LW#<;F]%C8''DP^ED\D@BX)?ES!/PAVVP9*D9NG2!+,"$Q\7/8],LQ?GB]
M9QV#02\#@<!T7#*8OH/B-J<=FF^=%'JM5&17[G&/0I7G5N>KU)Y*N+NO_T;;
MRZ9RQ\:8B8]Q;]OKO@X^MB=3Z6 8#U;HK%8F1Y6YP4MMYV?F;99EM K'<:IL
M:J$WN&B$]H9]Z9B4D*JW1E9L!)Z_R(&?N(.28)),Y9+/Y[/?)Z3:^3H (?+M
MY1D2&%Z,N_3FS23JC326+SV]KS7$<E17$CJ+C2R?[T=&CGF+J2A2YYP.P2R(
M$.H57;B""?VX%+>$O[?";<QQI:R-HMC[^9<?A'(L\XE<QB%S-<:^/',I(SPE
MY-%CS<A2-UL^;$N8S:C$G@C$< H[-3CDZ9@F;?^S7BB"H?/344+A2YTJV^\X
M#O:+P;1I"XQ_?5%MR">Z$A/%F\ZHK"^+8<-:;3TZ:_O-6TL/531QS5KK7]B;
M)(3"&U-H\V,_(M"S"2WS>>D=OK<*VS+-6T)_QI4X1([BN:*8+GUJL6#O)V A
MIF" %!@PNK^;CT;;;Y4(&2T0>T?G[O*'DX+[S85R3-,;-F0,K \"6W,%VSVL
M(-48(E$)B+[%=B2D;@<E=[&KSF+=/"YO]'VS4Y?]Q'4;%#,\[Y(FAXGD+VVP
M6.JAYNID"D2TICY9Z91+0(JVE^#IPZ>3%I3O>5CI]?]84]L#7#/T-D8KCU[?
M"F*9K1OP<$I&?^C?C9RR>7N42I9YW625N8]K:S0FX8J57AR:I-<5XG!$EDCL
M6ZLQ:&4^W?%26 (KR^55G.Y#!] 4-<_5.2V?Q@D2F9&X85?9NWGX@:/%<DKN
M'(5NK0"QP%.NXY7RLLWMY )M[-=6LJ.Z!VD"H2F_1 N6T%N)]$H++!:;9_1P
MZ61,1UE-**?0A_WVFN 8,!\H4'+$2/\/(#RFS],^6'E(J*Q"EMAKJA9(VN:@
MR=7@GV+#AU7O54O<D_"FI?VPSGP]7D_^_3.[1"BC]&>'=;[W]W<52J'[@?A,
M!_Z)=RW-B/RY 3(Y?:;5!&EY)4A6^1YWKA6@X0^ QB<3?FCP<DPQ34I9]LMV
M%-P1V$NA(56<QA]0<%RLN2(NO/HNL,C41.K>^ZFQ"H]>Q(^_;>DS_Z\R\#DD
MGMZY;[&ING:!T%DJ:/F#;&R-=Z9VZ4/T/\2><0SV$)C(H!B3L]'^:<6@#@,)
M?PR_>_CK=%D=+N-X73LE5 4]4L6HNPKP=&U\IUCPR$-,-,*^T"EBR2Z(Y$UU
M7)Z:L$3BA?%RI4'>90ZF^,5S#B*Z9",(498Q">GR5%Q"9Y7_ET]5_D?.I,9;
M "O1U.[*B63V^*-^_8$U,8<#&;[9>T'?!8/V.D8IX]BR3W46+JAS+_?K I//
MKD)%KGZ) UR^62Y 6_X /D;_ 7REU?P7_B_\7_B_\'_A_SW@2BM_ )*L?P"O
MV:NZN$S59$^YV7ND EVN:?\_GB:H_)G]7U!+ P04    "  "@F%4Q%QFQ_W"
M   !_   $@   &EM9S0U-#DW.#@V7S$R+FIP9YR[=U134=/P&XHBO?>J($6:
M] ZB B(" M*;"D@30J\!!*0W 0&I46D"0J0$I(7>FW0))23T$DBH 0)<?-[W
M^]YOW77_N/?NG'767GO/S)DY9<]O3M:Y_GN]#*!YKJFM"2 @( "\OOD!KN<!
M3P!$A(3_MIM&?+/=NG/K%C'Q+3(2DMMW*,@H*,C)R,DIJ>AH**EHJ<C):9AH
M:.D9&!D9*:B969@86.@8&!G^&2$@NM$AOD5ZZQ8I R4Y)</_YW;=#J"]0QA,
M3$-$< ] 2$M 1$MPW0W@!@ (;A'\IP'^NQ$0WOAXF^0.*1GYC0"4!D!(0$1$
M2$STS^N;V9";>0 Q[2VZNQ+JM^D-WI#<\V20#$_]=H?W<74'H^$XAD_JK5<$
M*1D3,PLKVWU^ 4&A!](RLG+R"HI/GFIH:CW3?F[TRMC$U,S<PL[>X9VCD[.+
MMX^OGW] 8%#DQZCHF-BX^+3TSQF965^R<[X7%A67E/XH*Z^IK8/6-_QN;.KL
MZN[I[>L?&)R8G)J>F?T[!T>B5E;7UC<VM[:Q!X='QR>GN+/S?W$1 (@(_E?[
M?XR+]B8N0F)B(F*2?W$1$/K_$Z EOG57XC:=N@')&T_Z>Y+A=Q@>IWZK[B#E
ME3+$,+[U&B=CXI-&WL?^"^T_D?V_"RSB_U=D_SNP_XD+#J @(KBY>$2T #7
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M <UFV)B(%MW RRQI&YXO5M86UFKGI=H1$:\*9 L )&4*I"X@[0L-T ML<4Y
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M,(2A2L&NBZ;O H:KBCE1GX6JT8%NC_M2VAHV3XNO%FRJ3._N2_\DWKMM/B
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MQUAW"NYC^>#OTU.H^'I51-\Y':3R\:KY[T7OG\8.5,4W JL-??G3#3WKFZ#
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M"1OS"@>NPH7N=+'YL&F=F"24;)-5!-[+%#OHSSMS3",L"'WO-]"+TRF^24O
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M< X-ZS)\DRD_H&#L/NYI(4K?L/(-"^ZFO,V=U,!F'/,QE,JUX [V:5"B''U
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M:')RTER2H5]0,:<'?12G7. _N;R0&!]VWT9>_+B7*-!='ZUCFC*E)_DZ>RT
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MXVB<B=[!+BO[CZUUBX6N,V2@F?RX*V:H)D.)'CGGU+&C>./GN;027+<%Q[]
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M93@C9;DK15#3\FY*:F67FE[=;:3'H;<CA[4M:WFE_QSQ%CR?1[N$YK:DTY=
M.SL[V6N7[Y^%**9CK@X+*9)*#*CW/QTJ)=%P-4U1%#LM6F)*?W/K[2C)K6(.
ML[.O>U$Q+OYJ_A_24^E3U=7M%35=-ZDFT6:S9*ES/%S*M1&/^P6-LSN'CZWK
M,L72RO/2.(FI:#DF'BQ^]7;I>>4GB];(ANJN">LF)&>@G_:W(E=WNG(5UN@7
M+I4H9 4WOVZ?!XQC$^%]D,,R+"*'9E]WS*WZTV.J81S0F(,23Q"):[QM$6Y@
M9?>%*N7-LE3F63GHUKLOIF(]M"('N;:4+I[SC9ZL0X)ZY?Z*<,DE11W=\SQT
M+Y]F6ERCN'/OR_G2($L'RUL0:^B"Z2T-_Q=6TLG1TI1:K0;_ZI#\SVQO?T68
M=]@+OQ$\K"NKJD%VBL)+JO;N6FYM&@F[OOWLWOFZILR.:$(K_S(2]$[\^AQ7
M(JE%W05M&W=YXWFNZ@[01@4=19N"5:8 W<4L39^DHP>,IH$NC) !$(6@RSZ,
M?#NNA09+'OS5M%HT/6C0[OD8<;.O-$<?9B+G$B/9##UJFP!CC/>XVR6])>4%
M:'A:NUVHH4N<3&%4TX;73G_7=:VR:'PVG;CZS4V5J"_@4-92U_*T%ZC/_%/C
M[7;A9# .6,9@*6TVI_-%DHCZU*)$TGL>,2YY@:1EJS,E7L$2=_L3:CD(S/^G
M%"O(18C"<,!Z2O3   8')+CDRW[9Q7S;KXW&L-MZ(&LLX(CZ>9E"T<^5(1O^
M<0+@L6(<\ @I@P/0Y$*[93%S.2!"C$*B=G_).)/5H]*:Q VGJEQ#$_5F'6^*
MVH?6#42%;?U%&+6Y#@1U6=1A6!-H5!#]<K3&QXC^W@<?GO 7KAM6-!)RVX;*
M#.=GTC>9P[6*3E64ZSCE\Y^5#2^GNRNCM%ZCZ.E*]X:%<JRMM<DW##1//U-I
M&8?9WB-\RK%LS-'VU+*M*?[N>DLBB;OI;!<;_;I>^%HKEH'XRR[OC9 NR&C:
M8MFVNA11\-#B!ZWM\[4A10'?<MSC.SU+3O-+PE>S-T 4XES9EL-3=+W/-U,K
MAMP%9C,JAN9U0H4^OS>)C"R2[<ZYL7B?G370WJ L(GG*,O&J.,%\!6![P>+8
M-+ \-CGLT5W?,::BUH6K?I<^D@Q&TS*.= E"N L$/HBX5F/%XMKHJ"2MG#!W
M)99@)&O0JR5@/PB6J?3D<<*G7=WIC2?E*K:E-<GIRPM*(=7VA#Z86]LA\&5T
M4]*Z/5J4>OAF*<IZ<WQ,]W)W[Z,LED]\9[,Y7-L8J@[S$\R3%W>6U-7';>.&
M%SU>B</O;5>NXTV3ZL48!(\H(L8IM8X]HUV&!<HCQ:09N6Z$2Q[[*=7LCY&^
MP 'TRIY\+CW8QD/HL5!.0$HUQZQ'1("*J:T!XLM"]KL#?X7QZF/;G[O+%NV#
M!WS?R/$NU0C5RS]EC44H<NVJ'#S\[E/(Z.%UO$_=S.__BNEY#YMFP5(=%>_5
MT>. E]'HQ(5_;7_X>V]_R! P2B@A6(*"4LMKD%B_C+* M/78X/3<^Q:9+7G2
M2]^:Q%@3:\/!\R2T'WRV[/7]WF(\YG  V<HQXW$D-C['H@ =.]\$F1.[;GFB
MU%Y>%D4E<_U!A:JJ[]?RJ2,' ^'F3?6!%D.20;@CWWF7QGV>4C6KBZNW6Z-S
MN&7=G8>[E@*OF9Z#BG03Z%\UU$&N-Y5500/V8OAJ^%$.$+E]ZNHRZ.4F\^=P
MFW2'JBTU2G^=UTYB[YZ;A(JJ$@U9]:KW\TU2E@!:-K7P^TD6$=/ZT3LIA!=H
M.^2:O;)2J_FO2VW)P6]E9Z_>%1W*+AU\#M_>_.C]I.J]R0/9A[YG58G"M">M
MF)DBY@Q37>WZK0A5O+=)?+5IVSBU!PHU9]QF$O9KF?W,9C:=&\(M5'EJ8@/#
M=:?E*3 CKJ\7*!0<=@M>$KF98+IZA#+-D*GW!_:M7\PQ2;9R62M_X_'LLC4/
M<^6@BI)*A]567/42=9[+M6 FJ_-3'> 5LM:54!),,RW2+-G1IC:(6Q0;=]O\
MNOB /*9BP>A,N3]\=D3<*LF\O!<^_.%@1#A\7*$Z)::W.8N1F99WQ\ZEF]QR
MF4:^HJYL<._=<V5XVLHQDDB^TR5VM#[O!O.3BP_$7WM3T! #*^><8C-]MTLY
M!<?1^9OPTFKRVVPCWT@>K& $K4$QU6?/B4N^J%QMT44>^L5)%59!2^ MIPL]
MC@XO^C9UV(S./R!L]**2:K^G%JZL!-C%2J;;SHY;\TX;QDJ_D2=C\19TBZ*Y
ME#L+!&G/$1.?JR*=#WMMF&GE0+58H]%P2^7L9R;60._<-)/+LFK^\_E84 ];
MWH<#T10]RS(NT=*-@U;3C]U@]Q;"0'[K7)%YV@9&B%JRQ>T541[?F.?ZX]_J
MHU Q9-J?LU15ZLX!AO]#&G.'V__17BXBC5'$;]!=%_BW\4V2#0>XAZ A2SW]
M:*O3?N@<+!R_ .L>'??^!M[!?QW<YBJ*3UO!<] (R1X?V'0ZEN8HU0>_KG<>
M[GO]:**_W57^]+>MNBHD;)OR%+)D;PR;_/P*_.5$&D\RLW,.M>*AO6'?0%X^
M+"^_TY/Z?[(O*#F#MOL3Y:68&5 :]:]D?9-K4.<. R2ORPN=SOA/R_<)'0UV
MV O$AS9=-J(TNT='\""BGJK5Y8HU1 W9G9RSA@=R30[PGO3(&M2CZ+*"J?N<
MC[UGN)Y$R<BH>6DF"'S)-T)_R\Q(3EV1E"FV35Y'6MW=-2^>^FGG/L\,A.22
M?P4;TR5_91F!L"]4#2ZRL[+-BAW5>B JE=EU$'E3?ON<V(=^M@37K2W)WH$T
MJ:IKP6RAWIZ[3%[.@@1[EU=7%>5$+_[2:%*X^]KK/'__+R<RZG(DG:V?]_];
MCQKZOU2-_[M^<X'/ZQJ0+;@H(IFE"$SPRU$&G*^/('_$<.K:_VB1I"XF;GWH
MZ70 'U:]QEN8Y?J#<TC4Z5:@?Y#&,:RG\8B%&4DZV&A?!FQ5T_&D#/$2TK*,
M:/5+/J0C0F:N?2];W?'XT1$>_[;-M,E='^W U[Q--FX1:B5@?G7<L,F#:;^$
MD[6PQN3#J'80O.)-Q2OC9*&0-(P(ZC0XVU1BNR5G4Z:?+EP^=_IA09"9U'T.
M'>.)2B#P35@L A77\BK$9\^#@D= U4^V8J@TP/KV6C3_!982R$3GB=XB6]ES
M?51EJU6'M2<;.DX5Q>C)58[25TJ><BET%\E /V^B"7,S9]4V31#A7Q+8FN8P
MDB,@;CCO)1EA^*$D8.!?E<N_K7+YHQJ3-1J$E54BQ#9^!Z)"5A2_K0&,O,$!
M+IEK"($ !NRF1A]6=HP+GP*4OB-;[-O@+YBSG SI> *80;0(Q5 ]Q"HSW,>3
M\*?X1:.0MSYO><+^1U4 SY H6)4&F+\3OZC6\%88)B_^P#XYLW_TV3ZMW4J
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MW)'?%0]GK*@_Y_?Q?>5]KC IYCAIARDJ5%!F0*+V77Z5!8OR?HO6):D4D<5
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M&*>K)9GZ>).(V;CXS%:C\?15]G_T Q1U &_U7PWF;+9;9"UGR1\(K%+MDWB
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M(H=/M8]@,5W^G,H^BO(+]09O6NK <C(_^;WFYHZ];=Q3:U]>?&+)'9I81_[
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M3>ULAYA]V02!+7$ZY2N=6YU$>+GB,;I?VLC#$LVL/N&IWP!49R0MJ0+O7[Z
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M8^I;^W1NJU$96Z49(:B\=_.- -\;0(P2(9IWL.WX6\6!'.^REY#_8Q#96^K
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M.,?? R%P8.%_<$VD.5^U3>>K*6S%E&6TEI5Q:*#!W@#D[W-?3EE&BPSF<K8
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M2%SZVD,4 4SGR[>B 9_W,XLK_+)G$@-F227*TH(.P>&<\0T:@ZJ5+"0#F3>
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MD'4$^TGB$*L[0.9Z',BIEZG#>%YE:] ^DU\7K P#_A 0(YU.7WYP ]"0G^0
MKE]FN5H0*D?GW8/ V2RUC@,D2, @+)6NR)7<YK;1J\9F:987&B?@Y<G!I3&
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M2!W#Z0YJ^.J=S4!IE>GSR_@P3O.E(4H#?(#Z'(-,TM#4\NQ\CZ+S+-Z$\PV
M'"-0?%V[B';4J)>.Y7AUG=O+A_D5 *((_QWVVHZUA;$L"PX)LZOSYT&F1<R_
M4'7Q*.FUE2$E-'&5(>W#$@2ZE!0&/WJ'D2YVGK^8-'<V-JZ%=<_7:I"U<0R0
MV'J^!?S6.WI5MG'$^FF" OWR*3(^"^;DIY17"/N.M>TIA143CUTCR@"\:XU.
M^>32IFC[@E=.2MPST"KI%Y/"DHM<,?NG(R,2OHPA3.NNTUMTO"DK6+DVC1",
M? %LE# OW]E;=$Q\59NEZI.[8,I#TGK1N^+PX >)["$64#U"H<30 /DO^SY_
MXG/#2LS?TF]4;:_0N1<WLV<G<8:/;IT-2[(D!@>(??EYZ:>6'BF1I<-_F.)A
M>SM.BV#IX-NMHW=7,6N%P;)S: ^XY.3.E$GO'_Z?,W+#/+D2Z*#QP_S;#HFN
MTRI&@*3!J;T7"P'<-A5@8Q!%#[,?L.AIG<5UFJ3JN]&(^"1UP&*/*7F>D"=-
M#E@"+[--Z-/'VLSQ:3.'-/G/68<;=WA4VNW9;P#W%C.XDJ42P+36?4$LEH3R
MB!FFBHJ#81&>[)+5'XMW </=AH:J$VJTC6H DCC\F%+6Z-(G6[[>=.5;SR\I
M@>$:Z9S':P=#I,OK7.]]F'])>L< ^NJ0(A'G=>4DRA3.QF$O":Q]Z?1Y83WC
M 2LB$SECEPVS?V:@-01HG\=.RSJ3$M\4BU[_G&]R[S<*K0^5*NOI:_DC3[[3
M5)9/;JV'MM@8,]>.%NG@S%\;=A?0??3*^>-W^Z2ZUD6<DS,WK)!3-%WU=@T/
M.?[-W46I%#[&JY\YSTG6D>XM]FQR4/WN WMY$Y9(VF]J  ,@]8N4L56;MVN>
M>UX\-B\[[9>;G@P)2_$PE<$Z0TN:ZYH:DWW9FV,8A=G&/A>IE&C Z#TH9X^,
M&!6#6;[Z\>&38.\=D:^;=LP=08%*R^;M3YC_?#*.:A9_" !,X[5&XI<?"@CT
M0.YBI.%L%&HVY(E?QA2:],W6U[@_N#?EEX5X"..MD3^*X*WREH#B)7223U+W
M:UA;4NA8>I:F>:DZL\&:-EW7I9GJ@@D?36=]00OTP9C33YUAY)]+AX.T.OPM
M9#:EN79Y'G^5WN6M]LN$X61C51D^$2Z1HW0Z.-1W7S(G=>N-0)9+H!+?9@[>
M&]I980;[C W4&9MYNR/<DEYG,NLI=.I0R--!/6IO$E9H\>G=\4L&)K?W[\7&
M78QC $,I/6T$L,/[*YFLF7]^$'/$ZKMHCO4[/0HW$VLAUP5<2A8 2V%+W3;-
M31'$VH\R-N/XTQP$A_!;';C^).N8_K\8+%F$X2!8 EN!J6XM%_KJ4=V)=E,R
M'*D9D=GP,U".\/05LFT*Y!^HVFR2TB*Q>* 6O"F&%T<@;[*]=YH@4R7'A\^Z
MV?/G]MHWNF:ER)*QJJ>YAGYQ:4F-O3S$,"Y.-P;>N$O)]\L:M0TNMB!;(%YC
MY.$D ]SHM/ WQ#N#C1]3<9J@I+]GPI=/ZH7T#N[DD$-/GD_5T"[^;7:/2!+_
M-KN3;[XN8N20)>D7$W5H6W7HU9NV5[_O!VCM5FRT!(C\8,)G_]4]YFFH1T11
M%B RP]$,;4!>YZ;"VRG+5<O6G]B6?)6<>7K $:S_4<#5:%04E,Z)7_;S'8:S
MP/0@76ZU*;94M<I2>.D77Q6G1;1) JN*M.B&EV*XB\$DD4P7&8:KZ4\V"1Q(
M:S-'?H >S"-?;FCWMF<*\L@->G=FW"AR&PTQ;9LYKCD7DOJSJSNT6-+:D*#1
M-"BVG5Q<JGKI/FD\1H.7"-HXNC7SJG4^?_)\T2NV^'1WEA,:[\IMI63RD>R'
M##,UK.0&\,'GV2D!_O.&4^/EP\?*#253H#B&NL361/C>D3EN:(S%&*%)Z V
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MZ4I9-N%2*F,&'"SW-D,,IM8,1WZEOJ\K@1J^6HD!Z5XM)'5=24SJDIKGJ%M
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M*2HW"H>SQQ"9H%1.MU)?9/0<W^1%6AF<JOR+24;.HH5<I?P'[Y=[O%F>FY&
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M2LJ 717PW VFQGU+PZA /=/ !B]C/?[!1<;4NM,5'N3N[K,)_K D\7R3IZ1
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MA$'3^6T;?EW=]/)57XIKJ<EE[!6H%)VVT?1>V):<K]\LF6?]]8$%@ /K^;^
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MS+UHK%.!.%'-#B:+J"W&_!_VWCNLZ2Y;&XZBHJ)$D-ZBTD5 D-YBHXF(H("
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M^9X *?%>/?)AX_4+;6X3,*>< 1.YS/O@3582I)?<:G%:6[>B+^/ ]:3O3U8
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MY4_4YC7T_[%+<+R:.X46/U[__WIW*/^$[NS0(& L6RE^8M&1UHN!_4XBXO\
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M<YMGJ38M5CK+8)5-ET>$#ZE]4&'><:J[RX.M;S,%GKD9TB];)"SV2ZJHMPT
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M&K4Y%KNLY9.LK;*>E[TB%OA#3GN"6*$"$XLYDZZF]7M>*W?][K^)N0.?CWY
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M?+JE[]N)#P%9KWPVAQVNJ?Y_"\A_S(.VW6'J&+774; EA:3&6RQHUY>K\_'
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ML<3?FDKJ'_S"?Y]GA.V\W.3]S@@IRH(U5.\.R-ST*//'\'^'.!?B[8?ICJQ
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M('Y3Y.[EG&^L[.SFR#O6%\@O/& \>1KE+JP@:OZ^:(?]$\-I",XT<5<]\+C
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M[?_I8_V/334ZO(^#@RUZ[P%GQ27 *G0S_JWIT+2EI2G^#HUI:XFMYQ+QY"4
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M?Z@S[@=>1GUZU7?=9QEU"R"Z?!(/?@1*Q(-'1>I#*83UN21F=Z8,<5 ,'AK
M8P-V\CUI6G@4H,\(OWE]\3"0$7-%AH:4?OXF(,G-K&!Y*$EKC@S@'GR3\378
MT\0<>::B'E($';>G+[4,1<QM=R=3U !Z]-WDF7)T^#.^9)-49%K\L$.^E$ZT
MH\5[7&DWI\&XW3R#;A#E-]G=\MP3FR=;:_U0RHE(5M%X>"FN/Q1?0=*ZT5V
M5=[Z1(3W+I !W)F0/]/_D::$]D",H:B29MF9)$)*",*V,59SL?>TA5>VT+DT
M_7NR"S2LGYML;;^$_I$(!S-M=[> O"B.9O-@8*TI+8.RR$0"#TX8!2B&^B@;
M4;B)TA.+WNNHU6X3J/S#S8)X[9R$&VGN%E"DJ&7.:;LADVMA+YU'84"SN&DI
MX:N4G"N].;5CHT3PHIVL/B35&N9')9\W4&QN[Y"4=+E:N0>U= P=VNU7CQQ:
M%!.MW6.2-1M(6Q^[S%)C%AB(I[D 4(3EG>4\;RBON7'?I@[)BG0&VW79RSD,
M%-%2GE%O6N8&M4P:ZDEE)\8G;*B4D@/2G,F !5GKSE4*>AS+_7Z_2C7EGV-]
MWY._$JRQ$+B^0ATWU^R>\H)86@$)V1\FHDAAEG.J^G&&BADMIZP=%4>;3;Z=
M-#T-5G^*_L 4%P50=DH:HZXZN)-67E%7&BD>Z%#U(:E27KIFXH/HQUJUP(V)
M0.Y .EG*W;E% UQYY93I!%8)T<"-6T"IXY8F>46=>W9U-&:=S"&M0,@;XX5C
M*R]9WHWI_.(5HR6*LL)9/5U&IDN\,BC02QQE=9,0YFAM>"U!!OSUO70X9>?#
M!U*7&M8/#,M6'?9T2V:3#"[R[U]-]S@&1;T@)Q>,CL4JL!ZZ!H4LYF45I\Z<
M)^W%O [J9>E: ;NCVJR]F_Z%:M?GR$70H.>+5#0=FF&5;L])]O4HV'2N2,HP
M8\-%\)WTN LN-W+6Y_=/#SALD)24%(,V[+VJD9_2,E7R=&;&JDWA\E7RH*%S
M7]-F/9;DQQFKF<'JN.)JXR*HK?(-B.'N(,+OT0%W3,_M51T56BXDTUDHS>X0
M#Q7GR[99&746U.P/7'LOW@+<&N.+"6I+,&\!G5C,9XD7"5M=MX#0&TPVYH42
M98.[^/Y2N>5I!5(122Z)A3>0)N.K+R0+DOT?;GO<$616X#EGOS!'9B1/0R6F
M85?&D5&!]6JHGK#8K'SR-@5X>Y:K;!];/>XC&0W >#/+'_^5]A;@O8:/';!D
M7%U> ^OQ%.$^HV]/X_QIUS^[%K:F4HCJ1Z;^)<UGF]FGN;7[I[5@HBM*K@3P
M+A "9!3HZ;;D_.IQLFTS^&+?B@F+234OYB__0;+R><Q@"28P\TL+7-8QP[UM
MAF02V%(]WJLLIU^:L#HYL;CHJ(](>HX:VW2<,[>59[5<!"F?K2LC^M@^;_":
MYT/JBO S=C4+B_T^DJBIS)[3!D4)9!4LC;72>2^.S#O7_P^CP?\7OY_RG[:Z
M_BTILQ[/)0WSYJ\6 Q1;=0L@EYF[A%^_[KK*!CU!&*6\ \VY$?[X2Z!KHFQ5
MP#0:T\ZX];/AL6IB^JZ618$H"^F-W3#Q>FQSTZ<F-<E,Z5GF(+78+8Z.9-!T
MNFBP%VGTR9OB<^?)L5G)L=6)):.0D!;"8MW J:UP)6??C-%"XQ--^X+^';[I
MS>*5(/GA#X[I=%)"224OE,,S.:@RNCUL#*;BR)AYENKMV\?LK*E?=[[@1\>X
M;DR5#L+/*MLQ6S)V'.\,F!\KDKZ"41M:;/([V$_%/</F6=H=<<;,E!^'O8_L
M"P7M6T9F1/9:U;DWUI&B7,E4S3O&]J+Z6*M3")J^.QI1B2MGT'TZ3/A86A*=
MZ(RC9U#YY*S'F#26>3/PK%$K>64ZP?<Z?'HC(=H.6!.R4'F=77ZL.2N/)VE2
MIQ59%G/D[(LZ6<VO")1AM5:,8YK<-7V.&*QM4U/9'E,TI'GNK2TT+14JYTY*
M;W$D$J8P:MQ@F>L;G>GF9/?=;AB_.\N&_G,(T==]? FJ6 VCCZ+/RZ#6O 5,
MCPSE<:.)DZQ+P/&%ZUR42_1\&IO4! ?GXMQCB@R6=B.8N%RDHWFVY3).I@)%
MVZ\W O$#"Q"22%.EYVG:;)[W41?R>:'( ^8F]\Z3>QF$%CB^>_9 IX*?[[L5
M,ZTEYC5N98)Y@_#4.:F?[BQ9:JG!CCX(/INHG;VDQ/\/5F8GHUM AY<?T5WL
M429-2ROF2;OX<-)G+'0$JT(8OA"_NUN"A^%N8T94/4WVW5*,IBB<ID#W^6[%
M!MP3#$X&\BD_AGZ,#5= "L$CI@UH'\NNB3P=D*NLO:*>1'KR6KNJ)RS:/0D6
MH_T*%N9N>5I0T5"1\(:0-0U7O",=]7L>1[-IA=_#(B:9H@O#4TV4]8.?Q79;
MFC7:"<H6K[^LCA([?A#%WXS$@R$175M\=L:#1D,1XDO,ARP2^$_+7N-&%B?6
M&$N2DW67<KB=\(T-+J4T_<*K"[.+5+7:^73&&=6A^WV3OK"F(O!T3,;<AZ7S
MM:TMF#?=-.V'N7U4EX.3"Z5E)84#N0V#2SO@- USYT'^.G%<?"B3M<L!; HL
M_4EZ$%*_/QME1S(%U'[U]4L2^8=V"0K4G&)+M:V6V#AUUFZ3ZE">3K8?>%]#
MK>=>=^0\QP&R 24X$B=7,D.B3'?[T4BXT["49C=EI':&Y3[2OHH'\HDE!^;Z
M\IAT/ECY0A;C6".7QB' ^:S)E^LC1DHK+O;F(S'W#"W=%D34A)GY11Y]_>*T
M8)PDTD=:Y>5^S4-\6DY3>(8 ,-O%D? 3TEN ="CCG&F8&=$D[\A?-H0!)C:2
MMP V<9/CL"-XJ(9 >I=A_UT)C_AP5O^G^3_=')\X)-0[ H4;U#ZSGIL@]_"O
MAWKI@C&K^)O OSIH%QY7YQ$"O9D+X8IB^/.D=[O]",/RMX"7[$(G0]4174C<
MQ>WM8X]DFDLG!99M.7=^43ZY,%)]6((-G'AS&I4GP2V"'B+\(/C&<J+UO86J
M0I*S%*DQYEO:ZC=[SAK?!AU[PE[A/NPZHV'D[B87"F4[5W470$$Y0.[[O#WP
MW+Q:DOM2;;3KR=SDC$1>"\E'9!L&3G3!K_F6[LB-P2N14E$]D:_3?W1>;Q4[
MTA1K01K7[9N+U/M,3EF.93EG;P'*WS_:S@(I6!<"UBW:([(T9B9U^^QUWF**
M?*L2%DJV,.=\O%$3,OUM=JKJ:]&*KT>DP U=; R#9<9F]Q"YB4D3 P)'-(W(
M\[H-/;USE*@BGCSNJI]^.LRR-8-4C</7RV;RO90?UDA'.MEK'\I2T=^\ZX;9
M75 $SR^-'^:QQU/HH6^:]:=W<2NU4*_@TP54-&)/:4G8P4W81'?WQ /'+:5T
M:5FI5[U+5?%RJA2NE=LIL+</+0VM2B9N/H)9N?2EHR(;0\PW"6IDYP* DTL#
MEO$UK$ET!T/E@AV&.9;.M,CC7Q=\HI>M2"_R=E\%GZ_2/OA2[LKW"=.0M$(A
M^CTJD9CEJQP#HZ0$\T;?K[R^)1,EJY4SM8;ZGG05YI:[WRSCY J)I C)EQWQ
M$W4%7'-'HPTK!M2"[+,3,6@RRM@Q=OG9]:YP&9#;5S<]^VQ/[FULQ+V-+8)'
M/"27I%[&UQR;%JOR;Z_[F(R/Y7N'\^ &=B&X]_MZ:CR$U!I$O6I^##>T7*R7
M$A<);,Q9X/B<0-H :^,[Q:N.@RO><)YY.F9O0P3,).Z>Q@4$U&>[SVGW;)#!
M>RN\2*V_HTZ[+R[ZJ+RX[S<8[TEQW2<8ZTUTM7>GU!)[]?"RE!@+9N_L'=C9
MQ'UON,]UK]^_R:6DA-'X!Q;1SY^(\08:\'B:2I66-LHJ5F@EHKR(6[::^M(A
M_ LI1SJP?6^GZK2S@?KC*F4X=U@/HKA@/"$9Q,HB-H[1T]S]PQ?:($>K)^&L
M1<'A\G:!+8'CQ"%)2%).=975#.-4S-'M4D+NC8HJ%&5WEOR_ZY%6Z+'B_R/"
M^G +:(T\@WUO/"QA+(D;:/SR9+I;D @93U$7.4P?'@$R('C+DROI@S" M)N(
M^B"E>9"B&-8\%6H:I.DX(Q ! 9"T&(IM00/)=<3$EA.@Z2#<V?B+<.I_W_#3
M9G01A ?5X92B-]DPD_H/J><#/X^.[KQGD_^$]QS%#KU?@VD#[MQG_7^]!O\X
MP&BM4E-_6M9%E8I#)>P=7M(^IL^'2>SGJ3:YIE$:)S/RX+#V02S:E/W7JS*2
M@%QFC@(3G#84Z*D-D?%[EP^]E&O5W/B<<78>3.'8V^Y?)^9[;*C&.ZZ^PRI$
M>"V <L?_;1<N,C;2^^5W'R;]2"(4)3&ZEHDQ]>N7"?+7^S97ZV.C^"'2>)L>
M=M6V!=P>3.W,UR]!]RW;@[< M!3X+<G_#';%42%F>L(@=/@25JYUD3IK< MH
MILZZ!0R@W (:^LCVOVP('?UHW"O74E&\HR*_[+-9!;L%_06 '?R7#E:*$B.E
M\$CHTQ9'8_S-*O,],P?P(8? S;1_4H58#4J,[,.I&N;OX$SC+)W+-#>'?V#L
MA& CYC6E[U*HK6L@ 75?P97B9&"LO B\M$MVUN9A[ H)B%8;%TP)3LQ(!$UL
M-RZ0#(/7@L!S*HW[H1N-1VV->_DCD!*(!E"H,PQ[:A1F2 _#Z>."N5;=G,C
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M@8E(L-U 3Q@H3@8:U"_E> MX+,\.6&[=_88HP"IN\=G1$>JM]/,?O!/B(_G
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MOA&7FJPJG.>9\\&C,LX/'9X]\2;$M>"E#U5]GK-#NO9./YJ']QEQ/W1\]WU
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M'+R+>&3X^&3<UZBN<?_3/V?U !$V6A2&,#J$#D C@J 30<Z: !IPG1<@YS_
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M-2H)HDH0G%]:HZ/[N[&<\@ZRI;NS$?C2N]?B5/ES,<Z HSP# 3D5DS _>KP
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MI<,S(/'T*/W86/T,2#FL6W^3"7OD,K:V9WNJNK[7DGL&B&W#)]7A3RQ2ML\
M@9-=]9RT]0H/03BSR[$I:LH2..6[*)7AA+ZE@)R= \.;2Y?(AB[HOVLD/"30
MAP]Q:2E^>)3;'II-(JE(/^BA(C<15QV>\*NI<B+U05X[%HY+IT/^(0!W!M!<
M.@.&8*=&/_=V&-\/+M2-PEO?&JX1SJGV:_Y6(VZO.PS?!ZU<]L_,]__VH_[-
M)U@C4/_%ZYNP Y["M"'!9SH)>KT'%09*,ZJ6BO1/M;O3(P@9[LM^)E0<ICJQ
ML"%QE=$>*JUF'=4W_OY^A-,QB,/>4LEP8[:JMK:D6_\D1:V,IKI2I7L_%2^,
MTOVI_$ <5U 2Y*F+X/K=3?/'!SY30=J/T?2#1 0(8H7=KTX&U(CDZ(?D6CN%
MA"?(]7 W'4$TLWHXA&%3H^36&69\@MZN"_1X8>)4V:')'O#+%JN/.4WZ[G>R
M#CU_F>>>P((4[*;@5:-[,2QS;%#:O2A*9,GWH6)@K6-W=]G-058:L[,>][7Y
MM]L9_;3W:U6R>JT,OY27MHZ+Y*#?_NB_AA4TL?-8D\Q^W.YY;/G&>(8H^;46
MDL=V9*OEPFI.DU@&!H8==AG+TA^M6]HS+T:LG+!F]#JV\7KR7[SX0,JVH%M)
M;<T,;1=,S?>$KX'6G?7IMVV7F^<W KLQUV+ISX#'PQR=>*S1!QK#^M&4RJ5:
M?[@"*/!854<^1?YA@OC!UG.>P>PT;W)Z[BP-!1KY)_8\K[A)4*T=:AV2#3H&
M]_[$Q/;Q\A1Y3R@$5X%>%,^$4%?'Q)&6[9&_ @RPI;E,5A;R1/8C:/8-M0H_
M11&62?(=-YL-5*".G#B_X3&,Y#6JFALD%:LF:=&R!//7G7C#W2^:,:>\]C-P
M'_J!R)?1UVT]6;AX_;VYB-;5>O1;VR,_?_<F4>R7^HXLLD+=<,+KQ6R-D=W-
M)7]Q0W+V2&TQE0#>S-$UE3C>IG6QV;7A'X..[P)/JVYN_Q5R7!VZU5P6F1[2
MOG>I(:@F>:%;PXJT.<&K1I_-Y>7EN+ 62NJ*M_"@6W8?-IYQRS#IK"(4J*QZ
M)<4"KZ[03^V.W=H/LG9*S"%(RLV@PWQ/3Z:"- P[AYVM:?J3L(?&U\<_#5-9
M5A;KZ!*&\*X3L65]J=@*GBC"SZ:NDV\\".?U-AM\*:K8_%5'?$V$142::><,
M"#HR'3;&+K\RSTPBC3GFKDK^_JD3N&:K@A@&N%!GOWT=/4V^A475P(>P[-*Y
M;P]"D"S<2KT5A)2\"8]+,V0<,EMI GN_N<43G6R,%R]R6V9LWHO/-\S/GP]Q
MH@AQ&J.->/1HCQ>2G^[J>]5Y=/5*Q%WZ+F2)?E:IB3/L<Z[QDK8!T>"]XHS#
MJ)'\_'ZK(C-U6S(MB1%O.H2,O<LU7<L.NC(,J7#4Y=&'C[?VK19ZTY_KD'N;
MM5&C>BS0J%LT<=S]LT:?HBI$8XZ8T)N%#>0V%=>D16V6M&,K?SM>_7YE(A,I
MF"RB% :6YKJ7SJUDR1#O.6]>WQF@&+CUCN]/(;9S"!MH(I=$S+>JL_A?6T2A
M-LF>,YIBV<?RD2>(?]UZ+F+1# 5:'ZNWZ:6 ]GS[%WLVT"$)(B(6,9\*#G?N
M.[=G-$5Z?CPI0EW'HEM$I1?54>VK:NZH3WY+=[<SQL.99D10>TE"Y+$2&N.K
M8,TD8[HQ8BU9]X%D] ];;D2_;[DQ_%K,]703"$L8V:5,(/;)QE]$M(=J_3CJ
M2/.71QW-,_#$@Q(B7S[S\$49-(CG X3T1S&YT_M[V K"_$-+%6$ ETZH!^+;
MD;J1^47 2'#W_)ZBLSCN:PLZ9UN%:^?W6SMHC5#JB$R*A>#*[:#^@9 ,?66C
MM+JJ'&OZ0V,V$=3=/Y&F)CDRP24#G*<.N?K)*;5@N#\Z3PCK8&SXM5'PVGM"
MY@J/B1:80WH%)5%!&@S^F2 .,2/_3HW)X*J+AGE/B:0[HXC'NX>$NK3K@/2/
M=Q7EZ%\?*I<*D;_D;O=;.C_MN)TQ"0IS,(6^"- 0\$"U0E5DNY(^E25LR^;[
M$-&CH@_9EP:1CVX[63*LU0_36<Z7RQ@Y4(\-^KK9/]90P%,!%XL.?8'Z/[6H
MI&H4^I^]5<;,HS=1.W/1DV[S"?OJ;&T_F?46W:S/LJ5[KW-%28!I<)JI>#/E
MFX520 GF0#&)R.YSPEYEVZE<#T>6F%42G5CHFS8S9XS>OU 2Y['B$U,JL>TQ
M[WV+!=_(U;*I[ -]<92V1EH"*5?'Q9-9&W?_&GVPJ,:Q/[ 3X!N6_"X#2\53
M"CX#MK#+SP"OFK*_$UE'SNO_N:$3!Y+F/XFL@V9IB#51O5\ML_%G4+/JQ0$*
MZ/'VR<@F[#BM]BYA?9<8Z>8UU RA\QR=1(-\>@>4&.DAPNJ6V.[&C^(J^JNE
MPP!2/]70LHKD=9^I]KJ5SJ-@PS6A&3]U1T]*/8JQ4[K!].*R"@4X^[5R(XW"
M\>>LI64TBSTHZ"_;5I"IC4:H#/L1'R\956R6^>HZ!;!6FX?4;W(QR>[39?0X
MLEM[6BLZ&%QI=X%*4[I>,U(^XF*L=>:2@.(4D47QKI1"(4=JF[*F. Y9KME-
M9\#FS:'\)U:./;3.9@P<ZWX10E2:G:6,P59W.<TT-=7JH:Q\39GR>XM8?#U&
M\5!(9.J24N8PR4N_,7F7S_5VT;H[,27_UQ/\7]H3)"'IS[JH\PC]^J7WU#7J
M)8&9@&ML01C<*77YE+V\?X)=DC(PQO@X[_]K[SO#HDJVM1M1$1 0! $16H&1
MT 1)2FZ"2!(!)4@05$!R$I!,HPR@Y" B('1+SBU(S@(2)>><<Y"<FN[^-HR(
M,W=F[IDYYWPW//?'YFEZ[[6K=M6[WK7JK>K:^Z=+#:N<_")KO3:6;JD._%1-
MR$ B(65S TQB(.A9D=4UE=N>&;]NP28Q*417LM5D-.1:UE@M:!<0R23/Z,?B
M)XU"(.PM.G$"Q]G/WVOEF%Z]$ R[\LQZ9D!@E]9&:8%RN\CRU48Y*?J%:1K-
MR^LR62Q/7F7-:87LZ*J5=&G*#SG)YDR;C^BM5=1.J&UFX"EU:E*9;:I__*@Z
MP,@:,2Q:FHSKV<8WS@<F=XBI:9A*3^@CJ$E9=_1(J9W0<-(I!B!%*'W'P<SR
MC?%C4>,0;OS'@FA(;\X2=X?\!WFA^R\DHK,Z]^!.#?#*#TT 8[DHY([Y(5YR
MX@V[<XDR 8&*?@2]MS:_R7E *?B_4$I!FHMAV]1(Q<$R#&F'P^V4OC.'.@4P
M/ /_,CS3O+?3UNB/.1FH<2#U[5K]+6U0Y;("#9W/O.*H,;,(B_SCV%SI],\3
M2T17I'BN2[@[),$J*UK+9SZZJ4YXWG(BN$TBKLO"NE8L.BQ@P$2^*1**N4#L
MB06)1*W%??^$I*G8('_H1 "WI"_/GMV- 3B=$$\""XIIVE4^_JCN/^I$<$WD
M%-VP.#I<^LN6^"JN!",.CWX07N.#VQ:,_MJVCX)U!9+IS+2):6'1KJ0 _=-9
M84$%$!/52U]M6FH?/9(8+)5-1BAKT3G\#V>&JU\ AQX3K/R=8=CI_%_S@//$
M;YGBSY*"XX4]/^RY]NVW#Y<! QZQ/U@J]9>.W]ULZ-M,]F_6EOR@AP"C^"N9
M>M4Z7!Y5V\$#]80"C][Y)$O<>_:*.\2G6- '\AP+\HPVQ8)$ Z7WV184=S>=
M!N9SG:G1C^$V9;$%X!V-;OCZ_ :LLAG@&KAZ'' .KYME6VC^%T, +:)(8*Q.
M*-B!<=4)3.U:!-]/&H0!P6CWI!865*ZC]<#>UT4+[Z59W M^#6H:QLA)9_6(
M5S_'*:> %=_(RA,?J!P?1 Z%WLP> "G>'.4+;S-9BW6]H&N7B@!Z>YR3M!H7
M3K./3_?Q0'-<&_M[*B7=AI*Q_..X5?IR)^:O4BZV95?=0DD\3Y$KWSV0%$"<
M>[U 8@%N+GL)/&:@#&R(8ATH/#T0O;J_,.NKN[/AC?[T@-\MR3_*-<2$.;9(
MD>K?)%BRLEC0NT/DZ1%,H*P:!=EWZSH"<[Y2AB.F3D\BZ*6=G<\28T%V^F;G
M%4NZTGE1M@7%Q3YG]"O4GU7PXCSS\2%\F?E0 Q&F_\I+M7.25,%K>=B1,8"E
M;9C'6]4L3'0#1^3_5/^CXWU1\8N&?GG?B)-6-=S-0R $?G)Z!D.UDUI)9K_!
MI/T5T:WF+J?EM>&:?OFH%#5F/6I#/7?F$TX0J%P/[]#3P9;$H5IK*GXV[P1)
MDE<YQIM/VB<ZKYAV+9RS,,+5]&GL<I&*G_4GFU=OT\I).G-IS?06RUVC-S*]
MW-?J'CX]@\#K^5O;]O%-Z9)!)_DL,5-.&8ZZ0(<1 3Y6^. ^=/Q=+W+LG3G0
M89^FCV9XSH8BDE-E!0D"RBQYL" 'PP%]^/)+X-G76PZS8$CN 15?:43N34-\
MCETO@V7?:*H&"SHAG=XF13'H4G#$^=X_B@K]OY(DG=Z"G\>X<8Y+'%@\/<37
M:1^BVWFL4#+(=FS AGIMX[CAW+4=P-,H?CHX?0(+ROB5:^D*(??JOCE@[J$#
M#E)T>,\[].7W707X,W[UQ3>>)J'X08+\3P?1O1RA3E^L3A9"PQPSG*!5+T-<
MSRMYW7[M>/T#7A;%D<]QEUBRUZ0D&X>G6*E50A#!J3?(+FTBE5Y.DV-!MNJO
M=Y!C%F$7>XE8FY>\^WGHX[](O+"!6VP.U:;VSU'F.5'E%7[R.Q5.\]KY/."I
M[[R05MUN5T-@YV=9.,*$/+T673#*+32EIYX)!GKGE#Z4YNMGZTX[W>F';H66
M0$CN=TVOL@[N/!,APUSA.M/#(_72'4\ ;R71 :G9:6MJR@Y6;+=<UF-.XZLF
M729PMPET HG2]2J:)\WGL2WW.Q08Y#Z&>9=!+\:M+-SQE5O5?67^*$1:$2H0
M_ J:88NYU*6Y_/F+ID)7= ZAI\;$  ,\J=2&#K^H# OZ>4+KQD6^S9P;BF4L
M"8$$8ML($KG84-Z<?[$:.\@8R1]N&Y!<EF[U?;#/&!N9F?D^V(-E5KPNH<DJ
M^G&; G$Z]QG^A0#CX$%)"$6 RA-:B0^,2B=S5)XJDE^FUK^)ESA]XEW D0T"
M[[_UEBX4S3MEC6IE'60BER4Z(%[Z;_<S18AL57W':9:>U)PT!RL&+-7OAO7Z
M*9VV?+'IP'>R,-^56T00TY>G0,:!LTTA61M*XZ\EV<YX<D"[I4A,:$G@TU9:
MGM7PW!O*_LT-I83]M.(&=D\EH2=I\]?SW2"M;'9:O#*Y-(9D-3QA9G;:>Q=!
M-3U)NF<=FGINOY0(%[0-F/4@+)3&H\O5=!5L;QEK>I-!SE_"@_^EO.9^S%-7
MB+-<JYV"J6IA5XG422L>,?.QY\3/3@CP15%ZNRCP*NT\&[MR4>6\(]P$;]JV
MA= '9._]V..SX'""3:K81_[GRI(!E $(I^[\*J%"#A<18<5B\]+.H,2)-I4@
MUKR4.-/(JVDB/=X/?8PRQTFI!B<:+NO9V8J2MPZ(M]WMER81"F5,%[P@8H3[
MM! ,I'C,,K"Y;-B/$SM]T&B0I?$]IBV#R/50 GA[IBQK]>G%]3G5G 1<N9Q1
M6"K B&?PDENZW2^&L/F&-3E:5C_#T_*@#2F]!R(^#6D49;3.T%K=I^CRP+"T
M^&"H:P#$+M(]/**S2]&GI._*MJK8K6O 5_NV^IA0L;L'6P?A91[IM-9TA7;%
M&$>?"8 I]7%Z. KP)FE-Y6 7!:S+*X+G&R_;#?+X/"STRSMMLY$B1O<Z2AT5
MMY8Y,54=HNIG\/'FT_0X"+SFG9B(&"\(3UR,E.^+R< =FXVD')^4@AGR)<06
M.(R*JH8?<19,(9>]\V3;PD%G<WQA6\I9W5>,CKJD G<*2?&[ZBTSKY*)09;R
M3K!N*;E];)FH[GFHK'<EP(\I!RO=0:I8D!88M0!0JPSC_<4Q]G?FM) 9(*)H
M@%$3NSVM6P@:F:<\:P1S59O"9@.+@0$&0=&%X\'+I#1X GLJ[CBM..*J(F*9
MH37G"O#+<[DX&)Y5-+N%7>4':LI,2TX T@^--R2"5]P+KO8M,*3;2!"?QXD#
M6?$?\+(CWF?U>)CS/[(J[QQO6CML)AFC.IW;M\-97?3,^Y$UT4)V3H@%%6V6
M]MONL*MV#T=GU-JD$]DK><RI6]I36A+[:!7XJ)7]*S.[!$;=*%Z*7IYE@'-]
MQ"RQ['B^I\L&4BGW'M\6NIFL39.1AN8$1HW3ZOSD+3D(\Y*9.>TZX!KB$'[@
MFG98Y:=66-G(=M.EU66P6L9^^ORPF&_!1N+A&^A6%[3+]]G8SZSHN\"*98 B
M+J\R!,:VM="-'=[U_8Q,;YHA5,XAR&RD_R.O^;-:'1]9LWH[_[PLAE*3"3_5
MJS$UW+Z^'V\:6P4,W++92 @Q\//OFVE_1R$M11Z/VXE[6_*N:K L]6>>):[E
M :!=F4&V(.5<6!&4%606PLIQQQK(PC34%(DR!X',BJ+_'(DR\(4[GO=Y7'#9
M\=1TPV^6"8I:C].0 <V)E%V-SHRR292W2Y.UZE:Z\N5:"+YHB7K4=\FU4UAV
M7$N$-&1XYDYA\7E<3"+[Q"J2DW:5H;72A:UAQ]0V<,R:S=Y2),MF"K+6AGR?
M&:A9'C+<*VXB7OR.E*KECNCVF':M)[M6E9-H0JJBR9RE-4NDD#Z8&]F>.4]'
MF[5JG=_-4%R4;TU]AC0O. 8!#+6^!'KYVMN/^<OU.]>:AMK11\@V"RRI\K'C
MNT#&EZ[.W(J$79_*&[K5?)]_V;H_:N6K?'AEY 5D\I"4PW)H?1X9M[;A"[S2
M^ZTEVGPBJA86&ZZ22Z'7>]5D/F1Q=KM3UN2_R4@_V6.[4,CKL')A&M?]Y\TF
M^XL"'[QOYP5\BLC("V0+?1>888.A7^4KIMZXVIZY?#6: '?JB7#P8/>V]T;+
M8@99?UO%H&_=QA:"B/J7EP"R/4WW^,5OGR- @CABI#1OJR@$6MKCC2G4K9M9
MGB$1^\D5(N6"('V;>&]">$.(;/OU*D/1RG@0L;N2"AU""9?0Z^6'.9\5^?7H
M.XL!,38PP>WVTY5<_3^N'/_C3:-/.^,]?\OIB6!",.WVW PG+<2Q"5W2;O&X
M&C#P:;6)Q]S_!IEBHK$MG-;X8F9VOV9\][:(WOG$-B946>Z1$B5H?%6FF0;J
MGB![X>9@Z<'KU$Y_X%.DG"O222*.RM/R32'A&L@<CUF:TXBD@1D'/@,>+F8M
M78\]<CIWY.*<&SCXPC3UY" PF!"IY,+T)!@/FNZ9763NTK0SO:545Q7=-XM7
M"C*JY6X$:".RARO.'+#/*H&.9PA5D_"J+3!2DCY=N5VL35Q+%U::JZA*#NJ@
M_WG8QL=$F]$_UP:>(/O<3\_GQ/-6 I#>EY>?[CQU396[C=M)H/D/)^X!1GHQ
M5WU4U/V]6:LNMY%S?2*K)6.E#R _BW-76>R?'BKKJ*\R8235L*!E]53UL(.T
M)ZBK'!7V]V+(OU.1]I ZG:A% 7Y%@6J3=H),3*WR;+QU.0@ (0>9,@ZL6QJS
M@[';D$+N.TEB1I'1/6A]V-? &=V;FEA0;3QT^2@ A (I>;O#I[\^V>^CQ,V?
M8L+BY#/ZI=R]1?<G+,A9QR\0MU7Y^2R451,R'9AW'K?53>6A$TG#&Q_0;1+Q
M7> ,BQ&"1&%'#=1AN8H%B7@ZG4&*[J@#[3^ !>TM0EJE[._ND*Y3?9VH.UC8
M-OFWE^G4'F@^](@8,;ZQ&/##LBM93_B5F>OYEA+7.L&;0,DC$B4ESMJS&U;&
M!<5G.WEW[" L[$S##&[$-:PP+L6/.5XU[4)&E&9&UQ#OVK86='>_@M&;T@,9
ML)D2V':7U0/:=R&+"OW^B$NCN$KHHAZ,<RT6Y*I\=*%4ZU/YK.NG;9Y':GHL
MY=5BM [.$H@.F&-!4-*#LGT1D^&/G32-+KN+U_'.ZWO^"WYDUN-">=:>CLR+
M1?UIR%.2[N0=;UD%Q<^1K)KT:7UDR_/75%UY[CD8+HVLO,""J@NN%%\I*9T!
M76QNY2VGZ5/,7F7SCKZ*\DT(Y;CEA',D6S%D]2 'Y%HYD:\-$,_?N8HA&=N]
M7PH+Q?7OE&C7TIN<QRO(9<;OKTVV*/<R;3N%KDG+&)FUYY+ZR5=")?O&%YY:
MON?FHT,P?4&*IFHFB?RH+[(XZ#'ME;<;Z4W$2:H7B! /M-^JH#,O/40.,UI!
M?NY<S!3F&T6?EG\;(R_O[+Y-</K9"0>HN);F5O@X*O"<-)_?A:?&;T;/L$^&
M4S,49KS26Q5H%3-BR^2<M!R6NH+NI7N-\T4JS;B_Y?.#JS,2!0&V*![?&M\/
MM0TD$SIP[1FO$BYBOPZ=+T%Y<3:8(IE69MQL/R=UZ?^*M_VME0,8OIB/!3TM
MO5N"'%?<]\K @@8ST\&K=US45YJO^S C'ZX?J9)G)F=9!4/NO(A#1G[!@@):
M\NJA0Y0'(N:HB-6_73&[R,S'W9N\+X,<]A%JTP5SOH+'5XV)2Y&K'.BM($),
M-G2[=AT9RPZ;: =OGW)9*5_0 Y .BW8E,<6"Z((.).0DDL[5CY;9"L!-92>.
M&HX.\L.P_3=;B_TF5V05$/0)B0M-SCS;N'-V,UMW.W>V#@B:NW%+1QHN0"<_
M$HCC=F7Y[ND1+*CGD<X+2%%X1>#;6AC=@;SO??GOC&MOU5&??"'DH>SX$=92
M/;(])#=BVTF;]JD)_I7>U9 D?DX.77MXJGQ[B,YL9'V5$[VM$%N2]G%60/W1
M\+<OI*-N[.\#(<>UPRAV\8?OY;*;2J'M/Z&J=N9>DY3!OY+,2)C=86V1G!6Y
M@1'/ZYO<-:W?4RU*2P3JRSV *42NI:G.L@<&PZN!9T^4^2=&OW12!SONEA\.
M?MM[WCF8UD2J!<9^-K0U($L1J)S.Q8+&](UTAZ,P.T@XDC\U9%.DGU^S.=*$
M23/H9DC.JXMIY<,/!7CW)@ZNFSV\+@YSX8XG>J[\JT]COW0AL@L"@PB=5=:&
M[;-%$Z(Z8"/DL,KZUO+2&^A5Z9Q J[T$V)3A(REK+&@EFY=3 [#J:]V7U1L_
M&9SN2TI=94&5F$09J]]"HD88J9R5)77")^[<_V_)_']Q'F#VK\T# N[$QB=/
MSD,\N#&X(F;AZ"4G;D'FV#(CU/=)L@XW"@#"UX'TMYA@@U3'=06)$0?X;[-7
M'>&S# 2:::Z1VJ #C;SNK\_XD);-)>/)11_^7;&Q'+^Y-PS&D)=* "S*N'>(
M (3KQL$">D%FL"-T&-P<>;X/+F%<OG8V#R!*T_W4+M4.V"0U$)NU>W954S<N
MU-8ICC^2(K_'^#=GBP\.3PSZ>C332&)/_6.8/^>]#6%*5(G(P4J%YYV_")-0
M0ECG >=!FM+:12]@0<D )SNHY;CQ^%[#@NP-XX!+^UU:_];VC;<=[PI;VMT&
M[C?^[IJU#TCS;TXG3\& EC\4FA,<U0&C8Z%Y!S[VSNY0:#XB=-)Z /J,@ _H
M\D7 :.'F(;"B@TDO]\U#DOXA+A6D+KE1P>J>+F *?=K#:P*T+5<8G9K(7^?^
M$S(SB5.$F8HHH_I7*=I99&!X=4L[RS[AP91 2.6O'"#I%P>(H?SF )*:L%_A
MO^V?P7\"@'^N(_QSO5:6<FG;.HJZ>(G[$,#] 8BAGU',TI>@Q@SW/2S+%Y*1
M8B>*4US.[/K9HPZGB26#?KNI@3K-P21![L'>V%J/L"#?\\<1ZOLNL/[;"F*"
M*DO;"N(ZQ.;[,G"M*BSH4W@R *%)N-AA'"<I.8@M4KA?DU!5NQWG>_?.*P#U
M,<A'V^A.J:4F1@&\UZB[-UW>D-&#R!.5@)T'GBOBBA3YQ?\<_X<_@?;5/-P7
M+J+R2 .5!+#?$8_:Z-]E4UQ-F'?S!K).>^_8@XD^P4,=OY1AS'+/MV7;T['4
M2;IR9),2_I6@.[#&^@FX @"_6&RQ8N1?7C9!!-1W/2V-?]]XO!$E7SBMI45Q
M@M='XJV+'?^"%IADTSB7_8)14E#)&WL2RX+-*W=PT! ZS+CEZ9W8O8U>13M3
M%X_&:QP3Y:W=(^XYCAL99-*%BARFA9%C09L/:OG11KBIF8KC;$]EQ_!+"OH:
MZOPDUJR([%YW2]FQ-E KGB3M=N=/(WGI=%;0M<22[7D(WTGS66LUV)B^ PSC
M# 0/%W5I=%@2%M025HY&D<,,C+&@]0E++,CM,\@&OI(M# 5&0_%84!FD9=]Z
M/%I(I>O*FR[#8%4KN01G\)8:' L2!>AS>_&N/W>U[4=WV "7YMWDN<8(TKL$
M)E]V.U Z)+MC0#1U448C\?97"@YN-%N^N,"YN^&!0?M /YK!9MI)4%N0I(6.
MQ4>;,MNBMI@>#XR#]D%@-OV$!0ES0+_Z['&BKM=B7"]C0>6/ Q<'P+\8BY:*
M?OI[%D]=-4^<OGQ0&5;HD@QL9G@"R"?B81_3RP\KP_+]$\2K:*MCQC#MY\^-
M1(I]M2HN ^@4RE\>@QG3Z7M8*L5&^)9=^/Z>^$&;@?NZ==?G\- HBL"N<5LL
MR$1E,3 *EDN/!<50@K<_@_N#82V$@:CQLA!,<S86!)>!?NV-0PDV'E4UK1J:
MR_I,NJG\Z,(B.,X.7+$]5RO"HMVAK14DIPX0H:$&K"4>##0Z+??GHKX*V-+;
MI(NL'--V-A?#+H]VS_!A081@P-?6^Q51H^U84&7="A:TOQ6*V<D,1$$4@6)I
M8*@M9DQ#!Q8T4S."01/TKC?;8"Y(>P/_Y\"!:O[8[W$_7 ?-!DK?705"9+F$
MNT#+C@8=&'BR]L,LZO<*V?BA$!_0V+[4Q!#9MGBA%_5/CK16Y.R.#[M&<=%2
MM>A572E_3D4\^H:#Z^R/F]-6N;HA))LKY18?;=\Z?*L$O%X)=%7<=U2IM\'Z
M\GYI<'+8DUX Q0?-HE:N ]>#IDH7KB?]@0GTMR;*FW-;)+^U. M+_H^ _88,
M9H>^7-,3E9^%!G>+47?!N]O_"":F!?&+8^:;6!G#_@HHPKO&H4MRT<'KEEOQ
MNM_J=I?SV].TZQ[=G1QV! OE30?OK02=NMU".QG)FMN4E_B9)F=Y=%HL5RG%
MY!TZ&YFOB#$8V!T;CBQF0#$NP%CO:V^:)Q]1@/8=CON^-K;_0/_^"D2M4W\1
M$02@&>@Q#RD?HG8&H_4C*?F7H_?(X7V:L/T=8!PUDB5&1SUN>:Y/9\=K?OS,
M,MT-X6MW2M04C_H,&5L3]?CTJ7>XF+[CGH)D\]?7L%QJK_Q<#!<\9@AH[NBW
M]G>E1$<!PT/1(-A(EO26>>"W;H,B%3^4I=#--,/[5W[IG\ E!^B,YR%:L:!C
MZ/Q@W9/4*_HKDXBK&?@,YPX187]\ZV-$^+O<3),,CJ:206NFIM%JK-O_@UVL
M3O+AU3Q +ZI_E5Y@_6%"#-,C2S+EAT\B?50>,K[\._T!K/P-Y'LEDBBU)'U'
M=8!-J(R=%#S[=1S;>.H+)9F4'WCOL\%(@#8PAG[U>'"E@XTF([IPK^9'A^_G
M4E83WNNBU2@L2Q( >I?A&R>-!Q[#A +(]HYCCB?X>U>_O_WEM^CX;E\$/40L
MD+=\;8W[ 5JX[[ @S^ Q@**6F-"KVBW^^Z;Q)I'T529/0L0O"TFHQ_^J+-S;
M'W3>J$T 6$F6K923B9".T( +8D&_CY#HWT&('=K)-0#VS_/,[UD<^_+<%F47
MP^!N4ZX# 7SP $F4!WWV]8^A<?7JG>([T@DOD&R,VH\Z=_._(TGY>_""S''^
M1TJ#1,VO"L%^'7X"CX"B*WM<)72TP5%C=(V#?PTHL:XKP_$#@WH,.[];!H"H
MF^MR@?*7PN#5(J<A5*330=R(DV9SG^__V',/OF46:@>9A?(Q$U 43N?;V_RJ
MDZ7WV0*_H=!G%@OZ(3X%'F,$(?U'\#O]AU"*@I+NBXJC-X!PZ(">SC6_^MZ&
MOLI*=>H)GJ&RKL2/>1+G,2+,;Y6D/(ACS0F3U_[#W.<H&3G.?6!(Q:SP@S[^
MATV8]S90>'_/ DB Y/7%#RSN'1.'ZT\_].EQY'+L8DFIK]\4B=3PE%-2DM?[
M<]Y@/N:<Y+T2A;^,),Y?![G,B0HZC@[>MQR>,]&DC\\,1IMV'U,4<<1#I\/$
M)]63ZO,0=4]M<X[ 18'WJT=ISWCX#^F,+>R 57:U#@*(]''..JN6A-/R>95$
M/%+EU=50FW<D(47IJZJWPA^FG\G./VE+SZ4V^U=%'1P"+U0%.#GA]W9)XI%7
MOM/.2,;+3"<6GQHS[<[81(WDZ[9PT1@S35.PF+A'^89G\,S,A[[G%R9J:,H@
MDIKEW7;EI-K&%Z_&;9W*\I/E+<:]P!3$)4;;;=1DW0][R6>N^&D[9$":M&NI
M*TZHF=(*P[F@N&.3:A*9[^6"?FSP9D6N83'NA+O@'L2]A\]X$TH!T]-T"#(F
M.7,6+ZRXF2FY/G.\G>513H! (D]=*J[,K1M@S3]\%]+! 5J5C=2<%I9-VO&^
M%]70G@M=K(M5&%<5F[Z%F:/U!-GVQ?'-7!?EZ]1;T5X;3@6"D[B56=66??,-
MU0P 9]JM)5*GHS/F3V @D\,AY/V/+9=1K7B.D=H]\)9TAQ"PC]J>R]>S3L)9
M< [>J:C!'LGQ$;*J,7_JK[22#6[WXYB^\H$LIWW&A8E@SFDY/3V:B_9W!G-?
M&S_'RW/NL?Q3-1P_4KM+1&;(%]^M(K7GY*,;MJ<+3.5;2'<,/W='NJ6EP$PT
M=#UR&\RNY=_EGV?&;>.Y9=IDL0D[!X37?L'NL.0S;#DSE9J++?W7'.N7-&/H
M>S:CX-X3JBLKGA81N#+M= RTJ_-&N/FQ'_9OV-LG.\@US#OB#M43:ZSZY5IC
M+G]<O1/T01OI$\\N/*8V4D?U280G$K31P$JC?#G7M]F\W9PF,"4E^4]Q%=]D
M50;Q^/P8DJ&EV*76#.$;SBN^@>^^$-H?5[1J@$F(-^K..ZDYK_FV_BG/%/-\
MA3V"&"7:69@I5"7X)L$X0]?!6:T(I;_"'$+XYD&B*L.[@-Y448IN%VF;"5?-
M*LT0TI,NG\Y*7E'/Y\49>>+7<VJ"2%=%E#&KS9SO2H*DX 73;,1D0!5?PBB[
MNDH7[RNO%%3]Y;<U'R?HC&A7Q6@-R G^Q"%"2Y^8*L_?N! [<N>U..,[ZM60
MF%%[!)%P6^0Z%D2RX%3FCS2)O%[LO+63\1 E]V"Q7VZ/5.56UOBC)%BEUM;4
M]:OF:4E+N[<%:I:&<W#F=H&&T!'NL5LP9U(L:]7W$M*(OIU=SIZS=2)_T]5V
MCN[" RFO74T^PI@H?Y"E8:3FNN42Y[D=$RQ(OJQSD\OU40J_+#U+?IW>MI5S
M3SR)YK=WD/Z+#_UL1JZ<D&LJRF_T6@E<I7EEA17)4ZFI'J9\%;L$V0D56^5(
M/1GI7]YK%C_./;*@3Z'6O]53-7RC&VE'??/"]@KD$V,T,9YBAIWUCE!5FTRV
M=,) &L3B)!-,LQ069]R?2J^K\9G[_:Y],C^"6*B2(*^,JLM.R&O-?/EV0.(=
M_IE(6&7Q@#R2I#EO&Q_"7D5&OI'9K$6HL8BI93S3O3,PM415FR">.!MI$7#)
M>,M:RQLUK#G!B].X4RI\([E/T7):*UJ9^/%:\T\D^PO)K7?'10CJ.>IYTEDO
MQ11^OB4L$$\D-H+V N>>A_,8-9NJ_6E#X&JWO-I73YH=UHG9#JIUM5F+S4*5
M31?=TU#'7&S;%(+GZ/1*\O;6;&L'BUWB?&EF]F0E!U<FS.)-]YAA08BHY*4U
MDZXF-/)5B7D<1Q1S-/OYIK".H!(]O.%B7Q'Z*L5<4RVM^^.>96NGJ'@CW?R3
MC'4,>\WIW0L;R;6?N/.;VZAT=(S7A-(,W\QFE-*0G03+A8\+<V4FC:%0=8US
M>=O4<%H0_R>^[J:QZ(OCJ*7VN161;IOIL-URP7(;8TM'B^[M<_$?/GQ2HR;'
MF>D_J:8.)EU&\K*_J*X\V72NDD=OMR>N2P$JG]6.6#,SCWO!_53B[)^^Z,RC
MW1VBJSM@G!?R0.?VAT]4C4)TIZPCG^3'.7C<PW3<:"W^P-4O0=*TF=F\53.@
MG&=J6J!V7^N%?QV?1$MET4^>E=J:<ZU2K*[M:>WNPBB%3O:2&V/^SO+EH8TE
MW#?"\<?B!QT&%C1[\"]XK@2_+X]XQ([/\$6DOAF27=2ZT;C0^Y7#[/V;<9XU
MF3IN5@5)^>PN\VK*[CEAL4F&3"F0W@[Q]/#,IR+K_ @#0CI\G5H^B4VOCQ,+
MSJI"L5D/UECFBHJBB*ZWR.>?T]"*)S5<OER1PI"3[S,V(Q-L "L9?6ITXD^W
ML@IY$^+.WT+J$"=34(JI$/0C%<*":JMX]$RV*4+370-Z=%>6/YI5S*DUM%)+
M#U'7D,P]<*W].8>F<-AQHY=.'=6L'JH>$/;8%@OZ0&.$J?=SO+]KA!O09N"M
MM>,/2^V#1AB;G_%NQF.=7/^LVFJG(&KIXY0JY7B^4.R$1[,KI#2KPVRC4=G<
MP/+2-;_]E]=8$\J]<ISE.YPMDS[1U@MPIXZ&BEV"5BLNH@TU<UOY'$6KS.DI
MY8=_OH'@0ZYT8\8G;KYI5R.K,K[B0UTQ+D6[D-R9XPI5][^+:1=R3X*4VOA$
M-C<,*.9K.<O<I0J/150@"'F5_J0MLC>'G*JJ^FUT=)NSF*0&K0OVU!*4.W-\
MB71^\L'T"TS<"\KDYA&[9)XVMS<4D\2H'M24.J_VY3F#0&_!J!II%UO/6+P.
MF .6$_8Y*Q\C/),I FD'&H;$6%"[QA3"_#[(ST)U&H[V3B221TDO*J&1&*>E
M:7=^&*U(GO^HB&#-VC1_?&"C-M?D!'6FK]+'CLV1$R^9"F_FA0P]:R8^\<X*
M)MC=F2-RXSX!'R%_YHD-,@[KNS"#/EKH(MA0,7MI8,I\@AQG*M(M/-,T,C$B
M7A%&M!R:]"%L^9P=9/N6<P_RN4^&7E*_<>L9LU$9/=K7CS/^VAN'_JL.68V8
MR[D%Q6V9#+DEIK(29-G)]5290F,N_='=OE<STA;8;:DCKA=Y$GKT""!(I&*!
M9&$."S*2MW;$C]A5(>9V>[V 6G"F>=HQ*(5O<:ZN]^06@E E=Z:<F*])3[6S
M1)PXR^92AKE-'I1S.76"OOB^G1:AKU>^UQI3A-O:Z4FE4_URL9'=40PR*:ZX
M5+M6-,MH$U-YE-:&84Y!@,&]%TJ3N&(7F#-QQZ]'C.MFTVJ)=TVZ:V4:Y.-'
M-PX&&".1ON5>W=O7->.]UD;/3+SE;)K>(]U$D(@G9&I5"CY)BS7FY"A-IZE_
M9_G$H,)/#1V38.#FUQW.]84RY5Z[.[NRRCV-#OWBZRG.N'>("?"FXPL[S=)K
M]Q0ZE6$E%4JG4EF"&B^ML@7SVUI($GO!_TWO"/WO>U @L:")R@E&DJ%\ICD=
M\<1^-'(T!O'BF6?PD,>M7A'3;CM_^A&MCLGL(NXS^E26[ WP+^J<YBMI5<_R
M>#1NYDOT/_(.7"+RV&O%.W7=US)IA[-RS^]N74^3[?,D;AN/_B(M:[Q7;@PF
M@F[9NP'-0VXM.&8GSDR5+CS1]72CB5+,SPH1"K6TL+]5;F3Y&F-G?W<']M[$
MJV_&QR!RZ#I;6T/#E"L^K1'N%UZMS=:<$5KQA*&4HH");4F!AZ4MK6HU8:/F
MM^S;-\-6+[&6LP74(1PCYHGLBZ#/<XC.#N5&^U@64T7 I]EW(I/T5D;$.Y!2
M346#?F1J#$+D=UTI^<EQ*APZJEH2'%XX-X%DV7.KG>UDVC[F\M3K2NJ$CS8J
MD/54K42?\3"98%P>M!D1W=!T8)+-#KP;<$64C_35]NWJX*46\C*J%;7@,?(P
MWM=O>(,FT^KN&ZXBB+:D;%DK*!Z]('*\X<E+Z*SK(YA;U*#9/+B;I?6F 4(W
MJI[>2/7FNO]'+RI^_DQ%Q1U+Q%Q16]?2Y]82]H+"Z "W.%Z<J-5;\ZOLO%$0
M9V2VE/VSK'HN:MQ>E)JYMR>',+NKZ$=7)&=OR8M RW,@:,=P*<G]MO3<(>X'
M4*6?Y2TO?Z*M+1#QUYL3/=%F^RRHFNF=L)N&UJM(,;P/CZW%Z*13^BGRVNQ*
M!:2BT\/C6=;M9:\-C;07O7*!FB>[/!BP%_XH_A/"!C]TJED$$F?Y\S"ED>8%
MKZE8M@=*@]?/Q3P5&$_*WC$<0Q'I$-TEM;480V7VG'78$-Y $&=W#T/D;5^<
M&KAXEGDC)?G?D'+^W_&'!Q3;]_\ 4$L#!!0    (  *"853[]8A!^3X   !:
M   2    :6UG-#4T.3<X.#9?,38N:G!G[;QW6%-;MR^\$*4747I5NM)4>@U*
M$Y&N@%0%E!)Z[Z%(D8XH;$&*% $A(-*[]"8=0N\E%(&$&B D7]RGW.T^[W[W
MON\YW[WWC[UX9IXG:\TYQOB-.>8H<\V G< N )<?**LJ W@7   /]P=@IP$%
M@(B @)#@$A$A(2$Q,1$)&34Y&2DI&<.5JY34+(QLK"R,S,S7. 5YKK'S<S S
M\XK?X+]U6T1$A(U'4E;BCHR@L,B='T3PB(F)R4C)Z,G)Z>]<9[Y^YW_[PGX%
MJ(CPKEV8P<=C!RY0X>%3X6'; #:<G)?P?KV ?[_P+N!?O$1 2$1,0HKK4'$9
MN("'CW_A(OZE2Q<OXI[ZXYX#%ZDN7;E^^R[!5>UGA.S.U'>"$CX0<=PK;:;1
M&4)P"IN[!!.3T-+1,S!R<?/PWK@I(BHF+B$II:"HI*QR7_6![J/'>OH&3PPM
M+)^_L+*VL75U<_?P]/+V"7D9&A8>\2KR=>*;MTG)O[Q+R<K.R?V8EU_PZ4M9
M>45E575-;4MK6WM'9U=WS_#(Z!AL?&)R:G%I>65U#;Z^L8G<VS\X/#I&G9S^
MP(4'X./]Q_4/<5'A<%VX>!'_(N$/7'@7/']TH+IXZ?IM@BMWM0F?.5]EOQ-$
M1'TOX4-I,S&'L Z"QMQEB(264V21"_D#VJ_(_AJPX'\)V7\"^U^XI@ R?#S<
MY.%3 2#@^)0W*Y#D7VT*:O>M\7OEN%#[1HC*)GNKC_6D9$DM"FO*]'!7RG6^
M*"P0VKXT<+)EA04""%%CNS'S>^)/(..OL<"ZHZF5:1JCEI-Z=C]4S]:>VW,>
M45W_! O(VH-VOV(!1M"BLU<9QF<*,A^$$?TZ9.C+".EYOOW)4WH796S*CP72
M*S..%R Q;#^/6K#.GAC!:!V-2:<=HP6%:"$#1IIG"%!'W$^#G$2TO]M@ 5Y?
MV[3^,PP=710(#LT[1[$MJ_QV3#4C[Y$(%G@C6Z$!]\<"I%'M&?NP$0R:$IG]
MVS'&Y-0_9&.=RG-M_ ^\-K_B'?II4#%!I&P,:)727K=F'M*RA+1"'Y9C@29\
MM/7/H\;QE5@[,O;"*PMF=IM^HP21GP:!@[+B+#1/%*8?[?R)YE1*\] ?_K+B
M#O^YXF37_];OOZ9?_[\M\[]GF7]9<0-*9:BZI8)=Z**W $DW>T$;_@>0X2GP
M7K_+QQ$=BANR50M9O]=8SUZ-U(HV7%5QH'50W2=5HM:_/DRMK03\2XV15P1O
MH8FI:<7A"Q8HX<("@W/U_0W"RY[H&)C9X4K3*=/XN_$2!92SS"<LT/9,B5KO
MXW4E:BV\/VHF)<$8EKYE)N*=[-'EBLO=9>![9G(G,WR1)6"4]/7P%L9O4>^S
M:>F/= WT4Z-E9_ORE1YX)*QB^!$S<]3C;.HISG(38S"M5 7\],FCXE8%E*QW
MD;7'5.+FT-2[Y?E5T1KS;![F'88N.!(:Q[J1@7B[D<X @R:Z&O=4#N.-!8%&
MP/H?-O03R'6.[X><FZ;94WL1!CI!/O*ENZ]V09MTO8;BI!L[7Z+,ONJ@,AZ/
M%EW55G,U;U<K5ZI:+!WAH!F86J^J#:LZ?_N,JKKF#OTH7J#S:,;=N0:S11 Z
M9HX7"_@W'0AKH%3!5S99N48?$*3<\*LXG'*90+=;;ST05+SY0)5!"WVU=F]D
M6^H\Y^KGM>M4=FS%BQD]U?,T**%'B)@>KKWLYAOL-Y;/H'%F"D]J&PM\"\">
M=./Z5QHZ4Z:-J_A".D:F6<?$2I;\P2;!]*("]XPB%@%V5@(5%^D,5\-[HE?5
MZ][UC92I&G1GQ0UD&/*!L_DNV7IYWJM!<E<1O+/UJ,_C7[%D/[8X6/JR!6N\
M/-EID[V5LBQH*H'.GV;S!!+CO@4\3GNR=[?<A-=5G=N[N"Y/)7M+W]#/TWS=
MJ"GI!?'GVRQ>W>LN?" .6? 0YLJ4X58 [RB3;D7PKI_<LZL=S 2<*_LFL9%S
MA$U(KMU0 30(7^9NJ[$:8]IW.83N<7A 1JAB8;6TB&'VMQ+7YCW>$I?A9PCE
MY*42E,+R4'9=M=UN;8U2(KQ9VGO%></X)8:@(F.I+>4B5_;G@??RDM=O$>,C
M150NIZ]SW2W.2[=\$7NXS;A3B, "&F.I+<>,%\&,V[%JU4M:%IS.^_[+AWW/
M_9X.'6RSDW/Q\V\O=#WMHWX0BI!><%4$S^; %F^*J>>5=G8NBLL1)+?MS15I
M%WWDW?YF^8X"TI ..AUS;)>[F-QR*A"6<QIL3/J5*,:<5_\::XWDEI'9Y>8A
M/YK%)DJK-2J&5>#PZ>V!\P.PXU(G^A4KZZD0)K"")"?5U*[)B@G$Z;7JEIQ^
M.862T!#U&K;M ,WU3V3O>-3BX^(Z(*,O;EJ!: !5UC,ML9#XU=)PW_*>?KN]
MFPZV'796?:<3F5BZ4JY3^STA_O!B7,_K\GWA/5QF\DMP)&_FA3]HI%*_=0,-
M)?'E\R<D.(<S[H9;MJ'^OL;T?4/S(9.AU-K&*D^UE:B!?Z5I66<.$@:C';!
M0FTOICX9"RCX[$L=#/PN VJ@7&S;*\0"5#ANAK_@/N0O_5'S%6H)J?J:<F9%
M3^:ZL2?J-2;+G21Z\W57I,^G&N!<Z;E.AM2J2)Z<BNM< -7F;5O6JZ^GG%@.
MSI*>\PM7:#BI8&2UT>*C\WI(\2A!-8?Y6]-;034JZQ6+JB*E%SA2% GS53A
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M?ACP,'0 8%4FS"^BT?E&[<[#?#9>@K:-^3!<+WT5T<6I.Q^?S]=%J*7LJO_
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M!;+I,.2ZF<)X:A3F^OHB)$QKO&G%=!1G9,-FY\!X-WMCY<\W1'\3/I7G0[#
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MV7]R2O'O]H?M@N5X#/HN:LQ_T8Q6,]O&QZ1BTT@1*MW5]]:BF]FCF2W-I[\
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MY1[7*?.''=\FMI!%J.R7B(U6"$7ZN(> H3;9<FGT5^0260V?QXUXW+K/&M:
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M;[I_T_V;[O\YNB]*%^PA YIRTFQ\(+&6R<X*,,8-#SOY_P%02P,$%     @
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M[*I,B,! LB17]-QU+DAD,,)P)4#D%%%S0O15(U7;JM(AV9G,XK.C\QQ1ZQ0
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M?49E=]B<#!<C8< S )UV/M6JQ;MTSA9J%5DH!_)LQF56"+6 #Q1CZA"'&AB
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M>1.A>'A1B3V_/VK?6-!2I(0]5 8#6N(Y\Q7V>DDV[LR_3S[0PK'5N]VYS)!
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M.*#G7^JDXJ?#P%M6/G9%^^'(HX&V_DSO.O*,E-B%=D*W?!#E6@/BI,>IXB+
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MA&A,+/Q<TOT]%4"XM_/*,"QM->DLU,UTA'E!N<TWR37B>['ICKL<R*;1W&"
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M.X1*O7\UBKQ"')+\3=B4XY.L0JXT49:,P+S$B+%9M8D7%[???E7V8C202:&
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M8N!.B7F^?=++FTO74)GP"OB4%M6UJB&[X:%"O#"[!W,-1+VSA\[>N0*:^J^
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M WG'/117NT<U09@' &+I]037_8#I$0^R,UW1S\5U(VZBKAAJ] "58(U G"0
M.>U)?_'K+0-G>_P)XWK"O6EHTFA<=-T#PM \KFC3AY6327>H4.!1PL$"2%;S
M\0SDSR9.%K088FY_71 LSG1=1"ZCF!"8^KB5T=5M':F6N4:!MJ?[?E=S5&:4
M\[V!^,S2Y$T5BJ6"F_K:9_B/W9S@I/V[)"L\P\26#P'G1I1<-FWDK$\*2<?(
MB357"=6.MN\ICT#UL]05[.X#.O6)Q[!<X!(U8_649ZJG+^*??MYGW,V3R$)O
M%\A\/8P, 2-K-MP^VDQ\M-GBXCYAGH0>I@%&6_*(8B^HLJ/GT#D6<!K0R?2:
MR^4OQ%988 (_CVZ3Q5*BOFWIC&43BBY@1+V7>1;3Z!!-@MGPCH-)=/<H6QYJ
MHF;V<;V=:+=%,Y_PL9)[9'A5ZX!/T"'D[4+BW:#N)#/\=Y^Q.ME40!WX6Q,G
M_G.7S'X.LI:/F;8?OMJ?:D,UC-T;PVZ3+Y5/]9$^QJ.K>M1'>$5_-L I,2B?
MQTC#Y\3#S>\ANTKN4:OF^FWBM0GJ@?=YM$S'<F>">%%I+2R7O"U%,6B8.XFT
M0L%/S:4^N6 C?"RC":@:0G6W^KV#'\/F[.;SS;:/ID'52:!G[P:EBE(8MYY\
M(N_8?AGKBOARX^3?9VU,)-4Y6EE8^[B\&_E01(PD0JG9LT_H3;VWW!N2O5Z1
M>?JL)HDEO)P-:][3IDT +I$[V;)%(R%)G;UV$1W,)Y:MH6#&4+ D+8(2M/@@
M&YPP6N0FWU]0*[E_1VIP:P\8/<38TRZ.-:Y_E/<.3NFD=PUX4=5_M(LS55^&
M_GJYZRX.@6XM4AO/:IVLS>VN#[8I.UO.&?B<TWE0[@A-[<?C'VTA]6]5"]_F
M<]3LXFIJF1[*D)=\1N[2CC8/HCL1@/:,:W=([+0^?2XC,-"$9WX@Y9#JU45I
M6I1MPN<78LUTS,";;V@XA:OH+>[2 "F=Q1X[:Y/0,@'Z/ _^J+ZU^!;=K:XM
M8;'PY;'C I;/_+1,"Q0\J3E<;CLE0>U-2]VQ.?(>!4F=42)[4L)\[X+370$[
MM88<](4PSBHHW^X.KWC;Q-[K*#^AETM7:)P5B-=SV829Q^T_U.PH/!E0.3:
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MN94ZHR ,=UZ,FU5T@!.6DQC%-G0+6;^%3;M7Y=]<5!MH7KWB>#KS>C<X*Q\
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MC'Z2 IC1+FNO9.]8Q0HGX(6MX^XL\,89KX8!S?VLIY+SQ<4!<C>G>XJL2OJ
MXM5;YL\?[Z@N;M]P1KD&S&* SH<YGJ,434T]W1GH7NME:=$B]:\3(NU84*#I
MB]0J.E]4^_):96T[ # R7";UF/%C<7& 5'X:,(S:($)#^1>Q!4<X_C<RH/M-
M!=+,L^ :\+7A !#X2Q888],_S@)CPD+PLU[>'PO?_;/EI^W)NQ#S'7M*%%.H
M@S7'*>X759ZA7#+(3;=K ()<HP4VK.G6P6)@9ANX/!E?\K/5HC@-])6"3/E+
MEF?/1 00 ^N3J]VE!@1/IZ)XC!A</4X/=/<+/YVE!0QM@M@OTK%CA.<!^XY7
M=TX;PJ\!P91[GDXU<-_+V0YP:WW: H3V8JII(U1(&\'JD5MFCYAGX#+?0@"0
M%G8O"'?!#Q&L_2(D@"=M$X2=(W(.@M_%)@3W-[B>,__$_+\S3HAV(22_6R@;
M>;GO;ULE5,'RPZ@?1OTPZH=1/QN5WD*IE?SJFU5@A%4VUX!8C\-O1[(6VH/Q
M( %T9RD8JBJFU?%Q0^G96TQXBAHDOU<+_</RM_7%OH.V^-E_BGN(62@\!\C]
M%&#CR7-[ILP&]%$2@ZM?6P'C;:F2$8]@*WH>"0NV)F"#:9DA=^+K]HT/^6-X
M[^Y2]_%TT#PJL7-*C>;_HFB8\$C?=RJG0G!/PHQF#\^A,06KJ"!I9G#0; "7
M;=K/*0W@;.8#N:E65A2-J;2Q(B%VASHJPJEIR1KM?%M[1A@[XQ%:2@J6W^ "
M@ZL.B33130VRHJ/3G!@^N\_N!299!XN,#J]6>SO6&_,*OT80I6"E\LQPE+C2
M?F2M-5N9:I^,99&0I$$^2*][P7VR9!.ZTPL!4*\ [ OTD0>#W(7I 1NR W<^
MI9JH8$!O<.HY84:T*$((ANP"2ZN_RO J0P2\Y?FO& BSSC>E/=F]AI^CR>XT
M[,5*3,98#O0Z79;U]L#+%4Z#V?&>H_;FZ)M-"[O."[S%$%WOR(]7"2?7Q6FR
MNAF]_=5B,DX;P@M,7M:VDH_\0+Q&BYQ>'J;W>2C+'*^B2O\Q]G1'-KJK:U=@
MF)4AWGT-W[[NR0-63VY[W@)]O%<N(!%DLFCA8'L6OFN B<FJ2Y &3L+1IG89
M$44D4O8;21CUZ2(5[GJK\P8]$_%]=WG.A'DLIRGE>Q!44U\\I&'FB7MR#1#C
M5^6Z#.:*DD'EI!$)X6 ^YD3,J!UR\.(,&6@T8'D/S53V.<J)GZ(CCI]X@$Z3
M?M$7U/*"%-P)G9Y/XXTHG6@QC)*D?9ELX S0$4 0\<C6NYEL\M1?IM&,OS7&
M2 ^ZP=XBRE0S8^*H^%4E>;M@DMMVFK? R=,5M"D38@K8L&A_)_Y&0U/* GC(
M BH-E:?G59A,+0Z?Z(7.H8^0IS-B/+7O);)1=XC)-R+K(I-Z^91NA6Q9]&A;
MY3,M<EJX545!EGEXZV'5DWC4@4=32QC)+MDF:&/V<H)O*L]/EQ=I'C"W"6Y2
M(I/?),)#JB_:P"F;DD8AO%N:_@'82"W<S$L$V_ KPBPE]+*(?/2<F!JSDMJ1
M.&_KMN8?TL(_I^':?X:(C)'%_HHNMK1GZ;\0$O W"RN"GNL%(0@O41JB[Z+2
MMB"@4<#_UG^&1_]SL][_#O+][YH#^8L-W-\O6U3>WH4Q7 .HT!N^96GN1_7[
M;BHF__N,S1%(QJE_$-WW_UGYNW&<, 1[H+K5,*-PA:Z:\5ON=Q6+EXUE@KS;
MJJ+$>E@+[/TKG@+0@ TT[]5K0/+8-6!W_*<=5'?BX6#$XV\P@ADCQZ16AYP]
M64$<7_MQ_,?Q_WW'_YP[&U#>[+L&"!<A>'H)G'/ ^,+5),Y6L]3[27KB%_WL
M'H#,WTC^KDF;^N'O0KO_UXLX K!VP=?A*DR<D6Q1@NB-*>B_:;%EY@2^ROFH
MNK $8 %$9#"/-:ROK,+A2C=&\-6V=(\.0=< ,.TEX97 %.+I=[[23,VY"H0G
M68)WERGUK@%9\<F7YR($GW(:?OU#\I<;/+^90U_XRV_%$^8+YRK$NXU$,@W(
M_>T/]U]N!/AQT__F39&^[STY9=XL37W67:'6!G,CU2+@Z_'_ U!+ P04
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M^8(PB-\EY-5T83+P:Y^26+A,8)$R"JPQG?U#[5^8_<>(!?]O,?L_B?U?O.
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M1^+YKO_NN@CVH8;$E)BV2[V6<KUV6_J,EG%QR$8KE_7-(;_1H)6':Z,HGFR
MA*OJM)\WN! T:9<TK]SUDN"UD K1.&H?37>),%<#QP)L:[LCW$3..<.FE\Q1
MT/;R?D0(Q)*\+N0QJM&)3#)/%)21#DNF+HP*51PQY01R?,U=MVIHFW6B%K+.
M(0<*OO<[Z>J2%(&P28!1.\,A5RH5;!N^P>\]#BYX;UBHL$KD\Y=>5L!\^4M+
MMW)8&>R8$RSE]O\XH3I[/ ,("NZ-M>PIU/J27;Z1RH-[I+]5FD52]%Z8=)G_
M5/[V_KYM:85S'K!!,^W4HS:6DB"A2BR:L,^^-O5&5)L/5ZPY5KA/,QZWHZ04
M/FA)S,@,%8]V[A=SKTQ!I)-9I9I0[''._V19RI%TC@I]5^ PT.F(DC*_/&'X
M*H<15GE)7RG0>F3P(M2;4^/CB?&^GQS[Q]2#=ZW!DQ_.1RD]%*IXE05LF-S"
MV<>CZVQ<?#XPIEC$%KJ0$!,J':(*D4^N8VQ'',?)X91,$208E_2J*:M(XT<;
MD%4V.;Q&H7&>FNK&<]%B+YQB^#,:C.NHW@++U0S;HYC Q&4; ,1#Y(J]PI5G
M&+T.>2S282?LF[0SS3RO]DY*$(3]DR@>P2P:(G2;59BB#R"I&7^I#:B8#EQH
MC)E2TX&"/I1LU-/W$C*-RMK8-NIIJJS$/\'MKB(N7N$+B@Y5JC+ZS!:LDMM=
MU-;>!#MB;&GYIH!BR;E)B+YEW/A%OJ[*V"MJM[1)V[QV,? KC8&_.JBLI3'J
MJ=_(D[X@'8OF@2"J7TO+CE+>0:GF>I; Y&W2[[5UYV8#M]=%)+U^8NW?@,M[
M1(2F0]JO6+Z5-*U%[5])*N,R=ZL,9R\;6S*R;^::LV91V0R(N6J'\W-/&!,@
M4E\1=H2[-7[=&.-:F"6#'.GW"5W34*G98ZC]X:DO#X.K;\0' DOD[0IGUG7W
M6N<S+_51A7L'$AESN&BVC5S0;CV/="5_;V0D'JSKUCM7-OI8]4W1(3.FS[V\
M<Q,MOVLW[7VT3G-MSJ^M;)/]Z)T7:ZRTM8#*V8?@B/LQR\'2AR'1/7,G]V=F
M:([?H1\=1L);("K.J%/QCOTH^Y$D$K0.XCAZX0^$\3&R_IG(30E"%I%*&67I
MG=NN,S2?.&;*K.BO[L8WF<L7L%>^EF&_W "UC]Y%]9P^ Z(X'V1*E-PIOJLJ
M$!;DMO;[W)",#9\)+2XI-OKH]DVW!?I8?78^B-$L'6E,G*.V9<STS=XB&?;R
M[1_WBM;[5=M4ERBRKG; T;1,CGR\$=<P99WO]+>T=%C(*WJ!'#&=B%!P"4C8
MQVV&B/3+FB&EY_<Y%!S+N/HCAG5<R%-QXZM4[3DU^MX RT^\1W,6]=<D7+X$
M1WO+L^(4'-EGKZ+!]9@,(8<P$^,!OAIYZ?0C';=<FA[_<H62Y3W8G ;/72=O
M+?XNKW:96M6G*/<?N1PVNI)_A-94:U\[B.L[[_NC?IBZ&A&7)\A^MT='2,6\
MJJZQRC$BH5^].+S!84@Q9&4DC&3.\U0?'/ 1&KAGU,$R*[#G%LM]H3MNZLHO
M-)!A4<QP1>T*?#2LTKO[_F@E!7(3WS+_33!^H5X9:VE:.RZPU=+*R-:=S\,4
M_Z/*A392,[+@/B#)U<Z1_M;:\I>_<Y!A?\QF54(%!&-W?DE;[U6$GP9I:&%/
M:26M?92^KDEU4\B*2"7Y$[,LF9+EI(/IU"IY-!AP@QQG&XN5J*^H7:W./9(-
M>Z.I1 <0@]'E<'Q_&# QX?\RY(+KM,QWQIO9/2'XE5] >  ?3M)X*\L0\E F
M@;\N&-*SC9VI1-=8][6YF64KP <IWJ>Z8GC^XG8NMU(![G)+_4C2'=@-Y2)O
MCG_7ZDM]'S!.&3],,F<'_TI1%*.?VON]D)PR#./Z=;Y;$7XDQ;M*EM/:)9(Q
MD"D;!7>=I:5@IH3^9V)UQM_:ZJ)DY4^OSRII:*8@E?#I$GZ X=<@CQ?.,*IG
MP%6I3O&1U2^QG_JM<_OB,^ZCK<7S^YI[%TOL)B/QW'QX1I+B>HX1?H8T83,8
MJ;'N3&NW)&8.Z%274@WIE2M[SH@5E> #A8OJ+)8TUQV"+4*-TTL1@36E=N!K
M=^WY[)A9 B/HMMKK_F9D3I^,BK(#L8!X++5 EV_R1PV&0:*2OOH9B VC7VF]
MC=\RE28Y1&5T>'HWA5S0]_0DW$L[(&M<8L<J\@W6OQB&7!.E/@"A6"M<=^DJ
MQ.T';I)2HGJVD^]%%0 A^[A2;=?2$:>&"\#2R:J<J==YOU@<Z5R#X@+%#KC;
MY$J MM$5*MQ<V;(\5%G74(@5.W_T')QDC:D9(N>$??8._XU AMP0,"E>W"-0
M-1"X*ZA! IQ#.+M7V#[-(EO:5QR-^N^ZL7,P-U%4JRV5U'0J>E5&7$VPA*'5
M<PW0Z&=N'N_L9>GSEGE-FLAV)2XOV%W(V_#@:1M__T7+*W*3+V##G?V9$()1
MW7O\L3EJE0@G:LW(CMUU1 7>=K#66,/69,)SJ$T\/. 0[5>X([)G&F' RGB*
MSIBA:]?BXHRE2Z)8AE>L]+J/4G$'HX#Q#FO])( 1V.?-2!&0+7D.S3ZGAXM<
MKF[77YX0SB'BY=H29UU4J#XI$5V92J<(O[-CG@F^/O54VK??\QD)JR-.W+OA
M$)-?,$PF"(G9R.@T]3UM?!\N,\7HVD#JE[0K%%4CW!MZP2CDP[742_"XIS0?
MWT.BG<?M279@86DJ$:6][ZF3$EZ"R(?ICEM/<R5$A!JTJ3K)((L\ PYFA:38
MC"1>U@-USE6? 3Z"25\O=ZBFR@6I#QO99HLAGLVS2Z 6<$X!7JZS1\*2VK_L
M*Y8752.N)/4!G\XY05E6<:)5''I3EV,(%;=/K1.J:;!*,-6VA42B1HELB &-
M^,PQ\QEN)=J,[7I=\DOA,U$<T1?U<=2#A3%;$5IJ=9/NDM8]"DU*5]C)P<+B
MNM\),1]03<)T,AA3^9NI9=FNT-J&^^^2,SI#/CL4UB=.9^PX)N\P?E0S"5\7
M$!+2BQ*H*./2$Y1U4I_X]L:)=VQ'8;IP/0,8/F-18E.SZZ8O6>%5NZ)V>BCV
M1U/P#U\*/*\Q)U J)<WR#(]+1;^IIA[&XI82G!YMSE/MX&Q8S@_*@%.T3,'J
M;$!R+F*S\967K=<UC0VI=UMXU)8B@#L;M.+3F]C#AH40V_%!.P\TOS(\UTL)
MK4.;X1$P\@)L>ZNC1$O.>?9).D1CEKM^4. V>PU 'UO[R8(/C1<*A(#/^*8&
M.?5;P".50U**%VW-E[N\:A_W!7TQU]E*0-G3)-#=)ZEP[>G9OXU_NS95X\IJ
MP6-C=MRBR@C1S'AFW()S#4:)SDY,YZ/-VXN_B%*/F8G%U0N9SV8B&04%<)@P
M&-3"7M>!*J(KS3F#/#97;4(T0<LB=1/5 3TD;6EI6=:LHX"QLIT,Y9BERB9T
M(-:-+[4Z2 S74ZUE:@N6UZ+0%D%X!G#Y82G9WF>Y2R-<-W.B%M-X;KALGD <
M+@K-6R^WG87K+$MV-H8HG3MJ&?FO9*@_ UISTYH<AW)K$UL2YTSAW(O5KO6C
MME5B]]#KNX &S^+AC_P2$@P,#GQ"_#%_V]$C$?2G?4;M7I,>D<&B]"+>0M"U
M!([6(3OP&M]1_;IY=D(I@]^0$EO.$A'2FRI%W6!8-<B]0]#?Z1WKZK%"!,Y8
M([Q1_54?^G3X9R'\G*32=E1YCURY_O7A_+*6\4U$FRY>$,C.==,_GR/RQ;$^
M'-#OZ;9=NOLD'F\TD]J]H);U_G>N9"8R\@+M3%IM+H]@/3X8S\%HW_U2QU7U
MV[L+18]\[FVIZ5Z5,R85Q>L6IL7KP1D+C[/+/M8/R4_$.OORM$3B+1QX"WVD
M:1V4F88-\FZAY!FOG>:1$XQW$9E4C2#!CEAGCC@KW0 &ZH[/KKH4)$RUS+I[
M4 _/*7V< ";XL'4BT*Y)F&B#[ST>BN52S2.';T\'<_T9:<X-+UMH@4BJL+3K
MV<G[TJFH5AF*R\W#]"8YI]E.PJ/7+8D<N&*^6S'9DPQ@*D\J&HX/ZF>Q'35%
MB\9[UV-<4]C-1^2--7<4U%B1)GGLEPNU-DJ:IJ8R'T%,(W^"11@HLP=V.;[7
MG#V&SL1[^TMP.3*5];P=2V6\A-) STNH_04=T4SM]>]DN:I3YX**MW5/!I")
M?<E+3NBNQT%+-G(E^T(911E+AJIU;WN_[&,,4OM,MVS[<9795:SQ^CO:"]PS
MVI'U?UII0D]*.C D]%,/^>/1-.E@W? A+-=C7!KGPS4?N!02LB G)RHY.GEW
MO:!>E[A_K$5,$%/WS4F:O2IC)I<YT?U]BZP%<4T:.ADZ^G+-%5>@\K0$B7,9
MI:NW31,^$CA<=%=QSW!RS,[]M&H;Q"%=:U3/!PX/..KD'1.0CSURG^E.,3'C
MV',M"P?"C@6*I]::]>HT5921?B-7?YZ$'P#=CS/N8MLG!VW3EUC1D:E!T>//
M@,W$I6? K.@S(+W,C_A,[G1[7VG](E_O>YMW_UJ<O'V1#..*C06#26.:NVL-
MS!U$;3JW:&#,>1JVT"Q#=>=Z59'?S(-A#_3U JY?J,/4D@G$D] SS)RQ\%Q
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M,,"M\V*B4TQB+W"G(,#-&%>9@V<T[<E'>$?A7]='!Y7)6=U./@/&Y!]V_UL
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M!ZB,IT (+?3?J8KY3V_.1!)WFY_162BBF(=<0>Y5W.MKFQKU..DC+7#D,>&
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MSLNHOW)@VHA(9P?%''J& CQ%<[(0E=/,[@"JV0?*P#+[F0E3,PV!"HG$'$L
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M12!C86&!&]?==W$TTYF_OAY-M=ZP_=#[:3]@XQK0#IHTG&(HS&FLKS,L;7U
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M'D#M*R@G26+\ITS,8&9K5#N7Y4.I%GW;6AE5@_@F#76@P*M09SWV0ZPH,>Z
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MD-Y'EQ1K+:";HZL^(N%ZO/N]-#347?T.'+@C,0WS488#\^-PX#8B?DV#AYC
MUU?-B^(?/31<>$[F45UM),>P8:F9VJU.<$ (79K\ G7A+8$S):[Y8WDPIS,'
M)A=*8KJ]Y^@>MCWXH,*J>8, ='.C?Y#QTZ T Q A-6.X@7+Q!GE--HQ=YMV4
M.3KQ! TL<_F@B-AQ6KJ2R F32JW.A_A1Y(<C_TY;?@<?'7TH*ZG-%9H\' "K
M0QE^B856B.B:!P?VMQ 'A :[!C.;VE_=2;>IU:VX\=Z2VL:G-FZ'(GA2490.
M[M]O:W16NN=RF<&%"/\'%:P_QER<T9:PY1H@;]E>;8;\S6BJ#W,!)46X0@-_
MZ<RD U]1JO2/&9!,>OR*@"( 6(OG6H$)7'PNN-#N>+*IYJRF]#6RB\K-=Z\7
MQ_TN,X)-^:TN45ZA;Z;&I$)5K<B$I)DS'7KQ;M4_G3=G;@4MNKD&P'SJ3%?I
MX0"!))2=_2X<&.)Y 45$P:7\I@+U,I!VULQY<V?P@?R%GAX"*M.L/UTB(F.'
M(N+9];:#3K!'08R@BWSA O52+^MXASDX0/)?=)M[5:37>EJG.^B1WH '>Q ?
M"-X@S7ZK!#Y4 7\].L2]07$<_"8/8XK(']^A_.7BWU[\U<75)1?T@TF:@SW5
M<6+=C(WPGTA2QP<*[^1V;\DQ&FR)ZZ9G!.70OW8?,,OL8"C$\?Z["^:%N*3,
M(-]3-'$3PSSO#/K](D?D8-3Q\8A4X7X'." \BK#-<A@^J642N*L"8>\[B GU
M0A-7YX@H/7Y: :BWU9F]$B4L6[GW3EA1<X[[H%#OR4'?E=C@F3EQ[%+-]YKV
M+5$L=,F:[;DZ?C&E-^%B+R\\LJ>@@G#@O?#JE*5+:.$HP^3 RCK8DVSYJ/".
M_ONK]^=:GGI4AU:0@LS- 8JI]NE"L,O>WJN7.UBW3TBME*;651I&,UBL60E(
M%%2\4=:M<<%U%J<HO+/L+6$YNJ[91KE!Z/74-<AD;@+^'!-K-\P",((W]UUQ
M7QZ<U&6^VY>+'ZQH#A;*YI.4F)(>'.7:<)(AEYCSDEF7#TL<K%(Q1](#K#\*
M;:"\+[MP\S+-E5_"O><:[.6B6%T1S:STZAZ+2%[/;<R>XJ<M<P"D06R!IAIQ
M(PG'+T?VLB-U-_O?X!PVK%N2$: B;>LMGVV@IU61PH$1+!/=FHTTGU1(8LX6
M]U56N8Y6'$<0Q1--6Q=&JL-3?*0^V85; 4&"/'E3<Y?<5^35WZ-G,V9>Z[PB
M_TX$\A-;I@PX=HUH)W&NS]GZ^A760_Q@H$H[\+O\-6HHI?N>.#[2:BF4;JS(
M$7Q70_LB;_CTDY(TF_ WE%Q@]241,HZ'49;T8JJ_WL.AA[XOXSLCA(,#N\\X
M)@NU8\M34^WXUHO<G?"1EHL.)$XV+#/8@U7?O/HH^\977J1E;W"?Z#'[%5AF
M=_' H>,0LT%E8FNZT"^OZNYR5$2BLU>=85W=4Q&R:E]/BCD\_C++1:>SZW('
M6(%)W]F6PY6Z J/9OS6+Q7FP!(:^8P%O+R"N1=?0V2CP\W%%>!>Y32!#>K")
MJ#B^\F]!)^TDW7?$6VB^#0X<L9FGGFX_0(Q;HKP"]_(!Y^#5Z2_?U2'(T$AY
M-XEHB?[3:(]P$/+NX:PLK&D-$0KZO;STJ;8IC\C'FK?W;&ZP)JSO+)FB"RR*
M,S&D-^+U_XQ:&96 NTO+_"693?-V:_.)H7K3A(\G-AR(ZKR&-2 ,3(+68]=-
MHWFI?*(5#MQ"7'F-_\?MHDL%,>%'B3%NW>KF:F/MR D0E"^0R]]4QV+3U(+L
MS?6O4>AQK$*]=ZE6EINV]IG[!"6.Y'.W)AXD--Y\F9QI%^['[HI+_^Z-=AB^
MXWZM@*&X,&FJK2NQNI/2"=G:Z35_LUT9Q9U+4W*PZDOF,?&"7YUZ022JM:"5
M #KUWDXO5K:6]A@UI$RJ=;/3KLM.UW7SYQ?!?G^1(A>!^MH_4'_HMU5GG?70
MYI4'N#?.E-T3DG\\0#>%;8/$<C"@KE=)<OB*^LF4>O_Q6DG(;XDVBA_),3?I
MWU-F8[83T(;+MSD!23<1J1O""(Y0(/C3IX%S]T#+4_KGN$=Y3 (1%V?Q-VW0
M7)3UK.N,35DIX8TK)4A.TE]M3=V:QP:O:"?"FE(1CU_K*.'4QK_YB!6A1/01
M\)=6Q/C&2G)) /%@R_F__M$*(T=&%# &0$3@E?09\$0%J'L"0W>]D_*2H9KR
M=!?WB*MUHESLPNR0&0[<\\-7U/KX4R;0!8P!!U;2I\ 3F,TG)(O,]1<@.$!+
M. JKD4-<$Z(*!P*H+2@[(O).O%CQU4,]#/[>2KZ<.'(P(/.+Q]9ZZ?>->RK;
M?*Y<[2\JK?"HNF;IQX^^NY5FK80C;&VG*VYL24)05;[*&3TSK?,<[.)@3A_/
MA#*&?B+4 =BZOW?18AT,"24)W7W48; J\UK8D#'6?V16>KMGQ[+L$&ULR&(*
M7U&>QI(+,J'ZQH9HPTN<-M7WI(#W%.V1AW^SN&Q\34R];#6OH9?;]@X3,SOJ
MYEE\5;7]G(5Z^13WMDM][1,W'2.4\"0%#*XE@;S7Y>.G<OS;>G4)@_V/-*SE
M*AOH! \K(K^@46,4V^GB^%'++_6KJ5\/FEMT463)\:^W3*F.Z+:R3'1^VTQ>
M_?( 5426K.Q.^!-ID-;$EQ'6-VRK=0%]Q\;!O!_+35=%?42(,&0#H?+:S15Z
M^X2T9W?BCV '1--)1E-EG+-TS@<#6?G8V@K^9M;%%+.L>\34+Z1FGJ $K/,-
M(.+E7H446V6!G/I@G?_2K,P2L7-F/MBOZQ K6,-1@)>S]F3LOE>*L[-GTTN=
M:+>K!&"%BUQ>!<+EP2HL8'EI".L//A,?W5?[_FER.8XEQZ9TF0LENPG-/UZH
MX_3]?8M'#-_W4:O1\?#BU)P,/6RE!]]60O1=M;Z>LE3UNUAR)1GR%K-F?V<0
MX:BHMI.O.AA(M2'/17>)GG.P6^MY:!K][!;+>C/J$#I.EOFM1CF*._MW=7LL
M;Y>^F]J3FK0>[*>Y) WJ0DJL)HC/UMM*:"SQWS49*V'U_&[SJ&9:^'64D2UR
MO'(O4N>"P\38A %X,5%V5ZX2K:ZI,N&YQMHU"TSC(YNS/]$Z,>A3H78)JE:7
M0[JF1IN@,V&$W<-H/N<&G&LI8R&'Y/DB0-3./%?+DF>.HG2<7=>T]%JW?M#^
M2!KU<^#URDI>U\O8C)QM)=<(I1'L GE43*NSWLBBB(]A!7C7T.DR6+]>^?"K
M@QV>^*K#>0N7$?:^H[XO\E3D=Y_>!4Y0?11=Y26LGMS9KEVX%AK(<CQ_\ER*
M[K'\MP#44)_6U@[ 42R+E6KS?[15ZUF=T+4$C;8)D[JM0 #U= )TFUC&H7UL
M57WL:D9(ZNM[ON0*AF&9W(%I58WJ%T@?U')&K:V*VH_]0O&\_9J,]B-D5L,8
M>[CCNI[G2[#2G3,I:O%;)>&).3@Y-;0BKUN0$7+.*GT3D#8PDR4R"97RJ?.V
M5/=+_7+6B 4KPS7?N8IA*-IP#!&*.QOY]';"CMCIU5M5X?=*;1G?\Z>U9S[)
MC7<;AN;<KCDKBM/6+-@P/MW2,T$C:"2,,+_=BCV?8,U&'"N3A-;:TIVM:18E
M1<_SE$V!>TSM,DCGR L#'VPRT=B<2:F79?DQ]@_0*BP@ZSQB6GN?(X$;Q4:D
MEK<(%Q%X?BQ7:JV>) L:,Y]2/U"4QU6:Q=D*?GE2>;[>^^>E>S+V=CAPB:H!
M!WZ!J"$YMS!WE]_.=,&^68:5'C3VPY()#NHKWF%2]E(X1+JX.Q:$=]&JS%0\
MWBBHYM<Y<R\PGV")DB%B= 91#8*S]&L/)KX7925>&\E^Z%6:IOX89V/0I57P
MZ:@<)WCZ(#L1/:>(22?[XI%$[.CU)''7Q7B1Q=2W_;:JJ8ZB)#5K4S,*AJ;-
M+G )O@Z^;K&#BKIVEM:DANO;:87ZTO CV?K/M^Z?B)]20"%A:Q'9KM:D]7EO
MJ!NQG<LDHD^>4U$(76;9QQ"W#.N..7.KZ3''/Y>C&]GBL:.*LW4@N1<M_*Y
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M9/%$2\_J>9U"52GJ,_4;<UALA+A96<1W#^Y 5Y4MAQRC#']8?W_12?Q#X^K
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MQ4+*8LZ-(#0+PFH9;ZVZAWN#2C3M&=5%!POFN9:TJ\G]:>IJX*S4MK(?4-A
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MUCXA,#7HD N)1\BQ\NZ_)+K*>$O-=7]%CP.C^;4H,=6ZRF[@N\'+NH08[U.
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MF_-G)W!H:&B8&)A$6%A$G,_(GG'^IZ_[%@ N*GPADC("'!4 'A<. 1?NOAU
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MA&DJ?7B^UQW@UJI+5K\):1F;/V5ET1W$:*:S.B,J<M$SRL[?"L3H"_8\C1;
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M=ZZ%L48D02L=YVK\QB>!$ %A^6WC;<AB7QF+;VT=Q2N#Q;4:&B^FWAA/\7L
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MCMWB%YPS!E(FQ\B+X>*70<WPC>B"(*L<3FE;=!GW.BFXFPY^LX>X,).TY+=
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M/_23[X_#O=CY<G@3\YS!KR_OSO>2UJ\.^]F%OMX9DK0M8ZUUA:T@=\K3_,S
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MJ*4MB5$Y:Z>^B<V^<RN,D<^3.!AM3V2D5I0CC5G/G657YC9+^[AE-)]859[
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M\L<](.]"=>W%S9G/Z WCSQ,GAN:-BKOT)>GXA>/O]P#E@U_G4KD/N^+!*Y\
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M;IA8,;4_0,6+N5U );IQF$2R_:ZZ#,H7%F_P=J(NT.2%_>%#:%18LDXO=M%
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M2%_ M_5;83/2TL-RAM<:6_&YVLLGFLJ>[K9W76\V2J[9RXP_6)U]$FD12.?
MJV;8?JS2WSJ014%WC*3->Y4HD8>,&#*[>F"J:J48D7146S1^8TLEXZ'&\G")
M=*;^QE@Z'M_T$-;AL/K3 L'F2.*3S(1,$A*HNKM7GRU=C=?F7#_$]96.5I"7
M/H>A;V3T_' <-'=2YEY<YOB7+SOSQ<P8--$ONCAT+/(X3>AW;V.3;C(FC,O2
M2=WXLD'H";OO(_<K2FWXJL[?S%=.N\,=>E$NX0AYOZ" Y=:*C+XM5<1.HQB1
M\G<]_W$)\WY*UHOT2'9F>8H;Y>]R&I<N>?/@XV#.AA.;3S)\L J:%#5\%GJ*
MX;7K*76GJ@OK,_(RPM?ZC9G0-YN[$QVM/(5*O0X4-'AF#<\&!H=HV#.$##?O
M)N1T&:PV7*OES3??R-$9^UI2<RF&)Y.),L/9F,KT@OX%5Q2P#=E+_+;KU5[#
M>S!;.R#[:&.;0M\B$O?CYN.6ZJU=$II0MX4V_[V31&4YV)5.RFJW:*CD/*.W
M(2E3[Y!@6Q,(=\+BOG)DO^S&K>AI3<G7[YT9>GNQ>1UGKDEO206K!"O[]C/5
ML3*YHX"RG+N*7B^S4ML*E$N&N:A "F&>0I_Y:SK6G\;,;GQYDY]VI$ZSP8X[
MM7U;+S77[%%UQ?MCS];]"L_4F$=C;W%N>?+D3S@WQDN\(<>N#C--PODJ>=!/
M.O8<22AA;0XTI*QV0$S5M.)OA^@TE[P$-47TE^7614?7)QI>C,XWX'>Y3F?*
M#S"V_%8@^?N'-_V,Q*@?SC4<45K71Z!MX56=#0<]?G3_UI,5&J1W>?=0GJ%O
M5G-W0",V-7-93SIX^5[!*LFQ;%AP]HBFKHRCX/C">SYB@F?)>EDK.EWE@RWO
M9MW-DLC4TU,;L^."BU_0%?/2'0J5Y7/QB[=6).:/:8P>*2U7J,M&>GRSKSQ1
M97F\R3]6*J 6H94#N"IZ]JF:9AFX)HB@19#V6^VY7V'UTZ^ .'^:VKFW@@(D
MT+(X6LW8E;B-./?&@GY5#V]7507UC\H$!][D,5#:7+<!B%M6&H@<)D15*\KY
MK-*MS5QOA_4?FTJW\+MA:DT*!)F=8A=(6.7OE)<">;#A]V9NY0>!AC-,-2""
MT">Z94X[9J)F&L-9@)$OG]%A"MZN!B+*[*-YK)/:J%QZ=D'XJ6>7!?6\'XS]
M %+X%%90[LDQI5 :]15:*;P\LJ''GCT&*86XC#H.AWG?^FIM3B4QNIT5TT'E
M9IM4OHR\.+AALJT7U$]WDX59^XZ?BT(SV(&ZOE;A(I7$K&39T%99)\VUU>-T
MS2)-XY(0R92W^%82>LAH"U7X'I]"N6B&?I<]2];87:@8QL9<&__NN'V+C=9F
MU/1<EDNX;MF05:P&-/$])GMHOV(O%L_XP\EJ\>WQI%O;FXFS5^L,/#DV]HJ)
MUVLP72.(.^[3/=L=\N9;A NFRV>(OHS4$?K(W7P#T^BY,\G+@XU]KO)X>(W%
MA*AL]4!W3*]&9[9V95DDW!G'\KF2JFW;5P36<(:+J%9",S5)*0Q"H&2FLO7M
M4 J;C!J&4<WW6QFCU4,6C2>W,61]+ H0,5]?^TMJ8-%1Z*:K+I&BU@>)Y^EW
M,Y*P8(3',QO3W QQQ,Z6 H8^,#7K0$<9_K4QU9)K=^OR94A=B<*YJ0??0F,9
M3 ^"^8.=GW61@AAH4[.%HA^Q=*^V"7M(&!DPH "<Q0^7=:S(VN<*[/<4G\:,
M75D6($ [XZ\#!E' WB6(UV_Y!CP:0L&D=_U*\>U;_ZA)9Z3@D<Q2S0]'F@D1
ME=E%FN\:J&.3OG9]CH!K)G&5!S6U>&&6B%W.:K%KOP$%#.&0V;FF"A*]V^5#
M"X1<"_F6E/J@+QAK;07D*"" <XH0#5Y#V#2'.-Z\,;\F?FY2JS?/&:TI8JKP
MJG7- 7WM61WW,T/.I+LOT"YWQXS8^V3:]O<I*, :>Q\2);4M'IRVHA[O^4'I
M52V6_,-V+?6>$UUS_AX,4_51XJ0( 67.1RX[=W?EXY,EUH0I!3^^JK\#5P_;
MZ]0\?3^ID?!5)UI39=[(8>,I+']SKR91EDN[?3,SAGZSG-WT2MI8ZZ,,%U#S
M$LB[4&;[T+^L!U>#0I#CYI,7XYL;5>/'Q5N/7>QE56#1LP^O24%UXK1MK8"V
M(L"&'O/J9SVF!MC^P\Q5-\>ZC&3#L-6I]:TJCX^4F,MB3M$]"'#CJ+S_4HP%
M 7\G([/QTKLJ'#[Z'F%!II2N_V816"0%3[[98$JCO**Z?#"E.$JN8>1^S'AG
MA8+3R]89V <O+@NY6-7RX9MMJD.65J/:3C$\J<4/]HRQ-B>G)E?"SBPN'3Z!
MW_]6?I7"XJKFK02EDY=VY:V7]3EYL S'B(N?FQ6,(SY2R2N60,O]*7AO7>"%
MQC"W>X*^I>"EO=W/S+CCS6NA:JG<//HQI?G]WOZCBFP^[%;=^JKV8S5F,\ID
M_%.>"&]=R)VKT"VCJ!KJ$V<3.&2U1[ZBZ,95C5<&9EIF#Z3&U^WDA?:EQYJT
M9#]F'B LKXQ?8@:Y+1"'*V7+#0I-7P$6]BTY9)DEB*"MIK/^PGE$_.0\5R]\
MX^6EV\#,(H/$B@[J;7>8"49^Z[)Z\YEG89?$D)[)S^?(H(Q&OCQ&:C[R^H:
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MKU_^J][TQXD/CC=$E]D0NO4WT8])GGR&T$<RAO_^L=XS+3QG !^B(A0\4/_
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M]4K>_)6^H_B5OD,;F@/03X7P2V/LJ4FX]/QLD_AQW^\[M/_)SGC3_GS -D3
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M<S4:JH,XG]^$J5,Z]W#)Z&U_C90>]8];3!3NH+AP3^/+12R/C#P\^_9;0<#
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M:"#IYJL\'EF?H/?PMW7\:J^0UWUGDKTRO0B?I:T0OV7IT]O:V9;WK+$7)HU
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MK)+5$B)S<P<8DC_-:VJZ?.(7!$C85?3P.'[NEF^Y?^N=ENY)_7L/,M.$JSM
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MV$F(*.]E.D9+)7X<#RIP.\/>EO1"^:=.="&_H+K^"BZS.E<RK%<U;C2J -^
MLA]TE_@VKR1'IV1LVQ@GL[EQU$M2EV>Y1>Q1)YL@^R&F)EH@7]JF8LC_X@M%
MK(/04P>NRI)9$^?0T(89,TA=30B]==4'OI#3?CQ2 4BP=HJ8C]28Q5[J][?D
M52&LN4*=0,.U4.&=VS^->7[M^PE$&&0,XYC(X5?@5QF.(\ F^,"'=JBUFM,N
MC1JW$Z/-)0^I:'BA5Y?,_Z[/PU](AVTD5'CWG_ 0<L]!M^,GW;8)YG3RM=5^
M*RUL'?BOR;CG^X<81)C:&QAY/GXL&:,:38OJB94+XV_U;Q+X+'1O@3FW?[2
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M#[?)(I*.TH\ >"FAUY!MXY_I2FEC=^+RZGJG-M74CA7'@^)>^%H 0(&Z#H\
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M_DS=J@X^-RU-KBD\H/'[:7R,ZJ3J 0^I;1/[/Q,E1'GI/Z.#\.-?,R_ULCN
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MAM5SJGD*7V^=3+:YV0.QY[8G&IE!H )O83I]LM[W!P4U84)/=G:/;\28T.\
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M$CQ:C=96@Q8G+EH'./UK558%QO$KM>_.K!X5M;ZAQ/)D9HEDMA+&O*:J2?9
M$G\^4I$^;_)2W"!2B:7#1O#5P:<&![B,33L#*%U;HS-.HGBH2_V9T2ITCIMD
MN[KR( 0FZYMMHH&;1_5%)=(_NCYUS2JQA&<S*KYO_)9,9]X4[VBSD:IV=)>#
M(J'7DEZ"3, ^TETK)+S3DV>RM/KP8>A2/TCBX)H+ET5#!F&4PD[9]_L'G%EA
M<D)#W_.1*/'R<8/X(X$7];G@W8=KR3NK 03DF(31!(,*H)%"6^[C<'3&T"RI
M#VII+*)TH:N29(YAK"X35 N>WS8UWO.ZIT[$PCZ&TCO(D![L+;C%6;-%[7<
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M3F?3!VR>9P:F:E@PG65KPU2C-M6\;QA1Q>E5^AXD-UX:>]=NJYW(@ 3B($C
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M>NAAL48!CPBPE,CU$H IFG?Q^+>>+$38&E@4\-YY8\>^8FU"^6H$ZLK=02$
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M!86#H/6DW_<#*DV'LN$O1U5W+<3]F!K7#PG0K7W!=[%UP;J^[TL+,6?G:,6
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M@(3ETB]HMK6$,:4O<PK\:Q?D!VA'+2%V-SW8-Q?1NU]W?^Y^_=E39J:Y]4&
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MV&LO\Q_NARQOIX:^[9=Q^?V61#VD:S\AM==&0^.E_(=BA4XL<80S]%U<'#S
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MNW?@,_&!?$]\A\1'8Z8RZ+$VQ*G[2#Y^VP\]I# QKPG=E:-_NCO+1VL6[42
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MA4Z,_ :,(WX#)L??_>)R/Q PE*+7R-KCEUHL:+C(<_6#*XN^<5>C=P#)K7S
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M74(+G65\]_S\[NJFTH[\X()\=817 <WWUS?^;RK#_PT ?T_]!U!+ P04
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M&#!@.\(!@@PQ67YZSG!0<";S^-[Q  Y A5TK7QOW,/$(VE?E>JU,<S.>*,+
MCO/]HR&?(YENA'.PNW-8*\,86G9EA_%H@;D#)+0X*?KHB2IWO"M^J*[&.]C7
M\ZNJ:?1:C+PU?9$P?SLGXOOGG(C;@,HTB)/ P*:?,.)\LFMG%-/4366B8;72
MU -M:8K^E'RJ7<^USDUF$R.PQ;\!?([/=RK(B8W0?0_;?78PY;9=Z?09#6/'
M//^7H.F+@3"@_KAU\5#*Q\G@8HJG?DHP1UD8;W  @=>BA@+0,1OE<]AE+.Y#
MD5*VP^Y46V1%ZAID^;+H_7M:FBDY^[%-'. ZF@V1"]<L2UJ41E0&@U98M2T<
M81CPGDS$TCOEK>?N+T8*.H.#)UM'4<&(0Q54QLK1B =J([5;6/!GQ]RW%\Z2
M3$1QZ3%S'UST@?[++<(P\%N/6+*==^*-FJ57ZQH>\8BT=BA\?3Z\ZD$W<PSE
M*3F^%U PL7LRC="B#QB5YT5H=3F"[K=!1X!R*U5L00JEJ)C%"^NB+\JAJC<;
M0XP99U0%:C7S/)@J"ZX0%BKVG;^N%$$:[&XMX\OL=L&A88)Y8ZT+H'X45%O!
MH-EXX+)V5MM^(BD9 P#$Q0N,00#RB8/&3]><E"PJHNR56CT_:2O1?7</H=6^
M3_S/L845!VBKUR! V7E'V$(<8 I_,VR-24XD_2@??1N0$ZLU-!MX:!'3(K?)
MJ*TZS5'I,IL1O)65+W)5B4,QE0^@K43[]T&@:VBMP:+CSL/D:'TC.4A>,8J]
M5^(,![@0M\VB\E,H\A.=JB$%A8O0-QH=+_B")]%[U ==]-1E3ZJ3!EXQ1*T:
M;,IU";@YBPN)QG,I3]^3-7RVC!&@^2I//"K/B))ZA*@-9AVQ/7]JKE&BQ1?7
ML2\XP*XZP+R;;Z0;' VU8;,7RANOM(S-:A4,&)X%=0N 25$&*U/10N*HXTK:
M]D\.,H-1HB;S1LHC?6M<=MKW/442Y\6&3ROJ.IC9$R^DMP/$#%#)Q3NI$C'O
M,%^P=$CBS>:F+U=,I$@%V"ZX>Q;R+.3.#0I1ARN]8?*W4.8;G8O<HSGC[J6A
M1LS CS/<NHEQ;(_XEP\86;'6]>12)ZHHYWR42I<Y>T2O3NI2UTWN">$*#VGK
MUH88*;(J\5WU*P?RFU^!$R7C9[2/%YC3?YAI46*BL7?E-KK(%1^.-]O@ %>5
MIJ+$P2A5,F'7 QS :JDLGFGW@]0"*4W/*Q%LV5042LL 29^\#*% M5NB,G+,
MA I)S;P6<0 CWUC*WJM-T_O#5A\+EA(8+[K2(S 42(9.2DJO+!-$;;F'XQT&
M+%-&P9A5=?(WOD:0(-S/_\ARN1@>N"DP((X#3+NM6&>YO#3FN+YDU'XWPWU@
MP0>F+MI^^F;$:59YW\6,JFNTR?^']_-2[@B?L#T>F* 8/*^5=E)0''1MD[R$
M)SK!(>FT:J#X_E?'S,6MIW-6TWN&T\';#ILYDL@AN+E#6<"0_/4IM&'J2<[L
M!%)]^I@J3ZML7C[EY"-R;>!$9TXT[])ED5ZUHQQ/:BW>EE=ZB=(2NT,/HNP?
M8(?Q"65#YE+$[4]_#M+&.K2?\$76^ 1_4RFDMP,':,!HZ/PV13@;<Y83 9#K
MA6,A0W!EN2:7]O-S@P]^%LBDPN5*:KOD<[_\D,+0X[V',TT<M^R>12S #VG9
M[TMOU&H*O$=6QLK?(.?5'@7KC+ACC""?/6X+'\U)!Y5)&2RJSWU)<5VEX[C'
MY5I-7N+-1I6SFI@RR(^,2K4]9PWP!QD[/Q/+"I#S%^A.AGE&>Y#KJ MX T'V
M'I0T"RCGQTFP66L3%R<>STQ3-6"/5:1]3[ZW]+S/-4&D;P_[G;%C-EEU[-<Q
M#PW>Q^-.4('26(GE>E_?=XZ0D7 /D6(1L>07%U*<G&,GHJVP$Z09I1=[&)+]
M*$"YF4L)U5^VA0.0'_LV$)</+D86HB#]J5LSJ:^;(SA$\AP[709JK_3"C0VR
M&)L5\U">W0$B]<%*69VI7A-<7T:Y[&BT16>^C?"],"P-N[W[E?^#61M$@KU'
MR==K^@3L_/T:2171T=Z@EV8R,K*7@47<9.'6F.:D,Y1%78!-5Z<J?G+A8;]8
M@X.SW$+$&5F19]'[1LP\E58=,C;\CCP56FD<:O+1V<-?JDM*\NNLZ>/W14:?
MGE2];X>#/V8$UG-'9;J9]VB/9SE?]LV4WDH%98TV0Y11&;"=6#J[/5_VJ$6V
M-J0&#A":6Q?$I+]'=',Y;^^&:_,9$>WT/<[0/?/V/D*)].)ZV\%LW;1G.1$"
M8O=_59Q? ][&?M0&CQDGB+]WLI6*B&;H91>M1Y*@N<X%]S.=),@A7=XM4S>3
M5DVZ'<1?W!NA?G@/LSYO^<QMUSU$/J# K2B[87\>S@TYWCQW0TT-"B*S>J)/
MLAA,5 LBO9MOY"TI90_2%ERI*&RQ-3H-8V):0$MSWMZ^*N?_LVN)T;8QM&A*
MXY/I5BO;^!&&02>0,U6@=,;)[XWU&Z8K[U1F:>SONLYQK+/JM_8HJU.QN<NE
M"^T'WXR*R: \@[7ZMJ)R81<[L5>]/LS;W=U,#79@H$\U^YQH<VEV=#G/DZC!
M2-F"^,W3Z7FWR5KH4@QS:PK%^Z3)\Y?)S,EAXH/*DFE>,0*E _7EG9(L&+6S
MM*IQ.$NQ+Q-)[;L]<TS3R!$=3%X450YW)ENTQ;+6UHQY9%$_3IYB8$B5>#OU
MWON5*G,.(U'?2)/W0)O0G C:B"X,[AS)+HKD"/13A^1'2W72GVLDI3J7[W-;
MMXB9W7&52A2]]_ **W]&&?>-!D):?K&1(Y+PX$:3+"5WPK8Q-/[X^"-V:LM<
M!9D DZ]<AM ^%O<2M&E@ON/:D1S_[<8A]WCY7NB:,B&+I443RY=[<@K;\NRH
M!-,)"2UZV]8;CO+^B@IM$=-F6Y^;J33CYWI%L7L9WSXO&H1R[I%$+:M4V[E)
MVI84JR?UVBG1ZBMG*]$^(?CW8<Z&'.OBH!=7W[/002P6K_PD07$ICLQIIQE/
MWC"I:VU@NK4TL%C O4P^'Z]% O6- 7W<P?KC ,9GD)./*!LD&%;8)<@N**8P
M E1$+*E2S>./=]LR_5\TU'9(-NJOY4<HO[K$3C%_F+K5.3.T9"<LEDSU/7N?
M%\*5@8J[,/+*'&@'7186A+)Q?34NC+IS"Q\'T09:\2<"AO HJEJ)L[[7P&?4
M"NR)1Z#V%@==I$W'@I1V*](Z$18Y-YZ8.U7#XGQKYD,UD0 3+UD+(_ORJ@$;
MC ?5>PDEUL4,?MM\ U)D,C/H6.;E4O'0F@&H/#D554CUAL'UF8U$Y848^M9X
M*QE:(%)QLL)Q7\*W]*)<9UOV#B9U477))108F*@=F.XQZ*S=.;/(_[TC&513
MDQD681XPGG4=*)SOT$;N(2OK^S-F9(=JRUA,T9X+VAKTPEA@+WCM6ESHO%A4
M8*98A/DMU I\@1(N]:Z9J@1M@2@,W*L1(+UL@G%3>AO]P/NF?MHSH?I.R[T-
M@K#)EDISE&[9-@?4,T3^A@IQ"F(_;66@7!2FG_BPP_,UW]N>1YT<:4#+B,,A
M6C]N5&0N=GA1!EGQ;AET!36G,K6WFQWH<7$4_>EN=ZB5+LNS^$=P5@*3GJ?L
M22;@]>?WIO0]1T]D]AS@/*>=L3-ANLC!T\B:+ [[)FX-6?U107T6D[EWW ?+
MT1;Z+Q/=@A0V[- ":$+4 *R-P4\*N1 ;3=S,00UDX>F2B7)Y4,R$:4^ZZE?5
M<P5>0+'DL^'GC3" ,?2JX_M>#B1];!Y:!E&;#'$IVJ[R,M!1L8Q3.1=^#_PL
M5E]-;1 TTWTKX4($A3_S=@^JF" VPH71)MFHM,Y38^LF-YB&$CM"ZS,FH_U:
MTSBK,#"P:3(^FET_S6 )"Y@K_YZN6W=<O#K9!F7HNA ./(=T%:(JE_W5=:R,
M.-I%MUP$=\,&#]"?=!Y<A+-4U;QR:$&57RA[M8[!1E'&6HRV.,!E?-G>=5"_
M$*B\;L?QTDQYW7*!6UGYAH7A] >Y@X*<,8B%O[,BBF99-OK:TJ/A "DOU=8Q
M^GP"Y0AD\X9UJ/=K]/9(7%!G<*_/+M!_!1(U&UKEY@%Z"Q1$LG0:=T>Q- M4
M+'0S;R8WB=R.T&4ZM+ >L/E)%?-QX^&FZI93@6E]>*7/QF<_MJEF=9ASZ+E0
M/@SE7@\]BVL^&1%*6O_QC#$DB5='F>G5*TH2B9FI..P Z(H'. ATI;Q9JMS,
M1*-(;J_[<,XPR<$!)/&%,[R.QX#-7[72M)*_4EAV;?IXR\U5R+$CXG99](,_
M*W_L(19R?F1 B)0U;AY!*RU3?IGO)W.S]PSR2@Q7G1#?*;Y4S^'EI'?OF.Y5
MK'A9>'H#UVO/Q0Q,(.9>+CKUK+ +3-]ZPQPMTIH).U0:<X;&$M>]N^/D/N?=
M:4CGI0?CR9-_+G#O1NA"'A4T].KVL=8[K,28A*#3.!LQO'KRI9^$'??D(:=#
M:7CY_/PWO\[P\;YE97EK'F7D$OBY@-.S*BI_2OLCWE@<P$Q8NIU1 BYCT,W!
MZ&!^*[;]I')E$ZCDX.U/OE@.I(9F=!CG-\%N/PQ,4K[0$;BT8=T+DE1RPQ*C
M^BL,T8+C3A5YU<U-HWZTP/O)#-0UF1X#6J^;C$[)1[!K@![*-D[M7:L7+<W"
MQ4=2=6HBO2\-$J;16DCBP<66LD>-HEXF2IF^3$>GAS3:F89EW>U>:2XZ1C'T
M<@W34DYR G'# 2#4CT,E!H9%CKK:!-VZJH3'+2TUOK*&/(WU,=>_6-O8Y6IS
M.DN\OMQSMX'6]ZI<R-YR;/;93FSG.>2\>G@D*)=-UB#2#LN-O)65X_<RV:0-
M.@YE([\:6,9LR,GBOOJ>R&QMA3OKHP U)>=AMZ]P!%9('>[.-6+2F93).>9.
M4FM;*)5 ^M'Q7?+WPVO%!O6;>G7$TOP^F=W;UYK=VW3GI>%+^1Q:R$'OTYZ?
M-$*QB)]=2$/[H#&3VMJ@9[6';^NCN>N?&GR5?>.<HO S2"!FLE7&(8F#JB?C
MFMWI+-N/;/]"9<>CG?<WXA<7C:3\RZ=5!'Z^+>UF]FN./M-5H[41#.,?#MP'
M#TS&5K*5?CU:BEX4&$-+Y6[[7* L/,.!TACHLTD[MS6C_C2/@_SVURF&\T*#
M@4;I+]O[[)V"D;D]BYRML0JU8>IUDY3A/1'.4#;1]1F_I+'9735'8[--N)-D
M\BK$$WH'V.\5SHY1<H60^NE!X%K$[<7V<29*13P3$XF]TYU7S);KXZDW&9.>
M+)KOY<6+165")_6I-86^;T:N&R@HT3[]0*NM!#";:(.O0.:Q!<4&*7Y>D_(2
M6ZW<8W"4U<H0Z8Z,NK'UMMEKY$KBK<7YV_H<0O,<Q1+KI;#*V>$WD!5BE'?L
MQ57\J;Y7H.2>)W>6Z,4/.P/MUVLVHT<&@R#$!^QDUM%-/R .T)[>AG:-1:E!
M'+3.J0+8<(#E'V"LM-ZQ#1IYT7_^'1*'Z1T=_Z\E:-F_+9%GA_RV0FM[:3%V
MD<,H]J"M_IS2&-$:"WM 45HPMTUD,F0+/%ZX2'E#HX+="7GB_XJ_MFH93($*
M$NB#"C*/GL@.V);MTUL.I9"]-.?FK:!*^6CQ7E5B.0N1&/ 7):%^O##0K#V\
MF_EQ !?".? E6G[J=F-(=V8NEQ8KT]GL7<OV9Z+W>\4SF)3 &?XPO6Q>)Y53
M]FY_Q,].F=I@E^R%34D#&8W!]L:DP=PSYA>>3#*KTERR8: ,EP#NV.5.KUM#
M3R;G.B"(=[;5_<^=/60?"CKF+]0^HEV]Y'F)2;J?-4C9850BFGZ@R\=L/;&H
M9W3KM(I1B,O(6!3YN9/\FP(3T<$5KLQ$Y"Q:9@(HC/"\WU2#P$(+S;P\>WU:
MNC-:8MY*$-5!DTS"D_2_\!@;1CE)?I!F26Q@RE>6'_,V%!B8P6>D,*C7D!'J
M:O9VZL/,VVT(CXRML4_^P,4?*;X2TH'O@T.5! [J[K6WTXT:X0 =93A 2**O
MA=,BL[SLQ)WOR9(IT95"@@L*UB*9/^H%O]X!\ ::<RVWA9AS)JS$MG.$8KE'
MG$#5:_4-X^B'UK4<#=# 1=CB-WW3MXL_K_.E/V=28=4SJ21$16(96,\?R]-/
MY(ZWK3P#1<"1=_0=3O3&R-]%\9MF K\N-5*QONZ;,^/_8)43]V.[WQ[FS^*
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MC/"KI7\B5]MP8I1CNQS,,W.K_VO476ZW&JH><J_HTTX.6JD];LX1]W)+._V
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MSUV\BQY5JUX.4'[%"IC>"30"_SW$0I2@R,KF0F,^M/"^?%).*SX.WA:>U.
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MWR.K?P5Z!&#JMU^"WZ?K>4NP&%KR\7P7J=\NYR1Z0IS*7W@"S4)COH+V2G"
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MP9=D.]#Q- ZP"YU\0B+[KP*7^V?N,V.C)?@!Z2#.]\$; O+K&TC2WY.TBA+
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M?[%!^HMM*O-MB$B$R!NMB&Q B3@-38]LP.-M7^__^F?:G-*M3>H6$$< F5;
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M#&.*WD6U_Y4ESNJ^V+>C"B[X_D&;"#8UJ2N=4'E?,)_ )D&.;:X)$@)APK)
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M-46038]GBN1AIJ3(GZ$7A\]>MO[L;5::7?UDN*3RB3XPA,AT*JMV\J;U/*W
M 8JK+F0T88W$U(W,[1-XX,W4.J34AR@FO6E(IJ41EJ-T?-SX=+K1%E+]3V8,
M(3K]I-O$YIMPI(PCTHP@<J/.0E!3IEY#168#"#Y[#Y# H308/@>AS0O1AGK(
MR?JOPN+",CI&6\U5,:.O55%Q'V5S!YD_ P*R$!$ 5#L1=IR1$U78"WD,-E5%
MMF6!<BSL_=G'^0_+G<P/@6OZ@F^LHAZ=1_<J@$*E48W.!+I.<_0]DF)]_(Q@
MJF6UR.ZKH*5G-:,M H6+&BE44Z/1#$[E=';=CC.K YCR[@H<@&&;G<4]?T9;
MT$_1S%4BOOY3M=E:!HF5(#:3!75LTQNV. MT\U,W311G!QP ;O3X6H;6?#M!
M;]04<G6Y%4"=OO:\6UO5M,@CZC/A(RE723K Y:#639L)$TFFJ0+:C^,\V6YU
MQE>AI-^EE$?(E-M><$:=T)[U@Q!/O!2WH[X'@Q+M3NB!I9#OZTA5"[PLM,(&
MROPB**1N+F8_Q\7&CJ.G.^3W&XW134HMFNKW/PC+_0JN5S01BZ][UWHA>+9'
M-K*)5*$<#77Z43,*+ G<H%R 8KD:+@-^.3[$*A,'2]WEJ]$PR0D]YWU5:\2C
MD%G&XAA=68=;H-R=P!R=\?BW=R='70! NK GJQ[OG#^\-E/S[9TUG=<C8&)=
M%O-0]U&S&7LO:EY?GO7(?B@E%]013R;<67,1=D2$G6)D1KVK7=4D,?853QCO
M3N^M+MHE1Y0LJ]L0U<_RYC;83?1_YO"PW>Q0BA$E;I#VG3QEBO G1?/W27;9
MMS$C_V24[1%8BF:<1PYZQ*=/69S%B?J?VI2/QT._3#H184B1U-_FWX"HN]*M
M,YY%<OR>\XV3P^GDZ K.1'CPL@;0QJ@ ;+*S25)/V^<O3._L^>T^8E7O16$6
MP> ZF5)8)Z1"P1-4\, OB]'QK^ S9T4O0=)OI_!N8&3XBHSIZN+W\;9%IBB1
MGM$I@XR!:]%]X\,'WSN7("[UCDI+?\ ]/!;51PBP>WP!YS?WY HZM1W6>X#Y
M&^CQ)1QT"S#[G27 ,.2('E^%!V-9=^KF-,-KI&0<-.J@4M]Y#]>)*U6S7*:O
MR^ZQL?T@DTH'7';-G^\U-8RWT)8.K@#_+A/OEW*;.32%%*#LSLM2C^<>M8W4
M'=#$A;4,+]/$A>@3JWM8$$(<>M#)J(CMS@JPF$[-Z-R%[G@91FY-D\_X+Y/5
M=6>X%O=+4#-[7'0N6+VKN?<FS9]2I"W:T1<GYR9#29<ABG7TC0M+TE"UDZ*%
M0%I7!;,0V4,5V W;*DE@#0G='B/_N*] @3$X0XN0ST,9-&F=Z*VS45]*J=/M
M.J_H%@'83]J>2TG,YP6X+),J'?X5NMG&OFYH,UW 0K8Q-PXUZ'!L.>)?O\%5
M <?SFA'IOZ$OL8-T'J6[@R4$M-;I*M*H+?.%CF  _>NO]RO_@-EM M29*#".
M$QBI-2)=57/) >M %.]*O)4@C[80[LDAT^_'F9Z7CI8LW]]7]#-VS@/\?_BY
MC,7]S%QFQ2"(CK\U?&&RZ V0YML^#YG.-<J]&^MW2U.;)DRU0[Q]:0ZV]:1I
MO-_[6[6_\;B^8.D@I(;*"6,44-,][5;U*7,(M5&VIH9T ;9J,S6:B.>#W**^
M5>9;6F6-3)PHQ_6=AUI[^DF"\8$T]X'O:O(>[N$0;F_1'D%/[VV&]C%RM*+E
MUWRV'.A)R'==>)O,3;O'WIAG!VJ^9'.+WR:-433\&BBW6<L?0S>T'28MECLC
M374<^7UU M.^+.L_S=$8W6D1]S?27Y'D2$;@W25&_&"< L0D,)==V=_1)]L^
M>)Q-(H+.1)EJ(XDKW2Q!V=%O>4//DW0?OO])">'2N6E38;ROJ*C]?3MJFK/8
M?XPN)$.DANCGC(I Q$:#:9Q^)FM3 J>BH5-\V^_LHB6]7Z_>=SP\/ZNLC]7R
MV0Q6F.]E$3S63,%G\0/T<\:TV&07IPB;-VL;VO\U>TYCMHTSHH67!5Y?$\U?
M:59_TIH?-"TFZFJNWKC(EC;2+3L$ZG]F<(*O-;LFNK(>04?28VZAC8R-$/$Y
M8.WD<\]\;G\>UW'\.=[8AIL^A9;HN\2GOPOWEB<TQ8?%)6BW\2H9L:?^.'<O
M1SPA*^-P13+'-E$#8U:U@8XMJ7DF*5J%S1]?SP#*.#L&B;4P"U_UI]>GPYP.
M,?Q%B$(3TYWZ8V^QQ\:+[XGL[%Y /?>KQ!H_==W+;!2G95M2#?G%_%)&WDWQ
MX:.Y!AE%<1E(]PA>-%ALG:]UG9\:[=^K1L!+K]$"=6^(,"0!/OD]B /8R"NQ
M[.=0]'I" 1(YHT;< BYQS9BN''T@5<#A53/BR>W-=QKKQS%M[19?CMJ8[B O
MUSJV.>L&UQ:GZ'^M"(ELO>.[!<1''-5S3]^,OLLPFEXB&S\C*.9[9DP8&W40
M][6C[S2;1.C7&5,F+6/N"5SASD2I5;$;RQ>G_^20\"7?]+<?[6:32/[?=0:#
MPRAD%7>LO5'LYD88TD60#W'5/8M+!TR-03:H;>[BH.X_:P:&/4S'@'^T7M8U
MH%536[9PH2J1QT([#U^DUKDLS_4_:#S>H-<@)@)XXQ6R%<+^U:KB?[::BYU+
MUT2_<H<?_E,]4AW@/:54A-GYI^DO_/\J9/Q/0<J"V/\KSW"3Q;L%Q%W= J8Y
ML<D[757NRP0S_\\RRYT>W4T18M6>5E1ANAX\KB&O_^_J?/Y_2C^V'[T04U%V
M/.K:E^"'IW?[ZMUVNLXVXU;:GDN:V_?/-SK^S&7U\3];;CG7O=U^;?N;YQ_2
M8W[4?@Q^!"QXG+-\WW?HE6SO#O:>=#%^4^8%W2NKQ3YOD)YHQAC@H,"XG6E?
MAQ;G6;F(!?Q--8*_!5[_JG]SO[1X;<SKJ/E'O..YLJO2NA]&S^YVW7QY^1[/
M9$WI(PT[4S6,5=:Q/;Z\X(6I_HWKX1_>M]?(K[GY2NIZSYZ\TOG<O6ZQ48\N
M*28NCXS3^71<H%/926#SML=[S[%QKM^Z[?<LLQ[0"6$1?R?MD__C^8&_]X]_
M_J/5LEFQ3-FY%U_+*5_=\_KFNSW?K'T"[_IR]_;XSYMXP(-CMX7%K[E^Q5\7
MGQ;9PK %V*L4@6)%R<49;X\"^WA3M@3"5[R"!X3*C\1_+9-_;U^?&!/^.&[M
MZHRR71=Z8MJ5;-[>NO$Z\C_#AZ:7\7=F__LWB^'SG/[ GQ<GOK*W^A*/B"%Y
M) 5KAH*"M8>O?UWW_>%_AC]->:"3RH&MM-#5]A^:,^O!"BY?^C*[5DZLZX:!
M6^[Q8K'G$O^F,!9-@]Y5/\@Q\_^; %!+ P04    "  "@F%4<)J=DL!]   B
MO   $@   &EM9S0U-#DW.#@V7S(P+FIP9^R\!U146[8NO!$0)8ID! H%R4%R
MID0EB8!D)",@.4L.)2"@2! 0D(SD'"3GG$1RSCFG*F(!1=5?GNX^]YSN.]Y_
MWWO=[W_W'UV..4:5>^^Y]MIKSF]^WUQ[@)I"+0%WGLO(RP 8-P   _T/0,T"
M3X%;-V_BW,2^A8.#<_OV+5Q\4@)\/#Q\JKLD1*2TU" Z6FH:&GI&+F;Z!QP,
M-#0L0JP<CWCX^?E!S"(2PKSB7'S\O+^<8-R^?1L?#Y^2@("2]S[-?=[_Z0^J
M!2"^=:,**QH3XP%P@Q@#DQ@#U0& T/>)C?';!_CK!^,&)A;V39Q;MW'QT"=4
MW@%N8&!BWL#"Q,;&PD(?]4$?!["(L>_>YY&Z2:)BC// D937+_+;+88G9:UD
MJL-01K[73OZW<<DI**FH'S(QL["R\0L("@F+B#Y])BTC*R?_7$U=0U-+^Y6.
MB:G9&W,+2ROGMRZN;NX>G@'O X."/WP,B8K^$A,;]S4^(3TC,RL[)S<O_WMY
M1655=4UM75M[1V=7=T_OCY'1L?&)R:GIF>65U;7UC<VM[1W8T?')Z=DY_.+R
MU[PP $R,OWW^TWD1H^=U PL+$POGU[PP;KC].H$8"_L^S\V[4BHXQHXD#WC]
M;I$^B?Q6UGJ;@4\52O;::1B7G)%_^2'LU]1^F]E_;6+^_TLS^WUB_S&O&0 ?
M$P.]>)C$ !@XOV2/@7\T\_!8ZIL8/;#C/"B:')#Q?_(^<#U(ZJ3?$8R-4'3Q
MX?J69;B@[,B%!:T8H;!Y:QSE,U&A/AN0L&7&EJ<H=2KA'](!>U/*#\);W!'!
M6/FP1[73G>4!:6W>M]72;ABSKV3?WB^*?EU83=BC7[=&$OY%)M'!>>]N@66N
MKO/,5C8%WOE7EG/A-&'[NM:FH'+^FDO6+/]P.<R%:,]5L2 )Y\?=PR\(*4T?
M,4QMQ&4!HB&A/7ZE^L[;"6XZ@ MIVPXA'N!S.].2S)T+9VR(/4I%<< 2+U=X
MCF\[X:9DB/G7M%6GS5'Q(6UNQG<2_1B.)^JOGYFTYUU2.QK=E+_QCE9:=B/G
M?!)YF28:!;@P[SXN_LB233[;2T_D+,>H*:REMD> R9B>&!G>H(JCN=4.Y<=&
MW\Q=UB5AYJG17 R+["B** >);:%BOAJ32?&7%"!I'GU=,6W0MWXN]_[?;O7=
M4EW EJ*8JXQS=Q'Z/XY*0-Y/FD?%E2V7K_DY=#/?]SNV/GS5,B,AL3L6$T 4
MXX=PUF(1SEQ495"1KZ@C2H]*&"@X_TJ4UREELI4=A,^;2;QGR1>>_:[FDHV'
MPW1)+AB)K9 TQ!Z1WG!O&5F2-X=X:>T5]OS(0DCA*H_9U8 O_':G5ZUP$9O:
MV_G0;0T-LJ$=-C /7]ANJF);<L+/,1?2+A>IXT<@M1#,FU=HW\Z/T4.6BIN;
MY%E)4M17CCSD,6A:Y.SHXA6ANJAW5&2OQU7ZL2DE[6A(^#8,(C-B]WKR0,=C
M0;]'9ZT_\#(E9AI';]6!>91?_M4T+F]=_9 /Z2"/D.U"[4D_-W\(K?1#4J!"
MZYV^-74:_ >G3(XG9W,%F7>DPQ6/7]?<*MEAYFK"2)80GD>\6GX.Y/Z8NJ^-
M1_?79O2-IK#SJ8RI">7]MJB*N\GUDY+Q:5SRTH*12=P+]$2JCNB[_LJHN=5R
M3<!*CQ\=472C9H<U<2ST@/*T_T&-?5W+-:$%U4/2&)ICQCL-WQ^I2W-TG-UX
MYWGW+E]HQ$!L@U?+91@*"/-]L+CKI*=4YY(K^>+&DSN;@5CF5-T"0IT@D)7.
MFSQ0\(D6CU(/_DANW]UY,A]PZO/9J28[I6RZ>2=GNFII[^-\2\@=!/?KA/6!
M/.=UJ.XU2V^Y!&].R"DXV.!17&<*K?6GT@(/&Z1>ISM!R_UW^Y\MDBG(?B8/
MJ15G<6D6#@R$0&WMN^@88=TALS+0N4-[N\(^4.P57N#.WGP^B[CL"@H(]KU?
M73YIE[(Q\H+\%>,QQHNE4I,!::WQ==O3/85.62_+N?,=MB\SR5G%B=??'!UI
M!.LQXVE+T^B2)C]Y/X.G"VA/*D(1Y\2/B^IT,TWNB=!^"7=$[(J^S1(RM52M
M,"H>=$VO.0RB$*+PQ2A-V? PCTEXT<L>:W*<DGFL!PFK2*6;=\_?T:=6:#7Z
MT608QZ,QZ,L2)M;;68^57TG&6.Q%0'9L5YIZAQ^/QRUO<6&V38^>:>W(!_S\
M1#E@=#=NQN44F>?H*-!06& W*L*X*M+EI1G]K8_.>N[#:Y&L/FNZ9&DF:XK.
MA$NX>;N69P&]Z\?'SY@/>81!08I&,?.1]9;LY78A%YN*=&#X.SO[?0$1DQ#!
M[CZ10.?K(0I:<%L%@F"UR.LY3,^79M+,8]7#.V CJ4%YZN! LK*^O2(Y)7=3
M^\O,J(Q7,MDF"B!!. H%OMTJXN"Y_N9*."E^H3!?MKMMX&0CR2"5C@+:E*^S
M7-:^W/UL=]LH!UY%!W[^5<5)RZX]V87"M-B'0-H13( PX_[T5H3Z^/7"3*G\
M<R@E<;M)]5,#CV)X7\<"#\PF@3DXQ\N"7#-<(*R*?+;UC5W-X,DWE>CH3R/M
M,>ZY>9QV7OUDQY6G*""\B=;*X=[\$_E8PWC-5Z&]] >$GEIUEI[K55G+?;:F
MWUOM.1YH<LTQ4XE(CN6K.L@??-V>4+/5Z:>NT/J$> K/P1[_DJ <7,S(L7E>
M'1E5 YP\$4%8Y\ EO%Q\EGK-ZNM25J1<5[W1B&UKP&L10R5#L\=@P)OZ0 *3
M0;AG,-O2NA?)II@+=S88$5<P<18.%8KCOR$S-;49F>0DC& ??5L/=]%GFT#.
M;;!_F)"^)$Z(PY-6J%7)\Q ^XQR6)KOI)TWZ$N-?;)BF80_#,ESPPW%+)5I+
M$O="4[#AQ0Q.SU3FODA4RUR#\2,OM$9D&A16@SZMZT]91W*)MZX]7WCOU'PE
MM*Y/:>DUP)W7%Q)1EUU'@12V-N:?)7C W)O<< &([X/<CD40!?9MQ)U+D, ,
ME5KEI#:[>:]:XQB0GI'6EZ?B2#"L*=INYPF'XV.OY3M.RJNI XTE*YSOX\!$
MIRR<6M=Z4FTEYUI1X/LZZGHA_*D_!Q*=G?+K+3SH8DQ6("%UE6/E.S?9M3]P
MUT;$QF_E9S2Q<L=U+.*Z[+I<>2E:,P_D%WKGJ8.^DDETR6[J<[<2&/S LU56
M2K!8J?4@5R=TT#/!@>6GWJO\=*^O2+!M1GLCX<[A_:?U;QS]X$NP?1W]*V5S
M6_R]F(>J2-BXM]PXA2I<)R$F(^;5#+-JYIJY",AOI489V]VM@XY_F&[.FG=Z
MV[58G8695V1M<[+HK2_3]]CV)<7 BHN[W+%RA[VOP4]U%K$?HX#WO'8X0IQ)
MFI9':K9N_-8IZ<IEF\A[C>,-1# Z3N+B%#GJ==O,3XY3.]T6-G3)SOKGG:GW
M]."N XN*H^A"H7]CD.TT#"?GF\@U@<,""PJ(6K;?OOYFBP*^X=;"F@8L&F1-
M/'N_FKU+D_B>D[.KN9(E7#U.W,\RFJ!/19X,+>](F(A*^'F9IM"KUA\N$O\I
M<I9Y#!8R"C=>U5<ENI-*8.W<R\(QW#4JN!$NO90GX5,P4D%T9UO+@**\,?P,
MVX]S2(3K9MO-6PS5SV%@ I[))IZ'\Y]_,IT>H'EG'T$2\D&6D(J\HHW:\\1/
M >.Q2 XK"D'PG1$+,Z/7X:QDSJWTF",5=DW4\!S]$:7R7&OLPVGQM2HG7P.^
M"D]0EJFWH2-%!_>CXJ6R9W*GE#1:U;/6EVI;M_.R]C@M2H.Y:!R [=.S=#6'
M'#IUXI!D^6.)"$&X]"K[5<%%@UC^SV/>^^YT3V/U<_ S4]M!8<ZI=T_%^H56
MWL>1CY2Z>^=(]\XF9U0*+;^U]8$)ZGYU7B<2?>V(>%B#?-M,_ 7<F1;*F[7<
M<S;#-J9:>'W+*3KC6*@"')3"5#O)O^^F/?:E.J%<D=CU&!AP3$F9*I#DA&Z&
M>VNL9%@IZ%@DGG5H.E:P@#R^T$193WI&M#7<O'HU*0Y9[1Z:5/.Z1QXSS*#V
MCDQJ+7PSI"LI2U5)/\SJR:,0G9TW\,3V211 <(JG4"2F>U?Q/N.'1/Q,B+LG
MS631PLRB^_ERY??9.5EK%]</^PSF=K(&*=D-J2O< 16#MZ1RVFV]!,;79G]F
MRZRQ=$D:S"MZ=@>>)G+B+=LEYR[^R,-Z27-9UKODF5!7U\:K&RTK_X/[F8?A
M1U^Z'5^RD82KES#:XL5ZFN>&;\.V*NV7R2/R=R19@[5XY3@XSNW=3()?9SV)
M,*A%L//JSI9\3.$E@G@1!(8XB6\_*>393.M=#_,J_@@.?CO+;LNMT%PZ]8[1
ML=LA\.LUQMIH@8@,S??YD"\,K,><D:WN@X_1I5;\)2?#O'6Z_>P]CG9+/:>!
MM+5)DI4(? .$:%UY0^G$^&9DN'?VS(ZL>/C21J5 LIL>K#EBL1VZPVUL^N91
MH7'I(QS&RY1*V15F_XI%G*DI66S$I%9YN?WQ/?AC4'MT.&)<K<Z*.X^,D[WW
M[0X:U<NXJJ%U^DHJ51YO+_#V5S=PG617#7B6%)3ON(<<[<J.5HK8TD=ZS\8'
MT 32 $0&\C1:>7#3 *CV*@BV*G1DM>9[$^.Z)#_)>2WB^I;ZT_G0F0-+L.]+
MY;(!]P"E"4DJ>,+\_BDK(T>30Z0\1I>OF?%B]:;AL^U)0]M16ZZ0?;ZVJ-51
MIX"(B0;=U6I$X-O!RR44\%.K%.Z- CJ%LE(OG8-1P&.R9(@G<31_6JTY2T8J
M/'L?U'XM%1E2RNJ?@W.(>]2,:6% #PN/EPC5::CRU*^/6B.)IZWW"CGE#LE!
M<AZD28RB@"=D 5!A2*> -V1[]5(MATN'2Z$F7S:A3MF:ACS9N<!; AY E\"U
MH/ULF_3#[6DVGA;ARX03%! B*1#7-J.N&0N"H0"/&H[4XUY9F(^/9,PFF!BR
M5M2* O1MFT]$)^#;UFP[,_K3.+WN"8^\3&E2AT+&N_B2[O&J.KP?>3 J26JM
M<Q!)5^911-I8$]$?*D9N0QQ9VZBH!W=9\=&Q?7[5.M/?WM!/$_F4,2PVK$5$
M[YRR7VO$ETS;J@Z[J0#TB3G\]@/"Q7K*T-48L)!=C-"[!G1BPER*!N)6:NU+
M./NJIV>&LI?];W-XJ;!*YS$='MUZ(M^991_?YA[7[D8-^A0MFP)5Y@BC8]H,
MV_>;'&D\;$DAJX.FQ#E:NGAR+;QJ:%D5Q\<(]XU90P%W>PP_">YU6P78R(N;
M;.X:7).6#=1GN#CNY A0?NQM8_KJ+JW^>;8VK#)I%(O+Y,FLK)K?2)/#J'ET
M-Y*^1ID8'K''HO[=WBA7R;%2:DEK^)ROW=::XYR@BG*L/(DDD-:=;$45SM#6
MQ#_.M09-J6*(]W6MBF*ZW;N3^>[Q6:<,;68R\JCL=KWN@8 W\[(A)=RMX\,9
M!6S!PNP=ASDVX],Y+O<'E4V,4_!1K5K_;JFPZ!<SXM,FR2K)']>(D_8Q0<D>
MR?76BX0-MO8F9TL'IJ'/(^5T1(C#'TFA  GV''C<RO4;>]*<X).KG+)J#+(>
M,85RSU0E::ME9A6!-Z;YTFJ6\Y0+K' /MZ5K3A?'8@9]=A:60HT!K[P=1X,,
M:'N'5@H#-+W/%VDV=I<RX87/DBC)8<CQ()6W:"FTY/U:<^VX>?W8J_&7?+98
MT0,WE:1=(%ARZ *FNAN) D#,%ZH%EJH;GN%1C@5]5<$DT$WD\W84T"AT6ERP
M4A)64F3_&CH1>DCV\]N+49DIXYHE>HG&P9%:PV#PD2;H>KNY2 N>9?H:'LT\
MDYP1M";3]IBO4ID*](*ZFHQMYNR^?#[7?']BR7O/]:"HRT+15ELE_F-\.3G&
M<#F"77WNML5[\]:>TNNQ:?N.'B:@K]]=+$FJ?)3<!SU;&^#*6=.6BGES[C]<
MRF\W]Q_Y87EYSTWDM"N"VCTUUI%Y6>[ABM)W%TDR="I\=4Y[3R7'2;Z8X;A!
M(AU",P3,[.-;I^;[5A=)E"D^-#RSH:?_LK"L1K_$@O/.NAS:_1YAO+QXE[%.
M'^%6=]^!*JR%E<WMPKF5KC+9<:GY-GSR5;T][NYK=K]XN@6YK_=%=FI;,;?8
M$V9+$$(P;W+_:QW%'OW7GRN<&&B, C3W!?I =5W6<U:J5X-9NQ'PM%\H(!T9
MKVW3BH-&@=T,'QC[ZKUWPA(%$?!LR,K"CB&4Z/J6%ADX3.^P ,J'N13Z76%Y
M]IBA/-)!Q"2EJV&AR\<.\H%"4$=ZMM/%6?QS0>PR:5+T?DN)#)P6!3Q81P'7
MWD1KUF%0X<$N\AX4$'NL96J3(^BHH"WEQ@ K":B$8./I:UOSZ<FS[UL&/'(Q
M[A$I,8425DHV+_41/-F-GWY%V]R@$1(-7Q7H0Z#Y1J3,[.2^@D[J+322X*XJ
MHX#B:,A65V&^I!6;LE>BFEY,DN:$6 )?OS.2?](.G=]>13HC6,E+[%^<'K<:
M\5U.@-XU0"@^G!3$5^I^4M"MR68P=LAX([P[V6B4U]L=;V.W(ZT0<^ 1.(F(
M10]@3(I\TLBPHE$=6OG0?[ ]4G2:C,GC=;+*U.;!Z0"/@;4)F[4A];>42=YG
M,T'7?=?C2ZDY9*/>VK"@$ML2Z;3M26YS\DY>4=JL/J]+HTG3E;F5N&>.3^2?
M*)Z^ 7V4I)Z'&SX3[=MU3.RIBJ9\J+VVNB[AQ&?P"9K8X;9 #QT+>/FY7Z(P
MQ3#!\_MJZ&4*@2,=,]S19'D09]ZJ+JA$8/X";SW/-E^[% <3+(0U<=[2?'%C
M)T#\8A<1QA:1$&VOFL>ED\=))!']<L(8'NQ#&,F?:I.R(?>@SV>^.[=H\2Y"
M!(837-$% R8RZVO?V25'?A4-7Z.KH;5F4&RN&I7D]BG>CZ%7.,??'W92%MA+
MO>/R"<\08R?Q@,&^8K:"!]M(H1P?WW-<_<N7E:@'=T(SF)E4X88KLQ$D[I[/
M&NUYS_K?VUUL2(4&G)X6/T$!K4TBL. /&\C9KU-3B)_O7M )4"UAJTTNQ"V5
M1@V^F*P4E+%(-Z"XZN!2 K-U#B?JPK-6=#_I[K_1M3;5C.M[VO*R!2B CQT=
MC46'?R3=[%=BTZEZV?Q)#6ZV4O-@M-(E64[+^)YW#3/V*T_SB(E&DQ7]447H
M@%=NW_TOSU9QL# ##,"KAX3;"Y0P[.)D8^>'[;=B-BQ!COC:L/V6;8,R&+"Y
M3!TY>&"T?4*JR+3,M:Q8D5U/Y[44AM,AR3>271ZA'3OXHM*Y'FM#UL[!QZHI
MVJ7 &PP/)H\YJXXBJN#@E8W^+FWRSG&WWVT1BP<%W,I:O/9.7==3CH"LE:)K
MFR'YXB5E=N:ZB/2>@G^8\&#>":=C,ZD+TZ@W9JZH*?^5[9&8O7#QCX:K50X;
M)$9,'+/9SV=^VPEKF7&BLK::XX(_4  VARH1CH(K3K^S0P<*:/'5V2]&2&08
M+'"N#\29"XQ\[N/_G.<@U;-)5:RVM!?B2Z>3*UXX$H "?!+L.Q;I(&W<.46!
MGS#SYO)F%H][(8VG)P517W8JJOD^O6=E.N/UY8:W#1 \4":<%>WWD!2'YCQ@
MW TX\&&#!-<)3 8W42\N_!34T\^88XO\43S'Y5LSN*KGUCZ/^:R^AOK\8Z7N
MD\[S3EN.=N?J\R2Z!?_&PGG+R[-H-^RP.:%;)CRI#]NQ>[8[+=7.'=4GYE]L
M+SBYW#L1MUZR>8YD'J,)_;J/03=MHQG1[3[6ER$IZ1/%<FFJR=W&#J]0OJ?_
M:E&TY?C)4/57UT 7D=;!D1)OVW';DDI%WA\CIO'+83_]^>JQ(OVZ?2L+E'<I
M9.1+"J8.."KLX2^:R"QCB43>*>*2?\;_C"'0B9"!ND8O<]_4Z38F?^/EMZ$'
MYD*X2017>C:_+[SW AH;]V:5@ 8O\G3S<I($U@+IY#9'+QI9(&NSM5G9L [>
MM+/$GBV"&2UZW'(@C<S((.O*3D=#7/!:\C8*.)1':Z"$69AKSG7D,J?J%2._
MPR-5,9X+*41/87:)2L9SN['1(W'G3HIJ$+$DX^Q65;A.VX(RI^.Y@^15:A_9
M06QLU8S9>\TAMD[[&]@J0P![M^_-[2:7L[R"OI\?"NZFZG?$HC$(HE'A=<VT
M,R*(.RJCHGV"%3)17ZY^R2 NVJ"O5*B\[R.&A.PW'^Z@@##)E8D^S?*C V/_
M@VGHD[I@S?.3$C(4$ @J,@'-G*4FHK]Z9B=%PI^V:L)V^ J84FW(7U%D&+D.
M%IFS2#_L.>B_+R)V7/! H3Z,J%6'\9Q.L3$P@0?"Q8A+.VB4D2=<0@[UJ9P,
M0[)4E:^358= *G[(]0 .!:?TOC&I^;MNJ7?%M2/G#3I-C#(O7IO/1,K.7965
M6$ ;4DB@R-2;,5E6FC8=1\_R#;0D!AOM?VS+]B<A?E1<,7IH=<4G*-][$NH>
M/JWAXR>"K-S7*:IC#C@L@@KBW2:AFR5P/^S:90[NF-"J5XZ1J-%?W,<</2J1
M&_/6R%: ;O@\W?_L>]F17_)5B,*T1<]E0)$U>QF/D(!U8#,)091(QSAF6_;%
MZW4'Z WFY>1WW2U1KF3WR;,9LYC*+L+MU8\JI9YK$5D>H)8^*L9Q 46Y8N('
MVLX[VILHP"P+GK=Z85><"3V(9M5^N5<7HX17?2YU@JYLEV,[4@,%H=+/'7.D
M!<V]E6 /W-L[7#UE0ILM%=QX,G(0E9$U8CZR]IZG@=#BPV"8N^D <=//TH9\
ML5!3/W3Z]-]K0U)4*USMFR@G:D9Z2#I%WI((;LXK4:NN]3^:9ZZ.>1C8I3&T
M1JRBH_F<9YI:)23:*78/=DCMCB<+C6B?C:M\*C$KYU><!=12;4F <;<D;Z.
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M*AJ=ZV655R]K/LRNNB4VV'87>ZK.&N@:=)A6UH2\Q<%.=V@!M;V[#5G=(<J
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M8MK?T+.I](LM- 6S4[.YPQ4%0"LJ!R_.2M%*%EU_.M&@C:> 5N"IUD179R@
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M%X*+EN-Z=>C,J4*'/'E-&0IHO4C^2K1*.X[FY?</?D^QIVC)3N>,3@U!I(;
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M>&+<-LTWOU 4L*A=;*A5!2./=S8K5,[DJD33KH=!WVR-'+(2L?5NBI=0BJ,
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M4NG1C0V_89+4/\&TWW']I_;BWSZ5CZ0MF7F_21WO5P&0?U56?#19L"W\;/1
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MU58]BVQG,:;.8F4K7JJMC\9N]!\F?2:5IY$[8.QT#C41:1003BA  %!"Z0$
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MV&608IL3K<@L<$1Z]BX9X[('BN>I\Q$>-[0MP@%D=/.\?(B%5FG#2G.<I\/
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M*AR2!\@[VEWFI!3,TOP/8*2V9POJF-*!%/"2#;,A58;+(8G+E55+\,E"P%O
M?;=(9B5P!]0Q\L7#+U:$W>7OD;K$5M 2K%8I/DE@2@%N4 =3A-69KW.0V2:P
MUR1G#1^=1G5?3NZWN:*H#'#SZ*32]I<=!JF+K[XY?*V>M'=/C+<1-F+9X2N<
M3..)X-A8$F--+HL)K4![47/[/>YA0CX J@N JOL&;XB.=&0QDFVRX$GH&B(I
MU6.M]ASB#]+\^*4_E#1%/#G'>.7A"FC5FG!D$BL3)0W:)N=RZ:ML)NCM+OW2
M-TT4N\)MNP*;_)8;[,&=9\,1BU$WY(]I#DK"_93O^#[T/Q-]\%)((L-0(9Z,
M$50[)4'63:R\H\_8]900I=N)G1!-0 @3#JBXYQ97.,LRU>>$4/8DT+ULBOG5
M/%_M$\U/#!'>8_'F.7/U%+*1+] F0*]?T4YN.:"@):"OA4%V*5>]-UP-TSWH
MFN>W62>V=YYX=QF Q6ES6ZA:JB=2[=L6I=KG)9ZQ'^EBM_J%,AA4OQ\_V%X=
M#=.X@LF.$)_W46V(T@:JN=\Z0IE*YE;E@2BJ(%AGF3:1\,)3@:!9175\0R$,
MF9LSN,VIF8/#&E/76<>0E*@54^HN;AU*YG/?Z\(^%WN+B+?)+@4Q,?I"2W2'
M'5+65CO&$K*?G26+W4X=2(P%J?*G!%&:R12?6"+DLEN%<FQ_;9[WCBV[FT5J
MX!.+J )!.*&'M%PN_)"7LT)2'9*9&2:&%^G[.Y04W'">,,Y$6<VK4VWTR8/C
M<0PKQ+@GP]66*D?4BD\=I0=S6^>(L'BA0P23U>;;\5 G\Z)D$<=>1QI)Q[ZO
MDX=-]XY$VT;'P-R\ G<)K!ZAWFJ_;@4^EGW"03HY4;%%0PN>Q#7=)L7X_&!;
MB"@WW8.A NVN$7Y,SO.MA>5W"R K"\*M$C6L-=U@RU4/CB/BZ *#+)4QC5GU
MQL+GGR+T/L:083_ U+*?>T"9^D#EU/?H%H!!PV=B\C'3WU(,9&"H"^?YL#8V
M$=U9OLN5:F* EK2240 E?RN4<BH?XZ9_#39G3%I[^A%FQ43JV(L]A_CRGMDZ
M=T0;[VR2\+<3"2'/]3RUNP5L>T"(+1)6 Q[V+"%9(GXDO:RMVA3"!+@W$66Y
MF[D;I8#+G=KF5)FWS%IR;E3NW^QL':9H&%;#NK4K"E&13^F9*>-&9KI/9H=H
M G;%\W..ITQ%60W1#<FP>QA\7\L9W4610WM.G4!RF+;X[:5J?=&^>>044R95
M\UUI()PKHC%E*N+Z#-(@<]=1K?<V<-D<>T_<L@^K<@?M@[_/7$2[L:W&PP%M
MB-\4_S8FJXP259VO_X<E;,3A)508<=0JCO#"X#CR67?NTL:3M5,<BZ>B'P%2
MNGMUEM1II67^DD/;6V:?T55;2H5QEWRE/?OZ80O5@,V/N1UFR:>?ZS?X"-HA
MB[YA+)IN8+2E(-3/&'A'D6/H(&'W,#;V\<>KS,B=^6R&]L0MB5D[:T3XKXW)
MR^>)V%1K<63KIQ[C7N6I0.?3#S-Z[<4@N_0::'G'!5)G+A*0FL@%7.[*R &:
MP +T].>](_"5;/BP^6,C1AY<*2D!!XI/"NC<]\*#Z:T7[TH8P%5+83JJ"@H*
M$ZX?6.U+:13V4D4'G %<L+=I\7JRW )"TJ#%I)!  LH)+MM0!?N/R:%S^3Y4
M;(![NY^<L'2D]_QB\S9HG3AJ@$P6*0B*#\.G='(^>OLOPB=_54M J_D0Q@T4
M#3R=\.Q"0,V=5TP^2.VGCO!9)L]HK/+IIZ4 %[!:G']"%L6_4M!NQ_\?4$L#
M!!0    (  *"852,0\WV/2,! '-K 0 1    :6UG-#4T.3<X.#9?,RYJ<&?L
M? 50'%NS_\"BP0GN"9I@P=U"@. 67(/#LKA[(+@%") L&@AN(<'=-;@L[JZ+
M$_3/O>_[WKOWDV=5_ZI7K]YL==7,SJ_[=/><TZ=[YLS<3]TO ;ARTK+2  (B
M " \_(#[64 20$-!045!1D-%145'1WN$28"%B8&!28K_&(> DHR:BI*,@H*&
MCHV1YBD++04%$]\SEA<<W-S<U(P"(OR<PFQ<W)R_"4% 1T?'Q, DP<(BX7Q"
M\83SO[S=MP!X:(A?0,L@A*< (AX"" _AO@.@?M 3&>'W#?C+AH (0D)&045#
M?X3Q *C$!1 10"!$)! R,A+2PUG?A_, $AXR_A,."93'JF]1GSH2<+Z+^X)&
M^[*\E5!M!$['9>(4B/Z(B)B$E(R>@9'IV7-N'EX^?@%!R5=2TC*O9>74WVAH
M:FGKZ)J:F5M86EG;.+NXNKE[>'H%O0\."0T+CXA/^)B8E/SI,S0K^VM.;EY^
M0>'W'Q655=4UM75M[1V=7=T]O7VC8^,3D["IZ9GEE=6U]8W-K>V=H^.3T[/S
MB\M?5[_9A0" $/ZZ_4.[\![L0D1" B&A_F87 J+[;P \).0G'"CX$JJH;QT?
M/^5\AT;P,NY+>2LZ+9<:G-#$:>01$1WW,OW1;Z;];ME_SK# _Y9E_VK8O]DU
M V""$!XN'@@/$ ,NKIBR A[]9PB+0 7!D/GH<7<3_;"/M7/>=EU@NTV<=%\(
MDBU^K7 <]!SZJW]E\^8C>/%J%><NR(#$JD#IYV9';Q?Q*S%XI8_E/2!A?@^T
M:#=?0L66;2Z'[@+[[X& <O\CGJX1@[NN#-.@F:'::?^VB:.,6^3D>P#!Y!Y8
ML;H'@HM6Q:XPV.\0.^^!#ABY%%57AO'YCP,WH_](J$QYWI1(\75:\@VK$>D]
M,*SC#R=BOV.(O=1MXKH',K_? TLL1C>*CA6J>];G.&#1S0=)&%I=_J=$1C?(
MD?= >/8=45G4/;#%TGR)07P//-:'$'B3^?ZO4E.VUK]!3% D4;1UWW)N[Q[X
MDW+<?\,.CD*B>N_G8J<Z$9 ]K;XG9BVZ:?D?Z6),<\J=&30<\7L3C'-[S?]^
M"]%9&0_N,)ST'>S_&TDR?W9/S<RS_VW7XG^$FEL+9)>)*P.2G8**B9.Y9?:.
M[A1.C-.KY!^_(9FQ2?DB&#WWX+N3\<6X:UY^:#C85TM?.[^+4U/&CDA)U9UY
MZA[H3O67O-E-/I*NS+>^@DJ"17M^2H1-X0B(9L_415)?'L=N^:<Y4G'? Q_&
M_<]:_+D,B2!J;^ '*FZ690'O+0VDY;8*[@%TZ?)[0,ST[K;L4O5/1YHBA,?-
M!AW^0B+W0*'*W1M;_S;58O^AAW:;P7<$?SP@C)6B_@V(\P![];\<)BU3@D$:
MYG7RXJH$9UVZ^X:>K/OF-O;ZO'E9Y@_[VK^R8DM-Q-)")ZS\G_.*+3--BFWN
M^2]6W@./_G30G94,<Z0>;-_Y*)9(3@W_"*8^.1<[G'GHKW\Z,!U1WJV)W7Q[
M)D?=$QU[*<<3^^N:^F+?O^V/^^5;.6=S,B??KG)PUOZY8J>J?P7].]J?JE\=
MT/Z:\E4+/<XVO<./-KWSZ[Z]-H)G_V&_V(OI7T&T_P?Z3X/2_C'HF:\[WLV>
M:('D+]6I2U/=<1XLC2]U&3XF3Z>F4 6H NO)3NX!Y'N@Q[%Y-\B?P_"=D=;'
M-XD*?-SS\]-+%@2KCPXX-"6D"+1R'9$)5,7_2^2S>N1\)\=S>.L8^A (R[*+
M-JDC,XY5R_QWH\2NL%R6Q<*<39I#'$Y5I;QDH 2J4L"_1X)B9P5W\#O74\:P
M!BGV$.XTFAD/6QL+#RW/5V*,?2($L"''>Z!$^2+TI,SSJ"SZ3 S-FHSQW$7S
M.^DRPLVI:133=B!S,F[IZ-Q.>T4"Y',33PBLPPA3SZAV9/"S/[I:6 M*JS''
MU-)F#4J5O6LW'!98H9=B@. JP!"M$8>[[C'HH6XHM1)+!4YG?F?<',^T/[[9
M^TXNFZ^@E^[.=0=Z#T16XJ!=$DO4CF55QZU+23\NH"5W[D(K7E=2E6,9Y8J$
M9%4UG]L3^W V31Q6T.;,SQ0)ZR6CTE+$(+0..<Y\%_8W@U&!X#Z\WYCUE<H+
M"YF0I[HJ>SR25Q@:5R(YP)YT''J6K(1UA#AGO0SUAX2]OCC!#>AL*6C0<X;P
MY=CKG[3ZV%D9+ 65CL[2[N5][&T&+M^[+F84W!7J@XOTX]A+.:IJ&B65ZT;+
M-LH;PSH=T6>VO*GM=<^%4O:I.^I^$C71PKL*<L'?]R.$(IWD&3R0^)=P\GDV
MJ02'E4.%55G#F^+AMEHZ]+8UJ#^H#9EU>>C6K4DUWK^Q?PS-BF#.W/R/TD[>
M&_)[@+8I^!XP@C],6"^;BLH2A?_N+S'2(]KAUAN6,M-[@$KU%N>DE+8KXY@L
M]JX&9P-<_3![Q#+=A?Z"X:TJ_\*2N0?T44]X3J:'KHM$BJMOERG6"52-*'S9
M5;(BF(!_0"1NI=_/'JO!?;28BC9:I&\P759OF!-*4]J<T34/%9T[>A-183<K
M]<?G.7RR9>%Z&XZFZJH:1$?N=".C(F+M6H)!F98?XZBDG:?\:HLO&SA\65X?
MRR(Q*-?%-Y%,-A71";K,*"77>#IR-F1?W7D6^C%6-R;H1V?KD&JSQVN5=_.7
MO:Q\9/.(U2BI;Z$^E7MGW DBY QV7S--8]OFH?\6]U*A&R2"T^3++'ZI=J.X
M5E'5=P^T)U\O2D1-#N9OW]9_I<6U(SY<+9/+*1*B)M.[Z0[,]'8M7L .YF%D
M=94_Y-$N'*MFKHJ^[19S?.L,\;%=X+1  HH&G;=U)=M@:Z8_J_'C,IAZ3_RT
M2^I#HH5=T1- '&^==V=^T%<UWP/OVQUT^$BKF=VF,XP4U*X2F63G^0[UAOWU
MBKB+1T<W--(3G#W])N6K!)(%\"E,"5T\-&\.R/=O.C?[<7Z3>+G >/3#TX-.
M,K2[Q')&S[ L6N>S6=>QSM#+FKLWDX\^JBD:'E?V>M25S OIZ'>.G8)+Y%:T
M::?BI?K1T4G.M]7TK?C<#@F\E^-U]*QB>'M1%T?K%%GC&E0+/PWU5SB).&J3
M:63M4#WU6(]K8?O9J1WH3Q9NO"TE_<R@:@3\6$W-:9K><;6MNEA'$RS]$?-3
M1P;?&$FA)E2AVDDNQ(K&*H9$X1I<.IJ#43*GVYKWBZ/[PPFO/%\>P[>ED5G-
M(\KAM]=AZS^C;YGE:LCDX\:T()6F@AYUT;**,WUKQ%0D#=7?X_>&;$>>'M!3
MI,;:/2<W0#S8F+"3;T52O-"UG(4.'U'ECD'&]K)<*D*#WM-P4 ]K%- $R8T6
M?]7C;4Q2>6%F\C)>1%#M*@=55X[Y=8FOS%G$T=<4K^J\+T&^V?/6)YT4K3B?
MQ&74$QE*Q8+M1R8,]<PQ134M6X;RY*:.I%>ID@Q>EG\PP^XJO*Q-V;_R.J !
MT#;G5-617Z:DV)Q7K^!V:D(CE&#-2\8V9)"NSXYK<PCQG(]2 Y_GN%)QK._%
M.E-OCM9ZG91_S)8KBG(3@E=2RLFIS3%E1:SS_;.A*LC^Q[G T'^I^1<VWZV#
M_0;S,/.>D]&%QLY0RL][8($ZZP'=:#KTGZHZ_T#X34Z7M?< /=G%74W[0YH+
M&VDL:FEBVA(<>!C?=@<LIRF[8;HD ?'D[JYT[,+O(K;:*O+<G$T2'+X++T3
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M25?OXO9-JH-O/CI]F04AK98 [IT37M^HU>7C(H[FU;0K8W%W,F;J'F8J"8A
MX#R+NR?'\Z.I,YX2TR*;.O_ LV^LE>1TU69Z#..XX7@4JP6[$<#^C4R1:-SR
M]>RU(T6">$HB!=SS,,9F/[C=P'H2A@U8F\B28 ?$04^BW5MF_%*6=M.4)@^V
MV14093>LPXE)6Y^\XV\M'=O'F_%@$UBO!9O)$S*8Z5?XTZQA;P3P-G0,\K'Y
M<DFX4FKC%)3AC'-/LW)W3!97B,@M>$Q35@K-9M'1??M5!8IQOH(9^6>UKU!3
M=2.OC6$XYQ3UQ;U6'_@5BA0S_U#! *<TK2$2J-LZ=>>Y,YK!OKY ]'IU^-<W
MSJVT,,)V/>X%PN]'D*0,X<"%7E-O55JBX^H81ZA%T1(8@QUE;F=XP8 M:[+)
M%H;%\=0V*O%MJO$PZI=M=V7?'%V#GL(R[N=[Q)ETEK$V%09:@2V^BI8>_G=2
M WS4)_O4=X',@S?JV8/"LIZ>)5:"(>7FM#C?92VY+ A/G^-0JXM3!9>!.;9T
M=1KCN9@6\@F5.&4[K0\-ZJLQO38CCM-,*-FU+CUMMQW=76P/WHO/FYM%.I)*
MG[6T#%AY9"B,?<E0'#:NG&!?#D%YFSLK^QY("'4?]%I#2!]'6%S0)V%A8Z.=
M&:"PW9W#1_$L]*.>H-8<9K'?Q.MF_2DQK0+'J0('P%.U!%T/PRJJ*^+;YEE\
MQG]P?7;#%]QDC'\.(6\E(BL+@O P%]5G^[#V2_!__JBW2@<@=!,@3.]<-5SY
M_<B>EJ* 4)Z6QG-9/@>&"+_I//2[,Y[-I.2Q'2/X^[EY@7B+) W+N[L%KBLM
M(5=NW8V2?/U=*FJ8*R29G0++LKXO_,TJ1A L"@J<^P1R/H_HS?>WE267L>,^
M0F-F.'R(5"]%.*!M<,J!FQD%^*+NHOBWGYHXU4]T,"WC4L^ZY8J\[P':JO)[
MP-A"K"] 2'&[9:%61"!/*ZYS6>@M_(K5>Y]/YDT@.R]IPT:',=\\B!]4XI7T
MF5GYZ_3/378ZM)^^LBI6B!-_^S#5(0-76*_ 2HN(2)"SZR*9U$(SUK]_%K0+
M/0@'E2F=K=BO8G&RAR?7-15:QB_,<1/UDJ%LM^[(."BOBE-]7FK&I<;WL,/8
M=KO--&=X]((/F^MR<J)SOC+5SWR@0R77L4X+C>L2EG###2L>ZZQ+3[,:Q6#N
MMH8D=CV*&T0;RC'@+?>H7LFY#2DE S.3R$9,Q^!^$.^EO-J$9^+(R<_J0*)_
MNK]H !47T3P7HTH,SKX<4Y@\PY@5DHU30#41CD&%SMV.I,:]<2E#F;8FJ\HF
M(-Z:@:QY0.ABB.<HI\_V%VK%0@794GA+2A594R&L'_=8/VUR+'U;"1!J!*DV
MQO1M0-RU1QDQF-!9OP8\C7(Q\=ZH0Z"#X"::29*25P<=K\)$$]?\<5P\*H>0
M/2*57/7[>7'C1JIN\DXZQ1?8H&/+$=N/' O1%6.3;^2";L2['SS2BCQ?,BZM
M!PZSB,+'Z%H.H)U[P[$S8SN&9C+.2J7F@&>AUG%ERM-A.&V]0'!I1)AXK9_5
M1\!? 8FEBQ[DE.A6'JU1QMU6U]DZ%XP2I0Z2B>KY8GXR?4 W^$)VR7L8M<PC
MH7/&/20[2K_ZLR,SY+5*5*S;*=4955&^4;]W;N]7,)FP9CS_2=**N*YJC9FT
MC(^9KZ,^>T<1N?43^-EN&]G&6J$BNX#K##_W/4"^G:2K'.9#;VUJFW2^R_^6
MS 6IIW97G*I$I(.H_+,=0PQ)-_)7X^P3[B28)LPQN;(FP@45.<NA_81PH]J!
M/=+O^5".3=1^WK2X#FMK6^UJ6:GSE9K^C-328KB@1E.4<(JBQ$MYJV*WF-<]
MU,& E\0XR_M1R?-^1SI3MG2; XD#KD[1R?/),_F9N7;!H$"3#_S4B9Z*5;'6
MQ3>&$YF-:G#DN9$0&C%*;(%.;7AGJB!C9XFDPEAKR,\VY7CTEL.63!R-K(1&
MUK][FF_.%E6T8CGI<U);TD&EN<!/MRD6;?,H!AP&Z;* \K=N&03<N:RYQA&.
M3'R,(562R,2<YY,VX%,=/T3:D/1E^E"@;]M"2W4+QKYN&16YN1!4:O3-H>^W
M3R<!GN_OB# 716R@IWY5[Z3%+HQ!)TP$KZ =\C3*RT?VZ;#B/:K]0+G7<A1K
MBSF,],)#3#ZT/7XKV,R#OE^6EF]PT#]2M#*2K[V ;8G#R"/B;D]Z9W)% TDR
M:!CSI)NTM$R^IL8;3?H+3[;A"Y.V^8>4U>_ <SNBQER"*:KGW6RBFB?_>2;F
ME(M&:(>:S9TGRWG;8M]L-Q+%)KQX0*MUT0Z&76!99+!]^/Q]K;S_+]OL/)$Z
MF.1YO;U0W_4K0TO%E*[#OA\YL.70CN&MG[A<+6.DF '&@8"^5^I#$AWDO3S/
MW-Z$.PZQRZIO+(?Z\[QGPHRS!-&F.T9MECC&4L:4BT27A(:?47JMV]$>?['2
M44/NZ37QK2G3&3,\UZ@CWK>Y_)PD1K-FNT<NLB-OO[>6F 3;*V(0P(-@7:F@
ML%4O"[@R+_N_+9[?UK(-%* +^K CB(BE"[\'0E:&HTYXYF#)U?Q<<X-^EMW*
M>;HP[S!3%BJK\?Q^%.,7(MLC??&YE_,&.-)J:)F8S!F8%>F,!C:+JNE3%29"
MD2XJF@Y<47>N/*&A\=WM^%99ZVD&=$9"%F@+LMN7D_7]%.*D=&^0EHCX>[^L
MO7I..2%/P<1(*AH8(*!WB.2;-:9(!*T<B#Y[+_K2H"V;):V5-&?$![].Z=M5
M*K1D8NU$?'C0DO2$4T9@B)(Y-WYG@1B=Y8@V/6(0@2=MA=)-!*65S0 I>/UU
M&S'&10S7I0H2%3E\+YWJ^HU\@:(SF#8I!)T  466#MMS5[,20NJJER9HD99]
M3=B2"M0NQBQ,?(WY3N-BO.-%*("2G;2S,!<,76'JW:)LVSS)Q&S&]7"B='WR
M05_1TMM.-G '%*I\1#6A+ 7_6.>667T54^E=.->58V(]."'NM2RQ:T N3U:8
M%/>&HX4^8&@46HTK#'FN2"[=J,W?\I <)C?!Q=(*!MSSP'Q06RW6NAT,'\C'
M5>I@\TM)R>_CPERE5J,HUQQ-2322YA]! <Z[!FM:N(-<F ^U&JDT*G7B\Z\O
M: G?1"OIA"%(>R>(4P0W!VB+?*RNV]_?FW0NCN-N>?N&N@[%XVHRNOO]Z JK
M(]8JSKZF6G<_=?WL]A!/DT68U,9G%9FH0Q:.V!*>@R=1'\:D:\ACM#%QC'(
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MMQ<(QUV>%'RFK6<T"Z$@:3V?']K6)1(EO"8.HFY?M&4CXXT=.CZ"-<W= [K
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M7JU?O67[#W>H/-I2$&:$M\Q-V4 &H^ \@@RFJSW==J;6XHFGM1L5Y>?)*DI
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M(U8UCMHV088H[67D4% ):_1G=?J0HK>E-%=G\]IMK$EBO6C;^SKR6;!Y@I5
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MVNG0I>=N[K+U';QWDT=%6=""#@T67G#=L:WZRJT]X\FQ\F;*9%\@>\[T03Q
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MVMM!*HB+M<*9.2T!PLRJ&"D:*%XV,AQHO':;"&5]/>KK/^:E!NR_N''+O:!
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MF;_/%F%6(I2-T<#8KJ'CI#%"6A1'" CE([9N+BR6(-"(CB$_[]U/#+TS-X^
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M$?82RB@U[')WMR";):;M8XG^?J/M"_HP[A!L/*^A)RT2O9!,=6/90D1_U?\
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MY>+.#G&,R>]P[[&O6<WB'@\D*/1@N9_X+-5C62\0. ,XO,P8HI)J$2G3)!7
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M?[V%.4C'"8R1&R.N&OIN"(I#F T[VO/UK((W-6713Z62=V%"T,MX2IXOL=;
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MF\YP:EF]C[=D<J%<M9]Q*;KSX0B!JMX0<%HR6\JN*XT"WOVT;C+YJ.;7FWM
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M88C[@#OIK?FAY&>_YM#$099F;'3GQ6,O$\*]E.)G6R"%NB78\B3K6N.(-S1
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M/?@W"OX&/DS ]Q[@[Z/88%*:W03\7</?X+^1QEDZQ"F:WG/Y\B_F^8N&?]4
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M8=J>:XT@#,F\V3[K4L<Y+MGKA&%-*.(%>)<_PJW0,G94Z-11AG$WD/MR>H$
MB4(Y%Y=5A2;7XE5Q#@ ]BSKLM+'N,Z]SC61'G*M(9V:*5^3::9D0$W*&V)/#
M0:C8TFV4S7G\7(-3Y#V@Y9MOXM@3P,//E:!6&46Q:J6,NA<]2+TR'&Z^P!8K
MO?J4UTII8J\VC;>VLCYZ\<G6)V!FQ9HF$QB3^E)"1/BVV 6XE^97=["P:;@F
MUN(4,]$0\OOVE"=_G406_[[_4_S)"]*\;'_.NDP,B_87\8Q3UG@;V8\9X$:1
MMT\+3SM0+KTD&T].;YF??MA#5/V+#X0Q/0HMRK&\GBJJAY:9- 7? S#.KW$'
M"IUCL+;)T*NW77%U[&[Z'&412@)EH(=FMAX"0RM^#9^-Q#U.I@LT8.7R]5^M
MHYM@I8\?AOWD-I/3V1_Z-+CF+U!2J_Q$3H%OHF?TAI4&6"OS(?EQ^HAGAA6.
MSJ3I9*OPN2BY3'UKW:+\N6.2\-BQZ[?#G^7?)DQ2 2=8.#TQ'B7:H@W!'95L
M-ODG^1X?..B"'P%TS^&IIU:W0I.J 8:MP7)DC;$OZ8S")/JT\\#H<9;3E0:C
M/@0O;&T?E5:;(CJ=S_.[\K1UR',(FW'JFCRZKH*#SP9X7<,!<)-#CE#C&^GD
MW#<=%I!4"7Z!Y]=' Y2<(+*,@+Q=/DNKPI^2#NB8S.V.'6\$RYB9D%G>'9XG
M@N<&B9)-"*L;X6:RP/>.5JD/0T1@[=P"&6WYUM:,@Z[\]\W LL#UR.63RQD7
M!60"I,=)1#7:Y"_9LJW>MXBD!]F*<FJ##()$1'/T;LM[Y$+)8WYMI,3DRT)6
M=*#*3V2<=W6\=B-FLS"<[ GD&)2&H[_,\J21&SG3-(BSSP\*"!KN><9CZ67[
M"\XB,%926N\!'#(AOF.O$S#GE^$ST=(?QZ9XL#A M3IZ4D,LGU1#<+Y5/#SK
M<)":,HI9PLH^HT1#/!97/XO%^LV<HYR/[&9>D$Q5_22Y0N@\?1H*RG,(B6TK
M7'3GC  ISFLEG5IYLNSTIH5DHZZ^*P2#?S ZY?EF+4-MH)=&?2I!/(I>/C_I
M8[53913LM.4.[&WBT /(NT#2DUA$/4[]0W- =ODPV<*^0I'G"[VA/ F,&ZI0
MDSR=;']F_>WZU/C>!OO/&J1$:H_CPE"?'[V]=BD;WFB;'PMKK*?KOJ(UD\+Z
MC9.2;ZJ.'BHOL6]%^DDVH1LN 'DWU'8H'7I&?N+EEJLS:*\HMY',"/5WT'M"
M@)3ID[6=FO2-YZ:%R;16^5%?Y!-(OI OX3M(UR+U)'U#TG>Y<%*VV5;%TI_O
MI83@F?T-%F#T))!-^;=X^EP:^B0)%O^'$*$@M>$?[U?[Z[XUBA_O24D]0^A\
MU3?U*8]PHKR5Z/=<W?B>06S$R"R-=[@OQ"EOX(MM7&MI'N*[E?< YI-[0(C&
MY%Q/Z=6A'-%NM71*B*-HC3C6E,B'HB7WZ%W9\3I*;D4Y,?KFCN=HY%GH.&WZ
MAPU1YE#:*387PE"Y!3Z^V+8:%%DH=@Z%IR9'X5;2-4ZD"WF96\_Q#DQOC2=V
M$%/?Y 6C0+_T1#,U\O8,YSW XF/<I2]$2?I]DGTPY\#N#+:C#^I'P, $0F>U
M \]C1L@V)V>.T+%J^V1M.&'R\30\_  AR=BS;9M..\D^3K( :11DV8KD'BR7
M4R=CFT^(DN@FJ\\L/A 0<F>-7/CLC7T7V$S)(3-S($;TD4@H_CO]?%7#SVS7
MJ^YE(UG$@_,!9*W,+3VS6,(JY^6H@]4U2Z3QX'X8;W!J$2$;'SOS(]E)?3Y]
MP&YM7*UCJ=5/\WU@*#CT%%E@M9K5+K?I4L\G^QY@O@1QL\)=:'^$O-'\\L /
M?<>;'W,<P:JE_Y+(H'*@A53&>E_$I Q@9J$OU*P4UN!Y7HQGN=IH$6<B'A"-
M@H*ZII)N#IF&69/MQ8+T0._4HX)Q\9FDMAQ1132D0E9*%LQ7>#<".X_TRG85
M"!RSWO0B[9[Q%MBMZ5GR""O0](BWZ=G2:RFEH1Z(4YB[2KGW 50NTUR*1V]C
MF!5I*IL_6)2EOVN6]??U*\BSM-)_?L0>Y+<RA]'2(FC6DFS3 T$=&M(3[_>T
MMQ2CW8:5]0?EZ,DB-375?1$=_1D;BRW8?=9O!>S3C%G%LNI.#<D+.7[+@)2D
M1<)E++D;N:R,*EWAGJ.1V?M]I0);$@?6;9>ZZ9 8Z2-\CNB3SG?/U)Y *!&'
M(93./>B:E*<O--8^-M0#D=5<K'3N >CN=P9XD@7#7@5ZTM5VSVW=!_O=?XVI
M&H5>]"_R5TX3=6]^?S?9"9MY6;5NZ!35$060N6,\$IV)/L-"5>2+HC"Y,#/M
MC(A<CQN\5J_ <$_32>A+SJ"8:1]E/7KIG/H$AK.R'=-?;*$Q@W'DI94.3C2R
MN(S+>:%$&?..E:V<>(WW='-1!=<_X,6;9]\\UPB0WG.07@;UD@WOD9EEY5DZ
MS+7WAI]Z3QQ[4NL#00<(8:<R74OXC6L?6WE<5<JZAC;QS3R56"*\^<:2GRSQ
M88K7=7&H=S"DNQWT@PM';Y8$4>*VDIA?9?7!W2YD2$LXR)QP\'OQ^LGN]I4R
MJL^_2:C]P0ZS _],VS1*;[4FS.35R/PZA:H(K9%%,_SS!Z)QNQL'^7T*CH*)
MYL2JNO [G?6 )S\*\63%-[XX$]1/\]4[*M&W8I#/ [^^5/G>4 3&X:I3C^FZ
M=J0)42GW!VR)?=P^9;&@AOC2?<W6^.+!1!(9FTLQO3566U<OY_#A6;A@ZYF\
M/=W=Q71ICXF5G8LH]!6-DD,,+T03(C^&FC+?7W^'<?0TZFDXI?:WXE/UQWA6
M=KVI!U\+=Z@H H>.69*MMM9I&+#J',6.*+%<CBR37O4Y$+A6E;JQZG^ X.%#
M4XNL5J*PAP0FYN0:/IM\D6_1)'%8]!>,\%!WJ2"%]=&4[15BXH8B+:W;JKGP
M?M]VVNGI>;0@(KN2PAK(]=W.@?@7:J&AE&R%E@^Y@H\VKT;-IZ7L?9U([TX3
MDN)D*KS#VZE[P%S!A(T^7/ $W2D5L%9NO9_9345)##H&Z7=KEU8\MJ4QR4":
M1QF/=.F37;D%W0%)YD ?52VN2T^ZNSAX$,2?Q4>F::LNRH]/%&J@UL-Y&Z5.
M.I60I-T^S8E3+$9)G-NO!5U6';](9AZ/H:#V.CT=8_.=: '?.(L9]CNV-*UU
M$$KWP4(_^^5O)S6;3D\ND1?>#23MD:YUP0,&2,[*8<?=D\I1M"T!#&\=:$HB
M5P(&@.GJU8<',04&<E[F!3H]3AP<- QH8!Q1J(%&_=%YZ32L/;% ?I<TJH[N
M9GR?VN%3)^DH8<VR<Y.-DU;JFOJD7?J4R%+EVR[D:SBY+"1KV"4U/R3/2J:H
M:%;"N=BQW1A.R!N:9IXWAV%%;K&_0HG'VPG&$0D7I%X1O0=\*>W4%98I@H)C
MB6ZY06+/IT4X@/X93VVM-[#0RUIQ7W&AWE$PK5/,F%L6P+1TR+UTG,/QY$B@
M]K*[VN=W^&-L=L.G9 K%N@F9KQ@%P=B>(S_3^IN?MHI/]N4$NF&NM&26F>QB
M%>MXOX7JSZA/G&Y3D2 *H DO$BQ&^FF1OZUKYM9%E7S$\#94=?YDHNTPH-]8
MZ** +S^=K77&0F(;IZ@FT]0'<*1"TZD_XBL2':G(-Y 99TK1DNI"-C5,B,I=
M$\6V;'_>[B%B?5Y_T6P;QZI1##K>)O[QA?.F&.*/ @3M.^]S063KB::)JG3>
M  -Y.XNO"\)JHVQR;.24 K=S;D(E!PF0( AA][E>*AK<'6D5I >W+4M+/H*M
M*,K],/JW"X8*?^8A81 _:L\C:\Z(1"-%:<9@HU:<S+<LW5L-E%:.'(_\(/WZ
M&MJ@0=10AJ';&9]"AR?=Z#-#^12,K:-369NYBAK6FS3>B/O.7C,:B?:XT&Z9
M92U*<V]\U9+'#)+<939*'>5RK 4;]L):CZ75[42'O* H%*%X'T&NXFL7C':>
MG:&=W+[8",9Y,0Z?FNQY\Q0ANU+BI5Q*W] 4@8>,>!U R@::G&_+#!7A,+/E
MF4[2)NDIG._V+A07?"+A_YH6F0Y]_\";$:QO$#$7Q3 M]PW^X^6P7L>$-:\P
ML&KQ9Y]H!TG43$#,.\!).O/KATA96$'SZ-''29^,]_LDY+3"2D.-RS.J#['A
MG3C^/6!FO6.D=@_!F[U]_)H^_ZL=1E<"/LURN>?4+@NYGAA1Z,CC4*Z^H0+Y
MC'Q_UO%_)_CXO[YI/ORW ^(X?T/S]R?81/ZVT&3\K[^'0F(:1JETL2/=$J+<
MKH':39!VA\[ZX+RSY*],DW.U&]=-1K".HOF-@3B&8BZU,_#N >!:@T2@.7OO
MC<R%T+S*'].I1O2"8-)-T_^@^E_(JY&:] ]=P]UM<$H4<9QS1V0>W+'%1KPA
M79-L>!YWX%+[?Y1LW,3Q.R3JPQJ1!_;7%AW,HM]:4&MCG,JR_Y/T',)!O^X?
MA\FW3[(1A0\!YM<5CFL,R2N5O8U9T5RO=!N2<KG?0?UN)G/VKGW:^5T'24>#
MWV4"5\S<Y>X"QWW5O 1=<2RIX#KA+/%_(_-O&OKS>Z77?[YK_E\F]Q7T4F,N
MZ7=9VA7UGXRL"D#]\/']60IR5Z<W7C)6_=OWLV1A5X.(^XH?OU@V<OE:PZF(
MA&5PMK'_O6MX4Y:DJ5^W7)[?*&S\'H#&EW@/ ,II^WP,.\F^#3'8,&LCC/MK
ML32"#J:)N&6C!F4AMD3_A_H_U/]+5 8KQCL\/<8[WZ282UGGS*MKD%B=Q%6L
M%WK'T/!'T&C-U)X+FKS&9)@]_S-1EC=UP6N\P\3.;W.86F2UF++#J]_\P_//
M_OAZS!M4XL[]>H9#83/',$%1[:73EI#&+<&DE1%/!OS!?:%//C@FM(B3G#O"
M@@=GAT\,U[,AU)_0&SQWV'MP<66_N3CQE XAX KHP<4%</JZ3(^GBN:VA-7$
MF/SFXBP?7-SCOJOQWR65UX?_<WH#C\H^_;SH-R^*9 2+TH.G8. 8B;G4^).G
MD#=(=ZG]?Y=L%F/)OK*W-KO>\1=S.?MUUSX,,H^,$;MEPP1>LFXXYE20?V!W
MTAR87*.7P+D@Q^\RJ7_O@EU'IF&J";V>GY"JP;]*W?K=QC,ZJ4SG\0=4(Z+1
M<G^5*OU7H,WSX]*UR?;_N%\W(\?_^UKV+^2^@IY?F%J+76YV^5()G:LRLWX8
MR+%6!=GAR0P7+R79PO^ZA%OAECVK/PK7%:]@X$S08/W+Y_PUWVAY+5F22=^Q
M'[ER 5=()SK@4Q;W@&#S=_> 3/4R3Q:.XK$[-8.&$L2/@;\6Y]SAIK/<^6C4
MG4A2JV<A/HFV&6R:22-HA301UV74AY';!B<[=17_?Z"E,EV7X:R_WM^Y!W#_
MD7G^.=E[/%6L1.+JF9=GQX\?,9=2SA579Z _LUD9\)C%/-CV+=5BQ0DW[9\M
M^A>FF6'2G)U:8!SJ/S#\UO _ 2UE\9\!_?\T.>\O9";MK7,^?%(;\--U&SI/
M]6NFLJRG72#F@<_OWKLE-*I($KX-^>V4',(G<[4:"0-AF%4U+T^?:Q(^3+'Z
M^$')81QUE)YWHI6Z!"=Z&KSJ,!P!Y&E_X2$6&B7\+64(9OS'\W<)F/W]'ZX@
M#672J]3XVW<4$\-GT.+UR#Z\5PL<E6"L9A;BGG::VB.4I&3E8;0$"\MLZ<=]
MWPY]A-2F%VG&*]B'\^J++-GZ98[CE75H8?Z\3,7\J?69!7*8FLF5K^D@UG(L
M(>P^J&5$0O6915\EH_:(&6CKE5[VV(A=;HL3%Q;/)$\WNY3,+\Y+VSWRV:8S
M+!;++^KXS/,V@T1'O0;O!U(49@X[CKPR2ADA08(T)AMK-;-4#OWL,I+V= ;]
M.,>!!FQ2HR;#:8(G!<\/'3"=W03$<_^E>'A[VQ9@FK2IB<$X&A+@UPIM\"R9
MOXR0L\(AT)(TX0JT'BH1':7[0%XA *'Z@C0UKL:+92X_\<;/PF .].NFW3K
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M-J5>27-7N9R-78CK!1W"7G8[R EV:]S^8Z,,W7+&PNU:61G>+RUIOJK8':Q
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MUJ/\,^-UA[>2$E'VMM.PFEV-A3 FAIR^ZE6#Y_\TE_CO2;OQ'/C@U'=JCUJ
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M71;#9[@'.YL_(])_*3 "WX6G?_OT>LA+^L:L:_Z7M-'?I]T!Y& GY%%W &)
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M*5C92,C@1DF,O/^2(9M2Q[_DS2TDFO^UP#Q'SD^M%BP58) ;MF7[\JP8V'X
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M)0I!3VEI%Y;7.)3_5#MR<TK>Z+V//-VD= #[>+XW%79QS'OPX?JLW]0]=DM
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MK@([Y1IT)<Y<62AC7HSN&Y;7?ZS#WO?B9=BLQ.9,=2NY^1*"%9?RXHT+/CT
M$W@HKRC3 I[O)"/0?IA0-^845%*L2VU(%&AK\O9BJG9Z*/E8K\D3-4*L[@.<
M?761-URTEXX2DM.A::!N.UM3#KX1!X!MF29]:];=8RS)RE*V:70%RNK$S+^3
MA=C4J5HHE>[T%>$#^-"*MV.$_-%[CN"38!>Z]'['8NOO8EI'-[8BC6I3X<$%
M\F^6+W:YKN/]MI\IKM"\$QE&^\R&$^Z*G L$G#TA!4F-T6*97U6%S80&B$7J
M4$<W\1J0)8=;2C4F==0X$\P_">M.LZ)Y7.T;VH<@H8V1UMZ*%9[\0:]"#$G\
M=[AT"_47']<]/AB21T=5E.T8/97[Q'U=^- 'HAK;VG.YK9VR'3<6<>8"9K4>
MQ.I]UC,Q<:7)0Z= 4J&ML]'1)5\KO)OQ%,PV9TXYLGL9K?(0[@IM]G.E]A.^
MXM&]])Z)N;I=5(RL$MTM-HX"V=S+J[?U&:J!YRM;S0WN>$'GV-GU-EL_3@5,
M&?[@0Y&1!/"\-O2AB]94DR1BZ0&H^B*$NI2*7C25W &,7?EWJ=\I>LTI]>@V
M:46,5'H]<?6%86,B U_N$2]]]QKD%5IU1;R5>F2^,T_/GU:E<Q/X1I+.W))3
M[#=TW,6*"_B8&1_MC0]6A+#^1&]$"Z,O+'#S )CBBIEQD22S:0'CCZSE @'3
M^;/8UW< [Y((9#![/ZNI0JSY[(L1R&LU\U[+S'J.9U\^M^'U:0<+"9>B\/,D
MT$?8W '4G;KK2@DZ8,$VMGSL?5"/<:V\*9%AZS#;@:,S&Q/'.DB_N/FSVLJ
M-R,O'EV"4^O?[I4X5)D:].,JOQ+_%42]5*QBE68)P56D3F;RD3G+GHUK8VX@
MF0C.M?S:H,M&)E>]3KY^6!(^AU==$XZ[J"R&]^W"BP=:I9VBHMPJ>&\[W*S5
ME^G4.@VLJI\*V)%MJ24H?F,T^X_,AFQ(=CH&4/%$D3AC(^:IR(VFNDY-,+0C
MS_S\N7>I[V4$K,DQGXF/T$ !CEHH=((6^2M_Q[?-TGT)G*.;8(;_Q.JO$\6V
M*&\K!GXOJ>2J%0J,?^V<T??%G_R9Z*X2\FM)4[.N) 5-@2AHW,!J&AJ'Z (%
M6G^BE;3&Q%.6HE/D,I]^-<X>X@K!SX.'\,_@TC'"P;T':UD\D!Q.W7?7K[ ;
ML6,WON4B?ICF+OW'[M)JTMJ#*H6,X7N.69MYW>T&3TM"5!JU246T V!X"^Z)
M/0?%22BTS;$F,I/)UZ"K8YVX>:%E>?<4+L]>V:P3:4DY&3E=TV<_*@JH]0@1
MW-_=_JI-]86._ZT DLCI#+&9)+H6 _JL C/:"9Y:U>14F*GLWD1=[]2LKJO)
M]L[$I^CA.@S1P/D[0+&N>A64P [5($H7T];<FG6I/JB' _GY)'BU6'1)?(G:
M*IK5FKV&/C?WM$B3AS1[=OF2N!FXV02Y3/'$_1;^P'RVL'J=@C@C?\O6?#Q\
M;[L1,XZSC]MDRX9J_+7#N5KBJB,K':N:\.VF&ZH]GE;RV[I"M6B+9/RBN3"^
MRG7>3#97DZ[I;] ]*9/DE.PSO)%1:LDP/%Q  0#@C'LU$L:M@$:CGK]+MX(;
M6QE0Q<G)O4U>8Z["5&(D7B>25:5VL%>,?J8\+<=4=!A6:YWM7#S:6Z0KW>%<
M$_C-[Q('XWENZ4B=Q6BRZ:YYX24I[I9DQW<HSZ9E_*C-ON.NLF._E/Q&Q[DU
M2,$RK]A<71TK1=8ZJ4Q1K1$?^&YT?4W]TG/0HO? ?S[)F 7]N]F\[:"MQ5,<
MV0F7^'HCZ35GI#*E[^DC0AI6/5_1OWZX-+V<(-GZNHU:ZF_F)!'KZ:NXY'[;
MH\>0KJP7W/YWC^I5E,7@^$@FF'/N )T]72Z\IK&^3**1]P!J=FP/U@,9Y/$R
MJ-5W>#V'6WG$-<C_89;3>GTTO42V^5:KS1&Z"=E3B;W>L!X9OE\#[.@'D$[L
MYQ1?:MOP8G(N+$9:@VEN;^;GWK1>H<UD5L0QR.3+6(2$R73Q=>U1$"XHRTF:
MB?5(1O-($VD04D4SC##$<RD5I .$D60DF9TPJ<D[@:#IRAX&3A9]@3N LG3@
M/FPVAV[YD^$E6540HL$)=U^GZ.=&64-ZJ^()13'0X'$)L*6^H,#1G;,@;9^Q
MWL:I0&!1DF)3TBDY\\>M*Q472*8W1=5UQ(]O\"X34]-_#4*-DT1=88YPUN#<
MNI9&D  O[WG$NAC^)G]!0])USW&6 ^B7M[[JO[R06H,=WFS SP/Y"Y)^]UI.
M]F L/J+(X@I2,6 Z9B1CBLW'A.;S8#@<6>2T[ \EOP]:,)67T1RYNX^Z_&SI
M,K/ VF:??""L_W;Y<@BIR$&N7VUF?DXTY<F/!M(?FOC\L2V;Q($)+DM/T,LT
M^0:W9;".\>XJ>WVD/<J;(>CT[[+%9;I*#4I"UZ")1]=*4-I@ U[><N;Z;OY)
MGH)0T]1/2_7$O^>7@.EW:H_FU:N/-"?[<G_5BNFHA<F'_BV?<J7YB-A%19_K
MTHJ[623$ER*F.5W!G.(LO$8PZ&(M//CSG1E<G0=WW%^)A0KY>G@)B[[2**;*
M4T=[ %A <U+G8Y"4Q.&OZ^L[16/(+(K\J\25!:P)V2TE'(1'X&=&LK0.E)6S
M=ZNM\XE4N72DTH\**>>RSJ7PV>QWSPB9#H$78?POYP]"-P]RYZ(/[+:/>$^[
M--(627*T/08QMK$W+;F8U]--A0,E4$0_%$,I>Y.<^2$J%E:2.J6ER]UIA$4G
M4<$LCM!O'04USC #+]Q4DH^NF$L06+!M.ZN@LF"ZR:*X4(FH<(N_LQ[: 5*+
MGTE]/6^TGNX,H)3&-YUH<SYY^/!A6]1%J=0LX&&^-OSXD>,LK$\D\*3@+*J%
M7L(SN7@0NI-OV<G5$NHR)15#&IZ;I:,S-_TH^I6^M5WK@#3P3)@#1JHJ7]U2
M0]$E]%:RI\E8P#Y@[62KVX/@7D=\&_KM@^Z<%)WY".[7)_J(6PEG1?AF2W!:
M9RQM#E>C<I\F5=X7K.,LZ8-[Y X;\9UK$UY5B>@N,PRLB03>)GOE-"F,KS$W
MF.T91!D%J&&$Y_H\<@O\((2:LP7"R/98.6:K,C!R^_B^5YS2UJM.-.PM[7R$
M".'F-'W U/%+_X.B'ELEQ6J4*^*-6,JGSH*EG:M^Z^3NVIPS9D6W!"H16L-%
MIX0!^&MX,40#')S@H1*3HIV![/V"^PG]X(][+TN*^MTQ*\TFF$,C&[S/\7*5
MOZ0:*?C92C$Q22=B"'_QJS.!3/8>K YY8O!$>1^59\<,8:1!+)]SN6"QE#US
M?!/9T63KS,-[KLB3A!-;(X,2UV#7]<[58G/7I'9D[Z5&4'3=K24X@/;Z<W3Y
M%,S4ZKW >2Z!2U-C>+;R*PUT/HI;QO8F1-N'OV &6EQ E?]28<R#\-[<!QH/
M;Q6/BK^LWKSHWG_]N5Q/:N&;*/E!O\,2Q,**+>?";"ZS15X^!7_X764M%0*R
M]=I5XE!.@;]25CIAKL80.%1-.79EE9X>>C\QF1)_[TIB=#P8T'5(ZU=S95_$
MV"QI*W8K6LSY8MBDS,'.05!HH)8Y^8-VI099.UMNY99%H8SJF>4;)%9<C37Q
MO^<OTCF#.+)P=Z4N2UI^!)+FN]C Q:OSK[X$)#N6!(0J(9-G>>9*ED&?MI3O
M"146#G(\Y(M9EZ1XU.5AC]KUVBUGZ$8\3^>KJ8N=I3O6\&X&QZZQ4L-+Y:C1
M8L>++%RXX$4/QIV3/K(M42:/3W.+60.RUOQMYW@U/]S]O_-+B9O? <B6?Y$&
M88I_\W4(JB1NJ$2^82L"721)2S"=Q_:V%1M.M!;GO?4]4*]%J>V*C4NH!B?I
M($*J6+U-4._G2\.N1G]SC;9UC\",O\UJ0C<[/?)5=$6?03+!V_R_W,J.'!D6
M0]5JIAYMGLZ]C(J8EW!Y6KO';(/[$=$ JN:3K//:<6V1EL;N\?2V>ZSE^W(.
MPE@WL63\.\#I>'?4$EZM3?E<!-VJEWZ2=\\5\1P: ( .-U)^JHOQZ*4->4.R
M8Y0[C+LW3R%ZS;=ER['^H.#2I*BQ_O%%YG;OL)'XN,ICD.BFQHF<3?DF_O =
MH*P6)G0' +8F="1F-<K03O6C/:/ %T+;CI)(5QY"5Q]92]'D9\;1C,>%4NVQ
MLM(2E53$ A5.5(;@E<S-&1"0.Z?<ZBH(E"+FM5,ZR%*V!/7Q7C]!L@PT3M%<
MD\^-.2T)RGOCVUN O9'H.$!:;#B#88]D/Q +G=D4'@A2]PVDE2P+R9!DRRH<
M+.A_PF1XKMUP!E/;Q^L<%BZ^PDRD!\#<\$8RF1C4 7"3ZJP6T[ON\IVN?=-U
M7EE1JDSXF<L3H$_*I>Y?='DN"5A77Q<O1RD\9Z" QODO6I8*RF#A'+=/@S#&
M:E%+P)SK/E'^6O;R/9\KE>_U\)\QH8JR.C=SVYO<?ELWID9,]T\RDKH_+A5*
M80;OB8S96>6TNPCRL;5\J==VC4>A#O;:8E ^*0%U -T2G//MY?H9:1TF->7
MZQVY=%M?2U<<-2T8?\SV#^_WVN\/+G'P(I98!7>G/#@PYR6/\TF]XBK YD1+
M%?E(?+7-$-4DO]BHF,5;N=TK^WW1IH@5NYM"O3HJT<\WBJU=58.;,,7CDDKB
M04R>Y:^LP\6NM&QF.S^ND:;_XO?SF=@3O74$K2NEYN3\U/3Z]PL[3U'UYR)V
M>'O%_"DG7JZA%B+G$V2(N9*.G&6X.FAMF5WD/&H]S,:R>"TZN4?#P5E&.6&W
M A=*/N"-#2,(8+1>;4H:,(5' DL05!.8+:2V!(ZD1UOFL?F->F88:SZB>-(8
MA3_<<)N\?IBO,J@>?KO^;/)5@42KT:>V%PCI3^QB9FZ993W<V/0 .YF4\4Y$
METG5PO5#B.[OMZGJF]J%^VCG*!8^W@&^][QS+*Q*,,]51.HT>4X0]Y!?Q2\^
MQMGKG.PT_Y?^8RBT?,@9C=GW>I#T%WXX9P4&!8FL84,UXM1.)H\19T-Y#TX6
MUI,GY%\_RIUSPYGL'K\#&'WZ'AK:XZHA%&I('FX&'S8[6G1N/:+[:<1)*Y7.
MAE8S_ GYTQ*'+29ST]J:IN/D&?S7]NMK1^^+LW+?W3-T!Z@HI?+QX".>F7[5
M>1G>X^[K[=J-NESB,?:=Y6N(F0LHJ[/VS4SDLY9Q;QS%%%TBXD6:.L3*J$#$
MGL%9ZFH!]2_?RD=+*&J#>M\<+3[]G"&8YG)>NTP>9C[TBX/\'G(6D<LZSA\>
MVOPXR:9+PKQJ.\F5OP.0W^_R?5Z8CQF\^R-<)7B5X3\!V-C*E V$/AA'39+3
MXO;3RVU[#&$WA*N) NV<KV8)PX!;YCX8 ^P.L(3L9_5A@!:] S9%?]+OOD#R
MMCJM#0<-U!GY-E1EQ!#<.=-]J!">N![@](@OW201YS.HFE\?BK8,>[2UZ[28
M%,;D3.<I\/:C<.0Z>1[W)O?RF=B%]+)C];SSH(:$&@:>S(I7 4A@*FG-+^N8
M?XOM=?[[B#>D]PNQ<^.W!;\H\E1^];UPH_[EQD9+"0CBXK26]F3MZ 83.^+2
MW+GP#A!>!HN#D"]1,PU OX^YDF%67##+1)"RMMWT<5MV7BF--W+F;4X^R?D0
M)[,SN0"=0G]+CFF>)Z@M?0=(!P\)G>;;G^^I@.U6A:87N@NL&UEYDNA>5./@
MM6U7U9$GR)XD'MXB]?@U<UD(O$NC+<F/#[H#H+ > T3)F">9MIEE;WO3]Y\X
MXX,9BL)\?M5H;Z6B5JB85E86G+@C"ER=IU5JCZ>DPWK;F 3&9^F8Z!4X=<J!
M>&C1OHVO^S963\*<=7FDZ1@?*-6 %+=U#8K('V_&S!):%^,F!2G88G P.J9X
MEEA[];BA!BR3&!EP.Z@DE"=4Q,]B)):=Y:N%W\IO,<)E-F"(%;BG+$UJR0F2
M/!;1=Y@JCF:/:3TO4=2N@TU"=RNG31\1ONO5C())O@DJ['O$Z_%$*7=0V%D[
M\0J_\#8K=R\N,(4<&Q1F;+[#+8K?[YS&I13*['Q2 ,Q)<<B9O^01]-.T_ RW
MO:FK$)73DS-9).>SGF"CJE-Y"WG-(/]>\#*%6SB%KZ[M1MN-H(L5'GRB\._X
M2/"_?=45N^*T(:U\XQS;9;K22T@CW#+QT+$AH[I"-2!1<?3>[&7'7LW^7H5R
MK/ZR:M'2AEI*BGHM-D%T_:"X/F"<$JE2&<X[#TE>4U8H4IFJJ"YG!??/@CU6
M9>3MAP<,D,P/P7HB(D]U-D7HH#M.<D\KM<0=#[.'0H4L,(EV0.QZK>[$A_L!
M/!I3I4%"*M8+X:Y&L3[1# ;V#MHJRJLQT<\*5OOQ\-V=@Y<><7;R,+ODS-(,
MIV:)<J1)"&JD6O8YM01<Y096X12[DJTNVAT+?[)&.2':$@ZWS+[P7 X64K=R
ML,I[$7\%R;**Y^Y%%S!%;A;O9U356 NI)[$0/.JW<#Y1,8DOY_EE4"0X4"#9
MV<BT!#<OW\L:"@%G3DZ([@"BQ4Z998TRN4FS7/68\\^/2T2!,1U7@=,GG2P@
M#_(OIU_ESIU(>2O&2-5!;O)J6Y4F57_K4),R2W^P]Z0L]7Z,U=9,JT:7A7H7
M/V(T^UY!B4^[9JY.>,99VLV&HGR]/>X LB81I -92_AUS1*E\,N(AJGSXXU7
M8RE2][9EV:Q41(5L49K<Y#9KAK:'ZZ)>4(8%4%Q.=_.UUJ+UU3TB?O5GK(A.
MC@=DJ5=.(Q>BMQ5)6P<W92E, "4;B^R[;!5+^/*Y7_I=&7=*7T2.V_CE'',9
MI,W8BY:>ELC9+PDKCQZ^N26J9S1GM/SYK<2].1L-FI"&.08\Z%M1F;KM$]W.
MN@,(I'HS7V)N,1R10]7O5U]+)"PSIA=D429E!H])>2N]++,BFE?(I81D0WDK
M^302-O86#"B]3\KJ!2EK,*2CX.,C"ZFX8>[>A]%@SZ_ 0H&G>'_)DGU$/E6D
M,H0$NB])]OQ:[3*+"T[_OIC<BFB5HIP8WDW@*:X;YA93%RX<NAU'M0(CW1T@
M(@3T U.*WV/*OYB3H!,<,9SA/P .HA_?\TB9 ;*S3=54!MK4G.B]&>T9$'IO
MM&$)AZ7B-227LD].9F^9)RQ[2P*G0&9)>O:?6SF$;W)@5=N9U865FE'^I"LW
M[6 &[N#:E,(O,,[7PHW$HD%O$&6,;?&"ML0O6\YTO+BWO.WZ#5Q'98@G_+B9
MJ3CZ48V%V_2D1%DT8B%?N;YM]20^(DXT/K(0T(5L/=9PC5<0[M(NQ3^@[WK$
M*WFP&Q^1WV-W%F3$;OTP$C=Y)2V?>Q?MRT91$='+7NH,7#5?7ZC:%F/IC[-(
M$XN?_S\I[8F^5TPV\ XP*#?&=X,"J]IR6FDAU/>ZW[SW2M?T7K.)WUH"18G9
M.T&/4K-R<Q-RIG+/WXA?H97)2WXGSH-A@9V,SKFUR0P/ Z5B-\?U:,J_S&Z6
M,[*(-J1B+DR6K'>X?[NO/'"GBB&H<]A'RJ&J 5R3I]61OSG!P_OPHS6UV8P'
M%OA8U)= I35Q() 3U /IWA@Z0^:'Q=5T*<R&ZC=H0D_=&3++>-$8^L7MW)!*
MX]9?XO3;!J?N>"@AGB@G_G2#(N -7,1W*\YLX7^]WM R18AFSLJF*B^45XM@
MA B$)]=%#6A?U$-WM3\:^T?HA(+G UQ+J+!?+ Z%H^19.VYKUWZG\^%LR.\1
M37'HS[*8DJO8K+B,7!?1=KH#;(^3C.6_E_OD13=3:?%>9/L&02UQ76.\I8)U
MS6Q1^;I=='"DVG$6>_253G<#A/J!U/;K.>*RVG"YI*^5QHE2W80&$?J;EYI2
M#!VC:[<[XQEZN4_WTD]NNF,U*")125%)&3L^@(&RV_R2F1_^BR^O_QXQ\ZI.
M<-V2+A.,?GP_6#^GC741^8Q)6U?[_Y#VUE%MM=_6:)"BQ=W; L6A%'<HQ1V*
M6RGN#D&#%"VNQ0(4]^+N7AP"%'=W3R' I7W?GQSY[OGNN7]DC&1LS=[K66O.
MO>8SMV)+_UQ%61Y=#*ZHTE8JH/E_V^>G=:JG.F,_^^QX%?73Y!YT#RQ/75=Y
MUA+/LR3!#$+;$63 23D^V=S*]69X $TVLE->;BAMNXS?&#-FLK7L[6:IZ==)
MCNRB/E$/'X+$M24S%I!H-62-VN8L^*-(4'-TQYE.C<X\O#OD/\@@_OY0WW=?
M5M!"7WA#SIYU[L\RP"(],R[!ZD$]F4N1T7L&IJ?"0DV8170WQU*[&+94:X-?
ME:"5O\ %!@+KT&C_A]=[RZ_J5),T=VR[*MX!,6YM13*\*)S:L6&"@E)KZ,TF
M>HOO!7=!RP;3G'F6VH<_RHCH]YKX0Y=,(O6)W[Y9)':AGDEG"H*JK^.5087I
M7]LL:3T"<MH\CZA<'K3*=S_\$"S+UZ,=P7\"\HRROV\$J:0S.'&P"_2]1?:,
M9\C:>4 HY-=VTY3V;7Z\??'[$E;Q<C?>?29P*P]-'L5$*UHX2Y'-R+,7$8&I
M.ELUZ&$VKGR7)2GH'[>%^F'7Y=_*(PTMR6(U,JL3@YZ(@MJ;WP4Z:T(L"S&7
M!B CJ,%:6<&:[(POK)G28&=#*5I,9,!4GSHI7;:>,/0*FY><7)/SC'/#U4>E
MY<TT3;R<)"G@SK?1Q]=#V:'Q*'4?WJ_W.YS0 577=?Z"C(;KRRV!*"GAZ5I)
M4L+\M*5]XA2#'#G3+#0=^O+X_PXCP,65[V;X? C?AM&\=S)\&M9.\H\ I3U]
M]G)=F4> Y)G^)07/YB/ \$"OMJ8(U>/G7DX97_^VZP=5A!$65_)."?P$.(R_
MU7I%^ZWU?WTK1^A);L=3T\O@I!">KME:IWO]5LLS8QB%2R6:^_.H7A,X6L9
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M+[#/P;K7IL96$0MU3HD[!7B=9$"7M+T-T6TT)GQ3CD=BBAC8P06!P@-9?1F
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MY]?!5XW!3N]5D:C+&54[Q6A6,6OQN;^+RH2_R;W:A)1F)Y0\#YQ)A6^_#BJ
MW>BXN+M="/_<?+X<D'*?9OX($)3:MCS37NBXVXBV]MR<A*"&];\NH7@'(2=)
M%HG4[J!&5#<NT#')I'$^MH \O_=2KJ>D@*30/@NJ^0Q:>=WP" B(M3VUF03Y
M[CT"Q/79(EALR[R)RN3(C?1M\CH''_9*E0)COSY0B2II@#4> ?TE%BMS(FK(
M,--=MR.05:FX?%84EHZ8ES4U(FX)7I^0I:Y2K1OS!+P27;QT'6%Q1^D+;"<^
MKJC\G;B?.QV9Q'G5='9II4X9?LQ V-?8RPH]ZR&+])P?")C3/=X?3DOGKT,H
MCJ*>78/E2T;1V1RP]AG'NI<LO0W7:EO;HSB\R+[FS\6FNPAYQNI";E8+SOGV
M[N(=?N64W?D4\>*Q*FB->JH;%>@@9-+XFI5N(,!_A^S^(\J%'.4?QFOZ;Z]@
MD<*Z AXKWK'!-L9\3W%^H/0?XEQ"BF7X#39M#*NG6:ZZNG+61SA_%07KYYLD
MQL^E%!7>\$7C$/><6G''(3#+(QA?EH<H05Y 6#2TM"CY#%8GZ]+,A@+A8[QP
MK<'M4ZR< IE'&#R.(7S 5N0K@EY:1HX=G=YC5XF^&GS*.%U0+$1.4!E@ZI!U
M"P'-$V9>+(%TQNJG:T84E[F3WFN(=(P$8!B0NJ8\ I*H+[BF48M*>M///V<=
MT2B1%[VUCZQG*\Q-LE@ER_U8LF_Y*9A7S<2ZUG,]+#O*9.'5L:'\M)4,UG50
MUM/&![](DQC64^0DUQ)<N1!^:G\C9 < !OFX1C+,CC=& V6_W\_1:O^RZBNS
MF%J<223Y\%.74%^\)UFS:F,@<(MD;^^> SIS.Y0O*6-(@P<Y? 0<J"N@RW"G
M&H5OP<5I+*[7B%27B>R$PD8D*=-46NH]DT.+/.;9)+*9>;!'8O&"^XU4.1@9
MS'@1B@K7ZH*??XVW\SRWDI1P9>Q^<44P&>7T5T0;SN2&[Z-FVC@A"3DPBAPN
M_+DE2N&3*%0NCD%V*8-9J&$ 7$^TLJ<\M6QZ;S4!", 25P?]?6  O\"0A]XK
M673*KH(1,8K(&D6*5W AWJF5DED:/-?%TASTU!4ZZFUU;FC5#'19N;;"TU\K
M/^-Z"*;B=DV3O^U"P!0;S%%F_H#E94N6X"%JU$G,]:FD-;(F2O_;LVBU>'E$
MHNM<O]=ZF65:R!'33\$5@/+9Q!DR7:HJ*D:[U,)6)?/N^Z%U,GB=V-N4?'_#
MYDL Z+FF$DM&RUB;=#?[2;S>6-@1=772Y#[]*<):L(+3^LE ;A-' ;J=.]&T
MU@&!/R PQHK/+LL_8/"%JH_E>%4+_>"-; !#U7RG %*24(_+YJRJNZ84!\E?
M*7KVJFAB1N)Y :,G:<5]FN6?H6_5]:K/'_LI'XOBZ/SS.>Z_-$H2:73QOZ;@
MMPB4_HA[_NB%_%A5/MS\I2PZB \'-$JH+2X77.0X>V8^+5(E+6JL_+/L2B0#
MH'I&%'SHK6!M:^L[A7)T'+<GF(SFGN\(QB*?&5%;]%'Z>S6];\4YN)[@D%:>
MOR1$3O]!$D5$7^R5!OE]<+6_OM_U!?PE6?HA6_3W>D6P7?B"4&\AZW4YXB.[
M_*; 'XEF4=;:\DZ2&]G(, FI+*C96/>Y@=+S>AY-]RC*]?V][J'72  :P!OA
M1)#CU6_-$^3W@8N7I&/E$ 86/K#OG')6XAHB@A.256@F1>-8MYB=1!!$D:\C
M?T?<P'30QWT213'RIPN980':>@HDK0\?E(O?( -4(4ARCL\1/:J>C<E##'\/
MS3F03IRUEAW*VS[BJ'0(:*XN\Z+'URQ2-)4/]P-F"*/7Y--(]C-Y&LE3.9&O
M1$/?Y&3E*R"J^57EKPKM^5-=!^6#9BL.].Q[J; E"H"$N^+T;Y=!.?D"@3?M
M\K,?;9@AA!8)<*,R(AL&(EM8H2NXO2W&_)AQBWY.5,B/ #.1[#+ZOO-M+VK2
MR:HMW6K=!VR")JBX=3YVY3X"D?18'ZU=U@-B^'8MAN8ZJ87(:=3B7""B_T<B
M]NBO%7=S>U"T&_, /NKS)3&Q\0^&<S/M%T./ $J1C0\EM9.;+?R[AT90ZNYK
M7]+30V["X0J>E888K):=BE5^K#P7CE\&XK\ZB >ZD4@0527L\0&A\7:*2IPW
M$K%HO#_ T_'Q=B?.%KT23F#S52%,K.? ]AX<9/BYNMIFYX#(4>&<5D]YGC>C
MTN&B/9Y/!Z[S&(OAN.)B_D=5VPX;&5SZ_.);:1A)0-$G!\ @E^&=Y-2#5\6F
MU1"]Z5-Z.)70^$=YY*+%BCI&S31Q0K*7_0IF)"Y=#;KI)]:X&BSZCM+[AHGL
M3MG!3.=#2WUB%TU6Y2Y?+K]K-LVOIZJZ>VB[[K"'_9R?/%7'?S.UNB) ^*U8
M8;6'IV]QP;!0%9#F$= 1RC4%$SL;J0M<V]9%#]UN;T;BA2<_HEB W7"- Y.[
MFC3#2R7*"U!M6_I?D;^E4@;U-8A@>5/SVX<3'J@T$\W;5FW/D?&Q_,39%2HI
M?ONY=*L)IJC]+M>>^"E3(BBML87.JIQF53>EUR[EEI&LQ/50BHF$49]6O*\@
M&W\9W04B/G$)([+-S^+I!!]Z&,X"84QS3/P_)IOV+=]I1H)W_4]L<SY5T#_G
MC[(>++=[V72?Q6*&B28.(+F9W[B=+94QM65*!@:R[SM9#U[* <L?!*Q*JAGL
MT3^:YZ-%'RA&S_N^J[C63#E$R!.G7<1NFZ-!\\&0YR4N-*VNS[@9)#;;2T_M
M6#3_"U,4E )!TF<$51)%<Q*NI.=I%^=WX8W_2C%^Q022@#T%[L^3YI'0_C68
M ;Z6M]B:I6G ]G3](*KWEH]FU%+G0>HE%BJT:;8'3%D/T?ZL]F:!&;3D.$O9
M7[&AJWF-O;(@AU\9S$9&1P?13/)^*;W:,EM#]GE(1X]0+TX@\1$P9VVV)&MW
MEX/NQ1^^P%%[=MQ.&;F:=M"P!2]C_*9+K)-Y$5XX9<39%_$4IM&.7A"^^2Q3
M/5P&E3H^QNU!/7*]RMOQC'2H:R;W:<SL':7%%41$MU_R_KBWGFWK1XXGEWRY
MU0<0Y>W 7]@,D',OI!WC7AX2'WYXOE_9NW9WS^HAZB7W3=('B^J. 78P-;-.
M)[HN,:\X+M.GE =L1#_=69=_!,QC!^98A3#0CQ*!"Q;QQB :H'#AEV0G1)8'
M^4D*E%U'VM)T>+R"E=>7L+MIV?@B5HO#@4A31<&J)<H+YHFNYM^EVHKM"%WI
MUV%[F1PS^^(+;?RW5PA<1->V!; SJI1R?<4JBX(H5Q:R8(16YCAF:?V?C%&7
M,0N]=KGO_<4V)P=QY8-H](KVZ>&QCLB4?AVWQQ;]C1K[=:+_1O>0F 5Q.Z6$
M-.?9>,DLZ>'"O*^KF#*%?S!LTT.MP+>F1*,8X*N2ITLT#QK#^97*!2]=OII2
MU__">)=15101#"C\5!. S$)N)',2KX:-\N*2$\[P[MW3N&0[4(PZ7]9$)<_^
M>HW_A)K$'P',3[!S8D[W_=I&*!(%I@*IOXC5&(0K34BX:W]?YL,7X/P[X4#>
M,@0#US.G_1694[TBTF?@<S'<.D4?W4M$]2[!2>GPN*TOYBE[OL29/;YDTS )
M\J/[W&0#US;^[WI), \UJ&8>5'<].-%]S5Y M4FKEDQ:*0/=U=N=LG'C;,0>
M2M<]OON .V6;]QFU1VR33[#R0'N9!JJ]MH+-(?\]C:EN<]"^P[[X$E:ICUM$
M4D]R-+X3R=#)(.Y;$+L[?W4.O.[NU6S.";X]+/KD*:F(<@O7OV;0O8$5FB2,
MRRW[D<?68<<IQY8^IUW18Z/6.1//F\'2Z/1VZI#]XU[$5^HB9+CHJW+W[F?>
MH#/<']L6'.9&5M',M@.+2 )79&<:$"M6]RH.19?,:MWJ:4&6#1_JWCVV:^<?
MM*'P9[+-6@@K1>OU)LWU0=>#]!J77)M-'RS70%')W-(E%&UY)#_#WQ2C++(_
M KQ]:W=)P24%"\ <A4D[:C6N2Z<WGZ0[]1NHHG3/RSUCJF^\*#B+];T6\FU
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M+?7;N, 8K\RT]VZP]=Z;6+0TH!\RQ8TUW\T1%/P1D>**/WSW89CZ5YO%1N0
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M4K(^9@3C_0['7M&$ENY]4A>*2(,?::7H+H/U-\8??1A+B[)KPFQ#6]Y"38\
M*ZW9"ZYES7289;R]_PS;R9+4+>E,7.M[8UU9FSUO#*K$57ULS[F^E=1 _6>F
M0 ,1NJXF></%ZC#0V83.- <TQ6&27EXE4$Y"1I(M[!+%6V;MH.RM-Q:74^1]
M/WD1#,.A'0TF;\MRW,)>)I]TX^F<&#WRL5%OPTXINY]@WZP!A MC&6]1*.;.
M$TS6N&%%VD"@UZ!N1*2TUI+E=HR-E)9+423+R-7$UH,W2N4#[*OX/ZB_E@#>
MWW0K@+I)("UT97HR--YI'DK,0LU4^4QYIVP]]-XR3_$Z(BE29<UN(JC0$4\A
M?7.%+PM._M(@6=*:6^J>H*HZ(]DI(R<C2H[5Q[-P>KWF/*2$_136O2[":-$_
M3B7#J&YL-JB@1TX@TJVYU9\Y#_==#^FS]FO0EDS,O8E'@-L2\IZNR!J;VC.8
M^:ZEB@3+)SM:#_N^2&'3J<L1M_FW9M\;R+Z"T,!BCX VOPJUXIN9&,,Y!4MG
MXCC4F)QL"K&2SXVF3HQ2J2SXEQB?9O4G6%S191!CAXC'"H4Z;\H$9_WU@$I]
M;10S]IS16'(.-M1&7GA,1KH4R(IM2]"R.Z5($=,I2A9#F8;H#V'<?DB$FC</
M)P<Z_#PSF-OLY4GQXU=+!^UF:\TD?1Z]_"WHLF<BH9<KY):I)Z$M T>NHLI,
M#F$DO,04E3.MITZ,C&H.BY.)ZFI&%M_"AR$,3[@?,1\E1MH$A2<VP'%$1H()
M3EQETK:6MVLTA/JXZE3"N'.-G>)<L!Y)UV63VG-62<)44(BON;:HQAH2OJ4D
M5IPMJOP&6=; TJ(LXE\3OC!H :P6([0>!;ULA 9[^?WB$Y1*1W(AN+'$0\\H
MD(0> 7D?7FP?AJ9#".;V$C0Q5D6HI-9=;/D?1*JMN5?#/E'#G74:W4NX(^3A
M?OE234Z36_[;?ECV^83,.&D/1- PR](=U=ZU6#?WN%/CS=PGI<E4A4,ZFGH>
M^EQBSII@_!#.&N5G9/>L*ZH2ND&C4S%2.C6QH1,JDOC/T>+"$_$SQA?3-)X&
MJ3I*P.RQS%^S7-60%-U]$Y+^::QR"8<\]PB8OZ>_$[DSS%.2 (A=@Z[;987'
M'F;W_KRM+?.^8C+Z"137WGZX5$:D,G\$6%_F'#ZE8]]$(?S_O/&[EYVC)Y/Q
M_Z?%_[_V_3[6QF:'<^Y?=J/_C>:#,B&!%+#ZP&)M+G,J/R[9HV?PW9_[JE_M
M]KDO5\6J$+8%)<;4X0]_!J6WJ@+5SK#*7YK(Z]I2D<(L>TV<=,/54XJ_!G:)
MR6- V,@;!AT 90 Q@A^3Y=UWE9.BST)[C6[CR@P6^!JOU_Y?\AS 4T.>DK*R
M_HQ@M)$<V-H89AS;&O).Z*S76N6=K<WK> XN$-:>SJ4E99$1QN3+'V%(;IE6
M%5E039G3(;T,QMD!(N9\"63JB VJE+(FA@L!+;WBF^\!2>$,^'^J&G[2F=PK
MP5BF&G,G7'XJJZ1P^"Z7O"?TQ<CT-<G+TN@CBBNCV T!"RV\>90W&Z1]C7#6
M%0O%ZH=1@T>]Z-&-EG\$5N&FC_7/<Z;/T,C5"JATS16$\VSK@-#8FS6=!+!C
M/SN9<;K3E]/3Y*QM2,6F44-F)M[IP+L4O:,[XESN>O$F_SYM$T3=]"TNO&.7
M,#QX>YM,NF5N4VMC@.SK6?QD'C(O)Z#F'_G\\^2D,C+/QI*611L:I#S0-J;G
MTU.QJEM$&X#*Y6;P=%Q?\*_K]G%47B$?/R2&G"6=R]5-M C8. LM=LX)23JT
MEWFZ!N5Z^F;:6Z+T./15%EXC$%3?6-(N=GI-V_^LEL"O#6M(0-.AAR_/L6"[
M'"J11,#KF;@X9M<KZ#K"J1%!9E9EG:,%2WV4$J3(>02(C6WHEW$"D   +[1R
MLYP?<@%.VWP*")T:\W1AKF7Z;O'>JWT-=^&2NF?,2FOA&P\D>'G01T#/[<M?
M*B;F8@<A'?=,LTP]@DK%T<^\/V9J6'SIYJJT#8P<5D-X!%#VVLHT)7\Y=)Z6
MS<AMXECHS!L!%@2TO=Q/XE^M/^.-M>72N"C;BG7 KMR@.@2#I_>.UD>PK;_O
M=BL'5>0AEEHY0_'V07GF_*J!E:5,[ZRVM_ #RUC^DHS_GS]:\[$SK&Q!K0F5
M<SJE7LM'XWPL]^,%5Z_]N"U*09A6//Q1Z2>NE;E1&J&R@>CTR"=8%_/%BTO[
MJ4FUKD;YRU+F!*D5*=3OR9N_#Q +&B/Y\3,R,77?IC?EIYHT2,B%YEJ8H3GQ
M%'52S]?^W_FRD_8P)@D!1IP>J-2\_CP58?\@LK- 4%VVY!,OW1!#E69'M&]5
M$'3D.Y:3@Q,<DR0RX)LXJ+9<1GP-V2LXGDAHWK53$?U-12M8H"LO#)]J$6A,
M+G,K_(KQ7"F*IK7-'_[**_GA76TV[+VQ(=3F"N.M")ULS9>[F.*'1+NO7^JX
M5,:?JQWP-):Z/9U-3%<41$44U4#]3*Z[6DO)=H."0M[=S0:C/TGX/"K"-^,1
M@':E$[Z.4EZV&6""11ZN#HD(P-#G:VA.@00DV)@!S0WKSUX'VA:)2IUH[BC[
M;D250$E_'AEPK35N01W/T.RQ]*LQZ)0=9B9Y1)700'&IUV_$1E&$:_;%$Y=L
M&-6V-;RR+Q,0),RL/#3[^;BA(/GHNQNI2[W9 FVI+:U.JAMCE5O-))C-_?DN
MX<_1@WS>VPC-DOX>*Z$@6Y&UGBZJGGAR!HO?&OS?<]LH$R5O)*=<Z638;%C*
M*5 8)WN(RX502RZ5TW11<V]X0>&4% _+I]XCN$A-5?<PK8-^9>%OI3#>,R(8
MC0%V79S4DJN=8-BYQ\ JWA7YK%;'VT3J%Q$X!D)K2<)(T#*OK $WR]OD$21%
M %WB;>8:S-K":]SQT(C-R4J?Y#!!33N X9.H.@D-&) ;]3X6(0=)8_-M>J!6
M!L)N+G[-?VL<$ERX?]N:%)(_""J4?UD?398><:Z(3 "<_>IMW>IR>A250<3F
MX02G @G:]*UUV1CAC-@?BF.5(/%EUQ\JUF=-R:X]SL1;HXW@7A=2RF/KSN ^
MZ6EC;#^+JD!G8O)P&[C'O^D?=WP$P'/M@BE/'S*S+"L[3<T1F0?:G"7]2(@Q
MR_:M/P)X 6CUJ@Q<B.:D3K:R-F<GH=@\G]M>6%(RU,J+"]@TH/>M\^_LH\!*
M9M>2^%9EOGV<: K6H$ 1PG VQ.:D@DJW4'E9E*2,>WQ_ CBM3",PEK. %:G3
M^^ 4'U-'SAEHE,R'"$8$_WX]?W^HNO9T@+4+JZFLK5#*,3YIA;G[LZMT38W)
MTN^RV;&04[&B4>OT/?EMF'L9Z"-40+E58X$M>:OWN+_@J@*G_536\A'P_+!%
M^GW N4R@3-(J-3<1E0&FST$#M-[Y=4FIA0%A'9]7V/LJN@I>P\WI.6B]1!0H
M9'9>#[6'.\W(T,4P^1?:?@&;.?&O]$3J(_*62'T$9=**D$.V3N0Q?QH152;9
M!JK/I-$++:C/F>?B9J1"[UA]#2>;]W?2/4PF)A3UQN5UZ+_E?O_GA#3#1KI[
M%]"VE6>%[3^,79T]6]K>DB;DR =@56$UR,AG#F_[\?]@PA*+-[2VCCXJ_"8C
M=9N1YW%[-%9K-,03/5RNNKSXVE?YN8\(GBA%KS.8Y4SLM+7V<UC!H _7T?R\
M!*YL)6P8%3%I@URC/.'F*+_'E?-]\P/7.Y2#(SVVWI/J^Y!ND%43]W<*,Y:+
MTF65"%M?]T< UHP?CTLF\9#KNB%4ZDJ?TI9-V0*CA_&"N>@50F"PP5M4<J]9
MM08\B/D4UT:EG'$!3.).,X2+KW8W4S;M:-*GXD@)VT"9N9%6AN8,/%=N*-U2
MJX0#95*=JK#);FAM,?(BJ#/XH"'BYJ$T/*PH23;I)QR^R&_B0S\PRG$[&[CK
M7S,6YE$7AV&POWV\I@K,!9:7C8WT]IC #PC@]>>9 X'ZPTTVDRM[&KXT#Q/P
ME@8R"RK.S=M1TM.H/S6%?%5F.>$.^OO:3&_"F,M<OI241.(8"^N])VQ@ V.[
M[2TW"3 E-U4&K$L;+&V%Z6?'!T?$QA4LNE20S'Q%?6 Q\9-HK9/F[<=0$R^8
MLUKF/UW*@S$XVWG3?.ZF8USRH&X%>$EZ[43K*(N1D\^.X2Q9O84)G'YVDD'?
M0R_4$W>SIW&TK]7_;,U!SZN(;, T(4S43Z-4QDQTC;<7X'HG2.J1>'0TBKD5
MN?2N*O/:Z1G DQ;?;W+\OR :Y7^;;ON4_NVAT/H_)D)XHGB3I#H_SE@+FWB"
MKS#$1@5#M4-FL^X54/5_*LSI3>TS)3WQ[7#-KC:2U.VWPK,\QV7]=^;MJWPP
M)JDNST K,-[DB7Z]#&V3O;T& N+#Q]DT:QKHR?I66S+56($EG4N/$ZI:?&81
MF;6.PTWMKJFJ[WZ]6@Y4?TUC_)*C<+GH81(BXO'2OJ70 _U!),C],AS>+\L!
M&7\_;'!P*1F%ON3%$XJ6^]^\CA!!1NZ)AGJ(]+!AZ._R%P-GNSMR3^L.&A(<
MNIN-QR]%=*Y2H][+&%MLJILXJ"<&BR'7/M4-@:>ZD5H9N6:(.P<M$?^B4ON1
M.+*J'VSLNSJS!*S+LW4_S>Q#+YHKC5X[N%E@-HX)F=KGC[8)OR:S/K >$1:
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M!MX_6F^\#H(,-&"?[!*W-QO6A(QHK6B-8ZE$B%Y]U"UOX\V?V"ZV3=AX:L^
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MEI0I-CS S=37:U#J>) EPX^G9;QDL$%A?)0]ZTDZL^EB;\F--^&R>4C @N"
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MYND&:+64 %I=OK.&+;K;W1%#'F>(@ZXP7Y\@HLR0*W>Y^)0^5$39&D@/[T\
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M-R5[_*KDKIG)\E8PK<RCK69^Z\W+(ZX<H&GVN(T L2^_2MIK\?N2:[_;Q5G
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MPY7+?*O0K"VF)=>666 C>M;HG9!*D$;(M_-OR>R3_'O9=S<"VG0HD]E'FG%
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MBL^GG#,)UMOY1C5#LV5]I&&QF[8V*J&+;#*RL*@C-]%J5Y!(?>]%9&<5B$5
M*+MO<< A1_O!\XZ/>8J57!040V9TL$(,Y]R]75E11L0(C)F;[WCM:9,? 51J
M=SR*;HKE7CP5U:JIC?+6MKU3+:L5JLU3M1]CCH#2WK-EOS8HQO"AU*&_F:1R
M:E%B+L<^Q?:VE(&MX<0N53#S:;1WTZ%;'F."0>NVA?.]@\4E,E"@F]M_ID;K
M L7J1=.+E8F&Z*,LHVY'SJ^&@1<JV%(#'_5XN1'6)R4E'<%/M&B,[L!PCDW)
MRGVV^7GY)0O*M27K0N^?M/.3RFTF3W_YS^]:UYSYK^TK.V 3E*5I7"#'^PKO
M?J$N1LMC0T/XF!?_/=9]KS*K\OD^K65DWOZ>$_E/(MOW[ WZ><Z'TNLU4E)\
M^*;P^8>30-?[O;ZZ=Q(13[(^_\>EI=7V1FL^SPU17UH%X@]Q5<Z_6!N!A,J]
M\.$PYB3H?J\^(14/!EMJ9G! I5X.2_:5>QE?.-#C[]NRVBRM9L:C7:/)YJ(7
M'IDTN?$56W@_*FM@0H-,2BI'ZI3RB4X5Y2EP/5&>$-Y@FO"5/!.ZV3@KF((-
M7#^I332X_^#!IRO^]?SC-60OV1O1,_7*O:VF9^N'?6YLI5Q4UFY^P=BNR>;9
M*S;H0U61?-:J=<0KXE7\H*H<Q"+<?S^$<S!T9QJM;K6,KS<V:J,.=VT_H[A#
M,?*'K%VI$*B>B3KG9Q'#=ZE6R64F]21V[$SY2V/QB8BNQO_5WG='-;EF_09%
M0A%0>D>ITJ5+#8ATZ0I(E28E B*]1D! J0("2I?>$>D00*DB()TH/0&I @DU
M0@@W.#-G/&=F=,ZWYKOK?G=]?SQ_)6L_[]Z__>SZO/N-V.^:^+"C'S/DR4GT
MS?@(X(XV&C,)?&[BDN%L=V8CDG!"_.R0411:2 U6'F )BI*]D^<$,TD[4\5A
MF/=XD/[]0H$*WRCDN^"_ATU:E-Y,'M)*A[BDV:4^$T+IX_@JY,Z9K!<Y-#V#
M&Q:)./!M3QW<:3S%(O#B[ F ZCM$Y?H5M3R?5SP"(T9^AR-#'%KS--QT_YY$
M:/1[JW[W=3]@^[L_*+\P_XNW^PW;'W6"QLK#P^.[D_WM&7[4B#MAPW]QL[\A
MCC,YO3@O>QK5#=^C_;-;Z_SE9]>__<RBA-)86U9']]B4*1<.>C.77912&XN9
MKF=\[391O@ZAD55%# @ZTRHCDP;*!SYM]X?U1SA^E;\-.(*5Q-%J7V-AABG@
M?)&!(LKC!+ K!&Y#$X][;[/U9%4^$F\C#Z!N'2DCD:A^N.XF?>.3C/L'GA.
M=R2"GZO*%6#FR. :O+D(PX0(5DR*7 _ND]=YO<(W<XI:??CW<'8+K5D(VA%<
M+\3.F*0FDMUZ "'WN(911&IL*3<\G5#Q53"ZGG<-4"&ZR?<([6L%0<0QK#)(
MY!#5#!EJ]8Z=E^)@+0;E^\7%0#47P*4.[,C,I\6=BU<SEFN7@073<>7V >*C
M%0'T-M[BV(BRZ;64P59?BJ%YLFS_;76,0VL*=6W5>F-OF2O-3)\-G-1BZ9R
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MU@D'=P>"9TII.X/HWJ!$/@DLCG;R5R2L@3B"4RP>+;+P7(M1@\LZ!P:*R5^
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ME<'$:6IO!NS1!241F3%6K=88VD?4%@4HP8^8+?"OI.@!B2&/=]EW"&K6_F4
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M52:GJT7N8X<P [+0W-7MP()!M>I(#R!8V:5D3D$AFSB3#248,S]S>4LH@\T
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MMCK1]%N%Q5H.?LY4>B;T_S*Y!3Y[\,"?@2<QA6;[1=L$OG/6EDVD@B\HPG.
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M(G]X=91ORCZ\3H:5 -VAABR,@FI)%'-\2*$]9[.-$$JH^/91VI-Z!M*^A(S
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MJAF -FFF#HU>0_X-BNGK%I)H7P2SN-B&ODSQ!KN=[=.[/NU)JP=J\WZW8">
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M]&;AF4I_4X(6Y!]641 GT//Y/ /:<"1_=GT1!RQOX !F^3]0Q4I7*-Z>".
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MPAX'O.3K QWB35T5NKVSN:9)5O(5X,V10X,9$"H"8G49(@V]P!C+(TA10Q?
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M%&AQD=;';?\\IAXP9L!E'LN%RL>8"Z3CMT;72MR^N,,1'K%X.,2X-1DB)Z^
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MHNQM<A^\6AKX?_\@'UT&#B"A?X4#Y-'!]=!>I2+H&-:B&G#4-H*B7CF ?N(
MAAT5+)>Q"A8'#)R-7RO^%\._&/[%\"^&_T&&Y"WBXBN"%L]SEQ[Z<XOXXAR$
M4/EZ'P=L3E*='\OW7NU)Z2Y[['  ./FW(PC:H+"QRZ!;?SKRX!V@Q;/X%]>_
MN/[%]2^N_UNY]&)Y@*)1?K_2 1S ML-.-"6ZDWW'V>C'7:$N..?]!PRRSV.!
MP]:G<U'<<6")8>96B/''2D#Q(.I*T;SQ(544/".^@8^E"9WXEBY^Z]:-^T\
MFR'Y_L7O!'4%Y6!8R8!0I/K#B3O$1,S>A*"GMC4;(:2\U8.E+YQN)2+/X$Q4
MJ&'><FQ,)=Y,LN1SW?A(XC >O&D]Q0J'#88W%B:,A3)FV'5XZ7@6RE&IHR%
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MOC-=LSLY,N6I2E90PXBONE ZV:[6O42DR8 Y^A)Z_.:0CV16OZ6U3WS<@QC
MUZ!B3YL/- X?9)Y-R-N2UD^J&"X->G6G.9;/COMS=V\G,>.AW%8./=HBJ5VH
M&+[%[-MG=*M!F65^-W4]9OMS0";P <V\HX<>&U!SQ8=;=&2_Y"5?)SF-87GS
M:CGL 9_@$(C* J&4G1$3*%AE04 [\N'^#RFIU1\AUX^E:C*0H#"L1@Y/+7HN
MPG(Y.#F_N4$[?8'81C[@UBK[3%2E"?8QY@-_26KY=^Y?IO*392=5R0:INL:&
MA_+RR'  B[=B-98'M5%&R].6(]68^"TA004=UW\"]XV4%<DW7OCD3'=(>B(\
M<!(+%-H/R0]D^0XX!]JC&G:7J>K-.!].U>P'#[M5<#;%%-DHLI GRX^)XH 8
M,-Z,K!+"C%AKDI/3<-+JX?M7D2]"'C-=WM)U/\JC8N^4)HX*'BC#\#U#4QT7
M:91H>[I0,_IR$I0$L![!*NOY%1M<J;;@X3P&+8V)^J961*]O"AW!V.K0FH."
M-TR_;<V>,4W$0VB6QNP5W!Z0@)]SRFG0=[32I4ARJEH+2Y=1<&A)L'JX23+E
MD0?Y]L*OM8EU;'RP8MVW]AW@:Q/,",]"J;@OM;L.PNN[& )-K!":E,HVDU4V
M/UU@0@?HGEMGP&/VHCE5=.?F@(&_<V,48D_P67/8EMKBJ -9UXCDP;#V<OD1
MW4>,5?^E'"HQ,=,G%37RN% [ UK[Q5S_\B?[1HA X,-0YV!1B(0F2)3^>/PV
M'WDB4Y1FMQX,SB*T@+&UC]I_^9DV?(QQP"E0&Q79A20S(QXPYF]A'HUW_&DB
M\.B X#G! FN\]T;+QWHH"U8''9GFC32C/LP6T;SU$4:CU$;,S=+"=7A(BW=(
M:/UF/*>(?"[J<N+=0%-4O'.CHMN\R?B*9<='+Q@[9C]_&S[-?&/R\%/;%%V/
M U$[_]V)(6XV'H(03!0*!US>Z*)R8+_7,.NZ.6/[2G:K.-EMP(,4_2J>>EB,
M.R&0B+^T[Y,FV]*.P9S_>D^D$=/"KUK8A&8FPBM'^A,/.C/HS5RR;NEG^F3[
M^GJD_F+.R&%G@W>=*T3.X5)^PEMM/S0S^)U#J9EF<#+\6F/L[<E[>DPCB9!]
M!2:P(+JFW ;%HM(6NS>E-?TBD3@+E(7M$B*NO<4>M",]M#)<BS+ <OD8[V&E
M<< WYO7H%^OO!Y$OK;@Y$]6]#,SQIV754")/)YZJ.U7,*Z2HT/7NROP_[9W]
M/Q,(',?G<L1YJ@N)\GBIC)S,TXVI"S=TZE*X(7?G80\A[<C&&58:8F7,M9SA
M;BO<K"4/LU4R4;EB0[1(VX31"IFGS7:O[J=[O>[N]>IUKW[TP_?G]Q_P^7[>
MGZ&ZB@6[V+"]J-^5H>4=[C[FY;YNIV!"KZ#:R /W,VE'+^JL0*TV79KQW:[]
M:CJ"N[NN\2<)-BAE#,Z,-Y98-A*5!5[4M2S<JYI;E?\(88P6F,!E1I44Z\Z3
M^4=Y=9ECDIC59(Q1IN#S,JB=7.DPT!LHRG*4#K5=S9YH[I?9<UK=C9P+-)TZ
M=;:0<J9V;:"W"8"@1Q]]H?_U4Z=$NV(7OJ?'R9@+DN>M* ^;IN45.Y,YNR,!
M-7MJ;++KW%M\'?@R8_+CCV-""0-&6'Q.I"LV;EZ9<N4;A84:\)U78)<3N/%E
M^?.LJ-%],E]3;IRH4!9TC-^T9M4E))>YB30930D7UL9'E?9C6FQO_YYO^0WR
MJ"-*@C)$G+^YXZ'0]'DS7T)V[ J\YEBA<0\[><"!,*NBGF&D/SL\YU,?YWT#
M%M\3G"?2O4'/PCCCN-B,;8 ' FX42G3+8&+(K^\EE^_J8GWK=D0N"R>)/<0F
M:8Y7%"R@/AD&.6S=FQ@[ICF7;YM\V!]UOZ8_E6J8CK[G8Z*Z=[N-/9 4F^%
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MS9(.&BVECV/1['T#91K9GTQ?[A8Q#C@XG+^1*Q#%M89^9G2IW;'OL%8Y$>R
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M:VOO5A3"#JL!U!FJ8G5,XKNCU@]S8K&A6@V #$&6Y._F"Z*^5.$:<&]F<$4
M+,WX)4[8=EZI!KSKGCSY2S*_CEY'KZ/7T>OH#XLFX_Y.KC)4/_T34$L#!!0
M   (  *"850<(=BBWU<  &V%   1    :6UG-#4T.3<X.#9?-RYJ<&?LNP=4
ME,NV+OHC.4O.04!!$9"<DT@222)!HH#$EIPSDG,44%2B)$F24Y-#@T@.C>1N
M<J:1T$!#7]:Y[YQ[UK[KW7'.?FOO?<\[^^_Q]1B3O[J*635KUC>K9J%GT,O
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M2M_;IHG"T_?R5)XI1 ,5#JAB3(I.9HZ/O8$T#5/K]6I>:1^>V?8&=T)T3$A
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M7T>$]EBM*4+.SUTF&.&MY#' T4<64M2SP[2&4]'(_5JCJWL"BK4-L&F#%VB
MA'(9WN#AA+EM>/ 6/GXB[5 A7&Q%HVWV/NV):V@' ?]1L,N.R1 EQLK%4M@U
M!_+K]VDFZPU5Q>JFF"<Q4Q^>+#.;#(RP%V-BIIIV*E("VO\ Z">AO-! HC3I
M=?,0&L@I]SWQ(84$(7^-HH&=LJ4+@NF9(#@[H_+A3_BQMJ(OY!VEMB+POT,E
M<"O?0>Y$DQ I^'A<2B"+$^%F+?[(O.&5R\BS1#CG>,5+[U)889'[PZ+#23WM
M?L_8R :YIHM*]AT=?PV]5J1;GJGAK=.H_A\#H[>^8)XCC+/#W$<P3+= : "?
MNDBZ+6>"RF!LYA;8,B\9*KT3"8_]]%$RD(Y+J9>/W$Z".#*.M6&,[_E1GRJ-
M^ZL#/+?O^YM=K:*]9S)XAQY#9319Y V-H#!>(I&Q0PR(>*]+ENAA8 :,QT\Q
M\=FOTQ%6OO6!]G9''.Y1&=8=9K()IX>I/9E"&4?@)SV#Y/53(^SI3%L:^FL+
MN9U&'W,[[=L$#WD6,]R<;& 83FX<5I89_5%O'"&LTPW= 7R/G2+/9BO*\^?,
MI,%'Y.-/*M8>5P*9'0B:*'],O]SYN<U%QO3QJXZC0EO=QZANJ4CIFMGF@_ )
MPSG4H\FUMK AVPP!.DN :;#.N\]NZ*[FD^F\B#KA^EX3BIX@4K!"J=&6"U))
MTH=7H\>K(8[HE.7^D/FV*?FW,9F'=LWV3VKLH +L45;G$>-*\B/V!^#[:  O
M/;=HL,Q;[4F=$1)#FS"19_(4ZU?<1<PO==F7[=! GIF%;>UST5M[EH^"1EA)
M1*ZI'CGNSW*3Z%6W56R X)^-.MJHIA,^>,#P[J4.OA3M=J">9RG!J0$KP/A(
MD-F=!W!9PL?I1X^_U/(73KWQ>-X:-6+8@1Q  ^PW<5?E#4DM]P@B^$7:'6]A
ME\#*QRLXL4^$!I[Z@Y/B)B:-YR?>T8\BY/NQW(6T.U>=29]R-]E7N)Q\N['(
MGC^R,-^@CH-S>@^^BR,T\+/7K]5;^?>RCW<E7'"B.X@8SQ>:MC0()Z5'7AJ,
M\DBIW8NT+ CK,G1QX;?"=9'V_!5SHC -7C]X=NC4\]E&NZZYKJEN6F@@<(2]
M+(3NIUR_U0.-5?$5X6%W\LT+FG@P/YQ;+*)&-$KH_A%OULFDNJ-+]RT-E1'S
MEZ?9E _O(NL\\E2_!N7@Z1':]A /#1^\ITB4GT1HS2M^14DB3-_:@>#<GW74
M)RNP<R<J\7S8GLM.WV=<9@;KI7_ ,CML/:E9A?2E$F+6.GMY7(SB#+<C^+J8
MZ=I //HO$[C3+A%*B>R<DZQB*'OSE1&2>>3SG1X1WT^N,W)%_E%A[]XXT[DT
MLEAP1]=,'9RH:QH$87M+JET^:K+=F*RT(5Q_VN[''>+]-9N 7!F,:#8)"%$6
M3&6MIFO@:?B<<SH$N"\1@-UH8J4$/Y:B =D7#?-G'^)RY%3[2/CC?'57D57+
MD5-HH(;&+'2/X=3&TL>O?:=0Y+JN8Y9NK]T:%/TFB:.<,-*#]B[1>PN5TZ&'
MIK2(Z=SER3I5?R+WESQR>F2-!.\OY^H/E8TO1G'+=[+8QZ5$"S\KZ+7'S,ZQ
MXEI^[CG5$I<-USI<2@0+PK=>1SZ9LFS,E'GVK)QA99(;4#FCZMDV)9T\(25
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MI^_CK\<IXH5;\]V3?_: 7WQ84E\5GDVUO;,2=KB85KQ%KZ!@6S,84%PI$)K
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M7(WLJQV,B>6 RU\>_C/M--0@/W]]^;/;@2G\XT.5V^1&G)C,=3W:<DP'*)X
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MJVO=O46,NN:J0^98!U]:X[O5!T3B3)"MF+FLONFML8WZ"#W-YA%:B_9GQZ7
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M8NAU/SP!%!=I$DM-#8J>_-:97].!(,R,9S=FB<RW?]A4S!FF0-9R9B)C)BE
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M$6;EX.$5$!"@8Q:5%.&3X.(7X/N)! D3$Q,'&X<<%Y><[Q[U/;[_^'7[&2#
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M30KKW@#LZB/+I.IM82+_^%Z*]S,,^%6-0+'%)@](JJVE_?.W23_FTNY,MEO
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M4FX9EN!*![:>YG1C6;XS=%KW3<Q](R2I?W6]?"<#$Q8)-<96KFZ/58YVRXG
M(7C"SQ:(MOYRZ3G+2JO[ @/DVILKGS$).V^'4K4?9\:JD/)EO<M!+]PUY#1+
M@14]TK0+A.FT?^I$E&YBQFAK=]Q59RAYHWW\="4FO8H]H7YZ^K&826Z6*2QC
M18>/I4UELQKES5S=V+!HCZ>!6J=XQ#5WQ>P.X:S!XG85)J&XQOMR<)T,^3;_
MUDQ-3:0T.,,DM<#8Q';&/S$;FW.7HVI0C/LP4129H>%.4$8D2IM_RS,']O7[
M;9!9!I%BEFO7?9MB( ?,\L_6G9O"R]C>,FU?M3.Z:+U2_-@+O/$J!>4I4$-
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M-9@0B/: CL.AX@U[-5T>QQQWA%P;&Y;2<  VTBG!*URV/M.6IKJ48:CB]8Y
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M.AU;:,U'62.7Z_>09^%0M=[=<_\@J,J@KB):&*7@G"!C%:/:[K;$]U9>3?1
M8PYF!ST?Z*0JU]%?KVLA<V#OE3+G/P:D-C=B:L?,H]31./O"S9N.4&;>01S!
MOM)5$E0^40GIWR].RS:O&;P.#6POFOIFW%*5=!3WKJ.K1)Z]T_7OQL>@Z^0'
M;Q_)$",-&</L3O;J(;8^'ZO!UZ"\WG.XTU 4Z:,&!Y&S(=M-2K5STG#[@A_K
M('J2$[WG=7H9F=&V"*IWQN2( 8V_+OV4F/8"6_X\X6DE[*9]I&9PX2V F1%T
M"\B2MXMY,']@;FR7>P[JM%Z^!2XQY12N'P30W0)945IZHLFN 6!$I?%ZI.L6
M."4 Q\*>7$O_/%;TT95K_88$@0(S,_P6V&0@H3O\  /!@WDUGJ\;#UVR(\.)
MI/%N@5%Y-NEE_L-;X ;%/*?C:W/JJ0[Z'^A_HXC1(Q?RP5-XLPSO#^Q_4HQ$
MY]MW&M/[ _N?!$GOOIA;S/GX!_K</RAR4 _^12",'EV!6P#?-J5L#S=Q7/5^
M!90,<IVB<]?2%J$GXG_^W1=%&V"$V H\""*P=>GOO["A>(I1MJ&##TL'1S%)
MAQJ--D;ND5;+-CN]CTK]E&9I_LGB<#%Y"8*@5FO-\[[E%N">2$A'.'HIW6&\
MK?0)[!VH4RGO%AB!!KAG3B&$X[L:/"<!);XU]7*>U[.-0%V1]2T(%;JXQ\='
MS#K7N(HO2E&0C@8_'X?CZNK9AS8'=A)B^!6MH/@O\?5YKL3:52.4\ #1XTA'
M*%PSIJA=PYGH#'*O!P_PS'1_Z(?!<=H;8E7!*_KA7R#K^N8QV-R<>D%1'Q=>
MN<Q9%"^MYT]*4'%E"U56:^J5GTE&,UHMNK)7 /?J[_*(61R5@V!* ID_KI6E
MEQG'01M'+)>3=.NF7KY8[0/=R8]/).2L2_USZ5X$91_7^>]>#'M=E^1X/:7;
MO3$9AB[GQ6HT^::5[-E$"BV'#"N*;,Q4_"ZVQA\,J^UH@3[X+^^R(<H7^D_C
MM445#C.W@ E1!T OAUO_SE*R_I-5?Z\/TI <7NAU.KH61.I[9OT08YMU\H6P
M191UFOD_P:GP#Y5V?=.&ZSP#X2K7SPBNU1[W<:6C?Y_]&NZ5R(.TXCSC_Z,T
MI2#R)K_85C=GJ>\<,\4XE7_]A?**Z$KY?S62QEF)]->VPY\62HDJV1SX3&(6
MC.>S[G M6*(G,T5*>?#]=)&G2N'< 2*?MUKRI9G&=5+-8!SAL@E*MT!F=RZ<
M4)49#B*,+=> O[@(_UAZ7:9BC+>[<+]YLFW<=(]T;/;'"V\J)?&(@[1+'7.8
MP(-X!\V;^'7QZ=;Z1KU;8%*<]R7)"$,:K;Q_Z;/?4?UF%:E:A1_)"[2=E<=5
M:;04\;ZSJ4-61TZ%*=]FBF+H6!FBV\[)7%]Y;4B6O%[ G7#DY'AI-1WR7?])
MU</,%UT?38)F/470J9$,07^7=]7-WR[VA+M%,M1TS>KCCHK6;BV5RF'OS(L$
M)R./TL2R%Q05-LVYPF1D5L%@EA+\/RZ5E$>!?#XZ5+"NA]'?*>'T \YR=QPX
MAV;8T?^(0[4_;XO&?W61%'_[_\$= _H-?0[BCI%$1H $N/V\&GW N85V4P8U
M3DS1G5^+G'M\M;?E_N.9Y?^+A3S8]N 6Z'>$P%MO@7,+(SF/6X (M"ILC8BH
M6^"*M^)^34P?KND;EAQPSATP2]Z_K!R,,[O4?I!S@7:^(:16,7KA <*57GW>
M> M46MP"V9S,G]S@C#[YG,0ZULX:_S6W()8FI0$N(' JN'IQ"QSC(XY5A+5:
MWLP<VQ_\P# "33\RE<Z\QC^3],N%QIG$3&A-)>/:>^)V!CYQI&RS8A5E/)7\
M(OY@#)73DTB6-I-IOR;TB69G 3VH1>&LY+['F)^HK:LU%D4%.85QLB>C;L'Q
MONZ!RLBJ]PZ=?\ZKFDSE \(9XB.2Q,YN0I4W%'GJ(B/4T-*9A;IRTG)["0T.
MGI"UD@K>+P>P9_"O*@J2/K9KSI>W@#:-I-^NRWM)\4L-8Y6YMO#E'=:7N5$2
MUU_8N79I&^")674?>Z"IK!9OY*?QJ_O3JV.553A;DX6:3)_> N\7Q*8OW*86
M&4+S*P86MLX8)\OVRU<(9,HTM%T^QGPOJG"GJ+D%L+=ZY_%5V!+G!C-8DDR)
MTQI/ZYW$45RJ'!22#2^.&[]H6L_I^A=0.,@EUAPX820*<RCG+SR:B'?I,9_)
MGY-B;0YYBM&<%L:1&ESA,R91GRAWXK1*T.<JRNZP[OI.5Z-RF\#.\WS&H:2/
M.YE^;K&S#[(U59?3O>/[PNU\V"(RU>OMV\@8OF[WE7PMOA[1 39#;R*.KB36
MAH-U[S5.-SA=@U ;U037'?8:A\0Y/J09UJ:=U+T[G>=:44^>3KT@[^\Q/V3_
M[EIL;_]MTGRQ=G5M_'QNO2@'?#(,J3H4GFN2@C9CK5SCPBMV;I:-0_WKM.$[
M1&M'M\ !(19+3BM1U.\?FMG? J5.V95 VRWP-G3ZQMUIPP1^"VS/;MI_=FI?
MO>=Z"Q@;_IA\O%$Y6BE'K)W6\7^N;9^A^9AVT?U 1WCVM.QU:6L%WG+R=<@!
M:"<+KKV@H^9:E]F)R-T,,O]Q',6# 0.6_ZFT1L]G CB)W]7\U>^1UA;_'FW-
MH(CV8RI$=JX$W;R?)C!0L !7=B.8TGB/@ [\5Y\MLE?#;&\!!M21&U^Z&TS[
MJ(J1Y<+K*#+ILUW0*5/>.5=F=ZQV#IB=O^&?(A!(5#I3L3F[9\; ]V2P41@'
M_9+. &@*V/,6O+A^S26]DUVI-X+6DG$%?TA&=S8Z/;*QB"*I9LH"6]5%X%S'
M<VL7JO242J5Y'56 <10CNE(HL$/C>*(6V$$D?V0M_L+X,YW=<#D*)!M?EFD(
MVFE]!28*0"_> &\7:K9L#%'8Q?B\S26?49'O47WUPYW(S]C H5G&[#AH$Y4/
MHM-8;9\4;N4H/>5HZ@HY*>1*X)M7(][_I #,,Q:^13>7=-4PUO?&EW,A;GM)
M:(DV6Q,L%BSN4>I$F,SO:_3ZX]YQ?OMIQ*[[["R54W6O13Q7]@O5CH!$>\7)
M$*]0IUK,SN#R)$EBBRR2-\BT@6D^KBJ?JJ.C,Y]0OC$OE>M9V')C\_+A_F P
ME#*=<:\U0S1+-TI^ W7,^:ODD&;#A'5C=?"4:H86L/NY8V.J9"FIE\]??%0[
M<$W/-R[&5HW P*%1<B 42[TVKIPN0A C)TR0EXX%59<UZ?.NJM!B-UG=M.O\
MXX\_JH^_/Y5.5Z^K2SI>I@]]=3![;3=N>UZMNOJHB/W)T\EY"JP^B(>]HG;W
MT(/\K6UK,3TO8Y&8QFFN_=>^\2B\#>XVN3.OI&_<18_D<PP]]]&T2LTET$<J
M!0T@RO8A[AO*SZ]X!H-38]=2'D/BH10FPQLC7F'KT;DLBF?4:=!R-9(C5[M^
MYRX'AW:-M]NZI.?\WWOQY7@'[[3 B56+C50+>RQG)8IBM$+7B\>,8EKERQ;C
M)G=M%\Y/[IYJR%G:>)B@W0*Z[O##BLZ&6P 95-IT"WCIFIDZ)(*:NG_X@:ZZ
M$<F^\O'*[[^)HOQO@9MRL7$+Z"P^,D'VOP7N86=>;B]^_?>#&1DB10'JE[J
M-^&M&:\Y@W#:5^E\$7C1CRN.JWS3:]J(_^-@SCI%Q,.72?=9AP=ZX\ZK#?TS
M;.'7#WQ %TRW0)L]?Q_=T<_OV1N-G%3HM-G3I.CFFF@M5TFV/+B3:*#\:NX
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M;<JH5[:\>GEQ_8\.'K!$V>2.WD%U:SI\QR2P6SNZH65-(<]IO%4TA+V>L2T
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M:8FHG/IR=RJX=-Y\24XUFIU<67S>_O>4PJG*KY2"JO=AE.W>#AE%"W[YETN
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MGN"\QQ>B#*T9T\7[_HC-_ D#UIHVM<X/4]9>@JZ?O;B*:^/WA/&.!Q/#*O/
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M(Y:B]4L?(!JQ%N.<N9$0UIGNGK9:#KE[-<?S,(7J2XY=03ZO_LQ?BRM+QJX
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M._:C[U17F!A%CR8.BOH!U_B^(_MP SD.CPWE_Y)%^6^7JR__ U!+ P04
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M,?XT)],F44<7;]:P>2Y&H"\I4F/L9)>.,%FS\?6P@)#.A^K75HAKA._LEN$
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M-\ !\XXBL!3"W#1HHCQ$C?4^:#+FFNS/;_SH65L=]G01HNY;=R@5_HZ:W*-
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M\,VIVL[T[%AE@,\BN?XG*(+YQW*4\&-E8D(4_1T$@?^><O]!OV7=5NT8,&"
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MCT-S<KJ'93=RZTW.-[,XR%46]9F02;U;IQN[@+O$QS:IT;3O-!D\.6A%V//
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M0[_@>Q@)Z._6G!I7*/]03K0IDZ=_]$!VA8.13MABU'VL6IK9M!0)P)6)%Q]
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MR,V_E3HCAC&=)FW_&)MYDN5^P]"X/YUK3WV/D1!U3\>APK2*J!<G;EXJELP
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MHIP5L7U9E(8?0NEIP>KU!23@_+1!;B!BH!X)X)D(2$*TU>["I%L0^! 4G'
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MU =X8TA %?!MKLSI2SQ!!(Z3C P3@G.;\_C<A?L+OX8JG_FSDS5RI1B0 (>
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M.U4#]:G*X<'>B,>(KMH]7B;F;)11(],Z0 )DCK;!#0'[=U.0@+AM)*!:#&:
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MTYC6U-^7(\OW+/ >8]\G1U[@(MGF%_XBW^+7*C.S8CGCNT[,Y<G_D.5\&/;
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MZI!FW8>KRU.!=81O+\RM: KL;%>9=8+E)OB6> -?7^HO?DU2+7%,V1\)'FL
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ML8@3)A126%Q@@Z,=2.%1,2*6MS@5$+E* ;>_^5#9#171R1)9OW9="GE?FA\
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M7YP:SF2#92 /?T!ZF)O44\+Z?ZV/[]\"T H(8:XANY2O>P':;76"6DN=*0-
M2R7=S^[H&X5!JT) S!:QK:2M^'U5*_]*6?E4:[UGY%(%3WE4C8T&.?*EO>B(
MXL37<_$BP;"; RD"@2SGU4 LK#7OX*F]/543 63Z>&"-ZW9FK1(2THTVQ$R$
M1';1H#O%^P#^/! (XK_OVY(-\+9^2A3B38GHNYLU $+)G^*8:")@>U, \!H
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M#-#FF5>B"A7U@I%5*DO="2N51J4/TNHBC$$HS/7S=(E6*T#"94+>+4[?=<W
M5S) 6;U4F<JQQ)/8;_YRIKVDV9B:"SAT5DTZJ!8-3010;ABK2QW3@BY6H@X
ML0B9QCZ+$(0"+.S6ME0*MHK[^O!JC#*K.]N$07>3C3T<][T\HC#RYFP#MU($
MH.P273;BFPEW="(%IML^BVH"(^/[X(:L8;&K,J$\1"@KM@AV3SP0*0,H^"1+
M>C%L*MNI914=$Y4BMJG ^#<V/&</J8:O\)'7G@&<A+MH9A/T91C.>*Y'C[F\
MAK*,=<HU-Z L@392&(,Q5:+:35]:SL]+) 9Q23_U)]$=W-.5;T2"4.WM'"[#
M,U<N11'QC*%25.@EJ*G.#'K#*;J<)9W;FM)D2-]437L9F1&;YLVY%<BP&X&)
M-R59"]7KV]N<;N^XSCC%L4WR"!'4Q$70T^1-M@M,*GMKC7X!JG3SI-X3>E!B
M>O[)G0O_KA#$PRU'B*#K1Y\TJZ_UI$/ IA)%9'&40B,!S0V K]^D7K)1KB&%
M)]ZN^3*N%=5C=-+O58Z)P(SU&?*;4WF#]\@77:,H1KE05H%4VR4(7O<Z0OLF
M+,,F+<:@N\XG1U_0E'+S=)35EQF1J3%,9GL<?Y^H91_5[7Y$/HEX HIL]348
M<5AIX(JQ?$**B+-<=]_;9/XP,AZJR 2DDBX!U@7A8]DB8&I3QO=?E'S+1J>K
MCV#!>D_*_0O@^$@5A?VRQMA\@()MO(Q(LD!5#F#3G]_5A*^XZ6J)64P/0+-$
M^%1&-TJ4/H(0["?<OYVA?0Y"T9DZ3 S'@TLC$POM5J)Z%SUA<P6<]B&A4L*S
M 9)2K+V$"";LYE+K;+B;R+PUI/?JA//G=[9-"9';<P[X/7&2!+K%V9AYZHWH
M6F#SJ]6%^Z?N+(9]*YNRUI8$1YF'L0>C$%W;;,RQHB4A*?!7U(DP8/2+X+%-
M=>(8[.O(-]<KQ[!$?D($G?,#O?AAV]J%E2L8[P$LM9"*=;AQ$X\IPWHI\J)K
MC,@S E#!4*?L15@^5,N>: R)XYZ;S.+/UR,]0W);,:XZY7^D@;-@<?.@?@%%
MW3J#/=:,V5J)RVBFJE5:FSFR7L-<*//B7LRGL^=KC#N.6YOQ\-1>R3N>,6%N
M&\K(&J'C?C&=5F9$/#MT.5 6:U"V3<V!J@"([PF"UG;1"L( \&34_E$-FJH"
MD[*8)W'93E_GK?S.QC8U*A-Q%AD2/YGW*H*& ?W%H]AFN5"V#T+(J[:ZV-]^
MLS)+0#]JCSK7=N2VO#IJT:-+1(G,Z"3(NWY&8U>G#H9+8KYI=%7KS8^FAV(,
M4B+%WD; 'P5%*8%M&*PDM$'S;(&8(@%BD^D4$,$,K=W1@),^?[?)1]<C2NI>
ML.+:/H7<*U#>8JUK]>:S C"@!$.466U[6AI2A*CQ",U)2JC;_MF<&P D,6J?
M>WO9*0Z@L&+-)XTD)L %$IQUY=&LY14K&H9B(28?!M>U NLJ&AWG5R"9AVV2
MQCL5&E*X'!GH[C503\?]@.."E^]KLG5(0<]11/[YG8[_UI"?"R6.<.)@@]9K
MR#W_:P=!_K%4:.X__ K^#X#P:^$_ %!+ P04    "  "@F%4H].)4GE:! !B
MW"\ $0   '!H870M,C R,3$R,S$N:'1M[+UI<]M(EBCZ_?X*//?,A"N>4D8N
MV.2JNJ&2I2YUVY;'DKNGWQ=%KA+:),$"0,F<7__.28";)-NT14F@"STQ98I,
M)#)/GGW+G__OI^$@N+)EE1>C7Y[1W?!98$>Z,/GHXI=G^Z<'Q\?/_N^O/_\_
MA 2OCH[?!F_M=;"OZ_S*OLHK/2BJ26F#YZ=O?@J.1X-\9(/_^>W]Z^!5H2=#
M.ZH#$ES6]7COQ8OKZ^M=X_)150PF-;RJVM7%\$5 2#/W06DE?AV\DK4-]EC(
M& DY">D9Y7LBW6/9+H^SY/\-P[TP7#Q5C*=E?G%9!\_U3P$^!&\>C>Q@, V.
M\I$<Z5P.@M/9*W=@C7HWV!\,@O?X5!6\MY4MKZS9Q2G_S\^7-< "X#&J?GFV
MM.YKOEN4%R]HEF4O/N&89\V@O4^J')A\/A;_]"-9&,8OFA]7AM9W#HV:H?7R
MT'QE <NC^0L 8@U;L[/Q /:/7QB./RM9S8=_NC5^97_XZVQH_NES\U)<!IXW
M'O=L^*@8O85C+W-]]V.F+E_4T[%] 0/)J!FY>%5]]T.+U[RH2SFJ7%$./:K@
M*B(2,L+BI4E(95??#G_O7A177YTG)9S.053E=P$(P$E?_,^;UZ?ZT@XEN7D.
M53TN5P]X]F[\!9YF\Q<8F]\]$G[P _\0LZ&3BEQ(.9X/=[)2?C7M#WXX$,K2
M\O.J$(PF7T*A9L1\.75)\&"JKYP;O"K$5RTV,KZ4J^>&7UP60_@'P.MI'-='
MV6)UNIB,ZG)Z]_[;'U> 597U[=W#EW?L?%*7G]UU]@)^??;K_PE^OK32P+_!
MSW5>#^RO-"1___E%\QF_'=I:>K9%[!^3_.J79P?%J 9F1LX !L\"W?SUR[/:
M?JI?-.S@!4[[HIWW9U68J9_)Y%=!54\']I=G)J_& SE%&K$OG_WZ<_YI#X?;
MLOF8&V-'_B,,."JE]LPP-[\\.SI/LE!F6F4DHVE*A+&&9"R,B:(B<ZG049@
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M85)F,Q5J%G76H?O%!!8+&%5B>D++<C>NS_Z)=0C %QH*;HERV$C8:?@D4T9
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M0+[VQQI?[%P7P:1J\MD!$A8.PP0XLO*)[;,R&RR_P7<-IOCRZQQ>#:\-1K#
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M#60YDP+(=KST^]+AWZDT>392C(!_M%MHIOJG#2XEO%])E##-$KXP]0"/ .8
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M_@[9+'MIG&_(<_,MP!NJ^8/-"U'.?PYVO;J^I83Y3R2NW#-1X)?75E4Y6F^
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M #V^"7>GDH(U@7G5=J1:41S\%XB4WDE=(Z:@JH2N-*P 6%(I=H/?BVOKVPR
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M\0B1Z:J'D]8U7BN\-9XDO@<6LE7%&!>@>$(1P$SI'3:D5.@Q9,03.?V" <6
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M=E>I8O\PO%,.A'^QQ'%A@8ZZ4^7 9842_\XK%C0L%;:<AJ0NA-4O5$A!*M0
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M93RC$_>T%[P+%R'P (ZFM%/FMQC __%:!$=Y"(!A_D-?__)6=:?<9GDRLZ7
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M1S,/&<'=@'_H]MD&.";@[;BJBJOPMK6.]@PJG=?Z6NO+W=4[JTI\PB31"2=
M2."%=+ODSIE7.+1SJ@%8EG<2I_)+H7PT=';%-T1 N-<C_^X'0T!HJK<4U L=
MWW42V49H1UQ*VS3*0UE,<KDFXV*$7,OYW^%:+A T/& C3X6]DKN'RB82Y,78
M0X),H]*B09K:/CH"\XK.VB8*<PV0**\WK^2K>+7.XT0)S5NG_YSN>,Q:@Y2T
M((4RD+5@1U8?(UOW['SM\\!)UJIPA52Q!J^G96:5VL?L3YLLXF?SKK^-UJ6K
M+F\98(E9OF;!;]=713TC[Y_N>FT:8ZT:TX4SX=JF]?!E]WGM#_G06*'$ #J
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M,9FI_(.J5!&295XB*;Y4?4ZUO&>-1%CQ (>*-45?3P8\#(%;:*Q/_14=QA2
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M$UWG8><Z'RH.WUUNW,DV-^ZDU8US&_G.+[H _2?Z#V37 _B4I3>BX/2O-19
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MA4JC/JQW$Z+U-@N@I/MBF/>V/$R[;J9N??W2@9DK ;:@/Z*(+\A7C!.%\:X
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MX*/'>J:V[MYC;1P*=B%S=?1&P0R5"$6+?[AE$$I>M>Y%/_@- 0A=RM.Z74K
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M&V2#V'ID16?Y)$::&/&.W-R+E/X2<Q4L-[PKA8[U46@!,\5 3=_-Z#1,\U"
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M=BFLSZ<B6K6"4R<Q/.6Z3 &-0;42(R&#>PW46H!DT15+4DGA]<"H2F^='OO
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MXJH+R?*I07I<L[41*]I11ILZM6W;!Z$&.K%PGQ H&10W40ID14<I[+M$4.4
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M(0&?42 ?[SR0G^'2&*X.H?<'\3@4=M%FDT,D?&/56S8>1%#Y.RXBX6\5G1:
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MLLE(+CL!'3#,*^\ZY$/&Z38AE67#/6%#3JWWY7>OR'QW:-->6F(+P2WE0VQ
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M:,4,H37$AJ;?=-HC/<E.22!(%K)AOC88;D5[+\R*HZXY5"T?1+Y#2E;[J
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ME&..9P*B]E"]F'#BA-61/"9%8+VYCAA^C.$@(OO!"+Y8ZOEUWE+[ ,/QNX3
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M#[]^IF;=0;B)_;4+ D]<VEQFX_B!>ZF#$*G822D#"5I"3$298B2=-RHLLNR
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MW"I!N;'0F3Q3Q*"T-N$(8<L!I(NR4>X@<Q,$S]$6U=[Q &/]YXN!&*1!;Y7
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M.#1=L3R];*[NA<5P% BS_@9PB!^X;@B](,W(>5[!G.!TZ<&B;)@TV_/9(8'
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M1ZV"Z#(S6Z4#6C"5&>@7"QD:I!R"K<RTSUU1A?$'R[GP ?LM,$T(\'-RC<M
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M[O ,\X:]VKK9I]*75PLTF:C89+^RTGNBTAM[;#8IO/\:&TRJ/O^#S 4+@?M
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M:;Z7+[  U&P5NI9LQK+BZL6:<&9BLN5'D62Z PSH!@(50WA=N:=M&=9MV(T
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M28K,A@[WL<@"?4@D%X.#JG?-D.$0%'Z $F3J#DY&AS*FN_H3,]*,[?+H/+;
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MD@ @3I%A6S]L">+L85-&. 2/!6\L.'*.6I!3^U]NY)23+H(=DEQ3S1M D^@
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MZ=9)9LSV1-H&HH?\>"Z!QAV!ZPHXB(@MN"L('<'=0Y-J#^M4,+1]A 0RUY=
M?A_&C:05D.B!OWUE:K_VT_[R (OI5$XW'TVH@\_C<QV?4O&/[37(WEU6/1^<
MZO'>G1.:LO?MA^!1D21>Z/"&#/V[#.LI&98T3SZR/3N+2A:5:Q85WQ(DR8DM
M];&NF2F2D@>FR]I3[<;P C1;2)U&U9K'".]DU,]=72XC L61U83=WN.UDX2U
M\4 $5=Z&C)R5)>FJ)6G6Z(#A8;&NV.E;R>0,\].9T2)MC6=GRZ;--Y[?\ <0
M6/]<+%XZC[<13@EC>2PA@T7D'ECD?&F*H5B=B=I8MTZZ8)4@&HYI4V?CE47N
MND7.#K7,Y<H)X2@R50+UB,%ZB$E;H> +(E9E"E$R>X[\ @>)B!E"S7+9]10G
M:HX\*9'5K0GSHE8G=_4L45FBKEBB[BL&ES85P<S#A9 JLE?G.\=YA)"VD(P:
ML6P>!5HUSGAD^+%W?&M_AXEW/O1!IC22H=PBF<%;$]@TS6WRJPMU>><(%(R<
M(G134I;$%;<=39>BO,?C*S*@&>>/.  &?9D,1#,>KW YRT@E6N.ZM3!=(BCG
M9!2Y*@<7")CA69Z[B08<!6"M+VD$:/'/$3>C*=!E-THZC6N1Z"D03F[>"_"B
M PW-O8"16EP5^UX)I>J6H2 QVXKP8QR ES9M>;74MH\8FN;GQZHQ2<I-=TOE
MON5%%ZC>NJ6M3J:QUEQ1F5?-Y&O\"#:P$B2">R%;;A: L&-P%?OE@CLWS(PF
M?T1'JG'W2 =$/9;!70I_]QC+*HG<\_@N&0WAE](EWVT$"+MW?E)@S>*C&M/:
M%9PE<#9A#_X4)]0H)I;;*D8R4FRT2(+$)DS$)1D6K@(;;C0!NN91/!<(;8^[
MZ<_2B?&Q=3NTKE=',PNNYR[N#[3]\4&D<&(W94VIP8O9]R?"""@$R=W#P!MG
M> '?'Z)C%HJI4)C!5M)G([6F><@'.U;G*S>Q$99YYD9[;QX[K5G8T>''&)X3
M'65*ZX6%,M/HEGPSX;BN>G+1!'A4@7#.XN;;(AS(KFNX=[CO&<S#0C[X[>RX
MM.;:I\-9)=%G4&/N&=8,E9T9WH"J]9V["MP78 G0,>!W))KL?=SVTA O3?,*
M1L2YR<HR3I2:1BQ,WD[ *R23BKIA[21'3APY.XKU^DY'@KQZ67)$?: X;3K"
M32@'T*IP&&F45,D7%<\PJ/M(2YN7*#OROMT,49A\00.W-+L*>JYY.%6^S!YH
M>-QU&MA)W9%$NLPJX%\$)O?_8&?/?^3.G@PE]\M#R;VBV5^O!HS590S)92T?
M4OCIGGF'L/BMBT*;IA;@..<.NP]=4'):D5:"SJC3+S9=6S$OVO]\_>IU80'?
MOBJ'X^+''BQIZ["<H,5#.,1\A.17$#)#3>3OB!H+DXP1#Z0!%3<"_A*,-RGE
MM%&8$G=[0Z$=O+R"=<>7Y4$7@L5X&NRH,<7Z$(S/$9XY.Z'O @OQ9_?>X-H[
M,_W"G9=EW1WKU>+K%KJ>^)2_[>[(F/[YQ=??%HL7[NTX?\&9SWK8(:<AR1!!
MZ!@"-@SXS>0J -A)R;C)LW7W<R>/3*0XK,=Z,[9;)+XI/"1NF-&MEKPMI(Z
M,.MYR(EO=E,]<X($X%E*1GA(YN%F\8-V6A!,SV'LA['D3BDL!T^$!PJ>,%-W
M\,FJ_+-A5?MZU7?+.B2D*"*$5":AUC^='(%2VEURSR4QN8H*B/-8Z'=$^MDF
MFT#B$.U!L@5V>Q^S%S%&%IJV K6UP+9\_/R3^Q;DG..: (W@7>XZY^[;ZQ(
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M=)L\C3T3"EU2>#B;0N9A!5Z!\S,8N1I(.MZR,L>/AT[V.$P/2/(CU<"NS1"
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MS8]"5&[.CAXHPML;!J4K,,(D4PU!,#FV#2567CJ>8BCTS4NG!079;M7E8'R
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M!'>FF86T4]T\7:C%^3$'FM%E@)L)M(>%0:-6SVZ)*Z*39MKB4J%&N.(4"X]
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MJ-$+!A&X/%Y?@9SF6(&_F:=+&/JR[X>N%&K?<=KA3)(T!@F0 Y"X1*M2.X8
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MM84M#>?O2;*,OJ\)QL:8*6L[G'C&B*DJ*<O>?DB$+@:.ET,79C3KC:57*^Q
M2H:V$"=^E(;T(U?"^9;V!Z70'[Z0I$]9S>$!M#Q'U<0Q4TI+NH<Y?M"C9+B!
M<RD,+3DEQ1W_&6E!4+[\Z7NY3*"D7^P^/&S.HE >A$= %X# @TR/?O8M5&9H
MK*UMZ1G/XM<,86Z! ,7CF]:UNZ;GSG-DZCDX2.HK^"&2@<U7G$88Z<)'X^KF
M^'K(.%)^R(3;T:KC-=\T], :%NQ22H7E^R([XN?6QSU,X[SU<P'Z'T:&,,3=
M9G343L$>T13^[C^^0A@<G.@_;'?5^_N8P9_"XJBW)RJWPZ+B>^A5Z(Y?T=@]
MJY$Q^@.*N_CNK&G<AU_<UIOC]1^^>/X%[/&_B:VTL:H;#@N'[$$7N&/P_)C\
M^LL7O_[L-Y_]^K=?_O[%;WX3Q@=AXWLTI\7 T4UJ_E1/=>Q^\<<$)CQG.HBK
M<!M/*'3=/HEF*@7082#TO\M:7];ZTQB[7_Q1I.1))'14+74RT(>AV.W"+P9)
MX"*/?-*NT65)+TOZ*2]I0= "F:U8)>>4,!GP#$[[R1#+V@H-3$K$CW75KA+R
M[V.;H2R6M;^L_:>\]H?&8$^*Z%-*^2ZX-("C=:#!O2R[X)IT&?GQV,59%OJR
MT)_R0J_"6[?[>AT"T?)=0P!B*OS6S7:GU>"#R,>HB%]8VYWIU"#UTJ*,(E22
MO=4$+)$D69WHT>L-L_KKLDN67?*D=PES8S4=&8'ZE.\+L)KNVI.2?^_W]567
MT(.L]0DS/L'1_&@%N$-]H_RDX0RYJ7:RS11!+%01RV98-L-3W@PQ-T-\[?JT
MVNZ E3*HOJ?X3,P )B6Q,>PU:(&E/<_\)PF@K=!<N )0&\Z>*ZV<:R^%D,2V
M;&JT;B@FN'UZ>]E*RU;ZM]A*68M'7NT('M70\>0)$08NL*SI94T_Y35]VW;O
M!%V<ZE7:+A%+CD0%B(\T-! C(N59N]^WS;*\E^7]E)>W5G,)EK]N.W"V]>KG
M4,N94('FM*+<8J_]9RR?E[=)#D[)0-A^X"@D<E#B."[ >;#LCF5W/.'=X7QQ
M$ T.!W':1_OCJFI3RJA<:^"0\DZWI8@UX!)M5_=[8E0;-'!#6J#N2]#%].X;
M51C>ZW\,Y3L$#L?3X;KE);>[MMVH:FC=><A8OGT6H/]]@?Z_68#^B]K5IP6K
M_N*/;PAQ>E,)17T([(%0_-I,R0]YL_8K42LZ?;(^[<<\\=*E_<DPR2D?9 WZ
MQ-AK3FG$PU9$Q<UWY,6-0-;I53+^@/ .FWI]7"5I'.&;;&<?X CA&+:![MI;
M)4!(C1OP[JZ&>B/IX"JRA-2;I=WY8R#)*L^Z.RGHL@%FYB-61WUT:P!9^*'W
M2^&NQ6,\-#ZSR1NWD*=>;41B/B.AB7QY>VT7D4<AV7.B;Q:F0?:<.(>G6%T.
MU R/[=['=@%U+A[^TQL[004Y0D5E0I1L?=3N$K(+Y?HO'*M2IBHWA[X>MQ9H
M20V=41(4"_^.] 4_J/7)3$/D:!)&*S3V@[$F_'])/2U;[REOO8PG-*<013B]
MCJS88;\=M)'@05LD8Y<D-U5$\NFW!*"MI-A..,!3:^076C;5LJF>\J:2%N\9
M.M_'GBYHE])F.B(]I%<].+?0I3\YFGG#BO!$12>V.8ACAJ8?@SN+9LJ7Y1'$
M@>'D?!N^U_YSW)SD0;GI5:IN*1DN>_!)[\%_;=986!O[^^:,"7"\$_T8/EKM
MP2-J5\:.;ILKHE->_O"W5]\\>_%E_-BR&9?-^)0WXRC *_<HVYOT5/A.".R4
M%D*@5H?RI&=5%<G3% $OLC@E>\?E$ L[J>MQ%#+F"A?47_^WR%,M>V/9&T]Y
M;Q"QN*F/%%PRQID]&8F0%T1.<,V57R0>FA'CHN^B.M--GO3F%[37LB.>]HZ
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M<(A97?V2ULR>NWJO=!;]KP1_B99 91O>15_Q)6N,\I0Q1?"_ROWAJ_0D;]7
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M8W[YV5*T6E@V?XZ5E27^ZJ3M]N(S@;B^UEZ]UQT89J*W< ':G0W]UY<P D2
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M;S=/1WMV.[H%$8/AR\HJYMPU1DB8TF@QN^>BG\5N?D3*(P3("++1O5W1]%A
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M*\/$'$\'L:[Y*Q=N@\/C25<]V65@W,3>3 XO!F/!6W@&\Q^3]2XG9@[!S,3
MFIR0&SC9!^,9,_$,D#B&$H0=8]\*]A?[@"?.?WVE_T_Q[BL7A*:U6G7I$S_
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M_!,T99NL":0"Z_8 6$6XVR#SD<3=D\Q,6#O7X=Z[4^(;+<[4PT5:026C_S%
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M <&#<!<J34:UQ#!PBT80C6#21A >,VYRGM!\ S6 :'?92&=9R$'!X+.0B6)
M Q5M)=K*E&UER%K&)Q#!.SNX"2G4^[SI#D%-B&@%;%@<F-0W&!(>DDPQ7JJR
M$!H?<0(;3E,II&N(U?;!&]L43@PJ1P$RK9XOLW\%;2U26(TV&6URTC;I05XM
MG-9)7#/.UW0(Z@J.,S:=S?:&.U9D98^K?>JK?<@$Y([_C/BM;DQE'2G4]YJ
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MH;'*N>U*=.-4M9TPETOMC$LU5*# 7'^%*(_&(-PE#7"F=3F*0O+ -1KXWRK
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M];S(;"%FZY'OA/AF.!^6CH+%*VD;SKM8[%(G5,C!7ZUVDT8&J9T.[Y)NU8P
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MP#UO\+@A5E@B54^'5*@R,6QG@K/M9<4_">I_7C<K;'4T5%@-,:K[K'U8S+9
M74O;<.H%8ZY6 [,&_T3(VM9JF&4M<Y)>[7NO=*^:C[(] !YR]P8.5.W 2H%>
MO0L,<7.II,5;X:"?]7SF^-52^;?&7MM+>!.9K"3<SWOX+[7I4BKL0E6B=C^%
MO X>.[!/6G+J]H3GW8<3T[V# (Q=E2^*B\HU8LE=7*[)=PE,N1E $<_K.B<
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M&M(NG>:K]KDW6IN&),$0;L)0+!:P&7O'R)^YIP>[V<(Z)TE48C>NDK._;3%
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M-F6!5$01]D01)8S+.1P1\)R.?:"*D$<W[1VBE2-Q$?IY+ [QH84"6,+/$U4
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MHLHM>RO874\)N/T/" =LV1E<,4PNUB(Y1OOGX;O#-/FA1XY*]!8DC VA3E[
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M>RA2G1R>G*%;R^M^5IKHU_8TCB^G.8$Q[+@3&?;IH_3ITSW/R]$VIS*/?Q[
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MQXL/0VXE&8P&EL00!&[$@'5S(QC<#G\7&R>X2J296NMZ'UAA7=G""\%R &X
M65L5S8Q,++@TXTD[W3%J=^H]9-36II$T#6X=-7Z\:IL61H_"/Y#+A)6_TZ@F
M.RV>EQO65_=DN?E3FE3VMDDE+QC0I!U:?2#*^/>=YVK<2\+'XK$]A6 DU3Q[
MJ%C\4H!]EQ7M-:W/.[9$*4?3OUK5Z=I9)1HT'T#6?W%CQB[),EC5-3!U*:OH
MI"HM^8507BEK9D8^KZY ;=?50KD7(+)& S<#KZ](0/BR5=8+L'V1%DN0%=2/
M5R!-G9J5*A!N&;Q/@03\"QX=QUB9U(U3XXRLD2VD(\T[8YD8'NEG_ 5] 9!
M] 6$$1.YO>]Q%-Z!%O^[E/LO%8SR[*+FY/,!>[4SXV^@ 59SC0:/;D-;&I]!
M@(6,V:&2L5<HE>*DEO3M.Y!65+@_@ER+S[*WKX4%3(HT0X5:&<R@!4*1_,Q!
MT!&Y^]5:>^+Z2G;/7%]2!?D3M.>F$U2V!4AWRH &I!6:+6O] M\D;/8Y:FPR
MR[L/\09CCK9(;;R"IS6K=-8];F(,!WAV,1@7!CO4%VIP_9CQR7BK,!CRHF0E
MV21%V;1%NQ* V<Y8*U"TA24@.P+_33B9%V2S""\!G[3!YS!L,>C&>(7S4@[>
M^HA_$9=TXSH*S-,2N:,YR38'@%-]661*7_)Z ?J3 5<5*&W X'#A!>K<90T:
M%M0O,/T"ID*V^FJ);/72L:R!N;\FC%_P@?C&GJ=7)",+]+*7H))!OLITAGXT
M#D[]I:QW?,NK @0!F+^&/^7WZFM$#KCB@<-^:0\'/#' HB?;>E: S&+H(E^1
M3U$)"WP(4>NS^YG&=)9=PJ"&Z/6JH"$W(($HP#O'+&B'8\W #A4QC9?^VKC$
M@$".&?H1EZR8DQ$#MZT:N!_MHG16\$NN?"<*0=156P%+F1BM*?("Y@$T *X%
M9RO/BY2EU^@R+:L"S1D,9X#9]'&&'H<K(\9-N\JN<9A]O+6SIF8<^%Q&;!<,
MG1W$)/)-U%<87:V!9!BC:*KEC%W _!J!ORQ%DXZFT;"< ])FK&43 9<$9/@2
M,-B /< 47"V752T^:U;)HJ#@#X52B*U_K%<7QMER"2J<C$?CE5J9WWX\ZSD.
MAHY/FA.=8'[P)8T&PS+XZ)(+]PM7:Y4BG@N\550A>M",R>I,!HL!FB,W>DKC
M$PJ!RJSFQH*W"*0@^A>SWMJT?=*$#O$),4H[*^J;^&2#0QQ_FT/DJ(2[N8M-
M<)(;K/**O39^!CJP)0( (P% 3D#:X%H/EI[4VZ+Z"M8WO+:D^#PJR^U+)\/K
MA*Z<,]#50('%=8JWPL><D69LR#(7"8-,K1_YPCAQJ:U:<(5;->2_38WE-4!E
M(5FIE(,G&Z%[A)PNO+A8"(X"WKL0831PW%540-EX=$6#"]0J8<!Y]=P&;.2&
M_"W-YE7R&G!HWJ\,7KJ+NS8HB'_V0VRVIOEXH7H%K,";MBH!,G%)Y2B!ZZH+
MCDR\KL@_"T3ZR.L<]0>^XU?U@ %^?2NK]U:?:Q&ON^*9KXI+@G*@,I+^_KAX
M"]<_:H"_4H)/NGW>Y$8PO8U>4^-?G*(]929DC2O\30%/&O6(3@/"A$A/"$U[
M5=6_4Z!)AAZ0/))+8>0UP!YIKQ7\1D'F]SU!)H+OOP*HMV"J@=;PAL&EM4$(
MLQ ^65-5I.1@P#3P!EBQR:]%Z'@N1E+SMJB5$XZQ+YX!AS52=Z/P@U%R652K
M!F-AP[@96.P%6*-@]L[1CB89^PR_ QV-?X($\FOC!PRHK>G1S__\P=BV%(["
MRM3U)KOJ32)=;Z+K39[*@>D1E50 H"#FNP!?/J1M1086P7JPCC&_XF4(26N1
M!N%U]$],*!F*'@=%_KI@/A@)S+@$6X9,*U:6*\!I@FC^'_Q5*O(+M%>P6D(8
M6/[4M_[860YXP<<:7?-/Y$DP- 30OB4#AK[^%[HBG\'JX:WQ=T!?4'ZOC>4<
M[#BLJ/SC^HS>J\%]&LY(*EJ8P9)=HRX#=C)!U60;DUGRFN:Q$--8RXFH*;E3
MU_\CZ;D%PY*-W[EZ:+-V0U6"&E"Z=7T5/*6N\0D)9BU;D;"!QZ]?Z4]N-%;O
M4L64O:G1ST$OI=JV/[PNDM)9!<+R*RLCXSD#;P,? *]422CQ&?]:4/$,&40T
MC0*]PUIFIW JRM;>8#YT:9)_8PH7OKO)T'ZUPW9\O<MXO-U*_E:?[%9#&DPK
M/M^'(;USMH/O7V]$#L@GNMU2O7/=?9%UN,\BK[]]G;5%+GT &F>HNH@\ZD)S
M<.%$VF J\I"P.4U 6%8BV]>]0)FQLN*(!(/^7+*"<$%(XP)@<3:_IL@?T%_(
MH"J;*LH5+O(*?IO3N]? [BCL**WL[A6MP]4&"6^,= 6B0%&=5(:GL%YE@G:Y
MA.B^@(5"?(TH+2'N;P;L/Y%LN<0L&3Q<E:"(1'/!%9==(J@@%@)7SU=D[+-!
M1%I=(/F8V)&"S@1(#$MK>$W_SK&DDD9 *G8 DTS5 !JLFS!Z)>RRJI4:H. Y
MNKTE/)ZE*<;TL!3QFG"XK%J#Y 8A"6ZU'<O(P+P4VNJR*E+^N@\2_3\0+.$K
MOH.1;/B_5 $ <T/P+$&@KE7<!GQ9\%Q%% !T'N<FR2:E'H'2%$&JD<PKWKM?
M#9L3'F^$5>3UC5K7]:";,$[4LSH**\2X8@5"-FKS\EK$_&'*TCGF/>'7I]EK
M=[AQSAE 4(#VM?&J@U%R6V^&7TD@%^V1O)K/JRM!BMMO4@O8BO[8 Y^QM[XV
M@[44:D)- HS^.Y!7.LO%_PH-!?JHF\/+>!C3U9!WI)!WU@S3:RKH7"4P=-87
MQUT@- E5V27T,-Q>(@,W*C\XJ,11(7[D)=JZ!3)<M!@R8D/#&".4%'S*9*0#
MP G95!;]#!X"@@NZ'C-[!(=D6$F+F))H*&+J&LV,1\J,[ZD>M.14EJFL7$I,
MU]<B+;V=427^!(-VM<6>JG1KS<[\E_BPMVCAGN6J3BGSP QPSQ+A3C8S5HL:
M6F0_5$X54JQ*?^\!W9D")$N8[3-@?=[KIG D9;L&45\:_OKH^UBLG ;X#C/>
M%9ON>"K&7,63I\:'[43:D$[,D&0@@0^]21@Y@PD/)RM4HKI<:4+^%6OU&E'B
M@^Z2-,2)<*@^99%SIXXSY?+" (1I+EUBDUZK'DA&?#KP\5^Z[M1S)X-4H<@U
MB'F)BW<M4;56"1&(2HBCP(6QA-[&6SGTKB\5I<CVCSR1+O'G?_Z@H??1I4-D
M<GLH*G:\71"THY9%T7RRJWIG1]V.0#Q5_H(Y"/S[7V (?();L-*[K"Z%I8D%
M,"CA/P-IC'^^?_]^8OPR_4B1L:2JZ^J*9YM)JAX2SR:&S&OW!8T2C3>K<:C,
M\9;,5__0'RB7*O)88G]&9_@/ZWC >\@Y&?42J[HGC&=;TZ'?KV7SX6&)M8P=
MR@#?""_G\TK$*%5TF0*5\%;>N?([@MTR/BYRGQCVMJ<AVC1@%6#\>VK\@\QR
M\@G CB_P%AS*I@V&%ZB(61>Q7ML0L!ZWZ_/"UUTQ\-3XN*K1/&B53RQ*D!@\
M+2-QE1^OTV(-I2HEHK;<E3#I M&R..A;GF9/=H4@9?1'6D!HHP 02@^FC[[+
M"?]]-;\>E#^3"<@V0]P\DZ'%'073E,1#U*GA.XI'+,$8(LS%RAYA<F'"6!73
M;.Q.!1 ;\P::70J_KT,9\\A?_+4H<^FZ-"NL_"HDE^7%G'P+N#3# BK6%U!1
MP.6W'T%C==[.SS^>J=U^M[!96JWFF:C]3SCY!3L9Z+?J<BT^[U#-!I;ST_V2
MAQ[.0KMR&QMIE%TT*+M2L'ZJG\'E!WM_()$WA_A[92HGT!- 121O#^#3ID89
M\YH(Q&-I6I-31$$(F020R*JDEN!-A?B5+T/VDLAVZ4U_C_?X^RH;9$O<2"NC
M3\*AAW65<>^Y,0BTXP)$E**5RJU33[L*4+=PGBS)@0QQ-.#D"RF@+V)/Y-E6
M]=""7%<770A7<<=D/;Z^GAWHRZT<# "K "WZ]</X[.Y$EGH.%6,NZPJ5]M;H
MMNBD4F?=.":8G5N?A*!3LX4IG:7-+E@A@^/B,QBEJDW:I@FM86_[ R]DN&_O
MQM >:QI^))O^=?'1KN*C6!<?Z>*CYW%\9-H.JTUE=K//RS*P-^ M7?BAW_NH
M<JGT\59"5@#;\.[^!I%[I6 MV!,78E]0,QE<<6/Z%:%M#D.8BWH'KG#\ FZM
M2UF1H8I4X)$9GU,41$VL3_6*HB6XI'LVV#2KFC0##J0&*:-'J\I2]8AA4Q5L
MML)JTB\XLKZ]C,KI"C+L(-I--)@7BT*FK\5N;H#R1%2A=MM#!Y&5M;I6"@2!
M;8B3XO4%%S:AV 605@O@1DR$4W\)F.H""V_[%9^Q\D)%JBE]#2-+:::;3YB
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M\TML]ELTOS>RCD4F(KK]A$QLD5&-GD3T[I+1P0 B58%-QE4[T83@I9W!ZSG
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MZ:H5S?#R(N7RU-TN9#8\3KU[H_;TM1B-78P&WLGZ-OY%WX.\5G%@U7 &8[Y
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MV.&^?QK;VG[!F_H.G(:F/%XPV]/Y8;C>/\^K*]U]Y!OZ<@\.HB7+'+L@8S(
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M@%949M'86MR*]+Q !N%=J )3X/2R6A0I\'5^QSO:HA4%6[LN,4"0RR:GN)J
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MJ^UJNS<_#8JXFU9$467%FFJJ471OQPK;&<MN%KG=XI7=8E&.7-IZ0R\Z/^\
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M?3Z(%H]4;$7N[8?I'SZTLS'GW8 ?'M@[0@/''?418][;/0H93L_[(-(Y=AF
MJ\[_#7C99 7MGQ]W0OW=] ^#_&F?:?U9S&3,TF[\?4!EH7 ^TF[O%E  \W<:
M!+X%!-I!C:0NEWITN52HRZ6>H5QJ_Y-6G$50CQ' \Z(H1@KE'\\^?1DU4K]_
M__Y8%+IMG9^+/LI5W9QWN:=SRBPUYUA?/E(N$/7J%BIT.?R)\5.7._LP9@81
M>3N1>WNG*OB-_XL>'C4V/F";6=UGZ(F[7*B&7/+@C[X"C!)#8H/GLJZ^7O=9
M#UDSAM5?V4;YU_;AE?@HQW(<E5#\E?-6'F%$76]GP!)T"JNLYOBQ?^U'>NUG
M]5K5BV?C8(!N)!BWG/<]ZFW'PMXYP-5YJQK"BQRYV/79MQ:Z(8@R&22G9KC+
MMKQHN@#E3W,Y2:J 5 +?M1GJ+NL!0 I9?PU*F[I.-?NR@U?LM?$#51E16.7#
M50DW8951%Y&C1HVBS&7]8:)A2;\#1VZZ&6[$T8[E,89MJXQR:^_DD8O4S1<D
M.&TT,!\C,*O>BM3.$7.WQLTK+*MGT!7DC:I6K126&)VI)(I" 1>J:W$ZI(+*
MOB^ W'Q[Q1-J^8TEO%=7TR4\?P: ,F,PE6E:+<11G;>,J#LB2B:OC8M5D7%<
MOD:=S(2WJ(AUU\BL[Y&VE/6FU%B[;'L=@F?1X;;^OM\C'KZC'L#%^SNH4STY
M\<Q26/?\6AP4I# UE5,0MW5(.2@Y7G!6*EW4=5L,5.)QO=UBWSW4<F@(9._)
MRS_QBY7<_/S9_/\VBCVOA@TG094NEBV=*B@JKHU7MFC6)H^_D?6@##1>II0M
MDDTM2-?6])Z\<DLAU^3V0K?^RT%:3]5XB77&1,!<_"5.2^^.(Z2NG?*PD'Q5
MIK)&%<;ZRMDUWRN&O0F'Q=?#<T_4M^( 1I%"; ;5(.M+;:C#G*@UOBSR[LZ(
MPI:H775Y+TEB2 O>E:F)"8$@56N/@LO$:+HRD>%Q-?*K#5&3[":J8;4*OJ\K
M:)\/',!A<_Z1ZFGA =K3/PBK;\P>'Z+ \$ 1;4@<HR'Q, ^O+]R2>-1(G8?.
M#<]V^"QK1\X@W(E&\8,D7Z=5I=-XL_>F/91]PZ-S?BZ;LEZ?5\I-/)=;0\YQ
MI\JH<=*9_N&S'/[ RT634VYN&7K!8\92&CNQ]Z R$__\),^%&<0YX!+<2:4=
M-XVWP]C//:5@%Z<](0)K]M@?>Q#FP4*]REYO.XQ[4M%:&1].&;OGG>8=[@UM
MSN7A8.?MJ)6Q._V# IQ/P^'W>FS,&AB8]PL>S,+2P7EG*BH/YFK&EQ@JTIFL
M$P36Q^O=.Q@>]QN($- :;VVE>'ZH6)VM,=G.#$^W2Z;;"B-N'.:/3A# CP?!
MO?/S+N)YWD<\SW-8LG,Z'W/4".Y-__"Q"]@>0:<UJG+DLHW'9W'\J':+-#QW
M@-DC:GOS'C#LUZ?V+!,['<@=TL67NXHO(UU\>2K%EY<C57[CK[W\Y_B5VBCL
M+Q^S?;,B*=IF5POM\V;4#7!M?VK\)(<_$?LHQ\R6P_[>H H_IS.>8?>'4?%J
M5ERJ,61%LYRSZS?YG'\=,F:PFR__O6K:(K_&4^RPP(1N,^EHV+?$?2:R7/,&
M&QS@O3MY=0$?7!59.R.;+_SC<52+*4(5)1&%Z/6@!]Q"NBV*@([OK*,=BR7&
M,$XZO?CKV7R^LZ5';^_!E.1/[0[LHX,\GI(GJLWP7WATRE=MD;(Y(.;[,IUB
M?\0+3BGFKB),=AR@CG6BWF<71#UPA'\NOL+<RM]6U%*%=-#/YW869;$?AF9J
M\<CTDB@P(ROWS=3)$]>R H^%Z0LJ>H*%^,3SO[QX=\[SR V<T#7C+&"FYWNI
MR7S+,E-X4))Z+'99\(+*BD J>/'F3)S[^QM\,-KE^ZDNF];X;[98OC7^!P9T
M8?SRR\=.)M8H]]?G4G&/F\F$:L@&;N2=#2LFZAB#[A2"'4</ !O^#.,Q;,O\
M_^XX=6 D:9-[*-*;4$IKTF?2I,[Q:M*?M\'>:)1%J=7I-PHSVBD=-0<-12I*
M)V1=G]3VIBB<V"/3A]U:&>0J1*N?P5$L58T?-K/JJNQJ5G<J\AKOI);3\*BV
MTGBG\>ZA>.<>+]XI/U\CVS<BFS&7AUFJP _!3P=4LO.@)#>E6+\:Q6+!,^RF
M/K_&!HTI[SH[8D=)L:> [+#=YT:M&6_'DD0]FAA>@"U8<!/W[^>BX__UO9C/
M\?V)^L]^]LA=,!4L<7]GYE#C)::5Y\J?0K)R'W0\]"%4XT@Y.<>><CJ"/-MW
MF<*-GSF%^UURUM-E<,=I0-\:!1Y5"NIQZWE#5NIDUU-8YFUE;)T=7+;C2BF.
M13Z?5<>W%-R1;Y$#PP&\8:NV>IO@:5TUO1<\J3?66[K<!#>\6H$37WSEV5OA
MN]L644K> &LX9\N&OVE$E_PN%E(3A>C9+_#],(!.:>"V;=%\_XVZ7UX$5V4=
M)>AUL3N-XP!C!7_^4YO=<!&(FN6M70._U)NOE:L6$06WWW>''%W!A(6F>R/T
M'7[P]I+7!%MR11=%ELTI9'$3CZG%H]6,[L-CUG/S6/08%MNY.GLDJ>2W;IJ^
M!8,TFFI>9+NF.Q;R'PRR[[.('\%XV[6$MPB/]X3"(VAX[]7S#B,\^S&\O0>H
M+25K3RADQT'Z.W#K/C2]&;=N87II"SP-UP/Y[DWW^QDE^R$\,V8UUC?\EXB9
MG@]2Z.=]"OU<I-"_]6!Z&?NYKQS1<#,\8I2R7&^H11LE"QYH&?:'C-RKT'SK
ML!$V5I]=\/FKC^_./OQ@O/_QS9,5S%ANS.,P=$TK]"S3BV+'3.(L-;F;\\B+
M69!F]IX*9I#R[[/1ADD\YRCK8UX_AQ$G]<M.PV@TR$<NRWC#<#^;XV8D1VO5
M!VC5A,VQ=^=Y,^/\VW:%'TIW_B!F8'S&&31#E:B11"/)MXS/U4CR "3I-\=4
M^;DXAOU;N^,="E(^KY6)?U!S43W)%S"(&2\;W,?Y2]5HS-&8LS_K76/.8S&G
M&71P/\=ZT_9^!3_C1I]A7_IN<_E/-#N-.QIW]C4^7^/. W GK18)'D\QV!&<
MLF9VGL^KJV\[XVT<H/,.)F/\C)/1&*,Q9E_C"S3&/ !C:%/+>5OU_0>.$UE^
M$YMS;J_'T?"BX>5;QQ?>!B_P+U82'7W=E2XS_M[9W-9%T,=<!$WYZN>H97BZ
M.M:^6F',784>5TDQ+J;96^'7!@&#1Y5]C9TRX\'H+Y4XM&L0NZ/<P7:7W3O[
MT'QGG/F@0OKOFS4?0[D/RZ*DH\K$;N9;7;+Q4U4SW!%@87? )%;/R4/KL-,1
M';R(^E>6H!A4@G(W(!JOVIDX:@+N?XVG+"*>;IZ72W +OU@3V;E+-%%?;P!6
MK6=VT[7,[KQJX(W#I-+_,41625R,(5**]](YD_@2/+^7VI"4XA3?27<JGWH]
MQ70>L+7;\R;JOV_:VKTC]C4T!L)["\!(>>P5[M_!SLV7V(F!>B7(9C.,%J3K
MX[RK@XSJTOR:CLJD(TT%2DYN;CH#8V_0L,Q94<^O\:1(@\WGQ@)/?"ZHP0,>
MZ]@VFX]85DVA3FH>L#&>?WH;"_=\U*SF@G>Q0<4&_^)']V)+<3(VG8P)W$SM
M[?XQ_3Q59Z@""4% N3@.MK>394/ZM39*XP?"DW<LG[?#P6.TYP^L*00[2O/C
MB"AY@,XJQVYD'*Z1QA<Z4'<G8&,K18F@2SSK6>S[W(#A_], @JNSS*;&!U %
M&]<7E,G@7Q'_$725JE &M7R0*M1H=@\&&W9EZEQ>LHN:J0%V$@Z2W= -<M@O
MLFM(*H,92HL,@AH?0.4W2$KI<[[Z1UF(X_]@%,UK0VS)>$UZ U^[T:!MV*B2
MWB85&GX]U%NH]^"E=4867#<NTB8YS^A$;GDN)!X#/6=73:?,!KW>:FHGAU_4
MW5EDW=$TG_O[Z7CIK^F,E1<TAD71-.HX4*('3NJ8M).&ER."%Y!0>9P\2F\G
MNC<)P=JY\3UW&E]F>-)Z_ZT4/7%0^!4WEN .$4?+T\N%L."KZ.SPA,Z)JCEK
MJI*$AS7-JJ97LZ1:P2-FHFWQC<8KRGM><^I*UEFL*$KJDDGWC&S%"?#JNJ*#
MU?,:!H)3&$" Z-PX!!#T]R;P*1XZ#N^".?'R F!5'#HO9D7]<,6LI#6+Y]+7
M)0Q%GN5N5'AZ>3\#$30'<)L:9V"!,Q&"'JS#%=^",DDM>!7EKXGHXN3X^[_.
M2("H.$5E4"]7]1*7D'K%D2:01\1O* .>Y\(G*5%9;*F:A\R7V M^15\#R2D5
M4%F)X^'EBT^C-YQ&WH,39VS(^V$(MK(?ML01X9E6*<]6M:@S 3Q$V2!KKVA^
M;VZ$.262NT#R#@B<# %Z<PB(X\)NS(2]A&!!0YD:GU%<!Q=WT^%?8?+8NWN"
M\,$,L-):-!0+& J_+.@L/[2.6-WUF&0+M/:$590533JO&OG,&Z<EC%I)2C9O
MJL$ +ME\Q=KNX;L<?V.%ABN^#_M;%CF8;T!&&&F!!$;K.>/8K;*WHB<8@;GB
M\SG^N_$*Q#N,FLA@"AL&1G8/_E_8;GA>\$NI+0?@#S1%*@'E!JHQZ3S/05A'
MVX<GC5*'B#_^J?F3<>M1!8=:TSW]3TO,*4O,03TJR@WAB::H6)K=010F&B^
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M?1E"&F-.$&-T,&(<ZZ#%8!SDUZKVL*HVYK:51IYEYK'KF)Z?)V;BVY%IIW;
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MR43Q0_F:@(M.DHO /320B8"-,!#\02@?.>SC=,6=\<C*JD*LQ Q)JB32Q."
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MK%U>+*?Z:1.N1S=;P$$G 3)PT! Y*+>UZM2A]UN!L540![;,D;8,^!"',Q<
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M'UJ) 4]$B2?J8!DB0!G#H R %" =/J3@485C"<]Z P"D .GP(06:!II^UAL
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M2*E*HQ TY:34.BC_5'4N_MJY+#KWXF'.=DV(.E3[-N".X7$'  O C@M8,%;
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M@U]ML6B*N8^<8.NI+V:]1R;]-OV<CH45R]:[HI[=&,U[ 7[[4_3;/WN0 5@
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MDK+$BI8Z*DR/V/_CQQ7KWJ<"]V=T)L8F50G]9X%]P'$QX%F +3 $\$$ 'U4
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M@9-F0),QE@TQ&-D "@(H"+<H""P(92K.4!E80*QD'AG-!!+"6X.#$X88B-N
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M2=AC^!!^\"'.DGL5;SROS3*-Z)$]"*J$  ^($_ :#'L:QK()!D/K)R?5P5,
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M\SA(EV@A_?;7M(FR8/N^ER8W2[OTB#_G9.M\@GU;PDVV9$&[\FEN":DX\B2
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M]VWQM9A@F4(,:\LY>3H!;= 6!@F#.>#5Q@=BH@9VKPP%>HF*;O/W)+@K3$C
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M;1GSE8!H7P6@R)@;*W=M?]YU;7^>T<]_"E[]YZN^_6UG_7]_%(V5-8<.P,:
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MG"L34=J7JJ":V;2ENAA7!%LJ3P(/J.Y02G2R@="D>2E$3%Z%9U!=2KV_ ?O
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M$5$4@%F2$9VH(I&;X!0%$UIO];5D2@; *8W8:(B,T1-=1 7VMQ7&6F8%I4^
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M<]?AM(&-9MH?[*^-K8Q@;3ZWJ%A[%Q8YN AP6(U$A%=7\PY>5]?CN.[0R5M
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M+N[0&WG8-^%U>2:4.1/TZ+H#[<;L-OFZ7N?Q6(H_!H.QX^)O_'R*2,]84W:
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M3=/HE^CCE8NSD6!G(YP6?S::7\916@"LX^BJFE17BZN1G4P6=MSZOJ[MS17
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MO,Z,*1+#X7.%MD06,1 3>4FT*93E7HI@Y6VNN)Z\@1SR('VNE3S>EO]M/VG
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MI@+@5F5K].CXN1TK:6-BP*I22\234$AS8-]$ 9-*)1C!>]EZHC0SDF&D$L'
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MYV;Q^/E3_G$W_OO[;S]M*E;8D?=8S.,D$R<7JFQH O]H%H5C"[?.HY]]F.9
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M;W"YX3_//5;$!(N54)8?+#(R6-ZC4CW=X>U;+>]0_'!\A_UKW?RS2O.8=_Z
MP8C-HLHC#(:@8N=PP4#8+A%V@%K/"[6LC9YCHE'R>5BRB!;9$#2RC-JD(P[)
M[<WJ?/8@1U:VKT'7OEFIVL,!+2"D>>Y-Q%T2@&X;W0?$-H[R9'IK!0;"#N;U
M*,TK=\(KQQ42BC#$/=7(!4G 5&KLI(O.J=BY2,9CFE=RR##&4>J:[K#T$P8P
MALJ-;ASY3_5%#:0)U64=)V$(,'84"PSD[2IY!\#US"/(L7)"8(JT] %Q:FC>
M$9Z0E280$[#D\GEWG7TN=;36OE\#N.@NX/IWG,^";4ZS$.1EV?S[(6WT M3.
M0-Z!O/TE;P^-9G?LX)6>'P3CF;L8X.<\Z;YM+=E>+ "_"?7%"UP8D$%:_.0G
MRQ#O^_:$'OSUGVXRWOU$^C7J]HH92O=V0OSI=!,%.K<?8JL_D$U YU=V\M%>
M-M]_4WWW$B7@NR^*P+ ([N8U-.L-,V%_(<WM^V96FY)WEAM5'VWS C:^:1FH
M#8$A>'>-N'7@^RKN$94A:B\8%40\J^_[MG5WRY[-9KWH^S]79WO2'FWYXT]P
MZAM'>7>/%_P8PV\+N*!YFTY*ZZ;]*6]]F3?E2S=N,M[UDO],^%CV;L%]YN#C
M9URIM;=2!,0HR1DO[9!QSB$!J%0[XUTT!]D;UU/&9?UCW.OKY$[*ZOF]]7.C
MLAAL,5O8"= J+_#\,*W_?7U=9VSW^6WV>BYFY6-%Z[\,S>ZY2B9HBKQ1H*63
M4<BP0%"@@>)HE-9BKQ7-&2.Q) 3%% 7BW'-DM9<HD60D"\(*ZJX+R&8K7IQ?
MU#[>+"^_S*878)J!\8O%?9]/;_OO/\Z:Q2^SQ7]%>)+U@98U>RLIVM_+>,7N
M^+/I8T)'./?O]TP4X,;^-&^TC9L):;/*Q6J+WV>@0RJ[CW/.BZ;)LF//S^>S
M3P4/32X?;3VCYDD0JC R-I<#6@<_,1T1,<G;J!0/&A\"0CP:H[6J^?5LOOI5
MOJZ'<RKP6'S%6NWN/'=U!G\^;<8W/>53/L87EV]_.>S07X_KVCC^.U"LO3@_
MT:L:A*SV\)A%95<KG3TL,[^G#[OKJ$8+AB"N=%\!]R#9:/.+LK!\O1GU0\:3
MQ6ILW&#X;08^(6]=A;NU5WQ^P2HZ!Z61+RCK5<?5^ZN%Z:,*_I9W!+=PZLV[
MM_D+WOK%+$,T:C)$(_#?#+%LOO8B?Z]?;5O/#Y^_;P76X%<H [XZ@2TYK>%-
M,KZ=E,MJ>+]Z9QI(54];C0Q/6)YI'N'?<535BZW7K1=;)G/KP^U&]Q4QMKYK
MZY)L,*OSI0-6GERBQ=SF[<=-7.0_G$=XO?:9Z]B,JY^6<4V#_$+YDJV;QD]Q
M[NMF_467+62-.[-.X1-;B^C;@+SYOMDYSZ;L8UX?=5.H&F+^.,A#J);YP?^]
M/LGV%O[[II N ?':WX3OJ[.X. 5$D&_61CS:,]U[H-WO+JS2 H]MCFL?(_YK
M"2^Z(D&V[1E8E5]MO=R**\MWME\YKYM_HOV6I^MOYBX!Z"3X^]1OZ/S[^#>X
MQSS:!NQP6VM4^>7\(M^JBBG!JU1VT3H'(%97S+YZF/(4[8+K_.<6)377,-+.
M:]UX8*N7V8RK"3O53^5%CMZU4)Y*&[%!F#D&?G0DR'J3P/>FC 2<>,![%:HR
M)JJ(8BA*\+AYHA2!#X(1=<H2Y@F60?6D8**@07 S<HZKB=-O_IP+*'KF8>PJ
MQ 3/##^LQ&>EDZI3X.5IS%[&N:U!V&QSNF'WIFCI,(/;3F>+E:ADP3FW6<]?
M7K^Z7GT1:.PFQK(*.BT70/'Q-DRX>2TWO:]G(A*U.(+/FQRUX&5(<(&Y\HC:
MZ$7T2:2XQZ>'6AR_S;';GNQ)CF^ N?GL?O@!,-U]8TT%$@YO<'DGBUK9%?D+
M^ZZ#0UO((H.GFU;)=]TG^%(>ZBXR].BKVPU^EM7M8GRWS>B8J[M=I\A=KB-C
M+>YTX5UO>.<'E'=:W6[&#(N[K8+G!WT\H>^R@=Z,%;O;IGJE[_(:\'SD;F26
M=WL\J>Y"EIL?[YF7#W_-4K2C7@GY?*U"1TW68=-FA^J)[K%I<QW!*_OMWRX7
MS0+@$ACW8?OFH0ZZK^IMV#T\:,27J!'7A1NHU8FK^HWV'S^OPKWMO][-:__4
M,YR.^/P'13DHRD%0CD-1_AK/;#W-.++\\\>KM%'[B[P@I&MBVE^&&#3GH#D'
M0>F/YCSY\&$>/^0!H$49O@'E6$^;VK?_+.G,O"&U_>?B=+9LP"E_\E6I1\P'
MCRZFCSX#Y^#!WV&ZS0]V8G,5BEWLE:+C^XO>T#[[J+AC(&]7R=O#MOVC*MTB
MP5LK=4*)Y%DW6B3DB&=(6<.E\P%3O;<FP4M*J!8.">(BXLHP9#U+R&#,)1;"
M4^L/W3:UE73X99F5[DZI5I,_VFQ7:+WYY?5GVT#H2%$]4IP.HVU>@)89R/NB
MR=L=)?P?@Y%]@48V&"4#4QQ1+PWB-&JD4X@(*\># 0N;W%Y'W#,;V6N-R>N4
M5DEF':@GF9(QN[TG>5!@@WT8R#N0]_G)>^S6\Y9F"2<8Y38D1!RVB$OID;'<
M(L:,\"0)Z\C>O  B> C2:I1P-G0Q>J1E%,A0RXRUQ#*,;S1:[LM&RWVUT=JD
M%[<2BSFE>$/W3M=[N<V87$47;V[F'E3.\:B<@;POFKS=T3N#O_H2_57A8E*:
M:!1]WIA+P/X[HN$_AB<6'55.N8[YJYOL^ U3L_)XH)4/RK9]4,0^&R)F?,39
M$!_NB$$8%MX>GW5YNSM9HJ.=6<<K4P-A^T78 1<]+RZB5$I"-$9,4< X (:0
M"8X#T%%:^J2B5/X@\R,..F/T+_-9TSPP74Y&BN8"V]L')PZZI=^Z92#L0-A^
M$7:PAL^\EU8X9<"ZY3FO'O'@.?QD/%@V;Q16S&BFG\0:-@\9N?T8F6VFQH0/
MEO)(]<Y V"=H+^JA<N\M0P^T'I3'H#P&AAYHW=UDQ;#<OANNT#IEL1[I'<K@
MT#:@5K6;)H8$84?1_D#>KI*WAT:D.RKIVZ.?+R]D$"EYAFP*-,_M9L@Y&5&,
M5.M$!&;D07.[ST_MXOY)E^UIWNMH4CB9AG)U\X]B$^Z2?FF U_[O-^CS>1B0
M,:'94)32+]3P@*$<1WP^/3=: WD'3'#$1I?B&(77$E$:)>(^):2%XH@H(ZWC
MG%II']_H?BFWLS:XS36#^X39'J+'6 T6^06HI(&\7Q>\?5G:O^?,/5!\4">#
M.AF8>Z!XG_)"0Q/+<WM/ZXR0SV,A)Y.AC:6#>NQ>A+W[9-OA")[]"'IH;KJC
MPHX_@Y1,9)$[AK1,%G$L*=*>)T2M<1%+YZT+7>C<>3V;IUCG/;B;>N6'=NX(
M,Y+ZV?MVCD>9=H?5.S?J_?Z+& ;+^&+EZ04<00_!R5%9?Q-HT,IA%!BF""RW
M0Y8:AA)V*4I,,:>'V?O^T&S6#>;_*=J5Z)@><A#GH-".5*$-]OU9VAF.VM <
MK[0,I]+%4QETV*##!FD93J6;Z;QA?]MC>XB?V=]&ABJ0CKHS#R#OX%?V[B!Z
M:&N.*ES& Y'2)8(\<QYQQQ2RR48DC0LI>!95-'N3_PUA."J+K-4JMVAQ9(/0
MR&,NJ'0XT&"ZOA..CXB6(T5--XJY!\W5%\TU^)1=.Y'>B$9W;,'SC/H?4$%?
M4 'U1'(=-5+<6<054<BE +8^81T,C\:+O4VQSXP*GF*)G1J+CK1C'X]2/';K
M-."%KIW((!I=.XAC-_??W+QUS_C$</(2S"K3B)N$D0Z"HT0I\TQPJ=G>ZIU[
MEZH,6_<^?T)ZS%F7MNX-:JPO:FRP\%T[D=Z(1G?4WQ 1&"("GXL(.$=\\HP#
M3"'@W0LJD(D^(,9U8LKJH#7I6$3@$=8$$C8R:@@!],X<#;W8QV>QKDWGM6X2
M*]M4LW3(6H][55H-\C80ME^$'=#5\Z(KR2/GDF)DO32 E)1&-FJ!+!$B$!*\
MB7OS]YX#7?U\I6L/4H5!1H2JD5:''*DW:)8N:9:!L -A^T78P18^KRT,1AMM
M6=XM2!CBC!&DJ?4("RV%#9P[(SMF"Y]B\*P9*S%8R2/5.0-A!\+VB[#';B5O
M2=DS*F2D.B&+14(\&(D,,>"W)>\D<X1IMU<N_QPI^]N-TVTI>]*_E+T:&W+P
ME/V@9KJD9@;"#H3M%V&/W3!V1_W?[#X2G0A)1.2M8> ^!IN0X8$B0835'DO,
MP][\IWN[CX>QT+N):G*03+4<Z><?!-DESC^6Q/.P'+8;VF>=?F[WP);-L/'3
M>?3Y'XM9^?7AT]'#Z(&NUB0.Y!TV3!PQJN*)Z@R1$!66(JZ9RV,"+/(T)D$=
M=CZE+@3EVX5P)]/P\TH7OY_E7QWY]( NR<(1*I^!O -Y^TO>P70^\T!J3P7'
MPB.GM<[A_X2T%A$Q'1074KDH:3],Y\MJL>^2E!RA6AK(.Y"WO^0]=J-Z2_I;
M>\JP,@H)'!GB2B9D!)$H:F5T$C88OE>;]1SI[Z^V94>4%>]:(WN7!.,(-=%
MWH&\_27OL=O1[IB%FYU3D70,%"<DG(N(<P*.9N($40>&/@297%3]<$Y//GR8
MQP_@<1YYVW>7Y./Y<^KP<ZZ@N 'IA/KB%DKQL6#L#Y\E%;F)5N2(L]GO3V-E
MUQ)4U6L1JBZR#.4D]NSNW=8E%PX_X.ICG,<*.-@O)[8DR9MJ 5\4ZI3@+WDR
MOXN+CS%.RZ]7MX[5>0XHY5OGWP)QXGQR"1*^>89\__PG/YDU^?= ^7_&Q>['
MLIJQT\O_\[\_44S,]PWHL+.S6:;\S/^SFN5OM(LJP&.-*J"I/VT?=C,&Y6@U
M/J56&FP2J&N?$)<D("M!F0>1E'$)<^T>Y,*= UU?_=B>S-_+P93XX-OT8SF
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M825&P!G>/<;13(F\\$D@ETT+XG9_;-6EK:D"+6QTNJNT'55@',BSI?1".N:
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MVPT!)A>6]*@VB2TH^GLO^C%EFRWD,HDW*/][+_]LLZ/E3>+,;DC_?E-T ;+
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M1HEKU:5QBYA8]+<8R[;KK\%V$*/K9/!U$&&,+AJ4LPD\YKHP)\;;B1'7*1J
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M8BO6SK)A!G99".OJ&HS0;\:&=7P8$U\]@*?J/N@,T4][+AB!++3P!^DY@U&
M-\B/!".^(:[(##OHSE'>5 _^C%(W"3A+9*8_[QQ%N)]+A#N%D7I.'ZD?J'.A
M1FY+=-J =XCZ9)G^A0C<=L$];.HE]%85YZ9KE4^QY>E:$UA+R?]%,KY+*4CQ
MOB$,U/*,S%E(_+. /U*!(93A.";(+$D+T-W W'EKB-]<BQO6B.8<6T$E)A-!
M)S!-#<=CB@OQC6 N'4T!K\E4TW/!.+0&10FK6M7I##,\^F#CA: T'MM,]X(Y
MAA<BF)TK:B^8D"$FAE#APJIV1WR:\F25NEG>&,)>?6BEE(24>_)&=7 1J,Q/
M$&O<P3+5-;!=I/+,)U(FHW@H;G$[.Y4=RLP0V0@T1R/\TEWZ*,K&3EL,MC.R
M^Q+-'J@8CN^H&PGE=)P1WZ?>Z2*&DS$@F&4S HOLYV<<B1)QJ.7&>@UO=.EL
M;!K4,B_ 38)K(K[24$W<N52[E!46,$V8%XH!?I*(ITJU?'7EJ%ZC073%=;\Y
M?&<6,ONJCBGVEZ L0C_?G5@SIX$0P1/(%0P:XF*>]DPYKH89[>OM+%,NB*OL
MMC-0V@F%A0MS[LB$EK.B&KID'&#9:P^#)?29,F75\8D+6D7C,M#N.#:UA%AE
M6PV^$\(U?CCXIXWD7 ??%9%;;?4\23<4Z "OPR[L<LB=D/.-H/,2+1V.AU&(
M;/:T)Q8?WU(3= 4/5FFHLRP:,T[531^"/:C.<3_J\VSN!PLJ<.="4+6(B<4U
M"=UI8LXI8^R.AJ&?1D VU5KW B88KG)#((W(Z3E[9!ZX:_]AU/=N,YZ.!:BC
M*I D1,=7!F+I+RR<WO/@ 8]M8+.7?!Z%2[E!^#42&+]0EQO"MYSY7V(KOD1/
M.V10Q4$>F"/4CE5ZY62R79@PK@'DSBP]/U&.F56XR^/-&&?8')[6B"/"V4NJ
M#/VMJG1& ZR<2')2\NH.1C*?P$#(G%0PFJXO90*'*V2 B'X'3K-H,VWM/.]@
M.9X1'L^JTL*<9>"=HE[@-1_G5/^]Y"WW4#.<6;>A7>::V66-2<QMME:SJ+[6
M+O,CN45&1>2&XWM)U9(#6J"NE<F$=JK9TZJ17>:6<@18,C" OF$XI4(OTK4[
MW9MIJS.\L]LZBF!]LU8<!E5F_4FH'07L;!3$D=_,&I7CURK5N^=)7!$\K6HP
M+&XI5)=W<2_ABN:Q34+W6D"EL?%V=3JW Z"3L?(W@!D_5I^O0U7$_;R4X.8U
MLN0R'M()%:\N8^;BG)1L5IY3<./9/+N160ORXMEJK2G*7%)[%LATVK'#=68*
MMBY?5P&?X#RB;K+BA:2DRN*N^)7V-29+PC4)X]W&6Q.L4R]'%&]G.H_H%_H<
MCIZH_TBO QY.91E/UFSPS\[%2_X?2L0%^.3K,2_;SE^$9T$D-L(SU<Y?@V>C
MJ: ;4;2XH;\(UYZ"C? ,F]E-CGT)N*N=I\_/KA_A1LT],"0 M^H/ZJG[.IET
MLSL_J];>'?Y<DV>\-%#O4\5!GTN.^77RFL%_(6 O[^=X2<64T4=5>SB^FU.7
MC1D%C_Z1^DI? B]R0U7/,&\K37?&XFK 6GT?HTX"BG-@XQ>A\ON+#0!WC^SL
MSNB_(R (98I;8T.^M#MZ$?B^2H\939GPH)XZ @6])5JRQ*C--MW1?;G6M,+7
M0(R"S3/1WG!'6?@%<^\"EU)/GHQA#3NG.)&H>=NCX@E6/2JDNGU;RHPWV[I:
M9P:GU0N$-0Q%K!)7ENZGS22\V*!VBEX7*#&7#>9B2^GV\5G .55N/6Y'9]?\
M#$?6;&>G>(;2U]D8>DVN2.S(G-XHB?.MW\Y.\RS.>M%W.MU$PIWB*P*K<*UU
M2SO%MW'C-(B&P%VQO:W$YR/"F6VQ$\$P>QQ/OPP?0@+K=6$S+3&RUVRD,ZIB
MMRM32@,ISV#278 EHBX[3$^3H(-:Y(P-/LN$"?[TVH:+66P#D<^<-J15E^^0
M/%,B3)P]YQ15%N\2B1D;&\V BP@L2&\4G%)]-O1$&N-A%)B)O61-6+N9CMKG
MJV^@=V"[?'OK@G$^<.HV%N<EWK!!_)OHP6>N.3BJ+@M*6=*N5F>&42M^)"Y8
M2'F>+/#:REAAJ;!#7,@,;/U:5*S]"=75 +M'Y1 D-=$'1"/,7\3COZ,G %W@
M1D=^GZY=G:Y, PU6#T/7.#U*9I1W.4NM&>SNZ$'%6[4J1<1+++OD,>.(CH+L
M4[/H?Y=E$F^\V5WBZ#S6$>4%7)$Y?,J<7J@NW[SUL(D\G#)\=091'44&(I=,
M15TV(_ZKTU-S3TJY+C>NL$M:6D;4B#R?J>E2N7$7VHTK]_K6:*!S;J#:\DH#
MS28E6YYD'0($&HZ54:?@U6GSF_@XN>'*)EKJJ!.AL"M<C'Z"_M!$@9XN4I#8
MJ51O).@C0^FY/JE<B-&4\/AM!57M9RK#S.4M+]5;]Q)75Z8\?\COY)$PA0(,
M0O5VA7[=U&1$K\WGEKUU+KUT9<)C-3*N<$:S@/8Q9?CJ$I:FLYZ\Y/K&F;69
MOE;??R)5K^;#3_$6D28ZY[B_5&]_(CYG7^XQ:?_X=H\>]#^KI^O69F^S3G:0
MJ]*B4(98N42LT:>EIY8,N#(7&G-]NTB4V"J=N%XG7I7,#7"IAU)D7@W4%JC;
MV-(E=4@Z9SMFLRA M'DRF\!WE6"<(33^YY&ZR4]UH.FJ/LW4NEH'YYAR$M1>
M;&O"*VMUQFVUQ^KBAS;3@1I,!)FE]HZ*/L)4EG55V]4I>*>JN!.*4* A;X2G
MT9=ZRJMK=<Y*O^>X_52]MY [1M00>(>T/7<\L7#C8U5I+N;6A4L>DXV2^#($
M=+TI=_'&=<9I[@J!9K Y/>W"Q>Q#,2$\3B56EZ=@.G7Z/@#:5LD#<VS"V9BY
MZ"3K.P!P@@Y 3\OXL86&.\>\D]%U>D6OFJ&N*<Y0A@?5Y<OVBA?@U9:O3(ZY
MMN":\&@,-=0*?$?%(UA>,D]9(]!N$IE>$1S-Y_XB.;NY3*$5KK/DY=-.BV25
MEW>5''QY36!P5,7I<=X(QB'X@;1 F!6RDR2>BV@2GV 9"GS\)52Y\SGBZF$Z
M29;)25T:5H6?.XU\(:&VG)A*L$X2IX^\#)=LS#QE]3 =)0N3WH1<)B3_:S=1
M%^0/1L45&],[L'E@:,O+7Z\8V)-Z@Y93L415\PJ=)/A_8&6-?!VZ>WS ,Q!7
MP?+@JH?I)%GYBTORY)27=9,,X'-B[BQ145;422*&<\KU>4G<JDYPQ@2=_Z5J
M/@/?XNHL3U[+2ITD/ Z57_)_,>[=L*_F?!:FZN2I;0+931+/+F_46W_ESDEE
M<3>)T9G*ZG1&+)%E>FH@.DE2<=\FW=8Q-A-,ZU\"3N-O>8)7K]]-=C"PH0+^
M,SYKL3@E_&OY@F<%ZR9QF4U0D$GF^*\2H-JQ6]+G5E5VD>A[SI;'<)L:G21Y
M1+Y2CRQ?>)4GLAZFPV3IY<*ET+>K;A"<$[Z([>DR$IO =YC<<@NUO*R;9,"\
M'P@B%F:%KU)(*UQ'R=,3_XGW6(P%511VFA!UTJ*6FC*(3I-43L9.H)XFCBS=
MXX$G&=PIE>HT3"E]K:KN-A.&O$)5V]3<;1:HV\]69$*N[HZSX2E8E0EIS6ZR
MX"D838-($G"F&*<AI=RDH6/F/GLL"7JWJ[,K9"?(*^^C$=7553I)]#U_5/F1
M.GDF3UUY62?),/9IYB*+/"TU )TDJ"9Q9(0M-D@PB>$T>:WR([SPXW2!YW2B
M!Y5ET?4TDQQ'-MQHA]F7V;7'XVOBD>(CP!<1'ILP1_DU&?H_^AR>^MG71E>N
MOSQD0E/4@=RL>8!OLPS'ISHO[6Y*:9C>\U/&A,8U.DOV%8.UUL,70F$.T!=!
M@D3!Z 8!*GU>%.AN5:6SA&<'.Q!2,MXKR%^A8F>9D,YGF).D"HF?5>9+KL**
MV%%\P'<4Y"^ DN4SQ#9:?G4V_G" 7)1@B<_(C_\/4$L#!!0    (  *"851E
M>%X7"@X  +7!   5    <&AA="TR,#(Q,3(S,5]C86PN>&UL[5W=<^,V#G_O
M7Z%S7]JY<QPG;6<WLVG'<>*=S&633#[N>D\=1:)C7671):DXOK_^0,FR]4%*
ME.V89'9?-AL'H/ #0!"$0/K3;Z_3T'E!A 8X.NWT#PX[#HH\[ ?1\VGG\;X[
MN!]>7G9^^_6[3W_K=IWST>6U<XWFSL!CP0LZ#Z@78AH3Y/QP_^5'Y_>SNROG
M*HC^?'(I<LZQ%T]1Q)RN,V%L=M+KS>?S W\<1!2',8,'T@,/3WM.M[L<?DB0
MRS]WSEV&G).CPZ.C[N%Q][#_T#\^^>G#R?&'@U]^_NGCWP\/3PX/<VQXMB#!
M\X0Y/W@_.IP+GAU%* P7SBB(W,@+W-"YSQ[Z#^<R\@Z<01@Z=YR+.G>((O*"
M_(-TS! 0G(09C%<:G%!O@J;N%?82\4X[.3RO3R0\P.2Y=W1X>-Q;<4DI^&_=
MC*S+/^KVC[K'_8-7ZG<<L$9$DV<K/"0C?ZW0SX\3ZO['CQ][R5]7I#00$<*P
M_=[O7Z[N$YQ=L! #K:'.K]\Y3JH.@D-TA\8.__EX=UD89#9QV01/X0>9NHE)
MP0;]_M%QO\?<5QSAZ:+'^7IW\,\?]PR,R_WBS WY0^XG"#$* B;/F1 T/NWP
M$;O9(%PSWRNPLL4,G79H,)V%J-/;L>AK5[]"H/HAGDX#QD6A]_%TZI+%S7@4
M,_CS((IB-_P21,$TGB:TM^XB(7R,?$1N9HB $T7/R9_H.6)N$-*C)OA[>OR;
MJK!HPM5_Z,UX*17,S4'D [8901,448@P5YBV=(WVXVH"/73I9!3B^1;X*D.\
M/92U(^;GX-*/>/CPXQ#=C&\)!MVSQ2W0,%#^Q5]Q,.-27Z^(E6#O_G'&J&C@
M>21&_L7K#%QR-15WJ97Z)^Q3$6\1M%IJZBU%V*<JS]$36YOX 3,WY!]MIA2U
MP?3!2VVSM,HM"2"3F[DA3/#+B"&"*"L8Z0&1Z15VHPT]Y"T>O4_505:+I^C!
M?47T#GD8! Z#9/4[0VR.4 1!\B7@>?X(DQQM FGU&U\E8X;\1PK._G@_0@#.
M#?FB$S-,%D-,9AAF B>^@Q^;:=H 2349A@N-HW3U/D=C1 CRX0\#2B&1W5J9
M;4:7*<!S0R\.$VOPG5R!&KTR!-[N9V-PL+O?"7!9!-(,B%<0QB5>)@?\MR)*
M<<NTI.A1'O7Y:-T 'IWQCPF>GG9BVGUVW=D?5X'[! [) K16%A;^>1B#AB/6
M<3 !YSOMP.9YCOB6$G;2'2>F(!&>\:>Y8:IB0V"MY*ZB@YP!Q^! $-W<IQ!9
MA3#U<R&JY"\6@JFQ%$_^^;8&?O!T]\4-^<0?L*%+R )"XK_<,$9V8,VY)B"Z
M9]C[<X)#D)MR9&S1, WM *D&ZY8LXW9";J<-!4[+%X8_EON1(7P:@(@/)'##
M;'-2GIM]D[&JF9)O-G DL*/1V#:9B[EM55)HB?A."4%:EYN;MH 6QAH</?,,
MG^\0KB%=M<E7&]<1B#@S-\BJ!&"_&S9!1+QB6H!4#%%>'K(#6X.#%LL3&?%"
MX*M')J-4BS8#WP]2B6_!;R^CH3L+F!OFPJT=:)43<KYHUNPZC 8IGY1%GTW>
MQ-V,'R$"<0X[P&VR5HJH;,!:8\CU>B$(.,<F@VH*JQQ9CL8V>&H>><<+0Q'R
M+UP2P72D$''B*1<5^>=H''B!)6C5XFFN?"LJ<+P#A/ELM0SO)_OA27*=,M*?
M59&&N @OY%T>F!2KL!P?!8 )N+%+GQ*$2Y&2(F</A8QFGR0%V^YA?]G7\7U-
MO G=)Q2*(Y()8I8,(9<V(]0FM*QR*11<0JQ/^,+J6A8V_:-FX1H46J#1)JIB
M450(08W7A$E9FVS*IZB831L@90@F"2VLSPJE%E&V%[OZ^D^]E%H02YE-W]RM
MU$O%T[1,IE5@:=E3*KN,0U]@D50WQ>%$3*QS/C97+V7SLY%3(ZRZBJ4$3PV+
M-B *E4DAFF8^?>F00OU1G",U,^K,GF5E1ED"+:$WQ-4J!44%-ROSZ(,B+JF)
M(0AI]8HNJ9G)Y1<S: .A4A(3@E%@U 9*5OD2 I$0&Y&D--0D!)2&Q*1JL:K-
MVE< \ZE7+M-=P>_[;N-[ZV,INBN2$DML498TNX<'P3*")$@R@YVO=V:%JG,=
M+Q@9/(57W/AQ! ](!U/^FQUJV=X+;&L:V<81I-IJ"]R .-TN0!LG_O;+C):E
MOJ7SE==_578S <I#97NTTK%,<]1=E0/,R(HV/I"J.^ROM)R>*2D<DA5%^*QT
M+%K&N^:M:N MN(AP"4#<)_ "VQ]NMY0TVQ!9EK*L352%R*\]@$'Y2Z]S]()"
MG)0+5SJQ ><U8HJ^FB>S ED[9TV=LVR[OMGSL<EX-3JP(8M6FH2?4<3/+<(<
M'/A3V!]3QGE>*DB-;@YLY:PC-R#)F[N!_]\X#;$WXW^[A+@1HR*\)KIN&\!)
MA;/9EY5[L[0D;-69*DO1<I3ZQ2Y//9G0*SIM(C>Z5$ET.;W&"K,L9Y+4F"7D
M&NO^M1F1I.1?QZ//G42+:]F%"C3:7TS4Z[E,I4W<QA5;*'X3ES8X#<NQ$$P]
MC]YWCVWC: .3%76%]450VA,CQ+@PR0T> /IL\4B1?QFEH1Z4FUP<*#UPD97G
M'O# ^RL.")(VM=A2<A"K8Y5V-*B#X'' +-JSBM$N[V"4H4TZ$X''0\BG(Q@P
M>24X)P&#B7,;/X6!=S,>(P(#Y,]K&JT)KH92(S'D"8P$'D/^LM&X^$&.\A:P
M8G[5#>'%SG.4_H3?P]A/4E5OXD;/B-]J<P&*\83')-IXG@T:W<RW<C-IY5Y)
MI]5- HQ>O"+B!91'9QLJ"MN%DW,T(\A+;UJ"_X<HD1T2DBDF+/A?\KD=>C!V
M>@G7N6\:W4*CP@EN14ULJX!UAV;+7.AFG.]HLJ4^ME6@NH=4&)V!"R7OR" -
M+X:F=VSV_#IU26G,KT63.(#1)U6WS'N3]NA_!NO+%K\&U/EE^&:\<I@AIKFR
MN-$'>+?#GVW$/1A"7"'_^1W'/+6W(K^\7_-7TX?E"9WL)DOA29V59CZ\8]^H
MJJ9T?IDG\94#&2O5?'Q_3I/4#*IJR0XV+I51.-^XSL-MW.=N["FE1O["C5=&
M[TAVZA@KKM(1'Y@XA8ZRPG[-QCQS8S]9K;YI/UTINO:/E</KGE]RM:PV5]^
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M,<T5V6V318*S,O^C  BEKL8((ZN!:;JX<U3\?PW_\FW3L<X: UA$Y U&2_*
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MID)@8$?QB(++?0B,[JA>3S")%+L0_N6D!3"9TS?V!\[O&\BCEXPFV%AG\VQ
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M2)0<3F>RTS.&"QCO4> ^+(-+#+"/$#NCV:T5%53/"3MA=9F/-5^$=L:%FUR
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MH<0X+/C^%OQM W%G/U 3MN!K//<^M3X'5Y.#J\E^74T.;J"VNH%^EP;^NXP
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M.2V<*:PL",5.7AJ/&5!?#\)DA:J4;K5'Y@CR<;5I4AY6DV</!UNKURY$L_O
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M!(R>VP].M;)$P) Y^SS:W _RLD? '@K.O@%D>%65E8"Q<OX9T%G "1@P9]\
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MYSLK'P4OW?+7]#\TI^C?_C]02P,$%     @  H)A5)<9YP IO@  F(X( !4
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M(>:"B%H144LBL";"%_5YBU#?/2C'5Y1C**>8D$P))0"AA# -Z4,JQ0*(,U$
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M88'G^2[/G&6\4M4T1\5JJ2:*/B!4'F#OKM7[72.S\'JI.V9%BG IPKHH[4G
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M!(<N5XP;\-:##";9OP$A""D 4W7<5IPL>1-T(6,&@C+L_%JYNL-M<2(W"^=
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MH?NB]:H(=D@O-AQ7&L8]>6FP(&\B3?3$$VFBQD9R=_@4<E^-1 O-SP5H9 M
MF ;HTH.S4W9R80MY)X;/#Z?$1#8QZ;$+H2PK6+WNM'S?:&Z^B=@I$,OT74MD
MGPP=?5!W-VA=DMOGPJ]RAU<D:TVJLK6,D4Y=X>X2[_$Q:'',WFY7;QZ0.D%4
M3_AL<EW$TPS=IRW_N,0XZ5+W8+&3/!DJ+XG@%4X9E$3$?,DBN9*\\E6[NK''
M*7-K3H5VU2?\>;'6WX:@2U.>'_0=Y^[@^X%&[ *"KM53?\4L2"ADA.P88:%V
M2LP3M/$.-ZFKTB]W^7A.&31SP#B77B67[I@3QK\TTB22KQUWB3+])%EWCA(W
M_)2Z2?2CRYV3!(\9V>MNMLQ;JLE2;.D!ZG@#RBE <?34)'E-MN30U97E@D6Q
M#15KS#K(B>>%].^/[^49L# MWYQCY[H=U/2" 75/ >T/ 0<B+(S?>"&$=LZL
MF$S2>%2S$&T:C%A-E#9!\S5"B#=>[B:'_J8%K"MW3^UTNZ<2U4Z*6UOQ;NEP
M]?MR\ Y<];##NDS5L Z3%&Q6:4[(,TS@K-9DG!*Q9F+(?9BC*V2:;3'A=< I
M@A%PIS0N]S<EZS(3FK0TH4FI"1UK0B^SG9^YT(.(\ QPGE#C,'5&^G&9 !$:
M--5\>-WRBV\B=D^S0RM/+=8]^<?!D?3%RE0)L,XX4=W]>AR\5*"/Y^_$;4K1
M;@3OGL/? #@QA])GMQQ\!1=;XS>60IV")F(ABU8#8CXX)LW?]AC&="B$JC#E
M*"0!6?27D$.?4 ]:NW>JT\+$>4:( *7QK37L9YF[FZO\RM0[84+>#[]J\]P?
M?.5V@$PWJQ6XXMD9LV.1Z+E2CW!39C%YGV;!J@#VPI[EQ35BQ9^KW$J.K&K=
MS9 (48LQA(K+Z0D/5\)4S;U/'):JBVJK,*\ .HZ3<Z5[VEV_GJ3+\\5]R4K&
M6/$< W;M,/&1=HBV[;P"1FW<:]?%?[4K^ F)H _)$O4>H;>'8?SFMEPR/U0>
M1<_B>_9G$BPRT9+XD:G)Z7T<AM>\]8;U4T3.2_*)Q?F!4Q.8FXC)>STT>A9-
MQ<6DQ//@$A/F8QPM@XAM-681\0VNLFYS<,R.YJD^AP2;U(PO7\WCRL'MA$FQ
MHPWFQ(FD:0DY_6/BS?!NQ=%)N]?GL,#X!=P8-Y'H#I/7[(4T_]$#V)_0(^AQ
M[3-=;>K'Z\.SG/B,X&3*)R!J4OV':EK"YR5BXL]"&H8UPT620P)K98LAG=3)
M9$(\/C_Y.4O8GEEZ8>K4C&WRVJ4-;CL-6%(ZZ@K>>YEQB(5M#GVE:3MGJ8[W
MF7M&=]SW*F\3E_W;?0&U,2E32'D<:@$:6>@$0TI'4@@R%- TPDPV]CE1]H4=
M'('5***7T*!Y%(P4D6\D-^"J7NB$R9<?8W;^?NL BAJO6H@8@PX(0(97P6O@
MT\C_>T!#WT+S,$F;=WGP!76R!?).6XA994KL.<4,0CY*J@3)NNPF9I47 \VC
MYNVXJJR,HV<(JP*BP >/'83H_KZ7: +855K"%D2^+(>[B?Y.O>0Z>.W$[OGI
M^1\^$[;$CH1I,4K-&S/E,Y-\:NS$F&-4L/>K"B39C0H+(+""ST0PQ>)G$!!4
MVA(?!+3*!93D F)6J093$?EYS213"K<@H"5;B<.@H&H&838^9C^X3*@/1CE-
MV3(6+]U;0Q2:0<./Q!Q$3G),?):FITHJO!P!NOK&"+]+%CB+0_40O"@<3^MJ
M YE27,/CGHZ/] U_U47C4;47HB2#8]H=&T/ZF7PCL+Z+U27N,(/=\F;&Y!_<
MOB8\8364,A&^M@+':FPWU_6 MG@P/Q7N=14$7<.KVF*A"A"SATP.$V(**LK2
MAW5"/7\6_>@E 7B#0>,\-)&OB+"%$Q ^ YE%1,Z!JK3#U$=7;-8"9CTALREG
MEKW35\FL&U@&!8(O,X6?PN#YH#:^1D,#E?:LR+GO6-"9@[!R\6->M;Z;5 M%
ME9?= PNU]Z-" X!!DEDH#^RD#+Q_N+LS59N!U0![;$K7*![E?#K"YQ-.S8D(
MB$TT6 ,<K/8MSNM.$'K^TU4,Z= '\EC(:.*T''K%NR_<;+.NK=X5[,IS0M%=
MC,A2W 9B-NIU$J^@]])L>1TD:0:W/WALO1"0X;H"Z,@I.?P4M_[0,,8&U1CA
M82KX$B9&19S/C-!RSE!U>A"#V),Y^_E<W'$"L_&.5[,EP0E)/B,"$!XQ]T:5
M68<=,*Z@W\T*DM80JVBYI <WS.P0"\U70/@2/B\!60N/:G*BN)*> J58F_ Q
MCL"OS9U.HBRNFV,)R8YYU>8&YU4F@B 13L O!4V'C4VM\:';'O7,]-&BE$VH
M&G78Z=6;MQKIHTUO6;[MOF%L6]4!%E($>BP:Z%E>584$QR T'=R28I!<0^']
M0#U(J/)GT3T%Q$9V:; ![)M.Y#_1&W,;1/2&?1B'&EDF0B@5&0+:.HA<"+B=
MU%)PE+X8X:'Z&=9#<$&?J^!V:I6.17I<DU8EZL+SRNWKKA937O@N"[:X3\*9
M.62'#6GQY,N7'O ;EV$(2ZLW+):J-^"J*%8K.&&[^8XFRSA9070*CU),C^[N
MU#=K22!$J4TD@*!PJJ/CTO!QZ96WZQT&-Y@*[S@DXX[38J%R6XX=YA!\I!GD
M!V'[&I_Z%ULH\KJ);B(!TS2%QF)=(/O9!#SQ24X!F@96DC$+6DU#\GF.D5?=
MX@"&T=C8I!P<,U!,>CTP"2&D/-6]:X4*!J1R<KW5J5GAH1A9<^AM\=9!)C"P
M?9FGB^#B_L4F^QAG?Z?9G1<<G'[/R1.=/I$3$#8#TZ RPN8@,,GQL6F ",FN
MWT8+;!7#2@W<6>%;2O.>)^PA3^!B.8;"FB7/7A3\$\]RU%DA)XVF\GAG-X<H
M7V*&8/ <!<M@ 0W$<W]<' :0IWNP]EVX3?3UB+@Q9JCE2T+II'E-59HOR_#2
MB86Y4E@'%YST<^D"XU8'YCQJ @/C1!:A@26M"4QW_HH%]6&T#"X\_5L]-@EV
M[L%1T3(-%;D/WB>(M@\&%%3=:H[KF6)]OPVI&O9@% $J5P#(Z1 0SV*%9?_J
M!2'>&TSK1B,1<PJKV]+IJ8;#(1Q4IA<<!4P$9FL@'P."1/0HPJ(;.Q8>V9,2
MU+GZ+(Y)!80$]\Z27E3S!NQ96ZBSGHDZ^Z50^B#_GN=9K#%+A#>'1$7G=V=_
MPB=_=_;[/YH]L1V&K&Q+0T>F:,3@=1Z\LLQ=:#)6#:%\-!R96=O5^]=APJ"P
MEN!XR!A;[Z7!=  P1[%#NZ0]P<,G0[X4_0D C?37J-T^GWK3]C:<]MB[W2:S
M8<&JY@Q.=0;=0L;89*;,3S A:_7.:/[.HJ/A::=EZ'I SK1R!)Y7>F X1F-*
MKZK(LU5O1)ZNXRO,$C_A+BNR%Y2KZ)CM-U)1'S(1L3'G"=.6^#"OW,N2TB^W
MP3ZAKE_'R6VP )WAL'8Y1<Q[V12=F:$AIRMT6V<H]W;XD->+;'G/UB_HN>WE
M8VGYQE<!,9L%LZ<"GXHTU[47^/H[&:'OI+%]BX .@4 7KQCHELN8HWMKX&03
MHF;Y;8EHF'Y":KTYMLUO4NSEJ/-][4O]'+J)_A9$_EWPJ]Z(N7O.A]P<[#4#
M?7)W\S?7;:H=<56X)X(JAESG=MCGK.(F9QS^*CDT>FD[S.68K?'BBIYOP<^-
M2.2SY6/*4P,/#9))F@2)<EAUQ*M,1:+?D?!CQ*T44R$RE0#IDWAYL@&]RQ'^
M:]Z^E4UY1?G_58%&>L<CV.":$AVC1/A:JU,[(#.EK*\OL/RE+U;P5>LXNN%[
M=1@?[EU&8JLKV<B)M1J?E(BYN=M2MA.3DM&K_YQD]PPCF+("1_'RATJ] )#W
M!\@59KK%^T\+K#+ZZ*VZ)<L+>D02)$!QO&L/^UUVFF2_W /]3E<_4G!XO7=<
MI9EJRT[+- L67BB3UE=.>@3RC [CEM,2YJ=)D+(?0V7G["GC?:8*EV#GG*'"
M1:BU%B$>GYZ7><9R 3W>E;T*ID+=T>L7Q+2\]%=-7*(1?18"J=.71K5-:K U
M#RJC*@$TJL38= EL9),GS7]=B7[JKLC+"4M5.*@]\J5JL#9)A-FP;.[KX!/F
MQ7:Z*Q5!Y$:2[*&SL#U.C-(PQ8ZGL=,#<B24_?(^NTQ%"C<0JGZ,O%7,--A_
M4E]FF5OPWQ?P(B,U+].$Q<1DD\_,1_EB;E>'2#^2$%NV "F:ST?4A$2;D:C"
M H=!@GX$H.]TF/%$[8,);(03*8<US.42>0G]JYI6D+/<O8!>(SO17J[S^*T]
MGL(*=C1NCH$-0RU#7D*UYWII#%B)'G)^>O;=V7GWVZ(.0 7F.#D[/S+NPM:,
M.7=_ WQQH+Q#LATKMQ!,7]&!#>J+[G ^8>Y#S#NJBMXI!:<B$=^%L[BW<PG(
M4(?@7/D(IZJ!KZB/+S@-R:6K4Z@GQLWLK,KW+N]#V>ZKL $<1C(W3RG]QP94
M@%?VQYP]TPFP+J='D" !BCT UUGCPTSN+V&FKPK/CK X.T6J#E%QP(=[)<ZX
M.YDP>]6QH8(D*!O5,)*(+3?BY8=]KUQH]%ZD .FLQ&N!(O$D27>F6.=U*SN+
MK3?'Y'.L+UA8MVD>Z8OO#77K-E[PI)5/08?8H(F\)6FRPX91=7C:6^3% -"O
M8LBI;@W!0<T,LJ!H3(M!:E$JA#[HREJA\\F[=Z>\7.B/[[[MK5S(F@1"DWG=
MG'6F1=I_C3N9[SU5[G=J+L.H=FPF]/O/A"U'/7/82OKPB/8AH7+?Z,'MEM@*
M^H'#GB=>E )831Q)>Q%BB]J/TY^"[$5_Q KHMS9!;C=CN%6?FL#<Q#'@]D!B
M*;99@T1Z>8U!W3I-7H.%2R,9TGCM)*]>AW&<.,I2M;-:L0<O,*_1;?)IPW;J
MH)E6?T&N-5.+O%0BZ>L,]5B;--UD+W$"D2&+E6(YT:/@I+IBS%,T^Z\:.YR?
M%I5C7@]O2%WRL[>()MVRZ96^@+1Z.+YL+-ZX(Q+OGX%+;/3'E,Z6$HCDT",6
M$KN8>J;(C'6YNF1AS7$O:R[/2MMVLVRK\O"V[NU;N_RT3*.;$/<Q:#M\E58%
MWM(T_9[$@_)7H8ZD%UO]-RXT+01/+[0O&D;WLL!LWTV-1*00-Z4HGK*#KBM#
MD'PO2CO;<5S9 AOJ<N?+Y^>?)-E3@H %-LJBP28O+B.DZW6(;FTOA+)N9HJ^
MW42(K(P62K=PHTZ=0QL#?:)-T$]?#C=,FD%AC5,_#[!"TUW@>PE\!_F<+@U]
MQ-QY>*$T$Z=2'O!-.[Y009P@=760:_1[>9]3_[\V*4]BGL>RTS7]2#,>JKF-
M4_;S,OQJ=;'G^-4=!:(MA<QCU?R; E*0[*$#ZX%?5F)[Y]I.OJ[?C"#-?@2Y
M-+.8)$J:$9-F"&)D/XV*J.&Y,I6CAG_O4&A1%OA!N($8F"@L8Q/R7%GJ@YL3
MRO\W_')E-HJ70)E'>D<3M,L[H8?H<Y-\<B)GYRY@;7ZTQL0*(/- ("JX0AP9
M5$:FVT(!;WH">'.#X/(./3&R>&,=1VP'SY;Z26P!HWVWVH9/!'>,>2[GDSFL
MNG'$9>X5%-S-JKESC+'OF%/]X"MP2#,O"'OK0]ZE3JK8<MQY!9&%I>^T$>]S
M_3)6*4)6,'^7;  5^E1(IU=83N&\65]G+L)R!HC;]A,VQ&_D!HG54]=XK#^*
MQBN'.V4$!><.EPXKU44KR/1UDHA4@VV7#,_"62)).DKSM,_'SL$8*+(3F:6R
MQ3[&[C]0:(YR.(BK^BZ!C%O4UHX++CU-UDY[TUS1)85&-'/ODUYH1;OV7)5T
M"2-LUHW1?OJO6F?,_" $=QGC3O/7.[0T-7YX\8GE=R2J:P9X/9W9J7PSO%;&
MP4O)&][=4]EBZ2Z)GQ-OE?>7_Q!'V<LT\B$+K5-SOT3- 2#',(G>5'[M",G0
M.8^E;?WRN8B8C.2S$9P.$R!A0C=U'N^CC-UL4]]G8U+QO]L@HN>=DM*0*!'D
M)O(O! B3^5L\<E;",BX,)AP4EP('(LQZS2QL+X1W;J%L2- DG"A/$G5;.F2+
MBW (!O(N=ND+_ < I:]>"'[9>Z:?),$BHS[\@AT#Y@^TD;S.:1>)3=0<2"@N
M2"=\OUS2 ^Z 0BO)H!RQ#WW%B$<#?Z'Y G^K<I-;"L2!?VB3DWQ9_'>07UW\
MF3Y>5+.5(0+*XA(%NH:9HWS-CNZN6DP_.W7:.V4T/9=ENV!11A<:P!H=UUV[
MX*RN *K'@NH?H+<VQ=JT3=K!AR/H$$[(N2NG\[*-IE7&VGLT,[!ZWZ*]A/3&
MOOX=]!-7UH+JH:EE0.B1$BW10GS1\]A,L.O8-:YH4VA=6_6DC"<18DDQQ**E
M8NA5(X6\/&<Y4,-+35J;6L-175IF0$I/V)%WPCPFA=33E/#N>CU$Y8:77T6[
MQSV%R+8<^S9W!.GN</D81\L@8JL*F.J<.[&@[R2VG<SCFIVT<6T6PQ.H];?,
M9W(>K7+'='@(O\?(J-% (HY.<G9UA-,EL/N*[/H.V>45JC3R:?*3!^TULO3]
M)YHL@A0^:5[],EMJ!3%=ZW5Q*O(FYF(*I)I,UL- GI]6)^.L+-<ATV(O"V;E
M'$2;1)9GL<M"K]HZ0E[U[?Q3^]?J$$Y4?J)<Y6-6M_;]"F1M?\;N,K N(;H:
M^>PS3.0_L:.X:GD[IXN7*/C'IAL$KG9V"<47? 'ZZ2;7169PHXFEX"A];:+=
M>=Z0-U]>#X"S(Y*K4<[U.0A7R+1C!BUGOY=TUT[K-5P)CF"Z574;O.'X.8("
M2V8'7M"(+H,LG;-S\:=X$_HWJS7C@+O2@E?*AMP?[EO6)T,[5TX'O;0R@A,2
M/B-14^) MR7K_0C!* 74)0'1Q"<IB0PD\8:2\'!"0I4D8&#BL,64"([-GL+@
M&3_RJPV]B:Z#),WF;TQ+V0+<!8;)NC8Y4#W48S47\=D1%41D"=.1#.=#Y!&R
MPAF=50DYY%KL>\5M/@=ADT!&/DY#^#R()L+#D*Z2AETR:U07E;Q?]F[!!.7O
M]_S;$WRM;B/,@.GKI2_0UA3L8T.3D]K837091Q'%6CV "M$!:3KEV(A)BZI=
MKMU#R$A-3=X 024TP*H_$ZGDMBL&QI1@"MI];@FP[R*?G4/+F'@]GXE@"H>B
M%%!PZ,[)H9X<=K2#NF)**RJ791TA.U4^TD]PI(2OM/MQ<GYZ[A!@NB^.E-T+
MTQ5=<5HYO2HLA3L")B5\5F=70P%I6[8NLQ,),SN2M8("/)N\^_8=AP(\^^.[
M/J$ ;;"ON2>+G>HF,K#IW!-IAY>PG WW@ ]FJC'T4.L$"UU,F :"/:!"V^*B
MIHYDXJC!7#D+U]["0E?OZ?-S@E 5XJ.';]XWL\#'SY!9 UA(8B=/<9+$;^QP
M\QS7/]IBI^)# 8+.:S@U+>O.2V8) N#ZZ+.2=9HV(+\8;3)+.+RN+UQBJE#U
MJ+BKA@%C=RD/BSC-&@@BBMW"DN!I QKH':/5K;8/21*=)@&B?53YV>.FD"H^
M%$L5WBR9. <)@ILP$[T)Q4W.D^O8Z+LX#1"UQKJ+3\U/U )$$;G(.!4)?O"0
M6L7G)J4"W+<0B)87(CMQ(.XN^/O6[D6!)Q($+.*%%_YUDP2I'Z!E::=MJ\.S
MR/+*0VW1:'X@7:(3[@/0SPO\F^AO08YV;,L-932^=^-@LL>$])TR0B=!= *D
M%/ZR(__/AR *5IO5!R_YE6:7WCI@)EKP3P[=TUGK%<3)"JF3A4'>F9[HAJ_0
M9(D3)B9E9VJC&Y8*OK@V;\NADVWJ^WCJ>R'_D 2''1(1UK*SC#3"U R\=#6(
MY/N;&%[9"51_\/@OYI@='\_L.$^RO;F^H,]!%!TIXV$YMS>*6\=I->XX,T&<
M%'MK?DO([]0ER&/*-+,%U-5<T5<:QFLX-$0EP5T<!HO#8?<Y9<R\T&@KO I.
M_:A8,X$K!7]>.7^\'QV63G@N(&GT-EO02,U*<S W'=FZ+C7L994%&(Y.#EH%
M&>+<)]MIM?W"AL0KF&)Q";I&LNUDTDA:1!#KP8RQLGPCDXWZ-'%YMM\EHB &
M;R;TT'5$6!4E/<(Y][O3KT]/3\]R)]V?=V'[R0GY]G3"AL%_Q .(K@5*CKP[
MFY#ST_,S/";97T[_3*)8/@4A8_ V0T?/399"*UN$*:Q[?M2"--WKS:(LD62]
M'$^%',Z^.TB,^>.C%F-1Z\\%*=1<I#K!G SJ]Z?K6V--5^Z;F.M1I;=QE&AQ
MY";.' >3+7 3EC+"^>@=7[][Q_K*W(U>.M?;YJIE0X0CXLB\/FJ;/$1Q=.+\
ME4'.3YSPFCMN2G6MI^0493TDI^FX(-(!,T8G6L<5B0^+%^IO0CI;[K;+M%/B
M*B: Q,:R-J!]%*VZ9]8([TB.XYSC]\X:A9K5%1U3FG@QB/O.K%W6NMN-588'
M/4=E(>A;GWN_4M^3":]6&G]PDBJ!U54NOXV5BPTB5JQRDATW^;"Q<OW++"Q_
MQ*LVKVISW0[/1QJR'S__0"/P*4PC?^JO@BB @BW(,Y6'F)V[6DQ&Q&SHX37G
MRYV@O=[D_4C!P&81(O"J1>".W?>K=1AO 6:&<3%;=TX4D/2$,<,I]N!:L\:'
MF:J1\^#P'4"]1";J)< OW<EM+(GQ)LY K@</LAT.#,U75?T(3'6G_GI,.7QB
MNK8/+0?8)\>CYG#@/B.@R,4V'R)J$:;LYO;%WICEGC'9^F+*.U_<4Y $^SEF
MO7F+;..%4!MS*"1DO@RB+Y5H:X7N-MHPL5R"ZY6;F6@K)G+)1*R9J$43;=58
M:N2PY.0(WH&!7"!;G#0+S9&F41Z<G'N?+A/J!]DETQ>VUW$"(LHA72T QQI1
M2U^+6D)NW@+G)@N8G"SY[#IZ+B3QN5)U>Q.(^!8KP].0K\GG)#@I$;/JT+IN
M '7[E4-E+%O?%7Q'I'U *.>P\-!!BS$L]">1R7HPGCUV$H.7*O,.!,'1<V Z
MS./7( 7Q?RDJZ[^"#Q206X$]]O&ZU#,M,52,@4F6^F-$]C"4A;'8V(J#EUQS
M7":],5L.^M01J2-OX*AJAN7,>/RHN?4V=GJWIAX@/OH63<L>D)&L(58"@R-J
MJ026-ZYS=![OP@F+3J/2O&,"0IA([AES 9Q[LPO/'+!S6#0\I7JZ40PK$=ZT
MOO%UAY!4?LKO@"@3V1%6N2+@4\,%2.2@?E%ZAY!/6:=EN1V:-Y#S,%*Q?2%@
M,BU \X$.B-3O<F/N]FZ<(.33@N?K\0F<1YHM,QA6\298F^:L'0U/!D"B[%;*
ME$R>PS(A3^JE^:XYF[+O<K:\97,=&H5A!%"=*<#A]A$78Q<W;]/)W@OBI48+
M>#74?XR8!B^N[JWUP*":EFCS$IR8X,Q2I]D.%"_L0RX5F+9W#X\Y]X^(#@F(
M09BDQ6X#=K2"GYC[=J"6TF6(&V+1'=58$9OO!7"N6QO<BVTY@0X \K8:"%]L
M214IUZ#T(Q*J4?90+@['SLJ+9F?E1=%9">T[LFT.)\ !YN<O7B3<F.JL^;@Y
M)'Q1S&Z4,-AE::^_6?'H&9(U G*8#CQ: >EA!G$%-\89Q#@ST, 7J@%GB-X-
M@&L9J3!$?O7SY3JRFRZ91LC.(5X:>9<$!2"SCL:UH"X+(]= OR]0:LN<26^3
MX$A4L2+=GI"G+3-DX(*T>$\C_.3%M_(C?B?,2 );?X%-%>!'6MA+@0C= ,!&
MQ&R>S@4;.2Z1HBD3K>4G++Y?L*ZH6!F@-KPZJ4D_.F%:.T^EN/G*T4R7:X=V
M(/!C(ZA;^>;Z;)ZC<IB908YA)Q$1W%_9T]PR)6V!)CIT(!C_QF3.730.&0\K
M>:YE^2AY+;IQ- \(,+CHAT'MLA'-#O*OR@;FENSCD%,]#EZ*EH6HBQ*MG2:B
M7NR8>#', %4(=90,5<.?Z45[SCD*O32=+46FZBRYAQ293MEL2!$T3T$3T.J0
M:@]);1:Y,;508"G.68H%2PZ+U=B#@(G9P7>%.&T<(]2QBZG+8HU:8[EBIXBR
MF]4&0V)7=)W01<#QX^DZI*B/1OYT%2>9P,BY2^!&R[:PL@QT3V8B8XY,9^":
M?!U$7\B$J*7P[&)M,1,BES-!QW$VP2%J33V"W PJ10,*QXD<^X3-&4B4!8!G
M!T)TCPT]B.#">IEI(IL61*8DQ@7&#4*YC,](4-]Q045HR\H##\HMOR>>)C5?
M6\QXW0[7<;*D0;9AT]Q$'#JS:QDO]PHLX%P)0R8(IDTL^2PNP]Q#"J)T1Y3D
MM><N*B6=SU,@KEQ-VIHP&<IQUNX(1&A6_0^SH] +/DN>O4B<H=AE;K:\8^-E
MS(&=I'D7WN Y"I;! @Y8WI2 K13+TX(#>^45PAOZ6C"5!JV7M;8<O*Q3K?=S
MOB0XI,6:R%HLRE4L9%"AB:_/$!;O#\BL5WT9>%/KK9\U8>5K(7(Q[L"QAY>9
M\;D=C^!V(#ID]F5GZ!3W]9Z=U[Q;@)^[::GSY=_<S3J5I]Z0.S+KH1SUX'4:
M.-5WL_'>MM7E=J);,,7@[>!*3&VAHUPJCW#_YH1=]"/MU#2:\NG/)31J>>D>
MHT:)]>C\^0BHW^D+%D7YU+_8/C+AW$3JQ,]+;SHF<7Y$8//TA<BIX$N$R<!*
MR"\SK1"ICWQ/]^P;7GS@?QG&;RE90M9F?@FZ+"<J"<)J($:87V4CP*PC-"'1
M<7-2[A!PN^[:!HD?O PR4.UDRC?V1I2S]9H<WP/_%1GQUQLP\8GL1L"EH?I#
M\A3Y@K!Z@>DK9C]TLB)K4CMZM&OL\%0.I3@$8Z4174,C4+],Q6_3,^N1:U-%
MT(:D:DSJ,#>[%R$82!F2.RH97X]4V[ZBZ2()4(4<S&[1UO!Y24C?$B(Y?,W6
M/R&^2X[1R:4WI!9W4P#MS-;BU@"?5Q M@C4"?LF.2D?1L'E8_@J>XENCX399
MJ:601*V%^X[%:M!Q+-MO37B'MSBBKAS$@\E)JG)&QW:2+X'D:^!>3RF?J=;A
MJ_?>UVV;@ -TS/PM[OAQO#M:1MHJZD83<YB+O<C8J4',45= U>I@Z@O\&Z R
MTL66U7^/=:F:^UR5JL,IR BN$_K"[F*H873+05[9_'ZYY%WD%3[//;.A[^DB
M9@=0R-,IK-=[JTF)!JT$\Q)SXH&JO=W+Q(34,%B^H-D;I1$QH8UR.0F,#>,'
MO.06BN6QO.GQZX>OB>@,@ZV=-UG,3.?+.%G'"4A9BMO1+?LQCL []D"SC"/R
MS)85+875T7@3V:O&$].35,W/FZGSYL,+O?DPZ)\*^7X+G>_Z*-GK6SZ&'\40
MRK>G9U_^^E6U!#X3 <B[+(ZXVUH3 CN-JMM2YS<W= GLI3L@6P1@.G"<O/L@
M_95#]L'?#JX]T2@2("2A">'O1\&)6=R@D45CHA=N3-VQ$%,")#/(/H S]8XF
M"WM-5'8"EG(J?EV*R8Z7[5) 54_P&@#8E4!T>XJ3)'X#P21.NV>70V>*7(E.
MF0>58*$24])]4H(#YO;I9NFV*>0UVXU>R-/^KMG/.AD1JDTDIRI2'PG2'3D;
MX1 <X+5N0+#?L5$O[,R B]1*NPP%+(^:"5D+^JC#N=+4+',D7DT!(E_2Y3J'
MXYX:ECDR?+HU;!T'-V9J_?N'NSN7B\^M2\,"O'P!'_Q-=.T%"=;KY]$8=FY?
M EY*D@7,^@078G=44(&82Q+3#%W@*L >6+)UB'Z23-F2W6J$RT(M!AV^#E%!
M>Y>4^%9U!X4I(3X[6 8P/X=6,&)Y<,]KBT"7[V<D($,I/V2WC,K'?X/XY_.7
MA'8*;Y^?GG_[N?!E-;8#>P.C.QDL95SQG0XRLA/7N8E$- "6X$:]?!]E0;:=
M^CX;DXK_W081[138YT2)(#>1?R% F,RBL;,2EG%A,#%&A#R1X2H3-E2I$^;B
MCPRK2"TR+Q_CA;S]81*-4<[E %N!$HFZ/[FI$PMIRO29$9?@:7G7 \,/EJ7_
MNX(8'(WTBOG\I26,1YC#;POKLU0>/63HUW3E$;XQ#:E_ZZH]DZC.,GHZ;/OM
MQ62!V[;N5+TQP_;8F&S56$E6VTW,-^HPC29/T._6:T.O+W#>;KC[JJM[#COM
M!(];3!2VINR A)0#@-?@3:5E_::+;C%R4K:A<%;<>IYH9JUZ??3<&Z8?28@=
MJB0@9N/P*X5VWCTW?^E'  5\$4U]\MKL"H>X8$F\##(;.5?"J?<ET/IJ O\,
M-SXO'4^XEIGQ3 #D,HNQY19D!\2\9_&-2EAUC$IT.,MB&W,"CE/W.KR87O+V
M=IP&=S';T^'_#=:7L=_)>"LZ0#AAPB@3(#UV5LH=(,Z92)/LEWF00:K=#3M9
M7@-_XX4=H F1%KC7<FK.0 JMK=UH3(\,Q#H#CJZ0AJ[F%JT0O:FY9S8U[]4.
M<<BQV'[-'>Q[L44<,EK5K+[\O?9GCUCT,(S,<:JK74?C*K4FSI8-"-RZ:YA6
MLZ#43Z&G$185OR5!EM'H;O,4!HO9<DD3\$S1KK:6G(?#"&RTF<@:IV(7 Y]K
M0B+JS+IRQFZNB7(VL<>5/@/A4Q Y!V&3'!N3!N[P?B]T^*JG/LJ=CH_+7:?/
M2B .8#M&(N.Z#L_CS5-*_[$!C^(KA?[MA^,)Y*0(TG)?:F]C\28 1%\<X$DA
MT"5$6K/WS/3]_V!J>; ,V.WHI2^S*,\D6(%7Y#H.0TQ0GK\$B=XG\D,0TC2+
MHT[<2["+M5H/F O_D"LBV-]Z*9= ,E@##%;--%=R%9^OO$)35'>&J-1B> 4(
MPB>K7 Q<$%$K(K@DHQ?IA\]?? 6UI-6.@Q*J/-V'B['5+G2EQ5PEFV=V__J;
M139+X,C(4":=<UN!+A&$ 6%9D3X"/L(2%F8:"ZY3CFWR4MBDR-,ZYRF5U!WL
M+\W;J73(FS3=P'0W49 %7FBJD58493D#$5,4E>4CY+-:5PX$CV5J,IP^@13&
M(DY=*E[.6#=C*R;S%2^8?'ES-_MJA$8_S\F8+:>^'\ C7LB;&$TWV4N<!/\\
MN#-]=R\*7QIXA//%R;9;^?)^$S(U7"FY,"(N(4@QXV+Q7KT@Q' 7E)O+#\V5
M&:ZI.9 P>PU&LC^/+RA\;=2?IC)-?1[+J@Y+]<^F5HB9S$N<'<)\3Q0YAV:6
M:9Z[SGZABHUZ*([N63AAF5PPB_E:E\N-DLM/FEQ4C4\/?6%[EDO12V=OW[C+
MN,H]_'.VA!2 2!GW\('[.[#?5QLZC[5AZ4]!]F(U"TT+ 9 LGXB?.'X):CCQ
M-QAMUP8S<;)E]96Q-JC\Q(=HA(J(-@&_P'S-WZ;24 !.:![K@]EG"G+K)P=N
M4+&9*M5#U=[J#\FBLB:Q1[ 36E,K.PJ\$\="JD8\P:+.$>"=.!: .$PJ$$]J
M"Y ' #W1-&,H3&2K]O*?Z(=%)P>(/@L&Z\UYS./3/1B#8Z9-S)2031Z+,+UN
M1F$?/NW?")I-LA</7KWVD*,/HQ2*5AI!#W0AJN@N/>BT=+$MHM+>4^C%*DMT
M#HDPF+>'4FV%-L=T$?UT8&H(SB<+<6#"SU4PI?B]_RT6<914MO"=2-\#^UV^
M'L(71)ZVN?4DGT@G1"R+O/_\Y5?07I0<WW(Y)ER.FH<BE^-"R?%-DV,BY%BR
M#QWZ@=NWF^BKR\8Q\EI,S<:PT@:89*I9OSTU@$/X#["I7[T0[N5[FF9)L,AX
M$([=TN8/M)$JA_PJ2-=QZH4_)/%F#75! )(%C<DVRAIB=WH7,<',$[XSM 7
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MJAJ+1;*A.EN6(#TY7>,M]HGO>;-:,\L:;]I$8G'SD.-M\ I]!4&L=O)>\JD
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M)W:EJ@GU?A4<NEO.Z:9514]\AT66VW+L.E3NGO6J5E3LK7M*!EKW%BZ#3,K
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M2E'H86(M<!@A59(OA\!ZB+8@+)56$N1K@I^)57$"GZ\ R]*LVN[%??>ANXM
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MRJ]F]7^G]#Q%T*,479G,G#(L=G@+HS_7&*7_=^/:UNN4Y5H6;?\//$/=^T1
MC L#*OGM+7@E+?7 +#\RXXLG#SM$$9G[VI@ !%D@B4O\0)6D$_MYOMH(?(15
M]@2B*O]"J\TS1+"R@-$;/XX!;4GB*(B& \$2%2I#Q$40JKK()"OW"5;3,BYN
M'$854D'%>-XJ\]B GC@5]*>2N,>IPQ6DEDIV^':6QHC3,>&.8"_SXI4^D*]^
M05;L8:2")QA*U]LL/;QN^04 .#1)0'\:Y,V2=.C]QPGQ,*\+9"MNY\@K.!6/
M\#=R(^E<(*LU\?EDEAV(T#HDWB))#G[,\4W'P/;S^( ",76^<X^GG?9@04)9
M*1;T=MMQV6&1A)])L4W#-$Y?CP/3S(<+M)HM1YLDLW%ITYPF47U^RURYR<O!
M_]49SGL3:4F^P\,0EQJ(^PQ3JJRHP["7O$1)ZG40)G>8_*XX%B?$@IY52E_N
M<;0<,]H"IM7R02>L'P9'4R&,O(,!;HCKUU ;[<I3)#Q%P[E[UP&?L95%$X>7
MP=H?.6L)DY_"^_)4>F^*)7\*EO2BA.+U  _,N9I=K0BA>E;9F)? 1VNIR$DP
M]QY( 1"BCUGZ%H6@67[)(6=!2>T+*)C-5,^!8A( HS&45$D*9"(@!B8Z1<XK
MZ4TB[[AGOP*EPE!OZ3G+N;M#Z2J>K^@X1+WK@T#UD";<P<VDNIS=W_KO@$+U
MD!:_D*+$IQKRE+!9?%_S^);BYI6G)L2%Y2L&WT7_M?".I-#0O:Z\!:O][OS-
MF<TRBH/5'QBMMI0Y7ZEJ&[6ZOU16]S>PG/I!K01Q,4?D]X;L1.(Z7*OZT S
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M_%T27[6W4;$2NF9%F<C*NALC6OOT8A[36OQ&8&<ZJQ_'N:L6['C,TM?,WZE
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MFJ\)VW"N :N>J=E -#1A5#BT/+EFNU("MFX,,J%5>-]%'%@Z_YWK0@:CY6?
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M-P_Q]-.O"&P.Y.9I).9QA>6)Q60W$K([V5A>4RQ4AA!P$![R07Y@,9+'AYK
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M+SS="<Y)00H-)Z:%UG%R%\QY1[Q<!$&I/$#N(^30\#]^*(/HKH3E;Y(<,@4
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MV_B)2\C0P!K([IHF]G7Y1C*0@AF'754BK(VQS0::=-)>Q<?<$KMDE9]%<,S
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MMDBY@^OM2QO]LJJX9EM@F\TM+WR'8$:B7U2\>9F86?A0ITJ&RBX"^@P<6 D
MJ& 51)8B 5V]T(^!>(?+4,A^[[:A/6IL@['HD3(H,>\@,QW=^_O<$(QP4G=T
MP?#35U9Q(A(Q0C7K9%L[;+2R*CZ$5D,#C'WV.[A//^S 18.I0SEZV-] ##$Q
MUZ\GII^10Y%9_(SZC^@GXX: 1RU>)B'Y^F=B49IJC5"-R67!YG5J@>:[ 94[
MRUF8OC"$*X@**IRD3837D8>>#<P4G(46+[ZQ(7+QFATX _WX^;#?QT?E2;/E
MA7=UF(NT4 U35?\LEER$3RR*.Q+2+Q*S'.<BS8YE?TLAB%$)8'O-_'P+51OH
M?^ 8O?DQ?,<>MI%>'><#@:@ R9/P-#1$>T?T9X3NH&5(YQ)1&9V;/1OZ<F=C
M;-,QN[I5D69[^(:Q(;HL;PFTD,$5ZKEJQCV>UATUC9D45-,(" GSQ8:>A5L"
M4*UTQE\ '>0]B^B_Y:P&3)Z;HH-/[#^K$$\JNZ\R#CO%OHQ,/37MT'X]+]4B
M8W("2]O93RE5=)@T-GKII/YDT?>-!7JOQU/:MR]J%0VJV4+1!6O1;?WG6>>/
MV+::,3JNEK71O,9=4D/]WIG_]XAD]]&&/ <1 )_DR[\(-#&P:"3$!M+?NR=J
MPKZPH96URPP:6WO+N6@Y(IV@:(E]M;7%_ *E';,T63:3QSN:8DNOKF(1N#!X
MEV;BGZ"=,2I\VAF@ATC4XICLGF'*SO/AY6]43H#0+>DE[A4<=>J@6";/8I_]
M=7E?,73R?\*VGO>PZ F]ANL_1E/ZJ8-@FU&V\. K:&D>,@O.^YB4__0,KF78
M2%_V(958%V&Z-X$IC34FMJIQ>,E9>D7QZ0V^8VMLJJ7MO%BX;RVV9FF+[O"A
MKP$43%ON]EGZ9K/K]FB._2W.E;2K_M'V=,W1B6 OFD3M8)#H1HXK+6;E0['E
MHREGHU$B.G4,="LN!$>V&6[+W[$WT[F'H_W>'#PJ^@T+CO%[GL2N@ ]:>>[H
M@J]9U@O-0=X7U2("'L-@K\_<L^O,HJ3:@.Y-+9&G#T!2JXV4].R3-[6;CVY
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MM_F $_Y[%&10#HOW5WX 8O9,Z^T&G.*O( A^":.7\!XX"50(/61\YI !J_V
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MJ67N[V_2I1MD'B[H Y<=/H$[)P67ZS7@6K &G(0^=TC)!'\HX!X^G4<)TY+
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M< D:[C-A7G5,HRG&.BR7 Z1P$^5.EEL#3L&,R00M#U+LA%D;K[6T"ID*.N/
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MC/(U++QGE/JC?9;5AH802YE[8[G28_+5#@,H!QO75A%&G-*ZKZO)#YV "&Y
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MGW&59:QR">4+?/\\,U8YTVHEJJ,/$.TF4A7U PK4?[05]3[IMQ87-T-YFE!
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M8.W1R>/J,VTC&02*%4@$"?Z6Q7[B^2Z:$I<HVWH9R+"E^;2Z_%;L;QPIX!_
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M&U^ QSI)JAO7-,(]B+MM#E_Q_J8MD6Q00VM"NW6(='UQ0F:%$@4#FP;*,MV
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MCB+':Z+&_&^EF%OF\I,Q_Q\2P2]0##-<;I' <17AL\:(,!VE7\"2$$<[,TQ
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MH6H1Z!O?K?8E?T85-*J@5 5K:J_OI57!SQ^P(_3!7SY_&$2N<_#_4$L#!!0
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M'7=^=A=C0JO1;KB/7TZ9Z929OIG,Y'TCF<G_E)GFTZD[&SZ8*L)3ECA5VT^
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M"(4.BQ3),AR.DD2@&:HG3)@IZ,=B_!0T5$QH :DP$MLTD8W95-@$%VAR")V
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MKY1="OKM\ANN?MM^_?4W4$L#!!0    (  *"8529;48J804  "LF   /
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M9/!E.D=QA^"[@R[&[@JPL-CCK%N<A)G]!NH!S&"PW:;Q8(0J&GZS)N@MGE:
M5KI:;IXI:)V*OR%"A%&ZK]O!B'JA!Z !M5N"6R&RF3$.5(R!!Q9-/X_6=4'>
M0+HH^'9%[8B%(G]!.]>HZ#FDZZ"1#\5-YS3@-%T#NJFE$*Z5K1<Y.X&G<6(M
MBV>X3N@>XGZ=LS'%ON1DHLG,S57+=]Q;*>^1E4B+A"U V\#/VBQ@F$! GDLF
MP<:'_GO]P/(=&GZ8JU7A0W R0F_DO<%>Y6D?BI<[>3U;/9A@ZB&V-3 9,P=*
M,)]PR1WK B>L*LT<+1'Z@TA@=A+);\!'=Y!P=4-[42BDBE^8 S_3-G?;2+AE
MI_>,Y-I61U8K<%0@8&]]F-$]FQQZOU:];;0->@89%+:"DL4(?\7'N:E]$!9@
MD$-^(G?9+8#-L]!^-A).S3%RBA-KV[;*\:-WS6#F]V/FGVD4*Z#Z8.AW-O2)
MPJ_;D,?U DQ9UT!O.2X4QY*DBZJ>A*XYN8G0W^D[8'R&"@,$ P; GL'4@7YD
MQCJR@S BG;F%Z8!9*:3M[,K82)OW32Y,#1\4:@JF" +LN=0%S7\"%'>#^.U'
M_'[1H&)STFB1HO=QZMV5S+V<WB;*#OIL9UY?51PTS,G[8P-==!MU!%K".5,T
M[*=;L/&LP9IZ+3;H*:Z%9J<V55X<YD35I7EDZ9SR;I/N,>CX.6_UF$?''E*?
M54X\^??@8\AE&>=O$^^$#HXXB" W4HUA)'(2R0,OM!SK@FXN1NGQ'[LM&AT@
MVEC;8H15M3XHRGV*,S'J56=C!^+^OG.)GGC2$4!%/HPJ:XI!,(HR%?CN)#IQ
MY]L@*R >W3&^[1A$(02Y*15Z)SGUQJK"Z>H-!>KH1*1Q0-]!0FG;_XW@\:.O
M"2CQ,59Y'T")ST2=[93X\&7'Y7X]>^*>K7I=Y1T='K]G IM6/3865$GW[&_?
MP5,!OH&&,+XG +^3/D=?FCY?8E/LO.B9C4/4<JH.QE;)-P?D&IW(8B&7#EZ\
M[\3Y2K7H'\N9V.2I_=2@SUY+S:=YE:G0G7<.;?O]$,ZOBL0,G?B &Q7TM_(&
MPZ7VMG:$EZ,Z+\*=!7R>W,&<(539CP#<6EDYB%#$^10#4*3S->'FK+0#B7<4
M !^)*ENBVDA4BNG7KEBU0PQ<W>"%&ATRW-K&>7I&IZ$O#L^'';^G'0\,>B%=
M+M^*YX49RT+\4]HWRHM?@$&@L@8R[[#K7V[8T 6#;2C(MC*GVTX*EOO4O^&[
M\L $ HPSIDYG;S!N7Y9C4[1 LU<_G]\>1ES8'YQ5NP!OSRNO#V[E&V7F0-S+
MR01H']!4A5R@YOE%+HAGR-*+_J7FU=I5../V_N!\V/$B#B$5_<OEE@?P8[0C
M+#-"#^\"*42D:3(ZW?]EIBER4<+N( GL(+!DT"0A59PH#3IO>@(S: I_(A">
MDKUMH*.(A6D<WM652E8!<^,5B;6![8;@_<=_4Z<?\AK,[]V29@L+:(_R%MJI
MV(EA74%P"MF>DP-%FG+,!^HP2SIK1_10O"\\%%>$QJV-<YI.\7#UT)'K<20A
MA_8KRZ:;T0Q47@UJ;L9GC]@Z5W2FG]*+.N\=_./%9KL4QB62UC,$[R4EJ2W\
M#HO6B.(/J]<5@TK3YWWT5#HL(V8C% 6]CN26 6FK2MV4@O0 TK!D!5Q;(%CK
MI+#[?BAN5V@SZI#0L*L4;)-1 -5ZWG:PEER[")[-C+(9GM'ZJ'EJB_/$FV="
M+U=@']XVN*';%F,]W-SN[(+V-S)RAH!)N7(P_0  :Z'-->Q);.:4HO-NVMJ$
MIB'9LZ8(T@E?3+2%W5>IJ?$:V860&=Z5:[?R!*"&O:'5O),P>%"IB6:;PRCW
MS"KI,$G'&M_AZ;#/VB L1X-@\SW7$F>P,G: Z-2FBEN[ B=B8C7L0X@>81\W
M%9[Q9=KS&"#TT&&R1L()@6_>9+Z!CPW!"8@! ;GG9#Z7H#&G',BV^SH %IUJ
MNP4%%N#^<99A-:O-6%G L*A*"$V(L'[@F(H2RCJ $@L&*=B/Y_^ZXOU/IO!5
M>Q<Z9!W]GE@W2F80V74U,"(Y180.6Z9-\,T1RB-#59L:?]^(K&]2_JWA75$9
M1*AGO/3K+@%3K)-T(ND(IK-YXD%(02Y5K@(Z-H/WV^MT!)*6-;D"(6NPIRZC
MU>SNZQ.5C"X W6$2>('<<!J<%H5KF!F(1HO.'M(J<G 0E_@MCT=@RG9,1.16
MH*3*! F1\0'"H$'VHT%NNCTK_JD4;K8A^-GUO."N"*6'H);"U2I#-Z!DFJ]F
M$$2D8":+0G4(:A* F420<C3"&_53-M-J(M0[E34,)."@(:@-],TK3QCB,>;N
MP9,()R) ,:N0?E[!%H=HV"K[@=<PU!OU'&<GG*-_!E'+"Q/BXN!UI>+ZPI00
M97!HQ,"<X(L-3/D$\HL?QQ09R\";RF"XAX*=J;Q!BTX6&WZI VHMD>C$4^:@
M> RKAMG"KQ,,PV6O<=0* <X#0T56<PI!E2,8,&2RM#D[Z 5T.B#)M:F2G5)"
M7$JJQ(H0O_ [G5N_$8X,K>DX%#.?U/:&@T+8CT*X+'3*\53LSUN?\U>+W*C$
M!? 5Z#J0?I]B_[MRIE1@'SO#Y+.O67B*URGU:Q'XF#$?N^@BZH%!JO;E[,KI
ME,JG_!@UU[.HN09@UP#L^IH7/0"VO@*EQ/9F@W^E7<@8PYL#0F!;%6I A<N*
MM''%.>I<(HK2.IRR<[[CD/SNP5))/FP=)>6DQ@J]2G(8823JA-J%T#*U3S@H
MEF!9.J]*G"R[F<$II>LI*B73RP/&JY*5BQ*<CX;EUM)")#FQIHRG3.%@WHSI
MYJYWT#1J3YVU%U.N^P,1,%Y<N0TW5Y3/O6);K:H+X-V&]/BMSNH]QVU^53M]
M<Y3;WFE^:K/[OTS:79W6< (5KF\K ]XE%9O9>KJSFMI/PLM'24*]RU3M^XG^
M([KW"1GU,=&6PU#*;6\3VD'=$!Z@J0-^1M8X.=X:6 ZCP#-I"EW]PHB09A\K
M4QE,GU]-N$]RRE*P9FB6)(=MJGRQM4;'X'CO_939X9F6N$RX<-&5/>&J-P/1
M/YM.:$NU89$4[=>L:"A)H\+E+9<LN5-B]E*K9@U-^CGKU7QTL1JZV%^YO-M:
MGV;8W/LIG!&!97WX'T3XOO%#HL,N&N173AI-LJYC8=E'1X^C%+5T#]4XQ46B
M37Y!H]ZBM$(MPXC%R94J61#&797%"/J*<A.DJBV32RZ'JJ8,34&A;U\=-PY8
MX_!2NQR'L]+V/3J)EZ)NQK!=('*@0E[MW%,-."' '49;& FY%"*(2B/H/M=A
MBB R09SCEIF+I@K.BQ*;9@B1WBAB_!)P&RZ-"4?H'QJ*8J!2$9)FXV!B(;&*
M&/E.7!230'"8%#Q6"/.K*K[SDU6\K6^_9/^-SC(Q]1>#S.<QSL+*9._A4$MH
M"!%EG.]B9A#V,%4T&+, O,5"TU4%G9DZ9S+Z"$185$P*;$@FI6,"I_J'3&0"
M(*:GX5NH@?:NP3@ZQ[Y'XOB[OQ"$ &-%LCUK%3Q_.'4]#[%/@P_;:8Q5Q/6!
M/VVGRHZX?H*(,:EPLE"C#L&1<IWA4NW6GD#G%5T+!TQ9),'F%?.Y@'I'M9ZR
M<"NCD[SN#I-!-@P498M%# "-U1NK'MX2_8+>[@H77UNKU@S&;3_&[6)F-//S
M)V.;<J#JEXF11U&9+U1[-X-Z&BNK\]D50:A2'Q3EK !9K3B>P:JX[ 1?@)-(
M=T 7,Y0AVSK Z+&H'E0^UFFASDW!<"O0UP6H(>ZS*4-62?L.Z3X0P27CMLES
MAJ^P\8EXH+]E#U99/>>)!?W#I5DRI<@=CE?2)J*R9[*81%SZ QUZD?&RV2$A
MJ=)A5DA-9X1X9 8VC+3M1.<-Z#*84M[X9:?_%M94T]S0@$L^(ICT2PJ.6I#[
M2*BR+LQ2*;Z"GA)  @C?<!V,E3/+D<C  ]?QQIK'0\Z!$][@J\EBWK<:.94:
M7L21I 5MBH<-2<W]?LV]P,LM/M%V5H<U?/P^-7>"%;IESGNK1$@B6A(0,T^.
M ]HYA;6;,\5@/+:TO/<H>36!_[QO0OVQX<&#^7MH/$535'5UT&AR6$\:W :I
M@8FYR;R%^83#Z([@"P(R!@-5$(K:->AMQCU,<'!>F&PW8*PNM,1]$J&2'_#W
M$OJ5P=,623UO\K/B>1>O#WW+SJN;J)QV!YZ,>\=VN1/KWV "+M=9K[KBE[K@
M$8/)V:UP5U=/-"F6WH/^[<&D-,&FQ W%);DR'W=64#>O*TH0(*V3U+2EHYL5
M:S)ILXZZPF*,"*9\(-"$OB^^=.2+38)H!PW9Y3HF$M4)TN/T#X_TA:K?OA6K
M0T%9>^\%8T3<A4P2A!AIB7J:PQ,\[,'CF"4J<A!AEP*K*6^)\R?XCFO9)2H!
M@U:.IGHU7*.][@+<4,K)!R=.5MW3P'1N1]YZUCI[S(M6R7TJ;WJ ) R0A &2
M\*6)<W_,UJ\SRLI(#_=2%Z5U"O.0]XDEQ[<J+4[-FT@\Q0"_C'S(T2JZ52Y%
MA26I84PRAIBF1P>#-O4.Z4ADKJI&I4?QH;QNE^T2;R-63%J:V=E5Q<.;@3$5
MQ@-SUE@ZSNA6E:RB*Y9)3F1 Q!-=>$2<!4\K]=PX1;#B2MX2F\[!@H0["717
M%U*3%< L6QJ]3?F+UCSY>U]<?SU@@&U3A%,TJZ9T8<:IN+ L,KOWY/!ET S_
M*P[MII.I<_3=8CK6!3A%F!O^JA6; 5#SJ7,34_J'LQ,"4(PAE.[IO 2@T:OY
MCR J.G#V7;& F!N_ 0+29C&NU4=?A(1?3CEN$1R@)[?\N81]X3CNB:+["G?/
MEZK-@1ME4VIHFG9.MM2M 037DT8):(1A),=2;QN\^QCQU3UZ%E060%?\-WZQ
M'YBK78I)@=GPP6H&GZ%7(&(3[(#_W,D$P?DALYWGASU1?BIX&@9E8G6:<0D;
M"DUTD]Q $F XEOU>28@-]7A!7MO*(EO$%>G?Y<SNORK(1Y4!P8#XSA(@G_#"
MZ-&3XZ,GQ]^W_WR$8/_]BP9T'V8SSQ[RW_P^>TA_+/R_4$L! A0#%     @
M H)A5*>6(K@1Y0$ QC<" !$              ( !     &EM9S0U-#DW.#@V
M7S N:G!G4$L! A0#%     @  H)A5"">F,^)90   )<  !$
M ( !0.4! &EM9S0U-#DW.#@V7S$N:G!G4$L! A0#%     @  H)A5 O-GI%8
MF@  C-4  !(              ( !^$H" &EM9S0U-#DW.#@V7S$P+FIP9U!+
M 0(4 Q0    (  *"853/)-0W-6@! %"_ 0 2              "  8#E @!I
M;6<T-30Y-S@X-E\Q,2YJ<&=02P$"% ,4    "  "@F%4Q%QFQ_W"   !_
M$@              @ 'E300 :6UG-#4T.3<X.#9?,3(N:G!G4$L! A0#%
M  @  H)A5#%]1HW9# $ WG$! !(              ( !$A$% &EM9S0U-#DW
M.#@V7S$S+FIP9U!+ 0(4 Q0    (  *"851"JHALFE,  (YI   2
M      "  1L>!@!I;6<T-30Y-S@X-E\Q-"YJ<&=02P$"% ,4    "  "@F%4
MEZM2/_UK    H0  $@              @ 'E<08 :6UG-#4T.3<X.#9?,34N
M:G!G4$L! A0#%     @  H)A5/OUB$'Y/@   %H  !(              ( !
M$MX& &EM9S0U-#DW.#@V7S$V+FIP9U!+ 0(4 Q0    (  *"853M_7$F!:X
M )X! 0 2              "  3L=!P!I;6<T-30Y-S@X-E\Q-RYJ<&=02P$"
M% ,4    "  "@F%4V_(;E,>T  !AX0  $@              @ %PRP< :6UG
M-#4T.3<X.#9?,3@N:G!G4$L! A0#%     @  H)A5!*ITAE?'0$ :FL! !(
M             ( !9X ( &EM9S0U-#DW.#@V7S$Y+FIP9U!+ 0(4 Q0    (
M  *"8535ZO%A+84  "Z2   1              "  ?:="0!I;6<T-30Y-S@X
M-E\R+FIP9U!+ 0(4 Q0    (  *"851PFIV2P'T  "*\   2
M  "  5(C"@!I;6<T-30Y-S@X-E\R,"YJ<&=02P$"% ,4    "  "@F%4C$/-
M]CTC 0!S:P$ $0              @ %"H0H :6UG-#4T.3<X.#9?,RYJ<&=0
M2P$"% ,4    "  "@F%4\ FN[-C)  #Z^@  $0              @ &NQ L
M:6UG-#4T.3<X.#9?-"YJ<&=02P$"% ,4    "  "@F%4];<20#Q^   0N0
M$0              @ &UC@P :6UG-#4T.3<X.#9?-2YJ<&=02P$"% ,4
M"  "@F%4M\H5?%=(   @:@  $0              @ $@#0T :6UG-#4T.3<X
M.#9?-BYJ<&=02P$"% ,4    "  "@F%4'"'8HM]7  !MA0  $0
M    @ &F50T :6UG-#4T.3<X.#9?-RYJ<&=02P$"% ,4    "  "@F%4-]15
M7F6H   ZP@  $0              @ &TK0T :6UG-#4T.3<X.#9?."YJ<&=0
M2P$"% ,4    "  "@F%44G+^TH&X  !R  $ $0              @ %(5@X
M:6UG-#4T.3<X.#9?.2YJ<&=02P$"% ,4    "  "@F%4H].)4GE:! !BW"\
M$0              @ 'X#@\ <&AA="TR,#(Q,3(S,2YH=&U02P$"% ,4
M"  "@F%4^70\Y#,7  !W  $ $0              @ &@:1, <&AA="TR,#(Q
M,3(S,2YX<V102P$"% ,4    "  "@F%497A>%PH.  "UP0  %0
M    @ $"@1, <&AA="TR,#(Q,3(S,5]C86PN>&UL4$L! A0#%     @  H)A
M5&:GWF@#-0   L@# !4              ( !/X\3 '!H870M,C R,3$R,S%?
M9&5F+GAM;%!+ 0(4 Q0    (  *"8527&>< *;X  )B."  5
M  "  77$$P!P:&%T+3(P,C$Q,C,Q7VQA8BYX;6Q02P$"% ,4    "  "@F%4
M63K010E0  !G)P8 %0              @ '1@A0 <&AA="TR,#(Q,3(S,5]P
M<F4N>&UL4$L! A0#%     @  H)A5.\3X^QU)0  H6@" !
M ( !#=,4 '!H870M97@Q,%\S,"YH=&U02P$"% ,4    "  "@F%4H_&8@WP#
M   7&@  #P              @ &P^!0 <&AA="UE>#(S7S$N:'1M4$L! A0#
M%     @  H)A5%?I:ZXL!0  :T<   \              ( !6?P4 '!H870M
M97@R-%\Q+FAT;5!+ 0(4 Q0    (  *"851 ,B>N4 @  (M    /
M      "  ;(!%0!P:&%T+65X,S%?,2YH=&U02P$"% ,4    "  "@F%4>R7"
MAGP(   N00  #P              @ $O"A4 <&AA="UE>#,Q7S(N:'1M4$L!
M A0#%     @  H)A5":M1ZUD!0  !"8   \              ( !V!(5 '!H
M870M97@S,E\Q+FAT;5!+ 0(4 Q0    (  *"8529;48J804  "LF   /
M          "  6D8%0!P:&%T+65X,S)?,BYH=&U02P$"% ,4    "  "@F%4
MQ;+-<B$3   S?   #@              @ 'W'14 <&AA="UE>#1?-BYH=&U0
52P4&     ", (P"H"   1#$5

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
